<SEC-DOCUMENT>0001828185-26-000012.txt : 20260313
<SEC-HEADER>0001828185-26-000012.hdr.sgml : 20260313
<ACCEPTANCE-DATETIME>20260313081315
ACCESSION NUMBER:		0001828185-26-000012
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		115
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260313
DATE AS OF CHANGE:		20260313

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Barinthus Biotherapeutics plc.
		CENTRAL INDEX KEY:			0001828185
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40367
		FILM NUMBER:		26750140

	BUSINESS ADDRESS:	
		STREET 1:		20400 CENTURY BLVD
		STREET 2:		SUITE 210
		CITY:			GERMANTOWN
		STATE:			MD
		ZIP:			20874
		BUSINESS PHONE:		44 (0) 1865 818808

	MAIL ADDRESS:	
		STREET 1:		20400 CENTURY BLVD
		STREET 2:		SUITE 210
		CITY:			GERMANTOWN
		STATE:			MD
		ZIP:			20874

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vaccitech plc
		DATE OF NAME CHANGE:	20210407

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vaccitech Ltd
		DATE OF NAME CHANGE:	20201014
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>brns-20251231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019b097a-6c16-78f4-806b-17184aaccbef,g:d518a941-6ac7-4029-9d1f-6f039bd073d0,d:a7cbadf995cd4920bb4d015b669c5879-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:brns="http://www.barinthusbio.com/20251231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>brns-20251231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-33">0001828185</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-34">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-35">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-36">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-37">00-0000000</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="f-381">http://fasb.org/us-gaap/2025#GeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-12" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="f-382">http://fasb.org/us-gaap/2025#GeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-1" xsi:nil="true" name="brns:NumberOfReportableSegmentsNotDisclosedFlag" id="f-427"></ix:nonNumeric><ix:nonNumeric contextRef="c-12" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList" id="f-557">http://fasb.org/us-gaap/2025#OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList" id="f-558">http://fasb.org/us-gaap/2025#OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</ix:nonNumeric><ix:nonNumeric contextRef="c-108" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-629">P7D</ix:nonNumeric><ix:nonNumeric contextRef="c-133" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-811">http://fasb.org/us-gaap/2025#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="c-134" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-812">http://fasb.org/us-gaap/2025#LicenseMember</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="brns-20251231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="gbpPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="subsidiary"><xbrli:measure>brns:subsidiary</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>brns:segment</xbrli:measure></xbrli:unit><xbrli:unit id="region"><xbrli:measure>brns:region</xbrli:measure></xbrli:unit><xbrli:unit id="vote"><xbrli:measure>brns:vote</xbrli:measure></xbrli:unit><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">brns:RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:SchemeSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">brns:BecaonTopcoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">brns:ClywedogTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:ClywedogCapitalStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-09-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">brns:SubsidiariesVOLTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">brns:VOLTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">brns:VOLTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">brns:OxfordUniversityInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">brns:OxfordUniversityInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">brns:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">brns:VTP1000CeliacMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">brns:VTP1000CeliacMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">brns:BarinthusLegacyAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">brns:BarinthusLegacyAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="brns:ResearchAndDevelopmentTypeAxis">brns:PersonnelRelatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="brns:ResearchAndDevelopmentTypeAxis">brns:PersonnelRelatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="brns:ResearchAndDevelopmentTypeAxis">brns:FacilityRelatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="brns:ResearchAndDevelopmentTypeAxis">brns:FacilityRelatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="brns:ResearchAndDevelopmentTypeAxis">brns:OtherIndirectCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="brns:ResearchAndDevelopmentTypeAxis">brns:OtherIndirectCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">brns:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-21</xbrli:startDate><xbrli:endDate>2021-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-06</xbrli:startDate><xbrli:endDate>2023-11-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">brns:AvideaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">brns:AvideaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">brns:RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-08</xbrli:startDate><xbrli:endDate>2021-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">brns:RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">brns:RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:EnterpriseManagementIncentiveShareOptionSchemeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:EnterpriseManagementIncentiveShareOptionSchemeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:EnterpriseManagementIncentiveShareOptionSchemeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:EnterpriseManagementIncentiveShareOptionSchemeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignTaxJurisdictionOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignTaxJurisdictionOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:InLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:InLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">brns:OxfordshireMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-03</xbrli:startDate><xbrli:endDate>2021-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">brns:OxfordshireMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">brns:OxfordshireMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-14</xbrli:startDate><xbrli:endDate>2022-06-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">brns:ExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">brns:ExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-22</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-143 f-144" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-213 f-249" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-314" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-3" order="3"/></ix:resources></ix:header></div><div id="ia7cbadf995cd4920bb4d015b669c5879_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">   </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December 31</ix:nonNumeric>, 2025</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">or</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:2.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Commission file number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-40367</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">BARINTHUS BIOTHERAPEUTICS PLC</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1.01pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-8">England and Wales</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.01pt;padding-right:0.01pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">Not Applicable</span></div></td></tr><tr><td colspan="3" style="padding:2px 1.01pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.01pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:0.01pt;padding-right:0.01pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">20400 Century Blvd</ix:nonNumeric></span></div><div style="padding-left:0.01pt;padding-right:0.01pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">Suite 210</ix:nonNumeric></span></div><div style="padding-left:0.01pt;padding-right:0.01pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Germantown</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">MD</ix:nonNumeric></span></div><div style="padding-left:0.01pt;padding-right:0.01pt;text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.01pt;padding-right:0.01pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">20874</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.01pt;padding-right:0.01pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.01pt;padding-right:0.01pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">443</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">917-0966</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-16">American Depositary Shares</ix:nonNumeric>*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-17">BRNS</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Global Market</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-19">Ordinary shares, nominal value &#163;0.000025 per share</ix:nonNumeric>**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%;padding-left:1pt">American Depositary Shares may be evidenced by American Depositary Receipts. Each American Depositary Share represents one (1) ordinary share.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">**</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%;padding-left:2pt">Not for trading, but only in connection with the listing of American Depositary Shares on The Nasdaq Global Market.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%">x</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%">x</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.532%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Smaller reporting company </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-25">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:114%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-26">x</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-27">o</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-28">o</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-29">o</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-30">x</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">As of the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s ordinary shares, nominal value &#163;0.000025 per share, in the form of American Depositary Shares, held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="dei:EntityPublicFloat" scale="6" id="f-31">13.7</ix:nonFraction> million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">The number of shares outstanding of the registrant&#8217;s ordinary shares, nominal value &#163;0.000025 per share, as of March&#160;6, 2026: <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-32">40,848,893</ix:nonFraction> shares.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">None.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">ANNUAL REPORT ON FORM 10-K</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">FOR THE FISCAL YEAR ENDED DECEMBER 31, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">2025</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">TABLE OF CONTENTS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_16">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_19">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_19">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_19">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_22">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_22">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_22">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_25">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_25">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_25">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_28">Item 1C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_28">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_28">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_31">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_31">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_31">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_34">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_34">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_34">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_37">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_37">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_37">97</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_40">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_43">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_43">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_43">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_46">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_46">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_46">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_49">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_49">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_49">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_82">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_82">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_82">114</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_85">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_85">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_85">114</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_88">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_88">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_88">114</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_91">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_91">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_91">114</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_94">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_94">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_94">115</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_97">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_97">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_97">115</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_100">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_103">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_103">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_103">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_106">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_106">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_106">123</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_109">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_109">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_109">130</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_112">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_112">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_112">131</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_115">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_115">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_115">132</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_118">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_121">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_121">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_121">133</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_124">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_124">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_124">135</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_127">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_127">136</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">W</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">e </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">own the registered trademark BARINTHUS in the United Kingdom ("U.K."), and we </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">have filed applications at the U.K. Intellectual Property Office </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">and other intellectual properties </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">to register trademarks for BARINTHUS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">, SNAP-TI, SNAP-CI</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> and a design logo</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> globally</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We also own various trademark registrations and applications, and unregistered trademarks, including the registered trademark VACCITECH, and trademarks relating to the technologies acquired as part of our acquisition of Avidea Technologies, Inc. in December 2021 including the registered trademarks SNAPVAX and SYNTHOLYTIC</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> All other trade names, trademarks and service marks of other companies appearing in this Annual Report on Form 10-K ("Annual Report") are the property of their respective holders. Solely for convenience, the trademarks and trade names in this Annual Report may be referred to without the &#174; and &#8482; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend to use or display other companies&#8217; trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, we may use our website, our X (formerly known as Twitter) account at @Barinthusbio and our LinkedIn account at linkedin.com/company/barinthus-bio to distribute material information about us and for complying with our disclosure obligations under Regulation FD. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.barinthusbio.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website, our X (formerly known as Twitter) posts and our LinkedIn posts are not incorporated into, and does not form a part of, this </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Annual Report.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report contains express or implied forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;objective,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing,&#8221; or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements and opinions contained in this Annual Report are based upon information available to our management as of the date of this Annual Report and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Forward-looking statements contained in this Annual Report include, but are not limited to, statements about:</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the transactions with Clywedog Therapeutics, Inc. (&#8220;Clywedog&#8221;) contemplated by the Agreement and Plan of Merger (as amended from time to time, the &#8220;Merger Agreement&#8221;), dated September 29, 2025, by and among us, Cdog Merger Sub, Inc. and Clywedog (the &#8220;Contemplated Transactions&#8221;), and expectations regarding the timing and benefits of, and our ability to consummate, the Contemplated Transactions;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the success, cost and timing of our product development activities and clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the timing, scope or likelihood of regulatory filings and approvals, including timing of Investigational New Drug Application ("IND"), New Drug Application ("NDA"), and Biologics License Application ("BLA") filings for our current and future product candidates, and final U.S. Food and Drug Administration ("FDA"), European Medicines Agency ("EMA"), U.K. Medicines and Healthcare products Regulatory Agency ("MHRA"), or other foreign regulatory authority approvals relating to our current and future product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our future expectations, plans and prospects, including the estimates of costs that we expect to incur in connection with the restructuring and the timing thereof;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to develop and advance our current and future product candidates and programs into, and successfully complete, clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to establish future or maintain current collaborations or strategic relationships;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our current and future product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any expectations surrounding the payments we could potentially receive pursuant to our collaborations and license agreements;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the ability and willingness of our third-party collaborators to continue research and development activities relating to our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to obtain, maintain, defend and enforce our intellectual property protection for our product candidates, and the scope of such protection;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our manufacturing, commercialization and marketing capabilities and strategy;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">future agreements with third parties in connection with the commercialization of our product candidates, if approved, and any other approved products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">regulatory developments in the United States and foreign countries;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">competitive companies, technologies and our industry and the success of competing therapies that are or may become available;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to attract and retain key scientific or management personnel;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the accuracy of our estimates of our annual total addressable markets, future revenue, expenses, capital requirements and needs for additional financing;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our expectations about market trends;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to anticipate and overcome challenges posed to the conduct of our business in the event of a global pandemic or similar event;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the impact of global economic and political developments on our business, including inflationary pressures, volatile interest rates, or intensified disruptions in the global financial markets, the change in the U.S. presidential administration, the conflict in Ukraine, the conflict in Israel and Gaza, disruptions in the banking industry, economic sanctions and economic slowdowns or recessions that may result from such developments; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to comply with the continued listing requirement of Nasdaq and expectations regarding the period during which we qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012, as amended ("JOBS Act").</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">You should refer to the section titled &#8220;Risk Factors&#8221; for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should read this Annual Report and the documents that we reference in this Annual Report with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements in this Annual Report by these cautionary statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">This Annual Report contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Unless the context otherwise requires, reference in this Annual Report to the terms &#8220;Barinthus Bio,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar designations refer to Barinthus Biotherapeutics plc and, where appropriate, our majority-owned subsidiaries. </span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our failure to complete the Contemplated Transactions would have a material adverse effect on our business, results of operations, financial condition and stock price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The failure to successfully integrate our business with that of Clywedog in the expected timeframe would adversely affect our future business and financial performance and the value of our stockholders&#8217; investment following the Combinations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our shareholders and Clywedog&#8217;s stockholders may not realize a benefit from the Contemplated Transactions commensurate with the ownership dilution they will experience in connection with the Contemplated Transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">During the period prior to the closing of the Contemplated Transactions, our business is exposed to certain inherent risks due to the effect of the announcement or pendency of the Contemplated Transactions on our business relationships, financial condition, operating results and business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Litigation may arise in connection with the Contemplated Transactions, which could be costly, prevent consummation of the Contemplated Transactions, divert management&#8217;s attention and otherwise materially harm our business.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We are subject to restrictions on our business activities under the Merger Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We are a clinical-stage biopharmaceutical company with a limited operating history. We have incurred significant losses since inception. We expect to incur losses for at least the next several years and may never achieve or maintain profitability.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have not yet generated any material revenue from our product candidates.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we engage in further acquisitions or future strategic partnerships, this may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Raising additional capital may cause dilution to our existing shareholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may require substantial additional funding in the future. If we are unable to raise capital when needed, we would be compelled to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to advance our current or future product candidates into and through clinical trials, obtain marketing approval or reimbursement and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Clinical development involves a lengthy and expensive process with uncertain outcomes, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results. We may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials on the expected timelines, if at all. If our preclinical studies and clinical trials are not sufficient to support marketing authorization of any of our product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Interim, &#8220;topline,&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more participant data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our product candidates are based on novel approaches to the treatment of diseases, which makes it difficult to predict the time and cost of product candidate development.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our product candidates may cause serious adverse events, serious side effects or have other properties that could halt their clinical development, prevent their marketing authorization, require expansion of the trial size, limit their commercial potential or result in significant negative consequences.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The market opportunities for certain of our oncology product candidates may be relatively small as it may be limited to those patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may form or seek additional collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such collaborations, alliances or licensing arrangements.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The marketing authorization processes of the FDA, the EMA, MHRA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain marketing authorizations for our product candidates, or the marketing authorization is for a narrower indication than we seek, our business will be substantially harmed.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Even if we receive marketing authorization for our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expenses, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to obtain and maintain patent protection for any products we develop and for our technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop and our technology may be adversely affected.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our rights to develop and commercialize our technology and product candidates are subject, in part, to the terms and conditions of licenses granted to us by others and if we fail to comply with our current or future obligations in any agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The pipeline prioritization and restructuring may be unsuccessful, lead to additional costs, disrupt our operations, create unintended problems in our workforce, or increase litigation, in which case our business could be harmed.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We will need to grow the size of our organization and we may experience difficulties in managing this growth.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we were classified as a passive foreign investment company, it could result in adverse U.S. federal income tax consequences to U.S. Holders (as defined below).</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we fail to regain compliance with the continued listing requirements of Nasdaq Stock Market LLC ("Nasdaq"), our ADSs may be delisted and the price of our ADSs and our ability to access the capital markets could be negatively impacted. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">A variety of risks associated with operating our business internationally could materially adversely affect our business.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">PART I</span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_19"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 1. Business</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We are a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases within the immunology and inflammation ("I&amp;I") space. Helping patients and their families is the guiding principle at the heart of Barinthus Bio. We aim to achieve this by developing truly transformational and highly disease-specific immunotherapies. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We are prioritizing the development of a pipeline for I&amp;I indications enabled by our proprietary and highly differentiated platform for promoting immune tolerance, referred to as SNAP-TI, that are designed to guide patient's T cells to reduce inflammation and restore the natural state of immune non-responsiveness to healthy tissue. Our lead candidate, VTP-1000, is designed to restore immune non-responsiveness to gluten in patients with celiac disease, and is currently being assessed in a Phase 1 clinical trial. Based on encouraging preclinical data, we believe that the SNAP-TI platform has the potential to impact multiple other I&amp;I indications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We are also exploring partnership opportunities for VTP-300, a product candidate to treat chronic hepatitis B ("CHB") that harnesses viral vector platform technologies, consisting of Chimpanzee Adenovirus Oxford ("ChAdOx") and Modified Vaccinia Ankara ("MVA"), which are designed to increase disease-specific CD8+ T cells. VTP-300 is a Phase 2 immunotherapeutic treatment modality that is a component of a treatment regimen to establish functional cure in patients who are chronically infected by the hepatitis B virus.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We believe our core capabilities at the intersection of T cell immunology and immunotherapeutic technology platforms combined with our track record of successfully executing development path activities uniquely position us to navigate towards delivering promising new treatments for patients with autoimmune and inflammatory diseases and building value for shareholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Our Approach</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are leveraging the latest understanding of how the immune system's T cells naturally function to control disease. Research has shown that T cells are key to our body&#8217;s ability to identify and respond to threats through recognition of antigens. Disease can occur when the T cell response is either inappropriate, as occurs in autoimmunity, or inadequate, as often occurs in chronic viral infections or cancer. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Many autoimmune and inflammatory diseases are characterized by an inappropriate or overactive immune response caused by an imbalance in the T cell population. T effector ("Teff") cells that normally fight infections and cancer can inappropriately attack the body and overwhelm the regulatory T ("Treg") cells that are meant to prevent inflammation. While there has been incredible progress in the treatment options over the last two decades, current therapies still rely heavily on the use of non-specific immunosuppressive agents and supportive therapies. These may efficiently dampen inflammation and slow disease progression, but they often require lifelong treatment and their lack of specificity for the pathogenic mechanism can lead to several, sometimes life-threatening, side effects. Therefore, there remains a need for more targeted, curative therapies that directly address the T cell (Treg/Teff) imbalance underlying many autoimmune and inflammatory diseases. Fortunately, improved understanding of the cause of inflammatory diseases is allowing the identification of the specific antigens that Teff cells are attacking. In autoimmunity, Teff cells recognize and attack tissues harboring self-antigens, such as pancreatic beta islet cell associated antigens in type-1 diabetes. Knowledge of the problematic antigens that the Teff cells are responding to allows for the development of highly specific treatments that only target the T cells involved in the disease and may provide a less aggressive and potentially curative approach. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We aim to directly address the disease process underlying autoimmunity and other inflammatory diseases by developing antigen-specific immune tolerance ("ASIT") therapies based on our proprietary SNAP-TI technology platform. Our approach is to use SNAP-TI to provide the immune system with problematic antigens within an appropriate tolerogenic context that promotes a reduction in Teff cells and increase in Treg cells, aiming to restore the natural state of immune tolerance and control over disease. Properties that differentiate SNAP-TI from other ASIT therapies are the use of synthetic, self-assembling nanoparticles to improve manufacturability of multiple antigen compositions; ability to administer by preferred intramuscular or subcutaneous routes; and use of an immunomodulator that aims to improve the Treg/Teff ratio and prevent unwanted inflammation associated with the treatment. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2025, we achieved a number of strategic, operational, and financial objectives, which we believe position us to deliver on our long-term plans:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">In January 2025, we announced a strategic business refocus and restructuring to prioritize immunology and inflammation indications, including the development of VTP-1000 in celiac disease and deprioritization of VTP-300 in CHB until a partner is identified. Partners are also being sought for the other assets that are based upon the viral vector platforms. As part of this refocus, we announced a reduction in workforce of approximately 65% and the expected closure of the U.K. site, focusing future operations at the U.S. site in Germantown, Maryland and extending the cash runway into 2027. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">In May 2025, we presented data from two Phase 2 clinical trials of VTP-300 in CHB at the European Association for the Study of the Liver (&#8220;EASL&#8221;) Congress 2025 showing VTP-300 induced meaningful and sustained reductions in hepatitis B surface antigen (&#8220;HBsAg&#8221;). Data from the HBV003 trial, evaluating VTP-300 in combination with low-dose nivolumab (&#8220;LDN&#8221;) showed in CHB participants with HBsAg levels of &lt;200 IU/mL, meaningful reductions in HBsAg (&gt;1 log decline) occurred soon after dosing on Day 29 in all treatment groups and were maintained to Day 169. In the two best treatment arms HBsAg declines of &#8805;1 log at Day 169 were observed in 33% (15/45) of participants with HBsAg &#8804;200 IU/mL at baseline, and 22% (10/45) of participants achieved HBsAg loss at any timepoint with two patients achieving functional cure. In partnership with Arbutus Biopharma, we presented end-of-study data from the Phase 2a clinical trial (IM-PROVE II, AB-729-202) in CHB evaluating the combination of imdusiran (&#8220;IDR&#8221;), Arbutus&#8217; RNAi therapeutic, followed by VTP-300, with or without LDN. The end of study data show 25% (2/8) of participants with starting baseline HBsAg levels less than 1000 IU/mL receiving the combination of IDR, VTP-300 and LDN achieved functional cure. 3 of 13 participants (23%) receiving IDR+VTP-300+LDN had undetectable HBsAg levels at week 48; all (3/3) of participants with HBsAg loss seroconverted. Treatment with VTP-300 in both studies was generally well-tolerated, with no serious adverse events or treatment discontinuations reported.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">In September 2025, we entered into the Merger Agreement to combine in an all-stock transaction with Clywedog, a private company advancing breakthrough medicines in diabetes. The newly combined company will advance a differentiated portfolio of clinical-stage candidates targeting metabolic and autoimmune diseases, with four clinical data milestones expected within 18 months of the closing of the transaction. Upon the closing of the transaction, the combined company ("Topco") will be renamed &#8220;Clywedog Therapeutics Holdings, Inc.&#8221; and is expected to trade on the Nasdaq under the new ticker symbol &#8220;CLYD.&#8221; The transaction is expected to close in the second quarter of 2026.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:113%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:113%;padding-left:14.5pt">In December 2025, we announced an update on the Phase 1 AVALON clinical trial of VTP-1000 for the treatment of celiac disease. The single ascending dose ("SAD") portion of the Phase 1 AVALON trial (NCT06310291) enrolled 18 patients in three placebo-controlled cohorts of ascending doses. VTP-1000 was well tolerated at all dose levels with no treatment-related SAEs. Pharmacological data collected showed a dose-dependent effect. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">VTP-1000: Antigen-specific Immune Tolerance Candidate for Celiac Disease</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Patients with celiac disease have an unwanted immune response against gluten proteins and can become severely ill following exposure to gluten found in various cereal grains, especially wheat.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">VTP-1000 is designed to suppress the unwanted immune response to gluten by restoring a beneficial regulatory T cell to effector T cell ratio. It is based on SNAP-TI and comprises multiple gluten antigens (representing the key antigens linked to celiac disease) and an immunomodulator co-delivered in nanoparticles of precise size and composition that are optimized to target the appropriate immune cells that promote tolerance. The immunomodulator is a key component of VTP-1000 and is intended to drive regulatory T cell expansion and prevent pro-inflammatory responses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">AVALON - Currently enrolling, ongoing Phase 1</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The AVALON clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VTP-1000. The trial aims to enroll 42 participants with celiac disease and will be conducted in two parts: a randomized double-blind placebo-controlled SAD part, followed by a randomized double-blind placebo-controlled multiple ascending dose ("MAD") part, incorporating a controlled gluten challenge to assess the impact of VTP-1000 administration on patients&#8217; exposure to gluten. In the AVALON trial, we are enrolling adults with celiac disease in the two-part trial, as described in the table below.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="brns-20251231_g1.jpg" alt="AVALON outline.jpg" style="height:142px;margin-bottom:5pt;vertical-align:text-bottom;width:660px" id="i-1"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part A - SAD Data </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:113%">In December 2025, we announced an update on the Phase 1 AVALON clinical trial of VTP-1000 for the treatment of celiac disease. The SAD portion of the Phase 1 AVALON trial (NCT06310291) enrolled 18 patients in three placebo-controlled cohorts of ascending doses. VTP-1000 was well tolerated at all dose levels with no treatment-related SAEs. Pharmacological data collected showed a dose-dependent effect. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The MAD portion of the trial, which includes a gluten challenge, is currently ongoing, with data expected in the second half of 2026. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As VTP-1000 is our first product candidate directed towards the treatment of an inflammatory disease, we believe demonstration of T regulatory cell induction and/or suppression of unwanted immune responses to gluten would pave the way for other therapeutic candidates based on SNAP-TI, including alternative autoimmune disease indications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Our Legacy Infectious Disease and Oncology Pipeline ("Barinthus Legacy Assets"): </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In January 2025, we announced a strategic focus on developing a pipeline in I&amp;I, and the deprioritization of our programs in infectious disease and oncology. The following assets shall be referred to collectively as "Barinthus Legacy Assets", and the future clinical development of which will only be advanced by a partner: VTP-300 HBV, VTP-500 MERS, VTP-850 Prostate Cancer. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">VTP-300: Our Legacy Hepatitis B Immunotherapy </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2025, we announced that our Phase 2 Hepatitis B immunotherapy, VTP-300, would only be advanced in the future, with support from a partner. VTP-300 is based on two viral vector platforms (ChAdOx and MVA), each encoding the same antigen sequence based on HBV genotype C antigen sequences, and is designed to stimulate the production of very high levels of Teff cells, such as CD8+ T cells that can recognize viral antigens or tumor antigens. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Patients with chronic hepatitis B infection live with the disease in the absence of symptoms for decades after initial infection. However, as the disease progresses and symptoms occur, it can cause serious health problems, including development of hepatocellular carcinoma or liver cirrhosis, especially if left untreated. There is an urgent need to develop an effective therapeutic strategy for CHB infection as less than 10% of patients achieve a functional cure with existing therapies. Experts agree that achieving functional cure in CHB patients will likely require a combination of agents with complementary mechanisms of action. VTP-300 has been designed to be one of those components by stimulating a highly potent and polyfunctional disease-specific immune response, mostly led by disease-specific effector T-cells. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">VTP-300 has completed three clinical trials to date. Meaningful, durable reductions of HBsAg were seen in patients receiving VTP-300 monotherapy and those receiving VTP-300 followed by a single low dose of nivolumab together with MVA. VTP-300, based on HBV genotype C sequences, was observed to lead to a decline in HBsAg in both genotype B- and C-infected CHB patients. Additionally, T cell responses to HBV core protein induced by VTP-300 in healthy subjects were shown to cross-react with other prevalent genotypes (A to E). Together, these results highlighted that T cell responses induced by VTP-300, based on genotype C, were cross-reactive to other common HBV genotypes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In May 2025, we announced primary endpoint data from the Phase 2 HBV003 clinical trial (NCT05343481). The preliminary analysis showed that in CHB participants with hepatitis B surface antigen (&#8220;HBsAg&#8221;) levels of &lt;200 IU/mL, meaningful reductions in HBsAg (&gt;1 log decline) occurred soon after dosing on Day 29 in all treatment groups and were maintained to Day 169. In the two best treatment arms HBsAg declines of &#8805;1 log at Day 169 were observed in 33% (15/45) of participants with HBsAg &#8804;200 IU/mL at baseline, and 22% (10/45) of participants achieved HBsAg loss at any timepoint. 71% of participants (48 of 68) met the criteria for discontinuation of NUC therapy. Treatment with VTP-300 in combination with LDN was generally well-tolerated, with no related serious adverse events reported.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Future Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the clinical data to date suggest that VTP-300 contributes to HBsAg loss, and could become part of a regimen that can attain and maintain functional cure. We are actively seeking a partner to take advantage of VTP-300's differentiated ability to achieve sustained HBsAg loss and functional cure in patients with low levels of HBsAg.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Our History and Team</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We were founded in May 2016 as a spin-out from a leading institution in the U.K., the Jenner Institute at the University of Oxford, with the aim of developing and commercializing innovative immunotherapeutics and vaccines to treat and prevent infectious diseases and cancer. Our strategic trajectory has grown with the acquisition of Avidea Technologies, Inc. ("Avidea") and the SNAP-TI platform in 2021, expanding our product candidate pipeline and strengthening our scientific leadership in immunotherapies and the autoimmune space. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have assembled a management team with extensive expertise in building and operating biopharmaceutical organizations that have discovered, developed and delivered innovative medicines to patients. Our management team has broad experience and successful track records in biopharmaceutical drug discovery, clinical development, regulatory affairs, manufacturing and commercialization, as well as in business, operations, and finance. Our management team&#8217;s experience was gained at leading institutions that include Altimmune, Celltech, GenVec and Roche.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has extensive expertise in the fields of science, business, and finance and works with our management team on business and scientific development initiatives and strategies.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Our Collaboration and License Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2017 License Agreement with OUI (Barinthus Biotherapeutics North America, Inc.)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In March 2017, Avidea entered into a license agreement (the "March 2017 OUI License Agreement") with Oxford University Innovation ("OUI") for the development and commercialization of products comprising thermo-responsive adjuvant scaffolds for use in all indications. All of Avidea&#8217;s rights, duties and obligations under this March 2017 OUI License Agreement were assumed by Barinthus Bio NA following the acquisition of Avidea by Barinthus Biotherapeutics plc on December 10, 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the March 2017 OUI License Agreement, OUI granted us a worldwide license under certain patent rights of OUI related to the use of thermo-responsive adjuvant scaffolds, among other rights (the "March 2017 Licensed Technology"), to develop, manufacture, use and commercialize licensed products. The license to patent rights are exclusive in all fields, and the license to know how is non-exclusive. The March 2017 Licensed Technology is sublicensable subject to obtaining OUI&#8217;s prior written consent (such consent not to be unreasonably withheld, conditioned or delayed) and inclusion in any sublicense agreement of restrictions on further sub-licensing, among other terms and conditions. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the March 2017 OUI License Agreement, all intellectual property rights resulting from improvements made by us belong to us. OUI retains the right for the University of Oxford, the U.S. National Institutes of Allergy and Infectious Diseases (&#8220;NIAID&#8221;), the Institute of Macromolecular Chemistry of the Czech Republic (&#8220;IMC&#8221;) and any person who works or has worked on the March 2017 Licensed Technology to use the March 2017 Licensed Technology and any licensee improvements for non-commercial use. Furthermore, the University of Oxford, NIAID or IMC may publish the March 2017 Licensed Technology and those improvements without our consent provided that they have first given us advance notice and delayed the publication if necessary for us to obtain patent protection. In addition, OUI retains the right to grant academic and research licenses to any third parties under the March 2017 Licensed Technology to encourage basic research for education and limited clinical patient care but may not grant licenses for commercialization of the March 2017 Licensed Technology that is exclusively licensed to us, nor for development or marketing or products or services that are produced or supplied using the March 2017 Licensed Technology. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Upon execution of the March 2017 OUI License Agreement, we paid OUI a one-time upfront fee of &#163;3,000. We are obligated to pay OUI a low single-digit royalty on net sales of any product or process produced by or using the March 2017 Licensed Technology. If we sublicense the March 2017 Licensed Technology, we will be required to pay OUI a mid-single-digit royalty on any non-royalty sublicensing income. As of March 6, 2026, OUI has not been paid any royalties under the 2017 OUI License Agreement. In the event that the royalties (excluding the royalty on sublicensing income) owed to OUI do not amount to a specified minimum ranging from the low to mid five figures based on the license year in each year following March 2020, the licensee must also pay OUI the difference between the royalty paid and the applicable minimum sum payable. In 2025, we paid &#163;59,360 to OUI, representing the difference between royalties paid and the minimum sum payable. In addition, we are required to pay OUI milestone payments of up to an aggregate of &#163;2.43 million upon the achievement of specified development, regulatory and commercial milestones. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Unless earlier terminated, the 2017 OUI License Agreement will continue for as long as anything within the definition of the licensed patent remains in effect or 20 years from the date of the agreement. The patent licensed under the March 2017 OUI License Agreement, if granted, is expected to expire in October 2035, without giving effect to any potential patent term extensions or patent term adjustments. Either party may terminate for the uncured breach of the other party. We may terminate the agreement at any time upon six months&#8217; prior written notice. OUI may terminate the agreement upon us filing for bankruptcy or in the event of liquidation or receivership proceedings, or upon 30 days&#8217; prior written notice upon the occurrence of certain other events. Upon termination of the March 2017 OUI License Agreement, we are required to, among other things, grant to OUI an irrevocable, transferable, non-exclusive license to develop, make and use any improvements to the March 2017 Licensed Technology which we made prior to the second anniversary of the date of the agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2017 Cooperative Research and Development Agreement with NIH (Barinthus Biotherapeutics North America, Inc)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In February 2017, Avidea entered into a Cooperative Research and Development Agreement (&#8220;CRADA&#8221;) with the U.S. National Institutes of Health (&#8220;NIH&#8221;) to carry out collaborative research for the evaluation of Avidea&#8217;s synthetic, polymer-based vaccine technology, &#8220;Immunotherapeutic Nanoscaffolds&#8221; (IMNs) for infectious disease prevention and cancer treatment in animal models. Under this CRADA Avidea committed to providing scientific staff together with materials for use in experiments to evaluate their performance in various animal models of infectious disease and cancer. Under this CRADA NIH committed to evaluating Avidea materials in animal models and to perform comprehensive immune analysis. No funding was exchanged under this CRADA.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In October 2019, the CRADA was amended (&#8220;1st CRADA Amendment&#8221;) to expand the scope of the collaborative research to evaluate the therapeutic potential of Avidea&#8217;s polymer-based vaccine technology, &#8220;Immunotherapeutic Nanoscaffolds&#8221; (IMNs), including Star polymers and self-assembling nanoparticles based on amphiphilic polymers (SNAP), in preclinical animal models for cancer, infectious and inflammatory diseases. Under this 1st CRADA Amendment Avidea committed to increase its scientific staffing contribution and to provide funding of $22,500 by October 15, 2019 and a further $62,500 by October 15, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, the CRADA was further amended (&#8220;2nd CRADA Amendment&#8221;) to defer payment of Avidea&#8217;s October 2020 funding contribution of the 1st CRADA Amendment to April 15, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the CRADA was further amended (&#8220;3rd CRADA Amendment&#8221;) to extend the term of the CRADA by 2 additional years and to defer payment of Avidea&#8217;s April 2021 funding contribution of the 2nd CRADA Amendment to October 31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the CRADA was further amended (&#8220;4th CRADA Amendment&#8221;) to expand the scope of the collaborative research to evaluate the therapeutic potential of Avidea&#8217;s polymer-based vaccine technology, &#8220;Immunotherapeutic Nanoscaffolds&#8221; (IMNs), including Star polymers and self-assembling nanoparticles based on amphiphilic polymers (SNAP), in preclinical animal models for cancer, infectious and inflammatory diseases (e.g., induction of suppression and/or tolerance for treating or preventing allergies, autoimmunity, and transplant rejection). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the CRADA was further amended (&#8220;5th CRADA Amendment&#8221;) to acknowledge that all of Avidea&#8217;s rights, duties and obligations under the CRADA were assumed by Barinthus Bio NA following the acquisition of Avidea by Barinthus Biotherapeutics plc on December 10, 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the CRADA as amended we own inventions made solely by our staff, and we have an option to enter an exclusive or nonexclusive license to any inventions made solely by NIH staff or made jointly by our staff and NIH under the CRADA (the "CRADA Licensed Technology"). NIH retains rights on behalf of the U.S. Government in the CRADA Licensed Technology as required by statute and NIH policy. The CRADA gave us the option to exclusively license any further inventions made under the CRADA. The CRADA expired on February 23, 2025. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 License Agreement with NIH (Barinthus Biotherapeutics North America, Inc)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, Avidea entered into a license agreement with the NIH for the commercial development of products and processes for the prevention and/or treatment of cancer and infectious diseases within the scope of Licensed Patent rights that had been developed under a CRADA entered into by NIH and Avidea in February 2017 and amended in March 2019, December 2020, May 2021, November 2021 and October 2022. We are co-owners of all the Licensed Patents under this agreement, and we have an option to exclusively license NIH rights in all inventions made under this CRADA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All of Avidea&#8217;s rights, duties and obligations under the 2019 License Agreement with NIH were assumed by Barinthus Bio NA following the acquisition of Avidea by Barinthus Biotherapeutics plc on December 10, 2021. The 2019 License Agreement with NIH was amended in September 2022 to note Barinthus Bio NA&#8217;s rights, duties and obligations and also to include newly filed patents developed under the 2017 CRADA as amended.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the 2019 License Agreement with NIH, NIH granted us a worldwide exclusive license under certain patent rights co-owned by us and NIH related to the use of the SNAP-TI and SNAP-CI platforms, among other rights (the "2019 Licensed Technology"), to develop, manufacture, use and commercialize licensed products. The license to patent rights are exclusive in all fields. The 2019 Licensed Technology is sublicensable subject to obtaining NIH&#8217;s prior written consent (such consent not to be unreasonably withheld) and inclusion of other customary provisions. NIH retains rights on behalf of the U.S. Government in the 2019 Licensed Technology as required by statute and NIH policy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the 2019 License Agreement with NIH, we paid NIH a one-time upfront fee of $20,000. We are obligated to pay NIH a low single-digit royalty on net sales of any product or process produced by or using the 2019 Licensed Technology. If we sublicense the 2019 Licensed Technology, we will be required to pay NIH a low-single-digit royalty on any non-royalty sublicensing income. As of March 6, 2026, NIH has not been paid any royalties under the 2019 License Agreement with NIH. In the event that the royalties (excluding the royalty on sublicensing income) owed to NIH do not amount to a specified minimum ranging from the low to mid five figures based on the license year in each year following September 2019, the licensee must also pay NIH the difference between the royalty paid and the applicable minimum royalty payment. In 2025, we paid $45,000 to NIH, representing the difference between royalties paid and the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">minimum sum payable. In addition, we are required to pay NIH milestone payments of up to an aggregate of $3.24 million upon the achievement of specified development, regulatory and commercial milestones for each Licensed Product. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the 2019 License Agreement with NIH will continue until expiry of the last to expire Licensed Patent. 5 patent families licensed under the 2019 License Agreement with NIH that cover the SNAP-TI and SNAP-CI platforms, if granted, are expected to expire in April 2038, in May 2039, in October 2039, in February 2042 and in June 2042, without giving effect to any potential patent term extensions or patent term adjustments. Two patent families licensed under the 2019 License Agreement with NIH that cover the syntholytic platform, if granted, are expected to expire in April 2040 and in October 2041, without giving effect to any potential patent term extensions or patent term adjustments. Either party may terminate for the uncured breach of the other party. We may terminate the agreement at any time upon 60 days&#8217; prior written notice. NIH may terminate the agreement upon the occurrence of certain events. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our success depends, in part, on our ability to obtain and maintain intellectual property protection for our product candidates, technology and know-how, to defend and enforce our intellectual property rights, in particular, our patent rights, to preserve the confidentiality of our know-how and trade secrets, and to operate without infringing the proprietary rights of others. We seek to protect our product candidates and technologies by, among other methods, filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements that are important to the development of our business. We also rely on trade secrets, know-how, continuing technological innovation and in-licensing of third-party intellectual property to develop and maintain our proprietary position. We, or our licensors, file patent applications directed to our key product candidates in an effort to establish intellectual property positions to protect our product candidates as well as uses of our product candidates for the prevention and/or treatment of diseases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March 6, 2026, we control a patent portfolio comprising in-licensed and co-owned patent families relating to our key SNAP-TI, SNAP-CI and star polymer technology platforms and product candidates, including one issued U.S. patent, twelve pending U.S. patent applications, seven issued foreign patents, 61 pending foreign patent applications. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Synthetic SNAP platform (SNAP-TI</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">and SNAP-CI</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our proprietary synthetic SNAP platform is covered by a patent portfolio that includes eight patent families that we co-own and one patent family that we in-license from OUI. As of March 6, 2026, we in-license a patent family from OUI that includes one pending U.S. patent application and one pending European patent application that are expected to expire in 2035, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. As of March 6, 2026, we co-own a patent family that includes one issued U.S. patent, five issued foreign patents, one pending U.S. patent application, one pending European patent application and a further eleven pending foreign patent applications that are expected to expire in 2038, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We have exclusively licensed rights in this patent family, which resulted from work carried out under a CRADA with the NIH. As of March 6, 2026, we co-own a patent family that includes one issued foreign patent, one pending U.S. patent application, one pending European patent application and a further five pending foreign patent applications that are expected to expire in 2039, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We have exclusively licensed rights in this patent family, which resulted from work carried out under a CRADA with the NIH. As of March 6, 2026, we co-own a patent family that includes one pending U.S. patent application and a further two pending foreign patent applications that are expected to expire in 2039, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We have exclusive rights in this patent family, which resulted from work carried out under a CRADA with the NIH. As of March 6, 2026, we co-own a patent family that includes one pending U.S. patent application, one pending European patent application and a further ten pending foreign patent applications that are expected to expire in 2042, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We have exclusive rights in this patent family, which resulted from work carried out under a CRADA with the NIH. As of March 6, 2026, we co-own a patent family that includes one pending U.S. patent application, one pending European patent application and a further four pending foreign patent applications that are expected to expire in 2042, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We have exclusive rights in this patent family, which resulted from work carried out under a CRADA with the NIH. As of March 6, 2026, we co-own a patent family that includes one pending U.S. patent application, one pending European patent application and a further two pending foreign patent applications that are expected to expire in 2041, without giving effect to any potential patent term extensions and patent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We have licensed exclusive rights in this patent family, which resulted from work carried out under a RCA with the IMC. As of March 6, 2026, we co-own a patent family that includes two pending U.S. patent applications, one pending European patent application and a further nine pending foreign patent applications that are expected to expire in 2043, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We have exclusive rights in this patent family, which resulted from work carried out under a CRADA with the NIH. As of March 6, 2026, we co-own a patent family that includes one pending U.S. patent application, one pending European patent application and a further two pending foreign patent applications that are expected to expire in 2043, without giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. We have exclusive rights in this patent family, which resulted from work carried out under a CRADA with the NIH.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Product Candidates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our VTP-1000 product candidate includes SNAP-TI platform technology to provide tolerizing immunotherapy for celiac disease. We co-own a patent family with claims directed to compositions and methods for treating celiac disease. As of March 6, 2026, the patent family includes two pending U.S. patent applications, one pending European patent application and a further nine pending foreign patent applications. If a patent were to issue from either of these pending applications or from a patent application claiming the benefit of either of these applications, such a patent would be expected to expire in 2043, without giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. In addition, we rely on patent protection afforded by the patent families directed to the SNAP technology platforms, which are expected to expire between 2030 and 2042, as discussed above.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Individual patents have terms for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, utility patents issued for applications filed in the United States are granted a term of 20 years from the earliest effective filing date of a non-provisional patent application. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. All taxes, annuities or maintenance fees for a patent, as required by the USPTO and certain foreign jurisdictions, must be timely paid in order for the patent to remain in force during this period of time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The actual protection afforded by a patent may vary on a product by product basis, from country to country and can depend upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions and the availability of legal remedies in a particular country and the validity and enforceability of the patent. Our patents and patent applications may be subject to procedural or legal challenges by others. We may be unable to obtain, maintain and protect the intellectual property rights necessary to conduct our business, and we may be subject to claims that we infringe or otherwise violate the intellectual property rights of others, which could materially harm our business. For more information about the risks associated with our efforts to obtain adequate intellectual property protection for our product candidates, and the enforcement of such intellectual property rights, as well as the risks associated with third party intellectual property rights, see the section titled &#8220;Risk Factors &#8212; Risks Related to Our Intellectual Property.&#8221; </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Government Regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (the "FD&amp;C Act") and biological products under the FD&amp;C Act and the Public Health Service Act (the &#8220;PHS Act&#8221;), and other federal, state, and local statutes and regulations. Both the FD&amp;C Act and the PHS Act and their corresponding regulations govern, among other things, the research, development, testing, manufacturing, quality control, approval, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, marketing, promotion, export and import, advertising, post-approval monitoring, and post-approval reporting involving drugs and biological products. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations, and international guidelines require the expenditure of substantial time and financial resources and we may not be able to obtain the required regulatory approvals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Further, even if we obtain the required regulatory approvals for our products, pharmaceutical companies are subject to myriad federal, state, and foreign healthcare laws, rules, and regulations governing all aspects of our operations, including, but not limited to, our relationships with healthcare professionals, healthcare institutions, distributors of our products, and sales and marketing personnel; governmental and other third-party payor coverage and reimbursement of our products; and data privacy and security. Such laws, rules, and regulations are complex, continuously evolving, and, in many cases, have not been subject to extensive interpretation by applicable regulatory agencies or the courts. We are required to invest significant time and financial resources in policies, procedures, processes, and systems to ensure compliance with these </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">laws, rules, and regulations, and our failure to do so may result in the imposition of substantial monetary or other penalties by federal or state regulatory agencies, give rise to reputational harm, or otherwise have a material adverse effect on our results of operations and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">U.S. Drug and Biological Products Development Process</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In the United States, the FDA is responsible for enforcing the laws in place to protect public health by ensuring the safety, efficacy, and security of drugs and biological products. The process required by the FDA before a product may be marketed in the United States generally involves the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">completion of extensive preclinical laboratory tests and animal studies performed in accordance with applicable regulations, including the FDA&#8217;s Good Laboratory Practices ("GLPs"), regulations and standards; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">submission to the FDA of an IND, which must become effective before clinical trials may begin; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">approval by an independent institutional review board ("IRB") or ethics committee representing each clinical site before the trial is commenced; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, Good Clinical Practices ("GCPs"), and other clinical trial-related regulations to establish the safety, purity and potency of the proposed product candidate for its intended purpose; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">preparation of and submission to the FDA of an NDA or BLA, which includes not only the results of the clinical trials, but also, detailed information on the chemistry, manufacture and quality controls for the product candidate and proposed labeling; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">payment of user fees for FDA review of the NDA or BLA (unless a fee waiver applies);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">a determination by the FDA within 60 days of its receipt of a NDA or BLA to file the application for review; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with current Good Manufacturing Practice requirements ("cGMPs") and to assure that the facilities, methods and controls are adequate to preserve the investigational product&#8217;s identity, strength, quality and purity, and of selected clinical trial sites that generated the data in support of the application to assess compliance with the FDA&#8217;s GCPs; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">satisfactory completion of an FDA Advisory Committee review, if applicable; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">FDA review and approval, or licensure, of an NDA or BLA to permit commercial marketing of the product for particular indications for use in the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Before testing any investigational product candidate in humans, the product candidate enters the preclinical development stage. The preclinical development stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. The conduct of the preclinical studies must comply with federal regulations, including GLPs. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, as well as other information, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human trials. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the IND on clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a drug product candidate at any time before or during clinical trials due to safety concerns, non-compliance, or other issues affecting the integrity of the trial. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that could cause the trial to be suspended or terminated. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Clinical trials involve the administration of the investigational product candidate to healthy volunteers or patients under the supervision of qualified investigators which generally are physicians not employed by, or under the control of, the trial sponsor. Clinical trials are conducted under written trial protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection (inclusion and exclusion criteria) and the parameters and criteria to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">An IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the trial at least </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">annually. The IRB must review and approve, among other things, the trial protocol and informed consent information to be provided to trial subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee. This group provides authorization as to whether or not a trial may move forward at designated check points based on access that only the group maintains to available data (if blinded) or to data available also to the sponsor (unblinded) from the trial and may recommend halting the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Certain information about certain clinical trials must also be submitted within specific timeframes to the NIH for public dissemination on its ClinicalTrials.gov website. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Phase 1. The investigational product is initially introduced into healthy human volunteers or patients with the target disease or condition. Phase 1 clinical trials are typically designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, including any side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Phase 2. The investigational product is evaluated in a limited patient population to identify possible adverse side effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Phase 3. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide substantial evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall benefit to risk ratio of the investigational product and to provide an adequate basis for physician labeling. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of an NDA or BLA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In some cases, the FDA may require, or companies may voluntarily pursue, post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical trial activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be submitted to the FDA and the investigators fifteen days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected adverse events, findings from other studies or animal or in vitro testing that suggest a significant risk for human volunteers and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within seven days of the sponsor&#8217;s initial receipt of the information of any unexpected fatal or life-threatening suspected adverse reaction. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor, acting on its own or based on a recommendation from the sponsor&#8217;s data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biological product has been associated with unexpected serious harm to patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the investigational product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHS Act emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing high quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency, stability, and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">U.S. Review and Approval Processes</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of an NDA or BLA requesting approval to market the product for one or more indications. This application must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Within 60 days following submission of the application, the FDA reviews an NDA or BLA submitted to determine if it is substantially complete before the FDA accepts it for filing. The FDA may refuse to file any application that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the application must be resubmitted with the required additional information. The resubmitted application also is subject to review to determine if it is substantially complete before the FDA accepts it for filing. In most cases, the submission of an NDA or BLA is subject to a substantial application user fee, although the fee may be waived under certain circumstances. Under the performance goals and policies implemented by the FDA under the Prescription Drug User Fee Act ("PDUFA") for original applications, the FDA targets ten months from the filing date in which to complete its initial review of a standard application and respond to the applicant, and six months from the filing date for an application with priority review. The FDA does not always meet its PDUFA goal dates, and the review process can be significantly extended by FDA requests for additional information or clarification.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the application. The FDA reviews the NDA or BLA to determine, among other things, whether the proposed product is safe and effective for its intended use, conducting a benefit-risk assessment based on the information provided as to whether the benefits (with their uncertainties) of the investigational product outweigh the risks (with their uncertainties and approaches to managing risks) under the conditions of use described in the proposed product labeling, and whether the product is being manufactured in accordance with cGMP to ensure its continued safety, purity and potency. The FDA may refer applications for novel investigational products or products that present difficult or novel questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians, patient representatives, and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy ("REMS") is necessary to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the application must submit a proposed REMS; the FDA will not approve the NDA or BLA without a REMS, if required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Before approving an NDA or BLA, the FDA typically will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. To assure cGMP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production and quality control. Additionally, before approving an NDA or BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with the protocol and following GCP.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Under the Pediatric Research Equity Act ("PREA") an NDA, BLA or supplement to either for a novel product (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">, new active ingredient, new indication, etc.) must contain data to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">After the FDA evaluates an NDA or BLA and conducts inspections of manufacturing facilities where the drug substance and/or drug product for commercial supply will be produced, the FDA may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter will describe all of the deficiencies that the FDA has identified in the application, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may recommend actions that the applicant might take to place the application in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of an NDA or BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, including to subpopulations of patients, which could restrict the commercial </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">value of the product. Further, the FDA may require that certain contraindications, warnings, precautions or interactions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a REMS, or otherwise limit the scope of any approval. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market trials and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing trials. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could impact the timeline for regulatory approval or otherwise impact ongoing development programs.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Orphan Drug Designation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Under section 526 of the FD&amp;C Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is defined as a disease or condition that affects fewer than 200,000 individuals in the United States, or 200,000 or more individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biological product for such disease or condition will be recovered from sales of the product in the United States of such drug. Orphan product designation must be requested before submitting a marketing application for the orphan indication. After the FDA grants orphan product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the indication for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same product for the same approved use or indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same approved use or indication, or the same drug or biologic for a different use or indication. Among the other benefits of orphan drug designation are tax credits for qualified clinical testing expenses and a waiver of the NDA or BLA application user fee.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">A designated orphan drug may not receive orphan drug exclusivity if the approved indication for a use is broader than the indication for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if the second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Orphan drug designation may also entitle a party to additional financial incentives such as opportunities for grant funding towards clinical trial costs.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Expedited Development and Review Programs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The FDA has various programs, including fast track designation, breakthrough therapy designation, accelerated approval and priority review, that are intended to expedite or simplify the process for the development and FDA review of drugs and biologics that are intended for the treatment of serious or life-threatening diseases or conditions or fulfill an unmet medical need. To be eligible for fast track designation, new drugs and biological product candidates must be intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for that disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biologic may request the FDA to designate the drug or biologic as a fast track product at any time during the clinical development of the product. One benefit of fast track designation, for example, is that the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted if certain conditions are satisfied, including an agreement with the FDA on the proposed schedule for submission of portions of the application and the payment of applicable user fees before the FDA may initiate a review. However, the review of the marketing application (NDA or BLA) does not formally start until the full application has been received by the FDA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Under the FDA&#8217;s breakthrough therapy program, a sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the product candidate is intended, alone or in combination with one or more other drugs or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that it may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, defined as those that measure an effect on irreversible morbidity or mortality or on symptoms that represent serious consequences of the disease. Breakthrough therapy designation comes with all of the benefits of fast track designation. The FDA may take other actions appropriate to expedite the development and review of the product candidate, including holding meetings with the sponsor and providing timely advice to, and interactive communication with, the sponsor regarding the development program.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">A product candidate is eligible for priority review if when approved, it would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious disease or condition. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biological product designated for priority review in an effort to facilitate the review. Under priority review, the FDA&#8217;s goal is to review an application in six months once it is filed, compared to ten months for a standard review. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, drug or biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical trials establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on an intermediate clinical endpoint other than survival or irreversible morbidity or mortality, that is reasonably likely to predict irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA generally requires that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials to verify the clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022 ("FDORA") the FDA is permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Sponsors are also required to send updates to the FDA every 180 days on the status of such studies, including progress toward enrollment targets, and the FDA must promptly post this information publicly. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a drug or indication approved under accelerated approval if, for example, the sponsor fails to conduct such studies in a timely manner and send the necessary updates to the FDA, or if a confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the FDA currently requires sponsors, unless otherwise informed by the agency, to request pre-approval of promotional materials for products receiving accelerated approval, which could adversely impact the timing of the commercial launch of the product. The FDA may withdraw approval of a drug or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Post-approval Requirements </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Rigorous and extensive FDA regulation of drugs and biological products continues after approval, particularly with respect to cGMP requirements, as well as requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. We currently rely, and may continue to rely, on third parties for the production of clinical and commercial quantities of any products that we may commercialize. Manufacturers of our products are required to comply with applicable requirements in the cGMP regulations, including quality control and quality assurance and maintenance of records and documentation. Other post-approval requirements applicable to drugs and biological products include reporting of cGMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information, and complying with electronic record and signature requirements. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. After a BLA is approved for a biological product, the product also may be subject to official lot release. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Manufacturers also must comply with the FDA&#8217;s advertising and promotion requirements, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), industry-sponsored scientific and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Failure to comply with the applicable United States requirements at any time during the product development process, approval process, or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, product detentions or refusal to permit the import or export of the product, restrictions on the marketing or manufacturing of the product, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with physicians or other stakeholders, debarment, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Drug and biological product manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws, including applicable tracking and tracing requirements. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved NDA or BLA, including withdrawal of the product from the market. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, legislation is drafted, introduced, passed in Congress and signed into law that could significantly change the statutory provisions governing the approval, manufacturing, and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations, guidance, and policies are often revised or reinterpreted by the agency in ways that may significantly affect the manner in which pharmaceutical products are regulated and marketed.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Marketing Exclusivity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Depending upon the timing, duration and specifics of the FDA approval of the use of our product candidates, some of our United States patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (the "Hatch-Waxman Amendments"). The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a marketing application (NDA/BLA) plus the time between the submission date of an NDA or BLA and the approval of that application. Only one patent applicable to an approved product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. In addition, a patent can only be extended once and only for a single product. The United States Patent and Trademark Office (the "USPTO") in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent term for one of our patents, if and as applicable, to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA or BLA. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our product candidates are regulated as biologics. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the "ACA") includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 ("BPCIA"), which created an abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product. This amendment to the PHS Act attempts to minimize duplicative testing. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical trial or trials. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product, and the FDA will not approve an application for a biosimilar or interchangeable product based on the reference biological product until 12 years after the date of first licensure of the reference product. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity, or potency.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the 12 year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of litigation. As a result, the ultimate implementation and impact of the BPCIA is subject to significant uncertainty.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">A new drug or biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity for all formulations, dosage forms, and indications of the most active moiety and, for drugs, patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection, and, for drugs, patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial, provided that at the time pediatric exclusivity is granted there is not less than nine months of term remaining.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Additional Regulation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Government Regulation Outside of the United States</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving biological products as well as authorization and approval of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In April 2014, the EU adopted the Clinical Trials Regulation (EU) No 536/2014, which replaced the current Clinical Trials Directive 2001/20/EC on January 31, 2022. The Regulation, which is directly applicable in all EU Member States (meaning that no national implementing legislation in each EU Member State is required), aims at simplifying and streamlining the approval of clinical trials in the EU. The main characteristics of the Regulation include: a streamlined application procedure via a single-entry point through the Clinical Trials Information System ("CTIS"); a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts (Part I contains scientific and medicinal product documentation and Part II contains the national and patient-level documentation). Part I is assessed by a coordinated review by the competent authorities of all European Union Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned) of a draft report prepared by a Reference Member State. Part II is assessed separately by each Member State concerned. Strict deadlines have also been established for the assessment of clinical trial applications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">European Union Drug Review and Approval</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In the European Union, medicinal products, including biological medicinal products, are subject to extensive pre- and post-market regulation by regulatory authorities at both the European Union and national levels.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">To obtain regulatory approval of a new medicinal product under the European Union regulatory system, we must submit a marketing authorization application ("MAA") either under a centralized procedure administered by the EMA or one of the procedures administered by competent authorities in the European Union: the decentralized procedure, national procedure, or mutual recognition procedure. A marketing authorization may be granted only to an applicant established in the European Economic Area (comprising the EU Member States plus Norway, Iceland and Liechtenstein) ("EEA").</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid throughout the entire territory of the EU and the additional Member States of the EEA. Pursuant to Regulation (EC) No. 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced-therapy medicinal products (gene-therapy, somatic-cell therapy and tissue-engineered medicines) and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of viral diseases, autoimmune and other immune dysfunctions and cancer. For those products for which the use of the centralized procedure is not mandatory, applicants may elect to use the centralized procedure where the product contains a new active substance not yet authorized in the European Union, and where the applicant can show that the product constitutes a significant therapeutic, scientific or technical innovation or for which a centralized process is in the interest of public health at a European Union level.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Under the centralized procedure, the Committee for Medicinal Products for Human Use (the "CHMP"), established at the EMA is responsible for conducting an initial assessment of whether a product meets the required quality, safety and efficacy requirements, and whether a product has a positive benefit-risk profile. The maximum timeframe for the evaluation of an MAA is 210 days from receipt of a valid MAA, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions asked by the CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, it provides the opinion together with supporting documentation to the European Commission, who make the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#8217;s recommendation. Accelerated evaluation may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts such a request, the timeframe of 210 days for assessment will be reduced to 150 days (excluding clock stops), but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For products not falling within the mandatory scope of the centralized procedure, national marketing authorizations may be obtained, which are issued by the competent authorities of the European Union Member States and only cover their respective territory. Where a product has already been authorized for marketing in an European Union Member State, this national marketing authorization can be recognized in another European Union Member State through the mutual recognition procedure. If the product has not received a national marketing authorization in any European Union Member State at the time of application, it can be approved simultaneously in various European Union Member States through the decentralized procedure. As with the centralized procedure, the competent authorities of the European Union Member States assess the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy before granting the marketing authorization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The marketing application (BLA/NDA) submitted in the United States is similar to that required in the European Union, with certain exceptions. Directive 2001/83/EC and the laws in the European Union Member States transposing this Directive into national law set out the requirements for an MAA. An MAA for a biological medicinal product must contain certain additional requirements to compared applications for other medicinal products, such as a description of the origin and history of the starting materials used for the product.</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Data and Marketing Exclusivity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Upon receiving marketing authorization in the European Union, innovative medicinal products (reference products), approved on the basis of a complete and independent package of data, generally receive eight years of data exclusivity and an additional two years of market exclusivity. Data exclusivity prevents generic or biosimilar applicants from referencing the innovator&#8217;s preclinical/nonclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the European Union for a period of eight years from the date on which the reference product was first authorized in the European Union. During the additional two-year period of market exclusivity, a generic or biosimilar marketing authorization can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar product can be marketed in the European Union until the expiration of the market exclusivity period. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with currently approved therapies. Even if an innovative medicinal product gains the prescribed period of data exclusivity, another company could nevertheless also market another version of the product if such company obtained a marketing authorization based on an MAA with a complete and independent data package of pharmaceutical tests, nonclinical tests and clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Orphan Designation and Exclusivity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Products with an orphan designation in the European Union can receive ten years of market exclusivity, during which time &#8220;no similar medicinal product&#8221; for the same indication may be placed on the market. A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan medicinal product can also obtain an additional two years of market exclusivity where an agreed pediatric investigation plan for pediatric trials has been complied with. No extension to any supplementary protection certificate ("SPC") can be granted on the basis of pediatric trials for orphan indications. The ten-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The criteria for designating an &#8220;orphan medicinal product&#8221; in the European Union are similar in principle to those in the United States. In the European Union under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as an orphan medicinal product if it meets the following criteria: (i) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (ii) either (a) the prevalence of such condition must not be more than five in 10,000 persons in the European Union when the application is made, or (b) without the benefits derived from orphan status, it must be unlikely that the marketing of the medicine would generate sufficient return in the European Union to justify the investment needed for its development; and (iii) there exists no satisfactory method of diagnosis, prevention or treatment of such condition, or if such a method exists, the product would be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers made available by the European Union and its Member States to support research into, and the development and availability of, orphan medicinal products. The application for orphan designation must be submitted before the MAA. The applicant will receive a fee reduction for the MAA if the orphan drug designation has been granted, but not if the designation is still pending at the time the MAA is submitted. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">A marketing authorization may be granted to a similar medicinal product to an authorized orphan product during the period of market exclusivity only in very select cases, specifically:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">if it is established that a similar medicinal product is safer, more effective or otherwise clinically superior to the authorized orphan product;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">with consent from the marketing authorization holder for the authorized orphan product; or</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the marketing authorization holder for the authorized orphan product cannot supply enough orphan medicinal product.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Pediatric Development</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In the European Union, companies developing a new medicinal product must agree upon a pediatric investigation plan ("PIP"), with the EMA&#8217;s Pediatric Committee ("PDCO") and must conduct pediatric clinical trials in accordance with that PIP, unless a waiver applies, (e.g., because the relevant disease or condition occurs only in adults). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the product for which marketing authorization is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults, in which case the pediatric clinical trials must be completed at a later date. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when this data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Products that are granted a marketing authorization with the results of pediatric clinical trials conducted in accordance with the PIP are eligible for a six-month extension of the protection under a SPC, provided an application for such extension is made at the same time as filing the SPC application for the product or at any point up to 2 years before the SPC expires, even where the trial results are negative. In the case of orphan medicinal products, a two-year extension of the orphan market exclusivity may be available. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">PRIME Designation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In March 2016, the EMA, launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIME scheme is intended to encourage product development in areas of unmet medical need (where there is no satisfactory method of diagnosis, prevention or treatment in the European Union or, if there is, the new medicine will bring a major therapeutic advantage) and provides accelerated assessment of products representing substantial innovation. The PRIME scheme is open to medicines under development and for which the applicant intends to apply for an initial MAA through under the centralized procedure. Applicants will typically be at the exploratory clinical trial phase of development, and will have preliminary clinical evidence in patients to demonstrate the promising activity of the medicine and its potential to address to a significant extent an unmet medical need. In exceptional cases, products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies, if compelling non-clinical data in a relevant model provide early evidence of promising activity, and first in human trials indicate adequate exposure for the desired pharmacotherapeutic effects and tolerability. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated EMA contact and rapporteur from the CHMP or Committee for Advanced Therapies are appointed early in the PRIME scheme facilitating increased understanding of the product at EMA&#8217;s Committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. Where, during the course of development, a medicine no longer meets the eligibility criteria, support under the PRIME scheme may be withdrawn. VTP&#8209;500, under development for the prevention of MERS caused by the MERS coronavirus, was accepted onto the PRIME scheme by the EMA in December 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Post-Approval Controls</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product. These include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The holder of a marketing authorization must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports ("PSURs").</span></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">All new MAAs must include a risk management plan ("RMP") describing the risk management system that the company will put in place to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the marketing authorization. Such risk-minimization measures or post- authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety trials. RMPs and PSURs are routinely available to third parties requesting access, subject to limited redactions.</span></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription medicines is also prohibited in the European Union. Although general requirements for advertising and promotion of medicinal products are established under European Union directives, the details are governed by regulations in each European Union Member State and can differ from one country to another.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">All of the aforementioned EU rules are generally applicable in the EEA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Brexit and the Regulatory Framework in the U.K.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The U.K. formally left the EU on January 31, 2020. As a result of the Northern Ireland protocol, following Brexit, the EMA remained responsible for approving novel medicines for supply in Northern Ireland under the EU centralized procedure, and a separate authorization was required to supply the same medicine in Great Britain (England, Wales and Scotland). On February 27, 2023, the U.K. government and the European Commission announced a political agreement in principle to replace the Northern Ireland Protocol with a new set of arrangements, known as the &#8220;Windsor Framework.&#8221; The Windsor Framework was approved by the EU-UK Joint Committee on March 24, 2023, and the medicines aspects of the Windsor Framework have applied since January 1, 2025. This new framework fundamentally changes the previous system under the Northern Ireland Protocol, including with respect to the regulation of medicinal products in the U.K. In particular, the MHRA is now responsible for approving all medicinal products destined for the U.K. market (i.e., Great Britain and Northern Ireland), and the EMA no longer has any role in approving medicinal products destined for Northern Ireland under the EU centralized procedure. A single U.K.-wide marketing authorization will be granted by the MHRA for all novel medicinal products to be sold in the U.K., enabling products to be sold in a single pack and under a single authorization throughout the U.K. In addition, the new arrangements require all medicines placed on the U.K. market to be labelled &#8220;U.K. only,&#8221; indicating they are not for sale in the EU. However, although a separate authorization is now required to market medicinal products in the U.K., under an international recognition procedure which was put in place by the MHRA on January 1, 2024, the MHRA may take into account decisions on the approval of a marketing authorization from the EMA (and certain other regulators) when considering an application for a U.K. marketing authorization. There is now no pre-marketing authorization orphan designation in the U.K. Instead, the MHRA reviews applications for orphan designation in parallel to the corresponding MAA. The criteria are essentially the same, but have been tailored for the U.K. market, i.e., the prevalence of the condition in U.K. (rather than the EU) must not be more than five in 10,000. Should an orphan designation be granted, the period of market exclusivity will be set from the date of first approval of the product in the U.K.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Coverage and Reimbursement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we may seek regulatory approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurers, and managed healthcare organizations. Decisions regarding whether to cover any of our product candidates, if approved, the extent of coverage, and amount of reimbursement to be provided are made on a plan-by-plan basis. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Moreover, product candidates may not be considered medically necessary or cost-effective. A decision by a third-party payor not to cover any product candidates we may develop could reduce physician utilization of such product candidates once approved and have a material adverse effect on our sales, results of operations, and financial condition. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time- consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization of the product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the United States government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement, and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged for medical products and services; examining the medical necessity of pharmaceutical or biological products; reviewing the cost-effectiveness of such products; and questioning the safety and efficacy of such products. Adoption of new price controls and cost-containment measures, or adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, that it will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available, or that the third-party payors&#8217; reimbursement policies will not adversely affect the ability of manufacturers to sell products profitably. Decreases in third-party reimbursement for any product or a decision by a third party not to cover a product could reduce physician usage and patient demand for such product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A Member State may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Other Healthcare Laws and Compliance Requirements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the United States federal Anti-Kickback Statute ("AKS"); the civil False Claims Act ("FCA"); the federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA"); and similar foreign, federal, and state fraud and abuse, transparency, and privacy laws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The AKS prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering, or paying remuneration to induce, or in return for, either the referral of an individual, or the purchase, lease, ordering, or arranging for or recommending the purchase, lease, or ordering, of any item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value, whether given directly or indirectly, in cash or in kind. The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, third-party payors, patients, and others on the other hand. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but they are drawn narrowly, and practices that involve remuneration, such as consulting agreements, that may be alleged to be intended to induce prescribing, purchasing, or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of an applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, a claim submitted to a federal healthcare program that includes items or services resulting from a violation of the AKS constitutes a false or fraudulent claim that may result in civil liability under the FCA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Civil and criminal false claims laws, and civil monetary penalty laws, including the FCA, which can be enforced through civil whistleblower or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to the federal government, including federal healthcare programs, that are false or fraudulent. For example, the FCA prohibits any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the United States government. Several pharmaceutical companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal healthcare programs for the product, or for subsidizing copays for patients, including indirectly through charitable patient assistance programs, as an inducement for patients to utilize their products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">HIPAA created additional federal civil and criminal liability for, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items, or services relating to healthcare matters. Similar to the AKS, a person or entity can be found guilty of violating HIPAA&#8217;s fraud and abuse provisions without actual knowledge of the statute or specific intent to violate it.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 ("HITECH") and their respective implementing regulations, impose certain requirements on HIPAA covered entities, which include certain healthcare providers, healthcare clearinghouses, and health plans, and individuals and entities that provide services on their behalf that involve individually identifiable health information, known as business associates, relating to the privacy, security, and transmission of individually identifiable health information. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of protected health information and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can require complex factual and statistical analyses, and may be complicated by the fact that the applicable rules are subject to changing interpretation. HIPAA mandates the reporting of certain breaches of health information to the United States Department of Health and Human Services ("HHS") affected individuals, and if the breach is large enough, the media. In addition to reputational harm, entities that are found to be in violation of HIPAA as the result of a breach of unsecured protected health information, a complaint about privacy practices, or an audit by HHS, may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing civil actions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The U.S. federal Physician Payments Sunshine Act ("Sunshine Act") requires certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the CMSs, information related to payments or other transfers of value made to physicians (currently defined to include doctors of medicine or osteopathy, dentists, optometrists, podiatrists, and chiropractors), other licensed non-physician health care practitioners, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Additionally, we may be subject to federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs and federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We are also subject to additional similar U.S. state and foreign equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or that apply regardless of payor; state laws which require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state and local laws which require pharmaceutical companies to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws which require the reporting of information related to drug pricing; state and local laws requiring the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we or our officers, directors, employees, contractors, or agents may be subject to penalties, including, without limitation, significant civil, criminal, and administrative penalties; damages; fines; exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions; entry into a corporate integrity agreement or similar reporting obligations to resolve allegations of non-compliance; disgorgement; imprisonment; contractual damages; reputational harm; diminished profits; and the curtailment or restructuring of our operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Data Privacy and Cybersecurity Laws</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We may also be subject to data privacy and cybersecurity laws in the U.S. and various jurisdictions around the world in which we operate or process personally identifiable information (&#8220;personal information&#8221; or &#8220;personal data&#8221;). In addition to HIPAA U.S. federal enforcement agencies, such as the Federal Trade Commission (the "FTC") require businesses to take appropriate steps to keep consumers&#8217; personal information secure. In addition, numerous U.S. states have enacted laws that govern the privacy and security of health information and other personal information, some of which may be more stringent than HIPAA and which differ from each other in significant ways thus complicating compliance efforts. For example, the California Consumer Privacy Act (the "CCPA") establishes certain requirements for data use, sharing and transparency, and provides California residents the ability to limit the sharing of their personal information. Similarly comprehensive laws have passed in a number of states. Certain states have passed or proposed more targeted privacy laws that focus on the privacy of health and medical information, such as Washington&#8217;s My Health My Data Act, which has a private right of action that may increase potential damages for noncompliance. Connecticut and Nevada have also passed similar laws regulating consumer health data. Such laws are continuously evolving and are likely to add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation as well as reputational harm.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Outside of the United States, we also face stringent privacy and data protection requirements. For example, in Europe, the collection, use, storage, disclosure, transfer, or other processing of personal data, including personal health data in the EEA and the U.K. is subject to the EU General Data Protection Regulation ("EU GDPR") (with regards to the EEA) and the U.K. General Data Protection Regulation ("U.K. GDPR") (with regards to the U.K.), as well as applicable data protection laws in effect in the Member States of the EEA and in the U.K. (including the U.K. Data Protection Act 2018). In this Annual Report, &#8220;GDPR&#8221; refers to both the EU GDPR and the U.K. GDPR, unless specified otherwise. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing special categories of personal data (such as health data), implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, conducting data protection impact assessments for high risk processing and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million (&#163;17.5 million for the U.K. GDPR) or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR is a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. Data protection authorities from the different EU member states may interpret the GDPR and national laws differently and impose additional requirements, which add to the complexity of processing personal data in the EU.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, various jurisdictions around the world continue to propose new laws that regulate the privacy and/or security of certain types of personal data. Complying with these laws, as they are enacted, would require significant additional resources and leave us vulnerable to possible fines, penalties, litigation, and reputational harm if we are unable to comply.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Healthcare Reform and Legislative Changes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality, or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biological products, especially under government-funded healthcare programs, and increased governmental control of drug pricing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The ACA, which was enacted in March 2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs and expanding enrollment in commercial health plans through new Health Insurance Marketplaces operated by the federal and state governments; a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; and annual fees based on pharmaceutical companies&#8217; share of sales to federal healthcare programs. Since its enactment, there have been judicial, Congressional, and executive branch challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, Congress has considered legislation that would repeal, or repeal and replace, all or part of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, which started on January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry health insurance, delaying the implementation of certain ACA-mandated fees, and increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, other legislative and regulatory changes have been proposed and adopted in the United States since the ACA was enacted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For example:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The U.S. Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2031, absent further legislative action.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The U.S. American Taxpayer Relief Act of 2012 further reduced Medicare payments to several types of providers.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The Inflation Reduction Act of 2022, or IRA, includes several provisions that will impact our business to varying degrees, including provisions that require Medicare Part D plans to cover with $0 in cost sharing the cost of adult vaccines recommended by the U.S. Advisory Committee on Immunization Practices, or ACIP. The IRA also includes provisions that reduce the out-of-pocket cap for Medicare Part D beneficiaries to $2,000 starting in 2025; impose new manufacturer financial liability on certain drugs in Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition, require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation, and delay the rebate rule that would limit the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one or more rare disease designation and for which the only approved indications are for rare diseases or conditions. The effects of the IRA on our business and the healthcare industry in general are not yet known.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">In addition, the One Big Beautiful Bill Act of 2025 imposed significant reductions in Medicaid funding, additional work requirements for certain Medicaid beneficiaries and more frequent eligibility redeterminations. These changes are expected to place increased pressure on state Medicaid budgets and could reduce enrollment, utilization and reimbursement levels for prescription drugs, including our products, which could adversely affect our business.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Trump Administration has issued executive orders and supported proposed regulatory initiatives in 2025 that could have a significant impact on the prices that we, or any collaborators, may receive for any approved products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On May 12, 2025, President Trump signed an executive order directing the Secretary of HHS to set and communicate most-favored-nation (&#8220;MFN&#8221;) price targets to manufacturers and propose a rulemaking plan to impose MFN pricing if &#8220;significant progress&#8221; is not made, and also directing the federal government to support regulatory paths to allow direct-to-patient sales for companies that meet these targets. The executive order further states that the Administration will take additional action (for example, examining whether marketing approvals should be modified or rescinded or considering individual drug importation waiver authorities) should manufacturers fail to offer American consumers the MFN lowest price. In July 2025, President Trump sent letters to certain pharmaceutical companies demanding that these companies extend MFN pricing to Medicaid and newly launched drugs as well as move to direct-to-consumer models priced at MFN pricing, and soliciting binding commitments by September 29, 2025. Since this time, multiple drug manufacturers have announced plans to, for certain of their drugs, lower prices to reflect similar pricing around the world, and to sell these reduced-price drugs on a direct-to-consumer purchasing platform developed by the federal government; however, it is not known what results will occur to the extent the recipients of these letters do not reduce their U.S. prices.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On December 19, 2025, CMS released two proposed rules that would incorporate MFN pricing principles into federal reimbursement for prescription drugs. The first proposal, the Global Benchmark for Efficient Drug Pricing Model (&#8220;GLOBE&#8221;) for Medicare Part B, would require manufacturers of specified single source drugs and sole source biologics to pay incremental rebates based on international benchmark prices, with participation triggered for products meeting CMS&#8217;s spending and eligibility criteria. The second proposal, the Guarding U.S. Medicare Against Rising Drug Costs (&#8220;GUARD&#8221;) model for Medicare Part D, would similarly mandate manufacturer rebates for qualifying sole source drugs where the Medicare net price exceeds an MFN benchmark derived from international reference pricing methodologies. As proposed, GLOBE would begin a five year performance period on October 1, 2026 and GUARD would begin its performance period in 2027. These proposals will likely be subject to legal challenges that could delay their implementation or modify their impact on manufacturer pricing and revenue. Additionally, in November 2025, CMS introduced the GENErating cost Reductions fOr U.S. Medicaid (&#8220;GENEROUS&#8221;) Model, a voluntary MFN framework for manufacturers participating in the Medicaid Drug Rebate Program. Although it is voluntary, the GENEROUS Model could also impact the drug pricing landscape for manufacturers.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Further legislative and regulatory changes under the Affordable Care Act remain possible. It is unknown what form any such changes or any law would take, and how or whether it may affect our business in the future. We expect that changes or additions to the Affordable Care Act, the Medicare and Medicaid programs, allowing the federal government to directly negotiate drug prices and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Individual States in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drugs or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations and prospects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We expect that additional federal, state and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, if approved, or additional pricing pressures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Employees and Human Capital Resources</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2025, we had 14 full-time and part-time employees, of which 4 were located in the U.K., and 10 located in the United States. As of December&#160;31, 2025, 57% of our workforce and 43% of our leadership (at Director level and above) were female. In addition, 14% of our workforce were racially or ethnically diverse. Of our full and part-time employees, 2 have Ph.D. or M.D. degrees, and 6 are engaged in research and clinical development activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. We engage with our employees in multiple ways including through company-wide events, social events and team events. We also have a bonus scheme and equity incentive plan in which all employees are entitled to participate. The principal purposes of our equity incentive plans are to attract, retain and reward personnel through the grant of equity-based compensation awards. We believe that attracting and retaining talent increases shareholder value and furthers the success of our company by motivating our employees to perform to the best of their abilities and achieve our objectives.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We employ individuals based on their experience and ability. We focus on hiring and retaining qualified candidates by promoting a supportive and inclusive working environment for all. We believe that fostering a workforce with a wide range of experiences and backgrounds is a key element to discovering, developing, and bringing transformative therapies to patients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The safety of our workforce, including consultants and visitors to our office/laboratory, has and remains of paramount importance to us. We have a Health and Safety Committee that focuses on implementing policies and training programs to enhance workplace safety. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Carbon emissions</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We have calculated the emissions for the year ended December&#160;31, 2025 and 2024 in tons of carbon dioxide equivalent (&#8220;tCO2e&#8221;). The carbon emissions for our company for the years ended December&#160;31, 2025 and 2024 are as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"><tr><td style="width:1.0%"/><td style="width:27.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Scope</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">tCO2e</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">% Total emissions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">tCO2e</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">% Total emissions </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Scope 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5.41</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6.23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Scope 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">442.94</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">99%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">391.91</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">98%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">448.35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">100%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">398.14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">100%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For clarity, Scope 1 emissions are direct emissions produced from activities owned or controlled by Barinthus Bio. Scope 2 emissions are indirect emissions related to the generation of the electricity consumed and purchased by Barinthus Bio. We have used the most recent evidence or estimates provided by our energy supply partners to generate our disclosure of emissions for the period. Standard emissions factors from the "U.K. Government GHG Conversion Factors for Company Reporting (2025)&#8221; guidance were applied to estimate emissions. Electricity usage at our leased facilities in the United States and U.K. are responsible for a significant amount of our greenhouse gas emissions, with the remainder due to operations conducted within our laboratory. The increase in emissions is primarily attributable to an increase in utilities </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">from activity in the U.S. laboratory and office, offset by a reduction in activity in the U.K. laboratory and office following the reduction in workforce with the wind down of the facility during the year. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We have elected not to include the voluntary disclosure for Scope 3 emissions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December&#160;31, 2025, the split of emissions by geography is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.212%"><tr><td style="width:1.0%"/><td style="width:57.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.351%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.351%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.798%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Scope</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">tCO2e</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">% Total emissions </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Scope 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">U.K.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.78</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:114%">1</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.63</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1.0%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Scope 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">U.K.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">60.27</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">13.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">382.67</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">85.4%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">448.35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">100%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.75pt">Indicates amount less than one percent.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We consider the intensity ratio of tons of carbon dioxide per full-time employee, as a suitable metric for its operations for the years ended December&#160;31, 2025, and 2024 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Ratio</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">tCO2e /employee</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Average employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">tCO2e /employee</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Average employees</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Intensity ratio</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3.24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">123</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The tons of carbon dioxide per employee has increased year on year, primarily as a result of our increased activity in the United States, notwithstanding the reduction in the number of employees that occurred during the year across both sites.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The directors have established that the nominations and corporate governance committee are to have oversight of the assessment and strategy on how to reduce our energy consumption and thereby reducing our carbon footprint.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Available Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We maintain an internet website at https://www.barinthusbio.com/ and make available free of charge through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act of 1934, or the Exchange Act. We make these reports available through our website as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the SEC. You can review our electronically filed reports and other information that we file with the SEC on the SEC&#8217;s web site at http://www.sec.gov. We also make available, free of charge on our website, the reports filed with the SEC by our executive officers, directors and 10% stockholders pursuant to Section 16 under the Exchange Act as soon as reasonably practicable after copies of those filings are provided to us by those persons. In addition, we regularly use our website to post information regarding our business, product development programs and governance, and we encourage investors to use our website, particularly the information in the section titled &#8220;Investors,&#8221; as a source of information about us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The information on our website is not incorporated by reference into this Annual Report and should not be considered to be a part of this Annual Report. Our website address is included in this Annual Report as an inactive technical reference only.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_22"></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1A. Risk Factors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investing in our American Depositary Shares ("ADSs") involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all other information in this report, including our consolidated financial statements and related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; as well as our other filings with the Securities and Exchange Commission. Our business, results of operations, financial condition, and prospects could also be harmed by risks and uncertainties not currently known to us or that we currently do not believe to be material. If any of the risks actually occur, our business, results of operations, financial condition, and prospects could be harmed. In that event, the market price of our ADSs could decline, and you could lose part or all of your investment.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to the Contemplated Transactions with Clywedog</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our failure to complete the Contemplated Transactions would have a material adverse effect on our business, results of operations, financial condition and stock price.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Completion of the Contemplated Transactions is subject to the satisfaction of various conditions, including (i) the effectiveness of a registration statement to register shares of common stock, $0.0001 par value per share, of Topco (the &#8220;Topco Common Stock&#8221;), to be issued in connection with the Combinations; (ii) the absence of any law or order that enjoins, prevents, prohibits, or makes illegal the consummation of the Contemplated Transactions; (iii) approvals by our shareholders of the Scheme Transaction and certain related matters, and sanction by the Court of the Scheme Transaction; (iv) approval by Clywedog&#8217;s stockholders of the Merger Agreement, the Merger and Contemplated Transactions; (v) the approval for listing by Nasdaq of the shares of Topco Common Stock issuable in the Combinations; (vi) certain consents, clearances and expirations or terminations of waiting periods under applicable antitrust laws; (vii) the absence of a material adverse effect with respect to either party; (viii) the completion of the Self-Tender Offer to the extent that Topco elects to commence the Self-Tender Offer; (ix) minimum cash requirements for each party; and (xi) subject to certain materiality and material adverse effect qualifiers, the accuracy of the representatives and warranties of the parties contained in the Merger Agreement and the compliance by each party with the covenants contained in the Merger Agreement. As of the date of this report, the transaction is expected to close in the second quarter of 2026, subject to the satisfaction or waiver of these conditions. There is no assurance that all of the various conditions will be satisfied or waived, or that the Contemplated Transactions will be completed on the proposed terms, within the expected timeframe, or at all.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Contemplated Transactions may be delayed, and may ultimately not be completed, due to a number of factors, including the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">We may fail to obtain the approval of the Scheme Transaction by our shareholders. Despite our board of directors having carefully and thoroughly considered a variety of strategic options and having determined that such strategic options either were unavailable to the Company, or would not provide value to shareholders greater than the value that would be provided in the Contemplated Transactions, we may be unable to secure the requisite approval of our shareholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">We may fail to obtain regulatory approvals from various governmental entities (or conditions, limitations or restrictions may be imposed on such approvals). We cannot provide any assurance that we will not face regulatory hurdles, blocks or delays with respect to the Contemplated Transactions. Material delays in obtaining any required approvals may result in the termination of the Contemplated Transactions, as either party may terminate the Contemplated Transactions if the Contemplated Transactions is not consummated by September 30, 2026, subject to certain extensions as further described in the Merger Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Potential shareholder litigation and other legal and regulatory proceedings may delay or prevent the Contemplated Transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">The parties may fail to satisfy one or more of the conditions to the completion of the Contemplated Transactions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Additional risks if the Contemplated Transactions are not completed include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">to the extent the current market price of our ADSs reflects an assumption that the Contemplated Transactions will be completed, the price of our ADSs could decrease; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">investor confidence could decline, stockholder litigation could be brought against us, relationships with existing and prospective customers, distributors, retailers, service providers, investors, lenders and other business partners may be adversely impacted, we may be unable to retain key personnel, and profitability may be adversely impacted due to costs incurred in connection with the Contemplated Transactions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The failure to successfully integrate our business with that of Clywedog in the expected timeframe would adversely affect our future business and financial performance and the value of our stockholders&#8217; investment following the Combinations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The combination of two independent companies is a complex, costly and time-consuming process. As a result, Topco will be required to devote significant management attention and resources to integrate our business practices and operations with those of Clywedog. The integration process may disrupt the business of either or both of the companies and, if implemented ineffectively, could preclude realization of the full benefits expected by us and our shareholders from the Contemplated Transactions. The failure of Topco to meet the challenges involved in successfully integrating our operations with those of Clywedog or otherwise to realize the anticipated benefits of the Contemplated Transactions could cause an interruption of the activities of Topco and could seriously harm its results of operations. In addition, the overall integration of the two companies may result in material unanticipated problems, expenses, liabilities, competitive responses, loss of customer relationships and diversion of management&#8217;s attention, and may cause Topco&#8217;s stock price to decline. The difficulties of combining our operations with those of Clywedog include, among others:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">managing a significantly larger company;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">coordinating geographically separate organizations, including extensive international operations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the potential diversion of management&#8217;s focus and resources from other strategic opportunities and from operational matters;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">performance shortfalls at one or both of the companies as a result of the diversion of management&#8217;s attention caused by completing the Combinations and integrating the companies&#8217; operations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">aligning and executing the strategy of the combined companies;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">retaining existing business relationships and executing new strategic or commercial relationships;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">maintaining employee morale and retaining key management and other employees;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the disruption of, or the loss of momentum in, each company&#8217;s ongoing business or inconsistencies in standards, controls, systems, procedures and policies;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">integrating two unique business cultures, which may prove to be incompatible;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the possibility of faulty assumptions underlying expectations regarding the integration process;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">consolidating corporate and administrative infrastructures and eliminating duplicative operations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">integrating IT, communications and other systems;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">changes in applicable laws and regulations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">managing tax costs or inefficiencies associated with integrating the operations of each company;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">unforeseen expenses or delays associated with the Contemplated Transactions; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">taking actions that may be required in connection with obtaining regulatory approvals.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Many of these factors will be outside of our control and any one of them could result in increased costs and diversion of management&#8217;s time and energy, which could materially impact our business, financial condition and results of operations </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">as Topco. In addition, even if our operations are integrated successfully with those of Clywedog, Topco may not realize the full benefits of the Contemplated Transactions, including the synergies, cost savings or growth opportunities that we and our shareholders expect. These benefits may not be achieved within the anticipated timeframe, or at all. As a result, we cannot assure our shareholders that the Contemplated Transactions will be completed successfully, that the integration will be accomplished within the expected timeframe, or that Topco will realize the full benefits anticipated from the Contemplated Transactions, any of which could adversely affect the value of our shareholders&#8217; investment.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our shareholders and Clywedog&#8217;s stockholders may not realize a benefit from the Contemplated Transactions commensurate with the ownership dilution they will experience in connection with the Contemplated Transactions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If Topco is unable to realize the full strategic and financial benefits currently anticipated from the Contemplated Transactions, our shareholders and Clywedog&#8217;s stockholders will have experienced substantial dilution of their ownership interests without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent Topco is able to realize only part of the strategic and financial benefits currently anticipated from the Contemplated Transactions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our shareholders and Clywedog&#8217;s stockholders will generally have a reduced ownership and voting interest in, and will exercise less influence over the management of, Topco following the completion of the Contemplated Transactions as compared to their current ownership and voting interests in the respective companies.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">After the completion of the Contemplated Transactions, our current shareholders and the current stockholders of Clywedog will generally own a smaller percentage of Topco than their ownership of their respective companies prior to the Contemplated Transactions. Immediately after the Contemplated Transactions, our shareholders as of immediately prior to the Scheme Transaction are expected to own approximately 34% of the outstanding shares of Topco and former Clywedog stockholders are expected to own approximately 66% of the outstanding shares of Topco.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">During the period prior to the closing of the Contemplated Transactions, our business is exposed to certain inherent risks due to the effect of the announcement or pendency of the Contemplated Transactions on our business relationships, financial condition, operating results and business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Inherent risks to our business during the period prior to the closing of the Contemplated Transactions that may adversely affect our business relationships, financial condition, operating results and business include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the possibility of disruption to our business and operations, including diversion of management attention and resources;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the inability to attract and retain key personnel, and the possibility that our current employees could be distracted, and their productivity decline as a result, due to uncertainty regarding the Contemplated Transactions;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the inability to pursue alternative business opportunities or make changes to our business pending the completion of the Contemplated Transactions, and other restrictions on our ability to conduct our business included in the Merger Agreement;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our inability to solicit other acquisition proposals during the pendency of the Contemplated Transactions;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the amount of the costs, fees, expenses and charges related to the Contemplated Transactions and the Contemplated Transactions; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">other developments beyond our control, including, but not limited to, changes in domestic or global economic conditions that may affect the timing or success of the Contemplated Transactions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Litigation may arise in connection with the Contemplated Transactions, which could be costly, prevent consummation of the Contemplated Transactions, divert management&#8217;s attention and otherwise materially harm our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Regardless of the outcome of any future litigation related to the Contemplated Transactions, such litigation may be time-consuming and expensive and may distract our management from running the day-to-day operations of our business. The litigation costs and diversion of management&#8217;s attention and resources to address the claims and counterclaims in any litigation related to the Contemplated Transactions may materially adversely affect our business, financial condition and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">operating results, including by decreasing our cash reserves for related expenses. If the Contemplated Transactions are not consummated, for any reason, litigation could be filed in connection with the failure to consummate the Contemplated Transactions. Any litigation related to the Contemplated Transactions may result in negative publicity or an unfavorable impression of our company, which could adversely affect the price of our common stock, impair our ability to recruit or retain employees, damage our relationships with our clients, or otherwise materially harm our operations and financial performance.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are subject to restrictions on our business activities under the Merger Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">While the Merger Agreement is in effect, we are generally required to conduct our business in the ordinary course consistent with past practice, and are restricted from taking certain actions without Clywedog&#8217;s prior consent, which is not to be unreasonably withheld, conditioned or delayed. These limitations include, among other things, certain restrictions on our ability to amend our organizational documents, acquire other businesses and assets, dispose of our assets, make investments, repurchase, reclassify or issue securities, make loans, pay dividends, incur indebtedness, make capital expenditures, enter into, amend or terminate certain contracts, change accounting policies or procedures, initiate or settle certain litigation, change tax classifications and elections, or take certain actions relating to intellectual property.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Our Financial Position and Capital Needs</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We are a clinical-stage biopharmaceutical company with a limited operating history. We have incurred significant losses since inception. We expect to incur losses for at least the next several&#160;years and may never achieve or maintain profitability.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We are a clinical-stage biopharmaceutical company with a limited operating history, and we are in the early stages of our product development efforts. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, obtain marketing authorization and become commercially viable. Currently, we have no products approved for commercial sale and are not generating any revenue from product sales. To date, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, undertaking preclinical studies and clinical trials of our product candidates, securing related intellectual property rights and conducting discovery, research and development activities for our programs. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses each year since inception through to December 31, 2021. For the year ended December 31, 2022, we generated net income of $5.3 million, primarily as a result of revenues (royalties/milestone payments) arising from AstraZeneca sales of Vaxzevria and our agreement with OUI, as amended (the "OUI License Agreement"). In December 2025, we delivered written notice to OUI to terminate the OUI License Agreement. The OUI License Agreement will remain in effect during the three-month notice period and terminated on March 2, 2026 in accordance with its terms. For the years ending December 31, 2025 and 2024, we incurred net losses of $66.5 million and $61.2 million, respectively. As of December 31, 2025 and 2024, we had an accumulated deficit of $304.1&#160;million and $237.7 million, respectively, and we do not currently expect profits or positive cash flows from operations in the foreseeable future. We anticipate that our expenses will increase substantially if, and as we:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">pursue the clinical and preclinical development of our current product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">use our technologies to advance additional product candidates into preclinical and clinical development;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">seek marketing authorizations for product candidates that successfully complete clinical trials, if any;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">attract, hire and retain additional clinical, regulatory, quality control and other personnel;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conduct preclinical studies and clinical trials for our current and future product candidates based on our proprietary synthetic platform, SNAP-TI and our other technologies;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">establish our manufacturing capabilities through third parties or by ourselves and scale-up manufacturing to provide adequate supply for clinical trials and commercialization;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">expand, maintain, protect and enforce our intellectual property portfolio;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or through a selected partner;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">acquire or in-license other product candidates and technologies for development and commercialization; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">incur additional legal, accounting and other expenses in operating our business, including the additional costs associated with operating as a public company.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development costs and other expenditures to develop and market additional product candidates and we may never generate revenue that is significant or large enough to achieve profitability. We may also encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital unless and until such losses are eliminated by revenue.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Accordingly, our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause you to lose all or part of your investment.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We have not yet generated any material revenue from our current product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our ability to become profitable depends upon our ability to generate revenue. We do not expect to generate significant revenue from our current or future product candidates unless or until we successfully complete clinical development and obtain marketing authorization for, and then successfully commercialize, at least one of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Certain of our product candidates are in the preclinical stages of development and will require additional preclinical studies, and all of our product candidates will require additional clinical development, regulatory review and approval, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. We have not yet administered certain of our product candidates to humans and, as such, we face significant translational risk as our product candidates advance into and through the clinical stage, as promising results in preclinical studies may not be replicated in subsequent clinical trials, and testing on animals may not accurately predict human experience. Our ability to generate revenue depends on a number of factors, including, but not limited to:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">timely completion of our manufacturing, preclinical studies and clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">delays out of our control, such as participant willingness to enroll in our clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our ability to complete INDs, enabling trials and successfully submit INDs or comparable applications, for our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">whether we are required by the FDA, the EMA, or the MHRA or similar foreign regulatory authorities, to conduct additional clinical trials or other studies beyond those planned to support the approval and commercialization of our product candidates or any future product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, potency, purity, efficacy and acceptable risk to benefit profile of our product candidates or any future product candidates and such regulatory authorities&#8217; acceptance of our development strategy;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future product candidates, if any;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the willingness of physicians, operators of clinics and patients to utilize or adopt any of our product candidates or future product candidates over alternative or more conventional approaches, including immune modulators, monoclonal antibodies, CRISPR editing, or other small molecules, RNA, DNA, nanoparticle, peptide, protein, other technologies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the actual and perceived availability, cost, risk profile and side effects and efficacy of our product candidates, if approved, relative to existing and future alternative immunotherapies and competitive product candidates and technologies; our ability and the ability of third parties with whom we contract to manufacture adequate clinical and commercial supplies of our product candidates or any future product candidates, remain in good standing with regulatory authorities and develop, validate and maintain commercially viable manufacturing processes that are compliant with cGMP;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our ability to successfully develop a commercial strategy and thereafter commercialize our product candidates or any future product candidates in the United States and internationally, if approved for marketing, reimbursement, sale and distribution in such countries and territories, whether alone or in collaboration with others;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">patient demand for our product candidates and any future product candidates, if approved;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our ability to establish, maintain, protect and enforce intellectual property rights in and to our product candidates or any future product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the ability of our licensees and collaborators to develop and commercialize our products effectively;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the possibility that immune tolerance with our SNAP-TI platform may not translate into clinical benefit; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the increased costs and complexities associated with manufacturing.</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Many of the factors listed above are beyond our control and could cause us to experience significant delays or prevent us from obtaining marketing authorizations for, or commercializing, our product candidates. Even if we are able to commercialize our product candidates, we may not achieve profitability soon after generating product sales, if ever. If we are unable to generate sufficient revenue through the sale of our product candidates or any future product candidates, we may be unable to continue operations without continued funding.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If we engage in acquisitions or future strategic partnerships, this may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We may evaluate acquisitions and strategic partnerships in the future, including licensing or acquiring complementary product candidates, intellectual property rights, technologies or businesses. Any acquisition or strategic partnership may entail numerous risks, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">increased operating expenses and cash requirements;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the assumption of indebtedness or contingent liabilities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the issuance of our equity securities which would result in dilution to our existing shareholders;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">assimilation of operations, intellectual property, products and product candidates of an acquired company, including difficulties associated with integrating new personnel;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such an acquisition or strategic partnership;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates to achieve marketing authorizations; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks and uncertainties arising from disagreements or other relationship-related matters with the other party to such a transaction; and </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a failure to generate revenue from acquired intellectual property, technology and/or products sufficient to meet our objectives or even to offset the associated transaction and maintenance costs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In addition, we may assume or incur debt obligations, incur large one-time expenses and/or acquire intangible assets that could result in significant future amortization expense.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We are a clinical-stage biopharmaceutical company with no approved products and a limited operating history. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, filing patent applications, identifying potential product candidates, undertaking preclinical studies, in-licensing product candidates for development, and establishing arrangements with third parties for the manufacture of initial quantities of our product candidates and component materials, as well as sponsoring and conducting clinical trials up to Phase 2b. We have not yet demonstrated our ability to successfully complete clinical trials beyond Phase 2b, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition at some point from a company with a research and development focus to a company capable of supporting additional commercial activities. We may not be successful in such a transition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We are currently advancing current and future product candidates based on our proprietary synthetic platform, SNAP-TI, and our other technologies through clinical development. Developing and commercializing products for therapeutic indications is expensive, and we do not expect to generate meaningful product revenues in the foreseeable future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As of December&#160;31, 2025, our cash, cash equivalents and restricted cash were $71.9 million. Based on our current business plan, our management believes that we have sufficient cash and other financial resources to support our operations for at least the next 12 months, without additional financing. Our fundraising efforts to raise additional capital may divert our management from their day-to-day activities, which may adversely affect our ability to develop our platforms. In addition, we cannot guarantee that financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our existing shareholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute our existing stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If we are unable to obtain funding on a timely basis, we may be required to revise our current business plan and strategy, which may result in us significantly curtailing, delaying or discontinuing one or more of our clinical trials, decreasing headcount or may result in our being unable to expand our operations or otherwise capitalize on our business opportunities. As a result, our business, financial condition and results of operations could be materially affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Raising additional capital may cause dilution to our existing shareholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We expect our expenses to increase in connection with our planned operations. Unless and until we can generate a substantial amount of revenue from our product candidates, we expect to finance our future cash needs through public or private equity offerings, debt financings, collaborations, licensing arrangements or other sources, or any combination of the foregoing. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">To the extent that we raise additional capital through the sale of ordinary shares, convertible securities or other equity securities, your ownership interest may be diluted, and the terms of these securities could include liquidation or other preferences and anti-dilution protections that could adversely affect your rights as a common shareholder. In addition, debt financing, if available, may result in fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, creating liens, redeeming shares or declaring dividends, that could adversely impact our ability to conduct our business. In addition, securing financing could require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management&#8217;s ability to oversee the development of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If we raise additional funds through collaborations, strategic alliances, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we would be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to third parties to develop and market our product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may require substantial additional funding in the future. If we are unable to raise capital when needed, we would be compelled to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Since our inception, we have invested a significant portion of our efforts and financial resources in research and development activities for our platforms and our product candidates developed using our platforms. Preclinical studies, clinical trials and additional research and development activities will require substantial funds to complete. We expect the research and development expenses for our programs to increase in parallel with the ongoing activities, particularly as we continue our preclinical and clinical development activities to identify new product candidates and conduct clinical trials of, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">product candidates, we expect to incur significant commercialization expenses related to product launch, product sales, marketing, manufacturing and distribution. Furthermore, we expect to incur significant additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">However, we have estimated our current additional funding needs based on assumptions that may prove to be wrong. Additionally, changing circumstances may cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We cannot be certain that additional funding will be available on acceptable terms, or at all. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of public or private equity offerings, debt financings, governmental funding, collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties. If we are unable to raise capital or generate revenue when needed or on attractive terms, we would be forced to delay, reduce or eliminate our discovery and preclinical development programs or any future commercialization efforts.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We had cash, cash equivalents and restricted cash of $71.9 million as of December&#160;31, 2025. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the scope, progress, results and costs of researching and developing our current and future product candidates and programs, and of conducting preclinical studies and clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the number and development requirements of other product candidates that we may pursue, and of other indications for our current product candidates that we may pursue;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the stability, scale and yield of future manufacturing processes as we scale-up production and formulation of our product candidates either internally or externally for later stages of development and commercialization;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the timing of, success achieved and the costs involved in obtaining regulatory and marketing approvals and developing our ability to establish license or sale transactions and/or sales and marketing capabilities, if any, for our current and future product candidates if clinical trials and approval processes are successful;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our ability to establish and maintain collaborations, strategic licensing or other arrangements and the financial terms of such agreements;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the costs of future commercialization activities, including product launch, product sales, marketing, manufacturing and distribution, for any of our current and future product candidates for which we receive marketing approval;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the timing, receipt and amount of commercial sales revenues, milestones or royalties or other income from, our future products, should any of our product candidates receive marketing approval;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, enforcing and protecting our intellectual property rights and defending intellectual property-related claims including litigation costs and any damages awarded in such litigation; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence and success or otherwise of competing autoimmune disease therapies and other market developments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Identifying potential product candidates, manufacturing them and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes&#160;years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many&#160;years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Recent volatility in capital markets and lower market prices for many securities may affect our ability to access new capital through sales of shares of our ordinary shares or issuance of indebtedness, which may harm our liquidity, limit our ability to grow our business, pursue acquisitions or improve our operating infrastructure and restrict our ability to compete in our markets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our operations consume substantial amounts of cash, and we intend to continue to make significant investments to support our business growth, respond to business challenges or opportunities, develop new product candidates, maintain optimal levels of personnel, enhance our operating infrastructure, and potentially acquire complementary businesses and technologies. Our future capital requirements may be significantly different from our current estimates and will depend on many factors, including the need to:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">finance unanticipated working capital requirements;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">develop or enhance our technological infrastructure and our existing solutions;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">pursue acquisitions or other strategic relationships; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">respond to competitive pressures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accordingly, we may need to pursue equity or debt financings to meet our capital needs. With uncertainty in the capital markets and other factors, such financing may not be available on terms favorable to us or at all. If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our ordinary shares. Any debt financing secured by us in the future could involve additional restrictive covenants relating to our capital-raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. If we are unable to obtain adequate financing or financing on terms satisfactory to us, we could face significant limitations on our ability to invest in our operations and otherwise suffer harm to our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and its financial condition and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Actual national and international events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial institutions with which we have financial arrangements directly, or the financial services industry or the global economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry or the life sciences industry. These factors could involve financial institutions or financial services industry companies with which we have financial or business relationships, but could also include factors involving financial markets or the financial services industry or life sciences industry generally. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to, the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">delays, inability or reductions in our ability to refund, roll over or extend the maturity of, or enter into new credit facilities or other working capital resources;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">potential or actual breach of contractual obligations that require us to maintain letters of credit or other credit support arrangements; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In addition, any further deterioration in the macroeconomic economy or financial services industry or life sciences industry could lead to losses or defaults by our third-party manufacturers or suppliers, which in turn, could have a material adverse effect on our current and/or projected business operations and results of operations and financial condition. For example, a third-party manufacturer or supplier may default under their agreements with us, become insolvent or declare bankruptcy, or determine that they will no longer deal with us as a customer. In addition, a third-party manufacturer or supplier could be adversely affected by any of the liquidity or other risks that are described above as factors that could result in material adverse impacts on us, including but not limited to delayed access or loss of access to uninsured deposits or loss of the ability to draw on existing credit facilities involving a troubled or failed financial institution. Any third-party manufacturer or supplier bankruptcy or insolvency, or any breach or default by a third-party manufacturer or supplier, or the loss of any significant third-party manufacturer or supplier relationships, could result in material losses to us and may have a material adverse impact on our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Our Business and Industry and Risks Related to Clinical Development</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If we are unable to advance our current or future product candidates into and through clinical trials, obtain marketing approval or reimbursement and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">All of our product candidates are in early stages of development, including our lead product candidate VTP-1000, and as such will require extensive preclinical and clinical testing, as applicable. Product candidates may not meet targeted clinical or safety endpoints during clinical trials such as the MVA-based influenza vaccine candidate, VTP-100, which did not meet defined primary clinical endpoints in two concurrent Phase 2b trials and we subsequently discontinued further development of this program. Our ability to generate product revenues, which we do not expect to occur for several years, if ever, will depend heavily on the successful development and eventual commercialization or out-license of the product candidates we develop, which may never occur. Before we are able to generate any revenues from product sales, our current product candidates, and any future product candidates we develop, will require additional preclinical and clinical development, management of preclinical, clinical, and manufacturing activities, marketing approval in the United States and other markets, the demonstration of effectiveness to pricing and reimbursement authorities, the obtaining of sufficient manufacturing supply of product for both clinical development and commercial sales, the building of a commercial organization, and substantial investment in significant marketing efforts for product launch. The success of our current and future product candidates will depend on several factors, including the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">successful completion, with sufficient safety and efficacy profiles, of preclinical studies and clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">acceptance of INDs or equivalent clinical trial authorizations in other regions for our planned clinical trials or future clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">successful enrollment and completion of our ongoing and future clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">sufficient data from our clinical program that support an acceptable risk-benefit profile of our product candidates in the intended populations;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">receipt and maintenance of marketing authorizations from applicable regulatory authorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">scale-up of our manufacturing processes and formulation of our product candidates for later stages of development and commercialization;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">establishing our own manufacturing capabilities or agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidate is approved;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">ability to develop product candidate designs and formulations that provide sufficient genetic and thermal stability for long term storage and shipment to meet market requirements;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">entry into collaborations, where needed, to further the development of our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">successful launch of our product candidates, if and when approved to generate product sales;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">acceptance of the product candidate&#8217;s benefits and uses, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the prevalence and severity of adverse events experienced with our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">maintaining a continued acceptable benefit/risk profile of the product candidates following authorization;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">effectively competing with other therapies, including new therapies that may be developed and approved;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">qualifying for, maintaining, enforcing, and defending intellectual property rights and claims; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the risk that foreign regulatory authorities may not authorize our clinical trial protocols and other clinical trial documentation, including manufacturing documentation, even when previously authorized by the FDA, EMA or MHRA, which could lead to a delay in starting such clinical trials. For example, our HBV002 clinical trial conducted in South Korea experienced delays due to additional regulatory review of our clinical protocol. We have limited experience obtaining such approvals in foreign jurisdictions and therefore may need more time to navigate the regulatory process as a result.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize the product candidates we develop, which would materially harm our business. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Clinical development involves a lengthy and expensive process with uncertain outcomes, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results. We may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials on the expected timelines, if at all. If our preclinical studies and clinical trials are not sufficient to support marketing authorization of any of our product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We may experience delays in obtaining the FDA&#8217;s or other regulatory agencies authorization to initiate clinical trials under future INDs, completing ongoing preclinical studies of our other product candidates, and initiating our planned preclinical studies and clinical trials. Additionally, we cannot be certain that preclinical studies or clinical trials for our product candidates will begin on time, not require redesign, enroll an adequate number of participants on time, or be completed on schedule, if at all. We may experience numerous adverse or unforeseen events during, or as a result of, preclinical studies and clinical trials that could delay or prevent our ability to receive marketing authorization or commercialize our product candidates, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">new treatments may become standard of care during the process of completing a clinical trial, which may impact the initial clinical trial design or future patient care pathways;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">significant changes in relevant regulatory requirements may cause a delay in the start of a clinical trial, due to additional requirements needing to be met;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon our research efforts for our other product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">clinical trials of our product candidates may not produce differentiated or clinically significant results across the disease areas that we focus on;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the number of participants required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of our clinical trials at a higher rate than we anticipate;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our third-party contractors may fail to comply with regulatory requirements, fail to maintain adequate quality controls or be unable to provide us with sufficient or timely product supply to conduct and complete preclinical studies or clinical trials of our product candidates in a timely manner, or at all;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we or our investigators might have to suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">undesirable side effects or other unexpected characteristics or a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the cost of clinical trials of our product candidates may be greater than we anticipate, for example, if we experience delays or challenges in identifying participants with the eligibility criteria required for our clinical trials, we may have to reimburse sites for the cost of testing of additional participants in order to encourage enrollment of additional participants;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the quality of our product candidates or other materials necessary to conduct preclinical studies or clinical trials of our product candidates may be insufficient or inadequate, and any transfer of manufacturing activities may require unforeseen manufacturing or formulation changes;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">future collaborators may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In addition, even after any of our product candidates obtain regulatory marketing authorization, the announcement of adverse events observed in individuals who receive these products may impact public perception and may result in increased regulatory scrutiny across our platform. If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only moderately positive or if there are safety concerns, our business and results of operations may be adversely affected and we may incur significant additional costs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs, or ethics committees of the institutions in which such clinical trials are being conducted, or by the FDA or other regulatory authorities, or suspended or terminated based on recommendations by the Data Safety Monitoring Board or equivalent for such clinical trial.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the product candidates, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, any disclosure of negative data of clinical trials being conducted by our collaborators could have an adverse impact on our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moreover, principal investigators for our future clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the clinical trial. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If we experience delays in the completion of any preclinical study or clinical trial of our product candidates, or our preclinical studies or clinical trials are terminated, the commercial prospects of our product candidates may be harmed, and our ability to generate revenues from any of these product candidates will be delayed or not realized at all. In addition, any delays in completing our preclinical studies or clinical trials may increase our costs, slow down our product candidate development and authorization procedure and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing authorization for our product candidates. If one or more of our product candidates generally prove to be ineffective, unsafe or commercially unviable, this would have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Interim, &#8220;topline,&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more participant data becomes available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">From time to time, we may publicly disclose preliminary or "topline" data from our preclinical studies and clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change, following a more comprehensive review of the more complete data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies or clinical trials, or different conclusions or considerations may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data is available. From time to time, we may also disclose interim data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues and more participant data become available or as participants from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our ADSs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Further, others, including regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and shareholders may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If the interim, topline, or preliminary data that we report differ from more complete results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain marketing authorization for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our product candidates are based on a novel approach to the treatment of autoimmunity, which makes it difficult to predict the time and cost of product candidate development.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We have concentrated our research and development efforts on components of our proprietary platforms to develop product candidates that promote immune tolerance for suppressing unwanted inflammation. Our future success depends on the successful development of these platforms. There can be no assurance that any development problems we experience in the future will not cause significant delays or unanticipated costs, or that such development problems can be solved. Should we encounter development problems, including unfavorable preclinical or clinical trial results, the FDA or foreign regulatory authorities may refuse to approve our product candidates, or may require additional information, tests, or trials, which could significantly delay product development and significantly increase our development costs. Moreover, even if we are able to provide the requested information or trials to the FDA, there would be no guarantee that the FDA would accept them or approve our product candidates. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process, or developing other testing and manufacturing methods, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In addition, the clinical trial requirements of the FDA and comparable foreign regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The FDA and comparable foreign regulatory authorities have limited experience with the approval of novel immunotherapies. Any novel immunotherapies that are approved may be subject to extensive post- approval regulatory requirements, including requirements pertaining to manufacturing, distribution and promotion. We may need to devote significant time and resources to compliance with these requirements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Difficulty in enrolling participants could delay or prevent clinical trials of our product candidates and prevent us from realizing the full commercial potential of any products we may develop.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Identifying and qualifying participants to participate in clinical trials of our product candidates is critical to our success. The timing of completion of our clinical trials depends in part on the speed at which we can recruit participants to participate in testing our product candidates, and we may experience delays in our clinical trials if we encounter difficulties in enrollment. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible participants to participate in these trials as required by the FDA, the EMA or other foreign regulatory authorities. We cannot anticipate the next pandemic or how that may or may not impact future clinical trial enrollment. In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates, and participants who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The enrollment of patients and participants further depends on many factors, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the phase of clinical testing;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the proximity of participants to clinical trial sites;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the increased inconvenience to patients by participating in a clinical trial, such as increased doctor visits, missed work, travel costs and time;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the design of the clinical trial, including the number of site visits, whether the clinical trial includes a placebo arm and invasive assessments required;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our ability to obtain and maintain participant consents;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">reporting of the preliminary results of any of our clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the risk that participants enrolled in clinical trials will drop out of the clinical trials before clinical trial completion; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">factors we may not be able to control, such as potential pandemics that may limit participants, principal investigators or staff or clinical site availability.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of participants who are available for our clinical trials at such clinical trial sites. Moreover, because certain of our product candidates represent a departure from more commonly used methods for treatment of disease, and because certain of our product candidates have not been tested in humans before, potential participants and their doctors may be inclined to use conventional therapies, rather than enroll participants in a future clinical trial.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If we experience delays in the completion or termination of any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenue from any of these product candidates could be delayed or prevented.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our product candidates may cause serious adverse events, serious side effects or have other properties that could halt their clinical development, prevent their marketing authorization, require expansion of the trial size, limit their commercial potential or result in significant negative consequences.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Serious side effects caused by our product candidates could cause us or regulatory authorities, including IRBs and ethics committees, to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of marketing authorization by the FDA, the EMA or other comparable foreign regulatory authorities. Further, clinical trials by their nature utilize a sample of the potential patient population. Because of our dose escalation design for our clinical trials, undesirable side effects in initial cohorts could also result in the need to expand the size of our clinical trials, increasing the expected costs and timeline of our clinical trials. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. If we do observe serious side effects in our clinical trials, our ongoing clinical trials may be halted or put on clinical hold prior to completion if there is an unacceptable safety risk for participants.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If unacceptable toxicities arise in the development of our product candidates, we could suspend or terminate our trials or the FDA, the EMA or other comparable foreign regulatory authorities, or local regulatory authorities such as IRBs or ethics committees, could order us to cease clinical trials. Competent national health authorities, such as the FDA, could also deny approval of our product candidates for any or all targeted indications and if an approval is granted for an indication, the regulatory authority may require us to include a warning in the patient information leaflet. Even if the side effects presented do not preclude the product from obtaining or maintaining marketing authorization, treatment-related side effects could also affect participant recruitment for a clinical trial, or the ability of enrolled participants to complete their participation in a clinical trial or result in potential product liability claims, particularly if they have not been described in the patient information leaflet. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Our Approach</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">The market opportunities for certain of our product candidates may be relatively small as it may be limited to those patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Immunotherapies for treating patients with autoimmune and other inflammatory diseases are sometimes staged based on disease severity or may be characterized by line of therapy (first line, second line, third line, fourth line, etc.), and the regulatory authorities, including the FDA, often approve new therapies initially only for a particular line or lines of use. Our product candidate VTP-1000 based on SNAP-TI is at an early stage of development and there is currently uncertainty as to how the may fit into existing treatment paradigms. We expect to seek approval of VTP-1000 as a first line therapy, but FDA or other regulatory authorities may disagree with this plan, and we may need to seek approval for use as a second or later line of therapy.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our projections of both the number of people who have the disease that we are targeting, as well as the subset of people with these conditions in a position to receive a particular line of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, commissioned reports, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new therapies may change the estimated incidence or prevalence of these conditions. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Even if we obtain significant market share for our product candidates within our addressable patient population, because the potential target populations are small, we may never achieve profitability without obtaining marketing authorization for additional indications, including use as first or second line therapy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Negative developments in the field of immunotherapeutics could damage public perception of any of our product candidates and negatively affect our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our product candidates will depend in part on public acceptance of the use of immunotherapies and nanoparticle-based antigen-delivery platforms. Adverse events in clinical trials of VTP-1000, or in clinical trials of similar products developed by others and the resulting publicity, as well as any other negative developments in the field of immunotherapeutics that may occur in the future, including in connection with competitor therapies, could result in a decrease in demand for any product candidates that we may develop. These events could also result in the suspension, discontinuation, or clinical hold of or modification to our clinical trials. If public perception is influenced by claims that the use of immunotherapies is unsafe, whether related to our therapies or those of our competitors, our product candidates may not be accepted by the general public or the medical community and potential clinical trial participants may be discouraged from enrolling in our clinical trials. In addition, responses by national or state governments to negative public perception may result in new legislation or regulations that could limit our ability to develop or commercialize any product candidates, obtain or maintain marketing authorization or otherwise achieve profitability. More restrictive statutory regimes, government regulations or negative public opinion would have an adverse effect on our business, financial condition, prospects and results of operations and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. As a result, we may not be able to continue or may be delayed in conducting our development programs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">VTP-1000 utilizes SNAP-TI to induce immune tolerance. Adverse developments in clinical trials of other immunotherapy products that promote antigen-specific immune tolerance, may result in a disproportionately negative effect for our platform, as compared to other products within the I&amp;I field that do not rely on antigen-specific immune tolerance. Future negative developments in the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our products. Any increased scrutiny could delay or increase the costs of obtaining marketing approval for our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify and successfully commercialize additional product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Part&#160;of our strategy involves researching and developing novel product candidates. We have developed a pipeline of product candidates and intend to pursue clinical development of additional product candidates. The process by which we identify product candidates may fail to yield product candidates for clinical development for a number of reasons, including those discussed in these risk factors and also:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we may not be able to assemble sufficient resources to acquire or discover additional product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">competitors may develop alternatives that render our potential product candidates obsolete or less attractive;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">potential product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">potential product candidates may, on further study, be shown to have harmful side effects, toxicities or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">potential product candidates may not be effective in treating their targeted diseases or symptoms;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the market for a potential product candidate may change so that the continued development of that product candidate is no longer reasonable;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a potential product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the regulatory pathway for a potential product candidate is highly complex and difficult to navigate successfully or economically.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Developing, obtaining marketing authorization for and commercializing additional product candidates will require substantial additional funding and is prone to the risks of failure inherent in all medicinal product development. We cannot provide you any assurance that we will be able to successfully advance any of these additional product candidates through the development process, which is a risk that applies to all medicinal product development.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We may choose to focus our efforts on and allocate resources to a potential product candidate that ultimately proves to be unsuccessful, or to license or purchase a marketed product that does not meet our financial expectations. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases that may later prove to have greater commercial potential, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to retain sole development and commercialization rights. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products because of the risks inherent in conducting clinical trials. If we are unable to evaluate the commercial potential or target market for a particular product candidate, identify and successfully commercialize additional suitable product candidates, this would adversely impact our business strategy and our financial position.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Sales, Marketing and Competition</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We face substantial competition in an environment of rapid technological change, which may result in others discovering, developing, obtaining marketing authorization approval or commercializing products before or more successfully than we do, which may adversely affect our financial condition and our ability to successfully market or commercialize our product candidates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries utilize rapidly advancing technologies and are characterized by intense competition. While we believe that our scientific knowledge, platform technology and development expertise provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceuticals, specialty pharmaceuticals and biotechnology companies, academic institutions and government agencies, as well as public and private research institutes that conduct research, development, manufacturing and commercialization. Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, marketing authorizations and product marketing than we do. In addition, many of these competitors are active in seeking patent protection and licensing arrangements in anticipation of collecting milestone payments and royalties for use of technology that they have developed. Our competitors may compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and participant registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result, our competitors may discover, develop, license or commercialize products before or more successfully than we do.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. Specifically, we expect that our product candidates based on SNAP-TI will compete against alternative or more conventional approaches, including anti-inflammatory compounds, monoclonal antibodies against cytokines or other pathways, immune cell depletion regimens (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, antibodies, CAR-T cells and T cell engagers) immunomodulatory small molecules, transgenic T cells, genetic therapies and other antigen-specific immune tolerance therapies based on proteins, DNA, RNA and peptides or other technologies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidates are approved for the indications for which we are currently conducting or planning clinical trials, they will likely compete with the competitor products mentioned above and with other products that are currently in development. Key product features that would affect our ability to effectively compete with other therapeutics include the safety, efficacy, formulation, stability, and convenience of our products. Our competitors may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. Our competitors may also obtain marketing authorizations from the FDA or other regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to the Development of Our Product Candidates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our preclinical studies and clinical trials may fail to demonstrate adequately the safety, potency, purity, and efficacy of any of our product candidates, which would prevent or delay development, marketing authorization and commercialization. Furthermore, success in preclinical studies or clinical trials may not be indicative of results in future clinical trials for the same or other product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing authorization for the commercial sale of our product candidates, we must demonstrate the safety, purity and potency of our investigational biologics and drugs for use in each target indication through lengthy, complex and expensive preclinical studies and clinical trials. Preclinical and clinical testing is expensive and can take many&#160;years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the preclinical study and clinical trial processes, and, because our product candidates are in an early stage of development, there is a high risk of failure and we may never succeed in developing marketable products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Although product candidates may demonstrate promising results in preclinical studies and early clinical trials, they may not prove to be effective in subsequent clinical trials. For example, testing on animals occurs under different conditions than testing in humans and therefore, the results of animal studies may not accurately predict human experience. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through preclinical studies and clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Product candidates in later stages of clinical trials may fail to show the desired risk-benefit profile despite having progressed through preclinical studies and initial clinical trials. Likewise, early, smaller-scale clinical trials may not be predictive of eventual safety or effectiveness in large-scale pivotal clinical trials. For example, VTP-100 demonstrated tolerability and immunogenicity during small Phase 1 clinical trials but did not demonstrate sufficient clinical activity during adequately powered Phase 2b clinical trials to warrant continued development of this product candidate. A number of companies in the biopharmaceutical industry have suffered significant setbacks in later phase clinical trials due to lack of potency or efficacy, insufficient durability of potency or efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. The vast majority of product candidates that commence preclinical studies and early phase clinical trials are never approved as products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any preclinical studies or clinical trials that we may conduct may not demonstrate the safety, potency, purity and efficacy necessary to obtain regulatory authorization to market our product candidates. If the results of our ongoing or future preclinical studies and clinical trials are inconclusive with respect to the safety, potency, purity, and efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be prevented or delayed in obtaining marketing authorization for certain of our product candidates. In some instances, there can be significant variability in safety, potency, purity, or efficacy results between different preclinical studies and clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with all investigational biologics and drugs, including novel immunotherapeutics such as those based on our SNAP-TI platform, it is likely that there may be side effects associated with their use. Results of our trials could reveal a high and unacceptable severity and prevalence of these side effects. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny authorization of certain of our product candidates for any or all targeted indications. Treatment-related side effects could also affect participant recruitment or the ability of enrolled participants to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some of the clinical trials we conduct may be open-label in trial design and may be conducted at a limited number of clinical sites on a limited number of patients. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain marketing authorization for our product candidates, the products may not gain market acceptance among physicians, patients, hospitals and others in the medical community.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The use of novel immunotherapeutics, such as our SNAP-TI product candidate to target the treatment and prevention of autoimmune diseases is a recent development and may not become broadly accepted by physicians, patients, hospitals and others in the medical community. Various factors will influence whether our product candidates are accepted in the market, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the clinical indications for which our product candidates are licensed;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">physicians, hospitals and patients considering our product candidates as a safe and effective treatment;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the potential and perceived advantages of our product candidates over alternative treatments, including the adoption of our treatment as the standard of care;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our ability to demonstrate the advantages of our product candidates over other medicines;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the prevalence and severity of any side effects;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the prevalence and severity of any side effects for other immunotherapeutics and public perception of other immunotherapeutics;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the prevalence and severity of any side effects for other nanoparticle-based therapeutics and public perception of other nanoparticle-based therapeutics;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects for other antigen-specific immune tolerance therapies or those utilizing rapamycin and public perception of other antigen-specific immune tolerance therapies and those utilizing rapamycin;</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">product labeling or product insert requirements of the FDA or other regulatory authorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">limitations or warnings contained in the approved labeling;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the timing of market introduction of our product candidates as well as competitive products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the cost of treatment in relation to alternative treatments;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the availability of adequate coverage, reimbursement and pricing by third-party payors and government authorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the willingness of patients to pay out-of-pocket in the absence of coverage by third-party payors and government authorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the effectiveness of our sales and marketing efforts.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If our product candidates are licensed but fail to achieve market acceptance among physicians, patients, hospitals or others in the medical community, we will not be able to generate significant revenue.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In addition, although our product candidates differ in certain ways from other immunotherapeutic based approaches, serious adverse events or deaths in other clinical trials involving immunotherapeutic based product candidates, even if not ultimately attributable to our product or product candidates, could result in increased government regulation, unfavorable public perception and publicity, potential regulatory delays in the testing or licensing of our product candidates, stricter </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">labeling requirements for those product candidates that are licensed, and a decrease in demand for any such product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We currently have no marketing and sales organization and have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved, we may not be able to generate product revenue.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We currently have no sales, marketing or distribution capabilities and have no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue arrangements with third-party sales, marketing, and distribution collaborators regarding the sales and marketing of our products, if approved. However, there can be no assurance that we will be able to establish or maintain such arrangements on favorable terms or if at all, or if we are able to do so, that these third-party arrangements will provide effective sales forces or marketing and distribution capabilities. Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">There can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United States or overseas.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, employment practices liability, property, umbrella, and directors&#8217; and officers&#8217; insurance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or marketing authorizations could be suspended.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We do not know if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We rely, and expect to continue to rely, on third parties to conduct certain of our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain marketing authorizations for, or commercialize, our product candidates and our business could be substantially harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We utilize and depend, and expect to continue to utilize and depend, upon independent investigators and collaborators, such as medical institutions, contract research organizations ("CROs"), contract manufacturing organizations ("CMOs"), and strategic partners to conduct and support certain of our preclinical studies and clinical trials under agreements with us. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We expect to have to continue to negotiate budgets and contracts with CROs, trial sites and CMOs and we may not be able to do so on favorable terms, which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our preclinical studies and clinical trials, and we control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCP, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory authorities enforce GCP through periodic inspections of trial sponsors, principal investigators and trial sites. If we, or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our MAAs. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. In addition, our clinical trials must be conducted with pharmaceutical product produced under cGMP regulations and will require a large number of test participants. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of participants may require us to repeat clinical trials, which would delay the marketing authorization process. Moreover, our business may be implicated if any of these third parties performing services or otherwise acting on our behalf violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Any third parties conducting our clinical trials are not and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and preclinical product candidates. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain marketing authorization for, or successfully commercialize, our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Switching or adding third parties to conduct our preclinical studies and clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may form or seek additional collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such collaborations, alliances or licensing arrangements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We may form or seek additional strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing shareholders or disrupt our management and business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety, potency, purity, and efficacy and obtain marketing approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Further, collaborations involving our product candidates are subject to numerous risks, which may include the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization of our product candidates based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">despite agreements, collaborators may develop our product candidates to standards that only meet their local regulatory requirements and therefore clinical data cannot be applied in support regulatory submissions in other jurisdictions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">collaborators in certain countries may require joint ventures to manufacture and commercialize products in their territory, which may increase costs, increase dilution to shareholders, and offer lack of clarity on revenue and intellectual property sharing;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing and distribution;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">collaboration and grant funding agreements may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As a result, if we enter into additional collaboration agreements and strategic partnerships or license our product candidates, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We currently rely and expect to rely in the future on the use of manufacturing suites in third-party facilities or third parties to manufacture our product candidates, if approved. Our business could be harmed if we are unable to use third-party manufacturing suites or if the third party manufacturers fail to provide us with sufficient quantities of our product candidates or fail to do so at acceptable quality levels or prices.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We do not currently own any facility that may be used as our clinical-scale manufacturing and processing facility and must currently rely on outside vendors to manufacture our product candidates. We will need to negotiate and maintain contractual arrangements with these outside vendors for the supply of our product candidates and we may not be able to do so on favorable terms. We have not yet manufactured our product candidates on a commercial scale and may not be able to do so for any of our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing of biologic and synthetic products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of synthetic products often encounter difficulties in production, particularly in scaling up, validating the production process and assuring high reliability of the manufacturing process, including the absence of contamination. These problems include logistics and shipping, difficulties with production costs and yields, quality control, including lot consistency, stability of the product, product testing, operator error and availability of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if contaminants are discovered in our supply of our product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability failures or other issues relating to the manufacture of our product candidates will not occur in the future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our anticipated reliance on a limited number of third-party manufacturers exposes us to a number of risks, including the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the production process for our product candidates is complex and requires specific know-how that only a limited number of CMOs can provide, as a result, we compete with other companies in the field for the scarce capacities of these organizations and may not be able to secure sufficient manufacturing capacity when needed;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we may be unable to identify manufacturers on acceptable terms, or at all because the number of potential manufacturers is limited and the FDA or other regulatory authorities may inspect any manufacturers for current cGMP compliance as part of our marketing application;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a new manufacturer would have to be educated in, or develop substantially equivalent processes for, the production of our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our third-party manufacturers might be unable to timely manufacture our product candidates or produce the quantity and quality required to meet our clinical and commercial needs, if any;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">contract manufacturers may not be able to execute our manufacturing procedures and other logistical support requirements appropriately;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our future contract manufacturers may not perform as agreed, may not devote sufficient resources to our product candidates or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store, and distribute our products, if any;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards and we have no control over third-party manufacturers&#8217; compliance with these regulations and standards;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our third-party manufacturers could breach or terminate their agreements with us;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our third-party manufacturers may prioritize another customer&#8217;s needs in front of ours, especially in the event of a global pandemic;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">raw materials and components used in the manufacturing process, particularly those for which we have no other source or supplier, may not be available or may not be suitable or acceptable for use due to material or component defects, may be in short supply, and may significantly increase in price;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our contract manufacturers and critical suppliers may be subject to inclement weather, pandemics, as well as natural or man- made disasters; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our contract manufacturers may have unacceptable or inconsistent product quality success rates and yields, and we have no direct control over our contract manufacturers&#8217; ability to maintain adequate quality control, quality assurance and qualified personnel.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Regional or single-source dependencies may in some cases accentuate these risks. For example, the pharmaceutical industry generally, and in some instances we, our collaborators or other third parties on which we rely, depend on China-based suppliers or service providers for certain raw materials, products and services, or other activities. Our ability or the ability of our collaborators or such other third parties to continue to engage these China-based suppliers or service providers for certain preclinical research programs and clinical development programs could be restricted due to geopolitical developments between the United States and China, including as a result of the escalation of tariffs or other trade restrictions or if the previously proposed federal legislation known as the BIOSECURE Act or a similar law were to be enacted.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if any CMO with whom we contract fails to perform its obligations, we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different CMO, which we may not be able to do on reasonable terms, if at all. In either scenario, our clinical trials or commercial distribution could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or product candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of our product candidate that such CMO owns independently. This would increase our reliance on such CMO or require us to obtain a license from such CMO in order to have another CMO manufacture our product candidates. In addition, in the case of the CMOs that supply our product candidates, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging or comparability studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Each of these risks could delay or prevent the completion of our clinical trials or the approval of any of our product candidates by the FDA, EMA or other appropriate regulatory authorities and result in higher costs or adversely impact commercialization of our product candidates. In addition, we will rely on third parties to perform certain specification tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm and the FDA, or other regulatory authorities could place significant restrictions on our company until deficiencies are remedied.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our manufacturing process needs to comply with FDA and comparable foreign regulatory authority regulations relating to the quality and reliability of such processes. Any failure to comply with relevant regulations could result in delays in or termination of our clinical programs and suspension or withdrawal of any marketing authorizations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In order to commercially produce our products either at our own facility or at a third party&#8217;s facility, we will need to comply with the FDA&#8217;s cGMP regulations and guidelines and similar requirements from comparable foreign regulatory authorities. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable foreign regulatory authorities to confirm compliance with applicable regulatory requirements. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our biologic products as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of our biological products for our clinical trials or the termination of or suspension of a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant non-compliance could also result in the imposition of sanctions, including warning or untitled letters, fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation and our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our research and development activities involve the controlled use of potentially hazardous substances, including biological materials, by our third-party manufacturers. Our manufacturers are subject to national, state, and local laws and regulations governing the use, manufacture, storage, handling, and disposal of medical and hazardous materials. Although we believe that our manufacturers&#8217; procedures for using, handling, storing, and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or national authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Government Regulation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">The marketing authorization processes of the FDA, the EMA, MHRA and other comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable, and if we are ultimately unable to obtain marketing authorizations for our product candidates, or the marketing authorization is for a narrower indication than we seek, our business will be substantially harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The time required to obtain marketing approval from the FDA, the EMA, MHRA and other comparable foreign regulatory authorities is unpredictable but typically takes many&#160;years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not yet obtained a marketing authorization for any product candidate and it is possible that none of our current or future product candidates will ever obtain marketing authorizations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our current and future product candidates could fail to receive marketing authorizations for many reasons, including the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the availability of financial resources to commence and complete planned clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the FDA, the EMA, MHRA or other comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA or NDA to the FDA, or an MAA to the EMA or other comparable submission to regulatory authorities in other regions, to obtain authorization in the United States, the European Union, or elsewhere;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA, the EMA, MHRA or regulatory authorities in other regions that a product candidate has an overall suitable benefit/risk profile for its proposed indication;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the FDA, the EMA, MHRA or other comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Inadequate funding for the FDA, the SEC and other government agencies, including from prolonged government shutdowns, or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA, the EMA, MHRA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the risk that foreign regulatory authorities may not authorize our clinical trial protocols and other clinical trial documentation, including manufacturing documentation, even when previously authorized by the FDA, EMA or MHRA, which could lead to a delay in starting such clinical trials. For example, the conduct of our HBV002 clinical trial in South Korea experienced delays due to additional regulatory review of our clinical protocol. We have limited experience obtaining such approvals in foreign jurisdictions and therefore may need more time to navigate the regulatory process as a result.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The unpredictability of clinical trial results may result in our failing to obtain marketing authorizations for any product candidate we develop, which would significantly harm our business, results of operations and prospects. The lengthy approval process in many regions may cause delays in market access, particularly if regulatory authorities have a large number of objections to the initial applications for marketing authorization which need to be addressed.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We have conducted, and intend to conduct, clinical trials of certain of our product candidates outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data are subject to certain conditions imposed by the FDA, including compliance with all applicable U.S. laws and regulations. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with GCP, including review and approval by an independent ethics committee and informed consent from participants. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In general, the participant population for any clinical trial conducted outside of the United States must be representative of the population for whom we intend to label the product in the United States. There can be no assurance the FDA will accept data from trials conducted outside of the United States. Additionally, recent policy proposals in the U.S., if enacted in the future, may make acceptance by the FDA or inclusion in a marketing application of foreign data more difficult or costly.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The FDA, the EMA and other comparable foreign regulatory authorities have substantial discretion in the approval process, and determining when or whether marketing authorization will be obtained for any product candidate that we develop. For example, even if we believe the data collected from future clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA, MHRA or any other comparable foreign regulatory authorities. In addition, U.S. Supreme Court&#8217;s July 2024 decision to overturn prior established case law giving deference to regulatory agencies&#8217; interpretations of ambiguous statutory language has introduced uncertainty regarding the extent to which FDA&#8217;s regulations, policies and decisions may become subject to increasing legal challenges, delays, and/or changes.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Even if we were to obtain a marketing authorization, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval conditional on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may seek Orphan Drug Designation for drug candidates we develop, and we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market exclusivity. In addition, even if we obtain orphan drug exclusivity for any of our product candidates, such exclusivity may not protect us from competition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As part of our business strategy, we may seek Orphan Drug Designation for any drug candidates we develop, and we may be unsuccessful in obtaining such designation. Regulatory authorities in some jurisdictions, including the United States and the EU, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Similarly, in the EU, the European Commission grants designation after receiving the opinion of the Committee for Orphan Medicinal Products on a designation application. Orphan Drug Designation is intended to promote the development of drugs that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than five in 10,000 persons in Europe and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the product would be a significant benefit to those affected). Additionally, designation is granted for drugs intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating, or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in Europe would be sufficient to justify the necessary investment in developing the drug. In Europe, Orphan Drug Designation entitles a party to a number of incentives, such as protocol assistance and scientific advice specifically for designated orphan medicines, and potential fee reductions depending on the status of the sponsor.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Generally, if a drug with an Orphan Drug Designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same drug and indication for that time period, except in limited circumstances. The applicable period is seven&#160;years in the United States and ten&#160;years in the EU. The EU exclusivity period can be reduced to six&#160;years if a drug no longer meets the criteria for Orphan Drug Designation or if the drug is sufficiently profitable such that market exclusivity is no longer justified.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Even if we obtain orphan drug exclusivity for a drug candidate, that exclusivity may not effectively protect the drug candidate from competition because different therapies can be approved for the same indication. Even after an orphan drug is approved, the FDA can subsequently approve a second drug candidate for the same indication if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure manufacture of sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug candidate nor gives the drug candidate any advantage in the regulatory review or approval process. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted. While we may seek Orphan Drug Designation for applicable indications for our current and any future drug candidates, we may never receive such designations. Even if we do receive such designations, there is no guarantee that we will enjoy the benefits of those designations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We may seek Breakthrough Therapy designation for certain of our current and future product candidates. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, defined as those that measure an effect on irreversible morbidity or mortality or on symptoms that represent serious consequences of the disease. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs and biologics designated as breakthrough therapies by the FDA may also be eligible for other expedited approval programs, including accelerated approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to candidate products considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product no longer meets the conditions for qualification. Thus, even though we intend to seek Breakthrough Therapy designation for certain of our current and future product candidates, there can be no assurance that we will receive breakthrough therapy designation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">A Fast Track designation by the FDA, even if granted for certain of our current or future product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If a drug or biologic is intended for the treatment of a serious or life-threatening condition and the product demonstrates the potential to address unmet medical needs for this condition, the product sponsor may apply for FDA Fast Track designation for a particular indication. We may seek Fast Track designation for certain of our current or future product candidates, but there is no assurance that the FDA will grant this status to any of our proposed product candidates. Marketing applications filed by sponsors of products in Fast Track development may qualify for priority review under the policies and procedures offered by the FDA, but the Fast Track designation does not assure any such qualification or ultimate marketing approval by the FDA. The FDA has broad discretion whether or not to grant Fast Track designation, so even if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive Fast Track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures, and receiving a Fast Track designation does not provide assurance of ultimate FDA approval. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. In addition, the FDA may withdraw any Fast Track designation at any time.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Accelerated approval by the FDA, even if granted for certain of our current or future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We may seek approval of certain of our current or future product candidates using the FDA&#8217;s accelerated approval pathway. A product may be eligible for accelerated approval if it treats a serious or life-threatening condition, generally provides a meaningful advantage over available therapies, and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. As a condition of approval, the FDA may require that a sponsor of a product receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. These confirmatory trials must be completed with due diligence and the FDA is permitted to require, as appropriate, that such studies be underway prior to approval or within a specified period after the date of approval. Sponsors must also update FDA on the status of these studies, and under FDORA, the FDA has increased authority to withdraw approval of a drug granted accelerated approval on an expedited basis if the sponsor fails to conduct such studies in a timely manner, send the necessary updates to the FDA, or if such post-approval studies fail to verify the drug&#8217;s predicted clinical benefit. In addition, the FDA currently requires sponsors, unless otherwise informed by the agency, to request pre-approval of promotional materials for products receiving Accelerated Approval, which could adversely impact the timing of the commercial launch of the product. Even if we do receive accelerated approval, we may not experience a faster development or regulatory review or approval process, and receiving accelerated approval does not provide assurance of ultimate full FDA approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If approved, our investigational products regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The Patient Protection and Affordable Care Act, as amended by the ACA, includes a subtitle called the BPCIA which created an abbreviated approval pathway for biologic products that are biosimilar to or interchangeable with an FDA-licensed reference biologic product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four&#160;years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company&#8217;s product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We believe that any of our product candidates approved as a biologic product under a BLA should qualify for the 12 year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our investigational medicines to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biologic products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing, including the potential for sponsors under FDA draft guidance issued in 2024 to demonstrate interchangeability without conducting so-called "switching" studies and the potential for sponsors under FDA draft guidance issued in 2025 to demonstrate biosimilarity without conducting comparative efficacy studies. Although the FDA has yet to finalize these draft guidance documents, these or similar efforts may increase the risk of competition for our biologic product candidates, if approved.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If competitors are able to obtain marketing approval for biosimilars referencing our products, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Even if we obtain FDA, European Commission or MHRA approval for our current or future product candidates that we may identify and pursue in the United States, the European Union or the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.K.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">, we may never obtain approval to commercialize any such product candidates outside of those jurisdictions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Obtaining and maintaining marketing authorization for our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain marketing authorizations in any other jurisdiction, while a failure or delay in obtaining marketing authorization in one jurisdiction may have a negative effect on the approval process in others. In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and effectiveness. Approval processes vary among countries and can involve additional product testing and validation and additional or different administrative review periods from those in the United States, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Seeking foreign marketing authorization could result in difficulties and costs and require additional preclinical studies or clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our current or future product candidates in those countries. The foreign marketing authorization process may include all of the risks associated with obtaining FDA, European Commission or MHRA approval, in addition to country-specific risks and challenges. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining marketing authorizations in international markets for our current or future product candidates. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if marketing authorization in international markets is delayed, our target market will be reduced and our ability to realize the full market potential of our current or future product candidates will be harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Future changes to tax laws could materially adversely affect our financial condition and results of operations, and reduce net returns to our shareholders.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We conduct business globally and file tax returns in multiple jurisdictions. The tax treatment of the Company or any of the group companies could be materially adversely affected by several factors, including: changing tax laws, regulations and treaties, or the interpretation thereof; tax policy initiatives and reforms under consideration (such as those related to the Organization for Economic Co-Operation and Development&#8217;s Base Erosion and Profit Shifting Project, the European Commission&#8217;s state aid investigations and other initiatives); the practices of tax authorities in jurisdictions in which we operate; the resolution of issues arising from tax audits or examinations and any related interest or penalties. Such changes (which may be retroactive) may include (but are not limited to) the taxation of operating income, investment income, dividends received or (in the specific context of withholding tax) dividends paid.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We are unable to predict what tax reform may be proposed or enacted in the future or what effect such changes would have on our business, but such changes, to the extent they are brought into tax legislation, regulations, policies or practices in jurisdictions in which we operate, could affect our financial position, future results of operations, cash flows in a particular period and overall or effective tax rates in the future in countries where we have operations, reduce post-tax returns to our shareholders and increase the complexity, burden and cost of tax compliance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Tax authorities may disagree with our positions and conclusions regarding certain tax positions, or may apply existing rules&#160;in an unforeseen manner, resulting in unanticipated costs, taxes or non-realization of expected benefits.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We operate in a number of countries throughout the world. Consequently, we are subject to tax laws, treaties, and regulations in the countries in which we operate, and these laws and treaties are subject to interpretation. We have taken, and will continue to take, tax positions based on our interpretation of such tax laws. A tax authority may disagree with tax positions that we have taken, which could result in increased tax liabilities. For example HMRC, the IRS or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid with respect to our intellectual property development. There can be no assurance that a taxing authority will not have a different interpretation of applicable law and assess us with additional taxes. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#8220;permanent establishment&#8221; under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions. A tax authority may take the position that material tax liabilities, interest and penalties are payable by us, for example where there has been a technical violation of contradictory laws and regulations that are relatively new and have not been subject to extensive review or interpretation, in which case we expect that we might contest such assessment. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in disputing the assessment, the implications could increase our anticipated effective tax rate, where applicable, or result in other liabilities. If we are assessed with additional taxes, this may result in a material adverse effect on our results of operations and/or financial condition.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may be unable to use net operating loss and tax credit carryforwards and certain built-in losses or tax credits to reduce future tax payments or to benefit from favorable U.K. tax legislation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our U.K. incorporated and tax resident entities are subject to U.K. corporation tax. Due to the nature of our business, we have generated losses since inception and therefore have not paid any U.K. corporation tax. As of December&#160;31, 2025, we had cumulative carryforward tax losses of approximately $160.4 million (December&#160;31, 2024: $101.7 million). Subject to any relevant criteria and restrictions (including those that limit the percentage of profits that can be reduced by carried forward losses and those that can restrict the use of carried forward losses where there is a change of ownership of more than half of our ordinary shares and a major change in the nature, conduct or scale of the trade), we expect these to be eligible for carry forward and utilization against future operating profits, if any. The use of loss carryforwards in relation to U.K. profits incurred on or after April 1, 2017 is generally limited each year to &#163;5.0 million plus an incremental 50% of U.K. taxable profits.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As a company that carries out extensive research and development activities, we seek to benefit from the U.K. research and development tax relief programs. From 2025, we benefit from the applicable United Kingdom research and development tax credit regime which is the merged scheme Research &amp; Development expenditure credit ("RDEC") and enhanced R&amp;D intensive support ("ERIS") that replaces the old RDEC and small and medium-sized enterprise ("SME") schemes for accounting periods beginning on or after April 1, 2024. For expenditure under the merged scheme, the rate of Research and Development expenditure credit is 20%, which is the same as the rate under the old RDEC scheme for expenditure incurred on or after April 1, 2023. For loss-makers and small profit-makers, a lower rate of notional tax restriction (currently 19%) applies at payment. The amount of the Pay As You Earn ("PAYE") cap for claims under both the merged scheme and ERIS is &#163;20,000 plus 300% of the company&#8217;s relevant PAYE and National Insurance contributions liabilities. The PAYE cap (where applicable) will limit the amount of payable credit that can be received in the accounting period under consideration. Any excess over the cap will be carried forward and treated as an amount of Research and Development expenditure credit to which the company will be entitled for the next accounting period. Based on prior claims and the split of qualifying spend it is expected that the PAYE cap is unlikely to affect the net benefit. Furthermore, legislation included in Finance Act 2024 restricts the extent to which payments to contractors for R&amp;D, and externally provided workers can qualify for R&amp;D relief where R&amp;D activity takes place outside the U.K., which may restrict the ability to include cost incurred on externally provided workers based in the U.S. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">A large portion of our research, clinical trials management and manufacturing development activities are eligible for inclusion within these tax credit cash rebate claims. Our eligibility to claim payable research and development tax credits may be limited or eliminated because we may no longer qualify based on the eligibility criteria. Unsurrendered U.K. losses may be carried forward indefinitely to be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each year is limited to &#163;5.0 million plus an incremental 50% of U.K. taxable profits. There was no tax loss restriction applied to the R&amp;D tax credits in the U.K. for the years ending December&#160;31, 2025 and 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Under both the current RDEC scheme and the historic SME scheme (which we relevant to us in prior tax years), a company qualifies as an R&amp;D intensive business if R&amp;D expenditure constitutes at least 30% of total expenditure.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">From the analysis performed, we have not and do not currently expect to claim under the loss-making R&amp;D intensive scheme criteria primarily due to the proportion of total relevant expenditure occurring outside the U.K.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We may benefit in the future from the U.K.&#8217;s &#8220;patent box&#8221; regime, which allows certain profits attributable to revenue from patented products (and other qualifying income) to be taxed at an effective rate of 10% by giving an additional tax deduction. When taken in combination with the enhanced relief available on our research and development expenditures, we expect a long-term effective rate of corporation tax lower than the statutory rate to apply to us. If, however, there are unexpected adverse changes to the U.K. R&amp;D tax credit regime or the &#8220;patent box&#8221; regime, or for any reason we are unable to qualify for such advantageous tax legislation, or we are unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments then our business, results of operations and financial condition may be adversely affected. This may impact our ongoing requirement for investment and the timeframes within which additional investment is required.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For completeness, it should be noted that the U.K. tax authority, His Majesty's Revenue and Customs ("HMRC"), currently has an increased focus on claims for R&amp;D tax credits and so the Company may be subject to increased scrutiny in respect of any claims it makes. In addition, the legislation on the U.K. R&amp;D tax credits regime is updated and changed frequently, so there can be no guarantee of our ability of to make use of such credits as we might currently expect to in future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Ongoing Regulatory Obligations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Even if we receive marketing authorization for our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Any marketing authorizations that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS and the EMA may also require additional rapid microbiological method approvals or educational materials in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs, good laboratory practice regulations and GCPs, for any clinical trials that we conduct post-approval, and compliance with applicable product tracking and tracing requirements. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance requiring remediation;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">revisions to the labeling, including limitation on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">imposition of a REMS, which may include distribution or use restrictions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">requirements to conduct additional post-market clinical trials to assess the safety of the product;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">fines, warning letters or holds on clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of our product candidates; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">injunctions or the imposition of civil, criminal, or administrative penalties.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Additionally, under FDORA, sponsors of approved drugs and biologics must provide 6 months&#8217; notice to the FDA of any changes in marketing status, such as the withdrawal of a drug, and failure to do so could result in a letter citing such failure to comply and public posting of such letter and redacted company response, which could damage the company's reputation. The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">that could prevent, limit or delay marketing authorization of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">The FDA and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory authorities strictly regulate the promotional claims that may be made about prescription products, if approved. In particular, while the FDA permits the dissemination of truthful and non- misleading information about an approved product, a manufacturer may not promote a product for uses that are not approved by the FDA or such other regulatory authorities as reflected in the product&#8217;s approved labeling. If we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees, corporate integrity agreements or permanent injunctions under which specified promotional conduct must be changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The insurance coverage and reimbursement status of newly-approved products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for any of our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The regulations that govern marketing approvals, pricing and reimbursement for new drugs vary widely from country to country. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and, recently enacted legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our or their commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if any product candidates we may develop obtain marketing approval. See section entitled &#8220;Business&#160;&#8211; Government Regulation&#160;&#8211; Coverage and Reimbursement.&#8221;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our ability to successfully commercialize our product candidates or any other products that we or they may develop also will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford treatments. Sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. If reimbursement is not available, or is available only at limited levels, we may not be able to successfully commercialize our product candidates, if approved. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about reimbursement for new medicines are typically made by CMS, an agency within the HHS, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for fundamentally novel products such as ours. Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs and commercial payors are critical to new product acceptance. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a covered benefit under its health plan;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">safe, effective and medically necessary;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">appropriate for the specific patient;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">cost-effective; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">neither experimental nor investigational.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and certain other major markets where we plan to commercialize may put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems, and pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost effectiveness of our product candidates to other available therapies. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medicines, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moreover, efforts by governmental and other third-party payors, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. Many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs. As a result, increasingly high barriers are being erected to the entry of new products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Healthcare legislative or regulatory reform measures may have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates or any future product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell a product for which we obtain marketing approval. Changes in applicable laws, rules, and regulations or the interpretation of existing laws, rules, and regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing arrangements; (ii)&#160;additions or modifications to product labeling; (iii)&#160;the recall or discontinuation of our products; or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. See the section titled &#8220;Business&#160;&#8211; Government Regulation&#160;&#8211; Healthcare Reform and Legislative Changes.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product candidate. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be modified or invalidated. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs, and could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our business activities will be subject to the Foreign Corrupt Practices Act ("FCPA"), and similar anti-bribery and anti- corruption laws in other jurisdictions.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As we engage in and expand our business activities outside of the United States, including our clinical trial efforts, we will be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules&#160;of other countries in which we operate. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non- United States government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-United States governments. Additionally, in many other countries, the healthcare providers who prescribe </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers will be subject to regulation under the FCPA. Recently the Securities and Exchange Commission, or the SEC, and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents, suppliers, manufacturers, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of facilities, including those of our suppliers and manufacturers, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries as well as difficulties in manufacturing or continuing to develop our products, and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Inadequate funding for the FDA, the SEC and other government agencies, including from government shutdowns, or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Without appropriation of funding to federal agencies, our business operations related to our product development activities for the U.S. market could be impacted. The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA's ability to perform routine function. Average review times at the agency have fluctuated in recent&#160;years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions and personnel turnover, including as a result of leadership changes, staff reductions or otherwise, at the FDA and other agencies may also slow the time necessary for new drugs and biologics or modifications to approved drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. Changes and cuts in FDA staffing also could result in delays in the FDA&#8217;s responsiveness or in its ability to review IND submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion or at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Over the last several&#160;years the U.S. government has shut down several times and certain regulatory authorities, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. In addition, the current U.S. presidential administration has issued certain policies and Executive Orders directed towards reducing employee headcount and costs associated with U.S. administrative agencies, including the FDA, and it remains unclear the degree to which these efforts may limit or otherwise adversely affect the FDA's ability to conduct routine activities. If a prolonged government shutdown occurs, or if renewed global health concerns, funding shortages or staffing limitations hinder or prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, including formal and informal interactions with product developers, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our business operations and current and future relationships with principal investigators, healthcare providers, including physicians, consultants, third-party payors and customers may be subject, directly or indirectly, to U.S. federal and state, as well as foreign, healthcare fraud and abuse laws, false claims laws, health information privacy and cybersecurity laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare providers, including physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors subject us to various U.S. federal and state fraud and abuse laws and other healthcare laws, including, without limitation, the AKS, the federal civil and criminal false claims laws, and the law commonly referred to as the Sunshine Act, along with regulations promulgated under such laws. These laws impact, among other things, our clinical research activities, proposed sales, marketing and educational programs, and other arrangements and relationships with third-party payors, healthcare professionals, and other parties through which we market, sell and distribute our product candidates for which we obtain marketing approval. In addition, we may be subject to patient data privacy and security regulation by both the U.S. federal government and the states in which we conduct our business, along with foreign regulators (including European data protection authorities). See section entitled &#8220;Business&#160;&#8211; Government Regulation&#160;&#8211; Other Healthcare Laws and Compliance Requirements.&#8221;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Even if precautions are taken, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including without limitation, civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participating in federal and state funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, diminished profits and future earnings, reputational harm and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, that person may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by applicable regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We are exposed to the risk that our employees, independent contractors, consultants, collaborators, CROs or CMOs, principal investigators, suppliers and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: comply with the regulations of the FDA and other comparable foreign regulatory bodies, provide true, complete and accurate information to the FDA and other comparable foreign regulatory bodies, comply with manufacturing standards we have established, comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws and regulations will increase significantly, and our costs associated with compliance with such laws and regulations are also likely to increase. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Misconduct by persons acting on our behalf could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, including, without limitation, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If we fail to comply with data protection, privacy, and cybersecurity laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We and our collaborators and third-party providers are subject to national, supranational, federal or state laws and regulations, regulatory guidance and industry standards relating to data protection, privacy and information security. With respect to Europe, the collection and processing of personal data regarding (i) individuals in the EEA and U.K., and/or (ii) carried out in the context of the activities of our establishments in the EEA or U.K.,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">is subject to the GDPR, as well as other national data protection legislation in force in relevant EEA member states and the U.K., (including the U.K. Data Protection Act 2018).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The GDPR</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">is wide-ranging in scope and impose numerous obligations on companies that process personal data, including special requirements in respect of the processing of special categories of personal data (such as health data), requiring that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">consent of individuals to whom the personal data relates is obtained in certain circumstances, requiring additional disclosures to individuals regarding data processing activities, requiring that safeguards are implemented to protect the security and confidentiality of personal data, creating mandatory data breach notification requirements in certain circumstances, requiring data protection impact assessments for high risk processing and requiring that certain measures (including contractual requirements) are put in place when engaging third-party processors. The GDPR also provides individuals with various rights in respect of their personal data, including rights of access, erasure, portability, rectification, restriction and objection. The GDPR defines personal data to include pseudonymized or coded data and requires different informed consent practices and more detailed notices for clinical trial participants and investigators than apply to clinical trials conducted in the United States. We are required to apply GDPR standards to any clinical trials that recruit participants in the EEA and U.K. as well as any clinical trials that our EEA and U.K. established businesses carry out anywhere in the world.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The GDPR imposes strict rules on the transfer of personal data to countries outside the EEA and U.K., including the United States in certain circumstances, unless a derogation exists or we incorporate a GDPR transfer mechanism (such as the European Commission approved standard contractual clauses (&#8220;SCCs&#8221;) or the U.K. International Data Transfer Addendum (&#8220;IDTA&#8221;)) into our agreements with third parties to govern such transfers of personal data and carry out transfer impact assessments to assess whether the data importer can ensure sufficient guarantees for safeguarding the personal information under the GDPR, including an analysis of the laws in the recipient&#8217;s country. Carrying out such restricted transfers, therefore, comes with a significant compliance burden, requiring significant effort and expense to overcome. Failure to implement valid mechanisms for personal data transfers from Europe may result in increased exposure to regulatory actions, substantial fines, and injunctions against processing personal data from Europe. If we are unable to export personal data, this may also restrict our activities outside of Europe and require us to increase processing capabilities within Europe at significant expense or otherwise segregate our systems and operations. Switzerland has adopted similar transfer restrictions as under the GDPR. Although the U.K. is regarded as a third country under the EU GDPR, the European Commission issued a decision recognizing the U.K. as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EEA to the U.K. remain unrestricted. Personal data transfers from the U.K. to the EEA remain free flowing by virtue of a U.K. government adequacy decision.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The GDPR may increase our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR. While we have taken steps to comply with the GDPR, and implementing legislation in applicable EEA member states and the U.K., including by seeking to establish appropriate lawful bases for the various processing activities we carry out as a controller or joint controller, reviewing our security procedures and those of our vendors and collaborators, and entering into data processing agreements with relevant vendors and collaborators, we cannot be certain that our efforts to achieve and remain in compliance have been, and/or will continue to be, fully successful. Given the breadth and depth of the applicable obligations, complying with the GDPR and similar data protection laws&#8217; requirements is rigorous and time intensive and require significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The U.K.&#8217;s data protection regime is independent from but aligned to the EU&#8217;s data protection regime. However following the U.K.'s departure from the European Union ("Brexit"), there will be increasing scope for divergence in application, interpretation and enforcement of the data protection laws between these territories. For example, the U.K. Data (Use and Access) Act 2025 (&#8220;U.K. Act"), now in force, further alters the similarities between the U.K. and EEA data protection regimes. In December 2025, the European Commission adopted a decision determining that the UK continues to provide a level of data protection that is &#8220;essentially equivalent&#8221; to the EU standards and extended the validity of the UK adequacy decision for six years, through December 2031. While this renewal reduces immediate adequacy concerns, uncertainty remains regarding how UK data protection laws will evolve in the medium to longer term. This lack of clarity on future U.K. laws and regulations and their interaction with those of the EU could add legal risk, uncertainty, complexity, and cost to our handling of European personal data and our privacy and security compliance programs; and any resulting divergence in laws could increase our risk profile and may require us to implement different compliance measures for the U.K. and EEA. In addition, EEA Member States have adopted national laws to implement the GDPR that may partially deviate from the GDPR. Further, the competent authorities in the EEA Member States interpret GDPR obligations slightly differently from country to country (particularly in relation to the processing of health data) and therefore we do not expect to operate in a uniform legal landscape in the EEA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Regulators and legislators in the U.S. are increasingly scrutinizing and restricting certain personal data transfers and transactions involving foreign countries. For example, the Department of Justice&#8217;s January 8, 2025, rule on &#8220;Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons,&#8221; prohibits data brokerage transactions involving certain sensitive personal data categories, including health data, genetic data, and biospecimens, to countries of concern, including China. The regulations also restrict certain investment agreements, employment agreements and vendor agreements involving such data and countries of concern, absent specified </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">cybersecurity controls. Actual or alleged violations of these regulations may be punishable by criminal and/or civil sanctions and may result in exclusion from participation in federal and state programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In the U.S., numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">, Section&#160;5 of the FTC Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators and third-party providers. For example, the CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used. The CCPA applies to certain sensitive personal information and created a new state agency vested with authority to implement and enforce the CCPA. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that may lead to increased litigation. U.S. states are constantly amending existing laws, requiring attention to frequently changing regulatory requirements, which may require us to modify our data collection or processing practices and policies and to incur substantial costs and expenses in an effort to comply with them. We are conducting a clinical trial in California, where the CCPA includes only a partial exemption for certain clinical trial data, and we may be subject to privacy compliance obligations on our business that raise new risks for potential fines and class actions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Numerous other U.S. state privacy laws have been enacted that are substantially similar in scope and contain many of the same requirements and exceptions as the CCPA, including a general exemption for clinical trial data and information governed by HIPAA. Any of these laws may broaden their scope in the future, and similar laws have been proposed on both a federal level and in more than half of the states in the United States. State laws feature several key differences in scope, application, and enforcement, that collectively impact how regulated businesses collect and process personal sensitive data, conduct data protection assessments, transfer personal data to affiliates, and respond to consumer rights requests.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In addition to general privacy and data protection requirements, many jurisdictions around the world have adopted legislation that regulates how businesses operate online and enforces information security, including measures relating to privacy, cybersecurity, data security and data breaches. Many of these laws require businesses to notify cybersecurity incidents and data breaches to applicable regulators and/or data subjects. These laws are not consistent, and compliance in the event of a widespread data breach is costly and burdensome.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">A growing number of legislators and regulators are adopting laws and regulations and have focused enforcement efforts on the adoption of artificial intelligence (&#8220;AI&#8221;) and use of such technologies in compliance with ethical standards and societal expectations. These developments may increase our compliance burden and costs in connection with use of AI and lead to legal liability if we fail to meet evolving legal standards or if use of such technologies results in harms or other causes of action we did not predict.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We may use and integrate AI into our business processes both in our own development and implementation of AI and through the adoption of commercially available tools. Use of this technology could pose cybersecurity, data privacy, IT, intellectual property, regulatory, legal, operational, competitive, reputational and other risks and challenges that could affect our business. Specifically, risks related to accuracy, bias, artificial intelligence hallucinations, discrimination, harmful content, misinformation, fraud, scams, targeted attacks (including model poisoning or data poisoning), surveillance, data leakage, inequality, environmental harms, and other harms may flow from our development, use, or deployment of AI technologies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The rapid evolution of AI will require the application of significant resources to design, develop, test and maintain such systems to help ensure that AI is implemented in accordance with applicable law and regulation and in a socially responsible manner and to minimize any real or perceived unintended harmful impacts. If we enable or offer solutions that draw controversy due to perceived or actual negative societal impact, we may experience brand or reputational harm, competitive harm or legal liability. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In the U.S., the AI regulatory environment is complex and uncertain. Over the past year, states have advanced, and in some cases passed, dozens of laws focusing on AI governance and regulation, including on deployment of AI in healthcare settings. At the federal level, the Trump Administration has endorsed a federal moratorium on the enforcement of state AI laws, including through a December 11, 2025, executive order on &#8220;Ensuring a National Policy Framework for Artificial Intelligence.&#8221; So far, these efforts have not been successful at curtailing state action on AI regulation, contributing to a complicated legislative patchwork, which may be litigated in state and federal courts. In Europe, the European Union began implementing the Artificial Intelligence Act (the &#8220;AI Act&#8221;) on August 1, 2024, with a significant part of the law scheduled to come into effect in August 2026. As currently enacted, the AI Act, which may be amended as part of the EU&#8217;s Digital Omnibus, imposes significant obligations on providers and deployers of high-risk artificial intelligence systems, and encourages providers and deployers of artificial intelligence systems to account for EU ethical principles in their development and use of these systems. The scope of requirements depends on judicial interpretations and forthcoming legislative amendments, and non-compliance can lead to significant fines.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In many jurisdictions, enforcement actions and consequences for non-compliance with protection, privacy and information security laws and regulations are rising. In the EU and the U.K., data protection authorities may impose large penalties for violations of the data protection laws, including potential fines of up to &#8364;20 million (&#163;17.5 million in the U.K.) or 4% of annual global revenue, whichever is greater. The authorities have shown a willingness to impose significant fines and issue orders preventing the processing of personal data on non-compliant businesses. Under the GDPR, data subjects also have a private right of action, as do consumer associations, to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of applicable data protection laws. In the United States, possible consequences for non-compliance include enforcement actions in response to rules&#160;and regulations promulgated under the authority of federal agencies and state attorneys general, legislatures and consumer protection agencies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The risk of our being found in violation of these laws is increased by their fact that the interpretation and enforcement is not entirely clear. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Compliance with data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. It could also require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business. Failure by us or our collaborators and third-party providers to comply with data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties and orders preventing us from processing personal data), private litigation and result in significant fines and penalties against us. Moreover, clinical trial participants about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend, could result in adverse publicity and could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The U.S. Congress, the Trump administration, or any new administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the U.S. Congress and the Trump administration made substantial changes to U.S. policies, which included comprehensive corporate and individual tax reform. In addition, the Trump administration called for significant changes to U.S. trade, healthcare, immigration and government regulatory policy. With the transition to the Biden administration in early 2021, changes to U.S. policy occurred and since the start of the Trump Administration in 2025, U.S. policy changes have been implemented at a rapid pace and additional changes are likely. Changes to U.S. policy implemented by the U.S. Congress, the Trump administration or any new administration have impacted and may in the future impact, among other things, the U.S. and global economy, international trade relations, unemployment, immigration, healthcare, taxation, the U.S. regulatory environment, inflation and other areas. For example, in September 2025, President Trump announced plans to impose 100% tariffs on imported branded or patented pharmaceuticals, unless the importing company is building U.S. manufacturing capacity. It is not yet clear whether these tariffs would apply to the importation of active pharmaceutical ingredients and possibly bulk drug products that are intended for use in clinical trials and not for commercial sale, which could increase the costs of materials for our clinical trials. Any direct tariffs, if imposed on pharmaceutical products, may result in increased costs for raw materials and contract manufacturing services, reduced ability to source critical contract manufacturing organizations, and a delay in our development timelines. Although we cannot predict the impact, if any, of these changes to our business, they could adversely affect our business. Until we know what policy changes are made, whether those policy changes are challenged and subsequently upheld by the court system and how those changes impact our business and the business of our competitors over the long term, we will not know if, overall, we will benefit from them or be negatively affected by them.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If we are unable to obtain and maintain patent protection for any products we develop and for our technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop and our technology may be adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates. We seek to protect our proprietary position by in-licensing intellectual property relating to our platform technology and filing patent applications relating to our technologies that are important to our business. If we or our licensors are unable to obtain or maintain patent protection with respect to our product candidates, our competitive position, business, financial conditions, results of operations, and prospects could be materially harmed. We do not own any issued patents with respect to our product candidates and rely primarily on in-licensed patents and patent applications. We can provide no assurance that any of our current or future patent applications will result in issued patents or that any issued patents will provide us with any competitive advantage. Failure to obtain issued patents could have a material adverse effect on our ability to develop and commercialize our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our patents. In addition, it is uncertain whether the World Trade Organization ("WTO") will waive certain intellectual property protections now or in the future on certain technologies. It is unknown if such a waiver would be limited to patents, or would include other forms of intellectual property including trade secrets and confidential know-how. We cannot be certain that any of our current or future product candidates or technologies would not be subject to an intellectual property waiver by the WTO. We also cannot be certain that any of our current or future intellectual property rights, whether patents, trade secrets, or confidential know-how would be eliminated, narrowed, or weakened by such a waiver. Given the uncertain future actions by the WTO and other countries and jurisdictions around the world, including the United States, it is unpredictable how our current or future intellectual property rights or how our current or future business would be impacted. With respect to both our in-licensed and owned intellectual property, we cannot predict whether the patent applications that we and our licensors are currently pursuing or that we may pursue in the future will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The patent prosecution process is expensive, time-consuming, and complex, and we and our licensors may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our owned or any licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent&#160;years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates or which effectively prevent others from commercializing competitive technologies and product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. We or our licensors may become subject to a third party pre-issuance submission of prior art to the USPTO, or opposition, derivation, revocation, reexamination, post-grant and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">inter partes </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">review, or interference proceedings and other similar proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we, or one of our licensors, may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge priority of invention or other features of patentability. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our rights to develop and commercialize our technology and product candidates are subject, in part, to the terms and conditions of licenses granted to us by others and if we fail to comply with our current or future obligations in any agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We are heavily reliant upon licenses to certain patent rights and proprietary technology from third parties that are important or necessary to the development of our product candidates. These and other future agreements impose, and may continue to impose, numerous obligations, such as development, diligence, payment, commercialization, funding, milestone, royalty, sublicensing, insurance, patent prosecution and enforcement obligations on us and may require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. In spite of our best efforts, our current and future licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technologies covered by these license agreements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In addition, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications covering the technology that we license from third parties. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our licensors fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our products that are the subject of such licensed rights could be adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Any termination of these licenses, or any failure of the underlying patents to provide the intended exclusivity, could result in the loss of significant rights and could harm our ability to commercialize our product candidates, and competitors or other third parties would have the freedom to seek marketing authorization for, and to market, products identical to ours and we may be required to cease our development and commercialization of certain of our product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Disputes may arise between us and our current and future licensors regarding intellectual property subject to a license agreement, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate intellectual property rights of the licensor that are not subject to the licensing agreement;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our right to sublicense patent and other rights to third parties under collaborative development relationships and the amount of fees payable as a result of sublicensing arrangements;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the priority of invention of any patented technology; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our current or future licensors and/or us and/or our partners.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In addition, the agreements under which we license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we license prevent or impair our ability to maintain our licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and other elements of our product discovery and development processes. Although we require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, trade secrets can be difficult to protect and we have limited control over the protection of trade secrets used by our collaborators and suppliers. We cannot be certain that we have or will obtain these agreements in all circumstances and we cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary information.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moreover, any of these parties might breach the agreements and intentionally or inadvertently disclose our trade secret information and we may not be able to obtain adequate remedies for such breaches. In addition, competitors and other third parties may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us and our competitive position would be materially and adversely harmed. Furthermore, the laws of some foreign countries do not protect proprietary rights and trade secrets to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful and could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">The intellectual property landscape around immunotherapeutic, nanoparticle and viral vector-based products is crowded and dynamic, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights and such claims may be costly and time-consuming and may prevent or delay our product discovery and development efforts.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The intellectual property landscape around immunotherapeutic, nanoparticle and viral vector-based products is crowded and dynamic, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. Our commercial success depends upon our ability to develop, manufacture, market and sell our current and future product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including derivation, interference, reexamination, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">inter partes </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">review, and post-grant review proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We or any of our licensors or strategic partners may be party to, exposed to, or threatened with, adversarial proceedings or litigation by third parties having patent or other intellectual property rights alleging that our current or future product candidates and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. We cannot assure you that our product candidates and other technologies that we have developed, are developing or may develop in the future do not or will not infringe, misappropriate or otherwise violate existing or future patents or other intellectual property rights owned by third parties. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, including our competitors, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our product candidates, technologies or methods. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If a third party (including any third party that controls the above referenced patents) claims that we infringe, misappropriate or otherwise violate its intellectual property rights (including the above referenced patents), we may face a number of risks, including, but not limited to:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">infringement, misappropriation and other intellectual property claims which, regardless of merit, may be expensive and time- consuming to litigate and may divert our management&#8217;s attention from our core business and may impact our reputation;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">substantial damages for infringement, misappropriation or other violations, which we may have to pay if a court decides that the product candidate or technology at issue infringes, misappropriates or violates the third party&#8217;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#8217;s attorneys&#8217; fees;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our proprietary technologies, unless the third party licenses its product rights to us, which it is not required to do, on commercially reasonable terms, or at all;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our products, or the license to us may be non-exclusive, which would permit third parties to use the same intellectual property to compete with us;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">redesigning our product candidates or processes so they do not infringe, misappropriate or violate third party intellectual property rights, which may not be possible or may require substantial monetary expenditures and time; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on our share price.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We may choose to challenge the patentability of claims in a third party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in an </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">ex-parte </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">reexamination, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">inter partes </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third party&#8217;s patent in patent opposition proceedings in the European Patent Office ("EPO") or other foreign patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Third parties may assert that we are employing their proprietary technology without authorization. Patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. There may be issued third-party patents of which we are currently unaware with claims to compositions of matter, methods of manufacture or methods for treatment related to our product candidates, their manufacture or use. Patent applications can take many&#160;years to issue. In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18&#160;months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications covering our product candidates or technology. If any such patent applications issue as patents, and if such patents have priority over our patent applications or patents we may own or in-license, we may be required to obtain rights to such patents owned by third parties which may not be available on commercially reasonable terms, or at all, or may only be available on a non- exclusive basis. There may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates or other technologies, could be found to be infringed by our product candidates or other technologies. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, we may fail to identify relevant patents or incorrectly conclude that a patent is invalid, not enforceable, exhausted, or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our product candidates, process for their manufacture or methods of use, including combination therapies or participant selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms, or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patent applications or any patents we in-license or may own in the future is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, could involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement, misappropriation or other violation against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need or may choose to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We also could be forced, including by court order, to cease developing, manufacturing, and commercializing the infringing technology or product candidates. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We currently have rights to intellectual property, through licenses from third parties, to develop and commercialize our product candidates. Many pharmaceutical companies, biotechnology companies, and academic institutions are competing with us in the fields of infectious disease, I&amp;I and oncology and filing patent applications potentially relevant to our business. Because our current and future product candidates may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our product candidates may also require particular vector components or gene sequences encoding antigenic peptides to work effectively and efficiently and these rights may be held by others. Similarly, efficient production, delivery or use of our product candidates may also require specific compositions or methods, and the rights to these may be owned by third parties. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We may be required to expend significant time and resources to develop or license replacement technology. Moreover, the molecules that will be used with our product candidates may be covered by the intellectual property rights of others.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program and allowing third parties to compete with us. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such programs and our business and financial condition could suffer.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would enable us to make an appropriate return on our investment or at all. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business, results of operations, financial condition and prospects could suffer.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may be involved in lawsuits to protect or enforce our intellectual property rights, including any patents we may own or in- license in the future, which could be expensive, time-consuming and unsuccessful.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Competitors may infringe any patents we in-license or may own in the future. In addition, any patents we may in-license or own also may become involved in inventorship, priority, validity or unenforceability disputes. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, in an infringement proceeding, a court may decide that one or more of any patents we may in-license or own in the future is not valid or is unenforceable or that the other party&#8217;s use of our technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271 (e)(1). There is also the risk that, even if the validity of these patents is upheld, the court may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question or that such third party&#8217;s activities do not infringe our patents. An adverse result in any litigation or defense proceedings could put one or more of any patents we in-license or may own in the future at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Post-grant proceedings provoked by third parties or brought by the USPTO may be necessary to determine the validity or priority of inventions with respect to our patent applications or any patents we may in-license or own in the future. These proceedings are expensive and an unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. In addition to potential USPTO review proceedings, we may become a party to patent opposition proceedings in the EPO, or similar proceedings in other foreign patent offices, where our foreign patents are challenged. The costs of opposition or similar proceedings could be substantial, and may result in a loss of scope of some claims or a loss of the entire patent. An unfavorable result at the USPTO, EPO or other patent office may result in the loss of our right to exclude others from practicing one or more of our inventions in the relevant country or jurisdiction, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Litigation or post-grant proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our ADSs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We may not be able to detect infringement of any patents we may in-license or own. Even if we detect infringement by a third party of any such patents, we may choose not to pursue litigation against or settlement with the third party. If we later sue such third party for patent infringement, the third party may have certain legal defenses available to it, which otherwise would not be available except for the delay between when the infringement was first detected and when the suit was brought. Such legal defenses may make it impossible for us to enforce any patents we may own or in-license against such third party.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and patent protection could be reduced or eliminated for non- compliance with these requirements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on any issued patents and patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse can in some cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors and other third parties might be able to enter the market with similar or identical products or platforms, which could have a material adverse effect on our business prospects and financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Any issued patents we in-license or may own now or in the future covering our product candidates could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the USPTO.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If we or our licensors or strategic partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of patentable subject matter, lack of written description, lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include reexamination, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">inter partes </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">review, post-grant review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (such as opposition proceedings). Such proceedings could result in revocation or amendment to our in-licensed patent applications or patents or any patent applications or patents we may own in the future in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, any rights we may have from our patent applications or any patents we in-license or may own in the future, allow third parties to commercialize our product candidates or other technologies and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. If we are unsuccessful in any such proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms, or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our patent application claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could have a material adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may be subject to claims challenging the inventorship or ownership of any intellectual property, including any patents we may in-license or own in the future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We may be subject to claims that former employees, collaborators or other third parties have an interest in any patents we in-license or may own in the future, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates or other technologies. We generally enter into confidentiality and intellectual property assignment agreements with our employees, consultants, and contractors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, those agreements may not be honored and may not effectively assign intellectual property rights to us. Moreover, there may be some circumstances, where we are unable to negotiate for such ownership rights. Disputes regarding ownership or inventorship of intellectual property can also arise in other contexts, such as collaborations and sponsored research. If we are subject to a dispute challenging our rights in or to patents or other intellectual property, such a dispute could be expensive and time-consuming. Litigation may be necessary to defend against these and other claims challenging inventorship of any patents we in-license or may own in the future, trade secrets or other intellectual property. If we were unsuccessful, in addition to paying monetary damages, we could lose valuable rights in intellectual property that we regard as our own, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates and other technologies. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information or alleged trade secrets of third parties or competitors or are in breach of non-competition or non- solicitation agreements with our competitors or other third parties.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We have received confidential and proprietary information from third parties. In addition, as is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information or trade secrets of these third parties. In addition, we may in the future be subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement. Litigation or arbitration may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims and possible aftermath could result in substantial cost and be a distraction to our management and employees. Any litigation or the threat thereof may adversely affect our ability to hire employees. A loss of key personnel or their work product could hamper or prevent our ability to commercialize product candidates, which could have an adverse effect on our business, results of operations and financial condition. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on our share price. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements that provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property, we may be unsuccessful in executing such an agreement with each party who, in fact, develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self- executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If we do not obtain patent term extension and data exclusivity for any of our current or future product candidates we may develop, our business may be materially harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Depending upon the timing, duration and specifics of any FDA marketing approval of any of our current or future product candidates we may develop, one or more U.S. patents we in-license or may own in the future may be eligible for limited patent term extension under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five&#160;years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">For biologics, separate non-patent exclusivity under the BPCIA may apply. The FDA cannot make approval of a biosimilar effective until 12 years after the reference product&#8217;s first licensure, but policy changes could affect the scope or duration of this exclusivity, and competitors may nonetheless pursue full BLAs. As a result, even with patents and any extensions, competition from biosimilars or other biologics could occur earlier than anticipated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If we are unable to obtain patent term extension or the term of any such extension is shorter than what we request, our competitors or other third parties may obtain approval of competing products following expiration of any patents that issue from our patent applications, and our business, financial condition, results of operations, and prospects could be materially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Changes to patent law in the United States and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we might obtain in the future. For example, in the case </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Assoc. for Molecular Pathology v. Myriad Genetics,&#160;Inc., </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. Any adverse changes in the patent laws of other jurisdictions could have a material adverse effect on our business and financial condition. Changes in the laws and regulations governing patents in other jurisdictions could similarly have an adverse effect on our ability to obtain and effectively enforce any rights we may have in our patent applications or any patents we may own or in-license in the future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Recent or future patent reform legislation could also increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any patents we in-license or may own in the future. The United States has enacted and implemented wide-ranging patent reform legislation. On September&#160;16, 2011, the Leahy-Smith America Invents Act ("America Invents Act"), was signed into law, which includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation, establish a new post-grant review system and switch the U.S. patent system from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i)&#160;file any patent application related to our product candidates or other technologies or (ii)&#160;invent any of the inventions claimed in our patent applications or any patents we may own or in-license. These changes also allow third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Accordingly, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents we in-license or may own in the future, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our European patents and patent applications could be challenged in the recently created Unified Patent Court (UPC) for the European Union, that was fully ratified and came into being in 2023. We may decide to opt out our European patents and patent applications from the UPC. However, if certain formalities and requirements are not met, our European patents and patent applications could be challenged for non-compliance and brought under the jurisdiction of the UPC. We cannot be certain that our European patents and patent applications will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC. Under the UPC, a granted European patent would be valid and enforceable in numerous European countries. A successful invalidity challenge to a European patent under the UPC would result in loss of patent protection in those European countries. Accordingly, a single proceeding under the UPC could result in the partial or complete loss of patent protection in numerous European countries, rather than in each validated European country separately as such patents always have been adjudicated. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize our technology and product candidates and, resultantly, on our business, financial condition, prospects and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We may not be able to protect our intellectual property and proprietary rights throughout the world.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. In addition, our intellectual property license agreements may not always include worldwide rights. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the relevant patent rights. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our marks of interest and our business may be adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our trademarks or trade names may be challenged, infringed or diluted, lapsed, abandoned, circumvented or declared generic or determined to be infringing on or become dilutive of other marks, or otherwise invalidated through administrative process or litigation. We intend to rely on both registration and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. Third parties may use trademarks similar to our trademarks and any potential confusion as to the source of goods or services could have an adverse effect on our business. However, if such third party continues to assert its claims, we cannot provide any assurance whether we could reach a settlement relating to such claims or whether we would prevail in any litigation or action related to such claims.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Moreover, during the trademark registration process, we may receive Office Actions from the USPTO objecting to the registration of our trademarks. Although we would be given an opportunity to respond to those objections, we may be unable to overcome such rejections. In addition, at the USPTO and at comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and/or to seek the cancellation of registered trademarks through opposition or cancellation proceedings against our trademarks, and if such third parties are successful, our trademarks may not survive such proceedings. In some cases, there may be third-party trademark owners who have prior rights to our trademarks or third parties who have prior rights to similar trademarks, and we may not be able to prevent such third parties from using and marketing any such trademarks. Litigation brought to protect and enforce our intellectual property rights could be costly, unpredictable, time-consuming and distracting to management, regardless of whether we are successful in such litigation. If we are unable to obtain a registered trademark or establish name recognition </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">based on our trademarks and trade names, we may not be able to compete effectively and our business, results of operations and financial condition may be adversely affected.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Numerous factors may limit any potential competitive advantage provided by the relevant patent rights.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The degree of future protection afforded by our intellectual property rights, whether owned or in-licensed, is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">patent applications that we own or in-license may not lead to issued patents;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">patents, that we in-license or may own in the future, may not provide us with any competitive advantages, may be narrowed in scope, or may be challenged and held invalid or unenforceable;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">others may be able to develop and/or practice technology, including compounds that are similar to the chemical compositions of our product candidates, that is similar to our technology or aspects of our technology but that is not covered by the claims of any patents we in-license or may own in the future;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we, or our licensors or collaborators, might not have been the first to make the inventions covered by a patent application that we own or in-license;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we, or our licensors or collaborators, might not have been the first to file patent applications covering a particular invention;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">others may independently develop similar or alternative technologies without infringing, misappropriating or otherwise violating our intellectual property rights;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our competitors or other third parties might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we may not be able to obtain and/or maintain necessary licenses on reasonable terms, or at all;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">third parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights, or any rights at all, over that intellectual property;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such trade secrets or know-how;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we may not be able to maintain the confidentiality of our trade secrets or other proprietary information;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we may not develop or in-license additional proprietary technologies that are patentable; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Employee Matters</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">The pipeline prioritization and restructuring may be unsuccessful, lead to additional costs, disrupt our operations, create unintended problems in our workforce, or increase litigation risk, in which case our business could be harmed.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June 12, 2024, we announced plans to prioritize our pipeline to focus on the development of VTP-300 in CHB and VTP-1000 in celiac disease, including a workforce reduction of approximately 25%. On January 10, 2025, we announced a restructuring plan that aims to prioritize our immune tolerance research and development programs, including a reduction in workforce. As of December 31, 2025, we had 14 full-time and part-time employees.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Despite our efforts, the pipeline prioritization and restructuring may be unsuccessful, lead to additional costs, disrupt our operations, create unintended problems in our workforce, and increase litigation risk, which could harm our business and results of operations. We may incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the pipeline prioritization and restructuring. We may not realize, in full or in part, the anticipated benefits and savings from the pipeline prioritization and restructuring due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from the pipeline prioritization and restructuring, our operating results and financial condition would be adversely affected. Moreover, our decision to focus on the development of VTP-1000 in celiac disease may cause us to fail to capitalize on viable commercial products or profitable market opportunities or limit the opportunities we are able to pursue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In addition, we may need to undertake additional workforce reductions or restructuring activities in the future. Furthermore, the pipeline prioritization and restructuring could yield unanticipated consequences, such as increased difficulties in our day-to-day operations, the loss of institutional knowledge and expertise, attrition beyond planned workforce reductions, reduced employee morale, and difficulty attracting and retaining qualified management, scientific, and other personnel critical to our business. In addition, while positions have been eliminated, certain functions necessary to our operations remain, and we may be unsuccessful in distributing the duties and obligations of departed employees among our remaining employees. If employees who were not affected by the workforce reduction pursue alternative employment, we may need to seek contractor support, which could harm our productivity and add unplanned expense. The implementation of the workforce restructuring could also lead to litigation brought by or on behalf of our former employees.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel, including Bill Enright, our Chief Executive Officer. The loss of the services of any of our executive officers, other key employees and other scientific and medical advisors, and an inability to find suitable replacements could result in delays in product development and harm our business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We may experience changes in key leadership or key positions in the future. The departure of key leadership personnel can result in loss of significant knowledge and experience from the company. This loss of knowledge and experience can be mitigated through successful hiring and transition, but there can be no assurance that we will be successful in such efforts. Attracting and retaining qualified senior leadership may be more challenging under adverse business conditions. Failure to attract and retain the right talent, or to smoothly manage the transition of responsibilities resulting from such turnover, would affect our ability to meet our challenges and may cause us to miss performance objectives or financial targets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We conduct our operations at our facilities in Germantown, Maryland. This region is the headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in these markets is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms, or at all. Changes to U.S. or similar foreign immigration and work authorization laws and regulations, including those that restrain the flow of scientific and professional talent, can be significantly affected by political forces and levels of economic activity. Our business may be materially adversely affected if legislative or administrative changes to the U.S. or similar foreign immigration or visa laws and regulations impair our hiring processes and goals or projects involving personnel who are not U.S. citizens.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">To encourage valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in our share price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on notice periods specified in their employment agreements. Although we have employment agreements with all our employees, these employment agreements with U.S. employees provide for at-will employment, which means that any of our U.S. employees could leave our employment at any time, by providing the required contractual notification of their intent to leave. The standard notice period for U.K. employed personnel is three calendar&#160;months or six calendar&#160;months for the senior executive team. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Our Business Operations and Growth</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2025, we had 14 full-time and part-time employees. As our development and commercialization plans and strategies develop, we expect to need additional managerial, operational, technical, sales, marketing, financial and other personnel, as well as additional facilities to expand our operations. Future growth would impose significant added responsibilities on members of management, including:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">identifying, recruiting, integrating, maintaining and motivating additional and existing employees;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">managing clinical trial sites in multiple countries;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">managing our internal development efforts effectively, including the clinical and regulatory review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">improving our operational, financial and management controls, reporting systems and procedures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing authorization for our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, or we are not able to effectively build out new facilities to accommodate this expansion, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our internal computer systems, or those used by our third-party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in the disclosure of confidential or proprietary information, including personal data, damage to our reputation, and subject us to significant financial and legal exposure and cause a material disruption of the development programs of our product candidates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We and our third-party CROs and other contractors and consultants rely extensively on information technology systems to conduct and manage our business. Despite the implementation of security measures, our internal computer systems and those of our current and future third-party providers are vulnerable to damage from computer viruses and unauthorized access, including cybersecurity incidents and data breaches. The risk of a security breach or disruption, particularly through cyberattacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Cyberattacks could include wrongful conduct by insider employees or vendors, hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware, including ransomware, denial-of-service, social engineering fraud, including phishing attacks, data breaches, or other means to threaten data security, confidentiality, integrity and availability, and may be enhanced or facilitated by Artificial Intelligence (AI). Further, attempts to disrupt or gain unauthorized access to our and our third-party vendors&#8217; information systems from malicious third-parties or insider threats may incorporate widely varying and frequently changing tactics, which may be enhanced or facilitated by AI. If such an event were to occur, it could result in the theft or destruction of intellectual property, data or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and result in a material disruption of our development programs and our business operations, such as the loss of clinical trial data from completed or future clinical trials. Such loss could result in delays in our marketing authorization efforts and significantly increase our costs to recover or reproduce the data.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Although we devote resources to protect our information systems, including organization-wide prevention software, we realize that cyberattacks are a threat, and there can be no assurance that our efforts will prevent information security breaches or data breaches that would result in business, legal, financial or reputational harm to us, or would have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Likewise, we rely on third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. We rely on our third-party providers to implement effective security measures and identify and correct for any such failures, deficiencies or breaches.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Like other companies in our industry, we, and our third party vendors, have experienced and will continue to experience threats and cybersecurity incidents relating to our information technology systems and infrastructure. Any breach in our or our third-party providers&#8217; information technology systems could lead to the unauthorized access, disclosure and use of non-public information, including information from our participant registry or other participant information, which is protected by HIPAA, and other laws. Any such access, disclosure, or other loss of information could result in legal notifications and disclosures, legal claims or proceedings, liability under laws that protect the privacy of personal information, damage to our reputation and the further development and commercialization of our product candidates could be delayed. If we or our third-party providers fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to our information technology systems, we or our third-party providers could have difficulty preventing, detecting and controlling such cyberattacks and any such attacks could result in losses described above as well as disputes with physicians, participants and our partners, regulatory sanctions or penalties, increases in operating expenses, expenses or lost revenues or other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows. If we are unable to prevent or mitigate the impact of such cybersecurity or data privacy breaches, we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our privacy and data security obligations. Further, although we maintain cyber liability insurance, this insurance may not provide adequate coverage against potential liabilities related to any experienced cybersecurity incident or breach.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our operations, and those of our CROs, CMOs and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics, pandemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any product candidate for which we receive marketing authorization. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">decreased demand for our product candidates or products that we may develop;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">injury to our reputation;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">initiation of investigations by regulators;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">costs to defend the related litigation;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a diversion of management&#8217;s time and our resources;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">substantial monetary awards to trial participants or participants;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">loss of revenue;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">exhaustion of any available insurance and our capital resources;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the inability to commercialize any product candidate; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a decline in our share price.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Failure to obtain or retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Although we have clinical trial insurance, our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. In the future, we may be unable to maintain this insurance coverage, or we may not be able to obtain additional or replacement coverage at a reasonable cost, if at all. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. In the past, global financial crises have caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including a reduced ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or international trade disputes could also strain our third-party suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Our International Operations</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">A variety of risks associated with operating our business internationally could materially adversely affect our business.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We plan to seek marketing authorization for our product candidates outside of the United States and, accordingly, we expect that we, and any potential collaborators in those jurisdictions, will be subject to additional risks related to operating in foreign countries, including:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">differing regulatory requirements in foreign countries;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">unexpected changes in tariffs (including tariffs that have been or may in the future be imposed by the United States or other countries), trade protection measures, trade barriers (including further legislation or actions taken by the United States or other countries that restrict trade), price and exchange controls, and other regulatory requirements;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">foreign taxes, including withholding of payroll taxes;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">difficulties staffing and managing foreign operations;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">potential liability under the FCPA Office of Foreign Assets Control Anti-Money Laundering Program as required by the Bank Secrecy Act and its implementing regulations, or comparable foreign laws, including the U.K. Bribery Act 2010 ("Bribery Act");</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">These and other risks associated with our planned international operations may materially adversely affect our ability to attain or maintain profitable operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our business is subject to economic, political, regulatory and other risks associated with international operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our business is subject to risks associated with conducting business internationally. Accordingly, our future results could be harmed by a variety of factors, including the following:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">economic weakness, including inflation, political instability in particular in foreign economies and markets;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">differing regulatory requirements for drug approvals;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">differing jurisdictions potentially presenting different issues for securing, maintaining or obtaining freedom to operate in such jurisdictions;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">potentially reduced protection for intellectual property rights;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">difficulties in compliance with different, complex and changing laws, regulations and court systems of multiple jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">changes in regulations and customs, tariffs and trade barriers;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">changes in currency exchange rates of the euro, U.S. dollar, pound sterling and currency controls;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">changes in a specific country&#8217;s or region&#8217;s political or economic environment;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">trade protection measures, import or export licensing requirements or other restrictive actions by governments;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">differing reimbursement regimes and price controls in certain international markets;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">negative consequences from changes in tax laws or practice;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States and EU;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">difficulties associated with staffing and managing international operations, including differing labor relations;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war, terrorism, pandemics, or natural disasters including earthquakes, typhoons, floods and fires.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Claims of U.S. civil liabilities may not be enforceable against us.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We are incorporated under English law and have our registered office in England. Many of the members of our senior management and certain members of our board of directors are non-residents of the United States, and all or a substantial portion of our assets and the assets of such persons are held outside the United States. As a result, it may not be possible to serve process on such persons or us in the United States or to enforce judgments obtained in U.S. courts against them or us based on civil liability provisions of the U.S. federal securities laws.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The United States and the U.K. do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the U.K. In addition, uncertainty exists as to whether the courts of England and Wales would entertain original actions brought in the U.K. against us or our directors or senior management predicated upon securities laws of the U.S. or any state in the United States. Any final and conclusive monetary judgment for a definite sum obtained against us in U.S. courts would be treated by the courts of England and Wales as a cause of action in itself and sued upon as a debt at common law so that no retrial of the issues would be necessary, provided that certain requirements are met. Whether these requirements are met in respect of a judgment based upon the civil liability provisions of the U.S. securities laws, including whether the award of monetary damages under such laws would constitute a penalty, is an issue for the court making such decision. If the courts of England and Wales give a judgment for the sum payable under a U.S. judgment, the English judgment will be enforceable by methods generally available for this purpose. These methods generally permit the courts of England and Wales discretion to prescribe the manner of enforcement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As a result, U.S. investors may not be able to enforce against us or certain of our senior management, board of directors or certain experts named herein who are residents of the U.K. or countries other than the United States any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Fluctuations in the exchange rate between the U.S. dollar and the pound sterling may increase the risk of holding our ADSs and may materially affect our results of operations and financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our ADSs trade on Nasdaq in U.S. dollars. Due to the international scope of our operations, our assets, earnings and cash flows are influenced by movements in exchange rates of several currencies, particularly the U.S. dollar, the pound sterling and the euro. Our reporting currency is denominated in U.S. dollars and our functional currency is the pound sterling (except that the functional currency of our U.S. subsidiaries is the U.S. dollar) and the majority of our operating expenses are paid in pound sterling. We also regularly acquire services, consumables and materials in U.S. dollars, pounds sterling, AUS dollars and the euro. Further potential future revenue may be derived particularly from the United States. As a result, our business and the price of our ADSs may be affected by fluctuations in foreign exchange rates between the pound sterling and these other currencies, which may also have a significant impact on our results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place. See Note&#160;4 in the notes to our annual financial statements appearing elsewhere in this Annual Report for a description of foreign exchange risks.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In addition, as a result of fluctuations in the exchange rate between the U.S. dollar and the pound sterling, the U.S. dollar equivalent of the proceeds that a holder of ADSs would receive upon the sale in the U.K. of any ordinary shares withdrawn from the depositary and the U.S. dollar equivalent of any cash dividends paid in euros on our ordinary shares represented by ADSs could also decline.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Risks Related to Ownership of Our ADSs</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">An active trading market for our ADSs may not be sustained.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prior to our IPO in May&#160;2021, there had been no public trading market for our ADSs. Although our ADSs are listed on the Nasdaq Global Market, an active trading market for our shares may not be sustained. If an active market for our ADSs is not sustained, it may be difficult for holders of our ADSs to sell ADSs without depressing the market price for the shares, or at all. Further, an inactive market may also impair our ability to raise capital by selling our ADSs and may impair our ability to enter into strategic partnerships or acquire companies or products by using our ADSs as consideration.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our principal shareholders and management own a significant&#160;percentage of our stock and exert significant influence over matters subject to shareholder approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As of March 6, 2026, our executive officers, directors, and 5% shareholders beneficially owned approximately 46% of our voting stock. Depending on the level of attendance at our meetings of shareholders, these shareholders either alone or voting together as a group may be in a position to determine or significantly influence the outcome of decisions taken at any such meeting. Any shareholder or group of shareholders controlling more than 50% of the share capital present and voting at our meetings of shareholders may control any shareholder resolution requiring a simple majority, including the appointment of board members, certain decisions relating to our capital structure and the approval of certain significant corporate transactions. This may prevent or discourage unsolicited acquisition proposals or offers for our ADSs that holders of our ADSs may feel are in their best interest as shareholders.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">The price of our ADSs is volatile and holders of our ADSs could lose all or part of their investment.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The trading price of our ADSs is highly volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Annual Report, these factors include:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the commencement, enrollment, or results of clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">adverse results or delays in preclinical studies and clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing clinical trial;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any delay in our regulatory filings or any adverse regulatory decisions, including failure to receive marketing authorization for our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">adverse developments concerning our manufacturers or our manufacturing plans;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our inability to obtain adequate product supply for any licensed product or inability to do so at acceptable prices;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our inability to establish collaborations if needed;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our failure to commercialize our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">additions or departures of key scientific or management personnel;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">unanticipated serious safety concerns related to the use of our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">introduction of new products or services offered by us or our competitors;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our ability to effectively manage our growth;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">actual or anticipated variations in quarterly operating results;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our cash position;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">publication of research reports about us or our industry, or immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">overall performance of the equity markets;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">sales of our ADSs by us or our shareholders in the future;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">trading volume of our ADSs;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">changes in accounting practices;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">ineffectiveness of our internal controls;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">disputes or other developments relating to intellectual property or proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">significant lawsuits, including intellectual property or shareholder litigation;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">general political and economic conditions; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">other events or factors, many of which are beyond our control.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In addition, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our ADSs, regardless of our actual operating performance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If we fail to regain compliance with the continued listing requirements of Nasdaq, our ADSs may be delisted and the price of our ADSs and our ability to access the capital markets could be negatively impacted. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2025, we received a deficiency letter from Nasdaq indicating that, for the last 30 consecutive business days, the bid price for our ADSs had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Global Market, referred to as the minimum bid price rule. In accordance with Nasdaq Listing Rules, we have an </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">initial period of 180 calendar days, or until June 29, 2026, to regain compliance with the minimum bid price rule. If we do not regain compliance with the minimum bid price rule by June 29, 2026, we may be eligible for an additional 180 calendar day compliance period. We intend to monitor the closing bid price of our ADSs and may, if appropriate, consider available options to regain compliance with the minimum bid price rule.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are many factors that may adversely affect our ADS&#8217; minimum bid price, including those described throughout this section titled &#8220;Item 1A. Risk Factors.&#8221; Many of these factors are outside of our control. As a result, we may not be able to sustain compliance with the minimum bid price rule in the long term. Any potential delisting of our ADSs from the Nasdaq would likely result in decreased liquidity and increased volatility for our ADSs and would adversely affect our ability to raise additional capital or to enter into strategic transactions. Any potential delisting of our ADSs from the Nasdaq would also make it more difficult for holders of our ADSs to sell our ADSs in the public market.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holders of our ADSs are not treated as holders of our ordinary shares.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Holders of ADSs are not treated as holders of our ordinary shares, unless they withdraw the ordinary shares underlying their ADSs in accordance with the deposit agreement and applicable laws and regulations. The depositary is the holder of the ordinary shares underlying our ADSs. Holders of ADSs therefore do not have any rights as holders of our ordinary shares, other than the rights that they have pursuant to the deposit agreement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Holders of our ADSs will not have the same voting rights as the holders of our ordinary shares, and may not receive voting materials or any other documents that would need to be provided to our shareholders pursuant to English corporate law, including the Companies Act 2006, in time to be able to exercise their right to vote.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Except as described elsewhere in this Annual Report and the deposit agreement, holders of the ADSs will not be able to exercise voting rights attaching to the ordinary shares represented by the ADSs. The deposit agreement provides that, upon receipt of notice of any meeting of holders of our ordinary shares, the depositary will fix a record date for the determination of ADS holders who shall be entitled to give instructions for the exercise of voting rights. Upon our request, the depositary shall distribute to the holders as of the record date (i)&#160;the notice of the meeting or solicitation of consent or proxy sent by us and (ii)&#160;a statement as to the manner in which instructions may be given by the holders. We cannot guarantee that ADS holders will receive the voting materials in time to ensure that they can instruct the depositary to vote the ordinary shares underlying their ADSs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Otherwise, ADS holders will not be able to exercise their right to vote, unless they withdraw the ordinary shares underlying the ADSs they hold to vote them in person or by proxy in accordance with applicable laws and regulations and our articles of association. However, ADS holders may not know about the meeting far enough in advance to withdraw those ordinary shares. A shareholder is only entitled to participate in, and vote at, the meeting of shareholders, provided that it holds our ordinary shares as of the record date set for such meeting and otherwise complies with our Articles. In addition, the depositary&#8217;s liability to ADS holders for failing to execute voting instructions or for the manner of executing voting instructions is limited by the deposit agreement. As a result, ADS holders may not be able to exercise their right to vote, and there may be nothing they can do if the ordinary shares underlying their ADSs are not voted as they requested or if their shares cannot be voted.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Holders of ADSs may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">ADSs are transferable on the books of the depositary. However, the depositary may close its books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the deposit agreement, or for any other reason, subject to the right of ADS holders to cancel their ADSs and withdraw the underlying ordinary shares. Temporary delays in the cancellation of ADSs and withdrawal of the underlying ordinary shares may arise because the depositary has closed its transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders meeting or we are paying a dividend on our ordinary shares. In addition, ADS holders may not be able to cancel their ADSs and withdraw the underlying ordinary shares when they owe money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s)&#160;in any such action.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The deposit agreement governing our ADSs representing our ordinary shares provides that, to the fullest extent permitted by law, holders and beneficial owners of ADSs irrevocably waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our ADSs or the deposit agreement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If this jury trial waiver provision is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial. If we or the depositary opposed a jury trial demand based on the waiver, the court would </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising under the federal securities laws has not been finally adjudicated by the United States Supreme Court. However, we believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which govern the deposit agreement, by a federal or state court in the City of New York, which has non-exclusive jurisdiction over matters arising under the deposit agreement. In determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit agreement and our ADSs. It is advisable that you consult legal counsel regarding the jury waiver provision before entering into the deposit agreement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If you or any other holders or beneficial owners of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or our ADSs, including claims under federal securities laws, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and/or the depositary. If a lawsuit is brought against us and/or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s)&#160;in any such action, depending on, among other things, the nature of the claims, the judge or justice hearing such claims, and the venue of the hearing.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with U.S. federal securities laws and the rules&#160;and regulations promulgated thereunder.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The trading market for our ADSs depends in part on the research and reports that securities or industry analysts publish about us or our business. Although we have obtained research coverage from certain analysts, there can be no assurance that analysts will continue to cover us, or provide favorable coverage. If one or more of the analysts who cover us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We are an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our ADSs less attractive to investors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We are an emerging growth company, as defined in the JOBS Act enacted in April&#160;2012. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and shareholder approval of any golden parachute payments not previously approved. We could be an emerging growth company for up to five&#160;years following the&#160;year in which we became a public company, although circumstances could cause us to lose that status earlier. We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal&#160;year (a)&#160;following the fifth anniversary of the date we became a public company, (b)&#160;in which we have total annual gross revenue of at least $1.235 billion or (c)&#160;in which we are deemed to be a large accelerated filer, which requires the market value of our ADSs that are held by non-affiliates to exceed $700 million as of the prior June&#160;30th, and (2)&#160;the date on which we have issued more than $1 billion in non-convertible debt during the prior three-year period.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption and, therefore, we will not be subject to the same timing of adoption of new or revised accounting standards as other public companies that are not emerging growth companies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company,&#8221; which may allow us to continue to take advantage of many of the same exemptions from disclosure requirements, including  reduced disclosure obligations regarding executive compensation in this Annual Report and our periodic reports and proxy statements. We cannot predict if investors will find our ADSs less attractive because we may rely on these exemptions. If some investors find our ADSs less attractive as a result, there may be a less active trading market for our ADSs and our stock price may be more volatile.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We will incur increased costs as a result of operating as an English public company listed in the U.S., and our board of directors will be required to devote substantial time to new compliance initiatives and corporate governance practices.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">As an English public company listed in the U.S., we incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities rules&#160;and regulations impose various requirements on foreign reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our board of directors, management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules&#160;and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. For example, these rules&#160;and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors. In addition, after we no longer qualify as an emerging growth company, we expect to incur additional legal, accounting and other expenses.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">However, these rules&#160;and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We are subject to the reporting requirements of the Securities Exchange Act of 1934, the Sarbanes-Oxley Act and the rules and regulations of The Nasdaq Global Market. Pursuant to Section 404 of the Sarbanes-Oxley Act, we are required to perform system and process evaluation and testing of our internal control over financial reporting to allow our management to report on the effectiveness of our internal control over financial reporting. See section entitled &#8220;Controls and Procedures &#8211; Management&#8217;s Annual Report on Internal Controls Over Financial Reporting.&#8221; However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. We will incur substantial additional professional fees and internal costs to expand our accounting and finance functions and expend significant management efforts.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">General Risk Factors</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. From time to time, we may enter into license or collaboration agreements with other companies that include development funding and significant upfront and milestone payments and/or royalties, which may become an important source of our revenue. Accordingly, our revenue may depend on development funding and the achievement of development and clinical milestones under current and any potential future license and collaboration agreements and, if approved, sales of our product candidates. These upfront and milestone payments may vary significantly from period to period and any variance could cause a significant fluctuation in our operating results from one period to the next.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Further, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including the following:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the timing and cost of, and level of investment in, research and development activities relating to our current and any future product candidates, which will change from time to time;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the timing and outcomes of clinical trials for our current and any other future product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the cost of manufacturing our current and any future product candidates, which may vary depending on regulatory guidelines and requirements, the quantity of production and the terms of our agreements with manufacturers;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">our ability to adequately support our future growth;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">potential unforeseen business disruptions that increase our costs or expenses;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">future accounting pronouncements or changes in our accounting policies; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the changing and volatile global economic environment.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The cumulative effect of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our ADSs could decline substantially. The price of our ADSs could decline even when we have met any previously publicly stated revenue and/or earnings guidance we may provide.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Holders of our ADSs may not receive distributions on our ordinary shares represented by the ADSs or any value for them if it is illegal or impractical to make them available to holders of ADSs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The depositary for the ADSs has agreed to pay to holders of our ADSs the cash dividends or other distributions it or the custodian receives on our ordinary shares or other deposited securities after deducting its fees and expenses. Shareholders will receive these distributions in proportion to the number of our ordinary shares those ADSs represent. However, in accordance with the limitations set forth in the deposit agreement, it may be unlawful or impractical to make a distribution available to holders of ADSs. We have no obligation to take any other action to permit distribution on the ADSs, ordinary shares, rights or anything else to holders of the ADSs. This means that holders of our ADSs may not receive the distributions we make on our ordinary shares or any value from them if it is unlawful or impractical to make them available to holders of our ADSs. These restrictions may have an adverse effect on the value of our ADSs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We do not intend to pay dividends on our ADSs, so any returns will be limited to the value of our ordinary shares.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Under current English law, a company&#8217;s accumulated realized profits must exceed its accumulated realized losses (on a non-consolidated basis) before dividends can be declared and paid. Therefore, we must have distributable profits before declaring and paying a dividend. In addition, as a public limited company incorporated in England&#160;and Wales, we will only be able to make a distribution if the amount of our net assets is not less than the aggregate of our called-up share capital and undistributable reserves and if, and to the extent that, the distribution does not reduce the amount of those assets to less than that aggregate.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We have not paid dividends in the past on our ordinary shares. We currently anticipate that we will retain future earnings for the development, operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, we may enter into agreements that prohibit us from paying cash dividends without prior written consent from our contracting parties, or which other terms prohibiting or limiting the amount of dividends that may be declared or paid on our ADSs. Any return to shareholders and holders of our ADSs will therefore be limited to the appreciation of their stock, which may never occur.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">As an English public limited company, certain capital structure decisions require shareholder approval, which limits our flexibility to manage our capital structure.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">English law provides that a board of directors may only allot shares (or grant rights to subscribe for or to convert any security into shares) with the prior authorization of shareholders, such authorization stating the aggregate nominal amount of shares that it covers and being valid for a maximum period of five&#160;years, each as specified in our Articles or relevant ordinary resolution passed by shareholders at a general meeting. Such authority from our shareholders to allot shares (or grant rights to subscribe for or to convert any security into shares) for a period of five&#160;years from April&#160;21, 2021 was included in the ordinary resolution passed by our shareholders on April&#160;21, 2021, which authorization will need to be renewed upon expiration (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">, at least every five&#160;years) but may be sought more frequently for additional five-year terms (or any shorter period).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">English law also generally provides shareholders with preemptive rights when new shares are issued for cash. However, it is possible for the Articles, or for shareholders to pass a special resolution at a general meeting, being a resolution passed by at least 75% of the votes cast, to disapply preemptive rights. Such a disapplication of preemptive rights may be for a maximum period of up to five&#160;years from the date of adoption of the Articles, if the disapplication is contained in the Articles, but not longer than the duration of the authority to allot shares to which this disapplication relates or from the date of the shareholder special resolution, if the disapplication is by shareholder special resolution. In either case, this disapplication would need to be renewed by our shareholders upon its expiration (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">, at least every five&#160;years). Such authority from our shareholders to disapply preemptive rights for a period of five&#160;years was included in the special resolution passed by our shareholders on April&#160;21, 2021, which disapplication will need to be renewed upon expiration (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">, at least every five&#160;years) to remain effective, but may be sought more frequently for additional five-&#160;year terms (or any shorter period).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">English law also generally prohibits a public company from repurchasing its own shares without the prior approval of shareholders by ordinary resolution, being a resolution passed by a simple majority of votes cast, and other formalities. Such approval may be for a maximum period of up to five&#160;years.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Shareholder protections found in provisions under the U.K. City Code on Takeovers and Mergers (the "Takeover Code"), will not apply if our place of central management and control is considered to be outside of the U.K. (or the Channel Islands or the Isle of Man).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We believe that our place of central management and control is not in the U.K. (or the Channel Islands or the Isle of Man) for the purposes of the jurisdictional criteria of the Takeover Code. Accordingly, we believe that we are not currently subject to the Takeover Code and, as a result, our shareholders are not currently entitled to the benefit of certain takeover offer protections provided under the Takeover Code, including the rules&#160;regarding mandatory takeover bids.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In the event that this changes, or if the interpretation and application of the Takeover Code by the Panel on Takeovers and Mergers, (the "Takeover Panel"), changes (including changes to the way in which the Takeover Panel assesses the application of the Takeover Code to English companies whose shares are listed outside of the U.K.), the Takeover Code may apply to us in the future.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The Takeover Panel has confirmed that, from February 3, 2027, the location of the Company&#8217;s place of central management and control will no longer be relevant in determining whether the Takeover Code applies to the Company. From February 3, 2027, the Takeover Code will only apply to the Company in the event that our securities are quoted on a UK regulated market (or U.K. multilateral trading facility or certain exchanges in the Channel Islands or the Isle of Man).</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The Takeover Code provides a framework within which takeovers of companies which are subject to the Takeover Code are regulated and conducted. The following is a brief summary of some of the most important rules&#160;of the Takeover Code:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">in connection with a potential offer, if following an approach by or on behalf of a potential bidder, the company is &#8220;the subject of rumor or speculation&#8221; or there is an &#8220;untoward movement&#8221; in the company&#8217;s share price, there is a requirement for the potential bidder to make a public announcement about a potential offer for the company, or for the company to make a public announcement about its review of a potential offer;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">when any person acquires, whether by a series of transactions over a period of time or not, an interest in shares which (taken together with shares already held by that person and an interest in shares held or acquired by persons acting in concert with him or her) carry 30% or more of the voting rights of a company that is subject to the Takeover Code, that person is generally required to make a mandatory offer to all the holders of any class of equity share capital or other class of transferable securities carrying voting rights in that company to acquire the balance of their interests in the company;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">when any person who, together with persons acting in concert with him or her, is interested in shares representing not less than 30% but does not hold more than 50% of the voting rights of a company that is subject to the Takeover Code, and such person, or any person acting in concert with him or her, acquires an additional interest in shares which increases the&#160;percentage of shares carrying voting rights in which he or she is interested, then such person is generally required to make a mandatory offer to all the holders of any class of equity share capital or other class of transferable securities carrying voting rights of that company to acquire the balance of their interests in the company;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a mandatory offer triggered in the circumstances described in the two paragraphs above must be in cash (or be accompanied by a cash alternative) and at not less than the highest price paid within the preceding 12&#160;months to acquire any interest in shares in the company by the person required to make the offer or any person acting in concert with him or her;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">in relation to a voluntary offer (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">, any offer which is not a mandatory offer), when interests in shares representing 10% or more of the voting rights of a class have been acquired for cash by an offeror (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">, a bidder) and any person acting in concert with it in the offer period and the previous 12&#160;months, the offer must be in cash or include a cash alternative for all shareholders of that class at not less than the highest price paid for any interest in shares of that class by the offeror and by any person acting in concert with it in that period. Further, if an offeror acquires for cash any interest in shares during the offer period, a cash alternative must be made available at not less than the highest price paid for any interest in the shares of that class;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">if, after making an offer for a company, the offeror or any person acting in concert with them acquires an interest in shares in an offeree company (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">, a target) at a price higher than the value of the offer, the offer must be increased to not less than the highest price paid for the interest in shares so acquired;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">an offeree company must appoint a competent independent adviser whose advice on the financial terms of the offer must be made known to all the shareholders, together with the opinion of the board of directors of the offeree company;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">special or favorable deals for selected shareholders are not permitted, except in certain circumstances where independent shareholder approval is given and the arrangements are regarded as fair and reasonable in the opinion of the financial adviser to the offeree;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">all shareholders must be given the same information;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">each document published in connection with an offer by or on behalf of the offeror or offeree must state that the directors of the offeror or the offeree, as the case may be, accept responsibility for the information contained therein;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">profit forecasts, quantified financial benefits statements and asset valuations must be made to specified standards and must be reported on by professional advisers;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">misleading, inaccurate or unsubstantiated statements made in documents or to the media must be publicly corrected immediately;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">actions during the course of an offer by the offeree company, which might frustrate the offer are generally prohibited unless shareholders approve these plans. Frustrating actions would include, for example, lengthening the notice period for directors under their service contract or agreeing to sell off material parts of the target group;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">stringent and detailed requirements are laid down for the disclosure of dealings in relevant securities during an offer, including the prompt disclosure of positions and dealing in relevant securities by the parties to an offer and any person who is interested (directly or indirectly) in 1% or more of any class of relevant securities; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">employees of both the offeror and the offeree company and the trustees of the offeree company&#8217;s pension scheme must be informed about an offer. In addition, the offeree company&#8217;s employee representatives and pension scheme trustees have the right to have a separate opinion on the effects of the offer on employment appended to the offeree board of directors&#8217; circular or published on a website.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We are incorporated under the laws of England and Wales. The rights of holders of ordinary shares and, therefore, certain of the rights of holders of ADSs, are governed by the laws of England and Wales, including the provisions of the U.K. Companies Act 2006, and by our Articles. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The principal differences include the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">under English law and our Articles, each shareholder present at a meeting has only one vote unless demand is made for a vote on a poll, in which case each holder gets one vote per share owned. Under U.S. law, each shareholder typically is entitled to one vote per share at all meetings;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">under English law, it is only on a poll that the number of shares determines the number of votes a holder may cast. You should be aware, however, that the voting rights of ADSs are also governed by the provisions of a deposit agreement with our depositary bank;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">under English law, subject to certain exceptions and disapplications, each shareholder generally has preemptive rights to subscribe on a proportionate basis to any issuance of ordinary shares or rights to subscribe for, or to convert securities into, ordinary shares for cash. Under U.S. law, shareholders generally do not have preemptive rights unless specifically granted in the certificate of incorporation or otherwise;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">under English law and our Articles, certain matters require the approval of 75% of the shareholders who vote (in person or by proxy) on the relevant resolution (or on a poll of shareholders representing 75% of the ordinary shares voting (in person or by proxy)), including amendments to the Articles. This may make it more difficult for us to complete corporate transactions deemed advisable by our board of directors. Under U.S. law, generally only majority shareholder approval is required to amend the certificate of incorporation or to approve certain significant transactions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">in the U.K., takeovers may be structured as takeover offers or as schemes of arrangement. Under English law, a bidder seeking to acquire us by means of a takeover offer would need to make an offer for all of our outstanding ordinary shares/ADSs. If acceptances are not received for 90% or more of the ordinary shares/ADSs under the offer, under English law, the bidder cannot complete a &#8220;squeeze out&#8221; to obtain 100% control of us. Accordingly, acceptances of 90% of our outstanding ordinary shares (including those represented by ADSs) will likely be a condition in any takeover offer to acquire us, not 50% as is more common in tender offers for corporations organized under Delaware law. By contrast, a scheme of arrangement, the successful completion of which would result in a bidder obtaining 100% control of us, requires the approval of a majority of shareholders voting at the meeting and representing 75% of the ordinary shares (including those represented by ADSs) voting for approval;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">under English law and our Articles, shareholders and other persons whom we know or have reasonable cause to believe are, or have been, interested in our shares may be required to disclose information regarding their interests in our shares upon our request, and the failure to provide the required information could result in the loss or restriction of rights attaching to the shares, including prohibitions on certain transfers of the shares, withholding of dividends and loss of voting rights. Comparable provisions generally do not exist under U.S. law; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the quorum requirement for a shareholders&#8217; meeting is one or more qualifying persons present at a meeting and between them holding (or being the proxy or corporate representative of the holders of) at least thirty-three and one-third&#160;percent (33 1/3%) in number of the issued shares (excluding any shares held as treasury shares) entitled to attend and vote on the business to be transacted. Under U.S. law, a majority of the shares eligible to vote must generally be present (in person or by proxy) at a shareholders&#8217; meeting in order to constitute a quorum. The minimum number of shares required for a quorum can be reduced pursuant to a provision in a company&#8217;s certificate of incorporation or bylaws, but typically not below one-third of the shares entitled to vote at the meeting.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our Articles provide that the courts of England and Wales are the exclusive forum for the resolution of all shareholder complaints other than complaints asserting a cause of action arising under the Securities Act or the Exchange Act, and that the United States District Court for the Southern District of New York will be the exclusive forum for the resolution of any shareholder complaint asserting a cause of action arising under the Securities Act or the Exchange Act.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Our Articles provide that, unless we consent by ordinary resolution to the selection of an alternative forum, the courts of England and Wales shall, to the fullest extent permitted by law, be the exclusive forum for: (a)&#160;any derivative action or proceeding brought on our behalf; (b)&#160;any action or proceeding asserting a claim of breach of fiduciary duty owed by any </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">of our directors, officers or other employees to us; (c)&#160;any action or proceeding asserting a claim arising out of any provision of the U.K. Companies Act 2006 or our Articles (as may be amended from time to time); or (d)&#160;any action or proceeding asserting a claim or otherwise related to our affairs (the &#8220;England and Wales Forum Provision&#8221;). The England and Wales Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our Articles further provide that unless we consent by ordinary resolution to the selection of an alternative forum, the United States District Court for the Southern District of New York shall be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act or the Exchange Act (the &#8220;U.S. Federal Forum Provision&#8221;). In addition, our Articles provide that any person or entity purchasing or otherwise acquiring any interest in our shares is deemed to have notice of and consented to the England and Wales Forum Provision and the U.S. Federal Forum Provision; provided, however, that our shareholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules&#160;and regulations thereunder.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The England and Wales Forum Provision and the U.S. Federal Forum Provision in our Articles may impose additional litigation costs on our shareholders in pursuing any such claims. Additionally, the forum selection clauses in our Articles may limit the ability of our shareholders to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our shareholders. In addition, while the Delaware Supreme Court ruled in March&#160;2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts, including the courts of England and Wales and other courts within the U.S., will enforce our U.S. Federal Forum Provision. If the U.S. Federal Forum Provision is found to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our results of operations and financial condition. The U.S. Federal Forum Provision may also impose additional litigation costs on our shareholders who assert that the provision is not enforceable or invalid. The courts of England and Wales and the United States District Court for the Southern District of New York may also reach different judgments or results than would other courts, including courts where a shareholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our shareholders.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Changes in U.S. tax law could adversely affect our financial condition and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The rules&#160;dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. For example, the One Big Beautiful Bill Act (the &#8220;OBBBA&#8221;) was signed into law on July 4, 2025 and made significant changes to U.S. federal tax law. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our ordinary shares or ADSs. We are evaluating the elections available under the OBBBA. Based on our current assessment, we do not expect the changes to Section 174 under the OBBBA to have a material impact on our financial position or results of operations. For example, under Section 174 of the Internal Revenue Code of 1986, as amended (the "Code"), in taxable years beginning after December 31, 2021, expenses that are incurred for research and development performed outside the U.S. will be capitalized and amortized, which may have an adverse effect on our cash flow. The OBBBA provides that for taxable years beginning after December 31, 2024, expenses that are incurred for research and development performed in the U.S. may, at the taxpayer&#8217;s election, be immediately deducted or capitalized and amortized. In addition, the OBBBA provides that for taxable years beginning after December 31, 2021 and before January 1, 2025, certain eligible taxpayers generally may elect to retroactively deduct expenses for research and development performed in the U.S. in such taxable years by filing amended tax returns for such taxable years, and all other taxpayers that are not eligible to make such an election and that amortized expenses for research and development performed in the U.S. in such taxable years generally may elect to accelerate and deduct the remaining unamortized amounts of such research and development expenses (i) in the first taxable year beginning after December 31, 2024, or (ii) ratably over the two-taxable year period beginning with the first taxable year beginning after December 31, 2024. In recent&#160;years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in U.S. tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisors regarding the implications of potential changes in U.S. tax laws on an investment in our ordinary shares or ADSs. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We believe we were a passive foreign investment company ("PFIC"), for prior taxable years and we may be a PFIC in the current or future taxable years, which could result in adverse U.S. federal income tax consequences to U.S. Holders.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Under the Code, we will be a PFIC, for any taxable&#160;year in which (i)&#160;75% or more of our gross income consists of passive income or (ii)&#160;50% or more of the average quarterly value of our assets consists of assets that produce, or are held for the production of, passive income. For the purposes of these tests, passive income includes dividends, interest, gains from the sale or exchange of investment property and certain rents and royalties. In addition, for purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as holding and receiving directly its proportionate share of assets and income of such corporation. If we are a PFIC for any taxable&#160;year during which a U.S. Holder holds our ordinary shares or ADSs, the U.S. Holder may be subject to adverse tax consequences regardless of whether we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred and additional reporting requirements. A &#8220;U.S. Holder&#8221; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of ordinary shares or ADSs and is: (i)&#160;an individual who is a citizen or individual resident of the United States; (ii)&#160;a corporation, or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States, any state therein or the District of Columbia; (iii)&#160;an estate the income of which is subject to U.S. federal income taxation regardless of its source; or (iv)&#160;a trust if (1)&#160;a U.S. court is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of the trust or (2)&#160;the trust has a valid election to be treated as a U.S. person under applicable U.S. Treasury Regulations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Based on the current and expected composition of our income and the value of our assets, we were a PFIC for the year ended December 31, 2025 and expect to remain a PFIC for our current taxable year (or the portion of our current taxable year ending on or prior to the consummation of the Scheme Transaction, as applicable). No assurances regarding our PFIC status can be provided for the current taxable year or any future taxable years. The determination of whether we are a PFIC is a fact-intensive determination made on an annual basis applying principles and methodologies that in some circumstances are unclear and subject to varying interpretation. Under the income test, our status as a PFIC depends on the composition of our income which will depend on the transactions we enter into in the future and our corporate structure. The composition of our income and assets is also affected by the spending of the cash we raise in any offering.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Each U.S. Holder should consult its own tax advisors with respect to the potential adverse U.S. tax consequences to it if we are or were to become a PFIC. If we are a PFIC for any taxable year during which a U.S. investor owns ADSs, certain adverse U.S. federal income tax consequences could apply to such U.S. investor. We will provide the information necessary for a U.S. investor to make a qualified electing fund election with respect to us.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If we are a controlled foreign corporation, there could be adverse U.S. federal income tax consequences to certain U.S. Holders.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Each &#8220;Ten Percent Shareholder&#8221; (as defined below) in a non-U.S. corporation that is classified as a &#8220;controlled foreign corporation (a &#8220;CFC&#8221;) for U.S. federal income tax purposes generally is required to include in income for U.S. federal tax purposes such Ten Percent Shareholder&#8217;s pro rata share of the CFC&#8217;s &#8220;Subpart F income&#8221; and investment of earnings in U.S. property, even if the CFC has made no distributions to its shareholders. In addition, if a non-U.S. corporation owns at least one U.S. subsidiary, under applicable law for taxable years ending before January 1, 2026, any current non-U.S. subsidiaries and any future newly formed or acquired non-U.S. subsidiaries of the non-U.S. corporation will be treated as CFCs, regardless of whether the non-U.S. corporation is treated as a CFC. Subpart F income generally includes dividends, interest, rents, royalties, gains from the sale of securities and income from certain transactions with related parties. Each Ten Percent Shareholder of a CFC is also required to include in income such Ten Percent Shareholder&#8217;s share of &#8220;global intangible low-taxed income&#8221; (for tax years beginning after December 31, 2017 and prior to January 1, 2026) and &#8220;net CFC tested income&#8221; (for tax years beginning after December 31, 2025) with respect to such CFC. In addition, a Ten Percent Shareholder that realizes gain from the sale or exchange of shares in a CFC may be required to classify a portion of such gain as dividend income rather than capital gain. A non-U.S. corporation generally will be classified as a CFC for U.S. federal income tax purposes if Ten Percent Shareholders own, directly or indirectly, more than 50% of either the total combined voting power of all classes of stock of such corporation entitled to vote or of the total value of the stock of such corporation. A &#8220;Ten Percent Shareholder&#8221; is a United States person (as defined by the Code) who owns or is considered to own 10% or more of (1) the value of all classes of stock of such corporation or (2) the total combined voting power of all classes of stock entitled to vote of such corporation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We do not believe that we were a CFC in 2025, and (prior to the consummation of the Scheme Transaction) we do not expect to be a CFC in 2026. The determination of CFC status is complex and includes attribution rules, the application of which is not entirely certain. An individual that is a Ten&#160;Percent Shareholder with respect to a CFC generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a Ten&#160;Percent Shareholder that is a U.S. corporation. Failure to comply with CFC reporting obligations may subject a United States shareholder to significant monetary penalties. We cannot provide any assurances that we will furnish to any Ten&#160;Percent Shareholder information that may be necessary to comply with the reporting and tax paying obligations applicable under the CFC rules&#160;of the Code. U.S. Holders should consult their own tax advisors with respect to the potential adverse U.S. tax consequences of becoming a Ten&#160;Percent Shareholder in a CFC.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In addition, testing required to be conducted by us in connection with Section 404 of the Sarbanes-Oxley Act, and any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Deficient internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our ADSs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">If we fail to establish and maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our ADSs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Implementing any appropriate changes to our internal controls, including changes relating to our application of the requirements of Section&#160;404 of the Sarbanes-Oxley Act, may distract our officers and employees, entail substantial costs to modify our existing processes, and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business. In addition, investors&#8217; perceptions that our internal controls are inadequate or that we are unable to produce accurate financial statements on a timely basis may harm our stock price and make it more difficult for us to continue to discover and develop novel immunotherapeutics for the treatment of immunetolerance.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">We could be subject to securities class action litigation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Historically, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent&#160;years. If we were to be sued, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">The U.K.'s withdrawal from the European Union could increase the regulatory burden of product development and authorization in the U.K. and European Union.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The U.K. formally left the European Union on 31 January 2020 (commonly referred to as Brexit). The European Union and the U.K. have concluded a trade and cooperation agreement (&#8220;TCA&#8221;) which has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not provide for wholesale mutual recognition of the U.K. and European Union pharmaceutical regulations. As a result, a separate application must be made to conduct a clinical trial in the U.K. as well as the European Union and a separate U.K. marketing authorization is required to commercialize a medicinal product in the U.K. as well as the European Union. Obtaining such regulatory approvals is a lengthy and expensive process and this therefore adds time and expense to the conduct of our business in both the U.K. and European Union. In addition, the U.K. is seeking to reform aspects of the medicines legislation following its departure from the European Union. For example, on December 12, 2024, the U.K. government introduced a legislative proposal that, if implemented, will replace the current regulatory framework for clinical trials in the U.K. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials and the development of medicinal products in the U.K. and/or European Union, our development plans may be impacted. If we fail to comply with the regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects will be adversely affected.</span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_25"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 1B. Unresolved Staff Comments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Not Applicable.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_28"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 1C. Cybersecurit</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">y</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-39" continuedAt="f-39-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-38" continuedAt="f-38-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">In the normal course of business, we may collect and store personal information and other sensitive information, including proprietary and confidential business information, financial information, trade secrets, intellectual property, information regarding trial participants in connection with clinical trials, sensitive third-party information and employee information. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-40" continuedAt="f-40-1">In an effort to protect this information from cybersecurity risks, we have developed a cybersecurity program that has been </ix:nonNumeric></span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><ix:continuation id="f-38-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%"><ix:continuation id="f-39-1"><ix:continuation id="f-40-1">integrated into our overall risk management process; it incorporates policies and practices designed to protect the confidentiality, integrity and security of our sensitive information.</ix:continuation></ix:continuation> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-42"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-41">As part of our cybersecurity risk management procedures, we perform system monitoring and scanning and utilize security tools supported by a third-party managed services provider.</ix:nonNumeric> We also conduct penetration testing performed by a third-party provider.</ix:nonNumeric> Employees are enrolled in cybersecurity awareness training courses designed to help them identify cybersecurity concerns and take appropriate actions, and we conduct periodic simulated phishing tests in an effort to further raise cybersecurity awareness and reduce the risk of a successful cyberattack. We have an incident response plan to guide us in responding to cybersecurity incidents, and have conducted tabletop exercises to test the plan. We also take steps to protect against business interruption and conduct annual restoration testing for major systems. In addition, we use a risk-based approach to assessing cybersecurity risks from certain critical third-party vendors. This program aims to assess the cybersecurity maturity of vendors who have access to our data or systems through an evaluation of the vendor&#8217;s cybersecurity practices.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-43" continuedAt="f-43-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-44" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-45" escape="true">Our cybersecurity program is managed by our <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-46">Manager of Operations and IT Systems</ix:nonNumeric>, who reports directly to senior management on matters regarding cybersecurity, as appropriate, and is supported by third-party vendors</ix:nonNumeric>. Together, our senior management and Manager of Operations and IT Systems are responsible for leading company-wide cybersecurity strategy, policies, standards, and processes.</ix:nonNumeric> </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-48" continuedAt="f-48-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-47" escape="true"><ix:continuation id="f-43-1">The Audit Committee, pursuant to its charter, has oversight over management of cybersecurity risks. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-49" escape="true">Senior management provide the Audit Committee with periodic updates on data management and cybersecurity initiatives, as well as on significant existing and emerging cybersecurity risks, including cybersecurity incidents, as applicable.</ix:nonNumeric></ix:continuation></ix:nonNumeric> </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-48-1">We have a process to record identified risks from cybersecurity threats in our risk register, along with an assessment of the severity of the potential impact and the likelihood of occurrence. This process is designed to facilitate a unified and integrated assessment of corporate risk and governance. The risk register is reviewed periodically by senior management and at least annually by the <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-50">Board of Directors</ix:nonNumeric>.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-51">We have not identified any cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition; however, like other companies in our industry, we and our third-party vendors may experience threats and security incidents that could affect our information or systems.</ix:nonNumeric> For more information about the cybersecurity risks we face, please see Section 1A. Risk Factors.</span></div><div><span><br/></span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_31"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 2. Properties</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We lease and occupy approximately 19,700 square feet of state-of-the-art wet laboratory and office space in Germantown, Maryland, United States. We also lease approximately 31,000 square feet of office and laboratory space on the Harwell Science and Innovation Campus, Harwell, Oxfordshire, U.K. We are currently marketing the Harwell facility for sublease for the remainder of the lease term.</span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 3. Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We are not currently a party to any material legal proceedings. From time to time, we may become involved in other litigation or legal proceedings relating to claims arising from the ordinary course of business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We have no penalties to report in accordance with The Revenue Procedure 2005-51 and Section 6707A(e) of the Internal Revenue Code, which requires the Company to disclose any IRS demand for payment of certain penalties related to tax-avoidance transactions under I.R.C. Sections 6662(h), 6662A, or 6707A.</span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">PART II</span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_43"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 5. Market For Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Market Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our ordinary shares, nominal value &#163;0.000025 per share, in the form of ADSs trade under the symbol &#8220;BRNS&#8221; on the Nasdaq Global Market.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Holders of Our ADSs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our ADSs each represent one ordinary share, nominal value &#163;0.000025 per share, of Barinthus Biotherapeutics plc. An ADS may be evidenced by an American Depositary Receipt issued by the Bank of New York Mellon as depositary bank. As of March 6, 2026, there was one holder of record of our ordinary shares, nominal value &#163;0.000025 per share, and 39 holders of record of our ADSs. The closing sale price per ADS on the Nasdaq Global Market on March 6, 2026 was $0.60.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Dividends</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We have never paid or declared any cash dividends on shares of our ordinary shares, ADSs or other securities and do not anticipate paying or declaring any cash dividends in the foreseeable future. We currently intend to retain all future earnings, if any, for use in the operation of our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Recent Sales of Unregistered Equity Securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Certain Material U.K. Tax Considerations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following discussion is limited to a general guide to current U.K. tax law and HM Revenue &amp; Customs, or HMRC, published guidance (which is not binding) applying as at the date of this Annual Report (both of which are subject to change at any time, possibly with retrospective effect) relating to the ownership and disposition of ordinary shares, or such shares represented by ADSs. Each shareholder should however seek individual tax advice as specific rules may apply in certain circumstances. The U.K. tax consequences discussed below do not constitute legal or tax advice and do not reflect a complete analysis or listing of all the possible U.K. tax consequences that may be relevant to holders of our ordinary shares or ADSs. It is written on the basis that we do not (and will not) directly or indirectly derive 75% or more of its qualifying asset value from U.K. land, and that we are and will remain solely resident in the U.K. for tax purposes and will therefore be subject to the U.K. tax regime and not the U.S. tax regime.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Except to the extent that the position of non-U.K. resident persons is expressly referred to, this guide relates only to persons who are resident for tax purposes solely in the U.K. and do not have a permanent establishment, branch or agency (or equivalent) in any other jurisdiction with which the holding of our ordinary shares or ADSs is connected, who are absolute beneficial owners of our ordinary shares or ADSs (and do not hold our ordinary shares or ADSs through an Individual Savings Account or a Self-Invested Personal Pension or any other wrapper or similar product) (a &#8220;U.K. Holder&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">This guide may not relate to certain classes of U.K. Holders, such as (but not limited to):</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">persons who are connected with us;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">financial institutions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">insurance companies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">charities or tax-exempt organizations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">collective investment schemes;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">pension schemes;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">market makers, intermediaries, brokers or dealers in securities or persons who hold ordinary shares or ADSs otherwise than as an investment; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">persons who have (or are deemed to have) acquired their ordinary shares or ADSs by virtue of an office or employment or who are or have been our officers or employees or any of our affiliates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The decision of the First-tier Tribunal (Tax Chamber) in HSBC Holdings PLC and The Bank of New York Mellon Corporation v HMRC (2012) cast some doubt on whether a holder of a depositary receipt is the beneficial owner of the underlying shares. However, based on published HMRC guidance we would expect that HMRC will regard a holder of ADSs as holding the beneficial interest in the underlying shares and therefore these paragraphs assume that a holder of ADSs is the beneficial owner of the underlying ordinary shares and any dividends paid in respect of the underlying ordinary shares (where the dividends are regarded for U.K. purposes as that person&#8217;s own income) for U.K. direct tax purposes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Chargeable Gains </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">A disposal or deemed disposal of ordinary shares or ADSs by a U.K. holder may, depending on such holder&#8217;s circumstances and subject to any available exemptions or reliefs (such as the annual exemption), give rise to a chargeable gain or an allowable loss for the purposes of U.K. capital gains tax (for individuals) and corporation tax on chargeable gains (for corporation tax payers).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">If an individual U.K. Holder who is subject to U.K. income tax at either the higher or the additional rate is liable to U.K. capital gains tax on the disposal of ordinary shares or ADSs, the current applicable rate will be 24% (for the tax year 2025/2026). For an individual U.K. Holder who is subject to U.K. income tax at the basic rate and liable to U.K. capital gains tax on such disposal, the current applicable rate would be 18% (for the tax year 2025/2026), save to the extent that any capital gains when aggregated with the U.K. Holder&#8217;s other taxable income and gains in the relevant tax year exceed the unused basic rate tax band. In that case, the capital gains tax rate currently applicable to the excess would be 24% (for the tax year 2025/2026).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">If a corporate U.K. Holder is or becomes liable to U.K. corporation tax on the disposal (or deemed disposal) of ordinary shares or ADSs, the main rate of U.K. corporation tax</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">would apply (currently at 25% for companies with profits of more than &#163;250,000 or 19% for companies with profits not exceeding &#163;50,000 with a marginal relief applying to profits between &#163;50,000 and &#163;250,000, in each case, for the 2025/2026 tax year).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Any chargeable gain (or allowable loss) will generally be calculated by reference to the consideration received for the disposal of the ADSs less the allowable cost to the U.K. Holder of acquiring such ADSs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">If you are not resident in the U.K. for U.K. tax purposes (or, in the case of an individual, not temporarily non-resident), you should not normally be liable for U.K. tax on capital gains realized or accrued on the sale or other disposition of ordinary shares or ADSs unless the ordinary shares or ADSs are held in connection with your trade carried on in the U.K. through a branch or agency (or, in the case of a corporate holder, a permanent establishment) and the ordinary shares or ADSs are or have been used, held or acquired for the purposes of such trade or such branch or agency. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">An individual holder of ordinary shares or ADSs who ceases to be resident in the U.K. for U.K. tax purposes for a period of less than five years and who disposes of ordinary shares or ADSs during that period may also be liable on returning to the U.K. (or upon ceasing to be regarded as resident outside the U.K. for the purposes of any relevant double taxation treaty) for U.K. capital gains tax despite the fact that the individual may not be resident in the U.K. at the time of the disposal. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Taxation of Dividends </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Under U.K. law, there is no withholding tax on dividends paid on the ordinary shares or ADSs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">An individual U.K. Holder may, depending on his or her particular circumstances, be subject to U.K. tax on dividends received from us. An individual holder of ADSs who is not resident for tax purposes in the U.K. should not be chargeable to U.K. income tax on dividends received from us unless he or she carries on (whether solely or in partnership) a trade, profession or vocation in the U.K. through a branch or agency to which the ADSs are attributable. There are certain exceptions for trading in the U.K. through independent agents, such as some brokers and investment managers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Dividend income is treated as the top slice of the total income chargeable to U.K. income tax for an individual U.K. Holder. An individual U.K. Holder who receives a dividend in the 2025/2026 tax year will be entitled to a dividend tax-free allowance of &#163;500. Income within the dividend tax-free allowance counts towards an individual&#8217;s basic, higher or additional rate limits and may, therefore, affect the level of income tax personal allowance to which they are entitled. Dividend income received in excess of the dividend tax-free allowance will (subject to the availability of any income tax personal allowance) be charged at 8.75% for the tax year 2025/2026 (rising to 10.75% for the tax year 2026/2027) to the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">extent the excess amount falls within the basic rate band, 33.75% for the tax year 2025/2026 (rising to 35.75% for the tax year 2026/2027) to the extent the excess amount falls within the higher rate band and 39.35% (for the tax years 2025/2026 and 2026/2027) to the extent the excess amount falls within the additional rate band. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">A corporate holder of ADSs who is not resident for tax purposes in the U.K. should not be chargeable to U.K. corporation tax on dividends received from us unless it carries on (whether solely or in partnership) a trade in the U.K. through a permanent establishment to which the ADSs are attributable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Corporate U.K. Holders should not be subject to U.K. corporation tax on any dividend received from us so long as the dividends qualify for exemption, which should be the case, although certain conditions must be met. It should be noted that the exemptions, whilst of wide application, are not comprehensive and are subject to anti-avoidance rules. If the conditions for the exemption are not satisfied, such anti-avoidance provisions apply, or such U.K. Holder elects for an otherwise exempt dividend to be taxable, U.K. corporation tax will be chargeable on the amount of any dividends (at the current rate of 25% for companies with profits of more than &#163;250,000 or 19% for companies with profits not exceeding &#163;50,000, with a marginal relief applying to profits between &#163;50,000 and &#163;250,000, in each case for the 2023/2024 and 2025/2026 tax years).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stamp Duty and Stamp Duty Reserve Tax </span></div><div style="margin-top:12pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The discussion below relates to the holders of our ordinary shares or ADSs wherever resident, however it should be noted that special rules may apply to certain persons such as market makers, brokers, dealers or intermediaries.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Stamp duty and/or stamp duty reserve tax (&#8220;SDRT&#8221;) are imposed in the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">U.K.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> on certain transfers of securities (including shares in companies which, like us, are incorporated in the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">U.K.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">) at a rate of 0.5% of the consideration paid for the transfer. Certain transfers of shares to depositaries or into clearance systems are charged a higher rate of 1.5%. Transfers of interests in shares within a depositary or clearance system, and from a depositary to a clearance system, are generally exempt from stamp duty and SDRT.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issue of Ordinary Shares</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Under current U.K. tax law </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(and except in relation to depositary receipt systems and clearance services (as to which see below)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">, no U.K. SDRT (or, where</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">effected by a written instrument, U.K. stamp duty) should generally be payable in respect of an issue of ordinary shares (including ordinary shares underlying our ADSs).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transfer of Ordinary Shares</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any transfer of, or unconditional agreement to transfer, our ordinary shares that occurs outside the DTC system, including repurchases by us, will ordinarily attract stamp duty or SDRT at a rate of 0.5% of the amount or value of the consideration payable for the transfer</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(and in the case of stamp duty, rounded up to the next multiple of &#163;5), unless the transfer is to a connected company and in which case a market value may apply. This duty must be paid (and where applicable the transfer document stamped by HMRC) before the transfer can be registered in our books. Typically stamp duty would be paid by the purchaser of the ordinary shares.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clearance Services and Depositary Receipts</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">An unconditional agreement to issue ordinary shares to a clearance service or a depositary receipt system (including to a nominee or agent for a person whose business is or includes the issue of depositary receipts or the provision of clearance services) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">should not attract the higher rate of 1.5% U.K. stamp duty or U.K. SDRT (which we refer to as the 1.5% Charge). Furthermore, subject to the below, no 1.5% Charge should arise in respect of a transfer of ordinary shares</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> to a clearance service or a depositary receipt system where the transfer is carried out in the course of &#8220;capital-raising arrangements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">, being arrangements pursuant to which the relevant ordinary shares are issued by the company for the purpose of raising new capital. Where any ordinary shares are subject to restriction that has the effect of preventing the transfer of such ordinary shares into a clearance service or depositary receipt system in the course of capital-raising arrangements, such ordinary shares must be transferred as soon as reasonably practicable after the time at which the restriction ceases to have effect in order to prevent the 1.5% Charge from applying.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Where a clearance service has made and maintained an election under section 97A of the U.K. Finance Act 1986, or a section 97A election </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">no 1.5% Charge will apply on any transfer of ordinary shares to that clearance service</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">It is </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">understood that HMRC regards the facilities of DTC as a clearance service for these purposes and we are not aware of any section 97A election having been made by DTC. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Any stamp duty or SDRT payable on a transfer of ordinary shares to a depositary receipt system or clearance service or in respect of a transfer within a depositary receipt system or clearance service, will strictly be accountable by the clearance service or depositary receipt system operator or their nominee, as the case may be, but will in practice generally be paid by the transferors or participants in the clearance service or depositary receipt system. Specific professional advice should be sought before incurring or reimbursing the costs of a U.K. stamp duty or U.K. SDRT charge in any circumstances.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Issue of ADSs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">No U.K. stamp duty or SDRT should be payable on the issue of ADSs in the Company.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Transfers of ADSs within a clearance system</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">No U.K. stamp duty or SDRT should be required to be paid in respect of a paperless transfer of ADSs through the facilities of DTC, provided that no section 97A election has been made and maintained by DTC, and such ADSs are held through DTC at the time of any agreement for their transfer. We are not aware of any section 97A election having been made by the DTC.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Issuance or Transfers of ADSs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On the basis of current published HMRC guidance, ADSs are not regarded as stock or a marketable security for the purposes of U.K. stamp duty or a chargeable security for the purposes of U.K. SDRT and, as such, no U.K. stamp duty or SDRT should be required to be paid on the issue or transfer of (including an agreement to transfer) ADSs in the Company.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Purchase of Equity Securities by the Issuer and Affiliated Purchases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 6. [Reserved]</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">   Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes appearing elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks, uncertainties and assumptions. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis. You should carefully read the &#8220;Special Note Regarding Forward Looking Statements&#8221; and &#8220;Risk Factors&#8221; sections of this Annual Report to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements contained in the following discussion and analysis.</span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We are a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases within the immunology and inflammation ("I&amp;I") space. Helping patients and their families is the guiding principle at the heart of Barinthus Bio. We aim to achieve this by developing truly transformational and highly disease-specific immunotherapies. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We are prioritizing the development of a pipeline for I&amp;I indications enabled by our proprietary and highly differentiated platform for promoting immune tolerance, referred to as SNAP-TI, that are designed to guide patient's T cells to reduce inflammation and restore the natural state of immune non-responsiveness to healthy tissue. Our lead candidate, VTP-1000, is designed to restore immune non-responsiveness to gluten in patients with celiac disease, and is currently being assessed </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">in a Phase 1 clinical trial. Based on encouraging preclinical data, we believe that the SNAP-TI platform has the potential to impact multiple other I&amp;I indications.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We are also exploring partnership opportunities for VTP-300, a product candidate to treat CHB that harnesses viral vector platform technologies, consisting of ChAdOx and MVA; which are designed to increase disease-specific CD8+ T cells. VTP-300 is a Phase 2 immunotherapeutic treatment modality that is a component of a treatment regimen to establish functional cure in patients who are chronically infected by the hepatitis B virus. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We believe our core capabilities at the intersection of T cell immunology and immunotherapeutic technology platforms combined with our track record of successfully executing development path activities uniquely position us to navigate towards delivering promising new treatments for patients with autoimmune and inflammatory diseases and building value for shareholders.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">In September 2025, we entered into the Merger Agreement to combine in an all-stock transaction with Clywedog. The newly combined company will advance a differentiated portfolio of clinical-stage candidates targeting metabolic and autoimmune diseases, with four clinical data milestones expected within 18 months of the closing of the transaction. Upon the closing of the transaction, the combined company will be renamed &#8220;Clywedog Therapeutics Holdings, Inc.&#8221; and is expected to trade on the Nasdaq under the new ticker symbol &#8220;CLYD.&#8221; The transaction is expected to close in the second quarter of 2026, supported by existing cash and additional investments by OrbiMed and TPAV, LLC, both existing shareholders in Clywedog, and new investors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We have incurred net losses in each annual and interim reporting period since 2023. For the years ending December 31, 2025 and 2024, we incurred net losses of $66.5 million and $61.2 million, respectively. As of December&#160;31, 2025 and 2024, we had an accumulated deficit of $304.1 million and $237.7 million, respectively, and we do not currently expect positive cash flows from operations in the foreseeable future. We expect to incur net operating losses for at least the next several years as we advance our product candidates through clinical development, seek regulatory approval, prepare for approval, and in some cases proceed to commercialization of our product candidates, as well as continue our research and development efforts, as and when appropriate.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">At this time, we cannot reasonably estimate, or know the nature, timing and estimated costs of all of the efforts that will be necessary to complete the development of any of our product candidates that we develop through our programs. We are also unable to predict when, if ever, material net cash inflows will commence from sales of product candidates we develop, if at all. This is due to the numerous risks and uncertainties associated with developing product candidates to approval and commercialization, including the uncertainty of:</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">successful completion of preclinical studies and clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">acceptance of INDs for our planned clinical trials or future clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">successful and timely enrollment and completion of clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">data from our clinical program supporting approvable and commercially acceptable risk/benefit profiles for our product candidates in the intended populations;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">receipt and maintenance of necessary regulatory and marketing approvals from applicable regulatory authorities, in the light of the commercial environment then existent;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">availability and successful procurement of raw materials required to manufacture our products for clinical trials, scale-up of our manufacturing processes and formulation of our product candidates for later stages of development and commercial production;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">establishing either our own manufacturing capabilities or satisfactory agreements with third-party manufacturers for clinical supply for later stages of development and commercial manufacturing;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">entry into collaborations or partnerships, where appropriate, to further the development of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining and maintaining intellectual property and trade secret protection or regulatory exclusivity for our product candidates as well as qualifying for, maintaining, enforcing and defending such intellectual property rights and claims;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">successfully launching or assisting with the launch of commercial sales of our product candidates following approval;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">acceptance of each product&#8217;s benefits and uses by patients, the medical community and third-party payors following approval;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the prevalence and severity of any adverse events experienced with our product candidates in development;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">establishing and maintaining a continued acceptable safety profile of the&#8201;product candidates following approval;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors if necessary or desirable; and</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">effectively competing with other therapies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">A change in the outcome of any of these or other variables with respect to the development of any of our current and future product candidates could significantly change the costs and timing associated with the development of that product candidate, in either direction. Furthermore, our operating plans may change in the future owing to research outcomes or other opportunities, and we may need additional funds to meet operational needs and capital requirements associated with such altered operating plans. Unless and until we can generate a substantial amount of revenue from our product candidates, if approved, we expect to finance our future cash needs through public or private equity offerings, debt financings, collaborations, licensing arrangements or other sources, or any combination of the foregoing. Based on our current standalone research and development plans, we expect that our existing cash, cash equivalents, restricted cash and other financial resources will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months. These estimates are based on assumptions that may prove to be wrong, and we could use our available capital resources more quickly than we expect. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">If we raise additional funds through collaborations, strategic alliances, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we would be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Recent Developments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Merger Agreement Amendment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In February 2026, we announced we have entered into an amendment to the Merger Agreement with Clywedog to update the exchange ratio framework to provide additional flexibility in finalizing the transaction terms and to revise certain minimum cash requirements to reflect anticipated transaction timing. All other material terms remain unchanged.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Nasdaq Listing Rule Compliance </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On January 6, 2026, we announced we received a letter from the Nasdaq indicating that the closing bid price of our ADSs, each representing one ordinary share of the Company, was below $1.00 per share for 30 consecutive business days, and that, therefore, we are not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Market. The notice from Nasdaq has no immediate effect on the listing of the ADSs, and the ADSs will continue to be listed on the Nasdaq Global Market under the symbol &#8220;BRNS.&#8221; Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), we have automatically been afforded a 180-calendar day period, or until June 29, 2026, to regain compliance with the minimum bid price requirement. The continued listing standard will be met if the closing bid price of the ADSs is at least $1.00 per share for a minimum of ten consecutive business days during the 180-calendar day period. If we are not in compliance by June 29, 2026, we may be afforded a second 180-calendar day period to regain compliance if it meets certain requirements. We intend to monitor the closing bid price of the ADSs and are currently evaluating our options for regaining compliance, which could include a reverse stock split of the ADSs.</span></div><div><span><br/></span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Impact of International Conflict</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In respect of the international conflicts in Gaza, Ukraine and Iran, we have no operations or suppliers based in Israel, Gaza, Ukraine, Belarus, Russia or Iran, and as a result, as of the date of this Annual Report on Form 10-K, we believe the impact on our business, operations and financial condition will be minimal.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Impact of Global Economic Conditions and Inflationary Pressures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Instability in global economic conditions and geopolitical matters, as well as volatility in financial markets, could have a material adverse effect on our results of operations and financial condition. Inflationary pressures, volatile interest rates, or intensified disruptions in the global financial markets could adversely affect our future financing capability or ability to access the capital markets. Additionally, we may incur future increases in operating costs due to additional inflationary increases.</span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_64"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Components of Our Operating Results</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">To date, we have not generated any revenue from direct product sales and do not expect to do so in the near future, if at all. Most of our revenue to date has been derived from the OUI License Agreement Amendment with OUI relating to Vaxzevria.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In April 2020, we entered into the OUI License Agreement Amendment with OUI in respect of our rights to use the ChAdOx1 technology in COVID-19 vaccines to facilitate the license of those rights by OUI to AstraZeneca. Under this agreement, we are entitled to receive from OUI a share of payments, including royalties and milestones, received by OUI from AstraZeneca in respect of this vaccine. In March, 2022, we were notified by OUI of the commencement of payments to us arising from AstraZeneca&#8217;s commercial sales of Vaxzevria. In May 2024, AstraZeneca announced the initiation of withdrawal of marketing authorization for Vaxzevria in Europe as demand had declined. In October 2024, we were informed of additional amounts due to the Company from Oxford University Innovation Limited (OUI) in relation to the Company's share of royalties received by OUI as a result of prior commercial sales of Vaxzevria by AstraZeneca. As a result there was no revenue for the year ending December&#160;31, 2025 (year ended December&#160;31, 2024 $15.0 million), representing the amounts we have been notified of as due by OUI to date. We do not expect to receive any further payments relating to future commercial sales of Vaxzevria and, if such payments are due, that we will be notified of such payments in a timely manner.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Operating Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our operating expenses since inception have consisted of research and development costs and general and administrative costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Since our inception, we have focused significant resources on our research and development activities, including establishing and building on our adenovirus platform, further enhancing our in-licensed ChAdOx1, ChAdOx2 and MVA vectors, developing a next-generation adenoviral vector, acquiring new technology platforms including SNAP-TI and SNAP-CI, conducting preclinical studies, developing various manufacturing processes, and advancing our clinical programs. Research and development activities account for a large portion of our operating expenses, and product candidates in later stages of development generally have higher development costs than those in earlier stages, due to larger and more complex clinical trials, manufacturing scale-up and an increase in research and development headcount to oversee these activities. We are currently seeking partners to fund or collaborate on certain of our programs, including VTP-300 and VTP-850, which we do not intend to develop beyond the completion of the ongoing trials, as applicable. We expect research and development expenses to increase in the future as we progress our program through the next stage of development. Research and development costs are expensed as incurred. These costs include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">salaries, benefits, and other related costs, including share-based compensation, for personnel engaged in research and development functions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">expenses incurred in connection with the development of our programs including preclinical studies and clinical trials of our product candidates, under agreements with third parties, such as consultants, contractors, academic institutions and CROs; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the cost of manufacturing drug products for use in preclinical development and clinical trials, including agreements with third parties, such as contract manufacturing organizations, consultants and contractors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">laboratory costs; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">leased facility costs, equipment depreciation and other expenses, which include direct and allocated expenses.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our general and administrative expenses consist primarily of personnel-related expenses, including share-based compensation, in our executive, finance, business development and other administrative functions. Other general and administrative expenses include consulting fees and professional service fees for auditing, tax and legal services, rent expenses related to our offices, depreciation, impairment of property and equipment and right-of-use assets, foreign exchange gains and losses on our cash balances, other central non-research costs and changes in the fair value of contingent consideration. When determining the fair value of contingent consideration, significant judgment is used to determine the probability of success of achievement of the technology and clinical milestones and the date of the expected milestone. Our general and administrative expenses would continue to increase in the future if we expand our operating activities and if we seek to manufacture and/or commercialize any of our current and future product candidates. These costs will increase if our headcount rises to allow full support for our operations as a public company, including increased expenses related to legal, accounting, regulatory and tax-related services associated with maintaining compliance with requirements of the Nasdaq and the SEC, directors&#8217; and officers&#8217; liability insurance premiums and investor relations activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Operating Income</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Other operating income includes grant income from an agreement (the "CEPI Funding Agreement") with the Coalition for Epidemic Preparedness Innovations ("CEPI") pursuant to which CEPI will provide funding to us to advance the development of VTP-500, a vaccine candidate against MERS. When there is reasonable assurance that we will comply with the conditions attached to a received grant, and when there is reasonable assurance that the grant will be received, grant income is recognized as other operating income on a gross basis in the consolidated statements of operations and comprehensive loss on a systematic basis over the periods in which we recognize expenses for the related costs for which the grants are intended to compensate. Payments received in advance of incurring reimbursable expenses are recorded as deferred income. Any remaining unused amounts of the cash payments received on the balance sheets will be disclosed as restricted cash in the notes of the consolidated financial statements. Minimal future activity is expected in relation to the VTP-500 program following the strategic decision to prioritize pipeline assets in the I&amp;I space.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Income/(Expense)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest Income</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Interest income results primarily from the interest earned on our short-term cash deposits and cash balances held by Barinthus Biotherapeutics (UK) Limited.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Interest expense results primarily from the asset retirement obligation discounted over the length of the relevant lease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and Development Incentives</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Research and development incentives contain payments receivable from the U.K. government related to corporation tax relief for qualifying expenditure on research and development projects in the U.K. We account for such relief received as other income.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Qualifying expenditures largely comprise employment costs for research staff, consumables, outsourced contract research organization costs, externally provided workers and utilities costs incurred as part of research projects. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For 2025, we benefit from the applicable U.K. research and development tax credit regime which is the merged scheme Research &amp; Development expenditure credit ("RDEC") and enhanced R&amp;D intensive support ("ERIS") that replaces the old RDEC and small and medium-sized enterprise ("SME") schemes for accounting periods beginning on or after April 1, 2024. For expenditure under the merged scheme, the rate of Research and Development expenditure credit is 20%, which is the same as the rate under the old RDEC scheme for expenditure incurred on or after April 1, 2023. For loss-makers and small profit-makers, a lower rate of notional tax restriction (currently 19%) applies at payment. The amount of the Pay As You Earn ("PAYE") cap for claims under both the merged scheme and ERIS is &#163;20,000 plus 300% of the company&#8217;s relevant PAYE and National Insurance contributions liabilities. The PAYE cap (where applicable) will limit the amount of payable credit that can be received in the accounting period under consideration. Any excess over the cap will be carried forward and treated as an amount of Research and Development expenditure credit to which the company will be entitled for the next accounting period. Based on prior claims and the split of qualifying spend it is expected that the PAYE cap is unlikely to affect the net benefit. Furthermore, legislation included in Finance Act 2024 restricts the extent to which </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">payments to contractors for R&amp;D and externally provided workers can qualify for R&amp;D relief where R&amp;D activity takes place outside the U.K., which may restrict the ability to include cost incurred on externally provided workers based in the U.S. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For 2024, we benefited from the applicable U.K. research and development tax credit regime, being the Small and Medium-sized Enterprises R&amp;D tax relief program (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">SME Program</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">), and, to the extent that our projects are grant funded or relate to work subcontracted to us by third parties, the Research and Development Expenditure Credit program. Under the SME Program, we were able to surrender some of our trading losses that arise from qualifying research and development activities for a cash rebate of up to 18.6% of such qualifying research and development expenditure, as the SME additional deduction is 86% and the SME credit rate is 10%.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Under both the merged RDEC scheme and the SME program, a company qualifies as an R&amp;D intensive business if R&amp;D expenditure constitutes at least 30% of total expenditure. From the analysis performed, we have not and do not expect to claim under the loss-making R&amp;D intensive scheme criteria primarily due to the proportion of total relevant expenditure occurring outside the U.K.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In future years, we may not be able to continue to claim research and development tax credits under the U.K. research and development tax credit regime if we no longer qualify based on the eligibility criteria. Unsurrendered U.K. losses may be carried forward indefinitely to be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each year is limited to &#163;5.0 million plus an incremental 50% of U.K. taxable profits. There was no tax loss restriction applied to the R&amp;D tax credits in the U.K. for the years ended December 31, 2025 and 2024.</span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">This discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of income and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to fair value of contingent consideration and impairment of intangible assets. Management bases its estimates on historical experience and on various other market specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We believe that the following accounting policies are critical to the process of making significant judgments and estimates in the preparation of our financial statements and understanding and evaluating our reported financial results.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Long-lived Assets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We review long-lived assets to be held and used, including property and equipment, intangible assets and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Evaluation of recoverability is first based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group and its eventual disposition. In the event such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the assets are written down to their estimated fair values. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Intangible assets </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In September 2025, we announced that we have entered into the Merger Agreement to combine in an all-stock transaction with Clywedog. The indicative offer price was below the fair value of our net assets expected at completion and below prior valuations utilized in our most recent impairment assessments, thereby constituting an impairment triggering event. As a result, we recorded a total impairment charge for acquired development technology intangible assets of $4.7 million during the quarter ended September 30, 2025. The determination of the fair value of our net assets expected at completion, is a non-recurring fair value measurement. Subsequently, we reviewed for additional indicators of impairment and did not identify any additional impairment triggers nor was any additional impairment expense recorded. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We recognize a contingent consideration liability related to the acquisition of Avidea. The liability is remeasured to fair value at each reporting date until the contingency is resolved. The fair value of the contingent consideration is a Level 3 valuation determined using significant unobservable inputs being the probability of success of achievement of the milestones and the expected date of the milestone achievement. Avidea&#8217;s stockholders may be entitled to receive an </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">aggregate of up to $40.0 million in additional payments, payable in a combination of cash and ADSs, upon the achievement of certain milestones. This contingent consideration is included within the purchase price and is recognized at its fair value on the acquisition date, and subsequently remeasured to fair value at each reporting date until the contingency is resolved. Changes in fair value are recognized in general and administrative expenses in the consolidated statements of operations and comprehensive loss. The fair value of contingent consideration is based on the probability of pursuit of the activity associated with the milestone, the probability of success of the achievement of the milestone, the expected date of milestone achievement and applying the relevant discount rate. </span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comparison of the Years Ended December&#160;31, 2025 and 2024</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the significant components of our results of operations (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">License revenue </span></div></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">14,969&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(14,969)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">25,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">42,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(16,672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">40,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">29,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 12.52pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Impairment of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 12.52pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">12,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(12,209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">71,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">84,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(13,054)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other operating income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(670)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(70,555)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(67,970)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(2,585)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other income/(expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(721)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Research and development incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,983)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,922&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,743&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(2,821)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss before income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(66,633)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(61,227)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(5,406)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(66,458)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(61,183)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(5,275)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December&#160;31, 2025 and 2024, our revenue consisted of nil and $15.0 million, respectively from the OUI License Agreement Amendment with respect to amounts owed to us by OUI for the commercial sales of Vaxzevria. In 2024, AstraZeneca announced it had made the strategic decision to initiate the withdrawal of marketing authorization for Vaxzevria within Europe, citing decline in demand as the reason for the decision. We do not expect to receive any further payments relating to future commercial sales of Vaxzevria and, if such payments are due, that we will be notified of such payments in a timely manner.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes our research and development expenses for the years ended December&#160;31, 2025 and 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Direct research and development expenses by program:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">VTP-1000 Celiac</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Barinthus legacy assets</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(9,692)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total direct research and development expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">14,594&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">23,709&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(9,115)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Indirect research and development expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Personnel-related (including share-based compensation)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Facility related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other indirect costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total indirect research and development expenses </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10,970&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">18,527&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,557)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">25,564&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">42,236&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(16,672)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In January 2025, we announced a strategic focus on developing a pipeline in I&amp;I, and the deprioritization of our programs in infectious disease and oncology. The following programs were previously presented separately and have been grouped collectively as "Barinthus Legacy Assets" for both years presented: VTP-300 HBV, VTP-850 Prostate Cancer, VTP-200 HPV, VTP-600 NSCLC, VTP-500 MERS and other and earlier stage programs. </span></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our research and development expenses for the years ended December&#160;31, 2025 and 2024 were $25.6 million and $42.2 million, respectively, and consisted of direct and indirect research and development expenses. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Direct expenses for the years ended December&#160;31, 2025 and 2024 were $14.6 million and $23.7 million, respectively, and consisted of outside services, consultants, laboratory materials, clinical trials, manufacturing of clinical trial materials, as well as costs for external preclinical services and sample testing. Of the $9.1 million decrease, $9.7 million pertains to a net decrease in spend across Barinthus legacy asset infectious disease and oncology programs as the ongoing trials reached clinical completion and following the strategic decision to partner these programs for future development. This decrease is partially offset by a $0.6 million increase in spend on VTP-1000 for the ongoing Phase 1 AVALON clinical trial. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Indirect research and development expenses for the years ended December&#160;31, 2025 and 2024 were $11.0 million and $18.5 million, respectively. Of the $7.6 million decrease, $7.5 million relates to the reduction in headcount and the associated reduction in personnel-related expense (including share-based compensation).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses for the years ended December&#160;31, 2025 and 2024 were $40.8 million and $29.7 million, respectively. The increase of $11.1 million relates primarily to a $12.0 million change in foreign exchange gains and losses (from a gain of $2.4 million for the year ended December&#160;31, 2024 to a loss of $9.6 million for the year ended December&#160;31, 2025), as well as an increase of $6.5 million in professional fees attributable to increased strategic activity. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">These increases are partially offset by a $2.6 million net reduction in depreciation and amortization reflecting the $5.3 million impairment charge recorded in the year ended December 31, 2024 in relation to the U.K. operating lease right-of-use assets and property and equipment. For the year ended December 31, 2025, depreciation includes a $1.1 million impairment charge in relation to U.S. right-of-use assets and leasehold improvements and $1.6 m accelerated depreciation due to a decrease in the estimated useful lives of the U.K. right of use and fixed assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Personnel-related expenses decreased $2.8 million due to the reduction in headcount and the associated reduction in personnel-related expense (including share-based compensation). Other general and administrative costs decreased $1.4 million which is attributable to reduced travel expenses, reduced communications expenses, lower insurance premiums and other reductions in facility-related expenses. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Impairment of intangible assets expense</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For the years ended December&#160;31, 2025 and 2024, impairment of intangible assets expense was $4.7 million and nil million, respectively. This increase relates to the impairment assessment performed during the third quarter of 2025, following an impairment triggering event identified in relation to us entering a definitive merger agreement to combine in an all-stock merger transaction with Clywedog. See Note 7 for further details.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Goodwill Impairment Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For the years ended December&#160;31, 2025 and 2024, goodwill impairment expense was nil and $12.2 million, respectively. The decrease relates to the impairment assessment performed during the fourth quarter of 2024, based on the expected utilization of Company assets and external market conditions. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest Income</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For the years ended December&#160;31, 2025 and 2024, interest income was $2.0 million and $2.7 million respectively, which primarily resulted from the reduction in interest rates and the reduction in cash amounts on short-term cash deposits held by Barinthus Biotherapeutics (UK) Limited.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and Development Incentives</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For the years ended December&#160;31, 2025 and 2024, research and development incentives were $2.0 million and $4.0 million, respectively. Such research and development incentives relate to corporation tax relief on research and development project incentive programs in the U.K. The decrease of $2.0 million is primarily due to a decrease in qualifying R&amp;D activities related to the strategic decision to stop development of the viral vector programs beyond the completion of the ongoing clinical trials in the U.K. and reduced R&amp;D recovery rate under the new merged scheme for 2025.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Tax benefit</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For the years ended December&#160;31, 2025 and 2024, the tax benefit was $0.18 million and $0.04 million respectively, which primarily relates to movements in deferred tax.</span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sources of Liquidity</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Since our inception, we have funded our operations primarily through private and public placements of our ordinary and preferred shares as well as from grants and research incentives, various agreements with public funding agencies, the issuance of convertible loan notes, and most recently from upfront royalty and milestone payments from OUI in connection with the OUI License Agreement Amendment for Vaxzevria. Through December&#160;31, 2025, we have received gross proceeds of approximately $330.1 million from the issuance of our ordinary and preferred shares and convertible loan notes. As of December&#160;31, 2025, we had cash, cash equivalents and restricted cash of $71.9 million. Key financing and corporate milestones include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Between July 2020 and November 2020, we raised gross proceeds of $41.2 million from the issuance of convertible loan notes;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">In March 2021, we raised gross proceeds of $125.2 million from the issuance of our Series B shares.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">In May 2021, we raised gross proceeds of $110.5 million from the initial public offering of our ordinary shares on Nasdaq.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Between April 2022 and November 2024, we received $59.5 million of cash from OUI for the commercial sales of Vaxzevria.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Between December 2022 and December 31, 2024, we raised net proceeds of $5.1 million from the issuance of 2,558,586 shares represented by ADSs through &#8220;at-the-market&#8221; offerings under the sales agreement with Jefferies LLC ("Jefferies"). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">We do not currently expect positive cash flows from operations in the foreseeable future, if at all. In most periods, we have incurred operating losses as a result of ongoing efforts to develop our immunotherapy platforms and our product candidates, including conducting ongoing research and development, preclinical studies, clinical trials, providing general and administrative support for these operations and developing our intellectual property portfolio. We expect to continue to incur net negative cash flows from operations for at least the next few years as we progress clinical development, seek regulatory approval, prepare for and, if approved, proceed to manufacture and commercialization of our most advanced </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">product candidates. Operating profits may arise earlier if programs are licensed or sold to third parties before final approval, but this cannot be guaranteed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">On September 29, 2025, we entered into the Merger Agreement providing for our combination with Clywedog. We have agreed to various covenants and agreements, including, among others, agreements to conduct our business in the ordinary course of business between the execution of the Merger Agreement and the closing of the Combinations. Outside of certain limited exceptions, we may not take certain actions without Clywedog&#8217;s consent, including (i) acquiring businesses and disposing of significant assets, (ii) incurring expenditures above specified thresholds; (iii) incurring additional debt outside the ordinary course of business, (iv) issuing additional securities, or (v) repurchasing ordinary shares or ADSs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash Flows</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth a summary of the primary sources and uses of cash (in thousands) for each period presented:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(47,979)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(28,940)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net cash provided by/(used in) investing activities</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">416&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(892)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net cash provided by financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Effect of exchange rates on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,013&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(2,021)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net decrease in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(40,548)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(29,690)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cash Used in Operating Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2025, net cash used in operating activities was $48.0 million, primarily resulting from our net loss of $66.5 million, adjusted by depreciation and amortization expense of $5.8 million, long-lived asset impairment charge of $5.8 million, unrealized foreign exchange loss of $3.7 million, non-cash lease expenses of $3.3 million, share based compensation of $0.5 million and changes in our operating assets and liabilities, net of $0.4 million primarily related to a $6.4 million decrease in research and development incentives receivable, a $6.0 million decrease in accounts payable and accrued expenses, a $2.0 million decrease in operating lease liabilities, a $1.7 million decrease in prepaid expenses, and a $0.5 million decrease in deferred income. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December&#160;31, 2024, net cash used in operating activities was $28.9 million, primarily resulting from our net loss of $61.2 million, adjusted by goodwill impairment expense of $12.2 million, depreciation and amortization of $5.8 million, an impairment charge of $5.3 million, share based compensation of $4.7 million, non-cash lease expenses of $1.4 million and changes in our operating assets and liabilities, net of $2.6 million primarily related to a $3.6 million decrease in prepaid expenses, a $1.8 million decrease in operating lease liabilities, a $1.7 million increase in deferred income, a $1.4 million increase in accounts payable and accrued expenses and a $2.3 million increase in research and development incentives receivable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net Cash Provided By / (Used In) Investing Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">During the years ended December&#160;31, 2025 and 2024, cash provided by/(used) in investing activities was $0.4 million and $(0.9) million, respectively. For the year ended December&#160;31, 2025, these amounts primarily related to proceeds received upon the sale of U.K. laboratory equipment. For the year ended December&#160;31, 2024, these amounts primarily related to lab and office equipment purchases in both our U.K. and U.S. facilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net Cash Provided by Financing Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2025 cash provided by financing activities related only to net proceeds from the issuance of ordinary shares in the form of ADSs through stock option exercises. During the year ended December&#160;31, 2024, cash provided by financing activities of $2.2 million primarily related to net proceeds received from the issuance of ordinary shares in the form of ADSs through the &#8220;at-the-market&#8221; sales agreement with Jefferies LLC.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Effect of Exchange Rates on Cash, Cash Equivalents and Restricted Cash </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">During the years ended December&#160;31, 2025 and 2024, the effect of foreign exchange on cash, cash equivalents and restricted cash was a $7.0 million gain and $2.0 million loss respectively, primarily as a result of fluctuations between the United States dollar and pound sterling exchange rates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Future Funding Requirements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">To date, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, undertaking preclinical studies and conducting clinical trials of our product candidates. As a result, we have incurred losses in each year since our inception in 2016, except for 2022 when we were profitable. We have negative operating cash flows for the periods ending December&#160;31, 2025 and 2024. As of December&#160;31, 2025, we had an accumulated deficit of $304.1 million. We expect to continue to incur significant losses and negative cash flows from operations for the foreseeable future. We anticipate that our expenses will increase substantially if, and as we:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">pursue the clinical and preclinical development of our current product candidates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">use our technologies to advance additional product candidates into preclinical and clinical development;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">seek marketing authorizations for product candidates that successfully complete clinical trials, if any;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">attract, hire and retain additional clinical, regulatory, quality control and other personnel;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conduct preclinical studies and clinical trials for our current and future product candidates based on our proprietary synthetic and biologic platforms, including SNAP-TI;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">establish our manufacturing capabilities through third parties or by ourselves and scale-up manufacturing to provide adequate supply for clinical trials and commercialization;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">expand, maintain, protect and enforce our intellectual property portfolio;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or through a selected partner;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">acquire or in-license other product candidates and technologies for development and commercialization; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">incur additional legal, accounting and other expenses in operating our business, including the additional costs associated with operating as a public company; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">incur additional legal, advisory, accounting, tax and other expenses in operating our business, including the additional costs associated with completing the Contemplated Transactions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development costs and other expenditures to develop and market additional product candidates and we may never generate revenue that is significant or large enough to achieve profitability. We may also encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital unless and until such losses are eliminated by revenue.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Accordingly, our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause you to lose all or part of your investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Since our foundation, we have invested a significant portion of our efforts and financial resources in research and development activities for our viral vector platform (ChAdOx and MVA), acquisition of additional complementary platforms such as SNAP-TI, development of new technologies, and our product candidates derived from these technologies. Preclinical studies and especially clinical trials and additional research and development activities will require substantial funds to complete. We believe that we will continue to expend substantial resources for the foreseeable future in connection with the development of our current product candidates and programs as well as any future product candidates we may elect to pursue, as well as the gradual gaining of control over our required manufacturing capabilities and other corporate functions. These expenditures will include costs associated with conducting preclinical studies and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">clinical trials, obtaining regulatory approvals, and potentially in-house manufacturing and supply, as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise as outlined above. Because the outcome of any preclinical study or clinical trial is uncertain and the rate of change of third-party costs is also unpredictable, we cannot reasonably estimate now the actual amounts which will be necessary to complete the development and commercialization of our current or future product candidates successfully.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our future capital requirements may depend on many factors, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing, outcome and terms of the Contemplated Transactions currently in progress as well as associated transaction and advisory costs;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the scope, progress, results and costs of researching and developing our current and future product candidates and programs, and of conducting preclinical studies and clinical trials;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the number and development requirements of other product candidates that we may pursue, and of other indications for our current product candidates that we may pursue;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the stability, scale and yield of future manufacturing processes as we scale-up production and formulation of our product candidates either internally or externally for later stages of development and commercialization;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing of, success achieved and the costs involved in obtaining regulatory and marketing approvals and developing our ability to establish license or sale transactions and/or sales and marketing capabilities, if any, for our current and future product candidates if clinical trials and approval processes are successful;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the success of our collaborations with current and any future collaboration partners;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to establish, maintain or terminate collaborations, strategic licensing or other arrangements and the financial terms of such agreements;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the costs of future commercialization activities, including product launch, product sales, marketing, manufacturing and distribution, for any of our current and future product candidates for which we receive marketing approval;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing, receipt and amount of commercial sales, revenues, milestones or royalties or other income from our future products, should any of our product candidates receive marketing approval; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, enforcing and protecting our intellectual property rights and defending intellectual property-related claims including litigation costs and any damages awarded in such litigation; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the emergence and success or otherwise of competing autoimmune or infectious disease therapies and other market developments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">A change in the outcome of any of these or other variables with respect to the development of any of our current and future product candidates could significantly change the costs and timing associated with the development of that product candidate, in either direction. Furthermore, our operating plans may change in the future owing to research outcomes or other opportunities, and we may need additional funds to meet operational needs and capital requirements associated with such altered operating plans. Unless and until we can generate a substantial amount of revenue from our product candidates, we expect to finance our future cash needs through public or private equity offerings, debt financings, collaborations, licensing arrangements or other sources, or any combination of the foregoing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Based on our current standalone research and development plans, we expect that our existing cash, cash equivalents, restricted cash and other financial resources will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months. These estimates are based on assumptions that may prove to be wrong, and we could use our available capital resources more quickly than we expect.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We may require substantial additional financing in the future to meet any such unanticipated factors, including if the Contemplated Transactions are not consummated timely or at all. If we raise additional funds through collaborations, strategic alliances, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we would be required to delay, limit, reduce or terminate our product development programs, future commercialization efforts, other operational plans or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease, Purchase, and Other Obligations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We have operating lease obligations related to our property, plant and equipment. The details of these leases are disclosed in Item 2. &#8220;Properties". The obligations related to both short- and long-term lease arrangements are set forth in Note 16 &#8220;Commitment and Contingencies&#8221; to our consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We enter into contracts in the normal course of business with CROs and other third parties for clinical trials and preclinical research studies and testing. These contracts are generally cancellable by us upon prior notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancellable obligations of our service providers, up to the date of cancellation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We have contingent payment obligations that we may incur upon achievement of clinical, regulatory and commercial milestones, as applicable, or royalty payments that we may be required to make under our licenses; however, the amount, timing and likelihood of such payments are not known as of December&#160;31, 2025. See section entitled &#8220;Business - Our Collaboration and License Agreements.</span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Emerging Growth Company Status</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We are an emerging growth company under the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. As an emerging growth company, we may delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We will remain an emerging growth company until the earliest of (1) the last day of the fiscal year (a) following the fifth anniversary of the date of the closing of our IPO, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a &#8220;large accelerated filer&#8221; as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our ADSs held by non-affiliates exceeded $700.0 million as of the prior June 30th, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_79"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">A description of recently issued accounting pronouncement that may potentially impact our financial position and results of operations is disclosed in Note 2 to our consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Foreign Currency and Currency Translation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to the risk of fluctuations in foreign currency exchange rates, specifically with respect to the euro, pound sterling, Swiss franc and Australian dollar. Our reporting currency is the United States dollar, and the functional currency of Barinthus Biotherapeutics plc and its consolidated subsidiaries, Barinthus Biotherapeutics (UK) Limited and Vaccitech Oncology Limited, is the pound sterling. The functional currency of our wholly owned foreign subsidiaries, Barinthus Biotherapeutics North America, Inc.</span><span style="color:#008080;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Beacon Topco, Inc. and Cdog Merger Sub, Inc., is the United States dollar. The functional currency of our wholly owned foreign subsidiary, Barinthus Biotherapeutics Pty Limited, is the Australian dollar. The functional currency of our wholly owned foreign subsidiary, Barinthus Biotherapeutics Switzerland GmbH, is the Swiss franc. Our cash, cash equivalents and restricted cash as of December&#160;31, 2025 consisted primarily of cash balances held by Barinthus Biotherapeutics (UK) Limited in United States dollars.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Assets and liabilities are translated into United States dollars at the exchange rate in effect on the balance sheet date. Revenue and expenses are translated at the average exchange rate in effect during the period. Translation adjustments are included in the consolidated Balance Sheets as a component of accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in operating expenses, net in the consolidated Statements of Operations and Comprehensive Loss as incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We incur significant operating costs in the U.K. and face exposure to changes in the exchange ratio of the United States dollar and the pound sterling arising from expenses and payables from our U.K. operations that are settled in pound sterling. For the year ended December&#160;31, 2025, an average 10% weakening in the United States dollar relative to the pound sterling would have resulted in a material change to our current and projected expenses denominated in pound sterling for the year ended December&#160;31, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest Rate Sensitivity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We are not currently exposed significantly to market risk related to changes in interest rates, as we have no significant interest-bearing liabilities. We had cash, cash equivalents and restricted cash of $71.9 million as of December&#160;31, 2025, which were primarily held as account balances with banks in the U.K. and United States. A hypothetical 10% relative change in interest rates during any of the periods presented would not have had a material impact on our financial statements.</span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 8. Financial Statements and Supplementary Data</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Consolidated Financial Statements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our audited consolidated financial statements are included at the end of this Annual Report, starting at page F-1.</span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_91"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 9A. Controls and Procedures </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Evaluation of Disclosure Controls and Procedures </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our principal executive officer and principal financial officer evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule&#8239;13a-15(e) and 15d-15(e) under the Exchange Act) as of December&#160;31, 2025. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The term &#8220;disclosure controls and procedures&#8221; means controls and other procedures of a company that are designed to provide reasonable assurance that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Based on our evaluation, our principal executive officer and principal financial officer, has concluded that, as of such date, our disclosure controls and procedures were effective.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, and for the assessment of the effectiveness of internal control over financial reporting. The Company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit the preparation of financial statements in accordance with U.S. GAAP, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of the effectiveness of our internal controls in future periods are subject to the risk that such controls may become inadequate because of changes in conditions, or that the degree of compliance with applicable policies, processes and documentation requirements may deteriorate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In making its assessment of the Company&#8217;s internal control over financial reporting as of December&#160;31, 2025, management used the criteria set forth in Internal Control&#8212;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) and evaluated the internal control over financial reporting. Based on our assessment, management concluded that our internal control over financial reporting was effective as of December&#160;31, 2025, based on criteria in Internal Control-Integrated Framework (2013) issued by the COSO.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Attestation Report of the Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report does not include an attestation report of our registered public accounting firm due to an exemption provided by the JOBS Act for &#8220;emerging growth companies.&#8221;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rules 13a&#8209;15(f) and 15d&#8209;15(f) under the Exchange Act) during the quarter ended December&#160;31, 2025 that have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 9B. Other Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Rule 10b5-1 Trading Plans</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">None of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) <ix:nonNumeric contextRef="c-6" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-52"><ix:nonNumeric contextRef="c-6" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-53">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-6" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-54"><ix:nonNumeric contextRef="c-6" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-55">terminated</ix:nonNumeric></ix:nonNumeric> a Rule 10b5-1 trading plan or arrangement or a non-Rule 10b5-1 trading plan or arrangement, as defined in Item 408(c) of Regulation S-K, during the three months ended December 31, 2025 covered by this Annual Report.</span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Not Applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">PART III</span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 10. Directors, Executive Officers and Corporate Governance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Directors and Executive Officers</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information about our current directors and executive officers as of the date of this Annual Report:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.326%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Name</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Age</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Present Position</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Year Elected to Present Position</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">William Enright</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer and Director</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2019</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Leon Hooftman</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chief Medical Officer </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2024 </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Robin Wright</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chairman of the Board of Directors</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2018</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Alex Hammacher</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-Executive Director</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pierre A. Morgon, PharmD</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-Executive Director</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2018</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Anne M. Phillips, MD</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-Executive Director</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Karen T. Dawes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-Executive Director</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Joseph C. Scheeren</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-Executive Director</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">William Enright</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> has been our Chief Executive Officer and a member of our board of directors since August 2019. From June 2008 to November 2018, Mr. Enright served as the Chief Executive, President and Director of Altimmune, Inc. (&#8220;Altimmune&#8221;), a biopharmaceutical company. Prior to joining Altimmune, Inc., Mr. Enright held various positions at GenVec, Inc. (acquired by Precigen, Inc.), leaving as Head of Business Development. He currently serves on the Board of Directors and Chair of the Compensation Committee of BullFrog AI, Inc. Mr. Enright brings a breadth of experiences in a variety of positions within the life science/biotech industry, including time as a consultant, a bench scientist and 12 years with Life Technologies, Inc. (acquired by Thermo-Fisher), working in various senior level licensing, business management, manufacturing and research roles. Mr. Enright holds a MA and BS in Biology from SUNY at Buffalo and a MS in Business Management from Johns Hopkins University. We believe that Mr. Enright is qualified to serve on our board of directors because of his considerable management experience in the biopharmaceutical industry.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leon Hooftman</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> has been our Chief Medical Officer since June 2024. Dr. Hooftman held Chief Medical Officer roles at several biotechnology companies, including ISA Pharmaceuticals from May 2018 to June 2024, Polyphor AG from September 2014 to May 2018, Synthon BV from October 2011 to August 2014 and Chroma Therapeutics from October 2004 to January 2011. Prior to that, he served as the Head of Clinical Development at Celltech, from December 2002 until its acquisition by UCB in October 2004. Earlier in his career, Dr. Hooftman held various senior management positions at Roche from May 1995 to December 2002. Dr. Hooftman holds a M.D. from Utrecht State University (Netherlands) and performed his specialist training in Cambridge and London (UK).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Robin Wright </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">has served as our chairman since October 2018 and a member of our board of directors since August 2018. Mr. Wright has extensive senior level experience as a Chief Financial Officer of public companies in both the pharmaceutical and biotechnology industries. Mr. Wright has served as the Chief Financial Officer of MiNa Therapeutics since January 2021. From September 2020 to October 2020, Mr. Wright was our interim Chief Financial Officer. From September 2015 to May 2020, Mr. Wright was the Chief Financial Officer of Pharming Group N.V., a biopharmaceutical company. Mr. Wright holds a BA degree in Chemistry from Oxford University and is a Fellow of the Institute of Chartered Accountants in England and Wales in the UK. We believe Mr. Wright is qualified to serve on our board of directors because of his extensive management experience and financial expertise in the life sciences industry.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alex Hammacher</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> has been a member of our board of directors since January 2020. Dr. Hammacher is Head of Strategic Operations &amp; Corporate Finance at Oxford Sciences Enterprises, a venture capital firm partnered with Oxford University, a position he has held since October 2019. Prior to joining Oxford Sciences Enterprises, Dr. Hammacher held positions of increasing seniority at Lazard, an investment banking firm, from October 2015 to October 2019, most recently as Director of Healthcare Investment Banking, and UBS, an investment banking firm, from July 2007 to September 2015. Dr. Hammacher received a BA and BM BCh from Oxford University. We believe Dr. Hammacher is qualified to serve on our board of directors because of his extensive investment experience in the life sciences industry.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Pierre A. Morgon</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> has been a member of our board of directors since January 2018. Dr. Morgon is Chief Executive Officer of MRGN Advisors, an investment strategy advisor, a position he has held since January 2015. Dr. Morgon was Regional Partner for Switzerland at M&#233;rieux Equity Partners, an investment firm, a position he has held since October 2014, and is currently a senior advisor to the firm. Dr. Morgon is also Chief Business Officer at Nuvamid, a position he has held from January 2024 to August 2025, Executive Vice President Portfolio Strategy and Supranational Affairs at CanSino Biologics until February 2024, Chief Business Officer at PLL Therapeutics since January 2025, Venture Partner at Rocket Bio Capital since June 2025 and Director at AlMorphous Health since November 2025. Dr. Morgon is also chair of the board of directors of Health Technologies Holding (HTH) Srl, a position he held from June 2020 to April 2025, chair of the board of directors of MYCB1, a position he has held since July 2020, chair of the board of directors of Eurocine Vaccines, a position he has held since May 2019, chair of the board of directors of Kupando GmbH, a position he held from December 2021 to April 2025, and a member of the board of directors of UNIVERCELLS, a position he has held since July 2018, and a member of the board of Amo&#233;ba SA, a position held since June 2021, and a member of the board of directors of CanSinoBio Switzerland, a position he has held since May 2022, and a member of the board of directors of Limula, a position he has held since July 2022. Dr. Morgon also served as a member of the board of directors of Alma Biotherapeutics from 2017 to 2018, chair of the board of directors of Virometix AG from January 2017 to November 2019, and chair of the board of directors of Theradiag from 2017 to March 2023. Pierre has over 35 years of experience in the global life science industry, especially with specialty care, vaccines and immunotherapy, at the helm of international operations, in C-level positions at global level in multinational corporations and as CEO of start-up companies. He is a lecturer in several MBA programs and in life science conferences, and at the Mass Challenge incubator in Switzerland where he is also a mentor for start-up life sciences companies. He holds a Doctorate of Pharmacy, a Master in Business Law and an MBA. He is also an alumnus of INSEAD and IMD.  We believe Dr. Morgon is qualified to serve on our board of directors due to his extensive experience as a director of life sciences companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Anne M. Phillips</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> has been a member of our board of directors since February 2021. Dr. Phillips was a Senior Vice President of Clinical, Medical &amp; Regulatory Affairs, North America Operations, for Novo Nordisk Inc., leading the drug development, clinical operations, medical, regulatory, health economics and outcomes research, and safety teams, a position she held from 2011 to 2022. Prior to joining Novo Nordisk, Dr. Phillips held positions of increasing seniority at GlaxoSmithKline from 1998 to 2010, most recently as Vice President, Medicine Development Leader. Dr. Phillips also served on the board of directors of Trevena Corporation, a biopharmaceutical company, a position she held from 2014 to 2024. Dr. Phillips also served as a member of the board of directors of Carmot Therapeutics, a private biopharmaceutical company, from 2022 to 2023. Dr. Phillips also served as a member of the board of directors of AMAG Pharmaceuticals, Inc., a pharmaceutical company, from 2019 to 2020, and Biotechnology Innovation Organization, a biotechnology trade organization, from 2017 to 2018. Dr. Phillips currently serves on the board of directors of Sagimet Biosciences since August 2024, as well as on the board of directors of vTv Therapeutics since March 2024. Dr. Phillips received a BSc in Zoology from the University of Western Ontario and an MD from the University of Toronto. She completed postgraduate training in Internal Medicine, Medical Microbiology and Infectious Diseases. We believe Dr. Phillips is qualified to serve on our board of directors because of her extensive expertise in the life sciences industry. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Karen T. Dawes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> has been a member of our board of directors since February 2021. Ms. Dawes is the President of Knowledgeable Decisions, LLC, biopharma pharmaceutical consulting firm focusing on development and commercial/corporate strategy, a position she has held since 2003. Ms. Dawes served from 1999 to 2003 as Senior Vice President and U.S. Business Group Head for Bayer Corporation&#8217;s U.S. Pharmaceuticals Group. Prior to joining Bayer, she was Senior Vice President, Global Strategic Marketing, at Wyeth LLC, a pharmaceutical company (formerly known as American Home Products). Ms. Dawes also served as Vice President, Chief Commercial Officer, for Genetics Institute, Inc. Ms. Dawes began her pharmaceuticals industry career at Pfizer, Inc. where, from 1984 to 1994, she held a number of marketing positions, serving most recently as Vice President, Marketing of the Pratt Division. Ms. Dawes also serves on the boards of directors of one publicly traded company, Repligen Corporation, one privately-held company, JPA Health, and one not-for-profit organization, Medicines 360. Ms. Dawes received a BA and an MA from Simmons College in English Literature and an MBA from Harvard University. We believe Ms. Dawes is qualified to serve on our board of directors because of her extensive experience with biopharmaceutical companies as well as her considerable background in the development and commercialization of pharmaceutical products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joseph C. Scheeren</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> has been a member of our board of directors since March 2021. Dr. Scheeren is also the founder and president of Scheeren HealthCare LLC, a consulting company specializing in pharmaceutical development and regulatory affairs, and has held these positions since August 2021. Dr. Scheeren serves as the co-chair of the Scientific Advisory Board of Fosun Shanghai Pharmaceuticals in Shanghai since February 2023 and is a member of the International Advisory Board of the French Clinical Research Infrastructure Network in France. He is also on the Supervisory Board of Connect 4 Children Stiechting ("C4C S"), a Dutch non-profit organization since May 2023. Dr. Scheeren served as President and Chief Executive Officer of Critical Path Institute, ("C-Path"), a non-profit organization, from April 2019 to March 2021. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to joining C-Path, Dr. Scheeren served in various senior roles at Bayer AG, a global pharmaceutical company, for 15 years, including serving as Senior Vice President, Senior Advisor to Research and Development from January 2018 to December 2018 and Senior Vice President, Head of Global Regulatory Affairs, Pharmaceuticals and Consumer Health from January 2015 to December 2017. He previously also held numerous executive positions at Aventis Pharmaceuticals, Roussel UCLAF, Ares Serono and Les Laboratoires Servier. Dr. Scheeren has served as an advisor to PathBiotech LLC from June 2021 until October 2023. Dr. Scheeren currently serves as a director on several boards of non- profit organizations, is an adjunct Professor of Regulatory Science at Peking University, Beijing, and was a lecturer at Yale University. Dr Scheeren earned his PharmD, MSc and BS degrees at the University of Leiden, Leiden, the Netherlands, School of Pharmacy. We believe Dr. Scheeren is qualified to serve on our board of directors because of his global expertise in research and development and regulatory affairs in the pharmaceutical industry.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are no material legal proceedings to which any of our directors is a party adverse to us or any of our subsidiaries or in which any such person has a material interest adverse to us or our subsidiary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Board of Directors Composition</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our board of directors seeks director candidates who represent a mix of backgrounds and experiences that will enhance the quality of our board of directors' deliberations and decisions. Such candidates are expected to have substantial experience with one or more publicly traded national or multinational companies or have achieved a high level of distinction in their chosen field.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Structure of our Board of Directors </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The leadership structure of our board of directors separates the positions of chief executive officer and chairman of the board in order to ensure independent leadership of the Board. Our Board believes that this separation is appropriate for the Company at this time because it allows for a division of responsibilities, with our chief executive officer focused on leading the Company while the chairman can focus on leading the Board in overseeing management, and for a sharing of ideas between individuals having different perspectives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Independence of our Board of Directors </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has determined that Robin Wright, Pierre A. Morgon, Anne M. Phillips, Karen T. Dawes and Joseph C. Sheeren are each independent within the meaning of the director independence standards of Nasdaq. Furthermore, our board of directors has determined that all of the members of our audit committee, compensation committee, and</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">nominating and corporate governance committee are independent within the meaning of the director independence standards of Nasdaq and the rules of the SEC applicable to each such committee.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has determined that Alex Hammacher and William Enright are not independent within the meaning of director independence standards of Nasdaq.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Family Relationships and Adverse Proceedings</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are no family relationships between any of our directors or executive officers. Neither we nor any of our subsidiaries are party to any material proceedings to which any of our directors, officers, affiliates, 5% or more shareholders, or any of their respective associates are a party. We do not believe that any of our directors, officers, affiliates, 5% or more shareholders, or any of their respective associates are adverse to us or any of our subsidiaries or have a material interest that is adverse to us or any of our subsidiaries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Code of Business Conduct and Ethics </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company has adopted a Code of Conduct that applies to all officers, directors and employees in connection with their work for us. The full text of our Code of Conduct is posted on the investor relations page of our website at investors.barinthusbio.com/corporate-governance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company intends to satisfy any disclosure requirements under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of this Code of Conduct by posting such information on our website, at the Internet address and location specified above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Board Oversight of Risk Management </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management is primarily responsible for assessing and managing risk, while our board of directors is responsible for overseeing management&#8217;s execution of its responsibilities. Our board of directors is supported by its committees in fulfillment of this responsibility. For example, our audit committee focuses on our overall financial risk by evaluating our internal controls and disclosure policies as well as ensuring the integrity of our financial statements and periodic reports. The audit committee also oversees the Company&#8217;s information security and technology risks, including the Company&#8217;s information security and related risk management programs. Our compensation committee strives to create incentives that encourage an appropriate level of risk-taking consistent with our business strategy. Our nominating and corporate governance committee ensures that our governance policies and procedures are appropriate in light of the risks we face.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Committees of our Board of Directors </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has three standing committees: the audit committee, the compensation committee and the nominating and corporate governance committee. The charters for each of these committees can be found on our website at www.barinthusbio.com, under the &#8220;Corporate Governance&#8221; subsection of the &#8220;Investors&#8221; section. Each such committee reviews its respective charter at least annually.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Name</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Audit</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Compensation</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Nominating and Corporate Governance</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">William Enright</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Robin Wright</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Alex Hammacher</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pierre A. Morgon. ParmD</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Anne M. Phillips, MD</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Karen T. Dawes</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Joseph C. Sheeren</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*denotes committee chairperson.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Audit Committee</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our audit committee is currently composed of Karen T. Dawes, Pierre A. Morgon and Robin Wright, and is chaired by Mr. Wright. Our board of directors has determined that each member of the audit committee meets the independence requirements of Rule 10A-3 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and the applicable Nasdaq rules. All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the Nasdaq listing rules. Our board of directors has determined that Mr. Wright is an &#8220;audit committee financial expert&#8221; within the meaning of SEC regulations and the applicable Nasdaq rules. The audit committee held 5 meetings during 2025. The audit committee's responsibilities include:</span></div><div style="margin-top:5.8pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recommending the appointment of the independent auditor to the general meeting of shareholders;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the appointment, compensation, retention and oversight of any accounting firm engaged for the purpose of preparing or issuing an audit report or performing other audit services;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pre-approving the audit services and non-audit services to be provided by our independent auditor before the auditor is engaged to render such services;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">evaluating the independent auditor&#8217;s qualifications, performance and independence, and presenting its conclusions to the full board of directors on at least an annual basis;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing the adequacy of our internal controls with management and any remediation plan associated with any significant control deficiencies or material weaknesses;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and discussing with management and our independent registered public accounting firm our financial statements and our financial reporting process; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing, approving or ratifying any related party transactions; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">determining whether the Company is required to prepare a financial restatement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Committee </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation committee is currently composed of Anne M. Phillips, Robin Wright and Joseph C. Scheeren, and is chaired by Dr. Phillips. Our board of directors has determined that each member of the compensation committee is &#8220;independent&#8221; as defined in the applicable Nasdaq rules. Each member of our compensation committee is a non-employee director, as defined in Rule 16b-3 promulgated under the Exchange Act. The compensation committee held 3 meetings during 2025. The compensation committee's responsibilities include:</span></div><div style="margin-top:5.8pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">annually reviewing and approving the corporate goals and objectives relevant to the compensation of our Chief Executive Officer;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">evaluating the performance of our Chief Executive Officer in light of such corporate goals and objectives and based on such evaluation determine and approve the Chief Executive Officer&#8217;s compensation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and approving the compensation of our other executive officers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and establishing our overall management compensation, philosophy and policy;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overseeing and administering our compensation and similar plans;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">evaluating and assessing potential and current compensation advisors in accordance with the independence standards identified in the applicable Nasdaq rules;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and recommending to the board of directors our policies and procedures for the grant of equity-based awards;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and recommending to the board of directors the compensation of our directors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparing our compensation committee report if and when required by SEC rules;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and discussing annually with management our &#8220;Compensation Discussion and Analysis,&#8221; if and when required, to be included in our annual proxy statement;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in the evaluation of compensation matters; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adopting and administering a compensation recovery policy.</span></div><div style="margin-top:5.85pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:122%">Our board of directors  has delegated to the compensation committee the authority to determine the compensation for all of our executive officers. Non-executive director compensation is recommended by our compensation committee to the board of directors for approval. Our Chief Executive Officer may participate in general discussions with our compensation committee and board of directors about these compensation matters but he does not participate in discussions during which his individual compensation is being considered and approved.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:122%">In 2025, the compensation committee retained the services of the Rewards Solutions practice at Aon plc ("Aon&#8221;), an independent compensation consultant, to assist the compensation committee with respect to compensation actions in 2025 with the goal of ensuring that our compensation arrangements for our Chief Executive Officer, our other senior executive officers and our non-executive directors were competitive. Aon provided data from comparable publicly traded biotechnology companies and otherwise assisted the compensation committee in its design of competitive compensation for our Chief Executive Officer, senior executives and non-executive directors. The compensation committee expects to continue to use compensation consultants to assist the compensation committee in determining competitive levels of executive and non-executive compensation and specific design elements of our executive compensation program and non-executive directors&#8217; compensation program. After review and consultation with Aon, the compensation committee determined that Aon is independent and that there is no conflict of interest resulting from retaining Aon in 2025. In reaching these conclusions, our compensation committee considered the factors set forth in the SEC rules and the applicable Nasdaq rules. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nominating and Corporate Governance Committee </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our nominating and corporate governance committee is composed of Pierre A. Morgon, Karen T. Dawes and Joseph C. Scheeren, which is chaired by Dr. Morgon. Our board of directors has determined that each member of the nominating and corporate governance committee is &#8220;independent&#8221; as defined under the applicable Nasdaq rules. The nominating and corporate governance committee held 1 meeting during 2025. The nominating and corporate governance committee's responsibilities include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:123%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:123%;padding-left:14.5pt">determining selection criteria and appointment procedures for directors;</span></div><div style="margin-top:4.75pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:123%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:123%;padding-left:14.5pt">recommending nominees for election to our board of directors and appointment to its committees;</span></div><div style="margin-top:4.2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:123%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:123%;padding-left:14.5pt">assessing the functioning of our board of directors and executive officers and reporting the results of such assessment to the board of directors;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:123%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:123%;padding-left:14.5pt">developing corporate governance guidelines and any other governance policies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:123%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:123%;padding-left:14.5pt">reviewing and discussing with management of the Company&#8217;s key human resource management strategies and programs; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:123%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:123%;padding-left:14.5pt">establishing the Company&#8217;s policies and procedures regrading on succession planning and continuing education of employees.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:122%">The nominating and corporate governance committee considers candidates for board of directors membership suggested by its members and the Chief Executive Officer. Additionally, in selecting nominees for directors, the nominating and corporate governance committee will review candidates recommended by shareholders in the same manner and using the same general criteria as candidates recruited by the committee and/or recommended by our board of directors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:122%">Our board of directors is responsible for filling vacancies on our board of directors and for nominating candidates for election by our shareholders each year in the class of directors whose term expires at the relevant annual general meeting. The board of directors delegates the selection and nomination process to the nominating and corporate governance committee, with the expectation that other members of the board of directors, and of management, will be requested to take part in the process as appropriate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:122%">Board and Committee Meetings Attendance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:122%">The full board of directors met 11 times during 2025. During 2025, each member of our board of directors attended in person or participated in 75% or more of the aggregate of (i) the total number of meetings of our board of directors (held during the period for which such person has been a director), and (ii) the total number of meetings held by all committees of the board of directors on which such person served (during the periods that such person served). Directors are encouraged to attend the annual meeting of stockholders. Last year, we held an annual meeting of stockholders on June 10, 2025, at which all of our directors were present.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Insider Trading Policy and Prohibition on Hedging and/or Pledging Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors <ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-56">adopted</ix:nonNumeric> our insider trading policy governing transactions in our securities by our executive officers, directors, employees and certain designated consultants, that the Company believes it is reasonably designed to promote compliance within insider trading laws, rules and regulations, and any listing standards applicable to the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain transactions in our securities (such as purchases and sales of publicly traded put and call options, and short sales) create a heightened compliance risk or could create the appearance of misalignment between management and stockholders. In addition, securities held in a margin account or pledged as collateral may be sold without consent if the owner fails to meet a margin call or defaults on the loan, thus creating the risk that a sale may occur at a time when an officer or director is aware of material, non-public information or otherwise is not permitted to trade in Company securities. Our insider trading policy allows our directors, officers, vice-president level or above employees, and members of the finance department involved in periodic financial reporting to pledge our securities as collateral for a loan (or modify an existing pledge) only if the pledge has been approved by the audit committee. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to comply with applicable insider trading laws, rules and regulations, and any exchange listing standards when engaging in transactions in Company securities. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Rule 10b5-1 Trading Plan Policy </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Rule 10b5-1 trading plan policy, which permits our officers, directors, employees and certain other persons to enter into trading plans complying with Rule 10b5-1 under the Exchange Act. Generally, under these trading plans, the individual relinquishes control over the transactions once the trading plan is put into place and can only put such plans into place while the individual is not in possession of material non-public information. Accordingly, sales under these plans may occur at any time, including possibly before, simultaneously with, or immediately after significant events involving our company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Compensation Recovery Policy</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Board adopted a Compensation Recovery Policy effective as of October 2, 2023 and adopted an Amended and Restated Compensation Recovery Policy effective June 21, 2023 in compliance with the Nasdaq listing rules, which requires recovery from executive officers of incentive-based compensation that is earned, granted or vested based on the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">achievement of a financial reporting measure in the event of that we are required to restate our previously issued financial statements due to our material noncompliance with any financial reporting requirement under securities laws. The recoverable compensation includes any compensation received after the effective date of the Compensation Recovery Policy and in the three-year fiscal period preceding the date we were required to prepare the accounting restatement that is in excess of the amount that would have been earned, paid or vested had it been calculated based on the restated financial statements. Recovery is required regardless of fault or a covered officer&#8217;s role in the financial reporting process.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 11. Executive Compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Director Compensation </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The table below shows all compensation earned by or paid to our non-executive directors during 2025. William Enright, our Chief Executive Officer, does not receive any compensation for his services as a director and, consequently, is not included in this table. The compensation received by William Enright during 2025 is set forth in the heading "Named Executive Compensation". </span></div><div style="margin-bottom:0.05pt;margin-top:0.15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.048%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.989%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3pt;padding-right:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Fees Paid</span></div><div style="margin-top:0.05pt;padding-left:4.15pt;padding-right:4.15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:92%">in Cash</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Option</span></div><div style="margin-top:0.05pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:92%">Awards</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.55pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:92%">Total</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:4.2pt;padding-right:4.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:80%">($)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:80%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:3.55pt;padding-right:3.55pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:80%">($)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:80%;position:relative;top:-2.8pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.35pt;padding-left:1.92pt;padding-right:1.92pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">($)</span></div></td></tr><tr><td colspan="3" style="background-color:#ccedff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:109%">Alex Hammacher</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:109%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ccedff;border-top:0.75pt solid #000000;padding:2px 5.5pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:109%">$42,182</span></td><td colspan="3" style="background-color:#ccedff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:109%">$17,295</span></td><td colspan="3" style="background-color:#ccedff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$59,477</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Pierre A. Morgon</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 5.5pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:109%">$61,295</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:109%">$17,295</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:109%">$78,590</span></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Robin Wright</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ccedff;padding:2px 5.5pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:109%">$92,272</span></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:109%">$17,295</span></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$109,567</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Anne M. Phillips</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:2px 5.5pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:109%">$55,363</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:109%">$17,295</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:109%">$72,658</span></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Joseph C. Scheeren</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ccedff;padding:2px 5.5pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:109%">$54,045</span></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:109%">$17,295</span></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$71,340</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Karen T. Dawes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="padding:2px 5.5pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$56,022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$17,295</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$73,317</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:58.05pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.46pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.8pt">The amounts reported have been converted from pounds sterling to U.S. dollars using the average exchange rate for 2025 of &#163;0.7586 to $1.00.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.46pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.8pt">Amounts shown reflect the grant date fair value of stock option awards granted during 2025. The grant date fair value was computed in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification Topic 718 (&#8220;ASC Topic 718&#8221;), Compensation&#8201;&#8212;&#8201;Stock Compensation, disregarding the effect of estimated forfeitures related to service-based vesting. The assumptions used in calculating the grant date fair value of the shares are set forth in Note 14 of &#8220;Notes to Consolidated Financial Statements.&#8221; These amounts reflect the accounting cost for the stock options and do not correspond to the actual economic value that may be received by the director upon exercise of the stock options.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.46pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.8pt">As of December 31, 2025, Dr. Hammacher held unexercised options to purchase 111,819 shares.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.46pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.8pt">As of December 31, 2025, Dr. Morgon held unexercised options to purchase 132,213 shares.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.46pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.8pt">As of December 31, 2025, Mr. Wright held unexercised options to purchase 132,213 shares.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.46pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.8pt">As of December 31, 2025, Dr. Phillips held unexercised options to purchase 111,819 shares.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.46pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.8pt">As of December 31, 2025, Dr. Scheeren held unexercised options to purchase 111,819 shares.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.46pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.8pt">As of December 31, 2025, Ms. Dawes held unexercised options to purchase 111,819 shares.</span></div><div style="margin-top:0.4pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Non-Executive Director Compensation Program</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We compensate our non-executive directors with a cash retainers and equity awards. The amount of each component of such director cash compensation may change from year to year and is generally established by the compensation committee in conjunction with the Board, and presented at our annual general meeting of shareholders for the period. The annual retainers in effect for services during 2025 are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="padding-left:58.5pt;padding-right:74.05pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.684%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.006%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Annual Retainer for Board Membership</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Annual service on the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#163;</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additional compensation for service as non-executive Chair of the Board of Directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Additional Annual Retainer for Committee Membership</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Annual service as Chair of the Audit Committee</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Annual service as member of the Audit Committee (other than Chair)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#163;</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Annual service as Chair of the Compensation Committee</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Annual service as member of the Compensation Committee (other than Chair)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#163;</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Annual service as Chair of the Nomination and Corporate Governance Committee</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Annual service as member of the Nomination and Corporate Governance Committee (other than Chair)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#163;</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:0.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our policy provides that, upon initial election to our board of directors, each non-executive director will be granted an option to purchase a number of ordinary shares equal to 0.10% of the outstanding ordinary shares as of the date of grant (the &#8220;Initial Grant&#8221;). Furthermore, on the date of each of our annual meeting of shareholders, each non-executive director who will continue as a non-executive director following such meeting will be granted an option to purchase a number of ordinary shares equal to 0.05% of the outstanding ordinary shares as of the date of grant (the &#8220;Annual Grant&#8221;). The Annual Grant will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the next annual meeting of shareholders, subject to continued service as a director through the applicable vesting date. The Initial Grant will vest in 36 equal monthly installments, subject to continued service as a director through the applicable vesting date. Such awards are subject to full accelerated vesting upon the sale of the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Employee directors will receive no additional compensation for their service as a director.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We will reimburse all reasonable out-of-pocket expenses incurred by directors for their attendance at meetings of our Board of Directors or any committee thereof.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee Interlocks and Insider Participation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Phillips, Mr. Wright, and Dr. Scheeren served as members of our compensation committee during the year ended December 31, 2025. None of the members of our compensation committee is, or has been at any time, one of our officers or employees. None of our executive officers currently serves, or has served in the past fiscal year, as a member of the board of directors or compensation committee of any entity that has one or more of its executive officers serving as a member of our board of directors or our compensation committee.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Named Executive Officer Compensation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth information concerning the compensation of our named executive officers for the years ended December 31, 2025 and 2024:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.767%"><tr><td style="width:1.0%"/><td style="width:19.143%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Name and Principal Position</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.35pt;padding-left:1.17pt;padding-right:1.17pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Salary ($)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Stock</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Awards&#160;&#160;&#160;&#160; ($)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.35pt;padding-left:1.05pt;padding-right:1.05pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Option Awards ($)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.32pt;padding-right:1.32pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Non-Equity Incentive Plan</span></div><div style="margin-top:0.05pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:92%">Compensation ($)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:92%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.35pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">All Other Compensation ($)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">William Enright</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:109%">653,432</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:109%">512,245</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47,986</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,213,663</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Executive Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:109%">634,400</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:109%">1,376,573</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">304,512</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47,474</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,362,959</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Leon Hooftman</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:109%">441,259</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">540,487</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:109%">119,524</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:109%">36,329</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:109%">1,137,599</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Medical Officer</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:109%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Geoffrey Lynn</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">301,795</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">268,257</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:109%">570,052</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Former Chief Scientific Officer</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:109%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gemma Jones</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">136,216</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">632,774</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:109%">768,990</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Former Chief Financial Officer </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:109%">357,875</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:109%">605,510</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">120,246</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23,294</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,106,925</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(1) The amounts reported reflect the grant date fair value of restricted share unit awards and option awards granted in 2025 and 2024 in accordance with ASC Topic 718, disregarding the effect of estimated forfeitures related to service-vesting conditions. The assumptions used in calculating the grant date fair value of the shares are set forth in the Note 14. These amounts do not correspond to the actual value that may be recognized by the named executive officers upon vesting of the applicable awards.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2) The amounts reported for 2024 represent the annual bonuses paid in February 2025 for the year ended December 31, 2024.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3) The amounts reported for Mr. Enright 401(k) matching contributions and health insurance coverage. The amounts reported for Dr. Hooftman consist of pension contributions and health insurance. The amounts reported for Dr. Lynn consist of 401(k) matching contributions and health insurance coverage, $146,667 in severance compensation, $11,846 of unused vacation and $69,167 of consulting fees. The 2025 amounts reported for Mrs. Jones consist of pension contributions, health insurance, $261,678 in severance compensation, $17,808 of unused vacation and $349,245 of consulting fees. The 2024 amounts reported for Mrs. Jones consist of pension contributions and healthcare. The amounts reported for Mrs. Jones and Dr. Hooftman have been converted from pounds sterling to U.S. dollars using the average exchange rate for 2024 of 0.7824 to $1.00 and 2025 of &#163;0.7586 to $1.00.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4) The amounts reported have been converted from pounds sterling to U.S. dollars using the average exchange rate for 2025 of &#163;0.7586 to $1.00. Dr. Hooftman was not a named executive officer for 2024.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5) Dr. Lynn was not a named executive officer for 2024. Dr. Lynn&#8217;s employment terminated effective as of September 5, 2025.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(6) The amounts reported have been converted from pounds sterling to U.S. dollars using the average exchange rate for 2024 of 0.7824 to $1.00 and 2025 of &#163;0.7586 to $1.00. Mrs. Jones' employment terminated effective as of April 30, 2025. She transitioned to a consultant after her termination date and serves as Chief Financial Officer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Narrative to the Summary Compensation Table</span></div><div style="margin-top:0.4pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Base Salaries</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For the fiscal year ending December 31, 2025, the base salaries for Mr. Enright and Dr. Hooftman were $653,432 and &#163;334,750 ($441,259 using the average exchange rate for 2025 of &#163;0.7586 to $1.00), respectively. At the time of Dr. Lynn's date of termination on September 5, 2025, his base salary was $440,000. At the time of Mrs. Jones' date of termination on April 30, 2025, her base salary was &#163;310,000 ($408,648 using the average exchange rate for 2025 of &#163;0.7586 to $1.00).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Annual Cash Bonuses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Subject to the attainment of certain company and individual performance goals, the Board may approve discretionary bonuses based on a percentage of the executive&#8217;s base salary. For the fiscal year ended December 31, 2025, each named executive officer was eligible to earn an annual cash bonus calculated as a percentage of each executive&#8217;s base salary and based on the achievement of corporate performance metrics. The corporate performance metrics were not satisfied and no annual cash bonus was awarded for the fiscal year ended December 31, 2025.</span></div><div style="margin-top:0.45pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Term Equity Incentives</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Although we do not yet have a formal policy with respect to the grant of equity incentive awards to our executive officers, we believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our shareholders. In addition, we believe that equity grants promote executive retention because they incentivize our executive officers to remain in our employment during the vesting period. Accordingly, our board of directors periodically reviews the equity incentive compensation of our named executive officers and may grant equity incentive awards to them from time to time. Equity awards granted during fiscal year 2025 are set forth below in the Outstanding Equity Awards at Fiscal Year-End table.</span></div><div><span><br/></span></div><div style="margin-top:4.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:123%">Employment Agreements with Our Named Executive Officers</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">William Enright</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">. We entered into a new employment agreement with Mr. Enright effective upon the closing of our IPO in May 2021. Pursuant to this employment agreement, Mr. Enright agreed to continue to serve as our chief executive officer. Mr. Enright shall be entitled to an annual base salary, subject to periodic increase (but not decrease), target annual bonus opportunity and employee benefits. Under Mr. Enright&#8217;s new employment agreement, in the event that Mr. Enright&#8217;s employment is terminated by us without &#8220;cause&#8221; or Mr. Enright resigns for &#8220;good reason&#8221; (as such terms are defined in the employment agreement), subject to the execution and effectiveness of a separation agreement, including a general release of claims in our favor), he will be entitled to receive (i) an amount equal to 12 months of his base salary, payable over the 12 month period following his termination, (ii) if his termination occurs following completion of a calendar year but prior to payment of an annual bonus, payment of such annual bonus, and (iii) if Mr. Enright is participating in our group health plans immediately prior to his termination and elects COBRA health continuation, continuation of such group health coverage at the same rate as if he were an active employee, until the earliest of (A) the 12 month anniversary of his termination; (B) his eligibility for group medical plan benefits under any other employer&#8217;s group medical plan; or (C) the cessation of his continuation rights under COBRA. The employment agreement also provides that, in lieu of the payments and benefits described above, in the event that Mr. Enright&#8217;s employment is terminated by us without cause or Mr. Enright resigns for good reason, in either case within 12 months following a &#8220;change in control&#8221; (as defined in the employment agreement), subject to the execution and effectiveness of a general release of claims in our favor, he will be entitled to receive (i) a lump sum cash payment equal to 1.5 times the sum of his then-current base salary (or his base salary in effect immediately prior to the change in control, if higher) plus his annual target bonus for the then-current year (or the annual target bonus in effect immediately prior to the change in control, if higher), and (ii) if Mr. Enright is participating in our group health plans immediately prior to his termination and elects COBRA health continuation, continuation of such group health coverage at the same rate as if he were an active employee, until the earliest of (A) the 18 month anniversary of his termination; (B) his eligibility for group medical plan benefits under any other employer&#8217;s group medical plan; or (C) the cessation of his continuation rights under COBRA. Mr. Enright&#8217;s new employment agreement further provides that in the event Mr. Enright&#8217;s employment is terminated by us without cause or Mr. Enright resigns for good reason, in either case within 12 months following a change in control, then any outstanding time-based equity awards shall immediately accelerate and become fully vested and exercisable or nonforfeitable on the date of termination.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Mr. Enright is also subject to an agreement relating to confidentiality, assignment of inventions, and a twelve-month nonsolicitation and noncompetition covenant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Dr. Leon Hooftman</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">. We entered into an employment agreement with Dr. Hooftman on February 21, 2024. Pursuant to this employment agreement, Dr. Hooftman agreed to serve as our chief medical officer. Dr. Hooftman is entitled to an annual base salary, subject to periodic review, target annual bonus opportunity and employee benefits. Dr. Hooftman&#8217;s employment agreement contains standard confidentiality provisions which survive termination and also twelve-month non-competition and non-solicitation restrictive covenants.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Dr. Geoffrey Lynn.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> We entered into an employment agreement with Dr. Lynn effective as of December 1, 2024. Pursuant to this employment agreement, Dr. Lynn agreed to serve as our chief scientific officer. Dr. Lynn was entitled to an annual base salary, subject to periodic review, target annual bonus opportunity and employee benefits. Dr. Lynn&#8217;s employment had no specified term but could be terminated at will by either party. Under Dr. Lynn&#8217;s employment agreement, in the event that Dr. Lynn&#8217;s employment was terminated by us without &#8220;cause&#8221; or Dr. Lynn resigned for &#8220;good reason&#8221; (as such terms are defined in the employment agreement), subject to the execution and effectiveness of a separation agreement, including a general release of claims in our favor), he would have been entitled to receive (i) an amount equal to 6 months of his base salary, payable over 9 months commencing within 60 days after his date of termination and (ii) subject to Dr. Lynn&#8217;s copayment of premium amounts at the applicable active employees&#8217; rate and proper election to receive COBRA health continuation, continuation of such group health coverage at the same rate as if he were an active employee, until the earliest of (A) the 6 month anniversary of his termination; (B) his eligibility for group medical plan benefits under any other employer&#8217;s group medical plan; or (C) the cessation of his continuation rights under COBRA; provided, however, that if we determined that we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">cannot pay such amounts to the group health plan provider or the COBRA provider without potentially violating applicable law, then we would convert such payments to payroll payments directly to Dr. Lynn for the time period specified above. The employment agreement also provided that, in lieu of the payments and benefits described above, in the event that Dr. Lynn&#8217;s employment was terminated by us without cause or Dr. Lynn resigned for good reason, in either case within 12 months following a &#8220;change in control&#8221; (as defined in the employment agreement), subject to the execution and effectiveness of a general release of claims in our favor, he would have been entitled to receive (i) a lump sum cash payment equal to one times the sum of his then-current base salary (or his base salary in effect immediately prior to the change in control, if higher) plus his annual target bonus for the then-current year (or the annual target bonus in effect immediately prior to the change in control, if higher), and (ii) subject to Dr. Lynn&#8217;s copayment of premium amounts at the applicable active employees&#8217; rate and proper election to receive COBRA health continuation, continuation of such group health coverage at the same rate as if he were an active employee, until the earliest of (A) the 6 month anniversary of his termination; (B) his eligibility for group medical plan benefits under any other employer&#8217;s group medical plan; or (C) the cessation of his continuation rights under COBRA; provided, however, that if we determined that we could not pay such amounts to the group health plan provider or the COBRA provider without potentially violating applicable law, then we would convert such payments to payroll payments directly to Dr. Lynn for the time period specified above.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On September 5, 2025, Dr. Lynn entered into a separation agreement and consulting agreement. Pursuant to Dr. Lynn&#8217;s separation agreement, his employment terminated effective as of September 5, 2025. Dr. Lynn was provided severance benefits equal to 6 months base salary and COBRA continuation and, subject to the closing of the Combination or another meaningful M&amp;A transaction, a $200,000 transaction bonus. Simultaneously, Dr. Lynn entered into a consulting agreement with us whereby he would provide advisory and transaction services to us until December 31, 2025. Dr. Lynn&#8217;s compensation for such services equaled $18,333.33 per month. If Dr. Lynn provides services after December 31, 2025, he is to be paid $213 per hour for such services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Gemma Jones.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> We entered into an employment agreement with Mrs. Jones on September 15, 2022. Pursuant to this employment agreement, Mrs. Jones agreed to serve as our chief financial officer. Mrs. Jones was entitled to an annual base salary, subject to periodic review, target annual bonus opportunity and employee benefits. On February 7, 2025, Mrs. Jones entered into a separation agreement. Pursuant to this settlement agreement, her employment terminated on April 30, 2025, and Mrs. Jones received payment equal to &#163;30,000 as settlement payment, &#163;155,000 as notice payment and &#163;13,509 accrued holiday payment (a total of $261,678 using the average exchange rate for 2025 of &#163;0.7586 to $1.00). Subsequently, we entered into an agreement with CFGI (UK) Limited for CFO services pursuant to which Mrs. Jones will serve as our Chief Financial Officer. </span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:5.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:123%">Additional Narrative Disclosure</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">401(k) Plan.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> We maintain a tax-qualified retirement plan that provides eligible U.S. employees, including our named executive officers, with an opportunity to save for retirement on a tax-advantaged basis. All participants&#8217; interests in their contributions are 100% vested when contributed. Contributions are allocated to each participant&#8217;s individual account and are then invested in selected investment alternatives according to the participants&#8217; directions. The retirement plan is intended to qualify under Section 401(a) of the Code. We match 100 percent of employee contributions, up to 6 percent of each employee&#8217;s compensation (as defined in the plan).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Health and Welfare Benefits.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> All of our full-time employees, including our executive officers are eligible to participate in certain medical, disability and life insurance benefit programs offered by us.</span></div><div><span><br/></span></div><div style="margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Equity Awards at Fiscal Year-End&#8201;&#8212;&#8201;2025</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes, for each of our named executive officers, the number of ordinary shares underlying outstanding share options and share awards held as of December 31, 2025.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.833%"><tr><td style="width:1.0%"/><td style="width:15.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.129%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.068%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.32pt;padding-right:0.32pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.5pt;font-weight:700;line-height:98%">Option Awards</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:3.57pt;font-weight:700;line-height:98%;position:relative;top:-1.92pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.5pt;font-weight:700;line-height:120%">Stock Awards</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.15pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.5pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.15pt;padding-right:11.15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.5pt;font-weight:700;line-height:115%">Vesting Commencement Date</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.4pt;padding-right:1.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.5pt;font-weight:700;line-height:115%">Number of Securities Underlying Unexercised Options (#) Exercisable</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.5pt;font-weight:700;line-height:120%">Number of Securities Underlying Unexercised Options (#) Unexercisable</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.17pt;padding-right:1.17pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.5pt;font-weight:700;line-height:115%">Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.5pt;font-weight:700;line-height:120%">Option Exercise Price ($)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;padding-right:7.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.5pt;font-weight:700;line-height:115%">Option Expiration Date</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.77pt;padding-right:0.77pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.5pt;font-weight:700;line-height:115%">Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights that have not Vested (#)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.5pt;font-weight:700;line-height:115%">Equity Incentive Plan Awards: Market or Payout Value of Shares, Units or Other Rights that have not Vested ($)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 1.15pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">William Enright</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">April 29, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">176,130</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.8pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">17.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">May 1, 2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.8pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.8pt;padding-left:1.25pt;padding-right:1.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">January 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">359,605</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">11.12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">March 14, 2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:1.25pt;padding-right:1.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">January 3, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">293,333</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">146,667</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">2.40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">January 3, 2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:1.25pt;padding-right:1.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">January 2, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">147,993</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">295,988</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">3.70</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">January 2, 2034</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:1.25pt;padding-right:1.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">February 3, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 6.65pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">600,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 9.6pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">1.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10.75pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">February 3, 2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:1.25pt;padding-right:1.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.15pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Leon Hooftman</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">June 3, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">65,055</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">130,111</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">2.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">June 3, 2034</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">February 3, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">140,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">1.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">February 3, 2034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">October 1, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">361,530</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">540,487</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.15pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Geoffrey Lynn</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">January 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">174,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">11.12</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">September 5, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">January 3, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">15,590</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">2.40</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">September 5, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">January 2, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">8,069</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">3.70</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">September 5, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.15pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Gemma Jones</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">September 6, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">30,900</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">14.96</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">April 30, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:1.25pt;padding-right:1.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">January 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">7,499</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">11.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">April 30, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:1.25pt;padding-right:1.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">September 15, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">222,666</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">3.07</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">April 30, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:1.25pt;padding-right:1.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">January 3, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">22,066</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">2.40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">April 30, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:1.25pt;padding-right:1.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">January 2, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">64,333</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">3.70</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">April 30, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.9pt;padding-left:1.25pt;padding-right:1.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:94%">&#8212;</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise specified, each option vests in three equal annual installments, with the first such annual installment vesting upon the first anniversary of the vesting commencement date, subject to such named executive officer&#8217;s continued employment as of each such date.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Policy Regarding Timing of Awards of Options and Other Like Instruments </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ecd:AwardTmgMnpiDiscTextBlock" id="f-57" continuedAt="f-57-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">It is the policy of our board of directors and our compensation committee to <ix:nonNumeric contextRef="c-1" name="ecd:AwardTmgMnpiCnsdrdFlag" format="ixt:fixed-false" id="f-58">not take material non-public information into account</ix:nonNumeric> when determining the timing of equity awards in order to take advantage of a depressed stock price or an anticipated increase in stock price. Similarly, it is our practice <ix:nonNumeric contextRef="c-1" name="ecd:MnpiDiscTimedForCompValFlag" format="ixt:fixed-false" id="f-59">not to time</ix:nonNumeric> the release of material nonpublic information based on equity award grant dates or for the purpose of affecting the value of executive compensation.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="ecd:AwardTmgMethodTextBlock" id="f-60" escape="true"><ix:continuation id="f-57-1">Our compensation committee generally grants annual equity awards, including stock option grants to our named executive officers, in the <ix:nonNumeric contextRef="c-1" name="ecd:AwardTmgPredtrmndFlag" format="ixt:fixed-true" id="f-61">first quarter of each fiscal year</ix:nonNumeric>. In addition, new hires receive stock option grants at the time of their hiring.</ix:continuation></ix:nonNumeric> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information as of December 31, 2025 with respect to our ordinary shares that may be issued under our existing equity compensation plans.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.321%"><tr><td style="width:1.0%"/><td style="width:44.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.322%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Plan Category</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Number of<br/>securities to be<br/>issued upon exercise<br/>of outstanding<br/>options, warrants<br/>and rights</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average<br/>exercise price of<br/>outstanding options,<br/>warrants and rights</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Number of securities<br/>remaining available for<br/>future issuance under equity compensation<br/>plans (excluding securities in first column)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Equity compensation plans approved by security holders</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,976,157</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-62">3,248,605</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Equity compensation plans not approved by security holders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2.9pt;padding-right:1.6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2.9pt;padding-right:1.6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:94%">&#8212;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2.9pt;padding-right:1.6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:94%">&#8212;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,976,157</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.28&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,248,605</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5.25pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:123%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:8.68pt">Includes the following plans: our Share Award Plan 2021 (the &#8220;2021 Plan&#8221;) and the Enterprise Management Incentive Share Option Scheme (the &#8220;EMI Plan&#8221;).</span></div><div style="margin-top:2.65pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:123%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:123%;padding-left:8.68pt">As of December 31, 2025, a total of 9,224,762 ordinary shares of our common stock have been reserved for issuance pursuant to the 2021 Plan. The 2021 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2025, by 4% of the outstanding number of ordinary shares on the immediately preceding December 31 or such lesser number of shares as determined by the compensation committee. This number will be subject to adjustment in the event of a share split, share dividend or other change in our capitalization. The Company no longer makes grants under the EMI Plan.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table and related footnotes set forth information with respect to the beneficial ownership of our ordinary shares, as of March 6, 2026, by:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each beneficial owner of 5% or more of our outstanding ordinary shares;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of our named executive officers and directors; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all of our executive officers and directors as a group.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Beneficial ownership is determined in accordance with the rules and regulations of the SEC. Under these rules, beneficial ownership includes any shares as to which a person has sole or shared voting power or investment power. In computing the number of ordinary shares beneficially owned by a person and the percentage ownership of that person, ordinary shares subject to options, or other rights held by such person that are currently exercisable or will become exercisable within 60 days of March 6, 2026 are considered outstanding. These ordinary shares, however, are not included in the computation of the percentage ownership of any other person. Applicable percentage ownership is based on 40,848,893 ordinary shares outstanding as of March 6, 2026.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise indicated, all of the shares reflected in the table are ordinary shares and all persons listed below have sole voting and investment power with respect to the shares beneficially owned by them, subject to applicable community property laws. The information is not necessarily indicative of beneficial ownership for any other purpose.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Except as otherwise indicated in the table below, addresses of the directors, executive officers and named beneficial owners are in care of Barinthus Biotherapeutics plc, 20400 Century Boulevard, Suite 210, Germantown, MD 20874.</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.303%"><tr><td style="width:1.0%"/><td style="width:71.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Ordinary Shares <br/>Beneficially Owned</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Name of Beneficial Owner</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.15pt;padding-right:0.05pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Percent</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">5% or Greater Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Oxford Science Enterprises plc</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,797,770</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">M&amp;G Investment Management Limited</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:109%">5,197,349</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Frank Cawood</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,384,513</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Named Executive Officers and Directors:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">William Enright</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,715,100</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Leon Hooftman</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">111,721</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Geoffrey Lynn </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">838,798</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gemma Jones</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">347,464</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Robin Wright</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">160,295</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Alex Hammacher</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">94,645</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pierre A. Morgon</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">122,545</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Anne M. Philips</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">94,645</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Karen T. Dawes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(12)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">93,345</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Joseph C. Scheeren</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(13)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">114,645</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">All Executive Officers and Directors as a Group (8 persons)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">14</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,506,941</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents beneficial ownership of less than one percent.</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">Based solely on a Schedule 13G filed with the SEC on February 11, 2022 by Oxford Science Enterprises plc. The business address for Oxford Science Enterprises plc is 46 Woodstock Road, Oxford, OX2 6HT, United Kingdom.</span></div><div style="padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">Based solely on a Schedule 13G filed with the SEC on September 30, 2024 by M&amp;G Investment Management Limited (&#8220;MAGIM&#8221;). The ordinary shares in the forms of ADSs are legally owned by Luxembourg Specialist Investment Fund FCP-RAIF. Luxembourg Specialist Investment Fund FCP- RAIF is advised by MAGIM. The business address for MAGIM is 10 Fenchurch Avenue, London, EC3M 5AG, UK.</span></div><div style="padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">Based solely on a Schedule 13G filed with the SEC on February 11, 2025 by Frank W. Cawood. The business address for Frank W. Cawood is 600 Edgewater Drive, Unit 402, Dunedin, FL 34698.</span></div><div style="padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">Consists of (a) 728,454 ordinary shares held by William J Enright TR UA Dated 03/04/2021 Enright Family 2021 Irrevocable Trust, (b) 514,923 ordinary shares held by William Enright Revocable Trust, and (c) 1,471,723 ordinary shares underlying options exercisable within 60 days of March 6, 2026. Mr. Enright is the trustee of the above referenced trusts and may be deemed to beneficially own these securities.</span></div><div style="padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">Consists of 111,721 ordinary shares underlying options exercisable within 60 days of March 6, 2026.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">Consists of (a) 638,442 ordinary shares held by Dr. Lynn, (b) 2,197 ordinary shares held in an account owned by Dr. Lynn's spouse, and (c) 198,159 ordinary shares underlying options exercisable within 60 days of March 6, 2026.</span></div><div style="padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">Consists of 347,464 ordinary shares underlying options exercisable within 60 days of March 6, 2026.</span></div><div style="padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">Consists of (a) 48,256 ordinary shares held by Mr. Wright and (b) 112,039 ordinary shares underlying options exercisable within 60 days of March 6, 2026.</span></div><div style="padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">Consists of (a) 3,000 ordinary shares held by Dr. Hammacher and (b) 91,645 ordinary shares underlying options exercisable within 60 days March 6, 2026.</span></div><div style="padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(10)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:0.18pt">Consists of (a) 10,506 ordinary shares held by Dr. Morgon and (b) 112,039 ordinary shares underlying options exercisable within 60 days of March 6, 2026.</span></div><div style="padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(11)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:0.18pt">Consists of (a) 3,000 ordinary shares held Dr. Philips and (b) 91,645 ordinary shares underlying options exercisable within 60 days of March 6, 2026.</span></div><div style="padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(12)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:0.18pt">Consists of (a) 1,700 ordinary shares held by Ms. Dawes and (b) 91,645 ordinary shares underlying options exercisable within 60 days of March 6, 2026.</span></div><div style="padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(13)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:0.18pt">Consists of (a) 23,000 ordinary shares held by Dr. Scheeren and (b) 91,645 ordinary shares underlying options exercisable within 60 days of March 6, 2026.</span></div><div style="padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(14)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:0.18pt">Consists of (a) 1,332,839 ordinary shares and (b) 2,174,102 ordinary shares underlying options exercisable within 60 days of March 6, 2026.</span></div><div style="margin-top:0.05pt"><span><br/></span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Other than compensation arrangements which are described under the section titled &#8220;Executive Compensation&#8221; and the transactions described below, since January 1, 2024, there was not, and there is not currently proposed, any transaction or series of similar transactions to which we have been or are to be a party in which the amount involved exceeded, or exceeds, $120,000 and in which any director, executive officer, holder of five percent or more of any class of our capital stock, or any member of their immediate family had, or will have, a direct or indirect material interest.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">License Revenue</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into the OUI License Agreement Amendment with OUI, in respect of our rights to the ChAdOx1 technology in COVID-19 vaccines to facilitate the license of those rights by OUI to AstraZeneca. Under this agreement, we are entitled to receive from OUI a share of payments, including royalties and milestones, received by OUI from AstraZeneca in respect of sales of Vaxzevria. We recognized $15.0 million and nil in revenue for the years ended December 31, 2024 and 2025, respectively, and were owed nil from OUI as of December 31, 2024 and 2025. In December 2025, we delivered written notice to OUI to terminate the OUI License Agreement, as amended. The agreement remained in effect during the three-month notice period and terminated in February 2026 in accordance with its terms.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Agreements with our Executive Officers</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into employment agreements with certain of our executive officers. These agreements contain customary provisions and representations, including confidentiality, non-competition, non-solicitation and inventions assignment undertakings by the executive officers and non-executive directors. The enforceability of the non-competition provisions may be limited under applicable law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into a deed of indemnity with each of our directors and executive officers. These agreements and our Articles of Association require us to indemnify our directors and executive officers to the fullest extent permitted by law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Related Party Transactions Policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a written related party transactions policy that provides that such transactions must be approved by our audit committee. Pursuant to this policy, the audit committee has the primary responsibility for reviewing and approving or disapproving &#8220;related party transactions,&#8221; which are transactions between us and related persons in which the aggregate amount involved exceeds or may be expected to exceed $120,000 and in which a related person has or will have a direct or indirect material interest. For purposes of this policy, a related person is defined as a director, executive officer, nominee for director, or greater than 5% beneficial owner of our common shares, in each case since the beginning of the most recently completed year, and their immediate family members.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 14. Principal Accounting Fees and Services</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The table below sets forth a summary of the fees billed to us by PricewaterhouseCoopers LLP, our independent registered public accounting firm, for professional services rendered during the fiscal years ended December 31, 2025 and December 31, 2024. All such services and fees were pre-approved by the audit committee, which concluded that the provision of such services was compatible with the maintenance of each firm&#8217;s independence in the conduct of its auditing functions. The amounts reported have been converted from pounds sterling to U.S. dollars using the average exchange rate for 2025 of 0.7586 to $1.00, and 2024 of &#163;0.7826 to $1.00, respectively.</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:58.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.212%"><tr><td style="width:1.0%"/><td style="width:57.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">($000)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">($000)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Audit fees (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">810</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">795</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Audit-related fees (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">405</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">324</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Tax fees (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All other fees (4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1,217</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1,121</span></td></tr></table></div><div style="margin-top:0.3pt;padding-left:58.5pt"><img src="brns-20251231_g2.jpg" alt="Line v2.jpg" style="height:0px;margin-bottom:5pt;vertical-align:text-bottom;width:124px" id="i-2"/></div><div style="padding-left:36pt;padding-right:68.3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:123%">(1) &#8220;Audit fees&#8221; consist of fees billed for the audit of our annual consolidated financial statements, statutory audits, review of interim condensed consolidated financial statements included in quarterly reports, assistance with review of documents filed with the SEC paid to PricewaterhouseCoopers LLP in connection with statutory and regulatory filings or engagements, attest services.</span></div><div style="padding-left:36pt;padding-right:66.95pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:123%">(2) &#8220;Audit-related fees&#8221; consist of fees paid to PricewaterhouseCoopers LLP in connection with registration statements filed with the SEC.</span></div><div style="padding-left:36pt;padding-right:66.95pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:123%">(3) &#8220;Tax fees&#8221; consist of fees paid to PricewaterhouseCoopers LLP in connection with tax compliance, tax advice and tax planning. We did not pay any &#8220;tax fees&#8221; to PricewaterhouseCoopers LLP in 2025 or 2024. </span></div><div style="padding-left:36pt;padding-right:62.35pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:123%">(4) &#8220;All other fees&#8221; consist of non-audit fees paid to PricewaterhouseCoopers LLP for access to its financial statement disclosure checklist.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Audit Committee Pre-Approval Policy and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The audit committee has adopted a policy (the &#8220;Pre-Approval Policy&#8221;) that sets forth the procedures and conditions pursuant to which audit and non-audit services proposed to be performed by the independent auditor may be pre-approved. The Pre-Approval Policy generally provides that we will not engage PricewaterhouseCoopers LLP to render any audit, audit-related, tax or permissible non-audit service unless the service is either (i) explicitly approved by the audit committee (&#8220;specific pre-approval&#8221;) or (ii) entered into pursuant to the pre-approval policies and procedures described in the Pre-Approval Policy (&#8220;general pre-approval&#8221;). Unless a type of service to be provided by PricewaterhouseCoopers LLP has received general pre-approval under the Pre-Approval Policy, it requires specific pre-approval by the audit committee. Any proposed services exceeding pre-approved cost levels or budgeted amounts will also require specific pre-approval. For both types of pre-approval, the audit committee will consider whether such services are consistent with the SEC&#8217;s rules on auditor independence. On an annual basis, the audit committee reviews and generally pre-approves the services (and related fee levels or budgeted amounts) that may be provided by PricewaterhouseCoopers LLP without first obtaining specific pre-approval from the audit committee. The audit committee may revise the list of general pre-approved services from time to time, based on subsequent determinations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">PART IV</span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_121"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 15. Exhibits, Financial Statement Schedules</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The following documents are filed as part of this report:</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Financial Statements.</span></div><div style="margin-top:12pt;padding-left:90pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The financial statements filed as part of this report are listed on the Index to Consolidated Financial Statements in Item 8.</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Financial Statement Schedules.</span></div><div style="margin-top:12pt;padding-left:90pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">No schedules are submitted because they are not applicable, not required, or because the information is included in the consolidated financial statements or the notes thereto.</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits. </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">EXHIBIT INDEX</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Exhibits number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Description of exhibit</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921149607/tm2135290d1_ex2-1.htm">Agreement and Plan of Merger and Reorganization, dated December 9, 2021, by and among Barinthus Biotherapeutics plc, VA Merger Sub 1 Inc., VA Merger Sub 2 Inc., Avidea Technologies Inc., and Benjamin Eisler, as the Securityholder Agent (Incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K (File No. 001-40367) filed on December 14, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2.2*&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465922037794/vacc-20211231xex2d2.htm">Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated March 11, 2022, by and between Barinthus Biotherapeutics plc and Benjamin Eisler, as Securityholder Agent (Incorporated by reference to Exhibit 2.2 to our Annual Report on Form 10-K (File No. 001-40367) filed on March 25, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465922087945/vacc-20220630xex2d1.htm">Amendment No. 2 to Agreement and Plan of Merger and Reorganization, dated May 9, 2022, by and between Barinthus Biotherapeutics plc and Benjamin Eisler, as the Securityholder Agent (Incorporated herein by reference to Exhibit 2.1 to our Quarterly Report on Form 10-Q (File No. 001-40367), filed on August 9, 2022).</a></span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2.4**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1828185/000110465925094754/tm2527141d1_8k.htm">Merger Agreement, dated as of September 29, 2025, by and among the Registrant, Topco Merger Sub, and Clywedog (Incorporated herein by reference to Exhibit 2.1 to our Current Report on Form 8-K (File No. 001-40367) filed on September 30, 2025).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001828185/000110465926018283/tm266347d1_8k.htm">Merger Agreement Amendment, dated as February 22, 2026, by and among the Registrant, Topco, Merger Sub and Clywedog, (Incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K (File No. filed No. 001-40367) filed on February 23, 2026).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921063872/tm2115595d1_ex3-1.htm">Articles of Association of the Registrant (Incorporated by reference to Exhibit 3.1 to our Form 8-K (File No. 001-40367) filed on May 10, 2021)).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921054698/tm2035121d14_ex4-1.htm">Form of Deposit Agreement (Incorporated by reference to Exhibit 4.1 to our Registration Statement on Form S-1/A (File No. 333-255158) filed on April 27, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921054698/tm2035121d14_ex4-1.htm">Form of American Depositary Receipt (included in Exhibit 4.1).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465922037794/vacc-20211231xex4d3.htm">Description of Registrant&#8217;s Securities (Incorporated by reference to Exhibit 4.3 to our Annual Report on Form 10-K (File No. 001-40367) filed on March 25, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.1#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921048698/tm2035121d10_ex10-1.htm">EMI Option Scheme and form of award agreement thereunder (Incorporated by reference to Exhibit 10.1 to our Registration Statement on Form S-1/A (File No. 333-255158) filed on April 27, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.2#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921054698/tm2035121d14_ex10-2.htm">2021 Stock Option and Incentive Plan and forms of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to our Registration Statement on Form S-1/A (File No. 333-255158) filed on April 27, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.3#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921054698/tm2035121d14_ex10-17.htm">2021 Employee Share Purchase Plan (Incorporated by reference to Exhibit 10.17 to our Registration Statement on Form S-1/A (File No. 333-255158) filed on April 27, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.4&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921048698/tm2035121d10_ex10-4.htm">License Agreement by and between the Registrant and Oxford University Innovation Limited, dated as of September 8, 2017 (Incorporated by reference to Exhibit 10.4 to our Registration Statement on Form S-1/A (File No. 333-255158) filed on April 27, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.5#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921048698/tm2035121d10_ex10-9.htm">Form of Deed of Indemnity between the Registrant and each of its directors and officers (Incorporated by reference to Exhibit 10.9 to our Registration Statement on Form S-1/A (File No. 333-255158) filed on April 27, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.6#**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921048698/tm2035121d10_ex10-10.htm">Form of Employment Agreement between the Registrant and William Enright (Incorporated by reference to Exhibit 10.10 to our Registration Statement on Form S-1/A (File No. 333-255158) filed on April 27, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465922058820/vacc-20220331xex10d1.htm">Registration Rights Agreement, dated March 28, 2022, by and among the Registrant and Benjamin Eisler, as the Securityholder Agent (Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q (File No. 001-40367) filed on May 11, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465922117255/vacc-20220930xex10d2.htm">Form of Indemnification Agreement between the Registrant and each of its directors and officers (Incorporated by reference to Exhibit 10.2 to our Quarterly Report on Form 10-Q (File No. 001-40367) filed on November 10, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.9**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20400_centuryxxxvaccitech.htm">Lease Agreement </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20400_centuryxxxvaccitech.htm">by and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20400_centuryxxxvaccitech.htm">between Barinthus Biotherapeutics North America</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20400_centuryxxxvaccitech.htm">, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20400_centuryxxxvaccitech.htm">Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20400_centuryxxxvaccitech.htm"> and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20400_centuryxxxvaccitech.htm">ARE-Maryland No. 52, LLC</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20400_centuryxxxvaccitech.htm">, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20400_centuryxxxvaccitech.htm">dated as of June 14</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20400_centuryxxxvaccitech.htm">, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20400_centuryxxxvaccitech.htm">2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20400_centuryxxxvaccitech.htm">.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.10#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000182818524000085/leonhooftman-executiveserv.htm">Service Agreement with Leon Hooftman, effective February 21, 2024 (Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q (File No. 001-40367) filed on November 6, 2024)</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.11#</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000182818525000021/brns-20241231xex1017.htm">Service Agreement with Geoffrey Lynn, effective December 1, 2024 (Incorporated by reference to Exhibit 10.17 to our Annual Report on Form 10-K (File No. 001-40367) filed on March 20 2025).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.12#</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000182818525000021/brns-20241231xex1018.htm">Termination Agreement with Nadege Pelletier, effective January 27, 2025 (Incorporated by reference to Exhibit 10.18 to our Annual Report on Form 10-K (File No. 001-40367) filed on March 20, 2025).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">19.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000182818525000021/brns-20241231xex191.htm"><ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-63">Amended and Restated Insider Trading Policy, effective June 21, 2023 (Incorporated by reference to Exhibit 19.1 to our Annual Report on Form 10-K (File No. 001-40367) filed on March 30, 2025).</ix:nonNumeric></a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">21.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="brns-20251231xex211.htm">Subsidiaries of the Registrant.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">23.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit231.htm">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">24.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Power of Attorney (included on signature page to this Annual Report).</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="brns-20251231xex311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="brns-20251231xex312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">32.1*+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="brns-20251231xex321.htm">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">97.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000182818525000021/brns-20241231xex971.htm">Amended and Restated Compensation Recovery Policy (Incorporated by reference to Exhibit 97.1 to our Annual Report on Form 10-K (File No. 001-40367) filed on March 30, 2025).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">104*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the iXBRL document).</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">___________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13pt">Filed or furnished herewith.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Certain portions of this exhibit have been omitted because they are not material and the Registrant customarily and actually treats that information as private or confidential.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Indicates a management contract or any compensatory plan, contract or arrangement.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">**</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Certain exhibits and schedules to these agreements have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant will furnish copies of any of the exhibits and schedules to the Securities and Exchange Commission upon request. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">+    The certification furnished in Exhibit 32.1 hereto is deemed to be furnished with this Annual Report and will not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_124"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 16. Form 10-K Summary</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Not Applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:59.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">March 13, 2026</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Barinthus Biotherapeutics plc</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/ William Enright</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">William Enright</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Chief Executive Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Each person whose signature appears below constitutes and appoints William Enright as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitutes, may lawfully do or cause to be done by virtue thereof.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.174%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/&#160;&#160;William Enright</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">March 13, 2026</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">William Enright</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(Principal Executive Officer and Principal Financial Officer)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/&#160;&#160;Gemma Jones</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">March 13, 2026</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Gemma Jones</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(Principal Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/&#160;&#160;Robin Wright</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Chairman and Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">March 13, 2026</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Robin Wright</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/&#160;&#160;Alex Hammacher</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">March 13, 2026</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Alex Hammacher</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/&#160;&#160;Pierre A. Morgon</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">March 13, 2026</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Pierre A. Morgon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/&#160;&#160;Anne M. Phillips</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">March 13, 2026</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Anne M. Phillips</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/&#160;&#160;Karen T. Dawes</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">March 13, 2026</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Karen T. Dawes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/&#160;&#160;Joseph C. Scheeren</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">March 13, 2026</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Joseph C. Scheeren</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:127%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_1">Report of Independent Registered Public Accounting Firm PricewaterhouseCoopers LLP </a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(PCAOB ID <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-64">876</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_136">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:127%">F-1</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_139">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:127%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:127%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_139">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_142">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:127%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:127%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_142">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_145">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:127%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:127%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_145">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_148">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:127%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:127%;text-decoration:none" href="#ia7cbadf995cd4920bb4d015b669c5879_148">5</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">To</span><span style="color:#ff0000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">the Board of Directors and Stockholders of Barinthus Biotherapeutics plc</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the accompanying consolidated balance sheets of Barinthus Biotherapeutics plc and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2025 and 2024, and the related consolidated statements of operations and comprehensive loss, of stockholders&#8217; equity and of cash flows for the years then ended, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-65">PricewaterhouseCoopers LLP</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Reading, <ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-66">United Kingdom</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;13, 2026</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company&#8217;s auditor since 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"/><td style="width:70.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.307%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of<br/>December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of<br/>December 31,<br/>2024</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-67">70,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-68">110,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">1,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">1,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Research and development incentives receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="brns:ResearchAndDevelopmentIncentivesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-71">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="brns:ResearchAndDevelopmentIncentivesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-72">7,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">4,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">6,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">77,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-76">125,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-77">3,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-78">7,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-79">14,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-80">21,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Right of use assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-81">1,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-82">4,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="f-83">930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="f-84">881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total assets</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-85">98,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-86">160,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="f-87">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-88">2,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-89">6,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-90">9,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Deferred income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredIncomeCurrent" format="ixt:num-dot-decimal" scale="3" id="f-91">1,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredIncomeCurrent" format="ixt:num-dot-decimal" scale="3" id="f-92">1,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease liability - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-93">2,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-94">1,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-95">10,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-96">15,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease liability - non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-97">9,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-98">10,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-99">2,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-100">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-101">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-102">1,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Deferred tax liability, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="f-103">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="f-104">438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-105">23,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-106">30,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Commitments and contingencies (Note 16)</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-8" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-107"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-9" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-108"></ix:nonFraction></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">Ordinary shares, &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-109"><ix:nonFraction unitRef="gbpPerShare" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-110">0.000025</ix:nonFraction></ix:nonFraction> nominal value; <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-111"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-112"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-113">40,848,893</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding (December&#160;31, 2024: authorized, issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-114"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-115"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-116">40,234,663</ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-117">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-118">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">Deferred A shares, &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="c-8" decimals="INF" name="brns:DeferredStockParOrStatedValuePerShare" scale="0" id="f-119"><ix:nonFraction unitRef="gbpPerShare" contextRef="c-9" decimals="INF" name="brns:DeferredStockParOrStatedValuePerShare" scale="0" id="f-120">1</ix:nonFraction></ix:nonFraction> nominal value; <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="brns:DeferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-121"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="brns:DeferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-122"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="brns:DeferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-123">63,443</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding (December&#160;31, 2024: authorized, issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="brns:DeferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-124"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="brns:DeferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-125"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="brns:DeferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-126">63,443</ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="brns:DeferredStockValueIssued" scale="3" id="f-127">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="brns:DeferredStockValueIssued" scale="3" id="f-128">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-129">393,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-130">393,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-131">304,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-132">237,664</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive loss &#8211; foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-133">15,731</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-134">25,868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total stockholders&#8217; equity attributable to Barinthus Biotherapeutics plc shareholders</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-135">74,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-136">130,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="f-137">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="f-138">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-139">74,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-140">130,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-141">98,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-142">160,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">___________________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_139"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">License revenue </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-143">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-144">14,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-145">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-146">14,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-147">25,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-148">42,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-149">40,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-150">29,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Impairment of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="3" id="f-151">4,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="3" id="f-152">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-153">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-154">12,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-155">71,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-156">84,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherOperatingIncome" scale="3" id="f-157">506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherOperatingIncome" format="ixt:num-dot-decimal" scale="3" id="f-158">1,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-159">70,555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-160">67,970</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other income/(expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-161">1,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-162">2,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-163">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-164">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Research and development incentives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:ResearchAndDevelopmentIncentiveIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-165">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="brns:ResearchAndDevelopmentIncentiveIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-166">3,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-167">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-168">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total other income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-169">3,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-170">6,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss before income tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-171">66,633</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-172">61,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-173">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-174">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss </span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-175">66,458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-176">61,183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-177">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-178">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss attributable to Barinthus Biotherapeutics plc shareholders</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-179">66,428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-180">61,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average ordinary shares outstanding, basic </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-181">40,527,218</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-182">39,348,240</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average ordinary shares outstanding, diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-183">40,527,218</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-184">39,348,240</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss per share attributable to ordinary shareholders, basic</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-185">1.64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-186">1.55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share attributable to ordinary shareholders, diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-187">1.64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-188">1.55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-189">66,458</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-190">61,183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other comprehensive gain/(loss) &#8211; foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-191">10,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-192">2,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-193">56,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-194">63,732</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Comprehensive loss/(gain) attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="f-195">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="f-196">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-197">56,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-198">63,627</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">___________________________</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.75pt"><ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote">All license revenue is from related parties and is generated in the U.K. for the year ended December&#160;31, 2024.</ix:footnote> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_142"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">(IN THOUSANDS, EXCEPT NUMBER OF SHARES)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.777%"><tr><td style="width:1.0%"/><td style="width:22.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.915%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.242%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.247%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.583%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.255%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="60" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary&#160;Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Deferred A Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Additional Paid-in-Capital</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Accumulated Deficit</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total stockholders&#8217; equity attributable to Barinthus Biotherapeutics plc stockholders</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Noncontrolling Interest</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Total Stockholders' Equity</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:69pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Balance, January 1, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-199">40,234,663</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-200">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-201">63,443</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-202">86</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-203">393,474</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-204">237,664</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-205">25,868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-206">130,029</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-207">106</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-208">130,135</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Share based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-209">468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-210">468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-211">468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Issue of ordinary shares, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-212">614,230</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-213">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-214">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-215">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-216">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-217">10,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-218">10,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-219">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-220">10,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-221">66,428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-222">66,428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="f-223">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-224">66,458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Balance, December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-225">40,848,893</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-226">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-227">63,443</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-228">86</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-229">393,944</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-230">304,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-231">15,731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-232">74,208</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-233">84</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-234">74,292</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.243%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="60" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Deferred A Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Additional Paid-in-Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total stockholders&#8217; equity attributable to Barinthus Biotherapeutics plc stockholders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Noncontrolling Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Balance, January 1, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-235">38,643,540</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-236">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-237">63,443</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-238">86</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-239">386,602</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-240">176,590</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-241">23,315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-242">186,784</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-243">211</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-244">186,995</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Share based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-245">4,709</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-246">4,709</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-247">4,709</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Issue of ordinary shares, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-248">1,591,123</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-249">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-250">2,163</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-251">2,163</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-252">2,163</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-253">2,553</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-254">2,553</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-255">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-256">2,549</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-257">61,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-258">61,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="f-259">109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-260">61,183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Balance, December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-261">40,234,663</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-262">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-263">63,443</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-264">86</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-265">393,474</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-266">237,664</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-267">25,868</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-268">130,029</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-269">106</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-270">130,135</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">__________________________________</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> <ix:footnote id="fn-2" footnoteRole="http://www.xbrl.org/2003/role/footnote">Indicates amount less than one thousand</ix:footnote></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_145"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS)</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-271">66,458</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-272">61,183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Share based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="f-273">468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-274">4,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:AssetImpairmentChargesExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-275">5,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="brns:AssetImpairmentChargesExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-276">5,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-278">12,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-279">5,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-280">5,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Non-cash lease expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:NonCashLeaseExpenses" format="ixt:num-dot-decimal" scale="3" id="f-281">3,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="brns:NonCashLeaseExpenses" format="ixt:num-dot-decimal" scale="3" id="f-282">1,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Unrealized foreign exchange loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="f-283">3,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="f-284">649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Change in contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="f-285">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="f-286">866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:NonCashInterestExpenseOnConvertibleLoanNotes" scale="3" id="f-287">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="brns:NonCashInterestExpenseOnConvertibleLoanNotes" scale="3" id="f-288">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Deferred tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-289">175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-290">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Profit on sale of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-291">245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="f-292">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-293">1,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-294">3,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Research and development incentives receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="brns:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-295">6,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="brns:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-296">2,345</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-297">2,202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-298">898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-299">3,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="f-300">456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Deferred income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="f-301">506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="f-302">1,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-303">1,979</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-304">1,789</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-305">47,979</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-306">28,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Proceeds from sale of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="f-307">453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-309">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-310">892</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Net cash provided by/(used) in investing activities</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-311">416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-312">892</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Issue of shares from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="f-313">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="f-314">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5pt;font-weight:400;line-height:114%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Proceeds from issue of ordinary shares, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-315">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-316">2,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Net cash provided by financing activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-317">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-318">2,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Effect of exchange rates on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-319">7,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-320">2,021</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-321">40,548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-322">29,690</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash, beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-323">112,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-324">142,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash, end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-325">71,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-326">112,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:115%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">___________________________</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><ix:footnote id="fn-3" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.75pt">Indicates amount less than one thousand</span></ix:footnote></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_148"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:700;line-height:115%"> </span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_151"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-327" continuedAt="f-327-1" escape="true">Nature of Business and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="f-327-1" continuedAt="f-327-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Nature of business</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Barinthus Biotherapeutics plc is a public limited company incorporated pursuant to the laws of England and Wales in March 2021. Barinthus Biotherapeutics plc and its direct and indirect subsidiaries, Barinthus Biotherapeutics (UK) Limited, Barinthus Biotherapeutics North America, Vaccitech Oncology Limited (&#8220;VOLT&#8221;), Barinthus Biotherapeutics Pty Limited, Barinthus Biotherapeutics Switzerland GmbH are collectively referred to as the &#8220;Company&#8221; or &#8220;Barinthus Bio&#8221;. During the quarterly period ended September 30 2025, the Company incorporated <ix:nonFraction unitRef="subsidiary" contextRef="c-47" decimals="INF" name="brns:NumberOfNewSubsidiaries" format="ixt-sec:numwordsen" id="f-328">two</ix:nonFraction> new subsidiaries, Beacon Topco, Inc. (&#8220;Topco&#8221;) and Cdog Merger Sub, Inc. (&#8220;Merger Sub&#8221;), for the purpose of the transactions contemplated by the recently announced merger agreement with Clywedog Therapeutics, Inc. ("Clywedog"). These entities are not material to the Company's consolidated financial position or results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases within the immunology and inflammation ("I&amp;I") space enabled by the proprietary and highly differentiated platform for promoting immune tolerance, referred to as SNAP-TI. The Company's lead candidate, VTP-1000, is designed to restore immune non-responsiveness to gluten in patients with celiac disease, and is currently being assessed in a Phase 1 clinical trial. The Company occupies laboratory and office space in Germantown, Maryland, United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company operates in an environment of rapid technological change and substantial competition from pharmaceutical and biotechnology companies. The Company is subject to risks common to companies in the biopharmaceutical industry that are also in a similar stage of its life cycle including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of any of its products that are approved, and protection of proprietary technology. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales. If the Company does not successfully commercialize any of its products or mitigate any of these other risks, it will be unable to generate revenue or achieve profitability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merger Agreement with Clywedog</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 29, 2025, the Company entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) by and among the Company, Topco, Merger Sub and Clywedog. The Merger Agreement provides that, among other things, upon the terms and subject to the conditions set forth therein: (i) Topco will acquire the entire issued and to be issued share capital of the Company pursuant to a scheme of arrangement (subject to any modification, addition or condition which (a) the Company, Topco and Clywedog mutually agree and which (if required) is approved by the High Court of Justice of England and Wales (the &#8220;Court&#8221;) or (b) is otherwise imposed by the Court and mutually acceptable to the Company, Topco and Clywedog, each acting reasonably and in good faith, in each case in accordance with the Part 26 of the United Kingdom Companies Act 2006 and the Merger Agreement (the &#8220;Scheme of Arrangement&#8221; and such transaction, the &#8220;Scheme Transaction&#8221;)), resulting in the Company becoming a direct wholly owned subsidiary of Topco, and (ii) Merger Sub will merge with and into Clywedog, with Clywedog continuing as the surviving corporation and a direct wholly owned subsidiary of Topco in accordance with the Delaware General Corporations Law (the &#8220;Merger&#8221; and, together with the Scheme Transaction, the &#8220;Combinations&#8221;, and, together with such other transactions contemplated by the Merger Agreement, the &#8220;Contemplated Transactions&#8221;). The Scheme Transaction will be consummated prior to the Merger. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At the effective time of the Scheme Transaction (the &#8220;Scheme Effective Time&#8221;), upon the terms and subject to the conditions set forth in the Merger Agreement, Topco will acquire each outstanding ordinary share of the Company, with a par value &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="c-48" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-329">0.000025</ix:nonFraction> per ordinary share (each such acquired ordinary share, a &#8220;Scheme Share&#8221;), which, for the avoidance of doubt, will include ordinary shares held by The Bank of New York Mellon (the &#8220;Depositary&#8221;) (or to the extent that the Depositary is not itself the registered holder of such shares that underly the Company&#8217;s American Depositary Shares (the &#8220;ADSs&#8221;), each representing one (<ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" name="brns:NumberOfDepositarySharesPerShareOfCommonStock" scale="0" id="f-330">1</ix:nonFraction>) ordinary share, whichever nominee, custodian or other entity is the registered holder under the terms of the Deposit Agreement, dated as of April 29, 2021, among the Company, the Depositary, and all holders from time to time of the ADSs, as may be amended from time to time), from the holders of Scheme Shares whose names appear in the register of members of the Company at the Scheme Effective Time) in accordance with the provisions of the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-327-2" continuedAt="f-327-3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Scheme of Arrangement, and each Scheme Share will be converted into the right to receive (i) one (<ix:nonFraction unitRef="number" contextRef="c-49" decimals="INF" name="brns:StockConversionRatio" scale="0" id="f-331">1</ix:nonFraction>) share of common stock, <ix:nonFraction unitRef="usdPerShare" contextRef="c-50" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-332">0.0001</ix:nonFraction> par value per share, of Topco (the &#8220;Topco Common Stock&#8221;) subject to and strictly in accordance with the terms of the Scheme of Arrangement plus (ii) cash in lieu of any fractional shares, rounded down to the nearest whole share. Following the Scheme Effective Time, Topco may in its discretion elect to commence a self-tender offer (&#8220;Self-Tender Offer&#8221;) to purchase up to $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" name="srt:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="f-333">27.0</ix:nonFraction> million in shares of Topco Common Stock then issued and outstanding, which Self-Tender Offer, if elected, will be consummated prior to the Merger.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At the effective time of the Merger (the &#8220;Merger Effective Time&#8221;), subject to adjustment in accordance with the terms of the Merger Agreement, each share of common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-51" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-334">0.0001</ix:nonFraction> par value per share, of Clywedog (the &#8220;Clywedog Common Stock&#8221;) and each share of Series Seed Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-51" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-335">0.0001</ix:nonFraction> par value per share, of Clywedog (the &#8220;Clywedog Preferred Stock&#8221;, and together with the Clywedog Common Stock, the &#8220;Clywedog Capital Stock&#8221;), other than Clywedog Capital Stock held as treasury stock or owned by Topco or Merger Sub immediately prior to the Merger Effective Time, will be converted solely into the right to receive (i) <ix:nonFraction unitRef="number" contextRef="c-52" decimals="INF" name="brns:StockConversionRatio" scale="0" id="f-336">4.358932</ix:nonFraction> of shares of Topco Common Stock rounded down to the nearest whole share plus (ii) cash in lieu of any fractional shares.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The closing of the Contemplated Transactions is subject to the satisfaction or waiver of certain customary conditions, including, among other things: (i) the effectiveness of a registration statement (the &#8220;Registration Statement&#8221;) to register the shares of Topco Common Stock to be issued in connection with the Combinations; (ii) approvals by the Company&#8217;s shareholders of the Scheme Transaction and certain related matters, and sanction by the Court of the Scheme Transaction; (iii) approval by Clywedog&#8217;s stockholders of the Merger Agreement, the Merger and Contemplated Transactions; (iv) the approval for listing by the Nasdaq Stock Market of the shares of Topco Common Stock issuable in the Combinations, subject to official notice of issuance; (v) the completion of the Self-Tender Offer to the extent that Topco elects to commence the Self-Tender Offer; (ivi) minimum cash requirements for each party.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Merger Agreement may be terminated and the transactions contemplated thereby abandoned at any time prior to the closing under certain specified circumstances. Either the Company or Clywedog may terminate the Merger Agreement if, among other things: (i) the closing date will not have occurred by September 30, 2026, subject to up to a <ix:nonNumeric contextRef="c-53" name="brns:MergerAgreementExtensionPeriod" format="ixt-sec:durday" id="f-337">60</ix:nonNumeric> day extension if the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) has not declared effective the Registration Statement by July 31, 2026, (ii) a governmental authority of competent jurisdiction has issued a final, non-appealable order prohibiting the Contemplated Transactions, (iii) the required Company shareholder approval or Clywedog shareholder approval is not obtained in accordance with the Merger Agreement, (iv) the Scheme of Arrangement is not sanctioned by the Court, or (v) another party breaches or fails to perform in any material respect any of its covenants or any of the other party&#8217;s representations or warranties are inaccurate and such breach, failure to perform or inaccuracy would result in certain of the closing conditions not being satisfied, subject to a cure period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis of presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:116%">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission for annual financial reporting. The Company&#8217;s reporting currency is the U.S. dollar. As of December&#160;31, 2025, the Company had cash, cash equivalents and restricted cash of $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-338">71.9</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-339">304.1</ix:nonFraction> million and the Company expects to incur losses for the foreseeable future as it continues to pursue its activities, including the commercialization of its research and development. The Company expects to continue to incur costs and expenditures in connection with the Contemplated Transactions, further in connection with the Contemplated Transactions Barinthus may pay up to $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" name="srt:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="f-340">27.0</ix:nonFraction> million to existing shareholders under a Self Tender offer. If the Contemplated Transactions are consummated, any additional funding will be sought by the combined company. However as the transaction is not yet consummated, when performing the going concern assessment, management have assessed the Company on a standalone basis and expects that its cash, cash equivalents and restricted cash will be sufficient to fund current operations for at least the next 12 months from the issuance of the consolidated financial statements. </span><span style="color:#242424;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:116%">In the future the Company will need additional cash inflows to </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:116%">pursue its activities, including the commercialization of its research and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-327-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:116%">development. There is no assurance that the Company will be successful in obtaining sufficient cash inflows on terms acceptable to the Company to fund continuing operations, if at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies" id="f-341" continuedAt="f-341-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Guarantees and indemnifications</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-341-1">As permitted under the laws of England and Wales, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company.</ix:continuation> Through the years ended December&#160;31, 2025 and 2024, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div></ix:continuation><div id="ia7cbadf995cd4920bb4d015b669c5879_154"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-342" continuedAt="f-342-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-342-1" continuedAt="f-342-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-343" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Principles of consolidation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying consolidated financial statements include the accounts of Barinthus Biotherapeutics plc and those entities in which it has a controlling interest. Intercompany amounts are eliminated on consolidation. Amounts attributable to the noncontrolling interest are presented as a separate element of equity in the accompanying consolidated financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-344" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">During the current year, the Company updated certain estimates related to the carrying value of long-lived assets as a result of the announced Contemplated Transactions with Clywedog. The adjustment reflects updated assumptions regarding expected future cash flows and market participant perspectives. Additional information regarding this change in estimate and its impact on the financial statements is included in Note 7.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of the date of issuance of these consolidated financial statements, the Company is not aware of any other specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#8217;s financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-345" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comprehensive loss</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Comprehensive loss for all periods presented is comprised primarily of net loss and other comprehensive loss, which solely relates to foreign currency translation adjustments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-346" continuedAt="f-346-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Foreign currency translation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s reporting currency is the United States dollar. The functional currency of the parent and each subsidiary is the currency of the country and economic environment in which it is located. Assets and liabilities of each legal entity denominated or measured in a currency other than British Pounds are first translated into British pounds and consolidated. The consolidated balances are then converted into United States dollars at period-end exchange rates. Revenues and expenses are translated into British pounds, then into U.S. dollars at average exchange rates for each reporting period. Translation adjustments are reflected as accumulated other comprehensive loss within stockholders&#8217; equity. Gains and losses on foreign currency transactions are included in the consolidated statements of operations and comprehensive loss in </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-342-2" continuedAt="f-342-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-346-1">general and administrative expenses.</ix:continuation> The aggregate net foreign exchange gain or loss included in determining net loss was a loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-347">9.6</ix:nonFraction> million and gain of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-348">2.4</ix:nonFraction> million for the years ended December&#160;31, 2025 and 2024, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="brns:MinorityInterestPolicyTextBlock" id="f-349" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Noncontrolling interest</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In 2018, Barinthus Biotherapeutics plc established VOLT with a related party. As of December&#160;31, 2021, Barinthus Biotherapeutics plc had contributed cash and intellectual property with an aggregate value of $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="brns:SubsidiaryCumulativeContributionsParent" scale="6" id="f-350">11.9</ix:nonFraction> million for a <ix:nonFraction unitRef="number" contextRef="c-55" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-351">76</ix:nonFraction>% controlling interest. The related party had contributed cash and intellectual property with an aggregate value of $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="brns:SubsidiaryCumulativeContributionsNoncontrollingOwner" scale="6" id="f-352">3.8</ix:nonFraction> million for a <ix:nonFraction unitRef="number" contextRef="c-57" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-353">24</ix:nonFraction>% noncontrolling interest. There were no further contributions in subsequent financial years. The contributed intellectual properties were initially recorded at investment date fair value by VOLT and immediately expensed as research and development costs. The Company accounts for the noncontrolling interest in the accompanying consolidated financial statements initially at fair value with the subsequent carrying value adjusted for the noncontrolling share of VOLT&#8217;s comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-354" continuedAt="f-354-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash and cash equivalents</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-354-1">The Company considers all highly liquid investments purchased with remaining maturities of three months or less on the purchase date to be cash and cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that are actively traded (a Level 1 input).</ix:continuation> As of December&#160;31, 2025, and 2024 there were <ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="0" id="f-355"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="0" id="f-356">no</ix:nonFraction></ix:nonFraction> cash equivalents.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-357" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into collaboration and license agreements, which are within the scope of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 606, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include licenses, or options to obtain licenses, to product candidates or future product candidates. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts recognized as revenue, but not yet received are generally recognized as accounts receivable or contract assets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">License revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s arrangements may provide the collaboration partner with the right to select a target for licensing either at the inception of the arrangement or in the future. Under these arrangements, fees may be due to the Company (i) at the inception of the arrangement as an upfront fee or payment, (ii) upon the exercise of an option to acquire a license or (iii) upon extending the selection period as an extension fee or payment. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services at their standalone selling prices, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For arrangements that include sales-based milestones and royalties, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This could require management to estimate the amount of revenue to recognize in the period if the actual data for the period has not been provided.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-342-3" continuedAt="f-342-4"><ix:nonNumeric contextRef="c-1" name="brns:ResearchAndDevelopmentServicesPolicyPolicyTextBlock" id="f-358" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and development services</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The promises under the Company&#8217;s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. For performance obligations that include research and development services, the Company recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for the purposes of recognizing revenue, which may include an input measure such as costs incurred during the reporting period or ratably over the service period. Reimbursements from the partner are evaluated as to whether the Company acts as a principal or an agent in such relationships. The Company evaluates whether control over the underlying goods or services were obtained prior to transferring these goods or services to the collaboration partner. Where the Company does not control the goods or services prior to transferring these goods or services to the collaboration partner, such reimbursements are presented net of costs. At the inception of each arrangement that includes development milestone payments in respect of development efforts, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular development milestone in making this assessment. There is judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each reporting period, the Company reevaluates the probability of achievement of all development milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. To date, the Company has not recognized any development milestone revenue resulting from any of its arrangements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="brns:OtherOperatingIncomePolicyPolicyTextBlock" id="f-359" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Operating Income</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Other operating income includes grant income from the CEPI Funding Agreement pursuant to which CEPI will provide funding to us to advance the development of VTP-500, a vaccine candidate against MERS. When there is reasonable assurance that we will comply with the conditions attached to a received grant, and when there is reasonable assurance that the grant will be received, grant income is recognized as other operating income on a gross basis in the consolidated statements of operations and comprehensive loss on a systematic basis over the periods in which we recognize expenses for the related costs for which the grants are intended to compensate. Payments received in advance of incurring reimbursable expenses are recorded as deferred income. Any remaining unused amounts of the cash payments received will be disclosed as restricted cash in the consolidated balance sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-360" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentrations of credit risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. Periodically, the Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses in these deposits. The Company&#8217;s standard payment terms are typically <ix:nonNumeric contextRef="c-1" name="brns:AccountsReceivableStandardPaymentTermsPeriod" format="ixt-sec:durday" id="f-361">30</ix:nonNumeric> days.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue earned in connection with the license and services provided to customers. The Company provides credit to licensees in the normal course of providing such services based on evaluations of their financial condition and generally does not require collateral. To manage accounts receivable credit risk, the Company monitors the creditworthiness of its licensees. Historically, the Company has not experienced any credit losses related to accounts receivable and does not maintain allowances for uncollectible amounts.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-342-4" continuedAt="f-342-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-362" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Licensees that represented 10% or more of the Company&#8217;s revenue are presented below:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.606%"><tr><td style="width:1.0%"/><td style="width:53.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.298%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.301%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Revenue</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Country</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Oxford University Innovation</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">U.K.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-58" decimals="2" name="brns:ConcentrationRiskThresholdPercentage" format="ixt:fixed-zero" scale="-2" id="f-363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-59" decimals="2" name="brns:ConcentrationRiskThresholdPercentage" scale="-2" id="f-364">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CreditLossFinancialInstrumentPolicyTextBlock" id="f-365" continuedAt="f-365-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Allowance for credit losses</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-365-1">The Company evaluates its cash equivalents and accounts receivable for expected credit losses. Expected credit losses represent the portion of the amortized cost basis of a financial asset that an entity does not expect to collect. An allowance for expected credit losses is meant to reflect a risk of loss even if remote, irrespective of the expectation of collection from a particular issuer or debt security. The Company has not historically experienced any credit losses on any of its financial assets.</ix:continuation> With respect to cash equivalents and accounts receivable, given consideration of their short maturity, historical losses and the current market environment, the Company concluded there are <ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="0" id="f-366"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="0" id="f-367">no</ix:nonFraction></ix:nonFraction> expected credit losses for these financial assets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-368" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and equipment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses. Expenditures for maintenance and repairs are charged to operating expenses as incurred, whereas major betterments are capitalized as additions to property and equipment. Impairment losses are recorded within general and administrative expenses. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-369" continuedAt="f-369-1" escape="true">Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:</ix:nonNumeric></span></div><ix:continuation id="f-369-1" continuedAt="f-369-2"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.787%"><tr><td style="width:1.0%"/><td style="width:73.323%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.477%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Asset Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-60" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-370">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-61" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-371">4</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lesser of lease term or estimated useful lives</span></td></tr></table></div></ix:continuation></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="f-372" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Intangible assets acquired through business combinations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets consist of acquired developed technology. Intangible assets are stated at cost less accumulated amortization and impairment losses. Amortization is computed using the straight-line method over the estimated useful lives of the respective assets, which is <ix:nonNumeric contextRef="c-62" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-373">10</ix:nonNumeric> years.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-374" continuedAt="f-374-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impairment </span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-374-1">The Company reviews long-lived assets to be held and used, including property and equipment, intangible assets and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Evaluation of recoverability is first based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group and its eventual disposition. In the event such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the assets are written down to their estimated fair values.</ix:continuation> There were impairments recorded during the year ended December&#160;31, 2025 and 2024.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-375" continuedAt="f-375-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill represents the excess of cost over the fair value of the net tangible and intangible assets of businesses acquired in a business combination. Goodwill is not amortized but rather is tested for impairment at least annually, or more frequently if events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. The Company has elected to first assess the qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis of determining whether it is necessary to perform the quantitative goodwill impairment test. If the Company determines that it is more likely than not that its fair value is less than its carrying amount, then the quantitative goodwill impairment test will be performed. The quantitative goodwill impairment test identifies and measures the amount of goodwill impairment loss, if any, to be recognized by comparing the fair value </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-342-5" continuedAt="f-342-6"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-375-1">of a reporting unit with its carrying amount. If the fair value exceeds the carrying amount, no further analysis is required; otherwise, if the fair value is less than the carrying amount, the difference is recognized as a goodwill impairment loss not to exceed the carrying amount of the goodwill. The carrying amount of goodwill was nil at December 31, 2024 . The Company has performed the annual impairment assessment and identified qualitative indicators of impairment, most notably the share price drop in November 2024, including the lack of recovery thereof, and the strategic considerations to partner VTP-300 for future clinical development. Therefore, the Company performed a qualitative impairment assessment and determined that it was more likely than not that the fair value of the reporting unit is less than its carrying amount. The reporting unit comprises the net assets of the Company. The Company then performed a quantitative impairment assessment using the income approach to determine the fair value of the reporting unit, including the net present value of clinical stage assets and overhead costs. Based on the quantitative assessment, the Company determined that the fair value of the reporting unit is less than its carrying amount as of December 31, 2024, and, as a result, recognized a goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-376">12.2</ix:nonFraction> million.</ix:continuation> For the year ended December&#160;31, 2025 there was <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-377">no</ix:nonFraction> impairment charge to Goodwill (December&#160;31, 2024: $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-378">12.2</ix:nonFraction> million).</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-379" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Financial instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s financial instruments consist of cash, cash equivalents, restricted cash, accounts receivable, accounts payable, certain accrued expenses and contingent consideration. The carrying amounts of cash, cash equivalents, accounts receivable, security deposits, accounts payable and accrued expenses approximate their fair value due to the short-term nature of those financial instruments.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-342-6" continuedAt="f-342-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-380" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fair value measurements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company follows the guidance in ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">, which defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">-</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.67pt">Level 1 &#8211; Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.67pt">Level 2 &#8211; Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.67pt">Level 3 &#8211; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company&#8217;s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may change for many instruments. This condition could cause an instrument to be reclassified within levels in the fair value hierarchy. There were no transfers within the fair value hierarchy during the years ended December&#160;31, 2025 and 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes a contingent consideration liability related to the acquisition of Avidea Technologies, Inc. The liability is remeasured to fair value at each reporting date until the contingency is resolved. The fair value of the contingent consideration is a Level 3 valuation determined using significant unobservable inputs being the probability of success of achievement of the milestones and the expected date of the milestone achievement. Changes in fair value are recognized in <span style="-sec-ix-hidden:f-381"><span style="-sec-ix-hidden:f-382">general and administrative expenses</span></span> in the consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-383" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Leases are accounted for under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(&#8220;ASC 842&#8221;) resulting in the recognition of lease liabilities and right-of-use assets. The Company only has operating leases. The Company has elected the practical expedient allowed under ASC 842 to account for each lease component (e.g., the right to use office space) and the associated non-lease components (e.g., maintenance services) as a single lease component. The Company also elected the short-term lease accounting policy for all asset classes; therefore, the Company is not recognizing a lease liability or right-of-use asset for any lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Variable lease payments such as the Company&#8217;s share of real estate taxes, utilities, and common area maintenance, are reported as non-lease operating expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets also include the effect of any lease payments made and exclude lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized as part of total operating expenses on a straight-line basis over the lease term. The difference between the value of the right of use asset and lease liability is due to the reclassification of prepaid rent and unamortized lease incentives.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-342-7" continuedAt="f-342-8"><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-384" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and development</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs are expensed as incurred on an accrual basis. Research and development costs include payroll and personnel expense (including share-based compensation), consulting costs, external contract research and development expenses, raw materials, drug product manufacturing costs, and allocated overheads including depreciation and amortization, facility costs, and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="brns:ClinicalTrialCostsPolicyTextBlock" id="f-385" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical trial costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activation, and other information provided to the Company by its vendors.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" id="f-386" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent and licensing costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Patent and licensing costs are expensed as incurred because there is uncertainty as to any future economic benefits arising from these costs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityPolicyTextBlock" id="f-387" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Ordinary shares</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Ordinary shares are classified in stockholders&#8217; equity and represent issued share capital.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="brns:AdditionalPaidInCapitalPolicyTextBlock" id="f-388" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Additional paid-in capital</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Additional paid-in capital is classified in stockholders&#8217; equity and represents the share premium account, where the difference between the price paid per share and the nominal value is recognized. The equity element of share based compensation is also recognized in additional paid in capital.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-389" continuedAt="f-389-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Share based compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company grants options over ordinary shares and restricted shares units to employees or non-executive directors and accounts for share based compensation using the grant date fair value. Share based compensation awards are classified in the accompanying statements of operations and comprehensive loss based on the function to which the related services are provided. For service-based awards, compensation expense is generally recognized over the requisite service period of the awards, usually the vesting period. The Company applies the &#8220;multiple option&#8221; method of allocating expense. In applying this method, each vesting tranche of an award is treated as a separate grant and recognized on a straight-line basis over that tranche&#8217;s vesting period. For performance-based awards where the vesting of the awards may be accelerated upon the achievement of certain milestones, vesting and the related share-based compensation is recognized as an expense when it is probable the milestone will be met. Assumptions used in the option pricing model include the following:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected volatility.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> Previously there was insufficient trading history for the Company&#8217;s ordinary shares, therefore the expected price volatility for the Company's ordinary shares was estimated using the average historical volatility of industry peers&#8217; shares as of the grant date of the Company's options over a period of history commensurate with the expected life of the options. When selecting industry peers used in measuring implied volatility, the Company considered the similarity of their products and business lines, as well as their stage of development, size and financial leverage. The Company applied this process consistently using the same or similar public companies until 2023. For options granted since 2023, the Company determined that there is sufficient historical information on volatility of its share price available and the expected volatility used in the fair value calculation of new option grants is calculated based on a blended volatility of both historical volatility of the Company's share price and the average historical volatility of industry peers&#8217; shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">. The expected term of the Company&#8217;s share options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The &#8220;simplified&#8221; method was determined to be appropriate as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-342-8" continuedAt="f-342-9"><ix:continuation id="f-389-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected dividend.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> Expected dividend yield of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-390"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-391">zero</ix:nonFraction></ix:nonFraction> is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company has elected to recognize the effect of forfeitures on share-based compensation when they occur. Any differences in compensation recognized at the time of forfeiture are recorded as a cumulative adjustment in the period where the forfeiture occurs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">When awards are modified, the Company compares the fair value of the affected award measured immediately prior to modification to its value after modification. To the extent that the fair value of the modified award exceeds the original award, the incremental fair value of the modified award is recognized as compensation on the date of modification for vested awards, and over the remaining vesting period for unvested awards.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:RegulatoryIncomeTaxesPolicy" id="f-392" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The financial statements reflect provisions for income taxes in the U.K. and foreign jurisdictions. Deferred tax assets and liabilities represent future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities and for loss carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is recorded when it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. To date, the Company has not incurred interest and penalties related to uncertain tax positions nor has it recorded any unrecognized tax benefits.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="brns:ResearchAndDevelopmentIncentivesPolicyTextBlock" id="f-393" continuedAt="f-393-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and development incentives</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="f-393-1" continuedAt="f-393-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In the U.K., the Company had previously been entitled to a research and development tax credit regime, being the Small and Medium-sized Enterprises R&amp;D tax relief program (&#8220;SME&#8221;),and, to the extent that our projects are grant funded or relate to work subcontracted to us by third parties, the Research and Development Expenditure Credit program, or RDEC Program. For the year ended December 31, 2025, we benefit from the applicable United Kingdom research and development tax credit regime which is the merged scheme Research &amp; Development expenditure credit ("RDEC") and enhanced R&amp;D intensive support ("ERIS") that replaces the prior schemes. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims. For expenditure under the merged RDEC scheme, the rate of Research and Development expenditure credit will is 20%, which is the same as the rate under the old RDEC scheme for expenditure incurred on or after April 1, 2023. For loss-makers and small profit-makers, a lower rate of notional tax restriction (currently 19%) applies at payment. Under both the merged RDEC scheme and the prior SME program, a company qualifies as an R&amp;D intensive business if R&amp;D expenditure constitutes at least 30% of total expenditure. From the analysis performed, the Company has not and do not currently expect to claim under the loss-making R&amp;D intensive scheme primarily due to the proportion of total relevant expenditure occurring outside the U.K. If the Company incurs tax losses, the Company is entitled to surrender the lesser of unrelieved tax loss sustained and the tax relief. As the realization of the tax relief does not depend on our generation of future taxable income or the Company&#8217;s ongoing tax status or tax position, the Company does not consider the tax relief as an element of income tax accounting under ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income taxes </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-393-2">and records the tax relief as a form of government grant or assistance.</ix:continuation> For the years ended December&#160;31, 2025 and 2024, the Company recognized research and development incentives of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="brns:ResearchAndDevelopmentIncentiveIncomeExpense" scale="6" id="f-394">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="brns:ResearchAndDevelopmentIncentiveIncomeExpense" scale="6" id="f-395">4.0</ix:nonFraction> million respectively. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-396" continuedAt="f-396-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net loss per share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding for the reporting period without consideration for potentially dilutive securities. Net loss attributable to ordinary shareholders is computed as if all net loss for the period had been distributed. During periods in which the Company incurred a net loss, the Company allocates no net loss to participating securities because they do not have a contractual obligation to share in the net loss of the Company.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-342-9" continuedAt="f-342-10"><ix:continuation id="f-396-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company computes diluted net loss per ordinary share after giving consideration to all potentially dilutive ordinary equivalents, including stock options outstanding during the period, except where the effect of such non-participating securities would be antidilutive.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Diluted net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares and dilutive ordinary share equivalents outstanding for the period, determined using the treasury-stock and if-converted methods.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ContingentLiabilityReserveEstimatePolicy" id="f-397" continuedAt="f-397-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contingent liabilities  </span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-397-1">A provision for contingent liabilities is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is a party to certain litigation and disputes arising in the normal course of business.</ix:continuation> As of December&#160;31, 2025, the Company does not expect that such matters will have a material adverse effect on the Company&#8217;s business, financial position, results of operations, or cash flows.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-398" continuedAt="f-398-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, new accounting pronouncements are issued by FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different applications dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time the Company either (i) irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualifies as an emerging growth company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time the Company either (i) irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualifies as an emerging growth company.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company has reviewed all recently issued standards and have determined that such standards do not or are not expected to have a material impact on its condensed consolidated financial statements or do not otherwise apply to its current operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In December 2025, the FASB issued ASU 2025-12, Accounting Standards Update Codification Improvements. The amendments in this update facilitates codification updates for a broad range of Topics arising from technical corrections, unintended application of the codification, clarifications, and other minor improvements. This standard is effective for fiscal years beginning after December 15, 2026, including interim periods within those fiscal years. The Company is currently evaluating the impact of adopting this standard to determine its impact on its disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. The amendments in this update clarify interim disclosure requirements and the applicability of Topic 270. This standard is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact of adopting this standard to determine its impact on its disclosures.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In May 2025, the FASB issued ASU 2025-03, Business Combinations (Topic 805): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity. This ASU amends the guidance for identifying the accounting acquirer in transactions involving variable interest entities (&#8220;VIEs&#8221;) where the transaction is achieved primarily through the exchange of equity interests, aligning it more closely with the guidance for voting interest entities. The amendments are effective for </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-398-1"><ix:continuation id="f-342-10"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">fiscal years beginning after December 15, 2026, including interim periods within those fiscal years, with early adoption permitted. The Company elected to early adopt ASU 2025-03 as of July 1, 2025. The adoption did not have a material impact on the consolidated financial statements. The Company will apply the amended guidance prospectively to applicable transactions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In January 2025, the FASB issued ASU 2025-01, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, in which the Board's intent in the basis of conclusion of Update 2024-03 is clear that all public business entities should initially adopt the disclosure requirements in the first annual reporting period beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact of adopting this standard to determine its impact on its disclosures.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40), which requires disaggregation of specific expense categories in the notes to the financial statements and a qualitative description of the remaining expense amounts not separately disaggregated. This standard is effective for annual reporting periods beginning after December 15, 2026, and requires prospective application with the option to apply it retrospectively. The Company is currently evaluating the impact of adopting this standard to determine its impact on its disclosures.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate). This standard is effective for fiscal years beginning after December 15, 2024. The Company has retrospectively adopted the ASU and the adoption did not have a material impact on the consolidated financial statements.</span></div></ix:continuation></ix:continuation><div id="ia7cbadf995cd4920bb4d015b669c5879_157"></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">. </span><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-399" continuedAt="f-399-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Segment information</span></ix:nonNumeric></div><ix:continuation id="f-399-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker ("CODM"), the Company&#8217;s Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The CODM approves key operating and strategic decisions, including key decisions in clinical development and clinical operating activities, entering into significant contracts and approves the Company's consolidated operating budget. The Company views its operations and manages its business as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-400">one</ix:nonFraction> operating segment, the research and development of immunotherapies and vaccines. The CODM uses loss before income tax to monitor budget versus actual results and decide how to use the Company's resources. As the Company operates in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-401">one</ix:nonFraction> operating segment, all required financial segment information can be found in these consolidated financial statements. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-402" continuedAt="f-402-1" escape="true">The following table is a summary of the Company's significant segment expenses:</ix:nonNumeric></span></div><ix:continuation id="f-402-1"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"><tr><td style="width:1.0%"/><td style="width:65.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.306%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Direct research and development expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">VTP-1000 Celiac</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="brns:DirectResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-403">6,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="brns:DirectResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-404">5,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Barinthus legacy assets</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="brns:DirectResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-405">8,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="brns:DirectResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-406">18,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total direct research and development expenses</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="brns:DirectResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-407">14,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="brns:DirectResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-408">23,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Indirect research and development expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Personnel-related (including share-based compensation)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="brns:IndirectResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-409">8,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="brns:IndirectResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-410">15,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Facility related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="brns:IndirectResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-411">1,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="brns:IndirectResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-412">1,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other indirect costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="brns:IndirectResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-413">1,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="brns:IndirectResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-414">1,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total indirect research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="brns:IndirectResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-415">10,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="brns:IndirectResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-416">18,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-417">25,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-418">42,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.212%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In January 2025, we announced a strategic focus on developing a pipeline in I&amp;I, and the deprioritization of our programs in infectious disease and oncology. The following programs were previously presented separately and have been grouped collectively as "Barinthus Legacy Assets" for both years presented: VTP-300 HBV, VTP-850 Prostate Cancer, VTP-200 HPV, VTP-600 NSCLC, VTP-500 MERS and other and earlier stage programs. </span></div></td></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company operates in <ix:nonFraction unitRef="region" contextRef="c-8" decimals="INF" name="brns:NumberOfGeographicRegionsInWhichEntityOperates" format="ixt-sec:numwordsen" id="f-419">two</ix:nonFraction> geographic regions: the U.S. and the U.K. <ix:nonNumeric contextRef="c-1" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="f-420" continuedAt="f-420-1" escape="true">The following table summarizes the Company&#8217;s long-lived assets, which include the Company&#8217;s intangible assets, property and equipment, net and right-of-use assets by geography:</ix:nonNumeric></span></div><ix:continuation id="f-420-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></div></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-421">19,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-422">28,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">United Kingdom</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:fixed-zero" scale="3" id="f-423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-424">4,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-425">19,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-426">33,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="ia7cbadf995cd4920bb4d015b669c5879_160"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyDisclosureTextBlock" id="f-428" continuedAt="f-428-1" escape="true">Foreign Currency Translation in General and Administrative Expenses</ix:nonNumeric></span></div><ix:continuation id="f-428-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The aggregate, net foreign exchange gain or loss recognized in general and administrative expenses for the year ended December&#160;31, 2025, and 2024, was a loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-429">9.6</ix:nonFraction>&#160;million and a gain of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-430">2.4</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_163"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-431" continuedAt="f-431-1" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-432" escape="true"><ix:continuation id="f-431-1" continuedAt="f-431-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the computation of basic and diluted net loss per share for the years ended December&#160;31, 2025 and 2024 (in thousands, except number of shares and per share amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Numerator:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-433">66,458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-434">61,183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-435">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-436">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss attributable to Barinthus Biotherapeutics plc shareholders</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-437">66,428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-438">61,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average ordinary shares outstanding, basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-439">40,527,218</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-440">39,348,240</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average ordinary shares outstanding, diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-441">40,527,218</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-442">39,348,240</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss per share attributable to ordinary shareholders, basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-443">1.64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-444">1.55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss per share attributable to ordinary shareholders, diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-445">1.64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-446">1.55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-431-2">Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential ordinary share equivalents outstanding would have been anti-dilutive. For the year ended December&#160;31, 2025, <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-447">5,976,157</ix:nonFraction> (December&#160;31, 2024: <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-448">7,285,275</ix:nonFraction>) potential ordinary shares issuable for stock options were excluded from the computation of diluted weighted-average shares outstanding because including them would have had an anti-dilutive effect.</ix:continuation> </span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_166"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-449" continuedAt="f-449-1" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><ix:continuation id="f-449-1"><ix:continuation id="f-369-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net consists of the following (in thousands):</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Office furniture and equipment</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-450">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-451">1,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-452">1,752</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-453">6,178</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-454">8,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-455">9,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, at cost</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-456">11,114</ix:nonFraction>&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-457">16,793</ix:nonFraction>&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation and impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-458">7,591</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-459">9,420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-460">3,523</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-461">7,373</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation expense for the year ended December&#160;31, 2025 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-462">2.9</ix:nonFraction> million (December&#160;31, 2024: $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-463">2.6</ix:nonFraction> million).</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2025 and 2024, the Company recorded a gain of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="6" id="f-464">0.2</ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and <ix:nonFraction unitRef="usd" contextRef="c-12" decimals="INF" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="0" id="f-465">nil</ix:nonFraction>, respectively, from the sale of U.K. laboratory equipment. The recorded associated proceeds from the equipment sale for the year ended December&#160;31, 2025 and 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="f-466">0.5</ix:nonFraction> million and <ix:nonFraction unitRef="usd" contextRef="c-12" decimals="INF" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="f-467">nil</ix:nonFraction>, respectively).</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company identified circumstances that could indicate that the carrying amount of leasehold improvements located in the U.S. and the U.S. operating lease right-of-use asset may not be recoverable as of December 31, 2025, as it was more likely than not that the Company would cease to utilize some of the laboratory and office space in Germantown, Maryland in 2026, before the end of the previously estimated useful lives. The Company performed an impairment assessment of the leasehold improvements within the U.S. asset group using the income approach as of December 31, 2025 and recorded an impairment charge within general and administrative expenses of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="6" id="f-468">0.7</ix:nonFraction> million (December 31, 2024: U.K. property and equipment impairment $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="6" id="f-469">2.7</ix:nonFraction> million) to write down assets to their estimated recoverable amount. The impairment charge is subject to a number of assumptions and actual results may differ. The Company will continue to refine these assumptions as additional information becomes available. The significant assumptions used in determining the estimated fair value of the leasehold improvements located in the U.S. included how much floor space would be relinquished during sub-leasing. Significant changes in these inputs could have a material effect on the fair value measurement. See Note 16 Commitments and Contingencies for details of the impairment assessment performed over the U.S. operating lease right-of-use asset, which is part of the U.S. asset group.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_169"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="f-470" continuedAt="f-470-1" escape="true">Intangible Assets, Net</ix:nonNumeric></span></div><ix:continuation id="f-470-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The gross amount of amortizable intangible assets, consisting of acquired developed technology, was $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-471"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-472">31.6</ix:nonFraction></ix:nonFraction> million at both December&#160;31, 2025 and 2024 and accumulated amortization was $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-473">17.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-474">9.7</ix:nonFraction> million as of December&#160;31, 2025 and 2024, respectively. The amortization expense for the year ended December&#160;31, 2025 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-475">3.0</ix:nonFraction> million (December&#160;31, 2024: $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-476">3.2</ix:nonFraction> million). The estimated annual amortization expense is $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="f-477"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="f-478"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="f-479"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="f-480"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="f-481"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="brns:FiniteLivedIntangibleAssetExpectedAmortizationYearSix" scale="6" id="f-482">2.5</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> million for the years 2026 through to 2031.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">During the quarter ended September 30, 2025, the Company announced it had entered into a definitive merger agreement to combine in an all-stock transaction with Clywedog. The indicative offer price was below fair value of the Company's net assets expected at completion and below prior valuations utilized in our most recent impairment assessments, thereby constituting an impairment triggering event. As a result, the Company recorded a total impairment charge for acquired development technology intangible assets of $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="f-483">4.7</ix:nonFraction> million during the third quarter of 2025. The determination of the fair value of the Company's net assets expected at completion is a non-recurring fair value measurement. Subsequently, we reviewed through to December 31, 2025, for additional indicators of impairment and did not identify any additional impairment triggers nor was any additional impairment expense recorded.</span></div></ix:continuation><div id="ia7cbadf995cd4920bb4d015b669c5879_175"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">8. <ix:nonNumeric contextRef="c-1" name="brns:PrepaidExpenseAndOtherAssetsCurrentTextBlock" id="f-484" continuedAt="f-484-1" escape="true">Prepaid and Other Current Assets</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-485" escape="true"><ix:continuation id="f-484-1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid and other current assets consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Prepayments</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-486">4,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-487">5,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Value Added Tax receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="3" id="f-488">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" format="ixt:fixed-zero" scale="3" id="f-489">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="f-490">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="f-491">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-492">4,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-493">6,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="ia7cbadf995cd4920bb4d015b669c5879_172"></div><div style="margin-top:12pt"><span><br/></span></div><div><span><br/></span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_178"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">9. <ix:nonNumeric contextRef="c-1" name="brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" id="f-494" continuedAt="f-494-1" escape="true">Accrued Expenses and Other Current Liabilities</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" id="f-495" escape="true"><ix:continuation id="f-494-1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued manufacturing and clinical expenses</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="brns:AccruedManufacturingAndClinicalExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-496">1,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="brns:AccruedManufacturingAndClinicalExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-497">3,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Value Added Tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-498">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-499">2,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued bonus</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:fixed-zero" scale="3" id="f-500">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-501">1,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="f-502">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="f-503">656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-504">3,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-505">737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-506">541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-507">616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-508">6,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-509">9,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_181"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"> 10. <ix:nonNumeric contextRef="c-1" name="us-gaap:OtherOperatingIncomeAndExpenseTextBlock" id="f-510" continuedAt="f-510-1" escape="true">Grant Income</ix:nonNumeric></span></div><ix:continuation id="f-510-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;) Funding Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On December 20, 2023, Barinthus Biotherapeutics (UK) Limited, the Chancellors, Masters and Scholars of the University of Oxford (&#8220;Oxford,&#8221; together with Barinthus Biotherapeutics (UK) Limited, the &#8220;Partners&#8221;) and the Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;) entered into a Funding Agreement (the &#8220;Funding Agreement&#8221;) pursuant to which CEPI would provide funding of up to $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="brns:FundingAmountMaximum" scale="6" id="f-511">34.8</ix:nonFraction> million to the Company to advance the development of VTP-500, a vaccine candidate against Middle East Respiratory Syndrome (&#8220;MERS,&#8221; and such development activities, the &#8220;Project&#8221;). In December 2023, VTP-500 received PRIME (PRIority MEdicines) designation by the European Medicines Agency. There have been no changes to the terms or conditions of the grant since the previous reporting period.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In January 2025, the Company announced its strategic focus on developing a pipeline in I&amp;I, and the deprioritization of its programs in infectious disease and oncology. The Company intends to exit the Funding Agreement as part of aligning resources in accordance with the Company's strategy.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December&#160;31, 2025, <ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:DeferredIncomeAddition" format="ixt:fixed-zero" scale="6" id="f-512">nil</ix:nonFraction> (December 31, 2024: $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:DeferredIncomeAddition" scale="6" id="f-513">3.0</ix:nonFraction>&#160;million) proceeds have been received. For the year ended December 31, 2025 $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:DeferredIncomeRevenueRecognized" scale="6" id="f-514">0.4</ix:nonFraction>&#160;million (December 31,2024: $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:DeferredIncomeRevenueRecognized" scale="6" id="f-515">1.2</ix:nonFraction>&#160;million ) income has been recognized in relation to this contract. This is presented as other operating income in the consolidated statements of operations and comprehensive loss. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Funding Agreement cash payments are restricted as to the use and management of the funds. The remaining unused amounts of the Funding Agreement cash payments of $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="f-516">1.4</ix:nonFraction> million as of December&#160;31, 2025 (December&#160;31, 2024: $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="f-517">1.7</ix:nonFraction> million), are reflected in restricted cash in the consolidated balance sheets until expenditures contemplated in the Funding Agreement are incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Deferred income</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Deferred income relates to payments received from CEPI in advance of the eligible research and development expenses being incurred and is disclosed as deferred income separately in the consolidated balance sheets. Deferred income is released to the consolidated statements of operations and comprehensive loss in the period in which such research and development activities are actually performed in a manner that satisfies the conditions of the Funding Agreement.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredIncomeTableTextBlock" id="f-518" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Changes in deferred income during the years ended December&#160;31, 2025 and 2024, are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"/><td style="width:71.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-519">1,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:DeferredIncome" format="ixt:fixed-zero" scale="3" id="f-520">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeAddition" format="ixt:fixed-zero" scale="3" id="f-521">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredIncomeAddition" format="ixt:num-dot-decimal" scale="3" id="f-522">2,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income recognized related to the Funding Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeRevenueRecognized" scale="3" id="f-523">435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredIncomeRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-524">1,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="brns:DeferredIncomeForeignExchangeTranslationGainLoss" scale="3" id="f-525">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="brns:DeferredIncomeForeignExchangeTranslationGainLoss" scale="3" id="f-526">75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-527">1,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-528">1,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_184"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-529" continuedAt="f-529-1" escape="true">Ordinary Shares</ix:nonNumeric></span></div><ix:continuation id="f-529-1" continuedAt="f-529-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">All ordinary shares rank pari passu as a single class. The following is a summary of the rights and privileges of the holders of ordinary shares as of December&#160;31, 2025:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Liquidation preference:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> In the event of the liquidation, dissolution or winding up of the Company, the assets of the Company available for distribution to holders of the ordinary shares shall be distributed amongst all holders of the ordinary shares in proportion to the number of shares held irrespective of the amount paid or credited as paid on any share.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Dividends:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> The Company may, subject to the provisions of the Companies Act 2006 and its Articles, by ordinary resolution from time to time declare dividends to be paid to shareholders not exceeding the amount recommended by the Company&#8217;s board of directors. Subject to the provisions of the Companies Act 2006, insofar as, in the board of directors&#8217; opinions, the Company&#8217;s profits justify such payments, the board of directors (the "Board") may pay interim dividends on the Company&#8217;s ordinary shares.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-529-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Voting Rights:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> Each holder of ordinary shares has the right to receive notice of, and to vote at, the Company&#8217;s general meetings. Each holder of ordinary shares who is present (in person or by proxy) at a general meeting on a show of hands has <ix:nonFraction unitRef="vote" contextRef="c-8" decimals="INF" name="brns:CommonStockNumberOfVotesPerShare" format="ixt-sec:numwordsen" scale="0" id="f-530">one</ix:nonFraction> vote and, on a poll, every such holder who is present (in person or by proxy) has <ix:nonFraction unitRef="vote" contextRef="c-8" decimals="INF" name="brns:CommonStockNumberOfVotesPerShare" format="ixt-sec:numwordsen" id="f-531">one</ix:nonFraction> vote in respect of for each share of which they are the holder.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Preemption rights:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> Pursuant to section 561 of the Companies Act 2006, shareholders are granted preemptive rights when new shares are issued for cash. However, it is possible under the Articles, for shareholders at a general meeting representing at least <ix:nonFraction unitRef="number" contextRef="c-8" decimals="2" name="brns:PercentageOfSharesNecessaryToExercisePreemptiveRights" scale="-2" id="f-532">75</ix:nonFraction>% of the Company's ordinary shares present (in person or by proxy) and eligible to vote at that general meeting, to disapply these preemptive rights by passing a special resolution. Such a disapplication of preemption rights may be for a maximum period of up to <ix:nonNumeric contextRef="c-1" name="brns:PeriodOfPreemptiveRightsToBeExercised" format="ixt-sec:durwordsen" id="f-533">five years</ix:nonNumeric> from the date on which the shareholder resolution was passed. In either case, this disapplication would need to be renewed by the Company's shareholders upon its expiration (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">, at least every <ix:nonNumeric contextRef="c-90" name="brns:PeriodOfPreemptiveRightsToBeExercised" format="ixt-sec:durwordsen" id="f-534">five years</ix:nonNumeric>) to remain effective.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On April&#160;21, 2021, the Company's shareholders approved the disapplication of preemptive rights for a period of <ix:nonNumeric contextRef="c-91" name="brns:PeriodOfPreemptiveRightsToBeExercised" format="ixt-sec:durwordsen" id="f-535">five years</ix:nonNumeric> from the date of approval by way of a special resolution of shareholders. This included the disapplication of preemption rights in relation to the allotment of the Company's ordinary shares in connection with the initial public offering ("IPO"). This disapplication will need to be renewed upon expiration (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">, at least every <ix:nonNumeric contextRef="c-91" name="brns:PeriodOfPreemptiveRightsToBeExercised" format="ixt-sec:durwordsen" id="f-536">five years</ix:nonNumeric>) to remain effective, but may be sought more frequently for additional <ix:nonNumeric contextRef="c-91" name="brns:PeriodOfPreemptiveRightsToBeExercised" format="ixt-sec:durwordsen" id="f-537">five-year</ix:nonNumeric> terms (or any shorter period).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On November 6, 2023, the Company held a general meeting where its shareholders approved resolutions granting the Board or any duly authorized committee of the Board the authority to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company free from pre-emption rights. Pursuant to such approval, the Board was authorized to allot shares up to an aggregate nominal amount of &#163;<ix:nonFraction unitRef="gbp" contextRef="c-92" decimals="0" name="brns:MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" format="ixt:num-dot-decimal" scale="0" id="f-538">1,928</ix:nonFraction> free from statutory pre-emption rights. The granting of this authority and the corresponding disapplication of preemptive rights was in addition to all subsisting authorities. This disapplication will need to be renewed upon expiration (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">, at least every <ix:nonNumeric contextRef="c-93" name="brns:PeriodOfPreemptiveRightsToBeExercised" format="ixt-sec:durwordsen" id="f-539">five years</ix:nonNumeric>) to remain effective, but may be sought more frequently for additional <ix:nonNumeric contextRef="c-93" name="brns:PeriodOfPreemptiveRightsToBeExercised" format="ixt-sec:durwordsen" id="f-540">five-year</ix:nonNumeric> terms (or any shorter period).</span></div><ix:nonNumeric contextRef="c-1" name="brns:ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock" id="f-541" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2025, the Company has reserved the following ordinary shares for future issuance:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-542">5,976,157</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shares available for future stock incentive plan awards</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-543">3,248,605</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-544">9,224,762</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ia7cbadf995cd4920bb4d015b669c5879_187"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">12. <ix:nonNumeric contextRef="c-1" name="brns:StockholdersEquityDeferredSharesDisclosureTextBlock" id="f-545" continuedAt="f-545-1" escape="true">Deferred Shares</ix:nonNumeric></span></div><ix:continuation id="f-545-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">All deferred shares rank pari passu as a single class. The deferred shares do not have rights to dividends or to any other rights of participation in the profits of the Company. On a return of assets on liquidation, the deferred shares confer on the holders thereof an entitlement to receive out of the assets of the Company available for distribution amongst the shareholders (subject to the rights of any new class of shares with preferred rights) the amount credited as paid up on the deferred shares held by them respectively after (but only after) payment shall have been made to the holders of the ordinary shares of the amounts paid up or credited as paid up on such shares and the sum of &#163;<ix:nonFraction unitRef="gbp" contextRef="c-8" decimals="-5" name="brns:OrdinarySharesLiquidationPreference" scale="6" id="f-546">1.0</ix:nonFraction> million in respect of each ordinary share held by them respectively. The deferred shares shall confer on the holders thereof no further right to participate in the assets of the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s deferred A shares with a nominal value of &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="c-8" decimals="INF" name="brns:DeferredStockParOrStatedValuePerShare" scale="0" id="f-547">1.00</ix:nonFraction> each remain in issue for the purposes of satisfying the minimum share capital requirements for a public limited company as prescribed by the Companies Act 2006.</span></div></ix:continuation><div id="ia7cbadf995cd4920bb4d015b669c5879_190"></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-548" continuedAt="f-548-1" escape="true">Fair Value</ix:nonNumeric></span></div><ix:continuation id="f-548-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s financial instruments consist of cash, cash equivalents and restricted cash, accounts payable, certain accrued expenses, and contingent consideration. The carrying amounts of cash, cash equivalents and restricted cash, accounts payable, and accrued expenses approximated their respective fair value due to the short-term nature and maturity of these instruments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2025, the Company had a contingent consideration liability of $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="f-549">2.9</ix:nonFraction> million related to the acquisition of Avidea. Avidea&#8217;s stockholders may be entitled to receive an aggregate of up to $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="f-550">40.0</ix:nonFraction> million in additional payments, payable in a combination of cash and American Depositary Shares, upon the achievement of certain milestones. To date, the Company has made settlement payments of $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="f-551">0.5</ix:nonFraction> million. The fair value of the contingent consideration is a Level 3 valuation and determined using the cost approach. The significant unobservable inputs used in the fair value measurement of the contingent consideration are the probability of success of achievement of the milestones and the expected date of the milestone achievement. Significant judgment is employed in determining the appropriateness of certain of these inputs. Significant increases (decreases) in the probability of success of achievement of the milestones would have resulted in a significantly higher (lower) fair value measurement. Significant extension (reduction) in the expected date of the milestone achievement would have resulted in a significantly lower (higher) fair value measurement.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-552" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes changes to the Company's financial instruments carried at fair value and classified within Level 3 of the fair value hierarchy (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-553">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-554">1,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Change in fair value recognized in net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-555">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-556">866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:f-557"><span style="-sec-ix-hidden:f-558">Foreign exchange translation recognized in other comprehensive loss</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="3" id="f-559">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="3" id="f-560">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-561">2,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-562">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_193"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">14. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-563" continuedAt="f-563-1" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-563-1" continuedAt="f-563-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On April&#160;8, 2021, the Board of the Company adopted the Barinthus Biotherapeutics plc Share Award Plan 2021 (&#8220;the Plan&#8221;) and the Barinthus Biotherapeutics plc Non-Employee Sub-Plan which is a sub-plan of the Plan. Under the terms of the Plan, the Board is permitted to grant awards to employees as restricted share units, options, share appreciation rights and restricted shares. The aggregate number of shares initially available for issuance under the Plan and the Barinthus Biotherapeutics plc Non-Employee Sub-Plan cannot exceed <ix:nonFraction unitRef="shares" contextRef="c-96" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-564">3,675,680</ix:nonFraction> ordinary shares (the &#8220;Initial Limit&#8221;). Beginning calendar year 2022, the total number of ordinary shares available for issuance under the Plan shall be increased on January 1 of each year in an amount equal to the lesser of (i) <ix:nonFraction unitRef="number" contextRef="c-96" decimals="2" name="brns:ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" scale="-2" id="f-565">4</ix:nonFraction>% of the Company&#8217;s issued and outstanding ordinary shares (which <ix:nonFraction unitRef="number" contextRef="c-96" decimals="2" name="brns:ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" scale="-2" id="f-566">4</ix:nonFraction>% limit shall be measured as of January 1 of such year) and (ii) such number of ordinary shares as determined by the Compensation Committee of the Board in its discretion (the &#8220;Annual Increase&#8221;). In accordance with the terms of the Annual Increase, the total number of ordinary shares available for issuance under the Plan increased by <ix:nonFraction unitRef="shares" contextRef="c-97" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-567">1,609,386</ix:nonFraction> as of January 1, 2025. The awards generally vest based on the grantee&#8217;s continued service with the Company during a specified period following grant as determined by the Board and generally expire <ix:nonNumeric contextRef="c-96" name="brns:ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance" format="ixt-sec:durwordsen" id="f-568">ten years</ix:nonNumeric> from the grant date. Option awards generally vest over <ix:nonNumeric contextRef="c-96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-569">three years</ix:nonNumeric>, but vesting conditions can vary at the discretion of the Company&#8217;s Board. As of December&#160;31, 2025 and 2024, <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-570">3,248,605</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-98" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-571">1,906,080</ix:nonFraction> ordinary shares are available for future grants, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In 2018, the Company&#8217;s board of directors adopted the Enterprise Management Incentive Share Option Scheme (the &#8220;EMI Plan&#8221;) which provided for the grant of incentive stock options and nonqualified stock options to non-director employees of the Company. The Company also has a nonqualified stock option plan for officers and directors. The awards generally vest based on the grantee&#8217;s continued service with the Company during a specified period following grant as determined by the board of directors and generally expire <ix:nonNumeric contextRef="c-99" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-572">ten years</ix:nonNumeric> from the grant date. Option awards generally vest over <ix:nonNumeric contextRef="c-99" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-573">three years</ix:nonNumeric>, but vesting conditions can vary at the discretion of the Company&#8217;s board of directors. A total of <ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-574">3,530,634</ix:nonFraction> ordinary shares were reserved for issuance in accordance with the provisions of the EMI Plan and restricted stock unit (&#8220;RSUs&#8221;) plan. Upon adoption of the Plan, no further awards are to be made under the EMI Plan.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-563-2" continuedAt="f-563-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-575" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of each stock option issued to employees was estimated at the date of grant using Black-Scholes with the following weighted-average assumptions:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"><tr><td style="width:1.0%"/><td style="width:65.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-101" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-576">114.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-102" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-577">108.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-101" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-578">6</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-102" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-579">6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-101" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-580">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-102" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-581">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-582">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-102" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-583">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected volatility: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Previously there was insufficient trading history for the Company&#8217;s ordinary shares, therefore the expected price volatility for our ordinary shares was estimated using the average historical volatility of industry peers&#8217; shares as of the grant date of our options over a period of history commensurate with the expected life of the options. When selecting industry peers used in measuring implied volatility, the Company considered the similarity of their products and business lines, as well as their stage of development, size and financial leverage. The Company applied this process consistently using the same or similar public companies until 2023. For options granted in and after 2023, the Company determined that there is sufficient historical information on volatility of its share price available and the expected volatility used in the fair value calculation of new option grants is calculated based on a blended volatility of both historical volatility of the Company's share price and the expected volatility of the average historical volatility of industry peers&#8217; shares. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected term (years): </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Expected term represents the period that the Company&#8217;s option grants are expected to be outstanding. There is not sufficient historical share exercise data to calculate the expected term of the stock options. Therefore, the Company elected to utilize the simplified method to value option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk-free interest rate: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined the risk-free interest rate by using a weighted-average equivalent to the expected term based on the daily U.S. Treasury yield curve rate in effect as of the date of grant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected dividend yield:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> The Company does not anticipate paying any dividends in the foreseeable future.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-584" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">A summary of stock option activity is presented below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Number of<br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Weighted-<br/>average<br/>Exercise<br/>Price Per<br/>Option</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Weighted-<br/>average <br/>Remaining <br/>Contractual <br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Aggregate <br/>Intrinsic Value <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding, January 1, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-585">7,285,275</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-586">5.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-12" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-587">7.61</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-588">942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-589">1,470,812</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-590">1.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-591">614,230</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="5" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-592">0.00010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited/expired</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-593">2,165,700</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-594">2.74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding, December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-595">5,976,157</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-596">6.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-597">2.28</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-598">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Exercisable, December 31, 2025</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-599">4,351,787</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-600">7.94</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-601">1.81</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="f-602">37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The weighted-average grant date per-share fair value of stock options granted during the year ended December&#160;31, 2025 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-603">0.85</ix:nonFraction> per share (December&#160;31, 2024: $<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-604">2.66</ix:nonFraction> per share). The aggregate intrinsic value of stock options exercised during the year ended December&#160;31, 2025 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-605">0.2</ix:nonFraction> million (December&#160;31, 2024: $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-606">0.4</ix:nonFraction> million). As of December&#160;31, 2025, there was $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-607">0.6</ix:nonFraction> million (2024: $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-608">3.1</ix:nonFraction> million) of unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-103" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-609">1.42</ix:nonNumeric> years (2024: <ix:nonNumeric contextRef="c-104" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-610">1.46</ix:nonNumeric> years).</span></div></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-563-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Restricted stock units:</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-611" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the Company's restricted stock units ('RSUs") under the Plan since December 31, 2025:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Number of Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Underlying RSUs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Grant Date Fair Value</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Unvested, January 1, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-105" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="f-612">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-105" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-613">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-106" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-614">886,018</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-106" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-615">1.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vested and settled</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-106" decimals="INF" name="brns:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" format="ixt:fixed-zero" scale="0" id="f-616">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-106" decimals="2" name="brns:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-617">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vested and deferred</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-106" decimals="INF" name="brns:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod" format="ixt:fixed-zero" scale="0" id="f-618">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-106" decimals="2" name="brns:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-619">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-106" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-620">21,294</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-106" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-621">1.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Unvested outstanding, December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-107" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-622">864,724</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-107" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-623">1.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vested but subject to deferred settlement at December 31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-107" decimals="INF" name="brns:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" format="ixt:fixed-zero" scale="0" id="f-624">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-107" decimals="2" name="brns:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-107" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-626">864,724</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-107" decimals="2" name="brns:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue" scale="0" id="f-627">1.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In October 2025, the Company granted an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-108" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-628">886,018</ix:nonFraction> restricted stock units (&#8220;RSUs&#8221;) to employees under the Plan. The RSUs will vest in full on the <span style="-sec-ix-hidden:f-629">seven</span>th day following the occurrence of either the closing of the Contemplated Transactions or the termination of the Merger Agreement pursuant to its terms, subject to the employee&#8217;s continued employment with the Company through such vesting date, and were granted as part of the Company&#8217;s equity incentive program to support employee retention and alignment with shareholder interests. The grant date fair value of the RSUs was $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-630">1.3</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Total share-based compensation expense for RSUs granted for the years ended December&#160;31, 2025 and 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-631">0.5</ix:nonFraction> million and <ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-632">nil</ix:nonFraction>, respectively. As of December&#160;31, 2025, the total unrecognized compensation expense related to RSUs was $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="f-633">0.8</ix:nonFraction> million, which is expected to be recognized over a weighted-average of <ix:nonNumeric contextRef="c-106" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-634">0.7</ix:nonNumeric> years. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="f-635" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Share based compensation expense is classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-636">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-637">1,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-638">335</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-639">3,029</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-640">468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-641">4,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><div id="ia7cbadf995cd4920bb4d015b669c5879_196"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">  15. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-642" continuedAt="f-642-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-642-1" continuedAt="f-642-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-643" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Loss before income before income taxes are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">United Kingdom</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-644">42,544</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-645">27,510</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-646">24,053</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-647">32,833</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="f-648">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="f-649">884</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss before income taxes</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-650">66,633</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-651">61,227</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-652" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The components of income tax benefit are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Current income tax benefit/(expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-653">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-654">70</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-655">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-656">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred income tax benefit:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="f-657">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="f-658">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total income tax benefit</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-659">175</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-660">44</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-661" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">A reconciliation of the U.K. statutory income tax rate to the Company's effective tax rate as reflected in the consolidated financial statements is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"/><td style="width:42.238%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.376%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.376%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.226%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Statutory tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-662">16,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-663">25.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-664">15,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-665">25.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Increase (decreases) resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign tax effects-United States:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Changes in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-666">6,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-114" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-667">9.17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-668">4,002</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-115" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-669">6.54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="3" id="f-670">118</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-114" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="f-671">0.18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:fixed-zero" scale="3" id="f-672">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-115" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" format="ixt:fixed-zero" scale="-2" id="f-673">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Non-taxable or non-deductible items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" id="f-674">506</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-114" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-675">0.76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" format="ixt:num-dot-decimal" scale="3" id="f-676">3,505</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-115" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-677">5.73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign tax effects-Switzerland:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="3" id="f-678">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-118" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" format="ixt:fixed-zero" scale="-2" id="f-679">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="3" id="f-680">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-119" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="f-681">0.05</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Effect of change in tax laws or rates enacted in the current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="f-682">598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="f-683">0.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="f-684">721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="f-685">1.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount" scale="3" id="f-686">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="brns:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" scale="-2" id="f-687">0.12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="brns:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount" format="ixt:num-dot-decimal" scale="3" id="f-688">3,501</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-12" decimals="4" sign="-" name="brns:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" scale="-2" id="f-689">5.72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Changes in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-690">7,513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-120" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-691">11.27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-692">2,116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-121" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-693">3.46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Non-taxable or non-deductible items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" format="ixt:num-dot-decimal" scale="3" id="f-694">2,496</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-120" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-695">3.75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" id="f-696">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-121" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-697">0.06</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-698">243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-699">0.37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-700">2,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-12" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-701">4.55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Effective tax rate</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-702">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-703">0.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-704">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-705">0.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company has adopted ASU 2023-09 and evaluated all required categories and determined that no additional jurisdictional disaggregation or reconciling items were individually material.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-642-2" continuedAt="f-642-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income and for tax carryforwards. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-706" continuedAt="f-706-1" escape="true">Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-706-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-707">40,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-708">26,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Research and development credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="f-709">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="f-710">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Share based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-711">4,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-712">4,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="brns:DeferredTaxAssetsLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-713">2,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="brns:DeferredTaxAssetsLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-714">3,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" id="f-715">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:fixed-zero" scale="3" id="f-716">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Intangible amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="f-717">459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="f-718">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Capitalized Research and Development expenditure</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-719">4,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-720">6,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="f-721">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="f-722">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Gross deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-723">53,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-724">40,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-725">46,266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-726">30,830</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-727">7,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-728">9,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-729">1,130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-730">1,815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use lease asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-731">1,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-732">1,149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Undistributed earnings of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" format="ixt:num-dot-decimal" scale="3" id="f-733">1,339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" format="ixt:num-dot-decimal" scale="3" id="f-734">1,248</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-735">3,932</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-736">6,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-737">7,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-738">10,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred tax, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="f-739">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="f-740">438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Specified research and experimentation costs under Section 174 of the Internal Revenue Code are required to be capitalized and amortized ratably over five years for domestic expenditures and over 15 years for foreign expenditures. This provision of Section 174 became effective for tax years beginning after December 31, 2021. As a result of the capitalization of these costs in the current year, the Company has recorded a $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="f-741">4.8</ix:nonFraction> million deferred tax asset (2024: $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="f-742">6.2</ix:nonFraction> million). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2025, the Company had a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-743">46.3</ix:nonFraction> million (2024: $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-744">30.8</ix:nonFraction> million) against its deferred tax assets, which consisted principally of net operating loss and research and development credit carryforwards. The Company considered the positive and negative evidence bearing upon its ability to realize the deferred tax assets. In addition to the Company&#8217;s history of cumulative losses, the Company cannot be certain that future taxable income will be sufficient to realize its deferred tax assets. Accordingly, a valuation allowance has been provided against its deferred tax assets. When the Company changes its determination as to the amount of its deferred tax assets that can be realized, the valuation allowance is adjusted with a corresponding impact to the provision for income taxes in the period in which such determination is made.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="f-745" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2025 and 2024 related primarily to the increase in net operating loss and credit carryforwards, and were as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Valuations allowance at beginning of year</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-746">30,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-747">25,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Changes in valuation allowance arising from in-year additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions" format="ixt:fixed-zero" scale="3" id="f-748">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions" format="ixt:fixed-zero" scale="3" id="f-749">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Increases recorded to income tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision" format="ixt:num-dot-decimal" scale="3" id="f-750">13,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision" format="ixt:num-dot-decimal" scale="3" id="f-751">6,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign exchange translation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation" format="ixt:num-dot-decimal" scale="3" id="f-752">1,802</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="brns:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation" scale="3" id="f-753">350</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-754">46,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-755">30,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-642-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2025, the Company had net operating loss ("NOL") carryforwards totaling approximately $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-756">160.4</ix:nonFraction> million which have an unlimited carryforward period, of which $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-757">114.0</ix:nonFraction> million originate in the U.K. As of December&#160;31, 2025, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-758">0.3</ix:nonFraction> million of research and development tax credit carryforwards which also have an unlimited carryforward period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2024, the Company had NOL carryforwards totaling approximately $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-759">101.7</ix:nonFraction> million which have an unlimited carryforward period, of which $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-760">75.6</ix:nonFraction> million originate in the U.K. As of December&#160;31, 2024, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-761">0.1</ix:nonFraction> million of research and development tax credit carryforwards which also have an unlimited carryforward period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2025 and 2024, the Company does not have any material unrecognized tax benefit liabilities. The Company files corporation/income tax returns in the U.K., the United States, Switzerland, Australia and Italy. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate. In the U.K., tax years from 2022 remain subject to examination by HMRC. In all other jurisdictions, the tax years since inception remain subject to examination by the applicable taxing authorities as of December&#160;31, 2025 and 2024.</span></div></ix:continuation><div id="ia7cbadf995cd4920bb4d015b669c5879_199"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">16. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-762" continuedAt="f-762-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-762-1" continuedAt="f-762-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">In-License Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company is party to a number of licensing agreements, most of which are with related parties. These agreements serve to provide the Company with the right to develop and exploit the counterparties&#8217; intellectual property for certain medical indications. As part of execution of these arrangements, the Company paid certain upfront fees, which have been expensed as incurred because the developing technology has not yet reached technical feasibility, the lack of alternative use, and the lack of proof of potential value. The agreements cover a variety of fields, including influenza, cancer, HPV, HBV and MERS. The Company&#8217;s obligations for future payments under these arrangements are dependent on its ability to develop promising drug candidates, the potential market for these candidates and potential competing products, and the payment mechanisms in place in countries where the Company retains the right to sell. Each agreement provides for specific milestone payments, typically triggered by achievement of certain testing phases in human candidates, and future royalties ranging from <ix:nonFraction unitRef="number" contextRef="c-124" decimals="2" name="brns:PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" scale="-2" id="f-763">1</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="c-125" decimals="2" name="brns:PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" scale="-2" id="f-764">5</ix:nonFraction>% for direct sales of a covered product to <ix:nonFraction unitRef="number" contextRef="c-124" decimals="2" name="brns:PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" scale="-2" id="f-765">3</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-125" decimals="2" name="brns:PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" scale="-2" id="f-766">7</ix:nonFraction>% of net payments received for allowable sublicenses of technology developed by the Company. The obligation to make these payments is contingent upon the Company&#8217;s ability to develop candidates for submission for phased testing and approvals, and for the development of markets for the products developed by the Company. The Company has not made or accrued any material payments under these license agreements during the years ended December&#160;31, 2025, and 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company leases certain laboratory and office space under operating leases, which are described below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The Harwell Science and Innovation Campus, Oxfordshire</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On September&#160;3, 2021, the Company entered into a lease agreement for the lease of approximately <ix:nonFraction unitRef="sqft" contextRef="c-126" decimals="-3" name="brns:NumberOfSquareFeetUnderLeaseAgreement" format="ixt:num-dot-decimal" scale="0" id="f-767">31,000</ix:nonFraction> square feet in Harwell, Oxfordshire, which expires in September 2031. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date, being the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The Company has provided the lessor with a refundable security deposit of $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:SecurityDeposit" scale="6" id="f-768">0.7</ix:nonFraction> million which is included in Other assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In 2024, an impairment charge to write down the U.K. operating lease right-of-use asset to the estimated recoverable amount was recorded and the estimated useful life of the asset reduced. In August 2025, the Company ceased the research and development activities undertaken in the laboratory and transitioned the remaining clinical and operational workforce to remote roles. The U.K. operating lease right-of-use asset has a value of <ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="6" id="f-769">nil</ix:nonFraction> as of December&#160;31, 2025. The Company is actively marketing the building in Harwell, Oxfordshire, for the remainder of the lease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Germantown, Maryland</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On June&#160;14, 2022, the Company entered into a lease agreement for the lease of approximately <ix:nonFraction unitRef="sqft" contextRef="c-129" decimals="-2" name="brns:NumberOfSquareFeetUnderLeaseAgreement" format="ixt:num-dot-decimal" scale="0" id="f-770">19,700</ix:nonFraction> square feet in Germantown, Maryland. The site houses the Company&#8217;s state-of-the-art wet laboratory in the United States of America. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-762-2" continuedAt="f-762-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The lease expires on February 28, 2034, with the Company having a single right to extend for an additional <ix:nonNumeric contextRef="c-129" name="brns:LesseeOperatingLeaseExtendedTerm" format="ixt-sec:durwordsen" id="f-771">five years</ix:nonNumeric> on the same terms and conditions other than for the base rent. The Company had a rent-free period up to February 29, 2024 and was entitled to up to $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:LeaseholdImprovementsGross" scale="6" id="f-772">3.5</ix:nonFraction> million for leasehold improvements to the premises desired by the Company. The Company has provided the lessor with a refundable security deposit of $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:SecurityDeposit" scale="6" id="f-773">0.2</ix:nonFraction> million which is included in Other assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded a right-of-use asset and a lease liability on the effective date of the lease term. <ix:nonNumeric contextRef="c-1" name="brns:LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" id="f-774" continuedAt="f-774-1" escape="true">The Company&#8217;s right-of-use asset and lease liabilities are as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-774-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use asset</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-775">1,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-776">4,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability, current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-777">2,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-778">1,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability, non-current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-779">9,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-780">10,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Other information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-781">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-782">1,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-8" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-783">6.98</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-9" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-784">7.98</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-785">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-9" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-786">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Lease Costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-787">3,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-788">1,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-789">3,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-790">1,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company identified circumstances that could indicate that the carrying amount of the U.S. operating lease right-of-use asset and the leasehold improvements located in the U.S. may not be recoverable as of December 31, 2025, as it was more likely than not that the Company would cease some of the operating activities undertaken in the laboratory and office space in Germantown, Maryland in 2026, before the end of the previously estimated useful lives. The Company performed an impairment assessment of the U.S. operating lease right-of-use asset, which is part of the U.S. asset group, using the income approach and recorded an impairment charge within general and administrative expenses of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" scale="6" id="f-791">0.4</ix:nonFraction> million (December 31, 2024: U.K. impairment $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" scale="6" id="f-792">2.6</ix:nonFraction> million) to write down the asset to the estimated recoverable amount. The impairment charge is subject to a number of assumptions and actual results may differ. The Company will continue to refine these assumptions as additional information becomes available. The significant assumptions used in determining the estimated fair value of the U.S. operating lease right-of-use asset are the timing of successful sub-leasing of the Company's U.S. lease obligations and the value of any charges associated with sub-leasing the Company's U.S. lease obligations. Significant changes in these inputs could have a material effect on the fair value measurement. See Note 6 Property and Equipment, Net for details of the impairment assessment performed over the property and equipment within the U.S. asset group.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-793" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Maturities of the Company&#8217;s minimum lease liabilities as of December&#160;31, 2025 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Maturity of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-794">2,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-795">2,050</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-796">2,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-797">2,102</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-798">2,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-799">3,940</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-800">14,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-801">3,041</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-802">11,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-762-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Non-lease and other costs paid to the lessors are primarily related to services provided by the lessors in operating the premises that includes fees, operating costs, taxes, and insurance related to the leased premises.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contemplated Transactions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 29, 2025, the Company entered into a merger agreement to combine with Clywedog, a private company advancing novel breakthrough medicines in diabetes. The Contemplated Transactions are expected to close in the second quarter of 2026, subject to customary closing conditions. In connection with this strategic combination, the Company may incur additional or contingent costs, including transaction-related legal and advisory fees, and other expenses. The Company accrued transaction-related legal and advisory fees in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="f-803">2.8</ix:nonFraction> million for the year ended December&#160;31, 2025 (December&#160;31, 2024: <ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:fixed-zero" scale="0" id="f-804">nil</ix:nonFraction>). Regardless of the outcome, there are anticipated additional costs and a focus of management resources on the strategic transaction which may or may not complete.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other contingencies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of the date of issuance of the audited financial statements included herein, the Company does not believe it is party to any claim or litigation the outcome of which, if determined adversely to it, would individually or in the aggregate be reasonably expected to have a material adverse effect on the Company's business. However, from time to time, the Company could be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. Regardless of the outcome, legal proceedings can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors.</span></div></ix:continuation><div id="ia7cbadf995cd4920bb4d015b669c5879_202"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">17. <ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="f-805" continuedAt="f-805-1" escape="true">Employee Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="f-805-1"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In the U.K., the Company has adopted a defined contribution plan (the U.K. Plan) which qualifies under the rules established by HM Revenue &amp; Customs. Contributions to the U.K. Plan are charged to the consolidated statements of operations and comprehensive loss in the year to which they relate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company has 401(k) defined contribution retirement plans in which all its employees located in the United States are eligible to participate. Eligible employees may elect to contribute up to the maximum limits, as set by the Internal Revenue Service, of their eligible compensation. Contributions to the plans are charged to the consolidated statements of operations and comprehensive loss in the year to which they relate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2025, the Company provided a total of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="f-806">0.5</ix:nonFraction> million (December&#160;31, 2024: $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="f-807">0.8</ix:nonFraction> million) in contributions under both the U.K. Plan and the 401(k) plans.</span></div></ix:continuation><div id="ia7cbadf995cd4920bb4d015b669c5879_205"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">18. <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-808" continuedAt="f-808-1" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="f-808-1" continuedAt="f-808-2"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2025, the Company incurred expenses of $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="f-809">0.4</ix:nonFraction> million (December&#160;31, 2024: $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="f-810">0.8</ix:nonFraction> million) from OUI which is a wholly owned subsidiary of the Company&#8217;s shareholder, the University of Oxford, primarily related to patent costs. </span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-808-2">During the year ended December&#160;31, 2025, the Company recognized <span style="-sec-ix-hidden:f-811"><span style="-sec-ix-hidden:f-812">license revenue</span></span> of <ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-813">nil</ix:nonFraction> (December&#160;31, 2024: $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-814">15.0</ix:nonFraction> million) from OUI which is a wholly owned subsidiary of the Company&#8217;s shareholder, the University of Oxford.</ix:continuation> </span></div><div id="ia7cbadf995cd4920bb4d015b669c5879_208"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">19. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-815" continuedAt="f-815-1" escape="true">Subsequent Events </ix:nonNumeric></span></div><ix:continuation id="f-815-1" continuedAt="f-815-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On February 22, 2026, the Company, Topco, Merger Sub and Clywedog entered into an amendment to the Merger Agreement (the &#8220;Merger Agreement Amendment&#8221;). Pursuant to the Merger Agreement Amendment, (i) the definition of &#8220;Scheme Exchange Ratio&#8221; as set forth in Section 1.1 of the Merger Agreement was amended and replaced in its entirety to mean a number between <ix:nonFraction unitRef="number" contextRef="c-135" decimals="2" name="brns:MergerAgreementSchemeExchangeRatio" scale="0" id="f-816">0.1</ix:nonFraction> and <ix:nonFraction unitRef="number" contextRef="c-136" decimals="6" name="brns:MergerAgreementSchemeExchangeRatio" scale="0" id="f-817">0.166667</ix:nonFraction>, as finally determined by the Company&#8217;s board of directors (or a duly appointed committee thereof), (ii) the definition of &#8220;Merger Exchange Ratio&#8221; as set forth in Section 1.1 of the Merger Agreement was amended and replaced in its entirety to mean a number between <ix:nonFraction unitRef="number" contextRef="c-135" decimals="6" name="brns:MergerAgreementMergerExchangeRatio" scale="0" id="f-818">0.000305</ix:nonFraction> and <ix:nonFraction unitRef="number" contextRef="c-136" decimals="6" name="brns:MergerAgreementMergerExchangeRatio" scale="0" id="f-819">0.000508</ix:nonFraction>, as finally determined by Clywedog and the Company in accordance with Section 2.6(d) of the Merger Agreement and correspondingly based on the change to the Scheme Exchange Ratio, in order to maintain the agreed ownership split of Topco following closing of the Combinations, and (iii) the Clywedog Minimum Cash and Beacon Minimum Cash (each as defined in the Merger Agreement) requirements as set forth in Section 8.9 and 9.6 of the Merger Agreement, respectively, are expanded to include required minimum cash amounts based on an assumed closing date of May 31, 2026 and June 30, 2026, </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia7cbadf995cd4920bb4d015b669c5879_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="f-815-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">respectively, in light of the unexpected delay in the overall transaction timeline due to the U.S. federal government shutdowns.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>2
<FILENAME>a20400_centuryxxxvaccitech.htm
<DESCRIPTION>EX-10.9
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i98eb5831f6964e7389e0e35787ddaa2d_1"></div><div style="min-height:18.72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:6.75pt"><font><br></font></div><div style="padding-left:141.45pt;padding-right:141.45pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEASE AGREEMENT</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:5pt;padding-left:18pt"><img alt="image_1.jpg" src="image_1.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:29px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:11.40pt">THIS LEASE AGREEMENT </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:11.40pt">(&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:11.40pt">this Lease</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:11.40pt">&#8221;) is made as of this  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:11.40pt">14 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:11.40pt">day of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:11.40pt">June</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:11.40pt">, 2022, between </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:11.40pt">ARE-MARYLAND NO. 52, LLC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:11.40pt">, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:11.40pt">Landlord</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:11.40pt">&#8221;), and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:11.40pt">VACCITECH NORTH AMERICA, INC.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:11.40pt">, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:11.40pt">Tenant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:11.40pt">&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:141.45pt;padding-right:141.45pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BASIC LEASE PROVISIONS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Address&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Suite 210, 20400 Century Boulevard, Germantown, Maryland 20874.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:90pt;padding-right:17.9pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Premises&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">That portion of the Project, containing approximately 19,692 rentable square feet, as determined by Landlord, as shown as the hatched area labeled &#8220;Premises&#8221; on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Ewing Cole, Inc., Landlord&#8217;s architect, has measured the area of the Premises pursuant to the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BOMA 2017 for Office Buildings&#58; Standard Methods of Measurement </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as adopted by the Building Owners and Managers Association International (ANSI&#47;BOMA Z65.1-2017) (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BOMA Standards</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Tenant acknowledges receipt of such measurement and confirms that (a) Tenant has had an opportunity to confirm such measurement with an architect of its selection before the date of this Lease and (b) such measurement shall be conclusive as to the area of the Premises&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that Landlord shall have no right to re-measure the Premises during the Term.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:90pt;padding-right:18.1pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Project</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;&#160;&#160;&#160;&#160;The real property on which the building (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Building</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) in which the Premises are located, together with all improvements thereon and appurtenances thereto as described on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit B</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:44.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:236%">Base Rent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:236%">&#58; $63,999.00, per month&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:236%">Rentable Area of Premises</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:236%">&#58; 19,692 sq. ft. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:236%">Rentable Area of Project</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:236%">&#58; 81,007 sq. ft.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:236%">Tenant&#8217;s Share of Operating Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:236%">&#58; 24.31% </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:236%">Security Deposit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:236%">&#58; $191,997.00&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:236%">Target Commencement Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:236%">&#58; May 15, 2022 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:236%">Rent Adjustment Percentage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:236%">&#58; 3%</font></div><div style="margin-top:0.15pt;padding-left:90pt;padding-right:17.75pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Base Term&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning on the Commencement Date and ending 128 months from the first day of the first full month following the Rent Commencement Date. For clarity, if the Rent Commencement Date occurs on the first day of a month, the Base Term will be measured from that date. If the Rent Commencement Date occurs on a day other than the first day of a month, the Base Term will be measured from the first day of the following month.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:99pt;padding-right:18.25pt;text-align:justify;text-indent:-81pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Permitted Use&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">research and development laboratory, manufacturing, related office and other related uses consistent with the character of the Project and otherwise in compliance with the provisions of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%"> hereof.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Address for Rent Payment&#58;&#160;&#160;&#160;&#160;Landlord&#8217;s Notice Address&#58;</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:36.021%"><div style="margin-top:0.15pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">For check payments remit to</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-top:11.45pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Regular mail</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-top:0.1pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:11.45pt">Alexandria Real Estate Equities, Inc.</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:11.45pt">P.O. Box 896541</font></div><div style="margin-top:0.05pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charlotte, NC 28289-6541</font></div><div style="margin-top:11.4pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Overnight delivery</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div></div><div style="display:inline-block;max-width:11.269%;min-width:10.269%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:52.710%"><div style="margin-top:0.15pt;padding-left:18pt;padding-right:134.15pt"><font><br></font></div><div style="padding-left:18pt;padding-right:134.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26 North Euclid Avenue Pasadena, CA 91101 Attn&#58; Corporate Secretary</font></div><div id="i98eb5831f6964e7389e0e35787ddaa2d_4"></div></div></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:18.72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 2</font></div></td></tr></table></div></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Truist</font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:360.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attn&#58; Lockbox #896541 5130 Parkway Plaza Blvd. Charlotte, NC 28217-1964</font></div><div style="margin-top:11.45pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">For wire&#47;ACH payments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:248.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On request, Landlord will provide information to Tenant via a secure format.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div id="i98eb5831f6964e7389e0e35787ddaa2d_7"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.428%"><div style="margin-top:4.65pt;padding-left:17.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tenant&#8217;s Notice Address (before Commencement Date)&#58;</font></div><div style="margin-top:0.15pt;padding-left:17.65pt;padding-right:43.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Schr&#246;dinger Building Heatley Road</font></div></div><div style="display:inline-block;max-width:7.142%;min-width:6.142%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.430%"><div style="margin-top:0.05pt;padding-left:17.65pt;padding-right:17.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Oxford Science Park Oxford</font></div><div style="padding-left:17.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:11.45pt">OX4 4GE</font></div><div style="margin-top:4.65pt;padding-left:17.65pt"><font><br></font></div></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:34.404%"><div style="padding-left:17.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tenant&#8217;s Notice Address (from and after Commencement Date)&#58;</font></div></div><div style="display:inline-block;max-width:14.005%;min-width:13.005%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:51.591%"></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.428%"><div style="margin-top:0.15pt;padding-left:17.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Suite 210</font></div><div style="padding-left:17.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20400 Century Boulevard</font></div></div><div style="display:inline-block;max-width:7.142%;min-width:6.142%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.430%"><div style="margin-top:0.05pt;padding-left:17.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germantown, MD 20874</font></div></div></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Exhibits and Addenda are attached hereto and incorporated herein by this reference&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:43.263%"><div style="margin-top:4.65pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;X&#93; EXHIBIT A - PREMISES DESCRIPTION</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;X&#93; EXHIBIT B - DESCRIPTION OF PROJECT</font></div><div style="margin-top:4.65pt;padding-left:18pt;padding-right:18.5pt"><font><br></font></div></div><div style="display:inline-block;max-width:0.674%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:56.063%"><div style="padding-left:18pt;padding-right:18.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;X&#93; EXHIBIT A-1 - LOCATION OF HAZMAT STORAGE SHED</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:11.40pt">&#91;X&#93; EXHIBIT C - WORK LETTER</font></div></div></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:11.45pt">&#91;X&#93; EXHIBIT D - COMMENCEMENT DATE&#160;&#160;&#160;&#160;&#91;X&#93; EXHIBIT E - RULES AND REGULATIONS</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:40.535%"><div style="padding-left:18pt;padding-right:1.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;X&#93; EXHIBIT F - TENANT&#8217;S PERSONAL PROPERTY</font></div></div><div style="display:inline-block;max-width:3.400%;min-width:2.400%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:56.065%"><div style="padding-left:36.75pt;text-indent:-18.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;X&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.43pt">EXHIBIT G - BUILDING ATTRIBUTES</font></div></div></div><div style="margin-top:11.45pt;padding-left:18pt;padding-right:17.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.72pt">Lease of Premises</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon and subject to all of the terms and conditions hereof, Landlord hereby leases the Premises to Tenant and Tenant hereby leases the Premises from Landlord. The portions of the Project that are for the non-exclusive use of tenants of the Project are collectively referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Areas</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; Landlord reserves the right to modify Common Areas, provided that such modifications do not materially adversely affect Tenant&#8217;s use of the Premises for the Permitted Use. Subject to Force Majeure (as defined in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 34</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), a Taking (as defined in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 19</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the provisions of the preceding sentence, and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below, Tenant shall have access to and egress from the Building, the Premises, the Common Areas, and the parking spaces provided by Landlord to Tenant pursuant to the terms of this Lease, 24 hours a day, 7 days a week.</font></div><div style="margin-top:0.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.72pt">Delivery&#59; Acceptance of Premises&#59; Commencement Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord shall use reasonable efforts to make the Premises available to Tenant for Tenant&#8217;s Work under the Work Letter within 5 days of full execution of this Lease and Tenant&#8217;s delivery of evidence of the insurance required hereby and by the Work Letter (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Delivery</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deliver</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Landlord shall Deliver the Premises in accordance with the Building Attributes attached hereto as a part hereof as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit G</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that the entry plaza work described in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit G </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be completed by no later than 90 days after the Commencement Date. If Landlord fails to timely Deliver the Premises, Landlord shall not be liable to Tenant for any loss or damage resulting therefrom, and this Lease shall not be void or voidable except as provided herein. If Landlord does not Deliver the Premises within 60 days of the Target Commencement Date for any reason other than Force Majeure Delays, this Lease may be terminated by Landlord or Tenant by written notice to the other, and if so terminated by either&#58; (a) the Security Deposit, or any balance thereof (i.e., after deducting therefrom all amounts to which Landlord is entitled under the provisions of this Lease), shall be returned to Tenant, and (b) neither Landlord nor Tenant shall have any further rights, duties or obligations under this Lease, except with respect to provisions that expressly survive termination of this Lease. As used herein, (i) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Force Majeure Delays</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means delays arising by reason of any Force Majeure (as defined in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 34</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and (ii) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tenant&#8217;s Work</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the improvements to be made to the Premises by Tenant pursuant to the Work Letter. If neither Landlord nor</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><div id="i98eb5831f6964e7389e0e35787ddaa2d_10"></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 3</font></div></td></tr></table></div></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:12.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tenant elects to void this Lease within 5 business days of the lapse of such 60 day period, such right to void this Lease shall be waived and this Lease shall remain in full force and effect.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commencement Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the date of this Lease. The &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rent Commencement Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall be the first day after the expiration of 12 full calendar months after the Commencement Date. Upon request of Landlord, Tenant shall execute and deliver a written acknowledgment of the Commencement Date, the Rent Commencement Date, and the expiration date of the Term when such are established in the form of the &#8220;Acknowledgement of Commencement Date&#8221; attached to this Lease as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit D</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tenant&#8217;s failure to execute and deliver such acknowledgment shall not affect Landlord&#8217;s rights hereunder. The &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of this Lease shall be the Base Term, as defined above in the Basic Lease Provisions and the Extension Term that Tenant may elect pursuant to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 39 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hereof.</font></div><div style="margin-top:0.65pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as set forth in the Work Letter and this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; (i) Tenant shall accept the Premises in their condition as of the Commencement Date, subject to all applicable Legal Requirements (as defined in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereof)&#59; (ii) Landlord shall have no obligation for any defects in the Premises&#59; and (iii) Tenant&#8217;s taking possession of the Premises shall be conclusive evidence that Tenant accepts the Premises and that the Premises were in good condition at the time possession was taken. Any occupancy of the Premises by Tenant before the Commencement Date shall be subject to all of the terms and conditions of this Lease.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing provisions of this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tenant shall have a period of 90 days after Landlord&#8217;s Delivery of the Premises to Tenant to reasonably identify in writing any latent defects in the mechanical, electrical, and plumbing systems and the structural components serving the Premises. For purposes of this paragraph, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">latent defects</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means those material defects in such systems and&#47;or components that could not have been identified or discovered through a reasonable inspection of such systems or components conducted by a qualified technician. Landlord will promptly repair such identified latent defects (subject to Landlord&#8217;s reasonable confirmation that such defects are, in fact, latent defects).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tenant agrees and acknowledges that neither Landlord nor any agent of Landlord has made any representation or warranty with respect to the condition of all or any portion of the Premises or the Project, and&#47;or the suitability of the Premises or the Project for the conduct of Tenant&#8217;s business, and Tenant waives any implied warranty that the Premises or the Project are suitable for the Permitted Use. This Lease constitutes the complete agreement of Landlord and Tenant with respect to the subject matter hereof and supersedes any and all prior representations, inducements, promises, agreements, understandings and negotiations that are not contained herein. Landlord in executing this Lease does so in reliance upon Tenant&#8217;s representations, warranties, acknowledgments and agreements contained herein.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18.3pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tenant acknowledges receipt of that certain Phase I Environmental Site Assessment prepared by Ramboll US Corporation and dated December 2020 with respect to the Project.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt">Rent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Base Rent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The first month&#8217;s Base Rent and the Security Deposit shall be due and payable on delivery of an executed copy of this Lease to Landlord. Beginning on the Rent Commencement Date (but subject to the abatement of Base Rent described in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(a))</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tenant shall pay to Landlord in advance, without demand, abatement, deduction or set-off, monthly installments of Base Rent on or before the first day of each calendar month during the Term hereof, in lawful money of the United States of America, at the office of Landlord for payment of Rent set forth above, or to such other person or at such other place as Landlord may from time to time designate in writing. Payments of Base Rent for any fractional calendar month shall be prorated. The obligation of Tenant to pay Base Rent and other sums to Landlord and the obligations of Landlord under this Lease are independent</font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 4</font></div></td></tr></table></div></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligations. Tenant shall have no right at any time to abate, reduce, or set-off any Rent (as defined in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) due hereunder except for any abatement as may be expressly provided in this Lease.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Additional Rent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition to Base Rent, Tenant agrees to pay to Landlord as additional rent (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Rent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#58; (i) Tenant&#8217;s Share of &#8220;Operating Expenses&#8221; (as defined in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and (ii) any and all other amounts Tenant assumes or agrees to pay under the provisions of this Lease, including, without limitation, any and all other sums that may become due by reason of any default of Tenant or failure to comply with the agreements, terms, covenants and conditions of this Lease to be performed by Tenant, after any applicable notice and cure period.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.72pt">Base Rent Adjustments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Base Rent shall be increased on each anniversary of the first day of the first full month after the Rent Commencement Date (each an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adjustment Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) by multiplying the Base Rent payable immediately before such Adjustment Date by the Rent Adjustment Percentage and adding the resulting amount to the Base Rent payable immediately before such Adjustment Date. Base Rent, as so adjusted, shall thereafter be due as provided herein. Base Rent adjustments for any fractional calendar month shall be prorated.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Base Rent Abatement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary contained in this Lease, but provided Tenant is not in Default hereunder, Landlord hereby grants Tenant an abatement of the Base Rent payable during the period beginning on the Rent Commencement Date and ending 8 months after the Rent Commencement Date (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Base Rent Abatement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). For the avoidance of doubt, if the Rent Commencement Date occurs on the first day of a month, the Base Rent Abatement will be measured from that date. If the Rent Commencement Date occurs on a day other than the first day of a month, the Base Rent Abatement will be measured from the first day of the following month. Except as provided in the preceding sentences, Tenant shall pay the full amount of Base Rent due in accordance with the provisions of this Lease. The administration rent set forth in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below shall not be abated and shall be based on the amount of Base Rent that would have been payable but for the Base Rent Abatement. Notwithstanding anything to the contrary in this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the adjustment in the Base Rent as set forth in this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall be based on the full and unabated amount of Base Rent payable for the first 12 month period from and after the Rent Commencement Date.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.72pt">Operating Expense Payments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord shall deliver to Tenant a written estimate of Operating Expenses for each calendar year during the Term (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Estimate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which may be revised by Landlord no more frequently than twice during such calendar year. Beginning on the date on which Landlord Delivers the Premises to Tenant and continuing through the day before the Rent Commencement Date, Tenant shall pay the cost of utilities furnished to the Premises as more fully provided in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Beginning on the Rent Commencement Date and continuing for the balance of the Term, Tenant shall pay Landlord on or before the first day of each calendar month during the Term hereof an amount equal to 1&#47;12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">th </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Tenant&#8217;s Share of the Annual Estimate. Payments for any fractional calendar month shall be prorated.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all costs and expenses of any kind or description whatsoever incurred or accrued each calendar year by Landlord with respect to the Project (including, without duplication, Taxes (as defined in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), capital repairs and improvements amortized over the lesser of 7 years and the useful life of such capital items, the cost of upgrades to the Building or Project or enhanced services provided at the Building and&#47;or Project that are intended to encourage social distancing (also referred to as physical distancing), promote and protect health and physical well-being and&#47;or intended to prevent or limit the spread or transmission of communicable diseases and&#47;or viruses of any kind or nature (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Infectious Conditions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the costs of Landlord&#8217;s third party property manager or, if there is no third party property manager, administration rent in the amount of 4% of Base Rent and the costs and expenses for maintaining, repairing, replacing, and operating the Shared Lab Area and the Shared Lab Systems (as such terms are defined in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), excluding only&#58;</font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 5</font></div></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18.15pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.83pt">the original construction costs of the Project and any renovation prior to the date of this Lease and costs of correcting defects in such original construction or renovation&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:90pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">capital expenditures for expansion of the Project&#59;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:18.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.39pt">interest, principal payments of Mortgage (as defined in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 27</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) debts of Landlord, financing costs and amortization of funds borrowed by Landlord, whether secured or unsecured and all payments of base rent (but not taxes or operating expenses) under any ground lease or other underlying lease of all or any portion of the Project&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18.3pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.83pt">depreciation of the Project (except for capital improvements, the cost of which are includable in Operating Expenses)&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18.15pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.83pt">advertising, legal and space planning expenses and leasing commissions and other costs and expenses incurred in procuring and leasing space to tenants for the Project, including any leasing office maintained in the Project, free rent and construction allowances for tenants&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:90pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">legal and other expenses incurred in the negotiation or enforcement of leases&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.83pt">completing, fixturing, improving, renovating, painting, redecorating or other work, which Landlord pays for or performs for other tenants within their premises, and costs of correcting defects in such work&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">costs of utilities outside normal business hours sold to tenants of the Project&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18.2pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.17pt">costs to be reimbursed by other tenants of the Project or Taxes to be paid directly by Tenant or other tenants of the Project, regardless of whether actually paid&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18.45pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.17pt">salaries, wages, benefits and other compensation paid to officers and employees of Landlord who are not assigned in whole or in part to the operation, management, maintenance or repair of the Project&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:18.15pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.39pt">general organizational, administrative and overhead costs relating to maintaining Landlord&#8217;s existence, either as a corporation, partnership, or other entity, including general corporate, legal and accounting expenses&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.17pt">costs (including attorneys&#8217; fees and costs of settlement, judgments and payments in lieu thereof) incurred in connection with disputes with tenants, other occupants, or prospective tenants, and costs and expenses, including legal fees, incurred in connection with negotiations or disputes with employees, consultants, management agents, leasing agents, purchasers or mortgagees of the Building&#59;</font></div><div style="margin-top:0.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.06pt">costs incurred by Landlord due to the violation by Landlord, its employees, agents or contractors or any tenant of the terms and conditions of any lease of space in the Project or any Legal Requirement (as defined in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:18.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.83pt">penalties, fines or interest incurred as a result of Landlord&#8217;s inability or failure to make payment of Taxes and&#47;or to file any tax or informational returns when due, or from Landlord&#8217;s failure to make any payment of Taxes required to be made by Landlord hereunder before delinquency&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 6</font></div></td></tr></table></div></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">overhead and profit increment paid to Landlord or to subsidiaries or affiliates of Landlord for goods and&#47;or services in or to the Project to the extent the same exceeds the costs of such goods and&#47;or services rendered by unaffiliated third parties on a competitive basis&#59;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(o)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">costs of Landlord&#8217;s charitable or political contributions, or of fine art maintained at the</font></div><div style="margin-top:0.05pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Project&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(p)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.83pt">costs in connection with services (including electricity), items or other benefits of a type that are not standard for the Project and that are not available to Tenant without specific charges therefor, but which are provided to another tenant or occupant of the Project, regardless of whether such other tenant or occupant is specifically charged therefor by Landlord&#59;</font></div><div style="margin-top:0.6pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(q)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">costs incurred in the sale or refinancing of the Project&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(r)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.06pt">net income taxes of Landlord or the owner of any interest in the Project (except to the extent such net income taxes are in substitution for any Taxes payable hereunder), franchise, capital stock, gift, estate or inheritance taxes or any federal, state or local documentary taxes imposed against the Project or any portion thereof or interest therein&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(s)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">reserves for future repairs and replacements&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(t)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.62pt">interest or penalties arising solely by reason of Landlord&#8217;s failure to pay timely any Operating Expenses&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(u)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.83pt">costs for which Landlord is reimbursed by its insurance carrier or is reimbursed by Tenant&#8217;s insurance carrier&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.39pt">costs directly resulting from the gross negligence or willful misconduct of Landlord or its employees&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18.2pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(w)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.17pt">any expenses otherwise includable within Operating Expenses to the extent actually reimbursed by persons other than tenants of the Project under leases for space in the Project.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding any contrary provision contained in this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, each line item of the Controllable Operating Expenses (as defined below) shall be capped so that no increase in any calendar year, on a line-item basis, exceeds 5% over the prior year&#8217;s line-item amount on a non-cumulative basis. As a result, the actual annual increase in each line item of Controllable Operating Expenses in any given calendar year from and after the calendar year in which the Lease Commencement Date occurs may be less than or equal to 5% (but shall not exceed 5% in any such year). For purposes of this Lease, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Controllable Operating Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all Operating Expenses except real estate taxes, utilities, snow and ice removal, expenses relating to limiting or preventing Infectious Conditions, and insurance premiums (such exceptions collectively referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Controllable Operating Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within 90 days after the end of each calendar year (or such longer period as may be reasonably required), Landlord shall furnish to Tenant a statement (an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Statement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) showing in reasonable detail&#58; (a) the total and Tenant&#8217;s Share of actual Operating Expenses for the previous calendar year, and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) the total of Tenant&#8217;s payments in respect of Operating Expenses for such year. If Tenant&#8217;s Share of actual Operating Expenses for such year exceeds Tenant&#8217;s payments of Operating Expenses for such year, the excess shall be due and payable by Tenant as Rent within 30 days after delivery of such Annual Statement to Tenant. If Tenant&#8217;s payments of Operating Expenses for such year exceed Tenant&#8217;s Share of actual Operating Expenses for such year Landlord shall pay the excess to Tenant within 30 days after delivery of such Annual Statement, except </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 7</font></div></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that after the expiration, or earlier termination of the Term or if Tenant is delinquent in its obligation to pay Rent, Landlord shall pay the excess to Tenant after deducting all other amounts due Landlord.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Annual Statement shall be final and binding upon Tenant unless Tenant, within 60 days after Tenant&#8217;s receipt thereof, shall contest any item therein by giving written notice to Landlord, specifying each item contested and the reason therefor. If, during such 60 day period, Tenant reasonably and in good faith questions or contests the accuracy of Landlord&#8217;s statement of Tenant&#8217;s Share of Operating Expenses, Landlord will provide Tenant with access (in the Washington D.C., metropolitan area) to Landlord&#8217;s books and records relating to the operation of the Project and such information as Landlord reasonably determines to be responsive to Tenant&#8217;s questions (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expense Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). If after Tenant&#8217;s review of such Expense Information, Landlord and Tenant cannot agree upon the amount of Tenant&#8217;s Share of Operating Expenses, then Tenant shall have the right to have an independent public accounting firm (or a real estate services firm) selected by Tenant that has a regional or national presence, working pursuant to a fee arrangement other than a contingent fee (at Tenant&#8217;s sole cost and expense) and approved by Landlord (which approval shall not be unreasonably withheld or delayed), audit and&#47;or review the Expense Information for the year in question (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Independent Review</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The results of any such Independent Review shall be binding on Landlord and Tenant. If the Independent Review shows that the payments actually made by Tenant with respect to Operating Expenses for the calendar year in question exceeded Tenant&#8217;s Share of Operating Expenses for such calendar year, Landlord shall at Landlord&#8217;s option either (i) credit the excess amount to the next succeeding installments of estimated Operating Expenses or (ii) pay the excess to Tenant within 30 days after delivery of such statement, except that after the expiration or earlier termination of this Lease or if Tenant is delinquent in its obligation to pay Rent, Landlord shall pay the excess to Tenant after deducting all other amounts due Landlord. If the Independent Review shows that Tenant&#8217;s payments with respect to Operating Expenses for such calendar year were less than Tenant&#8217;s Share of Operating Expenses for the calendar year, Tenant shall pay the deficiency to Landlord within 30 days after delivery of such statement. If the Independent Review shows that Tenant has overpaid with respect to Operating Expenses by more than 5% then Landlord shall reimburse Tenant for all costs incurred by Tenant for the Independent Review. Operating Expenses for the calendar years in which Tenant&#8217;s obligation to share therein begins and ends shall be prorated. Notwithstanding anything set forth herein to the contrary, if the Project is not at least 95% occupied on average during any year of the Term, Tenant&#8217;s Share of Operating Expenses for such year shall be computed as though the Project had been 95% occupied on average during such year.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tenant&#8217;s Share</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall be the percentage set forth in the Basic Lease Provisions as Tenant&#8217;s Share as reasonably adjusted by Landlord for changes in the physical size of the Premises or the Project occurring thereafter</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Landlord may equitably increase Tenant&#8217;s Share for any item of expense or cost reimbursable by Tenant that relates to a repair, replacement, or service that benefits only the Premises or only a portion of the Project that includes the Premises or that varies with occupancy or use. Base Rent, Tenant&#8217;s Share of Operating Expenses and all other amounts payable by Tenant to Landlord hereunder are collectively referred to herein as &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Security Deposit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant shall deposit with Landlord, upon delivery of an executed copy of this Lease to Landlord, a security deposit (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Security Deposit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) for the performance of all of Tenant&#8217;s obligations hereunder in the amount set forth in the Basic Lease Provisions, which Security Deposit shall be in the form of an unconditional and irrevocable letter of credit (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Letter of Credit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#58; (i) in form and substance satisfactory to Landlord, (ii) naming Landlord as beneficiary, (iii) expressly allowing Landlord to draw upon it at any time from time to time by delivering to the issuer notice that a Default is continuing and Landlord is entitled to draw thereunder, (iv) issued by an FDIC-insured financial institution satisfactory to Landlord, and (v) redeemable by presentation of a sight draft in the State of Maryland. If Tenant does not provide Landlord with a substitute Letter of Credit complying with all of the requirements hereof at least 10 days before the stated expiration date of any then current Letter of Credit, Landlord shall have the right to draw the full amount of the current Letter of Credit and hold the funds drawn in cash without obligation for interest thereon as the Security </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 8</font></div></td></tr></table></div></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposit. The Security Deposit shall be held by Landlord as security for the performance of Tenant&#8217;s obligations under this Lease. Upon each occurrence of a Default (as defined in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 20</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Landlord may use all or any part of the Security Deposit to pay delinquent payments due under this Lease, and the cost of any damage, injury, expense or liability caused by such Default, without prejudice to any other remedy provided herein or provided by</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">law. Upon any such use of all or any portion of the Security Deposit, Tenant shall pay Landlord within 5 business days after written demand the amount that will restore the Security Deposit (by posting a replacement or amended Letter of Credit) to the amount set forth in the Basic Lease Provisions. Tenant hereby waives the provisions of any law, now or hereafter in force, which provide that Landlord may claim from a security deposit only those sums reasonably necessary to remedy defaults in the payment of Rent, to repair damage caused by Tenant or to clean the Premises, it being agreed that Landlord may, in addition, claim those sums reasonably necessary to compensate Landlord for any other loss or damage, foreseeable or unforeseeable, caused by the act or omission of Tenant or any officer, employee, agent or invitee of Tenant. Upon bankruptcy or other debtor-creditor proceedings involving Tenant, the Security Deposit shall be deemed to be applied first to the payment of Rent and other charges due Landlord for periods prior to the filing of such proceedings. Upon any such use of all or any portion of the Security Deposit, Tenant shall, within 5 business days after demand from Landlord, restore the Security Deposit to its original amount (by posting a replacement or amended Letter of Credit). If Tenant shall fully perform every provision of this Lease to be performed by Tenant, the Security Deposit, or any balance thereof (i.e., after deducting therefrom all amounts to which Landlord is entitled under the provisions of this Lease), shall be returned to Tenant (or, at Landlord&#8217;s option, to the last assignee of Tenant&#8217;s interest hereunder) within 90 days after the expiration or earlier termination of this Lease.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Landlord transfers its interest in the Project or this Lease, Landlord shall either (a) transfer any Security Deposit then held by Landlord to a person or entity assuming Landlord&#8217;s obligations under this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or (b) return to Tenant any Security Deposit then held by Landlord and remaining after the deductions permitted herein. Upon such transfer to such transferee or the return of the Security Deposit to Tenant, Landlord shall have no further obligation with respect to the Security Deposit, and Tenant&#8217;s right to the return of the Security Deposit shall apply solely against Landlord&#8217;s transferee. The Security Deposit is not an advance rental deposit or a measure of Landlord&#8217;s damages in case of Tenant&#8217;s default. Landlord&#8217;s obligation respecting the Security Deposit is that of a debtor, not a trustee, and no interest shall accrue thereon.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:9.72pt">Use</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. The Premises shall be used solely for the Permitted Use set forth in the Basic Lease Provisions, and in compliance with all laws, orders, judgments, ordinances, regulations, codes, directives, permits, licenses, covenants and restrictions now or hereafter applicable to the Premises, and to the use and occupancy thereof, including, without limitation, the Americans With Disabilities Act, 42</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S.C. &#167; 12101, et seq. (together with the regulations promulgated pursuant thereto, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Requirements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and each, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Requirement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Tenant shall, upon 5 days&#8217; written notice from Landlord, discontinue any use of the Premises that is declared by any Governmental Authority (as defined in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) having jurisdiction to be a violation of a Legal Requirement. Tenant will not use or permit the Premises to be used for any purpose or in any manner that would void Tenant&#8217;s or Landlord&#8217;s insurance, increase the insurance risk, or cause the disallowance of any sprinkler or other credits. Notwithstanding the foregoing, Landlord expressly acknowledges and agrees that Tenant&#8217;s use of the Premises for research and development, laboratory, manufacturing, and general office purposes in accordance with Legal Requirements shall not be deemed to void Landlord&#8217;s insurance, increase the insurance risk, or cause the disallowance of any sprinkler or other credits. Tenant shall not permit any part of the Premises to be used as a &#8220;place of public accommodation&#8221;, as defined in the ADA or any similar legal requirement. Tenant shall reimburse Landlord promptly upon demand for any additional premium charged for any such insurance policy by reason of Tenant&#8217;s failure to comply with the provisions of this Section or otherwise caused by Tenant&#8217;s use and&#47;or occupancy of the Premises. Tenant will use the Premises in a careful, safe and proper manner and will not commit or permit waste, overload the floor or </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 9</font></div></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">structure of the Premises, subject the Premises to use that would damage the Premises or obstruct or interfere with the rights of Landlord or other tenants or occupants of the Project, including conducting or giving notice of any auction, liquidation, or going out of business sale on the Premises, or using or allowing the Premises to be used for any unlawful purpose. Tenant shall cause any equipment or machinery to be installed in the Premises so as to reasonably prevent sounds or vibrations from the Premises from extending into Common Areas, or other space in the Project. Tenant shall not place any machinery or equipment weighing 500 pounds or more in or upon the Premises or transport or</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">move such items through the Common Areas of the Project or in the Project elevators without the prior written consent of Landlord (which consent shall not be unreasonably withheld, conditioned, or delayed). Except as may be provided under the Work Letter, Tenant shall not, without the prior written consent of Landlord, use the Premises in any manner that will require ventilation, air exchange, heating, gas, steam, electricity or water beyond the existing capacity of the Project as proportionately allocated to the Premises based upon Tenant&#8217;s Share as usually furnished for the Permitted Use.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Modifications to Common Areas</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord shall, as an Operating Expense (to the extent such Legal Requirement is generally applicable to similar buildings in the area in which the Project is located) or at Tenant&#8217;s expense (to the extent such Legal Requirement is applicable solely by reason of Tenant&#8217;s, as compared to other tenants of the Project, particular use of the Premises) make any alterations or modifications to the Common Areas or the exterior of the Building that are required by Legal Requirements, including the ADA. Tenant, at its sole expense, shall make any alterations or modifications to the interior of the Premises that are required by Legal Requirements (including, without limitation, compliance of the Premises with the ADA). Notwithstanding any other provision herein to the contrary, Tenant shall be responsible for any and all demands, claims, liabilities, losses, costs, expenses, actions, causes of action, damages or judgments, and all reasonable expenses incurred in investigating or resisting the same (including, without limitation, reasonable attorneys&#8217; fees, charges and disbursements and costs of suit) (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Claims</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) arising out of or in connection with any failure of the Premises to comply with any Legal Requirements, and Tenant shall indemnify, defend, hold and save Landlord harmless from and against any and all Claims arising out of or in connection with any failure of the Premises to comply with any Legal Requirement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Shared Lab Area</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant shall have a non-exclusive license to use that portion of the Building identified on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit A </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shared Lab Area</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in accordance with the Legal Requirements and the terms and conditions of this paragraph. The Shared Lab Area contains certain equipment, furnishings, systems, and personal property, including a glass washer and autoclave (collectively, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shared Lab Systems</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The license granted hereby is personal to Tenant and shall not be assigned or otherwise pledged or transferred, directly or indirectly, except in connection with a Permitted Assignment and otherwise subject to the provisions of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 22</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the case of a Permitted Assignment involving an assignment of this Lease (as distinct from a sublease), the assignor shall have no further right to use the Shared Lab Area and the Shared Lab Systems.</font></div><div style="margin-top:0.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.17pt">Relocation&#47;Modification of Shared Lab Area</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord shall make the Shared Lab Area available for Tenant&#8217;s reasonable use during the Term subject to Landlord&#8217;s right at any time and from time to time in the exercise of its sole and absolute subjective discretion to reconfigure, relocate, or modify the Shared Lab Area and to revise or expand any of the Shared Lab Systems.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.95pt">Interference</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant shall use the Shared Lab Area and the Shared Lab Systems in a manner that will not interfere with the rights of any tenants or occupants in the Building or the providers of the services associated with the Shared Lab Systems. Landlord assumes no responsibility for enforcing Tenant&#8217;s rights or for protecting the Shared Lab Area from any person or entity, including, but not limited to, other tenants or occupants of the Building.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 10</font></div></td></tr></table></div></div><div style="margin-top:0.05pt;padding-left:89.75pt;text-align:justify;text-indent:-35.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:22.43pt">Limitations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord&#8217;s sole obligation for providing the Shared Lab Systems shall be&#58;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to provide the Shared Lab Systems as is determined by Landlord in the exercise of its sole and absolute subjective discretion, and (B) to contract with one or more third parties to maintain the Shared Lab Systems that are deemed by Landlord in the exercise of its sole and absolute subjective discretion to need periodic maintenance in accordance with the manufacturer&#8217;s or supplier&#8217;s standard guidelines or otherwise. During any period of replacement, repair, or maintenance of the Shared Lab Systems when they are not operational (including, but not limited to, any delays thereto due to the inability to obtain parts or replacements), Landlord shall have no obligation to provide Tenant with alternative, supplemental, temporary, or back-up Shared Lab Systems. The terms and provisions of this paragraph shall survive the expiration or earlier termination of this Lease.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:4.17pt">No Warranties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord makes no warranties of any kind, express or implied, with respect to the Shared Lab Area and Shared Lab Systems, and Landlord disclaims any such warranties. Without limiting the foregoing, Tenant expressly acknowledges and agrees that Landlord does not guaranty or warrant that the Shared Lab Systems will be operational at all times, will be of sufficient capacity to accommodate Tenant&#8217;s use thereof, will be free of Hazardous Materials, or will function or perform adequately, and Landlord shall not be liable for any damages resulting from the failure of the Shared Lab Systems.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.39pt">Other Lease Provisions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Although the Shared Lab Area does not form a part of the Premises, the provisions of this Lease (A) governing Tenant&#8217;s use, operation, and enjoyment of the Premises, (B) imposing obligations on Tenant for matters occurring in, on, within, or about the Premises or arising out of the use or occupancy of the Premises (including, but not limited to, those obligations relating to insurance, indemnification, Hazardous Materials Clearance, and environmental requirements), or (C) limiting Landlord&#8217;s liability, shall apply with equal force to Tenant&#8217;s use of the Shared Lab Area and the Shared Lab Systems.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:4.17pt">Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If Tenant Defaults in its obligations under this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Landlord shall have the right, in addition to any other rights and remedies available to Landlord for a Default by Tenant, to terminate immediately Tenant&#8217;s license to use the Shared Lab Area. The expiration or earlier termination of this Lease shall automatically terminate the license hereby granted to Tenant to so use the Shared Lab Area.</font></div><div style="margin-top:0.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.39pt">Alexandria FitLab</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As long as Tenant is not in Default, Tenant&#8217;s on-site employees shall have a non-exclusive license to use on a complimentary basis the Alexandria FitLab located at 910 Clopper Road, Gaithersburg, Maryland that is owned by an affiliate of Landlord (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">910 Clopper Landlord</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). As of the Commencement Date, the Alexandria FitLab contains locker rooms and showers. Although the Alexandria FitLab does not form a part of the Premises, the provisions of this Lease</font></div><div style="margin-top:0.1pt;padding-left:18pt;padding-right:18.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) governing Tenant&#8217;s use, operation, and enjoyment of the Premises, (ii) imposing obligations on Tenant for matters occurring in, on, within, or about the Premises or arising out of the use or occupancy of the Premises (including, but not limited to, those obligations relating to insurance and indemnification), or</font></div><div style="padding-left:18pt;padding-right:17.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) limiting Landlord&#8217;s liability, shall apply with equal force to Tenant&#8217;s use of the Alexandria FitLab. Landlord shall have the right at any time and from time to time in the exercise of its sole and absolute subjective discretion to reconfigure, relocate, or modify the Alexandria FitLab or modify its hours of availability for Tenant&#8217;s use so long as Landlord maintains the Alexandria FitLab throughout the Term in a first-class manner. Landlord or its designee may specifically condition the use of the Alexandria FitLab by any employee of Tenant upon such employee&#8217;s execution and delivery of the standard license, indemnification, and waiver agreement required by Landlord or, if applicable, any operator of the Alexandria FitLab. Tenant and its employees shall be required to comply with all of the rules, regulations, conditions, and scheduling procedures of the 910 Clopper Landlord in connection with the use of the Alexandria FitLab (including, but not limited to, the hours of operation of the Alexandria FitLab). As of the Commencement Date, Tenant shall cause the 910 Clopper Landlord to be named as an additional insured </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 11</font></div></td></tr></table></div></div><div style="padding-left:18pt;padding-right:17.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the commercial general liability policy of insurance that Tenant is required to maintain under this Lease. If Tenant Defaults in its obligations under this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Landlord shall have the right, in addition to any other rights and remedies available to Landlord for a Default by Tenant (excluding, however, the right to terminate this Lease solely on the basis of such Defaults under this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), to terminate immediately Tenant&#8217;s license to use the Alexandria FitLab. The expiration or earlier termination of this Lease shall automatically terminate the license hereby granted to Tenant to so use the Alexandria FitLab.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loading Dock</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The first floor of the Building contains a loading dock (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loading Dock</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Tenant shall have a non-exclusive license to use the Loading Dock in common with other tenants in the Building in accordance with the Legal Requirements and the terms and conditions of this paragraph. The license granted hereby is personal to Tenant and shall not be assigned or otherwise pledged or transferred, directly or indirectly. Tenant shall use the Loading Dock in a manner that will not interfere</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the rights of any tenants or occupants in the Building. Landlord assumes no responsibility for enforcing Tenant&#8217;s rights or for protecting the Loading Dock from any person or entity, including, but not limited to, other tenants or occupants of the Building. During any period of replacement, repair, or maintenance of the Loading Dock when it is not operational, Landlord shall have no obligation to provide Tenant with alternative, supplemental, temporary, or back-up loading docks. Landlord makes no warranties of any kind, express or implied, with respect to the Loading Dock, and Landlord disclaims any such warranties. Without limiting the foregoing, Tenant expressly acknowledges and agrees that Landlord does not guaranty or warrant that the Loading Dock will be operational at all times, will be of sufficient capacity to accommodate Tenant&#8217;s use thereof, will be free of Hazardous Materials, or will function or perform adequately, and Landlord shall not be liable for any damages resulting from the failure of the Loading Dock. Subject to the terms of this paragraph, Landlord shall maintain the Loading Dock in good working order throughout the Term. Although the Loading Dock does not form a part of the Premises, the provisions of this Lease (i) governing Tenant&#8217;s use, operation, and enjoyment of the Premises, (ii) imposing obligations on Tenant for matters occurring in, on, within, or about the Premises or arising out of the use or occupancy of the Premises (including, but not limited to, those obligations relating to insurance, indemnification, Hazardous Materials Clearance, and environmental requirements), or (iii) limiting Landlord&#8217;s liability, shall apply with equal force to Tenant&#8217;s use of the Loading Dock. If Tenant Defaults in its obligations under this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Landlord shall have the right, in addition to any other rights and remedies available to Landlord for a Default by Tenant, to terminate immediately Tenant&#8217;s license to use the Loading Dock. The expiration or earlier termination of this Lease shall automatically terminate the license hereby granted to Tenant to so use the Loading Dock. The terms and provisions of this paragraph shall survive the expiration or earlier termination of this Lease.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Freight Elevator</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant shall have a non-exclusive license to use the freight elevator (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Freight Elevator</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) in common with other tenants in the Building in accordance with the Legal Requirements and the terms and conditions of this paragraph. The license granted hereby is personal to Tenant and shall not be assigned or otherwise pledged or transferred, directly or indirectly. Tenant shall use the Freight Elevator in a manner that will not interfere with the rights of any tenants or occupants in the Building. Landlord assumes no responsibility for enforcing Tenant&#8217;s rights or for protecting the Freight Elevator from any person or entity, including, but not limited to, other tenants or occupants of the Building. During any period of replacement, repair, or maintenance of the Freight Elevator when it is not operational, Landlord shall have no obligation to provide Tenant with alternative, supplemental, temporary, or back-up Freight Elevator. Landlord makes no warranties of any kind, express or implied, with respect to the Freight Elevator, and Landlord disclaims any such warranties. Subject to the terms of this paragraph, Landlord shall maintain the Freight Elevator in good working order throughout the Term. Without limiting the foregoing, Tenant expressly acknowledges and agrees that Landlord does not guaranty or warrant that the Freight Elevator will be operational at all times, will be of sufficient capacity to accommodate Tenant&#8217;s use thereof, will be free of Hazardous Materials, or will function or perform adequately, and </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 12</font></div></td></tr></table></div></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Landlord shall not be liable for any damages resulting from the failure of the Freight Elevator. Although the Freight Elevator does not form a part of the Premises, the provisions of this Lease</font></div><div style="margin-top:0.1pt;padding-left:18pt;padding-right:17.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) governing Tenant&#8217;s use, operation, and enjoyment of the Premises, (ii) imposing obligations on Tenant for matters occurring in, on, within, or about the Premises or arising out of the use or occupancy of the Premises (including, but not limited to, those obligations relating to insurance, indemnification, Hazardous Materials Clearance, and environmental requirements), or (iii) limiting Landlord&#8217;s liability, shall apply with equal force to Tenant&#8217;s use of the Freight Elevator. If Tenant Defaults in its obligations under this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Landlord shall have the right, in addition to any other rights and remedies available to Landlord for a Default by Tenant, to terminate immediately Tenant&#8217;s license to use the Freight Elevator. The expiration or earlier termination of this Lease shall automatically terminate the license hereby granted to Tenant to so use the Freight Elevator. The terms and provisions of this paragraph shall survive the expiration or earlier termination of this Lease.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Break Room&#59; Exterior Amenity Pavilion and Seating</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As long as Tenant is not in Default, Tenant shall have the non-exclusive license to use the shared break room located in the Building and the exterior amenity pavilion and seating located within the Project (collectively, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amenities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) on</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the terms set forth in this paragraph. The Amenities shall be available to Tenant on a first come, first serve basis. Tenant shall cooperate with the other users of the Amenities to coordinate the use of the Amenities. Tenant shall use the Amenities in a manner that will not interfere with the rights of any tenants or occupants in the Project. Landlord shall maintain the Amenities in a first-class manner and at no additional cost to Tenant. Landlord assumes no responsibility for (i) monitoring the use of the Amenities,</font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) resolving disputes that may arise concerning the use of the Amenities, or (iii) enforcing Tenant&#8217;s rights or for protecting the Amenities from any person or entity, including, but not limited to, other tenants or occupants of the Project. Landlord shall have the right at any time and from time to time in the exercise of its sole and absolute subjective discretion to eliminate, reconfigure, relocate, or modify the Amenities, it being understood and agreed that Landlord makes no guaranty, assurance, or representation to Tenant that the Amenities will remain available for use by Tenant during all or any part of the Term. Landlord reserves the right to relocate the Amenities to other space within the Project. Tenant shall promptly execute and deliver to Landlord any documentation that Landlord may reasonably request to document the modifications, elimination, or relocation set forth in this paragraph.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Conference Rooms</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As long as Tenant is not in Default, Tenant shall have the non-exclusive license to use the 2 conference rooms located in the Building (collectively, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Rooms</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) on the terms set forth in this paragraph. The Conference Rooms shall be available to Tenant on a first come, first serve basis. To reserve the Conference Rooms for a specified time and date, Tenant shall use the reservation book for the Conference Rooms. Tenant shall cooperate with the other users of the Conference Rooms to coordinate the use of the Conference Rooms. Tenant shall use the Conference Rooms in a manner that will not interfere with the rights of any tenants or occupants in the Project.  Landlord assumes no responsibility for (i) monitoring the use of the Conference Rooms,</font></div><div style="margin-top:0.15pt;padding-left:18pt;padding-right:17.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) resolving disputes that may arise concerning the use of the Conference Rooms, or (iii) enforcing Tenant&#8217;s rights or for protecting the Conference Rooms from any person or entity, including, but not limited to, other tenants or occupants of the Project. Landlord shall have the right at any time and from time to time in the exercise of its sole and absolute subjective discretion to eliminate, reconfigure, relocate, or modify the Conference Rooms, it being understood and agreed that Landlord makes no guaranty, assurance, or representation to Tenant that the Conference Rooms will remain available for use by Tenant during all or any part of the Term. Landlord reserves the right to relocate the Conference Rooms to other space within the Project. Tenant shall promptly execute and deliver to Landlord any documentation that Landlord may reasonably request to document the modifications, elimination, or relocation set forth in this paragraph. Subject to the terms of this paragraph, Landlord shall maintain the Conference Rooms in a fist class manner throughout the Term.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 13</font></div></td></tr></table></div></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.72pt">Holding Over</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If, with Landlord&#8217;s express written consent, Tenant retains possession of the Premises after the termination of the Term, (i) unless otherwise agreed in such written consent, such possession shall be subject to immediate termination by Landlord at any time, (ii) all of the other terms and provisions of this Lease (including, without limitation, the adjustment of Base Rent pursuant to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereof) shall remain in full force and effect (excluding any expansion or renewal option or other similar right or option) during such holdover period, (iii) Tenant shall continue to pay Base Rent in the amount payable upon the date of the expiration or earlier termination of this Lease or such other amount as Landlord may indicate, in Landlord&#8217;s sole and absolute discretion, in such written consent, and (iv) all other payments shall continue under the terms of this Lease. If Tenant remains in possession of the Premises after the expiration or earlier termination of the Term without the express written consent of Landlord, (A) Tenant shall become a tenant at sufferance upon the terms of this Lease except that the monthly rental shall be equal to 200% of Rent in effect during the last 30 days of the Term, and</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tenant shall be responsible for all damages suffered by Landlord resulting from or occasioned by Tenant&#8217;s holding over (including consequential damages if Landlord has advised Tenant in writing in advance that a particular tenant has signed a new lease with Landlord for the Premises and any particular consequential damages that Landlord may incur or suffer under such new lease as a result of Tenant&#8217;s holding over, including, without limitation, consequential damages that Landlord may incur or suffer by reason of Landlord&#8217;s inability to lease the Premises or deliver occupancy to such particular tenant). Tenant shall pay Base Rent and Tenant&#8217;s Share of Operating Expenses on a per diem basis at such</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">monthly rental rate for each day that Tenant so retains possession. No holding over by Tenant, whether with or without consent of Landlord, shall operate to extend this Lease except as otherwise expressly provided, and this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall not be construed as consent for Tenant to retain possession of the Premises. Acceptance by Landlord of Rent after the expiration of the Term or earlier termination of this Lease shall not result in a renewal or reinstatement of this Lease.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.72pt">Taxes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord shall pay, as part of Operating Expenses, all taxes, levies, fees, assessments and governmental charges of any kind, existing as of the Commencement Date or thereafter enacted (collectively referred to as &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Taxes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), imposed by any federal, state, regional, municipal, local or other governmental authority or agency, including, without limitation, quasi-public agencies (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Authority</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) during the Term, including, without limitation, all Taxes&#58;</font></div><div style="margin-top:0.1pt;padding-left:18pt;padding-right:17.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) imposed on or measured by or based, in whole or in part, on rent payable to (or gross receipts received by) Landlord under this Lease and&#47;or from the rental by Landlord of the Project or any portion thereof, or (ii) based on the square footage, assessed value or other measure or evaluation of any kind of the Premises or the Project, or (iii) assessed or imposed by or on the operation or maintenance of any portion of the Premises or the Project, including parking, or (iv) assessed or imposed by, or at the direction of, or resulting from Legal Requirements, or interpretations thereof, promulgated by any Governmental Authority, or (v) imposed as a license or other fee, charge, tax, or assessment on Landlord&#8217;s business or occupation of leasing space in the Project. Landlord may contest by appropriate legal proceedings the amount, validity, or application of any Taxes or liens securing Taxes and any reduction in Taxes will be credited to the Operating Expenses during the Term or refunded to Tenant within 30 days if received after the expiration of the Term (which credit or refund shall be net of the costs and expenses &#91;including attorneys&#8217; fees&#93; incurred by Landlord in obtaining any such reduction). Taxes shall not include any net income taxes imposed on Landlord except to the extent such net income taxes are in substitution for any Taxes payable hereunder. If any such Tax is levied or assessed directly against Tenant, then Tenant shall be responsible for and shall pay the same at such times and in such manner as the taxing authority shall require. Tenant shall pay, prior to delinquency, any and all Taxes levied or assessed against any personal property or trade fixtures placed by Tenant in the Premises, whether levied or assessed against Landlord or Tenant. If any Taxes on Tenant&#8217;s personal property or trade fixtures are levied against Landlord or Landlord&#8217;s property, or if the assessed valuation of the Project is increased by a value attributable to improvements in or alterations to the Premises, whether owned by Landlord or Tenant and regardless of whether affixed to the real property so as to become a part thereof, higher than the base valuation on </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 14</font></div></td></tr></table></div></div><div style="margin-top:0.1pt;padding-left:18pt;padding-right:17.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which Landlord from time-to-time allocates Taxes to all tenants in the Project, Landlord shall have the right, but not the obligation, to pay such Taxes. Landlord&#8217;s determination of any excess assessed valuation shall be binding and conclusive, absent manifest error. The amount of any such payment by Landlord shall constitute Additional Rent due from Tenant to Landlord immediately upon demand.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.72pt">Parking</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to all Legal Requirements, Force Majeure, a Taking, and the exercise by Landlord of its rights hereunder, Tenant shall have the right, at no additional charge and in common with other tenants of the Project pro rata in accordance with the rentable area of the Premises and the rentable areas of the Project occupied by such other tenants, to park in those areas designated for non-reserved parking, subject in each case to Landlord&#8217;s rules and regulations. Landlord may allocate parking spaces among Tenant and other tenants in the Project pro rata as described above if Landlord determines that such parking facilities are becoming crowded. Landlord shall not be responsible for enforcing Tenant&#8217;s parking rights against any third parties, including other tenants of the Project. As of the Commencement Date, the current parking ratio is 2.5 standard sized spaces per 1,000 leased rentable square feet.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Electric Charging Stations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to the terms of this paragraph, Tenant shall have a license to install at its sole cost and expense not more than 4 electric vehicle charging stations (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EV Charging Stations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) in a location reasonably designated by Landlord from time to time (which location shall not be in a premium location for parking spaces as determined by Landlord). The parking spaces used for the EV Charging Stations shall count against Tenant&#8217;s pro rata of parking as set forth in the</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preceding paragraph. The EV Charging Stations will include electrical power and data and charging heads. Landlord makes no warranties of any kind, express or implied, with respect to the EV Charging Stations, and Landlord disclaims any such warranties. Without limiting the foregoing, Tenant expressly acknowledges and agrees that Landlord does not guaranty or warrant that the EV Charging Stations will be operational at all times, will be of sufficient capacity to accommodate Tenant&#8217;s use thereof, or will function or perform adequately, and Landlord shall not be liable for any damages resulting from the failure of the EV Charging Stations. Landlord shall have no obligation whatsoever to monitor or police the use of the EV Charging Stations. Tenant shall have the right to install signage indicating that the EV Charging Stations are for the exclusive use of Tenant and its employees, which signage shall be reasonably acceptable to Landlord. Tenant shall pay when due, as Additional Rent, the cost of all electricity consumed or used by the EV Charging Stations. Tenant shall install, operate, repair, and replace the EV Charging Stations in accordance with applicable Legal Requirements and in a good and workmanlike manner. During any period of replacement, repair, or maintenance of the EV Charging Stations when they are not operational (including, but not limited to, any delays thereto due to the inability to obtain parts or replacements), Landlord shall have no obligation to provide Tenant with alternative, supplemental, temporary, or back-up EV Charging Stations. The installation, modification, or replacement of any EV Charging Stations shall constitute an Alteration for purposes of this Lease. Tenant shall be responsible for obtaining any governmental permits or approvals for the installation of the EV Charging Stations. Although the EV Charging Stations do not form a part of the Premises, the provisions of this Lease (i) governing Tenant&#8217;s use, operation, and enjoyment of the Premises, (ii) imposing obligations on Tenant for matters occurring in, on, within, or about the Premises or arising out of the use or occupancy of the Premises (including, but not limited to, those obligations relating to insurance, indemnification, Hazardous Materials Clearance, and environmental requirements), or (iii) limiting Landlord&#8217;s liability, shall apply with equal force to Tenant&#8217;s use of the EV Charging Stations.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:22.11pt">Utilities, Services</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">General</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord shall provide, subject to the terms of this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, janitorial services to the Common Areas, water, electricity, heat, light, power, telephone, sewer, and other utilities (including gas and fire sprinklers to the extent the Project is plumbed for such services), and refuse and trash </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 15</font></div></td></tr></table></div></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collection (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Utilities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The hours of operation of the Premises shall be 24 hours per day, 7 days per week inclusive of any legal holidays recognized by the federal government. Landlord shall pay, as Operating Expenses or subject to Tenant&#8217;s reimbursement obligation, for all Utilities used on the Premises, all maintenance charges for Utilities, and any storm sewer charges or other similar charges for Utilities imposed by any Governmental Authority or Utility provider, and any taxes, penalties, surcharges or similar charges thereon. As of the Commencement Date, the electrical service for the Premises is separately submetered. Landlord may cause, at Tenant&#8217;s expense, any other Utilities to be separately metered or charged directly to Tenant by the provider. Tenant shall pay directly to the Utility provider, prior to delinquency, any separately metered Utilities and services that may be furnished to Tenant or the Premises during the Term. Tenant shall pay, as part of Operating Expenses, its share of all charges for jointly metered Utilities based upon consumption, as reasonably determined by Landlord. No interruption or failure of Utilities from any cause whatsoever shall result in eviction or constructive eviction of Tenant, termination of this Lease or, except as provided in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below, the abatement of Rent. Tenant agrees to limit use of water and sewer with respect to Common Areas to normal restroom use.</font></div><div style="margin-top:0.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Interruption of Essential Service</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If (i) a stoppage of an Essential Service (as defined below) to the Premises shall occur and such stoppage is due solely to the negligent acts or omissions of Landlord and not due in any part to any act or omission on the part of Tenant or any Tenant Party or any matter beyond Landlord&#8217;s reasonable control (any such stoppage of an Essential Service being hereinafter referred to as a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Service Interruption</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), (ii) the Service Interruption continues for more than 5 consecutive business days after Landlord shall have received written notice thereof from Tenant, and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) as a result of such Service Interruption, the conduct of Tenant&#8217;s normal operations in the Premises are materially and adversely affected, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">then</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the extent that such Service Interruption is covered by</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rental interruption insurance carried by Landlord under this Lease, there shall be an abatement of 1 day&#8217;s Base Rent for each day during which the Service Interruption continues after such 5 business day period&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that if any part of the Premises is reasonably useable for Tenant&#8217;s normal business operations or if Tenant conducts all or any part of its operations in any portion of the Premises notwithstanding such Service Interruption, then the amount of each daily abatement of Base Rent shall only be proportionate to the nature and extent of the interruption of Tenant&#8217;s normal operations or ability to use the Premises. The rights granted to Tenant under this paragraph shall be Tenant&#8217;s sole and exclusive remedy resulting from a failure of Landlord to provide services, and Landlord shall not otherwise be liable for any loss or damage suffered or sustained by Tenant resulting from any failure or cessation of services. For purposes hereof, the term &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Essential Services</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the following services&#58; water, sewer, and electricity, but in each case only to the extent that Landlord has an obligation to provide same to Tenant under this Lease.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.39pt">Emergency Generator</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord&#8217;s sole obligation for either providing an emergency generator (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emergency Generator</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) or providing emergency back-up power to Tenant shall be&#58; (i) to provide an Emergency Generator with not less than the stated capacity of the Emergency Generator located in the Building as of the Commencement Date (not less than 3.5 watts per rentable square foot), and (ii) to contract with a third party to maintain the Emergency Generator as per the manufacturer&#8217;s standard maintenance guidelines. Landlord shall have no obligation to provide Tenant with an operational Emergency Generator or back-up power or to supervise, oversee or confirm that the third party maintaining the Emergency Generator is maintaining the Emergency Generator as per the manufacturer&#8217;s standard guidelines or otherwise. Notwithstanding the foregoing, if Landlord plans any replacement, repair, or maintenance of the Emergency Generator or discovers the Emergency Generator is not functioning properly, Landlord shall use commercially reasonable efforts to provide Tenant with notice (e-mail notice shall suffice as long as Tenant has provided Landlord with the current e-mail address to be used for this notification) of such planned or unplanned outage. During any period of replacement, repair or maintenance of the Emergency Generator when the Emergency Generator is not operational, including any delays thereto due to the inability to obtain parts or replacement equipment, Landlord shall have no </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 16</font></div></td></tr></table></div></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligation to provide Tenant with an alternative back-up generator or generators or alternative sources of back-up power. Tenant expressly acknowledges and agrees that Landlord does not guaranty that the Emergency Generator will be operational at all times or that emergency power will be available to the Premises when needed, provided that if Tenant notifies Landlord that the emergency generator is not operational (e-mail notice shall suffice as long as Tenant has provided Landlord with the current e-mail address to be used for this notification), Landlord shall use commercially reasonable efforts in good faith to engage or contact as soon as reasonably practicable under the circumstances a third party service technician to repair the emergency generator so that it becomes operational. Tenant shall have the right to use its pro rata share of the available capacity of the Emergency Generator, and Tenant shall pay its pro rata share of the cost to maintain, repair, and replace the Emergency Generator. On request, Landlord shall provide Tenant with copies of Landlord&#8217;s maintenance logs for the emergency generator for the purpose of allowing Tenant to comply with audit requests relating to its business operations at the Premises.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Energy Data</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant agrees to provide Landlord with access to Tenant&#8217;s water and energy usage data on a monthly basis, either by providing Tenant&#8217;s applicable utility login credentials to Landlord&#8217;s designated online portal, or by another delivery method reasonably agreed to by Landlord and Tenant. The costs and expenses incurred by Landlord in connection with receiving and analyzing such water and energy usage data (including, without limitation, as may be required pursuant to applicable Legal Requirements) shall be included as part of Operating Expenses.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Alterations and Tenant&#8217;s Property</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any alterations, additions, or improvements made to the Premises by or on behalf of Tenant, including additional locks or bolts of any kind or nature upon any doors or windows in the Premises, but excluding installation, removal or realignment of furniture systems (other than removal of furniture systems owned or paid for by Landlord) not involving any modifications to the structure or connections (other than by ordinary plugs or jacks) to Building Systems</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(as defined in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Alterations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) shall be subject to Landlord&#8217;s prior written consent, which may be given or withheld in Landlord&#8217;s sole discretion if any such Alteration affects the structure or Building Systems, but which shall otherwise not be unreasonably withheld or delayed. Tenant may construct nonstructural Alterations in the Premises without Landlord&#8217;s prior approval if the aggregate cost of all such work in any 12 month period does not exceed $50,000 (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notice-Only Alteration</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), provided Tenant notifies Landlord in writing of the intended Notice-Only Alteration, and such notice shall be accompanied by plans, specifications, work contracts, and such other information concerning the nature and cost of the Notice-Only Alteration as may be reasonably requested by Landlord, which notice and accompanying materials shall be delivered to Landlord not less than 15 business days in advance of any proposed construction. If Landlord approves any Alterations, Landlord may impose such conditions on Tenant in connection with the commencement, performance and completion of such Alterations as Landlord may deem appropriate in Landlord&#8217;s reasonable discretion. Any request for approval shall be in writing, delivered not less than 15 business days in advance of any proposed construction, and accompanied by plans, specifications, bid proposals, work contracts and such other information concerning the nature and cost of the alterations as may be reasonably requested by Landlord, including the identities and mailing addresses of all persons performing work or supplying materials. Landlord&#8217;s right to review plans and specifications and to monitor construction shall be solely for its own benefit, and Landlord shall have no duty to ensure that such plans and specifications or construction comply with applicable Legal Requirements. Tenant shall cause, at its sole cost and expense, all Alterations to comply with insurance requirements and with Legal Requirements and shall implement at its sole cost and expense any alteration or modification required by Legal Requirements as a result of any Alterations. Tenant shall pay to Landlord, as Additional Rent, on demand an amount equal to 2.5% of all charges incurred by Tenant or its contractors or agents in connection with any Alteration to cover Landlord&#8217;s overhead and expenses for plan review, coordination, scheduling and supervision. Before Tenant begins any Alteration, Landlord may post on and about the Premises notices of non-responsibility pursuant to applicable law. Tenant shall </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 17</font></div></td></tr></table></div></div><div style="padding-left:18pt;padding-right:17.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reimburse Landlord for, and indemnify and hold Landlord harmless from, any expense incurred by Landlord by reason of faulty work done by Tenant or its contractors, delays caused by such work, or inadequate cleanup.</font></div><div style="margin-top:0.65pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tenant shall furnish security or make other arrangements satisfactory to Landlord to assure payment for the completion of all Alterations work free and clear of liens, and shall provide (and cause each contractor or subcontractor to provide) certificates of insurance (in form and substance satisfactory to Landlord&#59; form ACORD 28 &#91;2006&#47;07&#93; is not satisfactory to Landlord) for workers&#8217; compensation and other coverage in amounts and from an insurance company satisfactory to Landlord protecting Landlord against liability for personal injury or property damage during construction. Upon completion of any Alterations, Tenant shall deliver to Landlord&#58; (i) sworn statements setting forth the names of all contractors and subcontractors who did the work and final lien waivers from all such contractors and subcontractors&#59; and (ii) &#8220;as built&#8221; plans for any such Alteration.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than (i) the items, if any, listed on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attached hereto, (ii) any items agreed by Landlord in writing to be included on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the future, and (iii) any trade fixtures, machinery, equipment and other personal property not paid for out of the TI Fund (as defined in the Work Letter) that may be removed without material damage to the Premises, which damage shall be repaired (including capping or terminating utility hook-ups behind walls) by Tenant during the Term (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tenant&#8217;s Property</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), all property of any kind paid for with the TI Fund, all Alterations, real property fixtures, built-in machinery and equipment, built-in casework and cabinets and other similar additions and improvements built into the Premises so as to become an integral part of the Premises, such as fume hoods that penetrate the roof or plenum area, built-in cold rooms, built-in warm rooms, walk-in cold rooms, walk-in warm rooms, deionized water systems, glass washing equipment, autoclaves, chillers, built-in plumbing, electrical and mechanical equipment and systems, and any power generator and transfer switch (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Installations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), shall be and shall remain the property of Landlord during the Term and following the expiration or earlier termination of the Term, shall not be removed by Tenant at any time during the Term and shall remain upon and be surrendered with the Premises as a part thereof in accordance with </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 28</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following the expiration or earlier termination of this Lease&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that Landlord shall, at the time its approval of such Installation is requested or at the time it receives notice of a Notice-Only Alteration, notify Tenant if it has elected to cause Tenant to remove such Installation upon the expiration or earlier termination of this Lease. If Landlord so elects, Tenant shall remove such Installation upon the expiration or earlier termination of this Lease and restore any damage caused by or occasioned as a result of such removal, including, when removing any of Tenant&#8217;s Property that was plumbed, wired or otherwise connected to any of the Building Systems, capping off all such connections behind the walls of the Premises and repairing any holes. During any such restoration period, Tenant shall pay Rent to Landlord as provided herein as if such space were otherwise occupied by Tenant.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:4.16pt">Landlord&#8217;s Repairs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord, as an Operating Expense, shall maintain all of the structural, exterior, parking and other Common Areas of the Project, including plumbing, fire sprinklers, elevators and all other building systems serving the Premises and other portions of the Project (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Building Systems</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), in good repair, reasonable wear and tear and uninsured losses and damages caused by Tenant, or by any of Tenant&#8217;s agents, servants, employees, invitees and contractors (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tenant Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) excluded. Notwithstanding anything herein to the contrary, Landlord shall make necessary capital repairs to, and replace, the roof, foundation, slab, and structural walls of the Building. Subject to the waiver of subrogation provisions contained in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 17</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, losses and damages caused by Tenant or any Tenant Party to the structural components of the Building and Building Systems shall be repaired by Landlord, to the extent not covered by insurance, at Tenant&#8217;s sole cost and expense. Landlord reserves the right to stop Building Systems services when reasonably necessary (i) by reason of accident or emergency, or (ii) upon 2 business days&#8217; notice to Tenant for planned repairs, alterations or improvements, which are, in the reasonable judgment of Landlord, desirable or necessary to be made, until such repairs, alterations or </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 18</font></div></td></tr></table></div></div><div style="padding-left:18pt;padding-right:17.65pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">improvements shall have been completed. Landlord shall have no responsibility or liability for failure to supply Building Systems services during any such period of interruption&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that (A) Landlord shall, except in case of emergency, make a commercially reasonable effort to give Tenant 2 business days&#8217; advance written notice of any planned stoppage of Building Systems services for routine maintenance, repairs, alterations or improvements, and</font></div><div style="margin-top:0.2pt;padding-left:18pt;padding-right:17.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(B) Landlord shall use commercially reasonable efforts (but only as long as Landlord does not incur any additional cost or expense) to limit any such stoppage to evenings and weekends if the stoppage would materially, adversely interfere with Tenant&#8217;s business operations. Tenant shall promptly give Landlord written notice of any repair required by Landlord pursuant to this Section (or with respect to any emergency, verbal notice promptly followed by a written notice), after which Landlord shall have a reasonable opportunity to effect such repair. Landlord shall not be liable for any failure to make any repairs or to perform any maintenance unless such failure shall persist for an unreasonable time after Tenant&#8217;s written notice of the need for such repairs or maintenance. As may be required by applicable Legal Requirements in connection with any regulatory audit of Tenant, Tenant may request non-confidential and non-proprietary records of service or records of remediation for any Building System managed by Landlord. Tenant waives its rights under any state or local law to terminate this Lease or to make such repairs at Landlord&#8217;s expense and agrees that the parties&#8217; respective rights with respect to such matters shall be solely as set forth herein. Repairs required as the result of fire, earthquake, flood, vandalism, war, or similar cause of damage or destruction shall be controlled by </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 18</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:4.16pt">Tenant&#8217;s Repairs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereof, Tenant, at its expense, shall repair, replace and maintain in good condition all portions of the Premises, including, without limitation, HVAC, entries, doors, ceilings, interior windows, interior walls, and the interior side of demising walls. Such repair and replacement may include capital expenditures and repairs whose benefit may extend beyond the Term. Should Tenant fail to make any such repair or replacement or fail to maintain the Premises, Landlord shall give Tenant notice of such failure. If Tenant fails to commence cure of such failure within</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 business days of receipt of Landlord&#8217;s notice, and thereafter diligently prosecute such cure to completion, Landlord may perform such work and shall be reimbursed by Tenant within 10 days after demand therefor&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that if such failure by Tenant creates or could create an emergency, Landlord may immediately commence cure of such failure and shall thereafter be entitled to recover the reasonable out of pocket costs of such cure from Tenant. Subject to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 17</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">18</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tenant shall</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bear the full uninsured cost of any repair or replacement to any part of the Project that results from damage caused by Tenant or any Tenant Party and any repair that benefits only the Premises.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">HVAC Maintenance Contract</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant, at its expense, shall at all times during the Term maintain with qualified contractors maintenance and repair contracts (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HVAC Maintenance Contracts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) for the rooftop mounted HVAC units serving the Premises. The HVAC Maintenance Contracts shall be in form and content reasonably satisfactory to Landlord. Landlord shall be a third party beneficiary of the HVAC Maintenance Contracts and, within 30 days after Landlord&#8217;s request, Tenant shall deliver a copy of the HVAC Maintenance Contracts to Landlord.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:4.16pt">Mechanic&#8217;s Liens</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant shall discharge, by bond or otherwise, any mechanic&#8217;s lien filed against the Premises or against the Project for work claimed to have been done for, or materials claimed to have been furnished to, Tenant within 20 days after the filing thereof, at Tenant&#8217;s sole cost and shall otherwise keep the Premises and the Project free from any liens arising out of work performed, materials furnished or obligations incurred by Tenant. Should Tenant fail to discharge (or bond) any lien described herein, Landlord shall have the right, but not the obligation, to pay such claim or post a bond or otherwise provide security to eliminate the lien as a claim against title to the Project and the cost thereof shall be immediately due from Tenant as Additional Rent. If Tenant shall lease or finance the acquisition of office equipment, furnishings, or other personal property of a removable nature utilized by Tenant in the operation of Tenant&#8217;s business, Tenant warrants that any Uniform Commercial Code Financing Statement </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 19</font></div></td></tr></table></div></div><div style="padding-left:18pt;padding-right:17.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filed as a matter of public record by any lessor or creditor of Tenant will upon its face or by exhibit thereto indicate that such Financing Statement is applicable only to removable personal property of Tenant located within the Premises. In no event shall the address of the Project be furnished on the statement without qualifying language as to applicability of the lien only to removable personal property, located in an identified suite held by Tenant.</font></div><div style="margin-top:0.6pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:22.11pt">Indemnification</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">By Tenant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant hereby indemnifies and agrees to defend, save and hold Landlord harmless from and against any and all Claims for injury or death to persons or damage to property occurring within or about the Premises (including the Shared Lab Area), arising directly or indirectly out of use or occupancy of the Premises (including the Shared Lab Area) or a breach or default by Tenant in the performance of any of its obligations hereunder, unless to the extent caused by the willful misconduct or gross negligence of Landlord. Landlord shall not be liable to Tenant for, and Tenant assumes all risk of damage to, personal property (including, without limitation, loss of records kept within the Premises). Tenant further waives any and all Claims for injury to Tenant&#8217;s business or loss of income relating to any such damage or destruction of personal property (including, without limitation, any loss of records). Landlord shall not be liable for any damages arising from any act, omission or neglect of any tenant in the Project or of any other third party.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">By Landlord</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to the provisions of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 16(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">36</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Landlord hereby indemnifies and agrees to defend, save, and hold Tenant harmless from and against any and all Claims for injury or death to persons or damage to property occurring within or about the Common Area caused by Landlord&#8217;s willful misconduct or gross negligence, except to the extent caused by the willful misconduct or negligence of Tenant or any Tenant Party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Insurance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord shall maintain all risk property and, if applicable, sprinkler damage insurance covering the full replacement cost of the Project or such lesser coverage amount as Landlord may elect </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> such coverage amount is not less than 90% of such full replacement cost. Landlord shall further procure and maintain commercial general liability insurance with a single loss limit of not less than $2,000,000 for bodily injury and property damage with respect to the Project. Landlord may, but is not obligated to, maintain such other insurance and additional coverages as it may deem necessary, including, but not limited to, flood, environmental hazard and earthquake, loss or failure of building equipment, errors and omissions, rental loss during the period of repair or rebuilding, workers&#8217;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensation insurance and fidelity bonds for employees employed to perform services and insurance for any improvements installed by Tenant or that are in addition to the standard improvements customarily furnished by Landlord without regard to whether such are made a part of the Project. All such insurance shall be included as part of the Operating Expenses. The Project may be included in a blanket policy (in which case the cost of such insurance allocable to the Project will be determined by Landlord based upon the insurer&#8217;s cost calculations). Tenant shall also reimburse Landlord for any increased premiums or additional insurance that Landlord reasonably deems necessary as a result of Tenant&#8217;s use of the Premises.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tenant, at its sole cost and expense, shall maintain during the Term&#58; all risk property insurance with business interruption and extra expense coverage, covering the full replacement cost of all property and improvements installed or placed in the Premises by Tenant at Tenant&#8217;s expense&#59; workers&#8217; compensation insurance with no less than the minimum limits required by law&#59; employer&#8217;s liability insurance with such limits as required by law&#59; and commercial general liability insurance, with a minimum limit of not less than $2,000,000 per occurrence for bodily injury and property damage with respect to the Premises (such insurance may be satisfied through the evidencing of Umbrella Liability coverage in support). The commercial general liability insurance policy shall name Landlord and Alexandria Real </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 20</font></div></td></tr></table></div></div><div style="padding-left:18pt;padding-right:17.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estate Equities, Inc., and its and their respective members, officers, directors, employees, managers, and agents (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Landlord Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), as additional insureds&#59; insure on an occurrence and not a claims-made basis&#59; be issued by insurance companies that have a rating of not less than policyholder rating of A and financial category rating of at least Class X in &#8220;Best&#8217;s Insurance Guide&#8221;&#59; shall not be cancelable for nonpayment of premium unless 30 days prior written notice shall have been given to Landlord from the insurer&#59; contain a hostile fire endorsement and a contractual liability endorsement&#59; and provide primary coverage to Landlord (any policy issued to Landlord providing duplicate or similar coverage shall be deemed excess over Tenant&#8217;s policies). Copies of such policies (if requested by Landlord), or certificates of insurance (in form and substance reasonably satisfactory to Landlord&#59; form ACORD 28 &#91;2006&#47;07&#93; is not satisfactory to Landlord) showing the limits of coverage required hereunder and showing Landlord as an additional insured, along with reasonable evidence of the payment of premiums for the applicable period, shall be delivered to Landlord by Tenant upon Tenant&#8217;s execution and delivery of this Lease and upon each renewal of such insurance. Tenant&#8217;s policy may be a &#8220;blanket policy&#8221; with an aggregate per location endorsement that specifically provides that the amount of insurance shall not be prejudiced by other losses covered by the policy. Tenant shall, at least 5 days prior to the expiration of such policies, furnish Landlord with renewal certificates.</font></div><div style="margin-top:0.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each instance where insurance is to name Landlord as an additional insured, Tenant shall upon written request of Landlord also designate and furnish certificates so evidencing Landlord as additional insured to&#58; (i) any lender of Landlord holding a security interest in the Project or any portion thereof, (ii) the landlord under any lease wherein Landlord is tenant of the real property on which the Project is located, if the interest of Landlord is or shall become that of a tenant under a ground or other underlying lease rather than that of a fee owner, and&#47;or (iii) any management company retained by Landlord to manage the Project.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The property insurance obtained by Landlord and Tenant shall include a waiver of subrogation by the insurers and all rights based upon an assignment from its insured, against Landlord or Tenant, and their respective officers, directors, employees, managers, agents, invitees and contractors (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Related Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), in connection with any loss or damage thereby insured against. Neither party nor its respective Related Parties shall be liable to the other for loss or damage caused by any risk insured against under property insurance required to be maintained hereunder, and each party waives any claims against the other party, and its respective Related Parties, for such loss or damage. The failure of a party to insure its property shall not void this waiver. Landlord and its respective Related Parties shall not be liable for, and Tenant hereby waives all claims against such parties for, business interruption and losses occasioned thereby sustained by Tenant or any person claiming through Tenant resulting from any accident or occurrence in or upon the Premises or the Project from any cause whatsoever.  If the</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">foregoing waivers shall contravene any law with respect to exculpatory agreements, the liability of Landlord or Tenant shall be deemed not released but shall be secondary to the other&#8217;s insurer.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18.15pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Landlord may require insurance policy limits to be raised to conform with requirements of Landlord&#8217;s lender and&#47;or to bring coverage limits to levels then being generally required of new tenants within the Project that are consistent with such limits then being so required by landlords of buildings or projects comparable to the Building or Project in the Germantown&#47;Gaithersburg&#47;Rockville market area.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:4.16pt">Restoration</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If, at any time during the Term, the Project or the Premises are damaged or destroyed by a fire or other insured casualty, Landlord shall notify Tenant within 60 days after discovery of such damage as to the amount of time Landlord reasonably estimates it will take to restore the Project or the Premises, as applicable (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restoration Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). If the Restoration Period is estimated to exceed 12 months (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maximum Restoration Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), Landlord may, in such notice, elect to terminate this Lease as of the date that is 75 days after the date of discovery of such damage or destruction&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that notwithstanding Landlord&#8217;s election to restore, Tenant may elect to terminate this Lease by written notice to Landlord delivered within 5 business days of receipt of a notice from Landlord estimating a </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 21</font></div></td></tr></table></div></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restoration Period for the Premises longer than the Maximum Restoration Period. Unless either Landlord or Tenant so elects to terminate this Lease, Landlord shall, subject to receipt of sufficient insurance proceeds (with any deductible to be treated as a current Operating Expense), promptly restore the Premises (excluding the improvements installed by Tenant or by Landlord and paid for by Tenant unless covered by the insurance Landlord maintains as an Operating Expense hereunder, in which case such improvements shall be included, to the extent of such insurance proceeds, in Landlord&#8217;s restoration), subject to delays arising from the collection of insurance proceeds, from Force Majeure events or as needed to obtain any license, clearance or other authorization of any kind required to enter into and restore the Premises issued by any Governmental Authority having jurisdiction over the use, storage, handling, treatment, generation, release, disposal, removal or remediation of Hazardous Materials (as defined in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 30</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in, on or about the Premises (collectively referred to herein as &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hazardous Materials Clearances</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that if repair or restoration of the Premises is not substantially complete as of the end of the Maximum Restoration Period or, if longer, the Restoration Period, Landlord may, in its sole and absolute discretion, elect not to proceed with such repair and restoration, or Tenant may by written notice to Landlord delivered within 5 business days of the expiration of the Maximum Restoration Period or, if longer, the Restoration Period, elect to terminate this Lease, in which event Landlord shall be relieved of its obligation to make such repairs or restoration and this Lease shall terminate as of the date that is 75 days after the later of&#58; (i) discovery of such damage or destruction, or (ii) the date all required Hazardous Materials Clearances are obtained, but Landlord shall retain any Rent paid and the right to any Rent payable by Tenant prior to such election by Landlord or Tenant.</font></div><div style="margin-top:0.7pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tenant, at its expense, shall promptly perform, subject to delays arising from the collection of insurance proceeds, from Force Majeure events or to obtain Hazardous Material Clearances, all repairs or restoration not required to be done by Landlord and shall promptly re-enter the Premises and commence doing business in accordance with this Lease. Notwithstanding the foregoing, either Landlord or Tenant may terminate this Lease if the Premises are damaged during the last year of the Term and Landlord reasonably estimates that it will take more than 2 months to repair such damage, or if insurance proceeds are not available for such restoration. Rent shall be abated from the date all required Hazardous Material Clearances are obtained until the Premises are repaired and restored, in the proportion that the area of the Premises, if any, that is not usable by Tenant bears to the total area of the Premises, unless Landlord provides Tenant with other space during the period of repair that is suitable (in Tenant&#8217;s sole but reasonable determination) for the temporary conduct of Tenant&#8217;s business. Such abatement shall be the sole remedy of Tenant, and except as provided in this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 18</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tenant waives any right to terminate this Lease by reason of damage or casualty loss.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provisions of this Lease, including this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 18</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, constitute an express agreement between Landlord and Tenant with respect to any and all damage to, or destruction of, all or any part of the</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premises, or any other portion of the Project, and any statute or regulation that is now or may hereafter be in effect shall have no application to this Lease or any damage or destruction to all or any part of the Premises or any other portion of the Project, the parties hereto expressly agreeing that this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 18</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sets forth their entire understanding and agreement with respect to such matters.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:4.16pt">Condemnation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the whole or any material part of the Premises or the Project is taken for any public or quasi-public use under governmental law, ordinance, or regulation, or by right of eminent domain, or by private purchase in lieu thereof (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Taking</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Taken</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and the Taking would either prevent or materially interfere with Tenant&#8217;s use of the Premises or materially interfere with or impair Landlord&#8217;s ownership or operation of the Project, then upon written notice by either party to the other this Lease shall terminate and Rent shall be apportioned as of such date. If part of the Premises shall be Taken, and this Lease is not terminated as provided above, Landlord shall promptly restore the Premises and the Project as nearly as is commercially reasonable under the circumstances to their condition prior to such partial Taking and the rentable square footage of the Building, the rentable square footage of the </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 22</font></div></td></tr></table></div></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premises, Tenant&#8217;s Share of Operating Expenses and the Rent payable hereunder during the unexpired Term shall be reduced to such extent as may be fair and reasonable under the circumstances. Upon any such Taking, Landlord shall be entitled to receive the entire price or award from any such Taking without any payment to Tenant, and Tenant hereby assigns to Landlord Tenant&#8217;s interest, if any, in such award. Tenant shall have the right, to the extent that same shall not diminish Landlord&#8217;s award, to make a separate claim against the condemning authority (but not Landlord) for such compensation as may be separately awarded or recoverable by Tenant for moving expenses and damage to Tenant&#8217;s trade fixtures, if a separate award for such items is made to Tenant. Tenant hereby waives any and all rights it might otherwise have pursuant to any provision of state law to terminate this Lease upon a partial Taking of the Premises or the Project.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">17.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:4.16pt">Events of Default</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. Each of the following events shall be a default (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Default</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8221;) by Tenant under this Lease&#58;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Payment Defaults</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant shall fail to pay any installment of Rent or any other payment hereunder when due&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that Landlord will give Tenant notice and an opportunity to cure any failure to pay Rent within 3 days of any such notice not more than once in any 12 month period and Tenant agrees that such notice shall be in lieu of and not in addition to, or shall be deemed to be, any notice required by law.</font></div><div style="margin-top:0.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Insurance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any insurance required to be maintained by Tenant pursuant to this Lease shall be canceled or terminated or shall expire or shall be reduced or materially changed, or Landlord shall receive a notice of nonrenewal of any such insurance and Tenant shall fail to obtain replacement insurance at least 10 days before the expiration of the current coverage.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Abandonment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant shall abandon the Premises.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Improper Transfer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant shall assign, sublease or otherwise transfer or attempt to transfer all or any portion of Tenant&#8217;s interest in this Lease or the Premises except as expressly permitted herein, or Tenant&#8217;s interest in this Lease shall be attached, executed upon, or otherwise judicially seized and such action is not released within 90 days of the action.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:5.83pt">Liens</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. Tenant shall fail to discharge, bond-off, or otherwise obtain the release of any lien placed upon the Premises in violation of this Lease within 15 days after Tenant receives written notice that such lien has been filed against the Premises.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Insolvency Events</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. Tenant or any guarantor or surety of Tenant&#8217;s obligations hereunder shall&#58; (A) make a general assignment for the benefit of creditors&#59; (B) commence any case, proceeding or other action seeking to have an order for relief entered on its behalf as a debtor or to adjudicate it a</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.7pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, liquidation, dissolution or composition of it or its debts or seeking appointment of a receiver, trustee, custodian or other similar official for it or for all or of any substantial part of its property (collectively a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Proceeding for Relief</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;)&#59;</font></div><div style="margin-top:0.2pt;padding-left:18pt;padding-right:18.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(C) become the subject of any Proceeding for Relief that is not dismissed within 90 days of its filing or entry&#59; or (D) die or suffer a legal disability (if Tenant, guarantor, or surety is an individual) or be dissolved or otherwise fail to maintain its legal existence (if Tenant, guarantor or surety is a corporation, partnership or other entity).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.62pt">Estoppel Certificate or Subordination Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant fails to execute any document required from Tenant under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 23</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">27</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within 5 days after a second notice requesting such document.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 23</font></div></td></tr></table></div></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:5.83pt">Other Defaults</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. Tenant shall fail to comply with any provision of this Lease other than those specifically referred to in this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%;text-decoration:underline">Section 20</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">, and, except as otherwise expressly provided herein, such failure shall continue for a period of 15 days after written notice thereof from Landlord to Tenant.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any notice given under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 20(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereof shall&#58; (i) specify the alleged default, (ii) demand that Tenant cure such default, (iii) be in lieu of, and not in addition to, or shall be deemed to be, any notice required under any provision of applicable law, and (iv) not be deemed a forfeiture or a termination of this Lease unless Landlord elects otherwise in such notice&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that if the nature of Tenant&#8217;s default pursuant to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 20(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is such that it cannot be cured by the payment of money and reasonably requires more than 15 days to cure, then Tenant shall not be deemed to be in default if Tenant commences such cure within such 15 day period and thereafter diligently prosecutes the same to completion&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that such cure shall be completed no later than 60 days from the date of Landlord&#8217;s notice.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:22.11pt">Landlord&#8217;s Remedies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Interest</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon a Default by Tenant hereunder, Landlord may, without waiving or releasing any obligation of Tenant hereunder, make such payment or perform such act. All sums so paid or incurred by Landlord, together with interest thereon, from the date such sums were paid or incurred, at the annual rate equal to 12% per annum or the highest rate permitted by law (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Default Rate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), whichever is less, shall be payable to Landlord on demand as Additional Rent. Landlord shall have no obligation whatsoever to mitigate any damages resulting from a Default by Tenant under this Lease except for entering into and maintaining a listing of the Premises with a commercial real estate broker once Tenant vacates possession of the Premises in accordance with the provisions of this Lease (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mitigation Requirement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). On compliance with the Mitigation Requirement, Landlord shall be deemed to have fully satisfied its obligation to mitigate damages under this Lease and under any Legal Requirement in effect on the Commencement Date or at the time of Tenant&#8217;s Default&#59; and Tenant waives and releases, to the fullest extent permissible under applicable Legal Requirements, any right to assert in any action by Landlord to enforce the terms of this Lease, any defense, counterclaim, or rights of setoff or recoupment respecting the mitigation of damages by Landlord, unless and to the extent Landlord fails to comply with the Mitigation Requirement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Late Payment Rent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Late payment by Tenant to Landlord of Rent and other sums due will cause Landlord to incur costs not contemplated by this Lease, the exact amount of which will be extremely difficult and impracticable to ascertain. Such costs include, but are not limited to, processing and accounting charges and late charges that may be imposed on Landlord under any Mortgage covering the Premises. Therefore, if any installment of Rent due from Tenant is not received by Landlord within 5 days after the date such payment is due, Tenant shall pay to Landlord an additional sum of 6% of the overdue Rent as a late charge (provided that Tenant shall not be required to pay such late charge upon the first occurrence during any calendar year of a late payment by Tenant of Rent). The parties agree that this late charge represents a fair and reasonable estimate of the costs Landlord will incur by reason of late payment by Tenant. In addition to the late charge, Rent not paid when due shall bear interest at the Default Rate from the 5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">th </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">day after the date due until paid.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Re-Entry</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. While a Default exists and is continuing, Landlord shall have the right, immediately or at any time thereafter, without further notice to Tenant (unless otherwise provided herein), to enter the Premises, without terminating this Lease or being guilty of trespass, and do any and all acts as Landlord may deem necessary, proper or convenient to cure such default, for the account and at the expense of Tenant, any notice to quit or notice of Landlord&#8217;s intention to re-enter being hereby expressly waived, and Tenant agrees to pay to Landlord as Additional Rent all damage and&#47;or expense incurred by Landlord in so doing, including interest at the Default Rate, from the due date until the date payment is received by Landlord.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 24</font></div></td></tr></table></div></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.39pt">Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord shall have the right to terminate this Lease and Tenant&#8217;s right to possession of the Premises and, in accordance with Legal Requirements, take possession of the Premises and remove Tenant, any occupant and any property therefrom, without being guilty of trespass and without relinquishing any rights of Landlord against Tenant, any notice to quit, or notice of Landlord&#8217;s intention to re-enter being hereby expressly waived. Landlord shall be entitled to recover damages from Tenant for all amounts covenanted to be paid during the remainder of the Term (except for the period of any holdover by Tenant, in which case the monthly rental rate stated at </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> herein shall apply), which may be accelerated by Landlord at its option, together with (i) all expenses of any proceedings (including, but not limited to, the expenses set forth in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 22(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below) that may be necessary in order for Landlord to recover possession of the Premises, (ii) the expenses of the re-renting of the Premises (including, but not limited to, any commissions paid to any real estate agent, advertising expense and the costs of such alterations, repairs, replacements or modifications that Landlord, in its sole judgment, considers advisable and necessary for the purpose of re-renting), and (iii) interest computed at the Default Rate from the due date until paid&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that there shall be credited against the amount of such damages all amounts received by Landlord from such re-renting of the Premises, with any overage being refunded to Tenant. Landlord shall in no event be liable in any way whatsoever for failure to re-rent the Premises or, in the event that the Premises are re-rented, for failure to collect the rent thereof under such re-renting. No act or thing done by Landlord shall be deemed to be an acceptance of a surrender of the Premises, unless Landlord shall execute a written agreement of surrender with Tenant. Tenant&#8217;s liability hereunder shall not be terminated by the execution of a new lease of the Premises by Landlord, unless that new lease expressly so states. In the event Landlord does not exercise its option to accelerate the payment of amounts owed as provided hereinabove, then Tenant agrees to pay to Landlord, upon demand, the amount of damages herein provided after the amount of such damages for any month shall have been ascertained&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that any expenses incurred by Landlord shall be deemed to be a part of the damages for the month in which they were incurred. Separate actions may be maintained each month or at other times by Landlord against Tenant to recover the damages then due, without waiting until the end of the term of this Lease to determine the aggregate amount of such damages. Tenant hereby expressly waives any and all rights of redemption granted by or under any present or future laws in the event of Tenant being evicted or being dispossessed for any cause, or in the event of Landlord obtaining possession of the Premises by reason of the violation by Tenant of any of the covenants and conditions of this Lease.</font></div><div style="margin-top:0.6pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lien for Rent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon any default by Tenant in the payment of Rent or other amounts owed hereunder, Landlord shall have a lien upon the property of Tenant in the Premises for the amount of such unpaid amounts, and Tenant hereby specifically waives any and all exemptions allowed by law. In such event, Tenant shall not remove any of Tenant&#8217;s property from the Premises except with the prior written consent of Landlord, and Landlord shall have the right and privilege, at its option, to take possession of all Tenant&#8217;s property in the Premises, to store the same on the Premises, or to remove it and store it in such place as may be selected by Landlord, at Tenant&#8217;s risk and expense. If Tenant fails to redeem the personal property so seized, by payment of whatever sum may be due Landlord hereunder (including all storage costs), Landlord shall have the right, after 20 days written notice to Tenant of its intention to do so, to sell such personal property so seized at public or private sale and upon such terms and conditions as may appear advantageous to Landlord, and after the payment of all proper charges incident to such sale, apply the proceeds thereof to the payment of any balance due to Landlord on account of rent or other obligations of Tenant pursuant to this Lease. In the event there shall then remain</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the hands of Landlord any balance realized from the sale of such personal property, the same shall be paid over to Tenant. The exercise of the foregoing remedy by Landlord shall not relieve or discharge Tenant from any deficiency owed to Landlord that Landlord has the right to enforce pursuant to any of the provisions of this Lease. Tenant shall also be liable for all expenses incident to the foregoing process, including any auctioneer or attorney&#8217;s fees or commissions. At Tenant&#8217;s request, Landlord shall subordinate its lien rights as set forth in this paragraph to the lien, operation, and effect of any bona fide </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 25</font></div></td></tr></table></div></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third-party financing for equipment and trade fixtures pursuant to a subordination agreement in form and substance reasonably acceptable to Landlord. Such subordination shall be limited to specific items of equipment and shall not be in the form of a blanket lien subordination.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to the provisions of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 21(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below, Tenant shall pay, as Additional Rent and immediately upon written demand from Landlord, all costs and expenses incurred by Landlord, including, but not limited to, attorneys&#8217; fees, expert witness fees, paralegal fees, other litigation expenses (such as expenses for photocopying, electronic legal research, and deposition transcripts), and court costs in connection with or arising out of any Default by Tenant under this Lease, including, but not limited to, any action or proceeding brought by Landlord to enforce any obligation of Tenant under this Lease or the right of Landlord in or to the Premises. Such expenses are recoverable at all levels, including appeals and post-judgment actions or proceedings. The giving of a notice of Default by Landlord shall constitute part of an action or proceeding under this Lease, entitling Landlord to reimbursement of such fees and expenses, even if an action or proceeding is not commenced in a court of law and regardless of whether the Default is cured.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:5.83pt">Suspension of Funding</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. Upon a Default by Tenant hereunder and during the continuance thereof, Landlord shall have the right to suspend funding of any TI Allowance.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.62pt">Other Remedies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon a Default by Tenant hereunder and in addition to any other remedy available to Landlord under this Lease or otherwise, Landlord shall be entitled to recover damages from Tenant the amount of the unamortized portion of the Base Rent Abatement at the time of the Default. In addition to the remedies set forth in this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 21</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Landlord, at its option, without further notice or demand to Tenant, shall have all other rights and remedies provided at law or in equity</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Prevailing Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the event of any legal proceeding, litigation, or alternative dispute resolution between the parties respecting or arising out of this Lease, the prevailing party shall be entitled to recover its reasonable attorneys&#8217; fees and other costs in connection therewith, including, without limitation, any attorneys&#8217; fees incurred after a judgment has been entered by a court of competent jurisdiction.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:5.83pt">Consequential Damages</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. Notwithstanding anything herein contained in this Lease to the contrary, other than after a Default of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%"> or of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%;text-decoration:underline">Section 30</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">, Tenant shall not be liable to Landlord or Landlord Parties for any incidental, consequential, or punitive damages, or damages for lost profits.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:22.11pt">Assignment and Subletting</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Prohibition</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Without Landlord&#8217;s prior written consent subject to and on the conditions described in this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 22</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tenant shall not, directly or indirectly, voluntarily or by operation of law, assign this Lease or sublease the Premises or any part thereof or mortgage, pledge, or hypothecate its leasehold interest or grant any concession or license within the Premises, and any attempt to do any of the foregoing shall be void and of no effect. If Tenant is a corporation, partnership or limited liability company, the shares or other ownership interests thereof that are not actively traded upon a stock exchange or in the over-the-counter market, a transfer or series of transfers whereby 49% or more of the issued and outstanding shares or other ownership interests of such corporation are, or voting control is, transferred (but excepting transfers upon deaths of individual owners) from a person or persons or entity or entities that were owners thereof at time of execution of this Lease to persons or entities who</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18.15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were not owners of shares or other ownership interests of the corporation, partnership or limited liability company at time of execution of this Lease, shall be deemed an assignment of this Lease requiring the consent of Landlord as provided in this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 22</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 26</font></div></td></tr></table></div></div><div style="padding-left:18pt;padding-right:17.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Permitted Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If Tenant desires to assign, sublease, hypothecate or otherwise transfer this Lease or sublet the Premises other than pursuant to a Permitted Assignment (as defined below), then at least 10 days, but not more than 60 days, before the date Tenant desires the assignment or sublease to be effective (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assignment Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), Tenant shall give Landlord a notice (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assignment Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) containing such information about the proposed assignee or sublessee, including the proposed use of the Premises and any Hazardous Materials proposed to be used, stored handled, treated, generated in or released or disposed of from the Premises, the Assignment Date, any relationship between Tenant and the proposed assignee or sublessee, and all material terms and conditions of the proposed assignment or sublease, including a copy of any proposed assignment or sublease in its final form, and such other information as Landlord may deem reasonably necessary or appropriate to its consideration whether to grant its consent. Landlord may, by giving written notice to Tenant within 15 business days after receipt of the Assignment Notice&#58; (i) grant such consent, or (ii) refuse such consent, in its reasonable discretion (provided that Landlord shall have the right to review and approve or disapprove the proposed form of sublease prior to the effective date of any such subletting). No failure of Landlord to deliver a timely notice in response to the Assignment Notice shall be deemed to be Landlord&#8217;s consent to the proposed assignment, sublease or other transfer. Tenant shall pay to Landlord a fee equal to $1,500 in connection with its consideration of any Assignment Notice and&#47;or its preparation or review of any consent documents. Notwithstanding the foregoing, Landlord&#8217;s consent to an assignment of this Lease or a subletting of any portion of the Premises to any entity controlling, controlled by, or under common control with Tenant (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Permitted Assignment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) shall not be required, provided that Landlord shall have the right to approve the form of any such sublease or assignment.</font></div><div style="margin-top:0.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18.25pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:5.83pt">Additional Conditions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. As a condition to any such assignment or subletting, regardless of whether Landlord&#8217;s consent is required, Landlord may require&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:72pt;padding-right:18.1pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.12pt">that any assignee or subtenant agree, in writing at the time of such assignment or subletting, that if Landlord gives such party notice that Tenant is in default under this Lease, such party shall thereafter make all payments otherwise due Tenant directly to Landlord, which payments will be received by Landlord without any liability except to credit such payment against those due under this Lease, and any such third party shall agree to attorn to Landlord or its successors and assigns should this Lease be terminated for any reason&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in no event shall Landlord or its successors or assigns be obligated to accept such attornment&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A list of Hazardous Materials, certified by the proposed assignee or sublessee to be true and correct, which the proposed assignee or sublessee intends to use, store, handle, treat, generate in or release or dispose of from the Premises, together with copies of all documents relating to such use, storage, handling, treatment, generation, release or disposal of Hazardous Materials by the proposed assignee or subtenant in the Premises or on the Project, prior to the proposed assignment or subletting, including, without limitation&#58; permits&#59; approvals&#59; reports and correspondence&#59; storage and management plans&#59; plans relating to the installation of any storage tanks to be installed in or under the Project (provided, such installation of tanks shall only be permitted after Landlord has given its written consent to do so, which consent may be withheld in Landlord&#8217;s sole and absolute discretion)&#59; and all closure plans or any other documents required by any and all federal, state and local Governmental Authorities for any storage tanks installed in, on or under the Project for the closure of any such tanks. Neither Tenant nor any such proposed assignee or subtenant is required, however, to provide Landlord with any portion(s) of such documents containing information of a proprietary nature that, in and of themselves, do not contain a reference to any Hazardous Materials or hazardous activities.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.39pt">No Release of Tenant, Sharing of Excess Rents</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding any assignment or subletting, Tenant and any guarantor or surety of Tenant&#8217;s obligations under this Lease shall at all times remain fully and primarily responsible and liable for the payment of Rent and for compliance with all of </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 27</font></div></td></tr></table></div></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tenant&#8217;s other obligations under this Lease. If the Rent due and payable by a sublessee or assignee other than pursuant to a Permitted Assignment (or a combination of the rental payable under such sublease or assignment plus any bonus or other consideration therefor or incident thereto in any form) exceeds the sum of the rental payable under this Lease (excluding, however, any Rent payable under this Section) and actual and reasonable brokerage fees, marketing expenses, legal costs and any design or construction fees and construction allowances directly related to and required pursuant to the terms of any such sublease) (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Excess Rent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), then Tenant shall be bound and obligated to pay Landlord as Additional Rent hereunder 50% of the Excess Rent within 10 days following receipt thereof by Tenant. Landlord shall not be entitled to receive, and Excess Rent shall not include, any bona fide non-rent consideration paid in connection with a business sale or merger or other similar business transaction for which the assignment is necessary but fulfilling a larger purpose than solely the assignment. If Tenant shall sublet the Premises or any part thereof, Tenant hereby immediately and irrevocably assigns to Landlord, as security for Tenant&#8217;s obligations under this Lease, all rent from any such subletting, and Landlord as assignee and as attorney-in-fact for Tenant, or a receiver for Tenant appointed on Landlord&#8217;s application, may collect such rent and apply it toward Tenant&#8217;s obligations under this Lease&#59; except that, until the occurrence of a Default, Tenant shall have the right to collect such rent.</font></div><div style="margin-top:0.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">No Waiver</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The consent by Landlord to an assignment or subletting shall not relieve Tenant or any assignees of this Lease or any sublessees of the Premises from obtaining the consent of Landlord to any further assignment or subletting nor shall it release Tenant or any assignee or sublessee of Tenant from full and primary liability under this Lease. The acceptance of Rent hereunder, or the acceptance of performance of any other term, covenant, or condition thereof, from any other person or entity shall not be deemed to be a waiver of any of the provisions of this Lease or a consent to any subletting, assignment, or other transfer of the Premises.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Prior Conduct of Proposed Transferee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding any other provision of this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 22</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if (i) the proposed assignee or sublessee of Tenant has been required by any prior landlord, lender or Governmental Authority to take remedial action in connection with Hazardous Materials contaminating a property, where the contamination resulted from such party&#8217;s action or use of the property in question, (ii) the proposed assignee or sublessee is subject to an enforcement order issued by any Governmental Authority in connection with the use, storage, handling, treatment, generation, release or disposal of Hazardous Materials (including, without limitation, any order related to the failure to make a required reporting to any Governmental Authority), or (iii) because of the existence of a pre-existing environmental condition in the vicinity of or underlying the Project, the risk that Landlord would be targeted as a responsible party in connection with the remediation of such pre-existing environmental condition would be materially increased or exacerbated by the proposed use of Hazardous Materials by such proposed assignee or sublessee, Landlord shall have the absolute right to refuse to consent to any assignment or subletting to any such party.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estoppel Certificate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant shall, within 10 business days of written notice from Landlord, execute, acknowledge and deliver a statement in writing in any form reasonably requested by a proposed lender or purchaser, (i) certifying that this Lease is unmodified and in full force and effect (or, if modified, stating the nature of such modification and certifying that this Lease as so modified is in full force and effect) and the dates to which the rental and other charges are paid in advance, if any, (ii) acknowledging that there are not any uncured defaults on the part of Landlord hereunder, or specifying such defaults if any are claimed, and (iii) setting forth such further information with respect to the status of this Lease or the Premises as may be requested thereon. Any such statement may be relied upon by any prospective purchaser or encumbrancer of all or any portion of the real property of which the Premises are a part. Tenant&#8217;s failure to deliver such statement within such time shall, at the option of Landlord, be conclusive upon Tenant that this Lease is in full force and effect and without modification except as may be represented by Landlord in any certificate prepared by Landlord and delivered to Tenant for execution.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.5pt"><font><br></font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 28</font></div></td></tr></table></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:4.16pt">Quiet Enjoyment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. So long as Tenant shall perform all of the covenants and agreements herein required to be performed by Tenant, Tenant shall, subject to the terms of this Lease, at all times during the Term, have peaceful and quiet enjoyment of the Premises against any person claiming by, through or under Landlord.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:18.35pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">21.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:4.16pt">Prorations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. All prorations required or permitted to be made hereunder shall be made on the basis of a 360 day year and 30 day months.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:4.16pt">Rules and Regulations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant shall, at all times during the Term and any extension thereof, comply with all reasonable rules and regulations at any time or from time to time established by Landlord covering use of the Premises and the Project. The current rules and regulations are attached hereto as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit E</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If there is any conflict between such rules and regulations and other provisions of this Lease, the terms and provisions of this Lease shall control. Landlord shall not have any liability or obligation for the breach of any rules or regulations by other tenants in the Project and shall not enforce such rules and regulations in a discriminatory manner. Such rules and regulations may include, without limitation, rules and regulations relating to the use of the Project amenities and&#47;or rules and regulations that are intended to encourage social distancing, promote and protect health and physical well-being within the Building and the Project and&#47;or intended to prevent or limit the spread or transmission of Infectious Conditions.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:4.16pt">Subordination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Lease and Tenant&#8217;s interest and rights hereunder are hereby made and shall be subject and subordinate at all times to the lien of any Mortgage now existing or hereafter created on or against the Project or the Premises, and all amendments, restatements, renewals, modifications, consolidations, refinancing, assignments and extensions thereof, without the necessity of any further instrument or act on the part of Tenant&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that so long as no Default hereunder is continuing, Tenant&#8217;s right to possession of the Premises shall not be disturbed by the Holder of any such Mortgage. Tenant agrees, at the election of the Holder of any such Mortgage, to attorn to any such Holder. Tenant agrees upon demand to execute, acknowledge and deliver such instruments, confirming such subordination, and such instruments of attornment as shall be requested by any such Holder, provided any such instruments contain appropriate non-disturbance provisions assuring Tenant&#8217;s quiet enjoyment of the Premises as set forth in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 24</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereof. Notwithstanding the foregoing, any such Holder may at any time subordinate its Mortgage to this Lease, without Tenant&#8217;s consent, by notice in writing to Tenant, and thereupon this Lease shall be deemed prior to such Mortgage without regard to their respective dates of execution, delivery or recording and in that event such Holder shall have the same rights with respect to this Lease as though this Lease had been executed prior to the execution, delivery and recording of such Mortgage and had been assigned to such Holder. In securing any Mortgage on the Project, Landlord shall use its commercially reasonable efforts (but with no obligation to pay any out-of-pocket fees or sums) to obtain from any Holder of a first lien Mortgage at any time during the Term covering any or all of the Project or the Premises a non-disturbance agreement on Holder&#8217;s standard form (which is reasonably acceptable to Tenant and that shall not impose any additional material obligations on Tenant and shall not materially eliminate or reduce any rights granted to Tenant under this Lease), in favor of Tenant assuring Tenant&#8217;s quiet enjoyment of the Premises as set forth in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 24</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereof. The term &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mortgage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; whenever used in this Lease shall be deemed to include deeds of trust, security assignments and any other encumbrances, and any reference to the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holder</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of a Mortgage shall be deemed to include the beneficiary under a deed of trust unaffiliated with Landlord.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Surrender</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon the expiration of the Term or earlier termination of Tenant&#8217;s right of possession, Tenant shall surrender the Premises to Landlord in the same condition as received, subject to any Alterations or Installations permitted by Landlord to remain in the Premises, free of Hazardous Materials brought upon, kept, used, stored, handled, treated, generated in, or released or disposed of from, the Premises by any person other than Landlord or a Landlord Party (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tenant HazMat Operations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and released of all Hazardous Materials Clearances, broom clean, ordinary wear and tear and casualty loss and condemnation covered by </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 18</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">19</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> excepted. At least 3 months prior to the surrender of the Premises, Tenant shall deliver to Landlord a narrative description of the actions</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 29</font></div></td></tr></table></div></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proposed (or required by any Governmental Authority) to be taken by Tenant in order to surrender the Premises (including any Installations permitted by Landlord to remain in the Premises) at the expiration or earlier termination of the Term, free from any residual impact from the Tenant HazMat Operations and otherwise released for unrestricted use and occupancy (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Surrender Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Such Surrender Plan shall be accompanied by a current listing of (i) all Hazardous Materials licenses and permits held by or on behalf of any Tenant Party with respect to the Premises, and (ii) all Hazardous Materials used, stored, handled, treated, generated, released or disposed of from the Premises, and shall be subject to the review and approval of Landlord&#8217;s environmental consultant. In connection with the review and approval of the Surrender Plan, upon the request of Landlord, Tenant shall deliver to Landlord or its consultant such additional non-proprietary information concerning Tenant HazMat Operations as Landlord shall request. On or before such surrender, Tenant shall deliver to Landlord evidence that the approved Surrender Plan shall have been satisfactorily completed and Landlord shall have the right, subject to reimbursement as set forth below, to cause Landlord&#8217;s environmental consultant to inspect the Premises and perform such additional procedures as may be deemed reasonably necessary to confirm that the Premises are, as of the effective date of such surrender or early termination of this Lease, free from any residual impact from Tenant HazMat Operations. Tenant shall reimburse Landlord, as Additional Rent, for the actual out-of-pocket expense incurred by Landlord for Landlord&#8217;s environmental consultant to review and approve the Surrender Plan and to visit the Premises and verify satisfactory completion of the same, which cost shall not exceed $2,500. Landlord shall have the unrestricted right to deliver such Surrender Plan and any report by Landlord&#8217;s environmental consultant with respect to the surrender of the Premises to third parties.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Tenant shall fail to prepare or submit a Surrender Plan approved by Landlord, or if Tenant shall fail to complete the approved Surrender Plan, or if such Surrender Plan, regardless of whether approved by Landlord, shall fail to adequately address any residual effect consistent with best industry practices of Tenant HazMat Operations in, on or about the Premises, Landlord shall have the right to take such actions as Landlord may deem reasonable or appropriate to assure that the Premises and the Project are surrendered free from any residual impact from Tenant HazMat Operations, the cost of which actions shall be reimbursed by Tenant as Additional Rent, without regard to the limitation set forth in the first paragraph of this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 28</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Landlord shall provide no less than 50 access keys and&#47;or access cards to Tenant to provide access to the Premises. Upon the expiration or earlier termination of this Lease, Tenant shall immediately return to Landlord all keys and&#47;or access cards to parking, the Project, restrooms or all or any portion of the Premises furnished to or otherwise procured by Tenant. If any such access card or key is lost, Tenant shall pay to Landlord, at Landlord&#8217;s election, either the cost of replacing such lost access card or key or the cost of reprogramming the access security system in which such access card was used or changing the lock or locks opened by such lost key. Any Tenant&#8217;s Property, Alterations and property not so removed by Tenant as permitted or required herein shall be deemed abandoned and may be stored, removed, and disposed of by Landlord at Tenant&#8217;s expense, and Tenant waives all claims against Landlord for any damages resulting from Landlord&#8217;s retention and&#47;or disposition of such property. All obligations of Tenant hereunder not fully performed as of the termination of the Term, including the obligations of Tenant under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 30</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereof, shall survive the expiration or earlier termination of the Term, including, without limitation, indemnity obligations, payment obligations with respect to Rent and obligations concerning the condition and repair of the Premises.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:4.16pt">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. TENANT AND LANDLORD WAIVE ANY RIGHT TO TRIAL BY JURY OR TO HAVE A JURY PARTICIPATE IN RESOLVING ANY DISPUTE, WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE, BETWEEN LANDLORD AND TENANT ARISING OUT OF THIS LEASE OR ANY OTHER INSTRUMENT, DOCUMENT, OR AGREEMENT EXECUTED OR DELIVERED IN CONNECTION HEREWITH OR THE TRANSACTIONS RELATED HERETO.</font></div><div style="margin-top:0.6pt"><font><br></font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 30</font></div></td></tr></table></div></div><div style="padding-left:90pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Requirements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:90pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Prohibition&#47;Compliance&#47;Indemnity</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant shall not cause or permit any Hazardous Materials (as defined below) to be brought upon, kept, used, stored, handled, treated, generated in or about, or released or disposed of from, the Premises or the Project in violation of applicable Environmental Requirements (as defined below) by Tenant or any Tenant Party. If Tenant breaches the obligation stated in the preceding sentence, or if the presence of Hazardous Materials in the Premises during the Term or any holding over results in contamination of the Premises, the Project or any adjacent property or if contamination of the Premises, the Project or any adjacent property by Hazardous Materials brought into, kept, used, stored, handled, treated, generated in or about, or released or disposed of from, the Premises by anyone other than Landlord and Landlord&#8217;s employees, agents and contractors otherwise occurs during the Term or any holding over, Tenant hereby indemnifies and shall defend and hold Landlord, its officers, directors, employees, agents and contractors harmless from any and all actions (including, without limitation, remedial or enforcement actions of any kind, administrative or judicial proceedings, and orders or judgments arising out of or resulting therefrom), costs, claims, damages (including, without limitation, punitive damages and damages based upon diminution in value of the Premises or the Project, or the loss of, or restriction on, use of the Premises or any portion of the Project), expenses (including, without limitation, attorneys&#8217;, consultants&#8217; and experts&#8217; fees, court costs and amounts paid in settlement of any claims or actions), fines, forfeitures or other civil, administrative or criminal penalties, injunctive or other relief (regardless of whether based upon personal injury, property damage, or contamination of, or adverse effects upon, the environment, water tables or natural resources), liabilities or losses (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Claims</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) that arise during or after the Term as a result of such contamination&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that Tenant shall have no indemnification, remediation, or other obligation or responsibility under this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 30</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for any contamination or Environmental Claim if Tenant proves by a preponderance of the evidence that such contamination or Environmental Claim arises from any Hazardous Materials brought into, kept, used, stored, handled, treated, generated in or about, or released or disposed of from the Premises by Landlord, its employees or contractors, or another tenant unrelated or unaffiliated with Tenant or that existed in the Premises as of the Commencement Date and were not brought into, kept, used, stored, handled, treated, generated in or about, or released or disposed of from the Premises by Tenant, any Tenant Party, or any subtenant of Tenant or other occupant of the Premises. This indemnification of Landlord by Tenant includes, without limitation, costs incurred in connection with any investigation of site conditions or any cleanup, treatment, remedial, removal, or restoration work required by any federal, state or local Governmental Authority because of Hazardous Materials present in the air, soil or ground water above, on, or under the Premises. Without limiting the foregoing, if the presence of any Hazardous Materials on the Premises, the Project or any adjacent property caused or permitted by Tenant or any Tenant Party results in any contamination of the Premises, the Project or any adjacent property, Tenant shall promptly take all actions at its sole expense and in accordance with applicable Environmental Requirements as are necessary to return the Premises, the Project or any adjacent property to the condition existing prior to the time of such contamination, provided that Landlord&#8217;s approval of such action shall first be obtained, which approval shall not unreasonably be withheld so long as such actions would not potentially have any material adverse long-term or short-term effect on the Premises or the Project.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord acknowledges that it is not the intent of this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 30</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to prohibit Tenant from using the Premises for the Permitted Use. Tenant may operate its business according to prudent industry practices so long as the use or presence of Hazardous Materials is strictly and properly monitored according to all then applicable Environmental Requirements. As a material inducement to Landlord to allow Tenant to use Hazardous Materials in connection with its business, Tenant agrees to deliver to Landlord prior to the Commencement Date a list identifying each type of Hazardous Materials to be brought upon, kept, used, stored, handled, treated, generated on, or released or disposed of from, the Premises and setting forth any and all governmental approvals or permits required in connection with the presence, use, storage, handling, treatment, generation, release or disposal of such Hazardous Materials on or from the Premises (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hazardous </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 31</font></div></td></tr></table></div></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Materials List</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Tenant shall deliver to Landlord an updated Hazardous Materials List at least once a year and shall also deliver an updated list before any new Hazardous Material is brought onto, kept, used, stored, handled, treated, generated on, or released or disposed of from, the Premises. Tenant shall deliver to Landlord true and correct copies of the following</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">documents (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Haz Mat Documents</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) relating to the use, storage, handling, treatment, generation, release or disposal of Hazardous Materials prior to the Commencement Date, or if unavailable at that time, concurrent with the receipt from or submission to a Governmental Authority&#58; permits&#59; approvals&#59; reports and correspondence&#59; storage and management plans, notice of violations of any Legal Requirements&#59; plans relating to the installation of any storage tanks to be installed in or under the Project (provided, such installation of tanks shall only be permitted after Landlord has given Tenant its written consent to do so, which consent may be withheld in Landlord&#8217;s sole and absolute discretion)&#59; all closure plans or any other documents required by any and all federal, state and local Governmental Authorities for any storage tanks installed in, on or under the Project for the closure of any such tanks&#59; and a Surrender Plan (to the extent surrender in accordance with </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 28</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cannot be accomplished in 3 months). Tenant is not required, however, to provide Landlord with any portion(s) of the Haz Mat Documents containing information of a proprietary nature that, in and of themselves, do not contain a reference to any Hazardous Materials or hazardous activities. It is not the intent of this Section to provide Landlord with information that could be detrimental to Tenant&#8217;s business should such information become possessed by Tenant&#8217;s competitors.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Tenant Representation and Warranty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant hereby represents and warrants to Landlord that, as of the Commencement Date, (i) neither Tenant nor any of its legal predecessors has been required by any prior landlord, lender, or Governmental Authority at any time to take remedial action in connection with Hazardous Materials contaminating a property, which contamination was permitted by Tenant or such predecessor or resulted from Tenant&#8217;s or such predecessor&#8217;s action or use of the property in question, and (ii) Tenant is not subject to any enforcement order issued by any Governmental Authority in connection with the use, storage, handling, treatment, generation, release or disposal of Hazardous Materials (including, without limitation, any order related to the failure to make a required reporting to any Governmental Authority). If Landlord determines that this representation and warranty was not true as of the date of this Lease, Landlord shall have the right to terminate this Lease in Landlord&#8217;s sole and absolute discretion.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.39pt">Testing</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord shall have access to, and a right to perform inspections and tests of, the Premises and the Project to determine Tenant&#8217;s compliance with Environmental Requirements (as defined below), its obligations under this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 30</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or the environmental condition of the Premises and the Project. In connection with such testing, upon the request of Landlord, Tenant shall deliver to Landlord or its consultant such non-proprietary information concerning the use of Hazardous Materials in or about the Premises by Tenant or any Tenant Party. Access shall be granted to Landlord upon Landlord&#8217;s prior notice to Tenant and at such times so as to minimize, so far as may be reasonable under the circumstances, any disturbance to Tenant&#8217;s operations. Such inspections and tests shall be conducted at Landlord&#8217;s expense, unless such inspections or tests are conducted pursuant to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 21</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereof or reveal that Tenant has not complied with any Environmental Requirement, in which case Tenant shall reimburse Landlord for the reasonable cost of such inspection and tests. Tenant shall, at its sole cost and expense, promptly and satisfactorily remediate any environmental conditions identified by such testing in accordance with all Environmental Requirements. Landlord&#8217;s receipt of or satisfaction with any environmental assessment in no way waives any rights that Landlord may have against Tenant.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Underground Tanks</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under no circumstances whatsoever will Tenant have the right to install any underground storage tank on or about the Premises or the Project. If underground or other storage tanks storing Hazardous Materials located on the Premises or the Project before the Commencement Date are used by Tenant, Tenant shall install, use, monitor, operate, maintain, upgrade and manage such storage tanks, maintain appropriate records, obtain and maintain appropriate insurance, implement reporting </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 32</font></div></td></tr></table></div></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">procedures, properly close any underground storage tanks if required by applicable Legal Requirements, and take or cause to be taken all other actions necessary or required under applicable state and federal Legal Requirements, as such now exists or may hereafter be adopted or amended in connection with the installation, use, maintenance, management, operation, upgrading and closure of such storage tanks.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Control Areas</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Building contains a single control zone or area for the storage of up to 480 gallons of Hazardous Materials. Tenant shall be allowed to use its pro rata share of the control zone for Hazardous Materials use or storage, meaning that Tenant shall be allowed to use or store not more than 116.69 gallons (i.e., 24.31% of 480 gallons) of Hazardous Materials within the Premises.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Obligations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each party&#8217;s obligations under this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 30</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall survive the expiration or earlier termination of this Lease for the applicable statute of limitations period under federal, state, or local Legal Requirement. During any period of time after the expiration or earlier termination of this Lease required by Tenant or Landlord to complete the removal from the Premises of any Hazardous Materials (including, without limitation, the release and termination of any licenses or permits restricting the use of the Premises and the completion of the approved Surrender Plan), Tenant shall continue to pay the full Rent in accordance with this Lease for any portion of the Premises not relet by Landlord in Landlord&#8217;s sole discretion, which Rent shall be prorated daily.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.62pt">Definitions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As used herein, (i) the term &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Requirements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all applicable present and future statutes, regulations, ordinances, rules, codes, judgments, orders or other similar enactments of any Governmental Authority regulating or relating to health, safety, or environmental conditions on, under, or about the Premises or the Project, or the environment, including without limitation, the following&#58; the Comprehensive Environmental Response, Compensation and Liability Act&#59; the Resource Conservation and Recovery Act&#59; and all state and local counterparts thereto, and any regulations or policies promulgated or issued thereunder, and (ii) the term &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hazardous Materials</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means and includes any substance, material, waste, pollutant, or contaminant listed or defined as hazardous or toxic, or regulated by reason of its impact or potential impact on humans, animals and&#47;or the environment under any Environmental Requirements, asbestos and petroleum, including crude oil or any fraction thereof, natural gas liquids, liquefied natural gas, or synthetic gas usable for fuel (or mixtures of natural gas and such synthetic gas). As defined in Environmental Requirements, Tenant is and shall be deemed to be the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">operator</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Tenant&#8217;s &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">facility</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">owner</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of all Hazardous Materials brought on the Premises by Tenant or any Tenant Party, and the wastes, by-products, or residues generated, resulting, or produced therefrom.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">HazMat Storage Shed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant shall have the right, at its sole cost and expense, to install a Hazardous Materials storage shed (&#8220;&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HazMat Storage Shed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) on that portion of the Project shown on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit A-1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attached hereto, all in accordance with the Legal Requirements and the terms and conditions of this Section. The license granted hereby is personal to Tenant and shall not be assigned or otherwise pledged or transferred, directly or indirectly, except in connection with a Permitted Assignment and otherwise subject to the provisions of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 22</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the case of a Permitted Assignment involving an assignment of this Lease (as distinct from a sublease), assignor shall have no further right to use the HazMat Storage Shed. Subject to Section 1 of this Lease, Tenant shall have access to and egress from the HazMat Storage Shed 24 hours a day, 7 days a week.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Alterations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The installation and construction of the HazMat Storage Shed shall constitute an Alteration and comply with the applicable provisions of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that Landlord hereby approves the installation of a Hazmat Storage Shed that is no larger than the dimensions described in the quote obtained by Ewing Cole dated April 8, 2022 from U.S. Chemical Storage and agrees to cooperate with Tenant to provide final approval on the dimensions, type, and quality of shed as well as provide assistance, at Tenant&#8217;s sole cost and expense (if any), to procure and install the Hazmat Storage Shed at the Project. Landlord, however, makes no promise or guaranty that applicable Legal Requirements will allow the </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 33</font></div></td></tr></table></div></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">installation, construction, and placement of the HazMat Storage Shed. The HazMat Storage Shed shall be installed by a contractor reasonably acceptable to Landlord. Tenant shall, at its sole cost and expense, secure all necessary permits and approvals from all applicable Governmental Authorities for the size, placement, installation, and removal of the HazMat Storage Shed. If Tenant is unable to obtain the necessary approvals and permits from any Governmental Authorities for the HazMat Storage Shed, Tenant shall have no remedy, claim, cause of action, or recourse against Landlord, nor shall such failure or inability to obtain any necessary permits or approvals provide Tenant</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.65pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the right to terminate this Lease. Landlord shall cooperate with Tenant in securing all necessary permits and approvals for the HazMat Storage Shed, including reasonable adjustments to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A-1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> necessary to satisfy Governmental Authorities&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that Landlord shall not be obligated to spend any monies in connection with cooperating with Tenant or obtaining such permits and approvals and shall not be required to perform any act or otherwise take any action that would impose or create any liabilities on Landlord. Without limiting any other obligations of Tenant set forth in this Lease, Tenant shall, at its sole cost and expense, install, maintain, and repair the HazMat Storage Shed and keep the HazMat Storage Shed in good order and appearance.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.17pt">No Warranties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord makes no warranties of any kind, express or implied, with respect to the HazMat Storage Shed, and Landlord disclaims any such warranties. Without limiting the foregoing, Tenant expressly acknowledges and agrees that Landlord does not guaranty or warrant that the HazMat Storage Shed will be of sufficient capacity to accommodate Tenant&#8217;s use thereof or will function or perform adequately, and Landlord shall not be liable for any damages resulting from the failure of the HazMat Storage Shed.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.95pt">Storage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The storage of Hazardous Materials in the HazMat Storage Shed shall at all times comply strictly with applicable Environmental Requirements and Legal Requirements. Tenant shall be deemed to be the operator and owner of the HazMat Storage Shed. Tenant shall pay all costs, expenses, claims, fines, penalties, and damages that may in any manner arise out of or be imposed because of the failure of Tenant to comply with this Section. Tenant shall indemnify, defend, and hold harmless Landlord and its officers, members, directors, employees, managers, employees, agents, and contractors from all claims, injuries, damages, costs, expenses, losses, and liabilities (including, but not limited to, attorneys&#8217; fees) arising from Tenant&#8217;s failure to comply with this Section. Each party shall promptly give notice to the other of any notice of violation received by each party. Tenant shall retain all right, title, and interest in and to the Fuel Tank and all related infrastructure (including, but not limited to, piping, venting, and metering devices) during the Term, and Landlord hereby disclaims any right, title, and interest in and to the HazMat Storage Shed.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:4.73pt">Insurance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. If the presence of the HazMat Storage Shed is the sole cause of an increase in Landlord&#8217;s property or liability insurance premiums for the Project, Landlord shall so inform Tenant in writing and Tenant shall pay to Landlord as Additional Rent within 10 days after demand therefor an amount equal to such increase.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:4.17pt">Other Lease Provisions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Although the HazMat Storage Shed does not form a part of the Premises, all of the provisions of this Lease, including, without limitation, the insurance, maintenance, repair, release, indemnification, and Hazardous Materials Clearance provisions set forth in this Lease shall apply and be applicable to Tenant&#8217;s installation, placement, construction, operation, maintenance, and removal of the HazMat Storage Shed.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.39pt">Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If Tenant Defaults in its obligations under this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 30</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Landlord shall have the right, in addition to any other rights and remedies available to Landlord for a Default by Tenant, to terminate immediately Tenant&#8217;s license to use the HazMat Storage Shed. The expiration or </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 34</font></div></td></tr></table></div></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earlier termination of this Lease shall automatically terminate the license hereby granted to Tenant to so use the HazMat Storage Shed.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Removal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On the expiration or earlier termination of this Lease, (A) Tenant shall remove all Hazardous Materials from the HazMat Storage Shed and provide written confirmation reasonably acceptable to Landlord as part of the Surrender Plan that all Hazardous Materials have been removed in accordance with applicable Environmental Requirements and Legal Requirements and that the HazMat Storage Shed is free and clear of all Hazardous Materials, and (B) at Landlord&#8217;s request, Tenant shall remove the HazMat Storage Shed from the Premises in a good and workmanlike manner and in accordance with applicable Environmental Requirements and Legal Requirements and shall return the area on which the HazMat Storage Shed was located to the condition it was in prior to the installation</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Generator and HazMat Storage Shed. If Landlord does not direct that the HazMat Storage Shed be so removed, Landlord shall acquire sole ownership of the HazMat Storage Shed free and clear of all liens and encumbrances so that Landlord has good and marketable title thereto and Tenant shall execute and deliver to Landlord a bill of sale therefor (in the absence of a bill of sale, this Section shall constitute the bill of sale).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18.2pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">(vi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:4.17pt">Signage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. No promotional or advertising matter or signage shall be attached to, painted, or displayed on the exterior of the HazMat Storage Shed.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:4.16pt">Tenant&#8217;s Remedies&#47;Limitation of Liability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord shall not be in default hereunder unless Landlord fails to perform any of its obligations hereunder within 30 days after written notice from Tenant specifying such failure (unless such performance will, due to the nature of the obligation, require a period of time in excess of 30 days, then after such period of time as is reasonably necessary). Upon any default by Landlord, Tenant shall give notice by registered or certified mail to any Holder of a Mortgage covering the Premises and to any landlord of any lease of property in or on which the Premises are located and Tenant shall offer such Holder and&#47;or landlord a reasonable opportunity to cure the default, including time to obtain possession of the Project by power of sale or a judicial action if such should prove necessary to effect a cure&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Landlord shall have previously furnished to Tenant in writing the names and addresses of all such persons who are to receive such notices. All obligations of Landlord hereunder shall be construed as covenants, not conditions&#59; and, except as may be otherwise expressly provided in this Lease, Tenant may not terminate this Lease for breach of Landlord&#8217;s obligations hereunder.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, if any claimed Landlord default hereunder will immediately, materially, and adversely affect Tenant&#8217;s ability to conduct its business in the Premises (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Material Landlord Default</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), Tenant shall, as soon as reasonably possible, but in any event within 2 business days of obtaining knowledge of such claimed Material Landlord Default, give Landlord written notice of such claim and telephonic notice to Tenant&#8217;s principal contact with Landlord. Landlord shall then have 2 business days to commence cure of such claimed Material Landlord Default and shall diligently prosecute such cure to completion. If such claimed Material Landlord Default is not a default by Landlord hereunder, or if Tenant failed to give Landlord the notice required hereunder within 2 business days of learning of the conditions giving rise to the claimed Material Landlord Default, Landlord shall be entitled to recover from Tenant, as Additional Rent, any costs incurred by Landlord in connection with such cure in excess of the costs, if any, that Landlord would otherwise have been liable to pay hereunder. If Landlord fails to commence cure of any claimed Material Landlord Default as provided above, Tenant may commence and prosecute such cure to completion, and shall be entitled to recover the costs of such cure (but not any consequential or other damages) from Landlord, to the extent of Landlord&#8217;s obligation to cure such claimed Material Landlord Default hereunder, subject to the limitations set forth in this paragraph and the other provisions of this Lease. In no event whatsoever shall any curative action by Tenant</font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 35</font></div></td></tr></table></div></div><div style="margin-top:0.1pt;padding-left:18pt;padding-right:17.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) affect any Building Systems serving areas outside of the Premises, (b) interfere with another tenant&#8217;s operations at its premises at the Project or such tenant&#8217;s use and enjoyment of its premises at the Project, or (c) affect any portion of the Building&#8217;s structure, roof, or exterior.-</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All obligations of Landlord under this Lease will be binding upon Landlord only during the period of its ownership of the Premises and not thereafter. The term &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Landlord</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in this Lease shall mean only the owner for the time being of the Premises. Upon the transfer by such owner of its interest in the Premises, such owner shall thereupon be released and discharged from all obligations of Landlord thereafter accruing, but such obligations shall be binding during the Term upon each new owner for the duration of such owner&#8217;s ownership.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inspection and Access</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord and its agents, representatives, and contractors may enter the Premises at any reasonable time to inspect the Premises and to make such repairs as may be required or permitted pursuant to this Lease and for any other business purpose. Landlord and Landlord&#8217;s representatives may enter the Premises during business hours on not less than 3 business</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">days&#8217; advance written notice (except in the case of emergencies in which case no such notice shall be required and such entry may be at any time) for the purpose of effecting any such repairs, inspecting the Premises, showing the Premises to prospective purchasers and, during the last year of the Term, to prospective tenants or for any other business purpose. Landlord may erect a suitable sign on the Premises stating the Premises are available to let or that the Project is available for sale. Landlord may grant easements, make public dedications, designate Common Areas and create restrictions on or about the Premises, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that no such easement, dedication, designation or restriction materially, adversely affects Tenant&#8217;s use or occupancy of the Premises for the Permitted Use. At Landlord&#8217;s request, Tenant shall execute such instruments as may be necessary for such easements, dedications or restrictions. Tenant shall at all times, except in the case of emergencies, have the right to escort Landlord or its agents, representatives, contractors or guests while the same are in the Premises, provided such escort does not materially and adversely affect Landlord&#8217;s access rights hereunder.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:4.16pt">Security</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant acknowledges and agrees that security devices and services, if any, while intended to deter crime may not in given instances prevent theft or other criminal acts and that Landlord is not providing any security services with respect to the Premises. Tenant agrees that Landlord shall not be liable to Tenant for, and Tenant waives any claim against Landlord with respect to, any loss by theft or any other damage suffered or incurred by Tenant in connection with any unauthorized entry into the Premises or any other breach of security with respect to the Premises. Tenant shall be solely responsible for the personal safety of Tenant&#8217;s officers, employees, agents, contractors, guests and invitees while any such person is in, on or about the Premises and&#47;or the Project. Tenant shall at Tenant&#8217;s cost obtain insurance coverage to the extent Tenant desires protection against such criminal acts.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:4.16pt">Force Majeure</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Neither Landlord nor Tenant shall be responsible or liable for delays in the performance of its obligations hereunder when caused by, related to, or arising out of acts of God, strikes, lockouts, or other labor disputes, embargoes, quarantines, weather, national, regional, or local disasters, calamities, or catastrophes, inability to obtain labor or materials (or reasonable substitutes therefor) at reasonable costs or failure of, or inability to obtain, utilities necessary for performance, governmental restrictions, orders, limitations, regulations, or controls, national emergencies, delay in issuance or revocation of permits, enemy or hostile governmental action, terrorism, insurrection, riots, civil disturbance or commotion, fire or other casualty, and other causes or events beyond the reasonable control of such party (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Force Majeure</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that in no event shall Force Majeure excuse or delay either Landlord or Tenant from performing any monetary obligation under this Lease, or excuse or delay Tenant&#8217;s obligation to vacate and surrender timely the Premises in accordance with the terms and conditions of this Lease.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 36</font></div></td></tr></table></div></div><div style="padding-left:18pt;padding-right:17.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:4.16pt">Brokers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Broker</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) in connection with this transaction and that no Broker brought about this transaction, other than Scheer Partners, Inc. (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). SPI shall be paid by Landlord pursuant to a separate agreement between Landlord and SPI. Landlord and Tenant each hereby agree to indemnify and hold the other harmless from and against any claims by any Broker, other than SPI, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this leasing transaction.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitation on Landlord&#8217;s Liability. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTWITHSTANDING ANYTHING SET FORTH HEREIN OR IN ANY OTHER AGREEMENT BETWEEN LANDLORD AND TENANT TO THE CONTRARY&#58; (A) LANDLORD SHALL NOT BE LIABLE TO TENANT OR ANY OTHER PERSON FOR (AND TENANT AND EACH SUCH OTHER PERSON ASSUME ALL RISK OF) LOSS, DAMAGE OR INJURY, WHETHER ACTUAL OR CONSEQUENTIAL TO&#58; TENANT&#8217;S PERSONAL PROPERTY OF EVERY KIND AND DESCRIPTION, INCLUDING, WITHOUT LIMITATION TRADE FIXTURES, EQUIPMENT, INVENTORY, SCIENTIFIC RESEARCH, SCIENTIFIC EXPERIMENTS, LABORATORY ANIMALS, PRODUCT, SPECIMENS, SAMPLES, AND&#47;OR SCIENTIFIC, BUSINESS, ACCOUNTING AND OTHER RECORDS OF EVERY KIND AND DESCRIPTION KEPT AT THE PREMISES AND ANY</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AND ALL INCOME DERIVED OR DERIVABLE THEREFROM&#59; (B) THERE SHALL BE NO PERSONAL RECOURSE TO LANDLORD FOR ANY ACT OR OCCURRENCE IN, ON OR ABOUT THE PREMISES OR ARISING IN ANY WAY UNDER THIS LEASE OR ANY OTHER AGREEMENT BETWEEN LANDLORD AND TENANT WITH RESPECT TO THE SUBJECT MATTER HEREOF AND ANY LIABILITY OF LANDLORD HEREUNDER SHALL BE STRICTLY LIMITED SOLELY TO LANDLORD&#8217;S INTEREST IN THE PROJECT OR ANY PROCEEDS FROM SALE OR CONDEMNATION THEREOF AND ANY INSURANCE PROCEEDS PAYABLE IN RESPECT OF LANDLORD&#8217;S INTEREST IN THE PROJECT OR IN CONNECTION WITH ANY SUCH LOSS&#59; AND (C) IN NO EVENT SHALL ANY PERSONAL LIABILITY BE ASSERTED AGAINST ANY OF LANDLORD&#8217;S OFFICERS, DIRECTORS, EMPLOYEES, AGENTS OR CONTRACTORS. UNDER NO CIRCUMSTANCES SHALL LANDLORD OR ANY OF LANDLORD&#8217;S OFFICERS, DIRECTORS, EMPLOYEES, AGENTS OR CONTRACTORS BE LIABLE FOR INJURY TO TENANT&#8217;S BUSINESS OR FOR ANY LOSS OF INCOME OR PROFIT THEREFROM. TENANT ACKNOWLEDGES AND AGREES THAT MEASURES AND&#47;OR SERVICES IMPLEMENTED AT THE PROJECT, IF ANY, INTENDED TO ENCOURAGE SOCIAL DISTANCING, PROMOTE AND PROTECT HEALTH AND PHYSICAL WELL-BEING AND&#47;OR INTENDED TO PREVENT OR LIMIT THE SPREAD OR TRANSMISSION OF INFECTIOUS CONDITIONS, MAY NOT PREVENT OR LIMIT THE SPREAD OR TRANSMISSION OF SUCH INFECTIOUS CONDITIONS. LANDLORD SHALL HAVE NO LIABILITY AND TENANT IRREVOCABLY RELEASES AND WAIVES ANY CLAIMS AGAINST LANDLORD FOR ANY LOSS, DAMAGE, INJURY, OR DEATH IN CONNECTION WITH (X) THE IMPLEMENTATION, OR FAILURE OF LANDLORD OR ANY LANDLORD PARTIES TO IMPLEMENT, ANY MEASURES AND&#47;OR SERVICES AT THE PROJECT INTENDED TO ENCOURAGE SOCIAL DISTANCING, PROMOTE AND PROTECT HEALTH AND PHYSICAL WELL-BEING AND&#47;OR INTENDED TO PREVENT OR LIMIT THE SPREAD OR TRANSMISSION OF INFECTIOUS CONDITIONS, OR (Y) THE FAILURE OF ANY MEASURES AND&#47;OR SERVICES IMPLEMENTED AT THE PROJECT TO PREVENT OR LIMIT THE SPREAD OR TRANSMISSION OF ANY INFECTIOUS CONDITIONS.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:4.16pt">Severability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If any clause or provision of this Lease is illegal, invalid or unenforceable under present or future laws, then and in that event, it is the intention of the parties hereto that the remainder of this Lease shall not be affected thereby. It is also the intention of the parties to this Lease that in lieu of each clause or provision of this Lease that is illegal, invalid or unenforceable, there be added, as a part of this Lease, a clause or provision as similar in effect to such illegal, invalid or unenforceable clause or provision as shall be legal, valid and enforceable. This Lease, including the exhibits attached hereto, constitutes the entire agreement between Landlord and Tenant pertaining to the subject matter hereof and supersedes all prior agreements, understandings, letters of intent, negotiations, and discussions, whether </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 37</font></div></td></tr></table></div></div><div style="padding-left:18pt;padding-right:17.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oral or written, of the parties, and there are no warranties, representations, or other agreements, express or implied, made to either party by the other party in connection with the subject matter hereof except as specifically set forth herein or in the documents delivered pursuant hereto or in connection herewith.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signs&#59; Exterior Appearance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant shall not, without the prior written consent of Landlord, which may be granted or withheld in Landlord&#8217;s sole discretion&#58; (i) attach any awnings, exterior lights, decorations, balloons, flags, pennants, banners, painting or other projection to any outside wall of the Project, (ii) use any curtains, blinds, shades or screens other than Landlord&#8217;s standard window coverings, (iii) coat or otherwise sunscreen the interior or exterior of any windows, (iv) place any bottles, parcels, or other articles on the window sills, (v) place any equipment, furniture or other items of personal property on any exterior balcony, or (vi) paint, affix or exhibit on any part of the Premises or the Project any signs, notices, window or door lettering, placards, decorations, or advertising media of any type that can be viewed from the exterior of the Premises. Interior signs on doors and the directory tablet shall be inscribed, painted or affixed for Tenant by Landlord at the sole cost and expense of Tenant, and shall be of a size, color and type reasonably acceptable to Landlord. Nothing may be placed on the exterior of corridor walls or corridor doors other than Landlord&#8217;s standard lettering. The directory tablet shall be provided exclusively for the display of the name and location of tenants.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Identification Signage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant shall have the non-exclusive right, at its sole option, cost, and expense and in compliance with all applicable Legal Requirements, to install and affix to the exterior of the Building a single mounted, back-lit and electrified sign as desired by Tenant and permitted by applicable Legal Requirements (and related electrical connections and equipment) bearing the then-current name and the corporate logo of Tenant (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Identification Signage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Such right shall be personal to Vaccitech North America, Inc. and any transferee of this Lease or sublessee of all or any part of the Premises pursuant to a Permitted Assignment. Landlord shall have the right to approve the place, size, and design of the Identification Signage, which approval shall not be unreasonably withheld, delayed, or conditioned. Tenant shall, at its sole cost and expense, maintain the Identification Signage in first class condition and repair and have the right to replace, renovate, and&#47;or update the Identification Signage from time to time, subject to Landlord&#8217;s approval, which approval shall not be unreasonably withheld, delayed, or conditioned. On the expiration or earlier termination of the Term, Tenant shall, at its sole cost and expense, (i) remove the Identification Signage in a good and workmanlike manner and in compliance with all applicable Legal Requirements, and (ii) repair any damage to the fa&#231;ade or appearance of the Building caused by installation, replacement, renovation, updating and&#47;or removal of the Identification Signage.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:5.83pt">Monument Sign</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. Tenant shall have the non-exclusive right, at its sole cost and expense, to place its name&#47;corporate logo on the existing monument sign for the Project (the placement, size, and design of such name&#47;corporate logo shall be subject to Landlord&#8217;s reasonable approval).</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">30.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:4.16pt">Right to Extend Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. Tenant shall have the right to extend the Term of this Lease upon the following terms and conditions&#58;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:5.83pt">Extension Right</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. Tenant shall have a single right (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Extension Right</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8221;) to extend the term of this Lease for 5 years (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Extension Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8221;) on the same terms and conditions as this Lease (other than Base Rent) by giving Landlord written notice of its election to exercise the Extension Right at least 9 months prior, and no earlier than 12 months prior, to the expiration of the Base Term of this Lease.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Base Rent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon the commencement of the Extension Term, Base Rent shall be payable at the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">greater </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of (i) an amount determined by multiplying the Base Rent payable immediately before such adjustment by the Rent Adjustment Percentage and adding the resulting amount to the Base Rent payable immediately before such adjustment, and (ii) the Market Rate (as defined below). Base Rent shall thereafter be adjusted on each anniversary of the commencement of the Extension Term by a percentage as determined by Landlord and agreed to by Tenant at the time the Market Rate is determined. As used </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 38</font></div></td></tr></table></div></div><div style="padding-left:18pt;padding-right:17.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">herein, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Rate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the then fair market rental rate (including applicable market concessions) for comparable space in only those buildings of comparable age, location, and quality in the Germantown, Maryland submarket as determined by Landlord and agreed to by Tenant. Within 30 days of the delivery to Landlord of Tenant&#8217;s written notice of Tenant&#8217;s election to exercise the Extension Right, Landlord shall deliver to Tenant Landlord&#8217;s determination of the Market Rate and the rent escalations for the Extension Term, whereupon Landlord and Tenant shall use commercially reasonable efforts to negotiate in good faith the Market Rate and rent escalations for the Extension Term. If Landlord and Tenant are unable to agree on the Market Rate and rent escalations by the date that is 120 days before the expiration of the Base Term of this Lease, Tenant may by written notice to Landlord not later than 120 days prior to the expiration of the Base Term of this Lease elect arbitration as described in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 39(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below. If Tenant does not elect such arbitration, Tenant shall be deemed to have waived any right to extend the Term of this Lease and the Extension Right shall terminate.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Arbitration</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.65pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within 10 days of Tenant&#8217;s notice to Landlord of its election to arbitrate Market Rate and escalations, each party shall deliver to the other a proposal containing the Market Rate and escalations that the submitting party believes to be correct (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Extension Proposal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). If either party fails to timely submit an Extension Proposal, the other party&#8217;s submitted proposal shall determine the Market</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent and the escalations for the Extension Term. If both parties submit Extension Proposals, then Landlord and Tenant shall meet within 7 days after delivery of the last Extension Proposal and make a good faith attempt to mutually appoint a single Arbitrator (as defined below) to determine the Market Rate and escalations. If Landlord and Tenant are unable to agree upon a single Arbitrator, then each shall, by written notice delivered to the other within 10 days after the meeting, select an Arbitrator. If either party fails to timely give notice of its selection for an Arbitrator, the other party&#8217;s submitted proposal shall determine the Base Rent for the Extension Term. The 2 Arbitrators so appointed shall, within 5 business days after their appointment, appoint a third Arbitrator. If the 2 Arbitrators so selected cannot agree on the selection of the third Arbitrator within the time above specified, then either party, on behalf of both parties, may request such appointment of such third Arbitrator by application to any state court of general jurisdiction in the jurisdiction in which the Premises are located, upon 10 days prior written notice to the other party of such intent.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.17pt">The decision of the Arbitrator(s) shall be made within 30 days after the appointment of a single Arbitrator or the third Arbitrator, as applicable. The decision of the single Arbitrator shall be final and binding upon the parties. The average of the two closest Arbitrators in a three Arbitrator panel shall be final and binding upon the parties. Each party shall pay the fees and expenses of the Arbitrator appointed by or on behalf of such party and the fees and expenses of the third Arbitrator shall be borne equally by both parties. If the Market Rate and escalations are not determined by the first day of the Extension Term, then Tenant shall pay Landlord Base Rent in an amount equal to the Base Rent in effect immediately prior to the Extension Term and increased by the Rent Adjustment Percentage until such determination is made. After the determination of the Market Rate and escalations, the parties shall make any necessary adjustments to such payments made by Tenant. Landlord and Tenant shall then execute and deliver an amendment recognizing the Base Rent and escalations for the Extension Term.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.95pt">An &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arbitrator</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall be any person appointed by or on behalf of either party or appointed pursuant to the provisions hereof and&#58; (1) shall be (A) a member of the American Institute of Real Estate Appraisers with not less than 10 years of experience in the appraisal of improved office and high tech industrial real estate in the greater Rockville&#47;Germantown, Maryland metropolitan area, or (B) a licensed commercial real estate broker with not less than 15 years&#8217; experience representing landlords and&#47;or tenants in the leasing of high tech or life sciences space in the greater Rockville&#47;Germantown, Maryland metropolitan area, (2) devoting substantially all of their time to professional appraisal or </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 39</font></div></td></tr></table></div></div><div style="padding-left:18pt;padding-right:17.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">brokerage work, as applicable, at the time of appointment and (iii) be in all respects impartial and disinterested.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:5.83pt">Right Personal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. The Extension Right is personal to Tenant and is not assignable without Landlord&#8217;s consent, which may be granted or withheld in Landlord&#8217;s sole discretion separate and apart from any consent by Landlord to an assignment of Tenant&#8217;s interest in this Lease, except that the Extension Right may be assigned in connection with any Permitted Assignment.</font></div><div><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Exceptions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding anything set forth above to the contrary, the Extension Right shall not be in effect and Tenant may not exercise the Extension Right&#58; (i) during any period of time that Tenant is in Default under any provision of this Lease&#59; or (ii) if Tenant has been in Default under any provision of this Lease 3 or more times, regardless of whether the Defaults are cured, during the 12 month period immediately prior to the date that Tenant intends to exercise the Extension Right, regardless of whether the Defaults are cured.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:8.62pt">No Extensions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. The period of time within which the Extension Right may be exercised shall not be extended or enlarged by reason of Tenant&#8217;s inability to exercise the Extension Right.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. The Extension Right shall terminate and be of no further force or effect even after Tenant&#8217;s due and timely exercise of the Extension Right, if, after such exercise, but prior to the commencement date of the Extension Term, (i) Tenant fails to timely cure any default by Tenant under</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18.1pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this Lease&#59; or (ii) Tenant has Defaulted 3 or more times during the period from the date of the exercise of the Extension Right to the date of the commencement of the Extension Term, regardless of whether such Defaults are cured.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:4.16pt">Roof Equipment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant shall have the right at its sole cost and expense, subject to compliance with all Legal Requirements, to install, maintain, and remove on the top of the roof of the Building (based on Tenant&#8217;s proportionate share of the space available on the roof) directly above the Premises one or more satellite dishes, communication antennae, or other equipment such as HVAC and exhaust stacks&#47;fans (all of which having a diameter and height acceptable to Landlord) for the transmission or reception of communication of signals as Tenant may from time to time desire as well as ductwork&#47;conduit to connect such equipment to the Premises (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Roof Equipment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) on the following terms and conditions&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Requirements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant shall submit to Landlord (i) the plans and specifications for the installation of the Roof Equipment, (ii) copies of all required governmental and quasi-governmental permits, licenses, and authorizations that Tenant will and must obtain at its own expense, with the cooperation of Landlord, if necessary for the installation and operation of the Roof Equipment, and (iii) an insurance policy or certificate of insurance evidencing insurance coverage as required by this Lease and any other insurance as reasonably required by Landlord for the installation and operation of the Roof Equipment. Landlord shall not unreasonably withhold or delay its approval for the installation and operation of the Roof Equipment&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that Landlord may reasonably withhold its approval if the installation or operation of the Roof Equipment (A) may damage the structural integrity of the Building, (B) may void, terminate, or invalidate any applicable roof warranty, (C) may interfere with any service provided by Landlord or any tenant of the Building, (D) may reduce the leasable space in the Building, or (E) is not properly screened from the viewing public.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">No Damage to Roof</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If installation of the Roof Equipment requires Tenant to make any roof cuts or perform any other roofing work, such cuts shall only be made to the roof area of the Building located directly above the Premises and only in the manner designated in writing by Landlord&#59; and any such installation work (including any roof cuts or other roofing work) shall be performed by Tenant, at </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 40</font></div></td></tr></table></div></div><div style="padding-left:18pt;padding-right:17.65pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tenant&#8217;s sole cost and expense by a roofing contractor designated by Landlord. If Tenant or its agents shall otherwise cause any damage to the roof during the installation, operation, and removal of the Roof Equipment such damage shall be repaired promptly at Tenant&#8217;s expense and the roof shall be restored in the same condition it was in before the damage. Landlord shall not charge Tenant Additional Rent for the installation and use of the Roof Equipment. If, however, Landlord&#8217;s insurance premium or Tax assessment increases as a result of the Roof Equipment, Tenant shall pay such increase as Additional Rent within 10 days after receipt of a reasonably detailed invoice from Landlord. Tenant shall not be entitled to any abatement or reduction in the amount of Rent payable under this Lease if for any reason Tenant is unable to use the Roof Equipment. In no event whatsoever shall the installation, operation, maintenance, or removal of the Roof Equipment by Tenant or its agents void, terminate, or invalidate any applicable roof warranty.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:6.39pt">Protection</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. The installation, operation, and removal of the Roof Equipment shall be at Tenant&#8217;s sole risk. Tenant shall indemnify, defend, and hold Landlord harmless from and against any and all claims, costs, damages, liabilities and expenses (including, but not limited to, attorneys&#8217; fees) of every kind and description that may arise out of or be connected in any way with Tenant&#8217;s installation, operation, or removal of the Roof Equipment.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Removal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. At the expiration or earlier termination of this Lease or the discontinuance of the use of the Roof Equipment by Tenant, Tenant shall, at its sole cost and expense, remove the Roof Equipment from the Building&#59; provided, however, that within 5 business days after Landlord&#8217;s receipt of Tenant&#8217;s request to install Roof Equipment (which request shall provide reasonably detailed information about the proposed Roof Equipment), Landlord shall notify Tenant whether Landlord will require Tenant to remove the Roof Equipment at the expiration or earlier termination of this Lease. Such request shall</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">state the following in all capital letters in at least 12 point bold typeface&#58; &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TENANT HEREBY REQUESTS CONFIRMATION FROM LANDLORD WHETHER THE ROOF EQUIPMENT DESCRIBED IN THIS REQUEST WILL NEED TO BE REMOVED BY TENANT AT THE EXPIRATION OR EARLIER</font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TERMINATION OF THE LEASE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; Tenant shall leave the portion of the roof where the Roof Equipment was located in good order and repair, reasonable wear and tear excepted. If Tenant does not so remove the Roof Equipment, Tenant hereby authorizes Landlord to remove and dispose of the Roof Equipment and charge Tenant as Additional Rent for all costs and expenses incurred by Landlord in such removal and disposal. Tenant agrees that Landlord shall not be liable for any Roof Equipment or related property disposed of or removed by Landlord.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">No Interference</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Roof Equipment shall not cause measurable interference (as defined by applicable Legal Requirement) with the proper functioning of any telecommunications equipment or devices that have been installed or will be installed by Landlord or for any other tenant or future tenant of the Building. Tenant acknowledges that other tenant(s) with leases prior in time to that of this Lease may have approval rights over the installation and operation of telecommunications equipment and devices on or about the roof, and that Tenant&#8217;s right to install and operate the Roof Equipment is subject and subordinate only to the rights of such other tenants. Tenant agrees that any other tenant of the Building that currently has or in the future takes possession of any portion of the Building will be permitted to install such telecommunication equipment that is of a type and frequency that will not cause measurable interference to the Roof Equipment.</font></div><div style="margin-top:0.65pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Relocation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord shall have the right, at its expense and after 60 days prior notice to Tenant, to relocate the Roof Equipment to another site on the roof of the Building as long as such site reasonably meets Tenant&#8217;s sight line and interference requirements and does not unreasonably interfere with Tenant&#8217;s use and operation of the Roof Equipment&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that in no event shall Landlord have the right to relocate any chemical fume hoods, roof mounted HVAC unit(s), or exhaust systems serving the Premises.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 41</font></div></td></tr></table></div></div><div style="padding-left:18pt;padding-right:18.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.62pt">Access</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord grants to Tenant the right of ingress and egress on a 24 hour 7 day per week basis to install, operate, and maintain the Roof Equipment. Before receiving access to the roof of the Building, Tenant shall give Landlord at least 24 hours&#8217; advance written or oral notice, except in emergency situations, in which case 2 hours&#8217; advance oral notice shall be given by Tenant. Landlord shall supply Tenant with the name, telephone, and pager numbers of the contact individual(s) responsible for providing access during emergencies.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:5.83pt">Appearance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. If permissible by Legal Requirements, the Roof Equipment shall be painted the same color as the Building so as to render the Roof Equipment virtually invisible from ground level.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">No Assignment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The right of Tenant to use and operate the Roof Equipment shall be personal solely to Vaccitech North America, Inc., and (i) no other person or entity shall have any right to use or operate the Roof Equipment, and (ii) Tenant shall not assign, convey, or otherwise transfer to any person or entity any right, title, or interest in all or any portion of the Roof Equipment or the use and operation thereof, except that Tenant&#8217;s right to use and operate the Roof Equipment may be assigned in connection with any Permitted Assignment.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:22.11pt">Right to Negotiate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expansion in the Building</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If at any time during the Term, and a continual and on-going basis, any Available Space (as defined below) in the Building becomes available for lease, Landlord shall give notice of such availability to Tenant. (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Availability Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Availability Notice shall set forth the basic terms and conditions for the lease of the Available Space (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Space Terms</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Tenant shall respond to the Availability Notice within 10 business days after receipt thereof, which response shall state that Tenant either (i) declines to lease the Available Space, (ii) agrees to lease</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Available Space on the terms set forth in the Availability Notice (including the Available Space Terms), in which event Landlord and Tenant shall within 60 days thereafter execute and deliver an amendment to this Lease or a lease agreement for the Available Space (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Negotiation Right</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). If after the expiration of such 60 day period, no lease amendment or lease agreement for the Available Space has been executed and delivered, the Negotiation Right shall be waived and of no further force or effect with respect to such Available Space for a period of 180 days. Provided that no right to expand is exercised by any tenant with superior rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tenant shall be entitled to lease such Available Space upon the terms and conditions, if any, agreed to by Landlord and Tenant. The Negotiation Right is subject and subordinate to the rights of Amador Bioscience, Inc., a Delaware corporation, and its successors and assigns, with respect to the Available Space.</font></div><div style="margin-top:11.4pt;padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Available Space</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For purposes of this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 41(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Space</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean any space in the Project that is not occupied by a tenant or that is occupied by an existing tenant whose lease is expiring within 6 months or less and such tenant does not wish to renew (regardless of whether such tenant has a right to renew) its occupancy of such space.</font></div><div><font><br></font></div><div style="padding-left:18pt;padding-right:17.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Exceptions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding the above, the Negotiation Right shall not be in effect and may not be exercised by Tenant&#58; (i) during any period of time that Tenant is in Default under any provision of this Lease&#59; or (ii) if Tenant has been in Default under any provision of this Lease 3 or more times, regardless of whether the Defaults are cured, during the 12 month period prior to the date on which Tenant seeks to exercise the Negotiation Right.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.39pt">Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Negotiation Right shall terminate and be of no further force or effect even after Tenant&#8217;s due and timely exercise of the Negotiation Right, if, after such exercise, but prior to the commencement date of the lease of such Available Space, (i) Tenant fails to timely cure any default by Tenant under this Lease&#59; or (ii) Tenant has Defaulted 3 or more times during the period from the date of </font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 42</font></div></td></tr></table></div></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:17.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the exercise of the Negotiation Right to the date of the commencement of the lease of the Available Space, regardless of whether such Defaults are cured.</font></div><div><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Right Personal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Negotiation Right is personal to Tenant and is not assignable without Landlord&#8217;s consent, which may be granted or withheld in Landlord&#8217;s sole discretion separate and apart from any consent by Landlord to an assignment of Tenant&#8217;s interest in this Lease, except that the Negotiation Right may be assigned in connection with any Permitted Assignment of this Lease.</font></div><div><font><br></font></div><div style="padding-left:18pt;padding-right:17.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:5.83pt">No Extensions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. The period of time within which the Negotiation Right may be exercised shall not be extended or enlarged by reason of Tenant&#8217;s inability to exercise the Negotiation Right.</font></div><div style="margin-top:11.35pt;padding-left:90pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:22.11pt">Miscellaneous</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Notices</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All notices or other communications between the parties shall be in writing and shall be deemed duly given upon delivery or refusal to accept delivery by the addressee thereof if delivered in person, or upon actual receipt if delivered by reputable overnight guaranty courier, addressed and sent to the parties at their addresses set forth above. Landlord and Tenant may from time to time by written notice to the other designate another address for receipt of future notices.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:5.83pt">Joint and Several Liability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. If and when included within the term &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Tenant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">,&#8221; as used in this instrument, there is more than one person or entity, each shall be jointly and severally liable for the obligations of Tenant.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In connection with a sale or financing of the Project, or following a Default, Tenant shall furnish Landlord with true and complete copies of Tenant&#8217;s most recent annual financial statements (at Tenant&#8217;s option, such annual financial statements shall either be audited or certified by an officer of Tenant, but Tenant shall be under no obligation to create any financial statements merely to respond to Landlord's request in this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 42(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) within 120 days (or such longer period as</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.65pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may be reasonably required for an audit if Tenant is providing audited financial statements) of the end of each of Tenant&#8217;s fiscal years during the Term. Notwithstanding the foregoing provisions of this paragraph, (i) if this Lease is assigned by the originally named Tenant in this Lease pursuant to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">22</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or (ii) if Tenant&#8217;s parent entity, Vaccitech plc, is acquired or the shares of Vaccitech plc are no longer traded on a public stock exchange, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">then</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tenant shall upon written request from Landlord furnish Landlord with true and complete copies of Tenant&#8217;s most recent unaudited quarterly financial statements within 45 days of the end of each of Tenant&#8217;s fiscal quarters during each of Tenant&#8217;s fiscal years during the Term. All such statements shall be treated by Landlord as confidential information belonging to Tenant.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:6.39pt">Recordation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. Neither this Lease nor a memorandum of lease shall be filed by or on behalf of Tenant in any public record. Landlord may prepare and file, and upon request by Landlord Tenant will execute, a memorandum of lease, but any such recordation shall be at Landlord&#8217;s sole cost and expense.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Interpretation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Lease or any exhibits or amendments hereto. Words of any gender used in this Lease shall be held and construed to include any other gender, and words in the singular number shall be held to include the plural, unless the context otherwise requires. The captions inserted in this Lease are for convenience only and in no way define, limit or otherwise describe the scope or intent of this Lease, or any provision hereof, or in any way affect the interpretation of this Lease.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 43</font></div></td></tr></table></div></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:18.3pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">Not Binding Until Executed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The submission by Landlord to Tenant of this Lease shall have no binding force or effect, shall not constitute an option for the leasing of the Premises, nor confer any right or impose any obligations upon either party until execution of this Lease by both parties.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.62pt">Limitations on Interest</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. It is expressly the intent of Landlord and Tenant at all times to comply with applicable law governing the maximum rate or amount of any interest payable on or in connection with this Lease. If applicable law is ever judicially interpreted so as to render usurious any interest called for under this Lease, or contracted for, charged, taken, reserved, or received with respect to this Lease, then it is Landlord&#8217;s and Tenant&#8217;s express intent that all excess amounts theretofore collected by Landlord be credited on the applicable obligation (or, if the obligation has been or would thereby be paid in full, refunded to Tenant), and the provisions of this Lease immediately shall be deemed reformed and the amounts thereafter collectible hereunder reduced, without the necessity of the execution of any new document, so as to comply with the applicable law, but so as to permit the recovery of the fullest amount otherwise called for hereunder.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18.45pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:5.83pt">Choice of Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. Construction and interpretation of this Lease shall be governed by the internal laws of the state in which the Premises are located, excluding any principles of conflicts of laws.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:90pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Time</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Time is of the essence as to the performance of Tenant&#8217;s obligations under this</font></div><div style="margin-top:0.1pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFAC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant, and all beneficial owners of Tenant, are currently (i) in compliance with and shall at all times during the Term of this Lease remain in compliance with the regulations of the Office of Foreign Assets Control (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFAC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of the U.S. Department of Treasury and any statute, executive order, or regulation relating thereto (collectively, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFAC Rules</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), (ii) not listed on, and shall not during the Term of this Lease be listed on, the Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List, or the Sectoral Sanctions Identifications List, which are all maintained by OFAC and&#47;or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (iii) not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:9.17pt">Incorporation by Reference</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">. All exhibits and addenda attached hereto are hereby incorporated into this Lease and made a part hereof. If there is any conflict between such exhibits or addenda and the terms of this Lease, such exhibits or addenda shall control.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.17pt">No Accord and Satisfaction</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No payment by Tenant or receipt by Landlord of a lesser amount than the monthly installment of Base Rent or any Additional Rent will be other than on account of the earliest stipulated Base Rent and Additional Rent, nor will any endorsement or statement on any check or letter accompanying a check for payment of any Base Rent or Additional Rent be an accord and satisfaction. Landlord may accept such check or payment without prejudice to Landlord&#8217;s right to recover the balance of such Rent or to pursue any other remedy provided in this Lease.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.39pt">Non-Disclosure of Terms</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant acknowledges and agrees that the terms of this Lease are confidential and constitute proprietary information of Landlord. Disclosure of such terms could adversely affect the ability of Landlord and its affiliates to negotiate, manage, and administer other leases and impair Landlord&#8217;s relationship with other tenants. Accordingly, as a material inducement for Landlord to enter into this Lease, Tenant, on behalf of itself and its partners, managers, members, officers, directors, employees, agents, and attorneys, agrees that it shall not intentionally and voluntarily disclose the terms and conditions of this Lease to any publication or other media or any tenant or apparent prospective tenant of the Building or other portion of the Project, or real estate agent or broker, either directly or indirectly.</font></div><div style="margin-top:0.6pt"><font><br></font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 44</font></div></td></tr></table></div></div><div style="padding-left:18pt;padding-right:17.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.17pt">Counterparts&#47;Electronic Signatures</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Lease may be executed in 2 or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature process complying with the U.S. federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. Electronic signatures shall be deemed original signatures for purposes of this Lease and all matters related thereto, with such electronic signatures having the same legal effect as original signatures.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:18pt;padding-right:17.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:3.06pt">Hazardous Activities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding any other provision of this Lease, Landlord, for itself and its employees, agents and contractors, reserves the right to refuse to perform any repairs or services in any portion of the Premises that, pursuant to Tenant&#8217;s routine safety guidelines, practices or custom or prudent industry practices, require any form of protective clothing or equipment other than safety glasses. In any such case, Tenant shall contract with parties who are acceptable to Landlord, in Landlord&#8217;s reasonable discretion, for all such repairs and services, and Landlord shall, to the extent required, equitably adjust Tenant&#8217;s Share of Operating Expenses in respect of such repairs or services to reflect that Landlord is not providing such repairs or services to Tenant.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18.2pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.83pt">LEED</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant acknowledges that Landlord may, but shall not be obligated to, seek to obtain Leadership in Energy and Environmental Design (LEED), WELL Building Standard, or other similar &#8220;green&#8221; certification for the Project and&#47;or the Premises, and Tenant agrees to reasonably cooperate with Landlord, and to provide such information and&#47;or documentation as Landlord may reasonably request, in connection therewith.</font></div><div style="margin-top:6.05pt"><font><br></font></div><div style="padding-left:45pt;padding-right:45pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91; Signatures on next page &#93;</font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:46.8pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.255%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 20400 Century Boulevard&#8212;Vaccitech North America, Inc.&#8212;Page 45</font></div></td></tr></table></div></div><div style="padding-left:45pt;padding-right:45pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:25.55pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, Landlord and Tenant have executed this Lease under seal as of the day and year first above written.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:32.47pt;padding-right:32.47pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">TENANT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:198.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VACCITECH NORTH AMERICA, INC.,</font></div><div style="padding-left:198.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a Delaware corporation</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:198.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> &#47;s&#47; William Enright </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(SEAL)</font></div><div style="margin-top:0.1pt;padding-left:198.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:11.45pt">Name&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:11.45pt">William Enright</font></div><div style="padding-left:229.95pt"><img alt="image_4.jpg" src="image_4.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:185px"></div><div style="padding-left:198.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:10.45pt">Title&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:10.45pt;text-decoration:underline"> CEO&#160;&#160;&#160;&#160;</font></div><div style="margin-top:2.05pt"><font><br></font></div><div style="padding-left:202.6pt;padding-right:85.9pt;text-indent:-0.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:111%">X</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:111%">&#9633; I hereby certify that the signature, name, and title above are my signature, name, and title.</font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:198.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">LANDLORD</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:198.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:11.45pt">ARE-MARYLAND NO. 52, LLC,</font></div><div style="padding-left:198.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:11.45pt">a Delaware limited liability company</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:234.05pt;padding-right:103.9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;Alexandria Real Estate Equities, L.P., a Delaware limited partnership, managing member</font></div><div style="margin-top:11.45pt;padding-left:234.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;ARE-QRS CORP.,</font></div><div style="margin-top:0.05pt;padding-left:270.05pt;padding-right:103.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a Maryland corporation, general partner</font></div><div><font><br></font></div><div style="margin-top:11.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:270.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Gregory Kay </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(SEAL)</font></div><div style="margin-top:0.1pt;padding-left:270.05pt"><img alt="image_5.jpg" src="image_5.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:133px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:11.35pt">Name&#58;_Gregory Kay</font></div><div style="padding-left:270.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:12.15pt">Title&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:12.15pt;text-decoration:underline">SVP - Real Estate Le</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:12.15pt">gal Affairs</font></div><div><font><br></font></div><div style="margin-top:4.5pt"><font><br></font></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">Copyright &#169; 2007, Alexandria Real Estate Equities, Inc. ALL RIGHTS RESERVED. Confidential and Proprietary &#8211; Do Not Copy or Distribute. Alexandria and the Alexandria Logo are registered trademarks of Alexandria Real Estate Equities, Inc.</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>brns-20251231xex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ib965cab018bf438b94ac6b0dcffc01df_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 21.1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">SUBSIDIARIES</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:49.950%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.266%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Subsidiary</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Jurisdiction of Incorporation</font></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Barinthus Biotherapeutics Pty Limited (formerly Vaccitech Australia Pty Limited)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vaccitech Oncology Limited</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Barinthus Biotherapeutics (UK) Limited (formerly Vaccitech (UK) Limited)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Barinthus Biotherapeutics North America, Inc. (formerly Vaccitech North America, Inc.)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Barinthus Biotherapeutics Switzerland GmbH (formerly Vaccitech Switzerland GmbH)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Beacon Topco, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cdog Merger Sub, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>exhibit231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="id961b8628b204fbaa5fc2a51bd659386_1"></div><div style="min-height:151.92pt;width:100%"><div style="margin-bottom:100pt"><font><br></font></div></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-285968, No. 333-278111, No. 333-270815, No. 333-263844, No. 333-255664) of Barinthus Biotherapeutics plc of our report dated March 13, 2026 relating to the financial statements, which appears in this Form 10-K.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; PricewaterhouseCoopers LLP<br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">Reading, United Kingdom</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">March 13, 2026</font></div><div style="margin-bottom:8pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>brns-20251231xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ibe7f1c1c697a452bb3c5e57d7c28d466_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">RULES 13a-14</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">AND 15d-14</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">I, William Enright, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K for the year ended December&#160;31, 2025 of Barinthus Biotherapeutics plc&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:46.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58; March&#160;13, 2026</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; William Enright</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">William Enright</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Title&#58; Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>brns-20251231xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i157cadc5394f43ed8144cdea4ce76ac4_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 31</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">RULES 13a-14</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">AND 15d-14</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">I, William Enright, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K for the year ended December&#160;31, 2025 of Barinthus Biotherapeutics plc&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:46.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58; March&#160;13, 2026</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; William Enright</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">William Enright</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Title&#58; Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(Principal Financial Officer) </font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>brns-20251231xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i77d4053697894b02a47b7f6f5fe038e9_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 32</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">CERTIFICATIONS PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">18 U</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">S</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">C</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">SECTION 1350</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Annual Report of Barinthus Biotherapeutics plc (the &#8220;Company&#8221;) on Form 10-K for the fiscal year ending December&#160;31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company certifies, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, to the best of his or her knowledge that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.969%"><tr><td style="width:1.0%"></td><td style="width:42.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.118%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58; March&#160;13, 2026</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; William Enright</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">William Enright</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Title&#58; Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(Principal Executive Officer and Principal Financial Officer) </font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>brns-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019b097a-6c16-78f4-806b-17184aaccbef,g:d518a941-6ac7-4029-9d1f-6f039bd073d0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:brns="http://www.barinthusbio.com/20251231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.barinthusbio.com/20251231">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="brns-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="brns-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="brns-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="brns-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.barinthusbio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.barinthusbio.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>9952151 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>9952154 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentation" roleURI="http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentation">
        <link:definition>9952156 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952157 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segmentinformation" roleURI="http://www.barinthusbio.com/role/Segmentinformation">
        <link:definition>9952158 - Disclosure - Segment information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ForeignCurrencyTranslationinGeneralandAdministrativeExpenses" roleURI="http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpenses">
        <link:definition>9952159 - Disclosure - Foreign Currency Translation in General and Administrative Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.barinthusbio.com/role/NetLossPerShare">
        <link:definition>9952160 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNet">
        <link:definition>9952161 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNet" roleURI="http://www.barinthusbio.com/role/IntangibleAssetsNet">
        <link:definition>9952162 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidandOtherCurrentAssets" roleURI="http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssets">
        <link:definition>9952163 - Disclosure - Prepaid and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>9952164 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantIncome" roleURI="http://www.barinthusbio.com/role/GrantIncome">
        <link:definition>9952165 - Disclosure - Grant Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrdinaryShares" roleURI="http://www.barinthusbio.com/role/OrdinaryShares">
        <link:definition>9952166 - Disclosure - Ordinary Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredShares" roleURI="http://www.barinthusbio.com/role/DeferredShares">
        <link:definition>9952167 - Disclosure - Deferred Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValue" roleURI="http://www.barinthusbio.com/role/FairValue">
        <link:definition>9952168 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.barinthusbio.com/role/ShareBasedCompensation">
        <link:definition>9952169 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.barinthusbio.com/role/IncomeTaxes">
        <link:definition>9952170 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.barinthusbio.com/role/CommitmentsandContingencies">
        <link:definition>9952171 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.barinthusbio.com/role/EmployeeBenefitPlans">
        <link:definition>9952172 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.barinthusbio.com/role/RelatedPartyTransactions">
        <link:definition>9952173 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.barinthusbio.com/role/SubsequentEvents">
        <link:definition>9952174 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationTables" roleURI="http://www.barinthusbio.com/role/SegmentinformationTables">
        <link:definition>9955513 - Disclosure - Segment information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.barinthusbio.com/role/NetLossPerShareTables">
        <link:definition>9955514 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNetTables">
        <link:definition>9955515 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidandOtherCurrentAssetsTables" roleURI="http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsTables">
        <link:definition>9955516 - Disclosure - Prepaid and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>9955517 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantIncomeTables" roleURI="http://www.barinthusbio.com/role/GrantIncomeTables">
        <link:definition>9955518 - Disclosure - Grant Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrdinarySharesTables" roleURI="http://www.barinthusbio.com/role/OrdinarySharesTables">
        <link:definition>9955519 - Disclosure - Ordinary Shares (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueTables" roleURI="http://www.barinthusbio.com/role/FairValueTables">
        <link:definition>9955520 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationTables">
        <link:definition>9955521 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.barinthusbio.com/role/IncomeTaxesTables">
        <link:definition>9955522 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesTables">
        <link:definition>9955523 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentationDetails" roleURI="http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails">
        <link:definition>9955524 - Disclosure - Nature of Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesForeigncurrencytranslationDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesForeigncurrencytranslationDetails">
        <link:definition>9955525 - Disclosure - Summary of Significant Accounting Policies - Foreign currency translation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails">
        <link:definition>9955526 - Disclosure - Summary of Significant Accounting Policies - Noncontrolling interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails">
        <link:definition>9955527 - Disclosure - Summary of Significant Accounting Policies - Cash and cash equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails">
        <link:definition>9955528 - Disclosure - Summary of Significant Accounting Policies - Concentrations of credit risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAllowanceforcreditlossesDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesAllowanceforcreditlossesDetails">
        <link:definition>9955529 - Disclosure - Summary of Significant Accounting Policies - Allowance for credit losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails">
        <link:definition>9955530 - Disclosure - Summary of Significant Accounting Policies - Property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails">
        <link:definition>9955531 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesGoodwillDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails">
        <link:definition>9955532 - Disclosure - Summary of Significant Accounting Policies - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesFairvaluemeasurementsDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesFairvaluemeasurementsDetails">
        <link:definition>9955533 - Disclosure - Summary of Significant Accounting Policies - Fair value measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSharebasedcompensationDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesSharebasedcompensationDetails">
        <link:definition>9955534 - Disclosure - Summary of Significant Accounting Policies - Share based compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesResearchandDevelopmentIncentivesDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentIncentivesDetails">
        <link:definition>9955535 - Disclosure - Summary of Significant Accounting Policies - Research and Development Incentives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationAdditionalInformationDetails" roleURI="http://www.barinthusbio.com/role/SegmentinformationAdditionalInformationDetails">
        <link:definition>9955536 - Disclosure - Segment information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationSignificantSegmentExpensesDetails" roleURI="http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails">
        <link:definition>9955537 - Disclosure - Segment information - Significant Segment Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationLongLivedAssetsDetails" roleURI="http://www.barinthusbio.com/role/SegmentinformationLongLivedAssetsDetails">
        <link:definition>9955538 - Disclosure - Segment information - Long-Lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails" roleURI="http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails">
        <link:definition>9955539 - Disclosure - Foreign Currency Translation in General and Administrative Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareComputationDetails" roleURI="http://www.barinthusbio.com/role/NetLossPerShareComputationDetails">
        <link:definition>9955540 - Disclosure - Net Loss Per Share - Computation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAdditionalInformationDetails" roleURI="http://www.barinthusbio.com/role/NetLossPerShareAdditionalInformationDetails">
        <link:definition>9955541 - Disclosure - Net Loss Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetComponentsDetails" roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails">
        <link:definition>9955542 - Disclosure - Property and Equipment, Net - Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetAdditionalInformationDetails" roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNetAdditionalInformationDetails">
        <link:definition>9955543 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetDetails" roleURI="http://www.barinthusbio.com/role/IntangibleAssetsNetDetails">
        <link:definition>9955544 - Disclosure - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidandOtherCurrentAssetsDetails" roleURI="http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsDetails">
        <link:definition>9955545 - Disclosure - Prepaid and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>9955546 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantIncomeAdditionalInformationDetails" roleURI="http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails">
        <link:definition>9955547 - Disclosure - Grant Income - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantIncomeChangesinDeferredIncomeDetails" roleURI="http://www.barinthusbio.com/role/GrantIncomeChangesinDeferredIncomeDetails">
        <link:definition>9955548 - Disclosure - Grant Income - Changes in Deferred Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrdinarySharesAdditionalInformationDetails" roleURI="http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails">
        <link:definition>9955549 - Disclosure - Ordinary Shares - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrdinarySharesOrdinarySharesforFutureIssuanceDetails" roleURI="http://www.barinthusbio.com/role/OrdinarySharesOrdinarySharesforFutureIssuanceDetails">
        <link:definition>9955550 - Disclosure - Ordinary Shares - Ordinary Shares for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredSharesDetails" roleURI="http://www.barinthusbio.com/role/DeferredSharesDetails">
        <link:definition>9955551 - Disclosure - Deferred Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueAdditionalinformationDetails" roleURI="http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails">
        <link:definition>9955552 - Disclosure - Fair Value - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueChangeinFinancialInstrumentsClassifiedWithinLevel3Details" roleURI="http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedWithinLevel3Details">
        <link:definition>9955553 - Disclosure - Fair Value - Change in Financial Instruments Classified Within Level 3 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAdditionalInformationDetails" roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails">
        <link:definition>9955554 - Disclosure - Share-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationWeightedaverageAssumptionsDetails" roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails">
        <link:definition>9955555 - Disclosure - Share-Based Compensation - Weighted-average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofStockOptionActivityDetails" roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails">
        <link:definition>9955556 - Disclosure - Share-Based Compensation - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails">
        <link:definition>9955557 - Disclosure - Share-Based Compensation - Schedule of Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>9955558 - Disclosure - Share-Based Compensation - Share Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesLossBeforeIncomeTaxesDetails" roleURI="http://www.barinthusbio.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails">
        <link:definition>9955559 - Disclosure - Income Taxes - Loss Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails" roleURI="http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails">
        <link:definition>9955560 - Disclosure - Income Taxes - Components of Income Tax Benefit (Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationtotheEffectiveTaxRateDetails" roleURI="http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails">
        <link:definition>9955561 - Disclosure - Income Taxes - Reconciliation to the Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9955562 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>9955563 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesChangesintheValuationAllowancerorDeferredTaxAssetsDetails" roleURI="http://www.barinthusbio.com/role/IncomeTaxesChangesintheValuationAllowancerorDeferredTaxAssetsDetails">
        <link:definition>9955564 - Disclosure - Income Taxes - Changes in the Valuation Allowance ror Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>9955565 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails" roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails">
        <link:definition>9955566 - Disclosure - Commitments and Contingencies - Right-of-use Assets, Lease Liabilities and Other Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails" roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails">
        <link:definition>9955567 - Disclosure - Commitments and Contingencies - Maturities of minimum lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1" roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1">
        <link:definition>9955567 - Disclosure - Commitments and Contingencies - Maturities of minimum lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails" roleURI="http://www.barinthusbio.com/role/EmployeeBenefitPlansDetails">
        <link:definition>9955568 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails">
        <link:definition>9955569 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.barinthusbio.com/role/SubsequentEventsDetails">
        <link:definition>9955570 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="brns_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="brns_ResearchAndDevelopmentIncentivesReceivable" abstract="false" name="ResearchAndDevelopmentIncentivesReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" abstract="false" name="AccruedLiabilitiesAndOtherLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_DeferredStockValueIssued" abstract="false" name="DeferredStockValueIssued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_DeferredStockParOrStatedValuePerShare" abstract="false" name="DeferredStockParOrStatedValuePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="brns_DeferredStockSharesAuthorized" abstract="false" name="DeferredStockSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="brns_DeferredStockSharesIssued" abstract="false" name="DeferredStockSharesIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="brns_DeferredStockSharesOutstanding" abstract="false" name="DeferredStockSharesOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="brns_ResearchAndDevelopmentIncentiveIncomeExpense" abstract="false" name="ResearchAndDevelopmentIncentiveIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_DeferredSharesMember" abstract="true" name="DeferredSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_AssetImpairmentChargesExcludingGoodwill" abstract="false" name="AssetImpairmentChargesExcludingGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_NonCashLeaseExpenses" abstract="false" name="NonCashLeaseExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_NonCashInterestExpenseOnConvertibleLoanNotes" abstract="false" name="NonCashInterestExpenseOnConvertibleLoanNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" abstract="false" name="IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock" abstract="false" name="PrepaidExpenseAndOtherAssetsCurrentTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" abstract="false" name="AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="brns_StockholdersEquityDeferredSharesDisclosureTextBlock" abstract="false" name="StockholdersEquityDeferredSharesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="brns_MinorityInterestPolicyTextBlock" abstract="false" name="MinorityInterestPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock" abstract="false" name="ResearchAndDevelopmentServicesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="brns_OtherOperatingIncomePolicyPolicyTextBlock" abstract="false" name="OtherOperatingIncomePolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="brns_ClinicalTrialCostsPolicyTextBlock" abstract="false" name="ClinicalTrialCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="brns_AdditionalPaidInCapitalPolicyTextBlock" abstract="false" name="AdditionalPaidInCapitalPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="brns_ResearchAndDevelopmentIncentivesPolicyTextBlock" abstract="false" name="ResearchAndDevelopmentIncentivesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" abstract="false" name="AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock" abstract="false" name="ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" abstract="false" name="LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="brns_SchemeSharesMember" abstract="true" name="SchemeSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_ClywedogCapitalStockMember" abstract="true" name="ClywedogCapitalStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_BecaonTopcoIncMember" abstract="true" name="BecaonTopcoIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_ClywedogTherapeuticsInc.Member" abstract="true" name="ClywedogTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_NumberOfNewSubsidiaries" abstract="false" name="NumberOfNewSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="brns_NumberOfDepositarySharesPerShareOfCommonStock" abstract="false" name="NumberOfDepositarySharesPerShareOfCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="brns_StockConversionRatio" abstract="false" name="StockConversionRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="brns_MergerAgreementExtensionPeriod" abstract="false" name="MergerAgreementExtensionPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="brns_VOLTMember" abstract="true" name="VOLTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_SubsidiariesVOLTMember" abstract="true" name="SubsidiariesVOLTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_SubsidiaryCumulativeContributionsParent" abstract="false" name="SubsidiaryCumulativeContributionsParent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_SubsidiaryCumulativeContributionsNoncontrollingOwner" abstract="false" name="SubsidiaryCumulativeContributionsNoncontrollingOwner" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_OxfordUniversityInnovationMember" abstract="true" name="OxfordUniversityInnovationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_AccountsReceivableStandardPaymentTermsPeriod" abstract="false" name="AccountsReceivableStandardPaymentTermsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="brns_ConcentrationRiskThresholdPercentage" abstract="false" name="ConcentrationRiskThresholdPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="brns_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_NumberOfReportableSegmentsNotDisclosedFlag" abstract="false" name="NumberOfReportableSegmentsNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="brns_NumberOfGeographicRegionsInWhichEntityOperates" abstract="false" name="NumberOfGeographicRegionsInWhichEntityOperates" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember" abstract="true" name="ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_VTP1000CeliacMember" abstract="true" name="VTP1000CeliacMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_BarinthusLegacyAssetsMember" abstract="true" name="BarinthusLegacyAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_ResearchAndDevelopmentTypeAxis" abstract="true" name="ResearchAndDevelopmentTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="brns_ResearchAndDevelopmentTypeDomain" abstract="true" name="ResearchAndDevelopmentTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_PersonnelRelatedMember" abstract="true" name="PersonnelRelatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_FacilityRelatedMember" abstract="true" name="FacilityRelatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_OtherIndirectCostsMember" abstract="true" name="OtherIndirectCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_DirectResearchAndDevelopmentExpensesAbstract" abstract="true" name="DirectResearchAndDevelopmentExpensesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="brns_DirectResearchAndDevelopmentExpense" abstract="false" name="DirectResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_IndirectResearchAndDevelopmentExpensesAbstract" abstract="true" name="IndirectResearchAndDevelopmentExpensesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="brns_IndirectResearchAndDevelopmentExpense" abstract="false" name="IndirectResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationYearSix" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_AccruedManufacturingAndClinicalExpensesCurrent" abstract="false" name="AccruedManufacturingAndClinicalExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_CoalitionForEpidemicPreparednessInnovationsMember" abstract="true" name="CoalitionForEpidemicPreparednessInnovationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_FundingAmountMaximum" abstract="false" name="FundingAmountMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_DeferredIncomeForeignExchangeTranslationGainLoss" abstract="false" name="DeferredIncomeForeignExchangeTranslationGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_CommonStockNumberOfVotesPerShare" abstract="false" name="CommonStockNumberOfVotesPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="brns_PercentageOfSharesNecessaryToExercisePreemptiveRights" abstract="false" name="PercentageOfSharesNecessaryToExercisePreemptiveRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="brns_PeriodOfPreemptiveRightsToBeExercised" abstract="false" name="PeriodOfPreemptiveRightsToBeExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" abstract="false" name="MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_OrdinarySharesLiquidationPreference" abstract="false" name="OrdinarySharesLiquidationPreference" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_AvideaMember" abstract="true" name="AvideaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" abstract="true" name="BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_EnterpriseManagementIncentiveShareOptionSchemeMember" abstract="true" name="EnterpriseManagementIncentiveShareOptionSchemeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" abstract="true" name="RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" abstract="false" name="ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance" abstract="false" name="ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="brns_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="brns_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="brns_DeferredTaxAssetsLeasingArrangements" abstract="false" name="DeferredTaxAssetsLeasingArrangements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_ValuationAllowanceRollForward" abstract="true" name="ValuationAllowanceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions" abstract="false" name="ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision" abstract="false" name="ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation" abstract="false" name="ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_InLicenseAgreementsMember" abstract="true" name="InLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_OxfordshireMember" abstract="true" name="OxfordshireMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" abstract="false" name="PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" abstract="false" name="PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="brns_NumberOfSquareFeetUnderLeaseAgreement" abstract="false" name="NumberOfSquareFeetUnderLeaseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="brns_LesseeOperatingLeaseExtendedTerm" abstract="false" name="LesseeOperatingLeaseExtendedTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="brns_OtherInformationLesseeAbstract" abstract="true" name="OtherInformationLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="brns_OxfordUniversityInnovationLimitedMember" abstract="true" name="OxfordUniversityInnovationLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_ExpensesMember" abstract="true" name="ExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_MergerAgreementSchemeExchangeRatio" abstract="false" name="MergerAgreementSchemeExchangeRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="brns_MergerAgreementMergerExchangeRatio" abstract="false" name="MergerAgreementMergerExchangeRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>brns-20251231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019b097a-6c16-78f4-806b-17184aaccbef,g:d518a941-6ac7-4029-9d1f-6f039bd073d0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="brns-20251231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019b097a-6d1e-7833-865d-250998ca97c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019b097a-6d1e-7644-9c5a-20a0a51b80ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019b097a-6d1e-7833-865d-250998ca97c5" xlink:to="loc_us-gaap_CommonStockValue_019b097a-6d1e-7644-9c5a-20a0a51b80ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockValueIssued_019b097a-6d1e-7c78-87e8-5637341187b5" xlink:href="brns-20251231.xsd#brns_DeferredStockValueIssued"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019b097a-6d1e-7833-865d-250998ca97c5" xlink:to="loc_brns_DeferredStockValueIssued_019b097a-6d1e-7c78-87e8-5637341187b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_019b097a-6d1e-7468-ab0b-642e37ab433d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019b097a-6d1e-7833-865d-250998ca97c5" xlink:to="loc_us-gaap_AdditionalPaidInCapital_019b097a-6d1e-7468-ab0b-642e37ab433d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019b097a-6d1e-7fb7-bf00-4bb80e8590db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019b097a-6d1e-7833-865d-250998ca97c5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019b097a-6d1e-7fb7-bf00-4bb80e8590db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_019b097a-6d1e-7636-81a6-3504f2bcd132" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019b097a-6d1e-7833-865d-250998ca97c5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_019b097a-6d1e-7636-81a6-3504f2bcd132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019b097a-6d1e-7ccf-a0ba-ec3c9339b300" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019b097a-6d1e-7cfb-b24a-e2012ea939aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019b097a-6d1e-7ccf-a0ba-ec3c9339b300" xlink:to="loc_us-gaap_LiabilitiesCurrent_019b097a-6d1e-7cfb-b24a-e2012ea939aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019b097a-6d1e-777f-8b43-6c4a10d7a0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019b097a-6d1e-7ccf-a0ba-ec3c9339b300" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019b097a-6d1e-777f-8b43-6c4a10d7a0e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_019b097a-6d1e-7617-a22d-e8fd65201720" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019b097a-6d1e-7ccf-a0ba-ec3c9339b300" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_019b097a-6d1e-7617-a22d-e8fd65201720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_019b097a-6d1e-751d-9e30-95d42314d4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019b097a-6d1e-7ccf-a0ba-ec3c9339b300" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_019b097a-6d1e-751d-9e30-95d42314d4ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_019b097a-6d1e-71e6-960a-472497425a74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019b097a-6d1e-7ccf-a0ba-ec3c9339b300" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_019b097a-6d1e-71e6-960a-472497425a74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019b097a-6d1e-756c-8390-741db11e4d10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019b097a-6d1e-7cdc-8ade-6fc07d155dae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019b097a-6d1e-756c-8390-741db11e4d10" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019b097a-6d1e-7cdc-8ade-6fc07d155dae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_019b097a-6d1e-7226-9bdb-c6274560a056" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019b097a-6d1e-756c-8390-741db11e4d10" xlink:to="loc_us-gaap_RestrictedCashCurrent_019b097a-6d1e-7226-9bdb-c6274560a056" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentivesReceivable_019b097a-6d1e-78a5-b03c-b8af09fb4b58" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentIncentivesReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019b097a-6d1e-756c-8390-741db11e4d10" xlink:to="loc_brns_ResearchAndDevelopmentIncentivesReceivable_019b097a-6d1e-78a5-b03c-b8af09fb4b58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019b097a-6d1e-7cc1-b596-8d265efc67c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019b097a-6d1e-756c-8390-741db11e4d10" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019b097a-6d1e-7cc1-b596-8d265efc67c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019b097a-6d1e-79fb-92ce-14e72317710b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019b097a-6d1e-771b-b1af-20759a877e63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019b097a-6d1e-79fb-92ce-14e72317710b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019b097a-6d1e-771b-b1af-20759a877e63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019b097a-6d1e-7ff0-85e5-c49a88e1dd20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019b097a-6d1e-79fb-92ce-14e72317710b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019b097a-6d1e-7ff0-85e5-c49a88e1dd20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_019b097a-6d1e-7c56-9732-f4196b5f6a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019b097a-6d1e-79fb-92ce-14e72317710b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_019b097a-6d1e-7c56-9732-f4196b5f6a6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_019b097a-6d1e-78bc-b791-64195f48ea5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019b097a-6d1e-79fb-92ce-14e72317710b" xlink:to="loc_us-gaap_OtherAssets_019b097a-6d1e-78bc-b791-64195f48ea5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019b097a-6d1e-7313-9c51-e6f9eab96552" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019b097a-6d1e-79fb-92ce-14e72317710b" xlink:to="loc_us-gaap_AssetsCurrent_019b097a-6d1e-7313-9c51-e6f9eab96552" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-74e4-81ac-941d0c3b9948" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_019b097a-6d1e-77af-8793-e1b6f108b82c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-74e4-81ac-941d0c3b9948" xlink:to="loc_us-gaap_MinorityInterest_019b097a-6d1e-77af-8793-e1b6f108b82c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019b097a-6d1e-7827-ae10-7275c44c20f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-74e4-81ac-941d0c3b9948" xlink:to="loc_us-gaap_StockholdersEquity_019b097a-6d1e-7827-ae10-7275c44c20f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019b097a-6d1e-7e5d-98db-d9642dd603a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019b097a-6d1e-7cbd-979b-fcac25785295" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019b097a-6d1e-7e5d-98db-d9642dd603a0" xlink:to="loc_us-gaap_AccountsPayableCurrent_019b097a-6d1e-7cbd-979b-fcac25785295" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeCurrent_019b097a-6d1e-76c6-aa99-9cfc3000eb81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019b097a-6d1e-7e5d-98db-d9642dd603a0" xlink:to="loc_us-gaap_DeferredIncomeCurrent_019b097a-6d1e-76c6-aa99-9cfc3000eb81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019b097a-6d1e-7c29-bcdf-951a440e8d86" xlink:href="brns-20251231.xsd#brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019b097a-6d1e-7e5d-98db-d9642dd603a0" xlink:to="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019b097a-6d1e-7c29-bcdf-951a440e8d86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_019b097a-6d1e-7a65-a041-2d524b5084d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019b097a-6d1e-7e5d-98db-d9642dd603a0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_019b097a-6d1e-7a65-a041-2d524b5084d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019b097a-6d1e-7428-b025-ed0079b4d8be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019b097a-6d1e-7009-953d-5b3f3fdc6327" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019b097a-6d1e-7428-b025-ed0079b4d8be" xlink:to="loc_us-gaap_Liabilities_019b097a-6d1e-7009-953d-5b3f3fdc6327" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019b097a-6d1e-767b-845f-da265016324c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019b097a-6d1e-7428-b025-ed0079b4d8be" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019b097a-6d1e-767b-845f-da265016324c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-7cb3-bbd5-dbaf523f927d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019b097a-6d1e-7428-b025-ed0079b4d8be" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-7cb3-bbd5-dbaf523f927d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="brns-20251231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b097a-6d1e-7bde-9f68-e1b3695406ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019b097a-6d1e-7f05-a051-2859978a7d29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b097a-6d1e-7bde-9f68-e1b3695406ba" xlink:to="loc_us-gaap_OperatingIncomeLoss_019b097a-6d1e-7f05-a051-2859978a7d29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019b097a-6d1e-725f-8a8d-09b9c036b19f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b097a-6d1e-7bde-9f68-e1b3695406ba" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019b097a-6d1e-725f-8a8d-09b9c036b19f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019b097a-6d1e-7fee-a4f6-ec6eb427be7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-7686-bd9e-d667d09a06d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019b097a-6d1e-7fee-a4f6-ec6eb427be7c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-7686-bd9e-d667d09a06d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_019b097a-6d1e-76d8-b0ba-e0fff161f4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019b097a-6d1e-7fee-a4f6-ec6eb427be7c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_019b097a-6d1e-76d8-b0ba-e0fff161f4d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-7c3c-b931-f3af7211be04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019b097a-6d1e-7512-9ac3-ae7e82e64654" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-7c3c-b931-f3af7211be04" xlink:to="loc_us-gaap_ProfitLoss_019b097a-6d1e-7512-9ac3-ae7e82e64654" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019b097a-6d1e-76ac-8510-4af3955be15c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-7c3c-b931-f3af7211be04" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019b097a-6d1e-76ac-8510-4af3955be15c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019b097a-6d1e-76d0-9991-fd48fe99d188" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019b097a-6d1e-7201-aa8a-81be3acd6691" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_019b097a-6d1e-76d0-9991-fd48fe99d188" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019b097a-6d1e-7201-aa8a-81be3acd6691" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019b097a-6d1e-7c4a-905c-29418bee36e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_019b097a-6d1e-76d0-9991-fd48fe99d188" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019b097a-6d1e-7c4a-905c-29418bee36e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_019b097a-6d1e-79c3-b3bd-c8bc7fefc207" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_019b097a-6d1e-76d0-9991-fd48fe99d188" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_019b097a-6d1e-79c3-b3bd-c8bc7fefc207" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_019b2bd2-83f4-723d-99cb-c84d4180d46a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_019b097a-6d1e-76d0-9991-fd48fe99d188" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_019b2bd2-83f4-723d-99cb-c84d4180d46a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019b097a-6d1e-70a9-bb3a-f72206ceeee6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b097a-6d1e-7add-8e05-18b7ca905ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_019b097a-6d1e-70a9-bb3a-f72206ceeee6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b097a-6d1e-7add-8e05-18b7ca905ba9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019b097a-6d1e-73b0-99ca-acdc32a5dc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_019b097a-6d1e-70a9-bb3a-f72206ceeee6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019b097a-6d1e-73b0-99ca-acdc32a5dc4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019b097a-6d1e-7c58-9a2a-10c028d2e3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019b097a-6d1e-7212-8616-1760dac0a786" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019b097a-6d1e-7c58-9a2a-10c028d2e3c8" xlink:to="loc_us-gaap_ProfitLoss_019b097a-6d1e-7212-8616-1760dac0a786" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019b097a-6d1e-71d2-95be-75af5fc56e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019b097a-6d1e-7c58-9a2a-10c028d2e3c8" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019b097a-6d1e-71d2-95be-75af5fc56e1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019b097a-6d1e-791c-b487-24d6162dca9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019b097a-6d1e-7bd1-b555-1e363999f3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_019b097a-6d1e-791c-b487-24d6162dca9e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019b097a-6d1e-7bd1-b555-1e363999f3bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_019b097a-6d1e-744a-b3dd-a7858583e4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_019b097a-6d1e-791c-b487-24d6162dca9e" xlink:to="loc_us-gaap_InterestExpenseNonoperating_019b097a-6d1e-744a-b3dd-a7858583e4b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_019b097a-6d1e-72b5-86d7-6dc707a5a89f" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentIncentiveIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_019b097a-6d1e-791c-b487-24d6162dca9e" xlink:to="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_019b097a-6d1e-72b5-86d7-6dc707a5a89f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019b097a-6d1e-7370-82a9-93e0d51ce880" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_019b097a-6d1e-791c-b487-24d6162dca9e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019b097a-6d1e-7370-82a9-93e0d51ce880" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019b097a-6d1e-7cca-98be-244a7247a35a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019b097a-6d1e-7b1d-aa9c-e11c00883b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019b097a-6d1e-7cca-98be-244a7247a35a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019b097a-6d1e-7b1d-aa9c-e11c00883b2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019b097a-6d1e-76e9-9a00-a2143bb4175a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019b097a-6d1e-7cca-98be-244a7247a35a" xlink:to="loc_us-gaap_OperatingExpenses_019b097a-6d1e-76e9-9a00-a2143bb4175a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_019b097a-6d1e-7c7c-868c-b7e23d78e29a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019b097a-6d1e-7cca-98be-244a7247a35a" xlink:to="loc_us-gaap_OtherOperatingIncome_019b097a-6d1e-7c7c-868c-b7e23d78e29a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="brns-20251231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019b097a-6d1e-7283-ad25-182fd4a32860" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019b097a-6d1e-7172-adc7-d5e5d179ffe0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019b097a-6d1e-7283-ad25-182fd4a32860" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019b097a-6d1e-7172-adc7-d5e5d179ffe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019b097a-6d1e-7401-a614-a6fc184b32ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019b097a-6d1e-7283-ad25-182fd4a32860" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019b097a-6d1e-7401-a614-a6fc184b32ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019b097a-6d1e-7dad-9047-1c9b597f86c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_019bd5be-2545-7389-9fb0-4abb48d09d13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019b097a-6d1e-7dad-9047-1c9b597f86c7" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_019bd5be-2545-7389-9fb0-4abb48d09d13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019b097a-6d1e-7fbd-9bec-d99541a55599" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019b097a-6d1e-7dad-9047-1c9b597f86c7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019b097a-6d1e-7fbd-9bec-d99541a55599" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-73a1-84ee-93c61017c4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019b097a-6d1e-7644-9836-aef52b6dc95e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-73a1-84ee-93c61017c4ce" xlink:to="loc_us-gaap_ProfitLoss_019b097a-6d1e-7644-9836-aef52b6dc95e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019b097a-6d1e-7b05-a49f-1d1f5919ceca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-73a1-84ee-93c61017c4ce" xlink:to="loc_us-gaap_ShareBasedCompensation_019b097a-6d1e-7b05-a49f-1d1f5919ceca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_019b097a-6d1e-7b76-b7c9-e3d9276d4a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-73a1-84ee-93c61017c4ce" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_019b097a-6d1e-7b76-b7c9-e3d9276d4a1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_019b097a-6d1e-7783-9be1-3ad27d752ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-73a1-84ee-93c61017c4ce" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_019b097a-6d1e-7783-9be1-3ad27d752ef9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NonCashLeaseExpenses_019b097a-6d1e-7aed-a98f-7c6fb527caa4" xlink:href="brns-20251231.xsd#brns_NonCashLeaseExpenses"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-73a1-84ee-93c61017c4ce" xlink:to="loc_brns_NonCashLeaseExpenses_019b097a-6d1e-7aed-a98f-7c6fb527caa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_019b097a-6d1e-7701-9553-9c24f56eefa5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-73a1-84ee-93c61017c4ce" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_019b097a-6d1e-7701-9553-9c24f56eefa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019b097a-6d1e-7fc2-bd2e-dd7d9134a7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-73a1-84ee-93c61017c4ce" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019b097a-6d1e-7fc2-bd2e-dd7d9134a7fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NonCashInterestExpenseOnConvertibleLoanNotes_019b097a-6d1e-7472-91f1-1b066fa66575" xlink:href="brns-20251231.xsd#brns_NonCashInterestExpenseOnConvertibleLoanNotes"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-73a1-84ee-93c61017c4ce" xlink:to="loc_brns_NonCashInterestExpenseOnConvertibleLoanNotes_019b097a-6d1e-7472-91f1-1b066fa66575" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_019b097a-6d1e-7cb3-8054-4e9010eb7199" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-73a1-84ee-93c61017c4ce" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_019b097a-6d1e-7cb3-8054-4e9010eb7199" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_019bd5bb-91b8-7cde-82ce-523adb114352" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-73a1-84ee-93c61017c4ce" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_019bd5bb-91b8-7cde-82ce-523adb114352" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019b097a-6d1e-7e72-ac6e-7b840635cb22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-73a1-84ee-93c61017c4ce" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019b097a-6d1e-7e72-ac6e-7b840635cb22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_019b097a-6d1e-7bfd-a333-c0e2ac06271a" xlink:href="brns-20251231.xsd#brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-73a1-84ee-93c61017c4ce" xlink:to="loc_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_019b097a-6d1e-7bfd-a333-c0e2ac06271a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019b097a-6d1e-7eea-ae70-1a3e8003b489" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-73a1-84ee-93c61017c4ce" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019b097a-6d1e-7eea-ae70-1a3e8003b489" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_019b097a-6d1e-75c3-9e63-140228d98cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-73a1-84ee-93c61017c4ce" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_019b097a-6d1e-75c3-9e63-140228d98cd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_019b097a-6d1e-7d1a-bb93-7e2e78aa3f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-73a1-84ee-93c61017c4ce" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_019b097a-6d1e-7d1a-bb93-7e2e78aa3f5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019b097a-6d1e-73d1-825c-7ec917f6a3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-73a1-84ee-93c61017c4ce" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019b097a-6d1e-73d1-825c-7ec917f6a3f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AssetImpairmentChargesExcludingGoodwill_019b2bde-4c54-76a3-a809-f1f1ba129b10" xlink:href="brns-20251231.xsd#brns_AssetImpairmentChargesExcludingGoodwill"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-73a1-84ee-93c61017c4ce" xlink:to="loc_brns_AssetImpairmentChargesExcludingGoodwill_019b2bde-4c54-76a3-a809-f1f1ba129b10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019b097a-6d1e-7ae3-9cda-6b25ac0610aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-7bc2-a1f2-d54442960a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019b097a-6d1e-7ae3-9cda-6b25ac0610aa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-7bc2-a1f2-d54442960a9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019b097a-6d1e-70d9-bfb4-1c2ca6d061c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019b097a-6d1e-7ae3-9cda-6b25ac0610aa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019b097a-6d1e-70d9-bfb4-1c2ca6d061c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019b097a-6d1e-7996-aead-99331ed6f675" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019b097a-6d1e-7ae3-9cda-6b25ac0610aa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019b097a-6d1e-7996-aead-99331ed6f675" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019b097a-6d1e-7597-85b1-64d10fcfaea3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019b097a-6d1e-7ae3-9cda-6b25ac0610aa" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019b097a-6d1e-7597-85b1-64d10fcfaea3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SegmentinformationSignificantSegmentExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019b097a-6d1e-7bbe-9c3e-244200b6d5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IndirectResearchAndDevelopmentExpense_019b097a-6d1e-7ae1-8ec4-4e67a74f9aec" xlink:href="brns-20251231.xsd#brns_IndirectResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_019b097a-6d1e-7bbe-9c3e-244200b6d5c8" xlink:to="loc_brns_IndirectResearchAndDevelopmentExpense_019b097a-6d1e-7ae1-8ec4-4e67a74f9aec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DirectResearchAndDevelopmentExpense_019b097a-6d1e-7c6e-a97d-471cb28f5448" xlink:href="brns-20251231.xsd#brns_DirectResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_019b097a-6d1e-7bbe-9c3e-244200b6d5c8" xlink:to="loc_brns_DirectResearchAndDevelopmentExpense_019b097a-6d1e-7c6e-a97d-471cb28f5448" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NetLossPerShareComputationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#NetLossPerShareComputationDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/NetLossPerShareComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019b097a-6d1e-7341-b933-6b3d734ddbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019b097a-6d1e-78f0-88b7-69ff3222006e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019b097a-6d1e-7341-b933-6b3d734ddbd1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019b097a-6d1e-78f0-88b7-69ff3222006e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#PropertyandEquipmentNetComponentsDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019b097a-6d1e-798e-95ee-87c7e350110f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_019b097a-6d1e-79a7-bf86-7fbac5c254ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_019b097a-6d1e-798e-95ee-87c7e350110f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_019b097a-6d1e-79a7-bf86-7fbac5c254ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019b097a-6d1e-763b-83c8-ee7cd9ac3153" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_019b097a-6d1e-798e-95ee-87c7e350110f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019b097a-6d1e-763b-83c8-ee7cd9ac3153" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#PrepaidandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019b097a-6d1e-7883-8c80-9f34e1928195" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_019b097a-6d1e-7543-98d4-19bdeaff8723" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019b097a-6d1e-7883-8c80-9f34e1928195" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_019b097a-6d1e-7543-98d4-19bdeaff8723" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_019b097a-6d1e-750d-a386-08e9eada7fff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019b097a-6d1e-7883-8c80-9f34e1928195" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_019b097a-6d1e-750d-a386-08e9eada7fff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_019b097a-6d1e-7d04-8e5e-b5f9db1bd3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019b097a-6d1e-7883-8c80-9f34e1928195" xlink:to="loc_us-gaap_OtherAssetsCurrent_019b097a-6d1e-7d04-8e5e-b5f9db1bd3ec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019b097a-6d1e-7d2a-adf2-e8bd0cf1a78c" xlink:href="brns-20251231.xsd#brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedManufacturingAndClinicalExpensesCurrent_019b097a-6d1e-7860-891f-5e6246a14ffd" xlink:href="brns-20251231.xsd#brns_AccruedManufacturingAndClinicalExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019b097a-6d1e-7d2a-adf2-e8bd0cf1a78c" xlink:to="loc_brns_AccruedManufacturingAndClinicalExpensesCurrent_019b097a-6d1e-7860-891f-5e6246a14ffd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_019b097a-6d1e-7b26-9a7d-cac5588a51c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019b097a-6d1e-7d2a-adf2-e8bd0cf1a78c" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_019b097a-6d1e-7b26-9a7d-cac5588a51c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_019b097a-6d1e-71e6-b5aa-105a65890332" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019b097a-6d1e-7d2a-adf2-e8bd0cf1a78c" xlink:to="loc_us-gaap_AccruedBonusesCurrent_019b097a-6d1e-71e6-b5aa-105a65890332" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_019b097a-6d1e-7125-95ef-ac08a1f35490" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019b097a-6d1e-7d2a-adf2-e8bd0cf1a78c" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_019b097a-6d1e-7125-95ef-ac08a1f35490" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_019b097a-6d1e-7e53-aa38-8efa03976961" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019b097a-6d1e-7d2a-adf2-e8bd0cf1a78c" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_019b097a-6d1e-7e53-aa38-8efa03976961" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019b097a-6d1e-79ca-8c34-8a496894ec1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019b097a-6d1e-7d2a-adf2-e8bd0cf1a78c" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019b097a-6d1e-79ca-8c34-8a496894ec1a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/OrdinarySharesOrdinarySharesforFutureIssuanceDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#OrdinarySharesOrdinarySharesforFutureIssuanceDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/OrdinarySharesOrdinarySharesforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019b097a-6d1e-7363-a15d-24ea3f31ba81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b097a-6d1e-702e-bbfc-ad705972a7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019b097a-6d1e-7363-a15d-24ea3f31ba81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b097a-6d1e-702e-bbfc-ad705972a7f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019b097a-6d1e-7304-9631-5ba527693516" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019b097a-6d1e-7363-a15d-24ea3f31ba81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019b097a-6d1e-7304-9631-5ba527693516" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_019c927d-e41c-72a2-a148-b25fbb93aaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c927d-e41c-7991-a31d-4383d42a1b96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_019c927d-e41c-72a2-a148-b25fbb93aaa0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c927d-e41c-7991-a31d-4383d42a1b96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_019c927d-e41c-72b4-95e4-6ae687c21f83" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_019c927d-e41c-72a2-a148-b25fbb93aaa0" xlink:to="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_019c927d-e41c-72b4-95e4-6ae687c21f83" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#IncomeTaxesLossBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b097a-6e6c-7d1f-9598-8a9393f37981" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019b097a-6e6c-79af-82c3-ca29f51fac62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b097a-6e6c-7d1f-9598-8a9393f37981" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019b097a-6e6c-79af-82c3-ca29f51fac62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019b097a-6e6c-7146-993c-55e2288d2b01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b097a-6e6c-7d1f-9598-8a9393f37981" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019b097a-6e6c-7146-993c-55e2288d2b01" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019b097a-6e6c-7381-80aa-c06941403de6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_019b097a-6e6c-7d04-b836-ce3e1f19fde1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019b097a-6e6c-7381-80aa-c06941403de6" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_019b097a-6e6c-7d04-b836-ce3e1f19fde1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_019b097a-6e6c-79a8-8aa5-6efee533d28f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019b097a-6e6c-7381-80aa-c06941403de6" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_019b097a-6e6c-79a8-8aa5-6efee533d28f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019ce2d8-d8d2-7584-b769-2fed4690d9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019ce2d8-d8d2-7617-913f-04c63d566490" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019ce2d8-d8d2-7584-b769-2fed4690d9a7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019ce2d8-d8d2-7617-913f-04c63d566490" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019ce2d8-d8d2-7f19-bda6-fc58d8d4f12d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019ce2d8-d8d2-7584-b769-2fed4690d9a7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019ce2d8-d8d2-7f19-bda6-fc58d8d4f12d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_019ce2d8-d8d2-7323-98ae-9570d290fb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019ce2d8-d8d2-7584-b769-2fed4690d9a7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_019ce2d8-d8d2-7323-98ae-9570d290fb5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_019ce2d8-d8d2-7c31-8fb2-6f212202b26d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019ce2d8-d8d2-7584-b769-2fed4690d9a7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_019ce2d8-d8d2-7c31-8fb2-6f212202b26d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment_019ce2d8-d8d2-7d30-bf43-796b9198f410" xlink:href="brns-20251231.xsd#brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019ce2d8-d8d2-7584-b769-2fed4690d9a7" xlink:to="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment_019ce2d8-d8d2-7d30-bf43-796b9198f410" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019ce2d8-d8d2-7cb5-8e1d-a637eeb10050" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019ce2d8-d8d2-7584-b769-2fed4690d9a7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019ce2d8-d8d2-7cb5-8e1d-a637eeb10050" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019ce2d8-d8d2-795a-a25f-93305dfdb6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019ce2d8-d8d2-7584-b769-2fed4690d9a7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019ce2d8-d8d2-795a-a25f-93305dfdb6ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019ce2d8-a35b-7261-9297-b04b39e3f659" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019ce2d8-a35b-746c-a842-47569a4b4399" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019ce2d8-a35b-7261-9297-b04b39e3f659" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019ce2d8-a35b-746c-a842-47569a4b4399" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019ce2d8-a35b-7feb-bc0a-532318720423" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019ce2d8-a35b-7261-9297-b04b39e3f659" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019ce2d8-a35b-7feb-bc0a-532318720423" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_019ce2d8-a35b-73f5-9f3e-5dd2f4929bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019ce2d8-a35b-7261-9297-b04b39e3f659" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_019ce2d8-a35b-73f5-9f3e-5dd2f4929bfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_019ce2d8-a35b-7e94-9640-c4e73e416124" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019ce2d8-a35b-7261-9297-b04b39e3f659" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_019ce2d8-a35b-7e94-9640-c4e73e416124" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount_019ce2d8-a35b-7a11-a0c9-33ad7a27a86e" xlink:href="brns-20251231.xsd#brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019ce2d8-a35b-7261-9297-b04b39e3f659" xlink:to="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount_019ce2d8-a35b-7a11-a0c9-33ad7a27a86e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_019ce2d8-a35b-7dc1-9224-1bda1254f662" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019ce2d8-a35b-7261-9297-b04b39e3f659" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_019ce2d8-a35b-7dc1-9224-1bda1254f662" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019ce2d8-a35b-7028-a232-99cda3443b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019ce2d8-a35b-7261-9297-b04b39e3f659" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019ce2d8-a35b-7028-a232-99cda3443b3a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_019b097a-6e6c-77e9-852e-3cf996f86157" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_019b097a-6e6c-7927-9b01-2e14d883f13d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_019b097a-6e6c-77e9-852e-3cf996f86157" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_019b097a-6e6c-7927-9b01-2e14d883f13d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_019b097a-6e6c-741a-b131-903013b0407f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_019b097a-6e6c-77e9-852e-3cf996f86157" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_019b097a-6e6c-741a-b131-903013b0407f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_019b097a-6e6c-78ad-b6b8-648e68cb668a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_019b097a-6e6c-71d9-99c5-f2ca21151569" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_019b097a-6e6c-78ad-b6b8-648e68cb668a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_019b097a-6e6c-71d9-99c5-f2ca21151569" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_019b097a-6e6c-72f9-a6db-c5c468c36dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_019b097a-6e6c-78ad-b6b8-648e68cb668a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_019b097a-6e6c-72f9-a6db-c5c468c36dd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_019b097a-6e6c-730e-aae7-f63a35e7109e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_019b097a-6e6c-78ad-b6b8-648e68cb668a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_019b097a-6e6c-730e-aae7-f63a35e7109e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredTaxAssetsLeasingArrangements_019b097a-6e6c-785d-bcda-13f888da7a16" xlink:href="brns-20251231.xsd#brns_DeferredTaxAssetsLeasingArrangements"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_019b097a-6e6c-78ad-b6b8-648e68cb668a" xlink:to="loc_brns_DeferredTaxAssetsLeasingArrangements_019b097a-6e6c-785d-bcda-13f888da7a16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_019c702a-89c2-7f48-8b3f-26b1be50eb66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_019b097a-6e6c-78ad-b6b8-648e68cb668a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_019c702a-89c2-7f48-8b3f-26b1be50eb66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_019b097a-6e6c-7acd-b1e5-bae3506f3ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_019b097a-6e6c-78ad-b6b8-648e68cb668a" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_019b097a-6e6c-7acd-b1e5-bae3506f3ff1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_019b097a-6e6c-7f6f-8c8b-b58f08430442" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_019b097a-6e6c-78ad-b6b8-648e68cb668a" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_019b097a-6e6c-7f6f-8c8b-b58f08430442" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_019b097a-6e6c-70e3-af3c-414e575061b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_019b097a-6e6c-78ad-b6b8-648e68cb668a" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_019b097a-6e6c-70e3-af3c-414e575061b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_019b097a-6e6c-78e8-b1b9-53905036bc43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_019b097a-6e6c-7c9d-b896-f35f29b6e6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_019b097a-6e6c-78e8-b1b9-53905036bc43" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_019b097a-6e6c-7c9d-b896-f35f29b6e6d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_019b097a-6e6c-7190-8d23-8c249a116844" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_019b097a-6e6c-78e8-b1b9-53905036bc43" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_019b097a-6e6c-7190-8d23-8c249a116844" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_019b097a-6e6c-731c-83bd-5ae226095471" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_019b097a-6e6c-78e8-b1b9-53905036bc43" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_019b097a-6e6c-731c-83bd-5ae226095471" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_019b097a-6e6c-72fd-b584-54e21cb4ec99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_019b097a-6e6c-78e8-b1b9-53905036bc43" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_019b097a-6e6c-72fd-b584-54e21cb4ec99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_019b097a-6e6c-7186-ada8-a6840a503545" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_019b097a-6e6c-7f45-aae4-b9e221ce38b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_019b097a-6e6c-7186-ada8-a6840a503545" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_019b097a-6e6c-7f45-aae4-b9e221ce38b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_019b097a-6e6c-7fdc-95f6-b5017e5503a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_019b097a-6e6c-7186-ada8-a6840a503545" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_019b097a-6e6c-7fdc-95f6-b5017e5503a3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_019b097a-6e6c-7cc4-814f-4be97fb30a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_019b097a-6e6c-76cf-bdbb-a532b5e8bf14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_019b097a-6e6c-7cc4-814f-4be97fb30a5e" xlink:to="loc_us-gaap_OperatingLeaseCost_019b097a-6e6c-76cf-bdbb-a532b5e8bf14" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019b097a-6e6c-7263-8e61-813e7f78787c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_019b097a-6e6c-7ec7-9198-cc8307db303c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019b097a-6e6c-7263-8e61-813e7f78787c" xlink:to="loc_us-gaap_OperatingLeaseLiability_019b097a-6e6c-7ec7-9198-cc8307db303c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_019b097a-6e6c-728d-9d60-d9506faf6a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019b097a-6e6c-7263-8e61-813e7f78787c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_019b097a-6e6c-728d-9d60-d9506faf6a3c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1" xlink:type="simple" xlink:href="brns-20251231.xsd#CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019b097a-6e6c-7cbc-851e-d75036ae34bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_019b097a-6e6c-7ea8-8770-65d63841eae6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019b097a-6e6c-7cbc-851e-d75036ae34bd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_019b097a-6e6c-7ea8-8770-65d63841eae6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_019b097a-6e6c-750d-b5b6-431fbed653ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019b097a-6e6c-7cbc-851e-d75036ae34bd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_019b097a-6e6c-750d-b5b6-431fbed653ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_019b097a-6e6c-74f7-8059-3fdd51b4680d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019b097a-6e6c-7cbc-851e-d75036ae34bd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_019b097a-6e6c-74f7-8059-3fdd51b4680d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_019b097a-6e6c-74fe-8149-d0efaf20f46b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019b097a-6e6c-7cbc-851e-d75036ae34bd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_019b097a-6e6c-74fe-8149-d0efaf20f46b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_019b097a-6e6c-70b3-bdd1-11ab78f09e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019b097a-6e6c-7cbc-851e-d75036ae34bd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_019b097a-6e6c-70b3-bdd1-11ab78f09e8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_019b097a-6e6c-7658-8fed-484cf2a1307f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019b097a-6e6c-7cbc-851e-d75036ae34bd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_019b097a-6e6c-7658-8fed-484cf2a1307f" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>brns-20251231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019b097a-6c16-78f4-806b-17184aaccbef,g:d518a941-6ac7-4029-9d1f-6f039bd073d0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/Cover" xlink:type="simple" xlink:href="brns-20251231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_019b097a-6d1d-72de-83f4-bda4a0d6db23" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_DocumentInformationTable_019b097a-6d1d-72de-83f4-bda4a0d6db23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019b097a-6d1d-70b1-ba8b-76597aa756bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_019b097a-6d1d-72de-83f4-bda4a0d6db23" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019b097a-6d1d-70b1-ba8b-76597aa756bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019b097a-6d1d-70b1-ba8b-76597aa756bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019b097a-6d1d-70b1-ba8b-76597aa756bd" xlink:to="loc_us-gaap_ClassOfStockDomain_019b097a-6d1d-70b1-ba8b-76597aa756bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019b097a-6d1d-7f3b-9194-2c66f565bf42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019b097a-6d1d-70b1-ba8b-76597aa756bd" xlink:to="loc_us-gaap_ClassOfStockDomain_019b097a-6d1d-7f3b-9194-2c66f565bf42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AdrMember_019b097a-6d1d-765e-9f1a-967fd0c4d697" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AdrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019b097a-6d1d-7f3b-9194-2c66f565bf42" xlink:to="loc_dei_AdrMember_019b097a-6d1d-765e-9f1a-967fd0c4d697" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019b097a-6d1d-7716-a624-15c183ade56f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019b097a-6d1d-7f3b-9194-2c66f565bf42" xlink:to="loc_us-gaap_CommonStockMember_019b097a-6d1d-7716-a624-15c183ade56f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019b097a-6d1d-716d-a940-5d579e63bff9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_DocumentType_019b097a-6d1d-716d-a940-5d579e63bff9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_019b097a-6d1d-7af6-8a5d-5ca6500e4697" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_DocumentAnnualReport_019b097a-6d1d-7af6-8a5d-5ca6500e4697" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019b097a-6d1d-7d40-97b6-f0680cb5428e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_DocumentPeriodEndDate_019b097a-6d1d-7d40-97b6-f0680cb5428e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_019b097a-6d1d-7e22-9318-2d1f113123d7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_CurrentFiscalYearEndDate_019b097a-6d1d-7e22-9318-2d1f113123d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_019b097a-6d1d-7ce3-a8b0-e34facb6d6be" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_DocumentTransitionReport_019b097a-6d1d-7ce3-a8b0-e34facb6d6be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019b097a-6d1d-727b-8f07-302c7ee10838" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityFileNumber_019b097a-6d1d-727b-8f07-302c7ee10838" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019b097a-6d1d-7e34-83c9-b5a40f87e70e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityRegistrantName_019b097a-6d1d-7e34-83c9-b5a40f87e70e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019b097a-6d1d-7d88-a32a-d24416ac57f3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019b097a-6d1d-7d88-a32a-d24416ac57f3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019b097a-6d1d-7916-99de-fc61049c6d94" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityAddressAddressLine1_019b097a-6d1d-7916-99de-fc61049c6d94" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_019b097a-6d1d-70b0-8b1b-e225b4f5497b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityAddressAddressLine2_019b097a-6d1d-70b0-8b1b-e225b4f5497b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019b097a-6d1d-7ca2-a18e-f8e7616e9a5a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityAddressCityOrTown_019b097a-6d1d-7ca2-a18e-f8e7616e9a5a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019bb2be-b82c-7bc6-b820-3248fb0bb518" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityAddressStateOrProvince_019bb2be-b82c-7bc6-b820-3248fb0bb518" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019b097a-6d1d-7bcc-b643-797ff9839f2f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityAddressPostalZipCode_019b097a-6d1d-7bcc-b643-797ff9839f2f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019b097a-6d1d-7f79-bb2c-faeb7e14906d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_CityAreaCode_019b097a-6d1d-7f79-bb2c-faeb7e14906d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019b097a-6d1d-7479-b0f0-90f6108876e0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_LocalPhoneNumber_019b097a-6d1d-7479-b0f0-90f6108876e0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019b097a-6d1d-7bb4-809a-4dcac04a3ba9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_Security12bTitle_019b097a-6d1d-7bb4-809a-4dcac04a3ba9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019b097a-6d1d-7c11-bf66-1f2db4a058b2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_TradingSymbol_019b097a-6d1d-7c11-bf66-1f2db4a058b2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019b097a-6d1d-7429-9838-49ead16e67f1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_SecurityExchangeName_019b097a-6d1d-7429-9838-49ead16e67f1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_019b097a-6d1d-79f7-afad-302476e67858" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_019b097a-6d1d-79f7-afad-302476e67858" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_019b097a-6d1d-7905-afef-d3b7ddedcc42" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityVoluntaryFilers_019b097a-6d1d-7905-afef-d3b7ddedcc42" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_019b097a-6d1d-741e-b84e-64639dc98f0c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityCurrentReportingStatus_019b097a-6d1d-741e-b84e-64639dc98f0c" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_019b097a-6d1d-716c-9969-b1f46ce22708" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityInteractiveDataCurrent_019b097a-6d1d-716c-9969-b1f46ce22708" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_019b097a-6d1d-7243-a0af-c0a2090f8dab" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityFilerCategory_019b097a-6d1d-7243-a0af-c0a2090f8dab" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_019b097a-6d1d-7809-b9b2-c1ee17a5912e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntitySmallBusiness_019b097a-6d1d-7809-b9b2-c1ee17a5912e" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019b097a-6d1d-7c39-94c4-fc3ffd3194a4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityEmergingGrowthCompany_019b097a-6d1d-7c39-94c4-fc3ffd3194a4" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_019b097a-6d1d-72eb-a84a-2915aa91404f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityExTransitionPeriod_019b097a-6d1d-72eb-a84a-2915aa91404f" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_019b097a-6d1d-7a8d-89c4-a8758fd9a444" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_IcfrAuditorAttestationFlag_019b097a-6d1d-7a8d-89c4-a8758fd9a444" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_019b097a-6d1d-7348-a48b-a75bb7637a35" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_019b097a-6d1d-7348-a48b-a75bb7637a35" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_019b097a-6d1d-7bc2-8012-19ad6867811c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityShellCompany_019b097a-6d1d-7bc2-8012-19ad6867811c" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_019b097a-6d1d-760e-85f7-067cc6ecbf11" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityPublicFloat_019b097a-6d1d-760e-85f7-067cc6ecbf11" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_019b097a-6d1d-7f31-ab54-afb872ab47b7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_019b097a-6d1d-7f31-ab54-afb872ab47b7" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019b097a-6d1d-7e59-ac94-cb19aff80ebf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityCentralIndexKey_019b097a-6d1d-7e59-ac94-cb19aff80ebf" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_019b097a-6d1d-7ac8-bb0e-ed2d897cab72" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_DocumentFiscalYearFocus_019b097a-6d1d-7ac8-bb0e-ed2d897cab72" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_019b097a-6d1d-7213-8ad4-d3ee44a41c50" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_DocumentFiscalPeriodFocus_019b097a-6d1d-7213-8ad4-d3ee44a41c50" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019b097a-6d1d-7a69-b21b-349722f0c579" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_AmendmentFlag_019b097a-6d1d-7a69-b21b-349722f0c579" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019b097a-6d1d-7546-bb93-3338485692b3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityTaxIdentificationNumber_019b097a-6d1d-7546-bb93-3338485692b3" xlink:type="arc" order="35"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="brns-20251231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019b097a-6d1e-7a2b-90af-32f839056431" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_StatementTable_019b097a-6d1e-7a2b-90af-32f839056431" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019b097a-6d1e-7b50-a6e8-b5abe70a3044" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019b097a-6d1e-7a2b-90af-32f839056431" xlink:to="loc_srt_ProductOrServiceAxis_019b097a-6d1e-7b50-a6e8-b5abe70a3044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019b097a-6d1e-7b50-a6e8-b5abe70a3044_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019b097a-6d1e-7b50-a6e8-b5abe70a3044" xlink:to="loc_srt_ProductsAndServicesDomain_019b097a-6d1e-7b50-a6e8-b5abe70a3044_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019b097a-6d1e-7057-9a21-444e5029d13e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019b097a-6d1e-7b50-a6e8-b5abe70a3044" xlink:to="loc_srt_ProductsAndServicesDomain_019b097a-6d1e-7057-9a21-444e5029d13e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_019b097a-6d1e-7b13-a7f2-2daffb8b3b05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019b097a-6d1e-7057-9a21-444e5029d13e" xlink:to="loc_us-gaap_LicenseMember_019b097a-6d1e-7b13-a7f2-2daffb8b3b05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019b097a-6d1e-7975-b028-1f98f0d56709" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019b097a-6d1e-7975-b028-1f98f0d56709" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_019b097a-6d1e-75c3-9014-70aa2a6cc36c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_019b097a-6d1e-75c3-9014-70aa2a6cc36c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019b097a-6d1e-7040-82d2-29c6d93990a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019b097a-6d1e-75c3-9014-70aa2a6cc36c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019b097a-6d1e-7040-82d2-29c6d93990a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019b097a-6d1e-7e4c-9ae1-e5ff61039bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019b097a-6d1e-75c3-9014-70aa2a6cc36c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019b097a-6d1e-7e4c-9ae1-e5ff61039bfd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_019b2bd2-1df8-709c-b09d-0351fcdc2918" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019b097a-6d1e-75c3-9014-70aa2a6cc36c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_019b2bd2-1df8-709c-b09d-0351fcdc2918" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_019b097a-6d1e-78ef-99f0-c3c23573fb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019b097a-6d1e-75c3-9014-70aa2a6cc36c" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_019b097a-6d1e-78ef-99f0-c3c23573fb5e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019b097a-6d1e-7fa6-938f-68870c8a0404" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019b097a-6d1e-75c3-9014-70aa2a6cc36c" xlink:to="loc_us-gaap_OperatingExpenses_019b097a-6d1e-7fa6-938f-68870c8a0404" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_019b097a-6d1e-77a8-8b28-de29a8542397" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_OtherOperatingIncome_019b097a-6d1e-77a8-8b28-de29a8542397" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019b097a-6d1e-7468-b7b7-cfa76ce07778" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_OperatingIncomeLoss_019b097a-6d1e-7468-b7b7-cfa76ce07778" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7320-8662-422641659c51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7320-8662-422641659c51" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019b097a-6d1e-7486-9c9d-b895883a6dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7320-8662-422641659c51" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019b097a-6d1e-7486-9c9d-b895883a6dcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_019b097a-6d1e-7f0c-abb2-3b6ec15959ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7320-8662-422641659c51" xlink:to="loc_us-gaap_InterestExpenseNonoperating_019b097a-6d1e-7f0c-abb2-3b6ec15959ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_019b097a-6d1e-7b40-8bad-56b43d3e183d" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentIncentiveIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7320-8662-422641659c51" xlink:to="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_019b097a-6d1e-7b40-8bad-56b43d3e183d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019b097a-6d1e-7a84-802f-af0fdb1786fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7320-8662-422641659c51" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019b097a-6d1e-7a84-802f-af0fdb1786fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019b097a-6d1e-77d6-b194-926164e0b7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7320-8662-422641659c51" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019b097a-6d1e-77d6-b194-926164e0b7b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b097a-6d1e-7c29-8720-98a9588c30f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b097a-6d1e-7c29-8720-98a9588c30f3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019b097a-6d1e-74e1-9855-a915eb439170" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019b097a-6d1e-74e1-9855-a915eb439170" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019b097a-6d1e-7ee2-87af-bbc922aa9974" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_ProfitLoss_019b097a-6d1e-7ee2-87af-bbc922aa9974" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019b097a-6d1e-77d0-b59a-25acc9471587" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019b097a-6d1e-77d0-b59a-25acc9471587" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019b097a-6d1e-7dc6-8586-11d82add9c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_NetIncomeLoss_019b097a-6d1e-7dc6-8586-11d82add9c0f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019b097a-6d1e-7c83-9084-3d0db8d0d75f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019b097a-6d1e-7c83-9084-3d0db8d0d75f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019b097a-6d1e-7a62-81ee-765a9c94d7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019b097a-6d1e-7a62-81ee-765a9c94d7cf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019b097a-6d1e-742d-a8bc-ff30e8792c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_EarningsPerShareBasic_019b097a-6d1e-742d-a8bc-ff30e8792c8b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019b097a-6d1e-7025-8a0a-ca531f45f97d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019b097a-6d1e-7025-8a0a-ca531f45f97d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019b097a-6d1e-728d-b05d-1606455f74dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019b097a-6d1e-7d96-b486-5b29dd8648bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019b097a-6d1e-7d96-b486-5b29dd8648bf" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-748f-9d94-326f16bfdf95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-748f-9d94-326f16bfdf95" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_019b097a-6d1e-713a-82fb-872750cd1b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_019b097a-6d1e-713a-82fb-872750cd1b4f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019b097a-6d1e-7b6d-9418-c93faaa22ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_019b097a-6d1e-7b6d-9418-c93faaa22ed6" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="brns-20251231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019b097a-6d1e-7d8c-8b7b-485a48414ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019b097a-6d1e-7c5d-9364-9ccaadf42b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7d8c-8b7b-485a48414ab4" xlink:to="loc_us-gaap_StatementTable_019b097a-6d1e-7c5d-9364-9ccaadf42b3f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019b097a-6d1e-7e8b-b70f-577f28a261bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019b097a-6d1e-7c5d-9364-9ccaadf42b3f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019b097a-6d1e-7e8b-b70f-577f28a261bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019b097a-6d1e-7e8b-b70f-577f28a261bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019b097a-6d1e-7e8b-b70f-577f28a261bb" xlink:to="loc_us-gaap_EquityComponentDomain_019b097a-6d1e-7e8b-b70f-577f28a261bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019b097a-6d1e-770a-829f-0f35a83a341b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019b097a-6d1e-7e8b-b70f-577f28a261bb" xlink:to="loc_us-gaap_EquityComponentDomain_019b097a-6d1e-770a-829f-0f35a83a341b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_019b097a-6d1e-70cb-8154-c6290c5997ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019b097a-6d1e-770a-829f-0f35a83a341b" xlink:to="loc_us-gaap_ParentMember_019b097a-6d1e-70cb-8154-c6290c5997ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019b097a-6d1e-7d42-86af-0f85d1d425e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_019b097a-6d1e-70cb-8154-c6290c5997ef" xlink:to="loc_us-gaap_CommonStockMember_019b097a-6d1e-7d42-86af-0f85d1d425e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredSharesMember_019b097a-6d1e-758e-8d66-11d902605408" xlink:href="brns-20251231.xsd#brns_DeferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_019b097a-6d1e-70cb-8154-c6290c5997ef" xlink:to="loc_brns_DeferredSharesMember_019b097a-6d1e-758e-8d66-11d902605408" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019b097a-6d1e-77cd-90b9-ff3ffa5bf7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_019b097a-6d1e-70cb-8154-c6290c5997ef" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019b097a-6d1e-77cd-90b9-ff3ffa5bf7d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019b097a-6d1e-79f5-8f46-4f2b381fdc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_019b097a-6d1e-70cb-8154-c6290c5997ef" xlink:to="loc_us-gaap_RetainedEarningsMember_019b097a-6d1e-79f5-8f46-4f2b381fdc9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019b097a-6d1e-7d0c-9563-e497b78bada0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_019b097a-6d1e-70cb-8154-c6290c5997ef" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019b097a-6d1e-7d0c-9563-e497b78bada0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_019b097a-6d1e-76bf-b665-593a86cc9e76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019b097a-6d1e-770a-829f-0f35a83a341b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_019b097a-6d1e-76bf-b665-593a86cc9e76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019b097a-6d1e-70cb-a4a4-a49082c0d63b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7d8c-8b7b-485a48414ab4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019b097a-6d1e-70cb-a4a4-a49082c0d63b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_019b097a-6d1e-73cd-8b32-a473a70dfd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019b097a-6d1e-70cb-a4a4-a49082c0d63b" xlink:to="loc_us-gaap_SharesIssued_019b097a-6d1e-73cd-8b32-a473a70dfd8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-7798-b842-e67b9ff27a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019b097a-6d1e-70cb-a4a4-a49082c0d63b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-7798-b842-e67b9ff27a8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019b097a-6d1e-78f3-bd38-c2dde771b305" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019b097a-6d1e-70cb-a4a4-a49082c0d63b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019b097a-6d1e-78f3-bd38-c2dde771b305" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019b097a-6d1e-749e-a071-3077db9d374c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019b097a-6d1e-70cb-a4a4-a49082c0d63b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019b097a-6d1e-749e-a071-3077db9d374c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019b097a-6d1e-79f3-9380-22220d4b4680" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019b097a-6d1e-70cb-a4a4-a49082c0d63b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019b097a-6d1e-79f3-9380-22220d4b4680" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019b097a-6d1e-74d2-8045-d46c1e480afc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019b097a-6d1e-70cb-a4a4-a49082c0d63b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019b097a-6d1e-74d2-8045-d46c1e480afc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019b097a-6d1e-73f2-b875-6a75c3b62add" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019b097a-6d1e-70cb-a4a4-a49082c0d63b" xlink:to="loc_us-gaap_ProfitLoss_019b097a-6d1e-73f2-b875-6a75c3b62add" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_019b097a-6d1e-7ea2-aa0f-1523616a50e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-7656-ab75-669976e1db3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#NatureofBusinessandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramTable_019bd5df-9dd5-73eb-aeec-7f4915f8b724" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:to="loc_srt_ShareRepurchaseProgramTable_019bd5df-9dd5-73eb-aeec-7f4915f8b724" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_019bd5df-9dd5-7517-85d7-a7268904bf75" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ShareRepurchaseProgramTable_019bd5df-9dd5-73eb-aeec-7f4915f8b724" xlink:to="loc_srt_StatementScenarioAxis_019bd5df-9dd5-7517-85d7-a7268904bf75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_019bd5df-9dd5-7517-85d7-a7268904bf75_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_019bd5df-9dd5-7517-85d7-a7268904bf75" xlink:to="loc_srt_ScenarioUnspecifiedDomain_019bd5df-9dd5-7517-85d7-a7268904bf75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_019bd5df-9dd5-73f8-921f-c177062f45d3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_019bd5df-9dd5-7517-85d7-a7268904bf75" xlink:to="loc_srt_ScenarioUnspecifiedDomain_019bd5df-9dd5-73f8-921f-c177062f45d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_019bd5df-9dd5-7b8b-8d9f-0879b189a31d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_019bd5df-9dd5-73f8-921f-c177062f45d3" xlink:to="loc_srt_ScenarioForecastMember_019bd5df-9dd5-7b8b-8d9f-0879b189a31d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019bd5df-9dd5-70b9-8e39-4c175f16c2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ShareRepurchaseProgramTable_019bd5df-9dd5-73eb-aeec-7f4915f8b724" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019bd5df-9dd5-70b9-8e39-4c175f16c2cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019bd5df-9dd5-70b9-8e39-4c175f16c2cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019bd5df-9dd5-70b9-8e39-4c175f16c2cc" xlink:to="loc_us-gaap_ClassOfStockDomain_019bd5df-9dd5-70b9-8e39-4c175f16c2cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019bd5df-9dd5-70a0-8b60-0df0d5bb57ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019bd5df-9dd5-70b9-8e39-4c175f16c2cc" xlink:to="loc_us-gaap_ClassOfStockDomain_019bd5df-9dd5-70a0-8b60-0df0d5bb57ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SchemeSharesMember_019bd5df-9dd5-7a9a-995c-8788d9892307" xlink:href="brns-20251231.xsd#brns_SchemeSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019bd5df-9dd5-70a0-8b60-0df0d5bb57ac" xlink:to="loc_brns_SchemeSharesMember_019bd5df-9dd5-7a9a-995c-8788d9892307" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ClywedogCapitalStockMember_019bd5df-9dd5-7368-b1bd-54a975ed87e6" xlink:href="brns-20251231.xsd#brns_ClywedogCapitalStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019bd5df-9dd5-70a0-8b60-0df0d5bb57ac" xlink:to="loc_brns_ClywedogCapitalStockMember_019bd5df-9dd5-7368-b1bd-54a975ed87e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019bd5df-9dd5-778a-be3c-3d1a71c59f30" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ShareRepurchaseProgramTable_019bd5df-9dd5-73eb-aeec-7f4915f8b724" xlink:to="loc_dei_LegalEntityAxis_019bd5df-9dd5-778a-be3c-3d1a71c59f30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019bd5df-9dd5-778a-be3c-3d1a71c59f30_default" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_019bd5df-9dd5-778a-be3c-3d1a71c59f30" xlink:to="loc_dei_EntityDomain_019bd5df-9dd5-778a-be3c-3d1a71c59f30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019bd5df-9dd5-71d8-8cb3-94a8d283f394" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_019bd5df-9dd5-778a-be3c-3d1a71c59f30" xlink:to="loc_dei_EntityDomain_019bd5df-9dd5-71d8-8cb3-94a8d283f394" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_BecaonTopcoIncMember_019bd5df-9dd5-7c83-8739-9173451c0263" xlink:href="brns-20251231.xsd#brns_BecaonTopcoIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_019bd5df-9dd5-71d8-8cb3-94a8d283f394" xlink:to="loc_brns_BecaonTopcoIncMember_019bd5df-9dd5-7c83-8739-9173451c0263" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ClywedogTherapeuticsInc.Member_019bd5df-9dd5-7f9b-8184-48b3c9579388" xlink:href="brns-20251231.xsd#brns_ClywedogTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_019bd5df-9dd5-71d8-8cb3-94a8d283f394" xlink:to="loc_brns_ClywedogTherapeuticsInc.Member_019bd5df-9dd5-7f9b-8184-48b3c9579388" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfNewSubsidiaries_019c498f-64bb-7d9e-b345-16726fe99512" xlink:href="brns-20251231.xsd#brns_NumberOfNewSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:to="loc_brns_NumberOfNewSubsidiaries_019c498f-64bb-7d9e-b345-16726fe99512" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019bd5df-9dd5-7b45-a215-2351ac79efb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019bd5df-9dd5-7b45-a215-2351ac79efb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfDepositarySharesPerShareOfCommonStock_019bd5e2-c436-71ae-b001-52e2b60ec1ab" xlink:href="brns-20251231.xsd#brns_NumberOfDepositarySharesPerShareOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:to="loc_brns_NumberOfDepositarySharesPerShareOfCommonStock_019bd5e2-c436-71ae-b001-52e2b60ec1ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_StockConversionRatio_019bd5df-9dd5-74f5-948e-b5ed213d517c" xlink:href="brns-20251231.xsd#brns_StockConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:to="loc_brns_StockConversionRatio_019bd5df-9dd5-74f5-948e-b5ed213d517c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019bd5df-9dd5-702c-b67a-787a90a30eae" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019bd5df-9dd5-702c-b67a-787a90a30eae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019bd5df-9dd5-7f55-9cd6-98ae4f3edb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019bd5df-9dd5-7f55-9cd6-98ae4f3edb5d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MergerAgreementExtensionPeriod_019bd5df-9dd5-78f4-946d-765a99420577" xlink:href="brns-20251231.xsd#brns_MergerAgreementExtensionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:to="loc_brns_MergerAgreementExtensionPeriod_019bd5df-9dd5-78f4-946d-765a99420577" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019bd5df-9dd5-78a1-8b35-15a9843880be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019bd5df-9dd5-78a1-8b35-15a9843880be" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019bd5df-9dd5-7697-8a6b-33df8170fb89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019bd5df-9dd5-7697-8a6b-33df8170fb89" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_019b097a-6d1e-7697-9d3a-444e3d8c98ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_019b097a-6d1e-76c8-b9ae-abbfefbbd16e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_019b097a-6d1e-7697-9d3a-444e3d8c98ec" xlink:to="loc_us-gaap_MinorityInterestTable_019b097a-6d1e-76c8-b9ae-abbfefbbd16e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_019b097a-6d1e-7128-82e5-23a8fe745a1a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_019b097a-6d1e-76c8-b9ae-abbfefbbd16e" xlink:to="loc_srt_OwnershipAxis_019b097a-6d1e-7128-82e5-23a8fe745a1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_019b097a-6d1e-7128-82e5-23a8fe745a1a_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_019b097a-6d1e-7128-82e5-23a8fe745a1a" xlink:to="loc_srt_OwnershipDomain_019b097a-6d1e-7128-82e5-23a8fe745a1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_019b097a-6d1e-7cae-96f8-eeaaabd76eef" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_019b097a-6d1e-7128-82e5-23a8fe745a1a" xlink:to="loc_srt_OwnershipDomain_019b097a-6d1e-7cae-96f8-eeaaabd76eef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_VOLTMember_019b097a-6d1e-73e8-b3ab-bdf3532ee680" xlink:href="brns-20251231.xsd#brns_VOLTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_019b097a-6d1e-7cae-96f8-eeaaabd76eef" xlink:to="loc_brns_VOLTMember_019b097a-6d1e-73e8-b3ab-bdf3532ee680" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_019b097a-6d1e-76d0-b8f7-6f55af8ae816" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_019b097a-6d1e-76c8-b9ae-abbfefbbd16e" xlink:to="loc_srt_ConsolidatedEntitiesAxis_019b097a-6d1e-76d0-b8f7-6f55af8ae816" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_019b097a-6d1e-76d0-b8f7-6f55af8ae816_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_019b097a-6d1e-76d0-b8f7-6f55af8ae816" xlink:to="loc_srt_ConsolidatedEntitiesDomain_019b097a-6d1e-76d0-b8f7-6f55af8ae816_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_019b097a-6d1e-735b-952b-948c9148291a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_019b097a-6d1e-76d0-b8f7-6f55af8ae816" xlink:to="loc_srt_ConsolidatedEntitiesDomain_019b097a-6d1e-735b-952b-948c9148291a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SubsidiariesVOLTMember_019b097a-6d1e-7b81-9c3b-460b274b2079" xlink:href="brns-20251231.xsd#brns_SubsidiariesVOLTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_019b097a-6d1e-735b-952b-948c9148291a" xlink:to="loc_brns_SubsidiariesVOLTMember_019b097a-6d1e-7b81-9c3b-460b274b2079" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019b097a-6d1e-7ffa-aeba-4a196f20fe7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_019b097a-6d1e-76c8-b9ae-abbfefbbd16e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019b097a-6d1e-7ffa-aeba-4a196f20fe7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019b097a-6d1e-7ffa-aeba-4a196f20fe7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019b097a-6d1e-7ffa-aeba-4a196f20fe7f" xlink:to="loc_us-gaap_RelatedPartyDomain_019b097a-6d1e-7ffa-aeba-4a196f20fe7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019b097a-6d1e-7ff8-8ed8-18a2e640331b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019b097a-6d1e-7ffa-aeba-4a196f20fe7f" xlink:to="loc_us-gaap_RelatedPartyDomain_019b097a-6d1e-7ff8-8ed8-18a2e640331b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019b097a-6d1e-7223-9246-3ce3347233fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019b097a-6d1e-7ff8-8ed8-18a2e640331b" xlink:to="loc_us-gaap_RelatedPartyMember_019b097a-6d1e-7223-9246-3ce3347233fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SubsidiaryCumulativeContributionsParent_019b097a-6d1e-7ef4-b06a-07e7849cbf2a" xlink:href="brns-20251231.xsd#brns_SubsidiaryCumulativeContributionsParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_019b097a-6d1e-7697-9d3a-444e3d8c98ec" xlink:to="loc_brns_SubsidiaryCumulativeContributionsParent_019b097a-6d1e-7ef4-b06a-07e7849cbf2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_019b097a-6d1e-703c-8bd7-e96ee1012d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_019b097a-6d1e-7697-9d3a-444e3d8c98ec" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_019b097a-6d1e-703c-8bd7-e96ee1012d9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner_019b097a-6d1e-7f42-a0ca-bc534caf1c07" xlink:href="brns-20251231.xsd#brns_SubsidiaryCumulativeContributionsNoncontrollingOwner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_019b097a-6d1e-7697-9d3a-444e3d8c98ec" xlink:to="loc_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner_019b097a-6d1e-7f42-a0ca-bc534caf1c07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_019b097a-6d1e-7a31-ab4e-c22e6e1d28d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_019b097a-6d1e-7697-9d3a-444e3d8c98ec" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_019b097a-6d1e-7a31-ab4e-c22e6e1d28d8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_019b097a-6d1e-77b7-8661-3cc844e5e11f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_019b097a-6d1e-72bc-a379-7c88096ae007" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019b097a-6d1e-77b7-8661-3cc844e5e11f" xlink:to="loc_us-gaap_ConcentrationRiskTable_019b097a-6d1e-72bc-a379-7c88096ae007" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019b097a-6d1e-7c9b-8a0a-c6b06b09c47d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019b097a-6d1e-72bc-a379-7c88096ae007" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019b097a-6d1e-7c9b-8a0a-c6b06b09c47d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019b097a-6d1e-7c9b-8a0a-c6b06b09c47d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019b097a-6d1e-7c9b-8a0a-c6b06b09c47d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019b097a-6d1e-7c9b-8a0a-c6b06b09c47d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019b097a-6d1e-7db2-9a5b-ea491f70ac55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019b097a-6d1e-7c9b-8a0a-c6b06b09c47d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019b097a-6d1e-7db2-9a5b-ea491f70ac55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_019b097a-6d1e-7036-9b3f-f6336fe94441" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019b097a-6d1e-7db2-9a5b-ea491f70ac55" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_019b097a-6d1e-7036-9b3f-f6336fe94441" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_019b097a-6d1e-7cbd-8953-d6fcbfcc8b2e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019b097a-6d1e-72bc-a379-7c88096ae007" xlink:to="loc_srt_StatementGeographicalAxis_019b097a-6d1e-7cbd-8953-d6fcbfcc8b2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019b097a-6d1e-7cbd-8953-d6fcbfcc8b2e_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_019b097a-6d1e-7cbd-8953-d6fcbfcc8b2e" xlink:to="loc_srt_SegmentGeographicalDomain_019b097a-6d1e-7cbd-8953-d6fcbfcc8b2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019b097a-6d1e-713a-82f1-758ad4cb4e18" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_019b097a-6d1e-7cbd-8953-d6fcbfcc8b2e" xlink:to="loc_srt_SegmentGeographicalDomain_019b097a-6d1e-713a-82f1-758ad4cb4e18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_019b097a-6d1e-7bef-b06c-58daf5fef672" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019b097a-6d1e-713a-82f1-758ad4cb4e18" xlink:to="loc_country_GB_019b097a-6d1e-7bef-b06c-58daf5fef672" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_019b097a-6d1e-7616-8ef7-da72928bf821" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019b097a-6d1e-72bc-a379-7c88096ae007" xlink:to="loc_srt_MajorCustomersAxis_019b097a-6d1e-7616-8ef7-da72928bf821" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019b097a-6d1e-7616-8ef7-da72928bf821_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_019b097a-6d1e-7616-8ef7-da72928bf821" xlink:to="loc_srt_NameOfMajorCustomerDomain_019b097a-6d1e-7616-8ef7-da72928bf821_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019b097a-6d1e-791f-8313-976c473c27c8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_019b097a-6d1e-7616-8ef7-da72928bf821" xlink:to="loc_srt_NameOfMajorCustomerDomain_019b097a-6d1e-791f-8313-976c473c27c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordUniversityInnovationMember_019b097a-6d1e-7611-a7bc-ea97fa9a01df" xlink:href="brns-20251231.xsd#brns_OxfordUniversityInnovationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_019b097a-6d1e-791f-8313-976c473c27c8" xlink:to="loc_brns_OxfordUniversityInnovationMember_019b097a-6d1e-7611-a7bc-ea97fa9a01df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccountsReceivableStandardPaymentTermsPeriod_019b097a-6d1e-7f37-b12f-d539679d87c3" xlink:href="brns-20251231.xsd#brns_AccountsReceivableStandardPaymentTermsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019b097a-6d1e-77b7-8661-3cc844e5e11f" xlink:to="loc_brns_AccountsReceivableStandardPaymentTermsPeriod_019b097a-6d1e-7f37-b12f-d539679d87c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ConcentrationRiskThresholdPercentage_019b097a-6d1e-7571-8465-ec5e6d5dd562" xlink:href="brns-20251231.xsd#brns_ConcentrationRiskThresholdPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019b097a-6d1e-77b7-8661-3cc844e5e11f" xlink:to="loc_brns_ConcentrationRiskThresholdPercentage_019b097a-6d1e-7571-8465-ec5e6d5dd562" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019b097a-6d1e-7d3d-933f-d54bcccf0dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019b097a-6d1e-7299-86ee-fe68b357bf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019b097a-6d1e-7d3d-933f-d54bcccf0dcb" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019b097a-6d1e-7299-86ee-fe68b357bf7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019b097a-6d1e-733e-9785-9d2d3674bd03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019b097a-6d1e-7299-86ee-fe68b357bf7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019b097a-6d1e-733e-9785-9d2d3674bd03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-733e-9785-9d2d3674bd03_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019b097a-6d1e-733e-9785-9d2d3674bd03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-733e-9785-9d2d3674bd03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-752a-b26f-33cb815b902b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019b097a-6d1e-733e-9785-9d2d3674bd03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-752a-b26f-33cb815b902b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_019b097a-6d1e-7d2c-8bff-7b92d2d6e6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-752a-b26f-33cb815b902b" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_019b097a-6d1e-7d2c-8bff-7b92d2d6e6c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LaboratoryEquipmentMember_019b097a-6d1e-713c-bc7d-8fcf7e0779dd" xlink:href="brns-20251231.xsd#brns_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-752a-b26f-33cb815b902b" xlink:to="loc_brns_LaboratoryEquipmentMember_019b097a-6d1e-713c-bc7d-8fcf7e0779dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_019b097a-6d1e-7a37-a0ba-1adbe8440469" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019b097a-6d1e-7d3d-933f-d54bcccf0dcb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_019b097a-6d1e-7a37-a0ba-1adbe8440469" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-76c4-95e7-7f0738b84c19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_019b097a-6d1e-7f83-b2bb-ab95bd825f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-76c4-95e7-7f0738b84c19" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_019b097a-6d1e-7f83-b2bb-ab95bd825f5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019b097a-6d1e-7588-a7e8-037a424718c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_019b097a-6d1e-7f83-b2bb-ab95bd825f5e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019b097a-6d1e-7588-a7e8-037a424718c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019b097a-6d1e-7588-a7e8-037a424718c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019b097a-6d1e-7588-a7e8-037a424718c9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019b097a-6d1e-7588-a7e8-037a424718c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019b097a-6d1e-796d-87a7-055920f17ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019b097a-6d1e-7588-a7e8-037a424718c9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019b097a-6d1e-796d-87a7-055920f17ea2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_019b097a-6d1e-7206-8187-fdab1582c754" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019b097a-6d1e-796d-87a7-055920f17ea2" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_019b097a-6d1e-7206-8187-fdab1582c754" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_019b097a-6d1e-7a32-a2bd-24ce7219576c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-76c4-95e7-7f0738b84c19" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_019b097a-6d1e-7a32-a2bd-24ce7219576c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SegmentinformationSignificantSegmentExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_019b097a-6d1e-79e6-a249-433fe27f4ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019b097a-6d1e-787b-96a5-477d3d0c80e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019b097a-6d1e-79e6-a249-433fe27f4ddc" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019b097a-6d1e-787b-96a5-477d3d0c80e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019b097a-6d1e-7c9d-bb27-b8e0ba723f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019b097a-6d1e-787b-96a5-477d3d0c80e9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019b097a-6d1e-7c9d-bb27-b8e0ba723f2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019b097a-6d1e-7c9d-bb27-b8e0ba723f2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019b097a-6d1e-7c9d-bb27-b8e0ba723f2b" xlink:to="loc_us-gaap_SegmentDomain_019b097a-6d1e-7c9d-bb27-b8e0ba723f2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019b097a-6d1e-7d8a-b3a3-0e314f07f281" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019b097a-6d1e-7c9d-bb27-b8e0ba723f2b" xlink:to="loc_us-gaap_SegmentDomain_019b097a-6d1e-7d8a-b3a3-0e314f07f281" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember_019b097a-6d1e-7870-a9bd-bb374b574ebd" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019b097a-6d1e-7d8a-b3a3-0e314f07f281" xlink:to="loc_brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember_019b097a-6d1e-7870-a9bd-bb374b574ebd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019b097a-6d1e-7aa5-b07e-3ba71c761bfc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019b097a-6d1e-787b-96a5-477d3d0c80e9" xlink:to="loc_srt_ProductOrServiceAxis_019b097a-6d1e-7aa5-b07e-3ba71c761bfc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019b097a-6d1e-7aa5-b07e-3ba71c761bfc_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019b097a-6d1e-7aa5-b07e-3ba71c761bfc" xlink:to="loc_srt_ProductsAndServicesDomain_019b097a-6d1e-7aa5-b07e-3ba71c761bfc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019b097a-6d1e-79b2-a4e3-f48061feeacf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019b097a-6d1e-7aa5-b07e-3ba71c761bfc" xlink:to="loc_srt_ProductsAndServicesDomain_019b097a-6d1e-79b2-a4e3-f48061feeacf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_VTP1000CeliacMember_019b097a-6d1e-7263-a6e0-1d8435d7db1b" xlink:href="brns-20251231.xsd#brns_VTP1000CeliacMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019b097a-6d1e-79b2-a4e3-f48061feeacf" xlink:to="loc_brns_VTP1000CeliacMember_019b097a-6d1e-7263-a6e0-1d8435d7db1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_BarinthusLegacyAssetsMember_019c7024-2e3a-7d09-9b29-df61f4541100" xlink:href="brns-20251231.xsd#brns_BarinthusLegacyAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019b097a-6d1e-79b2-a4e3-f48061feeacf" xlink:to="loc_brns_BarinthusLegacyAssetsMember_019c7024-2e3a-7d09-9b29-df61f4541100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentTypeAxis_019b097a-6d1e-7229-be11-b2374e824bbe" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019b097a-6d1e-787b-96a5-477d3d0c80e9" xlink:to="loc_brns_ResearchAndDevelopmentTypeAxis_019b097a-6d1e-7229-be11-b2374e824bbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentTypeDomain_019b097a-6d1e-7229-be11-b2374e824bbe_default" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_brns_ResearchAndDevelopmentTypeAxis_019b097a-6d1e-7229-be11-b2374e824bbe" xlink:to="loc_brns_ResearchAndDevelopmentTypeDomain_019b097a-6d1e-7229-be11-b2374e824bbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentTypeDomain_019b097a-6d1e-763d-8ed3-cb6e2c1256ac" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_brns_ResearchAndDevelopmentTypeAxis_019b097a-6d1e-7229-be11-b2374e824bbe" xlink:to="loc_brns_ResearchAndDevelopmentTypeDomain_019b097a-6d1e-763d-8ed3-cb6e2c1256ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PersonnelRelatedMember_019b097a-6d1e-75c7-b9af-faf97de4c8de" xlink:href="brns-20251231.xsd#brns_PersonnelRelatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_ResearchAndDevelopmentTypeDomain_019b097a-6d1e-763d-8ed3-cb6e2c1256ac" xlink:to="loc_brns_PersonnelRelatedMember_019b097a-6d1e-75c7-b9af-faf97de4c8de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FacilityRelatedMember_019b097a-6d1e-7304-b9e0-5e71948b0128" xlink:href="brns-20251231.xsd#brns_FacilityRelatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_ResearchAndDevelopmentTypeDomain_019b097a-6d1e-763d-8ed3-cb6e2c1256ac" xlink:to="loc_brns_FacilityRelatedMember_019b097a-6d1e-7304-b9e0-5e71948b0128" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OtherIndirectCostsMember_019b097a-6d1e-74d9-b8e5-e6ea9448fc8b" xlink:href="brns-20251231.xsd#brns_OtherIndirectCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_ResearchAndDevelopmentTypeDomain_019b097a-6d1e-763d-8ed3-cb6e2c1256ac" xlink:to="loc_brns_OtherIndirectCostsMember_019b097a-6d1e-74d9-b8e5-e6ea9448fc8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DirectResearchAndDevelopmentExpensesAbstract_019b097a-6d1e-7f18-89a8-50bb8ab3e593" xlink:href="brns-20251231.xsd#brns_DirectResearchAndDevelopmentExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019b097a-6d1e-79e6-a249-433fe27f4ddc" xlink:to="loc_brns_DirectResearchAndDevelopmentExpensesAbstract_019b097a-6d1e-7f18-89a8-50bb8ab3e593" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DirectResearchAndDevelopmentExpense_019b097a-6d1e-7400-acde-172102e95e8a" xlink:href="brns-20251231.xsd#brns_DirectResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_DirectResearchAndDevelopmentExpensesAbstract_019b097a-6d1e-7f18-89a8-50bb8ab3e593" xlink:to="loc_brns_DirectResearchAndDevelopmentExpense_019b097a-6d1e-7400-acde-172102e95e8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IndirectResearchAndDevelopmentExpensesAbstract_019b097a-6d1e-7468-9937-cef8196ceab2" xlink:href="brns-20251231.xsd#brns_IndirectResearchAndDevelopmentExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019b097a-6d1e-79e6-a249-433fe27f4ddc" xlink:to="loc_brns_IndirectResearchAndDevelopmentExpensesAbstract_019b097a-6d1e-7468-9937-cef8196ceab2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IndirectResearchAndDevelopmentExpense_019b097a-6d1e-7c0c-aa82-526db3dc6ed4" xlink:href="brns-20251231.xsd#brns_IndirectResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_IndirectResearchAndDevelopmentExpensesAbstract_019b097a-6d1e-7468-9937-cef8196ceab2" xlink:to="loc_brns_IndirectResearchAndDevelopmentExpense_019b097a-6d1e-7c0c-aa82-526db3dc6ed4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019b097a-6d1e-7196-910c-2b2639072b56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019b097a-6d1e-79e6-a249-433fe27f4ddc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019b097a-6d1e-7196-910c-2b2639072b56" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SegmentinformationLongLivedAssetsDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SegmentinformationLongLivedAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/SegmentinformationLongLivedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_019b097a-6d1e-70d5-807e-6b1af7ccd280" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019b097a-6d1e-7462-85ae-040846c2fba0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019b097a-6d1e-70d5-807e-6b1af7ccd280" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019b097a-6d1e-7462-85ae-040846c2fba0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_019b097a-6d1e-79b2-9860-e124a60d49ee" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019b097a-6d1e-7462-85ae-040846c2fba0" xlink:to="loc_srt_StatementGeographicalAxis_019b097a-6d1e-79b2-9860-e124a60d49ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019b097a-6d1e-79b2-9860-e124a60d49ee_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_019b097a-6d1e-79b2-9860-e124a60d49ee" xlink:to="loc_srt_SegmentGeographicalDomain_019b097a-6d1e-79b2-9860-e124a60d49ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019b097a-6d1e-731a-ad42-4a3ad763dc3d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_019b097a-6d1e-79b2-9860-e124a60d49ee" xlink:to="loc_srt_SegmentGeographicalDomain_019b097a-6d1e-731a-ad42-4a3ad763dc3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019b097a-6d1e-79fc-8ae4-e5d3db1d0b68" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019b097a-6d1e-731a-ad42-4a3ad763dc3d" xlink:to="loc_country_US_019b097a-6d1e-79fc-8ae4-e5d3db1d0b68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_019b097a-6d1e-737f-baf3-7fa96bc7384b" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019b097a-6d1e-731a-ad42-4a3ad763dc3d" xlink:to="loc_country_GB_019b097a-6d1e-737f-baf3-7fa96bc7384b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_019b097a-6d1e-78e4-8fc0-40332e8f41f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019b097a-6d1e-70d5-807e-6b1af7ccd280" xlink:to="loc_us-gaap_NoncurrentAssets_019b097a-6d1e-78e4-8fc0-40332e8f41f1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#PropertyandEquipmentNetComponentsDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019b097a-6d1e-7460-923c-3b756f8d0d63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019b097a-6d1e-751f-a713-14b20e8815f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019b097a-6d1e-7460-923c-3b756f8d0d63" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019b097a-6d1e-751f-a713-14b20e8815f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019b097a-6d1e-7c54-a0a9-b90a375cbe6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019b097a-6d1e-751f-a713-14b20e8815f7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019b097a-6d1e-7c54-a0a9-b90a375cbe6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-7c54-a0a9-b90a375cbe6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019b097a-6d1e-7c54-a0a9-b90a375cbe6d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-7c54-a0a9-b90a375cbe6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-7f13-834b-75b5d4375d33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019b097a-6d1e-7c54-a0a9-b90a375cbe6d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-7f13-834b-75b5d4375d33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_019b097a-6d1e-7d21-8633-ca09b84446bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-7f13-834b-75b5d4375d33" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_019b097a-6d1e-7d21-8633-ca09b84446bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LaboratoryEquipmentMember_019b097a-6d1e-711c-8695-15757c8667a4" xlink:href="brns-20251231.xsd#brns_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-7f13-834b-75b5d4375d33" xlink:to="loc_brns_LaboratoryEquipmentMember_019b097a-6d1e-711c-8695-15757c8667a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_019b097a-6d1e-7125-a1ac-3c1adb1a3345" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-7f13-834b-75b5d4375d33" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_019b097a-6d1e-7125-a1ac-3c1adb1a3345" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_019b097a-6d1e-7839-9db9-397247adac57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019b097a-6d1e-7460-923c-3b756f8d0d63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_019b097a-6d1e-7839-9db9-397247adac57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019b097a-6d1e-7d55-9566-e46a43bec29a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019b097a-6d1e-7460-923c-3b756f8d0d63" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019b097a-6d1e-7d55-9566-e46a43bec29a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019b097a-6d1e-77e5-894b-ccf5cfa9b56d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019b097a-6d1e-7460-923c-3b756f8d0d63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019b097a-6d1e-77e5-894b-ccf5cfa9b56d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IntangibleAssetsNetDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#IntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/IntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_019b097a-6d1e-7839-b43e-5d0f6b288446" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_019b097a-6d1e-7839-b43e-5d0f6b288446" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019b097a-6d1e-79bd-ac97-aad2750e8944" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_019b097a-6d1e-7839-b43e-5d0f6b288446" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019b097a-6d1e-79bd-ac97-aad2750e8944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019b097a-6d1e-79bd-ac97-aad2750e8944_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019b097a-6d1e-79bd-ac97-aad2750e8944" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019b097a-6d1e-79bd-ac97-aad2750e8944_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019b097a-6d1e-742f-befe-a883720c1e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019b097a-6d1e-79bd-ac97-aad2750e8944" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019b097a-6d1e-742f-befe-a883720c1e7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_019b097a-6d1e-7a48-87d0-c0e55473a7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019b097a-6d1e-742f-befe-a883720c1e7a" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_019b097a-6d1e-7a48-87d0-c0e55473a7e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_019b097a-6d1e-7e8f-aa9f-da5663117626" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_019b097a-6d1e-7e8f-aa9f-da5663117626" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_019b097a-6d1e-7019-ae0a-0b1c17881c02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_019b097a-6d1e-7019-ae0a-0b1c17881c02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_019b097a-6d1e-79c3-9b6d-d63db4032ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_019b097a-6d1e-79c3-9b6d-d63db4032ab2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_019b097a-6d1e-7a60-95af-5a1216142414" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_019b097a-6d1e-7a60-95af-5a1216142414" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_019b097a-6d1e-7de6-a1f0-584b383623fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_019b097a-6d1e-7de6-a1f0-584b383623fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_019b097a-6d1e-7656-aa4d-741b37f9580a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_019b097a-6d1e-7656-aa4d-741b37f9580a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_019b097a-6d1e-747d-9c64-fa01da012ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_019b097a-6d1e-747d-9c64-fa01da012ce8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_019b097a-6d1e-7b49-ae54-34e318b65fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_019b097a-6d1e-7b49-ae54-34e318b65fdb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix_019b097a-6d1e-7723-b1c0-3fefc10c0c86" xlink:href="brns-20251231.xsd#brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:to="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix_019b097a-6d1e-7723-b1c0-3fefc10c0c86" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_019b097a-6d1e-72a6-99bf-9b889c015325" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_019b097a-6d1e-72a6-99bf-9b889c015325" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#GrantIncomeAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019b097a-6d1e-7beb-8ccc-659561bfabad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019b097a-6d1e-74fc-8f1f-e1ad3541ebf4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019b097a-6d1e-7beb-8ccc-659561bfabad" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019b097a-6d1e-74fc-8f1f-e1ad3541ebf4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019b097a-6d1e-79b6-9b89-f2c20822a20e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019b097a-6d1e-74fc-8f1f-e1ad3541ebf4" xlink:to="loc_srt_CounterpartyNameAxis_019b097a-6d1e-79b6-9b89-f2c20822a20e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019b097a-6d1e-79b6-9b89-f2c20822a20e_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_019b097a-6d1e-79b6-9b89-f2c20822a20e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019b097a-6d1e-79b6-9b89-f2c20822a20e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019b097a-6d1e-704f-850d-a08510c5f753" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_019b097a-6d1e-79b6-9b89-f2c20822a20e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019b097a-6d1e-704f-850d-a08510c5f753" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_CoalitionForEpidemicPreparednessInnovationsMember_019b097a-6d1e-7df3-983d-28577f2c558a" xlink:href="brns-20251231.xsd#brns_CoalitionForEpidemicPreparednessInnovationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019b097a-6d1e-704f-850d-a08510c5f753" xlink:to="loc_brns_CoalitionForEpidemicPreparednessInnovationsMember_019b097a-6d1e-7df3-983d-28577f2c558a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FundingAmountMaximum_019b097a-6d1e-703a-8f65-09748f22ab16" xlink:href="brns-20251231.xsd#brns_FundingAmountMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019b097a-6d1e-7beb-8ccc-659561bfabad" xlink:to="loc_brns_FundingAmountMaximum_019b097a-6d1e-703a-8f65-09748f22ab16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeAddition_019b097a-6d1e-7620-a0da-d3ad0cc2b300" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeAddition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019b097a-6d1e-7beb-8ccc-659561bfabad" xlink:to="loc_us-gaap_DeferredIncomeAddition_019b097a-6d1e-7620-a0da-d3ad0cc2b300" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeRevenueRecognized_019b097a-6d1e-7e52-8aac-511295e9c52c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019b097a-6d1e-7beb-8ccc-659561bfabad" xlink:to="loc_us-gaap_DeferredIncomeRevenueRecognized_019b097a-6d1e-7e52-8aac-511295e9c52c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_019b097a-6d1e-7328-bf5c-1b2f3fcdcd82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019b097a-6d1e-7beb-8ccc-659561bfabad" xlink:to="loc_us-gaap_RestrictedCashCurrent_019b097a-6d1e-7328-bf5c-1b2f3fcdcd82" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#OrdinarySharesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_019b097a-6d1e-7434-ad80-1308245c605f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_019b097a-6d1e-78d1-831b-1af4752505ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_019b097a-6d1e-7434-ad80-1308245c605f" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_019b097a-6d1e-78d1-831b-1af4752505ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019b097a-6d1e-7d31-b01a-f8b8ec44888e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_019b097a-6d1e-78d1-831b-1af4752505ce" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019b097a-6d1e-7d31-b01a-f8b8ec44888e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019b097a-6d1e-7d31-b01a-f8b8ec44888e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019b097a-6d1e-7d31-b01a-f8b8ec44888e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019b097a-6d1e-7d31-b01a-f8b8ec44888e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019b097a-6d1e-7702-ab8c-dc36677b0e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019b097a-6d1e-7d31-b01a-f8b8ec44888e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019b097a-6d1e-7702-ab8c-dc36677b0e7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_019b097a-6d1e-717e-9a71-0fb2024da8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019b097a-6d1e-7702-ab8c-dc36677b0e7d" xlink:to="loc_us-gaap_IPOMember_019b097a-6d1e-717e-9a71-0fb2024da8ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_CommonStockNumberOfVotesPerShare_019b097a-6d1e-7847-90ff-f062badf4425" xlink:href="brns-20251231.xsd#brns_CommonStockNumberOfVotesPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_019b097a-6d1e-7434-ad80-1308245c605f" xlink:to="loc_brns_CommonStockNumberOfVotesPerShare_019b097a-6d1e-7847-90ff-f062badf4425" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights_019b097a-6d1e-7722-a599-43c6c8e74d24" xlink:href="brns-20251231.xsd#brns_PercentageOfSharesNecessaryToExercisePreemptiveRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_019b097a-6d1e-7434-ad80-1308245c605f" xlink:to="loc_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights_019b097a-6d1e-7722-a599-43c6c8e74d24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PeriodOfPreemptiveRightsToBeExercised_019b097a-6d1e-70bc-9fbc-c06d87ccb7c3" xlink:href="brns-20251231.xsd#brns_PeriodOfPreemptiveRightsToBeExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_019b097a-6d1e-7434-ad80-1308245c605f" xlink:to="loc_brns_PeriodOfPreemptiveRightsToBeExercised_019b097a-6d1e-70bc-9fbc-c06d87ccb7c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights_019b097a-6d1e-708e-a8c4-e305446ca79b" xlink:href="brns-20251231.xsd#brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_019b097a-6d1e-7434-ad80-1308245c605f" xlink:to="loc_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights_019b097a-6d1e-708e-a8c4-e305446ca79b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#FairValueAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019b097a-6e6b-786c-9702-b0227c9e6567" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019b097a-6e6b-78a3-8801-d042e5a0bf58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019b097a-6e6b-786c-9702-b0227c9e6567" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019b097a-6e6b-78a3-8801-d042e5a0bf58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_019b097a-6e6b-767c-9cf7-8a9b8b8bbaa6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019b097a-6e6b-78a3-8801-d042e5a0bf58" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_019b097a-6e6b-767c-9cf7-8a9b8b8bbaa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019b097a-6e6b-767c-9cf7-8a9b8b8bbaa6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019b097a-6e6b-767c-9cf7-8a9b8b8bbaa6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019b097a-6e6b-767c-9cf7-8a9b8b8bbaa6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019b097a-6e6b-771e-a378-7b0ff2eb0336" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019b097a-6e6b-767c-9cf7-8a9b8b8bbaa6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019b097a-6e6b-771e-a378-7b0ff2eb0336" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AvideaMember_019b097a-6e6b-7cc9-81aa-d581a61102bc" xlink:href="brns-20251231.xsd#brns_AvideaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019b097a-6e6b-771e-a378-7b0ff2eb0336" xlink:to="loc_brns_AvideaMember_019b097a-6e6b-7cc9-81aa-d581a61102bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019b097a-6e6b-7ca5-8e89-1c3e86124cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019b097a-6e6b-786c-9702-b0227c9e6567" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019b097a-6e6b-7ca5-8e89-1c3e86124cbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_019b097a-6e6b-7366-9cd6-6f4b5de7b26a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019b097a-6e6b-786c-9702-b0227c9e6567" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_019b097a-6e6b-7366-9cd6-6f4b5de7b26a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_019b097a-6e6b-71a6-8a92-473fa2f5da3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019b097a-6e6b-786c-9702-b0227c9e6567" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_019b097a-6e6b-71a6-8a92-473fa2f5da3f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6b-74e5-9ccc-21f329d913c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6b-74e5-9ccc-21f329d913c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019b097a-6e6b-7014-9c90-43b3d5ae94ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6b-74e5-9ccc-21f329d913c5" xlink:to="loc_us-gaap_PlanNameAxis_019b097a-6e6b-7014-9c90-43b3d5ae94ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019b097a-6e6b-7014-9c90-43b3d5ae94ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_019b097a-6e6b-7014-9c90-43b3d5ae94ed" xlink:to="loc_us-gaap_PlanNameDomain_019b097a-6e6b-7014-9c90-43b3d5ae94ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019b097a-6e6b-7399-8a6b-d711f5003bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_019b097a-6e6b-7014-9c90-43b3d5ae94ed" xlink:to="loc_us-gaap_PlanNameDomain_019b097a-6e6b-7399-8a6b-d711f5003bbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_019b097a-6e6b-7ced-b320-6f52ac694530" xlink:href="brns-20251231.xsd#brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019b097a-6e6b-7399-8a6b-d711f5003bbf" xlink:to="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_019b097a-6e6b-7ced-b320-6f52ac694530" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_019b097a-6e6b-7aad-9cf9-7043cac7c27f" xlink:href="brns-20251231.xsd#brns_EnterpriseManagementIncentiveShareOptionSchemeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019b097a-6e6b-7399-8a6b-d711f5003bbf" xlink:to="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_019b097a-6e6b-7aad-9cf9-7043cac7c27f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019b097a-6e6b-751e-b118-62a6b4d0a0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6b-74e5-9ccc-21f329d913c5" xlink:to="loc_us-gaap_AwardTypeAxis_019b097a-6e6b-751e-b118-62a6b4d0a0c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b097a-6e6b-751e-b118-62a6b4d0a0c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019b097a-6e6b-751e-b118-62a6b4d0a0c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b097a-6e6b-751e-b118-62a6b4d0a0c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b097a-6e6b-7832-80cb-8899136044ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019b097a-6e6b-751e-b118-62a6b4d0a0c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b097a-6e6b-7832-80cb-8899136044ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_019b097a-6e6b-7843-ac9f-390ce6386de1" xlink:href="brns-20251231.xsd#brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b097a-6e6b-7832-80cb-8899136044ed" xlink:to="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_019b097a-6e6b-7843-ac9f-390ce6386de1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019b097a-6e6b-7723-af3f-ee4c7e0e0b82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b097a-6e6b-7832-80cb-8899136044ed" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019b097a-6e6b-7723-af3f-ee4c7e0e0b82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019b097a-6e6b-7283-bcd2-3ecde3f62b74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b097a-6e6b-7832-80cb-8899136044ed" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019b097a-6e6b-7283-bcd2-3ecde3f62b74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019b097a-6e6b-79d7-a070-15d1add87b40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019b097a-6e6b-79d7-a070-15d1add87b40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_019b097a-6e6b-70f9-8cd7-cdded369fc27" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_019b097a-6e6b-70f9-8cd7-cdded369fc27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019b097a-6e6b-73e7-b5c2-01a53e0fb3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019b097a-6e6b-73e7-b5c2-01a53e0fb3a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance_019b097a-6e6b-7de0-a010-45c2e9ee57a2" xlink:href="brns-20251231.xsd#brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance_019b097a-6e6b-7de0-a010-45c2e9ee57a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019b097a-6e6b-7e12-be71-381aa1df9d88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019b097a-6e6b-7e12-be71-381aa1df9d88" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b097a-6e6b-70c8-82a0-cbdf29c5aafe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b097a-6e6b-70c8-82a0-cbdf29c5aafe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019b097a-6e6b-7840-86b5-7fc2e453cc54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019b097a-6e6b-7840-86b5-7fc2e453cc54" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019b097a-6e6c-7307-9739-1bcaeb2f8f45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019b097a-6e6c-7307-9739-1bcaeb2f8f45" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019b097a-6e6c-7888-8a66-6d6cbf338007" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019b097a-6e6c-7888-8a66-6d6cbf338007" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019b097a-6e6c-76df-8547-1a41acab3f15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019b097a-6e6c-76df-8547-1a41acab3f15" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019b097a-6e6c-7cea-a5ca-d5cf740f4dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019b097a-6e6c-7cea-a5ca-d5cf740f4dfd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019b097a-6e6c-73e2-a2c0-7d93227f6dab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019b097a-6e6c-73e2-a2c0-7d93227f6dab" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019bd65e-a226-7fcc-a8c2-b2bea8f7d0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019bd65e-a226-7fcc-a8c2-b2bea8f7d0e2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019bd65e-a226-7e96-a2a5-54e010d5b944" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019bd65e-a226-7e96-a2a5-54e010d5b944" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019c2859-1a83-7558-9aa4-7b86ed1e4820" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019c2859-1a83-7558-9aa4-7b86ed1e4820" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_019c2859-1a83-7d6c-b3c6-9b829f794c81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_019c2859-1a83-7d6c-b3c6-9b829f794c81" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#ShareBasedCompensationWeightedaverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6c-75c1-8c60-30b90da9a62d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6c-79ef-b12d-bff457eb9252" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6c-75c1-8c60-30b90da9a62d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6c-79ef-b12d-bff457eb9252" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019b097a-6e6c-7336-b18c-9ec93e4100bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6c-79ef-b12d-bff457eb9252" xlink:to="loc_us-gaap_PlanNameAxis_019b097a-6e6c-7336-b18c-9ec93e4100bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019b097a-6e6c-7336-b18c-9ec93e4100bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_019b097a-6e6c-7336-b18c-9ec93e4100bb" xlink:to="loc_us-gaap_PlanNameDomain_019b097a-6e6c-7336-b18c-9ec93e4100bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019b097a-6e6c-70e5-8037-6ca10f64fa1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_019b097a-6e6c-7336-b18c-9ec93e4100bb" xlink:to="loc_us-gaap_PlanNameDomain_019b097a-6e6c-70e5-8037-6ca10f64fa1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_019b097a-6e6c-7cb7-810a-05ea4a63ba30" xlink:href="brns-20251231.xsd#brns_EnterpriseManagementIncentiveShareOptionSchemeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019b097a-6e6c-70e5-8037-6ca10f64fa1c" xlink:to="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_019b097a-6e6c-7cb7-810a-05ea4a63ba30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019b097a-6e6c-7c88-82bd-b33750776f34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6c-75c1-8c60-30b90da9a62d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019b097a-6e6c-7c88-82bd-b33750776f34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019b097a-6e6c-72b5-9433-315c3a27b0de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6c-75c1-8c60-30b90da9a62d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019b097a-6e6c-72b5-9433-315c3a27b0de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019b097a-6e6c-787a-a515-6f35cce7bbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6c-75c1-8c60-30b90da9a62d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019b097a-6e6c-787a-a515-6f35cce7bbeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019b097a-6e6c-75f0-9e10-26fc3837275e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6c-75c1-8c60-30b90da9a62d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019b097a-6e6c-75f0-9e10-26fc3837275e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c2845-fb35-70e8-b271-0176af8abbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019c2845-fb34-789c-9b17-af929f29a162" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c2845-fb35-70e8-b271-0176af8abbf1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019c2845-fb34-789c-9b17-af929f29a162" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019c2845-fb34-736d-9d9a-d5391bbb88f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019c2845-fb34-789c-9b17-af929f29a162" xlink:to="loc_us-gaap_AwardTypeAxis_019c2845-fb34-736d-9d9a-d5391bbb88f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c2845-fb34-736d-9d9a-d5391bbb88f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019c2845-fb34-736d-9d9a-d5391bbb88f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c2845-fb34-736d-9d9a-d5391bbb88f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c2845-fb34-78e3-8417-322193c7e8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019c2845-fb34-736d-9d9a-d5391bbb88f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c2845-fb34-78e3-8417-322193c7e8ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019c2845-fb34-7391-b7e1-f0cbbb8eef98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c2845-fb34-78e3-8417-322193c7e8ef" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019c2845-fb34-7391-b7e1-f0cbbb8eef98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019c2846-9312-7fef-8197-d4eb88d90cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c2845-fb35-70e8-b271-0176af8abbf1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019c2846-9312-7fef-8197-d4eb88d90cf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c2845-fb35-7553-9581-2e228ec93fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019c2846-9312-7fef-8197-d4eb88d90cf8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c2845-fb35-7553-9581-2e228ec93fe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019c2845-fb35-71a4-8336-7d40de60597d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019c2846-9312-7fef-8197-d4eb88d90cf8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019c2845-fb35-71a4-8336-7d40de60597d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_019c2845-fb35-77ea-95fe-9a256ee57218" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019c2846-9312-7fef-8197-d4eb88d90cf8" xlink:to="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_019c2845-fb35-77ea-95fe-9a256ee57218" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod_019c2845-fb35-720a-bd23-5642657f9dbe" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019c2846-9312-7fef-8197-d4eb88d90cf8" xlink:to="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod_019c2845-fb35-720a-bd23-5642657f9dbe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019c2845-fb35-7496-9720-8e168dc85d28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019c2846-9312-7fef-8197-d4eb88d90cf8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019c2845-fb35-7496-9720-8e168dc85d28" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c2848-4c11-79e5-b0e8-290914a7ece6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_019c2845-fb35-73bc-a224-16b4bf327559" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c2845-fb35-70e8-b271-0176af8abbf1" xlink:to="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_019c2845-fb35-73bc-a224-16b4bf327559" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_019c2845-fb35-755c-af1d-c18631496b80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c2845-fb35-70e8-b271-0176af8abbf1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_019c2845-fb35-755c-af1d-c18631496b80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019c2849-c15a-7b4d-ac14-4b6a5df23fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c2845-fb35-70e8-b271-0176af8abbf1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019c2849-c15a-7b4d-ac14-4b6a5df23fe9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019c2845-fb35-7e52-a915-c5845ff1cd07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019c2849-c15a-7b4d-ac14-4b6a5df23fe9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019c2845-fb35-7e52-a915-c5845ff1cd07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c2845-fb35-76ed-afc6-32dd7fed1466" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019c2849-c15a-7b4d-ac14-4b6a5df23fe9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c2845-fb35-76ed-afc6-32dd7fed1466" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue_019c2845-fb35-76e2-b840-7ef0dcbf5c45" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019c2849-c15a-7b4d-ac14-4b6a5df23fe9" xlink:to="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue_019c2845-fb35-76e2-b840-7ef0dcbf5c45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue_019c2845-fb35-7de1-901f-5cb35c525b9d" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019c2849-c15a-7b4d-ac14-4b6a5df23fe9" xlink:to="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue_019c2845-fb35-7de1-901f-5cb35c525b9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019c2845-fb35-736a-9f19-8832c8a81ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019c2849-c15a-7b4d-ac14-4b6a5df23fe9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019c2845-fb35-736a-9f19-8832c8a81ebd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019c284a-2766-7725-8cb9-2224efd9af19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue_019c2845-fb35-7033-b3e1-3837cb7bc1c2" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c2845-fb35-70e8-b271-0176af8abbf1" xlink:to="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue_019c2845-fb35-7033-b3e1-3837cb7bc1c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue_019c2845-fb35-718f-af99-ac8eca22ee5e" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c2845-fb35-70e8-b271-0176af8abbf1" xlink:to="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue_019c2845-fb35-718f-af99-ac8eca22ee5e" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6c-7e11-95cd-091f458cd79a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6c-7c6d-ac03-5994c34d1e21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6c-7e11-95cd-091f458cd79a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6c-7c6d-ac03-5994c34d1e21" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019b097a-6e6c-72fb-8ad2-4c82f23d17bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6c-7c6d-ac03-5994c34d1e21" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019b097a-6e6c-72fb-8ad2-4c82f23d17bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019b097a-6e6c-72fb-8ad2-4c82f23d17bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019b097a-6e6c-72fb-8ad2-4c82f23d17bd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019b097a-6e6c-72fb-8ad2-4c82f23d17bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019b097a-6e6c-7f05-8ebe-22a0748d6629" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019b097a-6e6c-72fb-8ad2-4c82f23d17bd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019b097a-6e6c-7f05-8ebe-22a0748d6629" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019b097a-6e6c-7b93-a0a9-358059d206a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019b097a-6e6c-7f05-8ebe-22a0748d6629" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019b097a-6e6c-7b93-a0a9-358059d206a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019b097a-6e6c-7847-b5fe-178be4c88b72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019b097a-6e6c-7f05-8ebe-22a0748d6629" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019b097a-6e6c-7847-b5fe-178be4c88b72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019b097a-6e6c-7121-ba30-e2958a00a39b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6c-7e11-95cd-091f458cd79a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019b097a-6e6c-7121-ba30-e2958a00a39b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#IncomeTaxesLossBeforeIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncomeTaxesLineItems_019b097a-6e6c-7501-bb8f-f277b419e7d5" xlink:href="brns-20251231.xsd#brns_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncomeTaxesTable_019b097a-6e6c-71e2-8377-001c2f3e949c" xlink:href="brns-20251231.xsd#brns_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_brns_IncomeTaxesLineItems_019b097a-6e6c-7501-bb8f-f277b419e7d5" xlink:to="loc_brns_IncomeTaxesTable_019b097a-6e6c-71e2-8377-001c2f3e949c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019c9156-9fae-7766-b525-472ee64bbfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_brns_IncomeTaxesTable_019b097a-6e6c-71e2-8377-001c2f3e949c" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019c9156-9fae-7766-b525-472ee64bbfe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c9156-9fae-7766-b525-472ee64bbfe2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c9156-9fae-7766-b525-472ee64bbfe2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c9156-9fae-7766-b525-472ee64bbfe2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c9156-9fae-7a57-96fa-4a7667bf7486" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c9156-9fae-7766-b525-472ee64bbfe2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c9156-9fae-7a57-96fa-4a7667bf7486" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019c9156-9fae-728e-8248-492cbd076390" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c9156-9fae-7a57-96fa-4a7667bf7486" xlink:to="loc_country_US_019c9156-9fae-728e-8248-492cbd076390" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignTaxJurisdictionOtherMember_019c9156-fe60-7661-b282-f632baf4a2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignTaxJurisdictionOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c9156-9fae-7a57-96fa-4a7667bf7486" xlink:to="loc_us-gaap_ForeignTaxJurisdictionOtherMember_019c9156-fe60-7661-b282-f632baf4a2ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019b097a-6e6c-737c-922b-506b3155d65a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_IncomeTaxesLineItems_019b097a-6e6c-7501-bb8f-f277b419e7d5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019b097a-6e6c-737c-922b-506b3155d65a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019b097a-6e6c-79a3-a57b-583bdd7f4d61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_IncomeTaxesLineItems_019b097a-6e6c-7501-bb8f-f277b419e7d5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019b097a-6e6c-79a3-a57b-583bdd7f4d61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b097a-6e6c-7765-8f77-dc801e416718" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_IncomeTaxesLineItems_019b097a-6e6c-7501-bb8f-f277b419e7d5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b097a-6e6c-7765-8f77-dc801e416718" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncomeTaxesLineItems_019b097a-6e6c-722f-8adc-8a4b602fd5df" xlink:href="brns-20251231.xsd#brns_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncomeTaxesTable_019b097a-6e6c-7116-84fd-5f6f5a701858" xlink:href="brns-20251231.xsd#brns_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_brns_IncomeTaxesLineItems_019b097a-6e6c-722f-8adc-8a4b602fd5df" xlink:to="loc_brns_IncomeTaxesTable_019b097a-6e6c-7116-84fd-5f6f5a701858" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019c9157-9a1c-7ce6-995d-0e5184da4939" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_brns_IncomeTaxesTable_019b097a-6e6c-7116-84fd-5f6f5a701858" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019c9157-9a1c-7ce6-995d-0e5184da4939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c9157-9a1c-7ce6-995d-0e5184da4939_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c9157-9a1c-7ce6-995d-0e5184da4939" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c9157-9a1c-7ce6-995d-0e5184da4939_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c9157-9a1c-78ce-a4e8-b77da42a8ede" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c9157-9a1c-7ce6-995d-0e5184da4939" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c9157-9a1c-78ce-a4e8-b77da42a8ede" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019c9157-9a1c-7af7-883a-363284fcbd90" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c9157-9a1c-78ce-a4e8-b77da42a8ede" xlink:to="loc_country_US_019c9157-9a1c-7af7-883a-363284fcbd90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignTaxJurisdictionOtherMember_019c9157-c4cd-73e9-a4a4-a44c78c6c1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignTaxJurisdictionOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c9157-9a1c-78ce-a4e8-b77da42a8ede" xlink:to="loc_us-gaap_ForeignTaxJurisdictionOtherMember_019c9157-c4cd-73e9-a4a4-a44c78c6c1a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b097a-6e6c-7435-a84f-24afd197c5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_IncomeTaxesLineItems_019b097a-6e6c-722f-8adc-8a4b602fd5df" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b097a-6e6c-7435-a84f-24afd197c5a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_019b097a-6e6c-710b-9567-14c07d09f005" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b097a-6e6c-7435-a84f-24afd197c5a3" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_019b097a-6e6c-710b-9567-14c07d09f005" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b097a-6e6c-7fdc-98b2-1d1f47ba1e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_IncomeTaxesLineItems_019b097a-6e6c-722f-8adc-8a4b602fd5df" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b097a-6e6c-7fdc-98b2-1d1f47ba1e0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_019b097a-6e6c-783c-8e8f-598b050c26e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b097a-6e6c-7fdc-98b2-1d1f47ba1e0c" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_019b097a-6e6c-783c-8e8f-598b050c26e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019b097a-6e6c-71be-8124-e8197fc48192" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_IncomeTaxesLineItems_019b097a-6e6c-722f-8adc-8a4b602fd5df" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019b097a-6e6c-71be-8124-e8197fc48192" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019cb025-71b3-792f-b6f6-4576886b42a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019cb025-71b3-7de8-8261-c3146b9f0d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019cb025-71b3-792f-b6f6-4576886b42a3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019cb025-71b3-7de8-8261-c3146b9f0d6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019cb025-71b3-729a-be69-b057df1ac7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019cb025-71b3-7de8-8261-c3146b9f0d6f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019cb025-71b3-729a-be69-b057df1ac7aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019cb025-71b3-729a-be69-b057df1ac7aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019cb025-71b3-729a-be69-b057df1ac7aa" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019cb025-71b3-729a-be69-b057df1ac7aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019cb025-71b3-7826-ab8f-feea54038f25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019cb025-71b3-729a-be69-b057df1ac7aa" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019cb025-71b3-7826-ab8f-feea54038f25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_019cb026-3c39-7cfe-abc9-7821c63c1ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019cb025-71b3-7826-ab8f-feea54038f25" xlink:to="loc_us-gaap_ForeignCountryMember_019cb026-3c39-7cfe-abc9-7821c63c1ef3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019cb025-faf5-72bd-90b5-971d71c934a4" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignCountryMember_019cb026-3c39-7cfe-abc9-7821c63c1ef3" xlink:to="loc_country_US_019cb025-faf5-72bd-90b5-971d71c934a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CH_019ce06e-6040-7d7f-a37c-e7672765f988" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CH"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignCountryMember_019cb026-3c39-7cfe-abc9-7821c63c1ef3" xlink:to="loc_country_CH_019ce06e-6040-7d7f-a37c-e7672765f988" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_019cb02b-fe96-751b-b847-97e18407b1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019cb025-71b3-7826-ab8f-feea54038f25" xlink:to="loc_us-gaap_DomesticCountryMember_019cb02b-fe96-751b-b847-97e18407b1d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_019ce2ac-b8d9-75bf-bbc4-0c3a50186632" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticCountryMember_019cb02b-fe96-751b-b847-97e18407b1d3" xlink:to="loc_country_GB_019ce2ac-b8d9-75bf-bbc4-0c3a50186632" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019ce06d-fdf9-7a1a-9350-92d0788b2455" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019cb025-71b3-792f-b6f6-4576886b42a3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019ce06d-fdf9-7a1a-9350-92d0788b2455" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019ce06e-6040-7ccf-8939-af0f4e22bdb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019ce06d-fdf9-7a1a-9350-92d0788b2455" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019ce06e-6040-7ccf-8939-af0f4e22bdb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019ce06e-6040-77e9-817d-247e9434ff05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019ce06d-fdf9-7a1a-9350-92d0788b2455" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019ce06e-6040-77e9-817d-247e9434ff05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_019ce06e-6040-7837-9950-535f5f152081" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019ce06d-fdf9-7a1a-9350-92d0788b2455" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_019ce06e-6040-7837-9950-535f5f152081" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_019ce2d4-ae3c-7740-9815-c42a666518a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019ce06d-fdf9-7a1a-9350-92d0788b2455" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_019ce2d4-ae3c-7740-9815-c42a666518a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_019ce06e-6040-73a5-9ba3-6a9ba85c5c55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019ce06d-fdf9-7a1a-9350-92d0788b2455" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_019ce06e-6040-73a5-9ba3-6a9ba85c5c55" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount_019ce35e-d850-7218-8341-93efb636d67b" xlink:href="brns-20251231.xsd#brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019ce06d-fdf9-7a1a-9350-92d0788b2455" xlink:to="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount_019ce35e-d850-7218-8341-93efb636d67b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019ce06e-6040-7a07-be28-ba0cd8b7b37e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019ce06d-fdf9-7a1a-9350-92d0788b2455" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019ce06e-6040-7a07-be28-ba0cd8b7b37e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019ce06e-6040-7d01-b7ca-b02d4253da3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019ce06d-fdf9-7a1a-9350-92d0788b2455" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019ce06e-6040-7d01-b7ca-b02d4253da3a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019ce070-9645-7eca-92d8-92811c1e7151" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019cb025-71b3-792f-b6f6-4576886b42a3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019ce070-9645-7eca-92d8-92811c1e7151" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019ce070-f2bb-7c41-8a99-858d43ab6bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019ce070-9645-7eca-92d8-92811c1e7151" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019ce070-f2bb-7c41-8a99-858d43ab6bc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019ce070-f2bb-7e5c-bf20-6875231efbde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019ce070-9645-7eca-92d8-92811c1e7151" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019ce070-f2bb-7e5c-bf20-6875231efbde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_019ce070-f2bb-72ff-91f8-0acf0e84724c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019ce070-9645-7eca-92d8-92811c1e7151" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_019ce070-f2bb-72ff-91f8-0acf0e84724c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019ce2d5-21ea-7564-b106-2ca9754fbac0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019ce070-9645-7eca-92d8-92811c1e7151" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019ce2d5-21ea-7564-b106-2ca9754fbac0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_019ce070-f2bb-711d-83e1-8e401eb871d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019ce070-9645-7eca-92d8-92811c1e7151" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_019ce070-f2bb-711d-83e1-8e401eb871d7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment_019ce070-f2bb-7344-946f-5c7706d5be86" xlink:href="brns-20251231.xsd#brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019ce070-9645-7eca-92d8-92811c1e7151" xlink:to="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment_019ce070-f2bb-7344-946f-5c7706d5be86" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019ce070-f2bb-74be-8db7-85420d6c063c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019ce070-9645-7eca-92d8-92811c1e7151" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019ce070-f2bb-74be-8db7-85420d6c063c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019ce070-f2bb-7202-ae1a-511f411c904a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019ce070-9645-7eca-92d8-92811c1e7151" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019ce070-f2bb-7202-ae1a-511f411c904a" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b097a-6e6c-7e64-8033-2ea6ea389d80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_019b097a-6e6c-7b3f-9527-b36d519c0fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b097a-6e6c-7e64-8033-2ea6ea389d80" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_019b097a-6e6c-7b3f-9527-b36d519c0fa8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019b097a-6e6c-76d4-a512-175b0e6af5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_019b097a-6e6c-7b3f-9527-b36d519c0fa8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019b097a-6e6c-76d4-a512-175b0e6af5b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019b097a-6e6c-76d4-a512-175b0e6af5b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019b097a-6e6c-76d4-a512-175b0e6af5b2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019b097a-6e6c-76d4-a512-175b0e6af5b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019b097a-6e6c-7668-a95b-ba66044a52c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019b097a-6e6c-76d4-a512-175b0e6af5b2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019b097a-6e6c-7668-a95b-ba66044a52c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_019b097a-6e6c-7b63-abba-c94400900338" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019b097a-6e6c-7668-a95b-ba66044a52c7" xlink:to="loc_us-gaap_DomesticCountryMember_019b097a-6e6c-7b63-abba-c94400900338" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_019c499d-7275-736d-b60a-3a0886dbf29a" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticCountryMember_019b097a-6e6c-7b63-abba-c94400900338" xlink:to="loc_country_GB_019c499d-7275-736d-b60a-3a0886dbf29a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_019b097a-6e6c-7e21-9339-5f44d56ad300" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b097a-6e6c-7e64-8033-2ea6ea389d80" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_019b097a-6e6c-7e21-9339-5f44d56ad300" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_019b097a-6e6c-7c79-8057-b6d27a36f147" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b097a-6e6c-7e64-8033-2ea6ea389d80" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_019b097a-6e6c-7c79-8057-b6d27a36f147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_019b097a-6e6c-736b-b167-a8cc531b70bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b097a-6e6c-7e64-8033-2ea6ea389d80" xlink:to="loc_us-gaap_OperatingLossCarryforwards_019b097a-6e6c-736b-b167-a8cc531b70bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_019b097a-6e6c-758a-b535-be9b71f88a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b097a-6e6c-7e64-8033-2ea6ea389d80" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_019b097a-6e6c-758a-b535-be9b71f88a9e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_019b097a-6e6c-78bb-93d4-befd495172c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:to="loc_us-gaap_OtherCommitmentsTable_019b097a-6e6c-78bb-93d4-befd495172c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019b097a-6e6c-777e-82cb-e9dffdddc4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_019b097a-6e6c-78bb-93d4-befd495172c0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019b097a-6e6c-777e-82cb-e9dffdddc4f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019b097a-6e6c-777e-82cb-e9dffdddc4f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019b097a-6e6c-777e-82cb-e9dffdddc4f5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019b097a-6e6c-777e-82cb-e9dffdddc4f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019b097a-6e6c-7ad9-8934-d4abc8cd37d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019b097a-6e6c-777e-82cb-e9dffdddc4f5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019b097a-6e6c-7ad9-8934-d4abc8cd37d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_InLicenseAgreementsMember_019b097a-6e6c-70e9-8f81-de510ec58a4e" xlink:href="brns-20251231.xsd#brns_InLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019b097a-6e6c-7ad9-8934-d4abc8cd37d1" xlink:to="loc_brns_InLicenseAgreementsMember_019b097a-6e6c-70e9-8f81-de510ec58a4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019b097a-6e6c-7175-99aa-6ffbc3e61839" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_019b097a-6e6c-78bb-93d4-befd495172c0" xlink:to="loc_srt_RangeAxis_019b097a-6e6c-7175-99aa-6ffbc3e61839" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019b097a-6e6c-7175-99aa-6ffbc3e61839_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019b097a-6e6c-7175-99aa-6ffbc3e61839" xlink:to="loc_srt_RangeMember_019b097a-6e6c-7175-99aa-6ffbc3e61839_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019b097a-6e6c-7a1e-98ab-3ff6340cf3aa" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019b097a-6e6c-7175-99aa-6ffbc3e61839" xlink:to="loc_srt_RangeMember_019b097a-6e6c-7a1e-98ab-3ff6340cf3aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019b097a-6e6c-79f3-ae4d-119ab12cfecb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019b097a-6e6c-7a1e-98ab-3ff6340cf3aa" xlink:to="loc_srt_MinimumMember_019b097a-6e6c-79f3-ae4d-119ab12cfecb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019b097a-6e6c-7c76-b702-fcf424823c50" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019b097a-6e6c-7a1e-98ab-3ff6340cf3aa" xlink:to="loc_srt_MaximumMember_019b097a-6e6c-7c76-b702-fcf424823c50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_019b097a-6e6c-7709-8cf7-39fdd32e97c9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_019b097a-6e6c-78bb-93d4-befd495172c0" xlink:to="loc_srt_StatementGeographicalAxis_019b097a-6e6c-7709-8cf7-39fdd32e97c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019b097a-6e6c-7709-8cf7-39fdd32e97c9_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_019b097a-6e6c-7709-8cf7-39fdd32e97c9" xlink:to="loc_srt_SegmentGeographicalDomain_019b097a-6e6c-7709-8cf7-39fdd32e97c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019b097a-6e6c-7f60-aefa-997e06fd1bd6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_019b097a-6e6c-7709-8cf7-39fdd32e97c9" xlink:to="loc_srt_SegmentGeographicalDomain_019b097a-6e6c-7f60-aefa-997e06fd1bd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordshireMember_019b097a-6e6c-7948-847b-352d0af4f60a" xlink:href="brns-20251231.xsd#brns_OxfordshireMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019b097a-6e6c-7f60-aefa-997e06fd1bd6" xlink:to="loc_brns_OxfordshireMember_019b097a-6e6c-7948-847b-352d0af4f60a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MD_019b097a-6e6c-78e1-8bcc-3b8867cade37" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_MD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019b097a-6e6c-7f60-aefa-997e06fd1bd6" xlink:to="loc_stpr_MD_019b097a-6e6c-78e1-8bcc-3b8867cade37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement_019b097a-6e6c-7942-aa86-3eaf44bfc40d" xlink:href="brns-20251231.xsd#brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:to="loc_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement_019b097a-6e6c-7942-aa86-3eaf44bfc40d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement_019b097a-6e6c-771a-a478-91e6e406d43b" xlink:href="brns-20251231.xsd#brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:to="loc_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement_019b097a-6e6c-771a-a478-91e6e406d43b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfSquareFeetUnderLeaseAgreement_019b097a-6e6c-7243-8299-bd0aca73a247" xlink:href="brns-20251231.xsd#brns_NumberOfSquareFeetUnderLeaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:to="loc_brns_NumberOfSquareFeetUnderLeaseAgreement_019b097a-6e6c-7243-8299-bd0aca73a247" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_019b097a-6e6c-7812-a71c-d9c979b86a66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:to="loc_us-gaap_SecurityDeposit_019b097a-6e6c-7812-a71c-d9c979b86a66" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_019c90cb-511d-7b8e-982f-1ec727fdd076" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_019c90cb-511d-7b8e-982f-1ec727fdd076" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LesseeOperatingLeaseExtendedTerm_019b097a-6e6c-7023-ad1c-a117b50dbb70" xlink:href="brns-20251231.xsd#brns_LesseeOperatingLeaseExtendedTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:to="loc_brns_LesseeOperatingLeaseExtendedTerm_019b097a-6e6c-7023-ad1c-a117b50dbb70" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_019b097a-6e6c-776f-aa41-cc2607b99d19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_019b097a-6e6c-776f-aa41-cc2607b99d19" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_019b097a-6e6c-76d3-984a-abb314802f39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_019b097a-6e6c-76d3-984a-abb314802f39" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_019c2863-3f1b-7fb5-a63b-88fc2afb56f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_019c2863-3f1b-7fb5-a63b-88fc2afb56f0" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_019b097a-6e6c-74f9-a0c9-c427b9cc0539" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019b097a-6e6c-7e22-a51f-2cfe92d53dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019b097a-6e6c-74f9-a0c9-c427b9cc0539" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019b097a-6e6c-7e22-a51f-2cfe92d53dc7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019b097a-6e6c-757d-b314-6c6613c363d8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019b097a-6e6c-7e22-a51f-2cfe92d53dc7" xlink:to="loc_srt_CounterpartyNameAxis_019b097a-6e6c-757d-b314-6c6613c363d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019b097a-6e6c-757d-b314-6c6613c363d8_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_019b097a-6e6c-757d-b314-6c6613c363d8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019b097a-6e6c-757d-b314-6c6613c363d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019b097a-6e6c-72ab-ab54-23a705112fe9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_019b097a-6e6c-757d-b314-6c6613c363d8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019b097a-6e6c-72ab-ab54-23a705112fe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordUniversityInnovationLimitedMember_019b097a-6e6c-78e1-adbf-cd431a2c95f3" xlink:href="brns-20251231.xsd#brns_OxfordUniversityInnovationLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019b097a-6e6c-72ab-ab54-23a705112fe9" xlink:to="loc_brns_OxfordUniversityInnovationLimitedMember_019b097a-6e6c-78e1-adbf-cd431a2c95f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_019b097a-6e6c-7620-824b-e5832484db71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019b097a-6e6c-7e22-a51f-2cfe92d53dc7" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_019b097a-6e6c-7620-824b-e5832484db71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_019b097a-6e6c-7620-824b-e5832484db71_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_019b097a-6e6c-7620-824b-e5832484db71" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_019b097a-6e6c-7620-824b-e5832484db71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_019b097a-6e6c-7f2d-ba7d-9dfe9dedf609" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_019b097a-6e6c-7620-824b-e5832484db71" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_019b097a-6e6c-7f2d-ba7d-9dfe9dedf609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ExpensesMember_019b097a-6e6c-7f63-8a1a-4f801036c2e4" xlink:href="brns-20251231.xsd#brns_ExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019b097a-6e6c-7f2d-ba7d-9dfe9dedf609" xlink:to="loc_brns_ExpensesMember_019b097a-6e6c-7f63-8a1a-4f801036c2e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019b097a-6e6c-754d-b489-0042c435068c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019b097a-6e6c-7e22-a51f-2cfe92d53dc7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019b097a-6e6c-754d-b489-0042c435068c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019b097a-6e6c-754d-b489-0042c435068c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019b097a-6e6c-754d-b489-0042c435068c" xlink:to="loc_us-gaap_RelatedPartyDomain_019b097a-6e6c-754d-b489-0042c435068c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019b097a-6e6c-7195-a60e-9335b2870587" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019b097a-6e6c-754d-b489-0042c435068c" xlink:to="loc_us-gaap_RelatedPartyDomain_019b097a-6e6c-7195-a60e-9335b2870587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019b097a-6e6c-7af3-a606-82715f4a0c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019b097a-6e6c-7195-a60e-9335b2870587" xlink:to="loc_us-gaap_RelatedPartyMember_019b097a-6e6c-7af3-a606-82715f4a0c2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_019b097a-6e6c-7542-8111-f5042d717495" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019b097a-6e6c-74f9-a0c9-c427b9cc0539" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_019b097a-6e6c-7542-8111-f5042d717495" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_019b097a-6e6c-75d9-93b9-82c5d6a65d17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019b097a-6e6c-74f9-a0c9-c427b9cc0539" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_019b097a-6e6c-75d9-93b9-82c5d6a65d17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019b097a-6e6c-7053-8013-94c6fe31a4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019b097a-6e6c-74f9-a0c9-c427b9cc0539" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019b097a-6e6c-7053-8013-94c6fe31a4cb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_019b097a-6e6c-785c-bbb8-22abf7c9d7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_019b097a-6e6c-7a7d-9a79-f34344301841" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_019b097a-6e6c-785c-bbb8-22abf7c9d7a7" xlink:to="loc_us-gaap_SubsequentEventTable_019b097a-6e6c-7a7d-9a79-f34344301841" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_019cd0fb-6b02-7d1b-a16e-fd07ac3b9e69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_019b097a-6e6c-7a7d-9a79-f34344301841" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_019cd0fb-6b02-7d1b-a16e-fd07ac3b9e69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019cd0fb-6b02-7d1b-a16e-fd07ac3b9e69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019cd0fb-6b02-7d1b-a16e-fd07ac3b9e69" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019cd0fb-6b02-7d1b-a16e-fd07ac3b9e69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019cd0fb-6b02-7ac8-855d-eb8b17352653" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019cd0fb-6b02-7d1b-a16e-fd07ac3b9e69" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019cd0fb-6b02-7ac8-855d-eb8b17352653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_019cd0fb-6b02-7264-8fc2-0799967aeb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_019cd0fb-6b02-7ac8-855d-eb8b17352653" xlink:to="loc_us-gaap_SubsequentEventMember_019cd0fb-6b02-7264-8fc2-0799967aeb5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019cd82e-b8c5-704c-a0be-9a86aa41c1b0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_019b097a-6e6c-7a7d-9a79-f34344301841" xlink:to="loc_srt_RangeAxis_019cd82e-b8c5-704c-a0be-9a86aa41c1b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019cd82e-b8c5-704c-a0be-9a86aa41c1b0_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019cd82e-b8c5-704c-a0be-9a86aa41c1b0" xlink:to="loc_srt_RangeMember_019cd82e-b8c5-704c-a0be-9a86aa41c1b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019cd82e-b8c5-79c5-9208-729b3f1cb751" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019cd82e-b8c5-704c-a0be-9a86aa41c1b0" xlink:to="loc_srt_RangeMember_019cd82e-b8c5-79c5-9208-729b3f1cb751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019cd82e-ce1d-7f02-871b-c1447105029e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019cd82e-b8c5-79c5-9208-729b3f1cb751" xlink:to="loc_srt_MinimumMember_019cd82e-ce1d-7f02-871b-c1447105029e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019cd82e-efbd-75a4-a307-f3732e19bb31" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019cd82e-b8c5-79c5-9208-729b3f1cb751" xlink:to="loc_srt_MaximumMember_019cd82e-efbd-75a4-a307-f3732e19bb31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MergerAgreementSchemeExchangeRatio_019cd0fb-6b02-7ed7-b35e-040901259211" xlink:href="brns-20251231.xsd#brns_MergerAgreementSchemeExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_019b097a-6e6c-785c-bbb8-22abf7c9d7a7" xlink:to="loc_brns_MergerAgreementSchemeExchangeRatio_019cd0fb-6b02-7ed7-b35e-040901259211" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MergerAgreementMergerExchangeRatio_019cd0fb-6b02-759b-a4eb-e5ded9db9dc6" xlink:href="brns-20251231.xsd#brns_MergerAgreementMergerExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_019b097a-6e6c-785c-bbb8-22abf7c9d7a7" xlink:to="loc_brns_MergerAgreementMergerExchangeRatio_019cd0fb-6b02-759b-a4eb-e5ded9db9dc6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="81"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>brns-20251231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019b097a-6c16-78f4-806b-17184aaccbef,g:d518a941-6ac7-4029-9d1f-6f039bd073d0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_019b097a-6f46-7382-ac8f-3986217fa825_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization for amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_019b097a-6f46-70d9-9fb6-e103c5861ac2_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_019b097a-6f46-7dd2-8175-91bb8ba3d9ce_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_019b097a-6f46-7276-b01f-cb126dd5aaca_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredSharesMember_019b097a-6f46-7f47-aff2-764cc328cb94_verboseLabel_en-US" xlink:label="lab_brns_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred Shares</link:label>
    <link:label id="lab_brns_DeferredSharesMember_label_en-US" xlink:label="lab_brns_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Shares [Member]</link:label>
    <link:label id="lab_brns_DeferredSharesMember_documentation_en-US" xlink:label="lab_brns_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to deferred shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredSharesMember" xlink:href="brns-20251231.xsd#brns_DeferredSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredSharesMember" xlink:to="lab_brns_DeferredSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue_019c2845-fb35-7b33-bdc6-db7182383179_terseLabel_en-US" xlink:label="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and deferred (in usd per share)</link:label>
    <link:label id="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Deferred In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Deferred In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_019b097a-6e6c-7238-9c2c-0a6fe7d769b7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_019b097a-6f46-7161-9e68-584843813afa_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_019b097a-6fcf-75ab-8c38-ccbb4f37197c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019b097a-6f46-72da-92a2-44e51642cfcc_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_019b097a-6f46-7910-8f6a-1476b012ba2a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in-Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_019b097a-6f45-78d8-8933-586e1a3220fe_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_019b097a-6e6c-7c45-8a85-8df4e8e440b4_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019b097a-6f46-7ede-90c5-0e38a03ecf5d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock_019b097a-6f46-7067-92aa-6de00fa911f6_terseLabel_en-US" xlink:label="lab_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of ordinary shares reserved for future issuance</link:label>
    <link:label id="lab_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock_label_en-US" xlink:label="lab_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Ordinary Shares Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The tabular disclosure of ordinary shares reserved for future issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock" xlink:href="brns-20251231.xsd#brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock" xlink:to="lab_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_019b097a-6f46-74c9-a083-c9c9f2ce547a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DirectResearchAndDevelopmentExpense_019b097a-6f46-7e5b-9b46-611825bd2e55_terseLabel_en-US" xlink:label="lab_brns_DirectResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total direct research and development expenses</link:label>
    <link:label id="lab_brns_DirectResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_brns_DirectResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Direct Research And Development Expense</link:label>
    <link:label id="lab_brns_DirectResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_brns_DirectResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Direct Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DirectResearchAndDevelopmentExpense" xlink:href="brns-20251231.xsd#brns_DirectResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DirectResearchAndDevelopmentExpense" xlink:to="lab_brns_DirectResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_019b097a-6fcf-7fd6-8922-0505380815b8_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License revenue</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_019b097a-6f46-7769-b23c-95c6a5de8410_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share attributable to ordinary shareholders, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_019b097a-6fcf-7011-b70e-706622f70ea6_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019b097a-6f45-7479-a6fd-3dfb91f157d8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019b097a-6e6c-7f9c-a608-b27a73fca9d9_totalLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019b097a-6e6c-70a0-a2a2-86a73dd10648_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_019b097a-6f46-7b36-b19a-3d94b64bafb1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_019b097a-6e6c-7bca-b541-dc88b2e17870_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_019b097a-6fcf-75a0-8479-a2505d0a687f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019b097a-6f46-74bd-84c1-1ccb09b4a165_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Significant Segment Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_LaboratoryEquipmentMember_019b097a-6f46-7043-800f-7c43e9152b48_terseLabel_en-US" xlink:label="lab_brns_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_brns_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_brns_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_brns_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_brns_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LaboratoryEquipmentMember" xlink:href="brns-20251231.xsd#brns_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_LaboratoryEquipmentMember" xlink:to="lab_brns_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_019b097a-6f46-709a-9e79-dba6450319e8_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_019b097a-6f46-73b6-b688-6a7b3d2affde_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_019b097a-6f46-7b67-9445-ed1c9b2bf819_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_SubsidiariesVOLTMember_019b097a-6e6c-79ee-a625-0b34f0411495_terseLabel_en-US" xlink:label="lab_brns_SubsidiariesVOLTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VOLT</link:label>
    <link:label id="lab_brns_SubsidiariesVOLTMember_label_en-US" xlink:label="lab_brns_SubsidiariesVOLTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries, VOLT [Member]</link:label>
    <link:label id="lab_brns_SubsidiariesVOLTMember_documentation_en-US" xlink:label="lab_brns_SubsidiariesVOLTMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subsidiaries, VOLT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SubsidiariesVOLTMember" xlink:href="brns-20251231.xsd#brns_SubsidiariesVOLTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_SubsidiariesVOLTMember" xlink:to="lab_brns_SubsidiariesVOLTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights_019b097a-6f46-7b1f-86f1-dc2109cd6c3d_terseLabel_en-US" xlink:label="lab_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of ordinary shares present to exercise preemptive rights</link:label>
    <link:label id="lab_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights_label_en-US" xlink:label="lab_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Shares Necessary To Exercise Preemptive Rights</link:label>
    <link:label id="lab_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights_documentation_en-US" xlink:label="lab_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum percentage of shares required to exercise preemptive rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights" xlink:href="brns-20251231.xsd#brns_PercentageOfSharesNecessaryToExercisePreemptiveRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights" xlink:to="lab_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019b097a-6f46-7b2f-8696-6a3f323b309a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_019b097a-6e6c-73d3-a335-35e63cb19e2e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_019b097a-6f46-73b2-8ced-3407a171b3d3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019ce070-9645-7c67-bdaf-a1a8a8603c0c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_019b097a-6e6c-7413-ba29-575572065333_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity attributable to Barinthus Biotherapeutics plc shareholders</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_019b097a-6f46-78a4-8148-9a5a544c2776_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_019b097a-6f46-7e14-b64d-ac1eaa364823_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_019b097a-6f46-7435-8b17-f551f27a17e5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_019b097a-6f46-74d8-a1fe-8ace2e06e22d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_BecaonTopcoIncMember_019bd5df-9dd5-7f58-ba6b-76b23721eca9_terseLabel_en-US" xlink:label="lab_brns_BecaonTopcoIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Becaon Topco, Inc</link:label>
    <link:label id="lab_brns_BecaonTopcoIncMember_label_en-US" xlink:label="lab_brns_BecaonTopcoIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Becaon Topco, Inc [Member]</link:label>
    <link:label id="lab_brns_BecaonTopcoIncMember_documentation_en-US" xlink:label="lab_brns_BecaonTopcoIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Becaon Topco, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_BecaonTopcoIncMember" xlink:href="brns-20251231.xsd#brns_BecaonTopcoIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_BecaonTopcoIncMember" xlink:to="lab_brns_BecaonTopcoIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_019b097a-6f46-748b-82ca-64214ce2d856_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019b097a-6f46-7c03-af1a-32d7a5890b26_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue of ordinary shares, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_019b097a-6f46-769b-b783-9da62b85dbf8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_019b097a-6f46-7cde-bb19-efe823e6705e_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_019b097a-6f46-7dc2-9978-382fc56834eb_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner_019b097a-6f46-75a6-bde9-933c2c411269_terseLabel_en-US" xlink:label="lab_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative contributions from noncontrolling interest owner</link:label>
    <link:label id="lab_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner_label_en-US" xlink:label="lab_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Cumulative Contributions, Noncontrolling Owner</link:label>
    <link:label id="lab_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner_documentation_en-US" xlink:label="lab_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subsidiary, Cumulative Contributions, Noncontrolling Owner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner" xlink:href="brns-20251231.xsd#brns_SubsidiaryCumulativeContributionsNoncontrollingOwner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner" xlink:to="lab_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019b097a-6f46-794a-87b4-f4f62a10f809_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_019b097a-6f46-7536-9a30-73b4ca6bb671_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_019b097a-6e6c-7d38-929f-9954979e8f89_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of credit risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ExpensesMember_019b097a-6e6c-7bf6-a490-e7aeab9372b5_terseLabel_en-US" xlink:label="lab_brns_ExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_brns_ExpensesMember_label_en-US" xlink:label="lab_brns_ExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses [Member]</link:label>
    <link:label id="lab_brns_ExpensesMember_documentation_en-US" xlink:label="lab_brns_ExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ExpensesMember" xlink:href="brns-20251231.xsd#brns_ExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ExpensesMember" xlink:to="lab_brns_ExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019b097a-6f46-707c-a55f-665aebc32ec8_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_019b097a-6e6c-75aa-93ab-50d98427a62a_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_019b097a-6e6c-790d-bbb6-a508d6e4757f_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_019b097a-6f46-797d-af9d-b3215b4a6f30_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_019b097a-6f46-7616-863f-48088df5e40f_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019b097a-6f46-7410-a57d-372cd0706ba6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at the end of the period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_019b097a-6f46-7407-a864-addadca2bd2a_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful life of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019b097a-6f46-778a-81be-3aab9453ea8e_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredStockSharesOutstanding_019b097a-6f46-7b86-ac6c-ab036bc10dea_terseLabel_en-US" xlink:label="lab_brns_DeferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred shares, outstanding (in shares)</link:label>
    <link:label id="lab_brns_DeferredStockSharesOutstanding_label_en-US" xlink:label="lab_brns_DeferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Shares Outstanding</link:label>
    <link:label id="lab_brns_DeferredStockSharesOutstanding_documentation_en-US" xlink:label="lab_brns_DeferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of deferred stock outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesOutstanding" xlink:href="brns-20251231.xsd#brns_DeferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredStockSharesOutstanding" xlink:to="lab_brns_DeferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_019b097a-6e6c-7a80-a530-33331fda14e1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_019b097a-6f46-7a35-a057-2b866a6fc0c5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of maturities of minimum lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6c-7885-8252-e14fea026ba5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019c6f58-649a-7385-9e08-79b1e47d4b3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant fair value of awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_019b097a-6f45-77fe-882c-f614f0e47625_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-712c-ac1d-3cd3a5a2dfde_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Line Items]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramLineItems_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramLineItems" xlink:to="lab_srt_ShareRepurchaseProgramLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_019b097a-6e6c-7dfc-b107-d0fa82ec7d0f_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AdrMember_019b097a-6f46-725c-b47d-9a3d8caab029_terseLabel_en-US" xlink:label="lab_dei_AdrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">American Depositary Shares</link:label>
    <link:label id="lab_dei_AdrMember_label_en-US" xlink:label="lab_dei_AdrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ADR [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AdrMember" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AdrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AdrMember" xlink:to="lab_dei_AdrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_019b097a-6f46-75d6-8e09-caf3a2487654_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of changes in the valuation allowance for deferred tax assets</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_OrdinarySharesLiquidationPreference_019b097a-6f46-74f7-aa77-db352bdb4016_terseLabel_en-US" xlink:label="lab_brns_OrdinarySharesLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, liquidation preference</link:label>
    <link:label id="lab_brns_OrdinarySharesLiquidationPreference_label_en-US" xlink:label="lab_brns_OrdinarySharesLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary Shares, Liquidation Preference</link:label>
    <link:label id="lab_brns_OrdinarySharesLiquidationPreference_documentation_en-US" xlink:label="lab_brns_OrdinarySharesLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of liquidation preference on ordinary shares to be paid after which the deferred shares have the entitlement to receive out of the assets of the Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OrdinarySharesLiquidationPreference" xlink:href="brns-20251231.xsd#brns_OrdinarySharesLiquidationPreference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_OrdinarySharesLiquidationPreference" xlink:to="lab_brns_OrdinarySharesLiquidationPreference" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b097a-6e6c-769b-8652-029a42855180_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_019b097a-6f45-704b-a58c-e59811dcc252_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_019b097a-6e6c-7902-8850-4ee03b5a6680_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_019bd5bd-bc9d-745e-92d9-7c0c69228d93_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_019b097a-6e6c-7de1-a634-673d89b3b26d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_019b097a-6e6c-7d26-b766-72421b1ba027_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_019b097a-6f46-7ed1-949d-18ff34c7e421_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_019b097a-6f46-70af-92e0-b69d393ba414_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_019b097a-6e6c-7473-b99b-2552e1b17372_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_019b097a-6f46-7d1e-be92-a7bbcef4308d_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_019b097a-6f46-7a8a-b3c2-9ee7d9bb3396_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss/(gain) attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_019b097a-6f46-7310-8fe1-045ebbb068e5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued bonus</link:label>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Bonuses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_019b097a-6f46-731b-a32a-0b0f0e3c1c5b_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_NumberOfDepositarySharesPerShareOfCommonStock_019bd5db-61f6-7bc8-ae09-2ebd6926308e_terseLabel_en-US" xlink:label="lab_brns_NumberOfDepositarySharesPerShareOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of depositary shares per share of common stock (in shares)</link:label>
    <link:label id="lab_brns_NumberOfDepositarySharesPerShareOfCommonStock_label_en-US" xlink:label="lab_brns_NumberOfDepositarySharesPerShareOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Depositary Shares Per Share Of Common Stock</link:label>
    <link:label id="lab_brns_NumberOfDepositarySharesPerShareOfCommonStock_documentation_en-US" xlink:label="lab_brns_NumberOfDepositarySharesPerShareOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Depositary Shares Per Share Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfDepositarySharesPerShareOfCommonStock" xlink:href="brns-20251231.xsd#brns_NumberOfDepositarySharesPerShareOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_NumberOfDepositarySharesPerShareOfCommonStock" xlink:to="lab_brns_NumberOfDepositarySharesPerShareOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_019b097a-6f46-7aa7-856e-89bfb6204ca2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of loss before income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTableTextBlock_019b097a-6f46-7ee7-b129-7ffb1b6cfc0e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of changes in deferred income</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTableTextBlock" xlink:to="lab_us-gaap_DeferredIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_019b097a-6f46-77b7-98ce-4f870de17af1_terseLabel_en-US" xlink:label="lab_brns_EnterpriseManagementIncentiveShareOptionSchemeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Enterprise Management Incentive Share Option Scheme</link:label>
    <link:label id="lab_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_label_en-US" xlink:label="lab_brns_EnterpriseManagementIncentiveShareOptionSchemeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enterprise Management Incentive Share Option Scheme [Member]</link:label>
    <link:label id="lab_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_documentation_en-US" xlink:label="lab_brns_EnterpriseManagementIncentiveShareOptionSchemeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the Enterprise Management Incentive Share Option Scheme.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember" xlink:href="brns-20251231.xsd#brns_EnterpriseManagementIncentiveShareOptionSchemeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember" xlink:to="lab_brns_EnterpriseManagementIncentiveShareOptionSchemeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019b097a-6f46-7139-a383-b589714611d5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_019b097a-6f46-79f0-a669-95a0eee4cb88_terseLabel_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accrued expenses and other current liabilities</link:label>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities And Other Current Liabilities [Table Text Block]</link:label>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the components of accrued liabilities and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:href="brns-20251231.xsd#brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_019b097a-6f46-7947-8c34-b25648d38c45_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_019b097a-6f46-79c4-a19c-9340ca22e6c8_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease liability, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_019b097a-6f46-7217-9523-f760b1fcbca7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of financial instruments carried at fair value and classified within Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_019b097a-6f46-7d24-ab89-e79a5cec6043_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_019b097a-6f46-772c-9dca-b2d25482a88b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_019b097a-6f45-7a1b-a168-a9c3d1eb1dcb_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_019b097a-6f46-7739-b092-639ab0d78816_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_019b097a-6f46-7aed-af97-eef412f8f037_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_019bd5df-9dd5-7436-9083-20cf7662ec8c_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_019b097a-6f46-75ae-8529-798ba4c724f6_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019b097a-6f46-7cba-beb6-cf5906e3553a_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_PeriodOfPreemptiveRightsToBeExercised_019b097a-6e6c-7c6a-b3d9-706ea7ee40eb_terseLabel_en-US" xlink:label="lab_brns_PeriodOfPreemptiveRightsToBeExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum period to exercise preemptive rights</link:label>
    <link:label id="lab_brns_PeriodOfPreemptiveRightsToBeExercised_label_en-US" xlink:label="lab_brns_PeriodOfPreemptiveRightsToBeExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Preemptive Rights To Be Exercised</link:label>
    <link:label id="lab_brns_PeriodOfPreemptiveRightsToBeExercised_documentation_en-US" xlink:label="lab_brns_PeriodOfPreemptiveRightsToBeExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The period allowed to exercise preemptive rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PeriodOfPreemptiveRightsToBeExercised" xlink:href="brns-20251231.xsd#brns_PeriodOfPreemptiveRightsToBeExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_PeriodOfPreemptiveRightsToBeExercised" xlink:to="lab_brns_PeriodOfPreemptiveRightsToBeExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_019b097a-6f46-7cac-bb28-cecfe628b774_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_019b097a-6e6c-72c1-9c35-a44d9c52d25d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019b097a-6fcf-788c-be90-08b8f8669bc9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_019b097a-6f46-7463-a089-326196eadca0_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_IndirectResearchAndDevelopmentExpense_019b097a-6f46-73bf-b47b-425a6e2d0337_terseLabel_en-US" xlink:label="lab_brns_IndirectResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total indirect research and development expenses</link:label>
    <link:label id="lab_brns_IndirectResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_brns_IndirectResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indirect Research And Development Expense</link:label>
    <link:label id="lab_brns_IndirectResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_brns_IndirectResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indirect Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IndirectResearchAndDevelopmentExpense" xlink:href="brns-20251231.xsd#brns_IndirectResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_IndirectResearchAndDevelopmentExpense" xlink:to="lab_brns_IndirectResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_019b097a-6f46-7dad-b97f-b196441ad48e_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_019b097a-6f46-7f04-986d-fb67d8f88f9c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019b097a-6f46-7597-95bf-4287e2ce8dbe_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019b097a-6e6c-7027-a6da-2d99d2d22689_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019b097a-6f46-7ecf-865a-eef4ad23e78b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredStockSharesAuthorized_019b097a-6f46-7ec4-b270-45dbae24f884_terseLabel_en-US" xlink:label="lab_brns_DeferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred shares, authorized (in shares)</link:label>
    <link:label id="lab_brns_DeferredStockSharesAuthorized_label_en-US" xlink:label="lab_brns_DeferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Shares Authorized</link:label>
    <link:label id="lab_brns_DeferredStockSharesAuthorized_documentation_en-US" xlink:label="lab_brns_DeferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum number of deferred shares permitted to be issued by an entity's charter and bylaws.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesAuthorized" xlink:href="brns-20251231.xsd#brns_DeferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredStockSharesAuthorized" xlink:to="lab_brns_DeferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_019b097a-6f46-7389-8be0-f61a7ba058fc_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_019b097a-6f46-75eb-9c9e-7256ae01efab_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_019b097a-6e6c-70e8-9edb-4b3741eb7be8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_019b097a-6e6c-7375-812a-c45ab1c6092e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSU's</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember_019b097a-6f46-7927-9c7a-c545ddd6ffe9_terseLabel_en-US" xlink:label="lab_brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development of Immunotherapies and Vaccines</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember_label_en-US" xlink:label="lab_brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Of Immunotherapies And Vaccines [Member]</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember_documentation_en-US" xlink:label="lab_brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Of Immunotherapies And Vaccines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember" xlink:to="lab_brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_019b097a-6f46-7380-bc26-ad6f777d1ff9_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Loss, Financial Instrument [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_NonCashLeaseExpenses_019b097a-6f46-72a9-a993-8e6f52bf7252_terseLabel_en-US" xlink:label="lab_brns_NonCashLeaseExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expenses</link:label>
    <link:label id="lab_brns_NonCashLeaseExpenses_label_en-US" xlink:label="lab_brns_NonCashLeaseExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Lease Expenses</link:label>
    <link:label id="lab_brns_NonCashLeaseExpenses_documentation_en-US" xlink:label="lab_brns_NonCashLeaseExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of non-cash lease expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NonCashLeaseExpenses" xlink:href="brns-20251231.xsd#brns_NonCashLeaseExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_NonCashLeaseExpenses" xlink:to="lab_brns_NonCashLeaseExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_OxfordUniversityInnovationMember_019b097a-6e6c-7830-9a35-713d03cb85e4_terseLabel_en-US" xlink:label="lab_brns_OxfordUniversityInnovationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oxford University Innovation</link:label>
    <link:label id="lab_brns_OxfordUniversityInnovationMember_label_en-US" xlink:label="lab_brns_OxfordUniversityInnovationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oxford University Innovation [Member]</link:label>
    <link:label id="lab_brns_OxfordUniversityInnovationMember_documentation_en-US" xlink:label="lab_brns_OxfordUniversityInnovationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent information related to Oxford University Innovation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordUniversityInnovationMember" xlink:href="brns-20251231.xsd#brns_OxfordUniversityInnovationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_OxfordUniversityInnovationMember" xlink:to="lab_brns_OxfordUniversityInnovationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_019b097a-6e6c-76e5-a442-4fc158c2394c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_019b097a-6e6c-7ac9-9d92-bdbec6254430_terseLabel_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_label_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities And Other Current Liabilities [Text Block]</link:label>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure of the components of accrued liabilities and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:href="brns-20251231.xsd#brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:to="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019b097a-6f46-7bc5-a1b7-1549feddbee3_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_019b097a-6e6c-74bf-8bea-cab88cc85d8a_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_019b097a-6e6c-7597-9c22-5917c747a97e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b097a-6f46-7aee-a557-0a658f6e0398_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b097a-6f46-7747-b53c-6df4a5ada7c6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b097a-6f46-74ed-9bd8-0d6ffd6281ec_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b097a-6f46-70ad-bade-b8524f3e2c71_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_019b097a-6f46-7845-b431-290257e27908_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_019b097a-6f46-7cdf-b0a3-56800c3691e5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_019b097a-6f46-79d4-950b-4a87e62a92fe_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019b097a-6f45-7187-99f2-3b683d161e40_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_019b097a-6f46-7a0d-90ef-a23bd6460c9a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of components of income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_019b097a-6e6c-702c-b3c3-644fa4dcaa48_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_019b097a-6f46-7ad7-a0ae-b6211f1c6d4e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_019b097a-6e6c-7004-8bd0-c77f55722a80_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_019b097a-6f46-7782-9345-b1ecff5241d6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_019b097a-6f46-77cc-8bbd-e3c82fb4302b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_019b097a-6f45-7746-b4cc-734cbc69dbc8_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized foreign exchange loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b097a-6f46-7f94-adf8-72b784dbfc1d_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income tax benefit/(expense):</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_019b097a-6f46-7d8c-94b7-813aef1423fe_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019b097a-6f46-7738-92d4-18ac7896ab03_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019ce2c4-e45d-784e-8d4e-aca5cc6b9147_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_019b097a-6e6c-79f8-a465-ddce59cd8421_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_019b097a-6e6c-792a-a9d0-53389fa9483d_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets acquired through business combinations</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019b097a-6e6c-7dd1-bf55-d4dad0c56b68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_019b097a-6f46-718e-9b48-e957d2589201_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019b097a-6f46-772c-9dad-160d1366619c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019b097a-6f46-7a34-a461-927736a9ee92_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_019b097a-6e6c-7efc-9649-48cc41a6ffd5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019c2846-9312-7df0-b21a-39d0cb01a007_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares Underlying RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019b097a-6fcf-7284-be98-667a12a3f54b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b097a-6f46-794d-b137-c68c321ddc48_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019b097a-6f46-763a-a848-b523e56a5893_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019b097a-6f46-79b2-9eca-f2307199f7c4_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019b097a-6f46-7d40-8cc7-82135d301114_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_019b097a-6f46-79e5-a5c4-8f6d142f6aee_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_019b097a-6f46-7f70-ab53-fc6f74c1f1ff_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_019b097a-6f46-7e86-8f83-1591a8dbad63_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_019b097a-6f46-74c7-8e59-75ef6894db6d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_019b097a-6e6c-7ddb-8191-8f23bbbd7d8b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredStockParOrStatedValuePerShare_019b097a-6f46-7e77-8b6d-d3b0bb266c68_terseLabel_en-US" xlink:label="lab_brns_DeferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred shares, nominal value (in gbp per share)</link:label>
    <link:label id="lab_brns_DeferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_brns_DeferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Par Or Stated Value Per Share</link:label>
    <link:label id="lab_brns_DeferredStockParOrStatedValuePerShare_documentation_en-US" xlink:label="lab_brns_DeferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Face amount or stated value per share of deferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockParOrStatedValuePerShare" xlink:href="brns-20251231.xsd#brns_DeferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredStockParOrStatedValuePerShare" xlink:to="lab_brns_DeferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_019b097a-6f46-711b-898f-6dc8307ab9ff_terseLabel_en-US" xlink:label="lab_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted share units, options, share appreciation rights and restricted shares</link:label>
    <link:label id="lab_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_label_en-US" xlink:label="lab_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Units, Stock Options, Share Appreciation Rights And Restricted Shares [Member]</link:label>
    <link:label id="lab_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_documentation_en-US" xlink:label="lab_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to aggregate awards under a specific share-based compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" xlink:href="brns-20251231.xsd#brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" xlink:to="lab_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_NumberOfGeographicRegionsInWhichEntityOperates_019c49dc-270c-73ae-a71d-ab91b5e304e7_terseLabel_en-US" xlink:label="lab_brns_NumberOfGeographicRegionsInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of geographic regions where the company operates</link:label>
    <link:label id="lab_brns_NumberOfGeographicRegionsInWhichEntityOperates_label_en-US" xlink:label="lab_brns_NumberOfGeographicRegionsInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Geographic Regions In Which Entity Operates</link:label>
    <link:label id="lab_brns_NumberOfGeographicRegionsInWhichEntityOperates_documentation_en-US" xlink:label="lab_brns_NumberOfGeographicRegionsInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Geographic Regions In Which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfGeographicRegionsInWhichEntityOperates" xlink:href="brns-20251231.xsd#brns_NumberOfGeographicRegionsInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_NumberOfGeographicRegionsInWhichEntityOperates" xlink:to="lab_brns_NumberOfGeographicRegionsInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_019b097a-6f46-7b69-96fa-1ede6a9aa1b0_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_019b097a-6f46-7ac3-b82d-f16f6afe482f_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_019b097a-6e6c-74d4-9fd1-fe6625ccba19_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock_019b097a-6f46-7b29-951c-6f099847ff8d_terseLabel_en-US" xlink:label="lab_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development services</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Services, Policy [Policy Text Block]</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for research and development services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock" xlink:to="lab_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_019b097a-6f46-733b-ad76-6a4ba982c4e7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_019b097a-6f46-727b-8100-4e8de0092fea_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity attributable to Barinthus Biotherapeutics plc stockholders</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_019b097a-6f46-767e-90a5-1d12a32ade60_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_019b097a-6f46-7bfb-a0d3-d5471a956132_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019b097a-6f46-737a-ba50-f5ec59d98b68_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_019b097a-6fcf-7df3-b423-e781fb51d2ee_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer contribution</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_019b097a-6f46-7ca6-ad75-185864011b77_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RegulatoryIncomeTaxesPolicy_019b097a-6f45-79d5-95b5-4589b92d91e1_terseLabel_en-US" xlink:label="lab_us-gaap_RegulatoryIncomeTaxesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_RegulatoryIncomeTaxesPolicy_label_en-US" xlink:label="lab_us-gaap_RegulatoryIncomeTaxesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Income Taxes, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegulatoryIncomeTaxesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegulatoryIncomeTaxesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RegulatoryIncomeTaxesPolicy" xlink:to="lab_us-gaap_RegulatoryIncomeTaxesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6f46-7d06-867c-c5afecc438c7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income/(expense):</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019b097a-6f46-7907-8a83-d9f6be922507_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_019b097a-6f46-7193-922b-fc04652a1f7b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_LesseeOperatingLeaseExtendedTerm_019b097a-6f46-7b76-a72a-014d6efcf24f_terseLabel_en-US" xlink:label="lab_brns_LesseeOperatingLeaseExtendedTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional lease term</link:label>
    <link:label id="lab_brns_LesseeOperatingLeaseExtendedTerm_label_en-US" xlink:label="lab_brns_LesseeOperatingLeaseExtendedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Operating Lease, Extended Term</link:label>
    <link:label id="lab_brns_LesseeOperatingLeaseExtendedTerm_documentation_en-US" xlink:label="lab_brns_LesseeOperatingLeaseExtendedTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term of lessee's operating lease extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LesseeOperatingLeaseExtendedTerm" xlink:href="brns-20251231.xsd#brns_LesseeOperatingLeaseExtendedTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_LesseeOperatingLeaseExtendedTerm" xlink:to="lab_brns_LesseeOperatingLeaseExtendedTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_019ce2c5-6b63-7376-9ce2-0fb199bca581_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other adjustments</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_019b097a-6e6c-76f8-afe1-89fe50fe093c_netLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Settlement payments related to contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_019b097a-6e6c-7258-bf86-b3e05518be68_terseLabel_en-US" xlink:label="lab_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Barinthus Biotherapeutics plc Share Award Plan 2021</link:label>
    <link:label id="lab_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_label_en-US" xlink:label="lab_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Barinthus Biotherapeutics plc Share Award Plan 2021 [Member]</link:label>
    <link:label id="lab_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_documentation_en-US" xlink:label="lab_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Barinthus Biotherapeutics plc Share Award Plan 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" xlink:href="brns-20251231.xsd#brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" xlink:to="lab_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c2848-c45b-7466-8123-a9c26386dabf_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested begining balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c2848-4c11-7b20-a800-5a2f0bfe74ed_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6f45-7d89-9a2a-9fad398760ef_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_MergerAgreementMergerExchangeRatio_019cd0fb-6b02-7643-96fd-f52ebc3ea7ca_terseLabel_en-US" xlink:label="lab_brns_MergerAgreementMergerExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merger exchange ratio</link:label>
    <link:label id="lab_brns_MergerAgreementMergerExchangeRatio_label_en-US" xlink:label="lab_brns_MergerAgreementMergerExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Merger Agreement, Merger Exchange Ratio</link:label>
    <link:label id="lab_brns_MergerAgreementMergerExchangeRatio_documentation_en-US" xlink:label="lab_brns_MergerAgreementMergerExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Merger Agreement, Merger Exchange Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MergerAgreementMergerExchangeRatio" xlink:href="brns-20251231.xsd#brns_MergerAgreementMergerExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_MergerAgreementMergerExchangeRatio" xlink:to="lab_brns_MergerAgreementMergerExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019b097a-6f46-7a13-a31f-0d18d16e001e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_019b097a-6e6c-7d78-aac6-1f1f576ddb07_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_019b097a-6f46-741e-9d35-aebf16c40c8c_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-lived assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019b097a-6f46-7349-b908-42d69b04e0b4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6f45-7739-961f-854794d903de_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_019b097a-6f46-78ad-aded-2801f5e83787_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019cb025-71b3-79ca-a210-d8fe04d38711_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_019b097a-6f46-7dad-977f-f0c1f7a46c49_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Useful Life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_019c4995-5c19-7efe-b079-cd9b8fbae794_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_019b097a-6f46-72d7-964c-33eca92aa5cf_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_019b097a-6f46-72de-a5d0-1df1f6fa26bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of weighted-average assumptions of fair value stock option issued to employees</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_019b097a-6e6c-7017-9edd-a1dca71d829f_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019cb025-71b3-7ce0-a2bf-fb8490d31916_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeRollForward_019b097a-6f46-7954-a4a3-91508ce3de10_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Income [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeRollForward_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeRollForward" xlink:to="lab_us-gaap_DeferredIncomeRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredTaxAssetsLeasingArrangements_019b097a-6e6c-778d-9abb-706274778de4_terseLabel_en-US" xlink:label="lab_brns_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_brns_DeferredTaxAssetsLeasingArrangements_label_en-US" xlink:label="lab_brns_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Leasing Arrangements</link:label>
    <link:label id="lab_brns_DeferredTaxAssetsLeasingArrangements_documentation_en-US" xlink:label="lab_brns_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredTaxAssetsLeasingArrangements" xlink:href="brns-20251231.xsd#brns_DeferredTaxAssetsLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredTaxAssetsLeasingArrangements" xlink:to="lab_brns_DeferredTaxAssetsLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_019b097a-6f46-7a97-ae67-761b12cfd2b7_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_019c2845-fb35-766a-862d-afc03074ad14_terseLabel_en-US" xlink:label="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested but subject to deferred settlement (in shares)</link:label>
    <link:label id="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_label_en-US" xlink:label="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Number</link:label>
    <link:label id="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_documentation_en-US" xlink:label="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:to="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_019b097a-6e6c-7991-85b4-4d4f26e6b5d2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_019b097a-6f46-7620-83ad-4cfe985edf16_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_019b097a-6f46-70e9-a80c-fcaaeda08bfa_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_019b097a-6f46-7930-b705-5ca88c1ffea3_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_019b097a-6f46-7314-9ff0-cd0d593dcf75_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_019ce2c4-e45d-7a91-8518-d38591e13b63_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_019b097a-6f46-783d-8e01-4340387dd177_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_VOLTMember_019b097a-6f46-738f-ba63-0f8d069d0a80_terseLabel_en-US" xlink:label="lab_brns_VOLTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VOLT</link:label>
    <link:label id="lab_brns_VOLTMember_label_en-US" xlink:label="lab_brns_VOLTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">VOLT [Member]</link:label>
    <link:label id="lab_brns_VOLTMember_documentation_en-US" xlink:label="lab_brns_VOLTMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent of VOLT Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_VOLTMember" xlink:href="brns-20251231.xsd#brns_VOLTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_VOLTMember" xlink:to="lab_brns_VOLTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_019b097a-6e6c-77b0-9893-338a07508ba8_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b097a-6f46-7437-aa61-d2be9822a7b4_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue_019cb0ca-d336-7706-974f-9993fb02c9d9_terseLabel_en-US" xlink:label="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and settled (in usd per share)</link:label>
    <link:label id="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Settled In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Settled In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_019b097a-6e6c-7634-8771-067dd91d278e_negatedLabel_en-US" xlink:label="lab_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development incentives receivable</link:label>
    <link:label id="lab_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_label_en-US" xlink:label="lab_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Research and Development Incentives Receivable</link:label>
    <link:label id="lab_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_documentation_en-US" xlink:label="lab_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) in research and development incentives receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:href="brns-20251231.xsd#brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:to="lab_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019b097a-6f46-79b1-94a7-db1b490ca342_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- average Exercise Price Per Option</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019ba4a1-26cb-79e6-b161-80d342db0897_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_019b097a-6f46-72e2-978b-94acd9b7d094_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use asset impairment charge</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_IncomeTaxesLineItems_019b097a-6f46-7701-ac48-60df1100c5fe_terseLabel_en-US" xlink:label="lab_brns_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_brns_IncomeTaxesLineItems_label_en-US" xlink:label="lab_brns_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_brns_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_brns_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncomeTaxesLineItems" xlink:href="brns-20251231.xsd#brns_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_IncomeTaxesLineItems" xlink:to="lab_brns_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_019b097a-6f46-70bf-85ff-c054bac39229_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredStockValueIssued_019b097a-6f45-783f-90a9-19ad1ac2c36d_terseLabel_en-US" xlink:label="lab_brns_DeferredStockValueIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred A shares, &#163;1 nominal value; 63,443 shares authorized, issued and outstanding (December&#160;31, 2024: authorized, issued and outstanding: 63,443)</link:label>
    <link:label id="lab_brns_DeferredStockValueIssued_label_en-US" xlink:label="lab_brns_DeferredStockValueIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Value Issued</link:label>
    <link:label id="lab_brns_DeferredStockValueIssued_documentation_en-US" xlink:label="lab_brns_DeferredStockValueIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate par or stated value of issued deferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockValueIssued" xlink:href="brns-20251231.xsd#brns_DeferredStockValueIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredStockValueIssued" xlink:to="lab_brns_DeferredStockValueIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_019b097a-6f46-718a-9641-85ed6858440a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_019b097a-6f46-74b1-bdf8-a9e7c3da6163_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019ce06d-fdf9-77c0-b173-aaa2cdbf7ec4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights_019b097a-6f46-7e2f-b42a-7f54ec369455_terseLabel_en-US" xlink:label="lab_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum aggregate nominal amount of shares authorized to be allotted free from pre-emption rights</link:label>
    <link:label id="lab_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights_label_en-US" xlink:label="lab_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Aggregate Nominal Amount Of Shares Authorized To Be Allotted Free From Statutory Pre-emption Rights</link:label>
    <link:label id="lab_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights_documentation_en-US" xlink:label="lab_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of maximum aggregate nominal amount of shares that the board of directors are authorized to allot free from statutory Pre-emption rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" xlink:href="brns-20251231.xsd#brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" xlink:to="lab_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ClywedogTherapeuticsInc.Member_019bd5df-9dd5-7258-bd45-300d7064feb8_terseLabel_en-US" xlink:label="lab_brns_ClywedogTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clywedog Therapeutics, Inc.</link:label>
    <link:label id="lab_brns_ClywedogTherapeuticsInc.Member_label_en-US" xlink:label="lab_brns_ClywedogTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clywedog Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_brns_ClywedogTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_brns_ClywedogTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clywedog Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ClywedogTherapeuticsInc.Member" xlink:href="brns-20251231.xsd#brns_ClywedogTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ClywedogTherapeuticsInc.Member" xlink:to="lab_brns_ClywedogTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_019b097a-6f46-7a22-a9b3-2f23391a00b4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_019b097a-6f46-74ba-9416-303e97857dd3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_019b097a-6e6c-70f7-b31c-8344230d11de_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_019b097a-6f46-797c-ae4c-2d75bcc2c1d1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_019b097a-6f46-7ba5-9c17-cc87ea7a76e3_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_019b097a-6f46-7be1-9c4a-fdcc40e66e88_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeAddition_019b097a-6f46-79d0-8fe7-7cd792deac0d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeAddition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash payments received</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeAddition_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeAddition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income, Addition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeAddition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeAddition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeAddition" xlink:to="lab_us-gaap_DeferredIncomeAddition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_019bd5df-9dd5-7458-acf1-5b5e971f3b5d_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_019b097a-6fcf-7d77-aa14-7881fe14c585_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used) in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_019b097a-6f46-7f23-af88-e2e286befd21_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_019b097a-6e6c-7fd8-9ee6-abe6155685bd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_019b097a-6e6c-7deb-b30e-188fd12d04ef_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_019b097a-6f46-73e6-a664-f518f6c22c15_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll and employee benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_019b097a-6f46-74c7-968e-687cff1329a7_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_019b097a-6e6c-7606-a236-d3934ae1de52_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized Research and Development expenditure</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_019b097a-6e6c-791d-b335-d5c70506e7ed_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets for capitalized research and development expenditure</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019b097a-6f46-7107-9106-29e4e2f6642e_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_019b097a-6f46-76db-a2e8-fd33d1cea452_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_019b097a-6f46-7eac-a315-16a304c5e20d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_FacilityRelatedMember_019b097a-6f46-74ba-b1aa-304ef72c4b8d_terseLabel_en-US" xlink:label="lab_brns_FacilityRelatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility related</link:label>
    <link:label id="lab_brns_FacilityRelatedMember_label_en-US" xlink:label="lab_brns_FacilityRelatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Related [Member]</link:label>
    <link:label id="lab_brns_FacilityRelatedMember_documentation_en-US" xlink:label="lab_brns_FacilityRelatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facility Related</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FacilityRelatedMember" xlink:href="brns-20251231.xsd#brns_FacilityRelatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_FacilityRelatedMember" xlink:to="lab_brns_FacilityRelatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_019b097a-6f46-71a9-aa3a-efcfbff6824a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_019c6f39-18de-7161-9745-797448f4caca_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction-related fees</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition-Related Cost, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_019b097a-6fcf-7764-be03-69656854b9fc_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvement expense</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019b097a-6f46-7d11-8aab-fd9ccb6f37ca_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period over which unrecognized compensation cost is expected to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019b097a-6f46-7ba5-80d2-6af8794c11db_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_019b097a-6e6c-7403-8d1a-86371b7996ca_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_019b097a-6e6c-71bf-83e4-b44749313e91_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_019b097a-6e6c-7010-b9e2-39c88a371557_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Valuations allowance at beginning of year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_019b097a-6e6c-70a4-9b50-29ea5c559493_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance at end of year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_019b097a-6f46-7d80-8466-98357cff0f86_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_019b097a-6f46-77c6-975a-921b66b43839_terseLabel_en-US" xlink:label="lab_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of issued and outstanding ordinary shares available for issuance</link:label>
    <link:label id="lab_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_label_en-US" xlink:label="lab_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation, Percentage Of Shares Available For Issuance As A Percentage Of Issued And Outstanding Shares</link:label>
    <link:label id="lab_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_documentation_en-US" xlink:label="lab_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total number of shares available for issuance under the Plan as a percentage of the Company's issued and outstanding shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" xlink:to="lab_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019b097a-6e6c-7a6a-9e02-785781000992_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_019b097a-6e6c-71f6-8d9d-1c4b26b4eaae_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DirectResearchAndDevelopmentExpensesAbstract_019b097a-6f46-7677-9aa5-c9c57a628ec1_terseLabel_en-US" xlink:label="lab_brns_DirectResearchAndDevelopmentExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Direct research and development expenses:</link:label>
    <link:label id="lab_brns_DirectResearchAndDevelopmentExpensesAbstract_label_en-US" xlink:label="lab_brns_DirectResearchAndDevelopmentExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Direct Research and Development Expenses [Abstract]</link:label>
    <link:label id="lab_brns_DirectResearchAndDevelopmentExpensesAbstract_documentation_en-US" xlink:label="lab_brns_DirectResearchAndDevelopmentExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Direct Research and Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DirectResearchAndDevelopmentExpensesAbstract" xlink:href="brns-20251231.xsd#brns_DirectResearchAndDevelopmentExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DirectResearchAndDevelopmentExpensesAbstract" xlink:to="lab_brns_DirectResearchAndDevelopmentExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredIncomeForeignExchangeTranslationGainLoss_019b097a-6f46-7bfd-acae-59d1640a7cb3_negatedTerseLabel_en-US" xlink:label="lab_brns_DeferredIncomeForeignExchangeTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange translation</link:label>
    <link:label id="lab_brns_DeferredIncomeForeignExchangeTranslationGainLoss_label_en-US" xlink:label="lab_brns_DeferredIncomeForeignExchangeTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income, Foreign Exchange Translation Gain (Loss)</link:label>
    <link:label id="lab_brns_DeferredIncomeForeignExchangeTranslationGainLoss_documentation_en-US" xlink:label="lab_brns_DeferredIncomeForeignExchangeTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Income, Foreign Exchange Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredIncomeForeignExchangeTranslationGainLoss" xlink:href="brns-20251231.xsd#brns_DeferredIncomeForeignExchangeTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredIncomeForeignExchangeTranslationGainLoss" xlink:to="lab_brns_DeferredIncomeForeignExchangeTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_019b097a-6e6c-7344-bc58-382687eb671d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019b097a-6e6c-74c0-9774-1fa5a937ddfd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_019b097a-6f46-7558-b983-3435c0a256f1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019b097a-6f46-7c89-8fcb-bd7e0aad6f6c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6f46-7c80-bf2b-84314c88b474_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_019b097a-6e6c-747a-afde-8c15ec06a26b_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_019b097a-6f46-7151-9c18-754a65393054_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense for intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_019b097a-6e6c-7af2-9675-752b94c5e6e6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList_019b097a-6f45-7566-a723-f21c470196d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_019b097a-6f46-75b1-84a4-19f4218ba179_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_019b097a-6e6c-7b52-ad15-615ffb387a28_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_019b097a-6f46-7422-b759-af8ae32e1c43_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019b097a-6fcf-737b-9109-96ebe9fdf0ac_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019b097a-6f46-71c3-a100-4225b5b4cdfb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Company&#8217;s Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_019b097a-6f46-7247-80ce-edc09ef2f191_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss &#8211; foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_NumberOfReportableSegmentsNotDisclosedFlag_019ba4aa-9815-7ab6-9ec9-3fbdf4754bf5_terseLabel_en-US" xlink:label="lab_brns_NumberOfReportableSegmentsNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments Not Disclosed Flag</link:label>
    <link:label id="lab_brns_NumberOfReportableSegmentsNotDisclosedFlag_label_en-US" xlink:label="lab_brns_NumberOfReportableSegmentsNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Reportable Segments Not Disclosed Flag</link:label>
    <link:label id="lab_brns_NumberOfReportableSegmentsNotDisclosedFlag_documentation_en-US" xlink:label="lab_brns_NumberOfReportableSegmentsNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Reportable Segments Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfReportableSegmentsNotDisclosedFlag" xlink:href="brns-20251231.xsd#brns_NumberOfReportableSegmentsNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_NumberOfReportableSegmentsNotDisclosedFlag" xlink:to="lab_brns_NumberOfReportableSegmentsNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_VTP1000CeliacMember_019b097a-6f46-7e7a-a823-defc4d602bc8_terseLabel_en-US" xlink:label="lab_brns_VTP1000CeliacMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VTP-1000 Celiac</link:label>
    <link:label id="lab_brns_VTP1000CeliacMember_label_en-US" xlink:label="lab_brns_VTP1000CeliacMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">VTP-1000 Celiac [Member]</link:label>
    <link:label id="lab_brns_VTP1000CeliacMember_documentation_en-US" xlink:label="lab_brns_VTP1000CeliacMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">VTP-1000 Celiac</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_VTP1000CeliacMember" xlink:href="brns-20251231.xsd#brns_VTP1000CeliacMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_VTP1000CeliacMember" xlink:to="lab_brns_VTP1000CeliacMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019b097a-6f46-77cb-93de-d6013fc3553c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019b097a-6f46-7fa5-8556-78377634a734_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019b097a-6f46-7927-abd6-5fb1f59bf4b7_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_019b097a-6f45-775a-89bf-a87e5cabf293_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019b097a-6f46-7190-ab3b-86d26d051352_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_019b097a-6f46-7284-a7f4-c13d52e547c2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019b097a-6f46-7201-ba59-17b1e1d8e88c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_019b097a-6f46-72f6-8fad-e9dd312f3bae_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019b097a-6f46-71ac-a096-53ba27292264_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_019b097a-6f46-7e39-a569-c6a1ded1e0d6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019b097a-6f46-751b-a744-4398ea3a780b_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod_019c6f3d-9b9e-73ba-aa67-de272f8c3ed6_negatedTerseLabel_en-US" xlink:label="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested and deferred (in shares)</link:label>
    <link:label id="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod_label_en-US" xlink:label="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Deferred In Period</link:label>
    <link:label id="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod_documentation_en-US" xlink:label="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Deferred In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod" xlink:to="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_019c6f57-7534-7c4a-97b0-14a0f6bf315d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy_019b097a-6f46-7b08-97c4-4007825c0c22_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy_label_en-US" xlink:label="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Liability Reserve Estimate, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:to="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019b097a-6f46-7f0d-a5d8-5459d9cc396d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_019b097a-6e6c-7870-b440-448126d56424_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019b097a-6f46-7315-aced-572ea2104002_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_StockConversionRatio_019bd5d8-6235-723c-8e80-310f18b12d6e_terseLabel_en-US" xlink:label="lab_brns_StockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock conversion ratio</link:label>
    <link:label id="lab_brns_StockConversionRatio_label_en-US" xlink:label="lab_brns_StockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Ratio</link:label>
    <link:label id="lab_brns_StockConversionRatio_documentation_en-US" xlink:label="lab_brns_StockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_StockConversionRatio" xlink:href="brns-20251231.xsd#brns_StockConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_StockConversionRatio" xlink:to="lab_brns_StockConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_OtherIndirectCostsMember_019b097a-6f46-71b6-b6c5-99be8de19b1a_terseLabel_en-US" xlink:label="lab_brns_OtherIndirectCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other indirect costs</link:label>
    <link:label id="lab_brns_OtherIndirectCostsMember_label_en-US" xlink:label="lab_brns_OtherIndirectCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Indirect Costs [Member]</link:label>
    <link:label id="lab_brns_OtherIndirectCostsMember_documentation_en-US" xlink:label="lab_brns_OtherIndirectCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Indirect Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OtherIndirectCostsMember" xlink:href="brns-20251231.xsd#brns_OtherIndirectCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_OtherIndirectCostsMember" xlink:to="lab_brns_OtherIndirectCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_019b097a-6f46-7380-bb42-8df3fac9b6e1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_MinorityInterestPolicyTextBlock_019b097a-6f46-725e-9754-3c57a63e3821_terseLabel_en-US" xlink:label="lab_brns_MinorityInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_brns_MinorityInterestPolicyTextBlock_label_en-US" xlink:label="lab_brns_MinorityInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minority Interest [Policy Text Block]</link:label>
    <link:label id="lab_brns_MinorityInterestPolicyTextBlock_documentation_en-US" xlink:label="lab_brns_MinorityInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for Minority (Non Controlling) interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MinorityInterestPolicyTextBlock" xlink:href="brns-20251231.xsd#brns_MinorityInterestPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_MinorityInterestPolicyTextBlock" xlink:to="lab_brns_MinorityInterestPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance_019b097a-6e6c-75d7-acac-cf27205b6cc0_terseLabel_en-US" xlink:label="lab_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance_label_en-US" xlink:label="lab_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiration Of Share Based Compensation Plan From Date Of Initial Issuance</link:label>
    <link:label id="lab_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance_documentation_en-US" xlink:label="lab_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The duration of grants awarded under a share-based compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance" xlink:href="brns-20251231.xsd#brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance" xlink:to="lab_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_019b097a-6f46-7ddd-bf45-519d2963cf95_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019c2845-fb35-7a1a-ae62-f59b40f7c38f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_019b097a-6f45-725c-a4c2-b32e8fc71b68_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_019b097a-6f46-75bf-ad29-68abe20eebb8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross amount of amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019b097a-6f46-70d4-b670-b73ba42de665_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_019b097a-6f46-70e0-b70d-741f2adba19c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_019b097a-6e6c-72ac-98b6-fb28731c01cb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_019b097a-6e6c-7393-87b2-4fa4d2dbaae9_totalLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock_019b097a-6f46-72c6-9b77-98541f6a8553_terseLabel_en-US" xlink:label="lab_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of right-of-use assets, lease liabilities and other information</link:label>
    <link:label id="lab_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock_label_en-US" xlink:label="lab_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Operating Lease Right of Use asset and Other Information [Table Text Block]</link:label>
    <link:label id="lab_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock_documentation_en-US" xlink:label="lab_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure for Company's right-of-use asset and lease liability and other information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" xlink:href="brns-20251231.xsd#brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" xlink:to="lab_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019b097a-6e6c-7abd-98bd-6347f652f9f4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_019b097a-6f46-7986-a81e-fec4ac550349_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_019b097a-6f46-7441-8cda-908d9b092546_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability - non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_019b097a-6f46-7673-841c-b05bae2e60df_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease liability, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_019b097a-6f46-7c5d-9ecb-8d7121f75b0a_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_019b097a-6f46-7046-a196-af7602ee944e_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_StockholdersEquityDeferredSharesDisclosureTextBlock_019b097a-6f46-7011-af92-6ebf34e5030d_terseLabel_en-US" xlink:label="lab_brns_StockholdersEquityDeferredSharesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Shares</link:label>
    <link:label id="lab_brns_StockholdersEquityDeferredSharesDisclosureTextBlock_label_en-US" xlink:label="lab_brns_StockholdersEquityDeferredSharesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders Equity Deferred Shares Disclosure [Text Block]</link:label>
    <link:label id="lab_brns_StockholdersEquityDeferredSharesDisclosureTextBlock_documentation_en-US" xlink:label="lab_brns_StockholdersEquityDeferredSharesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for Deferred Shares as disclosed by the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_StockholdersEquityDeferredSharesDisclosureTextBlock" xlink:href="brns-20251231.xsd#brns_StockholdersEquityDeferredSharesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_StockholdersEquityDeferredSharesDisclosureTextBlock" xlink:to="lab_brns_StockholdersEquityDeferredSharesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_InLicenseAgreementsMember_019b097a-6f46-7d4c-9a75-a1d3bf2b521c_terseLabel_en-US" xlink:label="lab_brns_InLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-License Agreements</link:label>
    <link:label id="lab_brns_InLicenseAgreementsMember_label_en-US" xlink:label="lab_brns_InLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In-License Agreements [Member]</link:label>
    <link:label id="lab_brns_InLicenseAgreementsMember_documentation_en-US" xlink:label="lab_brns_InLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to In-License Agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_InLicenseAgreementsMember" xlink:href="brns-20251231.xsd#brns_InLicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_InLicenseAgreementsMember" xlink:to="lab_brns_InLicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation_019b097a-6f45-7b7a-ac39-40e13633cb8d_terseLabel_en-US" xlink:label="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange translation</link:label>
    <link:label id="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation_label_en-US" xlink:label="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease) Resulting From Foreign Currency Translation</link:label>
    <link:label id="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation_documentation_en-US" xlink:label="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease) Resulting From Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation" xlink:href="brns-20251231.xsd#brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation" xlink:to="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_019b097a-6f46-76e4-911c-722f5b4c760a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019b097a-6f45-7ef3-93b0-602c58540e56_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_019b097a-6f46-71b1-b3d9-1f615d1229dc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AuditInformationAbstract_label_en-US" xlink:label="lab_brns_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_brns_AuditInformationAbstract_documentation_en-US" xlink:label="lab_brns_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AuditInformationAbstract" xlink:href="brns-20251231.xsd#brns_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AuditInformationAbstract" xlink:to="lab_brns_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019bd65e-a226-7813-9862-b2bbd4aaf7fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019c284b-aa7f-7913-b59b-154fa505a443_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019c2870-05c9-7009-9e6e-9a0edab6f4da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_019b097a-6f46-7fec-a686-a1a30ea422c0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_019b097a-6e6c-7685-a764-1637e7e71427_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_019b097a-6e6c-7ffd-b7ed-120f486fb68a_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_019b097a-6e6c-7817-a42f-69488abeb73a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_019b097a-6f45-777e-82c8-e1cf71600cdd_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patent and licensing costs</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Costs Incurred to Renew or Extend, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019b097a-6f46-7ecc-8c60-68766411c14a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Weighted-average remaining contractual term (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c2845-fb35-78f9-b84f-c2b18c7a9d83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019b097a-6f46-7213-bf8a-6a012f404dc5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_019b097a-6e6c-7fd4-876a-ae74530d1b93_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_019c49ac-57b1-7fef-b140-e82c495d6102_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_019b097a-6e6c-7435-b93e-a7d7272f1953_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019b097a-6e6c-7340-8bd3-8682a1032482_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_019b097a-6f46-7bd9-8d2e-358bffa8e4d1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_019b097a-6e6c-70c5-b815-72caf5d87db1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use lease asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_019cb0ca-3b1b-7082-99ae-62a6f3f97787_negatedTerseLabel_en-US" xlink:label="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested and settled (in shares)</link:label>
    <link:label id="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_label_en-US" xlink:label="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Settled In Period</link:label>
    <link:label id="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_documentation_en-US" xlink:label="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Settled In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" xlink:to="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_019b097a-6f46-7f0b-afd7-377c6ed16e95_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_019ce2c4-fdca-7d1b-be00-c5f8769062a6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of change in tax laws or rates enacted in the current period</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b097a-6f46-7397-a7eb-6ff77e7752b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncome_019b097a-6f46-7931-9949-72e28f3fb381_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredIncome" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_DeferredIncome_019b097a-6f46-77de-aaa8-0e38b4033cac_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredIncome" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_DeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncome" xlink:to="lab_us-gaap_DeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_019b097a-6e6c-7930-88d2-76c20df590a3_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_019b097a-6f46-7d16-a149-0a20146754b2_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_019b097a-6f46-7f89-9818-1240ba8e2fcc_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_019ba4d7-f587-735e-9860-1e722bc860f4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant Income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income and Expense [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeAndExpenseTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:to="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b097a-6f46-7fe2-93de-c75c6d1e86b5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax benefit:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CH_019ce06e-6040-75f8-a2dc-64976f6c629f_terseLabel_en-US" xlink:label="lab_country_CH" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Switzerland</link:label>
    <link:label id="lab_country_CH_label_en-US" xlink:label="lab_country_CH" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SWITZERLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CH" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CH"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CH" xlink:to="lab_country_CH" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019b097a-6fcf-7321-8fcc-8ad215c7c52c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue_019c2845-fb35-793e-87f1-8950f8a72c35_terseLabel_en-US" xlink:label="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in usd per share)</link:label>
    <link:label id="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue" xlink:to="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019c284e-aca8-7889-bd4d-a309b4f08ef0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019c284a-2766-738a-9251-47b1ee9ec62b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019b097a-6f46-7493-b31e-4df9535fc790_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019b097a-6f46-799e-a692-881ee47cacb9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_019b097a-6e6c-7d5a-9552-f0e6fbd10ee6_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_019b097a-6e6c-7d83-a0b6-c49d43902d30_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AccruedManufacturingAndClinicalExpensesCurrent_019b097a-6f46-7f8b-a15c-47b473a06f17_terseLabel_en-US" xlink:label="lab_brns_AccruedManufacturingAndClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued manufacturing and clinical expenses</link:label>
    <link:label id="lab_brns_AccruedManufacturingAndClinicalExpensesCurrent_label_en-US" xlink:label="lab_brns_AccruedManufacturingAndClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Manufacturing and Clinical Expenses, Current</link:label>
    <link:label id="lab_brns_AccruedManufacturingAndClinicalExpensesCurrent_documentation_en-US" xlink:label="lab_brns_AccruedManufacturingAndClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing and clinical expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedManufacturingAndClinicalExpensesCurrent" xlink:href="brns-20251231.xsd#brns_AccruedManufacturingAndClinicalExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AccruedManufacturingAndClinicalExpensesCurrent" xlink:to="lab_brns_AccruedManufacturingAndClinicalExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019b097a-6e6c-7238-a358-7cafe5fa0255_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ResearchAndDevelopmentTypeAxis_019b097a-6f46-72ae-aa65-4bc3a6902aff_terseLabel_en-US" xlink:label="lab_brns_ResearchAndDevelopmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Type [Axis]</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentTypeAxis_label_en-US" xlink:label="lab_brns_ResearchAndDevelopmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Type [Axis]</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentTypeAxis_documentation_en-US" xlink:label="lab_brns_ResearchAndDevelopmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentTypeAxis" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ResearchAndDevelopmentTypeAxis" xlink:to="lab_brns_ResearchAndDevelopmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredStockSharesIssued_019b097a-6f46-7bb3-8e20-27d62dd86903_terseLabel_en-US" xlink:label="lab_brns_DeferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred shares, issued (in shares)</link:label>
    <link:label id="lab_brns_DeferredStockSharesIssued_label_en-US" xlink:label="lab_brns_DeferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Shares Issued</link:label>
    <link:label id="lab_brns_DeferredStockSharesIssued_documentation_en-US" xlink:label="lab_brns_DeferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total number of deferred shares of an entity that have been sold or granted to shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesIssued" xlink:href="brns-20251231.xsd#brns_DeferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredStockSharesIssued" xlink:to="lab_brns_DeferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_OxfordshireMember_019b097a-6f46-781d-8660-8c05c471e175_terseLabel_en-US" xlink:label="lab_brns_OxfordshireMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oxfordshire</link:label>
    <link:label id="lab_brns_OxfordshireMember_label_en-US" xlink:label="lab_brns_OxfordshireMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oxfordshire [Member]</link:label>
    <link:label id="lab_brns_OxfordshireMember_documentation_en-US" xlink:label="lab_brns_OxfordshireMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oxfordshire</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordshireMember" xlink:href="brns-20251231.xsd#brns_OxfordshireMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_OxfordshireMember" xlink:to="lab_brns_OxfordshireMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount_019ce35f-5db6-7c9a-9ef2-a0296708a4d8_negatedTerseLabel_en-US" xlink:label="lab_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount_label_en-US" xlink:label="lab_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credits, Research And Development, Amount</link:label>
    <link:label id="lab_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount_documentation_en-US" xlink:label="lab_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credits, Research And Development, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount" xlink:href="brns-20251231.xsd#brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount" xlink:to="lab_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_019b097a-6f46-7101-b207-b7cb2d339771_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_019cb026-3c39-73ff-afa9-730ec8b4ee6b_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Effects</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_019b097a-6f45-7567-b2fd-82bdd196821a_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision_019b097a-6e6c-7ccc-9007-ccf29361d281_terseLabel_en-US" xlink:label="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases recorded to income tax provision</link:label>
    <link:label id="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision_label_en-US" xlink:label="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase Resulting From Income Tax Provision</link:label>
    <link:label id="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision_documentation_en-US" xlink:label="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase Resulting From Income Tax Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision" xlink:href="brns-20251231.xsd#brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision" xlink:to="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_019b097a-6e6c-7f6a-a93c-2e8dcef7b64e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_019b097a-6e6c-7e38-8974-c4832eab57f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019b097a-6f46-7bde-a1ec-14d9696e07b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentiveIncomeExpense_019b097a-6e6c-792f-8738-8a4e0fd4efdb_terseLabel_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentiveIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development incentives</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentiveIncomeExpense_label_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentiveIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Incentive Income (Expense)</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentiveIncomeExpense_documentation_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentiveIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the research and development incentives (expenses) for the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentIncentiveIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense" xlink:to="lab_brns_ResearchAndDevelopmentIncentiveIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_019b097a-6f46-7448-831f-10df6c468880_terseLabel_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value Added Tax receivable</link:label>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value Added Tax Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_019b097a-6f46-703a-b3bd-a9fa72cd1788_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange translation recognized in other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_NonCashInterestExpenseOnConvertibleLoanNotes_019b097a-6f46-7a06-9fda-e83542c25614_verboseLabel_en-US" xlink:label="lab_brns_NonCashInterestExpenseOnConvertibleLoanNotes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_brns_NonCashInterestExpenseOnConvertibleLoanNotes_label_en-US" xlink:label="lab_brns_NonCashInterestExpenseOnConvertibleLoanNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Expense On Convertible Loan Notes</link:label>
    <link:label id="lab_brns_NonCashInterestExpenseOnConvertibleLoanNotes_documentation_en-US" xlink:label="lab_brns_NonCashInterestExpenseOnConvertibleLoanNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of non-cash interest expense on convertible loan notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NonCashInterestExpenseOnConvertibleLoanNotes" xlink:href="brns-20251231.xsd#brns_NonCashInterestExpenseOnConvertibleLoanNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_NonCashInterestExpenseOnConvertibleLoanNotes" xlink:to="lab_brns_NonCashInterestExpenseOnConvertibleLoanNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_SchemeSharesMember_019bd5df-9dd5-7edf-9590-9680a6d1c334_terseLabel_en-US" xlink:label="lab_brns_SchemeSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scheme Shares</link:label>
    <link:label id="lab_brns_SchemeSharesMember_label_en-US" xlink:label="lab_brns_SchemeSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scheme Shares [Member]</link:label>
    <link:label id="lab_brns_SchemeSharesMember_documentation_en-US" xlink:label="lab_brns_SchemeSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Scheme Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SchemeSharesMember" xlink:href="brns-20251231.xsd#brns_SchemeSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_SchemeSharesMember" xlink:to="lab_brns_SchemeSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_019b097a-6e6c-701c-8102-3f553ca8d86c_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019b097a-6f46-7233-8307-c3defb949de5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_019b097a-6e6c-7b6e-bdd1-6b4cceefdb6f_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDeposit_019b097a-6f46-7407-aee5-a8d300d08554_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Refundable security deposit</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_019b097a-6f46-7888-8b26-1b1e19d83d74_terseLabel_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value Added Tax payable</link:label>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_label_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales and Excise Tax Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019b097a-6f46-7df9-9462-c7aca6e80613_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and impairment charges</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_019b097a-6f46-7be2-8976-29c927b0cf46_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_019b097a-6e6c-720b-b959-17014bcfd40e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement_019b097a-6f46-7731-9e87-b9e5f8dce180_terseLabel_en-US" xlink:label="lab_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of future royalties for direct sales of a covered product</link:label>
    <link:label id="lab_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement_label_en-US" xlink:label="lab_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Future Royalties for Direct Sales of Covered Product , License Agreement</link:label>
    <link:label id="lab_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement_documentation_en-US" xlink:label="lab_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of future royalties for direct sales of a covered product under the In-License Agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" xlink:href="brns-20251231.xsd#brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" xlink:to="lab_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_CommonStockNumberOfVotesPerShare_019b097a-6f46-7045-8449-ae7d6c98ddb4_terseLabel_en-US" xlink:label="lab_brns_CommonStockNumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of votes per common share (in votes)</link:label>
    <link:label id="lab_brns_CommonStockNumberOfVotesPerShare_label_en-US" xlink:label="lab_brns_CommonStockNumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Number of Votes Per Share</link:label>
    <link:label id="lab_brns_CommonStockNumberOfVotesPerShare_documentation_en-US" xlink:label="lab_brns_CommonStockNumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of votes that each common share is entitled.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_CommonStockNumberOfVotesPerShare" xlink:href="brns-20251231.xsd#brns_CommonStockNumberOfVotesPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_CommonStockNumberOfVotesPerShare" xlink:to="lab_brns_CommonStockNumberOfVotesPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_019b097a-6f46-7e2c-ad49-446db7af4ffe_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_019b097a-6fcf-716d-ade7-0b25aec9b736_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_019b097a-6f46-74dd-9005-af5830eefe33_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of significant components of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncome_019b097a-6f46-7044-8ee7-1dfa1f519d5f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncome_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncome" xlink:to="lab_us-gaap_OtherOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_019b097a-6e6c-7069-a533-634275747362_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, &#163;0.000025 nominal value; 40,848,893 shares authorized, issued and outstanding (December&#160;31, 2024: authorized, issued and outstanding: 40,234,663)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_019b097a-6f46-7084-848e-22a53f5e01c0_negatedLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019b097a-6e6c-7e9c-a02b-5b12e621dd6e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019b097a-6f46-7923-96f5-782c6f12d7b1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average ordinary shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019b097a-6f46-7a43-8c5c-f42a4437f922_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average ordinary shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_019b097a-6f46-7237-9c53-580bc39be4a5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 16)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue_019c2845-fb35-7018-87bb-e0d9069ad0d1_terseLabel_en-US" xlink:label="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested but subject to deferred settlement (in usd per share)</link:label>
    <link:label id="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock_019b097a-6f46-757d-95e5-d659e13fdfd1_terseLabel_en-US" xlink:label="lab_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid and Other Current Assets</link:label>
    <link:label id="lab_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock_label_en-US" xlink:label="lab_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Text Block]</link:label>
    <link:label id="lab_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock_documentation_en-US" xlink:label="lab_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure on prepaid expense and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:href="brns-20251231.xsd#brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:to="lab_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_SubsidiaryCumulativeContributionsParent_019b097a-6e6c-72e8-8fd3-042ba1a0efb0_terseLabel_en-US" xlink:label="lab_brns_SubsidiaryCumulativeContributionsParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative contributions from controlling interest owner</link:label>
    <link:label id="lab_brns_SubsidiaryCumulativeContributionsParent_label_en-US" xlink:label="lab_brns_SubsidiaryCumulativeContributionsParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Cumulative Contributions, Parent</link:label>
    <link:label id="lab_brns_SubsidiaryCumulativeContributionsParent_documentation_en-US" xlink:label="lab_brns_SubsidiaryCumulativeContributionsParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subsidiary, Cumulative Contributions, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SubsidiaryCumulativeContributionsParent" xlink:href="brns-20251231.xsd#brns_SubsidiaryCumulativeContributionsParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_SubsidiaryCumulativeContributionsParent" xlink:to="lab_brns_SubsidiaryCumulativeContributionsParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_019b097a-6f45-725f-8031-2cda298ab7ef_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_019b097a-6f45-742e-847e-53b3db6f8e98_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_019b097a-6e6c-7c41-a0bd-f17ebcde70b5_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-7d17-9128-ee88671a59e5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_019b097a-6f46-7c34-a83f-717637a49608_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_019b097a-6f46-7508-9685-40b26828bb24_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Undistributed earnings of subsidiaries</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Undistributed Foreign Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_019b097a-6f46-731a-83be-26037ed87f30_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock_019b097a-6fcf-7b28-9742-1e73aa00fdd7_terseLabel_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development incentives</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock_label_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development, Incentives [Policy Text Block]</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock_documentation_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for Incentives received o to be received from Research and Development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentIncentivesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock" xlink:to="lab_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_019b097a-6f46-72be-8b8d-6f1abd78ec95_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of concentration of credit risk</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_019b097a-6f46-7f89-992b-7ab716807193_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_019b097a-6f46-7cf0-b5d0-345b17c3d3ff_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_019b097a-6f46-7be0-afd9-a7614a772117_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019b097a-6f46-7b7e-83b1-19677aac5eec_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_019b097a-6f46-7686-9e1f-827fa0e51609_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_019b097a-6f46-7a58-859e-60a92f2c1f59_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited/expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_019b097a-6f46-7c7b-90f7-f55d41b89b0b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_019ba4c4-d48e-75b1-be67-f4dbb3033f7b_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_019b097a-6e6c-7046-9490-bd710a20bd24_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.K.</link:label>
    <link:label id="lab_country_GB_019b097a-6e6c-7bd6-b178-f9e5a0c9a394_verboseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_019b097a-6f46-784e-9e52-6a38cb23f5d9_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019b097a-6e6c-7201-abd7-f5a7d427bab1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Weighted-average remaining contractual term (Years) (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019b097a-6fcf-73e5-89a9-32c4473e4cd0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019b097a-6f46-7c42-ac58-37f509cfff46_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019b097a-6f46-7ebf-87c6-148be5fda5c5_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019b097a-6f46-7414-aaf2-677786563efb_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_019c90c9-da4d-7c53-9be6-1ff42c314c38_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019b097a-6f46-7d55-a18d-8d8f6368485b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_019c927d-e41c-7e3e-bd8a-3f0bea9efe1b_totalLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_019b097a-6e6c-74c2-aedd-996a1e5713a4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_019b097a-6e6c-769a-965f-d055bd35fb50_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_019b097a-6f46-70ef-8a80-9d4c68234dda_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_019b097a-6f45-7aba-90f6-c32cfa559175_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issue of ordinary shares, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_019b097a-6f45-7f07-950c-150dc2f17923_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019b097a-6f46-7a5c-8df6-9969c7889aed_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019b097a-6f46-7984-9673-2b32739c02f0_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_019b097a-6e6c-7c29-ac9a-978fc7a6ddb5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019b097a-6f46-7b6e-960c-51704a68a589_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019b097a-6e6c-71db-9cd0-1e183207a6cc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_019b097a-6f46-7e78-b025-dd422b02d7a6_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_019b097a-6e6c-7ac9-9da8-aef7e2b561fe_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment_019b097a-6f45-7ae8-bd80-8354d83535ab_terseLabel_en-US" xlink:label="lab_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment_label_en-US" xlink:label="lab_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credits, Research And Development</link:label>
    <link:label id="lab_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment_documentation_en-US" xlink:label="lab_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development tax credit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" xlink:href="brns-20251231.xsd#brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" xlink:to="lab_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AssetImpairmentChargesExcludingGoodwill_019ba4a7-a1fa-724f-835e-bea452686d20_verboseLabel_en-US" xlink:label="lab_brns_AssetImpairmentChargesExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_brns_AssetImpairmentChargesExcludingGoodwill_label_en-US" xlink:label="lab_brns_AssetImpairmentChargesExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges (Excluding Goodwill)</link:label>
    <link:label id="lab_brns_AssetImpairmentChargesExcludingGoodwill_documentation_en-US" xlink:label="lab_brns_AssetImpairmentChargesExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AssetImpairmentChargesExcludingGoodwill" xlink:href="brns-20251231.xsd#brns_AssetImpairmentChargesExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AssetImpairmentChargesExcludingGoodwill" xlink:to="lab_brns_AssetImpairmentChargesExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_019b097a-6e6c-775c-8291-e984c0beedfd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited/expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_019bd5d8-6235-76bc-8b2f-4eae91e0b553_terseLabel_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Self-tender offer authorized amount to purchase</link:label>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019b097a-6f46-76fd-97ab-73bc5dd98d4e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue of shares from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019b097a-6e6c-7562-af02-89ff3ea2c5e7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_OtherOperatingIncomePolicyPolicyTextBlock_019b097a-6f46-76f5-92ac-6a4523e28cb3_terseLabel_en-US" xlink:label="lab_brns_OtherOperatingIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Operating Income</link:label>
    <link:label id="lab_brns_OtherOperatingIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_brns_OtherOperatingIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income, Policy [Policy Text Block]</link:label>
    <link:label id="lab_brns_OtherOperatingIncomePolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_brns_OtherOperatingIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Operating Income, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OtherOperatingIncomePolicyPolicyTextBlock" xlink:href="brns-20251231.xsd#brns_OtherOperatingIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_OtherOperatingIncomePolicyPolicyTextBlock" xlink:to="lab_brns_OtherOperatingIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_019b097a-6f46-71ff-9118-25bb19f4cdad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_019b097a-6f46-7f98-9a1f-59b11d872146_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_019b097a-6e6c-71d5-a9a1-321a3c33ca7e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019b097a-6e6c-7e53-b9e5-fb371d101b4a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_019b097a-6f46-7768-a352-105cdc8548f6_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AvideaMember_019b097a-6f46-75ab-888b-23c64f34650e_terseLabel_en-US" xlink:label="lab_brns_AvideaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Avidea</link:label>
    <link:label id="lab_brns_AvideaMember_label_en-US" xlink:label="lab_brns_AvideaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Avidea [Member]</link:label>
    <link:label id="lab_brns_AvideaMember_documentation_en-US" xlink:label="lab_brns_AvideaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for Avidea.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AvideaMember" xlink:href="brns-20251231.xsd#brns_AvideaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AvideaMember" xlink:to="lab_brns_AvideaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_019b097a-6fcf-7c1d-8ec6-83c55f646d49_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentivesReceivable_019b097a-6f46-77f0-a4c3-c90e42cd3851_terseLabel_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentivesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development incentives receivable</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentivesReceivable_label_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentivesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Incentives Receivable</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentivesReceivable_documentation_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentivesReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of research and development incentives receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentivesReceivable" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentIncentivesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ResearchAndDevelopmentIncentivesReceivable" xlink:to="lab_brns_ResearchAndDevelopmentIncentivesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_019b097a-6e6c-7205-ab1f-af03dcf2c812_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net foreign exchange (loss) gain</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019b097a-6e6c-7b39-a80b-be7315791601_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_019b097a-6e6c-7463-a5f2-52c071942648_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share attributable to ordinary shareholders, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_019b097a-6e6c-7982-8178-8475467d60bd_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_019b097a-6e6c-780d-837f-4c2528a823fe_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019b097a-6f46-748a-9952-4025be651196_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_019b097a-6f46-7ede-9348-602d775531f9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019b097a-6e6c-722f-b7c8-ffdbd2650838_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_019b097a-6f46-725f-83c4-d69535203562_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_019b097a-6f46-7986-8c74-595f82cc833f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement_019b097a-6f46-7792-8b3d-d78220716aeb_terseLabel_en-US" xlink:label="lab_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net payments received for allowable sublicenses of technology developed</link:label>
    <link:label id="lab_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement_label_en-US" xlink:label="lab_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Net Payments Received For Allowable Sublicenses Of Technology Developed License Agreement</link:label>
    <link:label id="lab_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement_documentation_en-US" xlink:label="lab_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of net payments received for allowable sublicenses of technology developed under the In-License Agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" xlink:href="brns-20251231.xsd#brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" xlink:to="lab_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_019b097a-6f46-70f0-8976-b2b4dfa56574_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_019b097a-6f46-74cb-9fb5-a2eed3d5ec93_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Controlling interest percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Ownership Percentage, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ValuationAllowanceRollForward_019b097a-6f46-7b99-99a6-380e9696a3cf_terseLabel_en-US" xlink:label="lab_brns_ValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_brns_ValuationAllowanceRollForward_label_en-US" xlink:label="lab_brns_ValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_brns_ValuationAllowanceRollForward_documentation_en-US" xlink:label="lab_brns_ValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ValuationAllowanceRollForward" xlink:href="brns-20251231.xsd#brns_ValuationAllowanceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ValuationAllowanceRollForward" xlink:to="lab_brns_ValuationAllowanceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_019b097a-6e6c-7dcf-8f1f-e3312431ff04_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_OxfordUniversityInnovationLimitedMember_019b097a-6e6c-7f5f-8d40-8f7ff6280634_terseLabel_en-US" xlink:label="lab_brns_OxfordUniversityInnovationLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oxford University Innovation Limited (OUI)</link:label>
    <link:label id="lab_brns_OxfordUniversityInnovationLimitedMember_label_en-US" xlink:label="lab_brns_OxfordUniversityInnovationLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oxford University Innovation Limited [Member]</link:label>
    <link:label id="lab_brns_OxfordUniversityInnovationLimitedMember_documentation_en-US" xlink:label="lab_brns_OxfordUniversityInnovationLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to Oxford University Innovation Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordUniversityInnovationLimitedMember" xlink:href="brns-20251231.xsd#brns_OxfordUniversityInnovationLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_OxfordUniversityInnovationLimitedMember" xlink:to="lab_brns_OxfordUniversityInnovationLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_019b097a-6e6c-74a4-8dd9-8d7c0d284386_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_019b097a-6e6c-7a10-b68d-2f33227dd097_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_019b097a-6f46-7bc8-8c6e-64d70eb2d363_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_NumberOfNewSubsidiaries_019c498f-64bb-7525-bc60-7bd336f224ed_terseLabel_en-US" xlink:label="lab_brns_NumberOfNewSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of new subsidiaries</link:label>
    <link:label id="lab_brns_NumberOfNewSubsidiaries_label_en-US" xlink:label="lab_brns_NumberOfNewSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of New Subsidiaries</link:label>
    <link:label id="lab_brns_NumberOfNewSubsidiaries_documentation_en-US" xlink:label="lab_brns_NumberOfNewSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of New Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfNewSubsidiaries" xlink:href="brns-20251231.xsd#brns_NumberOfNewSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_NumberOfNewSubsidiaries" xlink:to="lab_brns_NumberOfNewSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_019b097a-6f46-70be-833c-3354f0e447b9_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019b097a-6f46-7e72-bf70-8873e9da615f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019b097a-6f46-72dd-9d3d-4016ef310bda_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_019b097a-6f46-7bcd-b240-4d519b26bba4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_019b097a-6f46-7df0-bbb2-b17dff58225b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019b097a-6e6c-7237-ba58-c43aaf9a84c5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_019b097a-6f45-7c3b-aa89-4b67003e53d8_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_019b097a-6f45-7d48-ac72-e5c0e139eb51_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019b097a-6f46-720b-9d08-8c59786d1746_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019b097a-6e6c-74d3-ad35-1703aebfb459_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary Shares</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ClinicalTrialCostsPolicyTextBlock_019b097a-6e6c-768f-a731-8c5f2578acc1_terseLabel_en-US" xlink:label="lab_brns_ClinicalTrialCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trial costs</link:label>
    <link:label id="lab_brns_ClinicalTrialCostsPolicyTextBlock_label_en-US" xlink:label="lab_brns_ClinicalTrialCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Trial Costs [Policy Text Block]</link:label>
    <link:label id="lab_brns_ClinicalTrialCostsPolicyTextBlock_documentation_en-US" xlink:label="lab_brns_ClinicalTrialCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for Clinical Trial costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ClinicalTrialCostsPolicyTextBlock" xlink:href="brns-20251231.xsd#brns_ClinicalTrialCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ClinicalTrialCostsPolicyTextBlock" xlink:to="lab_brns_ClinicalTrialCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_019b097a-6f46-7acc-a4b1-36d3a0cbf1e4_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to Barinthus Biotherapeutics plc shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_019b097a-6f45-70c6-a14b-faa27a65673e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_MergerAgreementExtensionPeriod_019ba4ba-d341-7f03-bcd3-68f6deba1e1c_terseLabel_en-US" xlink:label="lab_brns_MergerAgreementExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merger agreement extension period</link:label>
    <link:label id="lab_brns_MergerAgreementExtensionPeriod_label_en-US" xlink:label="lab_brns_MergerAgreementExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Merger Agreement, Extension Period</link:label>
    <link:label id="lab_brns_MergerAgreementExtensionPeriod_documentation_en-US" xlink:label="lab_brns_MergerAgreementExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Merger Agreement, Extension Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MergerAgreementExtensionPeriod" xlink:href="brns-20251231.xsd#brns_MergerAgreementExtensionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_MergerAgreementExtensionPeriod" xlink:to="lab_brns_MergerAgreementExtensionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_019b097a-6fcf-7e23-8c8c-aef2070c9be8_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_019b097a-6fcf-7f91-bb5a-d2de0f213a64_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_019b097a-6f46-7c6b-8c7b-2e7be1af60ea_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2030</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_019b097a-6f46-7c3b-a4d4-492195c6e390_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts of related party transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_019b097a-6f46-72d5-8d93-6e708a7a9284_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation to the effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019b097a-6f46-7d47-8279-d72e4137bd59_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AccountsReceivableStandardPaymentTermsPeriod_019b097a-6f46-7487-8d20-0bf9e49745cb_terseLabel_en-US" xlink:label="lab_brns_AccountsReceivableStandardPaymentTermsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standard payment terms</link:label>
    <link:label id="lab_brns_AccountsReceivableStandardPaymentTermsPeriod_label_en-US" xlink:label="lab_brns_AccountsReceivableStandardPaymentTermsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Standard Payment Terms, Period</link:label>
    <link:label id="lab_brns_AccountsReceivableStandardPaymentTermsPeriod_documentation_en-US" xlink:label="lab_brns_AccountsReceivableStandardPaymentTermsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Standard Payment Terms, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccountsReceivableStandardPaymentTermsPeriod" xlink:href="brns-20251231.xsd#brns_AccountsReceivableStandardPaymentTermsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AccountsReceivableStandardPaymentTermsPeriod" xlink:to="lab_brns_AccountsReceivableStandardPaymentTermsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019b097a-6f46-7aff-969f-c6f8aff5b3a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019b097a-6e6c-7d09-965f-26cdabbb417c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other adjustments</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_019b097a-6e6c-7446-a821-d286c6e8bf3f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_019b097a-6e6c-721a-8aa8-ce53c17a2bdb_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_019b097a-6f46-7a10-a78a-a55e8b990e4b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_019b097a-6e6c-7775-8610-f2514c399960_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_019b097a-6f46-7146-8b55-d376111a8045_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum additional contingent consideration payments upon achievement of milestones</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Range of Outcomes, Maximum, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeCurrent_019b097a-6f46-7b4c-bd5b-1ff39804f098_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeCurrent" xlink:to="lab_us-gaap_DeferredIncomeCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_019b097a-6e6c-7bc7-bbd7-dcf1f94b6d82_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_FundingAmountMaximum_019b097a-6fcf-7b09-866f-252edaec665e_terseLabel_en-US" xlink:label="lab_brns_FundingAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum funding amount</link:label>
    <link:label id="lab_brns_FundingAmountMaximum_label_en-US" xlink:label="lab_brns_FundingAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Funding Amount, Maximum</link:label>
    <link:label id="lab_brns_FundingAmountMaximum_documentation_en-US" xlink:label="lab_brns_FundingAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Funding Amount, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FundingAmountMaximum" xlink:href="brns-20251231.xsd#brns_FundingAmountMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_FundingAmountMaximum" xlink:to="lab_brns_FundingAmountMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_019b097a-6f46-7991-ad1d-8fc0c64634f5_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_CoalitionForEpidemicPreparednessInnovationsMember_019b097a-6f46-75bb-b37a-751ab77b4c6c_terseLabel_en-US" xlink:label="lab_brns_CoalitionForEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Coalition For Epidemic Preparedness Innovations</link:label>
    <link:label id="lab_brns_CoalitionForEpidemicPreparednessInnovationsMember_label_en-US" xlink:label="lab_brns_CoalitionForEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Coalition For Epidemic Preparedness Innovations [Member]</link:label>
    <link:label id="lab_brns_CoalitionForEpidemicPreparednessInnovationsMember_documentation_en-US" xlink:label="lab_brns_CoalitionForEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Coalition For Epidemic Preparedness Innovations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_CoalitionForEpidemicPreparednessInnovationsMember" xlink:href="brns-20251231.xsd#brns_CoalitionForEpidemicPreparednessInnovationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_CoalitionForEpidemicPreparednessInnovationsMember" xlink:to="lab_brns_CoalitionForEpidemicPreparednessInnovationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_019b097a-6f46-7000-b41a-384410e6233e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_019b097a-6e6c-7b66-90c6-16042836eb59_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_019b097a-6f46-7bc4-8b1b-b48fd273953b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_019c7014-703c-727f-837b-42907cb2cb74_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019ce2c4-bb8e-7451-b83d-54590a58c516_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Statutory tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_019b097a-6e6c-7ca5-a741-83cdb42deb61_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of share based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_019bd5bb-a1d1-7a02-a83d-31f91a314e94_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Profit on sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_019bd5e8-7fd0-7545-943e-c50f41dcf5ea_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_019b097a-6f46-76ba-b547-a846ad76dabb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019b097a-6f46-734b-9488-a98b750bd46d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_019b097a-6f45-7291-af58-83b7f045fa90_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_019b097a-6f46-7290-a6fa-607add180089_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_019b097a-6e6c-7b9b-8074-c4308347b109_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019b097a-6f46-75e4-9347-72c27829c089_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019b097a-6f45-77b9-ad78-5375cace9fe9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_019b097a-6e6c-77a0-a47f-0b9a8cf91c25_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019c2849-c15a-746e-91a4-81cfdb2fc2a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019b097a-6e6c-7bf2-8d09-b095d1be32fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future stock incentive plan awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_019b097a-6e6c-7d2d-8fc5-3c716e43ceb5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_019b097a-6f46-7533-8fa5-5ff16208c109_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AdditionalPaidInCapitalPolicyTextBlock_019b097a-6fcf-7891-91ee-95def1318f31_terseLabel_en-US" xlink:label="lab_brns_AdditionalPaidInCapitalPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_brns_AdditionalPaidInCapitalPolicyTextBlock_label_en-US" xlink:label="lab_brns_AdditionalPaidInCapitalPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid In Capital [Policy Text Block]</link:label>
    <link:label id="lab_brns_AdditionalPaidInCapitalPolicyTextBlock_documentation_en-US" xlink:label="lab_brns_AdditionalPaidInCapitalPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for Additional paid in capital.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AdditionalPaidInCapitalPolicyTextBlock" xlink:href="brns-20251231.xsd#brns_AdditionalPaidInCapitalPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AdditionalPaidInCapitalPolicyTextBlock" xlink:to="lab_brns_AdditionalPaidInCapitalPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019b097a-6e6c-75c5-a56d-1aaea52881e6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rates on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_019b097a-6f46-7c2a-b308-b66beb0ab56e_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019b097a-6f46-7ab6-a8fa-444c693330e3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019b097a-6f46-77fc-84eb-0ef294a9d527_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019b097a-6f46-72c7-a089-07a96e9fe540_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-taxable or non-deductible items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019b097a-6f45-71a0-a148-d3336c75eea0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignTaxJurisdictionOtherMember_019c9156-fe60-75da-9666-c9c09bd156fc_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignTaxJurisdictionOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other foreign</link:label>
    <link:label id="lab_us-gaap_ForeignTaxJurisdictionOtherMember_label_en-US" xlink:label="lab_us-gaap_ForeignTaxJurisdictionOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignTaxJurisdictionOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignTaxJurisdictionOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignTaxJurisdictionOtherMember" xlink:to="lab_us-gaap_ForeignTaxJurisdictionOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_019b097a-6f46-78b3-80aa-1c873f096589_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_019b097a-6f46-7247-a23a-181d6e09759d_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix_019b097a-6e6c-7d38-867e-c5820b974afb_terseLabel_en-US" xlink:label="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2031</link:label>
    <link:label id="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix_label_en-US" xlink:label="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Six</link:label>
    <link:label id="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix_documentation_en-US" xlink:label="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix" xlink:href="brns-20251231.xsd#brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix" xlink:to="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_019cb02d-be38-7691-956c-2699e2ebda2c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of change in tax laws or rates enacted in the current period</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_019b097a-6f46-7829-92de-2ee4da003cb4_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_OtherInformationLesseeAbstract_019b097a-6e6c-74aa-9342-4832f50c7dda_terseLabel_en-US" xlink:label="lab_brns_OtherInformationLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other information</link:label>
    <link:label id="lab_brns_OtherInformationLesseeAbstract_label_en-US" xlink:label="lab_brns_OtherInformationLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Information, Lessee [Abstract]</link:label>
    <link:label id="lab_brns_OtherInformationLesseeAbstract_documentation_en-US" xlink:label="lab_brns_OtherInformationLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Information, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OtherInformationLesseeAbstract" xlink:href="brns-20251231.xsd#brns_OtherInformationLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_OtherInformationLesseeAbstract" xlink:to="lab_brns_OtherInformationLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MD_019b097a-6e6c-7d75-a685-4ff8c4e0ec66_terseLabel_en-US" xlink:label="lab_stpr_MD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maryland</link:label>
    <link:label id="lab_stpr_MD_label_en-US" xlink:label="lab_stpr_MD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MARYLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MD" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_MD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MD" xlink:to="lab_stpr_MD" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019b097a-6f46-7a95-be73-dafa73effac6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issuable for stock options that were excluded from the computation of diluted weighted-average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019b097a-6fcf-7c9e-893e-11e0dc5cf867_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019b097a-6f46-7a5e-be83-b688b63abee0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_019b097a-6f46-7057-9c2a-b2e94cdc3afa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_PersonnelRelatedMember_019b097a-6f45-7718-a420-b23dfffbf470_terseLabel_en-US" xlink:label="lab_brns_PersonnelRelatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Personnel-related (including share-based compensation)</link:label>
    <link:label id="lab_brns_PersonnelRelatedMember_label_en-US" xlink:label="lab_brns_PersonnelRelatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Personnel Related [Member]</link:label>
    <link:label id="lab_brns_PersonnelRelatedMember_documentation_en-US" xlink:label="lab_brns_PersonnelRelatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Personnel Related</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PersonnelRelatedMember" xlink:href="brns-20251231.xsd#brns_PersonnelRelatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_PersonnelRelatedMember" xlink:to="lab_brns_PersonnelRelatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_019b097a-6f46-7955-9674-f9d3ddba4729_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_019b097a-6f46-70b7-aa28-584d8a7fe307_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_019b097a-6e6c-7f9c-b8e4-7e81ac292785_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions_019b097a-6f46-7f9b-baad-126a5ffba5fc_terseLabel_en-US" xlink:label="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in valuation allowance arising from in-year additions</link:label>
    <link:label id="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions_label_en-US" xlink:label="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase Resulting From Current Period Additions</link:label>
    <link:label id="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions_documentation_en-US" xlink:label="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase Resulting From Current Period Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions" xlink:href="brns-20251231.xsd#brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions" xlink:to="lab_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6f46-7f38-b343-ff5dfd2d837d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019b097a-6e6c-721a-a661-adc2b9fc6cb4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average ordinary shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_019b097a-6fcf-7a2e-ae8f-34bda0892247_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of computation of basic and diluted net (loss)/income per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramTable_019bd5df-9dd5-754b-a2c6-75e4c247148b_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Table]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramTable_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramTable" xlink:to="lab_srt_ShareRepurchaseProgramTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_019b097a-6f46-78a1-9db0-1bd5076e4a81_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019b097a-6f46-7e3a-a0b7-39e0ba7a558e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_NumberOfSquareFeetUnderLeaseAgreement_019b097a-6f46-734e-9b02-82cd152d39f4_terseLabel_en-US" xlink:label="lab_brns_NumberOfSquareFeetUnderLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Size of space under lease agreement (in square feet)</link:label>
    <link:label id="lab_brns_NumberOfSquareFeetUnderLeaseAgreement_label_en-US" xlink:label="lab_brns_NumberOfSquareFeetUnderLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Square Feet Under Lease Agreement</link:label>
    <link:label id="lab_brns_NumberOfSquareFeetUnderLeaseAgreement_documentation_en-US" xlink:label="lab_brns_NumberOfSquareFeetUnderLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to number of Square Feet Under Lease Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfSquareFeetUnderLeaseAgreement" xlink:href="brns-20251231.xsd#brns_NumberOfSquareFeetUnderLeaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_NumberOfSquareFeetUnderLeaseAgreement" xlink:to="lab_brns_NumberOfSquareFeetUnderLeaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_019b097a-6f46-780f-976a-dae0f2f7570c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_IncomeTaxesTable_019b097a-6e6c-7155-aa6b-7b29e5606ac0_terseLabel_en-US" xlink:label="lab_brns_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_brns_IncomeTaxesTable_label_en-US" xlink:label="lab_brns_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_brns_IncomeTaxesTable_documentation_en-US" xlink:label="lab_brns_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncomeTaxesTable" xlink:href="brns-20251231.xsd#brns_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_IncomeTaxesTable" xlink:to="lab_brns_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019b097a-6f46-7d60-8300-c83202acf2c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019b097a-6fcf-7994-80fd-d0eb5eb9f81a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_019b097a-6f45-7465-88f0-1c72e556e978_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeRevenueRecognized_019b097a-6f45-727e-93a7-20e8157b2924_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating income recognized related to the Funding Agreement</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeRevenueRecognized_019b097a-6f45-7ce1-9f36-9dddc306d5fe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other operating income recognized related to the Funding Agreement</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeRevenueRecognized" xlink:to="lab_us-gaap_DeferredIncomeRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019b097a-6f46-7f3b-ab52-6e2452977f0f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the beginning of the period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019b097a-6f46-7054-8950-f0d633a04c42_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the end of the period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6c-7703-86b9-4b432810f875_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_019b097a-6f45-753c-a677-4359f1bae7f7_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_019b097a-6e6c-70b8-b9b0-1aaa0c8264a7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, nominal value (in gbp per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_019b097a-6e6c-7f90-8985-d02add35c333_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, nominal value (per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_019b097a-6f46-7d03-8453-934766a819b5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_019b097a-6e6c-739d-9fe6-0a34926c3408_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019b097a-6e6c-786d-a36c-0be45fd86f76_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_BarinthusLegacyAssetsMember_019c7024-2e3a-75a1-8191-7ded9dd3eee9_terseLabel_en-US" xlink:label="lab_brns_BarinthusLegacyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Barinthus legacy assets</link:label>
    <link:label id="lab_brns_BarinthusLegacyAssetsMember_label_en-US" xlink:label="lab_brns_BarinthusLegacyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Barinthus Legacy Assets [Member]</link:label>
    <link:label id="lab_brns_BarinthusLegacyAssetsMember_documentation_en-US" xlink:label="lab_brns_BarinthusLegacyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Barinthus Legacy Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_BarinthusLegacyAssetsMember" xlink:href="brns-20251231.xsd#brns_BarinthusLegacyAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_BarinthusLegacyAssetsMember" xlink:to="lab_brns_BarinthusLegacyAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_019b097a-6f46-7d69-950c-f2019ea5cc0c_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_019b097a-6f46-7c4d-b264-5f2093416b92_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_MergerAgreementSchemeExchangeRatio_019cd0fb-6b02-7957-8924-f9d1b9d8820e_terseLabel_en-US" xlink:label="lab_brns_MergerAgreementSchemeExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scheme exchange ratio</link:label>
    <link:label id="lab_brns_MergerAgreementSchemeExchangeRatio_label_en-US" xlink:label="lab_brns_MergerAgreementSchemeExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Merger Agreement, Scheme Exchange Ratio</link:label>
    <link:label id="lab_brns_MergerAgreementSchemeExchangeRatio_documentation_en-US" xlink:label="lab_brns_MergerAgreementSchemeExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Merger Agreement, Scheme Exchange Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MergerAgreementSchemeExchangeRatio" xlink:href="brns-20251231.xsd#brns_MergerAgreementSchemeExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_MergerAgreementSchemeExchangeRatio" xlink:to="lab_brns_MergerAgreementSchemeExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_019b097a-6f46-72ba-aca5-3fb7fe014d96_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ConcentrationRiskThresholdPercentage_019b097a-6f46-72fe-83b4-9dbe82742544_terseLabel_en-US" xlink:label="lab_brns_ConcentrationRiskThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_brns_ConcentrationRiskThresholdPercentage_label_en-US" xlink:label="lab_brns_ConcentrationRiskThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Threshold Percentage</link:label>
    <link:label id="lab_brns_ConcentrationRiskThresholdPercentage_documentation_en-US" xlink:label="lab_brns_ConcentrationRiskThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">For an entity that discloses a concentration risk threshold Percentage in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ConcentrationRiskThresholdPercentage" xlink:href="brns-20251231.xsd#brns_ConcentrationRiskThresholdPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ConcentrationRiskThresholdPercentage" xlink:to="lab_brns_ConcentrationRiskThresholdPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019b097a-6f45-7a37-9ea7-c42acd9abf18_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value recognized in net loss</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_019b097a-6f46-7591-a7f4-4274688d64e4_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guarantees and indemnifications</link:label>
    <link:label id="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_label_en-US" xlink:label="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantees, Indemnifications and Warranties Policies [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:to="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_019b097a-6f45-7993-99c8-211d4258be2e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019b097a-6f45-7dcb-88f4-e0a599876a61_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive gain/(loss) &#8211; foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019b097a-6f45-7bd0-9bb4-0d3cc9959c4b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019b097a-6f46-7afc-a2d0-e46a81a05ee7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_019b097a-6f46-7159-842f-b4719846b321_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_019ce2d5-72d3-7d57-90d2-9cd3e15aac02_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-taxable or non-deductible items</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ClywedogCapitalStockMember_019bd5df-9dd5-7498-828e-2c384dd4a454_terseLabel_en-US" xlink:label="lab_brns_ClywedogCapitalStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clywedog Capital Stock</link:label>
    <link:label id="lab_brns_ClywedogCapitalStockMember_label_en-US" xlink:label="lab_brns_ClywedogCapitalStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clywedog Capital Stock [Member]</link:label>
    <link:label id="lab_brns_ClywedogCapitalStockMember_documentation_en-US" xlink:label="lab_brns_ClywedogCapitalStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clywedog Capital Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ClywedogCapitalStockMember" xlink:href="brns-20251231.xsd#brns_ClywedogCapitalStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ClywedogCapitalStockMember" xlink:to="lab_brns_ClywedogCapitalStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_019b097a-6e6c-7c35-bd70-e13684ccd272_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayments</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_019b097a-6e6c-7d57-a483-57518f593f3a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDisclosureTextBlock_019b097a-6f45-77f7-9edf-c2d9efc6226d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation in General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019b097a-6e6c-721e-9485-9c02f9d22efb_terseLabel_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019b097a-6e6c-70fc-8e41-216eb6cbdda5_totalLabel_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_label_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities and Other Liabilities, Current</link:label>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_documentation_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:href="brns-20251231.xsd#brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyAbstract_019b097a-6f46-7156-8c24-6c5f08f0c75e_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency [Abstract]</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyAbstract_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyAbstract" xlink:to="lab_us-gaap_ForeignCurrencyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_019b097a-6f46-778d-a1d7-dcbc9cb011f1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue of ordinary shares, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_019b097a-6f46-7406-a64c-ada31d47a3b1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ResearchAndDevelopmentTypeDomain_019b097a-6f46-71e5-9a04-d5d8d1a78b54_terseLabel_en-US" xlink:label="lab_brns_ResearchAndDevelopmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Type [Domain]</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentTypeDomain_label_en-US" xlink:label="lab_brns_ResearchAndDevelopmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Type [Domain]</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentTypeDomain_documentation_en-US" xlink:label="lab_brns_ResearchAndDevelopmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentTypeDomain" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ResearchAndDevelopmentTypeDomain" xlink:to="lab_brns_ResearchAndDevelopmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_019b097a-6f46-7db5-a1ac-6d7dd47cf460_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_019b097a-6f46-7591-ae74-03ca212b96d6_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_019c282b-5225-7441-8100-429c7ea882c7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Units activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_019b097a-6e6c-7c53-aedc-edd4964201eb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_019b097a-6f46-76a1-87b9-7cb1518f7c9d_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019b097a-6f45-78db-93ef-5bbc8ff6041b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional number of shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_019b097a-6fcf-7a74-b126-d2e7bfd1a5b2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_019b097a-6fcf-745a-92fa-0d1654b9635b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Ordinary&#160;Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019b097a-6f46-7abd-9f39-2fa187238048_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_IndirectResearchAndDevelopmentExpensesAbstract_019b097a-6e6c-740f-bdef-b24d5c14401c_terseLabel_en-US" xlink:label="lab_brns_IndirectResearchAndDevelopmentExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indirect research and development expenses:</link:label>
    <link:label id="lab_brns_IndirectResearchAndDevelopmentExpensesAbstract_label_en-US" xlink:label="lab_brns_IndirectResearchAndDevelopmentExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indirect Research and Development Expenses [Abstract]</link:label>
    <link:label id="lab_brns_IndirectResearchAndDevelopmentExpensesAbstract_documentation_en-US" xlink:label="lab_brns_IndirectResearchAndDevelopmentExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indirect Research and Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IndirectResearchAndDevelopmentExpensesAbstract" xlink:href="brns-20251231.xsd#brns_IndirectResearchAndDevelopmentExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_IndirectResearchAndDevelopmentExpensesAbstract" xlink:to="lab_brns_IndirectResearchAndDevelopmentExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_019b097a-6f46-75dd-a219-77b35a943686_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019b097a-6f46-71a6-92f9-8f4ab611cb05_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_019b097a-6f46-7e0a-bbff-99a1847253d8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>brns-20251231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019b097a-6c16-78f4-806b-17184aaccbef,g:d518a941-6ac7-4029-9d1f-6f039bd073d0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.barinthusbio.com/role/Cover" xlink:type="simple" xlink:href="brns-20251231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019b097a-6d1d-74df-84bf-d3141aadaca5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_019b097a-6d1d-72de-83f4-bda4a0d6db23" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b097a-6d1d-74df-84bf-d3141aadaca5" xlink:to="loc_dei_DocumentInformationTable_019b097a-6d1d-72de-83f4-bda4a0d6db23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019b097a-6d1d-70b1-ba8b-76597aa756bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_019b097a-6d1d-72de-83f4-bda4a0d6db23" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019b097a-6d1d-70b1-ba8b-76597aa756bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019b097a-6d1d-7f3b-9194-2c66f565bf42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019b097a-6d1d-70b1-ba8b-76597aa756bd" xlink:to="loc_us-gaap_ClassOfStockDomain_019b097a-6d1d-7f3b-9194-2c66f565bf42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AdrMember_019b097a-6d1d-765e-9f1a-967fd0c4d697" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AdrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019b097a-6d1d-7f3b-9194-2c66f565bf42" xlink:to="loc_dei_AdrMember_019b097a-6d1d-765e-9f1a-967fd0c4d697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019b097a-6d1d-7716-a624-15c183ade56f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019b097a-6d1d-7f3b-9194-2c66f565bf42" xlink:to="loc_us-gaap_CommonStockMember_019b097a-6d1d-7716-a624-15c183ade56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_019b097a-6d1d-72de-83f4-bda4a0d6db23" xlink:to="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019b097a-6d1d-716d-a940-5d579e63bff9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_DocumentType_019b097a-6d1d-716d-a940-5d579e63bff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_019b097a-6d1d-7af6-8a5d-5ca6500e4697" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_DocumentAnnualReport_019b097a-6d1d-7af6-8a5d-5ca6500e4697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019b097a-6d1d-7d40-97b6-f0680cb5428e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_DocumentPeriodEndDate_019b097a-6d1d-7d40-97b6-f0680cb5428e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_019b097a-6d1d-7e22-9318-2d1f113123d7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_CurrentFiscalYearEndDate_019b097a-6d1d-7e22-9318-2d1f113123d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_019b097a-6d1d-7ce3-a8b0-e34facb6d6be" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_DocumentTransitionReport_019b097a-6d1d-7ce3-a8b0-e34facb6d6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019b097a-6d1d-727b-8f07-302c7ee10838" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityFileNumber_019b097a-6d1d-727b-8f07-302c7ee10838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019b097a-6d1d-7e34-83c9-b5a40f87e70e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityRegistrantName_019b097a-6d1d-7e34-83c9-b5a40f87e70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019b097a-6d1d-7d88-a32a-d24416ac57f3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019b097a-6d1d-7d88-a32a-d24416ac57f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019b097a-6d1d-7916-99de-fc61049c6d94" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityAddressAddressLine1_019b097a-6d1d-7916-99de-fc61049c6d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_019b097a-6d1d-70b0-8b1b-e225b4f5497b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityAddressAddressLine2_019b097a-6d1d-70b0-8b1b-e225b4f5497b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019b097a-6d1d-7ca2-a18e-f8e7616e9a5a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityAddressCityOrTown_019b097a-6d1d-7ca2-a18e-f8e7616e9a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019bb2be-b82c-7bc6-b820-3248fb0bb518" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityAddressStateOrProvince_019bb2be-b82c-7bc6-b820-3248fb0bb518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019b097a-6d1d-7bcc-b643-797ff9839f2f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityAddressPostalZipCode_019b097a-6d1d-7bcc-b643-797ff9839f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019b097a-6d1d-7f79-bb2c-faeb7e14906d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_CityAreaCode_019b097a-6d1d-7f79-bb2c-faeb7e14906d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019b097a-6d1d-7479-b0f0-90f6108876e0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_LocalPhoneNumber_019b097a-6d1d-7479-b0f0-90f6108876e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019b097a-6d1d-7bb4-809a-4dcac04a3ba9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_Security12bTitle_019b097a-6d1d-7bb4-809a-4dcac04a3ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019b097a-6d1d-7c11-bf66-1f2db4a058b2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_TradingSymbol_019b097a-6d1d-7c11-bf66-1f2db4a058b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019b097a-6d1d-7429-9838-49ead16e67f1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_SecurityExchangeName_019b097a-6d1d-7429-9838-49ead16e67f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_019b097a-6d1d-79f7-afad-302476e67858" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_019b097a-6d1d-79f7-afad-302476e67858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_019b097a-6d1d-7905-afef-d3b7ddedcc42" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityVoluntaryFilers_019b097a-6d1d-7905-afef-d3b7ddedcc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_019b097a-6d1d-741e-b84e-64639dc98f0c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityCurrentReportingStatus_019b097a-6d1d-741e-b84e-64639dc98f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_019b097a-6d1d-716c-9969-b1f46ce22708" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityInteractiveDataCurrent_019b097a-6d1d-716c-9969-b1f46ce22708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_019b097a-6d1d-7243-a0af-c0a2090f8dab" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityFilerCategory_019b097a-6d1d-7243-a0af-c0a2090f8dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_019b097a-6d1d-7809-b9b2-c1ee17a5912e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntitySmallBusiness_019b097a-6d1d-7809-b9b2-c1ee17a5912e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019b097a-6d1d-7c39-94c4-fc3ffd3194a4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityEmergingGrowthCompany_019b097a-6d1d-7c39-94c4-fc3ffd3194a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_019b097a-6d1d-72eb-a84a-2915aa91404f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityExTransitionPeriod_019b097a-6d1d-72eb-a84a-2915aa91404f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_019b097a-6d1d-7a8d-89c4-a8758fd9a444" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_IcfrAuditorAttestationFlag_019b097a-6d1d-7a8d-89c4-a8758fd9a444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_019b097a-6d1d-7348-a48b-a75bb7637a35" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_019b097a-6d1d-7348-a48b-a75bb7637a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_019b097a-6d1d-7bc2-8012-19ad6867811c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityShellCompany_019b097a-6d1d-7bc2-8012-19ad6867811c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_019b097a-6d1d-760e-85f7-067cc6ecbf11" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityPublicFloat_019b097a-6d1d-760e-85f7-067cc6ecbf11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_019b097a-6d1d-7f31-ab54-afb872ab47b7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_019b097a-6d1d-7f31-ab54-afb872ab47b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019b097a-6d1d-7e59-ac94-cb19aff80ebf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityCentralIndexKey_019b097a-6d1d-7e59-ac94-cb19aff80ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_019b097a-6d1d-7ac8-bb0e-ed2d897cab72" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_DocumentFiscalYearFocus_019b097a-6d1d-7ac8-bb0e-ed2d897cab72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_019b097a-6d1d-7213-8ad4-d3ee44a41c50" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_DocumentFiscalPeriodFocus_019b097a-6d1d-7213-8ad4-d3ee44a41c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019b097a-6d1d-7a69-b21b-349722f0c579" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_AmendmentFlag_019b097a-6d1d-7a69-b21b-349722f0c579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019b097a-6d1d-7546-bb93-3338485692b3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019b097a-6d1d-73b5-aca7-c075bada6fbe" xlink:to="loc_dei_EntityTaxIdentificationNumber_019b097a-6d1d-7546-bb93-3338485692b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/AuditInformation" xlink:type="simple" xlink:href="brns-20251231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_brns_AuditInformationAbstract_019b097a-6d1d-7969-9c4c-2e1036dc561a" xlink:href="brns-20251231.xsd#brns_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_019b097a-6d1d-7fc6-96ba-125b482f427d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_AuditInformationAbstract_019b097a-6d1d-7969-9c4c-2e1036dc561a" xlink:to="loc_dei_AuditorFirmId_019b097a-6d1d-7fc6-96ba-125b482f427d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_019b097a-6d1d-788f-9987-181cbaf8c1d1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_AuditInformationAbstract_019b097a-6d1d-7969-9c4c-2e1036dc561a" xlink:to="loc_dei_AuditorName_019b097a-6d1d-788f-9987-181cbaf8c1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_019b097a-6d1d-74cf-a6ec-0682c14745c5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_AuditInformationAbstract_019b097a-6d1d-7969-9c4c-2e1036dc561a" xlink:to="loc_dei_AuditorLocation_019b097a-6d1d-74cf-a6ec-0682c14745c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="brns-20251231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019b097a-6d1d-7cac-92e6-4518ae287fce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_019b097a-6d1e-7ba9-8740-85a2befaeba9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019b097a-6d1d-7cac-92e6-4518ae287fce" xlink:to="loc_us-gaap_AssetsAbstract_019b097a-6d1e-7ba9-8740-85a2befaeba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019b097a-6d1e-757e-94bf-c4f5a3f00126" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019b097a-6d1e-7ba9-8740-85a2befaeba9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019b097a-6d1e-757e-94bf-c4f5a3f00126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_019b097a-6d1e-7b9c-9319-4572ac82ced0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019b097a-6d1e-7ba9-8740-85a2befaeba9" xlink:to="loc_us-gaap_RestrictedCashCurrent_019b097a-6d1e-7b9c-9319-4572ac82ced0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentivesReceivable_019b097a-6d1e-79a6-bec3-dfb6734a3ec9" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentIncentivesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019b097a-6d1e-7ba9-8740-85a2befaeba9" xlink:to="loc_brns_ResearchAndDevelopmentIncentivesReceivable_019b097a-6d1e-79a6-bec3-dfb6734a3ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019b097a-6d1e-7cc8-b110-f697cfbe5342" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019b097a-6d1e-7ba9-8740-85a2befaeba9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019b097a-6d1e-7cc8-b110-f697cfbe5342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019b097a-6d1e-7739-b944-92728d995a31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019b097a-6d1e-7ba9-8740-85a2befaeba9" xlink:to="loc_us-gaap_AssetsCurrent_019b097a-6d1e-7739-b944-92728d995a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019b097a-6d1e-7e8c-968b-20203d48a2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019b097a-6d1d-7cac-92e6-4518ae287fce" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019b097a-6d1e-7e8c-968b-20203d48a2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019b097a-6d1e-790f-8647-3b7361f948d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019b097a-6d1d-7cac-92e6-4518ae287fce" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019b097a-6d1e-790f-8647-3b7361f948d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_019b097a-6d1e-78a6-8796-303947e8480c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019b097a-6d1d-7cac-92e6-4518ae287fce" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_019b097a-6d1e-78a6-8796-303947e8480c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_019b097a-6d1e-7a5c-b532-6b3fa83fe158" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019b097a-6d1d-7cac-92e6-4518ae287fce" xlink:to="loc_us-gaap_OtherAssets_019b097a-6d1e-7a5c-b532-6b3fa83fe158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019b097a-6d1e-7620-bda8-6fa7209b9c39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019b097a-6d1d-7cac-92e6-4518ae287fce" xlink:to="loc_us-gaap_Assets_019b097a-6d1e-7620-bda8-6fa7209b9c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019b097a-6d1e-7021-b1c1-06065ef715ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019b097a-6d1d-7cac-92e6-4518ae287fce" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019b097a-6d1e-7021-b1c1-06065ef715ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_019b097a-6d1e-78b9-a2b7-f15e188dcf7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019b097a-6d1e-7021-b1c1-06065ef715ac" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_019b097a-6d1e-78b9-a2b7-f15e188dcf7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019b097a-6d1e-7754-9a15-c08712d5aaf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019b097a-6d1e-78b9-a2b7-f15e188dcf7d" xlink:to="loc_us-gaap_AccountsPayableCurrent_019b097a-6d1e-7754-9a15-c08712d5aaf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019b097a-6d1e-73fd-b8f6-89a1f882210b" xlink:href="brns-20251231.xsd#brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019b097a-6d1e-78b9-a2b7-f15e188dcf7d" xlink:to="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019b097a-6d1e-73fd-b8f6-89a1f882210b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeCurrent_019b097a-6d1e-7f4e-8e85-d169d04ebb03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019b097a-6d1e-78b9-a2b7-f15e188dcf7d" xlink:to="loc_us-gaap_DeferredIncomeCurrent_019b097a-6d1e-7f4e-8e85-d169d04ebb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_019b097a-6d1e-7193-81a7-321f15065d71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019b097a-6d1e-78b9-a2b7-f15e188dcf7d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_019b097a-6d1e-7193-81a7-321f15065d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019b097a-6d1e-7b76-aaac-d14fb728e8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019b097a-6d1e-78b9-a2b7-f15e188dcf7d" xlink:to="loc_us-gaap_LiabilitiesCurrent_019b097a-6d1e-7b76-aaac-d14fb728e8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_019b097a-6d1e-7fe2-804c-18b6ac18137c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019b097a-6d1e-7021-b1c1-06065ef715ac" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_019b097a-6d1e-7fe2-804c-18b6ac18137c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019b097a-6d1e-758c-ba5e-808406ab1b20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_019b097a-6d1e-7fe2-804c-18b6ac18137c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019b097a-6d1e-758c-ba5e-808406ab1b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_019b097a-6d1e-7fd4-800b-ea630d5f69c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_019b097a-6d1e-7fe2-804c-18b6ac18137c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_019b097a-6d1e-7fd4-800b-ea630d5f69c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_019b097a-6d1e-71d7-82c5-b0f02e742c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_019b097a-6d1e-7fe2-804c-18b6ac18137c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_019b097a-6d1e-71d7-82c5-b0f02e742c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_019b097a-6d1e-7ad1-8c22-67609b614b86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_019b097a-6d1e-7fe2-804c-18b6ac18137c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_019b097a-6d1e-7ad1-8c22-67609b614b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019b097a-6d1e-73dd-9139-8ebfe05e9f69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_019b097a-6d1e-7fe2-804c-18b6ac18137c" xlink:to="loc_us-gaap_Liabilities_019b097a-6d1e-73dd-9139-8ebfe05e9f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019b097a-6d1e-7e2a-abb9-2fc234d04526" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019b097a-6d1e-7021-b1c1-06065ef715ac" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019b097a-6d1e-7e2a-abb9-2fc234d04526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019b097a-6d1e-70cb-8294-6385393397c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019b097a-6d1e-7021-b1c1-06065ef715ac" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019b097a-6d1e-70cb-8294-6385393397c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019b097a-6d1e-7927-b28f-9c2a2d6d7da1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019b097a-6d1e-70cb-8294-6385393397c5" xlink:to="loc_us-gaap_CommonStockValue_019b097a-6d1e-7927-b28f-9c2a2d6d7da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockValueIssued_019b097a-6d1e-7622-80dc-70e235420d67" xlink:href="brns-20251231.xsd#brns_DeferredStockValueIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019b097a-6d1e-70cb-8294-6385393397c5" xlink:to="loc_brns_DeferredStockValueIssued_019b097a-6d1e-7622-80dc-70e235420d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_019b097a-6d1e-70ed-9439-fbdbaeb31f33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019b097a-6d1e-70cb-8294-6385393397c5" xlink:to="loc_us-gaap_AdditionalPaidInCapital_019b097a-6d1e-70ed-9439-fbdbaeb31f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019b097a-6d1e-74e5-b5bc-52193b5a7316" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019b097a-6d1e-70cb-8294-6385393397c5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019b097a-6d1e-74e5-b5bc-52193b5a7316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_019b097a-6d1e-7f96-946c-454872772243" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019b097a-6d1e-70cb-8294-6385393397c5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_019b097a-6d1e-7f96-946c-454872772243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019b097a-6d1e-7a09-b067-563019f90390" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019b097a-6d1e-70cb-8294-6385393397c5" xlink:to="loc_us-gaap_StockholdersEquity_019b097a-6d1e-7a09-b067-563019f90390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_019b097a-6d1e-7ac2-93d9-790ac9df6d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019b097a-6d1e-70cb-8294-6385393397c5" xlink:to="loc_us-gaap_MinorityInterest_019b097a-6d1e-7ac2-93d9-790ac9df6d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-7229-a7a0-6c07877f317c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_019b097a-6d1e-70cb-8294-6385393397c5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-7229-a7a0-6c07877f317c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019b097a-6d1e-7b5e-9352-2d19f10c30ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019b097a-6d1e-7021-b1c1-06065ef715ac" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_019b097a-6d1e-7b5e-9352-2d19f10c30ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="brns-20251231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019b097a-6d1e-79ea-b051-d7ff3303021f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019b097a-6d1e-7ddc-bcf4-027e7fb6ac24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019b097a-6d1e-79ea-b051-d7ff3303021f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019b097a-6d1e-7ddc-bcf4-027e7fb6ac24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019b097a-6d1e-752b-916e-1c6fa5b2437d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019b097a-6d1e-79ea-b051-d7ff3303021f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019b097a-6d1e-752b-916e-1c6fa5b2437d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_019b097a-6d1e-7944-96c4-8758c32aa19b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019b097a-6d1e-79ea-b051-d7ff3303021f" xlink:to="loc_us-gaap_CommonStockSharesIssued_019b097a-6d1e-7944-96c4-8758c32aa19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019b097a-6d1e-76b3-a803-edf27d6316a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019b097a-6d1e-79ea-b051-d7ff3303021f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019b097a-6d1e-76b3-a803-edf27d6316a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockParOrStatedValuePerShare_019b097a-6d1e-7da5-baf9-ec7d5cd7975e" xlink:href="brns-20251231.xsd#brns_DeferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019b097a-6d1e-79ea-b051-d7ff3303021f" xlink:to="loc_brns_DeferredStockParOrStatedValuePerShare_019b097a-6d1e-7da5-baf9-ec7d5cd7975e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesAuthorized_019b097a-6d1e-7106-9904-a2282cae1b51" xlink:href="brns-20251231.xsd#brns_DeferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019b097a-6d1e-79ea-b051-d7ff3303021f" xlink:to="loc_brns_DeferredStockSharesAuthorized_019b097a-6d1e-7106-9904-a2282cae1b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesIssued_019b097a-6d1e-76a9-8cab-824fe623779f" xlink:href="brns-20251231.xsd#brns_DeferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019b097a-6d1e-79ea-b051-d7ff3303021f" xlink:to="loc_brns_DeferredStockSharesIssued_019b097a-6d1e-76a9-8cab-824fe623779f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesOutstanding_019b097a-6d1e-77ff-8e92-8b25a52ca92e" xlink:href="brns-20251231.xsd#brns_DeferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019b097a-6d1e-79ea-b051-d7ff3303021f" xlink:to="loc_brns_DeferredStockSharesOutstanding_019b097a-6d1e-77ff-8e92-8b25a52ca92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="brns-20251231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_019b097a-6d1e-78bf-9420-71a113eaba6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019b097a-6d1e-7a2b-90af-32f839056431" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019b097a-6d1e-78bf-9420-71a113eaba6c" xlink:to="loc_us-gaap_StatementTable_019b097a-6d1e-7a2b-90af-32f839056431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019b097a-6d1e-7b50-a6e8-b5abe70a3044" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019b097a-6d1e-7a2b-90af-32f839056431" xlink:to="loc_srt_ProductOrServiceAxis_019b097a-6d1e-7b50-a6e8-b5abe70a3044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019b097a-6d1e-7057-9a21-444e5029d13e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019b097a-6d1e-7b50-a6e8-b5abe70a3044" xlink:to="loc_srt_ProductsAndServicesDomain_019b097a-6d1e-7057-9a21-444e5029d13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_019b097a-6d1e-7b13-a7f2-2daffb8b3b05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019b097a-6d1e-7057-9a21-444e5029d13e" xlink:to="loc_us-gaap_LicenseMember_019b097a-6d1e-7b13-a7f2-2daffb8b3b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019b097a-6d1e-7a2b-90af-32f839056431" xlink:to="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019b097a-6d1e-7975-b028-1f98f0d56709" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019b097a-6d1e-7975-b028-1f98f0d56709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_019b097a-6d1e-75c3-9014-70aa2a6cc36c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_019b097a-6d1e-75c3-9014-70aa2a6cc36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019b097a-6d1e-7040-82d2-29c6d93990a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019b097a-6d1e-75c3-9014-70aa2a6cc36c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019b097a-6d1e-7040-82d2-29c6d93990a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019b097a-6d1e-7e4c-9ae1-e5ff61039bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019b097a-6d1e-75c3-9014-70aa2a6cc36c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019b097a-6d1e-7e4c-9ae1-e5ff61039bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_019b2bd2-1df8-709c-b09d-0351fcdc2918" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019b097a-6d1e-75c3-9014-70aa2a6cc36c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_019b2bd2-1df8-709c-b09d-0351fcdc2918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_019b097a-6d1e-78ef-99f0-c3c23573fb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019b097a-6d1e-75c3-9014-70aa2a6cc36c" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_019b097a-6d1e-78ef-99f0-c3c23573fb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019b097a-6d1e-7fa6-938f-68870c8a0404" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019b097a-6d1e-75c3-9014-70aa2a6cc36c" xlink:to="loc_us-gaap_OperatingExpenses_019b097a-6d1e-7fa6-938f-68870c8a0404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_019b097a-6d1e-77a8-8b28-de29a8542397" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_OtherOperatingIncome_019b097a-6d1e-77a8-8b28-de29a8542397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019b097a-6d1e-7468-b7b7-cfa76ce07778" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_OperatingIncomeLoss_019b097a-6d1e-7468-b7b7-cfa76ce07778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7320-8662-422641659c51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7320-8662-422641659c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019b097a-6d1e-7486-9c9d-b895883a6dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7320-8662-422641659c51" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019b097a-6d1e-7486-9c9d-b895883a6dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_019b097a-6d1e-7f0c-abb2-3b6ec15959ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7320-8662-422641659c51" xlink:to="loc_us-gaap_InterestExpenseNonoperating_019b097a-6d1e-7f0c-abb2-3b6ec15959ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_019b097a-6d1e-7b40-8bad-56b43d3e183d" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentIncentiveIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7320-8662-422641659c51" xlink:to="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_019b097a-6d1e-7b40-8bad-56b43d3e183d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019b097a-6d1e-7a84-802f-af0fdb1786fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7320-8662-422641659c51" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019b097a-6d1e-7a84-802f-af0fdb1786fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019b097a-6d1e-77d6-b194-926164e0b7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7320-8662-422641659c51" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019b097a-6d1e-77d6-b194-926164e0b7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b097a-6d1e-7c29-8720-98a9588c30f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b097a-6d1e-7c29-8720-98a9588c30f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019b097a-6d1e-74e1-9855-a915eb439170" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019b097a-6d1e-74e1-9855-a915eb439170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019b097a-6d1e-7ee2-87af-bbc922aa9974" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_ProfitLoss_019b097a-6d1e-7ee2-87af-bbc922aa9974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019b097a-6d1e-77d0-b59a-25acc9471587" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019b097a-6d1e-77d0-b59a-25acc9471587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019b097a-6d1e-7dc6-8586-11d82add9c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_NetIncomeLoss_019b097a-6d1e-7dc6-8586-11d82add9c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019b097a-6d1e-7c83-9084-3d0db8d0d75f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019b097a-6d1e-7c83-9084-3d0db8d0d75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019b097a-6d1e-7a62-81ee-765a9c94d7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019b097a-6d1e-7a62-81ee-765a9c94d7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019b097a-6d1e-742d-a8bc-ff30e8792c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_EarningsPerShareBasic_019b097a-6d1e-742d-a8bc-ff30e8792c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019b097a-6d1e-7025-8a0a-ca531f45f97d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019b097a-6d1e-7025-8a0a-ca531f45f97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019b097a-6d1e-728d-b05d-1606455f74dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_ProfitLoss_019b097a-6d1e-728d-b05d-1606455f74dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019b097a-6d1e-7d96-b486-5b29dd8648bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019b097a-6d1e-7d96-b486-5b29dd8648bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-748f-9d94-326f16bfdf95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-748f-9d94-326f16bfdf95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_019b097a-6d1e-713a-82fb-872750cd1b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_019b097a-6d1e-713a-82fb-872750cd1b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019b097a-6d1e-7b6d-9418-c93faaa22ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7191-8aa6-de67effc946e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_019b097a-6d1e-7b6d-9418-c93faaa22ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="brns-20251231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_019b097a-6d1e-760a-af94-26d5b9373b88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019b097a-6d1e-7c5d-9364-9ccaadf42b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_019b097a-6d1e-760a-af94-26d5b9373b88" xlink:to="loc_us-gaap_StatementTable_019b097a-6d1e-7c5d-9364-9ccaadf42b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019b097a-6d1e-7e8b-b70f-577f28a261bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019b097a-6d1e-7c5d-9364-9ccaadf42b3f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019b097a-6d1e-7e8b-b70f-577f28a261bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019b097a-6d1e-770a-829f-0f35a83a341b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019b097a-6d1e-7e8b-b70f-577f28a261bb" xlink:to="loc_us-gaap_EquityComponentDomain_019b097a-6d1e-770a-829f-0f35a83a341b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_019b097a-6d1e-70cb-8154-c6290c5997ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019b097a-6d1e-770a-829f-0f35a83a341b" xlink:to="loc_us-gaap_ParentMember_019b097a-6d1e-70cb-8154-c6290c5997ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019b097a-6d1e-7d42-86af-0f85d1d425e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_019b097a-6d1e-70cb-8154-c6290c5997ef" xlink:to="loc_us-gaap_CommonStockMember_019b097a-6d1e-7d42-86af-0f85d1d425e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredSharesMember_019b097a-6d1e-758e-8d66-11d902605408" xlink:href="brns-20251231.xsd#brns_DeferredSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_019b097a-6d1e-70cb-8154-c6290c5997ef" xlink:to="loc_brns_DeferredSharesMember_019b097a-6d1e-758e-8d66-11d902605408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019b097a-6d1e-77cd-90b9-ff3ffa5bf7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_019b097a-6d1e-70cb-8154-c6290c5997ef" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019b097a-6d1e-77cd-90b9-ff3ffa5bf7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019b097a-6d1e-79f5-8f46-4f2b381fdc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_019b097a-6d1e-70cb-8154-c6290c5997ef" xlink:to="loc_us-gaap_RetainedEarningsMember_019b097a-6d1e-79f5-8f46-4f2b381fdc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019b097a-6d1e-7d0c-9563-e497b78bada0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_019b097a-6d1e-70cb-8154-c6290c5997ef" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019b097a-6d1e-7d0c-9563-e497b78bada0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_019b097a-6d1e-76bf-b665-593a86cc9e76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019b097a-6d1e-770a-829f-0f35a83a341b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_019b097a-6d1e-76bf-b665-593a86cc9e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019b097a-6d1e-7d8c-8b7b-485a48414ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019b097a-6d1e-7c5d-9364-9ccaadf42b3f" xlink:to="loc_us-gaap_StatementLineItems_019b097a-6d1e-7d8c-8b7b-485a48414ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019b097a-6d1e-70cb-a4a4-a49082c0d63b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019b097a-6d1e-7d8c-8b7b-485a48414ab4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019b097a-6d1e-70cb-a4a4-a49082c0d63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_019b097a-6d1e-73cd-8b32-a473a70dfd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019b097a-6d1e-70cb-a4a4-a49082c0d63b" xlink:to="loc_us-gaap_SharesIssued_019b097a-6d1e-73cd-8b32-a473a70dfd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-7798-b842-e67b9ff27a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019b097a-6d1e-70cb-a4a4-a49082c0d63b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-7798-b842-e67b9ff27a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019b097a-6d1e-78f3-bd38-c2dde771b305" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019b097a-6d1e-70cb-a4a4-a49082c0d63b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019b097a-6d1e-78f3-bd38-c2dde771b305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019b097a-6d1e-749e-a071-3077db9d374c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019b097a-6d1e-70cb-a4a4-a49082c0d63b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019b097a-6d1e-749e-a071-3077db9d374c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019b097a-6d1e-79f3-9380-22220d4b4680" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019b097a-6d1e-70cb-a4a4-a49082c0d63b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019b097a-6d1e-79f3-9380-22220d4b4680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019b097a-6d1e-74d2-8045-d46c1e480afc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019b097a-6d1e-70cb-a4a4-a49082c0d63b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019b097a-6d1e-74d2-8045-d46c1e480afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019b097a-6d1e-73f2-b875-6a75c3b62add" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019b097a-6d1e-70cb-a4a4-a49082c0d63b" xlink:to="loc_us-gaap_ProfitLoss_019b097a-6d1e-73f2-b875-6a75c3b62add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_019b097a-6d1e-7ea2-aa0f-1523616a50e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019b097a-6d1e-70cb-a4a4-a49082c0d63b" xlink:to="loc_us-gaap_SharesIssued_019b097a-6d1e-7ea2-aa0f-1523616a50e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-7656-ab75-669976e1db3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019b097a-6d1e-70cb-a4a4-a49082c0d63b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_019b097a-6d1e-7656-ab75-669976e1db3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="brns-20251231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_019b097a-6d1e-7f83-8f87-39c5fd0cc62a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019b097a-6d1e-73a8-81a1-9d44c2ad0348" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019b097a-6d1e-7f83-8f87-39c5fd0cc62a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019b097a-6d1e-73a8-81a1-9d44c2ad0348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019b097a-6d1e-776c-a358-a8cb0eedfc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019b097a-6d1e-73a8-81a1-9d44c2ad0348" xlink:to="loc_us-gaap_ProfitLoss_019b097a-6d1e-776c-a358-a8cb0eedfc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019b097a-6d1e-71e3-bcde-d1735a1a81c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019b097a-6d1e-73a8-81a1-9d44c2ad0348" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019b097a-6d1e-71e3-bcde-d1735a1a81c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019b097a-6d1e-7c0f-8e0f-2c676e8b4f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019b097a-6d1e-71e3-bcde-d1735a1a81c9" xlink:to="loc_us-gaap_ShareBasedCompensation_019b097a-6d1e-7c0f-8e0f-2c676e8b4f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AssetImpairmentChargesExcludingGoodwill_019b2bda-6431-7ead-9093-912bc750e337" xlink:href="brns-20251231.xsd#brns_AssetImpairmentChargesExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019b097a-6d1e-71e3-bcde-d1735a1a81c9" xlink:to="loc_brns_AssetImpairmentChargesExcludingGoodwill_019b2bda-6431-7ead-9093-912bc750e337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_019b097a-6d1e-77f7-a1e6-26c6b5f8ec5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019b097a-6d1e-71e3-bcde-d1735a1a81c9" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_019b097a-6d1e-77f7-a1e6-26c6b5f8ec5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_019b097a-6d1e-7b75-aa06-f269317725e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019b097a-6d1e-71e3-bcde-d1735a1a81c9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_019b097a-6d1e-7b75-aa06-f269317725e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NonCashLeaseExpenses_019b097a-6d1e-7f87-9087-4b382dacc52d" xlink:href="brns-20251231.xsd#brns_NonCashLeaseExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019b097a-6d1e-71e3-bcde-d1735a1a81c9" xlink:to="loc_brns_NonCashLeaseExpenses_019b097a-6d1e-7f87-9087-4b382dacc52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_019b097a-6d1e-79ce-8f9d-8bf143aa43f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019b097a-6d1e-71e3-bcde-d1735a1a81c9" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_019b097a-6d1e-79ce-8f9d-8bf143aa43f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019b097a-6d1e-7e87-8613-b3af39b7c699" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019b097a-6d1e-71e3-bcde-d1735a1a81c9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019b097a-6d1e-7e87-8613-b3af39b7c699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NonCashInterestExpenseOnConvertibleLoanNotes_019b097a-6d1e-7c37-a231-0636a4ccfce5" xlink:href="brns-20251231.xsd#brns_NonCashInterestExpenseOnConvertibleLoanNotes"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019b097a-6d1e-71e3-bcde-d1735a1a81c9" xlink:to="loc_brns_NonCashInterestExpenseOnConvertibleLoanNotes_019b097a-6d1e-7c37-a231-0636a4ccfce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_019b097a-6d1e-7415-9d98-3a5a4db99b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019b097a-6d1e-71e3-bcde-d1735a1a81c9" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_019b097a-6d1e-7415-9d98-3a5a4db99b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_019bd5bb-3f71-707e-a1a1-40de187fc409" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019b097a-6d1e-71e3-bcde-d1735a1a81c9" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_019bd5bb-3f71-707e-a1a1-40de187fc409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019b097a-6d1e-7b32-b7ac-937cc184f0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019b097a-6d1e-71e3-bcde-d1735a1a81c9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019b097a-6d1e-7b32-b7ac-937cc184f0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019b097a-6d1e-7331-9ab0-e2654307df12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019b097a-6d1e-7b32-b7ac-937cc184f0fa" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019b097a-6d1e-7331-9ab0-e2654307df12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_019b097a-6d1e-7d35-a7bf-f17a2646b32b" xlink:href="brns-20251231.xsd#brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019b097a-6d1e-7b32-b7ac-937cc184f0fa" xlink:to="loc_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_019b097a-6d1e-7d35-a7bf-f17a2646b32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019b097a-6d1e-7685-99bb-40476a94f916" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019b097a-6d1e-7b32-b7ac-937cc184f0fa" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019b097a-6d1e-7685-99bb-40476a94f916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_019b097a-6d1e-70ea-a2b8-c0211ab419d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019b097a-6d1e-7b32-b7ac-937cc184f0fa" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_019b097a-6d1e-70ea-a2b8-c0211ab419d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_019b097a-6d1e-7a62-badc-795ff17ea93c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019b097a-6d1e-7b32-b7ac-937cc184f0fa" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_019b097a-6d1e-7a62-badc-795ff17ea93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019b097a-6d1e-7bbf-8121-da292a72dc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019b097a-6d1e-7b32-b7ac-937cc184f0fa" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_019b097a-6d1e-7bbf-8121-da292a72dc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-77a7-8057-addbfa44b331" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019b097a-6d1e-71e3-bcde-d1735a1a81c9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019b097a-6d1e-77a7-8057-addbfa44b331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019b097a-6d1e-7aee-a955-39296edf1f80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019b097a-6d1e-7f83-8f87-39c5fd0cc62a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019b097a-6d1e-7aee-a955-39296edf1f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_019bd5bd-bc9d-71b2-bc7b-3fb980597c76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019b097a-6d1e-7aee-a955-39296edf1f80" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_019bd5bd-bc9d-71b2-bc7b-3fb980597c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019b097a-6d1e-724e-b7eb-17eaeda31709" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019b097a-6d1e-7aee-a955-39296edf1f80" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019b097a-6d1e-724e-b7eb-17eaeda31709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019b097a-6d1e-7dbd-8308-eb363f551fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019b097a-6d1e-7aee-a955-39296edf1f80" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019b097a-6d1e-7dbd-8308-eb363f551fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019b097a-6d1e-707f-9be4-7e9e8fe7aedc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019b097a-6d1e-7f83-8f87-39c5fd0cc62a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019b097a-6d1e-707f-9be4-7e9e8fe7aedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019b097a-6d1e-733c-afc0-3ddfaeb4ccec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019b097a-6d1e-707f-9be4-7e9e8fe7aedc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019b097a-6d1e-733c-afc0-3ddfaeb4ccec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019b097a-6d1e-73ee-a715-1725ec008edc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019b097a-6d1e-707f-9be4-7e9e8fe7aedc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019b097a-6d1e-73ee-a715-1725ec008edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019b097a-6d1e-7c3c-b411-d2c5f9a222bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019b097a-6d1e-707f-9be4-7e9e8fe7aedc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019b097a-6d1e-7c3c-b411-d2c5f9a222bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019b097a-6d1e-723c-8c18-b5800377c571" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019b097a-6d1e-7f83-8f87-39c5fd0cc62a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019b097a-6d1e-723c-8c18-b5800377c571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019b097a-6d1e-7b70-942f-92ba144eee38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019b097a-6d1e-7f83-8f87-39c5fd0cc62a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019b097a-6d1e-7b70-942f-92ba144eee38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019b097a-6d1e-75f7-876a-123d28bdf8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019b097a-6d1e-7f83-8f87-39c5fd0cc62a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019b097a-6d1e-75f7-876a-123d28bdf8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019b097a-6d1e-7847-8acc-6dac3e49636a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019b097a-6d1e-7f83-8f87-39c5fd0cc62a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019b097a-6d1e-7847-8acc-6dac3e49636a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="brns-20251231.xsd#NatureofBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019b097a-6d1e-75df-959b-487c1cc2d9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_019b097a-6d1e-7f8c-9707-142ffc424e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019b097a-6d1e-75df-959b-487c1cc2d9b5" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_019b097a-6d1e-7f8c-9707-142ffc424e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="brns-20251231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-728a-87ac-d05049a5c70d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_019b097a-6d1e-74b5-9b0a-905fec6110cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-728a-87ac-d05049a5c70d" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_019b097a-6d1e-74b5-9b0a-905fec6110cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/Segmentinformation" xlink:type="simple" xlink:href="brns-20251231.xsd#Segmentinformation"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/Segmentinformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019b097a-6d1e-7cee-a64e-2e8bd8a83851" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_019b097a-6d1e-7c17-99ad-5f8c219244f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019b097a-6d1e-7cee-a64e-2e8bd8a83851" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_019b097a-6d1e-7c17-99ad-5f8c219244f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpenses" xlink:type="simple" xlink:href="brns-20251231.xsd#ForeignCurrencyTranslationinGeneralandAdministrativeExpenses"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyAbstract_019b097a-6d1e-72d9-aba6-0c9e9bafcfc4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDisclosureTextBlock_019b097a-6d1e-7d92-a69e-77c27d8ee8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignCurrencyAbstract_019b097a-6d1e-72d9-aba6-0c9e9bafcfc4" xlink:to="loc_us-gaap_ForeignCurrencyDisclosureTextBlock_019b097a-6d1e-7d92-a69e-77c27d8ee8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="brns-20251231.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019b097a-6d1e-79c7-b688-d030106c3d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_019b097a-6d1e-7452-a9e8-0612088a5480" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019b097a-6d1e-79c7-b688-d030106c3d0d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_019b097a-6d1e-7452-a9e8-0612088a5480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="brns-20251231.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019b097a-6d1e-79ea-8dc7-c9ba147e30b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_019b097a-6d1e-729c-94ce-cc0265407fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019b097a-6d1e-79ea-8dc7-c9ba147e30b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_019b097a-6d1e-729c-94ce-cc0265407fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="brns-20251231.xsd#IntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/IntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_019b097a-6d1e-7265-ad26-8e5e3d0dc34e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_019b097a-6d1e-7e25-b2dc-2737e9e89b41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_019b097a-6d1e-7265-ad26-8e5e3d0dc34e" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_019b097a-6d1e-7e25-b2dc-2737e9e89b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssets" xlink:type="simple" xlink:href="brns-20251231.xsd#PrepaidandOtherCurrentAssets"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_019b097a-6d1e-7aa4-8a55-43a10fd7e98a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock_019b097a-6d1e-7721-8f14-1715434f8db1" xlink:href="brns-20251231.xsd#brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_019b097a-6d1e-7aa4-8a55-43a10fd7e98a" xlink:to="loc_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock_019b097a-6d1e-7721-8f14-1715434f8db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="brns-20251231.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019b097a-6d1e-77b2-ae8f-a1fe56337005" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_019b097a-6d1e-7776-9a88-39b219ffb908" xlink:href="brns-20251231.xsd#brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019b097a-6d1e-77b2-ae8f-a1fe56337005" xlink:to="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_019b097a-6d1e-7776-9a88-39b219ffb908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/GrantIncome" xlink:type="simple" xlink:href="brns-20251231.xsd#GrantIncome"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/GrantIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7320-be8e-f551179a9f31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_019ba4d7-f587-7748-aa08-119c588d134c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeAndExpenseTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7320-be8e-f551179a9f31" xlink:to="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_019ba4d7-f587-7748-aa08-119c588d134c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/OrdinaryShares" xlink:type="simple" xlink:href="brns-20251231.xsd#OrdinaryShares"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/OrdinaryShares" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019b097a-6d1e-7eb6-bb43-c84945e6bd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019b097a-6d1e-7b56-b178-a27005759bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019b097a-6d1e-7eb6-bb43-c84945e6bd8d" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019b097a-6d1e-7b56-b178-a27005759bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/DeferredShares" xlink:type="simple" xlink:href="brns-20251231.xsd#DeferredShares"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/DeferredShares" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019b097a-6e6b-7eb9-a6a5-f76a0ed4ca5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_StockholdersEquityDeferredSharesDisclosureTextBlock_019b097a-6e6b-708d-ad87-30c3868c36e2" xlink:href="brns-20251231.xsd#brns_StockholdersEquityDeferredSharesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019b097a-6e6b-7eb9-a6a5-f76a0ed4ca5d" xlink:to="loc_brns_StockholdersEquityDeferredSharesDisclosureTextBlock_019b097a-6e6b-708d-ad87-30c3868c36e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/FairValue" xlink:type="simple" xlink:href="brns-20251231.xsd#FairValue"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/FairValue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019b097a-6e6b-7092-be7a-125b45fe6e11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_019b097a-6e6b-76cc-8331-461725b3fcab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019b097a-6e6b-7092-be7a-125b45fe6e11" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_019b097a-6e6b-76cc-8331-461725b3fcab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="brns-20251231.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b097a-6e6b-7fda-b019-ad2479e3569e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019b097a-6e6b-7a5c-ad36-ebd6bfca8f50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b097a-6e6b-7fda-b019-ad2479e3569e" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019b097a-6e6b-7a5c-ad36-ebd6bfca8f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="brns-20251231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-723b-9e75-c8e4ea95d3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_019b097a-6e6c-7eba-88b0-50fa8fe1c66b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-723b-9e75-c8e4ea95d3cb" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_019b097a-6e6c-7eba-88b0-50fa8fe1c66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="brns-20251231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-7ac3-9f55-daa7f2229aac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019b097a-6e6c-7397-9fab-e08d43cdb3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-7ac3-9f55-daa7f2229aac" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019b097a-6e6c-7397-9fab-e08d43cdb3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="brns-20251231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_019b097a-6e6c-7bcf-8041-98b1e9223a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_019b097a-6e6c-72da-9199-b05792357225" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_019b097a-6e6c-7bcf-8041-98b1e9223a5e" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_019b097a-6e6c-72da-9199-b05792357225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="brns-20251231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_019b097a-6e6c-7f37-a331-b78b09637627" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_019b097a-6e6c-7a5d-b64c-1b6ee8700b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_019b097a-6e6c-7f37-a331-b78b09637627" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_019b097a-6e6c-7a5d-b64c-1b6ee8700b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="brns-20251231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_019b097a-6e6c-7e2b-a3c3-5b55b748a377" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_019b097a-6e6c-7bec-8877-7a0008ad1f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_019b097a-6e6c-7e2b-a3c3-5b55b748a377" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_019b097a-6e6c-7bec-8877-7a0008ad1f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="brns-20251231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_019b097a-6d1e-759b-9a6e-14fae4fde490" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_019b097a-6d1e-759b-9a6e-14fae4fde490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_019b097a-6d1e-7e69-b7d1-decb6edcd575" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_019b097a-6d1e-7e69-b7d1-decb6edcd575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_019b097a-6d1e-70db-aca0-ff0dae6f973f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_UseOfEstimates_019b097a-6d1e-70db-aca0-ff0dae6f973f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_019b097a-6d1e-7b93-9bef-d10b471bbaee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_019b097a-6d1e-7b93-9bef-d10b471bbaee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_019b097a-6d1e-7824-b2db-05aa5411906e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_019b097a-6d1e-7824-b2db-05aa5411906e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MinorityInterestPolicyTextBlock_019b097a-6d1e-7932-a843-9fd1bbc3c6e2" xlink:href="brns-20251231.xsd#brns_MinorityInterestPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_brns_MinorityInterestPolicyTextBlock_019b097a-6d1e-7932-a843-9fd1bbc3c6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_019b097a-6d1e-7826-883d-32fefcc2b0af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_019b097a-6d1e-7826-883d-32fefcc2b0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_019b097a-6d1e-7f1d-9278-0369ea4bd87b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_019b097a-6d1e-7f1d-9278-0369ea4bd87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock_019b097a-6d1e-70d8-a071-625a981578a4" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock_019b097a-6d1e-70d8-a071-625a981578a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OtherOperatingIncomePolicyPolicyTextBlock_019b097a-6d1e-75f4-9ada-c5f6fc7d2d62" xlink:href="brns-20251231.xsd#brns_OtherOperatingIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_brns_OtherOperatingIncomePolicyPolicyTextBlock_019b097a-6d1e-75f4-9ada-c5f6fc7d2d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_019b097a-6d1e-7908-80c7-2d19901fe5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_019b097a-6d1e-7908-80c7-2d19901fe5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_019b097a-6d1e-75e4-9448-d97c4decebcc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_019b097a-6d1e-75e4-9448-d97c4decebcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_019b097a-6d1e-7d31-8c66-2c45dacd27b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_019b097a-6d1e-7d31-8c66-2c45dacd27b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_019b097a-6d1e-7be1-9fc2-5195ff05f703" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_019b097a-6d1e-7be1-9fc2-5195ff05f703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_019b097a-6d1e-77f2-97c0-06c5dbfc6510" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_019b097a-6d1e-77f2-97c0-06c5dbfc6510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_019ce281-3ee5-76b1-88e5-9ed71bbf8345" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_019ce281-3ee5-76b1-88e5-9ed71bbf8345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_019b097a-6d1e-75d4-8776-f2f5d16a4c16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_019b097a-6d1e-75d4-8776-f2f5d16a4c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_019b097a-6d1e-7b4a-8aab-9c7943b9ed01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_019b097a-6d1e-7b4a-8aab-9c7943b9ed01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_019b097a-6d1e-7a9f-a763-ff5c16bfe3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_019b097a-6d1e-7a9f-a763-ff5c16bfe3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_019b097a-6d1e-779c-a00d-60f4cb7135aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_019b097a-6d1e-779c-a00d-60f4cb7135aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ClinicalTrialCostsPolicyTextBlock_019b097a-6d1e-762d-89ef-71f5bc1ac451" xlink:href="brns-20251231.xsd#brns_ClinicalTrialCostsPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_brns_ClinicalTrialCostsPolicyTextBlock_019b097a-6d1e-762d-89ef-71f5bc1ac451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_019b097a-6d1e-72ff-b4ec-e8f7d1bb2b94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_019b097a-6d1e-72ff-b4ec-e8f7d1bb2b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_019b097a-6d1e-70a6-ab29-fe53c42250a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_019b097a-6d1e-70a6-ab29-fe53c42250a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AdditionalPaidInCapitalPolicyTextBlock_019b097a-6d1e-7485-80fe-10b5e353d4a8" xlink:href="brns-20251231.xsd#brns_AdditionalPaidInCapitalPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_brns_AdditionalPaidInCapitalPolicyTextBlock_019b097a-6d1e-7485-80fe-10b5e353d4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_019b097a-6d1e-7353-81db-45905b6ae795" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_019b097a-6d1e-7353-81db-45905b6ae795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegulatoryIncomeTaxesPolicy_019b097a-6d1e-7827-b93f-76b50831460f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegulatoryIncomeTaxesPolicy"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_RegulatoryIncomeTaxesPolicy_019b097a-6d1e-7827-b93f-76b50831460f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock_019b097a-6d1e-70cf-8910-f59879eff862" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentIncentivesPolicyTextBlock"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock_019b097a-6d1e-70cf-8910-f59879eff862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_019b097a-6d1e-784b-95b0-e56e6aa4c158" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_019b097a-6d1e-784b-95b0-e56e6aa4c158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy_019b097a-6d1e-7adc-b582-ac966d633945" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy_019b097a-6d1e-7adc-b582-ac966d633945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019b097a-6d1e-7c10-a1f0-4accdafbd8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7598-99ac-a48c11cb3f8e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019b097a-6d1e-7c10-a1f0-4accdafbd8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="brns-20251231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-70db-9e9e-d5c0c5a684c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_019b097a-6d1e-75c2-990c-abbc6594d5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-70db-9e9e-d5c0c5a684c0" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_019b097a-6d1e-75c2-990c-abbc6594d5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_019b097a-6d1e-7371-9026-544992656213" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-70db-9e9e-d5c0c5a684c0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_019b097a-6d1e-7371-9026-544992656213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SegmentinformationTables" xlink:type="simple" xlink:href="brns-20251231.xsd#SegmentinformationTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SegmentinformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019b097a-6d1e-7a38-ae6e-629d6048a4d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019b097a-6d1e-77d7-ac84-4a2fac35bebe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019b097a-6d1e-7a38-ae6e-629d6048a4d6" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019b097a-6d1e-77d7-ac84-4a2fac35bebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_019b097a-6d1e-720d-8e30-3a935e36b901" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019b097a-6d1e-7a38-ae6e-629d6048a4d6" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_019b097a-6d1e-720d-8e30-3a935e36b901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="brns-20251231.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019b097a-6d1e-7cad-8347-c2d396d22d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_019b097a-6d1e-75b0-b891-09953d4c75ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019b097a-6d1e-7cad-8347-c2d396d22d0b" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_019b097a-6d1e-75b0-b891-09953d4c75ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="brns-20251231.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019b097a-6d1e-7778-8606-366e871e2637" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_019b097a-6d1e-72a2-884a-07f1c59fd01e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019b097a-6d1e-7778-8606-366e871e2637" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_019b097a-6d1e-72a2-884a-07f1c59fd01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsTables" xlink:type="simple" xlink:href="brns-20251231.xsd#PrepaidandOtherCurrentAssetsTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_019b097a-6d1e-7456-8ed8-eb560c68d671" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_019b097a-6d1e-7fbc-851f-251f9550628b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_019b097a-6d1e-7456-8ed8-eb560c68d671" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_019b097a-6d1e-7fbc-851f-251f9550628b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="brns-20251231.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019b097a-6d1e-7e51-a831-f0e8fed6044d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_019b097a-6d1e-7841-87d9-90fe5ced9b90" xlink:href="brns-20251231.xsd#brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019b097a-6d1e-7e51-a831-f0e8fed6044d" xlink:to="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_019b097a-6d1e-7841-87d9-90fe5ced9b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/GrantIncomeTables" xlink:type="simple" xlink:href="brns-20251231.xsd#GrantIncomeTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/GrantIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7c2f-a722-5508bfe721ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTableTextBlock_019b097a-6d1e-7532-9afe-bdf5a4857c99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7c2f-a722-5508bfe721ff" xlink:to="loc_us-gaap_DeferredIncomeTableTextBlock_019b097a-6d1e-7532-9afe-bdf5a4857c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/OrdinarySharesTables" xlink:type="simple" xlink:href="brns-20251231.xsd#OrdinarySharesTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/OrdinarySharesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019b097a-6d1e-78d4-b384-c18ed86106fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock_019b097a-6d1e-7383-9dc2-999ad5bdc2df" xlink:href="brns-20251231.xsd#brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019b097a-6d1e-78d4-b384-c18ed86106fe" xlink:to="loc_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock_019b097a-6d1e-7383-9dc2-999ad5bdc2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/FairValueTables" xlink:type="simple" xlink:href="brns-20251231.xsd#FairValueTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/FairValueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019b097a-6e6b-7ca2-bc95-bc04c04411f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_019b097a-6e6b-776c-b01a-755ee79bfad0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019b097a-6e6b-7ca2-bc95-bc04c04411f9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_019b097a-6e6b-776c-b01a-755ee79bfad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="brns-20251231.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b097a-6e6b-7eb1-a09b-dec335d03408" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_019b097a-6e6b-7de8-bb9d-c28eda6e4921" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b097a-6e6b-7eb1-a09b-dec335d03408" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_019b097a-6e6b-7de8-bb9d-c28eda6e4921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_019b097a-6e6b-7b55-afb5-d0ad4b6b88a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b097a-6e6b-7eb1-a09b-dec335d03408" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_019b097a-6e6b-7b55-afb5-d0ad4b6b88a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_019c282b-5225-75d4-816a-6ef870546c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b097a-6e6b-7eb1-a09b-dec335d03408" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_019c282b-5225-75d4-816a-6ef870546c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_019b097a-6e6b-7ef3-b58c-284244fd747f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b097a-6e6b-7eb1-a09b-dec335d03408" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_019b097a-6e6b-7ef3-b58c-284244fd747f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="brns-20251231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-7f5a-a245-d35ded5920fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_019b097a-6e6c-7a6a-99ec-d4a9b62cbe7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-7f5a-a245-d35ded5920fe" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_019b097a-6e6c-7a6a-99ec-d4a9b62cbe7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_019b097a-6e6c-7d9c-ade7-704bc877f85a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-7f5a-a245-d35ded5920fe" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_019b097a-6e6c-7d9c-ade7-704bc877f85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_019b097a-6e6c-755a-adea-b2dde1b8630c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-7f5a-a245-d35ded5920fe" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_019b097a-6e6c-755a-adea-b2dde1b8630c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_019b097a-6e6c-7523-90b6-76aa92be3004" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-7f5a-a245-d35ded5920fe" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_019b097a-6e6c-7523-90b6-76aa92be3004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_019b097a-6e6c-7137-99d9-8b45ee57e9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-7f5a-a245-d35ded5920fe" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_019b097a-6e6c-7137-99d9-8b45ee57e9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="brns-20251231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-7ce1-9187-4f91728c2043" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock_019b097a-6e6c-72ac-83d8-1d987c8daf4b" xlink:href="brns-20251231.xsd#brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-7ce1-9187-4f91728c2043" xlink:to="loc_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock_019b097a-6e6c-72ac-83d8-1d987c8daf4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_019b097a-6e6c-7e4d-a2ed-bcfa1e44aa9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-7ce1-9187-4f91728c2043" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_019b097a-6e6c-7e4d-a2ed-bcfa1e44aa9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#NatureofBusinessandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019b097a-6d1e-7d5e-8963-a642e67fe287" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramTable_019bd5df-9dd5-73eb-aeec-7f4915f8b724" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019b097a-6d1e-7d5e-8963-a642e67fe287" xlink:to="loc_srt_ShareRepurchaseProgramTable_019bd5df-9dd5-73eb-aeec-7f4915f8b724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_019bd5df-9dd5-7517-85d7-a7268904bf75" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramTable_019bd5df-9dd5-73eb-aeec-7f4915f8b724" xlink:to="loc_srt_StatementScenarioAxis_019bd5df-9dd5-7517-85d7-a7268904bf75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_019bd5df-9dd5-73f8-921f-c177062f45d3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_019bd5df-9dd5-7517-85d7-a7268904bf75" xlink:to="loc_srt_ScenarioUnspecifiedDomain_019bd5df-9dd5-73f8-921f-c177062f45d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_019bd5df-9dd5-7b8b-8d9f-0879b189a31d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_019bd5df-9dd5-73f8-921f-c177062f45d3" xlink:to="loc_srt_ScenarioForecastMember_019bd5df-9dd5-7b8b-8d9f-0879b189a31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019bd5df-9dd5-70b9-8e39-4c175f16c2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramTable_019bd5df-9dd5-73eb-aeec-7f4915f8b724" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019bd5df-9dd5-70b9-8e39-4c175f16c2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019bd5df-9dd5-70a0-8b60-0df0d5bb57ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019bd5df-9dd5-70b9-8e39-4c175f16c2cc" xlink:to="loc_us-gaap_ClassOfStockDomain_019bd5df-9dd5-70a0-8b60-0df0d5bb57ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SchemeSharesMember_019bd5df-9dd5-7a9a-995c-8788d9892307" xlink:href="brns-20251231.xsd#brns_SchemeSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019bd5df-9dd5-70a0-8b60-0df0d5bb57ac" xlink:to="loc_brns_SchemeSharesMember_019bd5df-9dd5-7a9a-995c-8788d9892307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ClywedogCapitalStockMember_019bd5df-9dd5-7368-b1bd-54a975ed87e6" xlink:href="brns-20251231.xsd#brns_ClywedogCapitalStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019bd5df-9dd5-70a0-8b60-0df0d5bb57ac" xlink:to="loc_brns_ClywedogCapitalStockMember_019bd5df-9dd5-7368-b1bd-54a975ed87e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019bd5df-9dd5-778a-be3c-3d1a71c59f30" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramTable_019bd5df-9dd5-73eb-aeec-7f4915f8b724" xlink:to="loc_dei_LegalEntityAxis_019bd5df-9dd5-778a-be3c-3d1a71c59f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019bd5df-9dd5-71d8-8cb3-94a8d283f394" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_019bd5df-9dd5-778a-be3c-3d1a71c59f30" xlink:to="loc_dei_EntityDomain_019bd5df-9dd5-71d8-8cb3-94a8d283f394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_BecaonTopcoIncMember_019bd5df-9dd5-7c83-8739-9173451c0263" xlink:href="brns-20251231.xsd#brns_BecaonTopcoIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_019bd5df-9dd5-71d8-8cb3-94a8d283f394" xlink:to="loc_brns_BecaonTopcoIncMember_019bd5df-9dd5-7c83-8739-9173451c0263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ClywedogTherapeuticsInc.Member_019bd5df-9dd5-7f9b-8184-48b3c9579388" xlink:href="brns-20251231.xsd#brns_ClywedogTherapeuticsInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_019bd5df-9dd5-71d8-8cb3-94a8d283f394" xlink:to="loc_brns_ClywedogTherapeuticsInc.Member_019bd5df-9dd5-7f9b-8184-48b3c9579388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramTable_019bd5df-9dd5-73eb-aeec-7f4915f8b724" xlink:to="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfNewSubsidiaries_019c498f-64bb-7d9e-b345-16726fe99512" xlink:href="brns-20251231.xsd#brns_NumberOfNewSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:to="loc_brns_NumberOfNewSubsidiaries_019c498f-64bb-7d9e-b345-16726fe99512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019bd5df-9dd5-7b45-a215-2351ac79efb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019bd5df-9dd5-7b45-a215-2351ac79efb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfDepositarySharesPerShareOfCommonStock_019bd5e2-c436-71ae-b001-52e2b60ec1ab" xlink:href="brns-20251231.xsd#brns_NumberOfDepositarySharesPerShareOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:to="loc_brns_NumberOfDepositarySharesPerShareOfCommonStock_019bd5e2-c436-71ae-b001-52e2b60ec1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_StockConversionRatio_019bd5df-9dd5-74f5-948e-b5ed213d517c" xlink:href="brns-20251231.xsd#brns_StockConversionRatio"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:to="loc_brns_StockConversionRatio_019bd5df-9dd5-74f5-948e-b5ed213d517c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019bd5df-9dd5-702c-b67a-787a90a30eae" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019bd5df-9dd5-702c-b67a-787a90a30eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019bd5df-9dd5-7f55-9cd6-98ae4f3edb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019bd5df-9dd5-7f55-9cd6-98ae4f3edb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MergerAgreementExtensionPeriod_019bd5df-9dd5-78f4-946d-765a99420577" xlink:href="brns-20251231.xsd#brns_MergerAgreementExtensionPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:to="loc_brns_MergerAgreementExtensionPeriod_019bd5df-9dd5-78f4-946d-765a99420577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019bd5df-9dd5-78a1-8b35-15a9843880be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019bd5df-9dd5-78a1-8b35-15a9843880be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019bd5df-9dd5-7697-8a6b-33df8170fb89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramLineItems_019bd5df-9dd5-7e42-a35c-0b010cca4038" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019bd5df-9dd5-7697-8a6b-33df8170fb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesForeigncurrencytranslationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SummaryofSignificantAccountingPoliciesForeigncurrencytranslationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesForeigncurrencytranslationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7cc6-9c3b-29b237a49f23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_019b097a-6d1e-7f2f-8382-cad04a302b89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7cc6-9c3b-29b237a49f23" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_019b097a-6d1e-7f2f-8382-cad04a302b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7650-a1fd-a75762cab9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_019b097a-6d1e-76c8-b9ae-abbfefbbd16e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7650-a1fd-a75762cab9ef" xlink:to="loc_us-gaap_MinorityInterestTable_019b097a-6d1e-76c8-b9ae-abbfefbbd16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_019b097a-6d1e-7128-82e5-23a8fe745a1a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_019b097a-6d1e-76c8-b9ae-abbfefbbd16e" xlink:to="loc_srt_OwnershipAxis_019b097a-6d1e-7128-82e5-23a8fe745a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_019b097a-6d1e-7cae-96f8-eeaaabd76eef" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_019b097a-6d1e-7128-82e5-23a8fe745a1a" xlink:to="loc_srt_OwnershipDomain_019b097a-6d1e-7cae-96f8-eeaaabd76eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_VOLTMember_019b097a-6d1e-73e8-b3ab-bdf3532ee680" xlink:href="brns-20251231.xsd#brns_VOLTMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_019b097a-6d1e-7cae-96f8-eeaaabd76eef" xlink:to="loc_brns_VOLTMember_019b097a-6d1e-73e8-b3ab-bdf3532ee680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_019b097a-6d1e-76d0-b8f7-6f55af8ae816" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_019b097a-6d1e-76c8-b9ae-abbfefbbd16e" xlink:to="loc_srt_ConsolidatedEntitiesAxis_019b097a-6d1e-76d0-b8f7-6f55af8ae816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_019b097a-6d1e-735b-952b-948c9148291a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_019b097a-6d1e-76d0-b8f7-6f55af8ae816" xlink:to="loc_srt_ConsolidatedEntitiesDomain_019b097a-6d1e-735b-952b-948c9148291a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SubsidiariesVOLTMember_019b097a-6d1e-7b81-9c3b-460b274b2079" xlink:href="brns-20251231.xsd#brns_SubsidiariesVOLTMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_019b097a-6d1e-735b-952b-948c9148291a" xlink:to="loc_brns_SubsidiariesVOLTMember_019b097a-6d1e-7b81-9c3b-460b274b2079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019b097a-6d1e-7ffa-aeba-4a196f20fe7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_019b097a-6d1e-76c8-b9ae-abbfefbbd16e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019b097a-6d1e-7ffa-aeba-4a196f20fe7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019b097a-6d1e-7ff8-8ed8-18a2e640331b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019b097a-6d1e-7ffa-aeba-4a196f20fe7f" xlink:to="loc_us-gaap_RelatedPartyDomain_019b097a-6d1e-7ff8-8ed8-18a2e640331b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019b097a-6d1e-7223-9246-3ce3347233fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019b097a-6d1e-7ff8-8ed8-18a2e640331b" xlink:to="loc_us-gaap_RelatedPartyMember_019b097a-6d1e-7223-9246-3ce3347233fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_019b097a-6d1e-7697-9d3a-444e3d8c98ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_019b097a-6d1e-76c8-b9ae-abbfefbbd16e" xlink:to="loc_us-gaap_MinorityInterestLineItems_019b097a-6d1e-7697-9d3a-444e3d8c98ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SubsidiaryCumulativeContributionsParent_019b097a-6d1e-7ef4-b06a-07e7849cbf2a" xlink:href="brns-20251231.xsd#brns_SubsidiaryCumulativeContributionsParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_019b097a-6d1e-7697-9d3a-444e3d8c98ec" xlink:to="loc_brns_SubsidiaryCumulativeContributionsParent_019b097a-6d1e-7ef4-b06a-07e7849cbf2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_019b097a-6d1e-703c-8bd7-e96ee1012d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_019b097a-6d1e-7697-9d3a-444e3d8c98ec" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_019b097a-6d1e-703c-8bd7-e96ee1012d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner_019b097a-6d1e-7f42-a0ca-bc534caf1c07" xlink:href="brns-20251231.xsd#brns_SubsidiaryCumulativeContributionsNoncontrollingOwner"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_019b097a-6d1e-7697-9d3a-444e3d8c98ec" xlink:to="loc_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner_019b097a-6d1e-7f42-a0ca-bc534caf1c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_019b097a-6d1e-7a31-ab4e-c22e6e1d28d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_019b097a-6d1e-7697-9d3a-444e3d8c98ec" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_019b097a-6d1e-7a31-ab4e-c22e6e1d28d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7ed5-a173-9649c73c02a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_019b097a-6d1e-769d-893d-d798f5549c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7ed5-a173-9649c73c02a8" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_019b097a-6d1e-769d-893d-d798f5549c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-78ba-a928-ef2d7061e347" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_019b097a-6d1e-72bc-a379-7c88096ae007" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-78ba-a928-ef2d7061e347" xlink:to="loc_us-gaap_ConcentrationRiskTable_019b097a-6d1e-72bc-a379-7c88096ae007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019b097a-6d1e-7c9b-8a0a-c6b06b09c47d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019b097a-6d1e-72bc-a379-7c88096ae007" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019b097a-6d1e-7c9b-8a0a-c6b06b09c47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019b097a-6d1e-7db2-9a5b-ea491f70ac55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019b097a-6d1e-7c9b-8a0a-c6b06b09c47d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019b097a-6d1e-7db2-9a5b-ea491f70ac55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_019b097a-6d1e-7036-9b3f-f6336fe94441" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019b097a-6d1e-7db2-9a5b-ea491f70ac55" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_019b097a-6d1e-7036-9b3f-f6336fe94441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_019b097a-6d1e-7cbd-8953-d6fcbfcc8b2e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019b097a-6d1e-72bc-a379-7c88096ae007" xlink:to="loc_srt_StatementGeographicalAxis_019b097a-6d1e-7cbd-8953-d6fcbfcc8b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019b097a-6d1e-713a-82f1-758ad4cb4e18" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_019b097a-6d1e-7cbd-8953-d6fcbfcc8b2e" xlink:to="loc_srt_SegmentGeographicalDomain_019b097a-6d1e-713a-82f1-758ad4cb4e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_019b097a-6d1e-7bef-b06c-58daf5fef672" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019b097a-6d1e-713a-82f1-758ad4cb4e18" xlink:to="loc_country_GB_019b097a-6d1e-7bef-b06c-58daf5fef672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_019b097a-6d1e-7616-8ef7-da72928bf821" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019b097a-6d1e-72bc-a379-7c88096ae007" xlink:to="loc_srt_MajorCustomersAxis_019b097a-6d1e-7616-8ef7-da72928bf821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019b097a-6d1e-791f-8313-976c473c27c8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_019b097a-6d1e-7616-8ef7-da72928bf821" xlink:to="loc_srt_NameOfMajorCustomerDomain_019b097a-6d1e-791f-8313-976c473c27c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordUniversityInnovationMember_019b097a-6d1e-7611-a7bc-ea97fa9a01df" xlink:href="brns-20251231.xsd#brns_OxfordUniversityInnovationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_019b097a-6d1e-791f-8313-976c473c27c8" xlink:to="loc_brns_OxfordUniversityInnovationMember_019b097a-6d1e-7611-a7bc-ea97fa9a01df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_019b097a-6d1e-77b7-8661-3cc844e5e11f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019b097a-6d1e-72bc-a379-7c88096ae007" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_019b097a-6d1e-77b7-8661-3cc844e5e11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccountsReceivableStandardPaymentTermsPeriod_019b097a-6d1e-7f37-b12f-d539679d87c3" xlink:href="brns-20251231.xsd#brns_AccountsReceivableStandardPaymentTermsPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019b097a-6d1e-77b7-8661-3cc844e5e11f" xlink:to="loc_brns_AccountsReceivableStandardPaymentTermsPeriod_019b097a-6d1e-7f37-b12f-d539679d87c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ConcentrationRiskThresholdPercentage_019b097a-6d1e-7571-8465-ec5e6d5dd562" xlink:href="brns-20251231.xsd#brns_ConcentrationRiskThresholdPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019b097a-6d1e-77b7-8661-3cc844e5e11f" xlink:to="loc_brns_ConcentrationRiskThresholdPercentage_019b097a-6d1e-7571-8465-ec5e6d5dd562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesAllowanceforcreditlossesDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SummaryofSignificantAccountingPoliciesAllowanceforcreditlossesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesAllowanceforcreditlossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7577-abc0-78bf18fb0cca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_019ba4c4-d48e-7eb7-b71f-7f3ae24cad50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7577-abc0-78bf18fb0cca" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_019ba4c4-d48e-7eb7-b71f-7f3ae24cad50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-739e-b228-eeba61919c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019b097a-6d1e-7299-86ee-fe68b357bf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-739e-b228-eeba61919c8c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019b097a-6d1e-7299-86ee-fe68b357bf7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019b097a-6d1e-733e-9785-9d2d3674bd03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019b097a-6d1e-7299-86ee-fe68b357bf7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019b097a-6d1e-733e-9785-9d2d3674bd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-752a-b26f-33cb815b902b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019b097a-6d1e-733e-9785-9d2d3674bd03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-752a-b26f-33cb815b902b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_019b097a-6d1e-7d2c-8bff-7b92d2d6e6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-752a-b26f-33cb815b902b" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_019b097a-6d1e-7d2c-8bff-7b92d2d6e6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LaboratoryEquipmentMember_019b097a-6d1e-713c-bc7d-8fcf7e0779dd" xlink:href="brns-20251231.xsd#brns_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-752a-b26f-33cb815b902b" xlink:to="loc_brns_LaboratoryEquipmentMember_019b097a-6d1e-713c-bc7d-8fcf7e0779dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019b097a-6d1e-7d3d-933f-d54bcccf0dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019b097a-6d1e-7299-86ee-fe68b357bf7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019b097a-6d1e-7d3d-933f-d54bcccf0dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_019b097a-6d1e-7a37-a0ba-1adbe8440469" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019b097a-6d1e-7d3d-933f-d54bcccf0dcb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_019b097a-6d1e-7a37-a0ba-1adbe8440469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7834-a529-e98109a95be3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_019b097a-6d1e-7f83-b2bb-ab95bd825f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7834-a529-e98109a95be3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_019b097a-6d1e-7f83-b2bb-ab95bd825f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019b097a-6d1e-7588-a7e8-037a424718c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_019b097a-6d1e-7f83-b2bb-ab95bd825f5e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019b097a-6d1e-7588-a7e8-037a424718c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019b097a-6d1e-796d-87a7-055920f17ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019b097a-6d1e-7588-a7e8-037a424718c9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019b097a-6d1e-796d-87a7-055920f17ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_019b097a-6d1e-7206-8187-fdab1582c754" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019b097a-6d1e-796d-87a7-055920f17ea2" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_019b097a-6d1e-7206-8187-fdab1582c754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-76c4-95e7-7f0738b84c19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_019b097a-6d1e-7f83-b2bb-ab95bd825f5e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-76c4-95e7-7f0738b84c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_019b097a-6d1e-7a32-a2bd-24ce7219576c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-76c4-95e7-7f0738b84c19" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_019b097a-6d1e-7a32-a2bd-24ce7219576c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SummaryofSignificantAccountingPoliciesGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019cd88f-0a7f-777a-8a66-c139b04c98b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_019cd891-6a9a-7c1b-9b1d-0b4a0a83bdb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019cd88f-0a7f-777a-8a66-c139b04c98b4" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_019cd891-6a9a-7c1b-9b1d-0b4a0a83bdb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesFairvaluemeasurementsDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SummaryofSignificantAccountingPoliciesFairvaluemeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesFairvaluemeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019ba4e2-d048-7873-bd3d-777797630bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_019ba4e2-d048-7ac5-a876-155247869778" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019ba4e2-d048-7873-bd3d-777797630bb1" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_019ba4e2-d048-7ac5-a876-155247869778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesSharebasedcompensationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SummaryofSignificantAccountingPoliciesSharebasedcompensationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesSharebasedcompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7340-ad96-bace31d4e3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019b097a-6d1e-7563-a5a1-cabee607bd9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7340-ad96-bace31d4e3c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019b097a-6d1e-7563-a5a1-cabee607bd9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentIncentivesDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SummaryofSignificantAccountingPoliciesResearchandDevelopmentIncentivesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentIncentivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7c90-bda1-a8643e4cf907" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_019b097a-6d1e-79ea-b7c1-71eb260a07c3" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentIncentiveIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019b097a-6d1e-7c90-bda1-a8643e4cf907" xlink:to="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_019b097a-6d1e-79ea-b7c1-71eb260a07c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SegmentinformationAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SegmentinformationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SegmentinformationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019b097a-6d1e-70a2-8333-8d491ac2f785" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_019b097a-6d1e-782d-9eb9-9d992e902c07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019b097a-6d1e-70a2-8333-8d491ac2f785" xlink:to="loc_us-gaap_NumberOfOperatingSegments_019b097a-6d1e-782d-9eb9-9d992e902c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfReportableSegmentsNotDisclosedFlag_019ba4aa-9815-712a-be8e-ebbbb18c0df4" xlink:href="brns-20251231.xsd#brns_NumberOfReportableSegmentsNotDisclosedFlag"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019b097a-6d1e-70a2-8333-8d491ac2f785" xlink:to="loc_brns_NumberOfReportableSegmentsNotDisclosedFlag_019ba4aa-9815-712a-be8e-ebbbb18c0df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfGeographicRegionsInWhichEntityOperates_019c49dc-270b-70f7-b493-45f23c4a9c69" xlink:href="brns-20251231.xsd#brns_NumberOfGeographicRegionsInWhichEntityOperates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019b097a-6d1e-70a2-8333-8d491ac2f785" xlink:to="loc_brns_NumberOfGeographicRegionsInWhichEntityOperates_019c49dc-270b-70f7-b493-45f23c4a9c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SegmentinformationSignificantSegmentExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019b097a-6d1e-736d-b6ca-078570805e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019b097a-6d1e-787b-96a5-477d3d0c80e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019b097a-6d1e-736d-b6ca-078570805e4a" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019b097a-6d1e-787b-96a5-477d3d0c80e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019b097a-6d1e-7c9d-bb27-b8e0ba723f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019b097a-6d1e-787b-96a5-477d3d0c80e9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019b097a-6d1e-7c9d-bb27-b8e0ba723f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019b097a-6d1e-7d8a-b3a3-0e314f07f281" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019b097a-6d1e-7c9d-bb27-b8e0ba723f2b" xlink:to="loc_us-gaap_SegmentDomain_019b097a-6d1e-7d8a-b3a3-0e314f07f281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember_019b097a-6d1e-7870-a9bd-bb374b574ebd" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019b097a-6d1e-7d8a-b3a3-0e314f07f281" xlink:to="loc_brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember_019b097a-6d1e-7870-a9bd-bb374b574ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019b097a-6d1e-7aa5-b07e-3ba71c761bfc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019b097a-6d1e-787b-96a5-477d3d0c80e9" xlink:to="loc_srt_ProductOrServiceAxis_019b097a-6d1e-7aa5-b07e-3ba71c761bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019b097a-6d1e-79b2-a4e3-f48061feeacf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019b097a-6d1e-7aa5-b07e-3ba71c761bfc" xlink:to="loc_srt_ProductsAndServicesDomain_019b097a-6d1e-79b2-a4e3-f48061feeacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_VTP1000CeliacMember_019b097a-6d1e-7263-a6e0-1d8435d7db1b" xlink:href="brns-20251231.xsd#brns_VTP1000CeliacMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019b097a-6d1e-79b2-a4e3-f48061feeacf" xlink:to="loc_brns_VTP1000CeliacMember_019b097a-6d1e-7263-a6e0-1d8435d7db1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_BarinthusLegacyAssetsMember_019c7024-2e3a-7d09-9b29-df61f4541100" xlink:href="brns-20251231.xsd#brns_BarinthusLegacyAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019b097a-6d1e-79b2-a4e3-f48061feeacf" xlink:to="loc_brns_BarinthusLegacyAssetsMember_019c7024-2e3a-7d09-9b29-df61f4541100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentTypeAxis_019b097a-6d1e-7229-be11-b2374e824bbe" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019b097a-6d1e-787b-96a5-477d3d0c80e9" xlink:to="loc_brns_ResearchAndDevelopmentTypeAxis_019b097a-6d1e-7229-be11-b2374e824bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentTypeDomain_019b097a-6d1e-763d-8ed3-cb6e2c1256ac" xlink:href="brns-20251231.xsd#brns_ResearchAndDevelopmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_ResearchAndDevelopmentTypeAxis_019b097a-6d1e-7229-be11-b2374e824bbe" xlink:to="loc_brns_ResearchAndDevelopmentTypeDomain_019b097a-6d1e-763d-8ed3-cb6e2c1256ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PersonnelRelatedMember_019b097a-6d1e-75c7-b9af-faf97de4c8de" xlink:href="brns-20251231.xsd#brns_PersonnelRelatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_ResearchAndDevelopmentTypeDomain_019b097a-6d1e-763d-8ed3-cb6e2c1256ac" xlink:to="loc_brns_PersonnelRelatedMember_019b097a-6d1e-75c7-b9af-faf97de4c8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FacilityRelatedMember_019b097a-6d1e-7304-b9e0-5e71948b0128" xlink:href="brns-20251231.xsd#brns_FacilityRelatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_ResearchAndDevelopmentTypeDomain_019b097a-6d1e-763d-8ed3-cb6e2c1256ac" xlink:to="loc_brns_FacilityRelatedMember_019b097a-6d1e-7304-b9e0-5e71948b0128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OtherIndirectCostsMember_019b097a-6d1e-74d9-b8e5-e6ea9448fc8b" xlink:href="brns-20251231.xsd#brns_OtherIndirectCostsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_ResearchAndDevelopmentTypeDomain_019b097a-6d1e-763d-8ed3-cb6e2c1256ac" xlink:to="loc_brns_OtherIndirectCostsMember_019b097a-6d1e-74d9-b8e5-e6ea9448fc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_019b097a-6d1e-79e6-a249-433fe27f4ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_019b097a-6d1e-787b-96a5-477d3d0c80e9" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_019b097a-6d1e-79e6-a249-433fe27f4ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DirectResearchAndDevelopmentExpensesAbstract_019b097a-6d1e-7f18-89a8-50bb8ab3e593" xlink:href="brns-20251231.xsd#brns_DirectResearchAndDevelopmentExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019b097a-6d1e-79e6-a249-433fe27f4ddc" xlink:to="loc_brns_DirectResearchAndDevelopmentExpensesAbstract_019b097a-6d1e-7f18-89a8-50bb8ab3e593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DirectResearchAndDevelopmentExpense_019b097a-6d1e-7400-acde-172102e95e8a" xlink:href="brns-20251231.xsd#brns_DirectResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_DirectResearchAndDevelopmentExpensesAbstract_019b097a-6d1e-7f18-89a8-50bb8ab3e593" xlink:to="loc_brns_DirectResearchAndDevelopmentExpense_019b097a-6d1e-7400-acde-172102e95e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IndirectResearchAndDevelopmentExpensesAbstract_019b097a-6d1e-7468-9937-cef8196ceab2" xlink:href="brns-20251231.xsd#brns_IndirectResearchAndDevelopmentExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019b097a-6d1e-79e6-a249-433fe27f4ddc" xlink:to="loc_brns_IndirectResearchAndDevelopmentExpensesAbstract_019b097a-6d1e-7468-9937-cef8196ceab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IndirectResearchAndDevelopmentExpense_019b097a-6d1e-7c0c-aa82-526db3dc6ed4" xlink:href="brns-20251231.xsd#brns_IndirectResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_IndirectResearchAndDevelopmentExpensesAbstract_019b097a-6d1e-7468-9937-cef8196ceab2" xlink:to="loc_brns_IndirectResearchAndDevelopmentExpense_019b097a-6d1e-7c0c-aa82-526db3dc6ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019b097a-6d1e-7196-910c-2b2639072b56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019b097a-6d1e-79e6-a249-433fe27f4ddc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019b097a-6d1e-7196-910c-2b2639072b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SegmentinformationLongLivedAssetsDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SegmentinformationLongLivedAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SegmentinformationLongLivedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019b097a-6d1e-7bfa-a0e8-5ebee0bbd46a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019b097a-6d1e-7462-85ae-040846c2fba0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019b097a-6d1e-7bfa-a0e8-5ebee0bbd46a" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019b097a-6d1e-7462-85ae-040846c2fba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_019b097a-6d1e-79b2-9860-e124a60d49ee" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019b097a-6d1e-7462-85ae-040846c2fba0" xlink:to="loc_srt_StatementGeographicalAxis_019b097a-6d1e-79b2-9860-e124a60d49ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019b097a-6d1e-731a-ad42-4a3ad763dc3d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_019b097a-6d1e-79b2-9860-e124a60d49ee" xlink:to="loc_srt_SegmentGeographicalDomain_019b097a-6d1e-731a-ad42-4a3ad763dc3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019b097a-6d1e-79fc-8ae4-e5d3db1d0b68" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019b097a-6d1e-731a-ad42-4a3ad763dc3d" xlink:to="loc_country_US_019b097a-6d1e-79fc-8ae4-e5d3db1d0b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_019b097a-6d1e-737f-baf3-7fa96bc7384b" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019b097a-6d1e-731a-ad42-4a3ad763dc3d" xlink:to="loc_country_GB_019b097a-6d1e-737f-baf3-7fa96bc7384b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_019b097a-6d1e-70d5-807e-6b1af7ccd280" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019b097a-6d1e-7462-85ae-040846c2fba0" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_019b097a-6d1e-70d5-807e-6b1af7ccd280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_019b097a-6d1e-78e4-8fc0-40332e8f41f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_019b097a-6d1e-70d5-807e-6b1af7ccd280" xlink:to="loc_us-gaap_NoncurrentAssets_019b097a-6d1e-78e4-8fc0-40332e8f41f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyAbstract_019b097a-6d1e-73d1-985c-778f61fa0aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_019b097a-6d1e-7465-abfc-39255eefd437" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignCurrencyAbstract_019b097a-6d1e-73d1-985c-778f61fa0aa4" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_019b097a-6d1e-7465-abfc-39255eefd437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NetLossPerShareComputationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#NetLossPerShareComputationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/NetLossPerShareComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019b097a-6d1e-7902-afae-1f81ecd3088a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_019b097a-6d1e-7b9e-83ba-cb42b11a73fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019b097a-6d1e-7902-afae-1f81ecd3088a" xlink:to="loc_us-gaap_NetIncomeLossAbstract_019b097a-6d1e-7b9e-83ba-cb42b11a73fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019b097a-6d1e-7a47-bb1b-df1e50c39e72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_019b097a-6d1e-7b9e-83ba-cb42b11a73fc" xlink:to="loc_us-gaap_ProfitLoss_019b097a-6d1e-7a47-bb1b-df1e50c39e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019b097a-6d1e-7d3b-ab0e-fcc149f1fb34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_019b097a-6d1e-7b9e-83ba-cb42b11a73fc" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_019b097a-6d1e-7d3b-ab0e-fcc149f1fb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019b097a-6d1e-7984-8392-78aa866268c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_019b097a-6d1e-7b9e-83ba-cb42b11a73fc" xlink:to="loc_us-gaap_NetIncomeLoss_019b097a-6d1e-7984-8392-78aa866268c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019b097a-6d1e-792d-80e6-e07ae9f1a599" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019b097a-6d1e-7902-afae-1f81ecd3088a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019b097a-6d1e-792d-80e6-e07ae9f1a599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019b097a-6d1e-7de2-b51d-0d7607b96465" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019b097a-6d1e-792d-80e6-e07ae9f1a599" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019b097a-6d1e-7de2-b51d-0d7607b96465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019b097a-6d1e-72ce-9df0-727f7eea1a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019b097a-6d1e-792d-80e6-e07ae9f1a599" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019b097a-6d1e-72ce-9df0-727f7eea1a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019b097a-6d1e-7e6b-a6c6-f671ceec02ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019b097a-6d1e-792d-80e6-e07ae9f1a599" xlink:to="loc_us-gaap_EarningsPerShareBasic_019b097a-6d1e-7e6b-a6c6-f671ceec02ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019b097a-6d1e-7e08-a39d-da1bf9ba3a19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019b097a-6d1e-792d-80e6-e07ae9f1a599" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019b097a-6d1e-7e08-a39d-da1bf9ba3a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NetLossPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#NetLossPerShareAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/NetLossPerShareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019b097a-6d1e-7890-9618-18e654dcdc3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019b097a-6d1e-7b6d-9bdd-de10ce452c83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019b097a-6d1e-7890-9618-18e654dcdc3e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019b097a-6d1e-7b6d-9bdd-de10ce452c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#PropertyandEquipmentNetComponentsDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019b097a-6d1e-7a9f-a578-0533077c536a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019b097a-6d1e-751f-a713-14b20e8815f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019b097a-6d1e-7a9f-a578-0533077c536a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019b097a-6d1e-751f-a713-14b20e8815f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019b097a-6d1e-7c54-a0a9-b90a375cbe6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019b097a-6d1e-751f-a713-14b20e8815f7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019b097a-6d1e-7c54-a0a9-b90a375cbe6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-7f13-834b-75b5d4375d33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019b097a-6d1e-7c54-a0a9-b90a375cbe6d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-7f13-834b-75b5d4375d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_019b097a-6d1e-7d21-8633-ca09b84446bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-7f13-834b-75b5d4375d33" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_019b097a-6d1e-7d21-8633-ca09b84446bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LaboratoryEquipmentMember_019b097a-6d1e-711c-8695-15757c8667a4" xlink:href="brns-20251231.xsd#brns_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-7f13-834b-75b5d4375d33" xlink:to="loc_brns_LaboratoryEquipmentMember_019b097a-6d1e-711c-8695-15757c8667a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_019b097a-6d1e-7125-a1ac-3c1adb1a3345" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019b097a-6d1e-7f13-834b-75b5d4375d33" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_019b097a-6d1e-7125-a1ac-3c1adb1a3345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019b097a-6d1e-7460-923c-3b756f8d0d63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019b097a-6d1e-751f-a713-14b20e8815f7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019b097a-6d1e-7460-923c-3b756f8d0d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_019b097a-6d1e-7839-9db9-397247adac57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019b097a-6d1e-7460-923c-3b756f8d0d63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_019b097a-6d1e-7839-9db9-397247adac57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019b097a-6d1e-7d55-9566-e46a43bec29a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019b097a-6d1e-7460-923c-3b756f8d0d63" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019b097a-6d1e-7d55-9566-e46a43bec29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019b097a-6d1e-77e5-894b-ccf5cfa9b56d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019b097a-6d1e-7460-923c-3b756f8d0d63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019b097a-6d1e-77e5-894b-ccf5cfa9b56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNetAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#PropertyandEquipmentNetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/PropertyandEquipmentNetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019b097a-6d1e-71bd-9b13-b6acfa9b8520" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_019b097a-6d1e-70de-8c19-5588f4f516ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019b097a-6d1e-71bd-9b13-b6acfa9b8520" xlink:to="loc_us-gaap_Depreciation_019b097a-6d1e-70de-8c19-5588f4f516ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_019bd5e7-b1d9-7ff9-8718-bfc6036e8459" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019b097a-6d1e-71bd-9b13-b6acfa9b8520" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_019bd5e7-b1d9-7ff9-8718-bfc6036e8459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_019bd5e7-b1d9-7f8e-9fed-5e771326bcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019b097a-6d1e-71bd-9b13-b6acfa9b8520" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_019bd5e7-b1d9-7f8e-9fed-5e771326bcbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_019c49ac-57b1-7633-aa06-56e2e7126eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019b097a-6d1e-71bd-9b13-b6acfa9b8520" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_019c49ac-57b1-7633-aa06-56e2e7126eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IntangibleAssetsNetDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#IntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/IntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_019b097a-6d1e-7885-9acc-d22d3464fbac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_019b097a-6d1e-7839-b43e-5d0f6b288446" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_019b097a-6d1e-7885-9acc-d22d3464fbac" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_019b097a-6d1e-7839-b43e-5d0f6b288446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019b097a-6d1e-79bd-ac97-aad2750e8944" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_019b097a-6d1e-7839-b43e-5d0f6b288446" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019b097a-6d1e-79bd-ac97-aad2750e8944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019b097a-6d1e-742f-befe-a883720c1e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019b097a-6d1e-79bd-ac97-aad2750e8944" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019b097a-6d1e-742f-befe-a883720c1e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_019b097a-6d1e-7a48-87d0-c0e55473a7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019b097a-6d1e-742f-befe-a883720c1e7a" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_019b097a-6d1e-7a48-87d0-c0e55473a7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_019b097a-6d1e-7839-b43e-5d0f6b288446" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_019b097a-6d1e-7e8f-aa9f-da5663117626" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_019b097a-6d1e-7e8f-aa9f-da5663117626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_019b097a-6d1e-7019-ae0a-0b1c17881c02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_019b097a-6d1e-7019-ae0a-0b1c17881c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_019b097a-6d1e-79c3-9b6d-d63db4032ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_019b097a-6d1e-79c3-9b6d-d63db4032ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_019b097a-6d1e-7a60-95af-5a1216142414" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_019b097a-6d1e-7a60-95af-5a1216142414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_019b097a-6d1e-7de6-a1f0-584b383623fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_019b097a-6d1e-7de6-a1f0-584b383623fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_019b097a-6d1e-7656-aa4d-741b37f9580a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_019b097a-6d1e-7656-aa4d-741b37f9580a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_019b097a-6d1e-747d-9c64-fa01da012ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_019b097a-6d1e-747d-9c64-fa01da012ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_019b097a-6d1e-7b49-ae54-34e318b65fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_019b097a-6d1e-7b49-ae54-34e318b65fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix_019b097a-6d1e-7723-b1c0-3fefc10c0c86" xlink:href="brns-20251231.xsd#brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:to="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix_019b097a-6d1e-7723-b1c0-3fefc10c0c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_019b097a-6d1e-72a6-99bf-9b889c015325" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_019b097a-6d1e-7f73-b39d-739315a0ce34" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_019b097a-6d1e-72a6-99bf-9b889c015325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#PrepaidandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_019b097a-6d1e-71e9-bfaa-13904ba6e542" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_019b097a-6d1e-7648-82e8-77198ded3547" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_019b097a-6d1e-71e9-bfaa-13904ba6e542" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_019b097a-6d1e-7648-82e8-77198ded3547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_019b097a-6d1e-71d1-a074-1f453e33e17b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_019b097a-6d1e-71e9-bfaa-13904ba6e542" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_019b097a-6d1e-71d1-a074-1f453e33e17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_019b097a-6d1e-76dd-9cc3-ce52cbf8da37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_019b097a-6d1e-71e9-bfaa-13904ba6e542" xlink:to="loc_us-gaap_OtherAssetsCurrent_019b097a-6d1e-76dd-9cc3-ce52cbf8da37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019b097a-6d1e-76b1-a58d-027b75ad3293" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_019b097a-6d1e-71e9-bfaa-13904ba6e542" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019b097a-6d1e-76b1-a58d-027b75ad3293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019b097a-6d1e-7e68-9e54-39fb3b94d26a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedManufacturingAndClinicalExpensesCurrent_019b097a-6d1e-77dc-b0b1-41af82b55646" xlink:href="brns-20251231.xsd#brns_AccruedManufacturingAndClinicalExpensesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019b097a-6d1e-7e68-9e54-39fb3b94d26a" xlink:to="loc_brns_AccruedManufacturingAndClinicalExpensesCurrent_019b097a-6d1e-77dc-b0b1-41af82b55646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_019b097a-6d1e-781d-80f7-e3696608968a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019b097a-6d1e-7e68-9e54-39fb3b94d26a" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_019b097a-6d1e-781d-80f7-e3696608968a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_019b097a-6d1e-7a56-a4b6-f0817b693ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019b097a-6d1e-7e68-9e54-39fb3b94d26a" xlink:to="loc_us-gaap_AccruedBonusesCurrent_019b097a-6d1e-7a56-a4b6-f0817b693ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_019b097a-6d1e-77aa-b869-1b3fda404767" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019b097a-6d1e-7e68-9e54-39fb3b94d26a" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_019b097a-6d1e-77aa-b869-1b3fda404767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_019b097a-6d1e-7095-84ba-ee364b2379ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019b097a-6d1e-7e68-9e54-39fb3b94d26a" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_019b097a-6d1e-7095-84ba-ee364b2379ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019b097a-6d1e-75d1-aaa3-c97b7187cc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019b097a-6d1e-7e68-9e54-39fb3b94d26a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019b097a-6d1e-75d1-aaa3-c97b7187cc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019b097a-6d1e-7027-ac9e-386b7e18b807" xlink:href="brns-20251231.xsd#brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019b097a-6d1e-7e68-9e54-39fb3b94d26a" xlink:to="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_019b097a-6d1e-7027-ac9e-386b7e18b807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#GrantIncomeAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7b8f-b90e-707d864b6623" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019b097a-6d1e-74fc-8f1f-e1ad3541ebf4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7b8f-b90e-707d864b6623" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019b097a-6d1e-74fc-8f1f-e1ad3541ebf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019b097a-6d1e-79b6-9b89-f2c20822a20e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019b097a-6d1e-74fc-8f1f-e1ad3541ebf4" xlink:to="loc_srt_CounterpartyNameAxis_019b097a-6d1e-79b6-9b89-f2c20822a20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019b097a-6d1e-704f-850d-a08510c5f753" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_019b097a-6d1e-79b6-9b89-f2c20822a20e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019b097a-6d1e-704f-850d-a08510c5f753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_CoalitionForEpidemicPreparednessInnovationsMember_019b097a-6d1e-7df3-983d-28577f2c558a" xlink:href="brns-20251231.xsd#brns_CoalitionForEpidemicPreparednessInnovationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019b097a-6d1e-704f-850d-a08510c5f753" xlink:to="loc_brns_CoalitionForEpidemicPreparednessInnovationsMember_019b097a-6d1e-7df3-983d-28577f2c558a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019b097a-6d1e-7beb-8ccc-659561bfabad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019b097a-6d1e-74fc-8f1f-e1ad3541ebf4" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019b097a-6d1e-7beb-8ccc-659561bfabad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FundingAmountMaximum_019b097a-6d1e-703a-8f65-09748f22ab16" xlink:href="brns-20251231.xsd#brns_FundingAmountMaximum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019b097a-6d1e-7beb-8ccc-659561bfabad" xlink:to="loc_brns_FundingAmountMaximum_019b097a-6d1e-703a-8f65-09748f22ab16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeAddition_019b097a-6d1e-7620-a0da-d3ad0cc2b300" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeAddition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019b097a-6d1e-7beb-8ccc-659561bfabad" xlink:to="loc_us-gaap_DeferredIncomeAddition_019b097a-6d1e-7620-a0da-d3ad0cc2b300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeRevenueRecognized_019b097a-6d1e-7e52-8aac-511295e9c52c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019b097a-6d1e-7beb-8ccc-659561bfabad" xlink:to="loc_us-gaap_DeferredIncomeRevenueRecognized_019b097a-6d1e-7e52-8aac-511295e9c52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_019b097a-6d1e-7328-bf5c-1b2f3fcdcd82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019b097a-6d1e-7beb-8ccc-659561bfabad" xlink:to="loc_us-gaap_RestrictedCashCurrent_019b097a-6d1e-7328-bf5c-1b2f3fcdcd82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/GrantIncomeChangesinDeferredIncomeDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#GrantIncomeChangesinDeferredIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/GrantIncomeChangesinDeferredIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7c66-8098-9c0b88fcdfcf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeRollForward_019b097a-6d1e-78e2-9e6c-b964debbeecf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_019b097a-6d1e-7c66-8098-9c0b88fcdfcf" xlink:to="loc_us-gaap_DeferredIncomeRollForward_019b097a-6d1e-78e2-9e6c-b964debbeecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncome_019b097a-6d1e-7c78-85cd-b715ee14f62e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeRollForward_019b097a-6d1e-78e2-9e6c-b964debbeecf" xlink:to="loc_us-gaap_DeferredIncome_019b097a-6d1e-7c78-85cd-b715ee14f62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeAddition_019b097a-6d1e-7333-b1d8-275a79667883" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeAddition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeRollForward_019b097a-6d1e-78e2-9e6c-b964debbeecf" xlink:to="loc_us-gaap_DeferredIncomeAddition_019b097a-6d1e-7333-b1d8-275a79667883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeRevenueRecognized_019b097a-6d1e-7956-baf8-66ae5ee660a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeRollForward_019b097a-6d1e-78e2-9e6c-b964debbeecf" xlink:to="loc_us-gaap_DeferredIncomeRevenueRecognized_019b097a-6d1e-7956-baf8-66ae5ee660a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredIncomeForeignExchangeTranslationGainLoss_019b097a-6d1e-7b4e-851f-bdc096087583" xlink:href="brns-20251231.xsd#brns_DeferredIncomeForeignExchangeTranslationGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeRollForward_019b097a-6d1e-78e2-9e6c-b964debbeecf" xlink:to="loc_brns_DeferredIncomeForeignExchangeTranslationGainLoss_019b097a-6d1e-7b4e-851f-bdc096087583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncome_019b097a-6d1e-7279-a6ab-e09399e9c3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeRollForward_019b097a-6d1e-78e2-9e6c-b964debbeecf" xlink:to="loc_us-gaap_DeferredIncome_019b097a-6d1e-7279-a6ab-e09399e9c3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#OrdinarySharesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019b097a-6d1e-76c6-977b-7a4d300f770e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_019b097a-6d1e-78d1-831b-1af4752505ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019b097a-6d1e-76c6-977b-7a4d300f770e" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_019b097a-6d1e-78d1-831b-1af4752505ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019b097a-6d1e-7d31-b01a-f8b8ec44888e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_019b097a-6d1e-78d1-831b-1af4752505ce" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019b097a-6d1e-7d31-b01a-f8b8ec44888e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019b097a-6d1e-7702-ab8c-dc36677b0e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019b097a-6d1e-7d31-b01a-f8b8ec44888e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019b097a-6d1e-7702-ab8c-dc36677b0e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_019b097a-6d1e-717e-9a71-0fb2024da8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019b097a-6d1e-7702-ab8c-dc36677b0e7d" xlink:to="loc_us-gaap_IPOMember_019b097a-6d1e-717e-9a71-0fb2024da8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_019b097a-6d1e-7434-ad80-1308245c605f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_019b097a-6d1e-78d1-831b-1af4752505ce" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_019b097a-6d1e-7434-ad80-1308245c605f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_CommonStockNumberOfVotesPerShare_019b097a-6d1e-7847-90ff-f062badf4425" xlink:href="brns-20251231.xsd#brns_CommonStockNumberOfVotesPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_019b097a-6d1e-7434-ad80-1308245c605f" xlink:to="loc_brns_CommonStockNumberOfVotesPerShare_019b097a-6d1e-7847-90ff-f062badf4425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights_019b097a-6d1e-7722-a599-43c6c8e74d24" xlink:href="brns-20251231.xsd#brns_PercentageOfSharesNecessaryToExercisePreemptiveRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_019b097a-6d1e-7434-ad80-1308245c605f" xlink:to="loc_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights_019b097a-6d1e-7722-a599-43c6c8e74d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PeriodOfPreemptiveRightsToBeExercised_019b097a-6d1e-70bc-9fbc-c06d87ccb7c3" xlink:href="brns-20251231.xsd#brns_PeriodOfPreemptiveRightsToBeExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_019b097a-6d1e-7434-ad80-1308245c605f" xlink:to="loc_brns_PeriodOfPreemptiveRightsToBeExercised_019b097a-6d1e-70bc-9fbc-c06d87ccb7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights_019b097a-6d1e-708e-a8c4-e305446ca79b" xlink:href="brns-20251231.xsd#brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_019b097a-6d1e-7434-ad80-1308245c605f" xlink:to="loc_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights_019b097a-6d1e-708e-a8c4-e305446ca79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/OrdinarySharesOrdinarySharesforFutureIssuanceDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#OrdinarySharesOrdinarySharesforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/OrdinarySharesOrdinarySharesforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019b097a-6d1e-7494-928c-bc91ee6c868b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b097a-6d1e-7085-8c62-4eec001aa922" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019b097a-6d1e-7494-928c-bc91ee6c868b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b097a-6d1e-7085-8c62-4eec001aa922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019b097a-6d1e-7e47-96e4-959cef42ed46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019b097a-6d1e-7494-928c-bc91ee6c868b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019b097a-6d1e-7e47-96e4-959cef42ed46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019b097a-6d1e-75b7-8752-e1f5ae4021c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019b097a-6d1e-7494-928c-bc91ee6c868b" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019b097a-6d1e-75b7-8752-e1f5ae4021c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/DeferredSharesDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#DeferredSharesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/DeferredSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019b097a-6e6b-7e7c-b49f-d7264bcfeb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OrdinarySharesLiquidationPreference_019b097a-6e6b-716b-90cb-352a7f17c40b" xlink:href="brns-20251231.xsd#brns_OrdinarySharesLiquidationPreference"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019b097a-6e6b-7e7c-b49f-d7264bcfeb2a" xlink:to="loc_brns_OrdinarySharesLiquidationPreference_019b097a-6e6b-716b-90cb-352a7f17c40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockParOrStatedValuePerShare_019b097a-6e6b-7b00-a8eb-e8f8931342ef" xlink:href="brns-20251231.xsd#brns_DeferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019b097a-6e6b-7e7c-b49f-d7264bcfeb2a" xlink:to="loc_brns_DeferredStockParOrStatedValuePerShare_019b097a-6e6b-7b00-a8eb-e8f8931342ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#FairValueAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019b097a-6e6b-799d-87ca-0d6c8025b24c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019b097a-6e6b-78a3-8801-d042e5a0bf58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019b097a-6e6b-799d-87ca-0d6c8025b24c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019b097a-6e6b-78a3-8801-d042e5a0bf58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_019b097a-6e6b-767c-9cf7-8a9b8b8bbaa6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019b097a-6e6b-78a3-8801-d042e5a0bf58" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_019b097a-6e6b-767c-9cf7-8a9b8b8bbaa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019b097a-6e6b-771e-a378-7b0ff2eb0336" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019b097a-6e6b-767c-9cf7-8a9b8b8bbaa6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019b097a-6e6b-771e-a378-7b0ff2eb0336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AvideaMember_019b097a-6e6b-7cc9-81aa-d581a61102bc" xlink:href="brns-20251231.xsd#brns_AvideaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019b097a-6e6b-771e-a378-7b0ff2eb0336" xlink:to="loc_brns_AvideaMember_019b097a-6e6b-7cc9-81aa-d581a61102bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019b097a-6e6b-786c-9702-b0227c9e6567" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_019b097a-6e6b-78a3-8801-d042e5a0bf58" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019b097a-6e6b-786c-9702-b0227c9e6567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019b097a-6e6b-7ca5-8e89-1c3e86124cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019b097a-6e6b-786c-9702-b0227c9e6567" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019b097a-6e6b-7ca5-8e89-1c3e86124cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_019b097a-6e6b-7366-9cd6-6f4b5de7b26a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019b097a-6e6b-786c-9702-b0227c9e6567" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_019b097a-6e6b-7366-9cd6-6f4b5de7b26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_019b097a-6e6b-71a6-8a92-473fa2f5da3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_019b097a-6e6b-786c-9702-b0227c9e6567" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_019b097a-6e6b-71a6-8a92-473fa2f5da3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedWithinLevel3Details" xlink:type="simple" xlink:href="brns-20251231.xsd#FairValueChangeinFinancialInstrumentsClassifiedWithinLevel3Details"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedWithinLevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019b097a-6e6b-71a7-be0c-93b274fc4413" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019b097a-6e6b-7c66-8d9e-6380428e4d42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019b097a-6e6b-71a7-be0c-93b274fc4413" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019b097a-6e6b-7c66-8d9e-6380428e4d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019b097a-6e6b-7774-99cf-64c409e987a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019b097a-6e6b-7c66-8d9e-6380428e4d42" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019b097a-6e6b-7774-99cf-64c409e987a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019b097a-6e6b-790a-b6f7-63fb1bb30cde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019b097a-6e6b-7c66-8d9e-6380428e4d42" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019b097a-6e6b-790a-b6f7-63fb1bb30cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_019b097a-6e6b-7a53-8e7b-4f19bd1a4b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019b097a-6e6b-7c66-8d9e-6380428e4d42" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_019b097a-6e6b-7a53-8e7b-4f19bd1a4b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019b097a-6e6b-7344-9a2d-46c333f3391b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_019b097a-6e6b-7c66-8d9e-6380428e4d42" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019b097a-6e6b-7344-9a2d-46c333f3391b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList_019b097a-6e6b-784a-be6f-b8ae63c8e54b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019b097a-6e6b-71a7-be0c-93b274fc4413" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList_019b097a-6e6b-784a-be6f-b8ae63c8e54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b097a-6e6b-73df-8576-444bbb915f80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6b-74e5-9ccc-21f329d913c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b097a-6e6b-73df-8576-444bbb915f80" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6b-74e5-9ccc-21f329d913c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019b097a-6e6b-7014-9c90-43b3d5ae94ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6b-74e5-9ccc-21f329d913c5" xlink:to="loc_us-gaap_PlanNameAxis_019b097a-6e6b-7014-9c90-43b3d5ae94ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019b097a-6e6b-7399-8a6b-d711f5003bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_019b097a-6e6b-7014-9c90-43b3d5ae94ed" xlink:to="loc_us-gaap_PlanNameDomain_019b097a-6e6b-7399-8a6b-d711f5003bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_019b097a-6e6b-7ced-b320-6f52ac694530" xlink:href="brns-20251231.xsd#brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019b097a-6e6b-7399-8a6b-d711f5003bbf" xlink:to="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_019b097a-6e6b-7ced-b320-6f52ac694530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_019b097a-6e6b-7aad-9cf9-7043cac7c27f" xlink:href="brns-20251231.xsd#brns_EnterpriseManagementIncentiveShareOptionSchemeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019b097a-6e6b-7399-8a6b-d711f5003bbf" xlink:to="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_019b097a-6e6b-7aad-9cf9-7043cac7c27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019b097a-6e6b-751e-b118-62a6b4d0a0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6b-74e5-9ccc-21f329d913c5" xlink:to="loc_us-gaap_AwardTypeAxis_019b097a-6e6b-751e-b118-62a6b4d0a0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b097a-6e6b-7832-80cb-8899136044ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019b097a-6e6b-751e-b118-62a6b4d0a0c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b097a-6e6b-7832-80cb-8899136044ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_019b097a-6e6b-7843-ac9f-390ce6386de1" xlink:href="brns-20251231.xsd#brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b097a-6e6b-7832-80cb-8899136044ed" xlink:to="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_019b097a-6e6b-7843-ac9f-390ce6386de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019b097a-6e6b-7723-af3f-ee4c7e0e0b82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b097a-6e6b-7832-80cb-8899136044ed" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019b097a-6e6b-7723-af3f-ee4c7e0e0b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019b097a-6e6b-7283-bcd2-3ecde3f62b74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b097a-6e6b-7832-80cb-8899136044ed" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019b097a-6e6b-7283-bcd2-3ecde3f62b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6b-74e5-9ccc-21f329d913c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019b097a-6e6b-79d7-a070-15d1add87b40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019b097a-6e6b-79d7-a070-15d1add87b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_019b097a-6e6b-70f9-8cd7-cdded369fc27" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_019b097a-6e6b-70f9-8cd7-cdded369fc27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019b097a-6e6b-73e7-b5c2-01a53e0fb3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019b097a-6e6b-73e7-b5c2-01a53e0fb3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance_019b097a-6e6b-7de0-a010-45c2e9ee57a2" xlink:href="brns-20251231.xsd#brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance_019b097a-6e6b-7de0-a010-45c2e9ee57a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019b097a-6e6b-7e12-be71-381aa1df9d88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019b097a-6e6b-7e12-be71-381aa1df9d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b097a-6e6b-70c8-82a0-cbdf29c5aafe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b097a-6e6b-70c8-82a0-cbdf29c5aafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019b097a-6e6b-7840-86b5-7fc2e453cc54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019b097a-6e6b-7840-86b5-7fc2e453cc54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019b097a-6e6c-7307-9739-1bcaeb2f8f45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019b097a-6e6c-7307-9739-1bcaeb2f8f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019b097a-6e6c-7888-8a66-6d6cbf338007" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019b097a-6e6c-7888-8a66-6d6cbf338007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019b097a-6e6c-76df-8547-1a41acab3f15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019b097a-6e6c-76df-8547-1a41acab3f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019b097a-6e6c-7cea-a5ca-d5cf740f4dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019b097a-6e6c-7cea-a5ca-d5cf740f4dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019b097a-6e6c-73e2-a2c0-7d93227f6dab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019b097a-6e6c-73e2-a2c0-7d93227f6dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019bd65e-a226-7fcc-a8c2-b2bea8f7d0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019bd65e-a226-7fcc-a8c2-b2bea8f7d0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019bd65e-a226-7e96-a2a5-54e010d5b944" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019bd65e-a226-7e96-a2a5-54e010d5b944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019c2859-1a83-7558-9aa4-7b86ed1e4820" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019c2859-1a83-7558-9aa4-7b86ed1e4820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_019c2859-1a83-7d6c-b3c6-9b829f794c81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6b-7e76-adbe-13d2564a7a4a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_019c2859-1a83-7d6c-b3c6-9b829f794c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#ShareBasedCompensationWeightedaverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b097a-6e6c-741b-9692-c72e0f0cf958" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6c-79ef-b12d-bff457eb9252" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b097a-6e6c-741b-9692-c72e0f0cf958" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6c-79ef-b12d-bff457eb9252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019b097a-6e6c-7336-b18c-9ec93e4100bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6c-79ef-b12d-bff457eb9252" xlink:to="loc_us-gaap_PlanNameAxis_019b097a-6e6c-7336-b18c-9ec93e4100bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019b097a-6e6c-70e5-8037-6ca10f64fa1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_019b097a-6e6c-7336-b18c-9ec93e4100bb" xlink:to="loc_us-gaap_PlanNameDomain_019b097a-6e6c-70e5-8037-6ca10f64fa1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_019b097a-6e6c-7cb7-810a-05ea4a63ba30" xlink:href="brns-20251231.xsd#brns_EnterpriseManagementIncentiveShareOptionSchemeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019b097a-6e6c-70e5-8037-6ca10f64fa1c" xlink:to="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_019b097a-6e6c-7cb7-810a-05ea4a63ba30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6c-75c1-8c60-30b90da9a62d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6c-79ef-b12d-bff457eb9252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6c-75c1-8c60-30b90da9a62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019b097a-6e6c-7c88-82bd-b33750776f34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6c-75c1-8c60-30b90da9a62d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019b097a-6e6c-7c88-82bd-b33750776f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019b097a-6e6c-72b5-9433-315c3a27b0de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6c-75c1-8c60-30b90da9a62d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019b097a-6e6c-72b5-9433-315c3a27b0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019b097a-6e6c-787a-a515-6f35cce7bbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6c-75c1-8c60-30b90da9a62d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019b097a-6e6c-787a-a515-6f35cce7bbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019b097a-6e6c-75f0-9e10-26fc3837275e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6c-75c1-8c60-30b90da9a62d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019b097a-6e6c-75f0-9e10-26fc3837275e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#ShareBasedCompensationScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b097a-6e6c-71ff-acdf-940a15ebc36d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019b097a-6e6c-7e1e-8ab6-6998c43b74b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b097a-6e6c-71ff-acdf-940a15ebc36d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019b097a-6e6c-7e1e-8ab6-6998c43b74b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b097a-6e6c-7b21-bf5b-133ec4011ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019b097a-6e6c-7e1e-8ab6-6998c43b74b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b097a-6e6c-7b21-bf5b-133ec4011ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019b097a-6e6c-705c-9a20-0317c2a857b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019b097a-6e6c-7e1e-8ab6-6998c43b74b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019b097a-6e6c-705c-9a20-0317c2a857b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019b097a-6e6c-7719-a07d-e534bde47900" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019b097a-6e6c-7e1e-8ab6-6998c43b74b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019b097a-6e6c-7719-a07d-e534bde47900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_019b097a-6e6c-7f52-8e89-38147937b3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019b097a-6e6c-7e1e-8ab6-6998c43b74b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_019b097a-6e6c-7f52-8e89-38147937b3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b097a-6e6c-76b5-b9e0-3f1ab26d678c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019b097a-6e6c-7e1e-8ab6-6998c43b74b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b097a-6e6c-76b5-b9e0-3f1ab26d678c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019b097a-6e6c-729f-8a7e-7c2ad6d607c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b097a-6e6c-71ff-acdf-940a15ebc36d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019b097a-6e6c-729f-8a7e-7c2ad6d607c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019b097a-6e6c-7c23-9bc5-bbc591f99542" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b097a-6e6c-71ff-acdf-940a15ebc36d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019b097a-6e6c-7c23-9bc5-bbc591f99542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019b097a-6e6c-7b2f-83d6-e936a03ff5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019b097a-6e6c-7c23-9bc5-bbc591f99542" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019b097a-6e6c-7b2f-83d6-e936a03ff5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019b097a-6e6c-7fe1-8104-859c51a28ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019b097a-6e6c-7c23-9bc5-bbc591f99542" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019b097a-6e6c-7fe1-8104-859c51a28ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019b097a-6e6c-72c6-b3ce-725767c0e0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019b097a-6e6c-7c23-9bc5-bbc591f99542" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019b097a-6e6c-72c6-b3ce-725767c0e0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_019b097a-6e6c-7a8f-bfb2-9d5eeb32be44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019b097a-6e6c-7c23-9bc5-bbc591f99542" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_019b097a-6e6c-7a8f-bfb2-9d5eeb32be44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019b097a-6e6c-7c5a-aa4f-4388df9930dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019b097a-6e6c-7c23-9bc5-bbc591f99542" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019b097a-6e6c-7c5a-aa4f-4388df9930dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019b097a-6e6c-75c5-8460-0050ed2990bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b097a-6e6c-71ff-acdf-940a15ebc36d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019b097a-6e6c-75c5-8460-0050ed2990bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019b097a-6e6c-74cf-b0ed-130beca0418e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b097a-6e6c-71ff-acdf-940a15ebc36d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019b097a-6e6c-74cf-b0ed-130beca0418e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019b097a-6e6c-7cbf-bc9d-b4069d16ca5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019b097a-6e6c-74cf-b0ed-130beca0418e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019b097a-6e6c-7cbf-bc9d-b4069d16ca5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019b097a-6e6c-7c7c-921d-7386d3d58093" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019b097a-6e6c-74cf-b0ed-130beca0418e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019b097a-6e6c-7c7c-921d-7386d3d58093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019b097a-6e6c-73bb-a85c-9cf1daa1ec2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019b097a-6e6c-74cf-b0ed-130beca0418e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019b097a-6e6c-73bb-a85c-9cf1daa1ec2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019b097a-6e6c-7b1d-8400-6042fa297f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019b097a-6e6c-74cf-b0ed-130beca0418e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019b097a-6e6c-7b1d-8400-6042fa297f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019c283a-067a-7c4a-a486-ec0bcb15a8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019c2845-fb34-789c-9b17-af929f29a162" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019c283a-067a-7c4a-a486-ec0bcb15a8a0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019c2845-fb34-789c-9b17-af929f29a162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019c2845-fb34-736d-9d9a-d5391bbb88f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019c2845-fb34-789c-9b17-af929f29a162" xlink:to="loc_us-gaap_AwardTypeAxis_019c2845-fb34-736d-9d9a-d5391bbb88f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c2845-fb34-78e3-8417-322193c7e8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019c2845-fb34-736d-9d9a-d5391bbb88f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c2845-fb34-78e3-8417-322193c7e8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019c2845-fb34-7391-b7e1-f0cbbb8eef98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c2845-fb34-78e3-8417-322193c7e8ef" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019c2845-fb34-7391-b7e1-f0cbbb8eef98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c2845-fb35-70e8-b271-0176af8abbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019c2845-fb34-789c-9b17-af929f29a162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c2845-fb35-70e8-b271-0176af8abbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019c2846-9312-7fef-8197-d4eb88d90cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c2845-fb35-70e8-b271-0176af8abbf1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019c2846-9312-7fef-8197-d4eb88d90cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c2845-fb35-7553-9581-2e228ec93fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019c2846-9312-7fef-8197-d4eb88d90cf8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c2845-fb35-7553-9581-2e228ec93fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019c2845-fb35-71a4-8336-7d40de60597d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019c2846-9312-7fef-8197-d4eb88d90cf8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019c2845-fb35-71a4-8336-7d40de60597d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_019c2845-fb35-77ea-95fe-9a256ee57218" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019c2846-9312-7fef-8197-d4eb88d90cf8" xlink:to="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_019c2845-fb35-77ea-95fe-9a256ee57218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod_019c2845-fb35-720a-bd23-5642657f9dbe" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019c2846-9312-7fef-8197-d4eb88d90cf8" xlink:to="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod_019c2845-fb35-720a-bd23-5642657f9dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019c2845-fb35-7496-9720-8e168dc85d28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019c2846-9312-7fef-8197-d4eb88d90cf8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019c2845-fb35-7496-9720-8e168dc85d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c2848-4c11-79e5-b0e8-290914a7ece6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019c2846-9312-7fef-8197-d4eb88d90cf8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c2848-4c11-79e5-b0e8-290914a7ece6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_019c2845-fb35-73bc-a224-16b4bf327559" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c2845-fb35-70e8-b271-0176af8abbf1" xlink:to="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_019c2845-fb35-73bc-a224-16b4bf327559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_019c2845-fb35-755c-af1d-c18631496b80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c2845-fb35-70e8-b271-0176af8abbf1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_019c2845-fb35-755c-af1d-c18631496b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019c2849-c15a-7b4d-ac14-4b6a5df23fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c2845-fb35-70e8-b271-0176af8abbf1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019c2849-c15a-7b4d-ac14-4b6a5df23fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019c2845-fb35-7e52-a915-c5845ff1cd07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019c2849-c15a-7b4d-ac14-4b6a5df23fe9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019c2845-fb35-7e52-a915-c5845ff1cd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c2845-fb35-76ed-afc6-32dd7fed1466" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019c2849-c15a-7b4d-ac14-4b6a5df23fe9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c2845-fb35-76ed-afc6-32dd7fed1466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue_019c2845-fb35-76e2-b840-7ef0dcbf5c45" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019c2849-c15a-7b4d-ac14-4b6a5df23fe9" xlink:to="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue_019c2845-fb35-76e2-b840-7ef0dcbf5c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue_019c2845-fb35-7de1-901f-5cb35c525b9d" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019c2849-c15a-7b4d-ac14-4b6a5df23fe9" xlink:to="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue_019c2845-fb35-7de1-901f-5cb35c525b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019c2845-fb35-736a-9f19-8832c8a81ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019c2849-c15a-7b4d-ac14-4b6a5df23fe9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019c2845-fb35-736a-9f19-8832c8a81ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019c284a-2766-7725-8cb9-2224efd9af19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019c2849-c15a-7b4d-ac14-4b6a5df23fe9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019c284a-2766-7725-8cb9-2224efd9af19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue_019c2845-fb35-7033-b3e1-3837cb7bc1c2" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c2845-fb35-70e8-b271-0176af8abbf1" xlink:to="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue_019c2845-fb35-7033-b3e1-3837cb7bc1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue_019c2845-fb35-718f-af99-ac8eca22ee5e" xlink:href="brns-20251231.xsd#brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c2845-fb35-70e8-b271-0176af8abbf1" xlink:to="loc_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue_019c2845-fb35-718f-af99-ac8eca22ee5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b097a-6e6c-7ad4-9bc8-4c8b861259f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6c-7c6d-ac03-5994c34d1e21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b097a-6e6c-7ad4-9bc8-4c8b861259f4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6c-7c6d-ac03-5994c34d1e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019b097a-6e6c-72fb-8ad2-4c82f23d17bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6c-7c6d-ac03-5994c34d1e21" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019b097a-6e6c-72fb-8ad2-4c82f23d17bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019b097a-6e6c-7f05-8ebe-22a0748d6629" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019b097a-6e6c-72fb-8ad2-4c82f23d17bd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019b097a-6e6c-7f05-8ebe-22a0748d6629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019b097a-6e6c-7b93-a0a9-358059d206a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019b097a-6e6c-7f05-8ebe-22a0748d6629" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019b097a-6e6c-7b93-a0a9-358059d206a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019b097a-6e6c-7847-b5fe-178be4c88b72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019b097a-6e6c-7f05-8ebe-22a0748d6629" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019b097a-6e6c-7847-b5fe-178be4c88b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6c-7e11-95cd-091f458cd79a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b097a-6e6c-7c6d-ac03-5994c34d1e21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6c-7e11-95cd-091f458cd79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019b097a-6e6c-7121-ba30-e2958a00a39b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b097a-6e6c-7e11-95cd-091f458cd79a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019b097a-6e6c-7121-ba30-e2958a00a39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#IncomeTaxesLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-77a8-a692-cd664bd5d635" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncomeTaxesTable_019b097a-6e6c-71e2-8377-001c2f3e949c" xlink:href="brns-20251231.xsd#brns_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-77a8-a692-cd664bd5d635" xlink:to="loc_brns_IncomeTaxesTable_019b097a-6e6c-71e2-8377-001c2f3e949c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019c9156-9fae-7766-b525-472ee64bbfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_IncomeTaxesTable_019b097a-6e6c-71e2-8377-001c2f3e949c" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019c9156-9fae-7766-b525-472ee64bbfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c9156-9fae-7a57-96fa-4a7667bf7486" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c9156-9fae-7766-b525-472ee64bbfe2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c9156-9fae-7a57-96fa-4a7667bf7486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019c9156-9fae-728e-8248-492cbd076390" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c9156-9fae-7a57-96fa-4a7667bf7486" xlink:to="loc_country_US_019c9156-9fae-728e-8248-492cbd076390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignTaxJurisdictionOtherMember_019c9156-fe60-7661-b282-f632baf4a2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignTaxJurisdictionOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c9156-9fae-7a57-96fa-4a7667bf7486" xlink:to="loc_us-gaap_ForeignTaxJurisdictionOtherMember_019c9156-fe60-7661-b282-f632baf4a2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncomeTaxesLineItems_019b097a-6e6c-7501-bb8f-f277b419e7d5" xlink:href="brns-20251231.xsd#brns_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_IncomeTaxesTable_019b097a-6e6c-71e2-8377-001c2f3e949c" xlink:to="loc_brns_IncomeTaxesLineItems_019b097a-6e6c-7501-bb8f-f277b419e7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019b097a-6e6c-737c-922b-506b3155d65a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_IncomeTaxesLineItems_019b097a-6e6c-7501-bb8f-f277b419e7d5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019b097a-6e6c-737c-922b-506b3155d65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019b097a-6e6c-79a3-a57b-583bdd7f4d61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_IncomeTaxesLineItems_019b097a-6e6c-7501-bb8f-f277b419e7d5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019b097a-6e6c-79a3-a57b-583bdd7f4d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b097a-6e6c-7765-8f77-dc801e416718" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_IncomeTaxesLineItems_019b097a-6e6c-7501-bb8f-f277b419e7d5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b097a-6e6c-7765-8f77-dc801e416718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-77e3-b530-1f8ea9d71de6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncomeTaxesTable_019b097a-6e6c-7116-84fd-5f6f5a701858" xlink:href="brns-20251231.xsd#brns_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-77e3-b530-1f8ea9d71de6" xlink:to="loc_brns_IncomeTaxesTable_019b097a-6e6c-7116-84fd-5f6f5a701858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019c9157-9a1c-7ce6-995d-0e5184da4939" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_IncomeTaxesTable_019b097a-6e6c-7116-84fd-5f6f5a701858" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019c9157-9a1c-7ce6-995d-0e5184da4939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c9157-9a1c-78ce-a4e8-b77da42a8ede" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c9157-9a1c-7ce6-995d-0e5184da4939" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c9157-9a1c-78ce-a4e8-b77da42a8ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019c9157-9a1c-7af7-883a-363284fcbd90" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c9157-9a1c-78ce-a4e8-b77da42a8ede" xlink:to="loc_country_US_019c9157-9a1c-7af7-883a-363284fcbd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignTaxJurisdictionOtherMember_019c9157-c4cd-73e9-a4a4-a44c78c6c1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignTaxJurisdictionOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c9157-9a1c-78ce-a4e8-b77da42a8ede" xlink:to="loc_us-gaap_ForeignTaxJurisdictionOtherMember_019c9157-c4cd-73e9-a4a4-a44c78c6c1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncomeTaxesLineItems_019b097a-6e6c-722f-8adc-8a4b602fd5df" xlink:href="brns-20251231.xsd#brns_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_IncomeTaxesTable_019b097a-6e6c-7116-84fd-5f6f5a701858" xlink:to="loc_brns_IncomeTaxesLineItems_019b097a-6e6c-722f-8adc-8a4b602fd5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b097a-6e6c-7435-a84f-24afd197c5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_IncomeTaxesLineItems_019b097a-6e6c-722f-8adc-8a4b602fd5df" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b097a-6e6c-7435-a84f-24afd197c5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_019b097a-6e6c-710b-9567-14c07d09f005" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b097a-6e6c-7435-a84f-24afd197c5a3" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_019b097a-6e6c-710b-9567-14c07d09f005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b097a-6e6c-7fdc-98b2-1d1f47ba1e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_IncomeTaxesLineItems_019b097a-6e6c-722f-8adc-8a4b602fd5df" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b097a-6e6c-7fdc-98b2-1d1f47ba1e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_019b097a-6e6c-783c-8e8f-598b050c26e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_019b097a-6e6c-7fdc-98b2-1d1f47ba1e0c" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_019b097a-6e6c-783c-8e8f-598b050c26e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019b097a-6e6c-71be-8124-e8197fc48192" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_IncomeTaxesLineItems_019b097a-6e6c-722f-8adc-8a4b602fd5df" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019b097a-6e6c-71be-8124-e8197fc48192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-7d1c-b51e-4d5b5afc71a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019cb025-71b3-7de8-8261-c3146b9f0d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-7d1c-b51e-4d5b5afc71a4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019cb025-71b3-7de8-8261-c3146b9f0d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019cb025-71b3-729a-be69-b057df1ac7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019cb025-71b3-7de8-8261-c3146b9f0d6f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019cb025-71b3-729a-be69-b057df1ac7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019cb025-71b3-7826-ab8f-feea54038f25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019cb025-71b3-729a-be69-b057df1ac7aa" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019cb025-71b3-7826-ab8f-feea54038f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_019cb026-3c39-7cfe-abc9-7821c63c1ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019cb025-71b3-7826-ab8f-feea54038f25" xlink:to="loc_us-gaap_ForeignCountryMember_019cb026-3c39-7cfe-abc9-7821c63c1ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019cb025-faf5-72bd-90b5-971d71c934a4" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignCountryMember_019cb026-3c39-7cfe-abc9-7821c63c1ef3" xlink:to="loc_country_US_019cb025-faf5-72bd-90b5-971d71c934a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CH_019ce06e-6040-7d7f-a37c-e7672765f988" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CH"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignCountryMember_019cb026-3c39-7cfe-abc9-7821c63c1ef3" xlink:to="loc_country_CH_019ce06e-6040-7d7f-a37c-e7672765f988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_019cb02b-fe96-751b-b847-97e18407b1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019cb025-71b3-7826-ab8f-feea54038f25" xlink:to="loc_us-gaap_DomesticCountryMember_019cb02b-fe96-751b-b847-97e18407b1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_019ce2ac-b8d9-75bf-bbc4-0c3a50186632" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticCountryMember_019cb02b-fe96-751b-b847-97e18407b1d3" xlink:to="loc_country_GB_019ce2ac-b8d9-75bf-bbc4-0c3a50186632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019cb025-71b3-792f-b6f6-4576886b42a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019cb025-71b3-7de8-8261-c3146b9f0d6f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019cb025-71b3-792f-b6f6-4576886b42a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019ce06d-fdf9-7a1a-9350-92d0788b2455" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019cb025-71b3-792f-b6f6-4576886b42a3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019ce06d-fdf9-7a1a-9350-92d0788b2455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019ce06e-6040-7ccf-8939-af0f4e22bdb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019ce06d-fdf9-7a1a-9350-92d0788b2455" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019ce06e-6040-7ccf-8939-af0f4e22bdb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019ce06e-6040-77e9-817d-247e9434ff05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019ce06d-fdf9-7a1a-9350-92d0788b2455" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019ce06e-6040-77e9-817d-247e9434ff05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_019ce06e-6040-7837-9950-535f5f152081" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019ce06d-fdf9-7a1a-9350-92d0788b2455" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_019ce06e-6040-7837-9950-535f5f152081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_019ce2d4-ae3c-7740-9815-c42a666518a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019ce06d-fdf9-7a1a-9350-92d0788b2455" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_019ce2d4-ae3c-7740-9815-c42a666518a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_019ce06e-6040-73a5-9ba3-6a9ba85c5c55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019ce06d-fdf9-7a1a-9350-92d0788b2455" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_019ce06e-6040-73a5-9ba3-6a9ba85c5c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount_019ce35e-d850-7218-8341-93efb636d67b" xlink:href="brns-20251231.xsd#brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019ce06d-fdf9-7a1a-9350-92d0788b2455" xlink:to="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount_019ce35e-d850-7218-8341-93efb636d67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019ce06e-6040-7a07-be28-ba0cd8b7b37e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019ce06d-fdf9-7a1a-9350-92d0788b2455" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019ce06e-6040-7a07-be28-ba0cd8b7b37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019ce06e-6040-7d01-b7ca-b02d4253da3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019ce06d-fdf9-7a1a-9350-92d0788b2455" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019ce06e-6040-7d01-b7ca-b02d4253da3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019ce070-9645-7eca-92d8-92811c1e7151" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019cb025-71b3-792f-b6f6-4576886b42a3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019ce070-9645-7eca-92d8-92811c1e7151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019ce070-f2bb-7c41-8a99-858d43ab6bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019ce070-9645-7eca-92d8-92811c1e7151" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019ce070-f2bb-7c41-8a99-858d43ab6bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019ce070-f2bb-7e5c-bf20-6875231efbde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019ce070-9645-7eca-92d8-92811c1e7151" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019ce070-f2bb-7e5c-bf20-6875231efbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_019ce070-f2bb-72ff-91f8-0acf0e84724c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019ce070-9645-7eca-92d8-92811c1e7151" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_019ce070-f2bb-72ff-91f8-0acf0e84724c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019ce2d5-21ea-7564-b106-2ca9754fbac0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019ce070-9645-7eca-92d8-92811c1e7151" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019ce2d5-21ea-7564-b106-2ca9754fbac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_019ce070-f2bb-711d-83e1-8e401eb871d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019ce070-9645-7eca-92d8-92811c1e7151" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_019ce070-f2bb-711d-83e1-8e401eb871d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment_019ce070-f2bb-7344-946f-5c7706d5be86" xlink:href="brns-20251231.xsd#brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019ce070-9645-7eca-92d8-92811c1e7151" xlink:to="loc_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment_019ce070-f2bb-7344-946f-5c7706d5be86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019ce070-f2bb-74be-8db7-85420d6c063c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019ce070-9645-7eca-92d8-92811c1e7151" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019ce070-f2bb-74be-8db7-85420d6c063c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019ce070-f2bb-7202-ae1a-511f411c904a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019ce070-9645-7eca-92d8-92811c1e7151" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019ce070-f2bb-7202-ae1a-511f411c904a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-7c53-a068-87535eeb3483" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b097a-6e6c-7fb9-bfed-58d1dbe5ece3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-7c53-a068-87535eeb3483" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b097a-6e6c-7fb9-bfed-58d1dbe5ece3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_019b097a-6e6c-7319-a2d6-068cb1bf6a77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b097a-6e6c-7fb9-bfed-58d1dbe5ece3" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_019b097a-6e6c-7319-a2d6-068cb1bf6a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_019b097a-6e6c-767f-92db-9f7b8c0ad495" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b097a-6e6c-7fb9-bfed-58d1dbe5ece3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_019b097a-6e6c-767f-92db-9f7b8c0ad495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_019b097a-6e6c-7352-85cc-4b82f4c16d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b097a-6e6c-7fb9-bfed-58d1dbe5ece3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_019b097a-6e6c-7352-85cc-4b82f4c16d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredTaxAssetsLeasingArrangements_019b097a-6e6c-7584-b7a0-245d252f955a" xlink:href="brns-20251231.xsd#brns_DeferredTaxAssetsLeasingArrangements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b097a-6e6c-7fb9-bfed-58d1dbe5ece3" xlink:to="loc_brns_DeferredTaxAssetsLeasingArrangements_019b097a-6e6c-7584-b7a0-245d252f955a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_019c7029-c6f9-7216-9bf2-f9e12af3d32c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b097a-6e6c-7fb9-bfed-58d1dbe5ece3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_019c7029-c6f9-7216-9bf2-f9e12af3d32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_019b097a-6e6c-794e-b38d-d828461fec78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b097a-6e6c-7fb9-bfed-58d1dbe5ece3" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_019b097a-6e6c-794e-b38d-d828461fec78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_019b097a-6e6c-7864-93df-5a0aa119aeba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b097a-6e6c-7fb9-bfed-58d1dbe5ece3" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_019b097a-6e6c-7864-93df-5a0aa119aeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_019b097a-6e6c-7d51-b945-fefcdcefe7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b097a-6e6c-7fb9-bfed-58d1dbe5ece3" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_019b097a-6e6c-7d51-b945-fefcdcefe7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_019b097a-6e6c-7468-91e8-c710eea637a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b097a-6e6c-7fb9-bfed-58d1dbe5ece3" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_019b097a-6e6c-7468-91e8-c710eea637a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_019b097a-6e6c-7bcc-9d05-00f56fbeb3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b097a-6e6c-7fb9-bfed-58d1dbe5ece3" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_019b097a-6e6c-7bcc-9d05-00f56fbeb3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_019b097a-6e6c-7cd4-86b3-02ec3e2aa2af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_019b097a-6e6c-7fb9-bfed-58d1dbe5ece3" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_019b097a-6e6c-7cd4-86b3-02ec3e2aa2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_019b097a-6e6c-75eb-b6f9-787270be5862" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-7c53-a068-87535eeb3483" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_019b097a-6e6c-75eb-b6f9-787270be5862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_019b097a-6e6c-72f6-bdbf-04db7e7c668c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_019b097a-6e6c-75eb-b6f9-787270be5862" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_019b097a-6e6c-72f6-bdbf-04db7e7c668c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_019b097a-6e6c-773c-ab1b-28ab8532d631" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_019b097a-6e6c-75eb-b6f9-787270be5862" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_019b097a-6e6c-773c-ab1b-28ab8532d631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_019b097a-6e6c-7d1d-be1c-25c307edfee7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_019b097a-6e6c-75eb-b6f9-787270be5862" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_019b097a-6e6c-7d1d-be1c-25c307edfee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_019b097a-6e6c-74b3-a5c1-4dae4768d279" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_019b097a-6e6c-75eb-b6f9-787270be5862" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_019b097a-6e6c-74b3-a5c1-4dae4768d279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_019b097a-6e6c-7abf-881d-fbe27c17ed5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_019b097a-6e6c-75eb-b6f9-787270be5862" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_019b097a-6e6c-7abf-881d-fbe27c17ed5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_019b097a-6e6c-7179-b7f9-08e87a362139" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-7c53-a068-87535eeb3483" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_019b097a-6e6c-7179-b7f9-08e87a362139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-7bb4-bfa7-cf047300eead" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_019b097a-6e6c-7b3f-9527-b36d519c0fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-7bb4-bfa7-cf047300eead" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_019b097a-6e6c-7b3f-9527-b36d519c0fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019b097a-6e6c-76d4-a512-175b0e6af5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_019b097a-6e6c-7b3f-9527-b36d519c0fa8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019b097a-6e6c-76d4-a512-175b0e6af5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019b097a-6e6c-7668-a95b-ba66044a52c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019b097a-6e6c-76d4-a512-175b0e6af5b2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019b097a-6e6c-7668-a95b-ba66044a52c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_019b097a-6e6c-7b63-abba-c94400900338" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019b097a-6e6c-7668-a95b-ba66044a52c7" xlink:to="loc_us-gaap_DomesticCountryMember_019b097a-6e6c-7b63-abba-c94400900338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_019c499d-7275-736d-b60a-3a0886dbf29a" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticCountryMember_019b097a-6e6c-7b63-abba-c94400900338" xlink:to="loc_country_GB_019c499d-7275-736d-b60a-3a0886dbf29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b097a-6e6c-7e64-8033-2ea6ea389d80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_019b097a-6e6c-7b3f-9527-b36d519c0fa8" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b097a-6e6c-7e64-8033-2ea6ea389d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_019b097a-6e6c-7e21-9339-5f44d56ad300" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b097a-6e6c-7e64-8033-2ea6ea389d80" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_019b097a-6e6c-7e21-9339-5f44d56ad300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_019b097a-6e6c-7c79-8057-b6d27a36f147" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b097a-6e6c-7e64-8033-2ea6ea389d80" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_019b097a-6e6c-7c79-8057-b6d27a36f147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_019b097a-6e6c-736b-b167-a8cc531b70bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b097a-6e6c-7e64-8033-2ea6ea389d80" xlink:to="loc_us-gaap_OperatingLossCarryforwards_019b097a-6e6c-736b-b167-a8cc531b70bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_019b097a-6e6c-758a-b535-be9b71f88a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_019b097a-6e6c-7e64-8033-2ea6ea389d80" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_019b097a-6e6c-758a-b535-be9b71f88a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IncomeTaxesChangesintheValuationAllowancerorDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#IncomeTaxesChangesintheValuationAllowancerorDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/IncomeTaxesChangesintheValuationAllowancerorDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-7e96-b0a9-59267ccc4b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ValuationAllowanceRollForward_019b097a-6e6c-726c-9f65-b8f2dc3ff09a" xlink:href="brns-20251231.xsd#brns_ValuationAllowanceRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019b097a-6e6c-7e96-b0a9-59267ccc4b8c" xlink:to="loc_brns_ValuationAllowanceRollForward_019b097a-6e6c-726c-9f65-b8f2dc3ff09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_019b097a-6e6c-7bcf-a19c-28deb38f12c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_ValuationAllowanceRollForward_019b097a-6e6c-726c-9f65-b8f2dc3ff09a" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_019b097a-6e6c-7bcf-a19c-28deb38f12c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions_019b097a-6e6c-7c21-8dd6-b5c01171a0c6" xlink:href="brns-20251231.xsd#brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_ValuationAllowanceRollForward_019b097a-6e6c-726c-9f65-b8f2dc3ff09a" xlink:to="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions_019b097a-6e6c-7c21-8dd6-b5c01171a0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision_019b097a-6e6c-798d-9374-11b34f072823" xlink:href="brns-20251231.xsd#brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_ValuationAllowanceRollForward_019b097a-6e6c-726c-9f65-b8f2dc3ff09a" xlink:to="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision_019b097a-6e6c-798d-9374-11b34f072823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation_019b097a-6e6c-7e19-bea1-014e8c49a3ff" xlink:href="brns-20251231.xsd#brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_ValuationAllowanceRollForward_019b097a-6e6c-726c-9f65-b8f2dc3ff09a" xlink:to="loc_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation_019b097a-6e6c-7e19-bea1-014e8c49a3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_019b097a-6e6c-79b6-b680-93eab92e3314" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_ValuationAllowanceRollForward_019b097a-6e6c-726c-9f65-b8f2dc3ff09a" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_019b097a-6e6c-79b6-b680-93eab92e3314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-73b7-a1ca-8a9d3bd3bc20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_019b097a-6e6c-78bb-93d4-befd495172c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-73b7-a1ca-8a9d3bd3bc20" xlink:to="loc_us-gaap_OtherCommitmentsTable_019b097a-6e6c-78bb-93d4-befd495172c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019b097a-6e6c-777e-82cb-e9dffdddc4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_019b097a-6e6c-78bb-93d4-befd495172c0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019b097a-6e6c-777e-82cb-e9dffdddc4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019b097a-6e6c-7ad9-8934-d4abc8cd37d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019b097a-6e6c-777e-82cb-e9dffdddc4f5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019b097a-6e6c-7ad9-8934-d4abc8cd37d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_InLicenseAgreementsMember_019b097a-6e6c-70e9-8f81-de510ec58a4e" xlink:href="brns-20251231.xsd#brns_InLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019b097a-6e6c-7ad9-8934-d4abc8cd37d1" xlink:to="loc_brns_InLicenseAgreementsMember_019b097a-6e6c-70e9-8f81-de510ec58a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019b097a-6e6c-7175-99aa-6ffbc3e61839" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_019b097a-6e6c-78bb-93d4-befd495172c0" xlink:to="loc_srt_RangeAxis_019b097a-6e6c-7175-99aa-6ffbc3e61839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019b097a-6e6c-7a1e-98ab-3ff6340cf3aa" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019b097a-6e6c-7175-99aa-6ffbc3e61839" xlink:to="loc_srt_RangeMember_019b097a-6e6c-7a1e-98ab-3ff6340cf3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019b097a-6e6c-79f3-ae4d-119ab12cfecb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019b097a-6e6c-7a1e-98ab-3ff6340cf3aa" xlink:to="loc_srt_MinimumMember_019b097a-6e6c-79f3-ae4d-119ab12cfecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019b097a-6e6c-7c76-b702-fcf424823c50" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019b097a-6e6c-7a1e-98ab-3ff6340cf3aa" xlink:to="loc_srt_MaximumMember_019b097a-6e6c-7c76-b702-fcf424823c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_019b097a-6e6c-7709-8cf7-39fdd32e97c9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_019b097a-6e6c-78bb-93d4-befd495172c0" xlink:to="loc_srt_StatementGeographicalAxis_019b097a-6e6c-7709-8cf7-39fdd32e97c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019b097a-6e6c-7f60-aefa-997e06fd1bd6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_019b097a-6e6c-7709-8cf7-39fdd32e97c9" xlink:to="loc_srt_SegmentGeographicalDomain_019b097a-6e6c-7f60-aefa-997e06fd1bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordshireMember_019b097a-6e6c-7948-847b-352d0af4f60a" xlink:href="brns-20251231.xsd#brns_OxfordshireMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019b097a-6e6c-7f60-aefa-997e06fd1bd6" xlink:to="loc_brns_OxfordshireMember_019b097a-6e6c-7948-847b-352d0af4f60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MD_019b097a-6e6c-78e1-8bcc-3b8867cade37" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_MD"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019b097a-6e6c-7f60-aefa-997e06fd1bd6" xlink:to="loc_stpr_MD_019b097a-6e6c-78e1-8bcc-3b8867cade37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_019b097a-6e6c-78bb-93d4-befd495172c0" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement_019b097a-6e6c-7942-aa86-3eaf44bfc40d" xlink:href="brns-20251231.xsd#brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:to="loc_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement_019b097a-6e6c-7942-aa86-3eaf44bfc40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement_019b097a-6e6c-771a-a478-91e6e406d43b" xlink:href="brns-20251231.xsd#brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:to="loc_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement_019b097a-6e6c-771a-a478-91e6e406d43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfSquareFeetUnderLeaseAgreement_019b097a-6e6c-7243-8299-bd0aca73a247" xlink:href="brns-20251231.xsd#brns_NumberOfSquareFeetUnderLeaseAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:to="loc_brns_NumberOfSquareFeetUnderLeaseAgreement_019b097a-6e6c-7243-8299-bd0aca73a247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_019b097a-6e6c-7812-a71c-d9c979b86a66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:to="loc_us-gaap_SecurityDeposit_019b097a-6e6c-7812-a71c-d9c979b86a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_019c90cb-511d-7b8e-982f-1ec727fdd076" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_019c90cb-511d-7b8e-982f-1ec727fdd076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LesseeOperatingLeaseExtendedTerm_019b097a-6e6c-7023-ad1c-a117b50dbb70" xlink:href="brns-20251231.xsd#brns_LesseeOperatingLeaseExtendedTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:to="loc_brns_LesseeOperatingLeaseExtendedTerm_019b097a-6e6c-7023-ad1c-a117b50dbb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_019b097a-6e6c-776f-aa41-cc2607b99d19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_019b097a-6e6c-776f-aa41-cc2607b99d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_019b097a-6e6c-76d3-984a-abb314802f39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_019b097a-6e6c-76d3-984a-abb314802f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_019c2863-3f1b-7fb5-a63b-88fc2afb56f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_019b097a-6e6c-72ee-b46b-cc46479425db" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_019c2863-3f1b-7fb5-a63b-88fc2afb56f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-7b41-b61f-b83d8e183f21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_019b097a-6e6c-7125-a22b-5ca4eebf5dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-7b41-b61f-b83d8e183f21" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_019b097a-6e6c-7125-a22b-5ca4eebf5dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_019b097a-6e6c-7517-b466-7d25d18af73e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-7b41-b61f-b83d8e183f21" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_019b097a-6e6c-7517-b466-7d25d18af73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019b097a-6e6c-798b-a1e9-a759c02cac55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-7b41-b61f-b83d8e183f21" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019b097a-6e6c-798b-a1e9-a759c02cac55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OtherInformationLesseeAbstract_019b097a-6e6c-78f7-8935-2d2bf660914c" xlink:href="brns-20251231.xsd#brns_OtherInformationLesseeAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-7b41-b61f-b83d8e183f21" xlink:to="loc_brns_OtherInformationLesseeAbstract_019b097a-6e6c-78f7-8935-2d2bf660914c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_019b097a-6e6c-7dc7-8273-84d599e14450" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_OtherInformationLesseeAbstract_019b097a-6e6c-78f7-8935-2d2bf660914c" xlink:to="loc_us-gaap_OperatingLeasePayments_019b097a-6e6c-7dc7-8273-84d599e14450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_019b097a-6e6c-7d9e-b2d5-a48106f5c366" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_OtherInformationLesseeAbstract_019b097a-6e6c-78f7-8935-2d2bf660914c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_019b097a-6e6c-7d9e-b2d5-a48106f5c366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_019b097a-6e6c-747e-844f-1e2fe4a15548" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_OtherInformationLesseeAbstract_019b097a-6e6c-78f7-8935-2d2bf660914c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_019b097a-6e6c-747e-844f-1e2fe4a15548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_019b097a-6e6c-7725-8bca-1fb7430f0195" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-7b41-b61f-b83d8e183f21" xlink:to="loc_us-gaap_LeaseCostAbstract_019b097a-6e6c-7725-8bca-1fb7430f0195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_019b097a-6e6c-741c-9225-af4d8e77460c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_019b097a-6e6c-7725-8bca-1fb7430f0195" xlink:to="loc_us-gaap_OperatingLeaseCost_019b097a-6e6c-741c-9225-af4d8e77460c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_019b097a-6e6c-7bdb-bfab-ac906c38a0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_019b097a-6e6c-7725-8bca-1fb7430f0195" xlink:to="loc_us-gaap_LeaseCost_019b097a-6e6c-7bdb-bfab-ac906c38a0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-76e1-8f9f-2fa76e9bde95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_019b097a-6e6c-766e-92cc-38f96072c81b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-76e1-8f9f-2fa76e9bde95" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_019b097a-6e6c-766e-92cc-38f96072c81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_019b097a-6e6c-7707-9e79-46813d7df183" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-76e1-8f9f-2fa76e9bde95" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_019b097a-6e6c-7707-9e79-46813d7df183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_019b097a-6e6c-7e4b-8fd0-ce98c7b76927" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-76e1-8f9f-2fa76e9bde95" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_019b097a-6e6c-7e4b-8fd0-ce98c7b76927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_019b097a-6e6c-73e2-889f-2944a63c4732" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-76e1-8f9f-2fa76e9bde95" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_019b097a-6e6c-73e2-889f-2944a63c4732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_019b097a-6e6c-7fbf-99af-e9b5f357ce9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-76e1-8f9f-2fa76e9bde95" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_019b097a-6e6c-7fbf-99af-e9b5f357ce9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_019b097a-6e6c-74c6-b849-22f3dfa47515" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-76e1-8f9f-2fa76e9bde95" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_019b097a-6e6c-74c6-b849-22f3dfa47515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019b097a-6e6c-797c-b101-f7d2e21e0c00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-76e1-8f9f-2fa76e9bde95" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_019b097a-6e6c-797c-b101-f7d2e21e0c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_019b097a-6e6c-739f-95db-ca7befe7ff5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-76e1-8f9f-2fa76e9bde95" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_019b097a-6e6c-739f-95db-ca7befe7ff5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_019b097a-6e6c-7046-afc7-9eafb01621f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019b097a-6e6c-76e1-8f9f-2fa76e9bde95" xlink:to="loc_us-gaap_OperatingLeaseLiability_019b097a-6e6c-7046-afc7-9eafb01621f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#EmployeeBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_019b097a-6e6c-7cd4-aa9b-9ff422f68356" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_019b097a-6e6c-7da1-8a58-20e3b36fe724" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_019b097a-6e6c-7cd4-aa9b-9ff422f68356" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_019b097a-6e6c-7da1-8a58-20e3b36fe724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_019b097a-6e6c-7168-9838-8b3bbc4f3810" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019b097a-6e6c-7e22-a51f-2cfe92d53dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_019b097a-6e6c-7168-9838-8b3bbc4f3810" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019b097a-6e6c-7e22-a51f-2cfe92d53dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019b097a-6e6c-757d-b314-6c6613c363d8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019b097a-6e6c-7e22-a51f-2cfe92d53dc7" xlink:to="loc_srt_CounterpartyNameAxis_019b097a-6e6c-757d-b314-6c6613c363d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019b097a-6e6c-72ab-ab54-23a705112fe9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_019b097a-6e6c-757d-b314-6c6613c363d8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019b097a-6e6c-72ab-ab54-23a705112fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordUniversityInnovationLimitedMember_019b097a-6e6c-78e1-adbf-cd431a2c95f3" xlink:href="brns-20251231.xsd#brns_OxfordUniversityInnovationLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019b097a-6e6c-72ab-ab54-23a705112fe9" xlink:to="loc_brns_OxfordUniversityInnovationLimitedMember_019b097a-6e6c-78e1-adbf-cd431a2c95f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_019b097a-6e6c-7620-824b-e5832484db71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019b097a-6e6c-7e22-a51f-2cfe92d53dc7" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_019b097a-6e6c-7620-824b-e5832484db71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_019b097a-6e6c-7f2d-ba7d-9dfe9dedf609" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_019b097a-6e6c-7620-824b-e5832484db71" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_019b097a-6e6c-7f2d-ba7d-9dfe9dedf609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ExpensesMember_019b097a-6e6c-7f63-8a1a-4f801036c2e4" xlink:href="brns-20251231.xsd#brns_ExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019b097a-6e6c-7f2d-ba7d-9dfe9dedf609" xlink:to="loc_brns_ExpensesMember_019b097a-6e6c-7f63-8a1a-4f801036c2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019b097a-6e6c-754d-b489-0042c435068c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019b097a-6e6c-7e22-a51f-2cfe92d53dc7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019b097a-6e6c-754d-b489-0042c435068c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019b097a-6e6c-7195-a60e-9335b2870587" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019b097a-6e6c-754d-b489-0042c435068c" xlink:to="loc_us-gaap_RelatedPartyDomain_019b097a-6e6c-7195-a60e-9335b2870587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019b097a-6e6c-7af3-a606-82715f4a0c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019b097a-6e6c-7195-a60e-9335b2870587" xlink:to="loc_us-gaap_RelatedPartyMember_019b097a-6e6c-7af3-a606-82715f4a0c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_019b097a-6e6c-74f9-a0c9-c427b9cc0539" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019b097a-6e6c-7e22-a51f-2cfe92d53dc7" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_019b097a-6e6c-74f9-a0c9-c427b9cc0539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_019b097a-6e6c-7542-8111-f5042d717495" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019b097a-6e6c-74f9-a0c9-c427b9cc0539" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_019b097a-6e6c-7542-8111-f5042d717495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_019b097a-6e6c-75d9-93b9-82c5d6a65d17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019b097a-6e6c-74f9-a0c9-c427b9cc0539" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_019b097a-6e6c-75d9-93b9-82c5d6a65d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019b097a-6e6c-7053-8013-94c6fe31a4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019b097a-6e6c-74f9-a0c9-c427b9cc0539" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019b097a-6e6c-7053-8013-94c6fe31a4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="brns-20251231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_019b097a-6e6c-75ad-9f58-3b8269cd30ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_019b097a-6e6c-7a7d-9a79-f34344301841" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_019b097a-6e6c-75ad-9f58-3b8269cd30ae" xlink:to="loc_us-gaap_SubsequentEventTable_019b097a-6e6c-7a7d-9a79-f34344301841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_019cd0fb-6b02-7d1b-a16e-fd07ac3b9e69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_019b097a-6e6c-7a7d-9a79-f34344301841" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_019cd0fb-6b02-7d1b-a16e-fd07ac3b9e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019cd0fb-6b02-7ac8-855d-eb8b17352653" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019cd0fb-6b02-7d1b-a16e-fd07ac3b9e69" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019cd0fb-6b02-7ac8-855d-eb8b17352653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_019cd0fb-6b02-7264-8fc2-0799967aeb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_019cd0fb-6b02-7ac8-855d-eb8b17352653" xlink:to="loc_us-gaap_SubsequentEventMember_019cd0fb-6b02-7264-8fc2-0799967aeb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019cd82e-b8c5-704c-a0be-9a86aa41c1b0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_019b097a-6e6c-7a7d-9a79-f34344301841" xlink:to="loc_srt_RangeAxis_019cd82e-b8c5-704c-a0be-9a86aa41c1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019cd82e-b8c5-79c5-9208-729b3f1cb751" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019cd82e-b8c5-704c-a0be-9a86aa41c1b0" xlink:to="loc_srt_RangeMember_019cd82e-b8c5-79c5-9208-729b3f1cb751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019cd82e-ce1d-7f02-871b-c1447105029e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019cd82e-b8c5-79c5-9208-729b3f1cb751" xlink:to="loc_srt_MinimumMember_019cd82e-ce1d-7f02-871b-c1447105029e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019cd82e-efbd-75a4-a307-f3732e19bb31" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019cd82e-b8c5-79c5-9208-729b3f1cb751" xlink:to="loc_srt_MaximumMember_019cd82e-efbd-75a4-a307-f3732e19bb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_019b097a-6e6c-785c-bbb8-22abf7c9d7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_019b097a-6e6c-7a7d-9a79-f34344301841" xlink:to="loc_us-gaap_SubsequentEventLineItems_019b097a-6e6c-785c-bbb8-22abf7c9d7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MergerAgreementSchemeExchangeRatio_019cd0fb-6b02-7ed7-b35e-040901259211" xlink:href="brns-20251231.xsd#brns_MergerAgreementSchemeExchangeRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_019b097a-6e6c-785c-bbb8-22abf7c9d7a7" xlink:to="loc_brns_MergerAgreementSchemeExchangeRatio_019cd0fb-6b02-7ed7-b35e-040901259211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MergerAgreementMergerExchangeRatio_019cd0fb-6b02-759b-a4eb-e5ded9db9dc6" xlink:href="brns-20251231.xsd#brns_MergerAgreementMergerExchangeRatio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_019b097a-6e6c-785c-bbb8-22abf7c9d7a7" xlink:to="loc_brns_MergerAgreementMergerExchangeRatio_019cd0fb-6b02-759b-a4eb-e5ded9db9dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>brns-20251231_g1.jpg
<TEXT>
begin 644 brns-20251231_g1.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" -]$!P# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF^;]W'.=H]?2OBBYN9;RXEGGD::>5B[R.<LS$Y))]:^K/V:_^2:)_P!?<O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K\HO^"EGB^;7OVB/[(+DVVB:;! D9Z!Y
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M9_AJOQ1\V_\ !.3QC+X:_:4T_31(5MM=LKBRE3/!*H9D/US%C\37U=_P4_\
M^3>]+_[&"W_]$SU\2?L.QM+^U1X!"*6(N9VP/06TI/Z5]M_\%/\ _DWO2_\
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MOL'QU^V#\*#\(/CYXDTJ&(Q:7>2_VE8<<>3*2VT>RMO3_@-?>O\ P3>^*/\
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M-6/+MK:[LU?L5/VK_P#5>&O]ZX_]IUSW[+7_ "/.I?\ 8.;_ -&1UT/[5_\
MJO#7^]<?^TZY[]EK_D>=2_[!S?\ HR.NG_FLWZ_^XSDP_P#R2C])?^EL]6_:
M(_Y)9J/_ %UA_P#1@KYS^$?_ "4OPY_U]I7T9^T1_P DLU'_ *ZP_P#HP5\Y
M_"/_ )*7X<_Z^TI\0?\ )3X7UI_^ECX<_P"1#B/^W_\ TE'VO7RS^U%_R4&R
M_P"P;'_Z,EKZFKY9_:B_Y*#9?]@V/_T9+7TO''_(J7^-?DSYCA#_ )&B_P +
M.F_9/_U/B;_>MO\ VI7>?&SXCR?#[PRGV(K_ &K?,8K<L,^6 /F?'?&0![D5
MP?[)_P#J?$W^];?^U*]G\1>%-#\1QA]9TVTO5A4XDN$!,:]3ANH''K6^54L1
M7X=ITL+/DFXV3?35W^=MNVX\XJ4*/$%2IB8N4$XW2Z^ZOU/BW3]+U[Q_K;I;
M176L:E+\[LS;FQZLQ. /<FM37_A+XN\,6#WNHZ++#:QC+RQR)*$'J=C' ]S7
MO%OX^^%_PNEO$T=D:XF(\Y-.#S[L9QAV.W')X#5R7C3]IF#5]*OM-TO1'$5U
M"\!GO9 "%8$'Y%SS@_WJ_/:^3Y/A,-)XK&<U?7X7S*_1;-^MVC[>EFV:XFO%
M83"6HZ?$N5VZVUMZ63.!^$_Q)U+P1XBLXEN'DTFXE6.XM78E,,<%@.S#KD=<
M5[9^TGH>HZ[X7TN+3=/NM1E2\W,EI"TK*-C#)"@X%?+=O_KX_P#>'\Z_0$=!
M7N\+4YYOE.(R^M-\MTD][+>R\M#R>)YPRS,,-CZ4%S>]?SM:U_O/S^N+>6TN
M)()XGAGB8H\<BE61@<$$'D$'M6]H/@SQ!J$ME>6NA:E<VCR*RSPV<CQL W)#
M 8[&F?$#_D?/$G_82N?_ $:U?5WP1_Y)9H'_ %R?_P!&-7RO#>34\TQDX3FX
M^SUTZV9])G6<5,MP5/$0@FYM*S\TV8_[1W_),+G_ *^8?_0J^??@Y_R4[P[_
M -?/_LIKZ#_:/_Y)A<_]?,/_ *%7SY\'/^2G>'?^OG_V4U]'GO\ R5.%]:?_
M *4>!P]_R(,1_P!O_P#I*/K7Q]_R(WB'_L'W'_HMJ^(=+O!I^IVET5+B"9)2
MH.,[6!Q^E?;WC[_D1O$/_8/N/_1;5\, 9( ZFLN.9RIYAAYPW4;KUYF+@I*6
M&KQ>S:_(]%OX?'/QQU&:_ALI[VVC8B.)7$=O#_LJ7(4G'7G)[UQ>O>'M3\+:
MBUCJEG+8W: -LD'4=B"."/<5]N^$M&M_#_AG3-/MHUBB@MT7:O<XY)]R<G\:
M\;_:MLHS8>'[O8/-666(N!S@A3@_D?UJL^X66#P$\?.M*=96<KVL[M)VZZ7[
MO1#RCB/V^/C@*=*,:3NHVW5DVK]-;=OF6?V;_B+?:\EWX?U.X:ZDM8A-;32M
ME]F0"A/?&1CZGTKUKQ=XFM?!WAV^U>\YAMDW! <%V/"J/<D@5\S?LUL5^):
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M5W:VZ[(H[2$A%[\M(03SWYKRCXK_ !I?XE6%O8)I26%K!-YX=I?,D8[2O7
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M_P _(X>+<KHX:4,;AU93T:6U]TUZK<^+O$W_ ",>J_\ 7W+_ .AFOL3X0_\
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M4+O_ *]X?_0:]X^ _P#R2C0?]V7_ -'/7@_[1O\ R5"[_P"O>'_T&OJ>*O\
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M%FO6/VI?^1#T[_L))_Z*EKR?]G?_ )*GIW_7*;_T6:>/_P"2NI^L/R1.5?\
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M?WGAW6(+NW)M[ZSF#KO7E'4]P?<=#7N&@_M57$:HFLZ)',?XIK*4I_XXV?\
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MRD<@@CH:_+>+:RP^>TJS5U%0?W2;/T7A*#J934@NLI+\$?H%7*?%#Q%8>&_
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MK[:[+[SULOSZOE6#GA:$;3<F[OIHEMWTZ_<?$7Q-T*T\,^.=4TNQ1DM;5D1
MQR3\BY)/J3D_C7T3^S7_ ,DT3_K[E_I7@_QN_P"2I^(/^NJ_^BUKWC]FO_DF
MB?\ 7W+_ $KX?A2,89_BHQ5DE/\ ]+B?:\13E4R&A.3NWR-_^ GI][<BSLYY
MV^[%&SG\!FO@.XG>ZN)9I#NDD8NQ/<DY-?=_B<%O#>K!>6-I*!C_ '#7P93X
M_DW5P\>B4OQ:_P CGX'BN3$2ZWC^I]R?#NQ73O GA^W0 !;&$G'J4!/ZDUXE
M^U99+'K'A^\ &Z6"6(GN0K*1_P"AFO>_"Q!\,:05P0;.'&/]P5X=^UC_ *SP
MO]+G_P!I5];Q?",<EFDMG&WWI'SG#LY//8M]7._W-F5^RQ?^5XLU:T+8$UF)
M,>I5Q_1C4G[5-^TGB31;/<=D5HTN/=G(_P#9!65^S(&/Q$EP0%%C)N'K\R5-
M^U$#_P + L3V.FQX_P"_DE?$5JLO]4*<>G/;Y<TG^9]C[./^M/-_<O\ .UOR
M-#]E6T23Q%K=R0"\5JB*>XW/D_\ H->\>.[)-1\%:];N PDL9ASZ[#@_GBO$
M_P!E$C[7XB&1NV0\=\9>O=?%/_(L:O\ ]><W_H!K[?(:<?\ 5N$7UC._SE(^
M.XBG+^W)/LX6^Y'PA%*T$J2(<.C!@1V(K[6\9ZTT7POU74E.'?3&=2.,,T?!
M_,U\35]>^.5?_A0]R#\SC2H<D?1,U\1PE5E#+\QMT@FO7EF?8\4TXSQ&"YNL
M[?)N)\CVT7GW,47]]POYFOORTMTM+6&",8CB144>P&!7P7HA UFP)P +B/.?
M]X5]\U[7 $4J&(EU;C^"?^9Y?'$GS8>/3WO_ &T^3_VEK);3XE&50 ;FSBE.
M.Y!9/_9*[;]E._WZ;X@LBW^KEBF _P!X,#_Z"*Y/]J+_ )*#9?\ 8-C_ /1D
MM;G[*(;[=XB.1L\N'CWR]>9E3Y.+:L8[.53\F_S1W8Q>TX6BY=(Q_P#2DCZ*
MHHHK]I/Q\\T_:(_Y)9J/_76'_P!&"OG/X1_\E+\.?]?:5]&?M$?\DLU'_KK#
M_P"C!7SG\(_^2E^'/^OM*_&N(/\ DI\+ZT__ $L_7>'/^1#B/^W_ /TE'U]X
MT_Y$[7?^O"?_ -%M7PUI]R+._MK@J6$4JR%1WP0:^Y?&G_(G:[_UX3_^BVKX
M2K+CJ<J>-P\X[J-_Q)X)2EAZZ?=?DST?4CXX^.6IS7EO93W=I$Q$<*.([>#_
M &06(4MCJ>IKB_$'AO5/"NHM9:K92V-THW;)!U'J"."/<&OM?P3HUOX?\):3
M8VT8BCBMDR!W8J"Q/N22:\E_:KLHVT;0KO8/-2XDBWX[%<X_\=J\]X66%P$\
M?4K2G65G*]K.[2=M+JU^_39%93Q'[7'QP%*E&-+51MNK7WZ:V[?-B?LW_$:^
MUA[GP[J=P]TT$7G6LLK9<(" R9[@9!'IS[5[O7R3^S@Q7XGVP'0VTP/_ 'S7
MUM7V_"F+JXO*J<JSNTVKO>R>GX:'R7%6&IX;,I*DK*23MY]?R"F2_P"J?Z&G
MTR7_ %3_ $-?5U?X<O1GR"W/S^4[7!]#FO1-8U3Q?\;]8:+3[2XN;*VP(;2)
M@L,*] 68D+N/J3ZXXXKSH]:^U/A'X=@\-?#[1X(D59)X%N9F'5G<!B3^8'X5
M^ <,974SAU<-.HXT59R2W;UY5^;Z^G5?O/$.8PRNG3Q*IJ5351OLK[O\$?(W
MB?P5KG@NXCBUG3IK%G^X[89&^CJ2"?H:]B^ 7Q@O)=1A\,ZU</<QS?+97,IR
MZL/^69/<'MGIT^GKGQ4\/0>)O .LVLR!GCMWN(6(Y61 64CTZ8^A-?%VFWTF
MF:C:WD3%9;>595([%2"/Y5WXBC4X0S:FZ%1NE.S=^JO9I]+K=.QP82O3XJRZ
MI#$02G'33H[:-=5YH^Z_$>NV_AG0K[5;LXM[2)I6 ZMCHH]R<#\:^,/%_C76
MOB'K9GO9I9S))BWLXR2D>3@*B^O09ZFOM.XL[/Q#I0AO;6*[M+A%9H)T#H>A
M&0?0X_*O.=7A^%GPYUN&_GCL;'5K<EHX[<O(Z'&.8U) Z\%@*^YXGRROCW!5
M,1&E0C\5W:[OJ^SLMD^I\5PYCZ. <[4)5*SVLKV\NZN]VNAX1_PH[QS]E^T?
MV!+Y>-V/.BWX_P!S=NS[8KF=)UG5O!VL?:+*>?3;^W<JP&58$'E64]?0@U]!
MZU^U/HULI72](O+YQQNN&6%/J,;B?R%?/GBC7Y?%/B&_U::*."6[E,C1Q9VK
M],U^69M0RS+Y4YY3B)2FGKY=FFDOU/TK*\1F6-4XYE048-:>?DTV_P!#ZUM?
M$$OC[X.76HQ0%[N\TR=#!""Q,H1E*J.O+#@>XKY#U70]1T*9(=2T^ZT^5UWK
M'=0M$S+G&0& R.#7U9^SK_R2VP_Z[3?^AFO+_P!J?_D<=)_Z\!_Z,>OKN*L+
M];RW#YK.7O.,-.GO+F?YGRO#^(^IYK7RVG'W'*6O;EO9'DND^'M5UXR#3-,O
M-1,6-XM('EV9Z9V@XZ&OK;X):;=Z1\,;"UOK6>RN4,VZ&XC,;KEV(R" :\W_
M &4?^/GQ'_N0?S>OH67_ %3_ $->IPGE%/#8/^T5-MU(--=%[W_ .#BW-9U:
MTLN<5:#3OU^'_@GY^GK7W;X-_P"10T/_ *\8/_1:U\)'K7VYI^HG1_AC;7Z\
MM:Z0LP^JP@_TKQ^ ZD:4<74ELE%_=S'K\:Q<X8>$=VW^AXO\=/C/>S:K<^'=
M"NFM;6W)CNKF%L/*_P#$@(Z*.AQU.>W7R_PQ\.?$GC.&2?1]*ENX4.#,66-,
M]P&<@$^PKG9)'N)FDD8L[L69F[D]37V=X7\5^#O#WAW3M.M_$6C116\"IM^W
MQ#G')/S=2<G\:\O+L/'BG%UL3F5;EC&UE=+>]DKZ65M=-3OQM5\-8.G1P%+F
ME+=V;VW;MK=WTU/DI)-?^'?B X-UHVJVYY!RIQ[CHRG\0:^L/A%\2$^(WAPS
MRJL6IVI$=U$O3..''L>?H0:\S_:2U#PYX@T;2[_3=5TZ_P!1@G\EEM+F.1S$
MRD\A23@%1_WT?6N9_9HU=['XA-9AOW5[:NA7U*_,#^A_.O2R6O/),[>5QJ\]
M&>VM]U=/UZ.V_P!QPYG2AG>3O'SI\E6";^[=>EM5V/3/VH/^2?6G_80C_P#1
M<E?/?@?QG<^!-7FU.SC22[-N\,1?E49L?,1WQSQ7T)^U!_R3ZT_["$?_ *+D
MKP7X4Z-!KWQ#T.RN8Q-;O/ODC;HP4%L'VXKCS^-:?$L88>7+.7(D^UTE?Y7-
M^'72613==7@N9M=TM;&@?AQX]\;1R:[+IEY?^</,,]Q(JNXZC:K,"1Z8&/2N
M.@N+W0M2$D3SV%];/C*DI)&P/(]0:^^@   !@#M7R'^T+91V?Q1U!HT"">**
M5L# )* $_I2XCX=IY-0IXRA5DY.5FWO>S=TU:VJ\_4>0<03S7$3PE6G&,;75
MNRLK/OOY>A]"_!WQO+X\\%6][=%3?0N;>X*\;F7!W8[9!!^N:^3_ !;X<U;1
MM2NI]0TN]L8)KB01R7-N\:OR3P2 #QZ5[Q^RJQ/AK6USP+M2!_P ?X4G[57_
M "+FB?\ 7VW_ *!7MYWAWFN04,QK2?/3BGZN3BFW]USRLLK++,^K8&C%<LW]
MUDY:??8^==-TF^UFZ%MI]G<7UP06\FVB:1\#J<*":^D_V<]*OO"WAC77UBQN
MM+43B7_2X&B)0)R0& R*\T_9M_Y*9%_UZ3?R%?4NNZ>VK:)J%BK!&N;>2$,>
MQ92,_K67"&4J%#^U:<FYVDE'IY&O%F:253^S917++E;?7?\ X!\=?$?XEZK\
M1=9E:262/30^+:Q0G:HSP2!U8^OOQQ4]I\#_ !Q?6JW$>@3+&PW 2S11MC_=
M9@?TKD9X+O0-5:*5&MKZSFP58<HZGT^HKVKP_P#M3W]NB1ZSH\-X1@&>TD,3
M?4J003]"*^-R_P#L[,*U2>=5YQFWHU^NDK>EDD?5XQ8W T*<,GHQE%='^%M5
M>_5WN>0 ZUX%UTC-UH^J6YY',;K_ (@_D17UQ\(OB!_PL+PHEW,%34;=O)ND
M08&[&0P'H1S]<UQ?_">_"WXFZG;W&M6_V?4$3RHSJ0:-=N2<%E8IC)/WCWKU
M;P_X=T;P_;,-&L+6RAF 8M:H )/0DCKUX^M?I7#&6U,%5J3PV)C4H/HG=KLW
MT3Z/O]Q\!Q%F$,70A#$X:5.NNK5EYI/=K\F:M%%%?HQ^>'S9^U+X<^S:WI6M
MQKA+J(V\I']]#D$_4-C_ (#6C^RMK^5UK17;IMNXQG_@+_\ LE>@?'?P[_PD
M7PVU+8NZ>RQ>1_\  /O?^.%J^=?@GX@_X1WXD:3*S!8;E_LLA/3#\#_Q[::_
M(,0O[(XKA4VA6_\ ;M'_ .3:GZO@G_:O#=2@]94[_P#DOO+\-#Z#_:#UW^Q?
MAI>QJVV6^D2U7GL3N;_QU6'XU\CVUP]I<Q3QG;)$X=3Z$'(KW3]JG7?,U+1=
M'1N(HGNI #W8[5_+:WYUXM>:)<V.DZ?J,JXM[[S!"?780&_F*^;XKQ-3$YM4
ME2VI)*_:UM?_  *5CW.%L/'#99!SWJ-OU_I*Y]SZ%JB:WHEAJ$9!2Z@288_V
ME!_K7R7\>?$']O\ Q+U((VZ&RVV:>VS[W_CY:O:O@MXRBA^#;WEPP(T99DD&
M>2JC>H_)@*^888KGQ'KB1C,MY?7 '^\[M_B:^DXOS!X["X2A1U=6T[>JLE][
M?W'A\,Y<L)C\54GM3O%??>_W)?>?4/[-_AS^QO  OG7;-J4S3<_W!\J_R)_&
MOES6_P#D-7__ %\2?^A&ONS1M+BT32++3X !#:PI"N!CA0!G]*^$];_Y#5__
M -?$G_H1KDXSPT<%A<#AH[04E]RAK\]SHX6Q3QN-QF(?VFG\KRM^!]216=QJ
M'[.D5M:P27-Q)I"JD,*%W<X'  Y-?+.IZ1?Z)<_9]1LKBPN-H;RKJ)HWP>AP
MP!Q7V?\ "C_DFWAO_KRC_E7S]^TS_P E'3_KQB_]">NOC'+XRP=',.;5*,;=
M.KN8<-8Z4<PKX'ET<I2OZ.QYQI/AG6->21],TJ^U%(R [6EL\H4GH#M!Q7U;
MX:LKC3?@3]FN[>6UN8])N \,R%'4[7X(/(KD?V4_^0)K_P#U\1_^@FO7/&G_
M ")VN_\ 7A/_ .BVKNX?RBG@\LJ8Z,VW5INZZ+<X.(\TGB,;' .*2A.+OU>G
M_!/A*O1+F'QQ\:;CS[:RN+RQML1PQ*XCMX<#H"Q"EL=3U_2O.Z^Z_!.C0:!X
M2TFPMT"1PVR X[L1EC]2237Q_"V3O.%7I5*CC27*Y*/5^]R[WVUZ'UW$>:+*
MHTJL*:E4=U%OHM+_ *'Q3XA\,:KX2U#['JUE+8W.-P5\88>JL."/<&O?OV</
MB1>ZX+KP]JEPUS+;Q>=:S2ME]@(#(3WQD$?CZ4G[5=HK:#H5SL&]+EX]_<!E
MSC_QVO/OV;W*?$ZW Z-;3 _EG^E>AE]&>0\2+!49MP;MKU3C=7\T^OEYV.#%
M5H9YD$L56@E))O3HXOIZV/K6BBBOW$_%S$\;:LV@^$-:U!&VR6]I+(A_V@IV
M_KBOA4DLV3DD_K7VK\7T:3X9^(@AP?LK'@=@03^E?%:':ZD]C7XEQW)RQU&G
M)^ZH_FW?\D?L'!,(K"UIK=RM]R_X+/N?P/HD7AWPAI&GQ+M$-L@;W8C+'\23
M6[5;37$NG6KJ<JT2$'VP*LU^V*$::Y(JR6A^259RJ5)3GNVVSFO''P^TGXA6
M=K;:JLNRVE\U# X5NA!4G!X/MZ"H/#?PK\*^$[F.YTW1X8KJ/[MQ(S2.IQC(
M+$X_#%=917']1PKK_672C[3^:ROIMKN="QN)C1^KQJ-0[7=M?(RO%'B.T\):
M!>ZM?-MM[9-Q ZL>BJ/<D@?C7QOXX^(6M?$353+?3.8=_P#H]C$3Y<7H O<^
M_4_I7MO[5&K26_AW1M.1B$NKAY7QW"*,#\WS^%>6? G^R(OB!;W>LW=K9VUI
M$\T;W<JQH9. O+$#(R2/I7Y3Q)BZN9YM#)XU.2FK<W:[5VWWLMEW/TOAO"4L
M%ET\TE#FGK;O9:67FWU[&9=_"'QC9:0=3FT&Y2T5=['*EU'J8P=P_$5>^%_Q
M:U/X?ZE#&\TEUHKMB:S8Y"@]63/W2.O'![U]3_\ "Q/"G_0S:-_X'Q?_ !5?
M(GQ1M=,M/'NL+H\]O<Z<\HEB>U=7C^90Q"E>, DC\*\O-<!3X;G2QN5XB^MF
MFT_/I:\7U3/3RO,:F?*I@\QH65KK1I=NO57T:/M:RO(=0LX+JWD$MO,BR1R+
MT92,@_E7R'^T!_R5;6/]V'_T4E>\?L]:N^J_#*R21MS6DLEMGV!R!^3"O!_V
M@/\ DJVL?[L/_HI*^BXRQ"Q63X;$1VG*+^^$F?/\+X=X3.:^'?V8R7W2B>Q_
MLO\ _)/;O_L(R?\ HN.N2_:N_P"0EX=_ZY3?S2NM_9?_ .2>W?\ V$9/_1<=
M<E^U=_R$O#O_ %RF_FE:YK_R2=+_  T_T#!?\E3/UE_Z2RK^RK_R,NM_]>B_
M^ABO8OBSX]'P]\)37T05[^9O(M4;IO(/S$>@ )_(=Z\=_95_Y&76_P#KT7_T
M,5]!Z[X:TGQ) D>K:?;7\<9)07$8;9GJ03T_"O2X?IUZO#E.GA9*,VI)-]/?
MEK]VWF>?Q!.C3SUSQ$>:"Y;I==%H?$X&N_$'7\#[5K.JW!)Y)=L?R51^ %;.
MK_!KQGH=A)>7FA2K;QJ6=HI8Y2H'4D(Q( ]<5[JOBOX6_"S4+N;37A74)$\N
M1-/+SD@'.W.2B\]1D5SWB+]J>U:&6+1]#DFWJ5$M_(% ^J+G(_X$*^&J9+E&
M%HR>88V];7X7S*_2^C;?>[7ZGU\<WS3$5(K+\':EI\2Y?NU22[;_ *'D'@#X
MA:IX!UB&YL[AS:%Q]HM"Q,<J]\CUQT/45]LV\Z75O%-&<QR*'4^H(R*_/VON
M2UU Z3\/H;X8S;:6)N>GRQ9_I7O\#XZI]6Q-.M*\*=FO*ZE?Y:;>O<\CC/"4
M^>A5IQM.3:?GM:YXG\<_C3?'5;GP[H-RUI;VY,=U=0MAY'[HI[ =#CDG/;KY
M5X8^'OB/QJLDND:7->QJ<-,65$SZ;G(!/MFL"222ZG>21B\LC%F8]22>37W7
MX3T2#P[X:TW3K:,1QV\"+@#&6Q\Q/N3D_C7B97@:G%^+K8G'5&H1M9+I>]DK
MW22MKIJ>KF&*I\*X.E1PD$YRZOK;=NVKWTUT/BO6O#VN^ ]4B2_MKG2;U?GB
MD#8)QW1U.#]0:^CO@-\5I_&MG-I.K2"35K1 Z3'@SQ],G_:!QGUR/>NW\>?#
M[2OB)IUO9ZIYR)!+YJ26[!7!P01D@\'/Z"L[PC\'/#/@K4DU#3;>?[:BLJS2
MW#-P1@\9 /Y5]9E/#^/R;,7+#U$\.]TWJ].R5KI]=+KU/FLQS[ YME_)BJ;5
M=;-+1/U;O9]5J=O1117Z.?GAQ7QG_P"27^(?^O<?^A+7QYH?_(;T_P#Z^(__
M $(5]A_&?_DE_B'_ *]Q_P"A+7QYH?\ R&]/_P"OB/\ ]"%?BW&'_(ZPW^&/
M_I<C]@X._P"1=6_Q/_TE'WQ1117[2?CY\D?M%:#%HGQ'FE@4(E_ ET5'0.25
M;\RN?QKL/V4]5<7&O:83F,K'<*/0@E3_ #7\JR?VIV!\9Z4H/(L!G_OX]/\
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M;HT$_>W?Z+U_X&MSZ5_X)D_#R?Q#\;;[Q2\3?8/#]@^)<<?:)OW:+_WQYI_
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MRU3P\_B@>&;BSL3>QN;'[49@'5& 7S$QC>#G)K]./VO?@4_Q]^#E]HUBL?\
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M5./Y/_(\3CA-_5I+;WO_ &T^(OB!_P CYXD_["5S_P"C6KZN^"/_ "2S0/\
MKD__ *,:OEOXI:=+IGQ%\10S*59KV649[J[%U/Y,*[7P/^T)=^#_  I::&ND
M0W36Y*QW+S%0%+$\H!SC)[BOG^&<QPV59AB%C)<M[K9O7FVTV_(]G/,!B,TR
MS#PPBYFN5[I:<KUU]3UC]H__ ))A<_\ 7S#_ .A5\^?!S_DIWAW_ *^?_937
MT#^T7(LOPLG=3E6N(2#[9KY^^#G_ "4[P[_U\_\ LIKT\]_Y*G"^M/\ ]*.#
MA_\ Y$&(_P"W_P#TE'UKX^_Y$;Q#_P!@^X_]%M7PS'_K%^HK[F\??\B-XA_[
M!]Q_Z+:OAF/_ %B_45EQQ_R,,/\ X?\ VYAP3_N]?U7Y'W[8_P#'E;_]<U_E
M7BO[57_(N:)_U]M_Z!7M5C_QY6__ %S7^5>*_M5?\BYHG_7VW_H%?H'%G_(G
MQ'R_]*1\1P[_ ,C>CZO\F>>_LV_\E,B_Z])OY"O0?VJK&27P_H=XH)CAN7C8
M^A=01_Z :\^_9M_Y*9%_UZ3?R%?2/C_PA#XY\*7VD2L(WE7=#*?^6<@Y4_3/
M7V)KY'*,%/,>%JF&I_$V[>J::7S:/J\ZQ<<#Q#1Q$]DE?T=T_P SYJ_9TU6+
M3?B5;QS.$%W!);J3W;A@/QVXKZWKX,U?2-2\):U)9WD4MCJ%JX/H00>&4]QW
M!%>@P?M)>,8=,%IOL9)0NT7CP$S?7[VTGZK7G<.<38?*<)+!XV,DXMVLN^Z:
MTLT_Z1W\0</ULVKPQ>#DFFDG=_<T^JL;O[4^LPW7B#1M-C8-+9P/+(!_"9"N
M ?P3/XBH?V6/^1OU?_KQ_P#:BUYCXCTO6A;6FO:P)2VKO(\<LY^>7;MR^/3Y
MACZ>E>G?LL?\C?J__7C_ .U%K@RK$U,9Q1#$5(\KDV[/=+D=OPL=V,PT,'P[
M/#PES**M==^;7\;GTW1117[P?B)%<S0PQ,9WCCB(P3(0!^M>.Z_\$/ _C2_N
M/[#U6'3M1QO>"PF2:->?O&+.0.1T(%;'Q\^'MQXW\,17.GQF;4].9I(XEZRQ
MD#>H]^ 1],=Z^9/"/BS4O FOQ:GI[!+F+*/'*I*NIZJPXX_PK\SXAS;#T<9#
M!YEA5*D]IWUL]VM%9I[I.]O5'Z'P_EE:OAI8K XEQJK[-M+]+ZNZ?>WY'HFM
M_LQ^)]/WMI]Q9:K&/NJKF*0_@WRC_OJO*]1TZ]\/ZI-:7<4EG?6S[70\,C#W
M'YY%>X-^U?<FUVKX;B%SC_6&\)3/KMV9_P#'J\:UW6=1\;^)+B_N$\_4;Z4?
MNX4/)X554<GH !7YYG-/)DX/)YR<F]5K9=K72=[^I]YE%3.&Y+-(Q44M'I=O
MY-JUO0^L_@GXKNO%_@"SNKYS+>0.UM)*W60KC#'WP1GWKYF^*OC:Z\;^+[VX
MEF8V4$K0VD.?E2,' ./4XR3_ ("OJ/X2>#Y?!'@:QT^YP+QLSS@?PNW.W\!@
M?A7R;\0?#%SX1\7ZGIUPC*%F9X6(XDC))5A]1^N1VKZ[B]XV&68.%5O;W_\
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MHS='XK.WK;3\3EI*#J153X;J_IU/A_Q!K^H>+M;GU"_F:YO+A^_0<\*H[ =
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MK4:G$T*M&')"7-RJUM'"26GGO\SCS.E6I\/U*5>?/-)<SO?7F3?W'2_M5?\
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M'_D:C]T;'G\,8A8O-\576TDW]\D?07[.'_),;;_KYF_]"KS3]J?_ )''2?\
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MI5Z?#]2E7GSU$O>=[Z\R;^Y'8?M4?\BCI'_7]_[3:O+OV=_^2IZ=_P!<IO\
MT6:]1_:H_P"11TC_ *_O_:;5Y=^SO_R5/3O^N4W_ *+->GC_ /DKJ?K#_P!)
M1YN5_P#),5?\,_U/KROD+]H?_DJFI_\ 7*#_ -%+7U[7R%^T/_R534_^N4'_
M **6O=X]_P"1;2_Z^+_TF9\]P9_R,9?X'^<3U;]EK_D2M2_Z_C_Z E>3?M!6
MKVWQ5U9V&!,D,BGU'E*O\U->L_LM?\B5J7_7\?\ T!*A_:1^'EQKMA;^(M/B
M::XL8S'<QJ,L8<DA@/\ 9).?8Y[5PYK@JF,X8PTJ2NZ:C+Y<MG]U[_(]3"8R
MGA.)JWM'93O&_F[-?BK%C]EW44G\$ZA9@CS;>]+$=]K(N#^:G\J]EKX>\!>/
M]3^'FL&_TXHX==DUO+DI*OH<=".Q_P#KUZ+XG_:<U;6=)DL],TN/29Y5V/<B
M<RN >NSY5VGWY_K6N4<6X##Y9"E7;52"MRV;O;16>VJMO8SSCAC&XG,)5<.D
MX3=[W2MWNM_NN>?_ !3OXM3^(OB"XA8/$;MU5@<@[?ER/RKZ+_9P_P"28VW_
M %\S?^A5\LZSHM[H-X+;4(6M[EHTE,;_ 'E# ,,^AP1Q7U-^SA_R3&V_Z^9O
M_0J\7@R4YYSB)55:3C*Z[/GC=?>>OQ3"%/)J4*;NDXI/NDF>HT445^V'XV?/
M_P"U?_JO#7^]<?\ M.N>_9:_Y'G4O^P<W_HR.NA_:O\ ]5X:_P!ZX_\ :=<]
M^RU_R/.I?]@YO_1D=?C/_-9OU_\ <9^N8?\ Y)1^DO\ TMGU#7P#J'_'_<_]
M=6_F:^_J^ =0_P"/^Y_ZZM_,UKX@_%A/^W__ &PY>!OBQ'_;O_MQ]L?#/_DG
MOAW_ *\8?_017E7[5W_'AX;_ .NL_P#)*]5^&?\ R3WP[_UXP_\ H(KRK]J[
M_CP\-_\ 76?^25]5Q5_R(*OI#_TN)X&2?\C^/^*?Y2.2_9B_Y*%<?]>,G_H2
M5Z[^T1_R2S4?^NL/_HP5Y%^S%_R4*X_Z\9/_ $)*][^*WAR;Q7\/]8TZW3S+
MEXA)"@ZLZ,' 'N=N/QKR,GI3K<*SITU=N-2R^;/5SNI&CQ%2J3=DG"_WGRE\
M)Y!%\2?#C-T^VQC\S@?SK[:KX!M+J?3+Z&XA9H;FWD#HW0JRG(_45[8G[5>I
M+I8B;0K9M0"X^T^>PC)]?+QG\-U>%PGG^!RO"5*&+DXOFYEHW>Z2MI?MUL>W
MQ1DN+S*M2JX6/-96>J5M;WU,;]INY2?XC1(IRT-A%&WL=SM_)A75_LG_ .I\
M3?[UM_[4KQ?Q4NM:E)%X@UD.9-6=Y(Y9!@R!<#('9>0!]/:O:/V3_P#4^)O]
MZV_]J5AD-:6)XEE7E%QYN9V>]FKK\+&V;T%AN''0YD^513:VNI*_XW-S]J7_
M )$/3O\ L))_Z*EKR?\ 9W_Y*GIW_7*;_P!%FO6/VI?^1#T[_L))_P"BI:\G
M_9W_ .2IZ=_URF_]%FNS'_\ )74_6'Y(XLJ_Y)FMZ3_(^H_&G_(G:[_UX3_^
MBVKX4C_UB_45]Z>(;%]3T#4K./[]Q;2PK]60@?SKX,='AE9'4HZ'!4C!!%+C
MM.&+P]1K2S_!_P#!)X(DG2KQZW7Y,^_+'_CRM_\ KFO\J\!_:Q_UGA?Z7/\
M[2K0\ _M#77B77]"T*32(;<S$0S7/G%MQ"GE5P,9('4FL_\ :Q_UGA?Z7/\
M[2KZ+B/,<+FF15J^$ES14DKV:UO%];/JCP\FR[$Y;G="GB8V;4FM4].62Z&3
M^RQ_R-^K_P#7C_[46O0/VF_^2<Q?]?\ %_Z"]>?_ ++'_(WZO_UX_P#M1:]
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M,8\JBDK7O:RVN][=^I^/XNK*OB)U92YFV];6OYV6U^P5\9_'"S>R^*6NJ_\
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MH\I7'0[%"9'M\M=QXK_:;U?6M,DM-+TV/1GE4J]QYYED /78=JA3[\^U>?>
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MC,7PK3C--R@^9+KRINWX.Z\K'A2QV%PG$KE%I1DN63Z<S_X*2?G>YXS\*?A
MGQ.M-0E&M#39+1U4Q?9O-+!@2#G>N.AKNS^R>%!)\58 Y).G_P#VVO(? OCO
M5/A[K/V_3F4EALF@E&4E7/0_T/:O0O%O[2^I>(-!GTZRTJ/2Y+A#%+<>>96V
MD8.T;1M)]>?ZUX&7UN&E@.;&4G[:*>EY^\^EK.ROYV/:S&EG[QEL%47LG;I#
MW>][J[[Z7+=C^SIH^IX^Q^/[&[ST\BW1\_E-7OGA+05\(^%]/TIKD7"V<0B,
MY39N]\9./SKX[^'/@6\\?^);?3X$86P8/=3@<11YY.?4] /6OK7QSX(@\6>"
M+O0(@L ,2K;$](W3!3\. #[$U]GPQ[/ZI6QV#P?([67OR?/;6RYKVUTOK=W[
M'R?$GM(UJ.$Q6+YTW=^[%<JVOI:_70Y;QO\ #GP'XZU0>=?VMCK<YP'L[J-9
M96QW0Y#'\,^]>;ZY^RUK5J6;2M5M+^,<[)U:%S[#[P/XD5Y+<6VJ>#M?\N5)
M=.U2QE##/#(X.01Z^H/0U[+IO[5E]!9JE]X?AN[D#!FAN3$K'UVE&_G7S<<P
MR#-95)9I1]C4OO'FU];+>^]XGO/ 9UEL*:RVM[:%MG;Y6N]O1GD'BGP?J_@O
M4!9:Q9M:3LN] 6#*ZYQD,"0:][_9B\87>J:;J.B7<KSI8A);=G.2J-D%/H"!
MCZFO%OB)\1-0^(^L1WM['%;I"GEPP0YPBYSR3U)]?TKW;]FWP+=>'M"N]8OH
MF@GU+:(8W&&$2Y(8CMN)S] /6LN%*=L\E]0;=!*5V^JMI?SYK6]/4Z.(IMY+
M_MR2JNUDOYK]/E>Y[+1117[F?BAX!^U=8,T'AV]"_(K30LWN0A4?^.M7+_LQ
MZI%9>/;FVD(5KNS=(\]V#*V/R!_*O??B9X)C\?>$;O2RRQW'$MM(W1)5Z9]C
MD@^Q-?'%Q;:MX*\0;)4FTS5;*0,,\,C#H1ZCWZ$5^+YXJF29_#-'%NG)I_\
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MA32?DD?DLL37DK2FVO5A4%_$TUC<1H,N\;*H]214]%;RBI1<7U.=.SN?'9^
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M:*>)94(.<A@"/YU\;_%CX?W/@'Q5<P^4PTVX=I;.;'RLA.=N?5<X(^A[U?\
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MB?E_Z4CXC(/^1O1_Q/\ )GF?[./_ "5"U_Z]YO\ T&OK>ODC]G'_ )*A:_\
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MSXD^'DIM(VEFL9UN_+49+* RM@>P8G\*^6?"_B2]\(Z[::M8,JW5LVY0XRK
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWIY*Y\__ /!5;Q3IUT_@/08+R";4;9KJZN+9'#20JPC5"P'W=V&QGKMK@O\
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M"<^3!<*4'M\Z,?UKL/!OPQ\.^! 6TJQ"W+#:UU,V^4CTR>@]A@5U5%<&'RG
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M+6J*M5I1E-;-Q3:MMJU?0Z*6-Q5"#ITJLHQ?1-I?<F%%%%=IQA1110 4444
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MO(SDL>IR3_*MFBN3"Y7@<%)RPU&,6]&TNG;T\CKQ.9XW&05/$57)+HV>>_\
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M*KDET;T^X****]$\X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHK)\6:[_P (OX5UG6?(^T_V=937GD;]
MGF>6A?;NP<9QC.#CTH UJ*R?">N_\)1X5T;6?(^S?VC90WGD;]_E^8@?;NP,
MXSC.!GTK6H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N4^
M+/\ R2OQE_V!;W_T0]=77*?%G_DE?C+_ + M[_Z(>@ ^$W_)*_!O_8%LO_1"
M5U=<I\)O^25^#?\ L"V7_HA*ZN@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#Y3_P""C_QN\:_ 3X'Z'X@\":U_86KW/B*"PEN/LL%Q
MN@:VNG9-LR.H^:-#D#/'7DU^</\ P\F_:-_Z*)_Y1-._^1Z^Y?\ @K__ ,FT
M^&O^QNMO_2.]K\@:^URK#T:F&4IP3=WND>+BJDXU+1;1],_\/)OVC?\ HHG_
M )1-._\ D>C_ (>3?M&_]%$_\HFG?_(]?,U%>Q]4PW_/N/W(Y/;5/YG]Y],_
M\/)OVC?^BB?^433O_D>C_AY-^T;_ -%$_P#*)IW_ ,CU\S44?5,-_P ^X_<@
M]M4_F?WGTS_P\F_:-_Z*)_Y1-._^1Z/^'DW[1O\ T43_ ,HFG?\ R/7S-11]
M4PW_ #[C]R#VU3^9_>?3/_#R;]HW_HHG_E$T[_Y'H_X>3?M&_P#11/\ RB:=
M_P#(]?,U%'U3#?\ /N/W(/;5/YG]Y],_\/)OVC?^BB?^433O_D>C_AY-^T;_
M -%$_P#*)IW_ ,CU\S44?5,-_P ^X_<@]M4_F?WGTS_P\F_:-_Z*)_Y1-._^
M1Z/^'DW[1O\ T43_ ,HFG?\ R/7S-11]4PW_ #[C]R#VU3^9_>?3/_#R;]HW
M_HHG_E$T[_Y'H_X>3?M&_P#11/\ RB:=_P#(]?,U%'U3#?\ /N/W(/;5/YG]
MY],_\/)OVC?^BB?^433O_D>C_AY-^T;_ -%$_P#*)IW_ ,CU\S44?5,-_P ^
MX_<@]M4_F?WGTS_P\F_:-_Z*)_Y1-._^1Z/^'DW[1O\ T43_ ,HFG?\ R/7S
M-11]4PW_ #[C]R#VU3^9_>?3/_#R;]HW_HHG_E$T[_Y'H_X>3?M&_P#11/\
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M_P ^X_<@]M4_F?WGTS_P\F_:-_Z*)_Y1-._^1Z/^'DW[1O\ T43_ ,HFG?\
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M_>?3/_#R;]HW_HHG_E$T[_Y'H_X>3?M&_P#11/\ RB:=_P#(]?,U%'U3#?\
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M ,CU\S44?5,-_P ^X_<@]M4_F?WGTS_P\F_:-_Z*)_Y1-._^1Z/^'DW[1O\
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M-11]4PW_ #[C]R#VU3^9_>?3/_#R;]HW_HHG_E$T[_Y'H_X>3?M&_P#11/\
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M_P ^X_<@]M4_F?WGTS_P\F_:-_Z*)_Y1-._^1Z/^'DW[1O\ T43_ ,HFG?\
MR/7S-11]4PW_ #[C]R#VU3^9_>?3/_#R;]HW_HHG_E$T[_Y'H_X>3?M&_P#1
M1/\ RB:=_P#(]?,U%'U3#?\ /N/W(/;5/YG]Y],_\/)OVC?^BB?^433O_D>C
M_AY-^T;_ -%$_P#*)IW_ ,CU\S44?5,-_P ^X_<@]M4_F?WGTS_P\F_:-_Z*
M)_Y1-._^1Z/^'DW[1O\ T43_ ,HFG?\ R/7S-11]4PW_ #[C]R#VU3^9_>?3
M/_#R;]HW_HHG_E$T[_Y'H_X>3?M&_P#11/\ RB:=_P#(]?,U%'U3#?\ /N/W
M(/;5/YG]Y],_\/)OVC?^BB?^433O_D>C_AY-^T;_ -%$_P#*)IW_ ,CU\S44
M?5,-_P ^X_<@]M4_F?WGTS_P\F_:-_Z*)_Y1-._^1Z/^'DW[1O\ T43_ ,HF
MG?\ R/7S-11]4PW_ #[C]R#VU3^9_>?3/_#R;]HW_HHG_E$T[_Y'H_X>3?M&
M_P#11/\ RB:=_P#(]?,U%'U3#?\ /N/W(/;5/YG]Y],_\/)OVC?^BB?^433O
M_D>C_AY-^T;_ -%$_P#*)IW_ ,CU\S44?5,-_P ^X_<@]M4_F?WGTS_P\F_:
M-_Z*)_Y1-._^1Z/^'DW[1O\ T43_ ,HFG?\ R/7S-11]4PW_ #[C]R#VU3^9
M_>?3/_#R;]HW_HHG_E$T[_Y'H_X>3?M&_P#11/\ RB:=_P#(]?,U%'U3#?\
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M ,CU\S44?5,-_P ^X_<@]M4_F?WGTS_P\F_:-_Z*)_Y1-._^1Z/^'DW[1O\
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M?_QRO/:*/90_E7W![6I_,_O/0O\ AHGXK?\ 13?&/_@_N_\ XY1_PT3\5O\
MHIOC'_P?W?\ \<KSVBCV4/Y5]P>UJ?S/[ST+_AHGXK?]%-\8_P#@_N__ (Y1
M_P -$_%;_HIOC'_P?W?_ ,<KSVBCV4/Y5]P>UJ?S/[ST+_AHGXK?]%-\8_\
M@_N__CE'_#1/Q6_Z*;XQ_P#!_=__ !RO/:*/90_E7W![6I_,_O/0O^&B?BM_
MT4WQC_X/[O\ ^.4?\-$_%;_HIOC'_P ']W_\<KSVBCV4/Y5]P>UJ?S/[ST+_
M (:)^*W_ $4WQC_X/[O_ ..4?\-$_%;_ **;XQ_\']W_ /'*\]HH]E#^5?<'
MM:G\S^\]"_X:)^*W_13?&/\ X/[O_P".4?\ #1/Q6_Z*;XQ_\']W_P#'*\]H
MH]E#^5?<'M:G\S^\]"_X:)^*W_13?&/_ (/[O_XY1_PT3\5O^BF^,?\ P?W?
M_P <KSVBCV4/Y5]P>UJ?S/[ST+_AHGXK?]%-\8_^#^[_ /CE'_#1/Q6_Z*;X
MQ_\ !_=__'*\]HH]E#^5?<'M:G\S^\]"_P"&B?BM_P!%-\8_^#^[_P#CE'_#
M1/Q6_P"BF^,?_!_=_P#QRO/:*/90_E7W![6I_,_O/0O^&B?BM_T4WQC_ .#^
M[_\ CE'_  T3\5O^BF^,?_!_=_\ QRO/:*/90_E7W![6I_,_O/0O^&B?BM_T
M4WQC_P"#^[_^.4?\-$_%;_HIOC'_ ,']W_\ '*\]HH]E#^5?<'M:G\S^\]"_
MX:)^*W_13?&/_@_N_P#XY1_PT3\5O^BF^,?_  ?W?_QRO/:*/90_E7W![6I_
M,_O/0O\ AHGXK?\ 13?&/_@_N_\ XY1_PT3\5O\ HIOC'_P?W?\ \<KSVBCV
M4/Y5]P>UJ?S/[ST+_AHGXK?]%-\8_P#@_N__ (Y1_P -$_%;_HIOC'_P?W?_
M ,<KSVBCV4/Y5]P>UJ?S/[ST+_AHGXK?]%-\8_\ @_N__CE'_#1/Q6_Z*;XQ
M_P#!_=__ !RO/:*/90_E7W![6I_,_O/0O^&B?BM_T4WQC_X/[O\ ^.4?\-$_
M%;_HIOC'_P ']W_\<KSVBCV4/Y5]P>UJ?S/[ST+_ (:)^*W_ $4WQC_X/[O_
M ..4?\-$_%;_ **;XQ_\']W_ /'*\]HH]E#^5?<'M:G\S^\]"_X:)^*W_13?
M&/\ X/[O_P".4?\ #1/Q6_Z*;XQ_\']W_P#'*\]HH]E#^5?<'M:G\S^\]"_X
M:)^*W_13?&/_ (/[O_XY1_PT3\5O^BF^,?\ P?W?_P <KSVBCV4/Y5]P>UJ?
MS/[ST+_AHGXK?]%-\8_^#^[_ /CE'_#1/Q6_Z*;XQ_\ !_=__'*\]HH]E#^5
M?<'M:G\S^\]"_P"&B?BM_P!%-\8_^#^[_P#CE'_#1/Q6_P"BF^,?_!_=_P#Q
MRO/:*/90_E7W![6I_,_O/0O^&B?BM_T4WQC_ .#^[_\ CE'_  T3\5O^BF^,
M?_!_=_\ QRO/:*/90_E7W![6I_,_O/0O^&B?BM_T4WQC_P"#^[_^.4?\-$_%
M;_HIOC'_ ,']W_\ '*\]HH]E#^5?<'M:G\S^\]"_X:)^*W_13?&/_@_N_P#X
MY1_PT3\5O^BF^,?_  ?W?_QRO/:*/90_E7W![6I_,_O/0O\ AHGXK?\ 13?&
M/_@_N_\ XY1_PT3\5O\ HIOC'_P?W?\ \<KSVBCV4/Y5]P>UJ?S/[ST+_AHG
MXK?]%-\8_P#@_N__ (Y1_P -$_%;_HIOC'_P?W?_ ,<KSVBCV4/Y5]P>UJ?S
M/[ST+_AHGXK?]%-\8_\ @_N__CE'_#1/Q6_Z*;XQ_P#!_=__ !RO/:*/90_E
M7W![6I_,_O/0O^&B?BM_T4WQC_X/[O\ ^.4?\-$_%;_HIOC'_P ']W_\<KSV
MBCV4/Y5]P>UJ?S/[ST+_ (:)^*W_ $4WQC_X/[O_ ..4?\-$_%;_ **;XQ_\
M']W_ /'*\]HH]E#^5?<'M:G\S^\]"_X:)^*W_13?&/\ X/[O_P".4?\ #1/Q
M6_Z*;XQ_\']W_P#'*\]HH]E#^5?<'M:G\S^\]"_X:)^*W_13?&/_ (/[O_XY
M1_PT3\5O^BF^,?\ P?W?_P <KSVBCV4/Y5]P>UJ?S/[ST+_AHGXK?]%-\8_^
M#^[_ /CE'_#1/Q6_Z*;XQ_\ !_=__'*\]HH]E#^5?<'M:G\S^\]"_P"&B?BM
M_P!%-\8_^#^[_P#CE'_#1/Q6_P"BF^,?_!_=_P#QRO/:*/90_E7W![6I_,_O
M/0O^&B?BM_T4WQC_ .#^[_\ CE'_  T3\5O^BF^,?_!_=_\ QRO/:*/90_E7
MW![6I_,_O/0O^&B?BM_T4WQC_P"#^[_^.4?\-$_%;_HIOC'_ ,']W_\ '*\]
MHH]E#^5?<'M:G\S^\]"_X:)^*W_13?&/_@_N_P#XY1_PT3\5O^BF^,?_  ?W
M?_QRO/:*/90_E7W![6I_,_O/0O\ AHGXK?\ 13?&/_@_N_\ XY1_PT3\5O\
MHIOC'_P?W?\ \<KSVBCV4/Y5]P>UJ?S/[ST+_AHGXK?]%-\8_P#@_N__ (Y1
M_P -$_%;_HIOC'_P?W?_ ,<KSVBCV4/Y5]P>UJ?S/[ST+_AHGXK?]%-\8_\
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M?_QRO/:*/90_E7W![6I_,_O/0O\ AHGXK?\ 13?&/_@_N_\ XY1_PT3\5O\
MHIOC'_P?W?\ \<KSVBCV4/Y5]P>UJ?S/[ST+_AHGXK?]%-\8_P#@_N__ (Y1
M_P -$_%;_HIOC'_P?W?_ ,<KSVBCV4/Y5]P>UJ?S/[ST+_AHGXK?]%-\8_\
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M?_QRO/:*/90_E7W![6I_,_O/0O\ AHGXK?\ 13?&/_@_N_\ XY1_PT3\5O\
MHIOC'_P?W?\ \<KSVBCV4/Y5]P>UJ?S/[ST+_AHGXK?]%-\8_P#@_N__ (Y1
M_P -$_%;_HIOC'_P?W?_ ,<KSVBCV4/Y5]P>UJ?S/[ST+_AHGXK?]%-\8_\
M@_N__CE'_#1/Q6_Z*;XQ_P#!_=__ !RO/:*/90_E7W![6I_,_O/0O^&B?BM_
MT4WQC_X/[O\ ^.4?\-$_%;_HIOC'_P ']W_\<KSVBCV4/Y5]P>UJ?S/[ST+_
M (:)^*W_ $4WQC_X/[O_ ..4?\-$_%;_ **;XQ_\']W_ /'*\]HH]E#^5?<'
MM:G\S^\]"_X:)^*W_13?&/\ X/[O_P".4?\ #1/Q6_Z*;XQ_\']W_P#'*\]H
MH]E#^5?<'M:G\S^\]"_X:)^*W_13?&/_ (/[O_XY1_PT3\5O^BF^,?\ P?W?
M_P <KSVBCV4/Y5]P>UJ?S/[ST+_AHGXK?]%-\8_^#^[_ /CE'_#1/Q6_Z*;X
MQ_\ !_=__'*\]HH]E#^5?<'M:G\S^\]"_P"&B?BM_P!%-\8_^#^[_P#CE'_#
M1/Q6_P"BF^,?_!_=_P#QRO/:*/90_E7W![6I_,_O/0O^&B?BM_T4WQC_ .#^
M[_\ CE'_  T3\5O^BF^,?_!_=_\ QRO/:*/90_E7W![6I_,_O/0O^&B?BM_T
M4WQC_P"#^[_^.4?\-$_%;_HIOC'_ ,']W_\ '*\]HH]E#^5?<'M:G\S^\]"_
MX:)^*W_13?&/_@_N_P#XY1_PT3\5O^BF^,?_  ?W?_QRO/:*/90_E7W![6I_
M,_O/0O\ AHGXK?\ 13?&/_@_N_\ XY1_PT3\5O\ HIOC'_P?W?\ \<KSVBCV
M4/Y5]P>UJ?S/[ST+_AHGXK?]%-\8_P#@_N__ (Y1_P -$_%;_HIOC'_P?W?_
M ,<KSVBCV4/Y5]P>UJ?S/[ST+_AHGXK?]%-\8_\ @_N__CE'_#1/Q6_Z*;XQ
M_P#!_=__ !RO/:*/90_E7W![6I_,_O/0O^&B?BM_T4WQC_X/[O\ ^.4?\-$_
M%;_HIOC'_P ']W_\<KSVBCV4/Y5]P>UJ?S/[ST+_ (:)^*W_ $4WQC_X/[O_
M ..4?\-$_%;_ **;XQ_\']W_ /'*\]HH]E#^5?<'M:G\S^\]"_X:)^*W_13?
M&/\ X/[O_P".4?\ #1/Q6_Z*;XQ_\']W_P#'*\]HH]E#^5?<'M:G\S^\]"_X
M:)^*W_13?&/_ (/[O_XY1_PT3\5O^BF^,?\ P?W?_P <KSVBCV4/Y5]P>UJ?
MS/[ST+_AHGXK?]%-\8_^#^[_ /CE'_#1/Q6_Z*;XQ_\ !_=__'*\]HH]E#^5
M?<'M:G\S^\]"_P"&B?BM_P!%-\8_^#^[_P#CE'_#1/Q6_P"BF^,?_!_=_P#Q
MRO/:*/90_E7W![6I_,_O/0O^&B?BM_T4WQC_ .#^[_\ CE'_  T3\5O^BF^,
M?_!_=_\ QRO/:*/90_E7W![6I_,_O/0O^&B?BM_T4WQC_P"#^[_^.4?\-$_%
M;_HIOC'_ ,']W_\ '*\]HH]E#^5?<'M:G\S^\]"_X:)^*W_13?&/_@_N_P#X
MY1_PT3\5O^BF^,?_  ?W?_QRO/:*/90_E7W![6I_,_O/0O\ AHGXK?\ 13?&
M/_@_N_\ XY1_PT3\5O\ HIOC'_P?W?\ \<KSVBCV4/Y5]P>UJ?S/[ST+_AHG
MXK?]%-\8_P#@_N__ (Y1_P -$_%;_HIOC'_P?W?_ ,<KSVBCV4/Y5]P>UJ?S
M/[ST+_AHGXK?]%-\8_\ @_N__CE'_#1/Q6_Z*;XQ_P#!_=__ !RO/:*/90_E
M7W![6I_,_O/0O^&B?BM_T4WQC_X/[O\ ^.4?\-$_%;_HIOC'_P ']W_\<KSV
MBCV4/Y5]P>UJ?S/[ST+_ (:)^*W_ $4WQC_X/[O_ ..4?\-$_%;_ **;XQ_\
M']W_ /'*\]HH]E#^5?<'M:G\S^\]"_X:)^*W_13?&/\ X/[O_P".4?\ #1/Q
M6_Z*;XQ_\']W_P#'*\]HH]E#^5?<'M:G\S^\]"_X:)^*W_13?&/_ (/[O_XY
M1_PT3\5O^BF^,?\ P?W?_P <KSVBCV4/Y5]P>UJ?S/[ST+_AHGXK?]%-\8_^
M#^[_ /CE'_#1/Q6_Z*;XQ_\ !_=__'*\]HH]E#^5?<'M:G\S^\]"_P"&B?BM
M_P!%-\8_^#^[_P#CE?H__P $W_&?B#QS\#M<O_$FNZEX@OH_$4\"7.JWDES*
ML8MK5@@9R2%!9CCIECZU^3U?J3_P2U_Y-^\0?]C/<?\ I):5Y>90C'#MI=4>
MOE<YRQ*3?1GV+1117R1]D?#7_!7_ /Y-I\-?]C=;?^D=[7Y U^OW_!7_ /Y-
MI\-?]C=;?^D=[7Y U]YDW^ZKU9X6,_BA1117N'"%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH_\ \F;^/OI9?^ED-?/YAC:N&Q-*E3VE:_SDU^1Z>#P\*Z;GW_1'X:4445]
M>8%%%% !1110 4444 ==\)?A=K?QH^(NA^"_#HA_M?5YC#"]RS+%'A2S.Y56
M(555B2 3@=#7UO\ \.@/C)_T,O@;_P #[S_Y$KN_^"0/P9-YK7BOXGWT!\JS
M0:-ICMT,CX>X8>X7RE!_Z:,*_4.OF<SS*IAJRI4;:+7U>OY6/0PE!5HN<]KV
M7RW_ !T^1_.%\3/AWK'PF\?:[X/U^-(M7T>Z:UG\HDQN1R'0D E64AE) )##
M@5S-?H?_ ,%>?@O_ &-XS\-?$VQA"VNL1?V5J+* ,7,0+1,?4M'N7Z0BOSPK
MUL!B?K6'C4>^S]5_5_1F6)I*C4<8[;K^O+8****] Y HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K<\"^$+SX@^-M \+Z=+!#J&M7\&G6
M\ETS+$DDLBQJ7*@D*"PR0"<=C6'7I?[,G_)Q_P +/^QITS_TJCJHJ\DF*3LF
MSZ9/_!(#XR $_P#"2^!N/^G^\_\ D2OB"ZMVL[J:!R"\3E&*],@XXK^EQ_N-
M]*_FKUS_ )#6H?\ 7Q)_Z$:^:RO'5L74G&KT2_4]C$X:G2H\\=[I?@_\C[,T
M;_@DG\7]<TBQU&#Q'X)2"\@CN(UDOKP,%=0P!Q:D9P?6OE/XL_#/5/@Y\1M=
M\%ZU/:76J://]GN)K!V>!FVALH656(PPZJ*_3WPM_P %;/A!H?AC2-.G\.>-
MGGL[.&WD:.QLRI9$"DC-T#C(]*_.#]I3XF:7\8_CIXQ\::+!=VNEZQ>?:+>&
M_14G5=BKAPK,H.5/1C71AJN-EBG&M&U.SL[=;JWX7.1QI?5XR3]_2_W._P"-
MCS2BBBO;.,**** "BBB@ HHHH **** "BBB@#ZK^"/\ P3@^)?Q[^&6C^.?#
M^N>%+/2=4\[R8=2N[E)U\N5XFW*ENZCYHR1ACQCITKNO^'0'QD_Z&7P-_P"!
M]Y_\B5]R?\$VO^3,O 'UO_\ TNN*UOVE/VW/ W[+/B'2-&\5Z5XAU"ZU.U:[
MA?1K:"5%0.5(8R31D'([ _6OD\5F&*AC:F&HZVE))6[7_1'K4</3E152?S^^
MQ\"-_P $@?C( 2/$G@9CZ"_O/_D2O,?BM_P3M^-_PGL)]0G\,Q^)=+@7?+=^
M')_M>P>\6%EP.I(3 ')(K[WT;_@K;\$]4O$AN=/\7:1&Q -Q>Z="R+[D13NW
MY#O7U1\+_BUX0^,_A>/Q#X+UZUU_27;RS-;DAHGP"4D1@&C;!!VL <$''-9S
MQ^8T%SU8:>FGX%1HX:;Y8O7U/YRNE%?IE_P4^_8ZTW3])G^,7@VP2RD255\1
M6%M&%CDWM@7:@=&W$!\==P;@AB?S-KZ+!XN&,I>TCH]FNS.'$4'0E;=/9A11
M17<<H4444 %%%% !1110 4444 %%%% !1110 4444 7-'TB]\0:M9:7IMM)>
MZA>S);V]M"NYY9'8*JJ.Y)(%?4WQ3_X)K_$GX-_#+5O''B;Q'X.M=*TRW6>:
MWCOKIK@LQ"K$H^S;2Y9@H^;&3UQS7JW_  29_9YC\4>,=5^*FL6PDL=!8V.D
MB09#7C+F20?]<XV 'O+GJM==_P %?_C,T4/A/X7V,Y7S0=;U-$8C*@M';H?4
M9$K8/=4->'B\946*IX2AN]_3?\M?FD=N&HQG"=:I\*V\_P"GI][/A?\ 9X_9
M\\1?M+^/G\(^&+W2[#4DLI+XRZM+)'#L1D4C,<;G=EQCC'7FOHG7?^"2?QFT
M71;_ %"/5_"&IO:P/.+*QOKHSSE5)V1A[95+'& "P&3U%0_\$E_^3IKG_L7;
MO_T9!7[)5RYICZ^%K*%)JUK[>;+P=&%92<^C_1,_F>EB>"1XY$:.1"59&&"I
M'4$4VON3_@J#^R]_PJ_XBK\1] M!'X8\43'[8D2X6UU @L_'990"X_VA)TXK
MX;KVL)B8XNBJL?FNSZK^NFIAB*+H5''IT]/Z_$^P?AM_P2\^*GQ2\ ^'_%VE
M:_X/M]-UJRCOK>*\O;I9D1UW .%MF ;!YP2/>OGSXY_!C6_V?_B7J?@?Q#=6
M%YJVGI"\LVF2/) PDC61=I=$;HXSE1SGK7[B?L>?\FL_"O\ [%VS_P#18K\H
MO^"F?_)Y'C/_ *X6'_I'#7D8;'5JN.EAY?"N;\&=<</!X3VSWY4_O:_S/EJB
MBBOHSRPHHHH ***[;X2?!?QE\<O%47A_P7H=SK-\Q'FO&N(;9#_'-(?EC7@\
ML>>@R<"DVDKL"U\"_@AXD_:%^(UCX,\++;+J5U'),UQ>LZV]O&BEF>1D5BJ]
M%R%/+*.]>S_'/_@G/\2?V?OAGJGCCQ#K?A6\TG3WA26'3+NYDG8R2K$NT/;H
MOWG&<L.,]>E?I?\ L9?L=:/^RIX0G\VXCUCQGJJJ=4U5%(10.1!"#R(U/<\N
M>3@;57'_ ."F?_)FOC7_ *[Z?_Z6PU\O7S:3Q4*6'?NWBF^]W9V_KS/4HX2]
M.4ZN]FU\EU/Q!I0"Q  ))X %)7W?_P $H/@-I/Q#^)>N^.==M$O;?PHL T^"
M9=T?VR4L5E([F-4)&>A=6ZJ*^DJU(T:<JL]HJ_\ 7J]#S$G*2BMWI_7YGF_P
MM_X)J?&_XGZ5'J3:-8^$K*9!)"_B6Y:WDD!_Z9(CR+_P-5ZC&:ZW7O\ @DI\
M;='TV:ZM+[PEKDT:EEL[#4IEED/HIF@C3/U8"OTR_:8_:7\,?LO> D\2>(HK
MB^FNIOLMAIMGCS;J7!.,GA5 &68].P)(!\4_9?\ ^"E?A?\ :&\>V_@W4O#%
MUX-UV^W_ -G[KU;RWN2JEBA?9&4<@$@%2#@C=G /RL<PQ^(4JM&"Y5_7S^1Z
MKP]"C957J_Z^7S/R&\??#OQ-\+?$USX>\6Z)>:#K-O\ ?M;R/:2,D!E/1U.#
MAE)4XX)K7^"OPDU'XY_$?2O!6D:II6DZKJ>];:;6)9(X'=4+;-T<;D,0IQQ@
MGC/(K]B/^"B'P(TCXO\ [/'B#5Y+:)?$7A6UEU;3[[8/,5(UW30YZ[713QTW
M!3VK\4O"_B2_\'>)=*U[2IC;ZGIEU%>6TH_@EC<,I_,"O:R[&_7J;YO=DM'V
MUV?_  /(Y<7AW0M*&J>WRZ?UW/<?VD/V&OB-^S!X?TW7?$TFD:MI%[.;8WFA
MSRS);R8RJR^9%&5W -@@$?*02#C/SU7]!'V7PU^UY^S; M[$LFA^,-'20J,,
MUM*R@@K_ +<4@X_VDK\&?B)X$U3X8^.M=\)ZU%Y.J:/>26<XP0&*G 9<_P +
M## ]P0:PR_&U*TYT*_QQ_+9_<_S1=>C!4HUZ7PO]=5]Z_(YVBBBO<. ****
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M^ATYE@:>&A&=+O9_I^I<^&'PYU;XM>/='\(Z(8%U35)3%"]TS+$F%+,SE02
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M??V2_%_[2.G:Q>^&=1T2QBTN6.&8:M/-&S%P2-OEQ/D?*>N*\;O_ /C^N?\
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M7_8/_P#:B5^+5<>7XN>*YO:):6V.W,<'#"<OLV];[_(^G?B%_P $]?B9\/?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OU)_X):_\F_>(/^QGN/\ TDM*_+:OU)_X):_\F_>(/^QGN/\
MTDM*\K,_]W?JCV,I_P!Y7HS[%HHHKX\^U/AK_@K_ /\ )M/AK_L;K;_TCO:_
M(&OU^_X*_P#_ ";3X:_[&ZV_]([VOR!K[S)O]U7JSPL9_%"BBBO<.$*_7S_@
MD%_R;AXD_P"QIN/_ $EM:_(.OU\_X)!?\FX>)/\ L:;C_P!);6O,S/\ W*KZ
M+_TI'3AOX\/G^3,#_@L;_P DI\ ?]AJ7_P!$-7Y15_1#\8_@#X#^/^DZ?IOC
MW0O[>LK"<W%M%]LN+;RY"NTG,,B$\'&"2*\QT[_@G5^SOIETEQ#\.('D0@@7
M&J7TZ=<\H\Y4].XKYO+<QI8.E*%1-MN^ENR7?R/3Q5"5:2<>BM^+/E/_ ((W
M:)KJ:K\1M7V31^&9(+6U+L"(Y;I69@%/0E$8Y]/,7U%?7'_!0"YM;7]C_P")
M#7>WRWLXHT#C.9&N(@F/?<17MWACPKHG@?0K?1_#^E66AZ1:@B&RL(%@AC!.
M3A5  R223W)K\R/^"H7[7FC>-[:W^$_@S4HM3LK6Y%SKM_:N&A>5,^7;*PX?
M:?F8C@,%&<A@,*LY9IC8NG&RT^Y;M_I\D:X:"P5-SF_/Y]$OZ[L^,/V>O@CJ
M_P"T-\6-$\$Z1(+9[UR]S>,I9;6W09DE([X' '&6*C(SFOV^^#O[+OPN_9\T
M*&/PYX:T^WNK:+]_KM_&DM[+@99WG894'&=J[5'8"OP^^!_Q]\9?L\>*9_$'
M@J]MK+4;BW^RSM<V<5P)(=ZN4^=25!*+DJ0>.M?2/BC]HO\ ::_;:^'I\&:9
MX+^WZ'<W*FZU#P]I<\$<Y3)\F:X>0PJN2K%?ER57GL?H\RH8BORQIR48==;=
M?R2Z=SR<+*G"3=17?3[OSO\ A\S]6- ^-/PX\8:K_8VB>._"VMZD25_L^PUB
MVN)CCJ/+1R>,>E>9?M%_L1_#7]H+P]?K-H5EH'BIT9K7Q#IMNL,ZRX^4S;<"
M9. "'R<9VE3S7YZ_#+_@E3\:]>O;.\UNYTCP''',&+W%[]INXL'(>-8-RD@X
M(!D4_2OV&L8)+6QMX9IC<2QQJCS$8+L!@MCWZU\QBJ5+".,L-6O+RZ?-'JT:
MLZC:G"R\S^;7Q-X?O/"7B/5=#U%!'J&F7<ME<HIR%EC<HX!^JFOW _9S_9T^
M%&N?L_?#74=1^&/@W4-0N_#>G3W%W=:!:2RS2-;1EG=VC)9B2223DDU^0G[6
M*+'^TY\5%50JCQ+?\ ?]-WK]OOV7_P#DVSX5?]BMIG_I+'7O9C6G/+J=6]FW
M%_?%LY(4E2QLZ72/,ON:1R7P>_8Z\!?"GXC^*_&]OH.EG6-5OFET^*"SCC@T
MBV"A5CMT  1FP69E /S8Z#FS^U9;^"&\.^$H_%GAG1O$5UJGBG2=(T^/5;..
M<J\UW&)-NX$C]TLI(Z$#!!!(/R=_P5!_:T\:?#SQGI'PY\$:[=^&E-@NH:G?
MZ;*8KF0R.PCB65?FC $98[2"=X&<#GX'^(G[1GQ'^+7A#2/#7C'Q7?>(]*TJ
M=KBU%^5DF#E=N7E(WR$#."Y.,GUKSL'@:^*5+$3EI%K2^O+%V_&WZO4Z*M:G
MAY2@EJ[OYM77Y[=%H?O[X/\  /ACX>:?-8>%?#FD^&;&:4S26VCV,5I$\F "
M[+&H!;"@9/. /2H/&?PS\'_$=+1/%OA30_%"6A8VZZUIT-V(2V-Q3S%;;G:N
M<=<#TKXU_P""/O\ R;_XL_[&63_TEMZXC_@LS_R!_A3_ -=]2_\ 0;:N*IA)
M0QRPW/KIK_V[?O\ +<WH356DYI6TEIZ7_.Q\I?\ !0WPIHG@K]J_Q9I'A[1[
M#0=)@ALC%8:9:I;01EK6)F*QH HR22<#DDFOF^BBONL/2="E&FW>RM?N>'7J
MJM4<TK;?@K!7MG[&GP:_X7I^T5X2\.3P>?I,4_\ :&I@C*_98?G=6]G(6/\
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M885.SJ(W5"HU=1/AJBON7_AT!\9/^AE\#?\ @?>?_(E'_#H#XR?]#+X&_P#
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M*\&ZO\0_%ND^&M LWO\ 6-4N4M;6W3^)V..3V ZDG@ $G@5^U/[,/[ ?P[^
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M!5O@W^TMKYMH/*T3Q$?[;L2!A1YK'SD';Y90_ Z*5]:TR>JZ%>>%GI?\UO\
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MP[=VSBU4<8:*$_(.W(%>._M9?L0>"/V@?"&K7FGZ+9:)X]CA>:QUFRB$+3S
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M]-R2,I#=<%AT)K@PN65G2CBH5+5&KK\TK^?W=-M3KQ&*C2DZ3C>*T?ZV]/\
MAC]R'^XWTK^:O7/^0UJ'_7Q)_P"A&OZ5'^XWTK^:O7/^0UJ'_7Q)_P"A&L\A
M_BU/1?FSIQG^[?\ ;R_*1^]W@7]FCX07?@GP]//\*O!,T\NG6[R2R>';-F=C
M$I)),>22>]?C;^V?H&E^%OVHOB)I6BZ;::1I=KJ.RWL;"!8((5\M#A$4!5&2
M> .]?NU\/?\ D0?#7_8,MO\ T4M?AI^W9_R=S\3O^PG_ .TDHRZI.69SBV[<
MLO\ TJ)R22^H0=M?=_\ 26?HQ_P3^^!'PT\9_LE^"-8\0?#SPIKNK7!O?.O]
M2T2VN)Y=M[.J[I'0L<* !D\  =JZ>_\ ^"?/PNU3XXW_ (]UG0-'M?#5K:01
M6'ABPM([2P$B F2XN$0*KY) VD8PI+;L@#2_X)M?\F9> /K?_P#I=<5\X?\
M!7[XOZSI2^$/AUIU^]II>H6\FIZG!$^TW(#A(5?')0%9&P>"0IZJ*SQ+K3S6
MI2I2:;G)+RWO^!M1C!X7FFKI*[^_3\;'WM\//&7P]\06DND^!=<\,ZE;:<HC
MDL?#UW;RI:KT"LD)(0<8P0.E>!_MD?L,^#/CAX&UG6= T.ST/X@VD,EU:ZA8
M0K#]ND49,5P% #[\8#GYE..<94_E!^ROXTU/P%^T3\/=4TJZ>UF.M6MK+L;
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MPW\MG&21E3^4_P"US\;=8^.OQT\3ZSJ%[)/IMK>S66E6VX^7;VL;E4"CH"P
M9CW9C[5Z=_P37^..L?#+]HG0_#2WTG_",^*IC87EB[DQ><RGR957H'#A5S_=
M8CTQP4,LK*BL3"=JEKI?C;U?W=/,Z,1B84Y2HN/NK1_J_E]_71Z'ZL:K^S'\
M'8]+O'3X3^!U=87(9?#EF"#M//\ JZ_GSK^E?6/^01??]<'_ /037\U%7D4Y
M3G5YG?2/_MP\=%*$++J_T"BBBOK3QS]R?^";7_)F7@#ZW_\ Z77%?'7_  6,
M_P"2L^ O^P))_P"CVK[%_P"";7_)F7@#ZW__ *77%?'7_!8S_DK/@+_L"2?^
MCVKXR7_(]E_CG^4CW:7^X3_PK_TJ)^?=?6O_  3)^+=]\._VFM)T)9R-&\5H
M^FW<!;"F0(SP/C^\'&T>TC5\E5[!^Q_YG_#4?PM\K=O_ .$@M/N9SCS!G],U
M]A."JPE3ELU;[SYZI)PBYK=:_=J?O'\0O"%IX_\  GB'PS?H)+/5]/GL95/]
MV2,KGZ\YK^<.^LY=.O;BTG0QSP2-%(A&"K*<$?F*_I<K\#?!OPVB^+/[9$7@
M^5,V>I^+IXKE%X_T=;AWE QT_=JU?'9%/EKS@]FK_<_^">_F#2P_,^C_ #6O
MY(^I_P!A3_@G)IGCSPUIWQ%^*<$MQI5\HGTKPZKM$)XC]V>X9<-M;JJ*1D8)
M)!VU^BG_ !;CX"^&XE9O#'P]T(-L0NUOIMON/;)VJ2?S-=1=W%GX9T*:<JMM
MI^GVS.5086.*-<X ] !7\^'Q\^.'B']H+XEZKXM\07<LIN)66SLV<F.RM\_N
MX8QT  QDC[QRQY)J8.MG&(E%RM!=.R>WJW9Z^7HA*$,'24Y:R?Y]?1+_ "\V
M?N]XC\"?#3]H/PM&^J:5X>\=:)<*WD7BK%=)R,%HIER5/^TC CUK\J/V[_V#
M)/V=)!XQ\&FYU#P!=3".6*8^9-I4K'Y4=OXHF/"N>0<*Q)(+<#^P?^T!K/P0
M^/?ARWAO9?\ A&O$%[#IFJV!<^4ZRL$2;;T#QLP8-UQN'0FOVQ^)'@73?B=X
M"U_PIJ\0FT[6+*6SE!'W0RD!AZ%3A@>Q -*O&KDU6,J<N:#Z=[;JW?L_^"BJ
M-2&-3IU%9KKVOL_\U_PY_/[\"?@]JWQZ^*N@>!]'=8+G4YBLETZEEMH5!:25
M@.NU5)QD9.!D9K]P?@O^RA\+/V>]"MTT'PW8'4+:/,_B#4HDFO9#@;G:9AE
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M"K\+T_RE_G^.Q;2QM!2BO>6WZK_+\-SZ/_8\_P"36?A7_P!B[9_^BQ7Y1?\
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M,'P;_P"B2^!O_";L_P#XU1_PS!\&_P#HDO@;_P )NS_^-5^07_&8_P#U7/\
M\K-'_&8__5<__*S7/_9U3_H(7W_\$Z?K$?\ GV8/[=_AK2/"'[6/C_2-!TJR
MT32;::U$%AIUNEO!$#:0,0L: *N6))P.I)K]</V1#H/@?]D3X>ZE-_9V@:<O
MA^WOKZ[?R[:(,8PTDTK<#)Y)9OQ-?AO\1/\ A+O^$SU+_A._[:_X2S<GV[_A
M(O.^W9V+L\WSOGSLV8W?PXQQBM+Q7\:?'/C?PIHGAC6O$U_>^'-%MX[6PTG>
M([6%$&$_=H K,!QO8%O>O6K8*>(PE+#J>UKOO96OYG)&K&&(E5:TUT]6C]G_
M (+?MG>'OV@?CYKW@GP9#]L\.:)I3W<FMR K]LG\Z- (5/(C4,WS'EB>   6
MR?\ @IG_ ,F:^-?^N^G_ /I;#7QM_P $>_\ DNGC#_L7C_Z4PU]D_P#!3/\
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MP/,M]J, /4B4_P#?-8O_  5)^'[ZQX$\(>*K:!I;C3;]]/EV#)\N=05)^CQ
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M]H[2-,U_2+#6]->SNV>SU*V2XA8B(D$HX()!Y'%?6_\ P5._Y(CX7_[&*/\
M])KBOEO_ ()S_P#)T>B_]>-Y_P"B37HY=_N=7TE_Z2>5FO\ OE+UA_Z6C[H_
M:2^!GPWT+X!>/]1TWX?>%M/U"VT:YE@N[71;:*6)PA(975 5(]0:_'ROV[_:
MG_Y-P^)'_8"NO_19K\1*C*92E[3F=]OU-\XC&+I\JMO^A^E?_!.WX3>!_&WP
M(N]0\1>#?#^OWZZS/$+K5-+@N90@CB(7<Z$X!)X]S7GG_!33X=>%/ 2?#_\
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M:OH3_@H[_P FOZK_ -A"S_\ 1E+,?]\I^L/_ $I&>6_[C6])_P#I)^6?P[\
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M?A-\4?$OA*Z#;M+O'BB=^LD)^:)_^!(5;\:_5K]ACXI_\+2_9XT%IY?,U/1
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MG_!.W_DUCP[_ -?=[_Z4/7S/_P %5?\ DI?@K_L$R?\ HXU?/+^THQOI=_\
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MHUZ:M?1_H_SO_P .8-%%%>^?.GZD?\$R/AM'X;^#.H>+98U^V^([U@DG?[/
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M\$%I_P#&Z_+?_C*S_JL?_E5H_P",K/\ JL?_ )5:XOJ,_P#G\OO._P"OT_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5^I/\ P2U_Y-^\0?\ 8SW'
M_I):5^6U?J3_ ,$M?^3?O$'_ &,]Q_Z26E>5F?\ N[]4>QE/^\KT9]BT445\
M>?:GPU_P5_\ ^3:?#7_8W6W_ *1WM?D#7Z_?\%?_ /DVGPU_V-UM_P"D=[7Y
M U]YDW^ZKU9X6,_BA1117N'"%?KY_P $@O\ DW#Q)_V--Q_Z2VM?D'7Z^?\
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MJJLD\$<K!>@+*"<?G7YL_ __ ()$ZAI/BZTU/XG^)]+OM(LYUE_LC0?-D^V
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M$_:!\:?&[X:>([/QG>RZS<>'[J&WMM7N!^^GC=&.R1_XV7;]X_,0XSGJ:?\
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M_P ?]S_UU;^9K]%?^"-'_(T?%'_KSL/_ $.>OSJU#_C_ +G_ *ZM_,U^BO\
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M0N//8HN6:SE*I,/HI$;Y[!&]:^*_V-?VQ/'OAO\ :)\)KXS\?>(M?\,ZG/\
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M5\3_ /!8/_DOOA'_ +%J/_TJN*Z/^9W/_'/_ -N.BC_N%3_"O_2XGQW\(O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'[/WBCQ+X9O_ .S=:LA;^1=>3'+LW7$:-\LBLIRK$<@]:^/?^"4O_([^/O\
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MR1T!KS&BOJVKJQ\@?L5_PWY\!O\ H>__ "CW_P#\8H_X;\^ W_0]_P#E'O\
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M .!_6Y^Q^H7BZ=87-VT<DJP1-*8XAEV"@G"CC)..*^0O^'I7PI_Z%_QC_P"
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MXJ_ZX67_ *2QUQX*?M<>YM6OS/[VCT\9#V>7N%[V45]S1]T_\$[?^36/#O\
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M-)IK\3\BJ_<+]F?1[G0/V??A[87B/'=1:):F1)/O(6C#;3Z8SC'M7R5\$_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!TT]'T_'\S1\.:Y/X8\0Z7K%JD<EUI]U%=Q),"49XW#J& (.,@9P1]:^U/\
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MO64^GWGB@>'])G7;)8>'8?L:N.X,@)E((X*E]I':OG"BIC@,+%W5-%?6*O\
M,PHHHKO.<[GX0_&[QM\"?$PUWP1KUQHMZP"S(F'AN4'\$L; JXY.,CC.1@\U
M]M^$?^"R7B6QTQ(O$WPVTS6;\=;C3-3DL8V';]V\<QS_ ,"_ 5^==%<M?"T<
M3_%C?\_O-(5)TW>#L?H%\1/^"P?C;7=*DM?!_@G2_"ES(K*;V]NVU&2/(X:,
M;(D##K\RN/:OAGQKXWU_XC>)K[Q#XFU:ZUO6KU_,GO+M]SL>P'8*!P%&
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M2RU*QG2YMKF(X>*5&#(P/J" :I45U)VU1BTGHS[BB_X*^?&6.)$;P[X(E95
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MU*O^S86-#[3W_-_>]O02BBBOJ#R0HHHH **** "BBB@ HHHH **** "BBB@
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M1^8-?(-%9_4L/_(C3Z]B?YV=[\5OCKXZ^-E_%=>,?$-QJPA),%MA8K>'W2)
M%!QQNQDCJ37!445U0A&FN6"LCDG.51\TW=A1115D!1110 4444 %%%% !7U]
M8_\ !3[XIZ?96]K'H'@]HX(UB4M9W62%&!G_ $GVKY!HK*I2IUE:HKFU*M4H
MN]-V-WQWXQO?B%XSUOQ-J,4$-_J]Y+>SQVJLL2N[%B%#$D#)XR2?>O?_ (7_
M /!0?XD?"?P%H_A+3-+\-W^GZ7$88)]1MKAYRFXL Q2=0<9P,*. *^8Z*4J-
M.4%2DO=73T&J]6-5UE+WG>[]=6>K_M _M)^*?VD-7TG4/$]MIEFVF0/!;P:5
M%)''AFW,Q#R.=QPHZXPHXJW^SU^U)XK_ &:SKI\,:?H]]_;'D?:/[6AEDV^5
MOV[/+E3&?,;.<]!TKQVBG&C3C3=%+W7T^=_SU!UZLJGM7+WN_P"![Q\??VR/
M&G[1GA:PT#Q)IF@V-G9WHOHWTJWFCD+A'3!+S.-N'/;.<<UX0"000<$4E%.G
M2A15J:LB:E6=9\U1W9]?_!W_ (*4>./A[H<&C^)M)M_'%K;1B."ZGN6MKP*.
M 'EVN),#')7=ZL:Z'QY_P5.\5ZWI$EKX5\'V'AB[D!4WUW>&_>,$=47RXU#
M\Y8,/8U\/T5S3P6'J2YY0U.F&.Q-./)&>A[]\(/VV/B'\';OQ+>6BZ9XBU#Q
M#<I=WUYK\<T\K.JE1@I*F!@XQSC  P!BL7]H3]J;Q7^TF-#'B;3]&L?[(\XP
M?V3#+'N\S9NW^9*^?N#&,=^M>-T5M]7I<ZJ<JNOT5ORT,5B*T8.FI.SO^+N_
MO>IZ?\ OVA/$7[.?B:_USPW9:7?7=[:&SD358I)(PF]7R DB'.5'<]^*]!^,
M?[>/C_XW?#[4?!VNZ1X;M-,OFB:273K:X28&.19%VEYV'5!G*GC-?-]%$Z%.
MI)3G&[6WRU_,5.O5I1<(2LGO\U;\A>E?9WPG_P""F_B[P1X;MM(\4>&[;QDU
MK&L4-^+TV=PR@8'FG9('.,#< I..<G)KXPHJJM*%:/)45T*E6J4)<]-V9]C_
M !N_X*.ZK\6OA_J_A.R\#6.BVFJP-;7,]U?O>.$/=,)&%;(&"=P]J\D_9]_:
MT\7_ +-VG:Q9>&=.T2^BU26.:8ZM!-(RE 0-OERI@?,>N:\3HK*&%HTXRA&.
MDM_.QK4Q=:K.-2<M8[>5]/R/=?C]^V'XS_:-\-Z=HOB73-"L;6QN_MD;Z5;S
M1N7V,F&,DSC&&/0#ZUZ/_P $P?\ DX;4_P#L7[C_ -'05\AU]>?\$P?^3AM3
M_P"Q?N/_ $=!2G2A2H5(TU96E^1=*K.MB:<JCN[K\S[O_;!O)]/_ &:_'=U:
MSR6UU!9++%-"Y1XW$J%65AR"" 017Q+\,/\ @I]XS\)Z)%I_BSP[:>,I(5"1
MWZW1LKAP.\I".KGW"KTYR>:^U/VS?^38/B%_V#__ &HE?BU7A991IUHU(U%=
M:'O9K6J4)4Y4W9Z_H?9OQ2_X*=>-O%^C2Z=X3T"T\%^<A22]^TF]N5'_ $S8
MHBH<9&2K'G@@C-?&]U=37UU-<W,TEQ<3.9)9I6+.[$Y+,3R22<DFHJ*^@HX>
ME0O[.-CYRMB:V(M[65['K'[/O[2?B;]F[5=7O_#-CI-]-J<*03+JT,LBJJL6
M!7RY$P<GOFNR^-?[<WCSX[^ [CPEK^D^';/3IYHYVETVVG28,C;@ 7G<8SUX
MKYUHHGAZ522G.-VK?AJA0Q%6G!PA*R>_ST85]+_ _P#;Z^(WP<TJUT2Y^S>+
M?#]L D-KJA83P1C.$CF4Y Z8#AP    *^:**UG"-2/)-71G3J3I2YX.S/T#?
M_@K)*8B$^%R++CAFU\E<_3[-_6OFSX^_M@>/_P!H.(:?K%S!I7AY'#KHVF*R
M0N0<JTI)+2$<=3M!&0H->'T5RPP6'IRYHPU^;_,ZZF/Q-2+A*>GR7Y!1117:
M<!H>']7/A_7=.U1;6WO6LKF.Y%M=J6AE*,&V. 02IQ@@$<9YKZU_X>D_%8?\
MR_X._P# *[_^2:^.J*RJT:=9)5%>QM2K5*#;INUSH_B+X^U7XH^.-9\5ZVT;
M:IJMP;B80J5C3H J DD*H 4 DG ')KG***N,8PBHQ5DC.<I3DYR=VPKZ1^#W
M[>GQ$^"O@&P\(Z1I^@:EIEBTA@DU6WGDF178L4RDR#:"3CCO7S=12J4XU8\D
MU=%4ZDZ4N>#LSVW]H']K3Q3^TAI6DV7B?1/#UFVF3/-;W6EV\\<P#+AD)>9Q
MM.%)&,Y4<UC_  /_ &F?'O[/UY*WA;4T.G3OYEQI-^AFM)FQC<4R"K=/F0J3
M@ D@8KRJBHC1IP@Z<8Z/H7.O5G-5)2?,NI]^Z9_P5AOHK2-=0^&EO=704;Y+
M;6FA1CW(5H'('MN-8?C7_@JAXLU73V@\,>#=-\/7#@@W5[=/?,@(ZJH2-01_
MM!A[5\/45R_V?AKWY/Q?^9U_VCBK6Y_P7^1M>,?&FN?$'Q'>:]XCU.XU?5[M
MMTUU<MEF] !T50. H  '  %8M%%=\8J*Y8JR//E*4WS2=V?2/P+_ &\?B)\%
M=,M=$D-OXJ\.6X"0V.J%O-MXQ_!%,IRHZ !@X    KW-O^"LDAB(7X7*),<,
M=?R,_3[-_6OS[HKDJX.A6ES3CK]WY'72QN(HQY83T^_\SZ$^._[;_P 1/CII
MTVC7$UOX=\.2D^9IFE!E,Z]EFD8EG'L-JGNO Q\]T45O2HTZ*Y::LC"K6J5Y
M<U25V>C_  7_ &@?&WP#UJ34/"6J>1%/C[5I]ROFVMR!TWID<_[2D,.0#@FO
MK/2/^"L&HPV,2:I\-K6\O H\R6SUAK>-CW(1H9"![;C]:^!:*SJX:E7=ZD;F
ME'%5L.K4Y61]C?%3_@IIX\\9Z7-IWA;1[/P5#.A22[CF:[NUSU\N0JJIQWV$
MCJ"#7Q]=74U[<RW%Q*\]Q,YDDEE8L[L3DL2>22><FHJ*='#TJ'\.-A5L36Q%
MO:RN>N?L^?M,^*/V;;W6KKPS8:1?2:M'%%.-6AED"B,L5V^7(F/OG.<]JZ[X
MU_MS>//COX#N/"6OZ3X=L].GFCG:73;:=)@R-N !>=QC/7BOG6BB>'I5)*<X
MW:M^&J%#$5:<'3A*R=_QW"OIGX4_M_\ Q"^#_@#2/"&C:-X9N=-TQ'2&6^M;
MAYF#.SG<5G4'ECT KYFHK6I3C5CR35UN9TZDZ4N>#LST?X[_ !VU_P#:%\9P
M>)O$=IIME?PV26*QZ7%)'$41W8$AW<[LR'OCIQ7"Z-K-_P"'=5M=3TN\GT_4
M;602P75M(4DB<=&5AR#5*BG"$:45&"LD*I.563E-W;/MWX??\%2O%N@:-%9^
M*_"=EXKNXE"B_MKLV$D@ ZR*(Y%+>ZA1[5SWQC_X*2^._B)H\^D^&M,M_ UE
M<(8YKBVN&N;T@\$),50(".ZIN'9A7R'17&\#AG+F<%^GW;'8L?B5'D4W;\?O
MW/IKX5_\% ?B'\(? .D^$='T?PS=Z=IJND4U_:W#S-N=G)8K.H)RQZ 5XW\9
M/BUJ_P ;_B!J'C#7;:RM-3O4B22+3HW2$".-47 =V/11G+'FN)HKH5"FJCJJ
M/O/KZF'UBK[/V/-[O;T/HWX,?MV>/?@9X LO"&@Z1X<N]-M))94EU&VN'F)D
M<NV2DZ#J3CBN&_: _:-\2_M'ZYI>J^);'2K&XTZW:VB72HI8T92V[+"21SG)
M[$5Y714_5Z7M/:\OO=_P#ZS6]G[+F]WM^/YGL7[/7[4GBO\ 9K.NGPQI^CWW
M]L>1]H_M:&63;Y6_;L\N5,9\QLYST'2M[X[?MK>./VA/!D/AGQ%I7A^RL(KQ
M+T2:7;SQR[U5U )>9QC#GMGIS7S_ $4YT*=2?M)QO+37TV'#$UJ<'3A*R=_Q
MW"OJ+X<_\%#_ (C_  Q\#:+X5TO1?"]QIVDVZVT$MY:7+2LHZ%BMPH)^@%?+
MM%74IPJQY9JZ,J=6=&7/3=GL>@?'#XUZY\??'+>*O$%KI]GJ#6T=J8M,C=(M
MJ9P<.[G/)[UZA\%_V)OB5\5/!&D^/O".L:):123.UL'OIH+N&2*0KNRL1"G<
MN00V>AXKYOK[J_X)Y?M4Z%X L+KX=>,-0CTJQN+EKK2]2N6"P1NP'F0R.>$!
M(#*3QDL"1D9YZL94*#6&6JU2_/\ S.FC*%>NGB7H]W\M/\C6\:_M!_M1_LN>
M&K%O&^F>'=<TZ:?[);ZO?@3N[[2P0^1-&WW5)RZY.#DDU\Y_&3]LSXH?'/3V
MTC5M3ATS1IL"32M%A,$4Q]')9G<'/W2Q7@<9K]>?&/@GPW\3_#4NC^(M+M->
MT:Y <PSJ'0^CJ1R",\,I!'8UY]X)_9 ^#OP]UF'5M$\"V,6H0N)(I[R::\,3
M@@AD$SN%8$ @@ CM7@4<903<J]-<WDOZU/HZV"Q#2C0JOE\W_ET.\^&.E2Z%
M\-O"FFSQM#/9Z3:V\D;=59854@_0@U^07[:.J1:Q^U%\0;B*02(M\MON'K'#
M'&P_ H1^%?J%^T3^TWX3_9\\+7=QJ-_;W?B-X2;#0XI09YW(.TLHY2/(Y<\<
M$#)P#^,&NZU>>)=;U#5]0E,]_?W$EU<2D8WR.Q9C^))K;+H3JXB>):T:?WMI
M_A8Y\R<*.%AA4[M6^Y)K7UN4:***^E/ESVC]GS]JWQ;^S;;:U!X9T[1;Y-6>
M)YSJT$TA4QA@NWRY4Q]\YSGM7KO_  ]*^*W_ $+_ (._\ KO_P"2:^.J*YZF
M'I59<]2-V=-+$UJ,>2G*R/L7_AZ5\5O^A?\ !W_@%=__ "37+^-/^"B_QD\7
M6+6MMJ&F>&4<%7?1;+;(P(Q@/*TA7ZJ0?>OF*BLU@\.OL(T>.Q+TYV6]5U:^
MUW4;C4-2O+C4+^X<R375U*TLLK'JS,Q))]S52BBNQ))61QMMN[-+P[XCU3PE
MK5IK&BZA<:7JEH_F07=K(8Y(V]01[9!]02*^P/AY_P %1/'/AZQ2U\5^'=-\
M6^6@5;N&4V%PY[ERJNA_X"BU\6T5C5HTZRM45S6E7J4'S4Y6/O;7?^"KVK7&
MGRIHWPYL]/OB/W<U]JSW4:GU*+%&3_WT*^1OB_\ ''QE\<]?75?%^KO?O%N%
MM:QCR[>U4G)6.,<#MDG+' R3BN"HK*EA*%&7-".O]=S>KC<17CRSGI]WY!7L
MWP+_ &M?B'^S^C6?A_4(;[1'8NVC:HAFM@QZLF&5D/\ NL 3U!KQFBNF48S3
MC)71R1E*$E*+LT?H#:?\%8[A($%U\,(II@/F>'73&I/LIMVQ^9KE/B!_P5&\
M;:_ITEKX5\,Z;X5DD4J;R>8WTT>1PT>51 1_M(P]J^*:*X?[/PU[\GXO_,]#
M^T<5:W/^"_R-#Q!X@U/Q7K5YJ^L7T^IZG>2&6XN[J0O)(Q[DG\O8#%5;2[GL
M+J&ZM9I+:YA<2131,5>-@<AE(Y!!&014-%=\4HI*.ECSI-R;<M6S[#^%W_!3
M/X@>#=.AT_Q1I5CXU@A38EU+(;2[;TWR*&5N.^S)ZDDUW.J?\%8;Z6RE73OA
MI;VMX5(CENM::>-6[$HL"$CVW#ZU\!T5Q3P.'J/FE#]/R.Z&/Q-./+&>GR?Y
MGHWQJ_: \:?'W7H]2\6:D)D@R+73[9?+M;4'J(TR>3W9B6. "2 ,><T45UPA
M&G'E@K(Y*E2=67--W844459F???_  2U^*R6NI>)_AY=R[?M0&K6 )ZNH"3*
M/<KY; ?[+5<_X*I_#UB/!GCB"(;1YFD7;CKWEA_]K?I7P]\-/'^I?"WQ[H?B
MO2'VW^E7*W"*3@2+T>,_[+*64^S&OUX^(FD:)^U_^S%>?V)*DT6MV N].=B,
MP7<9W*C8Z$.I1O\ @5>!F$70KPQBVT3_ "_])V\T?1Y;-8BA4P4GJT[?G^$K
M/T?D?COX3\27/@[Q3H^O6212WFEWD-["DX)C9XW#J& ()&5&<$'W%?5LG_!4
M?XJRQLA\/^#L,"#BRN__ ))KY"N[2:PNYK6YB>"XA=HY8I!AD8'!4CL01BH:
M]BI1I8A+G5U_F>)3K5<.VH-Q?7Y#YI3-*\C8#.Q8XZ<TRBBM]C!MR=V?4/PY
M_P""B7Q/^&W@G2?#-K9>'M7M-,A%O!=:K;3O<&,?=5F2= 0HPHXS@#.>M<%^
MT)^U-XK_ &DQH8\3:?HUC_9'G&#^R898]WF;-V_S)7S]P8QCOUKQNBN?ZO2]
MI[7E][>YT?6JWL_9<SY;6MY!11170<P4444 /B<1RHY19 I!VMG!]CCFOL"+
M_@J+\4X(DC3P]X-5$4*H%E=\ =/^7FOCRBLJM*%9)5%>QM2K5*+;INUS[%_X
M>E?%;_H7_!W_ (!7?_R31_P]*^*W_0O^#O\ P"N__DFOCJBN?ZEA_P"1'1]>
MQ/\ .SZF\?\ _!1;XD?$;P3K?A?4M$\+0:?J]I)9SR6MI<K*J.,$J6N& //<
M'Z5\LT45O3H4Z-_9QM<PJUZE:WM)7L%=U\%OC#K/P*\>VOBW0+:PN]2MXI84
MBU*-WA(=2IR$=#G!XYKA:*V:NFGU,-FGV:?S6J/I[XF_\%"/B+\5O >L^$]6
MT7PQ;Z=JL/D32V5K<K,JY!^4M<, >.X-?,-%2VUM+>7$5O!&TT\KA(XT&6=B
M<  =R36-*A3I75.-KFU7$5*UG5E>Q]^_\$J_A\S7/C3QO/$-BK'I%K(?4XEF
M'Z0_G47_  5+^*D=S>^%_A[:3!C;YU:_13]UB"D"GWVF4X_VE-?3_P ,M%T7
M]D/]F&S.NRK;QZ/8F]U-PPW2W<GS,B_WB781KZX6OR*^)OQ!U/XJ^/M<\6:N
MV;[5;EIV0'(C7HD:^RJ%4>RBO%BOKF/=1?!#]-OQO+[NY[TI?4LO5-_'4_)[
M_A:/W]CF****^@/FPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ K]2?^"6O_)OWB#_ +&>X_\ 22TK\MJ_4G_@EK_R;]X@_P"Q
MGN/_ $DM*\K,_P#=WZH]C*?]Y7HS[%HHHKX\^U/AK_@K_P#\FT^&O^QNMO\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OU)_X):_\F_>(/\
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M/\L?N?\ F'U*GW?]?(_#7_AVS^T;_P!$[_\ *WIW_P D4?\ #MG]HW_HG?\
MY6]._P#DBOW*HH_MS$_RQ^Y_YA]2I]W_ %\C\-?^';/[1O\ T3O_ ,K>G?\
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MX=L_M&_]$[_\K>G?_)%'_#MG]HW_ *)W_P"5O3O_ )(K]RJ*/[<Q/\L?N?\
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M *)W_P"5O3O_ )(K]RJ*/[<Q/\L?N?\ F'U*GW?]?(_#7_AVS^T;_P!$[_\
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M )(K]RJ*/[<Q/\L?N?\ F'U*GW?]?(_#7_AVS^T;_P!$[_\ *WIW_P D4?\
M#MG]HW_HG?\ Y6]._P#DBOW*HH_MS$_RQ^Y_YA]2I]W_ %\C\-?^';/[1O\
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M/\L?N?\ F'U*GW?]?(_#7_AVS^T;_P!$[_\ *WIW_P D4?\ #MG]HW_HG?\
MY6]._P#DBOW*HH_MS$_RQ^Y_YA]2I]W_ %\C\-?^';/[1O\ T3O_ ,K>G?\
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MX=L_M&_]$[_\K>G?_)%'_#MG]HW_ *)W_P"5O3O_ )(K]RJ*/[<Q/\L?N?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *Y3XL_\ )*_&7_8%O?\ T0]=77*?%G_DE?C+_L"WO_HA
MZ #X3?\ )*_!O_8%LO\ T0E=77*?";_DE?@W_L"V7_HA*ZN@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *Y3XL_\DK\9?\ 8%O?_1#UU=<I
M\6?^25^,O^P+>_\ HAZ #X3?\DK\&_\ 8%LO_1"5U=<I\)O^25^#?^P+9?\
MHA*ZN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M***X3K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM'LUL:X7&T<6G[-ZKH]RU1117FG<%%%% !1110 4444 %%%% !1110 4444
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M-[H%]\-_!M\FH37+>5K&HV[!HHT!Y@1APS$CYB. ..23CKPN%J8RJJ5-:O\
M!=W_ %Y&%>M##TW4J.R7X^2\S[PHK\Q?^":/_)?-6_[%^X_]'V]?IU73F.!_
ML^M['FYM+[6_5G+@<7]=INIRVL[;WZ+T[A17Q;_P4=^+'B#P+9^"M*\-Z_J>
M@7=W)<W4\NEWDEL[HH155BC D99C@^E?$/\ PT!\4?\ HI/B[_P>W7_QRN_
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M%W<6KI%!XJT8I'>B$;4N$8'9,J]L[6# < CC ( ZL=DU3"4O;TYJ<>K7]/\
M,Y<+FD*]3V,XN,GM_6A]!T445\Z>V%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445^9'QX_;'^
M,'@SXR>,="T;Q?\ 8]*T_4IK>VM_[,LW\N-6P!N:$L?J237H8+!5,?5=*DTF
ME?7Y+L^YR8K$PPE/VM1-J]M/.[_0_3>BOR-_X;M^.7_0\?\ E)L?_C%7]&_X
M* ?&G2[M)KGQ%9ZO&IR8+W2[=4;V)B1&_(U[3X<QB7Q1^]_Y'E+.\-_++[E_
MF?K'17S/^R_^VMHWQWNT\/:S9Q^'_%^PM' CEK>] &6,1/*L!D[#DX&03@X^
MF*^?Q.&JX2I[.M&S/8H8BGB8<])W04445RG0%%%% !1110 4444 %%%9_B'5
MX] T#4M3E($5E;2W+9Z812Q_E2;LKC2<FDC0HK\RV_X*;?%#<<:!X1 [ V=U
M_P#)-)_P\V^*/_0!\(_^ =U_\DU]+_J_CNR^\\/^V,)W?W'Z:T5\P_L7_M/>
M*?VBY_%J>)+#1[(:0MJ8/[*AECW>:9=V[?*^?]6N,8ZGK7DWQY_;X^('PN^+
MWB?PKI6C^&KC3]+N1##+>6MPTK+L5OF*SJ"<D] *XHY7B98F6$27.E??II_F
MCI>84%0^L:\M[?/7_(^]Z*_,K_AYM\4?^@#X1_\  .Z_^2:/^'FWQ1_Z /A'
M_P  [K_Y)KM_U?QW9?><O]L87N_N/TUHKY[_ &-_VA?$?[0WA3Q!J?B.RTNR
MN-/O4MHETN*2-64QALL'D<YR>Q%?0E>)B<//"U71J;K]5<]6A6AB*:JT]G_P
MP4445S&X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7S7_P4*_Y-HU7_K_M/_1HKZ4KYK_X*%?\FT:K_P!?]I_Z-%=F"_WN
MC_BC_P"E(PQ'\"K_ (9?^DL^.O\ @GI_R<OI7_7A=_\ HLU^K-?E-_P3T_Y.
M7TK_ *\+O_T6:_5FO?XD_P![C_A7YL\+(O\ =Y_XOTB?'/\ P46^"VE:W\-S
M\0+.SC@UW2)HH[JXB3#7%L[!,.1U*L5()Z#(KYR_X)Z^.Y_"O[05GI D(LO$
M%K-9RQY^7>B&6-L>H*%1_OFONG]LT _LR>.\_P#/I'_Z.CK\UOV3#(O[2'P^
M\K.[^U$!P,\8.?TS7H9-)U\NKT:FJ5TO*\4_P>ISYNE2Q-*M'1_G9_TO0_5S
MXR?%S1?@EX"OO%.N%WMX,1PVT6/,N9F^Y&N>YY.>P!/:OSH\:?\ !1+XL^(=
M1DDT6ZT_PK9;CY=O:6<=PX7MN>97W'W 4>PK[P_:)_9OTK]HS2-+L=5UO4M)
M339'FA6R\LQN[ #<ZLI)P <8(^\:\\^#?PN^%/[&T.JMKWC?1)_$%W)O%[J3
M16]U%  ,1)'O9L9R25^]D9'RBO&RZI@J-*4ZL/:5>D;:6_%>9ZF.ABJLXPI2
MY8=7U_K]3Y$\._\ !0;XRZ->I->ZS8:]"#S;W^FPHK#ZPK&WZU^@O[.OQ_T[
M]HCP ^N:?;'2]2MI3;7MA*WF""7:""",;D(.0>.A':OB']NWXU_"_P"+_P#8
M)\&2?VCKEG-(+K4X[)H%DA*\(6<*SD, 1Q@<X/-=[_P2TN)"WQ'@S^Z T]P/
M<_:!_2O8QN%HXC+I8KV/LIKIMU2[+OV/*P^(JX?&QH>U]I%_/I\^OGL<]XR_
MX*%_%OP+XQU?P]J?AWPDMWIEW):S 6=T-VQB,C_2.A R/J*_0'P=XGM/&OA/
M1]?L&W6>IVD5W$?174, ?<9Q^%?G5_P4D^%W_"-?$[3/&-K#ML_$%OY=PRC@
M7,0"G/\ O(4_[Y->_?\ !.7XD_\ "6?!>Y\-SR[[WPW=F)03S]GE)>,_]]>:
M/HHKAQ>&H5LLIXRA%)KXK?<_QV\F=E*O5HYA+#U)7B]OS7X73\SL_P!L']HV
M^_9V\%:3>Z+;6%[KNIWGDPP:BCO$(E4M(Y".I.,H.O\ %7&_L<_M.?$']HKQ
M'KJZ]I>@V.@Z5;(7FTVVG25IW;Y%R\SC&U9">,\"OF+_ (*'_$4>,/CH=$@D
MWV?ARU6TP.GGO^\E/ZHO_ :^Q_V%OAG_ ,*Z_9_TB>>+R]1UYCJUQD<A7 $0
M^GEJAQZL:3PU##92J]2-ZD]O*^W_ )*K^K'.O5K9DJ%.5HQW^6_XNWR/H2BB
MBOE#Z _*S]M'QCXU\=_M#Z_X)BU#4]6TZUNX8=.T.U!9-QA1OEB0?.V6;D@G
MGKBO-_C7^S_K?P(T[PH/$4L::QK5O+=2V,1#"T564*C,#AFY)..!T!/6OUXT
MGX<^&=#\4:IXDL=$LX/$&IL&N]3\O=<284+C><D+A5^48''2OA+_ (*B_P#(
MX>!/^O"Y_P#1B5]QE>9N53#X*E&RM[S[M1?ZJ]]V?,9A@%RXC%U)7?V5V3DK
M?@[6V1Z-_P $P_\ DE'BO_L-?^T(Z^RJ^-?^"8?_ "2CQ7_V&O\ VA'7V57A
MYW_R,*GR_)'HY5_N</G^;"BBBO#/6"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLF2,E0I R>>E?0_BK]I?X#> O#G]AS>(="O=+CB\E-(T> 7L10#&S;$K(/\
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M_!2/QU8>.M:T[PSHGAN[T:"^DM[&2ZMKB2::-7*JQ*SJ"6QG@#K7U_\ M/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3?%MO"_PQCU/5=/N+M;+3I-1E22:Y;.#)E$0*A.2,CA1DGT^]_\ @HA\;I/
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M?_P5%_Y'#P)_UX7/_HQ*_1"OSO\ ^"HO_(X>!/\ KPN?_1B5[>2?\C"E\_\
MTEGFYG_N-7T7_I43T;_@F'_R2CQ7_P!AK_VA'7V57QK_ ,$P_P#DE'BO_L-?
M^T(Z^RJ>=_\ (PJ?+\D9Y5_N</G^;"BBBO#/6"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH *QO&?\ R)^N_P#7A/\ ^BVK9K&\9_\ (GZ[_P!>$_\
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M5%@\!'!2GS5'J_OYG^.WD<^"C];QKQ4(\L(Z+[K?YMVZG24445\,?6!1110
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M?"'PQ&KLJ/K8WJ#@-B"7&1WK\]/"WCSQ-X&DN)/#?B+5O#\EP LS:7?2VQE
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'#4(24X02:ZV1X*_["OP/D=F;P3EF.23JU]R?^_]-_X82^!O_0C_ /E6OO\
MX_7OE%7]?Q?_ #^E_P"!/_,3PF'>KIQ^Y'@?_#"7P-_Z$?\ \JU]_P#'Z]9^
M'_P\\/\ PM\,6_A[PQI_]F:/;N[QVWG23;2[%F.Z1F8Y))Y-='16=3%8BM'E
MJ5&UV;;*AAZ--\T()/R2"BBBN4Z HHHH **** "BBB@ HHHH **** "BBB@
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M.%BG=--]5Z:_YGCW_!/;X5R>./C9'XAN+??I7AF(W3.P^4W+ K"OU'S/_P
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MD2*,*J@<   #%6J\;'8IXS$2KOKMZ=#OP>'6%H1I=M_7^OP"BBBN$[ HHHH
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MJ6XZ&OE']@;X9GQ]\>[#49X3)IOAR(ZE*Q'R^:/EA7/KO.X?]<S46A_\$_\
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M]_\ 1#T 'PF_Y)7X-_[ ME_Z(2NKKE/A-_R2OP;_ -@6R_\ 1"5U= !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44R65(8VDD=8
MXT!9F8X  ZDFN1D^,O@"&Z%M)XY\-I<G_EBVKVX?\M^:I1<MD2Y1CNSL:*@L
MKZVU*UCN;2XBNK:4;DFA<.CCU!'!J>I*"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHK"\0>/?#/A)PFN>(M)T9R-P74+Z* D>OSL*:3>B$VEJS=HK!\/\ C[PQ
MXMD*:'XCTG67 W%=/OHIR!ZX1C6]0TUHP33U04444AA1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 45R-_P#%[P)I5V;6]\:^';.Y!*F&XU6!
M'SW&TOG-=%I6LV&NV:W>FWUMJ-JQPL]I,LJ$^S*2*IQDE=HE2BW9,N4445)0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !113)94AC:21UCC0%F9C@ #J2: 'T5QTGQE\ 0W0MI/'/AM+D_\L6U
M>W#_ );\UU5E?6VI6L=S:7$5U;2C<DT+AT<>H(X-4XM;HE2C+9D]%%%24%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#$T?\ #8?P7_Z*)HW_ '\;_P")H]A5_D?W,/K%'^=?>CV.BO'/^&P_@O\
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M_P!#W_Y1[_\ ^,4?5J_\C^YA]:P__/Q?>CZ$HKY[_P"&_/@-_P!#W_Y1[_\
M^,4?\-^? ;_H>_\ RCW_ /\ &*/JU?\ D?W,/K6'_P"?B^]'T)17SW_PWY\!
MO^A[_P#*/?\ _P 8H_X;\^ W_0]_^4>__P#C%'U:O_(_N8?6L/\ \_%]Z/H2
MBOGO_AOSX#?]#W_Y1[__ .,4V3]O_P" Z1LR^.&D(!(1=(OLM[#, 'YFCZM7
M_D?W,/K6'_Y^+[T?0U%?-?\ P\0^!_\ T,E[_P""JY_^(H_X>(? _P#Z&2]_
M\%5S_P#$4_JM?^1_<+ZWA_\ GXOO1]*45\U_\/$/@?\ ]#)>_P#@JN?_ (BC
M_AXA\#_^ADO?_!5<_P#Q%'U6O_(_N#ZWA_\ GXOO1]*45\U_\/$/@?\ ]#)>
M_P#@JN?_ (BC_AXA\#_^ADO?_!5<_P#Q%'U6O_(_N#ZWA_\ GXOO1]*45\U_
M\/$/@?\ ]#)>_P#@JN?_ (BC_AXA\#_^ADO?_!5<_P#Q%'U6O_(_N#ZWA_\
MGXOO1]*45\U_\/$/@?\ ]#)>_P#@JN?_ (BC_AXA\#_^ADO?_!5<_P#Q%'U6
MO_(_N#ZWA_\ GXOO1]*45\U_\/$/@?\ ]#)>_P#@JN?_ (BC_AXA\#_^ADO?
M_!5<_P#Q%'U6O_(_N#ZWA_\ GXOO1]*45\U_\/$/@?\ ]#)>_P#@JN?_ (BC
M_AXA\#_^ADO?_!5<_P#Q%'U6O_(_N#ZWA_\ GXOO1]*45\U_\/$/@?\ ]#)>
M_P#@JN?_ (BC_AXA\#_^ADO?_!5<_P#Q%'U6O_(_N#ZWA_\ GXOO1]*45\U_
M\/$/@?\ ]#)>_P#@JN?_ (BC_AXA\#_^ADO?_!5<_P#Q%'U6O_(_N#ZWA_\
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M_P#@OC_^.T_J>(_D8OKN&_G1]:T5\E?\/-_A!_S[>)?_  7Q_P#QVC_AYO\
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M^=-_X>E?"G_H7_&/_@%:?_)-/ZEB/Y&+Z]AOYT?8M%?'7_#TKX4_]"_XQ_\
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M._!8R>&FDW[KW1^YM%?'7_#TKX4_]"_XQ_\  *T_^2:/^'I7PI_Z%_QC_P"
M5I_\DU\Q]2Q'\C/K/KV&_G1]BT5\=?\ #TKX4_\ 0O\ C'_P"M/_ ))H_P"'
MI7PI_P"A?\8_^ 5I_P#)-'U+$?R,/KV&_G1]BT5\=?\ #TKX4_\ 0O\ C'_P
M"M/_ ))H_P"'I7PI_P"A?\8_^ 5I_P#)-'U+$?R,/KV&_G1]BT5\=?\ #TKX
M4_\ 0O\ C'_P"M/_ ))H_P"'I7PI_P"A?\8_^ 5I_P#)-'U+$?R,/KV&_G1]
MBT5\=?\ #TKX4_\ 0O\ C'_P"M/_ ))H_P"'I7PI_P"A?\8_^ 5I_P#)-'U+
M$?R,/KV&_G1]BT5\=?\ #TKX4_\ 0O\ C'_P"M/_ ))H_P"'I7PI_P"A?\8_
M^ 5I_P#)-'U+$?R,/KV&_G1]BT5\=?\ #TKX4_\ 0O\ C'_P"M/_ ))H_P"'
MI7PI_P"A?\8_^ 5I_P#)-'U+$?R,/KV&_G1]BT5\=?\ #TKX4_\ 0O\ C'_P
M"M/_ ))H_P"'I7PI_P"A?\8_^ 5I_P#)-'U+$?R,/KV&_G1]BT5\=?\ #TKX
M4_\ 0O\ C'_P"M/_ ))H_P"'I7PI_P"A?\8_^ 5I_P#)-'U+$?R,/KV&_G1]
MBT5\=?\ #TKX4_\ 0O\ C'_P"M/_ ))H_P"'I7PI_P"A?\8_^ 5I_P#)-'U+
M$?R,/KV&_G1]BT5\=?\ #TKX4_\ 0O\ C'_P"M/_ ))H_P"'I7PI_P"A?\8_
M^ 5I_P#)-'U+$?R,/KV&_G1]BT5\=?\ #TKX4_\ 0O\ C'_P"M/_ ))H_P"'
MI7PI_P"A?\8_^ 5I_P#)-'U+$?R,/KV&_G1]BT5\=?\ #TKX4_\ 0O\ C'_P
M"M/_ ))JY;_\%._A'-"KO8>*(&/6.2PA+#Z[9B/UH^I8C^1C^O8;^='US17R
M5_P\W^$'_/MXE_\ !?'_ /':/^'F_P (/^?;Q+_X+X__ ([2^IXC^1C^NX;^
M='UK17R5_P /-_A!_P ^WB7_ ,%\?_QVC_AYO\(/^?;Q+_X+X_\ X[1]3Q'\
MC#Z[AOYT?6M%?)7_  \W^$'_ #[>)?\ P7Q__':/^'F_P@_Y]O$O_@OC_P#C
MM'U/$?R,/KN&_G1]:T5\E?\ #S?X0?\ /MXE_P#!?'_\=H_X>;_"#_GV\2_^
M"^/_ ..T?4\1_(P^NX;^='UK17R5_P /-_A!_P ^WB7_ ,%\?_QVC_AYO\(/
M^?;Q+_X+X_\ X[1]3Q'\C#Z[AOYT?6M%?)7_  \W^$'_ #[>)?\ P7Q__':/
M^'F_P@_Y]O$O_@OC_P#CM'U/$?R,/KN&_G1]:T5\E?\ #S?X0?\ /MXE_P#!
M?'_\=H_X>;_"#_GV\2_^"^/_ ..T?4\1_(P^NX;^='UK17R5_P /-_A!_P ^
MWB7_ ,%\?_QVC_AYO\(/^?;Q+_X+X_\ X[1]3Q'\C#Z[AOYT?6M%?)7_  \W
M^$'_ #[>)?\ P7Q__':/^'F_P@_Y]O$O_@OC_P#CM'U/$?R,/KN&_G1]:T5\
ME?\ #S?X0?\ /MXE_P#!?'_\=H_X>;_"#_GV\2_^"^/_ ..T?4\1_(P^NX;^
M='UK17R5_P /-_A!_P ^WB7_ ,%\?_QVC_AYO\(/^?;Q+_X+X_\ X[1]3Q'\
MC#Z[AOYT?6M%?)7_  \W^$'_ #[>)?\ P7Q__':/^'F_P@_Y]O$O_@OC_P#C
MM'U/$?R,/KN&_G1]:T5\E?\ #S?X0?\ /MXE_P#!?'_\=H_X>;_"#_GV\2_^
M"^/_ ..T?4\1_(P^NX;^='UK17R5_P /-_A!_P ^WB7_ ,%\?_QVC_AYO\(/
M^?;Q+_X+X_\ X[1]3Q'\C#Z[AOYT?6M5]1U"VTG3[F^O9TM;.VB:::>5MJ1H
MH)9B>P !-?*7_#S?X0?\^WB7_P %\?\ \=KQ?]K7]O3PO\5OA)<^%/ Z:Q:W
M6HSHE]->P)"OV4 ED&'8DLVT=N,UI3P-><U%Q:1G4Q^'A!RC)-]CF/VH?^"@
M7B3QOK%WH'P[OYO#OAF!VC.IVS;;N^&,$[NL:9S@+@G@D]A\=75U->W$D]Q-
M)//(=SRRL69CZDGDFHJ*^OHT84(\L$?%5J]3$2YJCN2VUS-97$<]O*\$\9W)
M)$Q5E/J".0:^Q?V7O^"@7B3P1K%IH'Q$OYO$7AF>18QJ=RV^[L1C .[K(F<9
M#<CD@]C\:T45J,*\>6:"C7J8>7-3=C^@;3]0MM6L+:^LYTN;.YB6:&>(Y61&
M *L#W!!!JQ7YQ?LE?MZ^&/A3\);?PGXY36+FZTV=TL9K&!)E^S$ JARZD%6W
M =>,5[1_P\W^$'_/MXE_\%\?_P =KY"I@:\)N*BVC[6GC\/."E*23['UK17R
M5_P\W^$'_/MXE_\ !?'_ /':/^'F_P (/^?;Q+_X+X__ ([6?U/$?R,T^NX;
M^='UK17R5_P\W^$'_/MXE_\ !?'_ /':/^'F_P (/^?;Q+_X+X__ ([1]3Q'
M\C#Z[AOYT?6M%?)7_#S?X0?\^WB7_P %\?\ \=H_X>;_  @_Y]O$O_@OC_\
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M  \C^#'_ #^ZS_X+6_QH^J8C^1_<'US#_P#/Q?>?4M%?+7_#R/X,?\_NL_\
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M"JY_^(H_X>(? _\ Z&2]_P#!5<__ !%'U6O_ "/[@^MX?_GXOO1]*45\U_\
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M"JY_^(H_X>(? _\ Z&2]_P#!5<__ !%'U6O_ "/[@^MX?_GXOO1]*45\U_\
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M"JY_^(H_X>(? _\ Z&2]_P#!5<__ !%'U6O_ "/[@^MX?_GXOO1]*45\U_\
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M_P C^YA]:P__ #\7WH^A**^>_P#AOSX#?]#W_P"4>_\ _C%'_#?GP&_Z'O\
M\H]__P#&*/JU?^1_<P^M8?\ Y^+[T?0E%?/?_#?GP&_Z'O\ \H]__P#&*/\
MAOSX#?\ 0]_^4>__ /C%'U:O_(_N8?6L/_S\7WH^A**^>_\ AOSX#?\ 0]_^
M4>__ /C%'_#?GP&_Z'O_ ,H]_P#_ !BCZM7_ )']S#ZUA_\ GXOO1]"45\]_
M\-^? ;_H>_\ RCW_ /\ &*/^&_/@-_T/?_E'O_\ XQ1]6K_R/[F'UK#_ //Q
M?>CZ$HKY[_X;\^ W_0]_^4>__P#C%'_#?GP&_P"A[_\ */?_ /QBCZM7_D?W
M,/K6'_Y^+[T?0E%?/?\ PWY\!O\ H>__ "CW_P#\8H_X;\^ W_0]_P#E'O\
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M\!O^A[_\H]__ /&*/JU?^1_<P^M8?_GXOO1]"45\]_\ #?GP&_Z'O_RCW_\
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MO^B@6?\ X"W/_P ;H^KUOY']S#ZS0_G7WH]SKGOB)XM_X0'X?^)_$_V7[?\
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M_'JVJ^&:L[,_0$[JZ"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M2?\ QJOU9HH_M3$>7W!_9.&\_O/RF_X=D_%__GY\-?\ @PD_^-4?\.R?B_\
M\_/AK_P82?\ QJOU9HH_M3$>7W!_9.&\_O/RF_X=D_%__GY\-?\ @PD_^-4?
M\.R?B_\ \_/AK_P82?\ QJOU9HH_M3$>7W!_9.&\_O/RF_X=D_%__GY\-?\
M@PD_^-4?\.R?B_\ \_/AK_P82?\ QJOU9HH_M3$>7W!_9.&\_O/RF_X=D_%_
M_GY\-?\ @PD_^-4?\.R?B_\ \_/AK_P82?\ QJOU9HH_M3$>7W!_9.&\_O/R
MF_X=D_%__GY\-?\ @PD_^-4?\.R?B_\ \_/AK_P82?\ QJOU9HH_M3$>7W!_
M9.&\_O/RF_X=D_%__GY\-?\ @PD_^-4?\.R?B_\ \_/AK_P82?\ QJOU9HH_
MM3$>7W!_9.&\_O/RF_X=D_%__GY\-?\ @PD_^-4?\.R?B_\ \_/AK_P82?\
MQJOU9HH_M3$>7W!_9.&\_O/RF_X=D_%__GY\-?\ @PD_^-4Z/_@F-\7GD56O
M/#,8) +M?RX7W.(2?R%?JO11_:F(\ON#^R<-Y_>?EM_PZU^*W_0P>#O_  -N
M_P#Y&H_X=:_%;_H8/!W_ (&W?_R-7ZDT4O[3Q'=?</\ LK#=G]Y^6W_#K7XK
M?]#!X._\#;O_ .1J/^'6OQ6_Z&#P=_X&W?\ \C5^I-%']IXCNON#^RL-V?WG
MY;?\.M?BM_T,'@[_ ,#;O_Y&H_X=:_%;_H8/!W_@;=__ "-7ZDT4?VGB.Z^X
M/[*PW9_>?EM_PZU^*W_0P>#O_ V[_P#D:C_AUK\5O^A@\'?^!MW_ /(U?J31
M1_:>([K[@_LK#=G]Y^6W_#K7XK?]#!X._P# V[_^1J/^'6OQ6_Z&#P=_X&W?
M_P C5^I-%']IXCNON#^RL-V?WGY;?\.M?BM_T,'@[_P-N_\ Y&H_X=:_%;_H
M8/!W_@;=_P#R-7ZDT4?VGB.Z^X/[*PW9_>?EM_PZU^*W_0P>#O\ P-N__D:C
M_AUK\5O^A@\'?^!MW_\ (U?J311_:>([K[@_LK#=G]Y^6W_#K7XK?]#!X._\
M#;O_ .1J/^'6OQ6_Z&#P=_X&W?\ \C5^I-%']IXCNON#^RL-V?WGY;?\.M?B
MM_T,'@[_ ,#;O_Y&H_X=:_%;_H8/!W_@;=__ "-7ZDT4?VGB.Z^X/[*PW9_>
M?EM_PZU^*W_0P>#O_ V[_P#D:G1_\$M/BF9%$GB+P>L9(W,MW=$@=\#[,,_F
M*_4>BC^T\1W7W!_96&[/[S\Q_P#AU=\0/^AM\-?G<?\ QJC_ (=7?$#_ *&W
MPU^=Q_\ &J_3BBE_:>)[K[A_V5A>S^\_,?\ X=7?$#_H;?#7YW'_ ,:H_P"'
M5WQ _P"AM\-?G<?_ !JOTXHH_M/$]U]P?V5A>S^\_,?_ (=7?$#_ *&WPU^=
MQ_\ &J/^'5WQ _Z&WPU^=Q_\:K].**/[3Q/=?<']E87L_O/S'_X=7?$#_H;?
M#7YW'_QJC_AU=\0/^AM\-?G<?_&J_3BBC^T\3W7W!_96%[/[S\Q_^'5WQ _Z
M&WPU^=Q_\:H_X=7?$#_H;?#7YW'_ ,:K].**/[3Q/=?<']E87L_O/S'_ .'5
MWQ _Z&WPU^=Q_P#&J/\ AU=\0/\ H;?#7YW'_P :K].**/[3Q/=?<']E87L_
MO/S'_P"'5WQ _P"AM\-?G<?_ !JC_AU=\0/^AM\-?G<?_&J_3BBC^T\3W7W!
M_96%[/[S\Q_^'5WQ _Z&WPU^=Q_\:H_X=7?$#_H;?#7YW'_QJOTXHH_M/$]U
M]P?V5A>S^\_,?_AU=\0/^AM\-?G<?_&J/^'5WQ _Z&WPU^=Q_P#&J_3BBC^T
M\3W7W!_96%[/[S\Q_P#AU=\0/^AM\-?G<?\ QJC_ (=7?$#_ *&WPU^=Q_\
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M_P .FO\ JJG_ );O_P!U5^@]%3_:.*_G_!?Y%?V9A/Y/Q?\ F?GQ_P .FO\
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M01=QW.X4<=^M9-?>_P#P3P_97U"37K?XH^*;%[6QM5;^Q;6X0J\LIX^T8/\
M"HW!?4G(X'//B*T:%-S9U8:A+$55"/S]#0_X=-?]54_\MW_[JH_X=-?]54_\
MMW_[JK]!Z*^3_M'%?S_@O\C[#^S,)_)^+_S/SX_X=-?]54_\MW_[JH_X=-?]
M54_\MW_[JK]!Z*/[1Q7\_P""_P @_LS"?R?B_P#,_/C_ (=-?]54_P#+=_\
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M_P""_P @_LS"?R?B_P#,_/C_ (=-?]54_P#+=_\ NJC_ (=-?]54_P#+=_\
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M ..U^C%%']HXG^;\$']F87^7\7_F?G/_ ,.H=6_Z*-9?^"E__CM'_#J'5O\
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MO^BC67_@I?\ ^.T?\.H=6_Z*-9?^"E__ ([7Z,44?VCB?YOP0?V9A?Y?Q?\
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M_P .J/%?_0]:-_X"RU^E%%']I8G^;\$']EX7^7\6?FO_ ,.J/%?_ $/6C?\
M@++1_P .J/%?_0]:-_X"RU^E%%']I8G^;\$']EX7^7\6?FO_ ,.J/%?_ $/6
MC?\ @++1_P .J/%?_0]:-_X"RU^E%%']I8G^;\$']EX7^7\6?FO_ ,.J/%?_
M $/6C?\ @++1_P .J/%?_0]:-_X"RU^E%%']I8G^;\$']EX7^7\6?FO_ ,.J
M/%?_ $/6C?\ @++1_P .J/%?_0]:-_X"RU^E%%']I8G^;\$']EX7^7\6?FO_
M ,.J/%?_ $/6C?\ @++1_P .J/%?_0]:-_X"RU^E%%']I8G^;\$']EX7^7\6
M?FO_ ,.J/%?_ $/6C?\ @++1_P .J/%?_0]:-_X"RU^E%%']I8G^;\$']EX7
M^7\6?FO_ ,.J/%?_ $/6C?\ @++1_P .J/%?_0]:-_X"RU^E%%']I8G^;\$'
M]EX7^7\6?FO_ ,.J/%?_ $/6C?\ @++1_P .J/%?_0]:-_X"RU^E%%']I8G^
M;\$']EX7^7\6?FO_ ,.J/%?_ $/6C?\ @++1_P .J/%?_0]:-_X"RU^E%%']
MI8G^;\$']EX7^7\6?FO_ ,.J/%?_ $/6C?\ @++1_P .J/%?_0]:-_X"RU^E
M%%']I8G^;\$']EX7^7\6?FO_ ,.J/%?_ $/6C?\ @++1_P .J/%?_0]:-_X"
MRU^E%%']I8G^;\$']EX7^7\6?B!^T-\!-7_9V\>)X:U:[BU$RVL=W!>V\;)'
M*C$@XW=PRD'Z5YA7ZZ_MQ_LRS_'SP):ZAH$2-XNT,M);(< W4)!WP9]<A67W
M!'>OR2O["ZTJ\FM+VVEM+N%BDL$Z%'1AU#*>0?8U]%@\2L133;]Y;GS&.PKP
MU5I+W7L5Z***[SSQT<;2NJ(I=V("JHR2?05]M:5_P2S\8:AIEG=3>,=)LYIX
M4D>VDMI2T3%02A/J"<?A7,?L)?LKZA\4O&]CXSU^Q>'P;H\XF3ST*B_G491$
MSU56VLQZ<8ZGC]6:\''8Z5*:A1>JW/HLOR^-:#J5EH]C\U_^'5'BO_H>M&_\
M!9:/^'5'BO\ Z'K1O_ 66OTHHKS/[2Q/\WX(]7^R\+_+^+/S7_X=4>*_^AZT
M;_P%EH_X=4>*_P#H>M&_\!9:_2BBC^TL3_-^"#^R\+_+^+/S7_X=4>*_^AZT
M;_P%EH_X=4>*_P#H>M&_\!9:_2BBC^TL3_-^"#^R\+_+^+/S7_X=4>*_^AZT
M;_P%EH_X=4>*_P#H>M&_\!9:_2BBC^TL3_-^"#^R\+_+^+/S7_X=4>*_^AZT
M;_P%EH_X=4>*_P#H>M&_\!9:_2BBC^TL3_-^"#^R\+_+^+/S7_X=4>*_^AZT
M;_P%EH_X=4>*_P#H>M&_\!9:_2BBC^TL3_-^"#^R\+_+^+/S7_X=4>*_^AZT
M;_P%EH_X=4>*_P#H>M&_\!9:_2BBC^TL3_-^"#^R\+_+^+/S'_X=7?$#_H;?
M#7YW'_QJC_AU=\0/^AM\-?G<?_&J_3BBG_:>)[K[A?V5A>S^\_,?_AU=\0/^
MAM\-?G<?_&J/^'5WQ _Z&WPU^=Q_\:K].**/[3Q/=?<']E87L_O/S'_X=7?$
M#_H;?#7YW'_QJC_AU=\0/^AM\-?G<?\ QJOTXHH_M/$]U]P?V5A>S^\_,?\
MX=7?$#_H;?#7YW'_ ,:H_P"'5WQ _P"AM\-?G<?_ !JOTXHH_M/$]U]P?V5A
M>S^\_,?_ (=7?$#_ *&WPU^=Q_\ &J/^'5WQ _Z&WPU^=Q_\:K].**/[3Q/=
M?<']E87L_O/S'_X=7?$#_H;?#7YW'_QJC_AU=\0/^AM\-?G<?_&J_3BBC^T\
M3W7W!_96%[/[S\Q_^'5WQ _Z&WPU^=Q_\:H_X=7?$#_H;?#7YW'_ ,:K].**
M/[3Q/=?<']E87L_O/S'_ .'5WQ _Z&WPU^=Q_P#&J/\ AU=\0/\ H;?#7YW'
M_P :K].**/[3Q/=?<']E87L_O/S'_P"'5WQ _P"AM\-?G<?_ !JC_AU=\0/^
MAM\-?G<?_&J_3BBC^T\3W7W!_96%[/[S\Q_^'5WQ _Z&WPU^=Q_\:H_X=7?$
M#_H;?#7YW'_QJOTXHH_M/$]U]P?V5A>S^\_,?_AU=\0/^AM\-?G<?_&J/^'5
MWQ _Z&WPU^=Q_P#&J_3BBC^T\3W7W!_96%[/[S\Q_P#AU=\0/^AM\-?G<?\
MQJC_ (=7?$#_ *&WPU^=Q_\ &J_3BBC^T\3W7W!_96%[/[S\Q_\ AU=\0/\
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M(****104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SWCGX?>&_B9H,FB^
M*=&M=;TQV#_9[I-P5AT93U5AD\@@\UT-%--Q=T)I25GL?$WC+_@EGX)U:\>;
MPWXKU?P_&Y)^SW,27L:>RG*-C_>9C[U1\,?\$J?"]E=1OX@\<ZKJT"\M%86<
M=F6_X$S2X'^<U]ST5W?7L2E;G//_ +/PK?-R?F<3\+?@QX-^#&C-IOA#0[?2
M8I OGS*"TUP5& 9)#EF/7J<#)P!7;445Q2DY.\G=G?&*@N6*L@HHHJ2@HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#^N3,TDNI:*RPO,Y[R(5*.<\DX#'GFO!)?\ @D_IQN]T?Q)NDMO^>;:.K/\
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M4GK78445<36K:5)7"EA:-#6G&P4445S'4%%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *\ ^,W[$/PP^-%Y/J5WILWA_7)F:274M%987F<]Y$*E'.>2<!
MCSS7O]%:4ZDZ3YH.S,JE*%5<M171\"R_\$G].-WNC^)-TEM_SS;1U9_^^O.
M_P#':]=^$_\ P3U^%GPUO(M0U"WNO&.I1X*OK)5K=&!SE85 7M_&6KZ=HKIG
MC<1-<KF<L,!AJ;YHP_7\Q%4(H50%4#  ' %+117$=X4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y!\:OV
M4OAS\>"UQXCT<P:P5"C6=-8078 & "V"K@>CJV.U?,^H?\$H=*ENRUC\1[RV
MM=V?+N-)25]OIN$J#/OM_"OO>BNNGBZ])<L):'%5P>'K/FG#7[OR/DWX8?\
M!-OX9>![V*^UV:^\:7<9R(M0*Q6F>Q\I!D_1F(]J^K+.RM].M(+6T@BM;6!!
M'%!"@1(T P%51P !P *FHK*I6J5G>I*YM2H4Z"M3C8****Q-PHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y
M3XL_\DK\9?\ 8%O?_1#UU=<I\6?^25^,O^P+>_\ HAZ #X3?\DK\&_\ 8%LO
M_1"5U=<I\)O^25^#?^P+9?\ HA*ZN@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M15+^V]._Y_[7_O\ +_C1_;>G?\_]K_W^7_&CVM/^9?>'LY_RLNT52_MO3O\
MG_M?^_R_XT?VWIW_ #_VO_?Y?\:/:T_YE]X>SG_*R[15+^V]._Y_[7_O\O\
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M?^_R_P"-']MZ=_S_ -K_ -_E_P :/:T_YE]X>SG_ "LNT52_MO3O^?\ M?\
MO\O^-']MZ=_S_P!K_P!_E_QH]K3_ )E]X>SG_*R[15+^V]._Y_[7_O\ +_C1
M_;>G?\_]K_W^7_&CVM/^9?>'LY_RLNT52_MO3O\ G_M?^_R_XT?VWIW_ #_V
MO_?Y?\:/:T_YE]X>SG_*R[15+^V]._Y_[7_O\O\ C1_;>G?\_P#:_P#?Y?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MY3XL_P#)*_&7_8%O?_1#UU=<I\6?^25^,O\ L"WO_HAZ #X3?\DK\&_]@6R_
M]$)75URGPF_Y)7X-_P"P+9?^B$KJZ "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *\DUO\ Y#5__P!?$G_H1KUNO)-;_P"0
MU?\ _7Q)_P"A&OG<Y_AP]3W<I^.7H4J***^4/I@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /6]$_Y MA_U[Q_^@BKM4M$_Y MA_P!>\?\
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M,*;Y>_;2^NGZGU'1117DGLA1110 4444 %%%% !1110 4444 %%%% !1110
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M<6O4SA5A4UA)/T=PHHHK,T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9.]U?\6OT.W"8N.+3<5:P4445PG>%%%% !1110 4444 %%%% !1110 4444
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M 4444 %%%% !1110 5^;W_!5K_D=/ '_ &#[G_T8E?I#7YO?\%6O^1T\ ?\
M8/N?_1B5VX'_ 'NEZO\ ])9PYA_N=7T7_I43Y;^%/[.?Q#^-]C?WG@KP]_;5
MO82+%<O]MMX-C,"0,2R*3P#TS74Z[^Q%\;_#MC+=W?P_O988UW,+&YM[N3'L
MD,C,?H!7UC_P2E_Y$CQ]_P!A&V_]%-7W77M8S'U</7=."5E;>_5)]SPL#EU+
M$T(U9MW=]K=&UV/Q ^"_Q]\;?L\>*A=Z%?3PVZ38OM$NBWV>YP<,LD9^ZW&-
MPPP]>HK]D?A/\3=(^,/P^T;Q;HCDV.HP[_*<@O#(#AXFQ_$K @_3(X-?GO\
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M_+:_>+>\SCJD29&<=V)P,]SD5YI\1O$$OBOQ_P"(M7F<R/>ZA/-EO[I<[1^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2R^$!&B^I-L0!7Y.? K4X-#^-?@*_NBJVUMKME)*S\!5$Z9)^@Y_"OV!_9;
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M\;?]@B/_ -'"OTMK'-?XZ]/\S7)_]W?J_P D%%%%>.>X%%%% !1110 4444
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M=CA;RD'_ 'R@K](_^"??PEN?AA\!+:\U*%H-4\1SG5)(W&&CA*A85(_W1O\
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MXQ\,66K^%;VSU#0[E-T$]CCRR.XP/ND="I ((P0#7YB?\%-O^3CK;_L!6O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OS>_X*M?\ (Z> /^P?<_\ HQ*_2&OS>_X*M?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7DFM_\AJ__P"OB3_T(UZW7DFM_P#(:O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(ZI?\$G_ /CT^)/^_8?RGJ,-_P BRKZ_^W(O%_\ (SH^GZ2.?_X*M?\ (Z>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P DK\9?]@6]_P#1#T 'PF_Y)7X-_P"P+9?^B$KJZY3X3?\ )*_!O_8%LO\
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M24XNS1ZTH1G%PDKIGXXWW[-7[07P0UV631M \3VER08QJ/A&66;S4S_>MSN
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MX@? _6/&D_C;0/[%BU&"U2U;[;;W'F%&D+#]U(V,;AUQUKZ$_:$^ 6@_M#^
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M45I6Q[J4_94XJ,?(SH9?&G4]K5DYR\_Z9\E?MR?LA7GQVM+3Q5X3$7_"7Z;
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MU-;=%-.VJ$U?1GGO_#.WPI_Z)EX._P#!!:?_ !NC_AG;X4_]$R\'?^""T_\
MC=>A45?M9_S/[S/V5/\ E7W'GO\ PSM\*?\ HF7@[_P06G_QNNK\,>$-"\$Z
M:=/\.Z)IV@Z>9#*;73+2.VB+D %MB #)P.<=A6O12<YM6;&J<(NZ2.)UCX'_
M  Y\0ZG<ZEJO@#POJ>HW+^9/=WFC6TLLK?WF=D)8^Y-=;INFV>C:?;6&GVL%
MC8VL:PP6MM&(XHD485%50 J@   <"K-%)RDURMZ%*,4^9+4YSQ9\-O"/CV2V
MD\3>%M%\126P98&U;3X;HQ!L;@ID4[<X&<=<"I_"G@7PUX$M9[;PUX>TKP];
MSOYDL.E645JDC8QN81J 3CC)K<HHYI)<M] Y8N7-;4:Z+(C*RAE88*D9!%>*
M^(OV+?@IXIU=]3OO -BMV[;F^QSSVD9.<Y,<4BI^E>V44X3E3?-!V?D*<(U%
MRS5UYG-:;\-?">C^$6\*V?AK2H/#3J4?219QFVD!Y.^,C#$D DD$D\FJ_AKX
M1^!?!>IC4?#W@OP]H6H!#&+O3-*@MY=IZKO1 <' XS76T4<\M7?<.2&BML%%
M%%06%>?_ !%^ /P[^+,GF^+/".FZO=8"_;&C,5Q@=!YR%7Q[;J] HIIN+NMQ
M-*2L]CQ3PO\ L7_!7P=J*7VG> -/>X0Y4ZA-->J#ZA)W=<^^*]ICC6)%1%"(
MH 55& !Z"G45<ZDZGQR;]3.%*G3^"*7HBO?V%MJMC<65[;17EG<1M#-;W"!X
MY488964\$$$@@\'-<?I7P,^&^A:E;:AIOP^\*Z?J%M()8+JUT6VBEB<'(975
M 5(]0:[BBI4I1^%V+E&,OB5PHHHJ2@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *^%O^"K/_ "(?@/\ ["5Q_P"BA7W316E*?LYQ
MGV:9E5A[6G*%]TU]Y^!_A3Q[XG\!SW$WAGQ'JWAV:X4)-)I-]+:M*H.0&,;#
M(!]:Z"?X[_%#5HS:S?$/Q=>1R?*8)-;NI WMM+\U^Z%%>Y+-(R^*E?Y_\ \&
M.43CI&JU\O\ @GXP_![]CSXG?&;5;?[/H%WHNCR.#-K6L1-!"J'JR!L-*?9
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** .5\=_"KP=\3K5(/%?AK3-?2,$1M>VRO)$#UV/C<
MG_ 2*\I;]@GX$/-YA\!INSG U6^"_EY^*^@**UA5J4](2:]&93I4ZGQQ3]4<
M=\/O@[X(^%4+Q^$O"^FZ$74))-:P 32+V#RG+L/J378T45$I2F[R=V7&,8*T
M59!1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!ZWHG_(%L/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-_$K_ ))U
MXJ_[!5U_Z):OPS\!:9;:UXY\.Z?>Q^=9W>I6UO-'N*[T:5589!!&03R#FOW,
M^)7_ "3KQ5_V"KK_ -$M7X2:#K,WAW7=.U6V6-[BQN8[J)902A9&# , 0<9'
M."*^AR5I5:C?]W_VX^<SS^%2MWE_[:?KW_PP'\!O^A$_\K%__P#'Z/\ A@/X
M#?\ 0B?^5B__ /C]?'7_  ]*^*W_ $+_ (._\ KO_P"2:FL_^"HGQ4N+N")M
M \'A7D521976<$X_Y^:2PF/D[*;_ / F#QF7)7<%_P" H_1OX<?#/PU\)/"\
M/AWPGIO]E:-%(\J6WGRS89SECND9FY/O5WQCXVT'X?:#/K7B35K31=+@^_=7
MD@1<]E'=F/91DGL*UUE @$KD*NW<Q/ ''-?C3^UI\?=5_:!^+-\T,\LGARPN
M&L]'L8R2I0-M\W:.KR$9SZ$#M7F8>C4QE;DOKU>_]>7_  #U,1B*>#H>TMIT
M6Q]S:]_P4U^$&D7[V]K;^)-;B7I=6&GQK&WT$TL;?FM>D_"#]L/X7?&N^BTW
M1-=-EK4O^KTK5HOLT[GT3)*.?]E&)]J^;OA/_P $N](OO"%K>?$#Q#JUMKMU
M$)6L-&:*-+0D9V.SH_F,.Y&T9R!G&3\Q_M2?LPZQ^S#XOL52_DU/0K_=+INJ
MJAB<,A!,;X/#KE3D'D'(QR!Z2P^!G/V$9/F[_P!:'F/$X^%/V\H+E[>7YG[,
M5^6/_!4#_DO^E?\ 8!@_]'35]:_L&_M"7OQP^%L]EKMP;KQ/X=D2UNKASE[F
M%@3#*W^T=K*3W*9[U\E?\%0/^2_Z5_V 8/\ T=-7/AJ,L/CHTY;J_P#Z2SJQ
M->.)R^=6/5+_ -*1]2_\$UO^3:(/^PO=_P#LE?'G_!2#_DYW4?\ L&V?_H!K
M[#_X)K?\FT0?]A>[_P#9*^//^"D'_)SNH_\ 8-L__0#76O\ D9_U_*<3_P"1
M5_7\Q]R?\$_O^34/!O\ OWO_ *635[QKVOZ9X6TBZU76+^VTO3;5-\]W=RK'
M%&OJS$X%>#_\$_O^34/!O^_>_P#I9-7Q!^WS^T+?_%+XJW_A2QNV7PIX<G:U
M2"-_DN+E>))6QP2&RJ^@!]37)7H2Q./J4X]W\E<[*%>.&P$*LNWWL^O/%7_!
M2GX.^'-0:UM&UWQ&JG!N-*L%$6?8S21D_4#%=9\*_P!N;X2_%C4H-,M-:FT+
M5;AML-EKL(MVD/0!9 S1DD]%WY/85\Q_L\_\$V+/QKX&L/$?Q"UK4]+EU.%;
MBUTO2?+CDAB891I7D1QN8$'8%&.YSD#R#]KK]CF]_9NFL=7TS4)M;\)7\I@C
MN9XPLUM+C(CEV\'(!(8 9P1@8&>CZO@?:>PYGS;7\^W;^K'-]9Q[I_6%%<N]
MO+OO?^KVL?KSTKPB3]N;X(PZNVER>-O*OEG-LT4FDWR[9 VTJ28,#!XR3BO*
MO^"<O[16H?$GPMJ'@;Q%=O>ZQH$2S65U,VZ2:S)V[6)Y)C;:,GLZCM7Q_P#M
MU?#K_A7/[2/B188O*L=8*ZO;X&!^]SYF/^V@D_2N>G@HK%_5ZSTM=-=?SZ7^
MXZ:F.E+!_6:"5T[-/I^76WWG[& Y&1TKQ7QA^V=\&_ 7B;4?#VN^,A9:OI\I
M@NK==-O)?+<=5W)"RGKV)K5^!7Q4M_%_[.?AKQK>3!A'H_FWTA/_ "T@4I,3
M_P "C8U^+_C#Q'<>,/%FM:[=$FYU.\FO),_WI'+'^=3AL%[7$3HS>D-[=[V7
MY,>*QSI8:G6IK6>U^UKO\T?O%X7\3Z9XT\.:;KVBW:WVDZC ES:W*JRB2-AE
M3A@"..Q ([BO/_BA^U%\,?@SX@BT/QAXH72-5D@6Z6W%C<SGRV+ ,3%&P&2I
MX)SQ7F/_  3E\<?\)9^S?9:=))ON= O9]/8$\["1*GX8EVC_ ':_/G]K'QQ-
M\5OVD/%U[;,UU$+_ /LRR5><I%B)0OU*D_\  JJ&!4\9+#ZV5WYVTM\W=?B*
MICW#!1Q.G,[+ROU^6C_ _8+X=?$CP[\6/"UOXC\*W[:GHMP[QQ736TL <HQ5
ML+*JM@$$9QC@UTU<7\%_ $7PM^%/A;PK$JJVF6$4,Q7HTV-TK?BY8_C7:5YU
M90C4E&F[Q3T/3HRG*E&516DUJ<[\0/B%X?\ A;X5N_$GB>__ +,T6T*":Z\F
M279N8*ORQJS')(' KA?AQ^UA\*OBWXHB\.^$_%/]JZS+&\J6W]G7<.5098[I
M(E7@>]<E_P % /\ DU;Q=_OVG_I3'7PU_P $X?\ DY_2_P#L'7G_ *+KNPF%
MAB*-6I)N\;V^4;G!C<7/#5J5."5I6O?SE8_6TD*"3T%>!I^WA\#)+U;1?'&;
MAI/*"?V3??>SC&?(QUKWJ7_5/]#7X'V/_(Z6_P#V$%_]&4LNPL,96E3J-I*V
MWFW_ )"S/%SP6']K32;\_2_D?O9?7L.FV5Q=W#^7;P1M+(^"=JJ,DX')X':O
M%_"O[:OP9\:^)--T'1?&7VS5M1G2VM;?^R[V/S)&.%7<T(49/<D"O5/&_P#R
M)>O_ /8/N/\ T6U?@YX?UC4?#^MV6HZ1<2VFJ6\H>VG@_P!8DG8K[YZ48#"Q
MQ<IQE?2UK>=_7L/,<7/!PA*%M;WOY6\UW/U]^+W[<OPL^#>MS:-?ZA>:[K%N
MVRXLM#@6=H#Z.[,B CNH8D=P*M_!O]M3X7_&W58M(TG5+C2=;F.(=,UJ$02S
M'T1@S(S?[(;=[5\^_#+_ ()?:/J?@ZWOO'OB76(?$MY&)GMM*:)8K5F&=CF1
M',C#/)!49R!GJ?C_ /:&^!>M?LV?$QM!NKTW4>Q;S3=4A4Q&:+)VMC/RNK*0
M0"<$9!Y%=5+#8.<O8<[<^_3Y?U\SDK8O&PC]8Y$H=NMNE_Z^1^W%%>&_L9_&
M>[^-_P "]*U?5)?.URPD?3-0E[RRQA2)#[LC(Q]R:]RKR*U*5"HZ<MT>S0K1
MKTXU([,****Q-PHHHH **** "BBB@ HHHH **** "N4^+/\ R2OQE_V!;W_T
M0]=77*?%G_DE?C+_ + M[_Z(>@ ^$W_)*_!O_8%LO_1"5U=<I\)O^25^#?\
ML"V7_HA*ZN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O)-;_ .0U?_\ 7Q)_Z$:];KR36_\ D-7_ /U\2?\ H1KYW.?X
M</4]W*?CEZ%*BBBOE#Z8**** ,OQ1XDL/!_AW4=;U286^GV$#3S2>BJ,X [D
M] .Y(K\OOC9\=_$GQU\2LUS)-#I"R[=/T>$DI&,X4D#[\A[GWP,#BOK7]O\
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\4?VOO\
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MJ5XY\#:/\1O#5UH&O6[W>EW)4RQ1S/$6*L&'S(0>H!QTK\K_ ('?\EE\#_\
M8:M/_1RU][_MF?$K4_AQ\(6.CSR6>H:M=+8+=1'#Q(59G*GL2$QGMG(YKV>)
M:-2OCL-3HNTGL^VJU^6YXG#%6%'"XJI5UBDFUW5G=?/8YS1O#WP'_9>\8WFL
M?\)(MOK!B-M]BFN/MLEJ"03MCC0NA.,98]/J:\__ &B_VP?!7Q#^'NL>$]%T
MO4-1DO @6]NHUAAC*NK!U!)8GY>A"]:\0_9T^ TOQ]\4W]E)JZZ596$*W%S-
ML\R5]S8"HI(Z\Y8]..#FO>_C-^R3\//A%\&_$>NQW&HWVK01(MK/J%T %E:1
M5 5(U4'.3P<TZN'R_"8RG'&59U:UXV^_3\?-ET,3C\7A:DL#1A2HN]_NU_#R
M/'_V)9&3]H?0@IP'M[M6]QY#G^8%?3/[?W_)$K+_ +#,'_HJ:OFK]B")9/VA
M-(9NJ6ETR_7RF'\B:^E?V_O^2)67_89@_P#14U&;_P#(^PWI'_TIDY&G_8>+
M]9_^D1/&/^">7_)4O$7_ &!F_P#1\5>F?\%$/^2>^%O^PHW_ **:O,_^">7_
M "5+Q%_V!F_]'Q5Z9_P40_Y)[X6_["C?^BFJ,;_R4=+Y?DRLM_Y)^O\ ]O?D
MCCO^"<__ "'?&_\ U[6O_H4E>;?MM^)IM>^/6J6;NQ@TFW@LXD)X7*"1B/J9
M#^0KTG_@G/\ \AWQO_U[6O\ Z%)7E/[9FC3Z3^T)XBDF&$OD@NHCZH8E7^:,
M/PKTJ2B^)*G-OR*WK:/Z7.&;DN&X\O6>OI=_K8]Z_9H^/'P@^$WPHTO2[SQ
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MQM\/K_P3\.Y[G4AJJ"*^U>2W>")(,Y:.-9 '+-C!)4  G&2>.'_X)N_ J_\
M%OQ-7XA7UL\>@>'PZVTKK\MQ>,I4*OJ$5BQ/8[/6GE].6&IU:U566FC\K_G>
MPLSJ0Q<Z5"B[O75>=ORM=GT/_P %/_\ DWO2_P#L8+?_ -$SUX+_ ,$KO^2P
M>+?^P$?_ $HBKWK_ (*?_P#)O>E_]C!;_P#HF>O!?^"5W_)8/%O_ & C_P"E
M$598'_<JWJ__ $E%YE_OM#_MW_TMGK'_  55_P"29>"O^PQ)_P"B6KB/^"4/
M_(P?$7_KULO_ $.6NW_X*J_\DR\%?]AB3_T2U<1_P2A_Y&#XB_\ 7K9?^ARU
M6$_W"M\_T'B_^1C2]%^;/*/^"CTEP_[3VIB?/EIIUHL.?[FS/'_ BU?<_P"P
M#!;0?LJ>#S;A09&NWE(ZE_M4H.??  _ 5X%_P4]^"E_>S:-\2],M6N+6W@&F
MZJ8QDQ ,3#*?]G+,I/8[?6O/?V'_ -L_2?@CI5UX,\:K<+X;FN#<V>HVT1E-
MF[ ;U=!\Q0X!!4$@YX(/%4HO$9=[.GO%_DW^:=R:LEALR]I4^&2W^2_56/T\
MU6*"?2[R.Z -L\+K*#TV%3G],U^#OA&26U^(6BOIW,T>J0FVQW82KL_7%?H1
M^TM_P4.\%R_#[4]"^&][<ZWK6J6[VW]H_99;>&S1AM9OWJJS/@G: N >2>,'
MYH_81^!5_P#%GXSZ7K$MLX\->&KB/4+RY9?D>5#NAA![EF )']U3ZC-973GA
MG4KUE9:;^5_\].Y.;588J,,/1?-)M[:VO9?\/Z(_2#]J[X<_\+2^ 'C'1(XO
M-O5LVO+0=_.A_>(!]=I7_@5?G)_P3]^*4/PT^.XCOI_(TK5].N+:X)/RAD0S
M(WUS&5'^_7ZZLH92I&01@@U^'_[1?@&7X2_'/Q?X?B#V\-M?/):E<K^XD^>/
M'ML<#\#7'ELN9U<.W\2?W[-_BON.S-8\JI8E?8:^[=?+1_>=5\!_#Q_:*_:S
MTUM4A^TVNJZO/J]_'(-RF)2\S*V>QP$_X%4_P9NIOV??VR-)LKIF@CTOQ!)I
M%PSGCR9': L?4;7#?E7MO_!*[P+]M\9^,?%\L>4T^SCTZ!B/XY6WOCW"Q ?\
M#]Z\]_X*-^!F\'?M&3:Q;H88->LX;]'0X_>K^[?'OF-3_P "KU_:QIXN.%7P
M\MK>>_\ Z2>-[*5;!U,6_BYKW\MO_2G^!YU^TGXKN?C3^TMXGN=/W71O-4&F
M:>@YW*A$,8'^\5S_ ,"K]A_ASX-MOAWX!\/>&;3'V?2;&&S5@,;RB %OJ3DG
MZU^4G[ ?PZ/Q#_:1T6ZN(S-9:"CZQ.S<C>F!%^/FNA_X":_7ZO.S&U"E2PL>
MB_X"_7[ST\MOB*U7%OJ[+\W^@4R7_5/]#3Z1EW*1ZC%?.U$Y0:78^B6Y^!MC
M_P CI;_]A!?_ $97[YU^"WCK0[WP+\1==TJY1X;W2]2FB(<8(9)#@_C@'\:_
M3S0/^"D'PDN/ MMJFJ7]_9Z^+<&?0X["627S0/F5)-OE$$]"7'&,@'BOJLPA
M*OAZ4Z2NM=O-*WY'RV!J0HXRNJCM=]=-G+_,^,_^"B$BO^U+XA"L"4M;-6 [
M'R$/\B*^^_V#_P#DU/P-_N77_I5+7Y7?'7XB:A\7OB=K/C:^L)-.CUJ3SK6%
M@<"!/W2 -_%@1X)'&X-]*_5']@__ )-3\#?[EU_Z52U&(IRI99"$MTXW];,,
M/4C5S24X;6=O_)=?F?G%^V__ ,G4_$#_ *^H?_2:*OTY_8_2&/\ 9E^'0@"A
M/[+0G;TW%F+?CNSGWK\QOVW_ /DZGX@?]?4/_I-%7N_[$W[<'AWX7>"D\"?$
M"6XL=-LY'DTW5HH'G6-'8LT4B("_#$E2H/WB#C S<J4JV64HP5VE%_\ DMOU
M)C6A0S6M*>B;FO\ R:_Z'U!^WS#;S?LJ^,C.%)3[*\6[^_\ :8L8_ FOA+_@
MG+).G[46CK%_JWL+Q9>?X?*)_P#0@M=]^W+^VAX=^,'A:W\$>!9)[W2&N$NK
M_5)H6A6;9RD:(X#8W88E@.5&.];?_!+GX37DOB#Q#\1+N!H]/AMSI5B[CB65
MF5I67_="JN?]LCL:C!TY8?!UI55:]]_.*C^9>-J1Q.,H0I._*U=KUO;[E^+/
MT8HHHKYP^G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"CKFDPZ_HNH:9<,Z6][;R
M6TC1$!@KJ5)!((S@]P:^5M!_X)G?##P[KNG:K;:]XN>XL;F.ZB66\M2A9&#
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M@G@9OF@[[^;O^'0_*71?%/Q1_9UU*ZMK235?"<TQQ+;W5L##*1QN"2*R-[,
M>.AIUMX?^)W[27BM+UK;4O$=]+B(W\T>RV@4=B^!'&HR3@8[X!)K]6**]_\
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M *]X_P#T$5=JEHG_ "!;#_KWC_\ 015VOTBE_#CZ(^ J?'+U"BBBM3,****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M** "BBB@ HHHH *Y3XL_\DK\9?\ 8%O?_1#UU=<I\6?^25^,O^P+>_\ HAZ
M#X3?\DK\&_\ 8%LO_1"5U=<I\)O^25^#?^P+9?\ HA*ZN@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY\__ "*G^-'_  ANL?\ /G_Y%3_&O3J*/['P_P#,_P /\@_M6OV7X_YGF/\
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MY!_:M?LOQ_S/,?\ A#=8_P"?/_R*G^-'_"&ZQ_SY_P#D5/\ &O3J*/['P_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *Y3XL_\ )*_&7_8%O?\ T0]=77*?%G_DE?C+_L"WO_HAZ #X
M3?\ )*_!O_8%LO\ T0E=77*?";_DE?@W_L"V7_HA*ZN@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *R?%FA?\)1X5UG1O/^S?VC936?G[-_
ME^8A3=MR,XSG&1GUK6HH R?">A?\(OX5T;1O/^T_V=90V?G[-GF>6@3=MR<9
MQG&3CUK6HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M $Z5^;7[6/\ P4"\07OB74?"GPSOO['TBRD:WN-<A -Q=N#AO*8Y\M <X8?,
M<9! Z_>'QNU2\T3X.>.-0T_<+VVT6\EA*=580L01].OX5^%ENL;W,0G<I$7
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MQB2Q-5+^9_F=. ;>#HM_RQ_)!1145U=06-K-<W,T=O;PH9))I6"HB@9+$G@
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MH9R2 "2<=.37$_MT?%7PI\7OV3H-;\(ZU;ZSIYURU1VBRKQ/LD^61& 9&]F
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M'=ERDH1<I;(]=HKDOA5\2+'XN> M*\6Z98:AIVG:FC26\.IQHDY0,5#%4=P
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M5Y-\(/VIOAK\<)Q9^&/$*/JVS>=*O8VM[G'4[5;A\#KL+8[UV?Q+\?Z=\+/
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MXM>#_A%HXU/Q?K]IH=HQ(C\]B9)2.HCC4%W(]%!K!*[LCH;LKLZZBODC5_\
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MO7@AT[Q3J$2G N;:PA$;>X#SJWYK7%3HU*W\.+9Z-6O2H_Q))'UU17D'P?\
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M@KLVG.--<TW9>9[O17Q_!_P5$^$TLXC;1O%T*$X\U[&V*CWXN"?TKWWX2_M
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MX?#'Q-\!_%VH_#_6[MIK2&9;ZW:,GR+E64JDZJ?NDKE2.N5P<X!K]Q:_-_\
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M  3.^%'_  EOQ=O_ !C=P[[#PU;_ +EF7@W4P*I_WR@D/L2M1ED51I5,5/\
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M=_X*I>/=2MCX-\'03-#I=S'+J5RBG F=6"1AO4+\YQZD>E87_!*7_D=/'_\
MV#[;_P!&/7OG[>/[,FI_'GP?IFK^&8UG\3Z#YGEV;,%^UP/@O&I/ <%05SP?
MF'<56,E"&/ISJ;+?\;?<[/\ $,%"=3+ZD*?Q.]OPO]ZNCXM_8S_99\/?M):A
MKO\ ;WBB728],$>W3+#RQ=W ;.9 7R%1< ?=;ENW&?H'XK?\$O- L?"-_>^
M_$6M3:W:PM-'9:N8IDNBH)\M3'&A1CT!PW/;G(_/[4M+UOP/KS6U]:W^@ZS9
MN"8IT>WN(6'0X.&4^]>K^"/VT/C+X#\M+/QQ?ZA;*03;ZQMOE8#^'=*&<#_=
M85Z6(I8BJ^?#U++MT_X)Y6&K8>BO9XFE=]^O_ .M_9Z^!/QZ\ ?$O0/%NA>
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M6,(C+N8 C<6SSG %?3OQ3^,'A+X+^'#K?B_6(M*LRVR)""\L[_W(XURS'Z#
MZD@<U\B^*/\ @JSX>M+AD\.^ M2U.'D"74K^.T/UVHLO\Q7-AIUY4'1P\=;W
M;7Y?EUVL=>*AAXUU6Q$M+:1?Y_GTW]#UGXA?\$_/@_XQT2YM],T ^%M4*$0:
MAIMQ+^[;MNC9BC#/7@''0BOB7]B7Q!K/PG_:TLO#'GGRKVZN=$U*!&/ER% ^
MUL>JR("#UP2.YKT>7_@HM\8OB/>2:?X"\ V7GN,!+2SN-2N4]QM(7\T(KP[]
MG>\U>_\ VQO"MSKX8:[+XD9[\.@1A<%V\P%1P#NSP.*]/!TL1!RA7>C6S=W_
M %_P#RL;6PTU">'7O)K5*R_K_@GZ<_M9?"W_ (6]\!?%&AQ1>;J,4!OK$=_/
MB^=0/]X K_P*OCK_ ();_$XZ7XQ\3> [N;;#J< U&SC8_P#+>+Y9 !ZLA!^D
M5?I'UK\C?BA8S?LE_MJC5;2-HM,MM435;=%X#V4Y/F1CZ*TL?_ :\[+G[1U,
M*]IK3U7])_(]/,TZ:IXN.\'KZ/\ IK_MX_7.ORE_;#U^\_:'_:\M?!NCR>=#
M97$/A^UVG*B0OF=_P9F!]HZ_23XJ?$JQ^'?PFU_QH94EM;'3FNX&!RLK%?W0
M'KN9E'XU^?G_  39^'UQX]^-.O\ Q!U4&Y71HG=9G'W[VY+#=]0GFD^[+4Y?
M%0J3KS6E-?B]O\OF/,IN=*&'@]:CM\EJ_P!'\F?I/X:\/V?A/P[I>B:=&(;#
M3K6*TMXQ_#&BA5'Y 5I445YDI.3<GNSUHQ4(J,=D,EE2")Y9&"1HI9F8X  Z
MDU^1OQ%\3>*/VY_VFH="TFZ,>DM<R6VEQR$F"SLTR7N&4?Q,J[SW)*KG@5^F
MO[06K3Z%\"_']_;;A<0:'>,A09(/DL 1],YKX&_X)8Z7!<?%[Q7?.H::UT79
M&2.1OFCR1_WSC\:]3+DHNI7:NX+3U=_\ON;/)S.3<:5!.RG*S]%;_/\ !'U=
MX/\ V O@QX8T".PO/#)\0W93;/J.HW4OFRGN0$953VV@?4]:^3?VQ_V0A^SU
M:_\ "<_#R\O;7PU<;K&_LC,S/9B52F _5XG!*D-D@D<D'C]/:\C_ &MM.@U/
M]FKXC17"!T31YIU![/&-ZG\&4&N:.,K1J<[DWW71KJK>FQU2P5"=/V:BEV?5
M/H[[_P"9\G_\$G?^/GXF_P"YIW\[FO3O^"CWQ*\3>%_AII_AKPU:Z@%UMI#J
M5_9P.RQ6J 9C+J,+O+#//*JPZ&O,?^"3O_'S\3?]S3OYW-?=7CWXA>'?AAX:
MN=?\4:M!H^DV_#SSD_,QZ*JC)9CV502?2NW,FHXWF:O;ET[Z+]3@RQ.6#E%.
MS=]>WF?$W['7["7A#Q+\-=.\9_$/3Y=9O-83[19::T\D,,$&?D=O+92S,!NY
M.,,.,YKW?Q9^P7\%?%&ES6L7A,:)<,I6.]TRZECDB/\ > +%&_X$IKR'QA_P
M52\):;<R1>&O!FJZ[&K%1/?7262O[J LIQ]0#["O/+O_ (*6_$_QM?#3_!'P
M^TX7<@(6!8KC4I_8J(RG/U4U=2&.Q$W42<5ZVM^1%.> PT%3;4GUTO?\U^)X
MW\,8]9_9E_;(TW0K>]:=['74T>Y>/Y5NK6614.Y<]T=6P>C >E?K]JW_ ""K
MW_KB_P#Z":_%2]UGQ9X@_:5TW4?'$,MMXKN-=LGOH9H! \;;XMJF, ;<+M&,
M9]>:_:O5O^05>_\ 7%__ $$UGFR?U6E*;O+E=WWT7X7;-,H<?K-:--6CS*R?
M35_C9(_#3X9:'XF\9^.AX0\*SRPW_B5O[,F6-MJR0F19'#D<[!Y8=O9#]*_4
MGX9?L%?"7P'X<AL]3\/0^+-5:,+=:GJNYC(W<I'NVQC/3 SC&6/6OC;_ ()K
MZ1!J7[3%Y<S*&DL-'N[B'(SAS)%'G_OF1OSK]5JZLSKSARTX.UU=_BOT.?+<
M/"HYU9J]FTO+K?\ KL?FG^V[^Q3H_P */#__  G_ ,/XY[+1X)D34=*,K2"U
MW$!)HF8E@NX@$$G!8$'' ^D_V"?CU??&GX1R6>N7+7?B+P[*ME<W,AR]Q$5S
M#*Q[L0&4GN4R>37I_P"TKIL&K?L_?$2VN2HB.AW;Y?H"L3,OZJ*^&O\ @E5J
M,T?Q.\:6*L1;S:.D[KZLDRA3^4C?G7-1G+$X6K3J.[A9I_UZ/[_(WQ$(X3%T
MJM-64[II?+_-?=YGZ7T445XI[I\V_M>_!/P'<?!_XB^,)?"FF2>*!ILEP-5:
M &?S%4*K;O4  ?A7RA_P3=^%GA'XGZUXZB\6>'K#7X[.WM&MUOH1((BS2ABN
M>F<#\J^Y?VM_^3:?B-_V!YOZ5\B?\$H?^1@^(O\ UZV7_H<M>U@Y2^K5]=DK
M>1XF-C'ZS0=MV[^>Q]??$/P%X=^'/[/'Q#TKPQH]IH>FMHFHSFULX]B%S;,"
MV/4A1^5?E3^R]\)KKX[_ !1T_P #O?W-EH-PWV_5/L[8_=0JV" <C=^\**2#
MCS"<'I7ZZ_'C_DB'Q!_[%^__ /2=Z_/W_@EC;QO\9O%,K(#)'H+!6[@&XAS_
M "%&75'%5YO5I+\.:Q&:4XMX>FM$Y-:>?+<^O+C]@[X(SZ=:VB^#$@:W962Y
MCO9_-8@@_,2Y#@XP0P(YXQ7EW_!17]H>_P#ACX6TSP%X9N3I^IZW TEY<6YV
MO!9@[0B$?=+D$9'\*D=Z^T:_)/\ X*+7<NH?M2:C;RN D%C9P1[C@*I3=_-V
M-<^$4L7B84JKNKMV?]=['7B^7"8:=2E%1=DKKU_X>QZW^Q[^P-H/C'P98>-_
MB1%/>PZFGG:?H<<KPIY)^[+*R$.2W554@ 8)SG ^@_'/[ 'P;\7:+-:6/AP^
M&K_9MAU#3+B0/&>Q*,Q1QZY&?0CK7O\ H&G0:/H6G6%J@CMK6VC@B1>BHJA5
M'Y 5?J<1C*M6JY1DTNEM PN#HTZ,5**;:UNKGY">"/%OB[]A#]HNZT?4;B2X
MTJ*=(M3MHLB'4+-N5F13_&%.Y3U!!4G!.?UDU>[AU#PG>W5O();>>R>2.1>C
M*8R01]0:_.3_ (*I:5;V_P 4?!VH1JHN;K2'BE(ZD),=I/\ WV?R]J^U_@7?
M3:E^RWX-N+AM\S>%X S'J<6X&?TK7'/ZQ@(XF7Q:I^>_^7XD9?'ZMF,L+#X=
M)+RO9_K^!^0WP;\.>)/'WC:T\$>&KV2SG\3LNGW)4D*T&X2.7QR47R]Y Z[*
M_3OP?_P3O^#/AW0(;+5-"N/$M^%Q-J-[?3Q/(W?"1.JJ/0 9]2>M?%O_  3>
MLHKO]IRPDD7+6VF7<L?LVP)_)S7ZUUZ&:5YTI1A!VNKNWJU^AYF4X>%6$JE1
M7L[*_HG^OX'X\?M=?!!/V7OC38#PK>7,&FW,::KI<KR9FM75R"F_J=K*""><
M$9R02?H7]FC]E"']I.TG^+WQBO;S7KC79G>TTU)F@1XU)3>[(0P7*D(B%0 H
M/.<#G_\ @JT!_P )KX!..?[/N>?^VB5]K?LRVT=I^SQ\-XXEVJ?#]D^/=H58
M_J367UBI]0A5O[UW&_6UWU_[=1M]6I_VC.BE[EE*W1NR_P#DGH?.'[47[!?P
MZT_X3Z]XB\$:7+X<UK1;22^\N*ZEGBN8XQN=&61FP=H."I'/7-<=_P $K/'U
M\][XS\&33O)8)#'JMM$QR(GW>7+CTW;H_P#OGZU]N?&-%D^$?C9'4,K:)>@J
MPR"/(>OSW_X)7?\ )8/%O_8"/_I1%6.$JSK4*].H[I)/7Y_Y(TQM*%"OAZE)
M6;DUIIV_S9^G%%%%>*>^<1X]^"_@7XEWD5_XI\+:;KUY;PF&*:^@$C(F2=HS
MVR2:_*S]B[P5H/CG]IS2]#U_2K75]'D2]+V5U'OC;;"Y7(]B ?PK]AY?]4_T
M-?DE^P)_R=YH_P#USU#_ -$25[&6R?[]7T4/TD>)FD5:C*VKG'\T?J!X$^$'
M@OX837DOA/PSIV@27BJMPUC"(S*%R5#8ZXR?SK\O/V<O^3]-/_[&'4?_ $&>
MOUSK\C/V<O\ D_33_P#L8=1_]!GJLMDY59N3O[K_ $#,XJ-*"BK>\OU/TL_:
M0_Y(!\1/^P#>?^B6K\GOV5/@_<?'WXHV/@JXOKFT\.\ZGJBV[X)CB&T$#IN)
MD"!B#CS"?8_K#^TA_P D ^(G_8!O/_1+5\*_\$K+>-_BCXSG* RIHR(K=P#.
MN1_XZ/RHRZ?LZ=>2Z)?K;\19I#VD\/!]9-?+W;_@?6D_["7P1EM;*&/P7';O
M:2)(D\5Y/YC;6!PY9R'!Q@A@>"<8KY8_X*B_$C59/&?AWP'!,]OH=O8KJ4L"
M959YG=T4MZA%3CT+&OTDKY5_;A_9)OOV@=,T[7_"[Q+XMTF)H%MIW")>P$EM
MF\\*ZL25)P/F()'!''0KOV].5=MQ3OKK:ZW^^WYG;B,.OJ]2-"*4FK::;/;[
MK_D.^"O["'P@TKP#H=WJFC1^,-4O+.*XFU.ZN93'*74-^[16"!.>#@G'4FN#
M_:L_8"\)GP#?^(?AEH=UI_B*PQ*=(L7EN$OD) 94C8LP< Y 3@X(QSD?*VF?
M$_\ :"_92:/29KC7O#6GQ/LCL=6M?/LFYR5B,BLF#SS$1WYKW'X>?\%4M9M9
M(H/&_@ZTOX20'O-#E:"15]?*D+!S_P #05ZM2ABI5/;4:G,KW5G^':QX]*OA
M(TU0KT^5VL[K\>Y[A_P3WTCXC>$OAKJOAOQWH6I:1965PDND-J0VOY4@8R1!
M2=RA64-@@?ZPUP/_  4B^$W@[PQ\)X_%&E>'-/L/$.H>((_M6I00A9IM\<S/
MN;OE@"?I7U7\&OCEX0^/'ADZUX2U$W,<;!+FTG7R[BU<C(61,G'?!!*G!P3@
MUX!_P4__ .3>]+_[&"W_ /1,]>;.I4EC(SDN63E&_P!Z_/\ $]2G3IQP4H0E
MS1496^Y_E^!QW_!/WX%?#[XC? F?5?$_A#2M<U)=8N(!=7EN'<($B(7/H"Q_
M.ONJUMHK*VAMX(UB@B01QHO15 P /PKY/_X)D_\ )N-S_P!AVZ_]%PU]:U68
M2?UB4;Z:?D1E<5]5A*VNOYL****\P]8**CN;F*SMY9YY4@@B4O)+(P544#))
M)X  [U^=?[7G[>TOB<W?@3X67$OV.5C;7FOV^?,N23@Q6V.0IZ;^K9^7 Y.U
M&C4KSY*:N_R]3"M7IX>#J5'9?GZ?UZF/_P %$OVF;/X@ZK;?#;PM="]TO3+G
MS=3NH#N2>Z&56)"/O!,G/JQ_V:^K?V'_ ((7?P2^"-I;ZO";?7]9F.IWT+#Y
MH"R@1Q'W5%&1V9F%>,?L5?L+MX1FL/'_ ,1;(?VTNV?3-#F7/V,]5FF'_/3N
MJ?P=3\W"_=5>EB*E/#T?JE%WZR?=_P!?DD>9AJ=3$UOKE96TM%=E_5_O;[!1
M117CGM'QI_P5(_Y(?X>_[#T?_HB:OF?]CK]FN^_:=OH;CQ5J-XO@'PJ#:Q6\
M;;3-([M*T$9_A&7+NP^;YE QD%?IC_@J1_R0_P /?]AZ/_T1-7:_\$[M(@TW
M]EKP_<1*!)?W=Y<S$#JPG>,?^.QK7N86JZ.!J36_-IZM+7[KG@XRDJ^.I0EM
MRZ^=G+];&_K7[#OP5UGPZ=('@FUT] FR.\LII$NHSCAO,+$L1_M[AZ@U^?'B
M+2_%/[!'[2D)T^]EN[*(I/$_*)J>GNWS1R*.,_*RGT90P[5^OU?GA_P5=TV!
M=0^'6H K]I>*]@8?Q%%,+#\,L?S-88'$U%B(PD[J5TT]>C?Z6]#?'X6F\/*<
M%:4=4UIU7Z?B??>D^([+7/#-GKUF[3Z?=VB7L+(N2\;('7 '4X(XK\HX/"OC
M']L_]JR2S\2+J.BVUQ)).Z7,#1MI^G1GA$1QP<%5SCEWR<\U^@W[&.HS:I^R
M]\/9IV+R+8&$$_W8Y7C4?]\J*Q?C?^W'\-O@CJL^C7-Q=>(?$$)VS:?HZ*_V
M=O261F"J?502P[@4J;>%Q=2-./,U=+RUW_+^F%2V,P=.=2?+%\K?GI>W]?H6
MM%_86^".BZ>EJ/ \%Z0H#W%[=3RRN<?>)+X!/^R /:OE']N?]C+PE\)/!<7C
MGP/'-I=G'=1VU[I4L[S1@/D+)&SDL#NP""2.1C&.=K6_^"KURXD31_AQ%$>=
MDU]JQ?/H2BQ#_P!"KR'XZ?M,?&OXY_#&Z_MWPRFC> VEB::ZL=*ECMY6#@Q@
MSRELG=CA2,XZ8KJI4<;&I&<Y65U>[W5]K>FQRUJ^ E2E"$;NSM9;.VCO;ON?
M7O\ P39\>ZEXP^ ,NG:E,]P= U%["VDD.3Y!1)$3/^R78#T 4=J\B_X*O?\
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M)N<E8C(K)@\\Q$=^:]Q^'G_!5+6;62*#QOX.M+^$D![S0Y6@D5?7RI"P<_\
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ME&6-L^$F'T'R/_P U1_X)H?$X>+?@I=^%KB;??>&;LQHI//V:8F2,_@_FCZ
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MEAEB*2=U3;M?Y_JK_,\=_9+_ &7+S]J_Q%K?CKQ[JM]-H<=V5N)1)_I&I7)
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MX*I/^6]ON5OQ9Y=^R)^RE/\ M1ZOJ_CWQ_J=]/H2WA21A*?M&IW/#/F0Y*H
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M=-X<U[2K62\2".ZEG@NU1=S(RRLQ4E0<%2.>H-?9UC"EO96\4:A(TC554#
M P!67XW_ .1+U_\ [!]Q_P"BVKS*^-K<TIPE9+9=%;96/6PV!HRC&%2*;=KM
M[N^[ON?GQ_P2T^)%_;^,O$_@::=GTNZLO[5@B9N(YHW1'VC_ &E<9_ZYBOK;
M]K[XX2? ;X+ZEK5@Z+KUZXT_3-^#MF<',F.^Q0S>F0 >M?"7_!,G_DXVY_[
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M\!:9=:WXM@6::.*UT]KZ3#J5D?RU!)X<\XXS7T[_ ,-)_M@_]"1KW_A&S?\
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M$,9^_P 32PW1>\_T_KM(VOVWOC_=? ?X1F31I1#XFUN4V-A+U, QF28#U5<
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MP+JH!C,T?GV,C#/0.NW<O3H2#6]*I''894^?EFK?>OT9C6IRP&*E6Y.:#O\
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M:6UXL]CYLA 7?)$PC!/;+[1]2*_86\O(-/M)KJZFCMK:%#)+-*P5$4#)9B>
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MWYH[L:G4R^G9=8_^DL_23]B#_DU;X?\ _7K-_P"E,M>YUXU^QYH.I^&/V;/
M^F:QIUWI.I6]M*LUG?0-#-$3/(0&1@"."#R.A%>RUYF,:>)JM?S/\STL FL'
M13_EC^2"OS _X*B>"I])^,&@^)1&?L>KZ6(-^WCS87(89]=KQU^G]>7?M%_
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M=_OVG_I3'7-?L1_L?7'P#M+OQ-XJ:&7QEJ,/D"WA8.EA 2"4W#AG8@;B.!M
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M:"LK'Q#X8F@@\7Z9"8!!<-LCOH,E@F_^%U).TGCYB"1P1V8JI"EF2G/96_\
M23APE.=7+9PI[N_SU7^1M?LU?LG_  P\)_##PSJ4GAK2O$FL7]A!?3ZKJ=NE
MV6DD0/\ NPX*HHW8&T#@#.3DU]!16^G>&],?RHK72]/MT+ML58HHT R2<8
M%?F#\/\ Q7^UC^S[IZ^&-.\(^(=0TJVRL-G/HCZC!#GM'+$#A?8/MZX'6NRE
M^'G[5?[58CTWQC=2^"_",S9N([J)+)"O<&!/WTI]%D^7('(ZUCB</.K4<_:K
ME?5O]/T-\+B84:4:?LI<R5FDNOJ?//COQO8_$;]KZ?Q'IC;].OO%-NUM)_ST
MC69$5_\ @04'\:_975O^05>_]<7_ /037Y/_ !O_ &1/%WP2^+6DQ^!_#7B;
MQCI%K#:7R:C9Z;+<!IU/[Q28E(0[DR%SD!AR>M?JJ-0&K^%?MP@GMA<V7G>1
M<Q-%+'N3.UT8 JPS@@C(-99DZ;P5)4G=14E^"7Z&N6*I'&U765I2:?WMM_==
M'Y%_L2_$^P^%G[26E7FJW"6FEZF)M+N+B0X6/S2-C,>P\Q8\D\ $GM7[$@Y%
M?B/^S_\ !?\ X7Y\3Y_"*:C_ &7=3VEU<6]RR;D$L:[E#CKM/0XY&<\XP?H*
MVU_]L+X"6H\*VVF:WKFG6JF*UGM]+&KQJ@X4I,J,P7&,*YX&!M'2O1Q]&->4
M$I)32Z]5=_C>YY^!KSH>T;BW#F>VMGI^%K'U=^W?\4K'X<_L]:_9R3JNJ^((
MCI=E;[L.^_B5@/14W<^I4=Z\._X)6_#ZYM-)\9>-+B)DM[QXM,M&/&_9EY2/
M49:,9]0?2O./#?[(GQS_ &GO&D'B'XIW=YHE@V!+>:OM6X$>>8X+5<>7]&5%
MY)Y/!_2#P!X$T;X9>#M*\,>'[46>DZ;"(88\Y8]V9CW9B2Q/<DUPMPP>'G24
ME*<][;)?U^;\CN2GC<1"JXN,(;7W;_JWW>IT-%%%>,>V>1_M;_\ )M/Q&_[
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MIP *Y\?4IPPRPM%W2NV^[U_S?WG5EU.I/%O%UERN322[+3?[D?E7_P $U?\
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MUAB)9I".PW;5'KD^AKR:P^._[9/BF%-)LO!FI6%VX"_;Y_#7V5L^I>=1$/R
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MP01@'H"/FGP[XD_:^^ ]C%X;M=!\1:CIUJOEP0_V2-6CB4= DT:N=H P%W8
MZ 5O-QS"G!\R52*L[Z7]/Q^\YX*6759KE;IR=U;IY?I\C[H_:K^,/_"DO@EK
M_B"VO4L];>/[+I195<FY?A2%8$-M&7(((PIKRS]@KXX_$CX[:-XFU/QI<VMW
MI=A)%:VES#:+"\LQ!:0';A3M7R^@'WZ^:+7]G/\ :)_:T\56-_\ $62^T72H
M3M^UZY$ML+="1N$-FH4[B.^U0<#+5^C'PH^%VA?!KP)IGA3P] T6GV2',DAS
M)/(>7E<]V8\GL. ,  5E.G2PM"4)-2G+MK9?U^?D;PJ5L57C*"<:<>^G,_\
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M$Y+^U$8+%8.$(R2<.;1_UY:>I4YO"XZ<Y1;C)*S7R_+J?HE1117AGO'YZ_\
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MB$9'<9K>@U'->9O3F;^^[,9Q;RJ,$M5&*^ZR_0_3:Q_X\K?_ *YK_*JOB/\
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M?BAI_C_XYPZ5I=S'=VGARS%C++$VY3<%RTJ@]]N54^ZD=J_3#X,_\D?\"_\
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M.R5@K$\;_P#(EZ__ -@^X_\ 1;5MUD>,()+KPEK<,,;2S26,Z)&BEF9C&P
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M%M*'<VW#'D8W"OFN\^-'[9/B6R_L=?#_ (GLI)1Y;W</A?[-(V>"?-,05/\
M>7;CL177?LV?\$\]?NO%<'C#XO,BK'/]J&AM.+F>[FSNW7,@)7;GDJ"Q;^+'
M(-4\'3I2Y\3-<JZ)ZO\ K^M":F-J5H\F&@^9]6K)?U_PVI]Z>#/$3^+O"6CZ
MV^GSZ4VHVL=U]BNL>;"'4,%?'&X C(KY[_X*%_"W_A87[/U]JEO%YFI>&I1J
M<1'4Q?=F7Z;#N_X *^G    !@#M5;4]-M]8TV[L+N(36EU$\$T;='1@58'Z@
MFO*<W&?M*:M9W2]-;?H>NH<T.2H[W5G\U9GY7>%OVDFTK]@WQ!X(-UC61J@T
MBW7/S"RGS,Y^GR3)_P "%?2W_!,SX6?\(I\']0\7W4.R]\2W1\EF'(M8247\
MW,I]QMKXF\4?LA?$G3/BG?\ A?3_  9X@N].75#9VVL)I<[6C0F3"3&8)LV[
M2"3G YSTK]A/!7A2R\">$-%\.Z<FRQTNSBLX1C!*HH7)]SC)]S7T&,JTXT93
MI/6JT_DDOUU^;/G,%2JRKQIU5I237S;?Z:?)&U7Y'?LE_P#)]6D?]A75/_1%
MS7ZXU^7G[,/P?\>:!^V;I>MZIX)\1Z;HJ:EJ4C:C=Z3/%;JK0SA6,C(% )90
M#GG(]:XLNDHSJ7?V)?D=V9Q<J<++[2_4^L?^"@O@2Y\;_LUZS)9Q--<:+<0Z
MKL7J43*R'\$=F_X#7A?_  2Z^+NG6MKXB^'5]<I;W]Q<?VIIR2$#S_D"S(OJ
MP"(V/3<>QK] KBWBO+>6">-)H)5*21R*&5U(P00>H(K\Y?CY_P $\/%?A;Q7
M)XI^#TQN;03?:8M+CNA;7E@^<CR)"0&4'D?,&' ^;K4X.K34)X:J[*>M^ST_
MR7XZE8ZC4<Z>)HJ\H:6[K7_-_@?H]7AW[47[4^D?LS:)I-Q<:;_;VK:E.4AT
MN.Z$#^4H^>4MM; !VCIR6Z\&OC:U^-G[9.@V9TEO#_B>[EC'EK=R^%?/=<<?
MZP0E7Z?>;=GKDU#X(_8E^,?[0GC9?$GQ5O+O1+*9E:YO-3E62^EC!_U<4()\
MON!N"A<Y"GI5PP,8S4JU2/(O/?\ K[^Q$\?*<7&C3ESONMOZ_P"'/O#]G?XX
MQ?M!^ /^$KMM!O-!M&NI+:*.\D5S-L W.A7JN25S@<JWI7AO_!3?X>_\)'\%
M-/\ $T,>ZY\/7ZEV"Y/D3?NVY]-_E&OJCP;X/TGP!X6TSP[H5HMCI.G0K!;P
M+SM4=R>Y)R23R22:S/BUX(B^)/PR\3^&)AD:II\ULA_NN5.P_@VT_A7GSJ0I
MUO:TE91=UZ+_ #7YGHTZ4ZE'V59ZR5F_7_(_*?XF_'7_ (2S]D7X8^!UG+WN
MFZA=+>)NY\N''V?(]-MQ@?[E?IQ^SIX C\ _ +P9X:FA"O'I<;749'_+64&2
M4'_@3L*_+#X2_LM?$37/BKX7TS6_ /B73M(EU.%;Z\O-(N(H(X X,A:1D"@;
M0<'/.17[-@!0 !@#H!7LYDZ<:7)!WYY.3_KY_@>'ED:DJO/45N2*BOOO^%OQ
M/R-^#WC9?V2OVH_&=O?-Y%E90ZIIQ5NCA5:6W'_ FCB _P!ZO2O^"9'@B?Q9
M\5?%WC_45,S:?;F".9Q]ZYN&+.P/J$5@?^NE9O[?G[//C#5/C[<Z_P"%?!^M
MZ_8:Q8P7$TVDZ=-=(DZ@QLK&-2 <(AP?6OK7]A/X3W?PG_9_TR#5;"?3=<U6
MXEU&]MKJ(QS1%CL1&5@"I$:(<$<$FM'7C]3]NW[[BH?B[_?K^!"H3^N^P2]Q
M2<_P5ONT_$^AJ***^;/IPK\F/^"BMR]E^U1=W$>/,BL+*1<^H7(K]9Z_-']M
MKX,^,?'G[54=YIW@SQ!K.@3PV$,U]I^F3RP;>!(/,12HP,YYXKTLN?+BH.]M
M_P F>7F:YL'-6OM^:/T#^%GQ$TOXK?#_ $3Q3I$Z3VFHVR2D(P)BDQ\\;>C*
MV5(]16SXC\0Z=X2T&_UG5KN.QTRQA:XN+B9MJHBC))-?G5K/P._:&_9#\1ZF
M_P *;K4/$7@ZZE,J164"7A(/02VK D2   O&O( Y'0<KXC\-_M6?M4S0:+XA
MTC6;'2%D5F@U*R&D62'/WW#*K2XZ]'(["K>#A6EST:B4'WW7R\C..,G0BJ=:
MFW-=MGYW\_P.=_9_M+O]H;]MNU\0I QM6UN7Q#.6'^I@BD\R,-^/E)]37U7_
M ,%/? EUXA^#>C>(;6-I1H.HYN HSMAF786_!Q&/QKU?]E?]ES1_V;/"<T"3
M)JOB;40K:EJFS:&QTBC!Y$:Y/7ECR<< >PZ_H&G^*=$OM'U:TCO],OH6M[BV
MF&4DC88(/X48K$Q52FJ'PT[6\[?YK0>$PTW3J2KZ2J7OY7O_ )M_@?'_ /P3
M,^+NG:]\*[KP#/<I'K6AW$MQ!;L<-+:RMOW+Z[9&<'TW+ZU]H5^9/Q4_8%^)
M?PA\9?\ "2_".]N=6L893-:&TNA;ZE9#GY3DJ)!@XRIRP)ROJP?'3]LHV7]E
M_P#".^)O/^Y]M_X1(>9_WWY.S\<?C6]>C#&3]M0FM=T]&G_7],Y\/7J8*'L*
M\'ILUJG_ %_P]CZO_:@_;,T3]FO5]%TE]';Q)JE\C3SVL%X(&M80<*YRC9+'
M.!Q]TG->I_!CXFK\8OAQI'B^/2+K1(-35I(;6\96DV!BH;([-C(]00>]?!'P
M?_8#^(7Q5\9_\)3\8;JXTVQFF$]U#=70GU&_Z?*2I(C4@8)8[@!@*.H_232]
M,M-$TVTT^PMX[2QM(E@@MXEVI'&H 50.P  %<E>G0HTE"+YI]6MEY'9AZM>O
M5<Y+EI]$]WY_UY'Y8?\ !3;_ )..MO\ L!6O_HR:OT^\#_\ (EZ!_P!@^W_]
M%K7YV?\ !1#X2^./&WQ]M]0\.^#/$&O:>-%MHC=:9I<]S$'$DI*[T0C(R.,]
MQ7Z+>#H)+7PCHD,T;Q31V,"/&ZE65A&H((/0@UM5DOJ%-7UN_P!3.E%_VA5=
MM++\D?E1^V7H6H?!K]KZZ\210D1W-Y;>(;%\85R"I89]1)&_Z5^J/@3QMI/Q
M'\(:3XET.Z2[TO4H%GAD4@XSU5O1E.5([$$5YW^TQ^S5H7[2/@U-.OY/[.UN
MR+2:;JR)N:!R.58?Q1M@97/8$<BOA#1_A=^U)^R?J%W;>$[+4[W2I9-S#1(5
MU.SN#_?$!5F0D #<45N,9Z4Z<J>+PT*$I<LX;7V:_I+[MM3.I&IA,3/$1BY0
MGO;=/_A[^6OD?J;//%:P2332)##&I=Y)&"JJ@9))/0 5^/7QGUP_M1_M?3Q:
M"3=V6J:G!I=E(G1H(]L9E_W<*\F?0UZ!XCE_:Y_:/MG\/:GHNOV&DS8$]M/I
MZZ/;NO?S'=4+KW*DL/:OJ?\ 9$_8IL/V?&;Q%KUU!K?C6>(Q"6 '[/8H?O+%
MG!9CT+D#C@ #.[7#PAE\W7J23DEHEK_7^5_0RQ-2>816'I1:BWJWI]W];VVW
M/3/VH(5M_P!FOXBQ(-J)H%TJCT B(%?&?_!*7_D=/'__ &#[;_T8]?;7[2.E
M7NN_ /X@:?IMG<:AJ%SHMS%!:VL32RRN8R JHH)8GT KY*_X)H?#3Q?X#\7>
M-YO$WA36_#L-Q8VZ0R:MITUJLK"1B0ID49('I6.#DE1KW>Z_S.C&0?ML/RK1
M-_H??M?EI_P4W\"W6@_'#3_$HC;[!KFG1A9<<":'Y'7Z[?+/XU^I=>=_'7X'
M^'_C]X"N?#.OHT66\ZTOH@#+:3 $+(N>O4@CN"1[C@PU9X>M&KV_+^M?D=^)
MH_6*,J7?\]RM^SC\7-.^-7PAT#Q#97*2W?V=+?4(0?F@ND4"16';GYAZJP/>
MO3:_*UOV;?VC_P!E?Q-=ZAX#^W:E:.=IO/#VVYCN5!.T2VC DD9[HP&3ACUK
M2UGXD_MB?%*R;0#H/B?3(;E?*E:#0?[-+@^L[HNSWPR^]>C5PD*TW4H37*^[
MM8\RCC)T(*EB*<N9::*]SZ$^(_\ P45T#P-\7+_P58>%+OQ/%:3I9G4-.O5S
M+<' :-(RG.UCMSOY(-?7%O(\MO$\D9AD906C)!*G'(R/2OB/]D/]@.Y^''B"
MR\;?$1[>?7+0B6PT:W<2QVLO:65QPSKV"Y4'!R3C'W!7+BHT*:C3I.[6[[G9
MA)XBHY5*RLGLNJ]0JKJEA'JNF7=E+_JKF%X6QZ,I!_G5JBO/:4DTST4W%W1^
M.G[//BD_LP?M76T7B0M9VEA>W&C:E(X^Y&^4$A_V0=CY_NBOV'@GCNH(YH9$
MFAD4.DD;!E92,@@CJ".]?*G[8'[$5M\>;G_A*?"]S;Z1XS2,1S+<96WU!%&%
MWD E7 X#8.0 #V(^8?"]W^US^SM:IX>TW0_$5YI4.1#:1Z:NL6\8Z 1NBR%%
M[[0P'M7NS<,PIP;DE4BK.^E_3^NNI\_!3RZK-*#=.3NK:V]?R^6A^EGQ \<Z
M5\-?!FK^)M:G6WTW3;=IY&8X+8'"#U9CA0/4BO /V:/VX+?]H[QG)X<M_!%[
MHT\-J]W-="]6X@B12 -QV(<EF4#CO[5\F:[\./VIOVK[ZUM/%.G:K9Z5%*&"
M:S NE6=N3_&8MJLY&3R%=N37W5^R_P#LR:+^S9X/EL;:?^U-?ORLFI:JR;?-
M(SMC1?X8UR<#J223U &#H4</2DZTE*;V2>WG_7;0W6(K8FK%48N,%NVM_)?U
MUU.4_:9_;7T[]F[Q/;:!<^$=1UN]N;1;R&9;A+>W=2S*0'PQR"O/R]Q7O/A'
MQ/IOQ \'Z5KNGO'=:9JMHES$<AE*.H.T^XS@CU!%>2?M9_LO6/[2G@ZVMXKJ
M/2_$VF%I-.OY%)3Y@-T4F.=C8'(R00#@\@_$7AKPO^U?^RZ9=(\/:3K<^D>:
M6%MIUHFKVC\\LBA7,>[J<!">]10HT:]'EYE&HGUV:_K^K&M>M7P];GY7*FUT
MW3_KY:]T?=/Q5_9%^$WQ+TJ^.I>%-.TB]:-W&K:7$MG-$V#^\8I@/CK\X(K\
M]/V!+J]T7]K31++3+AI[.=+VUN7C^[+ L,C GVWI&?RKM-?US]L#X^Z?/X;N
M]"U[3M,ND\NX@?2TTB*5>X>614)4CJN[!'8U]1?L<?L;Q?L[6]UKVO7<&J>,
M[^'R&:V!,%E#D$QQD@%F8@%FP.@ & 2W=2O@Z53VM1.ZLHIWZ-7\M_P//K6Q
MU2G[&FU9W<FK?\/_ )^5SQS_ (*J>!;J:#P3XPAC9[6#SM,N6 SL+8DBS]<2
M#\J]]_82^)ME\0_V=?#EM%<*^I:!$-*O(,_-'Y?$1QZ-'L(/J".QKV#XC_#S
M1/BMX+U3POXAM?M6E:A'Y<B@X=#U5T/9E(!!]17YQ:]^R7\>/V7O&5QKOPNN
M[S6K#D)>Z/M:9X\\)/:-G>?8*Z\9X/%<F&J4ZN'>$J/E:=T^G73\7]Z['7B:
M=2CB5C*<>:ZM)+?U7W+[O.Y^H5?GI\7/VT_B/+^U!/X+^&NIV5WHYO8-(M[:
M:SBFCDN"565PX ? <L/O8PN:XO5_B-^V+\4[%O#C:#XETV*Y3RII(M"&F>8#
MP=UPZ(%S_LLHY]*]]_8W_8</P7U&/QGXUE@OO%_EE;2RMVWPZ>&&&8O_ !RD
M$KD?*H)P6SD:TL/3PK=7$24K+2*UN_Z_,SK8FKBXJEAHN+;UD]++^OZU/(/^
M"IWC356\7>#_  EYSII$5@=2>->%EG:1XPQ'?:J''IO/K7N?[(/[*OPTT[X-
M>%O$E_X=TSQ1KFLV,5_/?:I MTL;.-PCC1P539G:2!DD')[#=_;._92;]H[P
MU87FBW,-EXMT<.+5KDE8KF)L%H7(!VG(!5L<'(/!R/CWX?:A^U;^S5 WAS2/
M"6OW>DQLS+IYTAM4M48G),<D0;:"<G"N!DDD9-/#253!^PA+EFFWVNKO_@?=
M8C$P=+&*O4@Y0LDNMG9?K?[[[W/U&L-+T[0+/R;*TM=.M(QGR[>-8HU ]@ !
M7XU_M5^/].^)?[3GB;7-(F2YTQKV&V@N(SE95A1(BX/<$H2#W&#7T+-X<_:V
M_:AA_LC7_.\%>%KD[;H7,*Z=&5[AHQ^_D!'\)^4]\=:\O_:._8D\4?"/Q-H-
MGX*T;Q%XVL9M/26YU"PTV6?%T'8.-L2MY8QL*J23CN:VP%.GA<3&=6:YGHDM
M?-W?R,\?5J8O#2A1@U'JWIY))==7?Y'ZT6_^HC_W1_*OR=_8]_Y/GL_^O_5?
M_14]?J5X'UF;Q%X-T/4[FRNM-NKNRBFFL[V!X9H)"@+(Z. RD'(P?2OSA_95
M^$7CKP[^V5:ZWJO@KQ%IFC+>ZDYU&\TJ>*W"M',%/F,@7!)&.><BN;!?NZE:
M,G]F2-L=>I0HN*^U%GTE_P %'_&VI^$?V>6M--E>W&M:C%I]S+&<'R2CNRY_
MVM@!]02.]>&_\$ZOV</ GQ&\*ZUXR\5:9;>([ZVU V-MI]Y^\@@58T<NT?1R
MV_ W @!>.:^U_CW\&M-^//PQU3PCJ,QM#<;9;6\5=QMYT.4?'<=01W!(XZU^
M<>B?"']I?]DOQ3>R^$M'U.[@G(2270[;^TK2]1?NEH@K,.IP656&3C&>7@9Q
M="I14N6;>C^[K\G]Y680E[>E7<>:$59KSUUM\U]WH?J/X?\ !N@>$H?)T/0]
M-T:+IY>GVD<"_D@%?G'_ ,%1/B#I?B#XB>&/#-A<1W-WH=K,]Z8SGRI)BA6,
M_P"T%0$C_:%;2_$3]LOXPQMI-EX>OO"D,H\N:Z;2UTLA3P3YMQ\PQZQ_-QQ7
M)?&S_@G_ .*?A]\*['Q!:SZEX\\<76HC^T[;2;>2X6.-T8EE 4R2'>!ND('W
MA\HY)="A&A7C5KS5T]$G=W>FO9:BQ&(EB*$Z6'INS6K:LK+73N]+'VI^Q!_R
M:M\/_P#KUF_]*9:^0?\ @JG R_%+P;,2-KZ.Z@=^)F_QKZM_8336]-_9WT;0
MO$6@ZMX>U31[BXM6M]6LI;5W1I#*CJ)%!*XDQD<94UP7_!03]F;Q+\:]+T#Q
M%X0M5U+5M%26"?3@X22>%RK QDX!*D'Y<Y(;C)&#$I1IYE[23TYF[^J=OS15
M.G*IE2I17O<L5;SBU?\ )GT)\ 65_@9\/64AE/A^PP0<@_Z.E?'O_!6#_CP^
M&O\ UUU#^5O7GO[/'BG]I?X>>+O!?AJZT+QK%X(MM2M[>ZM+KP_))%%:F0"0
M>:T)94"DGA@ !QBO8O\ @II\/?%7CVR^'R^&?#.L>(VM9+XSC2;"6Z,6X0;=
M_EJ=N<'&>N#5SI>RQU.IS)J4F_P>_P!Y%&M[3!3I<K3C&VJ\NGW'MG[$'_)J
MWP__ .O6;_TIEK\\/%C3_LQ?ML3ZE>PNMEIOB Z@-J\R64S%B5]?W<C#Z@BO
MT=_8\T'4_#'[-G@?3-8TZ[TG4K>VE6:SOH&AFB)GD(#(P!'!!Y'0BL#]K/\
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MO;^M3BOALUQ^TC^VU8ZM;0,UM?\ B'^UG5A_J[2%_,&[T^1%7ZD"OOG_ (*
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M> Q< $\8'*D5[A\'/A!X?^!W@2R\+>'(&2T@S)+/*<RW,QQOED/=C@>P  '
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVPM"K[6>)KZ2ET[)?TON"BBBO-/4"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\O_
M &AOBAJOPE\%V6KZ1;V=S<SZ@EHR7J.R!#'(Q("LISE!W]:^>?\ AM;QQ_T"
MO#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\
M@//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\
M\>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[
M6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG
M_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO'
M'_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP
M_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#
MS_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'
MJ/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&
MUO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?]
M KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__
M (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_
M /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H
M^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKX
MI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;
MQQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*
M\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^
M \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\
MQZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\
MAM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''
M_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP_
M_P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S
M_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J
M /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*
M^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;
M6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T
M"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\
M_@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__
M ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_
M (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;Q
MQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\
M/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P"
M\_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#Q
MZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:
MBOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^
M&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?
M] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_
M /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//
M_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H
M_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6
M\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"
MO#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\
M@//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\
M\>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[
M6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG
M_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO'
M'_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP
M_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#
MS_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'
MJ/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&
MUO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?]
M KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__
M (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_
M /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H
M^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKX
MI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;
MQQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*
M\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^
M \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\
MQZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\
MAM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''
M_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP_
M_P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S
M_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J
M /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*
M^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;
M6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T
M"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\
M_@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__
M ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_
M (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;Q
MQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\
M/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P"
M\_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#Q
MZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:
MBOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^
M&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?
M] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_
M /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//
M_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H
M_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6
M\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"
MO#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\
M@//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\
M\>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[
M6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG
M_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO'
M'_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP
M_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#
MS_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'
MJ/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&
MUO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?]
M KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__
M (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_
M /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H
M^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKX
MI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;
MQQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*
M\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^
M \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\
MQZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\
MAM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''
M_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP_
M_P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S
M_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J
M /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*
M^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;
M6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T
M"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\
M_@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__
M ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_
M (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;Q
MQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\
M/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P"
M\_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#Q
MZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:
MBOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^
M&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?
M] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_
M /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//
M_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H
M_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6
M\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"
MO#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\
M@//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\
M\>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[
M6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG
M_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO'
M'_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP
M_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#
MS_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'
MJ/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&
MUO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?]
M KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__
M (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_
M /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H
M^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKX
MI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;
MQQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*
M\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^
M \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\
MQZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\
MAM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''
M_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP_
M_P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S
M_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J
M /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*
M^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;
M6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T
M"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\
M_@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__
M ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_
M (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;Q
MQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\
M/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P"
M\_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#Q
MZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:
MBOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^
M&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?
M] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_
M /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//
M_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H
M_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6
M\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"
MO#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\
M@//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\
M\>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[
M6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG
M_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO'
M'_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP
M_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#
MS_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'
MJ/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&
MUO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?]
M KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__
M (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_
M /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H
M^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKX
MI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;
MQQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*
M\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^
M \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\
MQZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\
MAM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''
M_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP_
M_P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S
M_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J
M /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*
M^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;
M6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T
M"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\
M_@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__
M ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_
M (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;Q
MQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\
M/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P"
M\_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#Q
MZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:
MBOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^
M&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?
M] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_
M /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//
M_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H
M_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6
M\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"
MO#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\
M@//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\
M\>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[
M6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG
M_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO'
M'_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP
M_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#
MS_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'
MJ/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&
MUO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?]
M KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__
M (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_
M /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H
M^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKX
MI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;
MQQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*
M\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^
M \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\
MQZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\
MAM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''
M_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP_
M_P" \_\ \>H ^UJ*^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S
M_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J
M /M:BOBG_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*
M^*?^&UO''_0*\/\ _@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;
M6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\ @//_ /'J /M:BOBG_AM;QQ_T
M"O#_ /X#S_\ QZC_ (;6\<?] KP__P" \_\ \>H ^UJ*^*?^&UO''_0*\/\
M_@//_P#'J/\ AM;QQ_T"O#__ (#S_P#QZ@#[6HKXI_X;6\<?] KP_P#^ \__
F ,>KZ5^!?Q!U'XG?#ZWUW5(;6WNY)Y8BEFC+'A6P.&9C^M '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>brns-20251231_g2.jpg
<TEXT>
begin 644 brns-20251231_g2.jpg
M_]C_X  02D9)1@ ! 0$!] 'T  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  $ A4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#\JJ*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
K **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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/EZJ^     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
MB5!.1PT*&@H    -24A$4@   )X    %" 8   "T)%7[    "7!(67,  $SE
M  !,Y0%USO"5    )TE$051XVNW200T   @#L?DW#0;X+GS:Y PL2Y*1RIT,
;HY?C 0 U"Y'K,-[_>?+F     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_4.jpg
<TEXT>
begin 644 image_4.jpg
MB5!.1PT*&@H    -24A$4@   \H    &" 8    ;K6=F    "7!(67,  $SE
M  !,Y0%USO"5    1$E$051XVNW700T   @#,?R;!@,0!*R7U,!^J]IK
M"'1F'    !QE1QD   !'V5$&  " ]RA+DB1)DB1)DB1)DM(;]@,!TH-T:M\
+    245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_5.jpg
<TEXT>
begin 644 image_5.jpg
MB5!.1PT*&@H    -24A$4@   KL    %" 8   !%/"2N    "7!(67,  $SE
M  !,Y0%USO"5    -$E$051XVNW600T   @#L?DW#0KX VF3,[#7DJ0D29*D
HXXV,(TF2I+=G%P        !@@0:5JF3BZ6;=Z@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 06, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BARINTHUS BIOTHERAPEUTICS PLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">20400 Century Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Germantown<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">917-0966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,848,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001828185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BRNS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, nominal value &#163;0.000025 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">United Kingdom<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 70,456<span></span>
</td>
<td class="nump">$ 110,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">1,396<span></span>
</td>
<td class="nump">1,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ResearchAndDevelopmentIncentivesReceivable', window );">Research and development incentives receivable</a></td>
<td class="nump">1,108<span></span>
</td>
<td class="nump">7,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,830<span></span>
</td>
<td class="nump">6,203<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">77,790<span></span>
</td>
<td class="nump">125,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,523<span></span>
</td>
<td class="nump">7,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">14,288<span></span>
</td>
<td class="nump">21,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets, net</a></td>
<td class="nump">1,638<span></span>
</td>
<td class="nump">4,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">930<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">98,169<span></span>
</td>
<td class="nump">160,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">2,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">6,249<span></span>
</td>
<td class="nump">9,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Deferred income</a></td>
<td class="nump">1,396<span></span>
</td>
<td class="nump">1,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - current</a></td>
<td class="nump">2,023<span></span>
</td>
<td class="nump">1,920<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,018<span></span>
</td>
<td class="nump">15,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability - non-current</a></td>
<td class="nump">9,258<span></span>
</td>
<td class="nump">10,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">2,871<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">1,476<span></span>
</td>
<td class="nump">1,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability, net</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">23,877<span></span>
</td>
<td class="nump">30,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 16)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, &#163;0.000025 nominal value; 40,848,893 shares authorized, issued and outstanding (December&#160;31, 2024: authorized, issued and outstanding: 40,234,663)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockValueIssued', window );">Deferred A shares, &#163;1 nominal value; 63,443 shares authorized, issued and outstanding (December&#160;31, 2024: authorized, issued and outstanding: 63,443)</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">393,944<span></span>
</td>
<td class="nump">393,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(304,092)<span></span>
</td>
<td class="num">(237,664)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Accumulated other comprehensive loss &#8211; foreign currency translation adjustments</a></td>
<td class="num">(15,731)<span></span>
</td>
<td class="num">(25,868)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity attributable to Barinthus Biotherapeutics plc shareholders</a></td>
<td class="nump">74,208<span></span>
</td>
<td class="nump">130,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">74,292<span></span>
</td>
<td class="nump">130,135<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 98,169<span></span>
</td>
<td class="nump">$ 160,327<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredStockValueIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued deferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredStockValueIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ResearchAndDevelopmentIncentivesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of research and development incentives receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ResearchAndDevelopmentIncentivesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - &#163; / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, nominal value (in gbp per share)</a></td>
<td class="nump">&#163; 0.000025<span></span>
</td>
<td class="nump">&#163; 0.000025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, authorized (in shares)</a></td>
<td class="nump">40,848,893<span></span>
</td>
<td class="nump">40,234,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued (in shares)</a></td>
<td class="nump">40,848,893<span></span>
</td>
<td class="nump">40,234,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding (in shares)</a></td>
<td class="nump">40,848,893<span></span>
</td>
<td class="nump">40,234,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockParOrStatedValuePerShare', window );">Deferred shares, nominal value (in gbp per share)</a></td>
<td class="nump">&#163; 1<span></span>
</td>
<td class="nump">&#163; 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockSharesAuthorized', window );">Deferred shares, authorized (in shares)</a></td>
<td class="nump">63,443<span></span>
</td>
<td class="nump">63,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockSharesIssued', window );">Deferred shares, issued (in shares)</a></td>
<td class="nump">63,443<span></span>
</td>
<td class="nump">63,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockSharesOutstanding', window );">Deferred shares, outstanding (in shares)</a></td>
<td class="nump">63,443<span></span>
</td>
<td class="nump">63,443<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of deferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of deferred shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of deferred shares of an entity that have been sold or granted to shareholders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of deferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,564<span></span>
</td>
<td class="nump">42,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,830<span></span>
</td>
<td class="nump">29,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,667<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,209<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">71,061<span></span>
</td>
<td class="nump">84,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">506<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(70,555)<span></span>
</td>
<td class="num">(67,970)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income/(expense):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,957<span></span>
</td>
<td class="nump">2,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ResearchAndDevelopmentIncentiveIncomeExpense', window );">Research and development incentives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">3,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,922<span></span>
</td>
<td class="nump">6,743<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(66,633)<span></span>
</td>
<td class="num">(61,227)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">175<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(66,458)<span></span>
</td>
<td class="num">(61,183)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Barinthus Biotherapeutics plc shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (66,428)<span></span>
</td>
<td class="num">$ (61,074)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average ordinary shares outstanding, basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,527,218<span></span>
</td>
<td class="nump">39,348,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average ordinary shares outstanding, diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,527,218<span></span>
</td>
<td class="nump">39,348,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to ordinary shareholders, basic (in usd per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.64)<span></span>
</td>
<td class="num">$ (1.55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to ordinary shareholders, diluted (in usd per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.64)<span></span>
</td>
<td class="num">$ (1.55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (66,458)<span></span>
</td>
<td class="num">$ (61,183)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive gain/(loss) &#8211; foreign currency translation adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,145<span></span>
</td>
<td class="num">(2,549)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(56,313)<span></span>
</td>
<td class="num">(63,732)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss/(gain) attributable to noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(56,291)<span></span>
</td>
<td class="num">(63,627)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,969<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">All license revenue is from related parties and is generated in the U.K. for the year ended December&#160;31, 2024.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ResearchAndDevelopmentIncentiveIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the research and development incentives (expenses) for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ResearchAndDevelopmentIncentiveIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Total stockholders&#8217; equity attributable to Barinthus Biotherapeutics plc stockholders</div></th>
<th class="th" colspan="2"><div>Ordinary&#160;Shares</div></th>
<th class="th"><div>Deferred Shares</div></th>
<th class="th"><div>Additional Paid-in-Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,643,540<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">63,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 186,995<span></span>
</td>
<td class="nump">$ 186,784<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 386,602<span></span>
</td>
<td class="num">$ (176,590)<span></span>
</td>
<td class="num">$ (23,315)<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="nump">4,709<span></span>
</td>
<td class="nump">4,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue of ordinary shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,591,123<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issue of ordinary shares, net of issuance costs</a></td>
<td class="nump">2,163<span></span>
</td>
<td class="nump">2,163<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(2,549)<span></span>
</td>
<td class="num">(2,553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,553)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(61,183)<span></span>
</td>
<td class="num">(61,074)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,074)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,234,663<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">63,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">130,135<span></span>
</td>
<td class="nump">130,029<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">393,474<span></span>
</td>
<td class="num">(237,664)<span></span>
</td>
<td class="num">(25,868)<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="nump">468<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue of ordinary shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">614,230<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issue of ordinary shares, net of issuance costs</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">10,145<span></span>
</td>
<td class="nump">10,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,137<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(66,458)<span></span>
</td>
<td class="num">(66,428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,848,893<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">63,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2025</a></td>
<td class="nump">$ 74,292<span></span>
</td>
<td class="nump">$ 74,208<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 393,944<span></span>
</td>
<td class="num">$ (304,092)<span></span>
</td>
<td class="num">$ (15,731)<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Indicates amount less than one thousand</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (66,458,000)<span></span>
</td>
<td class="num">$ (61,183,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="nump">468,000<span></span>
</td>
<td class="nump">4,709,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AssetImpairmentChargesExcludingGoodwill', window );">Impairment of long-lived assets</a></td>
<td class="nump">5,794,000<span></span>
</td>
<td class="nump">5,260,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,209,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,845,000<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_NonCashLeaseExpenses', window );">Non-cash lease expenses</a></td>
<td class="nump">3,332,000<span></span>
</td>
<td class="nump">1,443,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange loss</a></td>
<td class="nump">3,742,000<span></span>
</td>
<td class="num">(649,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in contingent consideration</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="nump">866,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_NonCashInterestExpenseOnConvertibleLoanNotes', window );">Non-cash interest expense</a></td>
<td class="nump">51,000<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax benefit</a></td>
<td class="num">(175,000)<span></span>
</td>
<td class="num">(44,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Profit on sale of property and equipment</a></td>
<td class="num">(245,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,704,000<span></span>
</td>
<td class="nump">3,643,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable', window );">Research and development incentives receivable</a></td>
<td class="nump">6,417,000<span></span>
</td>
<td class="num">(2,345,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,202,000)<span></span>
</td>
<td class="nump">898,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(3,793,000)<span></span>
</td>
<td class="nump">456,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred income</a></td>
<td class="num">(506,000)<span></span>
</td>
<td class="nump">1,738,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(1,979,000)<span></span>
</td>
<td class="num">(1,789,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(47,979,000)<span></span>
</td>
<td class="num">(28,940,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">453,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(37,000)<span></span>
</td>
<td class="num">(892,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by/(used) in investing activities</a></td>
<td class="nump">416,000<span></span>
</td>
<td class="num">(892,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Issue of shares from the exercise of stock options</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issue of ordinary shares, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,163,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,163,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rates on cash, cash equivalents and restricted cash</a></td>
<td class="nump">7,013,000<span></span>
</td>
<td class="num">(2,021,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(40,548,000)<span></span>
</td>
<td class="num">(29,690,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of the period</a></td>
<td class="nump">112,400,000<span></span>
</td>
<td class="nump">142,090,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of the period</a></td>
<td class="nump">$ 71,852,000<span></span>
</td>
<td class="nump">$ 112,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.75pt">Indicates amount less than one thousand</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AssetImpairmentChargesExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Impairment Charges (Excluding Goodwill)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AssetImpairmentChargesExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in research and development incentives receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_NonCashInterestExpenseOnConvertibleLoanNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non-cash interest expense on convertible loan notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_NonCashInterestExpenseOnConvertibleLoanNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_NonCashLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-cash lease expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_NonCashLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text">Nature of Business and Basis of Presentation<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Nature of business</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Barinthus Biotherapeutics plc is a public limited company incorporated pursuant to the laws of England and Wales in March 2021. Barinthus Biotherapeutics plc and its direct and indirect subsidiaries, Barinthus Biotherapeutics (UK) Limited, Barinthus Biotherapeutics North America, Vaccitech Oncology Limited (&#8220;VOLT&#8221;), Barinthus Biotherapeutics Pty Limited, Barinthus Biotherapeutics Switzerland GmbH are collectively referred to as the &#8220;Company&#8221; or &#8220;Barinthus Bio&#8221;. During the quarterly period ended September 30 2025, the Company incorporated two new subsidiaries, Beacon Topco, Inc. (&#8220;Topco&#8221;) and Cdog Merger Sub, Inc. (&#8220;Merger Sub&#8221;), for the purpose of the transactions contemplated by the recently announced merger agreement with Clywedog Therapeutics, Inc. ("Clywedog"). These entities are not material to the Company's consolidated financial position or results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases within the immunology and inflammation ("I&amp;I") space enabled by the proprietary and highly differentiated platform for promoting immune tolerance, referred to as SNAP-TI. The Company's lead candidate, VTP-1000, is designed to restore immune non-responsiveness to gluten in patients with celiac disease, and is currently being assessed in a Phase 1 clinical trial. The Company occupies laboratory and office space in Germantown, Maryland, United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company operates in an environment of rapid technological change and substantial competition from pharmaceutical and biotechnology companies. The Company is subject to risks common to companies in the biopharmaceutical industry that are also in a similar stage of its life cycle including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of any of its products that are approved, and protection of proprietary technology. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales. If the Company does not successfully commercialize any of its products or mitigate any of these other risks, it will be unable to generate revenue or achieve profitability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merger Agreement with Clywedog</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 29, 2025, the Company entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) by and among the Company, Topco, Merger Sub and Clywedog. The Merger Agreement provides that, among other things, upon the terms and subject to the conditions set forth therein: (i) Topco will acquire the entire issued and to be issued share capital of the Company pursuant to a scheme of arrangement (subject to any modification, addition or condition which (a) the Company, Topco and Clywedog mutually agree and which (if required) is approved by the High Court of Justice of England and Wales (the &#8220;Court&#8221;) or (b) is otherwise imposed by the Court and mutually acceptable to the Company, Topco and Clywedog, each acting reasonably and in good faith, in each case in accordance with the Part 26 of the United Kingdom Companies Act 2006 and the Merger Agreement (the &#8220;Scheme of Arrangement&#8221; and such transaction, the &#8220;Scheme Transaction&#8221;)), resulting in the Company becoming a direct wholly owned subsidiary of Topco, and (ii) Merger Sub will merge with and into Clywedog, with Clywedog continuing as the surviving corporation and a direct wholly owned subsidiary of Topco in accordance with the Delaware General Corporations Law (the &#8220;Merger&#8221; and, together with the Scheme Transaction, the &#8220;Combinations&#8221;, and, together with such other transactions contemplated by the Merger Agreement, the &#8220;Contemplated Transactions&#8221;). The Scheme Transaction will be consummated prior to the Merger. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At the effective time of the Scheme Transaction (the &#8220;Scheme Effective Time&#8221;), upon the terms and subject to the conditions set forth in the Merger Agreement, Topco will acquire each outstanding ordinary share of the Company, with a par value &#163;0.000025 per ordinary share (each such acquired ordinary share, a &#8220;Scheme Share&#8221;), which, for the avoidance of doubt, will include ordinary shares held by The Bank of New York Mellon (the &#8220;Depositary&#8221;) (or to the extent that the Depositary is not itself the registered holder of such shares that underly the Company&#8217;s American Depositary Shares (the &#8220;ADSs&#8221;), each representing one (1) ordinary share, whichever nominee, custodian or other entity is the registered holder under the terms of the Deposit Agreement, dated as of April 29, 2021, among the Company, the Depositary, and all holders from time to time of the ADSs, as may be amended from time to time), from the holders of Scheme Shares whose names appear in the register of members of the Company at the Scheme Effective Time) in accordance with the provisions of the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Scheme of Arrangement, and each Scheme Share will be converted into the right to receive (i) one (1) share of common stock, 0.0001 par value per share, of Topco (the &#8220;Topco Common Stock&#8221;) subject to and strictly in accordance with the terms of the Scheme of Arrangement plus (ii) cash in lieu of any fractional shares, rounded down to the nearest whole share. Following the Scheme Effective Time, Topco may in its discretion elect to commence a self-tender offer (&#8220;Self-Tender Offer&#8221;) to purchase up to $27.0 million in shares of Topco Common Stock then issued and outstanding, which Self-Tender Offer, if elected, will be consummated prior to the Merger.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At the effective time of the Merger (the &#8220;Merger Effective Time&#8221;), subject to adjustment in accordance with the terms of the Merger Agreement, each share of common stock, $0.0001 par value per share, of Clywedog (the &#8220;Clywedog Common Stock&#8221;) and each share of Series Seed Preferred Stock, $0.0001 par value per share, of Clywedog (the &#8220;Clywedog Preferred Stock&#8221;, and together with the Clywedog Common Stock, the &#8220;Clywedog Capital Stock&#8221;), other than Clywedog Capital Stock held as treasury stock or owned by Topco or Merger Sub immediately prior to the Merger Effective Time, will be converted solely into the right to receive (i) 4.358932 of shares of Topco Common Stock rounded down to the nearest whole share plus (ii) cash in lieu of any fractional shares.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The closing of the Contemplated Transactions is subject to the satisfaction or waiver of certain customary conditions, including, among other things: (i) the effectiveness of a registration statement (the &#8220;Registration Statement&#8221;) to register the shares of Topco Common Stock to be issued in connection with the Combinations; (ii) approvals by the Company&#8217;s shareholders of the Scheme Transaction and certain related matters, and sanction by the Court of the Scheme Transaction; (iii) approval by Clywedog&#8217;s stockholders of the Merger Agreement, the Merger and Contemplated Transactions; (iv) the approval for listing by the Nasdaq Stock Market of the shares of Topco Common Stock issuable in the Combinations, subject to official notice of issuance; (v) the completion of the Self-Tender Offer to the extent that Topco elects to commence the Self-Tender Offer; (ivi) minimum cash requirements for each party.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Merger Agreement may be terminated and the transactions contemplated thereby abandoned at any time prior to the closing under certain specified circumstances. Either the Company or Clywedog may terminate the Merger Agreement if, among other things: (i) the closing date will not have occurred by September 30, 2026, subject to up to a 60 day extension if the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) has not declared effective the Registration Statement by July 31, 2026, (ii) a governmental authority of competent jurisdiction has issued a final, non-appealable order prohibiting the Contemplated Transactions, (iii) the required Company shareholder approval or Clywedog shareholder approval is not obtained in accordance with the Merger Agreement, (iv) the Scheme of Arrangement is not sanctioned by the Court, or (v) another party breaches or fails to perform in any material respect any of its covenants or any of the other party&#8217;s representations or warranties are inaccurate and such breach, failure to perform or inaccuracy would result in certain of the closing conditions not being satisfied, subject to a cure period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis of presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:116%">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission for annual financial reporting. The Company&#8217;s reporting currency is the U.S. dollar. As of December&#160;31, 2025, the Company had cash, cash equivalents and restricted cash of $71.9 million and an accumulated deficit of $304.1 million and the Company expects to incur losses for the foreseeable future as it continues to pursue its activities, including the commercialization of its research and development. The Company expects to continue to incur costs and expenditures in connection with the Contemplated Transactions, further in connection with the Contemplated Transactions Barinthus may pay up to $27.0 million to existing shareholders under a Self Tender offer. If the Contemplated Transactions are consummated, any additional funding will be sought by the combined company. However as the transaction is not yet consummated, when performing the going concern assessment, management have assessed the Company on a standalone basis and expects that its cash, cash equivalents and restricted cash will be sufficient to fund current operations for at least the next 12 months from the issuance of the consolidated financial statements. </span><span style="color:#242424;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:116%">In the future the Company will need additional cash inflows to </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:116%">pursue its activities, including the commercialization of its research and </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:116%">development. There is no assurance that the Company will be successful in obtaining sufficient cash inflows on terms acceptable to the Company to fund continuing operations, if at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Guarantees and indemnifications</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As permitted under the laws of England and Wales, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through the years ended December&#160;31, 2025 and 2024, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Principles of consolidation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying consolidated financial statements include the accounts of Barinthus Biotherapeutics plc and those entities in which it has a controlling interest. Intercompany amounts are eliminated on consolidation. Amounts attributable to the noncontrolling interest are presented as a separate element of equity in the accompanying consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">During the current year, the Company updated certain estimates related to the carrying value of long-lived assets as a result of the announced Contemplated Transactions with Clywedog. The adjustment reflects updated assumptions regarding expected future cash flows and market participant perspectives. Additional information regarding this change in estimate and its impact on the financial statements is included in Note 7.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of the date of issuance of these consolidated financial statements, the Company is not aware of any other specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#8217;s financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comprehensive loss</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Comprehensive loss for all periods presented is comprised primarily of net loss and other comprehensive loss, which solely relates to foreign currency translation adjustments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Foreign currency translation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s reporting currency is the United States dollar. The functional currency of the parent and each subsidiary is the currency of the country and economic environment in which it is located. Assets and liabilities of each legal entity denominated or measured in a currency other than British Pounds are first translated into British pounds and consolidated. The consolidated balances are then converted into United States dollars at period-end exchange rates. Revenues and expenses are translated into British pounds, then into U.S. dollars at average exchange rates for each reporting period. Translation adjustments are reflected as accumulated other comprehensive loss within stockholders&#8217; equity. Gains and losses on foreign currency transactions are included in the consolidated statements of operations and comprehensive loss in </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">general and administrative expenses. The aggregate net foreign exchange gain or loss included in determining net loss was a loss of $9.6 million and gain of $2.4 million for the years ended December&#160;31, 2025 and 2024, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Noncontrolling interest</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In 2018, Barinthus Biotherapeutics plc established VOLT with a related party. As of December&#160;31, 2021, Barinthus Biotherapeutics plc had contributed cash and intellectual property with an aggregate value of $11.9 million for a 76% controlling interest. The related party had contributed cash and intellectual property with an aggregate value of $3.8 million for a 24% noncontrolling interest. There were no further contributions in subsequent financial years. The contributed intellectual properties were initially recorded at investment date fair value by VOLT and immediately expensed as research and development costs. The Company accounts for the noncontrolling interest in the accompanying consolidated financial statements initially at fair value with the subsequent carrying value adjusted for the noncontrolling share of VOLT&#8217;s comprehensive loss.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash and cash equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company considers all highly liquid investments purchased with remaining maturities of three months or less on the purchase date to be cash and cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that are actively traded (a Level 1 input). As of December&#160;31, 2025, and 2024 there were no cash equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into collaboration and license agreements, which are within the scope of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 606, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include licenses, or options to obtain licenses, to product candidates or future product candidates. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts recognized as revenue, but not yet received are generally recognized as accounts receivable or contract assets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">License revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s arrangements may provide the collaboration partner with the right to select a target for licensing either at the inception of the arrangement or in the future. Under these arrangements, fees may be due to the Company (i) at the inception of the arrangement as an upfront fee or payment, (ii) upon the exercise of an option to acquire a license or (iii) upon extending the selection period as an extension fee or payment. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services at their standalone selling prices, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For arrangements that include sales-based milestones and royalties, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This could require management to estimate the amount of revenue to recognize in the period if the actual data for the period has not been provided.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and development services</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The promises under the Company&#8217;s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. For performance obligations that include research and development services, the Company recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for the purposes of recognizing revenue, which may include an input measure such as costs incurred during the reporting period or ratably over the service period. Reimbursements from the partner are evaluated as to whether the Company acts as a principal or an agent in such relationships. The Company evaluates whether control over the underlying goods or services were obtained prior to transferring these goods or services to the collaboration partner. Where the Company does not control the goods or services prior to transferring these goods or services to the collaboration partner, such reimbursements are presented net of costs. At the inception of each arrangement that includes development milestone payments in respect of development efforts, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular development milestone in making this assessment. There is judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each reporting period, the Company reevaluates the probability of achievement of all development milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. To date, the Company has not recognized any development milestone revenue resulting from any of its arrangements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Operating Income</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Other operating income includes grant income from the CEPI Funding Agreement pursuant to which CEPI will provide funding to us to advance the development of VTP-500, a vaccine candidate against MERS. When there is reasonable assurance that we will comply with the conditions attached to a received grant, and when there is reasonable assurance that the grant will be received, grant income is recognized as other operating income on a gross basis in the consolidated statements of operations and comprehensive loss on a systematic basis over the periods in which we recognize expenses for the related costs for which the grants are intended to compensate. Payments received in advance of incurring reimbursable expenses are recorded as deferred income. Any remaining unused amounts of the cash payments received will be disclosed as restricted cash in the consolidated balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentrations of credit risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. Periodically, the Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses in these deposits. The Company&#8217;s standard payment terms are typically 30 days.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue earned in connection with the license and services provided to customers. The Company provides credit to licensees in the normal course of providing such services based on evaluations of their financial condition and generally does not require collateral. To manage accounts receivable credit risk, the Company monitors the creditworthiness of its licensees. Historically, the Company has not experienced any credit losses related to accounts receivable and does not maintain allowances for uncollectible amounts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Licensees that represented 10% or more of the Company&#8217;s revenue are presented below:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.606%"><tr><td style="width:1.0%"></td><td style="width:53.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.298%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.301%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Revenue</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Country</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Oxford University Innovation</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">U.K.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">100&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Allowance for credit losses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company evaluates its cash equivalents and accounts receivable for expected credit losses. Expected credit losses represent the portion of the amortized cost basis of a financial asset that an entity does not expect to collect. An allowance for expected credit losses is meant to reflect a risk of loss even if remote, irrespective of the expectation of collection from a particular issuer or debt security. The Company has not historically experienced any credit losses on any of its financial assets. With respect to cash equivalents and accounts receivable, given consideration of their short maturity, historical losses and the current market environment, the Company concluded there are no expected credit losses for these financial assets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and equipment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses. Expenditures for maintenance and repairs are charged to operating expenses as incurred, whereas major betterments are capitalized as additions to property and equipment. Impairment losses are recorded within general and administrative expenses. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.787%"><tr><td style="width:1.0%"></td><td style="width:73.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Asset Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lesser of lease term or estimated useful lives</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Intangible assets acquired through business combinations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets consist of acquired developed technology. Intangible assets are stated at cost less accumulated amortization and impairment losses. Amortization is computed using the straight-line method over the estimated useful lives of the respective assets, which is 10 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impairment </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company reviews long-lived assets to be held and used, including property and equipment, intangible assets and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Evaluation of recoverability is first based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group and its eventual disposition. In the event such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the assets are written down to their estimated fair values. There were impairments recorded during the year ended December&#160;31, 2025 and 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill represents the excess of cost over the fair value of the net tangible and intangible assets of businesses acquired in a business combination. Goodwill is not amortized but rather is tested for impairment at least annually, or more frequently if events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. The Company has elected to first assess the qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis of determining whether it is necessary to perform the quantitative goodwill impairment test. If the Company determines that it is more likely than not that its fair value is less than its carrying amount, then the quantitative goodwill impairment test will be performed. The quantitative goodwill impairment test identifies and measures the amount of goodwill impairment loss, if any, to be recognized by comparing the fair value </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">of a reporting unit with its carrying amount. If the fair value exceeds the carrying amount, no further analysis is required; otherwise, if the fair value is less than the carrying amount, the difference is recognized as a goodwill impairment loss not to exceed the carrying amount of the goodwill. The carrying amount of goodwill was nil at December 31, 2024 . The Company has performed the annual impairment assessment and identified qualitative indicators of impairment, most notably the share price drop in November 2024, including the lack of recovery thereof, and the strategic considerations to partner VTP-300 for future clinical development. Therefore, the Company performed a qualitative impairment assessment and determined that it was more likely than not that the fair value of the reporting unit is less than its carrying amount. The reporting unit comprises the net assets of the Company. The Company then performed a quantitative impairment assessment using the income approach to determine the fair value of the reporting unit, including the net present value of clinical stage assets and overhead costs. Based on the quantitative assessment, the Company determined that the fair value of the reporting unit is less than its carrying amount as of December 31, 2024, and, as a result, recognized a goodwill impairment charge of $12.2 million. For the year ended December&#160;31, 2025 there was no impairment charge to Goodwill (December&#160;31, 2024: $12.2 million).</span></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Financial instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s financial instruments consist of cash, cash equivalents, restricted cash, accounts receivable, accounts payable, certain accrued expenses and contingent consideration. The carrying amounts of cash, cash equivalents, accounts receivable, security deposits, accounts payable and accrued expenses approximate their fair value due to the short-term nature of those financial instruments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fair value measurements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company follows the guidance in ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">, which defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">-</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.67pt">Level 1 &#8211; Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.67pt">Level 2 &#8211; Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.67pt">Level 3 &#8211; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company&#8217;s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may change for many instruments. This condition could cause an instrument to be reclassified within levels in the fair value hierarchy. There were no transfers within the fair value hierarchy during the years ended December&#160;31, 2025 and 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes a contingent consideration liability related to the acquisition of Avidea Technologies, Inc. The liability is remeasured to fair value at each reporting date until the contingency is resolved. The fair value of the contingent consideration is a Level 3 valuation determined using significant unobservable inputs being the probability of success of achievement of the milestones and the expected date of the milestone achievement. Changes in fair value are recognized in <span style="-sec-ix-hidden:f-381"><span style="-sec-ix-hidden:f-382">general and administrative expenses</span></span> in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Leases are accounted for under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(&#8220;ASC 842&#8221;) resulting in the recognition of lease liabilities and right-of-use assets. The Company only has operating leases. The Company has elected the practical expedient allowed under ASC 842 to account for each lease component (e.g., the right to use office space) and the associated non-lease components (e.g., maintenance services) as a single lease component. The Company also elected the short-term lease accounting policy for all asset classes; therefore, the Company is not recognizing a lease liability or right-of-use asset for any lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Variable lease payments such as the Company&#8217;s share of real estate taxes, utilities, and common area maintenance, are reported as non-lease operating expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets also include the effect of any lease payments made and exclude lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized as part of total operating expenses on a straight-line basis over the lease term. The difference between the value of the right of use asset and lease liability is due to the reclassification of prepaid rent and unamortized lease incentives.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and development</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs are expensed as incurred on an accrual basis. Research and development costs include payroll and personnel expense (including share-based compensation), consulting costs, external contract research and development expenses, raw materials, drug product manufacturing costs, and allocated overheads including depreciation and amortization, facility costs, and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical trial costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activation, and other information provided to the Company by its vendors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent and licensing costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Patent and licensing costs are expensed as incurred because there is uncertainty as to any future economic benefits arising from these costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Ordinary shares</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Ordinary shares are classified in stockholders&#8217; equity and represent issued share capital.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Additional paid-in capital</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Additional paid-in capital is classified in stockholders&#8217; equity and represents the share premium account, where the difference between the price paid per share and the nominal value is recognized. The equity element of share based compensation is also recognized in additional paid in capital.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Share based compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company grants options over ordinary shares and restricted shares units to employees or non-executive directors and accounts for share based compensation using the grant date fair value. Share based compensation awards are classified in the accompanying statements of operations and comprehensive loss based on the function to which the related services are provided. For service-based awards, compensation expense is generally recognized over the requisite service period of the awards, usually the vesting period. The Company applies the &#8220;multiple option&#8221; method of allocating expense. In applying this method, each vesting tranche of an award is treated as a separate grant and recognized on a straight-line basis over that tranche&#8217;s vesting period. For performance-based awards where the vesting of the awards may be accelerated upon the achievement of certain milestones, vesting and the related share-based compensation is recognized as an expense when it is probable the milestone will be met. Assumptions used in the option pricing model include the following:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected volatility.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> Previously there was insufficient trading history for the Company&#8217;s ordinary shares, therefore the expected price volatility for the Company's ordinary shares was estimated using the average historical volatility of industry peers&#8217; shares as of the grant date of the Company's options over a period of history commensurate with the expected life of the options. When selecting industry peers used in measuring implied volatility, the Company considered the similarity of their products and business lines, as well as their stage of development, size and financial leverage. The Company applied this process consistently using the same or similar public companies until 2023. For options granted since 2023, the Company determined that there is sufficient historical information on volatility of its share price available and the expected volatility used in the fair value calculation of new option grants is calculated based on a blended volatility of both historical volatility of the Company's share price and the average historical volatility of industry peers&#8217; shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">. The expected term of the Company&#8217;s share options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The &#8220;simplified&#8221; method was determined to be appropriate as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected dividend.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company has elected to recognize the effect of forfeitures on share-based compensation when they occur. Any differences in compensation recognized at the time of forfeiture are recorded as a cumulative adjustment in the period where the forfeiture occurs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">When awards are modified, the Company compares the fair value of the affected award measured immediately prior to modification to its value after modification. To the extent that the fair value of the modified award exceeds the original award, the incremental fair value of the modified award is recognized as compensation on the date of modification for vested awards, and over the remaining vesting period for unvested awards.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The financial statements reflect provisions for income taxes in the U.K. and foreign jurisdictions. Deferred tax assets and liabilities represent future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities and for loss carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is recorded when it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. To date, the Company has not incurred interest and penalties related to uncertain tax positions nor has it recorded any unrecognized tax benefits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and development incentives</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In the U.K., the Company had previously been entitled to a research and development tax credit regime, being the Small and Medium-sized Enterprises R&amp;D tax relief program (&#8220;SME&#8221;),and, to the extent that our projects are grant funded or relate to work subcontracted to us by third parties, the Research and Development Expenditure Credit program, or RDEC Program. For the year ended December 31, 2025, we benefit from the applicable United Kingdom research and development tax credit regime which is the merged scheme Research &amp; Development expenditure credit ("RDEC") and enhanced R&amp;D intensive support ("ERIS") that replaces the prior schemes. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims. For expenditure under the merged RDEC scheme, the rate of Research and Development expenditure credit will is 20%, which is the same as the rate under the old RDEC scheme for expenditure incurred on or after April 1, 2023. For loss-makers and small profit-makers, a lower rate of notional tax restriction (currently 19%) applies at payment. Under both the merged RDEC scheme and the prior SME program, a company qualifies as an R&amp;D intensive business if R&amp;D expenditure constitutes at least 30% of total expenditure. From the analysis performed, the Company has not and do not currently expect to claim under the loss-making R&amp;D intensive scheme primarily due to the proportion of total relevant expenditure occurring outside the U.K. If the Company incurs tax losses, the Company is entitled to surrender the lesser of unrelieved tax loss sustained and the tax relief. As the realization of the tax relief does not depend on our generation of future taxable income or the Company&#8217;s ongoing tax status or tax position, the Company does not consider the tax relief as an element of income tax accounting under ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income taxes </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">and records the tax relief as a form of government grant or assistance. For the years ended December&#160;31, 2025 and 2024, the Company recognized research and development incentives of $2.0 million and $4.0 million respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net loss per share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding for the reporting period without consideration for potentially dilutive securities. Net loss attributable to ordinary shareholders is computed as if all net loss for the period had been distributed. During periods in which the Company incurred a net loss, the Company allocates no net loss to participating securities because they do not have a contractual obligation to share in the net loss of the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company computes diluted net loss per ordinary share after giving consideration to all potentially dilutive ordinary equivalents, including stock options outstanding during the period, except where the effect of such non-participating securities would be antidilutive.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Diluted net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares and dilutive ordinary share equivalents outstanding for the period, determined using the treasury-stock and if-converted methods.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contingent liabilities  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">A provision for contingent liabilities is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is a party to certain litigation and disputes arising in the normal course of business. As of December&#160;31, 2025, the Company does not expect that such matters will have a material adverse effect on the Company&#8217;s business, financial position, results of operations, or cash flows.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, new accounting pronouncements are issued by FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different applications dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time the Company either (i) irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualifies as an emerging growth company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time the Company either (i) irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualifies as an emerging growth company.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company has reviewed all recently issued standards and have determined that such standards do not or are not expected to have a material impact on its condensed consolidated financial statements or do not otherwise apply to its current operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In December 2025, the FASB issued ASU 2025-12, Accounting Standards Update Codification Improvements. The amendments in this update facilitates codification updates for a broad range of Topics arising from technical corrections, unintended application of the codification, clarifications, and other minor improvements. This standard is effective for fiscal years beginning after December 15, 2026, including interim periods within those fiscal years. The Company is currently evaluating the impact of adopting this standard to determine its impact on its disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. The amendments in this update clarify interim disclosure requirements and the applicability of Topic 270. This standard is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact of adopting this standard to determine its impact on its disclosures.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In May 2025, the FASB issued ASU 2025-03, Business Combinations (Topic 805): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity. This ASU amends the guidance for identifying the accounting acquirer in transactions involving variable interest entities (&#8220;VIEs&#8221;) where the transaction is achieved primarily through the exchange of equity interests, aligning it more closely with the guidance for voting interest entities. The amendments are effective for </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">fiscal years beginning after December 15, 2026, including interim periods within those fiscal years, with early adoption permitted. The Company elected to early adopt ASU 2025-03 as of July 1, 2025. The adoption did not have a material impact on the consolidated financial statements. The Company will apply the amended guidance prospectively to applicable transactions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In January 2025, the FASB issued ASU 2025-01, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, in which the Board's intent in the basis of conclusion of Update 2024-03 is clear that all public business entities should initially adopt the disclosure requirements in the first annual reporting period beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact of adopting this standard to determine its impact on its disclosures.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40), which requires disaggregation of specific expense categories in the notes to the financial statements and a qualitative description of the remaining expense amounts not separately disaggregated. This standard is effective for annual reporting periods beginning after December 15, 2026, and requires prospective application with the option to apply it retrospectively. The Company is currently evaluating the impact of adopting this standard to determine its impact on its disclosures.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate). This standard is effective for fiscal years beginning after December 15, 2024. The Company has retrospectively adopted the ASU and the adoption did not have a material impact on the consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment information</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Segment information</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker ("CODM"), the Company&#8217;s Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The CODM approves key operating and strategic decisions, including key decisions in clinical development and clinical operating activities, entering into significant contracts and approves the Company's consolidated operating budget. The Company views its operations and manages its business as one operating segment, the research and development of immunotherapies and vaccines. The CODM uses loss before income tax to monitor budget versus actual results and decide how to use the Company's resources. As the Company operates in one operating segment, all required financial segment information can be found in these consolidated financial statements. The following table is a summary of the Company's significant segment expenses:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"><tr><td style="width:1.0%"></td><td style="width:65.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Direct research and development expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">VTP-1000 Celiac</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Barinthus legacy assets</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">18,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total direct research and development expenses</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">14,594&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">23,709&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Indirect research and development expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Personnel-related (including share-based compensation)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Facility related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other indirect costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total indirect research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10,970&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">18,527&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">25,564&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">42,236&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.212%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In January 2025, we announced a strategic focus on developing a pipeline in I&amp;I, and the deprioritization of our programs in infectious disease and oncology. The following programs were previously presented separately and have been grouped collectively as "Barinthus Legacy Assets" for both years presented: VTP-300 HBV, VTP-850 Prostate Cancer, VTP-200 HPV, VTP-600 NSCLC, VTP-500 MERS and other and earlier stage programs. </span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company operates in two geographic regions: the U.S. and the U.K. The following table summarizes the Company&#8217;s long-lived assets, which include the Company&#8217;s intangible assets, property and equipment, net and right-of-use assets by geography:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></div></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">19,449&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28,907&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">United Kingdom</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">19,449&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">33,704&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Foreign Currency Translation in General and Administrative Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyAbstract', window );"><strong>Foreign Currency [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDisclosureTextBlock', window );">Foreign Currency Translation in General and Administrative Expenses</a></td>
<td class="text">Foreign Currency Translation in General and Administrative Expenses<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The aggregate, net foreign exchange gain or loss recognized in general and administrative expenses for the year ended December&#160;31, 2025, and 2024, was a loss of $9.6&#160;million and a gain of $2.4&#160;million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-13<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479424/830-30-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the computation of basic and diluted net loss per share for the years ended December&#160;31, 2025 and 2024 (in thousands, except number of shares and per share amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Numerator:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(66,458)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(61,183)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss attributable to Barinthus Biotherapeutics plc shareholders</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(66,428)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(61,074)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average ordinary shares outstanding, basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">40,527,218</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">39,348,240</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average ordinary shares outstanding, diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">40,527,218</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">39,348,240</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss per share attributable to ordinary shareholders, basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1.64)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1.55)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss per share attributable to ordinary shareholders, diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1.64)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1.55)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential ordinary share equivalents outstanding would have been anti-dilutive. For the year ended December&#160;31, 2025, 5,976,157 (December&#160;31, 2024: 7,285,275) potential ordinary shares issuable for stock options were excluded from the computation of diluted weighted-average shares outstanding because including them would have had an anti-dilutive effect.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net consists of the following (in thousands):</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Office furniture and equipment</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">452&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,333&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,752&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, at cost</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,114&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">16,793&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation and impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(9,420)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,523&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,373&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation expense for the year ended December&#160;31, 2025 was $2.9 million (December&#160;31, 2024: $2.6 million).</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2025 and 2024, the Company recorded a gain of $0.2 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and nil, respectively, from the sale of U.K. laboratory equipment. The recorded associated proceeds from the equipment sale for the year ended December&#160;31, 2025 and 2024 was $0.5 million and nil, respectively).</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company identified circumstances that could indicate that the carrying amount of leasehold improvements located in the U.S. and the U.S. operating lease right-of-use asset may not be recoverable as of December 31, 2025, as it was more likely than not that the Company would cease to utilize some of the laboratory and office space in Germantown, Maryland in 2026, before the end of the previously estimated useful lives. The Company performed an impairment assessment of the leasehold improvements within the U.S. asset group using the income approach as of December 31, 2025 and recorded an impairment charge within general and administrative expenses of $0.7 million (December 31, 2024: U.K. property and equipment impairment $2.7 million) to write down assets to their estimated recoverable amount. The impairment charge is subject to a number of assumptions and actual results may differ. The Company will continue to refine these assumptions as additional information becomes available. The significant assumptions used in determining the estimated fair value of the leasehold improvements located in the U.S. included how much floor space would be relinquished during sub-leasing. Significant changes in these inputs could have a material effect on the fair value measurement. See Note 16 Commitments and Contingencies for details of the impairment assessment performed over the U.S. operating lease right-of-use asset, which is part of the U.S. asset group.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, Net</a></td>
<td class="text">Intangible Assets, Net<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The gross amount of amortizable intangible assets, consisting of acquired developed technology, was $31.6 million at both December&#160;31, 2025 and 2024 and accumulated amortization was $17.3 million and $9.7 million as of December&#160;31, 2025 and 2024, respectively. The amortization expense for the year ended December&#160;31, 2025 was $3.0 million (December&#160;31, 2024: $3.2 million). The estimated annual amortization expense is $2.5 million for the years 2026 through to 2031.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">During the quarter ended September 30, 2025, the Company announced it had entered into a definitive merger agreement to combine in an all-stock transaction with Clywedog. The indicative offer price was below fair value of the Company's net assets expected at completion and below prior valuations utilized in our most recent impairment assessments, thereby constituting an impairment triggering event. As a result, the Company recorded a total impairment charge for acquired development technology intangible assets of $4.7 million during the third quarter of 2025. The determination of the fair value of the Company's net assets expected at completion is a non-recurring fair value measurement. Subsequently, we reviewed through to December 31, 2025, for additional indicators of impairment and did not identify any additional impairment triggers nor was any additional impairment expense recorded.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock', window );">Prepaid and Other Current Assets</a></td>
<td class="text">Prepaid and Other Current Assets<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid and other current assets consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Prepayments</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,518&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,859&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Value Added Tax receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,830&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,203&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on prepaid expense and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued manufacturing and clinical expenses</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,786&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,326&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Value Added Tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued bonus</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,249&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,525&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of accrued liabilities and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeAndExpenseTextBlock', window );">Grant Income</a></td>
<td class="text">Grant Income<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;) Funding Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On December 20, 2023, Barinthus Biotherapeutics (UK) Limited, the Chancellors, Masters and Scholars of the University of Oxford (&#8220;Oxford,&#8221; together with Barinthus Biotherapeutics (UK) Limited, the &#8220;Partners&#8221;) and the Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;) entered into a Funding Agreement (the &#8220;Funding Agreement&#8221;) pursuant to which CEPI would provide funding of up to $34.8 million to the Company to advance the development of VTP-500, a vaccine candidate against Middle East Respiratory Syndrome (&#8220;MERS,&#8221; and such development activities, the &#8220;Project&#8221;). In December 2023, VTP-500 received PRIME (PRIority MEdicines) designation by the European Medicines Agency. There have been no changes to the terms or conditions of the grant since the previous reporting period.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In January 2025, the Company announced its strategic focus on developing a pipeline in I&amp;I, and the deprioritization of its programs in infectious disease and oncology. The Company intends to exit the Funding Agreement as part of aligning resources in accordance with the Company's strategy.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December&#160;31, 2025, nil (December 31, 2024: $3.0&#160;million) proceeds have been received. For the year ended December 31, 2025 $0.4&#160;million (December 31,2024: $1.2&#160;million ) income has been recognized in relation to this contract. This is presented as other operating income in the consolidated statements of operations and comprehensive loss. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Funding Agreement cash payments are restricted as to the use and management of the funds. The remaining unused amounts of the Funding Agreement cash payments of $1.4 million as of December&#160;31, 2025 (December&#160;31, 2024: $1.7 million), are reflected in restricted cash in the consolidated balance sheets until expenditures contemplated in the Funding Agreement are incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Deferred income</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Deferred income relates to payments received from CEPI in advance of the eligible research and development expenses being incurred and is disclosed as deferred income separately in the consolidated balance sheets. Deferred income is released to the consolidated statements of operations and comprehensive loss in the period in which such research and development activities are actually performed in a manner that satisfies the conditions of the Funding Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Changes in deferred income during the years ended December&#160;31, 2025 and 2024, are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:71.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,738&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income recognized related to the Funding Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,396&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other operating income and other operating expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary Shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Ordinary Shares</a></td>
<td class="text">Ordinary Shares<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">All ordinary shares rank pari passu as a single class. The following is a summary of the rights and privileges of the holders of ordinary shares as of December&#160;31, 2025:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Liquidation preference:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> In the event of the liquidation, dissolution or winding up of the Company, the assets of the Company available for distribution to holders of the ordinary shares shall be distributed amongst all holders of the ordinary shares in proportion to the number of shares held irrespective of the amount paid or credited as paid on any share.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Dividends:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> The Company may, subject to the provisions of the Companies Act 2006 and its Articles, by ordinary resolution from time to time declare dividends to be paid to shareholders not exceeding the amount recommended by the Company&#8217;s board of directors. Subject to the provisions of the Companies Act 2006, insofar as, in the board of directors&#8217; opinions, the Company&#8217;s profits justify such payments, the board of directors (the "Board") may pay interim dividends on the Company&#8217;s ordinary shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Voting Rights:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> Each holder of ordinary shares has the right to receive notice of, and to vote at, the Company&#8217;s general meetings. Each holder of ordinary shares who is present (in person or by proxy) at a general meeting on a show of hands has one vote and, on a poll, every such holder who is present (in person or by proxy) has one vote in respect of for each share of which they are the holder.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Preemption rights:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> Pursuant to section 561 of the Companies Act 2006, shareholders are granted preemptive rights when new shares are issued for cash. However, it is possible under the Articles, for shareholders at a general meeting representing at least 75% of the Company's ordinary shares present (in person or by proxy) and eligible to vote at that general meeting, to disapply these preemptive rights by passing a special resolution. Such a disapplication of preemption rights may be for a maximum period of up to five years from the date on which the shareholder resolution was passed. In either case, this disapplication would need to be renewed by the Company's shareholders upon its expiration (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">, at least every five years) to remain effective.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On April&#160;21, 2021, the Company's shareholders approved the disapplication of preemptive rights for a period of five years from the date of approval by way of a special resolution of shareholders. This included the disapplication of preemption rights in relation to the allotment of the Company's ordinary shares in connection with the initial public offering ("IPO"). This disapplication will need to be renewed upon expiration (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">, at least every five years) to remain effective, but may be sought more frequently for additional five-year terms (or any shorter period).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On November 6, 2023, the Company held a general meeting where its shareholders approved resolutions granting the Board or any duly authorized committee of the Board the authority to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company free from pre-emption rights. Pursuant to such approval, the Board was authorized to allot shares up to an aggregate nominal amount of &#163;1,928 free from statutory pre-emption rights. The granting of this authority and the corresponding disapplication of preemptive rights was in addition to all subsisting authorities. This disapplication will need to be renewed upon expiration (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">, at least every five years) to remain effective, but may be sought more frequently for additional five-year terms (or any shorter period).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2025, the Company has reserved the following ordinary shares for future issuance:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,976,157</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shares available for future stock incentive plan awards</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,248,605</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,224,762</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_StockholdersEquityDeferredSharesDisclosureTextBlock', window );">Deferred Shares</a></td>
<td class="text">Deferred Shares<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">All deferred shares rank pari passu as a single class. The deferred shares do not have rights to dividends or to any other rights of participation in the profits of the Company. On a return of assets on liquidation, the deferred shares confer on the holders thereof an entitlement to receive out of the assets of the Company available for distribution amongst the shareholders (subject to the rights of any new class of shares with preferred rights) the amount credited as paid up on the deferred shares held by them respectively after (but only after) payment shall have been made to the holders of the ordinary shares of the amounts paid up or credited as paid up on such shares and the sum of &#163;1.0 million in respect of each ordinary share held by them respectively. The deferred shares shall confer on the holders thereof no further right to participate in the assets of the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s deferred A shares with a nominal value of &#163;1.00 each remain in issue for the purposes of satisfying the minimum share capital requirements for a public limited company as prescribed by the Companies Act 2006.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_StockholdersEquityDeferredSharesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Deferred Shares as disclosed by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_StockholdersEquityDeferredSharesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text">Fair Value<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s financial instruments consist of cash, cash equivalents and restricted cash, accounts payable, certain accrued expenses, and contingent consideration. The carrying amounts of cash, cash equivalents and restricted cash, accounts payable, and accrued expenses approximated their respective fair value due to the short-term nature and maturity of these instruments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2025, the Company had a contingent consideration liability of $2.9 million related to the acquisition of Avidea. Avidea&#8217;s stockholders may be entitled to receive an aggregate of up to $40.0 million in additional payments, payable in a combination of cash and American Depositary Shares, upon the achievement of certain milestones. To date, the Company has made settlement payments of $0.5 million. The fair value of the contingent consideration is a Level 3 valuation and determined using the cost approach. The significant unobservable inputs used in the fair value measurement of the contingent consideration are the probability of success of achievement of the milestones and the expected date of the milestone achievement. Significant judgment is employed in determining the appropriateness of certain of these inputs. Significant increases (decreases) in the probability of success of achievement of the milestones would have resulted in a significantly higher (lower) fair value measurement. Significant extension (reduction) in the expected date of the milestone achievement would have resulted in a significantly lower (higher) fair value measurement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes changes to the Company's financial instruments carried at fair value and classified within Level 3 of the fair value hierarchy (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,650&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,823&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Change in fair value recognized in net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:f-557"><span style="-sec-ix-hidden:f-558">Foreign exchange translation recognized in other comprehensive loss</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,871&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,650&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On April&#160;8, 2021, the Board of the Company adopted the Barinthus Biotherapeutics plc Share Award Plan 2021 (&#8220;the Plan&#8221;) and the Barinthus Biotherapeutics plc Non-Employee Sub-Plan which is a sub-plan of the Plan. Under the terms of the Plan, the Board is permitted to grant awards to employees as restricted share units, options, share appreciation rights and restricted shares. The aggregate number of shares initially available for issuance under the Plan and the Barinthus Biotherapeutics plc Non-Employee Sub-Plan cannot exceed 3,675,680 ordinary shares (the &#8220;Initial Limit&#8221;). Beginning calendar year 2022, the total number of ordinary shares available for issuance under the Plan shall be increased on January 1 of each year in an amount equal to the lesser of (i) 4% of the Company&#8217;s issued and outstanding ordinary shares (which 4% limit shall be measured as of January 1 of such year) and (ii) such number of ordinary shares as determined by the Compensation Committee of the Board in its discretion (the &#8220;Annual Increase&#8221;). In accordance with the terms of the Annual Increase, the total number of ordinary shares available for issuance under the Plan increased by 1,609,386 as of January 1, 2025. The awards generally vest based on the grantee&#8217;s continued service with the Company during a specified period following grant as determined by the Board and generally expire ten years from the grant date. Option awards generally vest over three years, but vesting conditions can vary at the discretion of the Company&#8217;s Board. As of December&#160;31, 2025 and 2024, 3,248,605 and 1,906,080 ordinary shares are available for future grants, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In 2018, the Company&#8217;s board of directors adopted the Enterprise Management Incentive Share Option Scheme (the &#8220;EMI Plan&#8221;) which provided for the grant of incentive stock options and nonqualified stock options to non-director employees of the Company. The Company also has a nonqualified stock option plan for officers and directors. The awards generally vest based on the grantee&#8217;s continued service with the Company during a specified period following grant as determined by the board of directors and generally expire ten years from the grant date. Option awards generally vest over three years, but vesting conditions can vary at the discretion of the Company&#8217;s board of directors. A total of 3,530,634 ordinary shares were reserved for issuance in accordance with the provisions of the EMI Plan and restricted stock unit (&#8220;RSUs&#8221;) plan. Upon adoption of the Plan, no further awards are to be made under the EMI Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of each stock option issued to employees was estimated at the date of grant using Black-Scholes with the following weighted-average assumptions:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"><tr><td style="width:1.0%"></td><td style="width:65.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">114.07&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">108.73&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected volatility: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Previously there was insufficient trading history for the Company&#8217;s ordinary shares, therefore the expected price volatility for our ordinary shares was estimated using the average historical volatility of industry peers&#8217; shares as of the grant date of our options over a period of history commensurate with the expected life of the options. When selecting industry peers used in measuring implied volatility, the Company considered the similarity of their products and business lines, as well as their stage of development, size and financial leverage. The Company applied this process consistently using the same or similar public companies until 2023. For options granted in and after 2023, the Company determined that there is sufficient historical information on volatility of its share price available and the expected volatility used in the fair value calculation of new option grants is calculated based on a blended volatility of both historical volatility of the Company's share price and the expected volatility of the average historical volatility of industry peers&#8217; shares. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected term (years): </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Expected term represents the period that the Company&#8217;s option grants are expected to be outstanding. There is not sufficient historical share exercise data to calculate the expected term of the stock options. Therefore, the Company elected to utilize the simplified method to value option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk-free interest rate: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined the risk-free interest rate by using a weighted-average equivalent to the expected term based on the daily U.S. Treasury yield curve rate in effect as of the date of grant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected dividend yield:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> The Company does not anticipate paying any dividends in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">A summary of stock option activity is presented below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Number of<br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Weighted-<br/>average<br/>Exercise<br/>Price Per<br/>Option</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Weighted-<br/>average <br/>Remaining <br/>Contractual <br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Aggregate <br/>Intrinsic Value <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding, January 1, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,285,275</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5.76&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7.61</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">942&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,470,812</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(614,230)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.00010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited/expired</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(2,165,700)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding, December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,976,157</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Exercisable, December 31, 2025</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,351,787</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7.94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1.81</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The weighted-average grant date per-share fair value of stock options granted during the year ended December&#160;31, 2025 was $0.85 per share (December&#160;31, 2024: $2.66 per share). The aggregate intrinsic value of stock options exercised during the year ended December&#160;31, 2025 was $0.2 million (December&#160;31, 2024: $0.4 million). As of December&#160;31, 2025, there was $0.6 million (2024: $3.1 million) of unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted-average period of 1.42 years (2024: 1.46 years).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Restricted stock units:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the Company's restricted stock units ('RSUs") under the Plan since December 31, 2025:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Number of Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Underlying RSUs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Grant Date Fair Value</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Unvested, January 1, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">886,018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vested and settled</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vested and deferred</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(21,294)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Unvested outstanding, December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">864,724</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vested but subject to deferred settlement at December 31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">864,724</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In October 2025, the Company granted an aggregate of 886,018 restricted stock units (&#8220;RSUs&#8221;) to employees under the Plan. The RSUs will vest in full on the <span style="-sec-ix-hidden:f-629">seven</span>th day following the occurrence of either the closing of the Contemplated Transactions or the termination of the Merger Agreement pursuant to its terms, subject to the employee&#8217;s continued employment with the Company through such vesting date, and were granted as part of the Company&#8217;s equity incentive program to support employee retention and alignment with shareholder interests. The grant date fair value of the RSUs was $1.3 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Total share-based compensation expense for RSUs granted for the years ended December&#160;31, 2025 and 2024 was $0.5 million and nil, respectively. As of December&#160;31, 2025, the total unrecognized compensation expense related to RSUs was $0.8 million, which is expected to be recognized over a weighted-average of 0.7 years. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Share based compensation expense is classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">335&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,029&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">468&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Loss before income before income taxes are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">United Kingdom</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(42,544)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(27,510)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(24,053)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(32,833)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(884)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss before income taxes</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(66,633)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(61,227)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The components of income tax benefit are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Current income tax benefit/(expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(70)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred income tax benefit:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total income tax benefit</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">175&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">44&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">A reconciliation of the U.K. statutory income tax rate to the Company's effective tax rate as reflected in the consolidated financial statements is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"></td><td style="width:42.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.376%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.376%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Statutory tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">16,658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">25.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">25.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Increase (decreases) resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign tax effects-United States:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Changes in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(6,122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(9.17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(4,002)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(6.54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(0.18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Non-taxable or non-deductible items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(0.76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(3,505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(5.73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign tax effects-Switzerland:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(0.05)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Effect of change in tax laws or rates enacted in the current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(0.12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(3,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(5.72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Changes in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(11.27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(2,116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(3.46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Non-taxable or non-deductible items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(2,496)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(3.75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(0.06)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(0.37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(2,784)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(4.55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Effective tax rate</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">175&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.28&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">44&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.07&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company has adopted ASU 2023-09 and evaluated all required categories and determined that no additional jurisdictional disaggregation or reconciling items were individually material.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income and for tax carryforwards. Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">40,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">26,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Research and development credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Share based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Intangible amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Capitalized Research and Development expenditure</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Gross deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">53,473&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">40,643&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(46,266)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(30,830)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,207&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,813&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use lease asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,060)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Undistributed earnings of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,248)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(3,932)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(6,039)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,461)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(10,251)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred tax, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(254)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(438)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Specified research and experimentation costs under Section 174 of the Internal Revenue Code are required to be capitalized and amortized ratably over five years for domestic expenditures and over 15 years for foreign expenditures. This provision of Section 174 became effective for tax years beginning after December 31, 2021. As a result of the capitalization of these costs in the current year, the Company has recorded a $4.8 million deferred tax asset (2024: $6.2 million). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2025, the Company had a valuation allowance of $46.3 million (2024: $30.8 million) against its deferred tax assets, which consisted principally of net operating loss and research and development credit carryforwards. The Company considered the positive and negative evidence bearing upon its ability to realize the deferred tax assets. In addition to the Company&#8217;s history of cumulative losses, the Company cannot be certain that future taxable income will be sufficient to realize its deferred tax assets. Accordingly, a valuation allowance has been provided against its deferred tax assets. When the Company changes its determination as to the amount of its deferred tax assets that can be realized, the valuation allowance is adjusted with a corresponding impact to the provision for income taxes in the period in which such determination is made.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2025 and 2024 related primarily to the increase in net operating loss and credit carryforwards, and were as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Valuations allowance at beginning of year</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30,830&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25,057&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Changes in valuation allowance arising from in-year additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Increases recorded to income tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">13,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign exchange translation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,802&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(350)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">46,266&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">30,830&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2025, the Company had net operating loss ("NOL") carryforwards totaling approximately $160.4 million which have an unlimited carryforward period, of which $114.0 million originate in the U.K. As of December&#160;31, 2025, the Company had $0.3 million of research and development tax credit carryforwards which also have an unlimited carryforward period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2024, the Company had NOL carryforwards totaling approximately $101.7 million which have an unlimited carryforward period, of which $75.6 million originate in the U.K. As of December&#160;31, 2024, the Company had $0.1 million of research and development tax credit carryforwards which also have an unlimited carryforward period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2025 and 2024, the Company does not have any material unrecognized tax benefit liabilities. The Company files corporation/income tax returns in the U.K., the United States, Switzerland, Australia and Italy. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate. In the U.K., tax years from 2022 remain subject to examination by HMRC. In all other jurisdictions, the tax years since inception remain subject to examination by the applicable taxing authorities as of December&#160;31, 2025 and 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">In-License Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company is party to a number of licensing agreements, most of which are with related parties. These agreements serve to provide the Company with the right to develop and exploit the counterparties&#8217; intellectual property for certain medical indications. As part of execution of these arrangements, the Company paid certain upfront fees, which have been expensed as incurred because the developing technology has not yet reached technical feasibility, the lack of alternative use, and the lack of proof of potential value. The agreements cover a variety of fields, including influenza, cancer, HPV, HBV and MERS. The Company&#8217;s obligations for future payments under these arrangements are dependent on its ability to develop promising drug candidates, the potential market for these candidates and potential competing products, and the payment mechanisms in place in countries where the Company retains the right to sell. Each agreement provides for specific milestone payments, typically triggered by achievement of certain testing phases in human candidates, and future royalties ranging from 1 to 5% for direct sales of a covered product to 3% to 7% of net payments received for allowable sublicenses of technology developed by the Company. The obligation to make these payments is contingent upon the Company&#8217;s ability to develop candidates for submission for phased testing and approvals, and for the development of markets for the products developed by the Company. The Company has not made or accrued any material payments under these license agreements during the years ended December&#160;31, 2025, and 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company leases certain laboratory and office space under operating leases, which are described below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The Harwell Science and Innovation Campus, Oxfordshire</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On September&#160;3, 2021, the Company entered into a lease agreement for the lease of approximately 31,000 square feet in Harwell, Oxfordshire, which expires in September 2031. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date, being the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The Company has provided the lessor with a refundable security deposit of $0.7 million which is included in Other assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In 2024, an impairment charge to write down the U.K. operating lease right-of-use asset to the estimated recoverable amount was recorded and the estimated useful life of the asset reduced. In August 2025, the Company ceased the research and development activities undertaken in the laboratory and transitioned the remaining clinical and operational workforce to remote roles. The U.K. operating lease right-of-use asset has a value of nil as of December&#160;31, 2025. The Company is actively marketing the building in Harwell, Oxfordshire, for the remainder of the lease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Germantown, Maryland</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On June&#160;14, 2022, the Company entered into a lease agreement for the lease of approximately 19,700 square feet in Germantown, Maryland. The site houses the Company&#8217;s state-of-the-art wet laboratory in the United States of America. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The lease expires on February 28, 2034, with the Company having a single right to extend for an additional five years on the same terms and conditions other than for the base rent. The Company had a rent-free period up to February 29, 2024 and was entitled to up to $3.5 million for leasehold improvements to the premises desired by the Company. The Company has provided the lessor with a refundable security deposit of $0.2 million which is included in Other assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded a right-of-use asset and a lease liability on the effective date of the lease term. The Company&#8217;s right-of-use asset and lease liabilities are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use asset</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,638&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,384&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability, current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability, non-current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Other information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6.98</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7.98</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Lease Costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,332&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,443&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company identified circumstances that could indicate that the carrying amount of the U.S. operating lease right-of-use asset and the leasehold improvements located in the U.S. may not be recoverable as of December 31, 2025, as it was more likely than not that the Company would cease some of the operating activities undertaken in the laboratory and office space in Germantown, Maryland in 2026, before the end of the previously estimated useful lives. The Company performed an impairment assessment of the U.S. operating lease right-of-use asset, which is part of the U.S. asset group, using the income approach and recorded an impairment charge within general and administrative expenses of $0.4 million (December 31, 2024: U.K. impairment $2.6 million) to write down the asset to the estimated recoverable amount. The impairment charge is subject to a number of assumptions and actual results may differ. The Company will continue to refine these assumptions as additional information becomes available. The significant assumptions used in determining the estimated fair value of the U.S. operating lease right-of-use asset are the timing of successful sub-leasing of the Company's U.S. lease obligations and the value of any charges associated with sub-leasing the Company's U.S. lease obligations. Significant changes in these inputs could have a material effect on the fair value measurement. See Note 6 Property and Equipment, Net for details of the impairment assessment performed over the property and equipment within the U.S. asset group.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Maturities of the Company&#8217;s minimum lease liabilities as of December&#160;31, 2025 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Maturity of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,050&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,940&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">14,322&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(3,041)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,281&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Non-lease and other costs paid to the lessors are primarily related to services provided by the lessors in operating the premises that includes fees, operating costs, taxes, and insurance related to the leased premises.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contemplated Transactions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 29, 2025, the Company entered into a merger agreement to combine with Clywedog, a private company advancing novel breakthrough medicines in diabetes. The Contemplated Transactions are expected to close in the second quarter of 2026, subject to customary closing conditions. In connection with this strategic combination, the Company may incur additional or contingent costs, including transaction-related legal and advisory fees, and other expenses. The Company accrued transaction-related legal and advisory fees in the amount of $2.8 million for the year ended December&#160;31, 2025 (December&#160;31, 2024: nil). Regardless of the outcome, there are anticipated additional costs and a focus of management resources on the strategic transaction which may or may not complete.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other contingencies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of the date of issuance of the audited financial statements included herein, the Company does not believe it is party to any claim or litigation the outcome of which, if determined adversely to it, would individually or in the aggregate be reasonably expected to have a material adverse effect on the Company's business. However, from time to time, the Company could be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. Regardless of the outcome, legal proceedings can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit Plans<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In the U.K., the Company has adopted a defined contribution plan (the U.K. Plan) which qualifies under the rules established by HM Revenue &amp; Customs. Contributions to the U.K. Plan are charged to the consolidated statements of operations and comprehensive loss in the year to which they relate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company has 401(k) defined contribution retirement plans in which all its employees located in the United States are eligible to participate. Eligible employees may elect to contribute up to the maximum limits, as set by the Internal Revenue Service, of their eligible compensation. Contributions to the plans are charged to the consolidated statements of operations and comprehensive loss in the year to which they relate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2025, the Company provided a total of $0.5 million (December&#160;31, 2024: $0.8 million) in contributions under both the U.K. Plan and the 401(k) plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2025, the Company incurred expenses of $0.4 million (December&#160;31, 2024: $0.8 million) from OUI which is a wholly owned subsidiary of the Company&#8217;s shareholder, the University of Oxford, primarily related to patent costs. </span></div>During the year ended December&#160;31, 2025, the Company recognized <span style="-sec-ix-hidden:f-811"><span style="-sec-ix-hidden:f-812">license revenue</span></span> of nil (December&#160;31, 2024: $15.0 million) from OUI which is a wholly owned subsidiary of the Company&#8217;s shareholder, the University of Oxford.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On February 22, 2026, the Company, Topco, Merger Sub and Clywedog entered into an amendment to the Merger Agreement (the &#8220;Merger Agreement Amendment&#8221;). Pursuant to the Merger Agreement Amendment, (i) the definition of &#8220;Scheme Exchange Ratio&#8221; as set forth in Section 1.1 of the Merger Agreement was amended and replaced in its entirety to mean a number between 0.1 and 0.166667, as finally determined by the Company&#8217;s board of directors (or a duly appointed committee thereof), (ii) the definition of &#8220;Merger Exchange Ratio&#8221; as set forth in Section 1.1 of the Merger Agreement was amended and replaced in its entirety to mean a number between 0.000305 and 0.000508, as finally determined by Clywedog and the Company in accordance with Section 2.6(d) of the Merger Agreement and correspondingly based on the change to the Scheme Exchange Ratio, in order to maintain the agreed ownership split of Topco following closing of the Combinations, and (iii) the Clywedog Minimum Cash and Beacon Minimum Cash (each as defined in the Merger Agreement) requirements as set forth in Section 8.9 and 9.6 of the Merger Agreement, respectively, are expanded to include required minimum cash amounts based on an assumed closing date of May 31, 2026 and June 30, 2026, </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">respectively, in light of the unexpected delay in the overall transaction timeline due to the U.S. federal government shutdowns.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgDiscLineItems', window );"><strong>Award Timing Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiDiscTextBlock', window );">Award Timing MNPI Disclosure</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">It is the policy of our board of directors and our compensation committee to not take material non-public information into account when determining the timing of equity awards in order to take advantage of a depressed stock price or an anticipated increase in stock price. Similarly, it is our practice not to time the release of material nonpublic information based on equity award grant dates or for the purpose of affecting the value of executive compensation.</span></div>Our compensation committee generally grants annual equity awards, including stock option grants to our named executive officers, in the first quarter of each fiscal year. In addition, new hires receive stock option grants at the time of their hiring.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMethodTextBlock', window );">Award Timing Method</a></td>
<td class="text">Our compensation committee generally grants annual equity awards, including stock option grants to our named executive officers, in the first quarter of each fiscal year. In addition, new hires receive stock option grants at the time of their hiring.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgPredtrmndFlag', window );">Award Timing Predetermined</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiCnsdrdFlag', window );">Award Timing MNPI Considered</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MnpiDiscTimedForCompValFlag', window );">MNPI Disclosure Timed for Compensation Value</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgDiscLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgDiscLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMethodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMethodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiCnsdrdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiCnsdrdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiDiscTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiDiscTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgPredtrmndFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgPredtrmndFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MnpiDiscTimedForCompValFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MnpiDiscTimedForCompValFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">In the normal course of business, we may collect and store personal information and other sensitive information, including proprietary and confidential business information, financial information, trade secrets, intellectual property, information regarding trial participants in connection with clinical trials, sensitive third-party information and employee information. In an effort to protect this information from cybersecurity risks, we have developed a cybersecurity program that has been </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">integrated into our overall risk management process; it incorporates policies and practices designed to protect the confidentiality, integrity and security of our sensitive information. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As part of our cybersecurity risk management procedures, we perform system monitoring and scanning and utilize security tools supported by a third-party managed services provider. We also conduct penetration testing performed by a third-party provider. Employees are enrolled in cybersecurity awareness training courses designed to help them identify cybersecurity concerns and take appropriate actions, and we conduct periodic simulated phishing tests in an effort to further raise cybersecurity awareness and reduce the risk of a successful cyberattack. We have an incident response plan to guide us in responding to cybersecurity incidents, and have conducted tabletop exercises to test the plan. We also take steps to protect against business interruption and conduct annual restoration testing for major systems. In addition, we use a risk-based approach to assessing cybersecurity risks from certain critical third-party vendors. This program aims to assess the cybersecurity maturity of vendors who have access to our data or systems through an evaluation of the vendor&#8217;s cybersecurity practices.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">In the normal course of business, we may collect and store personal information and other sensitive information, including proprietary and confidential business information, financial information, trade secrets, intellectual property, information regarding trial participants in connection with clinical trials, sensitive third-party information and employee information. In an effort to protect this information from cybersecurity risks, we have developed a cybersecurity program that has been </span></div>integrated into our overall risk management process; it incorporates policies and practices designed to protect the confidentiality, integrity and security of our sensitive information.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The Audit Committee, pursuant to its charter, has oversight over management of cybersecurity risks. Senior management provide the Audit Committee with periodic updates on data management and cybersecurity initiatives, as well as on significant existing and emerging cybersecurity risks, including cybersecurity incidents, as applicable. </span></div>We have a process to record identified risks from cybersecurity threats in our risk register, along with an assessment of the severity of the potential impact and the likelihood of occurrence. This process is designed to facilitate a unified and integrated assessment of corporate risk and governance. The risk register is reviewed periodically by senior management and at least annually by the Board of Directors.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Audit Committee, pursuant to its charter, has oversight over management of cybersecurity risks. Senior management provide the Audit Committee with periodic updates on data management and cybersecurity initiatives, as well as on significant existing and emerging cybersecurity risks, including cybersecurity incidents, as applicable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Senior management provide the Audit Committee with periodic updates on data management and cybersecurity initiatives, as well as on significant existing and emerging cybersecurity risks, including cybersecurity incidents, as applicable.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">Our cybersecurity program is managed by our Manager of Operations and IT Systems, who reports directly to senior management on matters regarding cybersecurity, as appropriate, and is supported by third-party vendors. Together, our senior management and Manager of Operations and IT Systems are responsible for leading company-wide cybersecurity strategy, policies, standards, and processes.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our cybersecurity program is managed by our Manager of Operations and IT Systems, who reports directly to senior management on matters regarding cybersecurity, as appropriate, and is supported by third-party vendors. Together, our senior management and Manager of Operations and IT Systems are responsible for leading company-wide cybersecurity strategy, policies, standards, and processes. </span></div>The Audit Committee, pursuant to its charter, has oversight over management of cybersecurity risks. Senior management provide the Audit Committee with periodic updates on data management and cybersecurity initiatives, as well as on significant existing and emerging cybersecurity risks, including cybersecurity incidents, as applicable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">Our cybersecurity program is managed by our Manager of Operations and IT Systems, who reports directly to senior management on matters regarding cybersecurity, as appropriate, and is supported by third-party vendors<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies', window );">Guarantees and indemnifications</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Guarantees and indemnifications</span></div>As permitted under the laws of England and Wales, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Principles of consolidation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying consolidated financial statements include the accounts of Barinthus Biotherapeutics plc and those entities in which it has a controlling interest. Intercompany amounts are eliminated on consolidation. Amounts attributable to the noncontrolling interest are presented as a separate element of equity in the accompanying consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">During the current year, the Company updated certain estimates related to the carrying value of long-lived assets as a result of the announced Contemplated Transactions with Clywedog. The adjustment reflects updated assumptions regarding expected future cash flows and market participant perspectives. Additional information regarding this change in estimate and its impact on the financial statements is included in Note 7.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of the date of issuance of these consolidated financial statements, the Company is not aware of any other specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#8217;s financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive loss</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comprehensive loss</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Comprehensive loss for all periods presented is comprised primarily of net loss and other comprehensive loss, which solely relates to foreign currency translation adjustments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Foreign currency translation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s reporting currency is the United States dollar. The functional currency of the parent and each subsidiary is the currency of the country and economic environment in which it is located. Assets and liabilities of each legal entity denominated or measured in a currency other than British Pounds are first translated into British pounds and consolidated. The consolidated balances are then converted into United States dollars at period-end exchange rates. Revenues and expenses are translated into British pounds, then into U.S. dollars at average exchange rates for each reporting period. Translation adjustments are reflected as accumulated other comprehensive loss within stockholders&#8217; equity. Gains and losses on foreign currency transactions are included in the consolidated statements of operations and comprehensive loss in </span></div>general and administrative expenses.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_MinorityInterestPolicyTextBlock', window );">Noncontrolling interest</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Noncontrolling interest</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In 2018, Barinthus Biotherapeutics plc established VOLT with a related party. As of December&#160;31, 2021, Barinthus Biotherapeutics plc had contributed cash and intellectual property with an aggregate value of $11.9 million for a 76% controlling interest. The related party had contributed cash and intellectual property with an aggregate value of $3.8 million for a 24% noncontrolling interest. There were no further contributions in subsequent financial years. The contributed intellectual properties were initially recorded at investment date fair value by VOLT and immediately expensed as research and development costs. The Company accounts for the noncontrolling interest in the accompanying consolidated financial statements initially at fair value with the subsequent carrying value adjusted for the noncontrolling share of VOLT&#8217;s comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash and cash equivalents</span></div>The Company considers all highly liquid investments purchased with remaining maturities of three months or less on the purchase date to be cash and cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that are actively traded (a Level 1 input).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into collaboration and license agreements, which are within the scope of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 606, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include licenses, or options to obtain licenses, to product candidates or future product candidates. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts recognized as revenue, but not yet received are generally recognized as accounts receivable or contract assets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">License revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s arrangements may provide the collaboration partner with the right to select a target for licensing either at the inception of the arrangement or in the future. Under these arrangements, fees may be due to the Company (i) at the inception of the arrangement as an upfront fee or payment, (ii) upon the exercise of an option to acquire a license or (iii) upon extending the selection period as an extension fee or payment. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services at their standalone selling prices, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For arrangements that include sales-based milestones and royalties, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This could require management to estimate the amount of revenue to recognize in the period if the actual data for the period has not been provided.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock', window );">Research and development services</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and development services</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The promises under the Company&#8217;s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. For performance obligations that include research and development services, the Company recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for the purposes of recognizing revenue, which may include an input measure such as costs incurred during the reporting period or ratably over the service period. Reimbursements from the partner are evaluated as to whether the Company acts as a principal or an agent in such relationships. The Company evaluates whether control over the underlying goods or services were obtained prior to transferring these goods or services to the collaboration partner. Where the Company does not control the goods or services prior to transferring these goods or services to the collaboration partner, such reimbursements are presented net of costs. At the inception of each arrangement that includes development milestone payments in respect of development efforts, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular development milestone in making this assessment. There is judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each reporting period, the Company reevaluates the probability of achievement of all development milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. To date, the Company has not recognized any development milestone revenue resulting from any of its arrangements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_OtherOperatingIncomePolicyPolicyTextBlock', window );">Other Operating Income</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Operating Income</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Other operating income includes grant income from the CEPI Funding Agreement pursuant to which CEPI will provide funding to us to advance the development of VTP-500, a vaccine candidate against MERS. When there is reasonable assurance that we will comply with the conditions attached to a received grant, and when there is reasonable assurance that the grant will be received, grant income is recognized as other operating income on a gross basis in the consolidated statements of operations and comprehensive loss on a systematic basis over the periods in which we recognize expenses for the related costs for which the grants are intended to compensate. Payments received in advance of incurring reimbursable expenses are recorded as deferred income. Any remaining unused amounts of the cash payments received will be disclosed as restricted cash in the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentrations of credit risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. Periodically, the Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses in these deposits. The Company&#8217;s standard payment terms are typically 30 days.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue earned in connection with the license and services provided to customers. The Company provides credit to licensees in the normal course of providing such services based on evaluations of their financial condition and generally does not require collateral. To manage accounts receivable credit risk, the Company monitors the creditworthiness of its licensees. Historically, the Company has not experienced any credit losses related to accounts receivable and does not maintain allowances for uncollectible amounts.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock', window );">Allowance for credit losses</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Allowance for credit losses</span></div>The Company evaluates its cash equivalents and accounts receivable for expected credit losses. Expected credit losses represent the portion of the amortized cost basis of a financial asset that an entity does not expect to collect. An allowance for expected credit losses is meant to reflect a risk of loss even if remote, irrespective of the expectation of collection from a particular issuer or debt security. The Company has not historically experienced any credit losses on any of its financial assets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and equipment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses. Expenditures for maintenance and repairs are charged to operating expenses as incurred, whereas major betterments are capitalized as additions to property and equipment. Impairment losses are recorded within general and administrative expenses. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.787%"><tr><td style="width:1.0%"></td><td style="width:73.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Asset Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lesser of lease term or estimated useful lives</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible assets acquired through business combinations</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Intangible assets acquired through business combinations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets consist of acquired developed technology. Intangible assets are stated at cost less accumulated amortization and impairment losses. Amortization is computed using the straight-line method over the estimated useful lives of the respective assets, which is 10 years.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impairment </span></div>The Company reviews long-lived assets to be held and used, including property and equipment, intangible assets and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Evaluation of recoverability is first based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group and its eventual disposition. In the event such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the assets are written down to their estimated fair values.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill represents the excess of cost over the fair value of the net tangible and intangible assets of businesses acquired in a business combination. Goodwill is not amortized but rather is tested for impairment at least annually, or more frequently if events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. The Company has elected to first assess the qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis of determining whether it is necessary to perform the quantitative goodwill impairment test. If the Company determines that it is more likely than not that its fair value is less than its carrying amount, then the quantitative goodwill impairment test will be performed. The quantitative goodwill impairment test identifies and measures the amount of goodwill impairment loss, if any, to be recognized by comparing the fair value </span></div>of a reporting unit with its carrying amount. If the fair value exceeds the carrying amount, no further analysis is required; otherwise, if the fair value is less than the carrying amount, the difference is recognized as a goodwill impairment loss not to exceed the carrying amount of the goodwill. The carrying amount of goodwill was nil at December 31, 2024 . The Company has performed the annual impairment assessment and identified qualitative indicators of impairment, most notably the share price drop in November 2024, including the lack of recovery thereof, and the strategic considerations to partner VTP-300 for future clinical development. Therefore, the Company performed a qualitative impairment assessment and determined that it was more likely than not that the fair value of the reporting unit is less than its carrying amount. The reporting unit comprises the net assets of the Company. The Company then performed a quantitative impairment assessment using the income approach to determine the fair value of the reporting unit, including the net present value of clinical stage assets and overhead costs. Based on the quantitative assessment, the Company determined that the fair value of the reporting unit is less than its carrying amount as of December 31, 2024, and, as a result, recognized a goodwill impairment charge of $12.2 million.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial instruments</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Financial instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s financial instruments consist of cash, cash equivalents, restricted cash, accounts receivable, accounts payable, certain accrued expenses and contingent consideration. The carrying amounts of cash, cash equivalents, accounts receivable, security deposits, accounts payable and accrued expenses approximate their fair value due to the short-term nature of those financial instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fair value measurements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company follows the guidance in ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">, which defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">-</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.67pt">Level 1 &#8211; Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.67pt">Level 2 &#8211; Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.67pt">Level 3 &#8211; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company&#8217;s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may change for many instruments. This condition could cause an instrument to be reclassified within levels in the fair value hierarchy. There were no transfers within the fair value hierarchy during the years ended December&#160;31, 2025 and 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes a contingent consideration liability related to the acquisition of Avidea Technologies, Inc. The liability is remeasured to fair value at each reporting date until the contingency is resolved. The fair value of the contingent consideration is a Level 3 valuation determined using significant unobservable inputs being the probability of success of achievement of the milestones and the expected date of the milestone achievement. Changes in fair value are recognized in <span style="-sec-ix-hidden:f-381"><span style="-sec-ix-hidden:f-382">general and administrative expenses</span></span> in the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Leases are accounted for under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(&#8220;ASC 842&#8221;) resulting in the recognition of lease liabilities and right-of-use assets. The Company only has operating leases. The Company has elected the practical expedient allowed under ASC 842 to account for each lease component (e.g., the right to use office space) and the associated non-lease components (e.g., maintenance services) as a single lease component. The Company also elected the short-term lease accounting policy for all asset classes; therefore, the Company is not recognizing a lease liability or right-of-use asset for any lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Variable lease payments such as the Company&#8217;s share of real estate taxes, utilities, and common area maintenance, are reported as non-lease operating expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets also include the effect of any lease payments made and exclude lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized as part of total operating expenses on a straight-line basis over the lease term. The difference between the value of the right of use asset and lease liability is due to the reclassification of prepaid rent and unamortized lease incentives.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and development</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs are expensed as incurred on an accrual basis. Research and development costs include payroll and personnel expense (including share-based compensation), consulting costs, external contract research and development expenses, raw materials, drug product manufacturing costs, and allocated overheads including depreciation and amortization, facility costs, and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ClinicalTrialCostsPolicyTextBlock', window );">Clinical trial costs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical trial costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activation, and other information provided to the Company by its vendors.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend', window );">Patent and licensing costs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent and licensing costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Patent and licensing costs are expensed as incurred because there is uncertainty as to any future economic benefits arising from these costs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Ordinary shares</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Ordinary shares</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Ordinary shares are classified in stockholders&#8217; equity and represent issued share capital.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AdditionalPaidInCapitalPolicyTextBlock', window );">Additional paid-in capital</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Additional paid-in capital</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Additional paid-in capital is classified in stockholders&#8217; equity and represents the share premium account, where the difference between the price paid per share and the nominal value is recognized. The equity element of share based compensation is also recognized in additional paid in capital.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share based compensation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Share based compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company grants options over ordinary shares and restricted shares units to employees or non-executive directors and accounts for share based compensation using the grant date fair value. Share based compensation awards are classified in the accompanying statements of operations and comprehensive loss based on the function to which the related services are provided. For service-based awards, compensation expense is generally recognized over the requisite service period of the awards, usually the vesting period. The Company applies the &#8220;multiple option&#8221; method of allocating expense. In applying this method, each vesting tranche of an award is treated as a separate grant and recognized on a straight-line basis over that tranche&#8217;s vesting period. For performance-based awards where the vesting of the awards may be accelerated upon the achievement of certain milestones, vesting and the related share-based compensation is recognized as an expense when it is probable the milestone will be met. Assumptions used in the option pricing model include the following:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected volatility.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> Previously there was insufficient trading history for the Company&#8217;s ordinary shares, therefore the expected price volatility for the Company's ordinary shares was estimated using the average historical volatility of industry peers&#8217; shares as of the grant date of the Company's options over a period of history commensurate with the expected life of the options. When selecting industry peers used in measuring implied volatility, the Company considered the similarity of their products and business lines, as well as their stage of development, size and financial leverage. The Company applied this process consistently using the same or similar public companies until 2023. For options granted since 2023, the Company determined that there is sufficient historical information on volatility of its share price available and the expected volatility used in the fair value calculation of new option grants is calculated based on a blended volatility of both historical volatility of the Company's share price and the average historical volatility of industry peers&#8217; shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">. The expected term of the Company&#8217;s share options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The &#8220;simplified&#8221; method was determined to be appropriate as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected dividend.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company has elected to recognize the effect of forfeitures on share-based compensation when they occur. Any differences in compensation recognized at the time of forfeiture are recorded as a cumulative adjustment in the period where the forfeiture occurs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">When awards are modified, the Company compares the fair value of the affected award measured immediately prior to modification to its value after modification. To the extent that the fair value of the modified award exceeds the original award, the incremental fair value of the modified award is recognized as compensation on the date of modification for vested awards, and over the remaining vesting period for unvested awards.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RegulatoryIncomeTaxesPolicy', window );">Income taxes</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The financial statements reflect provisions for income taxes in the U.K. and foreign jurisdictions. Deferred tax assets and liabilities represent future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities and for loss carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is recorded when it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. To date, the Company has not incurred interest and penalties related to uncertain tax positions nor has it recorded any unrecognized tax benefits.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock', window );">Research and development incentives</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and development incentives</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In the U.K., the Company had previously been entitled to a research and development tax credit regime, being the Small and Medium-sized Enterprises R&amp;D tax relief program (&#8220;SME&#8221;),and, to the extent that our projects are grant funded or relate to work subcontracted to us by third parties, the Research and Development Expenditure Credit program, or RDEC Program. For the year ended December 31, 2025, we benefit from the applicable United Kingdom research and development tax credit regime which is the merged scheme Research &amp; Development expenditure credit ("RDEC") and enhanced R&amp;D intensive support ("ERIS") that replaces the prior schemes. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims. For expenditure under the merged RDEC scheme, the rate of Research and Development expenditure credit will is 20%, which is the same as the rate under the old RDEC scheme for expenditure incurred on or after April 1, 2023. For loss-makers and small profit-makers, a lower rate of notional tax restriction (currently 19%) applies at payment. Under both the merged RDEC scheme and the prior SME program, a company qualifies as an R&amp;D intensive business if R&amp;D expenditure constitutes at least 30% of total expenditure. From the analysis performed, the Company has not and do not currently expect to claim under the loss-making R&amp;D intensive scheme primarily due to the proportion of total relevant expenditure occurring outside the U.K. If the Company incurs tax losses, the Company is entitled to surrender the lesser of unrelieved tax loss sustained and the tax relief. As the realization of the tax relief does not depend on our generation of future taxable income or the Company&#8217;s ongoing tax status or tax position, the Company does not consider the tax relief as an element of income tax accounting under ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income taxes </span>and records the tax relief as a form of government grant or assistance.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net loss per share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding for the reporting period without consideration for potentially dilutive securities. Net loss attributable to ordinary shareholders is computed as if all net loss for the period had been distributed. During periods in which the Company incurred a net loss, the Company allocates no net loss to participating securities because they do not have a contractual obligation to share in the net loss of the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company computes diluted net loss per ordinary share after giving consideration to all potentially dilutive ordinary equivalents, including stock options outstanding during the period, except where the effect of such non-participating securities would be antidilutive.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Diluted net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares and dilutive ordinary share equivalents outstanding for the period, determined using the treasury-stock and if-converted methods.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentLiabilityReserveEstimatePolicy', window );">Contingent liabilities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contingent liabilities  </span></div>A provision for contingent liabilities is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is a party to certain litigation and disputes arising in the normal course of business.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, new accounting pronouncements are issued by FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different applications dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time the Company either (i) irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualifies as an emerging growth company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time the Company either (i) irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualifies as an emerging growth company.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company has reviewed all recently issued standards and have determined that such standards do not or are not expected to have a material impact on its condensed consolidated financial statements or do not otherwise apply to its current operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In December 2025, the FASB issued ASU 2025-12, Accounting Standards Update Codification Improvements. The amendments in this update facilitates codification updates for a broad range of Topics arising from technical corrections, unintended application of the codification, clarifications, and other minor improvements. This standard is effective for fiscal years beginning after December 15, 2026, including interim periods within those fiscal years. The Company is currently evaluating the impact of adopting this standard to determine its impact on its disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. The amendments in this update clarify interim disclosure requirements and the applicability of Topic 270. This standard is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact of adopting this standard to determine its impact on its disclosures.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In May 2025, the FASB issued ASU 2025-03, Business Combinations (Topic 805): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity. This ASU amends the guidance for identifying the accounting acquirer in transactions involving variable interest entities (&#8220;VIEs&#8221;) where the transaction is achieved primarily through the exchange of equity interests, aligning it more closely with the guidance for voting interest entities. The amendments are effective for </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">fiscal years beginning after December 15, 2026, including interim periods within those fiscal years, with early adoption permitted. The Company elected to early adopt ASU 2025-03 as of July 1, 2025. The adoption did not have a material impact on the consolidated financial statements. The Company will apply the amended guidance prospectively to applicable transactions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In January 2025, the FASB issued ASU 2025-01, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, in which the Board's intent in the basis of conclusion of Update 2024-03 is clear that all public business entities should initially adopt the disclosure requirements in the first annual reporting period beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact of adopting this standard to determine its impact on its disclosures.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40), which requires disaggregation of specific expense categories in the notes to the financial statements and a qualitative description of the remaining expense amounts not separately disaggregated. This standard is effective for annual reporting periods beginning after December 15, 2026, and requires prospective application with the option to apply it retrospectively. The Company is currently evaluating the impact of adopting this standard to determine its impact on its disclosures.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate). This standard is effective for fiscal years beginning after December 15, 2024. The Company has retrospectively adopted the ASU and the adoption did not have a material impact on the consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AdditionalPaidInCapitalPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AdditionalPaidInCapitalPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ClinicalTrialCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Clinical Trial costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ClinicalTrialCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_MinorityInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Minority (Non Controlling) interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_MinorityInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_OtherOperatingIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Operating Income, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_OtherOperatingIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ResearchAndDevelopmentIncentivesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Incentives received o to be received from Research and Development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ResearchAndDevelopmentIncentivesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for research and development services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentLiabilityReserveEstimatePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentLiabilityReserveEstimatePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.M.2.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483530/326-20-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479391/326-20-30-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479366/326-20-35-8A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3D<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479175/326-30-30-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3D<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 13A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479148/326-30-35-13A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479391/326-20-30-4A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479148/326-30-35-7A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-21<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/460/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the treatment of costs incurred to renew or extend the term of a recognized intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegulatoryIncomeTaxesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, including investment tax credits, and the related regulatory treatment (for example, whether deferred income tax accounting - normalization - is allowed in rate making).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 980<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479068/980-740-25-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 980<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479068/980-740-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegulatoryIncomeTaxesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of concentration of credit risk</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Licensees that represented 10% or more of the Company&#8217;s revenue are presented below:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.606%"><tr><td style="width:1.0%"></td><td style="width:53.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.298%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.301%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Revenue</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Country</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Oxford University Innovation</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">U.K.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">100&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text">Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:<div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.787%"><tr><td style="width:1.0%"></td><td style="width:73.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Asset Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lesser of lease term or estimated useful lives</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net consists of the following (in thousands):</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Office furniture and equipment</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">452&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,333&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,752&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, at cost</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,114&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">16,793&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation and impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(9,420)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,523&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,373&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Significant Segment Expenses</a></td>
<td class="text">The following table is a summary of the Company's significant segment expenses:<div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"><tr><td style="width:1.0%"></td><td style="width:65.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Direct research and development expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">VTP-1000 Celiac</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Barinthus legacy assets</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">18,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total direct research and development expenses</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">14,594&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">23,709&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Indirect research and development expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Personnel-related (including share-based compensation)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Facility related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other indirect costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total indirect research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10,970&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">18,527&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">25,564&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">42,236&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.212%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">In January 2025, we announced a strategic focus on developing a pipeline in I&amp;I, and the deprioritization of our programs in infectious disease and oncology. The following programs were previously presented separately and have been grouped collectively as "Barinthus Legacy Assets" for both years presented: VTP-300 HBV, VTP-850 Prostate Cancer, VTP-200 HPV, VTP-600 NSCLC, VTP-500 MERS and other and earlier stage programs. </span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule of Long-Lived Assets</a></td>
<td class="text">The following table summarizes the Company&#8217;s long-lived assets, which include the Company&#8217;s intangible assets, property and equipment, net and right-of-use assets by geography:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></div></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">19,449&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28,907&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">United Kingdom</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">19,449&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">33,704&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted net (loss)/income per share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the computation of basic and diluted net loss per share for the years ended December&#160;31, 2025 and 2024 (in thousands, except number of shares and per share amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Numerator:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(66,458)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(61,183)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss attributable to Barinthus Biotherapeutics plc shareholders</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(66,428)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(61,074)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average ordinary shares outstanding, basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">40,527,218</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">39,348,240</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average ordinary shares outstanding, diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">40,527,218</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">39,348,240</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss per share attributable to ordinary shareholders, basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1.64)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1.55)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss per share attributable to ordinary shareholders, diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1.64)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1.55)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text">Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:<div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.787%"><tr><td style="width:1.0%"></td><td style="width:73.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Asset Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lesser of lease term or estimated useful lives</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net consists of the following (in thousands):</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Office furniture and equipment</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">452&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,333&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,752&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, at cost</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,114&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">16,793&#160;</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation and impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(9,420)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,523&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,373&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid and other current assets</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid and other current assets consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Prepayments</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,518&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,859&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Value Added Tax receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,830&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,203&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of accrued expenses and other current liabilities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued manufacturing and clinical expenses</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,786&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,326&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Value Added Tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued bonus</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,249&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,525&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTableTextBlock', window );">Schedule of changes in deferred income</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Changes in deferred income during the years ended December&#160;31, 2025 and 2024, are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:71.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,738&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income recognized related to the Funding Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,396&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of deferred income not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary Shares (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock', window );">Schedule of ordinary shares reserved for future issuance</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2025, the Company has reserved the following ordinary shares for future issuance:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,976,157</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shares available for future stock incentive plan awards</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,248,605</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,224,762</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of ordinary shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of financial instruments carried at fair value and classified within Level 3</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes changes to the Company's financial instruments carried at fair value and classified within Level 3 of the fair value hierarchy (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,650&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,823&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Change in fair value recognized in net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:f-557"><span style="-sec-ix-hidden:f-558">Foreign exchange translation recognized in other comprehensive loss</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,871&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,650&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions of fair value stock option issued to employees</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of each stock option issued to employees was estimated at the date of grant using Black-Scholes with the following weighted-average assumptions:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"><tr><td style="width:1.0%"></td><td style="width:65.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">114.07&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">108.73&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">A summary of stock option activity is presented below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Number of<br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Weighted-<br/>average<br/>Exercise<br/>Price Per<br/>Option</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Weighted-<br/>average <br/>Remaining <br/>Contractual <br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Aggregate <br/>Intrinsic Value <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding, January 1, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,285,275</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5.76&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7.61</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">942&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,470,812</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(614,230)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.00010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited/expired</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(2,165,700)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding, December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,976,157</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Exercisable, December 31, 2025</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,351,787</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7.94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1.81</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Units activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the Company's restricted stock units ('RSUs") under the Plan since December 31, 2025:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Number of Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Underlying RSUs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Grant Date Fair Value</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Unvested, January 1, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">886,018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vested and settled</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vested and deferred</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(21,294)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Unvested outstanding, December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">864,724</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vested but subject to deferred settlement at December 31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">864,724</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of share based compensation expense</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Share based compensation expense is classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">335&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,029&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">468&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of loss before income taxes</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Loss before income before income taxes are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">United Kingdom</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(42,544)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(27,510)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(24,053)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(32,833)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(884)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss before income taxes</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(66,633)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(61,227)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of income tax benefit (expense)</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The components of income tax benefit are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Current income tax benefit/(expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(70)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred income tax benefit:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total income tax benefit</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">175&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">44&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation to the effective tax rate</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">A reconciliation of the U.K. statutory income tax rate to the Company's effective tax rate as reflected in the consolidated financial statements is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"></td><td style="width:42.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.376%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.376%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Statutory tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">16,658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">25.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">25.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Increase (decreases) resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign tax effects-United States:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Changes in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(6,122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(9.17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(4,002)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(6.54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(0.18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Non-taxable or non-deductible items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(0.76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(3,505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(5.73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign tax effects-Switzerland:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(0.05)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Effect of change in tax laws or rates enacted in the current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(0.12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(3,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(5.72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Changes in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(11.27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(2,116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(3.46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Non-taxable or non-deductible items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(2,496)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(3.75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(0.06)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(0.37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(2,784)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(4.55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Effective tax rate</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">175&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.28&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">44&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.07&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of deferred tax assets and liabilities</a></td>
<td class="text">Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">40,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">26,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Research and development credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Share based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Intangible amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Capitalized Research and Development expenditure</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Gross deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">53,473&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">40,643&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(46,266)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(30,830)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,207&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,813&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use lease asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,060)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Undistributed earnings of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,248)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(3,932)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(6,039)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,461)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(10,251)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred tax, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(254)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(438)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of changes in the valuation allowance for deferred tax assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2025 and 2024 related primarily to the increase in net operating loss and credit carryforwards, and were as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year ended<br/>December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Valuations allowance at beginning of year</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30,830&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25,057&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Changes in valuation allowance arising from in-year additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Increases recorded to income tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">13,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign exchange translation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,802&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(350)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">46,266&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">30,830&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock', window );">Schedule of right-of-use assets, lease liabilities and other information</a></td>
<td class="text">The Company&#8217;s right-of-use asset and lease liabilities are as follows (in thousands):<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use asset</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,638&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,384&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability, current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability, non-current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Other information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6.98</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7.98</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Lease Costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,332&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,443&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of minimum lease liabilities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Maturities of the Company&#8217;s minimum lease liabilities as of December&#160;31, 2025 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Maturity of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,050&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,940&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">14,322&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(3,041)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,281&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for Company's right-of-use asset and lease liability and other information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>subsidiary</div>
</th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 29, 2025</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramLineItems', window );"><strong>Share Repurchase Program [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_NumberOfNewSubsidiaries', window );">Number of new subsidiaries | subsidiary</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, nominal value (per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.000025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.000025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_MergerAgreementExtensionPeriod', window );">Merger agreement extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,400<span></span>
</td>
<td class="nump">$ 142,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 304,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 237,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramLineItems', window );"><strong>Share Repurchase Program [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, nominal value (per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.000025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_NumberOfDepositarySharesPerShareOfCommonStock', window );">Number of depositary shares per share of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Becaon Topco, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramLineItems', window );"><strong>Share Repurchase Program [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, nominal value (per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Self-tender offer authorized amount to purchase | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Clywedog Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramLineItems', window );"><strong>Share Repurchase Program [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, nominal value (per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Scheme Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramLineItems', window );"><strong>Share Repurchase Program [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_StockConversionRatio', window );">Stock conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Clywedog Capital Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramLineItems', window );"><strong>Share Repurchase Program [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_StockConversionRatio', window );">Stock conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.358932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_MergerAgreementExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger Agreement, Extension Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_MergerAgreementExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_NumberOfDepositarySharesPerShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Depositary Shares Per Share Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_NumberOfDepositarySharesPerShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_NumberOfNewSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of New Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_NumberOfNewSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_StockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_StockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=brns_BecaonTopcoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=brns_BecaonTopcoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=brns_ClywedogTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=brns_ClywedogTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=brns_SchemeSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=brns_SchemeSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=brns_ClywedogCapitalStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=brns_ClywedogCapitalStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Foreign currency translation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Net foreign exchange (loss) gain</a></td>
<td class="num">$ (9.6)<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Noncontrolling interest (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related parties</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner', window );">Cumulative contributions from noncontrolling interest owner</a></td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=brns_SubsidiariesVOLTMember', window );">VOLT</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_SubsidiaryCumulativeContributionsParent', window );">Cumulative contributions from controlling interest owner</a></td>
<td class="nump">$ 11.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=brns_VOLTMember', window );">VOLT</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Controlling interest percentage</a></td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=brns_VOLTMember', window );">VOLT | Related parties</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest percentage</a></td>
<td class="nump">24.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_SubsidiaryCumulativeContributionsNoncontrollingOwner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subsidiary, Cumulative Contributions, Noncontrolling Owner</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_SubsidiaryCumulativeContributionsNoncontrollingOwner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_SubsidiaryCumulativeContributionsParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subsidiary, Cumulative Contributions, Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_SubsidiaryCumulativeContributionsParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=brns_SubsidiariesVOLTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=brns_SubsidiariesVOLTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=brns_VOLTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=brns_VOLTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash and cash equivalents (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Concentrations of credit risk (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AccountsReceivableStandardPaymentTermsPeriod', window );">Standard payment terms</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue | U.K. | Oxford University Innovation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ConcentrationRiskThresholdPercentage', window );">Concentration risk, percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AccountsReceivableStandardPaymentTermsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Standard Payment Terms, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AccountsReceivableStandardPaymentTermsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ConcentrationRiskThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk threshold Percentage in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ConcentrationRiskThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-18<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=brns_OxfordUniversityInnovationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=brns_OxfordUniversityInnovationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Allowance for credit losses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts receivable allowance for credit losses</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=brns_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=brns_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=brns_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Intangible Assets (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 24: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12,209<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Fair value measurements (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">General and administrative<span></span>
</td>
<td class="text">General and administrative<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Share based compensation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Research and Development Incentives (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ResearchAndDevelopmentIncentiveIncomeExpense', window );">Research and development incentives</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 3,983<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ResearchAndDevelopmentIncentiveIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the research and development incentives (expenses) for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ResearchAndDevelopmentIncentiveIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>segment </div>
<div>region</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_NumberOfReportableSegmentsNotDisclosedFlag', window );">Number of Reportable Segments Not Disclosed Flag</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_NumberOfGeographicRegionsInWhichEntityOperates', window );">Number of geographic regions where the company operates | region</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_NumberOfGeographicRegionsInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Geographic Regions In Which Entity Operates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_NumberOfGeographicRegionsInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_NumberOfReportableSegmentsNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Reportable Segments Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_NumberOfReportableSegmentsNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information - Significant Segment Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_IndirectResearchAndDevelopmentExpensesAbstract', window );"><strong>Indirect research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">$ 25,564<span></span>
</td>
<td class="nump">$ 42,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember', window );">Research and Development of Immunotherapies and Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DirectResearchAndDevelopmentExpensesAbstract', window );"><strong>Direct research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DirectResearchAndDevelopmentExpense', window );">Total direct research and development expenses</a></td>
<td class="nump">14,594<span></span>
</td>
<td class="nump">23,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_IndirectResearchAndDevelopmentExpensesAbstract', window );"><strong>Indirect research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_IndirectResearchAndDevelopmentExpense', window );">Total indirect research and development expenses</a></td>
<td class="nump">10,970<span></span>
</td>
<td class="nump">18,527<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">25,564<span></span>
</td>
<td class="nump">42,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember', window );">Research and Development of Immunotherapies and Vaccines | Personnel-related (including share-based compensation)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_IndirectResearchAndDevelopmentExpensesAbstract', window );"><strong>Indirect research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_IndirectResearchAndDevelopmentExpense', window );">Total indirect research and development expenses</a></td>
<td class="nump">8,413<span></span>
</td>
<td class="nump">15,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember', window );">Research and Development of Immunotherapies and Vaccines | Facility related</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_IndirectResearchAndDevelopmentExpensesAbstract', window );"><strong>Indirect research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_IndirectResearchAndDevelopmentExpense', window );">Total indirect research and development expenses</a></td>
<td class="nump">1,370<span></span>
</td>
<td class="nump">1,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember', window );">Research and Development of Immunotherapies and Vaccines | Other indirect costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_IndirectResearchAndDevelopmentExpensesAbstract', window );"><strong>Indirect research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_IndirectResearchAndDevelopmentExpense', window );">Total indirect research and development expenses</a></td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">1,411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember', window );">Research and Development of Immunotherapies and Vaccines | VTP-1000 Celiac</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DirectResearchAndDevelopmentExpensesAbstract', window );"><strong>Direct research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DirectResearchAndDevelopmentExpense', window );">Total direct research and development expenses</a></td>
<td class="nump">6,063<span></span>
</td>
<td class="nump">5,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember', window );">Research and Development of Immunotherapies and Vaccines | Barinthus legacy assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DirectResearchAndDevelopmentExpensesAbstract', window );"><strong>Direct research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DirectResearchAndDevelopmentExpense', window );">Total direct research and development expenses</a></td>
<td class="nump">$ 8,531<span></span>
</td>
<td class="nump">$ 18,223<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DirectResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Direct Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DirectResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DirectResearchAndDevelopmentExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Direct Research and Development Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DirectResearchAndDevelopmentExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_IndirectResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indirect Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_IndirectResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_IndirectResearchAndDevelopmentExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indirect Research and Development Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_IndirectResearchAndDevelopmentExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ResearchAndDevelopmentTypeAxis=brns_PersonnelRelatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ResearchAndDevelopmentTypeAxis=brns_PersonnelRelatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ResearchAndDevelopmentTypeAxis=brns_FacilityRelatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ResearchAndDevelopmentTypeAxis=brns_FacilityRelatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ResearchAndDevelopmentTypeAxis=brns_OtherIndirectCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ResearchAndDevelopmentTypeAxis=brns_OtherIndirectCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=brns_VTP1000CeliacMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=brns_VTP1000CeliacMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=brns_BarinthusLegacyAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=brns_BarinthusLegacyAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment information - Long-Lived Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 19,449<span></span>
</td>
<td class="nump">$ 33,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">19,449<span></span>
</td>
<td class="nump">28,907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,797<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Foreign Currency Translation in General and Administrative Expenses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyAbstract', window );"><strong>Foreign Currency [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Net foreign exchange (loss) gain</a></td>
<td class="num">$ (9.6)<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Computation (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (66,458)<span></span>
</td>
<td class="num">$ (61,183)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Barinthus Biotherapeutics plc shareholders</a></td>
<td class="num">$ (66,428)<span></span>
</td>
<td class="num">$ (61,074)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average ordinary shares outstanding, basic (in shares)</a></td>
<td class="nump">40,527,218<span></span>
</td>
<td class="nump">39,348,240<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average ordinary shares outstanding, diluted (in shares)</a></td>
<td class="nump">40,527,218<span></span>
</td>
<td class="nump">39,348,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to ordinary shareholders, basic (in usd per share)</a></td>
<td class="num">$ (1.64)<span></span>
</td>
<td class="num">$ (1.55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to ordinary shareholders, diluted (in usd per share)</a></td>
<td class="num">$ (1.64)<span></span>
</td>
<td class="num">$ (1.55)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares issuable for stock options that were excluded from the computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">5,976,157<span></span>
</td>
<td class="nump">7,285,275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 11,114<span></span>
</td>
<td class="nump">$ 16,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and impairment charges</a></td>
<td class="num">(7,591)<span></span>
</td>
<td class="num">(9,420)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,523<span></span>
</td>
<td class="nump">7,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">1,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=brns_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">1,752<span></span>
</td>
<td class="nump">6,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 8,910<span></span>
</td>
<td class="nump">$ 9,282<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=brns_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=brns_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of property and equipment</a></td>
<td class="nump">245,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">453,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment charge</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated annual amortization expense for 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated annual amortization expense for 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated annual amortization expense for 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated annual amortization expense for 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Estimated annual amortization expense for 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix', window );">Estimated annual amortization expense for 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,667<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross amount of amortizable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,600<span></span>
</td>
<td class="nump">31,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization for amortizable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,300<span></span>
</td>
<td class="nump">$ 9,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, Year Six</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 24: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepayments</a></td>
<td class="nump">$ 4,518<span></span>
</td>
<td class="nump">$ 5,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">Value Added Tax receivable</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 4,830<span></span>
</td>
<td class="nump">$ 6,203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AccruedManufacturingAndClinicalExpensesCurrent', window );">Accrued manufacturing and clinical expenses</a></td>
<td class="nump">$ 1,786<span></span>
</td>
<td class="nump">$ 3,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Value Added Tax payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonus</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued payroll and employee benefits</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">3,677<span></span>
</td>
<td class="nump">737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">541<span></span>
</td>
<td class="nump">616<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 6,249<span></span>
</td>
<td class="nump">$ 9,525<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AccruedManufacturingAndClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing and clinical expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AccruedManufacturingAndClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Income - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 20, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeAddition', window );">Cash payments received</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeRevenueRecognized', window );">Other operating income recognized related to the Funding Agreement</a></td>
<td class="nump">435<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">1,396<span></span>
</td>
<td class="nump">1,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=brns_CoalitionForEpidemicPreparednessInnovationsMember', window );">Coalition For Epidemic Preparedness Innovations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_FundingAmountMaximum', window );">Maximum funding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeAddition', window );">Cash payments received</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeRevenueRecognized', window );">Other operating income recognized related to the Funding Agreement</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_FundingAmountMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding Amount, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_FundingAmountMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeAddition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in deferred income not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeAddition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized previously reported as deferred income not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=brns_CoalitionForEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=brns_CoalitionForEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Income - Changes in Deferred Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeRollForward', window );"><strong>Deferred Income [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncome', window );">Beginning balance</a></td>
<td class="nump">$ 1,738<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeAddition', window );">Cash payments received</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeRevenueRecognized', window );">Other operating income recognized related to the Funding Agreement</a></td>
<td class="num">(435)<span></span>
</td>
<td class="num">(1,176)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredIncomeForeignExchangeTranslationGainLoss', window );">Foreign exchange translation</a></td>
<td class="nump">93<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncome', window );">Ending balance</a></td>
<td class="nump">$ 1,396<span></span>
</td>
<td class="nump">$ 1,738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredIncomeForeignExchangeTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Income, Foreign Exchange Translation Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredIncomeForeignExchangeTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeAddition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in deferred income not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeAddition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized previously reported as deferred income not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary Shares - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 06, 2023 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th"><div>Apr. 21, 2021</div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>vote</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_CommonStockNumberOfVotesPerShare', window );">Number of votes per common share (in votes) | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights', window );">Percentage of ordinary shares present to exercise preemptive rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PeriodOfPreemptiveRightsToBeExercised', window );">Maximum period to exercise preemptive rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights', window );">Maximum aggregate nominal amount of shares authorized to be allotted free from pre-emption rights | &#163;</a></td>
<td class="nump">&#163; 1,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PeriodOfPreemptiveRightsToBeExercised', window );">Maximum period to exercise preemptive rights</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_CommonStockNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of votes that each common share is entitled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_CommonStockNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum aggregate nominal amount of shares that the board of directors are authorized to allot free from statutory Pre-emption rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum percentage of shares required to exercise preemptive rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_PercentageOfSharesNecessaryToExercisePreemptiveRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_PeriodOfPreemptiveRightsToBeExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period allowed to exercise preemptive rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_PeriodOfPreemptiveRightsToBeExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Ordinary Shares - Ordinary Shares for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Exercise of stock options</a></td>
<td class="nump">5,976,157<span></span>
</td>
<td class="nump">7,285,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future stock incentive plan awards</a></td>
<td class="nump">3,248,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">9,224,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deferred Shares (Details) - GBP (&#163;)<br> &#163; / shares in Units, &#163; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_OrdinarySharesLiquidationPreference', window );">Ordinary shares, liquidation preference</a></td>
<td class="nump">&#163; 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockParOrStatedValuePerShare', window );">Deferred shares, nominal value (in gbp per share)</a></td>
<td class="nump">&#163; 1<span></span>
</td>
<td class="nump">&#163; 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of deferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_OrdinarySharesLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liquidation preference on ordinary shares to be paid after which the deferred shares have the entitlement to receive out of the assets of the Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_OrdinarySharesLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value - Additional information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">49 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration liability</a></td>
<td class="nump">$ 2,871<span></span>
</td>
<td class="nump">$ 2,650<span></span>
</td>
<td class="nump">$ 1,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=brns_AvideaMember', window );">Avidea</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration liability</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum additional contingent consideration payments upon achievement of milestones</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlement payments related to contingent consideration liability</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of estimate for undiscounted range of outcomes in contingent consideration arrangement in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=brns_AvideaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=brns_AvideaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value - Change in Financial Instruments Classified Within Level 3 (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 2,650<span></span>
</td>
<td class="nump">$ 1,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value recognized in net loss</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Foreign exchange translation recognized in other comprehensive loss</a></td>
<td class="nump">195<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 2,871<span></span>
</td>
<td class="nump">$ 2,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Other comprehensive gain/(loss) &#8211; foreign currency translation adjustments<span></span>
</td>
<td class="text">Other comprehensive gain/(loss) &#8211; foreign currency translation adjustments<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which other comprehensive income (OCI) is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Apr. 08, 2021</div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares available for future grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,976,157<span></span>
</td>
<td class="nump">7,285,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,224,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.85<span></span>
</td>
<td class="nump">$ 2.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">4,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which unrecognized compensation cost is expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">886,018<span></span>
</td>
<td class="nump">886,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Grant fair value of awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which unrecognized compensation cost is expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 5 months 1 day<span></span>
</td>
<td class="text">1 year 5 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member', window );">Barinthus Biotherapeutics plc Share Award Plan 2021 | Restricted share units, options, share appreciation rights and restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,675,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares', window );">Percentage of issued and outstanding ordinary shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional number of shares available for issuance (in shares)</a></td>
<td class="nump">1,609,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares available for future grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,248,605<span></span>
</td>
<td class="nump">1,906,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=brns_EnterpriseManagementIncentiveShareOptionSchemeMember', window );">Enterprise Management Incentive Share Option Scheme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=brns_EnterpriseManagementIncentiveShareOptionSchemeMember', window );">Enterprise Management Incentive Share Option Scheme | RSU's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,530,634<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The duration of grants awarded under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares available for issuance under the Plan as a percentage of the Company's issued and outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=brns_EnterpriseManagementIncentiveShareOptionSchemeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=brns_EnterpriseManagementIncentiveShareOptionSchemeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Weighted-average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=brns_EnterpriseManagementIncentiveShareOptionSchemeMember', window );">Enterprise Management Incentive Share Option Scheme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">114.07%<span></span>
</td>
<td class="nump">108.73%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=brns_EnterpriseManagementIncentiveShareOptionSchemeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=brns_EnterpriseManagementIncentiveShareOptionSchemeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">7,285,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,470,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(614,230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited/expired (in shares)</a></td>
<td class="num">(2,165,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">5,976,157<span></span>
</td>
<td class="nump">7,285,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at the end of the period (in shares)</a></td>
<td class="nump">4,351,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- average Exercise Price Per Option</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of the period (in usd per share)</a></td>
<td class="nump">$ 5.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share)</a></td>
<td class="nump">0.00010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited/expired (in usd per share)</a></td>
<td class="nump">2.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period (in usd per share)</a></td>
<td class="nump">6.28<span></span>
</td>
<td class="nump">$ 5.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end of the period (in usd per share)</a></td>
<td class="nump">$ 7.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted-average remaining contractual term (Years)</a></td>
<td class="text">2 years 3 months 10 days<span></span>
</td>
<td class="text">7 years 7 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted-average remaining contractual term (Years) (in years)</a></td>
<td class="text">1 year 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Restricted Stock Units Activity (Details) - RSU's - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares Underlying RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested begining balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">886,018<span></span>
</td>
<td class="nump">886,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod', window );">Vested and settled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod', window );">Vested and deferred (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,294)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">864,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber', window );">Vested but subject to deferred settlement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">864,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested beginning balance (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue', window );">Vested and settled (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue', window );">Vested and deferred (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested ending balance (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested but subject to deferred settlement (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue', window );">Outstanding (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Deferred In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Deferred In Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Settled In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Settled In Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">$ 4,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">1,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">$ 335<span></span>
</td>
<td class="nump">$ 3,029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Loss Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United Kingdom</a></td>
<td class="num">$ (42,544)<span></span>
</td>
<td class="num">$ (27,510)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(66,633)<span></span>
</td>
<td class="num">(61,227)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(24,053)<span></span>
</td>
<td class="num">(32,833)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignTaxJurisdictionOtherMember', window );">Other foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">$ (36)<span></span>
</td>
<td class="num">$ (884)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignTaxJurisdictionOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignTaxJurisdictionOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Benefit (Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred income tax benefit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax benefit</a></td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current income tax benefit/(expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred income tax benefit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignTaxJurisdictionOtherMember', window );">Other foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current income tax benefit/(expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">$ (9)<span></span>
</td>
<td class="num">$ (22)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignTaxJurisdictionOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignTaxJurisdictionOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation to the Effective Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">$ 16,658<span></span>
</td>
<td class="nump">$ 15,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Effect of change in tax laws or rates enacted in the current period</a></td>
<td class="nump">598<span></span>
</td>
<td class="nump">721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount', window );">Tax credits</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(3,501)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="num">(243)<span></span>
</td>
<td class="num">(2,784)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax benefit</a></td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Effect of change in tax laws or rates enacted in the current period</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">1.18%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment', window );">Tax credits</a></td>
<td class="num">(0.12%)<span></span>
</td>
<td class="num">(5.72%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="num">(0.37%)<span></span>
</td>
<td class="num">(4.55%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.28%<span></span>
</td>
<td class="nump">0.07%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="num">$ (6,122)<span></span>
</td>
<td class="num">$ (4,002)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Share-based compensation</a></td>
<td class="num">(118)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-taxable or non-deductible items</a></td>
<td class="num">$ (506)<span></span>
</td>
<td class="num">$ (3,505)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="num">(9.17%)<span></span>
</td>
<td class="num">(6.54%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Share-based compensation</a></td>
<td class="num">(0.18%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-taxable or non-deductible items</a></td>
<td class="num">(0.76%)<span></span>
</td>
<td class="num">(5.73%)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_CH', window );">Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Share-based compensation</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Share-based compensation</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.05%)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="num">$ (7,513)<span></span>
</td>
<td class="num">$ (2,116)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-taxable or non-deductible items</a></td>
<td class="num">$ (2,496)<span></span>
</td>
<td class="num">$ (46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="num">(11.27%)<span></span>
</td>
<td class="num">(3.46%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-taxable or non-deductible items</a></td>
<td class="num">(3.75%)<span></span>
</td>
<td class="num">(0.06%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Credits, Research And Development, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 40,691<span></span>
</td>
<td class="nump">$ 26,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share based compensation</a></td>
<td class="nump">4,190<span></span>
</td>
<td class="nump">4,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredTaxAssetsLeasingArrangements', window );">Lease liability</a></td>
<td class="nump">2,965<span></span>
</td>
<td class="nump">3,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible amortization</a></td>
<td class="nump">459<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized Research and Development expenditure</a></td>
<td class="nump">4,765<span></span>
</td>
<td class="nump">6,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax asset</a></td>
<td class="nump">53,473<span></span>
</td>
<td class="nump">40,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(46,266)<span></span>
</td>
<td class="num">(30,830)<span></span>
</td>
<td class="num">$ (25,057)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">7,207<span></span>
</td>
<td class="nump">9,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(1,130)<span></span>
</td>
<td class="num">(1,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use lease asset</a></td>
<td class="num">(1,060)<span></span>
</td>
<td class="num">(1,149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Undistributed earnings of subsidiaries</a></td>
<td class="num">(1,339)<span></span>
</td>
<td class="num">(1,248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(3,932)<span></span>
</td>
<td class="num">(6,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">(7,461)<span></span>
</td>
<td class="num">(10,251)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Total deferred tax, net</a></td>
<td class="num">$ (254)<span></span>
</td>
<td class="num">$ (438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredTaxAssetsLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredTaxAssetsLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Deferred tax assets for capitalized research and development expenditure</a></td>
<td class="nump">$ 4,765<span></span>
</td>
<td class="nump">$ 6,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">46,266<span></span>
</td>
<td class="nump">30,830<span></span>
</td>
<td class="nump">$ 25,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">160,400<span></span>
</td>
<td class="nump">101,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_GB', window );">U.K.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 114,000<span></span>
</td>
<td class="nump">$ 75,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Changes in the Valuation Allowance ror Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ValuationAllowanceRollForward', window );"><strong>Valuation Allowance [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuations allowance at beginning of year</a></td>
<td class="nump">$ 30,830<span></span>
</td>
<td class="nump">$ 25,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions', window );">Changes in valuation allowance arising from in-year additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision', window );">Increases recorded to income tax provision</a></td>
<td class="nump">13,634<span></span>
</td>
<td class="nump">6,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation', window );">Foreign exchange translation</a></td>
<td class="nump">1,802<span></span>
</td>
<td class="num">(350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at end of year</a></td>
<td class="nump">$ 46,266<span></span>
</td>
<td class="nump">$ 30,830<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Increase (Decrease) Resulting From Foreign Currency Translation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Increase Resulting From Current Period Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Increase Resulting From Income Tax Provision</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ValuationAllowanceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ValuationAllowanceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 14, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 03, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,638<span></span>
</td>
<td class="nump">$ 4,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease right-of-use asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Transaction-related fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=brns_OxfordshireMember', window );">Oxfordshire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_NumberOfSquareFeetUnderLeaseAgreement', window );">Size of space under lease agreement (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Refundable security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MD', window );">Maryland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_NumberOfSquareFeetUnderLeaseAgreement', window );">Size of space under lease agreement (in square feet) | ft&#178;</a></td>
<td class="nump">19,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Refundable security deposit</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_LesseeOperatingLeaseExtendedTerm', window );">Additional lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvement expense</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=brns_InLicenseAgreementsMember', window );">In-License Agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement', window );">Percentage of future royalties for direct sales of a covered product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement', window );">Net payments received for allowable sublicenses of technology developed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=brns_InLicenseAgreementsMember', window );">In-License Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement', window );">Percentage of future royalties for direct sales of a covered product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement', window );">Net payments received for allowable sublicenses of technology developed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_LesseeOperatingLeaseExtendedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_LesseeOperatingLeaseExtendedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_NumberOfSquareFeetUnderLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to number of Square Feet Under Lease Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_NumberOfSquareFeetUnderLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of future royalties for direct sales of a covered product under the In-License Agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net payments received for allowable sublicenses of technology developed under the In-License Agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for acquisition-related cost incurred to effect business combination. Includes, but is not limited to, finder's fee; advisory, legal, accounting, valuation, and other professional and consulting fees; and general administrative cost, including cost of maintaining internal acquisition department.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=brns_OxfordshireMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=brns_OxfordshireMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=brns_InLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=brns_InLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Right-of-use Assets, Lease Liabilities and Other Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">$ 1,638<span></span>
</td>
<td class="nump">$ 4,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current</a></td>
<td class="nump">2,023<span></span>
</td>
<td class="nump">1,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, non-current</a></td>
<td class="nump">9,258<span></span>
</td>
<td class="nump">10,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_OtherInformationLesseeAbstract', window );"><strong>Other information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 1,979<span></span>
</td>
<td class="nump">$ 1,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">6 years 11 months 23 days<span></span>
</td>
<td class="text">7 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating leases</a></td>
<td class="nump">$ 3,332<span></span>
</td>
<td class="nump">$ 1,443<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 3,332<span></span>
</td>
<td class="nump">$ 1,443<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_OtherInformationLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Information, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_OtherInformationLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturities of minimum lease liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 2,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">2,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">2,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">2,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2030</a></td>
<td class="nump">2,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">3,940<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">14,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(3,041)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 11,281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contribution</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=brns_OxfordUniversityInnovationLimitedMember', window );">Oxford University Innovation Limited (OUI) | Related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</a></td>
<td class="text">License revenue<span></span>
</td>
<td class="text">License revenue<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=brns_OxfordUniversityInnovationLimitedMember', window );">Oxford University Innovation Limited (OUI) | Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amounts of related party transactions</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=brns_OxfordUniversityInnovationLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=brns_OxfordUniversityInnovationLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=brns_ExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=brns_ExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event<br></strong></div></th>
<th class="th"><div>Feb. 22, 2026</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_MergerAgreementSchemeExchangeRatio', window );">Scheme exchange ratio</a></td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_MergerAgreementMergerExchangeRatio', window );">Merger exchange ratio</a></td>
<td class="nump">0.000305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_MergerAgreementSchemeExchangeRatio', window );">Scheme exchange ratio</a></td>
<td class="nump">0.166667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_MergerAgreementMergerExchangeRatio', window );">Merger exchange ratio</a></td>
<td class="nump">0.000508<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_MergerAgreementMergerExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger Agreement, Merger Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_MergerAgreementMergerExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_MergerAgreementSchemeExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger Agreement, Scheme Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_MergerAgreementSchemeExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>136</ContextCount>
  <ElementCount>403</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>54</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentation</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Segment information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/Segmentinformation</Role>
      <ShortName>Segment information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Foreign Currency Translation in General and Administrative Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpenses</Role>
      <ShortName>Foreign Currency Translation in General and Administrative Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Prepaid and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssets</Role>
      <ShortName>Prepaid and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Grant Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/GrantIncome</Role>
      <ShortName>Grant Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Ordinary Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/OrdinaryShares</Role>
      <ShortName>Ordinary Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Deferred Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/DeferredShares</Role>
      <ShortName>Deferred Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Segment information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SegmentinformationTables</Role>
      <ShortName>Segment information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/Segmentinformation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/NetLossPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Prepaid and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssets</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Grant Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/GrantIncomeTables</Role>
      <ShortName>Grant Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/GrantIncome</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Ordinary Shares (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/OrdinarySharesTables</Role>
      <ShortName>Ordinary Shares (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/OrdinaryShares</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/FairValue</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/ShareBasedCompensation</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/IncomeTaxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/CommitmentsandContingencies</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Nature of Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails</Role>
      <ShortName>Nature of Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentation</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Summary of Significant Accounting Policies - Foreign currency translation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesForeigncurrencytranslationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Foreign currency translation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Summary of Significant Accounting Policies - Noncontrolling interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Noncontrolling interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Summary of Significant Accounting Policies - Cash and cash equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash and cash equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Summary of Significant Accounting Policies - Concentrations of credit risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Concentrations of credit risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Summary of Significant Accounting Policies - Allowance for credit losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesAllowanceforcreditlossesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Allowance for credit losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Summary of Significant Accounting Policies - Property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Summary of Significant Accounting Policies - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Summary of Significant Accounting Policies - Fair value measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesFairvaluemeasurementsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Fair value measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Summary of Significant Accounting Policies - Share based compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesSharebasedcompensationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Share based compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Summary of Significant Accounting Policies - Research and Development Incentives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentIncentivesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Research and Development Incentives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Segment information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SegmentinformationAdditionalInformationDetails</Role>
      <ShortName>Segment information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Segment information - Significant Segment Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails</Role>
      <ShortName>Segment information - Significant Segment Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Segment information - Long-Lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SegmentinformationLongLivedAssetsDetails</Role>
      <ShortName>Segment information - Long-Lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Foreign Currency Translation in General and Administrative Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails</Role>
      <ShortName>Foreign Currency Translation in General and Administrative Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpenses</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Net Loss Per Share - Computation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/NetLossPerShareComputationDetails</Role>
      <ShortName>Net Loss Per Share - Computation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Net Loss Per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/NetLossPerShareAdditionalInformationDetails</Role>
      <ShortName>Net Loss Per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Property and Equipment, Net - Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails</Role>
      <ShortName>Property and Equipment, Net - Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/PropertyandEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/IntangibleAssetsNetDetails</Role>
      <ShortName>Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/IntangibleAssetsNet</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Prepaid and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Grant Income - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails</Role>
      <ShortName>Grant Income - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Grant Income - Changes in Deferred Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/GrantIncomeChangesinDeferredIncomeDetails</Role>
      <ShortName>Grant Income - Changes in Deferred Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Ordinary Shares - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails</Role>
      <ShortName>Ordinary Shares - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Ordinary Shares - Ordinary Shares for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/OrdinarySharesOrdinarySharesforFutureIssuanceDetails</Role>
      <ShortName>Ordinary Shares - Ordinary Shares for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Deferred Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/DeferredSharesDetails</Role>
      <ShortName>Deferred Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/DeferredShares</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Fair Value - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails</Role>
      <ShortName>Fair Value - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Fair Value - Change in Financial Instruments Classified Within Level 3 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedWithinLevel3Details</Role>
      <ShortName>Fair Value - Change in Financial Instruments Classified Within Level 3 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Share-Based Compensation - Weighted-average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails</Role>
      <ShortName>Share-Based Compensation - Weighted-average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Share-Based Compensation - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Share-Based Compensation - Schedule of Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Share-Based Compensation - Share Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Share Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Income Taxes - Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Income Taxes - Components of Income Tax Benefit (Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax Benefit (Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Income Taxes - Reconciliation to the Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation to the Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9955564 - Disclosure - Income Taxes - Changes in the Valuation Allowance ror Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/IncomeTaxesChangesintheValuationAllowancerorDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Changes in the Valuation Allowance ror Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9955565 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9955566 - Disclosure - Commitments and Contingencies - Right-of-use Assets, Lease Liabilities and Other Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Right-of-use Assets, Lease Liabilities and Other Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9955567 - Disclosure - Commitments and Contingencies - Maturities of minimum lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Maturities of minimum lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9955568 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9955569 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="brns-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9955570 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/SubsequentEvents</ParentRole>
      <Position>90</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="brns-20251231.htm">brns-20251231.htm</File>
    <File>brns-20251231.xsd</File>
    <File>brns-20251231_cal.xml</File>
    <File>brns-20251231_def.xml</File>
    <File>brns-20251231_lab.xml</File>
    <File>brns-20251231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>brns-20251231_g1.jpg</File>
    <File>brns-20251231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/srt/2025</BaseTaxonomy>
    <BaseTaxonomy items="634">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="14">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="11">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>116
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "brns-20251231.htm": {
   "nsprefix": "brns",
   "nsuri": "http://www.barinthusbio.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "brns-20251231.htm"
     ]
    },
    "schema": {
     "local": [
      "brns-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "brns-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "brns-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "brns-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "brns-20251231_pre.xml"
     ]
    }
   },
   "keyStandard": 337,
   "keyCustom": 66,
   "axisStandard": 25,
   "axisCustom": 1,
   "memberStandard": 27,
   "memberCustom": 24,
   "hidden": {
    "total": 13,
    "http://fasb.org/us-gaap/2025": 7,
    "http://xbrl.sec.gov/dei/2025": 5,
    "http://www.barinthusbio.com/20251231": 1
   },
   "contextCount": 136,
   "entityCount": 1,
   "segmentCount": 54,
   "elementCount": 701,
   "unitCount": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 634,
    "http://xbrl.sec.gov/dei/2025": 40,
    "http://xbrl.sec.gov/cyd/2025": 14,
    "http://xbrl.sec.gov/ecd/2025": 11,
    "http://fasb.org/srt/2025": 2
   },
   "report": {
    "R1": {
     "role": "http://www.barinthusbio.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.barinthusbio.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "9952151 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "gbpPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "longName": "9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "longName": "9952154 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-33",
      "name": "us-gaap:SharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-33",
      "name": "us-gaap:SharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentation",
     "longName": "9952156 - Disclosure - Nature of Business and Basis of Presentation",
     "shortName": "Nature of Business and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952157 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.barinthusbio.com/role/Segmentinformation",
     "longName": "9952158 - Disclosure - Segment information",
     "shortName": "Segment information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpenses",
     "longName": "9952159 - Disclosure - Foreign Currency Translation in General and Administrative Expenses",
     "shortName": "Foreign Currency Translation in General and Administrative Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ForeignCurrencyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ForeignCurrencyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.barinthusbio.com/role/NetLossPerShare",
     "longName": "9952160 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.barinthusbio.com/role/PropertyandEquipmentNet",
     "longName": "9952161 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.barinthusbio.com/role/IntangibleAssetsNet",
     "longName": "9952162 - Disclosure - Intangible Assets, Net",
     "shortName": "Intangible Assets, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssets",
     "longName": "9952163 - Disclosure - Prepaid and Other Current Assets",
     "shortName": "Prepaid and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "longName": "9952164 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.barinthusbio.com/role/GrantIncome",
     "longName": "9952165 - Disclosure - Grant Income",
     "shortName": "Grant Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.barinthusbio.com/role/OrdinaryShares",
     "longName": "9952166 - Disclosure - Ordinary Shares",
     "shortName": "Ordinary Shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.barinthusbio.com/role/DeferredShares",
     "longName": "9952167 - Disclosure - Deferred Shares",
     "shortName": "Deferred Shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:StockholdersEquityDeferredSharesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:StockholdersEquityDeferredSharesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.barinthusbio.com/role/FairValue",
     "longName": "9952168 - Disclosure - Fair Value",
     "shortName": "Fair Value",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.barinthusbio.com/role/ShareBasedCompensation",
     "longName": "9952169 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.barinthusbio.com/role/IncomeTaxes",
     "longName": "9952170 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.barinthusbio.com/role/CommitmentsandContingencies",
     "longName": "9952171 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.barinthusbio.com/role/EmployeeBenefitPlans",
     "longName": "9952172 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.barinthusbio.com/role/RelatedPartyTransactions",
     "longName": "9952173 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.barinthusbio.com/role/SubsequentEvents",
     "longName": "9952174 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.barinthusbio.com/role/SegmentinformationTables",
     "longName": "9955513 - Disclosure - Segment information (Tables)",
     "shortName": "Segment information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.barinthusbio.com/role/NetLossPerShareTables",
     "longName": "9955514 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.barinthusbio.com/role/PropertyandEquipmentNetTables",
     "longName": "9955515 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R36": {
     "role": "http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsTables",
     "longName": "9955516 - Disclosure - Prepaid and Other Current Assets (Tables)",
     "shortName": "Prepaid and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "longName": "9955517 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.barinthusbio.com/role/GrantIncomeTables",
     "longName": "9955518 - Disclosure - Grant Income (Tables)",
     "shortName": "Grant Income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredIncomeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredIncomeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.barinthusbio.com/role/OrdinarySharesTables",
     "longName": "9955519 - Disclosure - Ordinary Shares (Tables)",
     "shortName": "Ordinary Shares (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.barinthusbio.com/role/FairValueTables",
     "longName": "9955520 - Disclosure - Fair Value (Tables)",
     "shortName": "Fair Value (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.barinthusbio.com/role/ShareBasedCompensationTables",
     "longName": "9955521 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.barinthusbio.com/role/IncomeTaxesTables",
     "longName": "9955522 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.barinthusbio.com/role/CommitmentsandContingenciesTables",
     "longName": "9955523 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails",
     "longName": "9955524 - Disclosure - Nature of Business and Basis of Presentation (Details)",
     "shortName": "Nature of Business and Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-47",
      "name": "brns:NumberOfNewSubsidiaries",
      "unitRef": "subsidiary",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-47",
      "name": "brns:NumberOfNewSubsidiaries",
      "unitRef": "subsidiary",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesForeigncurrencytranslationDetails",
     "longName": "9955525 - Disclosure - Summary of Significant Accounting Policies - Foreign currency translation (Details)",
     "shortName": "Summary of Significant Accounting Policies - Foreign currency translation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R46": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails",
     "longName": "9955526 - Disclosure - Summary of Significant Accounting Policies - Noncontrolling interest (Details)",
     "shortName": "Summary of Significant Accounting Policies - Noncontrolling interest (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-56",
      "name": "brns:SubsidiaryCumulativeContributionsNoncontrollingOwner",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "brns:MinorityInterestPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-56",
      "name": "brns:SubsidiaryCumulativeContributionsNoncontrollingOwner",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "brns:MinorityInterestPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails",
     "longName": "9955527 - Disclosure - Summary of Significant Accounting Policies - Cash and cash equivalents (Details)",
     "shortName": "Summary of Significant Accounting Policies - Cash and cash equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails",
     "longName": "9955528 - Disclosure - Summary of Significant Accounting Policies - Concentrations of credit risk (Details)",
     "shortName": "Summary of Significant Accounting Policies - Concentrations of credit risk (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:AccountsReceivableStandardPaymentTermsPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:AccountsReceivableStandardPaymentTermsPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesAllowanceforcreditlossesDetails",
     "longName": "9955529 - Disclosure - Summary of Significant Accounting Policies - Allowance for credit losses (Details)",
     "shortName": "Summary of Significant Accounting Policies - Allowance for credit losses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:AllowanceForDoubtfulAccountsReceivable",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:AllowanceForDoubtfulAccountsReceivable",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails",
     "longName": "9955530 - Disclosure - Summary of Significant Accounting Policies - Property and equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Property and equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-60",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-60",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails",
     "longName": "9955531 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets (Details)",
     "shortName": "Summary of Significant Accounting Policies - Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-62",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-62",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails",
     "longName": "9955532 - Disclosure - Summary of Significant Accounting Policies - Goodwill (Details)",
     "shortName": "Summary of Significant Accounting Policies - Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R53": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesFairvaluemeasurementsDetails",
     "longName": "9955533 - Disclosure - Summary of Significant Accounting Policies - Fair value measurements (Details)",
     "shortName": "Summary of Significant Accounting Policies - Fair value measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesSharebasedcompensationDetails",
     "longName": "9955534 - Disclosure - Summary of Significant Accounting Policies - Share based compensation (Details)",
     "shortName": "Summary of Significant Accounting Policies - Share based compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R55": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentIncentivesDetails",
     "longName": "9955535 - Disclosure - Summary of Significant Accounting Policies - Research and Development Incentives (Details)",
     "shortName": "Summary of Significant Accounting Policies - Research and Development Incentives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:ResearchAndDevelopmentIncentiveIncomeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://www.barinthusbio.com/role/SegmentinformationAdditionalInformationDetails",
     "longName": "9955536 - Disclosure - Segment information - Additional Information (Details)",
     "shortName": "Segment information - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails",
     "longName": "9955537 - Disclosure - Segment information - Significant Segment Expenses (Details)",
     "shortName": "Segment information - Significant Segment Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-67",
      "name": "brns:DirectResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.barinthusbio.com/role/SegmentinformationLongLivedAssetsDetails",
     "longName": "9955538 - Disclosure - Segment information - Long-Lived Assets (Details)",
     "shortName": "Segment information - Long-Lived Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails",
     "longName": "9955539 - Disclosure - Foreign Currency Translation in General and Administrative Expenses (Details)",
     "shortName": "Foreign Currency Translation in General and Administrative Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R60": {
     "role": "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails",
     "longName": "9955540 - Disclosure - Net Loss Per Share - Computation (Details)",
     "shortName": "Net Loss Per Share - Computation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R61": {
     "role": "http://www.barinthusbio.com/role/NetLossPerShareAdditionalInformationDetails",
     "longName": "9955541 - Disclosure - Net Loss Per Share - Additional Information (Details)",
     "shortName": "Net Loss Per Share - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails",
     "longName": "9955542 - Disclosure - Property and Equipment, Net - Components (Details)",
     "shortName": "Property and Equipment, Net - Components (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.barinthusbio.com/role/PropertyandEquipmentNetAdditionalInformationDetails",
     "longName": "9955543 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails",
     "longName": "9955544 - Disclosure - Intangible Assets, Net (Details)",
     "shortName": "Intangible Assets, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsDetails",
     "longName": "9955545 - Disclosure - Prepaid and Other Current Assets (Details)",
     "shortName": "Prepaid and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
     "longName": "9955546 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "brns:AccruedManufacturingAndClinicalExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "brns:AccruedManufacturingAndClinicalExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails",
     "longName": "9955547 - Disclosure - Grant Income - Additional Information (Details)",
     "shortName": "Grant Income - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredIncomeAddition",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-85",
      "name": "brns:FundingAmountMaximum",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.barinthusbio.com/role/GrantIncomeChangesinDeferredIncomeDetails",
     "longName": "9955548 - Disclosure - Grant Income - Changes in Deferred Income (Details)",
     "shortName": "Grant Income - Changes in Deferred Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:DeferredIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-40",
      "name": "us-gaap:DeferredIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails",
     "longName": "9955549 - Disclosure - Ordinary Shares - Additional Information (Details)",
     "shortName": "Ordinary Shares - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "brns:CommonStockNumberOfVotesPerShare",
      "unitRef": "vote",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "brns:CommonStockNumberOfVotesPerShare",
      "unitRef": "vote",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.barinthusbio.com/role/OrdinarySharesOrdinarySharesforFutureIssuanceDetails",
     "longName": "9955550 - Disclosure - Ordinary Shares - Ordinary Shares for Future Issuance (Details)",
     "shortName": "Ordinary Shares - Ordinary Shares for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "brns:ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "brns:ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.barinthusbio.com/role/DeferredSharesDetails",
     "longName": "9955551 - Disclosure - Deferred Shares (Details)",
     "shortName": "Deferred Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "brns:OrdinarySharesLiquidationPreference",
      "unitRef": "gbp",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "brns:OrdinarySharesLiquidationPreference",
      "unitRef": "gbp",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails",
     "longName": "9955552 - Disclosure - Fair Value - Additional information (Details)",
     "shortName": "Fair Value - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-94",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedWithinLevel3Details",
     "longName": "9955553 - Disclosure - Fair Value - Change in Financial Instruments Classified Within Level 3 (Details)",
     "shortName": "Fair Value - Change in Financial Instruments Classified Within Level 3 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
     "longName": "9955554 - Disclosure - Share-Based Compensation - Additional Information (Details)",
     "shortName": "Share-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "brns:ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails",
     "longName": "9955555 - Disclosure - Share-Based Compensation - Weighted-average Assumptions (Details)",
     "shortName": "Share-Based Compensation - Weighted-average Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-101",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails",
     "longName": "9955556 - Disclosure - Share-Based Compensation - Schedule of Stock Option Activity (Details)",
     "shortName": "Share-Based Compensation - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails",
     "longName": "9955557 - Disclosure - Share-Based Compensation - Schedule of Restricted Stock Units Activity (Details)",
     "shortName": "Share-Based Compensation - Schedule of Restricted Stock Units Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-105",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-105",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.barinthusbio.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
     "longName": "9955558 - Disclosure - Share-Based Compensation - Share Based Compensation Expense (Details)",
     "shortName": "Share-Based Compensation - Share Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-110",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.barinthusbio.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails",
     "longName": "9955559 - Disclosure - Income Taxes - Loss Before Income Taxes (Details)",
     "shortName": "Income Taxes - Loss Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails",
     "longName": "9955560 - Disclosure - Income Taxes - Components of Income Tax Benefit (Expense) (Details)",
     "shortName": "Income Taxes - Components of Income Tax Benefit (Expense) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-114",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails",
     "longName": "9955561 - Disclosure - Income Taxes - Reconciliation to the Effective Tax Rate (Details)",
     "shortName": "Income Taxes - Reconciliation to the Effective Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9955562 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "9955563 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.barinthusbio.com/role/IncomeTaxesChangesintheValuationAllowancerorDeferredTaxAssetsDetails",
     "longName": "9955564 - Disclosure - Income Taxes - Changes in the Valuation Allowance ror Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Changes in the Valuation Allowance ror Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "longName": "9955565 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails",
     "longName": "9955566 - Disclosure - Commitments and Contingencies - Right-of-use Assets, Lease Liabilities and Other Information (Details)",
     "shortName": "Commitments and Contingencies - Right-of-use Assets, Lease Liabilities and Other Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails",
     "longName": "9955567 - Disclosure - Commitments and Contingencies - Maturities of minimum lease liabilities (Details)",
     "shortName": "Commitments and Contingencies - Maturities of minimum lease liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.barinthusbio.com/role/EmployeeBenefitPlansDetails",
     "longName": "9955568 - Disclosure - Employee Benefit Plans (Details)",
     "shortName": "Employee Benefit Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails",
     "longName": "9955569 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-133",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.barinthusbio.com/role/SubsequentEventsDetails",
     "longName": "9955570 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-135",
      "name": "brns:MergerAgreementSchemeExchangeRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-135",
      "name": "brns:MergerAgreementSchemeExchangeRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20251231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r973"
     ]
    },
    "brns_AccountsReceivableStandardPaymentTermsPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "AccountsReceivableStandardPaymentTermsPeriod",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standard payment terms",
        "label": "Accounts Receivable, Standard Payment Terms, Period",
        "documentation": "Accounts Receivable, Standard Payment Terms, Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued bonus",
        "label": "Accrued Bonuses, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll and employee benefits",
        "label": "Accrued Employee Benefits, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of accrued expenses and other current liabilities",
        "label": "Accrued Liabilities And Other Current Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accrued Liabilities And Other Current Liabilities [Text Block]",
        "documentation": "The entire disclosure of the components of accrued liabilities and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total",
        "label": "Accrued Liabilities and Other Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "brns_AccruedManufacturingAndClinicalExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "AccruedManufacturingAndClinicalExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued manufacturing and clinical expenses",
        "label": "Accrued Manufacturing and Clinical Expenses, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing and clinical expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation and impairment charges",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r159",
      "r705"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss \u2013 foreign currency translation adjustments",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r173",
      "r590"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r10",
      "r16",
      "r560",
      "r563",
      "r624",
      "r739",
      "r740",
      "r1148",
      "r1149",
      "r1150",
      "r1206",
      "r1207",
      "r1208",
      "r1209"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r973",
      "r1360"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in-Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r763",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1306",
      "r1363"
     ]
    },
    "brns_AdditionalPaidInCapitalPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "AdditionalPaidInCapitalPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid In Capital [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for Additional paid in capital."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AdrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdrMember",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "American Depositary Shares",
        "label": "ADR [Member]",
        "documentation": "American Depositary Receipt (or American Depositary Share, ADS)."
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1029",
      "r1040",
      "r1050",
      "r1083"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1032",
      "r1043",
      "r1053",
      "r1086"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r1033",
      "r1044",
      "r1054",
      "r1078",
      "r1087",
      "r1091",
      "r1099"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r440",
      "r449"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesAllowanceforcreditlossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable allowance for credit losses",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r282",
      "r289",
      "r292",
      "r293",
      "r1327"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense for intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r187",
      "r326",
      "r333",
      "r884",
      "r890",
      "r891",
      "r893",
      "r895"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.barinthusbio.com/role/NetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issuable for stock options that were excluded from the computation of diluted weighted-average shares outstanding (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "brns_AssetImpairmentChargesExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "AssetImpairmentChargesExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Impairment of long-lived assets",
        "label": "Asset Impairment Charges (Excluding Goodwill)",
        "documentation": "Asset Impairment Charges (Excluding Goodwill)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r97",
      "r162",
      "r195",
      "r197",
      "r198",
      "r237",
      "r251",
      "r269",
      "r273",
      "r283",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r547",
      "r552",
      "r593",
      "r686",
      "r687",
      "r695",
      "r801",
      "r908",
      "r909",
      "r915",
      "r973",
      "r990",
      "r991",
      "r1003",
      "r1242",
      "r1243",
      "r1316"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r169",
      "r195",
      "r197",
      "r198",
      "r283",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r547",
      "r552",
      "r593",
      "r973",
      "r1242",
      "r1243",
      "r1316"
     ]
    },
    "brns_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.barinthusbio.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1013",
      "r1036"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.barinthusbio.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1013",
      "r1036"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://www.barinthusbio.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1013",
      "r1036"
     ]
    },
    "brns_AvideaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "AvideaMember",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Avidea",
        "label": "Avidea [Member]",
        "documentation": "This member stands for Avidea."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "BarinthusBiotherapeuticsPlcShareAwardPlan2021Member",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Barinthus Biotherapeutics plc Share Award Plan 2021",
        "label": "Barinthus Biotherapeutics plc Share Award Plan 2021 [Member]",
        "documentation": "Barinthus Biotherapeutics plc Share Award Plan 2021"
       }
      }
     },
     "auth_ref": []
    },
    "brns_BarinthusLegacyAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "BarinthusLegacyAssetsMember",
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Barinthus legacy assets",
        "label": "Barinthus Legacy Assets [Member]",
        "documentation": "Barinthus Legacy Assets"
       }
      }
     },
     "auth_ref": []
    },
    "brns_BecaonTopcoIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "BecaonTopcoIncMember",
     "presentation": [
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Becaon Topco, Inc",
        "label": "Becaon Topco, Inc [Member]",
        "documentation": "Becaon Topco, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Domain]",
        "label": "Business Combination [Domain]",
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r746",
      "r921",
      "r922",
      "r1294",
      "r1297",
      "r1298"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Axis]",
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r746",
      "r921",
      "r922",
      "r1294",
      "r1297",
      "r1298"
     ]
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction-related fees",
        "label": "Business Combination, Acquisition-Related Cost, Expense",
        "documentation": "Amount of expense for acquisition-related cost incurred to effect business combination. Includes, but is not limited to, finder's fee; advisory, legal, accounting, valuation, and other professional and consulting fees; and general administrative cost, including cost of maintaining internal acquisition department."
       }
      }
     },
     "auth_ref": [
      "r1292",
      "r1296"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in contingent consideration",
        "label": "Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r1194"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum additional contingent consideration payments upon achievement of milestones",
        "label": "Business Combination, Contingent Consideration, Range of Outcomes, Maximum, Amount",
        "documentation": "Maximum amount of estimate for undiscounted range of outcomes in contingent consideration arrangement in business combination."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r539",
      "r927",
      "r929"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1300",
      "r1301"
     ]
    },
    "country_CH": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "CH",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Switzerland",
        "label": "SWITZERLAND"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r157",
      "r885"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of the period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of the period",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r64",
      "r192"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r64"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesCashandcashequivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r1135",
      "r1326"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover",
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r163",
      "r164",
      "r165",
      "r195",
      "r198",
      "r226",
      "r227",
      "r229",
      "r231",
      "r239",
      "r240",
      "r283",
      "r354",
      "r356",
      "r357",
      "r358",
      "r361",
      "r362",
      "r366",
      "r367",
      "r369",
      "r370",
      "r372",
      "r374",
      "r377",
      "r378",
      "r381",
      "r384",
      "r390",
      "r593",
      "r752",
      "r753",
      "r754",
      "r755",
      "r763",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r789",
      "r810",
      "r834",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r1122",
      "r1200",
      "r1201",
      "r1210"
     ]
    },
    "brns_ClinicalTrialCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ClinicalTrialCostsPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical trial costs",
        "label": "Clinical Trial Costs [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for Clinical Trial costs."
       }
      }
     },
     "auth_ref": []
    },
    "brns_ClywedogCapitalStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ClywedogCapitalStockMember",
     "presentation": [
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clywedog Capital Stock",
        "label": "Clywedog Capital Stock [Member]",
        "documentation": "Clywedog Capital Stock"
       }
      }
     },
     "auth_ref": []
    },
    "brns_ClywedogTherapeuticsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ClywedogTherapeuticsInc.Member",
     "presentation": [
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clywedog Therapeutics, Inc.",
        "label": "Clywedog Therapeutics, Inc. [Member]",
        "documentation": "Clywedog Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "brns_CoalitionForEpidemicPreparednessInnovationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "CoalitionForEpidemicPreparednessInnovationsMember",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Coalition For Epidemic Preparedness Innovations",
        "label": "Coalition For Epidemic Preparedness Innovations [Member]",
        "documentation": "Coalition For Epidemic Preparedness Innovations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 16)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r87",
      "r698",
      "r788"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r347",
      "r348",
      "r865",
      "r1236",
      "r1238"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "calculation": {
      "http://www.barinthusbio.com/role/OrdinarySharesOrdinarySharesforFutureIssuanceDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesOrdinarySharesforFutureIssuanceDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Number of shares reserved for issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "verboseLabel": "Ordinary\u00a0Shares",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r993",
      "r994",
      "r995",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1206",
      "r1207",
      "r1209",
      "r1306",
      "r1359",
      "r1363"
     ]
    },
    "brns_CommonStockNumberOfVotesPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "CommonStockNumberOfVotesPerShare",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of votes per common share (in votes)",
        "label": "Common Stock Number of Votes Per Share",
        "documentation": "The number of votes that each common share is entitled."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, nominal value (in gbp per share)",
        "verboseLabel": "Ordinary shares, nominal value (per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r789"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r49",
      "r789",
      "r807",
      "r1363",
      "r1364"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, \u00a30.000025 nominal value; 40,848,893 shares authorized, issued and outstanding (December\u00a031, 2024: authorized, issued and outstanding: 40,234,663)",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r367",
      "r373",
      "r699",
      "r973"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1074"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/EmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plans",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r1250",
      "r1251",
      "r1252",
      "r1253"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Components of Deferred Tax Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r175",
      "r177",
      "r183",
      "r684",
      "r712",
      "r714"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Comprehensive loss/(gain) attributable to noncontrolling interest",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r32",
      "r37",
      "r175",
      "r177",
      "r182",
      "r683",
      "r712",
      "r713"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r82",
      "r175",
      "r177",
      "r181",
      "r682",
      "r712"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r280",
      "r747",
      "r748",
      "r864",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r280",
      "r747",
      "r748",
      "r864",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of credit risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r592"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r864",
      "r900",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r864",
      "r900",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217"
     ]
    },
    "brns_ConcentrationRiskThresholdPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ConcentrationRiskThresholdPercentage",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk Threshold Percentage",
        "documentation": "For an entity that discloses a concentration risk threshold Percentage in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]",
        "documentation": "Information by consolidated entity or group of entities."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r128",
      "r196",
      "r205",
      "r547",
      "r548",
      "r551",
      "r552",
      "r553",
      "r633",
      "r690",
      "r870",
      "r1131",
      "r1132",
      "r1133",
      "r1241",
      "r1244",
      "r1245"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]",
        "documentation": "Entity or group of entities consolidated into reporting entity."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r128",
      "r196",
      "r205",
      "r547",
      "r548",
      "r551",
      "r552",
      "r553",
      "r633",
      "r690",
      "r870",
      "r1131",
      "r1132",
      "r1133",
      "r1241",
      "r1244",
      "r1245"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r897"
     ]
    },
    "us-gaap_ContingentLiabilityReserveEstimatePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContingentLiabilityReserveEstimatePolicy",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent liabilities",
        "label": "Contingent Liability Reserve Estimate, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r195",
      "r203",
      "r204",
      "r363",
      "r379",
      "r631",
      "r639",
      "r693",
      "r887",
      "r888",
      "r889",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1302",
      "r1303",
      "r1304",
      "r1305"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditLossFinancialInstrumentPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit losses",
        "label": "Credit Loss, Financial Instrument [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1129",
      "r1198",
      "r1203"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current income tax benefit/(expense):",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1021",
      "r1110"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1021",
      "r1110"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1023",
      "r1112"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1023",
      "r1112"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1025",
      "r1114"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1023",
      "r1112"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1016",
      "r1105"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1017",
      "r1106"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1017",
      "r1106"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r1015",
      "r1104"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1015",
      "r1104"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r1015",
      "r1104"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1018",
      "r1107"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1020",
      "r1109"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1020",
      "r1109"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1021",
      "r1110"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1024",
      "r1113"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1022",
      "r1111"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1019",
      "r1108"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of prepaid and other current assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1198",
      "r1203",
      "r1291"
     ]
    },
    "us-gaap_DeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeChangesinDeferredIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Deferred Income",
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r1126",
      "r1328",
      "r1356"
     ]
    },
    "us-gaap_DeferredIncomeAddition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeAddition",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/GrantIncomeChangesinDeferredIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payments received",
        "label": "Deferred Income, Addition",
        "documentation": "Amount of increase in deferred income not accounted for under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r1328",
      "r1356"
     ]
    },
    "us-gaap_DeferredIncomeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income",
        "label": "Deferred Income, Current",
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "brns_DeferredIncomeForeignExchangeTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "DeferredIncomeForeignExchangeTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeChangesinDeferredIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign exchange translation",
        "label": "Deferred Income, Foreign Exchange Translation Gain (Loss)",
        "documentation": "Deferred Income, Foreign Exchange Translation Gain (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/GrantIncomeChangesinDeferredIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income recognized related to the Funding Agreement",
        "negatedTerseLabel": "Other operating income recognized related to the Funding Agreement",
        "label": "Deferred Income, Revenue Recognized",
        "documentation": "Amount of revenue recognized previously reported as deferred income not accounted for under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r1328",
      "r1356"
     ]
    },
    "us-gaap_DeferredIncomeRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeRollForward",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeChangesinDeferredIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Income [Roll Forward]",
        "label": "Deferred Income [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of changes in deferred income",
        "label": "Deferred Income [Table Text Block]",
        "documentation": "Tabular disclosure of deferred income not accounted for under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r1328",
      "r1356"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax benefit",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r105",
      "r1198",
      "r1203"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax benefit:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r86",
      "r471"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liability, net",
        "negatedTotalLabel": "Total deferred tax, net",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r456",
      "r696"
     ]
    },
    "brns_DeferredSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "DeferredSharesMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred Shares",
        "label": "Deferred Shares [Member]",
        "documentation": "Represents information pertaining to deferred shares."
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "DeferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.barinthusbio.com/role/DeferredSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred shares, nominal value (in gbp per share)",
        "label": "Deferred Stock, Par Or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of deferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "DeferredStockSharesAuthorized",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred shares, authorized (in shares)",
        "label": "Deferred Stock, Shares Authorized",
        "documentation": "The maximum number of deferred shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "DeferredStockSharesIssued",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred shares, issued (in shares)",
        "label": "Deferred Stock, Shares Issued",
        "documentation": "Total number of deferred shares of an entity that have been sold or granted to shareholders"
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "DeferredStockSharesOutstanding",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred shares, outstanding (in shares)",
        "label": "Deferred Stock, Shares Outstanding",
        "documentation": "Number of shares of deferred stock outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredStockValueIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "DeferredStockValueIssued",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred A shares, \u00a31 nominal value; 63,443 shares authorized, issued and outstanding (December\u00a031, 2024: authorized, issued and outstanding: 63,443)",
        "label": "Deferred Stock, Value Issued",
        "documentation": "Aggregate par or stated value of issued deferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible amortization",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax asset",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized Research and Development expenditure",
        "verboseLabel": "Deferred tax assets for capitalized research and development expenditure",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "brns_DeferredTaxAssetsLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "DeferredTaxAssetsLeasingArrangements",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets, Leasing Arrangements",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1285"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credit carryforwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accruals",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesChangesintheValuationAllowancerorDeferredTaxAssetsDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance",
        "periodStartLabel": "Valuations allowance at beginning of year",
        "periodEndLabel": "Valuation allowance at end of year",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Intangible assets",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right-of-use lease asset",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Depreciation",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Undistributed earnings of subsidiaries",
        "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences."
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer contribution",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r26",
      "r186",
      "r890",
      "r891",
      "r893",
      "r895"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r188",
      "r237",
      "r256",
      "r273",
      "r890",
      "r908",
      "r909"
     ]
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed technology",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1233",
      "r1234",
      "r1299"
     ]
    },
    "brns_DirectResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "DirectResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total direct research and development expenses",
        "label": "Direct Research And Development Expense",
        "documentation": "Direct Research And Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "brns_DirectResearchAndDevelopmentExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "DirectResearchAndDevelopmentExpensesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Direct research and development expenses:",
        "label": "Direct Research and Development Expenses [Abstract]",
        "documentation": "Direct Research and Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r404",
      "r435",
      "r436",
      "r438",
      "r924"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1013",
      "r1036"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1013",
      "r1036",
      "r1079"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Tax Jurisdiction",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to ordinary shareholders, basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r184",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r224",
      "r226",
      "r229",
      "r230",
      "r231",
      "r236",
      "r365",
      "r439",
      "r488",
      "r544",
      "r571",
      "r572",
      "r685",
      "r715",
      "r899"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to ordinary shareholders, diluted (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r184",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r226",
      "r229",
      "r230",
      "r231",
      "r236",
      "r365",
      "r439",
      "r488",
      "r544",
      "r571",
      "r572",
      "r685",
      "r715",
      "r899"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r233"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r232",
      "r234",
      "r235"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rates on cash, cash equivalents and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1312"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r926"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r200",
      "r459",
      "r479",
      "r926"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r926",
      "r1198",
      "r1204",
      "r1283"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of change in tax laws or rates enacted in the current period",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r926",
      "r1198",
      "r1204",
      "r1283"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective Income Tax Rate Reconciliation [Line Items]",
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r460",
      "r926"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-taxable or non-deductible items",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465",
      "r1198",
      "r1204",
      "r1283"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r926",
      "r1198",
      "r1204",
      "r1283",
      "r1284"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Share-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1282",
      "r1283",
      "r1284"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1282",
      "r1283",
      "r1284"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective Income Tax Rate Reconciliation [Table]",
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r460",
      "r926"
     ]
    },
    "brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credits, Research And Development",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development tax credit."
       }
      }
     },
     "auth_ref": []
    },
    "brns_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credits, Research And Development, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Credits, Research And Development, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average period over which unrecognized compensation cost is expected to be recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1280"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1280"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279"
     ]
    },
    "brns_EnterpriseManagementIncentiveShareOptionSchemeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "EnterpriseManagementIncentiveShareOptionSchemeMember",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Enterprise Management Incentive Share Option Scheme",
        "label": "Enterprise Management Incentive Share Option Scheme [Member]",
        "documentation": "Information pertaining to the Enterprise Management Incentive Share Option Scheme."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r1121"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1120"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r144",
      "r146",
      "r147",
      "r178",
      "r179",
      "r180",
      "r206",
      "r207",
      "r208",
      "r210",
      "r217",
      "r219",
      "r221",
      "r238",
      "r284",
      "r285",
      "r340",
      "r364",
      "r391",
      "r439",
      "r477",
      "r478",
      "r485",
      "r486",
      "r487",
      "r489",
      "r543",
      "r544",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r570",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r610",
      "r612",
      "r624",
      "r711",
      "r739",
      "r740",
      "r741",
      "r763",
      "r834"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1072"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1029",
      "r1040",
      "r1050",
      "r1083"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r1026",
      "r1037",
      "r1047",
      "r1080"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "brns_ExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ExpensesMember",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses",
        "label": "Expenses [Member]",
        "documentation": "Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "brns_ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period",
        "label": "Expiration Of Share Based Compensation Plan From Date Of Initial Issuance",
        "documentation": "The duration of grants awarded under a share-based compensation plan."
       }
      }
     },
     "auth_ref": []
    },
    "brns_FacilityRelatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "FacilityRelatedMember",
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility related",
        "label": "Facility Related [Member]",
        "documentation": "Facility Related"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r573",
      "r579",
      "r581",
      "r582",
      "r583",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r681",
      "r963",
      "r968"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedWithinLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r584"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of financial instruments carried at fair value and classified within Level 3",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r580",
      "r584"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedWithinLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value recognized in net loss",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r584"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedWithinLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign exchange translation recognized in other comprehensive loss",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r584"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Settlement payments related to contingent consideration liability",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r584"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails",
      "http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedWithinLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration liability",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r584"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r1308"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesFairvaluemeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r584"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedWithinLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement in which other comprehensive income (OCI) is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r584"
     ]
    },
    "brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationYearSix",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2031",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Six",
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, Year Six"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Estimated useful life of intangible assets",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated amortization for amortizable intangible assets",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r309",
      "r332",
      "r884"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r879",
      "r884"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2030",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r879",
      "r884"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r879",
      "r884"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r879",
      "r884"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r879",
      "r884"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r335",
      "r336",
      "r645",
      "r646",
      "r746",
      "r879",
      "r884",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross amount of amortizable intangible assets",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r332",
      "r646",
      "r884"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r332",
      "r335",
      "r336",
      "r338",
      "r645",
      "r879",
      "r884",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r335",
      "r336",
      "r746",
      "r879",
      "r884",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Effects",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r460"
     ]
    },
    "us-gaap_ForeignCurrencyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency [Abstract]",
        "label": "Foreign Currency [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation in General and Administrative Expenses",
        "label": "Foreign Currency Disclosure [Text Block]",
        "documentation": "The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r609",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1124"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesForeigncurrencytranslationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net foreign exchange (loss) gain",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r598",
      "r599",
      "r600",
      "r601",
      "r831"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized foreign exchange loss",
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r808",
      "r1001",
      "r1310",
      "r1311",
      "r1362"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_ForeignTaxJurisdictionOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignTaxJurisdictionOtherMember",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other foreign",
        "label": "Foreign Tax Jurisdiction, Other [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile, classified as other."
       }
      }
     },
     "auth_ref": [
      "r926",
      "r1196",
      "r1287"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1033",
      "r1044",
      "r1054",
      "r1087"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1033",
      "r1044",
      "r1054",
      "r1087"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1033",
      "r1044",
      "r1054",
      "r1087"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1033",
      "r1044",
      "r1054",
      "r1087"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1033",
      "r1044",
      "r1054",
      "r1087"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "brns_FundingAmountMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "FundingAmountMaximum",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum funding amount",
        "label": "Funding Amount, Maximum",
        "documentation": "Funding Amount, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture and equipment",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "GB",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails",
      "http://www.barinthusbio.com/role/SegmentinformationLongLivedAssetsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.K.",
        "verboseLabel": "United Kingdom",
        "label": "UNITED KINGDOM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Profit on sale of property and equipment",
        "verboseLabel": "Gain on sale of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r812"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r321",
      "r914"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment",
        "verboseLabel": "Impairment of goodwill",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r311",
      "r317",
      "r321",
      "r323",
      "r542",
      "r914",
      "r964"
     ]
    },
    "us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GuaranteesIndemnificationsAndWarrantiesPolicies",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantees and indemnifications",
        "label": "Guarantees, Indemnifications and Warranties Policies [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1013",
      "r1036"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r1195",
      "r1235"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charge",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r70",
      "r965"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r72"
     ]
    },
    "brns_InLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "InLicenseAgreementsMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-License Agreements",
        "label": "In-License Agreements [Member]",
        "documentation": "Represents the information pertaining to In-License Agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United Kingdom",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r199",
      "r458"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.barinthusbio.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income tax",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r90",
      "r96",
      "r686",
      "r688",
      "r707",
      "r892",
      "r894",
      "r896",
      "r903",
      "r908",
      "r1212",
      "r1220",
      "r1221",
      "r1222",
      "r1223"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r199",
      "r458"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r343",
      "r344",
      "r554",
      "r555",
      "r556",
      "r557",
      "r576",
      "r580",
      "r584",
      "r594",
      "r595",
      "r596",
      "r736",
      "r738",
      "r818",
      "r879",
      "r881",
      "r927",
      "r928",
      "r961",
      "r962",
      "r966",
      "r971",
      "r1293",
      "r1295",
      "r1329"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r554",
      "r555",
      "r556",
      "r557",
      "r576",
      "r580",
      "r584",
      "r594",
      "r595",
      "r596",
      "r736",
      "r738",
      "r818",
      "r879",
      "r881",
      "r927",
      "r928",
      "r961",
      "r962",
      "r966",
      "r971",
      "r1293",
      "r1295",
      "r1329"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r459",
      "r460",
      "r469",
      "r475",
      "r926",
      "r1288"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r459",
      "r460",
      "r469",
      "r475",
      "r926",
      "r1288"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r200",
      "r453",
      "r459",
      "r466",
      "r467",
      "r468",
      "r470",
      "r474",
      "r480",
      "r482",
      "r483",
      "r484",
      "r692",
      "r745",
      "r757",
      "r926"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax benefit",
        "negatedTotalLabel": "Total income tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r106",
      "r195",
      "r220",
      "r221",
      "r237",
      "r259",
      "r273",
      "r457",
      "r459",
      "r481",
      "r716",
      "r892",
      "r894",
      "r896",
      "r926"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Changes in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r926",
      "r1283"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Effect of change in tax laws or rates enacted in the current period",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r459",
      "r462",
      "r926"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r926"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-taxable or non-deductible items",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465",
      "r1283"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r926",
      "r1283",
      "r1284"
     ]
    },
    "brns_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "documentation": "Income Taxes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "brns_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "documentation": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r1194"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income",
        "label": "Increase (Decrease) in Deferred Revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1128",
      "r1194"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development incentives receivable",
        "label": "Increase (Decrease) in Research and Development Incentives Receivable",
        "documentation": "Amount of increase (decrease) in research and development incentives receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "brns_IndirectResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "IndirectResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total indirect research and development expenses",
        "label": "Indirect Research And Development Expense",
        "documentation": "Indirect Research And Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "brns_IndirectResearchAndDevelopmentExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "IndirectResearchAndDevelopmentExpensesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indirect research and development expenses:",
        "label": "Indirect Research and Development Expenses [Abstract]",
        "documentation": "Indirect Research and Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1033",
      "r1044",
      "r1054",
      "r1078",
      "r1087",
      "r1091",
      "r1099"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1103"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1103"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1103"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets, Net",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r337",
      "r339",
      "r878",
      "r879"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets acquired through business combinations",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r642",
      "r643",
      "r645",
      "r898",
      "r1225"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent and licensing costs",
        "label": "Intangible Assets, Costs Incurred to Renew or Extend, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the treatment of costs incurred to renew or extend the term of a recognized intangible asset."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r879"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r1231",
      "r1232"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r892",
      "r896",
      "r1152"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r254",
      "r273",
      "r908",
      "r1151"
     ]
    },
    "brns_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment",
        "label": "Laboratory Equipment [Member]",
        "documentation": "This member stands for laboratory equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r972"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Costs",
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvement expense",
        "label": "Leasehold Improvements, Gross",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r623"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "brns_LesseeOperatingLeaseExtendedTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "LesseeOperatingLeaseExtendedTerm",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional lease term",
        "label": "Lessee Operating Lease, Extended Term",
        "documentation": "Term of lessee's operating lease extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of maturities of minimum lease liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r1199",
      "r1205",
      "r1325"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r1199",
      "r1205",
      "r1325"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r1199",
      "r1205",
      "r1325"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r1199",
      "r1205",
      "r1325"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r1199",
      "r1205",
      "r1325"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r1199",
      "r1205",
      "r1325"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r1199",
      "r1205",
      "r1325"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of right-of-use assets, lease liabilities and other information",
        "label": "Lessee Operating Lease Right of Use asset and Other Information [Table Text Block]",
        "documentation": "Tabular disclosure for Company's right-of-use asset and lease liability and other information."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r47",
      "r195",
      "r197",
      "r198",
      "r283",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r548",
      "r552",
      "r553",
      "r593",
      "r787",
      "r902",
      "r915",
      "r1003",
      "r1242",
      "r1316",
      "r1317"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r89",
      "r702",
      "r973",
      "r990",
      "r991",
      "r1198",
      "r1202",
      "r1224",
      "r1309"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r156",
      "r195",
      "r197",
      "r198",
      "r283",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r548",
      "r552",
      "r553",
      "r593",
      "r973",
      "r1242",
      "r1316",
      "r1317"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License revenue",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1248",
      "r1249"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Lived Assets",
        "label": "Long-Lived Assets by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "stpr_MD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "MD",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maryland",
        "label": "MARYLAND"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r917",
      "r920",
      "r983",
      "r988",
      "r1328",
      "r1330",
      "r1331",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1354",
      "r1355",
      "r1357",
      "r1358"
     ]
    },
    "brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum aggregate nominal amount of shares authorized to be allotted free from pre-emption rights",
        "label": "Maximum Aggregate Nominal Amount Of Shares Authorized To Be Allotted Free From Statutory Pre-emption Rights",
        "documentation": "Amount of maximum aggregate nominal amount of shares that the board of directors are authorized to allot free from statutory Pre-emption rights."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r111",
      "r113",
      "r114",
      "r116",
      "r134",
      "r136",
      "r137",
      "r142",
      "r143",
      "r246",
      "r349",
      "r350",
      "r351",
      "r352",
      "r398",
      "r430",
      "r431",
      "r432",
      "r450",
      "r574",
      "r640",
      "r735",
      "r737",
      "r744",
      "r779",
      "r780",
      "r843",
      "r845",
      "r847",
      "r848",
      "r850",
      "r859",
      "r860",
      "r862",
      "r863",
      "r876",
      "r877",
      "r913",
      "r916",
      "r923",
      "r927",
      "r929",
      "r930",
      "r967",
      "r968",
      "r969",
      "r970",
      "r984",
      "r1246",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "brns_MergerAgreementExtensionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "MergerAgreementExtensionPeriod",
     "presentation": [
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger agreement extension period",
        "label": "Merger Agreement, Extension Period",
        "documentation": "Merger Agreement, Extension Period"
       }
      }
     },
     "auth_ref": []
    },
    "brns_MergerAgreementMergerExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "MergerAgreementMergerExchangeRatio",
     "presentation": [
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger exchange ratio",
        "label": "Merger Agreement, Merger Exchange Ratio",
        "documentation": "Merger Agreement, Merger Exchange Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "brns_MergerAgreementSchemeExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "MergerAgreementSchemeExchangeRatio",
     "presentation": [
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scheme exchange ratio",
        "label": "Merger Agreement, Scheme Exchange Ratio",
        "documentation": "Merger Agreement, Scheme Exchange Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r111",
      "r113",
      "r114",
      "r116",
      "r134",
      "r136",
      "r137",
      "r142",
      "r143",
      "r246",
      "r349",
      "r350",
      "r351",
      "r352",
      "r398",
      "r430",
      "r431",
      "r432",
      "r450",
      "r574",
      "r640",
      "r735",
      "r737",
      "r744",
      "r779",
      "r780",
      "r843",
      "r845",
      "r847",
      "r848",
      "r850",
      "r859",
      "r860",
      "r862",
      "r863",
      "r876",
      "r877",
      "r913",
      "r916",
      "r923",
      "r927",
      "r929",
      "r930",
      "r967",
      "r968",
      "r969",
      "r984",
      "r1246",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r88",
      "r195",
      "r197",
      "r198",
      "r283",
      "r354",
      "r356",
      "r357",
      "r358",
      "r361",
      "r362",
      "r701",
      "r791",
      "r1309"
     ]
    },
    "us-gaap_MinorityInterestLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterestLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest [Line Items]",
        "label": "Noncontrolling Interest [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest percentage",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Controlling interest percentage",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "brns_MinorityInterestPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "MinorityInterestPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest",
        "label": "Minority Interest [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for Minority (Non Controlling) interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterestTable",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest [Table]",
        "label": "Noncontrolling Interest [Table]",
        "documentation": "Disclosure of information about noncontrolling interest, including, but not limited to, name of subsidiary, ownership percentage held by parent, ownership percentage held by noncontrolling owner, amount of noncontrolling interest and its location in statement of financial position, explanation of increase (decrease) in noncontrolling interest, noncontrolling interest share of net income (loss) of subsidiary and its location in statement of income, amount of noncontrolling interest represented by preferred stock, description and dividend requirement of preferred stock, and nature of noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r34",
      "r53",
      "r57"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r917",
      "r920",
      "r983",
      "r988",
      "r1328",
      "r1330",
      "r1331",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1354",
      "r1355",
      "r1357",
      "r1358"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by/(used) in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r66"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to Barinthus Biotherapeutics plc shareholders",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r66",
      "r91",
      "r147",
      "r154",
      "r174",
      "r176",
      "r180",
      "r195",
      "r197",
      "r198",
      "r202",
      "r209",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r220",
      "r221",
      "r228",
      "r283",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r365",
      "r368",
      "r371",
      "r375",
      "r439",
      "r488",
      "r544",
      "r572",
      "r593",
      "r710",
      "r809",
      "r832",
      "r833",
      "r892",
      "r894",
      "r896",
      "r1001",
      "r1242"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss attributable to noncontrolling interest",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r83",
      "r174",
      "r176",
      "r217",
      "r220",
      "r221",
      "r709",
      "r1150"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "brns_NonCashInterestExpenseOnConvertibleLoanNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "NonCashInterestExpenseOnConvertibleLoanNotes",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-cash interest expense",
        "label": "Non-Cash Interest Expense On Convertible Loan Notes",
        "documentation": "Amount of non-cash interest expense on convertible loan notes."
       }
      }
     },
     "auth_ref": []
    },
    "brns_NonCashLeaseExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "NonCashLeaseExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expenses",
        "label": "Non-Cash Lease Expenses",
        "documentation": "The amount of non-cash lease expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r1033",
      "r1044",
      "r1054",
      "r1078",
      "r1087"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r391",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1363"
     ]
    },
    "us-gaap_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-lived assets",
        "label": "Long-Lived Assets",
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "brns_NumberOfDepositarySharesPerShareOfCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "NumberOfDepositarySharesPerShareOfCommonStock",
     "presentation": [
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of depositary shares per share of common stock (in shares)",
        "label": "Number Of Depositary Shares Per Share Of Common Stock",
        "documentation": "Number Of Depositary Shares Per Share Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "brns_NumberOfGeographicRegionsInWhichEntityOperates": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "NumberOfGeographicRegionsInWhichEntityOperates",
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of geographic regions where the company operates",
        "label": "Number Of Geographic Regions In Which Entity Operates",
        "documentation": "Number Of Geographic Regions In Which Entity Operates"
       }
      }
     },
     "auth_ref": []
    },
    "brns_NumberOfNewSubsidiaries": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "NumberOfNewSubsidiaries",
     "presentation": [
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of new subsidiaries",
        "label": "Number Of New Subsidiaries",
        "documentation": "Number Of New Subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r909",
      "r1219"
     ]
    },
    "brns_NumberOfReportableSegmentsNotDisclosedFlag": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "NumberOfReportableSegmentsNotDisclosedFlag",
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Reportable Segments Not Disclosed Flag",
        "label": "Number Of Reportable Segments Not Disclosed Flag",
        "documentation": "Number Of Reportable Segments Not Disclosed Flag"
       }
      }
     },
     "auth_ref": []
    },
    "brns_NumberOfSquareFeetUnderLeaseAgreement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "NumberOfSquareFeetUnderLeaseAgreement",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Size of space under lease agreement (in square feet)",
        "label": "Number Of Square Feet Under Lease Agreement",
        "documentation": "Represents the information pertaining to number of Square Feet Under Lease Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r892",
      "r896",
      "r903",
      "r1212",
      "r1220",
      "r1221",
      "r1222",
      "r1223"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r972"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use asset impairment charge",
        "label": "Operating Lease, Impairment Loss",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1313"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability - current",
        "verboseLabel": "Lease liability, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability - non-current",
        "verboseLabel": "Lease liability, non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r619"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use assets, net",
        "verboseLabel": "Right-of-use asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r972"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term (years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r972"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "brns_OrdinarySharesLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "OrdinarySharesLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/DeferredSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, liquidation preference",
        "label": "Ordinary Shares, Liquidation Preference",
        "documentation": "The amount of liquidation preference on ordinary shares to be paid after which the deferred shares have the entitlement to receive out of the assets of the Company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Business and Basis of Presentation",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r148",
      "r149",
      "r151",
      "r749",
      "r750"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r161",
      "r694",
      "r909",
      "r990",
      "r991",
      "r1003"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r973"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive gain/(loss) \u2013 foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustments",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r711"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income/(expense):",
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "brns_OtherIndirectCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "OtherIndirectCostsMember",
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other indirect costs",
        "label": "Other Indirect Costs [Member]",
        "documentation": "Other Indirect Costs"
       }
      }
     },
     "auth_ref": []
    },
    "brns_OtherInformationLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "OtherInformationLesseeAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other information",
        "label": "Other Information, Lessee [Abstract]",
        "documentation": "Other Information, Lessee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r960"
     ]
    },
    "us-gaap_OtherOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income",
        "label": "Other Operating Income",
        "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_OtherOperatingIncomeAndExpenseTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherOperatingIncomeAndExpenseTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant Income",
        "label": "Other Operating Income and Expense [Text Block]",
        "documentation": "The entire disclosure for other operating income and other operating expense items."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "brns_OtherOperatingIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "OtherOperatingIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Operating Income",
        "label": "Other Operating Income, Policy [Policy Text Block]",
        "documentation": "Other Operating Income, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1042",
      "r1052",
      "r1085"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1045",
      "r1055",
      "r1088"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1045",
      "r1055",
      "r1088"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "brns_OxfordUniversityInnovationLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "OxfordUniversityInnovationLimitedMember",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oxford University Innovation Limited (OUI)",
        "label": "Oxford University Innovation Limited [Member]",
        "documentation": "Represents the information pertaining to Oxford University Innovation Limited."
       }
      }
     },
     "auth_ref": []
    },
    "brns_OxfordUniversityInnovationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "OxfordUniversityInnovationMember",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oxford University Innovation",
        "label": "Oxford University Innovation [Member]",
        "documentation": "Represent information related to Oxford University Innovation."
       }
      }
     },
     "auth_ref": []
    },
    "brns_OxfordshireMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "OxfordshireMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oxfordshire",
        "label": "Oxfordshire [Member]",
        "documentation": "Oxfordshire"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ParentMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stockholders\u2019 equity attributable to Barinthus Biotherapeutics plc stockholders",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of future royalties for direct sales of a covered product",
        "label": "Percentage of Future Royalties for Direct Sales of Covered Product , License Agreement",
        "documentation": "Percentage of future royalties for direct sales of a covered product under the In-License Agreements."
       }
      }
     },
     "auth_ref": []
    },
    "brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net payments received for allowable sublicenses of technology developed",
        "label": "Percentage Of Net Payments Received For Allowable Sublicenses Of Technology Developed License Agreement",
        "documentation": "Percentage of net payments received for allowable sublicenses of technology developed under the In-License Agreements."
       }
      }
     },
     "auth_ref": []
    },
    "brns_PercentageOfSharesNecessaryToExercisePreemptiveRights": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "PercentageOfSharesNecessaryToExercisePreemptiveRights",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of ordinary shares present to exercise preemptive rights",
        "label": "Percentage Of Shares Necessary To Exercise Preemptive Rights",
        "documentation": "The minimum percentage of shares required to exercise preemptive rights."
       }
      }
     },
     "auth_ref": []
    },
    "brns_PeriodOfPreemptiveRightsToBeExercised": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "PeriodOfPreemptiveRightsToBeExercised",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum period to exercise preemptive rights",
        "label": "Period Of Preemptive Rights To Be Exercised",
        "documentation": "The period allowed to exercise preemptive rights."
       }
      }
     },
     "auth_ref": []
    },
    "brns_PersonnelRelatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "PersonnelRelatedMember",
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Personnel-related (including share-based compensation)",
        "label": "Personnel Related [Member]",
        "documentation": "Personnel Related"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r377"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid and Other Current Assets",
        "label": "Prepaid Expense and Other Assets, Current [Text Block]",
        "documentation": "The entire disclosure on prepaid expense and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r307",
      "r308",
      "r886"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issue of ordinary shares, net of issuance costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of shares from the exercise of stock options",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r14"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of property and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r140",
      "r276",
      "r644",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r882",
      "r891",
      "r894",
      "r896",
      "r917",
      "r918",
      "r982",
      "r984",
      "r985",
      "r989",
      "r992",
      "r1127",
      "r1134",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1239",
      "r1240",
      "r1328",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1354",
      "r1355",
      "r1357",
      "r1358"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r140",
      "r276",
      "r644",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r882",
      "r891",
      "r894",
      "r896",
      "r917",
      "r918",
      "r982",
      "r984",
      "r985",
      "r989",
      "r992",
      "r1127",
      "r1134",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1239",
      "r1240",
      "r1328",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1354",
      "r1355",
      "r1357",
      "r1358"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r154",
      "r174",
      "r176",
      "r189",
      "r195",
      "r197",
      "r198",
      "r202",
      "r209",
      "r217",
      "r220",
      "r221",
      "r283",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r365",
      "r439",
      "r488",
      "r544",
      "r546",
      "r549",
      "r550",
      "r572",
      "r593",
      "r686",
      "r688",
      "r708",
      "r762",
      "r809",
      "r832",
      "r833",
      "r958",
      "r959",
      "r1002",
      "r1150",
      "r1242"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r623"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r101",
      "r103",
      "r104"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, at cost",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r158",
      "r706"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "verboseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r623",
      "r691",
      "r706",
      "r973"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r101",
      "r103",
      "r704"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetTables",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of property and equipment",
        "terseLabel": "Schedule of property and equipment, net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r623"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Useful Life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r111",
      "r113",
      "r114",
      "r116",
      "r134",
      "r136",
      "r137",
      "r142",
      "r143",
      "r246",
      "r349",
      "r350",
      "r351",
      "r352",
      "r395",
      "r398",
      "r430",
      "r431",
      "r432",
      "r438",
      "r450",
      "r574",
      "r637",
      "r638",
      "r640",
      "r735",
      "r737",
      "r744",
      "r779",
      "r780",
      "r843",
      "r845",
      "r847",
      "r848",
      "r850",
      "r859",
      "r860",
      "r862",
      "r863",
      "r876",
      "r877",
      "r913",
      "r916",
      "r923",
      "r927",
      "r929",
      "r930",
      "r967",
      "r968",
      "r969",
      "r970",
      "r984",
      "r995",
      "r1237",
      "r1246",
      "r1307",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r111",
      "r113",
      "r114",
      "r116",
      "r134",
      "r136",
      "r137",
      "r142",
      "r143",
      "r246",
      "r349",
      "r350",
      "r351",
      "r352",
      "r395",
      "r398",
      "r430",
      "r431",
      "r432",
      "r438",
      "r450",
      "r574",
      "r637",
      "r638",
      "r640",
      "r735",
      "r737",
      "r744",
      "r779",
      "r780",
      "r843",
      "r845",
      "r847",
      "r848",
      "r850",
      "r859",
      "r860",
      "r862",
      "r863",
      "r876",
      "r877",
      "r913",
      "r916",
      "r923",
      "r927",
      "r929",
      "r930",
      "r967",
      "r968",
      "r969",
      "r970",
      "r984",
      "r995",
      "r1237",
      "r1246",
      "r1307",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1026",
      "r1037",
      "r1047",
      "r1080"
     ]
    },
    "us-gaap_RegulatoryIncomeTaxesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RegulatoryIncomeTaxesPolicy",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Regulatory Income Taxes, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, including investment tax credits, and the related regulatory treatment (for example, whether deferred income tax accounting - normalization - is allowed in rate making)."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related and Nonrelated Parties [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r201",
      "r202",
      "r281",
      "r396",
      "r397",
      "r628",
      "r629",
      "r697",
      "r703",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r806",
      "r842",
      "r1361"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related parties",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r201",
      "r202",
      "r628",
      "r629",
      "r630",
      "r631",
      "r697",
      "r703",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r806",
      "r842"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts of related party transactions",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r201",
      "r202",
      "r628",
      "r629",
      "r1315"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r201",
      "r202",
      "r1315"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r201",
      "r202",
      "r281",
      "r628",
      "r629",
      "r631",
      "r813",
      "r814",
      "r818"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related and Nonrelated Parties [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r201",
      "r202",
      "r281",
      "r396",
      "r397",
      "r628",
      "r629",
      "r697",
      "r703",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r806",
      "r842",
      "r1315",
      "r1361"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r626",
      "r627",
      "r629",
      "r632",
      "r758",
      "r759",
      "r760",
      "r815",
      "r817",
      "r818",
      "r839",
      "r841"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r195",
      "r203",
      "r204",
      "r363",
      "r379",
      "r631",
      "r639",
      "r693",
      "r887",
      "r888",
      "r889",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1302",
      "r1303",
      "r1304",
      "r1305"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "totalLabel": "Total research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r879",
      "r892",
      "r893",
      "r908",
      "r1324"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "brns_ResearchAndDevelopmentIncentiveIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ResearchAndDevelopmentIncentiveIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentIncentivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development incentives",
        "label": "Research And Development Incentive Income (Expense)",
        "documentation": "Represents the research and development incentives (expenses) for the period."
       }
      }
     },
     "auth_ref": []
    },
    "brns_ResearchAndDevelopmentIncentivesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ResearchAndDevelopmentIncentivesPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development incentives",
        "label": "Research And Development, Incentives [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for Incentives received o to be received from Research and Development."
       }
      }
     },
     "auth_ref": []
    },
    "brns_ResearchAndDevelopmentIncentivesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ResearchAndDevelopmentIncentivesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development incentives receivable",
        "label": "Research and Development Incentives Receivable",
        "documentation": "Amount of research and development incentives receivable."
       }
      }
     },
     "auth_ref": []
    },
    "brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember",
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development of Immunotherapies and Vaccines",
        "label": "Research And Development Of Immunotherapies And Vaccines [Member]",
        "documentation": "Research And Development Of Immunotherapies And Vaccines"
       }
      }
     },
     "auth_ref": []
    },
    "brns_ResearchAndDevelopmentServicesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ResearchAndDevelopmentServicesPolicyPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development services",
        "label": "Research And Development Services, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for research and development services."
       }
      }
     },
     "auth_ref": []
    },
    "brns_ResearchAndDevelopmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ResearchAndDevelopmentTypeAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Type [Axis]",
        "label": "Research and Development Type [Axis]",
        "documentation": "Research and Development Type"
       }
      }
     },
     "auth_ref": []
    },
    "brns_ResearchAndDevelopmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ResearchAndDevelopmentTypeDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Type [Domain]",
        "label": "Research and Development Type [Domain]",
        "documentation": "Research and Development Type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1027",
      "r1038",
      "r1048",
      "r1081"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1028",
      "r1039",
      "r1049",
      "r1082"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1035",
      "r1046",
      "r1056",
      "r1089"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1135",
      "r1197"
     ]
    },
    "brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share units, options, share appreciation rights and restricted shares",
        "label": "Restricted Share Units, Stock Options, Share Appreciation Rights And Restricted Shares [Member]",
        "documentation": "Information pertaining to aggregate awards under a specific share-based compensation plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSU's",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedTerseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r75",
      "r700",
      "r742",
      "r743",
      "r756",
      "r790",
      "r973"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r146",
      "r147",
      "r206",
      "r207",
      "r208",
      "r210",
      "r217",
      "r219",
      "r221",
      "r284",
      "r285",
      "r340",
      "r364",
      "r439",
      "r477",
      "r478",
      "r485",
      "r486",
      "r487",
      "r489",
      "r543",
      "r544",
      "r559",
      "r561",
      "r562",
      "r564",
      "r570",
      "r610",
      "r612",
      "r739",
      "r741",
      "r763",
      "r1363"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue recognized",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r237",
      "r252",
      "r253",
      "r267",
      "r273",
      "r276",
      "r278",
      "r280",
      "r392",
      "r393",
      "r394",
      "r644",
      "r892",
      "r896"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r1214",
      "r1215"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer."
       }
      }
     },
     "auth_ref": [
      "r917",
      "r918"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesAndExciseTaxPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value Added Tax payable",
        "label": "Sales and Excise Tax Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]",
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r1130"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r150",
      "r152",
      "r222",
      "r399",
      "r1123"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of share based compensation expense",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of components of income tax benefit (expense)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1290"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of significant components of deferred tax assets and liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1285"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of computation of basic and diluted net (loss)/income per share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1211"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation to the effective tax rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r926",
      "r1283"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset, Finite-Lived [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r332",
      "r335",
      "r336",
      "r338",
      "r645",
      "r879",
      "r884",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of loss before income taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1198",
      "r1203"
     ]
    },
    "brns_ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of ordinary shares reserved for future issuance",
        "label": "Schedule Of Ordinary Shares Reserved For Future Issuance [Table Text Block]",
        "documentation": "The tabular disclosure of ordinary shares reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetComponentsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r623"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Table]",
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r201",
      "r202",
      "r628",
      "r629",
      "r631",
      "r813",
      "r814",
      "r818"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company\u2019s Long-Lived Assets",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r55"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Significant Segment Expenses",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r403",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r438"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Units activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of stock option activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r76"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of weighted-average assumptions of fair value stock option issued to employees",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of concentration of credit risk",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r1213",
      "r1218"
     ]
    },
    "brns_SchemeSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "SchemeSharesMember",
     "presentation": [
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scheme Shares",
        "label": "Scheme Shares [Member]",
        "documentation": "Scheme Shares"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refundable security deposit",
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97",
      "r237",
      "r248",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r275",
      "r280",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r338",
      "r345",
      "r346",
      "r536",
      "r539",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r905",
      "r908",
      "r909",
      "r914",
      "r987",
      "r1328",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1354",
      "r1355",
      "r1357",
      "r1358"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/SegmentinformationLongLivedAssetsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r112",
      "r115",
      "r117",
      "r124",
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r135",
      "r136",
      "r137",
      "r243",
      "r278",
      "r279",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r686",
      "r687",
      "r688",
      "r689",
      "r776",
      "r777",
      "r778",
      "r844",
      "r846",
      "r849",
      "r851",
      "r859",
      "r861",
      "r862",
      "r863",
      "r866",
      "r867",
      "r868",
      "r869",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r883",
      "r900",
      "r917",
      "r919",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r986",
      "r995",
      "r1328",
      "r1330",
      "r1331",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1354",
      "r1355",
      "r1357",
      "r1358"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/Segmentinformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r237",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r263",
      "r265",
      "r266",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r280",
      "r904",
      "r906",
      "r907",
      "r908",
      "r910",
      "r911",
      "r912"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationLongLivedAssetsDetails",
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards granted (in shares)",
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "calculation": {
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails": {
       "parentTag": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested begining balance (in shares)",
        "periodEndLabel": "Unvested ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares Underlying RSUs",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested beginning balance (in usd per share)",
        "periodEndLabel": "Unvested ending balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested and deferred (in shares)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Deferred In Period",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Deferred In Period"
       }
      }
     },
     "auth_ref": []
    },
    "brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and deferred (in usd per share)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Deferred In Period, Weighted Average Grant Date Fair Value",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Deferred In Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested and settled (in shares)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Settled In Period",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Settled In Period"
       }
      }
     },
     "auth_ref": []
    },
    "brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and settled (in usd per share)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Settled In Period, Weighted Average Grant Date Fair Value",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Settled In Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant fair value of awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber",
     "calculation": {
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails": {
       "parentTag": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested but subject to deferred settlement (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Number",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Number"
       }
      }
     },
     "auth_ref": []
    },
    "brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested but subject to deferred settlement (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Grant Date Fair Value",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesSharebasedcompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r403",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r438"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "calculation": {
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Outstanding (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78"
     ]
    },
    "brns_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Grant Date Fair Value",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional number of shares available for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1281"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "calculation": {
      "http://www.barinthusbio.com/role/OrdinarySharesOrdinarySharesforFutureIssuanceDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesOrdinarySharesforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future stock incentive plan awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Disclosures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at the end of the period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercisable at the end of the period (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of stock options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited/expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited/expired (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "calculation": {
      "http://www.barinthusbio.com/role/OrdinarySharesOrdinarySharesforFutureIssuanceDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesOrdinarySharesforFutureIssuanceDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "verboseLabel": "Shares available for future grants (in shares)",
        "periodStartLabel": "Outstanding at the beginning of the period (in shares)",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Stock Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at the beginning of the period (in usd per share)",
        "periodEndLabel": "Outstanding at the end of the period (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average Exercise Price Per Option",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r408",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ]
    },
    "brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of issued and outstanding ordinary shares available for issuance",
        "label": "Share-Based Compensation, Percentage Of Shares Available For Issuance As A Percentage Of Issued And Outstanding Shares",
        "documentation": "Total number of shares available for issuance under the Plan as a percentage of the Company's issued and outstanding shares."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ShareRepurchaseProgramLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ShareRepurchaseProgramLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Line Items]",
        "label": "Share Repurchase Program [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1247"
     ]
    },
    "srt_ShareRepurchaseProgramTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ShareRepurchaseProgramTable",
     "presentation": [
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Table]",
        "label": "Share Repurchase Program [Table]",
        "documentation": "Disclosure of information about share repurchase program."
       }
      }
     },
     "auth_ref": [
      "r1247"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, Weighted-average remaining contractual term (Years) (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, Weighted-average remaining contractual term (Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97",
      "r153",
      "r237",
      "r248",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r275",
      "r280",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r338",
      "r342",
      "r345",
      "r346",
      "r536",
      "r539",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r905",
      "r908",
      "r909",
      "r914",
      "r987",
      "r1328",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1354",
      "r1355",
      "r1357",
      "r1358"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover",
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r163",
      "r164",
      "r165",
      "r195",
      "r198",
      "r226",
      "r227",
      "r229",
      "r231",
      "r239",
      "r240",
      "r283",
      "r354",
      "r356",
      "r357",
      "r358",
      "r361",
      "r362",
      "r366",
      "r367",
      "r369",
      "r370",
      "r372",
      "r374",
      "r377",
      "r378",
      "r381",
      "r384",
      "r390",
      "r593",
      "r752",
      "r753",
      "r754",
      "r755",
      "r763",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r789",
      "r810",
      "r834",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r1122",
      "r1200",
      "r1201",
      "r1210"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r49",
      "r52",
      "r53",
      "r144",
      "r146",
      "r147",
      "r178",
      "r179",
      "r180",
      "r206",
      "r207",
      "r208",
      "r210",
      "r217",
      "r219",
      "r221",
      "r238",
      "r284",
      "r285",
      "r340",
      "r364",
      "r391",
      "r439",
      "r477",
      "r478",
      "r485",
      "r486",
      "r487",
      "r489",
      "r543",
      "r544",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r570",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r610",
      "r612",
      "r624",
      "r711",
      "r739",
      "r740",
      "r741",
      "r763",
      "r834"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/SegmentinformationLongLivedAssetsDetails",
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r112",
      "r115",
      "r117",
      "r124",
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r135",
      "r136",
      "r137",
      "r243",
      "r278",
      "r279",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r686",
      "r687",
      "r688",
      "r689",
      "r776",
      "r777",
      "r778",
      "r844",
      "r846",
      "r849",
      "r851",
      "r859",
      "r861",
      "r862",
      "r863",
      "r866",
      "r867",
      "r868",
      "r869",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r883",
      "r900",
      "r917",
      "r919",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r986",
      "r995",
      "r1328",
      "r1330",
      "r1331",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1354",
      "r1355",
      "r1357",
      "r1358"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r238",
      "r366",
      "r367",
      "r369",
      "r372",
      "r612",
      "r644",
      "r751",
      "r764",
      "r775",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r789",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r811",
      "r812",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r834",
      "r894",
      "r896",
      "r996",
      "r1361"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r150",
      "r152",
      "r222",
      "r399",
      "r1123",
      "r1125"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r238",
      "r281",
      "r366",
      "r367",
      "r369",
      "r372",
      "r612",
      "r644",
      "r751",
      "r764",
      "r775",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r789",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r811",
      "r812",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r834",
      "r894",
      "r896",
      "r996",
      "r1361"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1041",
      "r1051",
      "r1084"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279"
     ]
    },
    "brns_StockConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "StockConversionRatio",
     "presentation": [
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock conversion ratio",
        "label": "Stock Conversion Ratio",
        "documentation": "Stock Conversion Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of ordinary shares, net of issuance costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r48",
      "r49",
      "r75",
      "r752",
      "r834",
      "r853"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r48",
      "r49",
      "r75",
      "r414"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of ordinary shares, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r48",
      "r49",
      "r75",
      "r763",
      "r834",
      "r853",
      "r1002"
     ]
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Self-tender offer authorized amount to purchase",
        "label": "Share Repurchase Program, Authorized, Amount",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1247"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity attributable to Barinthus Biotherapeutics plc shareholders",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r52",
      "r53",
      "r68",
      "r791",
      "r807",
      "r835",
      "r836",
      "r973",
      "r1003",
      "r1198",
      "r1201",
      "r1202",
      "r1224",
      "r1309",
      "r1363"
     ]
    },
    "brns_StockholdersEquityDeferredSharesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "StockholdersEquityDeferredSharesDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/DeferredShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Shares",
        "label": "Stockholders Equity Deferred Shares Disclosure [Text Block]",
        "documentation": "The entire disclosure for Deferred Shares as disclosed by the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r35",
      "r144",
      "r145",
      "r146",
      "r147",
      "r179",
      "r206",
      "r207",
      "r208",
      "r210",
      "r217",
      "r219",
      "r284",
      "r285",
      "r340",
      "r364",
      "r391",
      "r439",
      "r477",
      "r478",
      "r485",
      "r486",
      "r487",
      "r489",
      "r543",
      "r544",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r570",
      "r602",
      "r603",
      "r607",
      "r611",
      "r624",
      "r740",
      "r741",
      "r761",
      "r791",
      "r807",
      "r835",
      "r836",
      "r857",
      "r990",
      "r991",
      "r1002",
      "r1198",
      "r1201",
      "r1202",
      "r1224",
      "r1309",
      "r1363"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinaryShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r376",
      "r378",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r558",
      "r569",
      "r837",
      "r840",
      "r858"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r838"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r635"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r635"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r635"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r635"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r635"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r634",
      "r636"
     ]
    },
    "brns_SubsidiariesVOLTMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "SubsidiariesVOLTMember",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VOLT",
        "label": "Subsidiaries, VOLT [Member]",
        "documentation": "Subsidiaries, VOLT"
       }
      }
     },
     "auth_ref": []
    },
    "brns_SubsidiaryCumulativeContributionsNoncontrollingOwner": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "SubsidiaryCumulativeContributionsNoncontrollingOwner",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative contributions from noncontrolling interest owner",
        "label": "Subsidiary, Cumulative Contributions, Noncontrolling Owner",
        "documentation": "Subsidiary, Cumulative Contributions, Noncontrolling Owner"
       }
      }
     },
     "auth_ref": []
    },
    "brns_SubsidiaryCumulativeContributionsParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "SubsidiaryCumulativeContributionsParent",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative contributions from controlling interest owner",
        "label": "Subsidiary, Cumulative Contributions, Parent",
        "documentation": "Subsidiary, Cumulative Contributions, Parent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of changes in the valuation allowance for deferred tax assets",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r1286"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credit carryforwards",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitExpenseDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails",
      "http://www.barinthusbio.com/role/IncomeTaxesReconciliationtotheEffectiveTaxRateDetails",
      "http://www.barinthusbio.com/role/SegmentinformationLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r241",
      "r244",
      "r245",
      "r246",
      "r686",
      "r688",
      "r901"
     ]
    },
    "brns_VOLTMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "VOLTMember",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesNoncontrollinginterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VOLT",
        "label": "VOLT [Member]",
        "documentation": "Represent of VOLT Member"
       }
      }
     },
     "auth_ref": []
    },
    "brns_VTP1000CeliacMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "VTP1000CeliacMember",
     "presentation": [
      "http://www.barinthusbio.com/role/SegmentinformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VTP-1000 Celiac",
        "label": "VTP-1000 Celiac [Member]",
        "documentation": "VTP-1000 Celiac"
       }
      }
     },
     "auth_ref": []
    },
    "brns_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesChangesintheValuationAllowancerorDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange translation",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease) Resulting From Foreign Currency Translation",
        "documentation": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease) Resulting From Foreign Currency Translation"
       }
      }
     },
     "auth_ref": []
    },
    "brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesChangesintheValuationAllowancerorDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in valuation allowance arising from in-year additions",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase Resulting From Current Period Additions",
        "documentation": "Valuation Allowance, Deferred Tax Asset, Increase Resulting From Current Period Additions"
       }
      }
     },
     "auth_ref": []
    },
    "brns_ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesChangesintheValuationAllowancerorDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases recorded to income tax provision",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase Resulting From Income Tax Provision",
        "documentation": "Valuation Allowance, Deferred Tax Asset, Increase Resulting From Income Tax Provision"
       }
      }
     },
     "auth_ref": []
    },
    "brns_ValuationAllowanceRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.barinthusbio.com/20251231",
     "localname": "ValuationAllowanceRollForward",
     "presentation": [
      "http://www.barinthusbio.com/role/IncomeTaxesChangesintheValuationAllowancerorDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Allowance [Roll Forward]",
        "label": "Valuation Allowance [Roll Forward]",
        "documentation": "Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValueAddedTaxReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/PrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value Added Tax receivable",
        "label": "Value Added Tax Receivable, Current",
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average ordinary shares outstanding, diluted (in shares)",
        "totalLabel": "Weighted-average ordinary shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r231"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average ordinary shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r231"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "980",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479068/980-740-25-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "980",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479068/980-740-25-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "3",
   "Publisher": "SEC"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-4A"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-5A"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479366/326-20-35-8A"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-17"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-21"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3C"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.M.2.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483530/326-20-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479175/326-30-30-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "13A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-13A"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-7A"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3C"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3D"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-6"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/460/tableOfContent"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2AG",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AG"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-5A"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-13"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-14"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-15"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-16"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d-3"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-3"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481174/470-10-25-2"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "11",
   "Subsection": "03",
   "Publisher": "SEC"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-7"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>117
<FILENAME>0001828185-26-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001828185-26-000012-xbrl.zip
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MR1ZXUK#1HR5<MQC"\>^?GW?&[3L7$\5LLZ'F2]S1ZI^3:%Y/GG0[KIV1)S]
M_ EYOA_O[9V:"1F/Y+ 5;KW7]PO4RS!=;T'*P:2"L^OBTTKG XK2 :B;_;\,
M($+O]0Q,,3C37^E54:7#Z9[]LWU0/J>@?$8D-W"RZ#IZ62SAB)ZQ]_0*#O.A
M)NE7=1/M'W.6;R!U$YTG:"O35/RN2XR[J\O!)N3P+YL#.5YL$*L]/1ZC6T"&
M ;I)_-(#!)U^U#"7%) %LQ,MW,Z6(+-5Y^0([!\\9]NABN9EL:0+YFE9U9$D
MY=T'\P;,8/IM-"^RK+@V7B')6N<ID^BGHHQFF4*5%4?I_);?1L4,5%ME1AP,
M0/$S8XZ?F>D%PYP#(S:>*<-7-058)M'K#1^H^$%D[</E7SZ"O@FT\T5W>E07
M^JS/A3[89+,\WW^ZS;)_BCXT9@!J#(_^4>D!TALTB%)7&@-WM"L2?:6S8D5R
MDJDI1G&*$J1WJ?)FKF8UA4)B<+$SPB\6'(C&*UF S!<->I2S(J_2JK810I2$
M&=@S<!_X:9A)<?>X!C,9753$.V0I>I7N:@JE52G<]X'Q,AO-U6W!K?<2YSQ]
M^@6,R!F?;[BI]K^F="YE.TB#_:YN4"AO#?YT4C^_%36*IY\;7ON^%N,*5IW!
MN9KODK1:9>KFAS2GD4ZS8O:Q VPL5@)H/#R9[!WLMVYQQQ'_B!-\WS MG5H+
M/?L8K7C.,9< :BJJBX&"?9L(]GX+?O%HLWJOQ-UM\_Q.7S9@'(!J3;,13RQI
MC.&$E9<5%$*F/\'VAGN!/E!9=%'5:,9<_+-)ZU17G/T=7)FM'?[OD[>3Z,?B
M4_3\[.3X:/^S449/JR:^^_M+.*ZS DR4./KM973P_.#YV;--7P!?_JO:D6]!
MI>>4#4ITEL(?-Z/8EYTY[CV.ENK3,SG#]B<')V=_>8&%'.94XT^Z1U9? <C]
M3KOC@\GI?OO W."T:]OHAT>;ES#<\V9/LW(')V!OE&"H7C2S+$VB\RN=-V#?
MJDJ!>Z'BZ.5Y=+:_O[<?G==USM;^2\%KZ@CLQU+7RHF<>^G-:GF.O@OEY7-+
M:O8W3DO(VU.%$,7C<#N1 P![IU,S9*Z2TI ]=XF:5D76U.LO\?PV6M]NA<I>
MIT)EKZ]"Y7#O\TI4GA]0B8H N<Q[E* XGH%,96I5Z1_,/UZTM@]=]#D//=J;
M')UB^.AO-2Q"G;0,U0G-TG_62?>[L^>3L[WU7\..M-_])]V;[P]O4*U4_C^_
M._RNM=%^@/>/6EEHW'OME^#QWZ(*GG<TP7TVZ8=T"5[E;_HZ>E> 0PK;M;53
MG]]Y'!_CF6;KZ]!M.'L1'>SMG<;11A9&=/[F3?3N]<^_?'@?O;MX?_'NORY>
M36 ;Y_,48PB@1,B1!:=V5::TGPFKM[__(GI5H#]"U7T1F-BOP#,NTVF#H1KO
MT7@U>KK>1V^*RX*RLZ6^1'>:P&LE*!68VH_D"'^&<>16_S])0ON4QZ)T<G )
M!T&IU<=G:@XC^$%EU^JF:JWT)H6#3[N'3H\F!\?'W]8>.OFB/?0 OOG=H&82
M^8,7_Z5F,X2#+>1@/%_" V>*Q5%^\SM(5G1P']D<@UG/N."R@>WX):9\RVPY
M/-D3=^$)W\(9(V_ SIN"B_(]^RC1\?[A'I@OY4?8ZM'OF?J7BG[,KA)0=VVG
M8/_TV3Z8):/RT[\@^G&=EIK IN<O?[%!D%&X E\D7@='SR?'3RU>;W,XMO[9
MZ*IVT&S.' @L,DKS>5$N&?5;%P:%>H5G851AQA?3!_B##0.<AW=Z$9L9U*=]
MOM'#10F/3B9'!\_7^TU'DY/NHI[2AT^J[5MXA#"D&NT(KK>38-J]3X!IW8NV
M<4Z'3Z\>$5#X?K8H__K]P=')"QR,+AV*_1>MZDS?@#VJDB]SVD\G^T<'OL]^
MPA\\ALN.HG=XJ\O>HT]Z5P0_'6!!WGZ:HQIY/TM1YNB,DL\V#!D\ZCY:&P1\
M^]]'T='/%YMLBKMW_UKVC<?,;!Q-CO:.6K<8NX:BK#0!5=%SV4Q3W3OD=@1S
M>QR$W [YDT<)N>U/CL_8_WCL%;_KE+I%>3^I5K ^R2@5 ,<'^WVE?XMCXTDG
M.BBH?<6EM!LIRLZ[C"I1OOXX=.@:P;QS71UH0)TGBD)'JJX5E9$:>#Y\G^:&
M+D ^3W,NTTLQXSN'#T!-WL.,N]OP?GCU=#@Y.#F\IQ']U%B&OWY_MO_BO^%_
M#U]$%__]R^L?7W^(SJ-GT>_O+GY]_?[B??3JXOW+=Z]___#Z[6^#2]GFK_ C
MO((W\NCM3T@M\+\N7FY$6+5N9;K0K0U,GLWUY=[DY/3(UY<L@X]S3)],]CK"
M>:\7'E ^G^W#\KYY^_+<K.TOY__GU_,/T?L/;]^=_WP1O?_EXM7XA-5Q@'1?
MZ26\T#_>OOO_HC<7'SY<O-OH1!CR18[7O<@K>)&7;W_]]>*WETQ<]NK\P\4Z
M3%3?#2[@!N_^> .:!VF/WEW\_,<;6N;UA" /J+'W)L>'Q_?=%$A,,?B>^ FF
M[</%;^>_?1!?XWWT^\6[]V]_.W^#F@_^_>%_?YEV.@3QW?.UTP%_\&C:Z=:%
M.#SQ,.8&(XN9G0$5U%.7$88'U#$8P/CN1B)^!HGX\8_7;UZ]_NWGZ/S#AW>O
M?_SCP\7[^QJ;:V/BGP?Z/SR>G#VUS;W_J.17=Z_,V80K'9A.8*!Z.T-*\L=*
M2F.K9DK89C2XL\P@GI'WI3(<# EA("K!\'HQ<OP K/$,7Z@**W5=E!QO8F@;
MUO^>(B#FQI,(70:ALZG:*&RJ'U <<J<O\B)_IC\9ZH6&)Y>J?>O.Q<Q EA'E
MPQ5RX) 70>GJPC@8PFHS6/DUAG]@=; (<0C9,$P]=ID1?5]>R8I9*H)ED<"N
MCOS!QB9ADO B,54&_@[4.Z]E4L!RU1$2$.%080%4 OJ_PJ50\SDN42M69M8S
MD!99^: X81*]=[+\4U'.=/2K^E-C<F:'2KWGQ&24/FZA]WV3>0:4?WCT]$N-
M+(71!_61V ;&/T7[9X-,4;>H@S_1,TT)E@JY\O*9?GS*Q\^=N(.GG[=HJK/B
M.C::WZ,S4;,9QKPEP*,ON8;"E&69M%4<;/C8%LDY56-02"M5D@!7*X7D#E8#
M>8QEWFG4)L[B@RY@^HFC@Z-H46#I&=6=Q=$I_@?_NM;ZXQ,3)X!!]7R<]M3!
M2.RI5P*$9E:E<Q"O54TE69Z)Q=\-6GAL+*\6Q0\>;RC014ZH,SV'LZVF[;%4
M'ULL/^I*I1G]S DT'H6M$Q/9^"-2 W0Y_?E&U[50I8!V/V:!A@FB@E']2<\:
M1QT84%ZU[FU0Y_A+C1M-)AH?E.954]+,(YPB+;6U$/%&PJ[FCV8XAIM7 X+G
MA0>Q',[ E+<?D@ZNM0MD1*&XHRD^@W,M"0LL+;+AO!9T:M7-':"VAI.A%J<%
M/QB.WN?G08!96XJY+<5<. WDE.$6@O,/5/B*\)+7J) =#]8CV_YW;)0!N!@,
M10#5<FOA <V+"(O$A6W@;$\,P'DM.JJ'2>'UW"FU.9S3S "9+M&S[5-O<5L'
MHE\\U<2FWSGAD50_*\!0AG\G"JM'T"MOLEKX'4J-%K0QBNT!'MSXJD@3O![_
MR[;&)S254#5:HYDC(.'+) 4H6+Q'KY(6B^)DSYH41$*XANG%O@R;/#ZE0^BQ
M(UW\#=G]]F66Z@9?@RF)5=TR\:T9A)]>EQ@5R''4B+,16Y\>QG.4SJ.J:-U*
MI_@]XXR1:Q0O:=/YQ)&,?ZHR.I5J.5]VTHF>Q"(A,)/-+%P:"JZI9='D;-PQ
MN9T=/;PDEF;42)SL++>VUVFF IQ22SH*QUU3YMKS<6)+59KS*[G'Y&Z6?(\,
MWF?>E$R.@#L#YCUIL"H#W[:8@M<AT1LS-.<JB0S1X0P2N9+PBS=R4CKZTPK]
M/-@*8")>89C.S'W'ZIQ$YQ3T,<(8P]SN#F<K]8GE<%;C4JN<C'!21V5*O;FF
M;CO-:3&WP:\-@U^X3](AI:O'<QM:N,B3"X@T"V+0P>9'HDBM\@?)6Q-7\=P\
M.DWZ5-&V:G-;M;FMVOQWK-K<O,)E?\_""#Z_U//HA.1C6^FYK?3<H-+S\)Z5
MGH]&7G!G:N" ...>%LO+QSWU3"#3@+Q*STNS$>8I-H[%W([O%]*&LOT>V&E$
M;N2T2&+^S.:7VS>V'L^U BL@Z7=UP3!1\'3X?PILS\D0ICP3Y98?K#QO\^3-
M!NV*ADC>?!@:X#!P'L;8O"PV:/FNZ?O!6)3!IJJ?&G/H^9KJ%H>FBXR!IY^6
MUJW?/^"-""<*XOQ+PV-Z:R2-L$E2D8LW<8VG@M@%9ZVT<$)R:$K9T(]K-$-W
M%OW3>5I\"P&IRS%[+^4DQ%",+N!II+K0DH(APR&15@MVMIE8%'XE5X@<G;LN
M.&9TG:>;&;>I#?*L7&YNR(3&JVU"8YO0&$%"HQ4^P; [M<8I>I4#;])0+[@(
MN:#/.@2='!&E8"2]], ' NJ< ;/6\UZ3+"!=EM:!''!4T^)*&TT(/TEG<NWO
M+D)LM.S%)U#<^!$K5@H<B\;'V#_9G$&@:4R[P(8RSP;(8=V+7??V NU[U0&-
MT[:]L'FM2E/Z#+P]D4 ??6(=B#&*T0"0/<E\I;NAF:4(4-5!9L#?:>G0X3C;
MZVVL%LA<K589N-X8>WFC+U4&]A?AA3C>_!7D*YZ609L!E;S'=]D.HJS%FF9Q
M+F%GLZTPG>2ORRX(47&2!;'K;D^^FI'!JZ*"WU9!9UF1@[[6AQ85YNMO%J(6
MYI\WH&K)UC6\)P[TLB@27[[X9YA0]T=TK6B<.I]$Y_"BV#)@I?+936>H+E7A
MM7GLYJ?M&]VC+B+T%S?L&_" (8:1JN'?BAJ#015V'S5M*'#F+PN2JFYN>XP[
M?0 ]W N:EB 9SE6(1NG8JZ\\A.::DAQJ)"F0TYN(\POS&^JY!]XS]8E&O(FB
MM@@MW;'4LX7*,40<LT56\K]Q3ZRR9CDE+/9-5>NEL^RJNFRP,0.H>H39%#DI
M>JPJ,8)A1LD=2<#(@SVNG6BL5*DN2[5:Q,-9WN%\#)^F+0@3PW4T_BJ1F^.M
M -'$(6&^FWG2NK.BR1)R?4C$IEKG1A9238":)*UF8+YS)^JR:"[!??+!RFE.
M@ \Y&8+GAL]#90D"P#@;%?VS 4U%#\%X/ A3JO))EWIMN:JI0&NE4G'>O.&U
MI'/'T]==%\X-6?H#"Y6;+5(RMU$E6"L8/5;8BSM\QNX JGVLT6,YU2]++>=X
MT->9YK47?(1Z15U*R,O5$6+/<\07,#(,H4+8!XL%JX0SOBSA<3<=E!$U:[$6
M H)?\*3FITCU8$<+FLHQK@>,_0U"FJI):S5-,\1\W7ZI+4(3X<:?MPPHDP*)
M_2)(2E]4-,84N\> +-L7[%I#K6=BB)&'F.EU57 ?G(..W6WJM":(- ^5,8Z\
M<LOV.OBC[)EJL\5@]^#)8Y#55$2ZPAJ^1-Z+!(+V<%J4K06M<'_!?+&Q3Q6#
M H>T8X)_TTEL+ >6L!P,ASH5()JM 47U!6]9*W(7#'S1X>IR4]Q YXR=&,(T
M5@5^7VKIX-.L*/(0K&!G[+)4E/L.0TFR#^Q+=(>UF?HX>CCW'%NNCEE]K.D%
MSZ>3+G'VHM\7N%ZOHXO\*BV+'*<6CKOWF/0])R^ I'B%IT3)Y\L[M9P6('U_
MO+?<]:D4.R>$]7P%CUI.08(/]@[V>B5=MMNCKAAUS MX"PZ?FJ?P<. *KH/3
MR<DIOO-3=^G=OT\+Y,_?CX-NO5MZ'PXTW10XYYRAM$(6+6L'91V&-N[:^>5)
MPT']E;JA0Q!3<I['HXS"U^BBKVY:$6O/.IQ$G2Z,:_H0[DR;VH\'X$_5%+XQ
M!Z@;_Y/547RN/WNTHW9W!_=I8?'\I:!*K^1*41$UZN.BP:E<PM>QF^G8X.K9
M*JQT_:R8SV.6)?1CP=:!F_/A&ZP*7^#%?8+FCUJ! Q FJ$'*2N.94B["4%_
M0#-U/6^HR::V)N(?>8H"]Q[!<8R;,^ BL>>D":%O;*'U)L3=^#D-U,6K*6]"
MU08P3^2B<*D$VEG\.L9UD<\S-:.DL+T_IDRXK!I#9E*+@@(*Z@BEVGG[$].Y
MKC5M)GHXQVZ(,.NJG<=WNQ*L..+HXSWN12"M44Q5 3"D<*_SX*MF607R8-2
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MCAQ.KJ6TMVQV#1PQ(O$'?5UY#2+I(THHH@]3ZLN&F^51-\4$/V/20'3Q8E&
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M=H"(K4Z$HP$(=M6(^QZ?!PJ'P5-B #K$4\]L@+UD3C\O=IF*8NM_G+ !F.U
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M(_NMG=?Y.GS7SK#'X;^VA_48+FS[&?=S8Q_"1>K; INZ28.ZT5VI^9I=Z2T
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MWWD$DA9]0ZK*6EI!$IX-HIC<R2;/")UOJTG$_DZ%4[0S OK4>ZX-.G@-YRU
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M""/VG7F?.ZZIB07YN](.(>C$RF-N0X1-!,H!@A%P2-9">Q7:K%^A L?);LT
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MNCL8J"R/__I=2>4=?L;)&WBQF\++VWNVCZAK8IR!39;!?!ALQ)U3QT3S:!^
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M:^WISY6;* -8YDH4MWW-0<2:!"-$WE;'&$?WY3A(22A4M"4L_PZE[A-7:F'
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MJ\S*$]8<7X@ F,B@%FR 'BB5C026V%KLVL(CDM:\<2K-<87ZL^\=NUS*A0)
M,.!K=$URL-3J7GBI28HG#:?6=4X],CT*^76C:8\@B+?=YC2W(J*N7'HM33=7
MJ9^'S<W\Y[FZ@K+-KTG?K^'>%-;/I7!'WDX5K@)7D3 1GF?C@@<H4CV/"PN!
M6JJHIVS;TXK]'*BVKPCE5AB/S31]<.G!Y/@O[;IH/]+BBN_PA<W>,YF72]-2
MKJWOPF'S*ESIGLYW^"FR)8>Q'J+ S,C#1$F/X6IV\%B!5+.%3IK,Q'@,(HJ4
MVX\:P42VZEV#7]56Z"U]OB*-D+-:ZC(\\E%%NUAZ03#CIA3']T> ,G7=6JHM
MF&0+)MF"2;9@DBV89!1;Z%L$DYP^'G'5" *)EL'(:Q1B,MF&!9G+F1=%YIFO
M8-0LR6O!.J98.L:QI=:;4IH:; &%M17883=LIR=%KF\UB6(#2R5+U?6=PJNE
M8;KI,1#-,JWR9K4IT<=#IHN/AT[^]*]O8"T),Y T1V>F!VRB(:X>]96X%(L9
M"]&J.2U!8 TS/0-Y*:9SGP$$A,YVVV>@U9Z76AQ&),^FOO'8KCWV_ &3R-VA
MGQ%_#Q=D69$03B[O Y?_W8UFJ+/(+V#STCDG.VDN_.EDWDX9A++V3;G2F"XX
M?_GVW:OHX#DW6(<C^>2OWQ^=OM@[E6;J',E;=Z-=FB%\?_!532MVG"QX<PGU
M6!)8,NBY681X%<+_RN6"?@DWQW?6+Q3,2(W>@T<V;OOI6+)Q=@I,\^TT_Q.5
M)5?&<&]I*6R4,NXPS//'RCB>;M7;09Y  "7JT9IE*:>I8(9RKHT1$=0UETJ2
MAN:(P])Y_K[;)"OJ?W2] +<Z98.%9(^F,:4L(,A<=*U2*ES@F34AV]MORB)A
M:V4D4*L0PI)FM2E&9)_=5(BV@DX;ZJ;#3773P.?'6Y<OW!&6DI0#^9P*0 +D
MBI$-CYJE6E-P]FD!+F4=_?3D&;+O_J[J6J%''7$UA="XH$30!!G(1@MW86+9
MC.6SJ(9_N]F3I,R\J;G])F\YF4!R,& O?\(O0=26,-%P!^PX8NM//)UJU9M5
M:JBM;0+=ZS#QX77T4X./"M.K^-4_4(6\T4B)M!O0[5&Z7B<V;61BC49SMB +
M)E9O"L9=SQ%$_NG$)_^>J=6*$ANEHYZ#/PVZ:%$4B,6M$/R "(9KN%6UZQE3
M+9:_T5"3C@:!XA)-8GFP>/BP$"LF-N,@0M*)BL8$\W!W<?))IP-8@4Y0.3#G
M:J7L+[#LW)Y6,SBD<RT60,CQ:8$R;*G[0!FZ%V;!VE1DQ*M%B@5ALFQ-U/H2
M\Z']_63HZ()KYLT2:5R+1'#<8+CHNB0""832%LCMBJ%%G3=+ZO?JOQ"Z#<C
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M%(?Y=F1S!IMK'/A6<<#177/D8I+V;JURT!NL78UXPP+(!';3#6+XBK(-,.8
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MX((F*=[?Z^D-EV11_S-%U3\<3,HRQH3.=I/LC%1=8LF"Y89UA@X57HV3Z?(
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M>2H:*>J0&K^2[DF*UN8>3O8O>71.[VGICK)*7ML,%<E+SAQ1(DI(.!K@T3:
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M="E_)*/NQ9UIHPN/S%-ZE3VVT G#'%I5,:?X,HC1RME5U4="\AZMG@0O<4\
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M]WD?G)MF,:P3MO<]OU^ <!NX&26+"CMRO$*X'6*U*F7#2Z<U7,?U!P\\??2
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MUN8;*DKSN.JN\EAW'/O_ZLD9Q9[5+CS(NM-B3ND.8DCA<R*PS6TVY:9%ZR$
MID<_GN+\<""P8W0*)K'? Z(WT&#B5O[UUF*?<-DG7!Y(N 1E&('3,T"E6B2"
M",,F^*132T;-@T+BK)K>6!DQF?>MTS"T"D$.MVUHF8C.=;(,:T,L>L9_<>R4
M++Z5SI'1F[6"$^7>" 1V<^.'M*3E/+NL[2[P2H%5LA3M&#K4NXL(#WDTCF7
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MI>6RIH3=;7S'T@9N1WLU,]_+@U5YQ\_D))!NXG+JD$ (BR-@@5^;C]V$^Y<
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M?>=:9#M.$WN0N)9J]$; Y.-WI ,&;I+<<3?TF !YI/_6'_[.VYN/\J!]8N_
M @<-0RBG4"FT"CM]:#XQK]D>]Z#96^0AV?P6L/5'7Z:^<O$/S1O=<1#U(Q)<
M[4)[&N5D]>S;TNV#(/S6L0K(BF@O!^5&6.^]SI.$R1/!Z+QFF\,I8>?PBY-%
M"I#M.] 5228QMEXM=JS-%W3DS^MES:INBT61YDM?/M;3!7M+6OEJ)Z;56)J=
MQN:+/&'RYSL&(7-%-E$ @6UWU7?0!2;R/C3;/(7X9YQ?ZF.IQ!O-S1T?WNNH
M&]:H95;.SK/&9O,)_LSN]R6"=4L/NSA.S"T1FJ5O-IGJO,ET_."%/\-I24O]
MCM0QW-* [\$;;$S1LNNF/ ]PSTF<HY<:A#E^DF3Y-J^K0W2EAGB,P$YIJ42
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M-TJ&)ZC;G<XIA!.3,T5R(30."(S>]S%K<]QT1YKC&!SP46@I>NF-ZP KI%7
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M,S$N:'1M[+UI=]O&MBCX_?X*M,YD]R5EDIKEQ*]I64YT8DMJ24YNNE>OMXI
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M=RGBC_!-8J;9W7J'VU_5!)?P>.05I]C;>O?Q]V^?H NC>S1#( 9;#C.['[>
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M9^O=_5S,3[UU'-L*. .>6_?\_$OWDW-U>GEQ=>-<?KFZ_M(]OW%N+AQ@V#?
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M<\:8_(0/3G&;)V,W3VD^7U:W+"C4N]M[&E_\$-T&QTWZZME#M<R1/^>TQ;/
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M8YB(%W9J5K@9T+J,HS$>KJQEPBKS0035T4'-!S>%LG85']RI^>!F0.N3'(C
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M8^S L#%,/.%,;$HC,LX$-HF9.#PZ.95DQ&JM3A]3<5H4Y4?)VA,'H_SX<J0
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MSJ\SH;K]L,IA"S14GK%(PM9I\=ZI7@D\8W&)GLV_\JI]% QGH9-5;::XI)K
MG^&J03KP1PT3>Q>-\<5" -TX5K(#%KP0J<AM%67,U"&PVBE#,FBF"@26JWNS
M@,R9,0*(.L)[#,NF8#(7W@PX5;FR M<_*5ID!9 *7U&W>#"Z@BYQ(0\S>WA=
MKHKGI6!ANO>4"8;78/)EN&PNSEXCX/.HS+,*@9K.$ #),+K%)">43H0[Y#Y_
M7+1>BE3S$ ]D9&[QPCX;U+23HJJ-@>9\7^A:L:K,(=;WAB&FUF'SJ?G(\%<*
MJ=ROZT3\=:(C:ZZV8JZ6FX1P+FR3;(($;U6#&?4]YH:J2 <2O<B5H-)T\H;K
MUKTV%('NW^K.$-ISES4_,T=*;!BK!<AZ(DPLMS;+TG@P#;9QZMF,+IB7%F4%
M4E^TMKIG.CBAYQRFHBZU]3W[/'&*JE)!1(I"%K*?FK))M(;&RD$4NMPV:PX*
M4^,BOMY S$]&F%\DZ*XMM4.B>QI3!<?P,)?(&T9TMV-35'] #5"I:HK"<(RD
ME":L2%_O>:&N0JD-[M",1G-2270]5$ 9V*2:$7!RK!JXFK7GR7LUXCV;-90Z
MJ&(!!2F_%I7+^<7! :]\06VLJ74S:NQLU<I?Y[+$Q,<PL7%@Y[)IHRK;&Y1V
M:X<]4G9\WI6'U=#B@AK%1<R>KD:CY^1?TZ8-96_*N<+'#UVV,YQ^AC^P\8C5
MC\]J$;B@ XG.G%,6K@9I"TV.]](-)W2,(N:MADJSP'$9X?S<BIO;1'*#R+3U
MU=Y3LK!<KVJ'..\\5/<ZX8#*'D=W1#:>5HM!9@AQ84B(<TRMEEFLMK8^(XZ?
M@H"FT$979I\'XD78H7.W>P4KB6JI:>.ZW>Z<]6!=,L)ZB'L+YEKU9(YD9S'E
MO)J5Q7B+JX$'0&"EI'?:+U[\Y2H6A458U;"*EDB@*%, B.K@ GV-DKR]>^T#
MK8H+2W$\CE7386DB5:Y'NTRYY5&R_4BZF&[1USWA^CS]8@%S;GY0'IR7@&G0
M2<F$CO;J.!)>0S5 X.*Q6"B#]2M["47WEUDH.=O,JDS>,2Z."OV0H90<]<G,
M!H#E+C=+N=B0M.RU%8]&4UXY>:CFY\]E!<@#-.9C4 EFJ@G2+).HXJ!8S(IL
MY8UB=KUBXIZ.5^OKMAV),\"R'ZR29=39FH2AQ))49K'@V=YF^]Y0]3^L*N@<
M^&PJ!>G&(;/[$ZCC46E'=N5TNUA'P?-D5;A282^S4SCR'? 23'49HN< U5*]
M-@TD7=8YKY93FJ&FFN>1],?^F/RD; D =+;:'Q0;ORD&EX4Y]\3NV=Q6N>S$
M-/71ILJT8K1FBL.83N%&DO YQO\NBK]2MPU5#D[%=P8FSX2(4N6+Z,A/@YDF
M@Z26II\YM'\(CV&U',F98281&ZN#FR+@98V-90.-4,3DN+ZX5OVXQ#A'=]+X
M>845:U#+YF %#A1SA-$MSCXL&U]T(X\:49X%44A?PI@ZA \6L5.5NOYCS(I1
M/!"AS884; LWDW(TJEI>E.;%"9-^HDKCU?!\+MWC3E(DD$A4T4XJ%3;&C[>Y
MX<=*=E?Y/0TT8Y=#!;27ABIW]J5'F3=P!6!H0BKN"\X,Q"!Z[F>5;(TMSCW9
M)[6C!Q+@W2,*&=9(\'U(H&5:K)*G8Y7(FKMDG<S$*I1Y304X/K,/Y=.G$^SF
M3+]04V-@$=T/U\;'X$D<37JF[@(5[M#,A)Z<H0$*#OFG99DH<JHCFPL0VH/&
M=X<@76[Y<E,U0GTK0G6=6ZSMQ4TP.2D=F$GD^F1W8EW#I'R4"DN#=A:JMN&D
MVB,HK7C6F:4]'J]RU*7$GB[NY6 EI<3VZU)B+S58YOD+AUUVKVZ<LVGJ7!(7
MC[:JN*FS5(Z<]K:I$/W]S.\9%W\!;!R=)15=].R;]O$9\/W(S51DIK)I4EL;
M"M+T1Z,LM.MH.EZ<#6PS9E]'=BBG5D2O2.50[0<"RVE0;ST5T$EWJW+H\_#&
M2FJ>1Z7LU=;9/\5H_/9LZ[4#9^A*$,%E0&LSX2=*&O.QRAL<(REJ+&\-,I_2
ML4!."UU_C)'&'"4ZE%BU''A#H5(H)1,(?\12&Z?;DYK7F]B'DL89W.HI%@$Q
M95H%U^O7=@G>95,54'8+)[BB4J+/CTW&;*?K!94"_D5NX4-\4("SW-2)(\EO
M9 J*<_%5F0K5I<\<GRJ"S&(85EVA2),^9S^.(D(SA6)I%,"IAFC"H_JOL50I
MM,[U>?>R>7/6R$W 7"U6&00RC,932/2OQ+EQ7!D$*A63\NL*B*B-E!C03O4:
M1)K%E--!V7=]O9PP"IOPW#BBK!F=W OX%F!*3>HG208X3#G%:,\T--1P?KVY
M;,+=WVH@]MHKU=,NG&& PE;(+@0=EH7B*VS*%Z[&2&422[3]GQ(ZB&8IXYA+
M"0OG<HBVSG8I%0 8N [>IFR;F TA=H8+!MB3A0QT8D4^BN(4,')@PA2L0YGX
M0LR,YZ8@([2W(+ER<,<,3'IY-:IMMATD$=J@8#YF=*8:P8PP/T2;'<0:,2/4
M'1U)R)8==QA' ") 1$0/0$/G/?#6DY_? U\E&,&M$'*XS:V/>'TKL71_#BX[
M"[E!MA&E6*. -42XA?^1TNF"?AG!",!0+^[A16SV<#+L>A?W,!'BWN?(8]/-
MKZ 7 ]8(IQM^%;& YS[_VD6MFZWM97(UMODIWGKRX?"_-?5NZ^- '-=XW)EQ
M@>59!J/($ZRJXS'0:W@G1J'A:OFSL1P I"GE&VA2J!R8C/NMX&6:413D=&2D
M.G[!!2396:MK=-L@H9-;@7+X3#C;89S5Q,Y.]EB66EBGJIM"BOJPJ_/6&&)3
ME_\TI'(?JD9&*E?8(]N;<0>B(?\K1M@@SG'87VZ/E_?2S0A;"ZG1 HO^V,6=
M_#\S5-BU$JLR\T-QB]X@I"8LLY^0'0BSDHCY12,N%H!M"JS@5KJK"IQX*;&(
M*\_Y 8DM7-831[)K"BP0'C:#]TW)V:2,XY785=E &[[!V=8&Q=P#JO$TT#(4
M5I1+TE+;",#?H7)7*(Q))@DH49:8HN0/;-ZB^(]*7TWC*-#XM.U<2?@C!GZ*
MUVT"@ZI6('H87!$ZS;1+//(F>?FZW(;)L2[]B1:#@#VJ0'#$^,2DHR/]#4(_
MSTU-_8&$V]KYP O"J\F),%";*Q[@#A4C4"(-=4J0/MW[?EBHSP\[H%<Y/D%3
M$ZQ0.6^%)__,S)-]%(?RY_4%R+<;\V =G.RB^!AO/%W-1KO/%,FQ%.^ABTJ@
M1Q2F^@_?4"(L@H%".!"#.3];#6J 1XDPYL513P3"-)$PH,[#][?A*TZ(@6%?
M;=W WR G*$$<\31$!8NP'+=DPXW"8@APA%2%1:+1-4WQ0J!H<$!JTT40T"[@
M8KA6).(-S@V?BW/C>8RD"AC1F3:V4@#ZXA [RZ742P(IK"=)!G<Q;!BM3U1]
MP^I#:"4WJF@77)-B!%@)[@Y#BES 9!2R5(Q.WJ(<4(@H!0-X)=Q*\%^5C$[=
MGOJD&Y243DPAQR4@M,3 *,PJL]R_E8ZEEMY05QAR@5HQ=!Z(W[2ODCZ$+>4T
M^IBM4M $]CZA2L%,ACK_*/#[</N2"JW/(5?> X07WMQJ_<AZ^BHH&J_J"!8/
MNQI)3.WUDQ&!70>%J,IY#>K.DA+IX&1-9E RI$QV._^*]@H*(_6)8@#&<D3=
M8 0[C7%NRE_FY!,LS$())H4C8TSQ8'-N2D9_Z@MK(_LK1*PWB-FO+8)@F^:$
M@UV6)-!MYR/)_H3@#=25L'F5-WUWL*M)H<1L6D<YUZX#KAB\CB?7_68T*FE&
MKBX/V(QU?S"IP4C4%JO(F*U'U=WP'Y7NK>B3%.($U8\>:SN)#/I-/5^#TS>
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M4A JF[ OC,O7<$<]7G;;1@+XU(\#?4#9.4J+WB,3B6BD-(#R*4=L1 PR%[K
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M$3BY,NT5*DP%>&Y,*I'WT?;Q1C1/B +,#H8QMK'IY/F>9[9&-RU(^1=,7NV
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M>O:R!H6-:V#*XF_I)_9[9]"=W39*9SPY][.I^+SJ1F3#A16W$14BHHD ; D
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M4E'C/_@G?@ 7R>D>%>$$'.D#T0:+&B$TE>YF4/7BK)*KY/4)\LMR@QXX5[O
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M*NH 7LO-JQSH!5Z+^-Q!V;K(,B&2]O;,*1S)N<F%+W6=7O\$'Q?@FHV[I^K
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MK8[[T1V8FYL8&WE;R "(/+.&KX"Z/13T_&<SNO5G'<%57N+#2VZ?"_4F@K0
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M()"A4K6KV\<^8535Q)+'U/$TH7X!AD)A#"% AK0/BXLNT[F)HZYVG'WZCV6
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M9=V41]59"J4.?^9L51P9]!1.*^S^U0]2</36XN[&8W(U# 59L5YJB&!H/J;
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MU,GY]JOQ.!W+F/K1[Q6^%+#6^JD(/COW3MON3.^-_6';L3N4,&"^HY[FDQ<
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MQ-4W5X5.BPT\BPUT3M;6K_];=[)R>V ?,)@N_V2H,6E\G8?4<'-7DU%2!0#
M=W6:.1+N6Q;Y>189M:JF:Y8Z9%2M(VXG'$JB]C_0<0U!0S+E^/$['Q4/6-&X
M'/C+C :HILY"=,PR$XU2;)DK WT^KY/R LSCLP]J'I\]V3RL(LJVZE7MQ$"&
M[7:^$^&< YP87?\$H\)B^#MHX#R]VOH"S.1&O4AIN30F,[1H)!H*S@246E-!
M]_";UO2Y3!44S@[GB%FFQ;(71A+^T_!;F$OL=KWCZ9K@PXP]!02::S!QP=;
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M*K#M]F6]XU9F8[N%YA92:*I1#@S#//!;X:'#XJ03IJ\ T,?\&J1)IEP9N&O
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M/YFE3(X810@)CCN2]UZ/\M#1">TW,0JUCZ4_> ;'U-'ZA.2_(W^,9Y6^_/(
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M).\;#GUF(ATZ"J_"[!7J;#-+*$S.E*]E/=)UGN@67_FE[(P3DDBO@HY&&AQ
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MO('BX' *DNWJ+/@,8T3:,O>9XC]YQB"8<[3^%1!J/H7XZ!9MX<*IABO6B-/
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M3%%1-80!DF,WID 4J(AAK[OU22A+SY6B!5<1'F_!%P*^\+,%7[C@"Y_9PV6
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M=\ \2WX+/4C+P#J86^\$FP&-,70B CIA JWW0]ZR&,937$D#/3;L&:5\ZX^
M-E1!7!P-I(+WU5K<RQH^#YV^5G$M?[YE-H;]V96P>=VF0Z8ZHBVF2K^)W-P/
MFWKLH59]LK*RR[I^X 2:*MGS.XTI6+>D[B:':[;CA.7X^17\1:&!?[N@@7]1
M:.#%%[V?XFVV&0PW_>D?/P=I4:S\4" Y]G/>J0!<EC^A*IHC1WRFVV)Z 3D%
ML.*<.+0,N<JQ/+7=<@ ]GX["L7-8GA>*>VB!TD!B0*+2.'4 ^FR#U/ 2/'R@
MM;-A8+D*J!53IN5]^ALHU]HR[0S40]O;<25P6<_G2=0$YD$P/-:3H'TF61GI
M2%A8 @P)!X$)%;=>:P+'NG!+.>9&,K:]*^MAORD[HK;3DHFRZ\2('IY26<['
M#[*,?D5J5BKQR?*<4%!QC?*/%0DB\9^?QK:ZK.,3XQP\!-%! EK1O[*9AE80
M2N%#T&4JXUA@:?W31/Q9\4>V[69$OG.9?!:?'1?RDX]!K$5A- 1F0.)4G\*M
MX#0*/,U?OGQ=K/[\U6LH[WSU7]^\%G!F/+%4$@H;074#<,(AV&\S@8PGXS_P
MO/_UIW]\\LEGZ3.Q] [)4'W;^MM:_5__-LLH-F3D]W9D?+OA]=07#L_FEUK
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MX(\^*1LLV-/G6N<,T(Q;'.P[4B?ASPZ(W8GW'%&294\LP<#3T5('U/_C ?G
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M:Z7N?_#AV$Z,XI^N/8+"Z(]N"P]53<5##<Q,ALD83_1/LLDBT"X:;G^XT>C
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M"$@-+I#&1[5_&D[.7N+5ZAO#W) = ".[>'! #X$".GC=B$Z^=S!CR) U\"5
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MS%W[EE5/4W,4H&+IQ/]G?4KV0*1(=*F@4$U_!EDYX.)MP\*[_4 BS9:*L#R
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M^<\2#-8G0&XH<=0\J FCJNXC M6\]P#=8*P@$8Z#+H/\%)A.-3@5*3KVXG#
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M,6%GS-YT .-;+*^YN2[,T$F39-2I#TWU_S66/"%QOI\HEZ+1Z%+IJN&691I
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M4LZQTBQ71L^1D!IK)J/#P0#PT8S(G.5E<_A-27E>P.W" X4K1MIA4VY.6B9
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M= RQ"X[]F/!3>-P'J0O_D,)U.S3MW25,XR40GYM<;!/Y[W3=YJJVI$$+.D%
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M*8>7CYG0(%/B"8+HXYXM$68BPRY^#A!'2/^=0Q^$HZM:?/_].^P_"=]@&X_
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M[K"BJ[EO"G\I/^4@GA$&:$D1%)UKT@WW#-]Y4%\DMT4$.\1FCX21-6;]Y&Y
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M&F]1NB02CX\,>[P-Y$.F4GXT-ZE1V4*K ]HME)3?XA0 )%![ O-R5B?LK'N
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M!7",<F5!WG)-0KLL8H.W5+KF$ I&;55W6+[H^VLO+SZ#)XMJMK_&VE:)H ]
MH*6VOP8K7\EOH0Z]"W9^;77D"/#>S=)F7A>C"1LTLQ$]OI&F.]YNFPKMFW '
MYW=HM.ML>\T,ET1DQ'\&^05 J>4W6'8#S:]\-V^T>"%78X<<^3'/_O&._D?N
MEF.1G^Y0<<#"OS #AV1T?;6I>FZ+9&?MW0A6+9SKSY#>'T[R2*!<E"AV8W..
MOHMK6J1JQWNK;]!9E1,M+V+(BH7#[A!58#/V&!1^7<#J#$M)LMEQ.8 C.;\T
MR*1,C':NW6Q^ ;D\*-2#$#77H^^J*Y@>L6 D<KLV&=A9FM+K[H#(H;7.5L_S
M2\02Q'3HS:]:7E=J#"$E]KNI\Y\1+) U,Y!-\% >+:]$-0"W7 2[KO[&L'A@
M5HE:KH.AY&>%<F+*!_GP5Z+*I?Y89S?_1S;E<RLPO?5XY*L8=/]0&(\_W6,\
M_B@8CUOCY/RMHNY=#G1@8865DBFFPU_;8/E#I,G-^F*_1@QYJH^0G5?7W@=#
MY09R$OT2_6QK%ZVQ?Y1ISSF#BPUL:?W(E3JTK.&IX[EMMN(#T]>+56H1ST\A
M;MU#E\5H3!I K=#F'VB6DH'A#ES8QN]&#[U7C*ZU*!LV0APNI+M$?XM&LIJ"
M0*&=#WT+ O$YR5^BMX[=H!P*?-;U3[+KD7@/-M5;)=\UEKJ%$1&!1T,UX<2W
M/L5P\7&8.6@]/E$C!^]TYWRW1$25&T_S(JH%U_0)=([_KH?SKB=WIL#H+KCZ
M(_BRNW#2#QUCF\+Z;D8LZU-]%'$K]9Z*\0 HF7JHL!S7N2Y'2^)IGP/\C/Y1
M0Y^[[^:1UM$H_XH>$^0.4-^ =.>F4CGE:7D@3/D(0%D_Q*3R0"(7H(MD^!K
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M<')+&(YHTYRP-R$,#\Z< KKE!.#L%3X $0*$V]CF!"V>$VM??\J7@2OR53;
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MF(#;RF@ 0Y^)U1XMWW5</(CHUQ,W>EJU](5(69&L,'().JX(JK-N21:E(:[
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M;XB8"?AWXB/QA+C475[34?(=_B^L)I<\\BRIZ%,B$(:<'D'(G"U4V&\/PGX
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M_FSQ*JQV>+'B- D7HBI%-(\'WWSH>!K8&XMJ2%''N%?F"]=$<"=W=?J0@DO
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M.N19)-^2'#]X6O3(P8W82W&NK<X[XA LH\J,P9_=M1*^ '3<S /,P,U=4A^
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M6DP35)XB]QAO!<1F!MZC^T60?DBX!83;!R/V6PH7U51KVLW<B\T4#6]H5:(
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M]7(J_H:;+X,\Q&A"S /^%"Z#GQ0!GI(]6W0. W'J(B':K2-/:?AIB L)+Y0
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MT3,2D"_C9<A:*[T[5$5J!DNBZ,CPUP5ZV0,-J7?0^7L)Z7OJKHGX;=*EE_F
M-"E,+'XQ]-KHNAX"O:GW[<1KP\2L'0CQXQCZ;^T:@1-$J=WH<Y/[$+]+K870
M2T O@!S(BC"<"EP4D&80$'PU'OILWZ#Y,Y* ^/6(<W+&U933ES5+176 &@)E
M#3'GGHB[9!S?POAAGWB\7R"/H!ZV\7ZUB?$"@$PLWFU1;31535EHD@YX&&'+
M[;,7+X1:DER5K?]3+L5'[_[&'>+&"6VUXM]PGZQ=N+,;5:X?]ZNYZ'01(5ZX
M.L393D,2]$VXR\-_DN[EC?P;*:TJX*1RL,@@6SS%C?*,HH1(UH4GOV,M]HS
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M ?\JR/FMO*^<<OL;IAV&+SJ\>Q04>7"PHY]9O\<;*>4G4F6%K^O+JNRV%$3
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MPG!Q -_T(.9!RX1_DXY6;(C&"DJPTM/^U_.G+S[Y;''AAT#BF4>KB4O2;B4
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M5:+A*R+ 2$3M1#Z>\NGKD@J&3-E!->3C TP#<(4FYV3UH9 @Y-#LK-!_Z2M
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M)2?=@S*GJZ]*/Y4/DHB*:@FK83=P*=KT)O>)S,R(K@THY42>D89HJ"6VB]@
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MQL60\#O77M)_/Z(O_TX_PY=_]W@9^W/9%I?2_E05#"FA2AL<K)2\1IMEV..
MZE"PCJ:O)CS?(_'W7FT+D-U\VU%".=#7^W_B^]\5]</;JKDDTAW'C\LX[S14
MP8WV&YY8DT(5V^I647^RWXG^W0K].%D$63-?+OLEG?;TE#&[FS$*)->;8),8
MG;[C*UJ=$KHD*Q_T/(2<%.OU+@WI:"0[)!!-Q&V1/%/>M&68-B*5!+&,<T-
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MCR!A7+GZDFJ7^C+>W44XS.E'^FH\OT)G G&=N!:!E3*\(#U"7#)"INL=:N"
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MS]@E@_V8?*E^&B=?3+Q'.U&V[>'^W+8]W(>74K(UP_AV7E02@ZV8 R]I+(*
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M\A*>C8\C^;;3H'D?)H2;WG5MY2+J,T-U_%%EN@]ML$/<#I8SGC@('.^5],%
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M6*&W1HJ?6C3W<@>1:8@.4)VP^J9=AW#0)YTY8C+3>-F3B EQ!8[@>*^U0H\
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MD/W1+%*F7(6-NHZM6G"@E[^^U@21W-F3.C:VHU]>!'-'Z$D>E'=^RR6,0PF
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MCS;;&S!MG&0"2>N5X2*J#Q%Y"0+U. H SWA3%I%)P^:SPN E.%\%MB#^@'2
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M]=A:H!L:8Q>YIKAXY\!9B*J%N!OL"VU99LI+L-[VT,CF P;>"D:+E+O%\R+
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M[?)]=GA-/<77]T][QW^S);JK/->S3D/UG? +O0KQV$@#6#0,3^'Y%B  UZD
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M 23O.1/0*[5V6?E8#TO0282]D/E!+2=9]P8_-&T2S(VAB>PM$?D9,9,T(7$
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MBVG@(["7R$*3.RF=M=ER$+V7XFO*DOX)J@,,VPDJ<X[BX*7595+$P;]J,,U
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M=2X.B) "H&S *VX0#BO2=444":@G=2I=2< M23C<<;!_Z @E;JR9]XOSE)H
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MZB*$%A)4PM^$,I.R]M*4Z#HO/GL949C8%%.F1$<(KTAQTU_:(<*0#')W9I$
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MO@+U%*ZE+;DAB^7\PSL_HM'D[%C$MN&#C*Q3X:.-*N;>5^/;#0J7D=U+JJ5
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M V]S$[Y'#8H'AX%*4_J"#2$F%$FM*-)*\B0H.UP?0Z64=VB[*Q=N8![X6 .
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MSB3?NN%\-W7TX+S^;>W(&<0?O!D5AYZGA^E7!@#"!  \SR\!@.H'9Q1>30$
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MN#(,I35J6!^#\!(+'+[,1#A_?422?1_>_<%L=N^,?F@ .%H][OO2^M@ ]L8
MWR*RK8]W8?)#V_X@/QCT*6^VUN;-=I&C]N2U^>\BE+[UK6&]%M?RF+RS0;ZW
MRD-MMEJ<_911O"^>/C19]EL0R<7,.F]8%^"!8PGM$0GR09%3]E0W6ZOM#2S^
M,^5I;5UH]+#Y@*7U-B4]NHO/V!\.VK0*ZB0TEI++W38=ZPIKSO4%JJ!FK /!
M:9I?Y&))^FAY"5#&8:+#AO46V^G3$,1VLWF&^1>?@BM^#SIAX("$#0T"FFO,
MO2NHOC:[&)LR-]R);@6A60.7,/)B%WOS23451E<R)]=U.;,-VQB[P0+#&\*A
MN2-4X$;%W^ 7\=#$P/I7P&UQ<B_.+I?ZBE\)>&8966EG#Q%;[Z3_IW3T8JAU
MA"K$@#TX[J7T^3=8CR?%E2HC_U4* F@RG_6UO))>H.:A_RJ-7NX$J4CWC%B/
MR7.R+8;NS0)WZ4><JYDI%7^U]#Q $VSVO5JQN<DQUIQ@,QS,>)_$U)$=.WV$
MKJ0>ZC1? ($@N<M-"@>C!:7G3J45.?3(SP!_FJKD^A,<B[,R&R52KTHU$\3'
M"0:"JF2 0GV<[XUOB''4-A52MFGV@.JB_ $_\0W>Z^.H)NJ L Y]K/6<!Z=O
MW0C^ <#'XFXU<T'C,9(^TH"'H%?SFZG943*SW.SP"/]>3H43ZT;ODW06>1AX
MV#@^0R^!AUTCK(\CNO75!7[WE<NCI6CNQ,4?G_X7Z>?5<CH57J#X[B/?J!=@
M-&BDAWX+9@#M7X,%;"7"QO4XW-6-5]1N?RP]G(;-I2[F8MP(RTH][@4*%$\4
MI4OU"WC;Z%6!.;HT\F<B0TJV-:KY4]+0#3C7V4TC_F [3>PHZ0NS("H@Y_-'
M]BR^E;!N=\&!!'K1ZV9I5_P@T3K2;80SSN$'Q>(^DW92Y&YR^ON+$4>9$[I0
MLU<^BA6I!B3*9"T@_ -OM9@!9X[>*5Z1BSA1)%V\6S]I6Q<K/YX!T%_]R?=^
M!AI6=[;PSE1%=96DA+L$B8=D&E7NP29]XC=@>.RHA"\RU 4WBIK)G ;3 OU<
MS: W!3J"ZUQZ'L+)YH\E%7SPM;8:_$S=2M+60RC$_CA_A;QE+@W8FH9#8]$V
MLZ<()?8)7,=@3LX9K)O18%\#9R93A+2&PQYN-+/$/(%H\=9XW> G_XA!>H"L
MH8$'AF2R3CY)K)[&$6415\6KYK8 .UP^=2D&[HJHQ96KY^*<BSFHH\DE-\[]
M$/@3[%KRQ^_/J]T@:4=Q8695/,:D/5P#2HN4EJFH0^<!L)0P..KLMN;A&:M'
MM5/\)+:WX_%7&35L*!6R#5@*I:TFM!Q"\X/[=20B!\EF'(!]0)W/LGH(EYV5
M5$HSN5IS&TLKLDT+5_#1_923)$JN)J*CW5)VL2G"VDWDKQ2L[:9M+N%:H8&:
M,KCSL@44O+C52V5CP4MOV V):&2_=^!4+JQ/C3\;-]C0)MR41'@UTLVKD(EG
M<NZB^E<2]@?P_<04#C3%$Q][*ZF!M3)@W_O H?&2ZX3 M VY08LY/0/>_L:_
MI,&'^/__$EXZ/.R/WS/VD+'*.UI"*<T6FT'4'3 !+?T0XZBZ M,X.CK3J#BQ
MY-%LHZV%F,',3:4&]2:0GK3BOXBQUO$2!)(QZ^_O8KYX:51",M])U+J*&2XT
M.;Q!;E_@9$/L\&YAG3IU\A4+A#"W(EH )_C$"N0'K?$3/I@T*9Q)VBQ9 FN"
M?%C@ &]<47;?]-),@TOX #:<H8[U),^)O6/K@_@/P)5FX+D^^+$TQY$&<>D&
M2_::W=;+BL?6$+RO(.(6E.02P[;,D "@P(MG: >!Y$B^\8J_P2TL_WAUL<4:
M?EMZB.?F !>0%:QYS%,[3-(2*/+(Q_MHO3J?E4BZC$!:HZ']R"1C;^NNV:ZR
MY[A:"/3K3OU/KQG  >O*?);6(6I+M/E1TO$.4,R5A9S1DO[Z[I,UFERY$;44
MR$KJB%4KR'V^X08U9RRAEUD"VL#8\)"F<']A74H=^\PQVA@[^_M_M3N=ER!
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MS(0T;8BJK6#?;N_RH0\N#L':DF3:&98@?D@C)]M];^3-!;)JO!:-!8"3%<Z
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MQ(;FTV<Z5D,;XY58 50-Q97,[:''\GE%]'2!=J?7V+2'Z[+%V*"^R0%*S_)
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M 3 &C4H$7287.$@26,M86F T_6U8GQ-$*$6M.(RF-JD5NBH3<@'J [Q@/#A
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M.5Y [FPHJ>D;.FA89(B^+DVI[C6:/3Y:#^?6V>GO&.P%1<OFEB7@_@G%@>.
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M%XDY<;>/C3K@0\O$#J5?](%1ZOQ%N0^$2U>!144PTV.CGVG.]MJ1USJD#[8
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M$\P!1[PM*C-2/4S,I&HJ;]()V\L%IIC_D*&#;4 T),Q//PV!TJF20*&:J]>
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MV<:?>$$X3A!R!^MK-YY9HXMSZUNP<!UKT#JSK8D;A?)2A!/=AQ0,.UP>S@$
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MJ?J^G'-:,X?>7HM8[H=UC)$1;$R3^0VDA34B$POWMNN\HYN!CLU \R"G:U4
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MK]U)/ ,H(1#,I\9!' ?S%\WT$3&. F\9ES]RGR[3EFALM<]R(M[XWUFH5[(
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M9'-"MG_ .E;EM;$XJ=5R?1_"LQ]I.4REUIGTU99:2VJM7+76L]NW'.5OI^Z
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MA**;_QSST0@;Y5,?5M)JWITMK^-G$.OEP0E_+>C>0[+S-W8<LS<YA$YT!F!
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MMB_TULXN6PT)W]N";RG:)R_:]=V(=J8*/JU2Q9EQH-X21G%+X=^#[2;!XU3
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M[=+,=R:YU"Q2L^Q*L\P-3]R59FD=[H3S(U(M$D\DGN2*)X4< :FU^5CU=NU
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MC.Q)]L$#"QX'/?UG9C\&J_=*]?J\'Y.^=%ZR8,%8<,XA+C8+UB0+'@ +9N+
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MBPMY#8+1Q9<O[^_OY9]]SRZ[WLL7K5*I?@$I9E_"SYY=WCDF["Z E>E#8/9
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MF$S5BGIV64\81RKMZ@)QRW;!>(Y),BGT:H4*G)M5:78?.AA'NE<TG) V]M:
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MNSJ2>Q')99S+:I4BL1FVH:J!EY*@$@Z3S4[8(<FB%QAV^UZF$5(&:/E6+ZI
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M/Q@'H1%6C>.KX*NX!_BK.3:"&&J5HB-Q/7\*]8"!IH_4 BWVQK7#]'O]L6&
M] W&MDWG-<1>6,"]_^;G_S)9%(;=P!ZAGB.P26*M07QE?NPX:/%H:>%#X,\!
MXU:)Z%H> MZ$5XA#T-0"%NTCT" LC G4^&-CJI$:;32_^HA.C,Q8?(O8O]#,
MMHV/F=W=R&9D__&%AN<:6U]H+LR^"0.+9 ..40&'?=?#U_##FSP82!/11"P+
MJ$V?%N?L,>H;C8E(+V-;(%AXXK0&\9R0DI,'AB^='!;L[<U"I5)6;M\0B >)
M>X@3B U@IP$W0B9$ O@/4#K1WO%HG>^O#+ 3'@C?]::M3UK'"R@!1!?*_[8
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M>$.ZA<3A/ 0_F.AM&;SLE"Q3RMCB8!!EJX31<(1!CI;\Z@5_+JY28O7U84]
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M 4DRG=OB*=*Z93\C+@\:+T@L>1K-6-A%U#W/DI/A!L_,$>+/58CV3Y=N'9.
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MZ",)46(IJE!KISLMZ#"CA318%)QL6M=J,J./#+E98D9=G(\0@R.>^+\@N&*
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M6EZI2\N\PI[Q*)UY&H^.#FSM0EX%,/>N?K=PDG!KM$6QNZ\X@5K1*V.F'Y"
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MY02F<XOEPLQ^^AEY-ZPOV#[$46HDR&6*X^H0G$934QXZXRYBU@4DZO;.N,$
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M(8M_+UPE"MDB]UV/^OAD4!@S[(C&VNJT\T.E4A?6AK!%'#H>N'!6X0ZKJ%5
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M)Y\/.T1MUL_S^)DF\AVW<)X3F(5^=F*Z$U,<6<>G>DJ,&%@#B,*F\J@S23O
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M GZWT(TUHC4PXHMP5,X"WZ[@529>:M U,[;GZN08L<D9[$80)A2X )\O?GQ
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MW:-GUNY1ZWS:'@UZAVIWMI8]V8%7Q,U^W8(T?F9!&H-F3]O]_L&N4T625%%
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M"O6J%&K/<WF+1HT//IF?1:,*8TCH37W9#5N#FF /;&GSZ[?.?]C./(8.3I@
MMB-A 62/.'7%F:L5GN2VN]#P]D7\G-5)9S-8N0]"@UC^^3UW;?PS?I3@RGW1
MK4>O<[$1V#97"4>!P,GO0<J<():C-![<<*43"YCP[3-ZLWUO=8S/Q6$2*LT
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MR/"?)AUB7]%S@1.CK:D:GOC65#K;8+P)R 0/HL))H7,7+U%]_#6!,V,Y^0(
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MF.;^;6RJ2_AKYLSU_O\#4$L#!!0    ( *-!;5QI5Y%%PQ8  %X+ 0 1
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MS6#X;2^M=</,B-]%>?P$5R#9-@BO.\A"BLCT*@RPCX( ^NX5#'! IO<QO6Q
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MH>9;UTNH7 V=Q%E\QT89TCK=N*%^5M(MD_3GZ":_EQ$(V\*/O_P_4$L#!!0
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MT2HH%0-TI9P'P7($J;+<*9J!_YJASX;UKFI=YUKVP35>S[Q"( TR(+J*S-#
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M<;'>T!CR<*1OU&L/?4#?1RB3RM=TP$OBQ2A4BX !=CH$(PTQ<-/!VCY;^@L
MPP4)&4DI<FFTA]Z1U_Z+G\S\VRCW99&RB';ZC]'T]G)638L[7[[Y:L>SE#2^
MJ"H?_\_%X&85LA(,&(@E0"$57#K&!=R4 -C'"/: .7S_R<QN8-_4]&!-5]$]
MTJD^]\W7^V3CU86IYL!7@3%+HO>#:)PZ6F/-K25\T\GL/C;3".;D+2./FGO8
M+*Y]Y>,'WL8%\W6TWG%QGX1^1+FV:%(()'9QJ9MW$"$JNL.Y^T=O!#2\'60B
M;FVAR*7U'DSB%S^),H\CM@MW%Q6<Y$T%W0WP/+5Q)_4(>!;295BB3,C]ML 6
M2.=B%CDUG[&7YA.\=W?W>E0F2[T*[R93/;D9Q3 Y;6;3ZFU2N1]'L(O20FRB
MP2(79!1<V;BE*0<@82A89[':V!%D'P-I">U<#*4/)C+VY/QFST7A_AB-Q\]P
MWQ?5VD8J?0!*!0@LL9@P08)AN3.G]4C.Q1PRZ#ECH\Y&65<!A>@\*2(#X%(*
M:*6..UVKE&(7E_)<..^FW8QM/+\!FM[Z\ANJU(KP;FW'$EH":6)TXSQ66C**
MR<96Z7LQ7H/C]..'KLKMP1U8@5.WY% N@1%& !NTX-9#(43NK;\&QNG3W5&U
M/>SE<PM<P(G^Z;:EC. 8LW". <684\29LBSWR>%F1*=O _D4WL/F_F[RQ5?3
M13U&@CB_^!M_LF:F,NY"-KJ<1BHF)='<V=QIHR8L!]CJ,W*VZO+G4'@/V8(G
M'(_"?B@FQ=/BM>:10 NT,1@0P[U%3+$8O6:WA48X9V8.>=2>T2](Y4,-F:VH
M@U1>]<4OE-&0SS IT66T XP;2ASQ2)*53-)ZB=+.HYZ%&?2KZ[[<AV4KW8A.
MR]2-#0>@ PS.("%YV-0P>&_WH1'165A)#\KOP95H#4PX#DQZ"TYACCCU,/J_
MFPK3][&*[\,@\JB\AR3"<[SS=(@ZFLPBR,> J)A4KWPHRL>U[;/^ZJLW7Z,^
MXOBCB2X?YFYWE"X5R45=C^?RU3M*%BL@1=2:DCIY2I; C4]-[.>-]";.R<<W
MQT)U;U8<(3_.JE=^$OE9=]4]BH@8 UHAYN,VK)#(O9XU0#D3Z^FFXHS/W3S!
M^E@6$45=OL9['&U0!V",51AKK93(G>Q^'OWD^=U3D1G?K?FV5_KI\U)U,9V6
M(S.;IOK@ST6[U4<X"$R,N0!FVD:A!6(R=])[9Y G;R#]TI+Q39Q:P*M@G.5
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M9\^BS40WV4QGA?=09[R"J;ZK1RVH71H8[9+SJ@,T;".C'HA;38!ET_JA3$+
MY 6K & @3$NB"479L][#F4)#=Z,CL82-RN[! C[J]+Q<?5\>:&/D@Q@%EF,%
M+5,J>M6Y,Z%+XP\?4V2@9+7J9E]]]M"99JDA?CT@1S&07"?))',H?LM\[KJ:
M-1##L[P_)^LQ8P>%9IR]\\L+KWWP9?ETF%H/B$D/I./S,@X%,8>,KC["V7 A
MI.[33Y"Z/)KJX>[OA7-SW>GQ1SUR[R:7^GXTU>-Z<,)&)Q0:E4Y&0]#,!.%R
MMPW:".@$F<^OZ!XN]5S[:52&=T_'I/6H5&! !LH!#3'ZD"@XJW)OQ/5(3ICW
M#*KMX:K.A;6SN]DX^IBNZ62O86N!%BC&"?!4"2/2S3.=N]2]-;@3-HM^".CA
M"D3]$44]-FX",)PSP!31DENKO,A]&+ )SSEX[MGTW<L5<5MZ7?G7?O'?=PLG
M]+88Q\^O%KJXCL#?%N4?NEROKHD31%--XQ\*2FRAXR1W!+\CQ&,\/]HI/=PG
M)3W$@@O7]UU5S=:+KTAT>J0A.&(11 OH0M1$[LSOTOC#<]\K6:LYX'TUW<.Z
ML2YECDH,H20P,H:ZG@NC0L!"R_P/=>1 ?N:6-CR[O03"3\5IU>>B(5B;SRD3
MU>G2CA]]M7E9V[6/0E>CJ7]L5+YX.NS:V^)F0?/?]7BV=J C P'&$0DL=LX+
M@0S)WK^];YG.VZZ/RB)Z"/KGFEML$*]G99JM<YB+C>.#_V/^5^OMRI0'&@H$
M"!3"&>6(H-EWZ5;(SMOZ>F"GASQ" \JY?3>"5-'0%9$0X/@_T%%#N<R=0V@%
M[+NTH [<]-5LM/>Z<NK2(^J4 4>Y19Y*J$/V-P_.Y.+ D"9Z!.P/VCN"!!R=
M6L$ UZE)L.'I2O- EWK.S7;VU'(/C24VA=I>QRA;PP 0PX0CKAGTN5.BS4F-
M8PG5.>- F\0(5TIPCYQ9;0AX5*%Z]IKI#WHZ*WT17LVJT<17E9ZX=/>T*L+'
M.&I<N^9+V>MT5C2N]BF;WFV 3)73':3J6#R=G@B;F_VUOY^5]C:N-7$]N"GU
MW<NTJF,N7==Q+#VR$6<B819  Q&T5E-(6K6PWO(JWA8875[\J__HY_K0)>F(
MCTNG]Q:(0!5B01J!<[SJN0%"WP75N3E>?O,OEV8/76(]E^7I1.&3]9,X3XMO
M)8)+4C D@&1. "TPEPI2$T2K=-,V^Z@;?.@2ZJR,%CDUF_D)T"<<OTVJ>V]'
M811#N^<CQVV@,CX VPAD^ =@,Y!4]*7A0]%/@@0*HP L$@)R'"ASK5IB'A?M
M&UZ /1#K&Q7;$]LI$+;Z10W $B(C#9 N%1=(H0R22A/4RK5N2?7+T8=]!#83
M+35$=]!I'Z?B3\9\.=95=17FH4R=0:>20.F) C0*R@+B%F=_A*$1S#GLZGDU
MWL,QY#*>>ENO1=33U:AU- >^%]6-KM4Z^CRZ[J%@H@4RG=K^<PB@2X\+&\.$
MSKT2#,5^VZM00Y._2<6Y;U%\LK=1QK6; 4MPM-) J1C;2B'CYB05)G#EEDS#
M'8KUSQX^,]Q5W44^767<P.=P+L</?WA7W#R5!*S<RUG>HM)37\@XP*A6@GDG
MQ6HRN('"YC%.F\I,NLLX&YT?_?[>W^CQF\ET-'VH6V>$U,!X8@%Q2 MDF0ID
MT_EUY>V?;XHO/\>/7BR[\8OGU;9FP'/PM+KJ,6/!2X*R0%%OKK4X6GA4VWE=
M'G58SZFS^HN,NLL\/3?A04X":0T!BFKIL"2!J$UY\&/@L,'_&8K"C2K+[>>\
MBF%W,?E<W-OBW<36+_6I<;,4T8]32!#*D(68DU;;9-VG#[=!=E-TD5-+??DX
MGV]]J>_];#JR543VYWIH0:6;4)("*@VQB@E%9+OKOIO'.44J,VHN]UQ\ZH;]
MP?_Q:6:JD1OI<K0H";-4I0>GJ3&I*:<')EH80%Q@'GQTK!%NQ6;#  ,G$7LX
M0LRFOG[;+7S4Y54Y#Y\757]/W8_7\IT1G<:( 4P8TE8H'TR/#1B:8)V^7?3%
M05\S_[6_+ZH8>)4/BVCZ"=Q56)+@$:G'P%+"X]JGHT%#B ##'L<HSUNDS4[K
M0:MA3]\:>E9U[A=?YP@NB\D77R:_]#H5[ZS*30.+6YZ,J&($CA%Q# G;BONZ
M3S\3BCLK+F.LNS@;C7C6!+V836^+<O0_WEW<%;/)%*UE;; %A@L-A!1:04V@
M;_>J\]82D59P3M\8^M)]#_<V/I9/O6AVV:,"BT9L'4_/+WH:B'>&Y2]?;H/L
M](VE1R8R7M.8KV^_^O+&EQ<WI5]TI$NEFVFA6]PG684F XTK'7>+-W,4Q9")
M=N<4F\<Y?<IS*[.'JPN7NKI-_Y\*J+_H<;K[>.VK:3FRT2+37UQ,W,L?+/WF
M&GB-TC7S&/E$[)+&2!::W!>T.P$^?9,:GK<>[D^LMDA:ZHWS.G)B'U^#74+(
ME0!2<P,(<4$B 8.1*K-E;4=U/N:3F8'&1S>SWZOX-+N[BR%5$3Z-;B:CB%1/
MIA%\\K'F]S[&$;M?>5QZ]'C5H\-MBQS#9KJ#D5T#F=K:_SJ:1(\W7<)9C/6^
MJ=U-LB3EB :44D^<M$KZW)4LC6"Z+EVK'US;NYM;"8R*H;PV)OA@C$,\]SY8
M"V2HEO=YN%Y=E+KK]AAN9US],?%E=3NZKVO<C+ $$ON4]-,R>$&91CI#R/UB
MT$,UM,_ 7Y%#CYG+LK\!J6_V5@LEX\V+E>&'OV_1@8@Z.CMH<5AB;312Q8,$
MWFNMC1/<MVM#?@R$;KA),0B?&Y67^W3C[U?O/]<W3"0^KC9$&V!<((Q@[]<Z
MCS3D)IX_<UBOOY->B^Y*R7A F<2Y+"95=$E=BBSFY^O1-ZVS.^X@,#((P -C
M.DCM)6IU;7[+9&L:_SSVR"S:S7BLU(2IWI9K467<.9N1#+^)YF%J"_4=U)QY
M:VV/CC #%,,F'999A:C$*HM'/#3Y&S;< W*_4;O9KS0L%<4T[SY&(J L,8!R
M:+"@!D.A6FW)]9\_[/:<2_5%7KWU4%9T[>?IP(^ZG"[W8JI>/2S_39T=AZ"!
M]B8&_1I%7P7#Z$?F?S:@+;K3W^E[9J27YR6>\=3/CEI$/5UJ7$=SF$N-??&W
MP4PZ*+^'6XYMD,7PTSL)D-38<PH)R?[FVU#FL.66XQ%9PP:=]VP%]5L=Q@0H
M3#D@UA-"!28DM/()][2"0UVLZ\K-!JKW4&SN*P3?W)J'R\79XNB+OTQG4JDE
M6[+TQ=LJ:PWT @4&<@V@\$)294W >C?_</. P_.<][BD-^7VX$2N2OXMN_4Q
M.E*I7]R-?_50#Q62]"J&$\ K[CV""#N5>RO8 =ZI6TW?C/063#89^,L3[KD8
M:ZMG*HF 5@-C&:%6!V3;WJ#?8_13MY!AU-Y#"Y56)EV#>TU-FJ 8B%$/+(Z;
MK4<.2]>J8V3N):<.[*F;U[!L-0:U!ZI(BG,H"5?.&Z161;"E=Z,XJZI_]EZ5
MM'WH02N3=M1$INJD%Z->Q\$:C5D8 23G*/K(5D9[9AZAW-FK9C3=+P.N?')M
MV@D;"S01*ETJEE!Q[>'JQIA?QD$KE#+QO7[/K[-Z#UVCU"C*JX=7?F)OXQ3^
M9UW6P::;RAIJ8'F,(.+?6"IRWP79ANE0N=P<M&^SI"[J[Z,CV1J^)W0-A0EU
M^/KJ4K<%VV'2NWD9W6HN&>@X K-Q!@.EF0%>4X6"@-JRW*^B'<9<MJ1_C\I:
M-K+02PKXBY_,_-NHE7EPJ>WT'Z/I[>6LFA9WOFQX;IEPH P)('!"4E^%&&V@
M[%GA%L .T($M*Y]K:>/<9&2N(?O6#_(7GZ[ W-_&R&)<.T>, U(Q AP/UH3H
MSQF<YT)S X S\$?R*3AS'=FGA9N[#*EAJZL#E;/U?1.0 [:^[T94T9>6<S=$
M;PL.D?3@>D! ,*D=M89ZE.6IEV&I;]/^?GCF-RHW(^/S1%'Y\/LOK]9*GWQ(
MIU86,.ET8,$'+O &>I]Z_#U^XH+AQV^>"7X>;^![G7D47W326N8M^E?]WT7Y
MY#'4%S<B#J0/ C@ML,+2!(E;>6];INCZR&>R*7=4:>86,Q_TG;\*+S U5!O7
M@<JX&S<"&7XW[LI0T9=Z,V_#K<'%4 -(@@A0@L?PE%@<C?ST.-^P#1^"\HU:
MS7WL?O4UQ,_Y;3*:][9*IW23XLM\1:N/ SE"0(NXIGFM1-!*0^163DL:CMBW
MC33LIIR)C:(O5>8NSGH\EZNNO?6C+VFCBA[FQ.G2?=0/R3WY[,N[:JE'S?+Y
M/A' (!R 8T1QH9P4MEV[WEU&/8(L2[<SHW[UG+WA[YKW$IFLTO.JS^?RJP"9
M0$!2SH"WS'/'G&.\7:/8-J.=AP%DUVOCBG^@RH:/91&=Y.E#M&K_K]GH/AEU
M[S4-FP8=M)JAM?29ZAB>QOLX3G F[LW3H(VFZH@#BI"TBE!CK0W0V=QUE-M1
M=7XQS=YZ-QO'/;IQK/IP2ZDX4;T'P?/4XDJ8L-J_M/L#:BVQ#57[D-E&UIY2
MZX.*8ZF*:!3IU</G^!%U'C\A/CJ#D@'EL"-<4.-@J[<W<TRP9UB'2GOT8PYK
M33/STM+#F6:S]/$#&JZ(UD'LJ6:B!;S#E$UDI[:MZ73DY3A,B&$-#.8!$&*-
M1,PHB ?;W?LVG2TE%$=H.1OIZ,%BWL[*J.A9Z2.\MZ.OZ:NJ/KO@<+J\$0(0
M1N$H//?<YJZ>:$8S?"R7G;RB%\WG#N/?:U.4Z1<>O@E<CPH1"XP5#LA@@_!0
M".7<MN!L\Q#G0W)&50ZY3?Q6^3 ;OQ^%-6=+$P$T-!H@[8R7E$+*<_?/;0'K
MB"PD3RR4FXK&Y>! R9UWDZF>W(RB^WY157Y:]9[8:1IPT*1.*ZDS)73>)EG\
M^]$7[U:';311;BE0S L@ A1$&DDMRCV;V^#*E]39,%IM\!@DB:NX,4 ;Q8R3
MF 66N\-N>W1#)7:RVTIS:B<K(<>2W-D@U*N'Q=E?>NJX+G!@4@(MO 20"$TQ
M%4C: :?<*KS#)WOR&LBJ<]T347U$8,U0GX&FT^4&=[0.;D\IH!VA'B8=U!OU
M[4TL&V_'9VZ*QRA%: $@8PK#@(37FRHI3];,MJ2.3L3*-M+5@W6]]E_\.$8T
M[K.WMY-B7-P\7(]N;J<-F0T,>7J\5H#@M$%,8BO8IK>W][&F+9"&CRA[I;3H
MCX\>NOLTJV)3^(N!QL8!3*T7&"D67=3!5J!#IB)Z]]ZSTS%@-F+AX(\FH2CO
MYJ4R2P'ZXU^^^7H?5W??*0>QQS"Y,@]=)<R4;W@<ZMK?%V7*>;Q[!M1HA<KS
M:"14 4I(\%@$ZESV(HH6N/+E&S:,]NKA\2]KPQ@I#%!<,T!%RA1"*Z'/'0?N
M 7.H#$1VZVG.0/1#T;&D(K[=YWHUJZ+BJNI1HEJ7TRH'C,$"&.FAT0*3D/V0
M=R.@PZ<;>K*&5>O+QDH/SODCEJ9^#S5@>LHCO !RF"Q!1J)63:"SEH>FWDF=
MGG,A 'J":/03 Y:Y3_8'H'Q+Q'X@QC<J-_?EFVM?^?AIZ>W6Q\@O ;L*[^[N
M9I-B>NM+?9_>CIBXOVMKDQ;JXT I(-#*)!T000T3U)MV9_O[(A@^FNK 6C&T
MRC-?MOU8%FYFIU?E)U]^&=G:0B<==SP#A0<DFC^R@B,36KGL6Z[BU8U][MY!
M%IUG[H[QB"<9YB.BAF=(:D%EO(_;"&3X^[C=.5HG/).",]_(;0U.&0PT]00$
M*B%'P7MM<[QA.##K&V[D'H;TC7K-_KSAYX\(0GCIQR-M&S*_G #-/03(24J8
M$\ZLOIO1],[A^H</>_,VD\Z+C K+793YZBDC^-[?:/OP>%CP#9<5$%. /='1
M<X$*1$$5<"&*2!E%49)61&X8Y.0)S:7 81SVIN)S'%$9CQ P./J(7F)JS-:4
M=8MQSMW_RJWJC*U1MD"KM_M:</4NV<[V< C?*SL_[7COH-SAUH&&+B[$I6=]
M"+"&>VP19ES;(V:^P?\Z*N(WZC0WX1]]6163B1\_OKE4[V0P*]+K?@$$'91P
MGEKIVBWX]9\_W#[> P-%7O7E]M'>:CL:CZ8/&Q$12".BZ#4R+Y"BTD"$92M"
M:S_^;/CLKKSL?8Q2ZN[=Q(U*;Z>71=54,D.=2DEB!CSW6E$J@Y7M J>F$<Z&
MU"PJS)CVFH-Z/4=3+_13^<2%J>9=C-=*D)$$4FD)&#1&:D,\4^WZ%NTRZL%2
MX?D/Y?O5>.X5O 70-=.%$&CK/$ "(XB]8EZV>VNPQ6 #+P3]\;2C->RDY-SK
M_M-ZM9\>*)= *2* ]4$BQ:W7IEU#J]W&/;<UHD>M'\1 ULZ3H05:2PP8YLX0
M9[EW-)]=#+Q2],G6SE:QDZI[>8IB!W!17*!01(@-YD1!@0WCF4LMCL12!JOX
MRT= HZ\Y0+GR^V)R,Z^\[GY/NNUG]U:8W$:6 U8C0\> 3*=YW" =A+4.2YAY
M$@Y;C?SX DN5GF!Y$Q5;3O3XN<GPQ*T04IM)IQP#R;0'D$))N<7!Z.Q:Z83X
MF&N4-]I4<XUR[\0=NEQYIZ<GTGF>DAP"CS#5'#JJ_%D^OS.D >SS3,]&(@[U
M1DLMJ._\F9[-1.WS6$LK+1_*! C20#N* =5$NY2*M*35$Z+'17V.9WKR,[]1
MN1D9?WIPYK=/:S(%"Z3V%'CFB#/(0<,W/?^PVS,]OWTZTF=Z-BN^Z*2UC#G2
MYH>"B C Z$! >G6 &RN(I)NN%YW)\TH[\;:CUGI(5'PH)G96EE&TA2^Q5DH3
M34@&"P&%A& O T4A]S6050RGD8[8R;GOI.;A+DPO]9W_UG/N@Y]>%G?WQ21=
MB^F0@6C]V9DR$/O)<K"&^C3NV@H3"X@1C ?IH..#]?ON(?NP6]MNA@+0 A&
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M.XPI%!DIR=RR[-K?STI[JRM_<5/ZN;"K$)LJBFI 9NQBUQK8\%WMNG-8#$7
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MGL4]R%J 42!8.86(S=U:*1OXP0JUA[72YKXA0Y)]+#GL]%)?S77UN0 0T2B
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MKEZ4]9O:%U_T:)R2#V^+\EU5S?3$^HMJ^??23[V+2\#5;%I-];QM[.+?KB7
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M7_P\T>9H47W*!V 0=L"$0)GP1F&6/6C]SINC;;/289JC;2/[Z)NCI5P2X5$
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M@4 HH91 )&GN0YLZ'$,5&67A>:VXJ*MB#UT[U"1(_&=/ :)U,!C #<1 .&2
M1MR#X*#0-NZ7GN?.OS= .5@VKC/%6VQF'U7WX)#4P'J.'+<"ZRG!U@CJ,'FV
M+-1M-X<.>C^D86@K@63, 6^D08(PS!DY;8/8DFD[J#UL5'?_=O"<!UH&A=/S
M$\%B (52B@OM#<N=8*L%,GS4D8FHS?3OH>4^&\U:)[$'1EH6HQIJ8Q05-U&E
M)4_WOBPR.3KL';S1;+8=?W_U]=MG=BN,L^PSVU[YS7U*=]9<OWUFE^&H^(?"
M4,;501D2D#6"M8K?#DU@VSZSN?G;J+"^^\PN@%B?;LN'N*1+$7T$BR@5"#*(
MVSUK=3)]9MNK?5.?V=8ZZ[O/[ *(#R8"89H"3:"(&X$@V,==PI <T^YX^LSN
M1][>.LM=2O:K+V]\^:UZ.Q77W/DW7^UMDO(ZU5FO>E?>I3?;F0>00@419@JC
M%4H;RLNVCW5P-[5;WJL/C>;N4;8";_'M1GA,Q?B,^E0TZ;Q3SBAG^3Z$UXQU
MAH1WU6CC#-_SQ&,MAIQKRWMW]_/SF=^;R>QNWKH@?6JZ9+_UU&.'.#4-6#VO
MWVGHW8Y",HB0ZSCDJ2GM57CJ"G!?^ML$X8M?/'-^8:KY,5CNL'Z'D3.]]+?Z
M^:F+Q=NB]*.;R>6L+/W$OJAAF+CY=^-%*P/WW[-JWB[A@X^0T\%G7GWT!'+X
M]6AWBVIZ/; ?OFH:2FQ>D!Y_G/XPNO+_\6__/U!+ P04    " "C06U<KH+V
M)G# ! "?4P8 %    &)R;G,M,C R-3$R,S%?9S$N:G!G[+MW5%-=]RX:*PHB
MHA0IDE=!D2Y-.E&4+B*]$Y$. B*])390NO27KA2I(;30(=*E=R*)]%X"H85
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MNH1E<DHO9O],QL[+ _C3W+LG1^-?R;DD*X]:/X^/.K"*@-IQ2*T835K,3UE
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M1$KB0G.BU;S("RI ?26*B8.PKX9CRQ ]=,T6@SQ^IB:C+7!@1"D !*+B?M%
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M2#I1J+D:"F Z92[0$9\@T+[/4# 930$XS#^*_EN&3@6<PKFPGVCJ65K)/13
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M$&<8<+\Y>"U#PU,#UDJ"TF9,&)EXNIOQ>L_VV)_DE\Z;5@7.%F^DUX;B7KG
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MV%"Y#=J"\4R-JD1>4N\ Z0L[8C])^%]/$[(%J7+Q,L<XD*"B''"7:I(1S!2
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MU?%&%&-L$5#FI2MTO8PH%=9A@S+-%C@Y,.LQ-VW00<P;!G',J/SM=+O,2YM
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M^M0,&3H6>/-1_'\4@]=&P&-KF?K"HN)&ZKJQ1=W@H/D 3_/JYW@QDS';":^
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MXVFLV'\?$P:!5*%F "3>Q_C&D-6J2;!G?@7_WUFUA[ZWR&!S&C+J&Q7*.H-
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MZ0:/R>P*1$F:*G5;&\2)*DW]I@"F+MD$]W](Z-!P??S*ZM[B]B&_]MFK"Q0
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M?W'Q$"[50WA);^(+7\Z'?/)RH(9$D-U)_7[W"MSFIR^M%SDX=$9OK' T=]$
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M_$2?Y+8U,9-0U/9;^V=4;1;"GUD-])P.;^]'8[:*4,L>1>R3.9._VQ!S4C1
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M]$IORJWN]*?\*7^P16M(M%'D!PAD0*129:GLRU,6\KF*Q3VYFCF*_+Q&I)2
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M,F+I>,YML/V?;HZ8C,Y[!Z+"F,^W@(8OEQ -00$( ^&N.^5O]A@=-F&X>NN
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M!6N=6P?HI!R*BIS";-0,\V MTT*WN?Q3C:>J+7&=*T_-(Y*<-??GI,ZPK],
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M'PQ,OY@2VU:^TC45>/2Z?A_UN1Y$,J->Q81ZN:FG.*"O$LO;=5KFVRG[%VF
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MJR-OM73$<0M]0;A7,'1O,2Q:I/Z>E/+6,)'?=L"-[VZB4:M^[O4A?*1'?/B
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M?995<Q/<*. 2LG6 8"'$X46?$A**VGW\>*RLFG/%M^T%/OQ4B=<W=)?V7U-
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M_4*>\%M;X\U_7[YX$26"LG<_A.GQU:M(??,<_F^%1N5_WY0RHGTM*ENS-\=
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MGRBR(,6K,L]*_HXD0RB%RAW?O_>8SGQASH#]-6H:;806^#W/^N3U(\;#=8
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M?@;Y1U+XNT\^M)_#'#_I*MF[$H B*18Y3D9B[+IIEIA!=XV["QY%@O8.J+Z
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M,58-'7U(+[0^XZ0R(SEN/=K.PD5,L3"K)0.P*@(&O&($<S7NM5+?YU_ KVK
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M9!^\ YJJZGP]QN[\8#X62:FZ>7D3W>%D@%W\R'8SM!P3G]FHR%+7NR;%79J
M[RC4X'9=4U'F$F]=]#:UBO%:J(\:@D\EP*^5FUTE Y[$0[ 1N7M?Y6=^MAXN
M=<OJ\UE;K"=IL#T[_=UZEPE(N PE::4NDEK&,,1KU,'M$!&'>%1XT2>U0N,C
MOU*LIX616G<V\0KX_;*E+[?OG$K<0QXCEF?Y[$J,HT>))-K0(U%X(PJ/P##L
MT"EQ1LCKB!]9/JPR,;L7TMUF\_;T+/$3GQ9HNGKOZ[MW,TL%)0?%W06D:D>+
M5UE+3]V6^_H."=I?@UGA#:**@H&Z6& DP2P'1@)6]GD5\F\B9VKKJHW>L/L
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M.TC?*S&'-Y< >,WC 0V8/>I2RH#SQP/.8R@#I$G?*Z"'-T&%_UG5:_?WHLB
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M!)(DKYDGW^S)FW=)5>V=%I/Q?V=CC$K?71O!@@ER0S.51'J.BV3 ]S$,2:5
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MRN=.XWT!?LJU([@\?!)$N-';\01'M^BPA4^FG]"649L-8U13J0945X8"9J@
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M@JL9A0'I1,.VAG'WF=7KHX7I=\U9ZID=$UC?:M&!C2C]L'KG=VT70OA&6Z[
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M-[5F)7)/2!@JMGR=\*--'=O^^HND3W!^FWF+ZMUY^"DD]/'IOPY)&I!$BW^
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MXVT2[MP>+5)[NDGB:@4Z!@H(Q<8S)X<K:NQ=@+9KM"D%Y!U O[NT\46$BTW
M_\;1(9G8/K_5X6?L#S 8\K#L_Q!"!92)6@?TW>:(8DP-/20-CR;%PJI1G51
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M%Q$"@J,JJ[5O;YF-+C9^NIQXE<\[3_U<CLY@X!J)>PR-C-0^!Z,)&%H VY.
M1M4*H4!$<9-8Y.#LLCMJI7@^/LOYNW&P)XE+B&*\<$SIK >=R@H>@ A2]*>(
M* 3M+,EYCY^:6F4YA"K3&-3X!S:N?^5Z;0WB\+L7\'^W4@/X!K1=&K'\DU!$
M^45#T/PE>-F_=F#@OJNN+!50.0DZM6"1[B7O)_U'JUQJ.K215BWJ$8?O Y-(
M7-XT.U]+N\A[<-<<WK^^,F_'[#[-;OH'A2C.=3R^ZC@M)>$T,Q<OPG:U;>:R
M_.5WMQ8CP%'@:A0I QX-Q"O\<X]/A"'+ME1 ;P%J5VV__"#(@]/\:U/:X8XC
M0BG_>G&1\:CAD$[P?#T!*$&9!5UH.8.&3I?U"-8E+'JR; @67)WJ#74HL.G4
MY/)F=Z\LYG?D9&6[[=:+6*0Y5!;M*YAAIH!5,%> Q5T<=]UQ^@#3YHR/FC'[
MC>5(18E?ZL(Z4HL#_\-Z#I"X?V ,6GY,B* "P).P4UG#79]K4>WF+;OSL.]5
M^MG2=[TT(B_N6P\9(><SDN]0&$VPS>TYYPE6Z& $2X#^;>S1^,QPFMCITZ\L
MU4V!G,+E?XO_]4)NV-&N_KD-K%\8!IK8% 5;TF$S1F[SW<EQJIV0$6V,44]G
MYY<*5SPCJA.H<IA!XM&G&-"_AV[3!*YN'QD.;9>'+J-K042^7="A#T_Z!=,
MS0K$ZK]Y5JB*[34U<-FE.,] !:$.B+,A]['O-46BT5"V $,7S]P4C/EH35R
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MEE3NU'05T7'MNT0/LK7H^E4]N1H@-Y11<@B4)MT9Z6-D=[SV!SB79O_,=XM
MRUQ#;D??X(Y6MR6>@Z,Z5%8 X18136GOCU9-FJWMA36DWPQK$SS]5_71\?4@
MD^]^![R43*U!(OD-3A0UDP'==D6*'6E,0P]U!?39T&L]8PBK/=J[TH_S+P2/
MU:+.9L%UL]8P(Y"9K4]UUA2%9?/T^IFH<S"O+XFFCOO)D7%P9]EC*@$G)D\K
M@HYU(_: -Q C2 ?6G2:R-2E,\1-(\;-KGKL_A1,$Q#K%G\74]=VY%7%7]/+K
MX2$T07_Z0#[J' ,T/+E%_Z*&."H ,V: 8A-G,!3F#@"?1T!5<959EU;<&:#L
MBKA8R*A1?-51JV*DJ5RBL],!JEX,$ =D5I3P)VH.4A[&7L$ P<P>N2YL4C0V
MTE^E_1S[V?:"7><0=21D;# ##ME/YZTI)] C9M7$6HF;5=?_[BX[24D+C0;X
M>]UH2E 27@(Y=S![L% YW;>H^H<..(H+5 ,Y >7:,PB 5ORIR5].=+(N@NI=
M2(%_C @*^RWJ?77UTBOLJ05!;^,W+JG.A;>\* E[CI "3U?E#XTUA@Y;T%XX
M60#GQ]Z$"4PD>@CA>9&\?_<>-45<Z%MEKG.)+$ZI:WM[3O<UVMR]I>>3^DGR
M>&:/]5P$Z]"B>WBV<JIAH96%8/?E;^\N*BHJ/8V\=]ETMN]%MT#3A'!I1=&!
MG_&KBPHNO]1<TEV@/U$@A('W/,3/ZN30'M_CPP!2E)-\<UYQ[,761?6%!;I\
M@BR+A*KQ.[=)NOMF:*.-34A*1OL7)]>5E1W(1?5;"/EZ,H0HW2S(CHLV4$_\
M\.KYP$L]OF-9"+>)\#R!BE 2?*2&I >IU S>K++\H.V$X,W6*OAHK?*Z[FMX
M, ?NL\V)E'SF8UVO7S! ?C'/VYPH^M!V_[/.N>8Z2P(6#M"%3.P!+:0.S.(/
M>0-EQG.>2* /K+I@;UDNOII!9WZ!9H;NILL8-A1..ZSL#&T14+[_BB^+?E5F
MFS6G5O83H>+I\;.H$QX/9N\$F8\_Z*O$G7&XT('5")3S!3$EQE!2SST/4<^M
MVV_#G5%GIP\FG]W#C<F!ST^VYHH,58KG7_]5\<XYQ$:8X#DR^G2"GSQ-9W4F
M>AL/T(7,J.K5OSP^JBGTB?\J\ACQ5?N== 67_VS4=Z1,/7X;BC<('IMN0O&O
M'-7IC8\Y7I ).C +2)*Y\W#&9\&ZD6=I]KUL,WZ\TPT.WX$?TM@U>:,"+Z!,
M(U1R< <B-&3>.@L>-6HQN_29>CIC>:S'ERI:NIIPH0#N7-"3,5Z7J \@A@OW
MFVN>QGKMR1\$4.P\4+J$FHW;\T[2C_J=Y")DIBRLS\9_9F.^S01C$\C_=BQ6
M>\;U.NYUG5))XQR<W<&KOH;J[7BAS/(1?>V;]2$_%4&K98 6UNI\&"#+$M1N
M++\G8E673\1PS0YED>ERT<CLAK*N;NM4@IU?[R.>/99.<": _, '3 @- "B%
M2=-..NZRDV].4U.J@FA!&[C=QWM+ /'\_SYC1Y$!.N#3' )_,<!T D^WA.B@
M*<X'II:F33W!RE%-F&!S]M#=G_PJ]3(KU\?R!%][-L>@WQAU^D1\J#3MSWN#
M\!Z@^Q9+VPP4.Y7.JF2DR\>S%WYG1@;B>%%OP2?Q,P9C!FU>MN47-[*QE+>Z
MX2#11U]]U\]\9L]!-E*E=U"SYAZZ?Z:74*_-X3NRO]QCD_YX+^(D<3-96BP;
M]XJ<GK"9/8_S'3CP8(!8#R18269+>BA/)(3 _KVU:_S?:G;-ONT^ &'C<3:8
MT9-KI-#!37F?5YZ5TR<<^H(W18-"X"*MB*\A%R\R7WCW_A3H]0(RW>/.K"F^
MQT^9JSH@PY[.5U83MK^_65CZ#,5=@?L]LO=&GG>=1M@<GS5MQ)PF.T[)1VQ(
M",$2#"/VS]WIG ZK0,8?X(XB-'FVR&-_7BIGAHP1CL*K7XIQFJ_4N"KR<^Q,
M[(_-AEA_M>.I-LY_J@J?M;U*%TPMX4']=-T9AI-=5-64S<Z(-0]$+&SLUQMM
M]Z,,'B*31M>LF,CX',NQ,2C9O?70GC;9?$OO!%5(+?4XGB!/3-SPIH <WB^;
MTF7)T%<D=Y/"_BFRV^5*ERO_TB<$C3]U;+<QG[G!;(UE)_L0F2S)T+D-2'.Z
M #86_ZP\6EGY-NN\:I;O?DS0"0-#(,RP(Z LS>!C9._FZI5_C44C#[S*XM+2
M7YT4)]N! S2$V)]*5YG+]!].U]K.ELGM2#G*9Y0"3C293*]%^Y$2*J"6#YS@
M7'K.LL7.K?X2Z_H@II_"PVOP]7X*.UEZ5C100AJAFS7JD=+J<JW;Q37_?@7>
MD0J68G[YS G2%M&\L'#F&&&XC9UU!<4$<3(5-*OY*^E*D;1^PIZ@*#"?-,#^
M2 3X\AQNJ+Y?4WX6D[U!\OZA4TS:\J]*##01;+LR; +AO1.8IVSNLD:6E-X9
M^-=%>!\IEJ-<^\-\6F6-+.Z5BLTCPF>W JK ZQ$/6M/Y^J3_?J:<^%,$9R[T
M9I=,Y1@/-V8/GF92%Z3:]0E*<Y!=] 8?$N<D-6[$O[-AB>[]@[NU[J%X-+&*
MAY['S218W:CXE8 Z2:[1'Y)\GO29OTFM>+4^T8O%5#U[7;"IO$Y^'CQF1Y(G
M\+3ZB_K%SN,[Y!*U?5R95F^/%C"]?WXEY;66UF004X+-Q/!QO%'JL_S!?>JN
MVNE71?<15?F4=/-T%HHNE:6>EHZ\,>7AZ)"^KQ=S8BC%:_58.@"BW!0GLF70
MKG] UZ)&:TBH09P])CB:C&QZ8)MW%VT_4,69DC!VWKEA<]W#<"WN+W\6,8_D
M3\QKVWA@\(L8L%'5VS_8-Z0"TYHU\X\VL]58_-.[']*JN K;%:>?3IRQ5X40
M!->:U<UI-= !6[=$\)TX]LT8E^6+.J@9XRWEJO<C^EZUW4CW?L(@6K7 J.75
MP(W)>W1^2[JRT 3R @)$]B9(/]2J4\MX_ES[#!0WN#EHM?E$Z4WL&[XVQ)D;
MZZ"2<3UX ^JBW/CX)0L&Z!QYK DR.6F!E^,E2J$"!BXP+</F#<AB!LTT4]TR
M L9W_=WKZOX][@0&Z(G9"":=QZ\Y(K+P'.D*,3JO"@$AP.>0)03O.?60N;1K
M<UIO*M(0Y-[O4E>$/6-N;?)]4%I^[_4)UM8T4V@SNV&K9E%^H()$+7I[%+NJ
M8AT#%.U+4.FX.S9K6^,NI,O]JI>^32'ND=W?#"6[5ML.?M3J>!TH.^3ATOX$
MN?V1*>;3*8R_^.$Q;'DE\5R$LX,KYX39M$6E4?/\U7G71F9O?ZA_NAJAWT.Z
M3? J@5+VIJ^*+4SR]RV+KI@X2.3$L(EI2.I$_H![==$>5'JX?;[[_<!,EE5R
MU2XJB[H%=,-+(&YOH961V:A&&?5+FK,X?^6@,-L(Y/B<RM!I451%PV-'R-92
M,DJ,T$,6@T2B3<DELSVLK0?5O97S'V; !TXJ+NA,#?3^H,\H1<9>>[9G=&OV
M7ZC&M=80F'@^G1H3 F: !%V@"=":D\5C;1NZ\Z.Z6V;O7E5#K2]SY$)NP19G
M:-4.XK04NN#6JL]#!FAT.S^'5$*F3.=$<LV84A.F@Q@@TBTSU,I]T\W42*&(
MU-TGVBV N0% &CM.8(#HK6SLM!LZM!Z UD9IXR;@_TS35.ZG,$"\RQ(15L:\
M9)110E210_IMPEYIEHV$>6!<_GC(JVA$AX0^-GUF5YZ\3[%!]L0"[E/A K-C
MBV);'<=\3&*_^@2=?N:P51\R></ _%"7?KJ#HN&IG+;?%.&VM.!I6_LW)WKW
M;4+"-''Q$0/D2V$]3"'ED#E@E+O4ZP-R F5M)1:+6]H_D:J_XEE8#?9?V!J4
M]3P1#YOJ<KY)2R1C=J!+3G]6\A?-/!]L/,+%0;.@0T'!J/\4JP\&@,]W5!$9
M=K3[T1C/,ICPV$EFZQ%9>UY G3ZEJSMNP-G-3-"Y16S_?I]/:_T>LRF: 6HT
M@PQ2Y8_*-S98EPO[?\\-)]*C;1XI_HLU\(;0;F0Q0,P]9(=9=D$/BS89<DI3
MK6AP3DU=M1G4I#^CUMY74_AFC/ZQAI45J#V0Q%00-QF@3-N9+>IY<Q2QENI-
M-F2 V+S7O8*HXA"R'K9K470<-<M->=--5D'T"(7/*TYN62Y1;>UH)A!JX? ;
MV;-B5:F#^I:5!\*>7\\\L[<>5'JZZ.YUV('#V^P)T?G&9PUH7-(LJ!F_?@8H
MHA?@TQN$/'I(HC^.<,^! 6I=VYZFRU30B\!T8^!UPHL9H,(V!BC>?.XPG %:
MVJ;\ 2 $<"6:?5,-1F>%$?:;IHX/( 6E Q'R663G=YDXV8CK3>*&MY^>G*2;
M1XQ,C/0\1IL7$+KHK#;%9*;&,=&@=ZHG<E<O).NEFCRIK]I-^-W!?\+H0]0?
M%O6]';N6*+(Y\ET2T.([=$X&2);3QY_.V5-E!Y9.^N=)PRYNX-:7JCQI7@.W
M>CU<=8H6!W$M=-.R^>&6CE>VYJ$+M3K3(G13M4LD7W*'"W%M+KU@_E(84X[D
MV -NDY/S/1>68PHWV*L^G#XS_=%G?@]SI$3RQEXY/8-R;\+1+70MS^'P,0/D
M%,W^)82UV-Z@P/H'^^$;'_$&[#D$'_%.FS3?.-D%?T'#<_JLL^OUAQ=B[))$
MWC4@7Q..R5/.$KAF#((@=@8@S8P59NV;-'I6H?[Q#M<;EW^A7._.FBH:KFI?
MO^WJ\)*P^<4K-W9[C $:VEJ"-1D613:+E2_WP[L=$ZGGPA;2>3?0<S H&_(W
M5C5]Y1/%TO=[B$N7MNRI!K!>,^T8IJ7SL)^T3RN01,J1<Z>;TB_^XE4_WRLB
M-6Q(ZUHKYI&YN1EZVEAMNRWZV7 D_0_XN*O!&-N<;520A']CWE5>_C3"90N+
MXW? ^U&3AA,Q(YRWNV[4RN48Y28.]THQ0&&["MVPUGK[_KR2RCUX)I6WI"<#
M,I,.KF"ABJI?,PA1%ZY@GZ5=?^OP_C%.<G(,O?=5S4CV  NI?>2S5(IPZ)/K
MB1#D)\/>/1KZ63!NX/.!FP@[KM&BBZI<5Q0,;9X/7T3H$[<"(+;L?I*>/,4*
MR>_BWE6;FR1$5$[H^0D%NPM'/T^)^_3;I1MQ@G*>/&U*CJ$X/)IS\EJ87*V-
MK]_=Z1CA.MV4OUX(>J(".N'\:U%>S-CK/D=\_=NQ@SV4L)N*[<>"?FAS:A9*
M4QC=.:R[N*^^3JM +8RH7T6-0!@@1Q&DI.F&] 80J*XW$MGHC0P0Q5"<Z(@1
M98 2T=(#J6MT2RH#]& #3!:9CD1KDG]BR%::+=55N0?+V7O))]L;&* /VA"Q
M?1SY9A[>GJI',&IK,=3(W<>[%UH2=WS2/P@!#N5SH F -?"Z7E$:+RF+<*:Q
M.@0N7*U.?RUS':+ <UA"T5K6G3/X!#E?2;)<U#NW\=<&HOSP3QYXZT9.,L0V
M.,]*'>K/ (E?*P_86'Z&KX<?%DFW*" O REC-ZCK_V[W_?_SB\P&PK0D:F&Z
M[AX#9*/61H\U-_U7]=^.Q@/!YQ?NF3>? :5SUVZDTO 1PI.4AX<23 &&I( ^
MBQJ9=&* LMVK#IB@F.G_=M0S#E6+,?$PZYD#S&4UV\1S> !D #\&*.X]4906
M<0=\J N#1KO^EZ-6;^SH_TQ[42M:*WB4(!C2D0:F<A?-[T>I@Q#JA,"<&4EW
MRDD2 _0L=FH16C8^<1 3''8L).N]$E\[:'@)CVK4AM@/,8.#\]!Z7/I@"ASZ
M"FB?#6KA"YF)CC=B@)8#,9UBVQ\<N0O_QA4P3]]YAG[H-F]W0U],:@Q93 ('
MHZM96J&AM6]KW4.05QWWO1"=1C 5.UW%-T\'7VOQ\+15'!=OR\_$)G#/:IMS
MZ/::[8@H&<RYJS<#812&_,TOW38=4EM:,_?K7KZ'31.Q1=QAFWURZD6[1:<V
M"_':9S?;K6W_>&'P8$_8]$4J%^7.4=7P9__F_9O9]@G_G(#/U:ZNZ^?:K2/>
MRP:HO@<QQX*ZC\2_F9V)BV@G'R)[8W_79?/XOG%'M_SNG<<A6*7WD-%I/@ +
M>)N.,$#5[.LM3I1G" F#LP+/EFMS(L96^7W6-!<UR@->W[SF=UK#U#JF75%U
MGF5!-N2GC9!^EB-;XJ;;K[WZX<ZQ]'2KN+R;M"(<WG:GE]H31W4'V%U,WZS#
M-8(=/N57U0TWR[6:KF,F&U]?L?] C=^#9HY)KJTJJP5,%!8)$S3%3RRSW1 %
MIR'?4MF!OGBXRF\05B(/":&+]FU5ABD-0=<C6+KC-CY=#HA]SBD3JL7'FAT3
MS><UO.):_+W[7<2[%6'%ILK7/ WSX3[B4>#+W$(79UU]K'#2*Y?^NOY36%V.
M6EHB50*>DDXN OQ4$D!@45ZT^O]4[B3G4>R7*Y;!578MERP^/<#^5/O;WM9U
M>P=P48%HTPV[=0#27!\E%-%;G&09(&T;S%/^_D[[*EH/321V<H>_Q#V1_B6J
M TZ^^6\]$5K-&VJ#<*JN^!YRFS9=H4&E2\'^*1\FTEGM&"#1F'G(X:PUX._O
MA[N,U_\52 B(NVE*6=,)-"'@8-9>/_T4!7@6 S370^%[#0 K"Z\YR$P%9)N%
M_)0!LMR3IIT<JT63A;!E3I!&S*45V+647TX>+SH$D2]C+5H+G9<?&QSP[QF,
MCY,>#J,<I\^2C<!G5P_?)18NNS]5ES>)L8Z]:<Q$[<V*;FC]<>G]!T^>G1\_
M6Q/>YJEQ @&XSW#4SV$V[9<>TFY.DF<558EIT 4P;L5<?(]?E8"^Y"L/)Z=-
M["CS=6'4;:;SWV+?7_JPA)7U_>MIZ^.C'%UR0OG=2KK<K-B'?['#U#TYZNW9
MKJV+'G$Z?S_^J*/I/OT5VCDF,8\H5WP(3N*A<2)$R9[6!/0L)K .G!NUJ\??
M*O[HK8N0&'739[3F]OYUG.B1,NQ)U*PZ>=]YCM+^,!GZ61+[-R#P@94.WU6P
M7PATI'!X%;PA1+22]H,PU5G/B[H^WUWCI5S#:?Y$33;@PL.32-V(5F_+FC-R
MKMXXTTSHL M..J?'<  9MH.2Q"Z^([?-@GV1UZSNN<_A3@!\?O^]YK\'ZA4Y
M]]R(N2Y5Y@]?G=16Y(FP 8:;<+^TTY8$_0)9JF]SZE'RI6!5-?O8AZL?BHN%
MVJ]\NG?93YQ0CW-D#P]O1H=9*74L17%,L=,*M!F@LQ!B'#UT.!)%R*YC@.:K
M;G<4M9C+.^TGZ_+I&YA-T /6B%ETUB2"&4*1]LVTY8("W21FG@U5'?OMA,4/
M0ES^X:(2>T'T<!^*H(,9,[ DQ]C-;3%[M#6;!P6[_E*P-&G:,JV/79S=&.?H
M]%T0WM#@B 8<5%+/6Y3*;3-31L93Y-8^C#8NP:PNP3>*U+(DNOC12B>5E()_
MMGTHLD+82!1=$G3/340:4-/I0<9*$K9\CR2AB]5'+H@4-,K %Z@=R\[$W0W[
MYY"U%#4A($MGO4=1'E^ICM$FLK\-X11G7]=[.//I&( "O"H8('816BIN.9,!
M^L<.A,P%+ZI\)M9UX:O;5K=T/2IF\K*M5@YW0M"F*54UD?0!@.IA#- 7-<##
M8I89H*!8^A_HKB%J.Z@ M:V&Y._5I;"?I?91A@]X]L;2$O=VU!>/2GKH?:AS
M$'MY,D+UV!QD@P%:S_(A]>Q>2H&+_]Y60)5&R*9%]"NVJ17-)M_ 0,\&!G+&
MYIQ<Q^!2?O:85Q9UZ%CYY9_X),HTA'M6QW640PAG%Z/LO(NH]X?W;'\&7-?^
MV.4AR1/_Y?Q=9VE,"=+$=(.7R@4G)?5CI:G\_74"^5;7/-J:JKL<)"LC@GY6
M/):0_28J<7Q#8_?EZ=;9%YZI1?UXBLZY(:]#5 /M 7O[:O[ *!TUV-.Y-0:?
M:4:#D'?(Z,8'&S)F(Q/P[S]^-<9ZFQ[+_'#W6&2_WUVF#S5,%S'J?^L>%)(M
MG@49];JJ= L9?EX4[SH]=3H+LEX;K3D#VT>1OM(BZY@HAJ.CN)!K/_NKNKAO
MCZUYV8B]N&:G;K%I5)JDU,C'IZ*SL/1/3XA^JC?K05%Q<EZ+^%JWM/.DDUUF
M3MV"VW&3Y$<LTW:S+Q0?3X5E9@7'9\>GIQRL3*PW6U]*B1?)6AD_7/9"4;FX
M2+[$O-:MP'2A"F+:>FUW6]!F1DWUX";+5EY$;V0'F#SJ1IO?.3^OM'I406JQ
M*Z[W@.38+\_G5C*%QHQ_O1BIY9%C8KAW$4+@/_2?J6F$G*8>(TAB/E,%\E(D
M%:[+=$F48+V3@H_EQ),GEIC^@HX^U#7 R!7T7F5XJ*L/[ZQ)T,?$L,P)@0?/
M$X3B==,"K@6I=1;]M!XIC_SF.V^E6-<J@]?H7*'&E]+=J/J=M^//R-4786.I
M<-OM6DJ4VG^IK>R-&L?1]7CG[&C^FO0('>K2__F<:14&R"LHDSJ:8/KKB*='
MM4F/\M+U_6?AM' %U*$\[!!4#Y!Y)09H+04E1D<Q0*^A!\KL 3C2K5$ -PQB
MEH_OTU6!!Y4Z48NR@I&L*-+^LHLMK@V=C5("=UME,$#@?<C>("X)TPLE"VE2
M(\#<J+4_> !.I^.4J]C)#-#1RK\2:C<R%.AG?LB"/1G@Q59NX,/+>QOSN(FE
M99<>VA)]BF8 /-NO!&A-?C<#9/T+0DNO$Z6?ZLYO%"PAFC2FLB6][+=[V"-B
M6,H3-6.)NFUUI)1H >1&PQ0ZW@U%44/"D<WHRC/0"G1;O5 S?Y@,V>O@TN/!
M4+\6R04Q1 .+960^K8.UX0.LN;.@$\O$H:'2@6M\A*G/=E_D(KG>Z"F'NLMA
MR. L*,%$^IPE#%H^X3ZT;*4F^J+JUX\V0FN7,-!'V)Q[Y.%Y8Y26UU#$[%9H
M^JF?_9BLJF&J;.GS]?>E@I>^"ENQEJ=_/O^ :?D>)D *-1-IQ9[8*NG.VRSP
M"LR6.$F+)UU,WC"E9"Y73S<W>>RM/;<U6_4P^Q/A(P^D"QS38TM1R_L?]\IK
MYB89(,XE*L<2WCT!?*K.J43ODJ9#_AH'_MWS]^".X'<OO<,[H@J3$^EL'$?K
MZQNAI%L,T$;E( F"/\O4B&.7>T9@\8\=^M./CWX8ZS"T];.D.27I<5"!.UY)
MPOWRIMH]R&54XRO(0HB'.+T53*M._BD:;%;<*F]4_B&BGB>6>N)^U'>\HJ<V
M=7*<VI..FXE&;W] 7F6 RLSG&2"=$M@FBGR# :(FX:*P"=##YV<1MX%X]!FP
M1AR1G18Z##XTAD%= 'MK'I4G4GUVC^;\VF%_ <M.YZ/&<8<69VIF$S'+40FH
MF?#]O[D51*/?\3L+-?TY3Y!$8]@GYXU$:!^62,M V9]E(L$(Q\FXYF2WD@('
MU-O([CC-0"5;C?<MSS_'7F&+;W5)_3Z'NXQ[N155C:M8VCB1XS@&0"8[PE01
MEX-Y=MYF"W> CHYFIE:^-GUSE99-KB#@\3A![,75*<YA69=,F,):R,:+=P^B
MB=V7/L@4\_@N7':)ADFLID2*\61C^,R!?,2_5X7=D< Z%#SU9H"2>VE+G6#"
M/@/DC]J5] !&!D@"H )2463@QT;<X84ZH-V?+J"HB5:7P%2.KE:F5@<F,N4!
M_/36 29ARAKY]*_%3*XWJF2?A.FSE&U(/T_V)DP;_,TI+XMJHH/[^TXHAPJU
M<7-<Z5*YU?9H0GLKSFSN@H4.Z[.MZ]2Q<@J.R1QEGGH@DC>'E$%.02MK @!^
M*QUR" ZFBEL7.9!,E.^O;.>6G3'4Z3N=@_"]''O\1[3KE255TV[Y56CE4K,T
M.\* /#GGX][D)1\8,!N$;N]W^D@1KM((O,6M8\B#M&MTB4&GL.1X.OF\.<>:
M+L@1[NDUNHDIS4L+34E[L[ Y&#\<6[/,0^$%[)U/OH4X1N!?:N6MIEL5S5'0
M:FQG;E6$W3Q%->NDSP[A1.G<5%4<N8PHBK=B[V?RJ7B.#>U](;4E^1SK>6K7
M>*)M5 _U,/T"83+('R&;8Z_\@LTI=R6A[/GX_:QC0A'W\ZF?,'>4F[TEE+/3
M*U!^PSLU<Q=UD'U5AYK0E%XD[E.Z*"$W9-Z2WTFHV5P=C7&0Y9$9<70K<&$.
MT+*5O.27QWQ<1O$*_RP#-/M5_2P#U"M"N$/G<D-1'7$B$!ATG'>.)11E#[G8
M/<L>+"CR%R%KY_:1PJ8'-OM1]2E;J$OF1$2#RNCSG>$S:N+MD-D\N@RJUYS8
M0^=.1%/=ZE+5C:T^9AG)_ELTK:XWT*B^?CY_9G C@W:<[(XWU_PL!W,2NM]7
M7*DG-L)Q(C+M70+AX6F)^ZV?Q!9B/02T,9&XF4+<B:!F]D\$C];.B:XB\OWY
MGE=A"3 EG6S\<K;&P3I'/6P.-S),:B9N!3) ]NC3F'"JSYPD"J^<"D!:]X2Q
M(8RSZQFD>]?E7Z\_<!>GG%M_+;7U%%JA+DR@186IJA4L)Z>RN>8Y*O29OV@Z
M^O-:K(%V3[XM%&_25=A4LKF/2_;")$]W)%L7]6.Z]8<L()K#.P=9!QA-^\GG
M9D4WVU^^OX>I1]EMD<790ZDGLD>6H1QR!F0]"<FFYMKZNCF!>S;@G;_GC=R8
MF(0S%+MD!6'=R&.:LUNC%J2_=01,\X;0XT$Y%>^"2HNPM%=_E+*JSW4.[7]2
MO'JL^?7W5DZ-11P4>Q5QC9#7 @WD;_/;*GX9=G=($I&K<"JD(DLX)OIV_,OB
M<Z<Z(S.Q_K=;#9_-]ABD<YKJDRAU&\N>9"].4GG4'8G,#1J" 1)JP0H"[)?.
M1*8Y926VR'J8'[Z-*O<([-T@V5#ZI<B:\R(^/-DP<_:H.N7$6DM2VIPDZZ&"
M\8_*!)4BV.>%6Q/91>>^A5++AX%0/<UQ9=A<DK>5?K&^MP918SHW-S4O2)3X
M((7:R/L'12$[T!7AX/+])GOJE>2!6MKOQ-CI22O5-\(R/XS'+WNG. 8\$O!4
M4K5C:FKI;2A$[(HI4% 6B#]C3YMOYO]1=H< $7(F9[K")(!P::XTILC#J%NN
MYQPY\[2=I3)'\,8[&UO.8IO,#$ZA$\NG7]X",>TFDLX/ H/H-3S0Y6YGUX44
MTILQE\!0TXB@Q5SL"2!55E&M^^K@1!A^ZFQ?GF[6K*X#=E+"3JQ&]LMUB</,
MUJ1=*<TGL '<3.QTI9Z_O7)BD^0;XI6!J^EZF@^Y%(][3+RQ?TK+>?FZS4B@
MAY"\FZ;\(SQ3RKQ#A1H'VW8X%$HO"I#X$-NO"S&)HPY/C<ZA"";UUV'@,:_6
MC<'/=[#@*H^)79'72:? >ED[F-!/'0T+PYL]&S&4RRO@JJB W>4_.33?.9^K
MJ2N'>?&+&9JM9-O'X05CIZ[\TVIO%P;'8YE0C<)[N'.(>_VNF&#Z]5ZXG)/"
MJDI.OYR!@HW7D\W30EV7K7FOO :-\O'Q=<,2; B[WSO3GC]O98#4X'E[N(2,
M\ PC8Z65HDEI[)#Z\6%U5NI]0DO!SR$$RYS3]8DS!\-C:LTWHXJN\)"FJ1PX
M(S]P,([CX_X-*;N^DMR[2-) DK_-N(P4BI7&3QXGHAZ0N0A=YL3(>N5'#GE-
MCV\ML/S\&C79Y/]+]J7WF;B&ZSA>E*W!V"M4 +A*LJ99^KR^7F2-J_.%^FLW
M(;4_??JT6%X(IP@W+)WV':K"SQ6^^5+8OU"=K+*WC,-(+2J&LIW)>)I22(D;
M/@0<E@2;[VFE<9$\R7#O>3B'V:K[H5YV[P,)\\>&';=D%!\INC]JU>KIGL):
M JP"1[W$ &7 VB#D8P#][G#=PT35<<SB(E%GJJ3/K0;(0\ZND:P1:PY,)S6.
M927<67@M4%K2WGX2IP 'G"W2ZI;@[?.C'I2'<%;9'6]G^"WLP]UMT(UFKX.B
M]+J/&'0#_K24_:MQ_4-4(H"[9/LP8JF%'UWI-6IM=$$&B "G!V N _<Y@6:
M1(9;4#73&\:STF-9+>I< U31/)CR1V6]U*'^B#>G7KG9O<?#$R62+K(4\%!.
MS/0$3/&0;0E=FH0O"FZ86=JY%J?!JE.]O@_Y'(2%;80WWZC):&/P46-;<Y
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M2+G$<S'%9(PQ\1S:-=>\*OMFUHM&3AE>"=W35Z/CXD:B<A#JUXKM[;B*U+X
M%*-&>F _O_3M);])#.TGY"_U"J8(<E1^=P:NBJ(\M5=.OMN3Z_%&R=7B9VAL
MX7WN )>_MV,&?)<C5J!.#H"_:6'\2.[.W0H5\RKD ;^7/P8D_2!E-]^6''!
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M7I1,)L1G\KW67KS/KY"@S7&*M4' 5U^+3[%=7>-I%'[V^T2\59E3U=0F Y2
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M-'88( W3 %2CZ:)-*>).&/G"U$'00"73H6DMT(7_NR8< 446VZ>&0\^AUH8
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MGO[PM&ER>=MI$KUP*-$ND)YI\7)K8/<+<$!['ZVQ;;"G&2>PNX;A%1P@=K2
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M48C7G'^1&-Q![G-W>A16D[XWL IZ__"U/T/:-UQ19U65T]%<DZ[1W ;OAU>
M/?(OJ0XO-J_K^\)>CUQ10PM@RQHP#[>8SB*"RZQ[*@OBAH2QA]\^!A9>I[ZA
M\%QK-5@0,88*;UB\B7$,>=#FVY'F_]+),NRJ9E"7*X?VE:4\X>"ZE) "@[LA
MBN8U5JRL+^S,GJX;+?A B#3$=;\4=Z-X<:\\97-..&EAW S<"/-C)E+IH&-Z
M[I="Z%VRZ9I/56R>_"S\4$7<Z4(&;W= -A.NX370B.X (7&\V(J8=/?M?QZG
MUN[D?^HVN"MOG*K<QXA.[T'B^!8K E<R!_<C%WG&*HYB2C),QKT1LCQ.M(I,
MFF-ZV[<\4HVN7QGX<P[;]3[GL GZF9[17E/N%R(&MIBH2)N8F\D3J[W![G&:
M>?V))@N?.<?QSW>FSDL%6A-%_' W913ZC?]1J5V.J7')-;Y [#@2?Y.+5+FN
M<1.RO&[@F2\ -Q7_&5\:EPFP*EZ9#!H.9OJK8.72_T->BD)8SOM>O-;WKDN8
M;,XW\I/KFW7G&8D@SB[%'M:M.G $VLF,PSIT@X2=VX&X1Q0A3/;IEM-_7Z;,
MA1ZJN=)'2@%UFW-CCT^K3O2@R><44*]:G 3F,_?4&S5$)%3E]OC?]<0J#KHW
M0U)5NV0.6IOD8=C*(09A\^\311M_\>5'IX5M^AS0DE]#0J:S<_B_E40]Z6TD
M3OC-9[&^#N1-%'>-AFLE^<?X:"Y*=X.51CSD\!;25UD4+S&J+ -5FE02JHAP
M532,=<V^*M>Y%!%O\D@JGVS3GXL2$4PJ;"&F?EU$.H^;N&G5"T"8+PP?5"X=
M6(X@N/<.D>B"Y8AHCU$>I7'Q'@E!KQ'5/Q?253CW5O %BIW"N;>0)/%5X90(
M>0@+D]G9X[)9M,UQ+=3C:]GCE>4U%797H<B^(;,)JF9 S8#JF+OV&[I=9UQ>
MTB67&)5O]C=1Y Q2F^]L!"NQY^+OX0(*< $&'I#<S;27]V6ZKIV:./Q);&05
M\+R_9)^!3R04@9PHE?F"QIB597Z)WZ@=K;P;J?X)@;:J7TOFBN/?X!J2MHT
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M:S&V Z,2AIF2R2R)X+F24;P"9I(DYX!<3EQB8\OUC1->5C.(BI56,R>;T5#
MLH46*\=2Z#[XN0Y)C ;@^A[H1W;97K\2;!QS<YBD)$[ MPSUZ[G2[O&9R7W+
M43!^\]3G-73L\_H[]BM9,1Q>ZVUYV%>$<CSX7!BU,QU$/UZKIZ[W2O!E(]L0
MO3:#NG7EB/@S=)#GEXT&;8RVB'.G=$Q8ZKC YR9/;^5,PE?DTE<821@X R-_
M+NW3.RVR5(VS;8O4B"=#/#CFQN59DWQ9_FRLX2$_+P".!K_'N^&UJ#B$DM@R
M9$&XSZC^6Z :W#Q#,\]I2O-7:4K<P.O^6_=CR480:>:(H!]@KD)")E%V,UOJ
M@+=UW [E7&+9%7=HV2^Y[-F[]*21/#8%\)'F!=6=''W#KA[^OT2?\2-A;P?9
M+PM[IV#PQ+G<\D@G[9P<5N.70&@7W6:0&+HM0\M]]L'T@*?;;3)/ENY"(>:F
M.7: OCZES.JB."GE$5 WC'*"6%P&#M(EU7\?N\>C_W$XKUWIU,'P> ZN:[[C
MVP6+MJ7'=2P'!,(ZV=:R6PKTOYZFC5T=39*N_N=\M'%$^/N=+5O3"N)W% "J
MNB+DW3(2@06ZI>+[F$[,)1];3??'FR9< #C7V]7E9QY6GQWSH@H;#ENFS^:Q
MC^)*BB+AJT5XLDY2Z4S<*7.Y - 0[^'RGF4?G!V:3Z<'Y03P:)Z(?PP9LFBR
M^ZR@0#2]O!OTXU1NY/)T5]O=@:A*;ZN8*JZ'Y>[A H>?@KQ/R$^4;^ 8EQ[;
M![)W<-&-WPX'+\Q:=E(* -REM)1N:3T:0/0@YY!8>"@V$]?>T"R7T4XW>D_V
MH?F7 LOG5E+Z)@<M_2P46<5-@#_&>= N2=,<=C6+,\$RB;:"(@CV1L\+]V%I
MWS<7 #G^N?/*A0O T!(IPL!94#>RAB)N'VJ\#.$4O@ \;?X6J+ Z=2]-,\R5
M]RT=^5MUWU=\&_(=2O[^R-X1G!!%-S(!2",#(]LY X:+'F49_#@L''<5-_(^
M6+.X/G9R*R^%]4>V-%AH%&QC3*M=.[&MON=ZX(L?X69T-%CRH3H+P/J0 A>.
M?TJ /RASO:[@"C5?AD!%+6V_L=15PWPH4R)4QJGF4NS"&0]I&"NTW<NXM*,W
M?\HQ>S>=68*6:JI/Y4$WC'_V+5X PC[NC8SOPJ?:[0GY2#=8%+@V'LX?%2C6
M$($7'&FJ=>5Y&_5= :RLSI??5_0C[+W/GZO*KKF-SFLSED8;L3*GR*$MOXR?
M5I\$<Z./XHU'VZ] WTZ!'-T^?/0;>3Q6&V=NWA#R[*[-*U:':*"DJZ,AQP=?
MU_FF8<F^!(/\.@1.Q*W7QE$=.=X;M31'YDO^,;!TK'=3[]::2-M-Z^H(UOY^
MGKOV;+CLZ+6*\+P/OA4,1_5M<<Z36<S^;Q8>)^D;\%\6^'NFGUFDDLIOJ5!\
MA.Q5B!"I5C'INN.BNW.J:(?EAG!N.3E9N5<6/L7L\Q6_V..EW $#FR(KVB)4
MM4+3VC)V7C&Q!10_F5_YF^^1858M"'E!=T&Q4)7\S5E]A%BMSS@-$^7+>-?/
M5']YDYZ G6]^.3)=C3X&_]XG4G%B#)9N)4.^]GE 5I#45N&:7C^=I&5J[7 O
M/FO:LRQ=GR^+9S ?8C Z:Y-PW'UG+O&B.3FE:6ZZZ<P&B&?R5[E-BPZVU'T[
MN&)T/0AN#QIN1:P"\8R>*[!N3JE5'71EYHNEFT+C=O.SFM/F2UPYKYZ7?N:<
MDNPJ?@&F&[7V&)3T\#6Y #!= &3=CDM10UH>'F)KW34C(B-*Y;9:]B^'=O6U
M> ^T'FW;R!FUC-:Q6Q&4MR'L.Q9F3N*N?^X/,$2_K2Q7,+I!?J>_=,*\N'9F
MS?]OX#0ZG4BU@&'NR+"VA,5"045^>_?T2@(VV&\VG"1.VK#'WN(Q[N/-^.N=
M@!,=+G@45E( %:JK;A/^Q],64N'!UO#2T'65-^ ZT!(_E]OZ>ZU1.VD]1>84
MT;\9P5W.F((TGE(&!4T ;\.<]5Q$]EFW.ZVL7NH5)MM'L(M8QVMK).D ]^^_
MVOORW#QY5,W7N(C*\$]A>:RC@@ETS-=Q#%P#WSO&@+">X[FCHN*NK5K+3G-"
M>3O"P]^N!KT@CU;5@.M67]6:2_(\FH5U.#K<)O&P&X8%?:+MO/<\C\X%CA$_
MA472ZBEH/J0_TK0AH!*]=DSR*RARCBX >T!2.:'$I9__X^S+1A[GN@RBTM5,
MUQG3<6O2'U0:\I4G498G0G^+KK8_SXU>C*-ZYG<P%O>QU#3+_%T+W AZ@[0,
MH_ :A.QV]F=^ ET9 N$(KS*A5VD*=3HZGP7XM6[6:UMSKXIZ',0_@@03"BX
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M/P+5PC<NO8I2H1:DTA2*=\6U.2C#WZT$+Q/XO>?X(B-?G+,U_J5^_UF3)Z0
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M>/?HT?7L<F];F'C??=>#01X+;K#,R8*1 G*<F+:2:^O&Q!Y\!D;E89T%-8"
M)0W.OBT4^^32F%.EMB(MK[%K/.ES/%CEE4?K%]XYE*"&G!,S<=)/.XE=P+GD
MYBFJ#H9(AAE&])^2B#!V$QW9,OY<L%">"$ZY\_6;RC>-WRO+MMNAM;TCO_UK
M:CC2D.S(R61ULN#T<86C#BJZP?);XWIGX\X.NN2+/7SLL183^V794#E?F/2"
MEH;0I^BN)-KDS%J)RK;,&9;!'1)NA=[K>U^Z^CU&]UK[JK:?-2\$FK&FCE&H
MP1,X<H=)R,Y/DVMDNGT!\E\I\?(V(O&E99$0!Z,C6C-H3D<;4.'W4*+"C43K
M:F)GC=G@ 1M[@<;DT:5N! /0OO8CTP39[UY=C!NP;>2V_.^1LZP0#"'<859E
M#( =<2*5#-7O0RBX9SI>77$Y5!:?( >6_G4OK^$5\@6TL]AL,).M8#ZQ\E*F
M^3.[7H/1U>>LK1P1SQ=;\2)EH=6:\,S1Y1,NHMEAMR/ZY;(_BZA6]$K5/ ^N
M1XU\FH4V&QURU- @1!:D6FI+]@S7;WQ]M2YXYEW^:NX-F8F*0U>?BX$7]B@Y
M]&/SE+N_;(#OE62ON1/7U65;9N?SBVMNS;^J%_XN]OC2M1F6TY=B6_0/Z.CX
M+;?<E58,LLPSH3* KJ4T:6A^\ME?.R@Y2-LP$;/&2C&F=R8+%;@*+R6+XJXL
M95+.UF*0A]8WBK]K_300#AB2DJ]0OB:)ZT$)0IQ[0T$B6Z1^11=#T<LZGPX8
M@+7?U/.T]K4_\6&%/"NP817$X- "9*E&%#=543YJ5DY^P*8O_R]/]F51CK1L
MD5>7&V4.>2LN3AVCO=,X254?MATJ-CHPTIQU??9F9G4BO)'[U=''W*J!#_XZ
M_>+HFLUA$;M#$SD#]Z?T]P;W5$;.:]VZ(EL+4Z);G_P]$QDG'T@8;TAT)A9?
M'EVZ6KJI,VD6SVO"\>,U[!VL-#*;KX!BC- L#]4\([<YOBY6T"CB##GP!LF[
M%TBY01] <M/0:G(^[EGX\4ERQ,RY1JW0._9);:KZTO,2;?.](J<NN7',':G*
ML_%-L!I4#+ANJDZC-25 N:(C-E7Y'I%CX,Z5W#EOD\_F":'\'>E\UWY+L2G?
MLS6M,J?$P&%6[QU20_=,YWL=:&B($YZ/WETZ-B@F.%!L]7,H6>KS\@\#<5.!
M!U6("E,08O':FDW5W[Y7R/O;]PJOL02VC3_?*\Q] R=_%8NS\!R,&!W0Y[8,
M]Y/I:*/PT\7BB%9T9B'%BIKFQ3, 29S"G!%9&MMBQ'^O)*\TY:NOG0BO3Y]S
M:5M=^ .U/''8MW<!*PNR8,77C9CO$6*J7%N+=C50\UJ<EW"$EDEU^:#"NDB[
MXM!@WOG"@N6N+CVIB:%;TOE-,>:ZPBY51?J-M1)#:F?S+.%"\BGN&<OQ40N:
M/O _BZ4&.=?>!6B>J:TC^S&3S0UB;W"N":X9*3J L)K_8E859&KKMECA\>T7
M:EJZA.C"&V%Y905\%ZJ889/!VFUHKD'"H:9SQDI:T+(.^)/.6Y19B(\B*7?'
M.'M;ND#'B+8%_ND:Q@!$$';$7I@UM'FO"E]M%5B2^ZBSK,3$PURY]6"I7J<(
M>VSH=%9NMJVT<<(5"<SVQ%2^$J>-6E$RVN<G[RJ>F9?AL+>HHCU%=/#V4==B
MW8=K:4YOGY2R/R^TC7O' "KKN >%B(G@K\;A ^%Q?>V"M[A,PHIT?YW(I/)&
MSIS6]"(TR'P]N.#K-2 4N_IULF W<5[C-*K>N-H%L]3/K-$:55P#'T??^M2^
MH#2@&]VH&W>#J2["U7-F$\'!%,@)_TVD K57BZ++"_>D'Z=&<)SR?6U*M"GQ
MRUGA'UA^GO0SR"JL*OMXNX383W3G"+N9E7[%JGQ*94FB/OS#?3V>OHO0B)=M
M=A+O- 4/W;T"19B$WE*Y]SM]XI/'4-$J)!!/,(6\%3LQD#) -<ZX1QX^:OK0
M6E^\N,K58%/:[JGJ:ONRGN+$\A^IM.2<8:W*E$IY,R82\2N6CG/FJ[?.'[U)
MFM H(8CR-JN=%$M;> \Q:EL/@G ;JA4DHZ5VDR.(.:07Q,S6R>?J^LV)[SZ>
M;BL96$OH+"EAS8JXY*<^&O*(*=#8_;IYH/?%A=SG7Q5>D[V;9.%I,!G(8VS^
M)&#GSWI;<FY\94((7<RZLVSM+Z=A(#G_BV2'>L>N,RM%#@J9_H;BN!=UQ'?V
M:%#?@B/_4Y6=>! M;P_:B#^AALI&R!'7@V=KQ$GX)2C8+=3P4%C?'&2U,-YT
MM05KHW'&44AJ#46Y:(-Z>"M6.V_D>,VUD?!Z'\&)K)%?6MDZS+H=^O*#]@\,
M^\/Q&PQ @2;E>B5 S$KQ;8KI8:D<0SQZ!@S1_8E4)1LU)6B<)!I&82PD3:8<
M?=Y--<2^>F0?T9CUX*BDG8Z;Y@[OMC.:<!<56MC2AH!,KUXX/=OQMZ'Y$URE
MERN_4%(1,ET>.';MX;L_VV:8J)[2D14BR1IGO-5/LD9]G#7-@YX<>^T>@-1:
M>-\-;AMA7[TWEWFE0SJ/=,&E?1)]AWKMS^H%A!'993I)JO%JJ8W8T-J5-NUJ
M?LN\X@VW1R OBYAGAZ0;(B^_N)Q<4H_\@2Y18J8ZQXLI4=R.>XI1)-W/#^CM
M0?=V_#XIN?X^^[<W9UA+8B48O;Q5DUDROU-6T;?];:IWU%/#RG)*4YL'JMGU
M9Y&TAA1G1Z3Q8S;-L=%ZDO)";5T8G2V,:'@TY@IAY[49Y_4L/BB"98!N Y_K
M ,L6I_Q399'ZI[+XQY=3NE1U\&P9[?C_6)#DH[)M&4"T*,BFB0&H:GPE,@ J
MC]6L;I/KH14D_V"QT7'-S&52C$7OV;R,CHZLN4/9\"#@]P0H U&DS5NCPO,+
M/]J"NY!CDP'WU[.IM\;5NX:K]-9AQ,;(97^5?J\:S)N-YPDSB9CB$KWU^<VS
M:_5SB3,.>8F5CML71C-',W];IBUMA& )=Z+>8GFK67/)1N9]B(NNF4[?=[GU
M[> >1;(_0>]+&@'?]1.(1FU]%Q>Y^29S@LZ $?A-Y!5!^X=N@&B[8H0LSY*U
M:42^"Y33I"2)69WBL81;V. NG,858C7Q1&C!$E\AR#3D"2@=DJ3-Y#]]<K9H
M]T8@76SLML#XHCE6&^+U5N8 .N"K:13I/8Y9I;,76_.3M&@?G'NJ9,=;TT8^
M31HTGNB?;/]]26$GQ)L3D\^'/5-[CJHY2)<E4^X3G^2/U@X]M?3^RT/")D2(
M(AMHO)I:?0^3_VA2FZ"U-4ZLKEU?K)$)T%>XBV\UW?2G\T7A1Q:DF4GGX$+#
M/^U\NF__-L.:H*;CL9NN4Z<90$'R' /0DP-OCOUS5SNZ&, D_IMZ>"9M_OGE
M54OIU%HUBND,A@QF1OHGHR#LZM-2!M"O.D9]B<%M_'-7J]NQD] <M?/VQ.NA
MTABWF?^=+7;_M7;E&8AS>8IWT/1.GY?^I!CM"-=RP\QT'#+\#><N[AFV&-]R
MUB!MMC7RP-:8FJY?%$W0QE'[1HH@]=:<05X$AH<\WF1SK4:_EPN^E_E6OL\[
MKR7'[VQ7J/I!5>[0YM30]/=F,4?&AYC$?YO),7=8_@.,-2"-_@/"@U"U$TV.
M(THUC]FE:SE9C:Z4&>N\_B';!O!RO$6J(/2(WDER057$X\V60V_2G.,K(TL\
MU0S5V:K>H81F?N5.*BOY\.[P9)Q-M=7F,7_S_]6SY$$_RE;K&<"Y 4("O5E4
M@@'<G,488"[]X^S;KIWKK/X0VI@CD/EO%GQ_^_REX\^2CQCHG +EP!0#^!6<
MG_]WLV]; .+<GQ;3>,J!4=2O-W\:_-WLVX___N1M_"G,]-F.11@P(__1GW.8
M]. _<OY^!LY1?R[JVZ4<ZK7GEPD]S%C^8=3]_S<&.IG0".%6LYTN9Q<3(]I4
M?*DSG!/[F-7]-'UO1H!MM)S, (C7U\]%HD+$Y!.O"LB<JWI61S]R:]HARRT\
M:4S.T-W<(,9(+>&RWI7^*X5MS<FZ#[N:MB63OZ:EAA;^9[NV;_\+^W^;$.8A
M?Q8BUH.$J/YD4 H959>H0%K'N,Q**\R74>[R41Y8P=/M)R^GHA-O"+"J;4WC
M%CFHJO:D" :0ZL, XFI4F4,5O",;NDT837*6@]@?REM$_;XF:YMB?K_?F:K(
M (*=Z7W8+4,&L%F6B=K4!A'6T&-*]! \W7QK@WX3,_$-G$/QY*864-"['P-N
MH7UHB*A&&-F[=XTYW&\PE2SX.1-'TI@!G!REI:%^)3& >5?FK_T,I76D1JUU
M&6VVKJ,60":9DPP )D' T46+*$QUW<>\KXXI9N-V'E1C*<H!OR>%VK4:P.Z>
MP7IDI?T38/!@]@X*U_:ONDUI^@13*9Y'+M)MMV4#\-N;D!.HF7%(L2N-&TO-
M6\)3HW7_V0<#*;L(Z015,( /^][M>[?OW;YW^][M>[?OW;YW^][M>[?OW;YW
M^][M>[?OW;YW^][M>_?_Y%TD_[1N4(G"$00'V6^&]G!\]7EM[,RD2L,F_CDV
M3LV\+SVD0L^\44;01+/U$,Y+FW?ZEJ&)1X#A5FXNC['VS88_;PK_?3]RB2?G
MS,"Q(E0%8G#0JF20\-HCG>J!O)\5#PO.Q]01LSU8Q#5M/Q]P'\&9:E^9L'0P
MN:7W%6G% !KSD+(,X$?]] ;U1!6S/YP@,\-87M2O!P0?^A%F9VPJ(M.-;3"D
M9(E*2I0$!7QBE+8XCZ6JX&8Q-':Q/_.WXUBZ3AI=%$Z$TH,X6%'3+G@&( %=
MUN9!.<ZJ8LHAA=\GT5/_:BC=OR&]W@?:!]H'V@?:!]H'V@?:!]H'V@?:!]H'
MV@?:!]H'V@?:!]H'V@?:!]H'V@?:!]H'V@?:!]H'V@?:!]H'V@?ZOP*(HD2Z
M2&:=Y1C%S2"S9[!<-HYE.)QE5V6H7H:^9/31L:,20,(-U2)N[Y:CBP-3OW+!
MC^#08$F24LJ+M&"TFH);:BCXQ=;U_^S/O?XKVK_KPI5]V[=]^Z]GX/?D(@8@
MB6F!D0[7,( ^#FMK#S0?ZF<<N9->5X;=$_\%D W^-*C'D@X7,AL<^]/@&);9
M0(E>5PK;$P?G_.=3X;[MV[[]Y]F^%-FW_R)6"_]S?""JO=@)N\T '!E FK;+
M=71I#ANT[++^AO>9] J9CH!8E$?%5@8O66]F@QTN)C\X8/BC^-,:_(Z7?&FB
M5U$O6%I0\LP!-U8;<"9ZVJBI4[IK *%&O'^T^B/H1L4="%?<]N;,F)MWO+A"
M @-P1G1Y9O?>ZW-=9   K3@5RX<4I0:00P@^T$@#[B;+P-3Q6LG^]9^.<FC6
M.-][<^.GCXB^Q0SB1XM(+P<@#C @O\B%:V29%"ZWK:Y\%1'B_N[NMG1C',1X
M4&C3?5?=F5T];S=M\MFV.OLY>R->R!/<^2JQ(FT>Z M_\7_8S\=T6/$3!\>2
MCTI\IM\1=.:X> S\T\<#ND*1&1\(AY%6R#%LR6%LJRN7I<.4F"-DAK-O,E'&
MVOM3>UM] NN[+X^EU:9CGD\_O\=^XG: F:&0/*9LNT_$M_KNA?=)>M0$U$KV
M7HXV@OE\#S4R@!CC62SE!&KMZ,KJMU[AH+WD,W<5_*VL*^_[WM8=SFHIR?.G
M>[-)IY8;?D_]MY^)\7^1Z2B;!&0KV;GQA5(_X;!/C2)*+1?27#DBO+5XNZ)3
M&8#=O<_2#X'VX/XL9G'O3?5@ "ES#$#F*H3ZL/:;FFK8^[OOTS"?&(!$?;)G
M<*82*[]7IM%OR/TL3 ?L)*K^.O*20QE<CI27Z?M*?/@X[:JDB<;WM[TK,$]Z
M-ZC$)QCKD*0!=YA640@]/\=E[6C27GW)7NRQP<N:2W^I'4@/WSY$?+CI;'/R
M9'J,NS74J#U) #' \39!TLI@1_W/AD+LVZ_^(5W\!D4Q - ST.CO>O3X\P;U
M^<G&#\[/1NZ=3[CT2/(Q;4C4HJ)%]] [CD5<& .83L'S(S2SU"JUZ>B9,(-6
MNYJX<--W-657.G8UIEE6P</U=A\^/_=(SQ/;>/2:-S+M36'6=@#?XG(2[VX
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M%R1JP9.!:BJ=TJ9YT&B'+6\?Q]+:G>Q%\SC[#T-)*HANQV\#^F"Z$,@#H4'
MK^X2S?OUHXZ1[>N>C[6PQ*@&" WJGU(_WM(7?)_RTJ;;WMXUTZ+>T?&0=^EW
MG0+M0]*<$MH"9F8B  "P]&.Y;3^UH(H6FW)?>\Y@>7\-O.B,?N>KK-SV[$'
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M(./( X$QS:O]JA7T3I)7>3G[Z#N9^OE;!^X=<+?YRG?OMAW,EEUA?>\6GJ"
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M^6,SEI_KI)XAY9IT7CS+^>7(K:F"T5:TB0VZ'R-. QX:1T+P061$R<!B1O<
M69O5J>P81#8=X6B,]0L%;Z93."BYB//HELU@&RGL\#7!02]7INP>+3CJ:SSX
M>A,5M+A0BQRZ(I$,RBURMR[:ISK86,3XU!F9V93ZD=R1JZ5S_(MD;N1T7'@Q
M;-GA%D%[+B65[:E#94658YY$N_=Y92!99?:<QVAC]H"L4=['4>L,WZ)3;7JR
M(QL IW;-T<HFT6-\S<TB(@7H;VPC/-/9Q$+"=JL?G. [&O .,^H]%G8MBE.
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M]GO3Z:@G$12#B\WT'%]RM[3OB8[NG6^M3+>^B?1C>&F 4WS8*7ST+#02KI7
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M#\GU1:IHW:ZW7M0N3#'6P&+B<>!E>6K".NSCPEO^WVN:O'W+U%O$=Q=E4KA
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M,XP&EO+9]D+;,96+Z]53-( /+E^/#P]T7QS*'R* Y@\J$X]/![);  EFT4K
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M!A%LDHNZ&*3=79]_?"+T423\Z'C4VLH3'AXG21Z^2Y+M$TS_UN* +LJNN](
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M83L#=$2]QW'G>UG +]@OV"_8+]@OV#\@S!-=&(QG_T!O2]KG9*>_>^UVV9C
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MZ;R"L2M,Q%@J9X867S"?K/P]PEC%P*I3+M;2],^H#JY_BF4<:>\"Z; _K7
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ML\(B_?;Z%:4BJ\6IUAGV,9X&7HT:G^.\]-6+(P?U.R[<TN188&F<L&A<$J9
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MB9(U DQQHV .+\QUPE(?JQ7/AI,:GU&T2K68D/4K%KSVF9%7\1J6B<)<LUA
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M\E$9&<\ZKBP#=R&@OSJS7BR?S,8=?*AI;OJ5:=BR*6PI7$IZ60/D>;I\F^I
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MI$ 8^UY?7W\6FFV>5N,8*UR$J"+.7<\K8U;67Z[Q2.AUE_5#N^5/WR[Q\T=
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M:D[,X?!JVS\7V^W^??[P+^G_;W(Q(M&8Y+.GWV)!6EIG0+B[\W]7F8'_M]P
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M2YO_>:2R&-EMQAI\# \EA774LD<Z<N?' A0/GBUJG ?V5\RQ-57B_9H88_&
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M ?,/IMUQYQB_N6B_:#,_18"3R$D'L\25Z"=T@.62\M8W["S_6K<M999DLYA
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ML=8IR9T$S!??B/@Q$$%^Y,7%N&MJO[6>1F?Q]0')SG4@6PJ>6JXM-L'PD'3
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MIA:4W_A_GK&N@X)'YWV8-1[=X)RJZ\4K+ ,:G9O1I,=SF.,DXYLVC2<8%$=
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MPTZ#C>:EUG?/I(_NNC[DF'D81BG9;Y\G5K)'!9^=GS$]?8Y[%@633UG[HU?
MC8=L8?!)BZT8SCR";ED#\LG&R@]Y\4/'^A,',2$JCO#]OD"P&5F,-IKN\DI1
MM?'BHMK3VN$KSLH"G\ROMI0^>Y)X4\S+\,I+U0$V0 _56"E7<T4R-[I=QDW?
M*I5L0QG67U8+<?U]6.W.E^;:2PQ1:83D0IZK8Z9P+<TBA/B"N>Z?FEK%&V]@
MYWY^J)JZ[G7R:97U3(6I0ECLD0#I3P>(C0*>EU1L&--4*%VM*:?98@NMC8\K
M/,K,SKPI!B!L00IW*0@2]%S:Y,=NA)"<H]_(R!,W.=J<YP2Q,SB,#$$P_!:I
M,GL"[M(N-SU["PJ7^3VRI'/!Z[9\^)W'WZC;>;*FD6JESUC]U#D*0BV 5[UV
M_:U,:M=&<-HM<^Z]G]4MQQ2,OMO,%.8U[M?VE/T5_0S@:"JE \9YS*B"YP)A
ME MFM#N8,XP+MR%47@>G__(6,P8?%14$ZAXJ2-72#"GZI1B1Y___*;MI_S['
MUY1A1;$3O5Z:Y_QK#X[)+$C31I^H4E[E*Z==*&&828-$*"Q"0I2*( CR4KAJ
M:7<@/,AQ(Q#U@N00Q@-UJ(+DHC+TV%ZP[P(=@#<#\:_YI=+$\+]^3%L=I700
M[*=TA$^YC5P'LV3E/395GUM9&Z?-0+CV3$#S&;/G8VC7]V?T%GB@!@\5VCE5
MGPT=.WAF 6!_B-)Q\%(/-R0P&\DNA!W*V&%,V,VET:;\)Y)3!],/FZ&R8%^8
M^0IJ_#G-E.DN8X9KH*D\T#7L%)9F *9V2C/@>:P?^66%DL'V@0YP\(<<28T-
MHVK?BLV!3=/S,;N!>\\3#H&/,5M8ZO4L9X:>N*H)H3(L)4^X'3.7!=FU:&0
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M5=-\S26EW^="">S$5\?2QA)G,2","V[2K OX=2Q&Z4)E):\RF$UX9$_ZCF+
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ML(<O+J"FYM]YGIDR<+70\_O!\:1??SUEQ[%8)]AE;]K*1>?^ESS7G=Q@8K\
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MB0/U-UW$_5=;R5H84PI@I_ZTBC.L#4'0:69P)+P+J7$,R3C*UQ5)@[&X:%,
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MW0JO1H''KO<1MR'%CJK8Z\DX_C:P[;DFG\,PAVYS&=-?."ZIEN>_G@E]% A
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M2RV^0WONLCXJ=0QFD=R6=AH:7#DIQ%=U("UTSP$7$)#I]O2[TOKH@^EYWW/
MID#43HX)I2X3Z:[]0H\348A$F08=AHK4X$;PZE[I&UIS;DZ2BC]M_SR>S7M^
M_Q,)8WH.:"S$ I<& AV0G#C*EGG6\HZIHQ26]V,?VP]"*9SR'PML0[["?P%;
MLC!TV-@AQQ*>AT8V@F>M.[-1FY^85]9K@3@JQ,3681G[JQQU&JX(T@4B]'"D
MQRFT&,QT5B?>1_KT,HFH2Z15B$URB=VZ#Y'5?JR8,WG&5X-CMR"G:3DH8A#9
MW2F#]].@-%[;SQK0XJUFGFHU*L$GZJ,_0T-8[L0]"\0M MM16A)T."'*9O68
M"S-VR3E$8CI2K G^++K9B._PR6D"[\S:#:VGILZ1'[T0!;UWA'$^NMDE%3-]
M(E"5GM=V3Z,?U.;M>DYHI*)Z<0,DZCO<J%WUY1M%5.HFDJ]E@7?H#KB1>&+@
M.6!UE$!+6IL@):A#$A8XH=QV0&:D@+W"(^2O>,T8X_C^BL^?&C^!W#Y*85ZK
M!*BP!_J+'*M@R3XI7A<MA4^"G.F+*7.GYEM]":K2E#HNNR;_8JR/3]K!VHF0
M!/E^VH9W(OND4<*3<P B#W:4+$Q\3(P9)HN^=Y"0IX ,T._!M 8IIK<+T3L;
M\ZC[*+)&/I6!AP*/C^E(\4KF^_A;T%DN3IS98C9:H)7*4=1MYC&7AI1!.&6:
MA<K;/H;0CZAKJCH_B,O7[SUTR1&>LA)L,LLAFS9NYIA?,N.99+'0GY1D\OB(
M,^ KZ,*]F3Z\,*ZSG^$K7J2M#G\.L(U@(5 A@E"+J;\UX15,T:6P0E^:MB3X
MTD$8.;H'3/CC74C3Y.&;ENQAE[R85/?=@JO5"XDZ-L:,*=9";#P?)^>"^3ZN
M*<N.+Q!N;BQ)KB)O8\AAJYI-7H'=-<>P+IHOX;NQ >3D:<$&\;<L6R3GXS=H
M]QQ]XY.%?F'0=Z_IV-85P:?Q*!&P_3@6G[0\,!0NF(G\</;A_ZE3Y?\_YD)T
M378+XD]M\/</_8DGE0<F+X9NL(CDZRC>CEP\N8(T&(0M?E^X)B=;LCE=7-FP
MO%%=6A.]Q9=X,)IA^;KQ'E/C"D\J/<1DR$2G6"?0,:4,EO'9CF$[NZ =2X0M
M!80+%FDT5VM%P"_)L6,Z%,U$VLZ>^P0YQXV?"+[T9.KU^;;*@5",'5RT9-O[
M\S-%<]M9(KE,@6;B'+#XU5B^#X\,PS#A-7\+K 6? ]35\RG'Q@W)^1#2?@1*
M0X[:<@J<!-$QAXHH<WLXFSW3#A=/7F:'+7MTY&U6<EK@_\WM]H6'$-TA,P1G
MF//:!JG!4YKI(G5.7R<*(1903[/2L6.R&#/-WLY$XL%PY2.F((HVB?9<2<Z7
MG!D,WET*^=SOLH'*9=PO!_,*"+OH1I2IO%]BB_V07&L-)]S B600+J(?>(%;
M3HP_KZ=6W30-<W],OS:+Z^SFON:\:>Z *<.RHP4ZX)Q]RWTP PQC>I8H_4RY
ML4,OU54]EDN4G_O]O1&9-H78,?G<"E3#[,"D+A;:DS2WXPRG)#':@BZ1N#;3
MKP_NB3N6]\EUOTUZY>:=TAN;[=#&J *6;HZ^;P#E]1-'H]I0M.H_<&4O @U'
M3/>H[CYKQ36Z.0<KL\H%T+KKZ6FZI*:N'OLD/Z4/\N8N5V# 0 @WLUJ2S@+5
MEP:X[&0DLVY"!_(,^38AK[LQSL>7\!-&Z"P251::[-3/OK+%A!W+#K#//6D:
MGO9*G.[]XD+SG.:A/\VN?!,"\:<$A7CK[>V]<+Q1TW9\35Q*BINHL!NZ&"!B
MR!/,,LQB\2J,PXY1_TDCX/K'ZV-\#.#K^/3@&2"?5P2)*@U=UNI#RBGH*L05
M]*MO?[]K/#^\-_4VLHY)^%-Q%_7#CU1RGH@\.9&E.O$K. O50;<UJY&CNA=%
MQ2U?3'JB+MQ]<5$ 8!T^EEF98!<?$)3C%LGS]"O_EO(CI_Q#4)L33N"D)29B
M7F&LWJS #LHS<LRI,:ZZ-.+H,,S9=&&/8M&%:B9^0,=^6N$F08R<Y'M=5$<'
M?W0$OAQIV4G<3?CYI:ZL[+'^*U51'XKI.FI!]P(9N_BDVEJ?"QFJ>NY?_3<F
M_FD>VSIK6<J+D7/A[F(/*(I\P,+U(QS7LYQ$N'6K"7EOPGJT7F19!'&EN.4[
M;^FC@(,IJM53^P96RLIERO?717:I18SUK95-1^>^1QE+;'?$9=8J&.$8_RG1
MCP8VT[Z;,1LKV<"DU]DMJWL[O3%T>.T\- XP$95E?@=8_'BU3[&(O.ZED&SV
MZ?>0&-ZSC?#ALP.2AO*+E;I*>BJN9W< ["X>JT?]SO/(XLRJLW4>^+1K7>HY
M0*?%%V356?/RG^;7G4EDU3JI0,ZZE"J@7'[L2O'+^P&,'ZT<7#IO*"MR^8#W
MP.'O?X[6WR^<-LG][BR?.J3\_:+K@QM7M"[&SZ-$D*S0%@A[O3R&I[GV9\8B
MO&S2<*NR2NKF.<!NLK)SV.K=>]'55( F@+^!(SU'QOW=ED3\V@)I7HZPGJ96
MOEG@[-AO8D_('06Q@!:3H5084IU"\9+_.]C%@0]KZ^7AHV;&E@=J*@W4UH./
MAB:IAW!DL7UI RW5/.<Q8SI1(1+#;E=9PENE7N@>T"_%$7(OH.T;5THJ O^X
M"5'T!R$CW?O\SL[H'*JD+CWREZ'WP+0:]3E@0H/LADH>EO^?EGG_]YV/S,S^
M;36A/X#_K/&1"_S?EA/Z#S^1\I?_ _[;RM50R$QTP,HI=^3Y:_+GO *7-JNJ
MDETLX<_3@FQ,C^]5*761F!HY0S<A;X?,@VF $/'"W0\'9=M39ZDLO8S7_,4M
MS*4@X8<JJ^.%> 4_]:&]Z7G8!?N#%[F7IB=5/\ #VUFU%NT+T< =?\S#]A-G
MJG(I]&[$(][Z<;KX7[ )\>.@,[_J8VZ49AZB ,[\=E:,S5D+B4H8^!IS=8EA
M;TNU9!KJ(2T>"**4@ 2DWXAY/JR8;JW@L$8(OY2DL[+/X7;QAWG+:)S6-^@L
MDG&\W@1=I58^>!1!M-N4U(O],;*;[JE_D,T>_H/W6NQ @S^KDE^QJ+OAV_$'
MT*-X9(-603IU?+,<IV0/4_)(SD XZ@T=P"NKF4L*(WIV$GSL?Y/*;>W%VNA[
MJRJPDP3'A2T*Z1V1;2?@C(;WHA;]S$SKX<#=E ^Q;3<3K2UN 0 <<5IV"YGE
MO?</>N^#C+Z^/QH9'!!K5!'+V"'OEP7= _SB?C,=ERV,28[3VWL13F]LK%@X
MW25ZN/DPV_E'@NJ[M]\ UU4E3U1VI=!06.0YX-I=B90K2N-B_"8SP'M+YDJ7
M& 0JU]ZQ[CB;EREYKAQV3TX?E5(+/P@>/ZYI2EK]^D&B8&C=)4J#DV1_#.)Q
MV][G(-!@/*?%VK.6S#QN# $?<>9,R 444=?&4:S>^$"7XT."H_$KD%U%"X6<
M9?5M3-:429?S^XG!J]S57^\(_FH.SXC@DEH!W.J2 P[)B(PB6@\*OJX\%2[
MFU1LYDS,#SP(N=;^-97/7#/>I\/^;&K[A.?0$VN-EHKVH\#4M; ALQ9A-TUL
MEZVKTKTE(CX;CNO9G)0*?:1XK;I#@<@]!SCL7[/G$L6!;*TR-J6F^Y:W!CL=
MCO#6Z4\"'BLZY%&UO]B8!0^Z@;]'].>&M^NTR]BJ,9U.S1ZAO47O>1E7O^BK
M'D5U;RTD(%>6Q2>UEO;#_>Y@@.8U$WZ213:5P[;\$BG:OQ+G. E_^@?-G@@
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M,2:$9(V#Q<X1"R&_";#>0^"_>H<$K)F]"#8 )REI81":F3$[?J!#4 LA$&^
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M3<AEU.#=UZWF<N_\N@P;!!S* YU#42(YS <LI$(AYJ.W'7Z;V'Q@3\NM/GS
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M52[J7(>WWXD6101<N,;A*8GE\Q9OB9DV:0$R*-RPA],?%=(:+SP;OMR5/G_
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M< &7*H]!L5AWVF$D<;"#6V&4\/1%=35ZY62_U!R;4<]GSQL=F!LX0(T"70H
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M0_X4N7U$RSU,PQW]_;-@%GNO2E25@H+&EQ2#)R"KJ#8I;9</NF+"(!./7U2
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MR8%<Y4Y 1B!*MY NS9MR4/9;^PKXUU1 \B$MZ&X[C<$.^3:KIE4M,I-1353
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M81EV>-9VB0KX>QT6205X1J72^%U44)= !> W@)$@!I(J!@;T[T:W.?(T)%V
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M.D4":%]8 >N)[ "?;A7"I /7VI^6A+@S]3:W0E>'8ATY(L=_Y-)G6!G/H4J
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M<0#K)LH93COH(F_/7DCYA;\";$<YK5 !YE2 -C@)7"%!REZEQ4W[(S8RNWC
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M1*UIJ#INK$,QVK,X1\FPCNVAG&Y^S,N5GL< W^PKU_&]=XDTBV@2U_0B,.S
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M$\/,9;:AR$<M]P7'4,&7'^M*P)OS$Z>&+I7J\#R(QX[9_@D-J-^<[M\5O.N
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M\K'WK_/,J^P4G:+@@V\U51\VM<U$G<=W0X&5]6KE9B]8K3DCE6>G#:31TBK
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M^7]JK4:B.2DLA)%%NBI%Q!*:W1X+%DBSR7B7%83&)!KO-9P"*UG]4>=P13U
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M SWI J?;[3077C'2AMT9"3=J+@F]WY[Z1R2CM^"4ZX%"KD.1N:)G'='C\AG
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M8-<>5%PQDC#ME!::,U^GV$&;ATQ>>RR^2HX2L-*!JQZ='.SO:7R'AT,NP-U
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M6U@7J<4EQK#\:3;5<3RO]K+ RE+[<QC[ U:_O]_C2[3$0N':/JL<']Q[>VW
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M3=^GP=V76@?_ZM47&\_<FE.-)<WC$6U>,0C:6K22)6[G^^<9:[V/M09.<+&
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MM]#TFB:)0-B+11,';3;MNYQ9VB2^I9C69L(G#E#+77GBJX-/2K4:[+$5L#/
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M?9)9>KS+&-#X;Q(KM1LI? IPVQ/46P'&!@=G7HUX8O*R%&L7+O(RD=FR*^/
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MHW.0*'D*B(4#8;(5>(9O)QE)VKZ!14E8+4^)!9/(1'6#J^\9E.\&A]??8EP
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MJ"?<Z"'-3I @'DR4G&P%78(J$MXDF>'97Y-OY[JMFM3%SV^%6!#P7EI*#?.
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MR\W^'G,74A+X'O[/:_,%VP%6E(]4#7BGD$+E$)7?,*C0TK-X<BFBY*=,4$*
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MFU!\U;F7 ^F.*@^B4V(F[-8Q)VQV5"6^H,\N03HWB5)0<B(-.(GXC1&F?H!
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MZM7E:NHMH-Q;APE:WSM)OU[S0'"U-9:/./3TH4R7\;)2R=49G3^B2<+WM&E
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M>)7HT*[Y=<[=Y&Y7MZ3<W?P;,C>;C.\G;EK\VQUN$K/P>VPY]CA4S[S5/4#
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MP\+*R<K**<++S2M",OA_@$&0@X&%292948F!29"169#Q_Q$&>08&1E9&,&"
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M%S,KXMT#JQ@1!&&[K1ZB:IOO[#C!U+EEYP)M&4*2HPNTY>D"-25*&+HA.;U
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MNCDS2D UWG+#WS>TX4<4N@F.NEK230%IRQ7ZTOUWEGJN*?"8,A8Z+"QK5R:
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MU3VR__W?(L<._X?TPIJ7P1"'-Z3*B^9A7:,W>=D\<-R?V+K)TQH]K=*]R0[
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M"T51^YTM5&_1[9G:^RXMZ"UK\DI^F8Y.JFY[J&8I3FPKQ-3*2.2P-*2P*GL
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M[_A_:NZ<7Q;T _]]?E\<C&X_/,,@(8[\@.$H3K(D<"PO);"TI&G\S)VYU.M
MN#K:OP):]3D5?[4OFP51A:E]']#NVV?0<^(";?B3U6(=A_-V+#2#E_$)LWK<
MO-)<V4G0G9XF.VU9/2NYJ7#9T!LS@8R%.+&=&(=9EMA)D&:II>0QJ!!;T+[U
M.JS2*;5IH]BIF2]3B,!LT[;TK#-%<QH<%0D-69-14HN:"A6A#^V TCT: 9CW
MXB#SJ<IK]BLI2-M$D],0G=^>6?L=(8=S"@UY9,<G(81)B.,H9=C+HM"BS Y)
MIE16HLW!S.9@QQ+:\82V3&T^@25;J.4+$$C0@EPA#C,WD# KHH'A^;$.AL $
M!&?F!E4O1G-5R,&%;=M'5C4D+\09=5/*-HP:T)MJV3@%KM$XCM;"RX5SILB]
M%]69M-!B;1\W;N?A3F"[,29NY.+$C^+0]@+;IJ 3]0F\S+PG_%;D(D'^?W%F
M:/DX>[O&+<)JGN)"N,&V@&GM%C?\O6I_Q4.07J]_XI:3'[T_XB%D!OH?#I;4
M<'2[W(9>IRC^S2R;1W5Y#KV_C'_HQIF%21#$./:)Q1CSTB2*E-U=?3X6_ 8F
M7?H-^RXFK/&/81& DDD+2+O?V]2GH. !+X,MS AN,IEZI!'G"K4=Y#J^]OX*
M^-XV"C# *UX&:,T&Z219KTB%Z&[&>M>>G-N3I[(0Q1#]=[SW(H^_YJ9\Y.G@
MC7K*$Y9?SE^>CL&>UVQ@.:-3WD\DG,9>B*/4]7#B^($743=*/1/#WI?)/-V5
MDAW,?4<8G>M\:0*\U,/$CE,<NYZ5$L=A01K!:A?-P:=5J/AQ'[:+65!3^UXP
MAP1L-QPK1S2>XJLFI*D.JN/$ENVBJB3XH).JVEUZAO(#R2LQQ8OU+'%WFD^O
MBULF5(&3?D/JO/ZM*).:5<_"4%\53^M&#!DL4GZ7] 1..N:.'7*?W'%Q%@96
M8F=IDA)0,[0YF%S0:\_R@G ."$>_J)M*^DXU2@EGFOLYI$$9ET^.#&32TTE7
MI*[S3/SQ6]X\Y 57RF?^[%R809KET:J9L==^8##C)[B50PA[=D]XG1N.Q=B>
M+<](,GV!^FPCR3?:9WS6\[DY 39D>&=A<5%S/2?(AT9^5EIFD@R^][MYLX$?
M2!WN!R91C%D8$S]E:6!YH.;:9^C-;+"WI^MB,FO/%RP8T \$PA8ZW'.F*>'?
M'M3QO<@A491LJNSOU&ML3*"W7TI_!R^WD;?L#;F= 4"U+<C@VP3;30[3-,0$
M[?V!!". 3$[4."'F3+D:A]1>-5WCA.CG,C9.W0:?U?.NBXM]R.N4K&Y8E9?T
M _]=?3BRAXB".CN(,(E3E]HLL6F:J([L.4EE;@/9T44M8=121I*T^@2?TQB-
MJ[4QR8'*K",T:*[/6:&TQON<7G6Q*3]G!>L/^SE_\81&#JQY*.GN$P;:R6'_
M]IFU;+^W@22MT<'A0.)QU3(D+/#X92@G_V R^:FD(-:T#@X':R[?PN&X4$=[
M.)RX5#-FM*Z*O!&=\PKZ(?\N_E6?R$!T8\Q_=G#@QB2Q:!A%:@.ASY.:.ZB>
M97G*4+:A/V6BS@A>BN$4(R@ @R)[DF^HGD\%A(<RS@IG*B!QFM"R886S @^"
M ^?OT&S'(NT#O_?R>SYHO$X8Q22+0\Q8YME.%F66"PK;[JV^S+[)+T-?!#E@
MR^9](-2T4EL\K9U203)XKY5C$ICJL;*W]K*]58Z)->BI<O0B^$??1W9/5N_E
MK,JM$E&?9CBFE'_J>6Z 8RMR.4!I%@:!P](H5?W4.UA[9A62U%!+#J1$QV X
M_S4W03B8 D'D GVZG9! ZX/M<*W%/M-."-'_.#MUB>:>4]>L&6PV/F$X\D65
M6APEQ$M#Q\L"2(^A=EF0BNC&-XDD!=Q@6JD5=Q:P+, M95P ^#ZRQZ^I#:1=
M=-F=8T^0P9:Q_U?=OELK_F,I3O2?V655B:)&>2#,?3O9R_+XG^_XOVJ2RCS<
MCWG!Y+3Q0R5*$X(3E@0XS?S8"ICK^RZ!I>*89&_VQ)T]9E&/'?G-TO^YS>IL
M'DB!]F_Z(KA%DEV@RVCT0:K9A==Z.##KLM13T>@H9AX^8RW(#+*V<,\R\Z .
MFYS-0$.C5J&-2XLILXP]/@EJM_G]0U/?E6_8^^^L2O.:T</)2&D@VJB+H=/<
M(I.0,<]B2H<]ZB1G_C#XE7S/']>/HJ)1''XT)6(=9?2T90M5DB] 2KP:FN.6
M<1Z,8/:N.Q.Z%M.DMVBT'*"[$KUA:,N$<70 M0'&4=(L WA@FQ>)K%;E-W;F
MA3*5W0\2?S217VVEY7+V09+MI>?#[M1LZ"1J8]\0OI!H5<FX01:O2ULLR\WW
MMH963.RN;\I5GKX,W%J2XB1Q(IRR-&.!$R5AZ(&:.,%YF-FDMJ7>B6!)EK]L
M> (V:]+ 5LW3G!DQF(&5S&#)#>K&INRYD5]:!F9JO:2/A*EV2QH<+-MB21^B
M05NE"4MI'F;FHH#\(U^3K][P=RI/5JS]TK]\+*LF_Z=DX7U;<?F)OV)WW]CJ
MF?U:%LU#?>CL.:F-X]3U,?$\&J>^R.FCH //2>S,;+7>UTW^*%(#^9=<L1:1
ML!Y+FZ)4E)45XB]Q #PDG?8<U,S:<NC"+%S+%Y:,H1UG2+)V@00_<@Q@G\EN
M-MAU87 RF!E\3)W73F-FV3-=(\ -SGW-K H_U.)?SC0O[C^_/";EJN^.I1D.
MHR@5PPHM;$5)E$5!$"=IK'JDM;?RS.:JHX5:8NIG6?O2CUN623+!C(2B.* C
MK*.L:QU@[:^TV/'540'ZAU?'+YA_SN<'_A@//V2\P,7$BF+L.H$=!XS0E%CS
MC?D4+,P>@^<O03S?E$^)HMK>/B<R,$75FO$I6'J=$9]],%YAPJ<D_\,.^.R#
M,V6^Y]XZ&J'GJX+F%7<";UG-5TL?^,?0.U$46LI\Q,X#& SN23*<>&&"/<<G
M 7.HY:IE<*F3G'L+EP?N><<)JCI6Y$D2W3&S;8@#"+"J(:H0?C:.$\S:;,BC
M#7W9QJ;' >I8,(X-(/AL'"/=_HQ3L8(%G4%BCP:=U59:+N@,DFPOZ R[$V8J
MZZKY^IG=BX7^PLK[BCP]Y"E9O2L?25X,"E8)Q4D<<A/)?3'/LPGUU,84C5*9
MV2#V":(O+4G%Q(5Q<,8-G3&18;8-)JVR;BI),^8*\05Z;A#_:><"C:^]B((J
MB;?12;6+IW9A*NOZ+:FJEZRL1-YMV^SI4"$SR\-Q%%"<)4%(HRR*LE@I5U:1
MWLRJV7/WQ2B./?I=,PA@BM$Y_-0^C RB M/>28!,Z"HT*J;QMD+'J;U27Z%1
MT4\W%AJ_34_YWV<9W^6W4PGOR/=;TK#]5A5OY4R'JV)3DRVF>\OPIFB%(:^X
M%#D"A*,P2!B.15,A_H'C.5'(G)1%- &-M3#,W\S&Y>UN^L7SAG:;0"&(P\R*
MZ2>C9H9>$6^8V=HRVN_@('@]:/!S@5IVQ3/9-GT0U[8LHRW/:,OTA2@@3XTV
M4YL)5D-FTC1WBYK5F: ]-,-SD8$?^W0U'I1R[:C?\G]>5W?EM^+PD-MR0DP"
M2K!#XY@ZU'&"2/D Z 2-N4^NV^J?CBS77/%362%!6OU@Z!0^YX^(#$@--&(Z
M H..CLZ(I'6(=&K-Q8Z3S@C5/U@Z=ZF>U_2)-6])_7!3E<\Y9?3-RV^U./S=
MNFJ7PE*TG723NJE(.F@HQ=(,1X%/9-DNH8[+PD@IWUB?A;E]G\O/_XD^?+S^
MZV?TX?;Z5W1]\_[V\N[JTU_0Y=N[J]^O[J[>?_XSS 72@%G-RYD7/)@-$(R@
M#2<H>4$_"6:XN_)S[VBJ8^CE0G@[J[4\87Z7UVG;_Y]?ONW_C[YL6#;XU::/
MER$/18.!19T0?8 ._8P)*VD<6&T\%3GFN)V ?+EN'LHJ_^=>C41GLT3O[=#"
MGD\3PAPOBR*E#-_SI&:V35O'OQWX?H'(EK+F'/AQX!3.HXS! ;,V6R0DW8O-
M:/(=:6,8 ,Z=C&&A7^SPV%7/%.W\]C+;]4=L7PY1#O&8-TU;"9'P[\FZ7K<&
MFQ2(23?CC[68?UGQ%U0>?28O*_+-6&F$$DBCIU/C*RQW*J4DR=YIE-H=N@.\
M]G/VWFTG7YQLE>U&,8X29N$LL$F8$,N/,E (7('FS!;Q,'WU3,=+;>34_#'#
M>,!,X@ *M"-ON-N9AKS&9F:=I[CP;"QE"(8SL-1OG=94>1O .=(2V&<)CM.8
MX=#Q \(LFV5\!4 OC&-$0%H/[XS!*>SU_=5JDG$4'#4]GRJRIJ^S"_=**R=V
M]R-A7_/M?H^):;C'[QZ)5VGL>TS(4]U\CUX+[QGZJ2QN6/F)E9?/]Z("B7\3
MK<EJ]2(2-2\?&]7>H6>6F7D'YM3QS?MK](G__^4S_[J[9ZA?3H4V[,C\4U%4
MLE9M::B"T;C"&H8'IK=FD0&U(E646:LEZ;FU%VM-JBADOT6IZBU39NA^YI]M
MLE3THWA$_#D/$L+:<PT6X9C1!'N)&WHV2\*$*0V05*(VL])OJ8H]J#NXW#!P
M@=Z0E=B(@!EC:BBJ.N*&L(%IO"%8-&?:GA'7Z-3:4[1>82[M&;&/3YX]=Y.>
M ;AE=5/EHGA2?N&+:='U[>??!NV*I0%P0Q]'MD-PZODDL=/ BAU03LDHM9D-
M *?S1Z"_/0Z.FEX;$QFFUSNR;;P12<+H)TZZ_GF&+L5*8AK2YW%:B^JSDMB'
M^JQVD\:9PO&4\>OLZO%Q7<CYL.2IG3'Z.TG3O#C5ECQV0OZ!S7],?<^GE 99
MQI02&"9Q,;?^]VMC^B4-8N/;9TU>LF$.$);7QE_AU&()5,$FYGB-R/40T,L>
MH.>MCT%D 6<A2R"L=TRBB[2A\X^IP(P>C6@OOMRIR53Y]PY4)B^FV5:U8C1O
M1"+SA\VTS:OML,VV4<S(H8N%D]0),.$[01B&U,XRI>U A_C,N\ VYBC;L*22
M,;3BG*D:>BU U5S%N6""F?66"UF2<(&VC* =)_/VD](!P52340CI99N(:H R
M:!*JLP8\0GP8H_J]EEULNUF=X"E3BLO-G6%W.@;Z7/^IZ]/;\:0>*%:%ZGS
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M'!7,^VL^'=A.T'LPDB#ZK7TP[:?5-EN__5N?8]2RC"[WSZ(V&?SGJL87>$Z
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MS-E%EFO_HBK/7J\7Y9LFSB@6I61%FJ_:"03M,+3=![D<!,"<U,=!$KBBIBO
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MFWV@BO;GU1X3T'#UGM!(<;AD=U<$ON48]5CN8B8SS5*?!4]39M,L<\O:VUF
M'1CJ>:CH67C9ZU;D@QPFU5LV][$8Y2;*IBD);1HY<08YGMZN///I<SLHH^W+
M+)+J8 9Q)[^:+=.2"F:&NE;<;\=D =N, =^&U'VW[J*:.A#G4,F&%\QWKO(Q
M+]A5PQ[KP[.5E%F8.$F&LR3R8HNZ=FP'IL]6MM1_F/,5P1&2+,UPR+(#V]Q!
MBQ:$<QVVJ* WRXG+ (4%3UUVM'^XDY<!+#JG+\-%IHT!:DG=EJO5A[(23L-@
M?+/O8>(1%\>V;T4I<RFS+9V9/P-*,YN9[0B;3D^^"-*HHPVT)Z?14K,=1C"
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MU1,<#TF\_YZRNN8WO&$%R_*F/2J5QP',23W,/)^*(SKQ\6]'F+J1']O,=I/
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ME ?-.ZLT=_W5JOA!&/W[R;@.NW\'B4EPX-F^&?EAZ#%+&Z2U)*#.KJ8V(,4
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M.#/>Q%:JG3EGWU+8X30[IT</M_F@+W<XSL[!G<-U?FCP6GA1K'RD,YADQ?O
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M8]+N?Q3[JB%-$QSY-,&F9:1.X*61%Q!8J *(P>P1!_99^3 #'<I#.7M]1K[
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M*++B$Q&N\RORG-5D)2(?T7XX^HZ;9%56TV^T?,EBVLQ3YF&TAURL<M04M>P
M$]L-L!^3E+HI85L+ZI0T-\(S'VG-!':!&XI[R,&,VMEW3<XL?DM[ 3PI;Z^O
M+HYG(>T.?FPC 4V>?U6C'HKZ+.^E^*C)=I\=W46M_Z68OW]_6 RNP@WDCE;,
M7H@?V;'S@;[05?',\11#Y8[,MK<(GW'FN=B)8IMXH6&15*I]E 2LF=5Q!UQ8
M7SWP[9Q&P+1[&;Y)7"7T<0.F$)=E!.!JH(\A:E>!4<9H,I#E:!PUB">66,X
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M;^/P%DZE:P<0 65O@F62LJB/$4#9Y(!%0FT#NBFC;H#/D$LG2:<N 9Z MJQ
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MZCVYZ,");(.TAIF)?>K5R;SFN*0HV094V('YW/*7]OC;#DQO^=KDO&IK[:+
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MYXQ=)_:/12\D./3<%">&ZT:)[::1"TKI&( SMP=T Q4],["8777B!C"P9G"
M2W)'HP;:81+:(ULTAF%D7TV0#:\ '"=*5\G? )1E:_S&23THZIMX'%X,<%L6
MR3JN;\IOM'S)8GJL%L"@*0Y(8. P<6(OL&PG28AL+< Q #.+9@M2>--;J."J
M@*-\&9=)'=3"A%&!T/]7W;?^QJTC^7Z_?P5Q%UCD .:NWH]=X +.ZZSO36(C
M\9G!(!\.*(FR-=-6>R2U$\]??TE*ZE9WJR46FY0=8";'=DNL!YO%8K'J5Z#R
M@"EISJ@.&!UVL>* *:&&M0&3SZGMB&S(E-*L_L@8NJKK#<\KX"T]'A[6I;CR
MW%MY/N^K03B01H!3UTESXONQ'8*Z ,U2-+\4!?VV+U;!.!"(BTQI14FJYRXZ
M>(%*=L1D?R\Z%E&ZKJ$PC//*E=M2M:H,O)X'VNJ)MQU_.'DDZ.O;:*5%U;3E
MSM-;=/.5%O]P&Y9_4<U.?*5/M-Q0/GR?>/W7HKE_MZF;]0.M1OK$,UN16R&.
M?2O%MF]EJ9/;8>R NO%(435L+SH>8"M?3EURJU^[$F 6H"/?&H"> ?2#<8!Z
M%M!;6J;W#Z3ZAX%&\B#Q-5D%.9J+6@:0&@ZM ^QE(Q;BP\\N6XHG'K#_\1R$
M8]C&%$<9\RWB.(C3,(IB0C.-]F*,!\/6HTUEK@S8$!F%QI&'XR!TL9.X3NC&
MJ>7DEAPHR$(J54(1Z4U21=/U75G\BYX&.]2F62VV^EQM:;?<O+*PSX#M>>(9
M88N9[RF-+&/,1SEX3:9]2D5 0S\YE )$RVJU"X37G5,CB\DR\J[I^.AJ-0C<
M0WJ\C<DY?UUQKHC ,.B^=!H]L3E9U$!1Q@9<#@5E0IP]V).IY]3\I(^DJ/Y"
M5ALZ@+:Y3&JQ5@\O(E(GQB3EMQ%AE*<A";(L 05;IH@97FV<-!*T]T%\>O+
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M?JV\[4$U$+%-2=L)*>)90LR1[E2]J$C(^@J0^'1.V4M#]&F1Y=? [M,Y;=I
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MDP"[D47C( Z(FTI%&.=)&;8<6]IH2QQ]Y^111Q^" CBM,XGCL39-P$S#@DH
MG"ZU*4/M?#BB%$V'-RG!)H]?TR,L=X"2DF3O""3W!CS'^G*3%4SEG[CF^3?K
M('$E2W,<Y7:.J>O:CN?:>6YYLBG6!V,;MD@=-=23DT^M/M3!M,$Y4S*8A9$6
M"I11?8)]I83JP[$6RZ<^(<0PG?K4(RKMKW_F[-D_RN*)?3.%%U&NG[HD@X>B
MH=EXE6W.,P(RCYW]\S#/ R>R E=J_4"(&EY8+1=HQP;:\8$Z1M";ZS^N).OD
M0?J4V/P-: FV2*44I ".+*LC2 ]L_;I2\Q*^TD<.S<:CQCSH6Y2,KX=68^S\
MV9"")P3PJU<9Y>J*#@.U,]TO6W*L!;MEPZ3;[Y4-?%<M*#/:V*?%\CM")R$>
M,ZQ9S/X)4RMS(L^-0%W])F@9MJ<G(3 ;\E-#PZ\I)<J%732I!F9$3_3LND M
M87W1%0GI-$53IB@M&CV1$/DP6B+SBFIA]Z DI0WIWJQ71?K<_KOK37VPXHEM
MX22(,NSDKNLX89:Q#V$%WG*$C<=<AR4Y'*H(6M4MJ3^YQ6Y"*["5/U:C=(%:
M\NA[]U^M/;]59==6^"U)=N$"<)@RC@O!@>\K-@YEX]9-D;[CIJAZ'F\ DZ01
MCM* XL#+0HLF3N8&H"N:42J&#4-/4[2O_+^;JJBS(I6/9$PK2,X8G"TV;.6?
ME%@C#I*4:+JZ<8[26+;GYI281YTU)Q]6B))\V? 1>)+&C^VU6=%V;4F].,K9
M>DP2'/J.CY,TL-A"S5PWR!W'HU+88U-$#*_.EFJ;\O2#IS1M"0-.]*?T(Q'E
MT" U;'%V HO,O1_HFUZ! 2$+#8*KA2@4%  +-\Q(-AE>./7N<N&$&>[WP@=S
MSQJH[_BCS(HZY8:-9A]^INS1HT!"FYB54!RY;HI=U_=RBWI>F,1_EO2.8Z[*
M.0M*?$A]?^/V^SOD1OKKR[GZ+U0\/ I0TSZ[0V/]QTD-R_D:YK1FK!)DR!5J
MV=(>GCA++4O4A)SDX?44ALRI"50=,CN8H3[C]4QSVP\_:946-:VORAM:%>OL
MK[2XNV=,7CXQ.>YH__E-5:1'Z:@T='"2AQ:.HM"E<48"VP>5MBW+OF'?KJ=U
M/O;SPK,J9VE?[US!3+1,Q_):MF7Y5B:V-:)6J@O4RX4ZP;9/(2':@EW,C4S)
M4FW-]3+_NOJ<&YD8<.-S,UR<V_;DW7K%/ECS7?2)#KF]++,O3/\G/AZV.SCL
MB=+B*F09CC,WPYYE!S1W;2O)B%I/%%TL&K\D&/"QU^>17QH.?[\6E1G-/2G1
M_DMG=E;1-I>2>]2+SA#TPL+XY)S1O$6W_K1W=M'&X NU?=&MX-,]8;134D1(
M*\JB80>B)YI=E0VCPI'7+MF1J>%'H:HI_B6VIZXPAY?0W_Y8'U_)9#AQ/ M[
MF<\^<8(D(5*9<&=Q8?K@4#?%@^C/1,IR0U:(##CI>WN+:EBV'D(@7)F2UN6L
MK7%=P@QJRPX6_* =0TAP="$:B*?"*Q_PUF%Q,+XT8HF=HQ9=8&%*/"R+!G:.
MFH[@OLX:#-Z_0WC)MP]W[XLZ_20)XW?R/7-+0I!#M\4#CT1RFJLU1T"K-:/H
MS4JFU+1B?,3%NE9,"C1L6S']H-IFN8LBKNMZF#Q5?QI!!Q5;8Y9;.$D2!R<V
M^SGW(\?QI5!< #0-;X2#J#GOO;;'PQF0G3+*E-OQ-*L(MIC/UPYX*P/(JVGC
MDJ&XZ#8%4,'AI@1Y]87"_[^S)QMH[+\%(W9#G! _PJGG$I+')/)2_T_V8K)>
M+/HOSSUD50YED%Z<@I77$/H'S.A"<7\SL_2"0?]6H%\SX@^?C-<2[@=P_FO%
M^N%3HCW0K\ "O$CX0]D4S?-?Z6KU_\KUC_(;)?6Z9.>UNMX<Y-[Z.$S=!!,2
MQ=A+@I#-"O7=3 KK?I:2Z6".H(TX<?P/3AWUY%%+7[ZB>%IAT]9;JQI@ME9=
M Z#R8RGIE(J1IT=>K#192L!AH;+<"VJ>YDW% 92:YQLVU<UEF7WXYZ80]6:[
MJ,)8S8U8RYD789*&#J9^:E';C6GBVY"3*82XX>7=LR(N:;9\7'!<2IBC!U*H
MG*=F2DVPY=]S<8$$'_N*&@2AT'<CU3@J2M#DXH!(+^JCJ"CET,E0&L,LY/K1
M#;^5X#BS>-6.'X=1D-FA%T#@$64)@XR,*EKB0U$6#YL'M.)<;.%1S4"O:X9<
M?]D$VQW4^O+XZDOFT [)OIZTV1%EJ.*HGQL=:Y@INE^OV!LUMU;-\Y=U0Z<=
MEA86(',QR5P?VZ'E$IKDB>>#>D]*4S8=4*^RHB15%]8 V@YY]4D&DDPH!7@T
M$60->1Y@^71%5J3I+AL7@:KC**H!'D"AUO =^Z!(R>JV*LCJW;INZAD @2#*
M,0E=F_L8N>.'$4E3J<.,'#G3&8$=?=1P!E#*.0 4XLUK:]H4Z-<!;/UOQ1>T
MD2 . @=040F@2E&K:M3J%0<'M'6.V)>;5ZEP/^NQU1)/0SI0H_@6Z4)/DE;!
M9&'C_"C+E3A*2[17["C_EB+F/&U:> 5^.7EXD&+3CHF7V-@-,I=8:9+;%(8S
M/QS=\&F)MP3A "B(-,RJ)9M&M(M@AX"WI"K*YGY3H[>%@)XGCW33%&F-'E=I
M>SO7;2] '/H]U<DY/\H*@1DXKHL>9E[T=$:7!TK1#3,]*I@NN/F]L9>%F!\3
MZPA6?O0AQ</*)JGI/S=L;CX\\>S;HPH&'X=6&F!B>PG."7%"$OA!Z%+0N62$
MB&&/8T<2"9J*%05CVI$\=IPI,VP!@L6%'S,FY-%UHA@CL>SA84+(HW/"U+,*
M1X+/M+JCU;:W2]<F?-U=CHHUR?9&@C/7LW&86RY.TLS%[& 09#0A-K53Z?/
M-"W#2[,ECDA/'=&>/$]?8?0!;O",TB2.!?I4 5NQG1:VA'FF>*^&&\UJ !P%
M]*E#[1QPAEI@#K^<H)/>_LP0R[GZ<K+L^?F2K\!3U&^K[+*J/OQ\+"HQ\^])
M(^4KG'K7=-[$EACBU.36W$DYI^V-#A%A1N:V(AD_1 _+^F0E!J7A3XFEE(4_
M.N!B2?A3X@QS\">?4[R$W#6.YU5RFXJ?F\9ZMJ<Y#JGCXBB-V*F9YH[%'/4X
MH1$L&W:2'N2;J92_RDCBCB9:[3CY+^!UXZ3.Y/QU;7J K= !V0NT(VRDC;N4
MB+IN$"=I+7MM*"/VT5VAU$N*538\*'29IM6&MW3<TGG7$CE<XWELXR3QF>/O
M9-3*'=LE :CV=)J<X?VUH]OV8 36STRK26Y9ZQ,>MJ[;XOE>^KU5WM'66"XC
M):.N2IEI8LL6R4@)?E0?(_?64N7FO&/[82 \#1*VKX<)=FB84)OD@45!F"%J
M;)CVM0$%YZYENN!<Z%W.B)C7)LRXG%%RSAE[R9KSH6)>K.A<,/'*J\Z'BCJ_
M['QO-#7+]I6N^-J](57S/ #I:/$$>;_JW=^.S!FOJO R#WNQ8\=^&E WMB#F
M#$#;M#_3DN27U%7+%'KD7*%F@%L",UT0Q<K9*T/J@AFIC@DDN$ #DGU7%*'$
MP=_UF24%^379(@CE10V0@DH.K8[*$.>"LGW(<[:5;7LRW)*?7QD/7RF7FOEM
MPLR)FY?Q*A !O^;C*(M='-#0BDA(8B<"'9_.8<;T)6?'&E](^VSP*W?>FHSV
M+(O^3)5TA%/+3,@9JZ7T"[->0]5N^>IS''C'!\[:H=+;2U<S[5YTJ$D[&IH"
M*R^$>Z:NM-,(9V>,J2NSG%%>;7B(_X:[?<P8#])N;M<"9JULF,;8H'=][_"Q
M8+) <O%"'#EAC+/0H9[MADEV;OKY.>R9MIT#9O_]WR+'#O\;4<$T,/BL>5(D
MC>:+J1IF1EO>+M"6.]2Q=Y0@ML\AZEDT$@@WHSUC>?5G,??"R?<Z%#N?H:^%
MBD+.SF6;IUPSFT^+)T[M&SN.9Z3JT0YN:?50#S)X!N;6BYBYS1P+6TD>4R\.
M/3^5 LX"4S9N25O"?:T@:CAI0/8*2(O3]M&H;F"FK^<"[=BX0%M=]2 O@I4+
M>,8/2&> _!]3NE/+!M*I0UAZD(H>)I.%0 ,NESJD(N=>(I'2 (9@QT[!S8A_
M_L*[Q;$=0G!B'Y4>Y#F.@SC':9!'[!<_<0DH1*F3.<,&NR,&RK8T,@>2ONX+
M:188,)" ^II!^FIA4_O9T67.3*IQ*9 N"&NO"X5+0:E@F"T5&FH66";BT5ZO
M9W_?U(THJ#^L9,VLF%E:/\=.D&8D21+/#J4RU\]APK!%;;,]R(X>S*@JJ57.
M>)I6%C <(!E)O>B:3PR8$OY=JC5OYAS=:+)\2BPL:N'.4=*A)3MK+,T 8E]H
M<X2_P1Q!$CDVSIPH2 ,:);D+ZBLW1<RP!=H#"*,[@+!2&T#8B,(<F^"(D BG
MU'=3.R1.DB60>EUM"H.7[RZC,#DCK4L-,&,\B9@V#2VG#QYM(*%I.#1.ZG7
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M,,T?Y3JI:?7$S=15R1@[",.15;I9B1^_[C??&2)4IC'%4>Q2;-O4RE(_S:,
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MW2\][/+C *4RWV)3[J"73:%[:D?U-+?.-:-YO@2$IV;_'T#XE4)VGCHI*(P
MW\JORIH-7C';)AI*L<$8O?0R6S\R1T&$?R2W]=F!#&_Q'7W4[X0]%UW"]CJE
MV4;TAVXYDO< YC4T[PUH50[,8@#U@KYS=C3%H*7%5O(;YD=?S(>0%G3H3\B_
M!%_6W474Y<^BEEW @U<,+]6.DB1:]Z$X\ZM-41+8NNJ(H.^<C*;U,L*XTLH8
MCK/8&AAA?OAM'_M8,0C=X^Y_8D/2 Y0[X>=LRH87M'7EC4?QZ23$A#@1]B,O
MBTB84]<")=1 &3"\G+8XEGWJ8M:Q(&IM@?%KJ&XE0]L&-0:,>F^[A A61E!
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MEF=.%KEA!CDZ2- TO+-]6I=W'4;?[1Y"'_K>T@>FY<EH4<[[UZP;V(9SAEK
MSCM 4$W>N0S%1=UO@ H._6O(JVJ&X2"F\67#<WHZ=[Z^WE4M\_J3]#"ZX-@$
MDR"P,<E2)XGS- !B:8&H+Q3_W)9N,S46):F>1VJX+U#".5(OY8:I7<ZF&%,F
MS+H<14);1GA\IBNYOQXJ4G"CS]XH*4&3Y8'17M0&*:GET!JI#7)N*/2P_%J,
MSFSA^Q9RX63\4U0]$X=B0J,<NUZ2\;Z?CN.!+FD4^5@PZ'F 1-$:)GXKWV-2
M\'[T;WAS^M_^LVA1/K=]ZE1CH[ Y@09$C6D:& 4=*'D,.N+M5M,=8PM%0974
MHSWT">/BA>*=2JHZ'>14&PZ(2%4U;7N!K_21?3'OV?&0>8%W%7G854EE[$"&
MXRSS<>A["29.RLYK/O529MQL+Y("_Y^A8]J <<IH1QIUM&'E4G.ZFC8\&C6@
M<+VB(KP\0I:<:%-&@0TQ, CLMP%ZULSHRZ!JR8FX1=N2?%S-6^DJ(FX(.ZO=
M5J2LB>A(-!Y8B8C-%F]B89LM9"L,J$<B&^*33%(SO'#[PB%!' VH*X94IC4G
MYSEHTP=L&9^A"O#N+R6BICU^FM:B.[F4V(?[M=Q++].>^\-/6J5%S4U.>WPZ
M- [4)9CPU#(WIE9"0N+[D51-E#$.#1N4 3U$&H&M1YE+S7QN_F/;R>',EEQ:
MYTOR,/.2LZ#@C6CJCCU@^Z*+^[R>QM<G=?I*6EL?\_=+-:\^J5[=[:E/$U+(
M(=D&L?ZY820_4MK\4;)71;[?Y5U%!4.'1MKU*&9_<'#DI)GM.YD;YU)Q;WF2
MIL]?Q;_:C+E'DE*TX?312MQ7DYZ#UN@*'E'.F(24Q,MI==J4FM$5S#9VH>OK
M'+4,(,X!$BRTB;]HRX1V[0"2*+1K22TY@AVMVE8#M=B[!\#X?!]OF/?%TR":
M-2IW-P)S:OT/38D1(!5-)CS(C;1<(@-(LKT$!=B;B@[S)JGI/S=LH ]/_)LQ
MT@:B/11;.8[#@.",4"MW\M /+5 GLU.$3!O2+5G4T@5W09C5E*3'J4%^H..H
M(CK<ZYN12Y?S=HK,LC[8C+!'KM3<\XJ+EM[QI<_L.6]]6-Y!OXHG7C?X56PI
MHBU),U_%&;ET?15/D5GVJS@C[-%7<>YY>/7IS=/CP4VB9 WJT8N&-P%V2$%/
MXFY0>#P\:WK74^D""5[DJU2/Q9Y>=F=+#%MK(\*:N/><E$JIG/5XM,6*6D\*
M,BQM/?V0PKEVV[:1'J$KBM0MV_<Q(4&"P\2)J1]8 4GE@=P.1S>\OG;-22D0
M4'%<%Q('SW,DA*TGW<(!SHWG"*EV1 0)"SOAG1)F\C!W]-)RY[93_.X=T4X^
M!-]-/S(NUZ5HX?I$J^?W&WJ[_DNQ7G5=+OZ'T7G'RUFKYT_DQ^5#([O90L<U
M;"LZ=E#/#\HVE,<<MBSQL -G"G5<(<;6;!^8\[4YOX>;5"3,))G1(6CK5U6&
MDF< )K:8XZ"JAJ%?H3S&PE>DVTX(EW6]>6AC_5^+^A\?*TJO2F8*:"UJ[0]#
M1UE@X<BU+)Q&+IM6DN9."LOQ-,VQZ9P,1A+GC"8J.J(*D!WFITTR>/":)@,8
MA3C_)G77P08-Q+A 7!#$)4&]* )7Y!5<KD+5_M*7K=+\_AJ7KU#U:[N,!1.&
M=\_X4#8"+^#G5<:H%GF1"N:.$V=XIG\<>SBR\@QG%DU\FL1Y9$NU"YBE9#H!
M1M 6M</[U.<2*(#ZFC:_6K4 ,YO*"@!UZ) 23JECQ_3(BW7PD!)PV-%#[@6%
M[/64EJ0JUG^4]2--V;@T&TF$]7'H!3Z.HMS"=AHZU/<#&H>1=.[Z*2JF+_PZ
MNL!\UVG%3*]-;>("W1EI26%YZ7.2G).5?G+LY7+2Y\3;RTB??5CM#-8##;3A
MHZ_TB98;<0"\*XM_T>QP(3HAQ;%+0J9,&MD^#PD[H#K>&7J&EV3;@F:]A>3K
MJMRJ+7W4=_YHUB(SY>.F[<0,3-Y1U&Y*;1SG;L K=K+4M8+,S^F?);WC+-TN
MJ^2X5?(1\5]6UW*'2HW?3Y@-W4+#M)390:ZEC7;$]9WA)*74= *;H[;H^4E2
M],/3C^QK+U,L,"BI/BB][E)@Z4U5I$?QL-Q-,$E\!P?4\7PG#L/<RO]L,^F_
M-:1J#$?%8-Q#UMZA#/)6:\=+7V20T+NB% F)QZ4&FSK;U4@O7'&@..F6SXZ_
ML6_AW,H"UR66EWI.-^D?RNP7G_)>@G,F?+RJY%>8:L.!4W.3MWCX=%N(L@<Q
M<H1(T@N$A$2O((BJ-@4O'4H%<OUK!%35ID)WC0N4O)YT@ \_.:L<Z("G[J>"
MT3,S 4X,^4)) !TW M%CQX^>V_]3RE.[^->@-SUW_HHJ._NR?T8!VN[Y3]%Y
MT2O^&>'G;O?G7E_X./.I*.E50Q_JPR3$T')Q%"0Q]A+/=2+;RJ,0ADY_-DNF
MH\7G^C3H.V<5"5ZA!27GSY=ASU-I%A9V*N4F8#E7\4AG+^T%[ACZ-1R\(P5J
M\]V.1X9?GKUCSM]Z560\A"HNZ I:BWY5!T%EWTTQ"<(0>ZX?YW9":)A+)3U-
M$3%L#(=D44]WKO.5O(;F+]%TR TS/THB@Z[3YF0ZXS;MY-"+7:;-"3>\2YM]
M5LWK83;@H6MD<4.JZ^I;PPF(S)<>!N[0K;&2""<Q!W@BA%AIY 0> 24D2M T
M?:6VCWU[@<HU;U>\$ATBJ(B<W26/RI$S!:7FL86C./)Q9CDDRUP_=5WW3^;R
M)NL74NN0MC;%FM2HG#>G64M0>\F)(T']@B-KL;6*6@ZZM,@M *<^7PP@L29G
M2X;BHMX40 6'[A+DU;--<(LU?%77FX-[=IX'SD^3GN_BV/7"(" 1^QATFCQ!
M9VE36PBJZIA7I]0%7OZJ2CAGR7_KE-!2-;+&Q\32OZ[WJ+S46AX3=6+]CCYN
MH+OJ5_K0@L&(#V]I]6 ?;O=NG.$XIP&VB.O%3I"ZGB65&ZC*@.%5?M1=M>I9
MZ'"7V)@/Z UOK@5=[V!5RQD"DPJ$68CY9JM;=CKX(,[00JU6)S2Q1*O5,?*O
MI]7JA') K5:GQGF9W)S?V8--?56V;9I^K];U470["C),7/:3E5#/S[,HR,,
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MS/P0QU;FX#C-7&K[A*26HU0$(,V"PF6[0E$ HXP;\E/<TZXK5+)?=YR@@GL
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MR,*,N?8I^ZL%\>VEJ!I>KYRXV"U2_@/=L0'S^.44*'<(T*X6V&K>:D3\L.-
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M<95);5_]T"1)MW[ZFQ-M_&3YNW]SOOK;\JL79KZ8:;OXVS,"'7) 4!> I"8
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MJSJ)2=G4JU/%O2:PMO$0]FY7T/,8+&TE9-S6_!FQTU_,(V)EZ?1%#GQ</>V
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M@7GD7P"27E^!O^J?+[EJOFMKAX"T& ,N.%2&(VID[GJ"/205<W_,C*F<FB@
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M8Q=&C(ZWG*HJ ''7?J&KJ7?O]6P:132_L/;^]GZB%][%3579JB$EZADPS%C
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M\H7==M&6R:R\U[-HT6Z>%FG#C[("&"YE],,)1)!;XK+?UMIHZ9W5L?'=]IL
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MH>K<@NZYY%\"E):4IU$ 3Q/Y+J=11/?)\N[;)CYN$THE<$I8ZKSUQF;/R3Z
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M-Y.MQ(R<VY,#!YN^7A[!CUTW\LC%2C;+-C1K-C[5BW?5W$[JZ*I^F.B;=<Q
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MA]/Q@4@Z2.!C ^CQ5#].;I1+H!01P/H@D>+6:]-MHN!AZY:5H9K7-@VH@;,
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MK;YN#,?\.-44D8O9RM-OLRU96Y*DN<Q& :($ID([;5GNN,-NB@IUFXY$0%>
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MV>+E$'HAS!?ULN'U>BKG\XF;6!-D-YE]M/=VBF,D,OI_-7Z6(Y($$J1 H&1
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MW_@:?7P6NU]"1'C%>CD!;F')C>;4H,N)N>RP=Z'O.E^3#3H,<G^'3;G'8^:
M: C#=%H:ZN@X0*(0D$AFM2TO9DOV"="4OS9DIG!+_,SZ+'9$>]P**PTD0@3
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MUF_\9*GA4@+AH "<8Z2YY-"JRRGZ/87S5U^.\0IL_M&0_*KW_^DQ$PD0*TO
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M-[7@"@%HH"-,26B+V$4. \C-XR*.<RZ>2VL9'(Q/K#YNN3T<[[PTPEZ0ECM
M/6\%+30J;>PQ1=TH2_R^_UQ V0/0B%K+XKCLR A4%G"("+!A&*#3Q/]GM.+B
M'GA+E^ [Z9B+(>W!TT7/FJ/[8G4UTY/II%EX47DW^YUS5H>GE?XO?/$4Q<G1
MG?"A,7)T??D\?X[.0 T4A1800Q653C,H8_?A&2%'][3TLU2?OQ%DNRG^Y^"
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M<<1]&>=GN!KJ>SOW^^=*ZWHIIZMH "N0 +H,Y:((ED HAX 3%B+IL,%HK'D
MIU&:-C>4Q1DX5'\YHO2WJC)_3:93S],'K\_9;4C3KOYH6YR"6* P-\!PQ$D)
MG=4L=FWB*?2E3?DD0&0L7>6(PP^SSW452E_VYZ8VIAZ4! AL'*"RD!)"(:V*
M'?\^E<:T.9L$>(RILQPQV:27=KJ54PB4(!0XZ[31_M\P%7O^=#LE:;,L*:(]
M)\L_1Q3]5E?SG?.9E!P(:#G0#!;6RA*SZ T$VBGIA"+QBE!TNORC9=TBHJB]
M5GJ=)>5]:V$*"HK"T=(IJ[ 9W3SK61,/BU<$L(&JR6)&TPY3G^QNYL@0P$N%
M08&LQA9)Z1V<L0'FZ>B&J->4YCA5^!D<6'NDM)8EWR<J:E5X:1CZ9C/$"B\K
M7L:>^]6=NDQ:IITGCSM4.WF96VO<>+_DAZT7#Y^G<K;P7LF[_RPGK3X)<B50
M1CE0$*.89;HL^8CQMBXD9IG4'8R4_4=>=+7ETW:AG<L.P6Z&-9 **H"X5)QB
M9$H<^XU[9^*R3.R>!Y!#594[%/^8F8D7WD0M%\]S1]_)>N9YWF'4VS% 6:@!
MHAH7S!IG[8BU+QVIS#(U>QYP1E->[B@]$/<^%@<GWF*65$- C+2$E=P@-F*<
MI1_16>9ZSX/AL52;'Z2?3?LU[K=9DMZBX=QO5:<L8AKZ?;I=4A -K6WT9)GC
M'0N(@Q623Z>E0RRUQ!(@$T Q+ZZ"6\XD+A'$8QV*>TC*I ]S9#<[IAXN:P;W
ME3&3L*2<?IBYJKYKUH_S[N/@TF.\]NC.R_G?>"A%@'*2 >T*PG 1<A<F\M8=
M\8W'_OKMYQ%&&]QB!P1%#"A<&@J%+IR,G=(X0M+%O.LXB(SM@RJF'C(( NZ?
MY[M1@1WZ??LC!D!&56%+Z:B*'6C.<79V5&5WGIC=6?)9XN=E?N,&']X.D()Z
M8U.694&(I$C'#H%<VL3L[GH^86)V9Z%G )Z](Q\W-E7IS4BE)-""$&^J>3IP
M].1\[\&H269F=]=QU\&HG06>SV!4(H0!WF>E@/G3UCNQA018%IR71CDD#CG_
MKV0P:G>EM0]&[2K!#$Z*_1?QQ_4VO.L2L24!W$L!("M+*S$7AL?N?]:!K+0I
MH#$-F-@ZR0!F0^MT+0HS%[  U!%B:"F-]R8NH;8Z@07=$R21*ZL/:BR+B= ]
MBN8T$UZ"U&_CTJ 0'7.0C/[6/K<>OV='WD"]9'#\G= CH/0&)RP9D%QKBJ%B
MA8K]''E@\X;10N!C RN2%C+ 4^LS_Y>119MO5"50%%.@K% ,.LZEB-W"_  Y
M:?/(8R,JEAZB06K<C,JJR^@\_"6[>RC75;US=,=)M_3_[ABYF$A2.'^BQHH2
MJ$)ZDTR@DFFMB8I>6#I"HJ9YGK\KZ"_5=/I^M>-V2C']#\*5?J]QAXS&SA7;
M88L];1 .?B:3N-5 16]T/8@GU@QNQ5ZO8!R0WAT'B!NK,'<019]M$^V!4FQD
MQ49 C$=)!]31&V'>")A4YNM"UHOA;5EVF=CFTV_4VLJF-<-R&HR/]U[BU\LZ
MJ.)S0\I3-G_'^-#>:>;&^-U+=0$A@[+0W?I51R4KC7\Y$AP3:RUU&Z&>G#_?
M-I_KZGXR]_]^IYT#-T!@1@"$"A-7,,01'A.KNR2E<5<SQ.E ;5T.1M_:%NX?
MZ\Q7FU4_?*OE;#YMUMLQC*#P_I>$H(#$<DV$]+J(C-D324SC(.>!X3&U>9GV
MJ%#^%BEY$09,2R60Q1B23.W1Z$77^=FC!]4QT!Y]-S/C!FZNJ[N[R6H(@9R9
M5=_W6[^E)O%+8_M^*EIX)@JOD2(R:[1<;=%RW'7'BGD/2,LP==-@Y?^O4>Q$
MYTD$#DY]A(8Y:U]L38]SI4(;)N*/<Q=ZT$*&HH]4:R4D^</FD9"RD_H8K(4,
M[M-O_N_=N+6'KVWU?HQ9P)%6P KCG#%&$Q>["W4K(8G+ 88K>#NW,5C:&4!F
M_96TWV*?_#7P\CN-:>EW5O#IVXN_I!& "TR (5)IK@UF)O:;]Q-)3 NS"*"H
MSJ>AU'[M!V_)Z-"E]>JVMBL6V[DHK.?"<0B,I;"PFG))CAI=AS^1%B>C:K6*
M+N*$0)G7B__Y$B33MI,@HT (Z7_IG-+8EI!W>Q7I5UT[>_RO7LZ=C0\FKB2*
M=FGUEV(.JM^S": %@DL%O%M;8E)HAV6GE]==E)_RD!B@K&UU]Y!<8H7_/IE-
M[I9W[80+AX&TQ(#0B59!I)W5G:J_CJA\XZ.)E=Y'954,^:56O/RYGW#-2J!8
M@8#3CB#"$=:TDP-\3/'K'TUSV$=3?&_Y)5;\5R_CQC+YS5:WM?SQ?:+EM-5N
M+KR)HAT#6'BK&2,KF(YQV^\E('&Y9]3;/XZ44T/%WFZST/XXS96%/^B<]%<E
MLT7I#%2F4\?O8U#91T"Z2R.28JO84D[M7-[\=%[L\^^3>L_)*@@'G#!_LE)D
M"NF(9Z=;%=S.T@FU'T=7533!I3PA%C_J__G][<X1:2'@H9TS5IR73$MC\:%'
M*4^/-,-RJ[,@_&SM'%A])IVU$%?G?:260>1R^W;\N*]@'5D+%"D5T)J4Q(,7
M41/]Q<@^8A*7]T</>L>1>NJKX;.M==##K;UQ[Y>+96V_5 ]R&EH^O:_JM_[@
MTXNO<FKG-^ZZNK>>NL]U999ZL1U+VST9$9"2EP!;?RP2Y30I3*<K)1I)>:59
M>N*C2JZLG"#ZR2X^RX=&GE^LMI/[IG7HJBC#;^BO2S5=L>I%\,WJ[[-J6MT^
M/+X]]60?D0.#$DC"FN$:I25%:0A6)X,V,I%Y!5XCPSBE0E,#^],RF)0W[NM_
MEEX5[ZU=_#'SR@Q=F_=SA @&' D!E+<WM618HNUWQ7L@VNES>?GY$< 67\@9
M6'Q?K5XV[6CLCVH^V1U5!OUQSJ &1FC!A.*E+&,/^=HB(2_K;AAN8D@Y Y"\
MO&AM"F<GM]\7-^Z/^:H?<=-\1A1: 0JA 4SQ$%M%#D"K&6+.F(+%ALQ!@M(V
M[QT'0/$TD+0+1G..?K2>:+O)T;O'*LAOMK[;2:(C#*3QNT-"R!0MC%*LZ'1/
M'?M2VL&I(UQ1446;P<'3,/"]FIH/=S]J[X<T<FJ=8\=*Y_T. KV,4%DP)82!
ML5LY[Z<F[<33<8Z<2++/ $6;^\&S(R=UX.9C"R^EP?[L)#*T7\.0\ *YZ"W!
M#]&3=K;I.2ZO ?+/ $MOEG,OD_G<"TE-9BO%Z/\L)_.FW/^+G8:6X]?5?#6F
M02->8H =5&$2'@6RQ IP[C22_I>EBUUNWIVZM--/Q\'92+K)N4_*@2<HC9%8
MN>6CD=B,<+)K??C]WV_4,/ICG &$G..I3BPYY?"01_E+6)70 <6QX19R[%#L
MTO'S/N0YYO=L5/$AOXL1\FZ0EL1:Y:AQL:?&#/<\\WS8<Q Y)WNCG;6214_&
M37:>MO[#8Q^&G9Y:D(4KJ03,^,L(<ND8CMW;[#!%R><0)H'9(+WDC+-/U4RW
MLR2X\IZY%4 R*G2!M-0T]K.RHT0E'RR8%FT]M9,^S+9MM*QB0_M$Q1T+CU\H
M0 8I5Y:%@$0?,_HZ?"?Y2+^1T1-;U!FXN)L;X2FGNLV%T9X+Q##@Q% A+"2D
M6_%X[[/IB9*$?<MB*OK@\=-+ZMEAYY\VF(;67/E#3=YZUS;4TSW]88A'PQW^
MA/?WD?$6(^&P*!W5.'J^\50:$S8F.QO>(FLJ=R2&PS_TR_TB%_:QAF2;/Q+>
M$Q,2DFC(62(AI62\D6O=:$S8>BP5$H=J*@,D-FR%L.,^:3'O(7.E)8!.,8(+
MY_\\MIF_0T3R$;=G,NN'23\#^&QNC\#)S@: &@@4PBR.>'DP1LHB=HOE72K2
M!KL&JO7@$72RC#- R5["E5%A'*9W5;4H2HVY+%3LH.AIF!@M,A47$_TDVA\*
MXX\I/I $^5TN0H&:_UGE[E:/G:>!_^E+'F2<Y- )'SY',JBO'')(_I3A<9$3
M#B G_2^$,C:Z&7'6Y$];-=-S7.[)0WZ[M)^\]+_]9:?W]G=/T/?=FH+2^K,[
MO+KRXBD+AC2'L1\K]:7U@E-&!_&V>YJ>09=91/F[<OHO*^MO?U6[#XH9$)8)
M0$H.L6'&>?LV$5@?2;S@?-,H&.VCN<N#IL?:SK-&2Y07IRF MH)KIE@I4.Q1
M="<3><$)JO'@>;+V+@Z@[ZOESB-Z;!'@/,A3$")+K G#L2?;GTKC!6? 1H/G
MR;J[/'1.[G?VGU,N=!ESP$N2.DR9WX<N)3H]C1<<!AP/G:?J+HOX3S?^KIS_
MYCXFB2Z!XD0 A!PV3A)&8?Q = ]"TS[4R0^E_;5X05#=J;=A&BA80."8019!
M6^CHX[B[TI;VP4]^@#Q)5]%BI"-A\(^9><PZ6O/N9Y@^WCY=%7LA"FH4T)(I
MSP=SCL8/K?<@-.TCHDS0&46+IT-5K* ZL[?AM<F8=:,[CSE)":33(0@AG2I@
MB: ;]^G:,REI7Q.=#W Q-)'S<Z)W=S^FU8.U;^S,NLGB\U3.AN1]#BT7+9O3
MF>9X.9H?=C9?H7MFOMC%I&X>QQ['FC8$2"D4$,X1;YV5'-/8U6TGD!=AU-AD
M9IL-5T_4,GPQ2/]1(77X8&V;*4CUP_I?:C^'C?0;45+N6;)8X=*?Q&B$*60#
M*$Z>JQD%=RT3R\ZEU9R/PL?GHI]EO7A8GQTQX#@\MF2T(_$DVB,=B_N^N0^3
ML.1 <,P!5U@I31SF,+8W=XRFP<V3]'=KEE-[X_9]Z<W#QI^TM8JT" %)H3=
MM+,"&8J-CIU3Z45HVN,N*IYV^C&-KKC$/;VO&[^G_A&(_R3O6H=>4&9 Z+$
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M%!!1@>#62;*GL/#XM[+R'7HJM!I/NIF!9?7+@^Q0X1UT8D-IKK%&&"6,+ON
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M9/Z(TNY&]U"6,^ZFFIY%(X8C@M+W-694EO"]=AK=O?JZ]^0\.N^PE>GS;8Q
MB>I?HWK.A=+W=0VH+FT__7MEKB1VA5\)[L;C<4H9GF!!2UY?R^MP NI.LYE>
M\I]"]_-*6!\[E:1N_@S[(&4)ZQI8*?;TP^DECSV>SXPE;N7$N!U]3@@?H>]4
MC*A P\0M<=LN;M5L2?A%B^+K%_[GPN9W%&(N(5W$<H1.0L&8KMUC*'JQ'D*P
M*SE+U'+(,[L/Q6>^0U+-=F;^ %!+ P04    " "C06U<P@IAAT,(  #:+
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MJ"A-@4BVON2(8VV$-\"7GC>08R6A$-#8 @6M%!+!LCJ %E>4+)"I7P-LX_6
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MY@]FN").&\RGXU6\LH)HQ4=$5XVM7608Y@\3V=0CZ^7@Q=L6Y."U<^I+<-J
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MM;E '=07MU]02P$"% ,4    " "C06U<'H&/8 ?\  !O^P8 '@
M    @ $     83(P-# P7V-E;G1U<GEX>'AV86-C:71E8V@N:'1M4$L! A0#
M%     @ HT%M7)=-BH]%5@0 HRDB !$              ( !0_P  &)R;G,M
M,C R-3$R,S$N:'1M4$L! A0#%     @ HT%M7&E7D47#%@  7@L! !$
M         ( !MU(% &)R;G,M,C R-3$R,S$N>'-D4$L! A0#%     @ HT%M
M7 L('5("(   >GD! !4              ( !J6D% &)R;G,M,C R-3$R,S%?
M8V%L+GAM;%!+ 0(4 Q0    ( *-!;5R>+H2&XTP  ,[E P 5
M  "  =Z)!0!B<FYS+3(P,C4Q,C,Q7V1E9BYX;6Q02P$"% ,4    " "C06U<
MKH+V)G# ! "?4P8 %               @ 'TU@4 8G)N<RTR,#(U,3(S,5]G
M,2YJ<&=02P$"% ,4    " "C06U<Q\M->+@!  #[ @  %
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M+FAT;5!+ 0(4 Q0    ( *-!;5S""F&'0P@  -HL   7              "
M 9%7# !B<FYS+3(P,C4Q,C,Q>&5X,S$Q+FAT;5!+ 0(4 Q0    ( *-!;5Q9
M[T:+4 @  ,@M   7              "  0E@# !B<FYS+3(P,C4Q,C,Q>&5X
M,S$R+FAT;5!+ 0(4 Q0    ( *-!;5QBK6V.U00  +87   7
M  "  8YH# !B<FYS+3(P,C4Q,C,Q>&5X,S(Q+FAT;5!+ 0(4 Q0    ( *-!
M;5P ^_L-BP(  +\)   .              "  9AM# !E>&AI8FET,C,Q+FAT
7;5!+!08     #@ . *H#  !/< P    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>brns-20251231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:brns="http://www.barinthusbio.com/20251231"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="brns-20251231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <instant>2026-03-06</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">brns:RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:SchemeSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">brns:BecaonTopcoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">brns:ClywedogTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:ClywedogCapitalStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <instant>2025-09-29</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">brns:SubsidiariesVOLTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">brns:VOLTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">brns:VOLTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">brns:OxfordUniversityInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">brns:OxfordUniversityInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">brns:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">brns:VTP1000CeliacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">brns:VTP1000CeliacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">brns:BarinthusLegacyAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">brns:BarinthusLegacyAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="brns:ResearchAndDevelopmentTypeAxis">brns:PersonnelRelatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="brns:ResearchAndDevelopmentTypeAxis">brns:PersonnelRelatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="brns:ResearchAndDevelopmentTypeAxis">brns:FacilityRelatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="brns:ResearchAndDevelopmentTypeAxis">brns:FacilityRelatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="brns:ResearchAndDevelopmentTypeAxis">brns:OtherIndirectCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">brns:ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="brns:ResearchAndDevelopmentTypeAxis">brns:OtherIndirectCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">brns:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-20</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-21</startDate>
            <endDate>2021-04-21</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <instant>2023-11-06</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-06</startDate>
            <endDate>2023-11-06</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">brns:AvideaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">brns:AvideaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">brns:RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-08</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">brns:RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">brns:RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:EnterpriseManagementIncentiveShareOptionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:EnterpriseManagementIncentiveShareOptionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:EnterpriseManagementIncentiveShareOptionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:EnterpriseManagementIncentiveShareOptionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignTaxJurisdictionOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignTaxJurisdictionOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:InLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:InLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">brns:OxfordshireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-03</startDate>
            <endDate>2021-09-03</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">brns:OxfordshireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-03</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">brns:OxfordshireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-14</startDate>
            <endDate>2022-06-14</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-14</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">brns:ExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">brns:ExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-22</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-22</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="gbpPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:GBP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="subsidiary">
        <measure>brns:subsidiary</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>brns:segment</measure>
    </unit>
    <unit id="region">
        <measure>brns:region</measure>
    </unit>
    <unit id="vote">
        <measure>brns:vote</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-33">0001828185</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-34">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-35">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-36">false</dei:AmendmentFlag>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-37">00-0000000</dei:EntityTaxIdentificationNumber>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="c-1" id="f-381">http://fasb.org/us-gaap/2025#GeneralAndAdministrativeExpense</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="c-12" id="f-382">http://fasb.org/us-gaap/2025#GeneralAndAdministrativeExpense</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <brns:NumberOfReportableSegmentsNotDisclosedFlag contextRef="c-1" id="f-427" xsi:nil="true"/>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList contextRef="c-12" id="f-557">http://fasb.org/us-gaap/2025#OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList contextRef="c-1" id="f-558">http://fasb.org/us-gaap/2025#OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-108" id="f-629">P7D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-133" id="f-811">http://fasb.org/us-gaap/2025#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-134" id="f-812">http://fasb.org/us-gaap/2025#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-40367</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">BARINTHUS BIOTHERAPEUTICS PLC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">20400 Century Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">Suite 210</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Germantown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">20874</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">443</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">917-0966</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-2" id="f-16">American Depositary Shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-17">BRNS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-19">Ordinary shares, nominal value &#xa3;0.000025 per share</dei:Security12bTitle>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-27">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-28">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-29">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-30">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-4" decimals="-5" id="f-31" unitRef="usd">13700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-32" unitRef="shares">40848893</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-39">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In the normal course of business, we may collect and store personal information and other sensitive information, including proprietary and confidential business information, financial information, trade secrets, intellectual property, information regarding trial participants in connection with clinical trials, sensitive third-party information and employee information. In an effort to protect this information from cybersecurity risks, we have developed a cybersecurity program that has been &lt;/span&gt;&lt;/div&gt;integrated into our overall risk management process; it incorporates policies and practices designed to protect the confidentiality, integrity and security of our sensitive information.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-38">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In the normal course of business, we may collect and store personal information and other sensitive information, including proprietary and confidential business information, financial information, trade secrets, intellectual property, information regarding trial participants in connection with clinical trials, sensitive third-party information and employee information. In an effort to protect this information from cybersecurity risks, we have developed a cybersecurity program that has been &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%"&gt;integrated into our overall risk management process; it incorporates policies and practices designed to protect the confidentiality, integrity and security of our sensitive information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As part of our cybersecurity risk management procedures, we perform system monitoring and scanning and utilize security tools supported by a third-party managed services provider. We also conduct penetration testing performed by a third-party provider. Employees are enrolled in cybersecurity awareness training courses designed to help them identify cybersecurity concerns and take appropriate actions, and we conduct periodic simulated phishing tests in an effort to further raise cybersecurity awareness and reduce the risk of a successful cyberattack. We have an incident response plan to guide us in responding to cybersecurity incidents, and have conducted tabletop exercises to test the plan. We also take steps to protect against business interruption and conduct annual restoration testing for major systems. In addition, we use a risk-based approach to assessing cybersecurity risks from certain critical third-party vendors. This program aims to assess the cybersecurity maturity of vendors who have access to our data or systems through an evaluation of the vendor&#x2019;s cybersecurity practices.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-40">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-42">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-41">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-43">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Our cybersecurity program is managed by our Manager of Operations and IT Systems, who reports directly to senior management on matters regarding cybersecurity, as appropriate, and is supported by third-party vendors. Together, our senior management and Manager of Operations and IT Systems are responsible for leading company-wide cybersecurity strategy, policies, standards, and processes. &lt;/span&gt;&lt;/div&gt;The Audit Committee, pursuant to its charter, has oversight over management of cybersecurity risks. Senior management provide the Audit Committee with periodic updates on data management and cybersecurity initiatives, as well as on significant existing and emerging cybersecurity risks, including cybersecurity incidents, as applicable.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-44">Our cybersecurity program is managed by our Manager of Operations and IT Systems, who reports directly to senior management on matters regarding cybersecurity, as appropriate, and is supported by third-party vendors. Together, our senior management and Manager of Operations and IT Systems are responsible for leading company-wide cybersecurity strategy, policies, standards, and processes.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-45">Our cybersecurity program is managed by our Manager of Operations and IT Systems, who reports directly to senior management on matters regarding cybersecurity, as appropriate, and is supported by third-party vendors</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-46">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-48">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The Audit Committee, pursuant to its charter, has oversight over management of cybersecurity risks. Senior management provide the Audit Committee with periodic updates on data management and cybersecurity initiatives, as well as on significant existing and emerging cybersecurity risks, including cybersecurity incidents, as applicable. &lt;/span&gt;&lt;/div&gt;We have a process to record identified risks from cybersecurity threats in our risk register, along with an assessment of the severity of the potential impact and the likelihood of occurrence. This process is designed to facilitate a unified and integrated assessment of corporate risk and governance. The risk register is reviewed periodically by senior management and at least annually by the Board of Directors.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-47">The Audit Committee, pursuant to its charter, has oversight over management of cybersecurity risks. Senior management provide the Audit Committee with periodic updates on data management and cybersecurity initiatives, as well as on significant existing and emerging cybersecurity risks, including cybersecurity incidents, as applicable.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-49">Senior management provide the Audit Committee with periodic updates on data management and cybersecurity initiatives, as well as on significant existing and emerging cybersecurity risks, including cybersecurity incidents, as applicable.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-50">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-51">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-6" id="f-52">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-6" id="f-53">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-6" id="f-54">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-6" id="f-55">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-56">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:AwardTmgMnpiDiscTextBlock contextRef="c-1" id="f-57">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is the policy of our board of directors and our compensation committee to not take material non-public information into account when determining the timing of equity awards in order to take advantage of a depressed stock price or an anticipated increase in stock price. Similarly, it is our practice not to time the release of material nonpublic information based on equity award grant dates or for the purpose of affecting the value of executive compensation.&lt;/span&gt;&lt;/div&gt;Our compensation committee generally grants annual equity awards, including stock option grants to our named executive officers, in the first quarter of each fiscal year. In addition, new hires receive stock option grants at the time of their hiring.</ecd:AwardTmgMnpiDiscTextBlock>
    <ecd:AwardTmgMnpiCnsdrdFlag contextRef="c-1" id="f-58">false</ecd:AwardTmgMnpiCnsdrdFlag>
    <ecd:MnpiDiscTimedForCompValFlag contextRef="c-1" id="f-59">false</ecd:MnpiDiscTimedForCompValFlag>
    <ecd:AwardTmgMethodTextBlock contextRef="c-1" id="f-60">Our compensation committee generally grants annual equity awards, including stock option grants to our named executive officers, in the first quarter of each fiscal year. In addition, new hires receive stock option grants at the time of their hiring.</ecd:AwardTmgMethodTextBlock>
    <ecd:AwardTmgPredtrmndFlag contextRef="c-1" id="f-61">true</ecd:AwardTmgPredtrmndFlag>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-7" decimals="INF" id="f-62" unitRef="shares">3248605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-63">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-64">876</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-65">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-66">United Kingdom</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-8" decimals="-3" id="f-67" unitRef="usd">70456000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-9" decimals="-3" id="f-68" unitRef="usd">110662000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c-8" decimals="-3" id="f-69" unitRef="usd">1396000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-9" decimals="-3" id="f-70" unitRef="usd">1738000</us-gaap:RestrictedCashCurrent>
    <brns:ResearchAndDevelopmentIncentivesReceivable contextRef="c-8" decimals="-3" id="f-71" unitRef="usd">1108000</brns:ResearchAndDevelopmentIncentivesReceivable>
    <brns:ResearchAndDevelopmentIncentivesReceivable contextRef="c-9" decimals="-3" id="f-72" unitRef="usd">7139000</brns:ResearchAndDevelopmentIncentivesReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-8" decimals="-3" id="f-73" unitRef="usd">4830000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-9" decimals="-3" id="f-74" unitRef="usd">6203000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-8" decimals="-3" id="f-75" unitRef="usd">77790000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-9" decimals="-3" id="f-76" unitRef="usd">125742000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-8" decimals="-3" id="f-77" unitRef="usd">3523000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-9" decimals="-3" id="f-78" unitRef="usd">7373000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-8" decimals="-3" id="f-79" unitRef="usd">14288000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-9" decimals="-3" id="f-80" unitRef="usd">21947000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-8" decimals="-3" id="f-81" unitRef="usd">1638000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-9" decimals="-3" id="f-82" unitRef="usd">4384000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssets contextRef="c-8" decimals="-3" id="f-83" unitRef="usd">930000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="c-9" decimals="-3" id="f-84" unitRef="usd">881000</us-gaap:OtherAssets>
    <us-gaap:Assets contextRef="c-8" decimals="-3" id="f-85" unitRef="usd">98169000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-9" decimals="-3" id="f-86" unitRef="usd">160327000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-8" decimals="-3" id="f-87" unitRef="usd">350000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-9" decimals="-3" id="f-88" unitRef="usd">2474000</us-gaap:AccountsPayableCurrent>
    <brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-89" unitRef="usd">6249000</brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="c-9" decimals="-3" id="f-90" unitRef="usd">9525000</brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:DeferredIncomeCurrent contextRef="c-8" decimals="-3" id="f-91" unitRef="usd">1396000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent contextRef="c-9" decimals="-3" id="f-92" unitRef="usd">1738000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-8" decimals="-3" id="f-93" unitRef="usd">2023000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-9" decimals="-3" id="f-94" unitRef="usd">1920000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-95" unitRef="usd">10018000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-9" decimals="-3" id="f-96" unitRef="usd">15657000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-8" decimals="-3" id="f-97" unitRef="usd">9258000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-9" decimals="-3" id="f-98" unitRef="usd">10087000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-8" decimals="-3" id="f-99" unitRef="usd">2871000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-9" decimals="-3" id="f-100" unitRef="usd">2650000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-8" decimals="-3" id="f-101" unitRef="usd">1476000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-9" decimals="-3" id="f-102" unitRef="usd">1360000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-8" decimals="-3" id="f-103" unitRef="usd">254000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-9" decimals="-3" id="f-104" unitRef="usd">438000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities contextRef="c-8" decimals="-3" id="f-105" unitRef="usd">23877000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-9" decimals="-3" id="f-106" unitRef="usd">30192000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-8" id="f-107" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-9" id="f-108" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-9"
      decimals="INF"
      id="f-109"
      unitRef="gbpPerShare">0.000025</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-110"
      unitRef="gbpPerShare">0.000025</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-111" unitRef="shares">40848893</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-8" decimals="INF" id="f-112" unitRef="shares">40848893</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-8" decimals="INF" id="f-113" unitRef="shares">40848893</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-9" decimals="INF" id="f-114" unitRef="shares">40234663</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-9" decimals="INF" id="f-115" unitRef="shares">40234663</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-9" decimals="INF" id="f-116" unitRef="shares">40234663</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-8" decimals="-3" id="f-117" unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-9" decimals="-3" id="f-118" unitRef="usd">1000</us-gaap:CommonStockValue>
    <brns:DeferredStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-119"
      unitRef="gbpPerShare">1</brns:DeferredStockParOrStatedValuePerShare>
    <brns:DeferredStockParOrStatedValuePerShare
      contextRef="c-9"
      decimals="INF"
      id="f-120"
      unitRef="gbpPerShare">1</brns:DeferredStockParOrStatedValuePerShare>
    <brns:DeferredStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-121" unitRef="shares">63443</brns:DeferredStockSharesOutstanding>
    <brns:DeferredStockSharesIssued contextRef="c-8" decimals="INF" id="f-122" unitRef="shares">63443</brns:DeferredStockSharesIssued>
    <brns:DeferredStockSharesAuthorized contextRef="c-8" decimals="INF" id="f-123" unitRef="shares">63443</brns:DeferredStockSharesAuthorized>
    <brns:DeferredStockSharesAuthorized contextRef="c-9" decimals="INF" id="f-124" unitRef="shares">63443</brns:DeferredStockSharesAuthorized>
    <brns:DeferredStockSharesIssued contextRef="c-9" decimals="INF" id="f-125" unitRef="shares">63443</brns:DeferredStockSharesIssued>
    <brns:DeferredStockSharesOutstanding contextRef="c-9" decimals="INF" id="f-126" unitRef="shares">63443</brns:DeferredStockSharesOutstanding>
    <brns:DeferredStockValueIssued contextRef="c-8" decimals="-3" id="f-127" unitRef="usd">86000</brns:DeferredStockValueIssued>
    <brns:DeferredStockValueIssued contextRef="c-9" decimals="-3" id="f-128" unitRef="usd">86000</brns:DeferredStockValueIssued>
    <us-gaap:AdditionalPaidInCapital contextRef="c-8" decimals="-3" id="f-129" unitRef="usd">393944000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-9" decimals="-3" id="f-130" unitRef="usd">393474000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-8" decimals="-3" id="f-131" unitRef="usd">-304092000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-9" decimals="-3" id="f-132" unitRef="usd">-237664000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax contextRef="c-8" decimals="-3" id="f-133" unitRef="usd">-15731000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax contextRef="c-9" decimals="-3" id="f-134" unitRef="usd">-25868000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-135" unitRef="usd">74208000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-136" unitRef="usd">130029000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-8" decimals="-3" id="f-137" unitRef="usd">84000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-9" decimals="-3" id="f-138" unitRef="usd">106000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-8" decimals="-3" id="f-139" unitRef="usd">74292000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-9" decimals="-3" id="f-140" unitRef="usd">130135000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-8" decimals="-3" id="f-141" unitRef="usd">98169000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-9" decimals="-3" id="f-142" unitRef="usd">160327000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-143" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-144" unitRef="usd">14969000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-145" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-146" unitRef="usd">14969000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-147" unitRef="usd">25564000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-12" decimals="-3" id="f-148" unitRef="usd">42236000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-149" unitRef="usd">40830000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-12" decimals="-3" id="f-150" unitRef="usd">29670000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-1" decimals="-3" id="f-151" unitRef="usd">4667000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-12" decimals="-3" id="f-152" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-3" id="f-153" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-12" decimals="-3" id="f-154" unitRef="usd">12209000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-155" unitRef="usd">71061000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-12" decimals="-3" id="f-156" unitRef="usd">84115000</us-gaap:OperatingExpenses>
    <us-gaap:OtherOperatingIncome contextRef="c-1" decimals="-3" id="f-157" unitRef="usd">506000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome contextRef="c-12" decimals="-3" id="f-158" unitRef="usd">1176000</us-gaap:OtherOperatingIncome>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-159" unitRef="usd">-70555000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-12" decimals="-3" id="f-160" unitRef="usd">-67970000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-161" unitRef="usd">1957000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-12" decimals="-3" id="f-162" unitRef="usd">2678000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-163" unitRef="usd">51000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-12" decimals="-3" id="f-164" unitRef="usd">53000</us-gaap:InterestExpenseNonoperating>
    <brns:ResearchAndDevelopmentIncentiveIncomeExpense contextRef="c-1" decimals="-3" id="f-165" unitRef="usd">2000000</brns:ResearchAndDevelopmentIncentiveIncomeExpense>
    <brns:ResearchAndDevelopmentIncentiveIncomeExpense contextRef="c-12" decimals="-3" id="f-166" unitRef="usd">3983000</brns:ResearchAndDevelopmentIncentiveIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-167" unitRef="usd">16000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-12" decimals="-3" id="f-168" unitRef="usd">135000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-169" unitRef="usd">3922000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-12" decimals="-3" id="f-170" unitRef="usd">6743000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-171" unitRef="usd">-66633000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-172" unitRef="usd">-61227000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-173" unitRef="usd">-175000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-174" unitRef="usd">-44000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-175" unitRef="usd">-66458000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-12" decimals="-3" id="f-176" unitRef="usd">-61183000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-177" unitRef="usd">-30000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-178" unitRef="usd">-109000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-179" unitRef="usd">-66428000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-180" unitRef="usd">-61074000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-181" unitRef="shares">40527218</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-12" decimals="0" id="f-182" unitRef="shares">39348240</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-183" unitRef="shares">40527218</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-12" decimals="0" id="f-184" unitRef="shares">39348240</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-185"
      unitRef="usdPerShare">-1.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-12"
      decimals="2"
      id="f-186"
      unitRef="usdPerShare">-1.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-187"
      unitRef="usdPerShare">-1.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-12"
      decimals="2"
      id="f-188"
      unitRef="usdPerShare">-1.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-189" unitRef="usd">-66458000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-12" decimals="-3" id="f-190" unitRef="usd">-61183000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">10145000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-12" decimals="-3" id="f-192" unitRef="usd">-2549000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-193" unitRef="usd">-56313000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-194" unitRef="usd">-63732000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">-22000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-196" unitRef="usd">-105000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">-56291000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-12" decimals="-3" id="f-198" unitRef="usd">-63627000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="c-13"
      decimals="INF"
      id="f-199"
      unitRef="shares">40234663</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-200" unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-14"
      decimals="INF"
      id="f-201"
      unitRef="shares">63443</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-202" unitRef="usd">86000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-203" unitRef="usd">393474000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-204" unitRef="usd">-237664000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-205" unitRef="usd">-25868000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-18" decimals="-3" id="f-206" unitRef="usd">130029000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-19" decimals="-3" id="f-207" unitRef="usd">106000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-9" decimals="-3" id="f-208" unitRef="usd">130135000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-20" decimals="-3" id="f-209" unitRef="usd">468000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-21" decimals="-3" id="f-210" unitRef="usd">468000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">468000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-22"
      decimals="INF"
      id="f-212"
      unitRef="shares">614230</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-22" decimals="-3" id="f-213" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-20" decimals="-3" id="f-214" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-21" decimals="-3" id="f-215" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-216" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-23" decimals="-3" id="f-217" unitRef="usd">10137000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-21" decimals="-3" id="f-218" unitRef="usd">10137000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-24" decimals="-3" id="f-219" unitRef="usd">8000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-220" unitRef="usd">10145000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-25" decimals="-3" id="f-221" unitRef="usd">-66428000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-21" decimals="-3" id="f-222" unitRef="usd">-66428000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-24" decimals="-3" id="f-223" unitRef="usd">-30000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-224" unitRef="usd">-66458000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="c-26"
      decimals="INF"
      id="f-225"
      unitRef="shares">40848893</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-26" decimals="-3" id="f-226" unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-27"
      decimals="INF"
      id="f-227"
      unitRef="shares">63443</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-3" id="f-228" unitRef="usd">86000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-3" id="f-229" unitRef="usd">393944000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-3" id="f-230" unitRef="usd">-304092000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-3" id="f-231" unitRef="usd">-15731000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-3" id="f-232" unitRef="usd">74208000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-3" id="f-233" unitRef="usd">84000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-8" decimals="-3" id="f-234" unitRef="usd">74292000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-33"
      decimals="INF"
      id="f-235"
      unitRef="shares">38643540</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-3" id="f-236" unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-34"
      decimals="INF"
      id="f-237"
      unitRef="shares">63443</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-34" decimals="-3" id="f-238" unitRef="usd">86000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-35" decimals="-3" id="f-239" unitRef="usd">386602000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-36" decimals="-3" id="f-240" unitRef="usd">-176590000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-37" decimals="-3" id="f-241" unitRef="usd">-23315000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-38" decimals="-3" id="f-242" unitRef="usd">186784000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-39" decimals="-3" id="f-243" unitRef="usd">211000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-40" decimals="-3" id="f-244" unitRef="usd">186995000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-41" decimals="-3" id="f-245" unitRef="usd">4709000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-42" decimals="-3" id="f-246" unitRef="usd">4709000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-12" decimals="-3" id="f-247" unitRef="usd">4709000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-43"
      decimals="INF"
      id="f-248"
      unitRef="shares">1591123</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-43" decimals="-3" id="f-249" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-41" decimals="-3" id="f-250" unitRef="usd">2163000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-42" decimals="-3" id="f-251" unitRef="usd">2163000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-12" decimals="-3" id="f-252" unitRef="usd">2163000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-44" decimals="-3" id="f-253" unitRef="usd">-2553000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-42" decimals="-3" id="f-254" unitRef="usd">-2553000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-45" decimals="-3" id="f-255" unitRef="usd">4000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-12" decimals="-3" id="f-256" unitRef="usd">-2549000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-46" decimals="-3" id="f-257" unitRef="usd">-61074000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-42" decimals="-3" id="f-258" unitRef="usd">-61074000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-45" decimals="-3" id="f-259" unitRef="usd">-109000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-12" decimals="-3" id="f-260" unitRef="usd">-61183000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="c-13"
      decimals="INF"
      id="f-261"
      unitRef="shares">40234663</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-262" unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-14"
      decimals="INF"
      id="f-263"
      unitRef="shares">63443</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-264" unitRef="usd">86000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-265" unitRef="usd">393474000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-266" unitRef="usd">-237664000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-267" unitRef="usd">-25868000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-18" decimals="-3" id="f-268" unitRef="usd">130029000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-19" decimals="-3" id="f-269" unitRef="usd">106000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-9" decimals="-3" id="f-270" unitRef="usd">130135000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-271" unitRef="usd">-66458000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-12" decimals="-3" id="f-272" unitRef="usd">-61183000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-273" unitRef="usd">468000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-12" decimals="-3" id="f-274" unitRef="usd">4709000</us-gaap:ShareBasedCompensation>
    <brns:AssetImpairmentChargesExcludingGoodwill contextRef="c-1" decimals="-3" id="f-275" unitRef="usd">5794000</brns:AssetImpairmentChargesExcludingGoodwill>
    <brns:AssetImpairmentChargesExcludingGoodwill contextRef="c-12" decimals="-3" id="f-276" unitRef="usd">5260000</brns:AssetImpairmentChargesExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-3" id="f-277" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-12" decimals="-3" id="f-278" unitRef="usd">12209000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-279" unitRef="usd">5845000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-12" decimals="-3" id="f-280" unitRef="usd">5800000</us-gaap:DepreciationDepletionAndAmortization>
    <brns:NonCashLeaseExpenses contextRef="c-1" decimals="-3" id="f-281" unitRef="usd">3332000</brns:NonCashLeaseExpenses>
    <brns:NonCashLeaseExpenses contextRef="c-12" decimals="-3" id="f-282" unitRef="usd">1443000</brns:NonCashLeaseExpenses>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-1" decimals="-3" id="f-283" unitRef="usd">-3742000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-12" decimals="-3" id="f-284" unitRef="usd">649000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-3" id="f-285" unitRef="usd">26000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-12" decimals="-3" id="f-286" unitRef="usd">866000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <brns:NonCashInterestExpenseOnConvertibleLoanNotes contextRef="c-1" decimals="-3" id="f-287" unitRef="usd">51000</brns:NonCashInterestExpenseOnConvertibleLoanNotes>
    <brns:NonCashInterestExpenseOnConvertibleLoanNotes contextRef="c-12" decimals="-3" id="f-288" unitRef="usd">48000</brns:NonCashInterestExpenseOnConvertibleLoanNotes>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-289" unitRef="usd">-175000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-290" unitRef="usd">-44000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-3" id="f-291" unitRef="usd">245000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-12" decimals="-3" id="f-292" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-293" unitRef="usd">-1704000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-12" decimals="-3" id="f-294" unitRef="usd">-3643000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <brns:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable contextRef="c-1" decimals="-3" id="f-295" unitRef="usd">-6417000</brns:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable>
    <brns:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable contextRef="c-12" decimals="-3" id="f-296" unitRef="usd">2345000</brns:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-297" unitRef="usd">-2202000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-12" decimals="-3" id="f-298" unitRef="usd">898000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-299" unitRef="usd">-3793000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-12" decimals="-3" id="f-300" unitRef="usd">456000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c-1" decimals="-3" id="f-301" unitRef="usd">-506000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c-12" decimals="-3" id="f-302" unitRef="usd">1738000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-303" unitRef="usd">-1979000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-12" decimals="-3" id="f-304" unitRef="usd">-1789000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-305" unitRef="usd">-47979000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-12" decimals="-3" id="f-306" unitRef="usd">-28940000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-307" unitRef="usd">453000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-12" decimals="-3" id="f-308" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-309" unitRef="usd">37000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-12" decimals="-3" id="f-310" unitRef="usd">892000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-311" unitRef="usd">416000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-12" decimals="-3" id="f-312" unitRef="usd">-892000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-3" id="f-313" unitRef="usd">2000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-12" decimals="-3" id="f-314" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-315" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-12" decimals="-3" id="f-316" unitRef="usd">2163000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-317" unitRef="usd">2000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-12" decimals="-3" id="f-318" unitRef="usd">2163000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-1" decimals="-3" id="f-319" unitRef="usd">7013000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-12" decimals="-3" id="f-320" unitRef="usd">-2021000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-321" unitRef="usd">-40548000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-12" decimals="-3" id="f-322" unitRef="usd">-29690000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-9" decimals="-3" id="f-323" unitRef="usd">112400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-40" decimals="-3" id="f-324" unitRef="usd">142090000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-3" id="f-325" unitRef="usd">71852000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-9" decimals="-3" id="f-326" unitRef="usd">112400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-327">Nature of Business and Basis of Presentation&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Nature of business&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Barinthus Biotherapeutics plc is a public limited company incorporated pursuant to the laws of England and Wales in March 2021. Barinthus Biotherapeutics plc and its direct and indirect subsidiaries, Barinthus Biotherapeutics (UK) Limited, Barinthus Biotherapeutics North America, Vaccitech Oncology Limited (&#x201c;VOLT&#x201d;), Barinthus Biotherapeutics Pty Limited, Barinthus Biotherapeutics Switzerland GmbH are collectively referred to as the &#x201c;Company&#x201d; or &#x201c;Barinthus Bio&#x201d;. During the quarterly period ended September 30 2025, the Company incorporated two new subsidiaries, Beacon Topco, Inc. (&#x201c;Topco&#x201d;) and Cdog Merger Sub, Inc. (&#x201c;Merger Sub&#x201d;), for the purpose of the transactions contemplated by the recently announced merger agreement with Clywedog Therapeutics, Inc. ("Clywedog"). These entities are not material to the Company's consolidated financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases within the immunology and inflammation ("I&amp;amp;I") space enabled by the proprietary and highly differentiated platform for promoting immune tolerance, referred to as SNAP-TI. The Company's lead candidate, VTP-1000, is designed to restore immune non-responsiveness to gluten in patients with celiac disease, and is currently being assessed in a Phase 1 clinical trial. The Company occupies laboratory and office space in Germantown, Maryland, United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company operates in an environment of rapid technological change and substantial competition from pharmaceutical and biotechnology companies. The Company is subject to risks common to companies in the biopharmaceutical industry that are also in a similar stage of its life cycle including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of any of its products that are approved, and protection of proprietary technology. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales. If the Company does not successfully commercialize any of its products or mitigate any of these other risks, it will be unable to generate revenue or achieve profitability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Merger Agreement with Clywedog&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 29, 2025, the Company entered into an Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;) by and among the Company, Topco, Merger Sub and Clywedog. The Merger Agreement provides that, among other things, upon the terms and subject to the conditions set forth therein: (i) Topco will acquire the entire issued and to be issued share capital of the Company pursuant to a scheme of arrangement (subject to any modification, addition or condition which (a) the Company, Topco and Clywedog mutually agree and which (if required) is approved by the High Court of Justice of England and Wales (the &#x201c;Court&#x201d;) or (b) is otherwise imposed by the Court and mutually acceptable to the Company, Topco and Clywedog, each acting reasonably and in good faith, in each case in accordance with the Part 26 of the United Kingdom Companies Act 2006 and the Merger Agreement (the &#x201c;Scheme of Arrangement&#x201d; and such transaction, the &#x201c;Scheme Transaction&#x201d;)), resulting in the Company becoming a direct wholly owned subsidiary of Topco, and (ii) Merger Sub will merge with and into Clywedog, with Clywedog continuing as the surviving corporation and a direct wholly owned subsidiary of Topco in accordance with the Delaware General Corporations Law (the &#x201c;Merger&#x201d; and, together with the Scheme Transaction, the &#x201c;Combinations&#x201d;, and, together with such other transactions contemplated by the Merger Agreement, the &#x201c;Contemplated Transactions&#x201d;). The Scheme Transaction will be consummated prior to the Merger. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the effective time of the Scheme Transaction (the &#x201c;Scheme Effective Time&#x201d;), upon the terms and subject to the conditions set forth in the Merger Agreement, Topco will acquire each outstanding ordinary share of the Company, with a par value &#xa3;0.000025 per ordinary share (each such acquired ordinary share, a &#x201c;Scheme Share&#x201d;), which, for the avoidance of doubt, will include ordinary shares held by The Bank of New York Mellon (the &#x201c;Depositary&#x201d;) (or to the extent that the Depositary is not itself the registered holder of such shares that underly the Company&#x2019;s American Depositary Shares (the &#x201c;ADSs&#x201d;), each representing one (1) ordinary share, whichever nominee, custodian or other entity is the registered holder under the terms of the Deposit Agreement, dated as of April 29, 2021, among the Company, the Depositary, and all holders from time to time of the ADSs, as may be amended from time to time), from the holders of Scheme Shares whose names appear in the register of members of the Company at the Scheme Effective Time) in accordance with the provisions of the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Scheme of Arrangement, and each Scheme Share will be converted into the right to receive (i) one (1) share of common stock, 0.0001 par value per share, of Topco (the &#x201c;Topco Common Stock&#x201d;) subject to and strictly in accordance with the terms of the Scheme of Arrangement plus (ii) cash in lieu of any fractional shares, rounded down to the nearest whole share. Following the Scheme Effective Time, Topco may in its discretion elect to commence a self-tender offer (&#x201c;Self-Tender Offer&#x201d;) to purchase up to $27.0 million in shares of Topco Common Stock then issued and outstanding, which Self-Tender Offer, if elected, will be consummated prior to the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the effective time of the Merger (the &#x201c;Merger Effective Time&#x201d;), subject to adjustment in accordance with the terms of the Merger Agreement, each share of common stock, $0.0001 par value per share, of Clywedog (the &#x201c;Clywedog Common Stock&#x201d;) and each share of Series Seed Preferred Stock, $0.0001 par value per share, of Clywedog (the &#x201c;Clywedog Preferred Stock&#x201d;, and together with the Clywedog Common Stock, the &#x201c;Clywedog Capital Stock&#x201d;), other than Clywedog Capital Stock held as treasury stock or owned by Topco or Merger Sub immediately prior to the Merger Effective Time, will be converted solely into the right to receive (i) 4.358932 of shares of Topco Common Stock rounded down to the nearest whole share plus (ii) cash in lieu of any fractional shares.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The closing of the Contemplated Transactions is subject to the satisfaction or waiver of certain customary conditions, including, among other things: (i) the effectiveness of a registration statement (the &#x201c;Registration Statement&#x201d;) to register the shares of Topco Common Stock to be issued in connection with the Combinations; (ii) approvals by the Company&#x2019;s shareholders of the Scheme Transaction and certain related matters, and sanction by the Court of the Scheme Transaction; (iii) approval by Clywedog&#x2019;s stockholders of the Merger Agreement, the Merger and Contemplated Transactions; (iv) the approval for listing by the Nasdaq Stock Market of the shares of Topco Common Stock issuable in the Combinations, subject to official notice of issuance; (v) the completion of the Self-Tender Offer to the extent that Topco elects to commence the Self-Tender Offer; (ivi) minimum cash requirements for each party.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Merger Agreement may be terminated and the transactions contemplated thereby abandoned at any time prior to the closing under certain specified circumstances. Either the Company or Clywedog may terminate the Merger Agreement if, among other things: (i) the closing date will not have occurred by September 30, 2026, subject to up to a 60 day extension if the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) has not declared effective the Registration Statement by July 31, 2026, (ii) a governmental authority of competent jurisdiction has issued a final, non-appealable order prohibiting the Contemplated Transactions, (iii) the required Company shareholder approval or Clywedog shareholder approval is not obtained in accordance with the Merger Agreement, (iv) the Scheme of Arrangement is not sanctioned by the Court, or (v) another party breaches or fails to perform in any material respect any of its covenants or any of the other party&#x2019;s representations or warranties are inaccurate and such breach, failure to perform or inaccuracy would result in certain of the closing conditions not being satisfied, subject to a cure period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:116%"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the Securities and Exchange Commission for annual financial reporting. The Company&#x2019;s reporting currency is the U.S. dollar. As of December&#160;31, 2025, the Company had cash, cash equivalents and restricted cash of $71.9 million and an accumulated deficit of $304.1 million and the Company expects to incur losses for the foreseeable future as it continues to pursue its activities, including the commercialization of its research and development. The Company expects to continue to incur costs and expenditures in connection with the Contemplated Transactions, further in connection with the Contemplated Transactions Barinthus may pay up to $27.0 million to existing shareholders under a Self Tender offer. If the Contemplated Transactions are consummated, any additional funding will be sought by the combined company. However as the transaction is not yet consummated, when performing the going concern assessment, management have assessed the Company on a standalone basis and expects that its cash, cash equivalents and restricted cash will be sufficient to fund current operations for at least the next 12 months from the issuance of the consolidated financial statements. &lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:116%"&gt;In the future the Company will need additional cash inflows to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:116%"&gt;pursue its activities, including the commercialization of its research and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:116%"&gt;development. There is no assurance that the Company will be successful in obtaining sufficient cash inflows on terms acceptable to the Company to fund continuing operations, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Guarantees and indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As permitted under the laws of England and Wales, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through the years ended December&#160;31, 2025 and 2024, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <brns:NumberOfNewSubsidiaries
      contextRef="c-47"
      decimals="INF"
      id="f-328"
      unitRef="subsidiary">2</brns:NumberOfNewSubsidiaries>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-48"
      decimals="INF"
      id="f-329"
      unitRef="gbpPerShare">0.000025</us-gaap:CommonStockParOrStatedValuePerShare>
    <brns:NumberOfDepositarySharesPerShareOfCommonStock
      contextRef="c-48"
      decimals="INF"
      id="f-330"
      unitRef="shares">1</brns:NumberOfDepositarySharesPerShareOfCommonStock>
    <brns:StockConversionRatio
      contextRef="c-49"
      decimals="INF"
      id="f-331"
      unitRef="number">1</brns:StockConversionRatio>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-50"
      decimals="INF"
      id="f-332"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-50" decimals="-5" id="f-333" unitRef="usd">27000000.0</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-51"
      decimals="INF"
      id="f-334"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-51"
      decimals="INF"
      id="f-335"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <brns:StockConversionRatio
      contextRef="c-52"
      decimals="INF"
      id="f-336"
      unitRef="number">4.358932</brns:StockConversionRatio>
    <brns:MergerAgreementExtensionPeriod contextRef="c-53" id="f-337">P60D</brns:MergerAgreementExtensionPeriod>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-5" id="f-338" unitRef="usd">71900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-8" decimals="-5" id="f-339" unitRef="usd">-304100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-50" decimals="-5" id="f-340" unitRef="usd">27000000.0</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies contextRef="c-1" id="f-341">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Guarantees and indemnifications&lt;/span&gt;&lt;/div&gt;As permitted under the laws of England and Wales, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company.</us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-342">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying consolidated financial statements include the accounts of Barinthus Biotherapeutics plc and those entities in which it has a controlling interest. Intercompany amounts are eliminated on consolidation. Amounts attributable to the noncontrolling interest are presented as a separate element of equity in the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#x2019;s actual results may differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the current year, the Company updated certain estimates related to the carrying value of long-lived assets as a result of the announced Contemplated Transactions with Clywedog. The adjustment reflects updated assumptions regarding expected future cash flows and market participant perspectives. Additional information regarding this change in estimate and its impact on the financial statements is included in Note 7.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of the date of issuance of these consolidated financial statements, the Company is not aware of any other specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Comprehensive loss for all periods presented is comprised primarily of net loss and other comprehensive loss, which solely relates to foreign currency translation adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Foreign currency translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s reporting currency is the United States dollar. The functional currency of the parent and each subsidiary is the currency of the country and economic environment in which it is located. Assets and liabilities of each legal entity denominated or measured in a currency other than British Pounds are first translated into British pounds and consolidated. The consolidated balances are then converted into United States dollars at period-end exchange rates. Revenues and expenses are translated into British pounds, then into U.S. dollars at average exchange rates for each reporting period. Translation adjustments are reflected as accumulated other comprehensive loss within stockholders&#x2019; equity. Gains and losses on foreign currency transactions are included in the consolidated statements of operations and comprehensive loss in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;general and administrative expenses. The aggregate net foreign exchange gain or loss included in determining net loss was a loss of $9.6 million and gain of $2.4 million for the years ended December&#160;31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Noncontrolling interest&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In 2018, Barinthus Biotherapeutics plc established VOLT with a related party. As of December&#160;31, 2021, Barinthus Biotherapeutics plc had contributed cash and intellectual property with an aggregate value of $11.9 million for a 76% controlling interest. The related party had contributed cash and intellectual property with an aggregate value of $3.8 million for a 24% noncontrolling interest. There were no further contributions in subsequent financial years. The contributed intellectual properties were initially recorded at investment date fair value by VOLT and immediately expensed as research and development costs. The Company accounts for the noncontrolling interest in the accompanying consolidated financial statements initially at fair value with the subsequent carrying value adjusted for the noncontrolling share of VOLT&#x2019;s comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company considers all highly liquid investments purchased with remaining maturities of three months or less on the purchase date to be cash and cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that are actively traded (a Level 1 input). As of December&#160;31, 2025, and 2024 there were no cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has entered into collaboration and license agreements, which are within the scope of Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include licenses, or options to obtain licenses, to product candidates or future product candidates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts recognized as revenue, but not yet received are generally recognized as accounts receivable or contract assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;License revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s arrangements may provide the collaboration partner with the right to select a target for licensing either at the inception of the arrangement or in the future. Under these arrangements, fees may be due to the Company (i) at the inception of the arrangement as an upfront fee or payment, (ii) upon the exercise of an option to acquire a license or (iii) upon extending the selection period as an extension fee or payment. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services at their standalone selling prices, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For arrangements that include sales-based milestones and royalties, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This could require management to estimate the amount of revenue to recognize in the period if the actual data for the period has not been provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Research and development services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The promises under the Company&#x2019;s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. For performance obligations that include research and development services, the Company recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for the purposes of recognizing revenue, which may include an input measure such as costs incurred during the reporting period or ratably over the service period. Reimbursements from the partner are evaluated as to whether the Company acts as a principal or an agent in such relationships. The Company evaluates whether control over the underlying goods or services were obtained prior to transferring these goods or services to the collaboration partner. Where the Company does not control the goods or services prior to transferring these goods or services to the collaboration partner, such reimbursements are presented net of costs. At the inception of each arrangement that includes development milestone payments in respect of development efforts, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular development milestone in making this assessment. There is judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each reporting period, the Company reevaluates the probability of achievement of all development milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#x2019;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. To date, the Company has not recognized any development milestone revenue resulting from any of its arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Other Operating Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other operating income includes grant income from the CEPI Funding Agreement pursuant to which CEPI will provide funding to us to advance the development of VTP-500, a vaccine candidate against MERS. When there is reasonable assurance that we will comply with the conditions attached to a received grant, and when there is reasonable assurance that the grant will be received, grant income is recognized as other operating income on a gross basis in the consolidated statements of operations and comprehensive loss on a systematic basis over the periods in which we recognize expenses for the related costs for which the grants are intended to compensate. Payments received in advance of incurring reimbursable expenses are recorded as deferred income. Any remaining unused amounts of the cash payments received will be disclosed as restricted cash in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Concentrations of credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. Periodically, the Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#x2019;s deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses in these deposits. The Company&#x2019;s standard payment terms are typically 30 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes revenue earned in connection with the license and services provided to customers. The Company provides credit to licensees in the normal course of providing such services based on evaluations of their financial condition and generally does not require collateral. To manage accounts receivable credit risk, the Company monitors the creditworthiness of its licensees. Historically, the Company has not experienced any credit losses related to accounts receivable and does not maintain allowances for uncollectible amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Licensees that represented 10% or more of the Company&#x2019;s revenue are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.298%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.301%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Country&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Oxford University Innovation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;U.K.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Allowance for credit losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company evaluates its cash equivalents and accounts receivable for expected credit losses. Expected credit losses represent the portion of the amortized cost basis of a financial asset that an entity does not expect to collect. An allowance for expected credit losses is meant to reflect a risk of loss even if remote, irrespective of the expectation of collection from a particular issuer or debt security. The Company has not historically experienced any credit losses on any of its financial assets. With respect to cash equivalents and accounts receivable, given consideration of their short maturity, historical losses and the current market environment, the Company concluded there are no expected credit losses for these financial assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses. Expenditures for maintenance and repairs are charged to operating expenses as incurred, whereas major betterments are capitalized as additions to property and equipment. Impairment losses are recorded within general and administrative expenses. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.323%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.477%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Asset Category&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lesser of lease term or estimated useful lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Intangible assets acquired through business combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets consist of acquired developed technology. Intangible assets are stated at cost less accumulated amortization and impairment losses. Amortization is computed using the straight-line method over the estimated useful lives of the respective assets, which is 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Impairment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company reviews long-lived assets to be held and used, including property and equipment, intangible assets and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Evaluation of recoverability is first based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group and its eventual disposition. In the event such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the assets are written down to their estimated fair values. There were impairments recorded during the year ended December&#160;31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Goodwill represents the excess of cost over the fair value of the net tangible and intangible assets of businesses acquired in a business combination. Goodwill is not amortized but rather is tested for impairment at least annually, or more frequently if events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. The Company has elected to first assess the qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis of determining whether it is necessary to perform the quantitative goodwill impairment test. If the Company determines that it is more likely than not that its fair value is less than its carrying amount, then the quantitative goodwill impairment test will be performed. The quantitative goodwill impairment test identifies and measures the amount of goodwill impairment loss, if any, to be recognized by comparing the fair value &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;of a reporting unit with its carrying amount. If the fair value exceeds the carrying amount, no further analysis is required; otherwise, if the fair value is less than the carrying amount, the difference is recognized as a goodwill impairment loss not to exceed the carrying amount of the goodwill. The carrying amount of goodwill was nil at December 31, 2024 . The Company has performed the annual impairment assessment and identified qualitative indicators of impairment, most notably the share price drop in November 2024, including the lack of recovery thereof, and the strategic considerations to partner VTP-300 for future clinical development. Therefore, the Company performed a qualitative impairment assessment and determined that it was more likely than not that the fair value of the reporting unit is less than its carrying amount. The reporting unit comprises the net assets of the Company. The Company then performed a quantitative impairment assessment using the income approach to determine the fair value of the reporting unit, including the net present value of clinical stage assets and overhead costs. Based on the quantitative assessment, the Company determined that the fair value of the reporting unit is less than its carrying amount as of December 31, 2024, and, as a result, recognized a goodwill impairment charge of $12.2 million. For the year ended December&#160;31, 2025 there was no impairment charge to Goodwill (December&#160;31, 2024: $12.2 million).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s financial instruments consist of cash, cash equivalents, restricted cash, accounts receivable, accounts payable, certain accrued expenses and contingent consideration. The carrying amounts of cash, cash equivalents, accounts receivable, security deposits, accounts payable and accrued expenses approximate their fair value due to the short-term nature of those financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Fair value measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company follows the guidance in ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.67pt"&gt;Level 1 &#x2013; Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.67pt"&gt;Level 2 &#x2013; Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.67pt"&gt;Level 3 &#x2013; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company&#x2019;s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may change for many instruments. This condition could cause an instrument to be reclassified within levels in the fair value hierarchy. There were no transfers within the fair value hierarchy during the years ended December&#160;31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes a contingent consideration liability related to the acquisition of Avidea Technologies, Inc. The liability is remeasured to fair value at each reporting date until the contingency is resolved. The fair value of the contingent consideration is a Level 3 valuation determined using significant unobservable inputs being the probability of success of achievement of the milestones and the expected date of the milestone achievement. Changes in fair value are recognized in &lt;span style="-sec-ix-hidden:f-381"&gt;&lt;span style="-sec-ix-hidden:f-382"&gt;general and administrative expenses&lt;/span&gt;&lt;/span&gt; in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Leases are accounted for under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(&#x201c;ASC 842&#x201d;) resulting in the recognition of lease liabilities and right-of-use assets. The Company only has operating leases. The Company has elected the practical expedient allowed under ASC 842 to account for each lease component (e.g., the right to use office space) and the associated non-lease components (e.g., maintenance services) as a single lease component. The Company also elected the short-term lease accounting policy for all asset classes; therefore, the Company is not recognizing a lease liability or right-of-use asset for any lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Variable lease payments such as the Company&#x2019;s share of real estate taxes, utilities, and common area maintenance, are reported as non-lease operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets also include the effect of any lease payments made and exclude lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized as part of total operating expenses on a straight-line basis over the lease term. The difference between the value of the right of use asset and lease liability is due to the reclassification of prepaid rent and unamortized lease incentives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development costs are expensed as incurred on an accrual basis. Research and development costs include payroll and personnel expense (including share-based compensation), consulting costs, external contract research and development expenses, raw materials, drug product manufacturing costs, and allocated overheads including depreciation and amortization, facility costs, and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Clinical trial costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Clinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activation, and other information provided to the Company by its vendors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Patent and licensing costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Patent and licensing costs are expensed as incurred because there is uncertainty as to any future economic benefits arising from these costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Ordinary shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Ordinary shares are classified in stockholders&#x2019; equity and represent issued share capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Additional paid-in capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additional paid-in capital is classified in stockholders&#x2019; equity and represents the share premium account, where the difference between the price paid per share and the nominal value is recognized. The equity element of share based compensation is also recognized in additional paid in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Share based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company grants options over ordinary shares and restricted shares units to employees or non-executive directors and accounts for share based compensation using the grant date fair value. Share based compensation awards are classified in the accompanying statements of operations and comprehensive loss based on the function to which the related services are provided. For service-based awards, compensation expense is generally recognized over the requisite service period of the awards, usually the vesting period. The Company applies the &#x201c;multiple option&#x201d; method of allocating expense. In applying this method, each vesting tranche of an award is treated as a separate grant and recognized on a straight-line basis over that tranche&#x2019;s vesting period. For performance-based awards where the vesting of the awards may be accelerated upon the achievement of certain milestones, vesting and the related share-based compensation is recognized as an expense when it is probable the milestone will be met. Assumptions used in the option pricing model include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Expected volatility.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Previously there was insufficient trading history for the Company&#x2019;s ordinary shares, therefore the expected price volatility for the Company's ordinary shares was estimated using the average historical volatility of industry peers&#x2019; shares as of the grant date of the Company's options over a period of history commensurate with the expected life of the options. When selecting industry peers used in measuring implied volatility, the Company considered the similarity of their products and business lines, as well as their stage of development, size and financial leverage. The Company applied this process consistently using the same or similar public companies until 2023. For options granted since 2023, the Company determined that there is sufficient historical information on volatility of its share price available and the expected volatility used in the fair value calculation of new option grants is calculated based on a blended volatility of both historical volatility of the Company's share price and the average historical volatility of industry peers&#x2019; shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The expected term of the Company&#x2019;s share options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The &#x201c;simplified&#x201d; method was determined to be appropriate as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Expected dividend.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has elected to recognize the effect of forfeitures on share-based compensation when they occur. Any differences in compensation recognized at the time of forfeiture are recorded as a cumulative adjustment in the period where the forfeiture occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;When awards are modified, the Company compares the fair value of the affected award measured immediately prior to modification to its value after modification. To the extent that the fair value of the modified award exceeds the original award, the incremental fair value of the modified award is recognized as compensation on the date of modification for vested awards, and over the remaining vesting period for unvested awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The financial statements reflect provisions for income taxes in the U.K. and foreign jurisdictions. Deferred tax assets and liabilities represent future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities and for loss carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is recorded when it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. To date, the Company has not incurred interest and penalties related to uncertain tax positions nor has it recorded any unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Research and development incentives&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the U.K., the Company had previously been entitled to a research and development tax credit regime, being the Small and Medium-sized Enterprises R&amp;amp;D tax relief program (&#x201c;SME&#x201d;),and, to the extent that our projects are grant funded or relate to work subcontracted to us by third parties, the Research and Development Expenditure Credit program, or RDEC Program. For the year ended December 31, 2025, we benefit from the applicable United Kingdom research and development tax credit regime which is the merged scheme Research &amp;amp; Development expenditure credit ("RDEC") and enhanced R&amp;amp;D intensive support ("ERIS") that replaces the prior schemes. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims. For expenditure under the merged RDEC scheme, the rate of Research and Development expenditure credit will is 20%, which is the same as the rate under the old RDEC scheme for expenditure incurred on or after April 1, 2023. For loss-makers and small profit-makers, a lower rate of notional tax restriction (currently 19%) applies at payment. Under both the merged RDEC scheme and the prior SME program, a company qualifies as an R&amp;amp;D intensive business if R&amp;amp;D expenditure constitutes at least 30% of total expenditure. From the analysis performed, the Company has not and do not currently expect to claim under the loss-making R&amp;amp;D intensive scheme primarily due to the proportion of total relevant expenditure occurring outside the U.K. If the Company incurs tax losses, the Company is entitled to surrender the lesser of unrelieved tax loss sustained and the tax relief. As the realization of the tax relief does not depend on our generation of future taxable income or the Company&#x2019;s ongoing tax status or tax position, the Company does not consider the tax relief as an element of income tax accounting under ASC 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Income taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;and records the tax relief as a form of government grant or assistance. For the years ended December&#160;31, 2025 and 2024, the Company recognized research and development incentives of $2.0 million and $4.0 million respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding for the reporting period without consideration for potentially dilutive securities. Net loss attributable to ordinary shareholders is computed as if all net loss for the period had been distributed. During periods in which the Company incurred a net loss, the Company allocates no net loss to participating securities because they do not have a contractual obligation to share in the net loss of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company computes diluted net loss per ordinary share after giving consideration to all potentially dilutive ordinary equivalents, including stock options outstanding during the period, except where the effect of such non-participating securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Diluted net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares and dilutive ordinary share equivalents outstanding for the period, determined using the treasury-stock and if-converted methods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Contingent liabilities  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A provision for contingent liabilities is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is a party to certain litigation and disputes arising in the normal course of business. As of December&#160;31, 2025, the Company does not expect that such matters will have a material adverse effect on the Company&#x2019;s business, financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, new accounting pronouncements are issued by FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#x201c;opt out&#x201d; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different applications dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time the Company either (i) irrevocably elects to &#x201c;opt out&#x201d; of such extended transition period or (ii) no longer qualifies as an emerging growth company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#x201c;opt out&#x201d; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time the Company either (i) irrevocably elects to &#x201c;opt out&#x201d; of such extended transition period or (ii) no longer qualifies as an emerging growth company.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has reviewed all recently issued standards and have determined that such standards do not or are not expected to have a material impact on its condensed consolidated financial statements or do not otherwise apply to its current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2025, the FASB issued ASU 2025-12, Accounting Standards Update Codification Improvements. The amendments in this update facilitates codification updates for a broad range of Topics arising from technical corrections, unintended application of the codification, clarifications, and other minor improvements. This standard is effective for fiscal years beginning after December 15, 2026, including interim periods within those fiscal years. The Company is currently evaluating the impact of adopting this standard to determine its impact on its disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. The amendments in this update clarify interim disclosure requirements and the applicability of Topic 270. This standard is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact of adopting this standard to determine its impact on its disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2025, the FASB issued ASU 2025-03, Business Combinations (Topic 805): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity. This ASU amends the guidance for identifying the accounting acquirer in transactions involving variable interest entities (&#x201c;VIEs&#x201d;) where the transaction is achieved primarily through the exchange of equity interests, aligning it more closely with the guidance for voting interest entities. The amendments are effective for &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;fiscal years beginning after December 15, 2026, including interim periods within those fiscal years, with early adoption permitted. The Company elected to early adopt ASU 2025-03 as of July 1, 2025. The adoption did not have a material impact on the consolidated financial statements. The Company will apply the amended guidance prospectively to applicable transactions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2025, the FASB issued ASU 2025-01, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, in which the Board's intent in the basis of conclusion of Update 2024-03 is clear that all public business entities should initially adopt the disclosure requirements in the first annual reporting period beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact of adopting this standard to determine its impact on its disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40), which requires disaggregation of specific expense categories in the notes to the financial statements and a qualitative description of the remaining expense amounts not separately disaggregated. This standard is effective for annual reporting periods beginning after December 15, 2026, and requires prospective application with the option to apply it retrospectively. The Company is currently evaluating the impact of adopting this standard to determine its impact on its disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate). This standard is effective for fiscal years beginning after December 15, 2024. The Company has retrospectively adopted the ASU and the adoption did not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-343">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying consolidated financial statements include the accounts of Barinthus Biotherapeutics plc and those entities in which it has a controlling interest. Intercompany amounts are eliminated on consolidation. Amounts attributable to the noncontrolling interest are presented as a separate element of equity in the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-344">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#x2019;s actual results may differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the current year, the Company updated certain estimates related to the carrying value of long-lived assets as a result of the announced Contemplated Transactions with Clywedog. The adjustment reflects updated assumptions regarding expected future cash flows and market participant perspectives. Additional information regarding this change in estimate and its impact on the financial statements is included in Note 7.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of the date of issuance of these consolidated financial statements, the Company is not aware of any other specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-345">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Comprehensive loss for all periods presented is comprised primarily of net loss and other comprehensive loss, which solely relates to foreign currency translation adjustments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-346">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Foreign currency translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s reporting currency is the United States dollar. The functional currency of the parent and each subsidiary is the currency of the country and economic environment in which it is located. Assets and liabilities of each legal entity denominated or measured in a currency other than British Pounds are first translated into British pounds and consolidated. The consolidated balances are then converted into United States dollars at period-end exchange rates. Revenues and expenses are translated into British pounds, then into U.S. dollars at average exchange rates for each reporting period. Translation adjustments are reflected as accumulated other comprehensive loss within stockholders&#x2019; equity. Gains and losses on foreign currency transactions are included in the consolidated statements of operations and comprehensive loss in &lt;/span&gt;&lt;/div&gt;general and administrative expenses.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-1" decimals="-5" id="f-347" unitRef="usd">-9600000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-12" decimals="-5" id="f-348" unitRef="usd">2400000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <brns:MinorityInterestPolicyTextBlock contextRef="c-1" id="f-349">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Noncontrolling interest&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In 2018, Barinthus Biotherapeutics plc established VOLT with a related party. As of December&#160;31, 2021, Barinthus Biotherapeutics plc had contributed cash and intellectual property with an aggregate value of $11.9 million for a 76% controlling interest. The related party had contributed cash and intellectual property with an aggregate value of $3.8 million for a 24% noncontrolling interest. There were no further contributions in subsequent financial years. The contributed intellectual properties were initially recorded at investment date fair value by VOLT and immediately expensed as research and development costs. The Company accounts for the noncontrolling interest in the accompanying consolidated financial statements initially at fair value with the subsequent carrying value adjusted for the noncontrolling share of VOLT&#x2019;s comprehensive loss.&lt;/span&gt;&lt;/div&gt;</brns:MinorityInterestPolicyTextBlock>
    <brns:SubsidiaryCumulativeContributionsParent contextRef="c-54" decimals="-5" id="f-350" unitRef="usd">11900000</brns:SubsidiaryCumulativeContributionsParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c-55" decimals="2" id="f-351" unitRef="number">0.76</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <brns:SubsidiaryCumulativeContributionsNoncontrollingOwner contextRef="c-56" decimals="-5" id="f-352" unitRef="usd">3800000</brns:SubsidiaryCumulativeContributionsNoncontrollingOwner>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-57" decimals="2" id="f-353" unitRef="number">0.24</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-354">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;The Company considers all highly liquid investments purchased with remaining maturities of three months or less on the purchase date to be cash and cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that are actively traded (a Level 1 input).</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-8" decimals="-5" id="f-355" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-9" decimals="-5" id="f-356" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-357">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has entered into collaboration and license agreements, which are within the scope of Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include licenses, or options to obtain licenses, to product candidates or future product candidates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts recognized as revenue, but not yet received are generally recognized as accounts receivable or contract assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;License revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s arrangements may provide the collaboration partner with the right to select a target for licensing either at the inception of the arrangement or in the future. Under these arrangements, fees may be due to the Company (i) at the inception of the arrangement as an upfront fee or payment, (ii) upon the exercise of an option to acquire a license or (iii) upon extending the selection period as an extension fee or payment. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services at their standalone selling prices, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For arrangements that include sales-based milestones and royalties, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This could require management to estimate the amount of revenue to recognize in the period if the actual data for the period has not been provided.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <brns:ResearchAndDevelopmentServicesPolicyPolicyTextBlock contextRef="c-1" id="f-358">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Research and development services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The promises under the Company&#x2019;s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. For performance obligations that include research and development services, the Company recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for the purposes of recognizing revenue, which may include an input measure such as costs incurred during the reporting period or ratably over the service period. Reimbursements from the partner are evaluated as to whether the Company acts as a principal or an agent in such relationships. The Company evaluates whether control over the underlying goods or services were obtained prior to transferring these goods or services to the collaboration partner. Where the Company does not control the goods or services prior to transferring these goods or services to the collaboration partner, such reimbursements are presented net of costs. At the inception of each arrangement that includes development milestone payments in respect of development efforts, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular development milestone in making this assessment. There is judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each reporting period, the Company reevaluates the probability of achievement of all development milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#x2019;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. To date, the Company has not recognized any development milestone revenue resulting from any of its arrangements.&lt;/span&gt;&lt;/div&gt;</brns:ResearchAndDevelopmentServicesPolicyPolicyTextBlock>
    <brns:OtherOperatingIncomePolicyPolicyTextBlock contextRef="c-1" id="f-359">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Other Operating Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other operating income includes grant income from the CEPI Funding Agreement pursuant to which CEPI will provide funding to us to advance the development of VTP-500, a vaccine candidate against MERS. When there is reasonable assurance that we will comply with the conditions attached to a received grant, and when there is reasonable assurance that the grant will be received, grant income is recognized as other operating income on a gross basis in the consolidated statements of operations and comprehensive loss on a systematic basis over the periods in which we recognize expenses for the related costs for which the grants are intended to compensate. Payments received in advance of incurring reimbursable expenses are recorded as deferred income. Any remaining unused amounts of the cash payments received will be disclosed as restricted cash in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</brns:OtherOperatingIncomePolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-360">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Concentrations of credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. Periodically, the Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#x2019;s deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses in these deposits. The Company&#x2019;s standard payment terms are typically 30 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes revenue earned in connection with the license and services provided to customers. The Company provides credit to licensees in the normal course of providing such services based on evaluations of their financial condition and generally does not require collateral. To manage accounts receivable credit risk, the Company monitors the creditworthiness of its licensees. Historically, the Company has not experienced any credit losses related to accounts receivable and does not maintain allowances for uncollectible amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <brns:AccountsReceivableStandardPaymentTermsPeriod contextRef="c-1" id="f-361">P30D</brns:AccountsReceivableStandardPaymentTermsPeriod>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c-1" id="f-362">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Licensees that represented 10% or more of the Company&#x2019;s revenue are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.298%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.301%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Country&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Oxford University Innovation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;U.K.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <brns:ConcentrationRiskThresholdPercentage contextRef="c-58" decimals="2" id="f-363" unitRef="number">0</brns:ConcentrationRiskThresholdPercentage>
    <brns:ConcentrationRiskThresholdPercentage contextRef="c-59" decimals="2" id="f-364" unitRef="number">1</brns:ConcentrationRiskThresholdPercentage>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock contextRef="c-1" id="f-365">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Allowance for credit losses&lt;/span&gt;&lt;/div&gt;The Company evaluates its cash equivalents and accounts receivable for expected credit losses. Expected credit losses represent the portion of the amortized cost basis of a financial asset that an entity does not expect to collect. An allowance for expected credit losses is meant to reflect a risk of loss even if remote, irrespective of the expectation of collection from a particular issuer or debt security. The Company has not historically experienced any credit losses on any of its financial assets.</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-9" decimals="-5" id="f-366" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-8" decimals="-5" id="f-367" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-368">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses. Expenditures for maintenance and repairs are charged to operating expenses as incurred, whereas major betterments are capitalized as additions to property and equipment. Impairment losses are recorded within general and administrative expenses. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.323%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.477%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Asset Category&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lesser of lease term or estimated useful lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-369">Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.323%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.477%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Asset Category&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lesser of lease term or estimated useful lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment, net consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: accumulated depreciation and impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-60" id="f-370">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-61" id="f-371">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c-1" id="f-372">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Intangible assets acquired through business combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets consist of acquired developed technology. Intangible assets are stated at cost less accumulated amortization and impairment losses. Amortization is computed using the straight-line method over the estimated useful lives of the respective assets, which is 10 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-62" id="f-373">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-374">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Impairment &lt;/span&gt;&lt;/div&gt;The Company reviews long-lived assets to be held and used, including property and equipment, intangible assets and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Evaluation of recoverability is first based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group and its eventual disposition. In the event such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the assets are written down to their estimated fair values.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-375">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Goodwill represents the excess of cost over the fair value of the net tangible and intangible assets of businesses acquired in a business combination. Goodwill is not amortized but rather is tested for impairment at least annually, or more frequently if events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. The Company has elected to first assess the qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis of determining whether it is necessary to perform the quantitative goodwill impairment test. If the Company determines that it is more likely than not that its fair value is less than its carrying amount, then the quantitative goodwill impairment test will be performed. The quantitative goodwill impairment test identifies and measures the amount of goodwill impairment loss, if any, to be recognized by comparing the fair value &lt;/span&gt;&lt;/div&gt;of a reporting unit with its carrying amount. If the fair value exceeds the carrying amount, no further analysis is required; otherwise, if the fair value is less than the carrying amount, the difference is recognized as a goodwill impairment loss not to exceed the carrying amount of the goodwill. The carrying amount of goodwill was nil at December 31, 2024 . The Company has performed the annual impairment assessment and identified qualitative indicators of impairment, most notably the share price drop in November 2024, including the lack of recovery thereof, and the strategic considerations to partner VTP-300 for future clinical development. Therefore, the Company performed a qualitative impairment assessment and determined that it was more likely than not that the fair value of the reporting unit is less than its carrying amount. The reporting unit comprises the net assets of the Company. The Company then performed a quantitative impairment assessment using the income approach to determine the fair value of the reporting unit, including the net present value of clinical stage assets and overhead costs. Based on the quantitative assessment, the Company determined that the fair value of the reporting unit is less than its carrying amount as of December 31, 2024, and, as a result, recognized a goodwill impairment charge of $12.2 million.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-12" decimals="-5" id="f-376" unitRef="usd">12200000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-5" id="f-377" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-12" decimals="-5" id="f-378" unitRef="usd">12200000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-379">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s financial instruments consist of cash, cash equivalents, restricted cash, accounts receivable, accounts payable, certain accrued expenses and contingent consideration. The carrying amounts of cash, cash equivalents, accounts receivable, security deposits, accounts payable and accrued expenses approximate their fair value due to the short-term nature of those financial instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-380">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Fair value measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company follows the guidance in ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.67pt"&gt;Level 1 &#x2013; Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.67pt"&gt;Level 2 &#x2013; Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.67pt"&gt;Level 3 &#x2013; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company&#x2019;s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may change for many instruments. This condition could cause an instrument to be reclassified within levels in the fair value hierarchy. There were no transfers within the fair value hierarchy during the years ended December&#160;31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes a contingent consideration liability related to the acquisition of Avidea Technologies, Inc. The liability is remeasured to fair value at each reporting date until the contingency is resolved. The fair value of the contingent consideration is a Level 3 valuation determined using significant unobservable inputs being the probability of success of achievement of the milestones and the expected date of the milestone achievement. Changes in fair value are recognized in &lt;span style="-sec-ix-hidden:f-381"&gt;&lt;span style="-sec-ix-hidden:f-382"&gt;general and administrative expenses&lt;/span&gt;&lt;/span&gt; in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-383">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Leases are accounted for under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(&#x201c;ASC 842&#x201d;) resulting in the recognition of lease liabilities and right-of-use assets. The Company only has operating leases. The Company has elected the practical expedient allowed under ASC 842 to account for each lease component (e.g., the right to use office space) and the associated non-lease components (e.g., maintenance services) as a single lease component. The Company also elected the short-term lease accounting policy for all asset classes; therefore, the Company is not recognizing a lease liability or right-of-use asset for any lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Variable lease payments such as the Company&#x2019;s share of real estate taxes, utilities, and common area maintenance, are reported as non-lease operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets also include the effect of any lease payments made and exclude lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized as part of total operating expenses on a straight-line basis over the lease term. The difference between the value of the right of use asset and lease liability is due to the reclassification of prepaid rent and unamortized lease incentives.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-384">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development costs are expensed as incurred on an accrual basis. Research and development costs include payroll and personnel expense (including share-based compensation), consulting costs, external contract research and development expenses, raw materials, drug product manufacturing costs, and allocated overheads including depreciation and amortization, facility costs, and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <brns:ClinicalTrialCostsPolicyTextBlock contextRef="c-1" id="f-385">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Clinical trial costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Clinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activation, and other information provided to the Company by its vendors.&lt;/span&gt;&lt;/div&gt;</brns:ClinicalTrialCostsPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend contextRef="c-1" id="f-386">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Patent and licensing costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Patent and licensing costs are expensed as incurred because there is uncertainty as to any future economic benefits arising from these costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c-1" id="f-387">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Ordinary shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Ordinary shares are classified in stockholders&#x2019; equity and represent issued share capital.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <brns:AdditionalPaidInCapitalPolicyTextBlock contextRef="c-1" id="f-388">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Additional paid-in capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additional paid-in capital is classified in stockholders&#x2019; equity and represents the share premium account, where the difference between the price paid per share and the nominal value is recognized. The equity element of share based compensation is also recognized in additional paid in capital.&lt;/span&gt;&lt;/div&gt;</brns:AdditionalPaidInCapitalPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-389">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Share based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company grants options over ordinary shares and restricted shares units to employees or non-executive directors and accounts for share based compensation using the grant date fair value. Share based compensation awards are classified in the accompanying statements of operations and comprehensive loss based on the function to which the related services are provided. For service-based awards, compensation expense is generally recognized over the requisite service period of the awards, usually the vesting period. The Company applies the &#x201c;multiple option&#x201d; method of allocating expense. In applying this method, each vesting tranche of an award is treated as a separate grant and recognized on a straight-line basis over that tranche&#x2019;s vesting period. For performance-based awards where the vesting of the awards may be accelerated upon the achievement of certain milestones, vesting and the related share-based compensation is recognized as an expense when it is probable the milestone will be met. Assumptions used in the option pricing model include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Expected volatility.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Previously there was insufficient trading history for the Company&#x2019;s ordinary shares, therefore the expected price volatility for the Company's ordinary shares was estimated using the average historical volatility of industry peers&#x2019; shares as of the grant date of the Company's options over a period of history commensurate with the expected life of the options. When selecting industry peers used in measuring implied volatility, the Company considered the similarity of their products and business lines, as well as their stage of development, size and financial leverage. The Company applied this process consistently using the same or similar public companies until 2023. For options granted since 2023, the Company determined that there is sufficient historical information on volatility of its share price available and the expected volatility used in the fair value calculation of new option grants is calculated based on a blended volatility of both historical volatility of the Company's share price and the average historical volatility of industry peers&#x2019; shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The expected term of the Company&#x2019;s share options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The &#x201c;simplified&#x201d; method was determined to be appropriate as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods that are approximately equal to the expected term of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Expected dividend.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has elected to recognize the effect of forfeitures on share-based compensation when they occur. Any differences in compensation recognized at the time of forfeiture are recorded as a cumulative adjustment in the period where the forfeiture occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;When awards are modified, the Company compares the fair value of the affected award measured immediately prior to modification to its value after modification. To the extent that the fair value of the modified award exceeds the original award, the incremental fair value of the modified award is recognized as compensation on the date of modification for vested awards, and over the remaining vesting period for unvested awards.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="INF" id="f-390" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-12"
      decimals="INF"
      id="f-391"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:RegulatoryIncomeTaxesPolicy contextRef="c-1" id="f-392">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The financial statements reflect provisions for income taxes in the U.K. and foreign jurisdictions. Deferred tax assets and liabilities represent future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities and for loss carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. A valuation allowance is recorded when it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. To date, the Company has not incurred interest and penalties related to uncertain tax positions nor has it recorded any unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;</us-gaap:RegulatoryIncomeTaxesPolicy>
    <brns:ResearchAndDevelopmentIncentivesPolicyTextBlock contextRef="c-1" id="f-393">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Research and development incentives&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the U.K., the Company had previously been entitled to a research and development tax credit regime, being the Small and Medium-sized Enterprises R&amp;amp;D tax relief program (&#x201c;SME&#x201d;),and, to the extent that our projects are grant funded or relate to work subcontracted to us by third parties, the Research and Development Expenditure Credit program, or RDEC Program. For the year ended December 31, 2025, we benefit from the applicable United Kingdom research and development tax credit regime which is the merged scheme Research &amp;amp; Development expenditure credit ("RDEC") and enhanced R&amp;amp;D intensive support ("ERIS") that replaces the prior schemes. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims. For expenditure under the merged RDEC scheme, the rate of Research and Development expenditure credit will is 20%, which is the same as the rate under the old RDEC scheme for expenditure incurred on or after April 1, 2023. For loss-makers and small profit-makers, a lower rate of notional tax restriction (currently 19%) applies at payment. Under both the merged RDEC scheme and the prior SME program, a company qualifies as an R&amp;amp;D intensive business if R&amp;amp;D expenditure constitutes at least 30% of total expenditure. From the analysis performed, the Company has not and do not currently expect to claim under the loss-making R&amp;amp;D intensive scheme primarily due to the proportion of total relevant expenditure occurring outside the U.K. If the Company incurs tax losses, the Company is entitled to surrender the lesser of unrelieved tax loss sustained and the tax relief. As the realization of the tax relief does not depend on our generation of future taxable income or the Company&#x2019;s ongoing tax status or tax position, the Company does not consider the tax relief as an element of income tax accounting under ASC 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Income taxes &lt;/span&gt;and records the tax relief as a form of government grant or assistance.</brns:ResearchAndDevelopmentIncentivesPolicyTextBlock>
    <brns:ResearchAndDevelopmentIncentiveIncomeExpense contextRef="c-1" decimals="-5" id="f-394" unitRef="usd">2000000.0</brns:ResearchAndDevelopmentIncentiveIncomeExpense>
    <brns:ResearchAndDevelopmentIncentiveIncomeExpense contextRef="c-12" decimals="-5" id="f-395" unitRef="usd">4000000.0</brns:ResearchAndDevelopmentIncentiveIncomeExpense>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-396">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding for the reporting period without consideration for potentially dilutive securities. Net loss attributable to ordinary shareholders is computed as if all net loss for the period had been distributed. During periods in which the Company incurred a net loss, the Company allocates no net loss to participating securities because they do not have a contractual obligation to share in the net loss of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company computes diluted net loss per ordinary share after giving consideration to all potentially dilutive ordinary equivalents, including stock options outstanding during the period, except where the effect of such non-participating securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Diluted net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares and dilutive ordinary share equivalents outstanding for the period, determined using the treasury-stock and if-converted methods.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ContingentLiabilityReserveEstimatePolicy contextRef="c-1" id="f-397">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Contingent liabilities  &lt;/span&gt;&lt;/div&gt;A provision for contingent liabilities is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is a party to certain litigation and disputes arising in the normal course of business.</us-gaap:ContingentLiabilityReserveEstimatePolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-398">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, new accounting pronouncements are issued by FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#x201c;opt out&#x201d; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different applications dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time the Company either (i) irrevocably elects to &#x201c;opt out&#x201d; of such extended transition period or (ii) no longer qualifies as an emerging growth company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#x201c;opt out&#x201d; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time the Company either (i) irrevocably elects to &#x201c;opt out&#x201d; of such extended transition period or (ii) no longer qualifies as an emerging growth company.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has reviewed all recently issued standards and have determined that such standards do not or are not expected to have a material impact on its condensed consolidated financial statements or do not otherwise apply to its current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2025, the FASB issued ASU 2025-12, Accounting Standards Update Codification Improvements. The amendments in this update facilitates codification updates for a broad range of Topics arising from technical corrections, unintended application of the codification, clarifications, and other minor improvements. This standard is effective for fiscal years beginning after December 15, 2026, including interim periods within those fiscal years. The Company is currently evaluating the impact of adopting this standard to determine its impact on its disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. The amendments in this update clarify interim disclosure requirements and the applicability of Topic 270. This standard is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact of adopting this standard to determine its impact on its disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2025, the FASB issued ASU 2025-03, Business Combinations (Topic 805): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity. This ASU amends the guidance for identifying the accounting acquirer in transactions involving variable interest entities (&#x201c;VIEs&#x201d;) where the transaction is achieved primarily through the exchange of equity interests, aligning it more closely with the guidance for voting interest entities. The amendments are effective for &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;fiscal years beginning after December 15, 2026, including interim periods within those fiscal years, with early adoption permitted. The Company elected to early adopt ASU 2025-03 as of July 1, 2025. The adoption did not have a material impact on the consolidated financial statements. The Company will apply the amended guidance prospectively to applicable transactions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2025, the FASB issued ASU 2025-01, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, in which the Board's intent in the basis of conclusion of Update 2024-03 is clear that all public business entities should initially adopt the disclosure requirements in the first annual reporting period beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact of adopting this standard to determine its impact on its disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40), which requires disaggregation of specific expense categories in the notes to the financial statements and a qualitative description of the remaining expense amounts not separately disaggregated. This standard is effective for annual reporting periods beginning after December 15, 2026, and requires prospective application with the option to apply it retrospectively. The Company is currently evaluating the impact of adopting this standard to determine its impact on its disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate). This standard is effective for fiscal years beginning after December 15, 2024. The Company has retrospectively adopted the ASU and the adoption did not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-399">&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Segment information&lt;/span&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker ("CODM"), the Company&#x2019;s Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The CODM approves key operating and strategic decisions, including key decisions in clinical development and clinical operating activities, entering into significant contracts and approves the Company's consolidated operating budget. The Company views its operations and manages its business as one operating segment, the research and development of immunotherapies and vaccines. The CODM uses loss before income tax to monitor budget versus actual results and decide how to use the Company's resources. As the Company operates in one operating segment, all required financial segment information can be found in these consolidated financial statements. The following table is a summary of the Company's significant segment expenses:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.461%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Direct research and development expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;VTP-1000 Celiac&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Barinthus legacy assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total direct research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Indirect research and development expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Personnel-related (including share-based compensation)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Facility related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other indirect costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total indirect research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:2pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;In January 2025, we announced a strategic focus on developing a pipeline in I&amp;amp;I, and the deprioritization of our programs in infectious disease and oncology. The following programs were previously presented separately and have been grouped collectively as "Barinthus Legacy Assets" for both years presented: VTP-300 HBV, VTP-850 Prostate Cancer, VTP-200 HPV, VTP-600 NSCLC, VTP-500 MERS and other and earlier stage programs. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company operates in two geographic regions: the U.S. and the U.K. The following table summarizes the Company&#x2019;s long-lived assets, which include the Company&#x2019;s intangible assets, property and equipment, net and right-of-use assets by geography:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.659%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United Kingdom&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;33,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-400"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-401"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-402">The following table is a summary of the Company's significant segment expenses:&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.461%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Direct research and development expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;VTP-1000 Celiac&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Barinthus legacy assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total direct research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Indirect research and development expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Personnel-related (including share-based compensation)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Facility related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other indirect costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total indirect research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:2pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;In January 2025, we announced a strategic focus on developing a pipeline in I&amp;amp;I, and the deprioritization of our programs in infectious disease and oncology. The following programs were previously presented separately and have been grouped collectively as "Barinthus Legacy Assets" for both years presented: VTP-300 HBV, VTP-850 Prostate Cancer, VTP-200 HPV, VTP-600 NSCLC, VTP-500 MERS and other and earlier stage programs. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <brns:DirectResearchAndDevelopmentExpense contextRef="c-63" decimals="-3" id="f-403" unitRef="usd">6063000</brns:DirectResearchAndDevelopmentExpense>
    <brns:DirectResearchAndDevelopmentExpense contextRef="c-64" decimals="-3" id="f-404" unitRef="usd">5486000</brns:DirectResearchAndDevelopmentExpense>
    <brns:DirectResearchAndDevelopmentExpense contextRef="c-65" decimals="-3" id="f-405" unitRef="usd">8531000</brns:DirectResearchAndDevelopmentExpense>
    <brns:DirectResearchAndDevelopmentExpense contextRef="c-66" decimals="-3" id="f-406" unitRef="usd">18223000</brns:DirectResearchAndDevelopmentExpense>
    <brns:DirectResearchAndDevelopmentExpense contextRef="c-67" decimals="-3" id="f-407" unitRef="usd">14594000</brns:DirectResearchAndDevelopmentExpense>
    <brns:DirectResearchAndDevelopmentExpense contextRef="c-68" decimals="-3" id="f-408" unitRef="usd">23709000</brns:DirectResearchAndDevelopmentExpense>
    <brns:IndirectResearchAndDevelopmentExpense contextRef="c-69" decimals="-3" id="f-409" unitRef="usd">8413000</brns:IndirectResearchAndDevelopmentExpense>
    <brns:IndirectResearchAndDevelopmentExpense contextRef="c-70" decimals="-3" id="f-410" unitRef="usd">15867000</brns:IndirectResearchAndDevelopmentExpense>
    <brns:IndirectResearchAndDevelopmentExpense contextRef="c-71" decimals="-3" id="f-411" unitRef="usd">1370000</brns:IndirectResearchAndDevelopmentExpense>
    <brns:IndirectResearchAndDevelopmentExpense contextRef="c-72" decimals="-3" id="f-412" unitRef="usd">1249000</brns:IndirectResearchAndDevelopmentExpense>
    <brns:IndirectResearchAndDevelopmentExpense contextRef="c-73" decimals="-3" id="f-413" unitRef="usd">1187000</brns:IndirectResearchAndDevelopmentExpense>
    <brns:IndirectResearchAndDevelopmentExpense contextRef="c-74" decimals="-3" id="f-414" unitRef="usd">1411000</brns:IndirectResearchAndDevelopmentExpense>
    <brns:IndirectResearchAndDevelopmentExpense contextRef="c-67" decimals="-3" id="f-415" unitRef="usd">10970000</brns:IndirectResearchAndDevelopmentExpense>
    <brns:IndirectResearchAndDevelopmentExpense contextRef="c-68" decimals="-3" id="f-416" unitRef="usd">18527000</brns:IndirectResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-67" decimals="-3" id="f-417" unitRef="usd">25564000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-68" decimals="-3" id="f-418" unitRef="usd">42236000</us-gaap:ResearchAndDevelopmentExpense>
    <brns:NumberOfGeographicRegionsInWhichEntityOperates contextRef="c-8" decimals="INF" id="f-419" unitRef="region">2</brns:NumberOfGeographicRegionsInWhichEntityOperates>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock contextRef="c-1" id="f-420">The following table summarizes the Company&#x2019;s long-lived assets, which include the Company&#x2019;s intangible assets, property and equipment, net and right-of-use assets by geography:&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.659%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United Kingdom&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;33,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:NoncurrentAssets contextRef="c-75" decimals="-3" id="f-421" unitRef="usd">19449000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-76" decimals="-3" id="f-422" unitRef="usd">28907000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-77" decimals="-3" id="f-423" unitRef="usd">0</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-78" decimals="-3" id="f-424" unitRef="usd">4797000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-8" decimals="-3" id="f-425" unitRef="usd">19449000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-9" decimals="-3" id="f-426" unitRef="usd">33704000</us-gaap:NoncurrentAssets>
    <us-gaap:ForeignCurrencyDisclosureTextBlock contextRef="c-1" id="f-428">Foreign Currency Translation in General and Administrative Expenses&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The aggregate, net foreign exchange gain or loss recognized in general and administrative expenses for the year ended December&#160;31, 2025, and 2024, was a loss of $9.6&#160;million and a gain of $2.4&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyDisclosureTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-1" decimals="-5" id="f-429" unitRef="usd">-9600000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-12" decimals="-5" id="f-430" unitRef="usd">2400000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-431">Net Loss Per Share&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table sets forth the computation of basic and diluted net loss per share for the years ended December&#160;31, 2025 and 2024 (in thousands, except number of shares and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(66,458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(61,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net loss attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net loss attributable to Barinthus Biotherapeutics plc shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(66,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(61,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average ordinary shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,527,218&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39,348,240&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average ordinary shares outstanding, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,527,218&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39,348,240&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net loss per share attributable to ordinary shareholders, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net loss per share attributable to ordinary shareholders, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential ordinary share equivalents outstanding would have been anti-dilutive. For the year ended December&#160;31, 2025, 5,976,157 (December&#160;31, 2024: 7,285,275) potential ordinary shares issuable for stock options were excluded from the computation of diluted weighted-average shares outstanding because including them would have had an anti-dilutive effect.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-432">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table sets forth the computation of basic and diluted net loss per share for the years ended December&#160;31, 2025 and 2024 (in thousands, except number of shares and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(66,458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(61,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net loss attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net loss attributable to Barinthus Biotherapeutics plc shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(66,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(61,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average ordinary shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,527,218&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39,348,240&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average ordinary shares outstanding, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,527,218&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39,348,240&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net loss per share attributable to ordinary shareholders, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net loss per share attributable to ordinary shareholders, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-433" unitRef="usd">-66458000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-12" decimals="-3" id="f-434" unitRef="usd">-61183000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-435" unitRef="usd">-30000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-436" unitRef="usd">-109000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-437" unitRef="usd">-66428000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-438" unitRef="usd">-61074000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-439" unitRef="shares">40527218</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-12" decimals="0" id="f-440" unitRef="shares">39348240</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-441" unitRef="shares">40527218</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-12" decimals="0" id="f-442" unitRef="shares">39348240</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-443"
      unitRef="usdPerShare">-1.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-12"
      decimals="2"
      id="f-444"
      unitRef="usdPerShare">-1.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-445"
      unitRef="usdPerShare">-1.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-12"
      decimals="2"
      id="f-446"
      unitRef="usdPerShare">-1.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-447" unitRef="shares">5976157</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-12" decimals="0" id="f-448" unitRef="shares">7285275</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-449">Property and Equipment, Net&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment, net consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: accumulated depreciation and impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depreciation expense for the year ended December&#160;31, 2025 was $2.9 million (December&#160;31, 2024: $2.6 million).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2025 and 2024, the Company recorded a gain of $0.2 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and nil, respectively, from the sale of U.K. laboratory equipment. The recorded associated proceeds from the equipment sale for the year ended December&#160;31, 2025 and 2024 was $0.5 million and nil, respectively).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company identified circumstances that could indicate that the carrying amount of leasehold improvements located in the U.S. and the U.S. operating lease right-of-use asset may not be recoverable as of December 31, 2025, as it was more likely than not that the Company would cease to utilize some of the laboratory and office space in Germantown, Maryland in 2026, before the end of the previously estimated useful lives. The Company performed an impairment assessment of the leasehold improvements within the U.S. asset group using the income approach as of December 31, 2025 and recorded an impairment charge within general and administrative expenses of $0.7 million (December 31, 2024: U.K. property and equipment impairment $2.7 million) to write down assets to their estimated recoverable amount. The impairment charge is subject to a number of assumptions and actual results may differ. The Company will continue to refine these assumptions as additional information becomes available. The significant assumptions used in determining the estimated fair value of the leasehold improvements located in the U.S. included how much floor space would be relinquished during sub-leasing. Significant changes in these inputs could have a material effect on the fair value measurement. See Note 16 Commitments and Contingencies for details of the impairment assessment performed over the U.S. operating lease right-of-use asset, which is part of the U.S. asset group.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-60" decimals="-3" id="f-450" unitRef="usd">452000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-79" decimals="-3" id="f-451" unitRef="usd">1333000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-61" decimals="-3" id="f-452" unitRef="usd">1752000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-80" decimals="-3" id="f-453" unitRef="usd">6178000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-81" decimals="-3" id="f-454" unitRef="usd">8910000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-82" decimals="-3" id="f-455" unitRef="usd">9282000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-8" decimals="-3" id="f-456" unitRef="usd">11114000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-9" decimals="-3" id="f-457" unitRef="usd">16793000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-8" decimals="-3" id="f-458" unitRef="usd">7591000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-9" decimals="-3" id="f-459" unitRef="usd">9420000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-8" decimals="-3" id="f-460" unitRef="usd">3523000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-9" decimals="-3" id="f-461" unitRef="usd">7373000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-462" unitRef="usd">2900000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-12" decimals="-5" id="f-463" unitRef="usd">2600000</us-gaap:Depreciation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-5" id="f-464" unitRef="usd">200000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-12" decimals="INF" id="f-465" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-466" unitRef="usd">500000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-12" decimals="INF" id="f-467" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="c-1" decimals="-5" id="f-468" unitRef="usd">700000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="c-12" decimals="-5" id="f-469" unitRef="usd">2700000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-470">Intangible Assets, Net&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The gross amount of amortizable intangible assets, consisting of acquired developed technology, was $31.6 million at both December&#160;31, 2025 and 2024 and accumulated amortization was $17.3 million and $9.7 million as of December&#160;31, 2025 and 2024, respectively. The amortization expense for the year ended December&#160;31, 2025 was $3.0 million (December&#160;31, 2024: $3.2 million). The estimated annual amortization expense is $2.5 million for the years 2026 through to 2031.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the quarter ended September 30, 2025, the Company announced it had entered into a definitive merger agreement to combine in an all-stock transaction with Clywedog. The indicative offer price was below fair value of the Company's net assets expected at completion and below prior valuations utilized in our most recent impairment assessments, thereby constituting an impairment triggering event. As a result, the Company recorded a total impairment charge for acquired development technology intangible assets of $4.7 million during the third quarter of 2025. The determination of the fair value of the Company's net assets expected at completion is a non-recurring fair value measurement. Subsequently, we reviewed through to December 31, 2025, for additional indicators of impairment and did not identify any additional impairment triggers nor was any additional impairment expense recorded.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-62" decimals="-5" id="f-471" unitRef="usd">31600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-83" decimals="-5" id="f-472" unitRef="usd">31600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-62" decimals="-5" id="f-473" unitRef="usd">17300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-83" decimals="-5" id="f-474" unitRef="usd">9700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-475" unitRef="usd">3000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-12" decimals="-5" id="f-476" unitRef="usd">3200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-8" decimals="-5" id="f-477" unitRef="usd">2500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-8" decimals="-5" id="f-478" unitRef="usd">2500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-8" decimals="-5" id="f-479" unitRef="usd">2500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-8" decimals="-5" id="f-480" unitRef="usd">2500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-8" decimals="-5" id="f-481" unitRef="usd">2500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <brns:FiniteLivedIntangibleAssetExpectedAmortizationYearSix contextRef="c-8" decimals="-5" id="f-482" unitRef="usd">2500000</brns:FiniteLivedIntangibleAssetExpectedAmortizationYearSix>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-84" decimals="-5" id="f-483" unitRef="usd">4700000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <brns:PrepaidExpenseAndOtherAssetsCurrentTextBlock contextRef="c-1" id="f-484">Prepaid and Other Current Assets&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Value Added Tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</brns:PrepaidExpenseAndOtherAssetsCurrentTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c-1" id="f-485">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Value Added Tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-8" decimals="-3" id="f-486" unitRef="usd">4518000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-9" decimals="-3" id="f-487" unitRef="usd">5859000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent contextRef="c-8" decimals="-3" id="f-488" unitRef="usd">197000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent contextRef="c-9" decimals="-3" id="f-489" unitRef="usd">0</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-8" decimals="-3" id="f-490" unitRef="usd">115000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-9" decimals="-3" id="f-491" unitRef="usd">344000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-8" decimals="-3" id="f-492" unitRef="usd">4830000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-9" decimals="-3" id="f-493" unitRef="usd">6203000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock contextRef="c-1" id="f-494">Accrued Expenses and Other Current Liabilities&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued manufacturing and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Value Added Tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued bonus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock>
    <brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-495">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued manufacturing and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Value Added Tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued bonus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock>
    <brns:AccruedManufacturingAndClinicalExpensesCurrent contextRef="c-8" decimals="-3" id="f-496" unitRef="usd">1786000</brns:AccruedManufacturingAndClinicalExpensesCurrent>
    <brns:AccruedManufacturingAndClinicalExpensesCurrent contextRef="c-9" decimals="-3" id="f-497" unitRef="usd">3326000</brns:AccruedManufacturingAndClinicalExpensesCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent contextRef="c-8" decimals="-3" id="f-498" unitRef="usd">0</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent contextRef="c-9" decimals="-3" id="f-499" unitRef="usd">2416000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:AccruedBonusesCurrent contextRef="c-8" decimals="-3" id="f-500" unitRef="usd">0</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent contextRef="c-9" decimals="-3" id="f-501" unitRef="usd">1774000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c-8" decimals="-3" id="f-502" unitRef="usd">245000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c-9" decimals="-3" id="f-503" unitRef="usd">656000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-8" decimals="-3" id="f-504" unitRef="usd">3677000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-9" decimals="-3" id="f-505" unitRef="usd">737000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-506" unitRef="usd">541000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-9" decimals="-3" id="f-507" unitRef="usd">616000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-508" unitRef="usd">6249000</brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="c-9" decimals="-3" id="f-509" unitRef="usd">9525000</brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:OtherOperatingIncomeAndExpenseTextBlock contextRef="c-1" id="f-510">Grant Income&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Coalition for Epidemic Preparedness Innovations (&#x201c;CEPI&#x201d;) Funding Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On December 20, 2023, Barinthus Biotherapeutics (UK) Limited, the Chancellors, Masters and Scholars of the University of Oxford (&#x201c;Oxford,&#x201d; together with Barinthus Biotherapeutics (UK) Limited, the &#x201c;Partners&#x201d;) and the Coalition for Epidemic Preparedness Innovations (&#x201c;CEPI&#x201d;) entered into a Funding Agreement (the &#x201c;Funding Agreement&#x201d;) pursuant to which CEPI would provide funding of up to $34.8 million to the Company to advance the development of VTP-500, a vaccine candidate against Middle East Respiratory Syndrome (&#x201c;MERS,&#x201d; and such development activities, the &#x201c;Project&#x201d;). In December 2023, VTP-500 received PRIME (PRIority MEdicines) designation by the European Medicines Agency. There have been no changes to the terms or conditions of the grant since the previous reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2025, the Company announced its strategic focus on developing a pipeline in I&amp;amp;I, and the deprioritization of its programs in infectious disease and oncology. The Company intends to exit the Funding Agreement as part of aligning resources in accordance with the Company's strategy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the year ended December&#160;31, 2025, nil (December 31, 2024: $3.0&#160;million) proceeds have been received. For the year ended December 31, 2025 $0.4&#160;million (December 31,2024: $1.2&#160;million ) income has been recognized in relation to this contract. This is presented as other operating income in the consolidated statements of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Funding Agreement cash payments are restricted as to the use and management of the funds. The remaining unused amounts of the Funding Agreement cash payments of $1.4 million as of December&#160;31, 2025 (December&#160;31, 2024: $1.7 million), are reflected in restricted cash in the consolidated balance sheets until expenditures contemplated in the Funding Agreement are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Deferred income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred income relates to payments received from CEPI in advance of the eligible research and development expenses being incurred and is disclosed as deferred income separately in the consolidated balance sheets. Deferred income is released to the consolidated statements of operations and comprehensive loss in the period in which such research and development activities are actually performed in a manner that satisfies the conditions of the Funding Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in deferred income during the years ended December&#160;31, 2025 and 2024, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.807%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.143%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other operating income recognized related to the Funding Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign exchange translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherOperatingIncomeAndExpenseTextBlock>
    <brns:FundingAmountMaximum contextRef="c-85" decimals="-5" id="f-511" unitRef="usd">34800000</brns:FundingAmountMaximum>
    <us-gaap:DeferredIncomeAddition contextRef="c-86" decimals="-5" id="f-512" unitRef="usd">0</us-gaap:DeferredIncomeAddition>
    <us-gaap:DeferredIncomeAddition contextRef="c-87" decimals="-5" id="f-513" unitRef="usd">3000000.0</us-gaap:DeferredIncomeAddition>
    <us-gaap:DeferredIncomeRevenueRecognized contextRef="c-86" decimals="-5" id="f-514" unitRef="usd">400000</us-gaap:DeferredIncomeRevenueRecognized>
    <us-gaap:DeferredIncomeRevenueRecognized contextRef="c-87" decimals="-5" id="f-515" unitRef="usd">1200000</us-gaap:DeferredIncomeRevenueRecognized>
    <us-gaap:RestrictedCashCurrent contextRef="c-88" decimals="-5" id="f-516" unitRef="usd">1400000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-89" decimals="-5" id="f-517" unitRef="usd">1700000</us-gaap:RestrictedCashCurrent>
    <us-gaap:DeferredIncomeTableTextBlock contextRef="c-1" id="f-518">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in deferred income during the years ended December&#160;31, 2025 and 2024, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.807%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.143%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other operating income recognized related to the Funding Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign exchange translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredIncomeTableTextBlock>
    <us-gaap:DeferredIncome contextRef="c-9" decimals="-3" id="f-519" unitRef="usd">1738000</us-gaap:DeferredIncome>
    <us-gaap:DeferredIncome contextRef="c-40" decimals="-3" id="f-520" unitRef="usd">0</us-gaap:DeferredIncome>
    <us-gaap:DeferredIncomeAddition contextRef="c-1" decimals="-3" id="f-521" unitRef="usd">0</us-gaap:DeferredIncomeAddition>
    <us-gaap:DeferredIncomeAddition contextRef="c-12" decimals="-3" id="f-522" unitRef="usd">2989000</us-gaap:DeferredIncomeAddition>
    <us-gaap:DeferredIncomeRevenueRecognized contextRef="c-1" decimals="-3" id="f-523" unitRef="usd">435000</us-gaap:DeferredIncomeRevenueRecognized>
    <us-gaap:DeferredIncomeRevenueRecognized contextRef="c-12" decimals="-3" id="f-524" unitRef="usd">1176000</us-gaap:DeferredIncomeRevenueRecognized>
    <brns:DeferredIncomeForeignExchangeTranslationGainLoss contextRef="c-1" decimals="-3" id="f-525" unitRef="usd">-93000</brns:DeferredIncomeForeignExchangeTranslationGainLoss>
    <brns:DeferredIncomeForeignExchangeTranslationGainLoss contextRef="c-12" decimals="-3" id="f-526" unitRef="usd">75000</brns:DeferredIncomeForeignExchangeTranslationGainLoss>
    <us-gaap:DeferredIncome contextRef="c-8" decimals="-3" id="f-527" unitRef="usd">1396000</us-gaap:DeferredIncome>
    <us-gaap:DeferredIncome contextRef="c-9" decimals="-3" id="f-528" unitRef="usd">1738000</us-gaap:DeferredIncome>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-529">Ordinary Shares&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;All ordinary shares rank pari passu as a single class. The following is a summary of the rights and privileges of the holders of ordinary shares as of December&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Liquidation preference:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; In the event of the liquidation, dissolution or winding up of the Company, the assets of the Company available for distribution to holders of the ordinary shares shall be distributed amongst all holders of the ordinary shares in proportion to the number of shares held irrespective of the amount paid or credited as paid on any share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Dividends:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Company may, subject to the provisions of the Companies Act 2006 and its Articles, by ordinary resolution from time to time declare dividends to be paid to shareholders not exceeding the amount recommended by the Company&#x2019;s board of directors. Subject to the provisions of the Companies Act 2006, insofar as, in the board of directors&#x2019; opinions, the Company&#x2019;s profits justify such payments, the board of directors (the "Board") may pay interim dividends on the Company&#x2019;s ordinary shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Voting Rights:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Each holder of ordinary shares has the right to receive notice of, and to vote at, the Company&#x2019;s general meetings. Each holder of ordinary shares who is present (in person or by proxy) at a general meeting on a show of hands has one vote and, on a poll, every such holder who is present (in person or by proxy) has one vote in respect of for each share of which they are the holder.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Preemption rights:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Pursuant to section 561 of the Companies Act 2006, shareholders are granted preemptive rights when new shares are issued for cash. However, it is possible under the Articles, for shareholders at a general meeting representing at least 75% of the Company's ordinary shares present (in person or by proxy) and eligible to vote at that general meeting, to disapply these preemptive rights by passing a special resolution. Such a disapplication of preemption rights may be for a maximum period of up to five years from the date on which the shareholder resolution was passed. In either case, this disapplication would need to be renewed by the Company's shareholders upon its expiration (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;i.e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, at least every five years) to remain effective.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On April&#160;21, 2021, the Company's shareholders approved the disapplication of preemptive rights for a period of five years from the date of approval by way of a special resolution of shareholders. This included the disapplication of preemption rights in relation to the allotment of the Company's ordinary shares in connection with the initial public offering ("IPO"). This disapplication will need to be renewed upon expiration (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;i.e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, at least every five years) to remain effective, but may be sought more frequently for additional five-year terms (or any shorter period).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On November 6, 2023, the Company held a general meeting where its shareholders approved resolutions granting the Board or any duly authorized committee of the Board the authority to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company free from pre-emption rights. Pursuant to such approval, the Board was authorized to allot shares up to an aggregate nominal amount of &#xa3;1,928 free from statutory pre-emption rights. The granting of this authority and the corresponding disapplication of preemptive rights was in addition to all subsisting authorities. This disapplication will need to be renewed upon expiration (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;i.e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, at least every five years) to remain effective, but may be sought more frequently for additional five-year terms (or any shorter period).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2025, the Company has reserved the following ordinary shares for future issuance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,976,157&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shares available for future stock incentive plan awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,248,605&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,224,762&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <brns:CommonStockNumberOfVotesPerShare contextRef="c-8" decimals="INF" id="f-530" unitRef="vote">1</brns:CommonStockNumberOfVotesPerShare>
    <brns:CommonStockNumberOfVotesPerShare contextRef="c-8" decimals="INF" id="f-531" unitRef="vote">1</brns:CommonStockNumberOfVotesPerShare>
    <brns:PercentageOfSharesNecessaryToExercisePreemptiveRights contextRef="c-8" decimals="2" id="f-532" unitRef="number">0.75</brns:PercentageOfSharesNecessaryToExercisePreemptiveRights>
    <brns:PeriodOfPreemptiveRightsToBeExercised contextRef="c-1" id="f-533">P5Y</brns:PeriodOfPreemptiveRightsToBeExercised>
    <brns:PeriodOfPreemptiveRightsToBeExercised contextRef="c-90" id="f-534">P5Y</brns:PeriodOfPreemptiveRightsToBeExercised>
    <brns:PeriodOfPreemptiveRightsToBeExercised contextRef="c-91" id="f-535">P5Y</brns:PeriodOfPreemptiveRightsToBeExercised>
    <brns:PeriodOfPreemptiveRightsToBeExercised contextRef="c-91" id="f-536">P5Y</brns:PeriodOfPreemptiveRightsToBeExercised>
    <brns:PeriodOfPreemptiveRightsToBeExercised contextRef="c-91" id="f-537">P5Y</brns:PeriodOfPreemptiveRightsToBeExercised>
    <brns:MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights contextRef="c-92" decimals="0" id="f-538" unitRef="gbp">1928</brns:MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights>
    <brns:PeriodOfPreemptiveRightsToBeExercised contextRef="c-93" id="f-539">P5Y</brns:PeriodOfPreemptiveRightsToBeExercised>
    <brns:PeriodOfPreemptiveRightsToBeExercised contextRef="c-93" id="f-540">P5Y</brns:PeriodOfPreemptiveRightsToBeExercised>
    <brns:ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock contextRef="c-1" id="f-541">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2025, the Company has reserved the following ordinary shares for future issuance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,976,157&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shares available for future stock incentive plan awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,248,605&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,224,762&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</brns:ScheduleOfOrdinarySharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-8" decimals="INF" id="f-542" unitRef="shares">5976157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="c-8" decimals="INF" id="f-543" unitRef="shares">3248605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-8" decimals="INF" id="f-544" unitRef="shares">9224762</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <brns:StockholdersEquityDeferredSharesDisclosureTextBlock contextRef="c-1" id="f-545">Deferred Shares&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;All deferred shares rank pari passu as a single class. The deferred shares do not have rights to dividends or to any other rights of participation in the profits of the Company. On a return of assets on liquidation, the deferred shares confer on the holders thereof an entitlement to receive out of the assets of the Company available for distribution amongst the shareholders (subject to the rights of any new class of shares with preferred rights) the amount credited as paid up on the deferred shares held by them respectively after (but only after) payment shall have been made to the holders of the ordinary shares of the amounts paid up or credited as paid up on such shares and the sum of &#xa3;1.0 million in respect of each ordinary share held by them respectively. The deferred shares shall confer on the holders thereof no further right to participate in the assets of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s deferred A shares with a nominal value of &#xa3;1.00 each remain in issue for the purposes of satisfying the minimum share capital requirements for a public limited company as prescribed by the Companies Act 2006.&lt;/span&gt;&lt;/div&gt;</brns:StockholdersEquityDeferredSharesDisclosureTextBlock>
    <brns:OrdinarySharesLiquidationPreference contextRef="c-8" decimals="-5" id="f-546" unitRef="gbp">1000000.0</brns:OrdinarySharesLiquidationPreference>
    <brns:DeferredStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-547"
      unitRef="gbpPerShare">1.00</brns:DeferredStockParOrStatedValuePerShare>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-548">Fair Value&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s financial instruments consist of cash, cash equivalents and restricted cash, accounts payable, certain accrued expenses, and contingent consideration. The carrying amounts of cash, cash equivalents and restricted cash, accounts payable, and accrued expenses approximated their respective fair value due to the short-term nature and maturity of these instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2025, the Company had a contingent consideration liability of $2.9 million related to the acquisition of Avidea. Avidea&#x2019;s stockholders may be entitled to receive an aggregate of up to $40.0 million in additional payments, payable in a combination of cash and American Depositary Shares, upon the achievement of certain milestones. To date, the Company has made settlement payments of $0.5 million. The fair value of the contingent consideration is a Level 3 valuation and determined using the cost approach. The significant unobservable inputs used in the fair value measurement of the contingent consideration are the probability of success of achievement of the milestones and the expected date of the milestone achievement. Significant judgment is employed in determining the appropriateness of certain of these inputs. Significant increases (decreases) in the probability of success of achievement of the milestones would have resulted in a significantly higher (lower) fair value measurement. Significant extension (reduction) in the expected date of the milestone achievement would have resulted in a significantly lower (higher) fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes changes to the Company's financial instruments carried at fair value and classified within Level 3 of the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Change in fair value recognized in net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:f-557"&gt;&lt;span style="-sec-ix-hidden:f-558"&gt;Foreign exchange translation recognized in other comprehensive loss&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-94" decimals="-5" id="f-549" unitRef="usd">2900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="c-94" decimals="-5" id="f-550" unitRef="usd">40000000.0</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-95" decimals="-5" id="f-551" unitRef="usd">500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-552">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes changes to the Company's financial instruments carried at fair value and classified within Level 3 of the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Change in fair value recognized in net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:f-557"&gt;&lt;span style="-sec-ix-hidden:f-558"&gt;Foreign exchange translation recognized in other comprehensive loss&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-9" decimals="-3" id="f-553" unitRef="usd">2650000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-40" decimals="-3" id="f-554" unitRef="usd">1823000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-1" decimals="-3" id="f-555" unitRef="usd">-26000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-12" decimals="-3" id="f-556" unitRef="usd">-866000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome contextRef="c-1" decimals="-3" id="f-559" unitRef="usd">-195000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome contextRef="c-12" decimals="-3" id="f-560" unitRef="usd">39000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-8" decimals="-3" id="f-561" unitRef="usd">2871000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-9" decimals="-3" id="f-562" unitRef="usd">2650000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-563">Share-Based Compensation&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On April&#160;8, 2021, the Board of the Company adopted the Barinthus Biotherapeutics plc Share Award Plan 2021 (&#x201c;the Plan&#x201d;) and the Barinthus Biotherapeutics plc Non-Employee Sub-Plan which is a sub-plan of the Plan. Under the terms of the Plan, the Board is permitted to grant awards to employees as restricted share units, options, share appreciation rights and restricted shares. The aggregate number of shares initially available for issuance under the Plan and the Barinthus Biotherapeutics plc Non-Employee Sub-Plan cannot exceed 3,675,680 ordinary shares (the &#x201c;Initial Limit&#x201d;). Beginning calendar year 2022, the total number of ordinary shares available for issuance under the Plan shall be increased on January 1 of each year in an amount equal to the lesser of (i) 4% of the Company&#x2019;s issued and outstanding ordinary shares (which 4% limit shall be measured as of January 1 of such year) and (ii) such number of ordinary shares as determined by the Compensation Committee of the Board in its discretion (the &#x201c;Annual Increase&#x201d;). In accordance with the terms of the Annual Increase, the total number of ordinary shares available for issuance under the Plan increased by 1,609,386 as of January 1, 2025. The awards generally vest based on the grantee&#x2019;s continued service with the Company during a specified period following grant as determined by the Board and generally expire ten years from the grant date. Option awards generally vest over three years, but vesting conditions can vary at the discretion of the Company&#x2019;s Board. As of December&#160;31, 2025 and 2024, 3,248,605 and 1,906,080 ordinary shares are available for future grants, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In 2018, the Company&#x2019;s board of directors adopted the Enterprise Management Incentive Share Option Scheme (the &#x201c;EMI Plan&#x201d;) which provided for the grant of incentive stock options and nonqualified stock options to non-director employees of the Company. The Company also has a nonqualified stock option plan for officers and directors. The awards generally vest based on the grantee&#x2019;s continued service with the Company during a specified period following grant as determined by the board of directors and generally expire ten years from the grant date. Option awards generally vest over three years, but vesting conditions can vary at the discretion of the Company&#x2019;s board of directors. A total of 3,530,634 ordinary shares were reserved for issuance in accordance with the provisions of the EMI Plan and restricted stock unit (&#x201c;RSUs&#x201d;) plan. Upon adoption of the Plan, no further awards are to be made under the EMI Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of each stock option issued to employees was estimated at the date of grant using Black-Scholes with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;114.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;108.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Expected volatility: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Previously there was insufficient trading history for the Company&#x2019;s ordinary shares, therefore the expected price volatility for our ordinary shares was estimated using the average historical volatility of industry peers&#x2019; shares as of the grant date of our options over a period of history commensurate with the expected life of the options. When selecting industry peers used in measuring implied volatility, the Company considered the similarity of their products and business lines, as well as their stage of development, size and financial leverage. The Company applied this process consistently using the same or similar public companies until 2023. For options granted in and after 2023, the Company determined that there is sufficient historical information on volatility of its share price available and the expected volatility used in the fair value calculation of new option grants is calculated based on a blended volatility of both historical volatility of the Company's share price and the expected volatility of the average historical volatility of industry peers&#x2019; shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Expected term (years): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected term represents the period that the Company&#x2019;s option grants are expected to be outstanding. There is not sufficient historical share exercise data to calculate the expected term of the stock options. Therefore, the Company elected to utilize the simplified method to value option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Risk-free interest rate: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company determined the risk-free interest rate by using a weighted-average equivalent to the expected term based on the daily U.S. Treasury yield curve rate in effect as of the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Expected dividend yield:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Company does not anticipate paying any dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of stock option activity is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Number of&lt;br/&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Exercise&lt;br/&gt;Price Per&lt;br/&gt;Option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Weighted-&lt;br/&gt;average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Aggregate &lt;br/&gt;Intrinsic Value &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding, January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,285,275&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,470,812&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(614,230)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.00010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited/expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,165,700)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding, December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,976,157&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercisable, December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,351,787&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The weighted-average grant date per-share fair value of stock options granted during the year ended December&#160;31, 2025 was $0.85 per share (December&#160;31, 2024: $2.66 per share). The aggregate intrinsic value of stock options exercised during the year ended December&#160;31, 2025 was $0.2 million (December&#160;31, 2024: $0.4 million). As of December&#160;31, 2025, there was $0.6 million (2024: $3.1 million) of unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted-average period of 1.42 years (2024: 1.46 years).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Restricted stock units:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the Company's restricted stock units ('RSUs") under the Plan since December 31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Number of Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Underlying RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Unvested, January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;886,018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested and settled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested and deferred&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(21,294)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Unvested outstanding, December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;864,724&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested but subject to deferred settlement at December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;864,724&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2025, the Company granted an aggregate of 886,018 restricted stock units (&#x201c;RSUs&#x201d;) to employees under the Plan. The RSUs will vest in full on the &lt;span style="-sec-ix-hidden:f-629"&gt;seven&lt;/span&gt;th day following the occurrence of either the closing of the Contemplated Transactions or the termination of the Merger Agreement pursuant to its terms, subject to the employee&#x2019;s continued employment with the Company through such vesting date, and were granted as part of the Company&#x2019;s equity incentive program to support employee retention and alignment with shareholder interests. The grant date fair value of the RSUs was $1.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total share-based compensation expense for RSUs granted for the years ended December&#160;31, 2025 and 2024 was $0.5 million and nil, respectively. As of December&#160;31, 2025, the total unrecognized compensation expense related to RSUs was $0.8 million, which is expected to be recognized over a weighted-average of 0.7 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Share based compensation expense is classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c-96"
      decimals="INF"
      id="f-564"
      unitRef="shares">3675680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <brns:ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares contextRef="c-96" decimals="2" id="f-565" unitRef="number">0.04</brns:ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares>
    <brns:ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares contextRef="c-96" decimals="2" id="f-566" unitRef="number">0.04</brns:ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-97"
      decimals="INF"
      id="f-567"
      unitRef="shares">1609386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <brns:ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance contextRef="c-96" id="f-568">P10Y</brns:ExpirationOfShareBasedCompensationPlanFromDateOfInitialIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-96" id="f-569">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-7" decimals="INF" id="f-570" unitRef="shares">3248605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-98"
      decimals="INF"
      id="f-571"
      unitRef="shares">1906080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-99" id="f-572">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-99" id="f-573">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-100"
      decimals="INF"
      id="f-574"
      unitRef="shares">3530634</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-575">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of each stock option issued to employees was estimated at the date of grant using Black-Scholes with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;114.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;108.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-101" decimals="4" id="f-576" unitRef="number">1.1407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-102" decimals="4" id="f-577" unitRef="number">1.0873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-101" id="f-578">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-102" id="f-579">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-101" decimals="3" id="f-580" unitRef="number">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-102" decimals="3" id="f-581" unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-101"
      decimals="INF"
      id="f-582"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-102"
      decimals="INF"
      id="f-583"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-584">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of stock option activity is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Number of&lt;br/&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Exercise&lt;br/&gt;Price Per&lt;br/&gt;Option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Weighted-&lt;br/&gt;average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Aggregate &lt;br/&gt;Intrinsic Value &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding, January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,285,275&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,470,812&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(614,230)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.00010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited/expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,165,700)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding, December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,976,157&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercisable, December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,351,787&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-9" decimals="INF" id="f-585" unitRef="shares">7285275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-9"
      decimals="2"
      id="f-586"
      unitRef="usdPerShare">5.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-12" id="f-587">P7Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-9" decimals="-3" id="f-588" unitRef="usd">942000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-589" unitRef="shares">1470812</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-590"
      unitRef="usdPerShare">1.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-591" unitRef="shares">614230</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="5"
      id="f-592"
      unitRef="usdPerShare">0.00010</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-593" unitRef="shares">2165700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-594"
      unitRef="usdPerShare">2.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-8" decimals="INF" id="f-595" unitRef="shares">5976157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-8"
      decimals="2"
      id="f-596"
      unitRef="usdPerShare">6.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-597">P2Y3M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-8" decimals="-3" id="f-598" unitRef="usd">37000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-8" decimals="INF" id="f-599" unitRef="shares">4351787</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-8"
      decimals="2"
      id="f-600"
      unitRef="usdPerShare">7.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-601">P1Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-8" decimals="-3" id="f-602" unitRef="usd">37000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-603"
      unitRef="usdPerShare">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-12"
      decimals="2"
      id="f-604"
      unitRef="usdPerShare">2.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-5" id="f-605" unitRef="usd">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-12" decimals="-5" id="f-606" unitRef="usd">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-8" decimals="-5" id="f-607" unitRef="usd">600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-9" decimals="-5" id="f-608" unitRef="usd">3100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-103" id="f-609">P1Y5M1D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-104" id="f-610">P1Y5M15D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-611">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the Company's restricted stock units ('RSUs") under the Plan since December 31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Number of Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Underlying RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Unvested, January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;886,018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested and settled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested and deferred&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(21,294)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Unvested outstanding, December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;864,724&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested but subject to deferred settlement at December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;864,724&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-105"
      decimals="INF"
      id="f-612"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-105"
      decimals="2"
      id="f-613"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-106"
      decimals="INF"
      id="f-614"
      unitRef="shares">886018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-106"
      decimals="2"
      id="f-615"
      unitRef="usdPerShare">1.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <brns:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod
      contextRef="c-106"
      decimals="INF"
      id="f-616"
      unitRef="shares">0</brns:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod>
    <brns:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-106"
      decimals="2"
      id="f-617"
      unitRef="usdPerShare">0</brns:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue>
    <brns:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod
      contextRef="c-106"
      decimals="INF"
      id="f-618"
      unitRef="shares">0</brns:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod>
    <brns:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-106"
      decimals="2"
      id="f-619"
      unitRef="usdPerShare">0</brns:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-106"
      decimals="INF"
      id="f-620"
      unitRef="shares">21294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-106"
      decimals="2"
      id="f-621"
      unitRef="usdPerShare">1.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-107"
      decimals="INF"
      id="f-622"
      unitRef="shares">864724</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-107"
      decimals="2"
      id="f-623"
      unitRef="usdPerShare">1.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <brns:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber
      contextRef="c-107"
      decimals="INF"
      id="f-624"
      unitRef="shares">0</brns:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber>
    <brns:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c-107"
      decimals="2"
      id="f-625"
      unitRef="usdPerShare">0</brns:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c-107"
      decimals="INF"
      id="f-626"
      unitRef="shares">864724</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <brns:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue
      contextRef="c-107"
      decimals="2"
      id="f-627"
      unitRef="usdPerShare">1.50</brns:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-108"
      decimals="INF"
      id="f-628"
      unitRef="shares">886018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-108" decimals="-5" id="f-630" unitRef="usd">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-106" decimals="-5" id="f-631" unitRef="usd">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-109" decimals="-5" id="f-632" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-107" decimals="-5" id="f-633" unitRef="usd">800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-106" id="f-634">P0Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c-1" id="f-635">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Share based compensation expense is classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-110" decimals="-3" id="f-636" unitRef="usd">133000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-111" decimals="-3" id="f-637" unitRef="usd">1680000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-112" decimals="-3" id="f-638" unitRef="usd">335000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-113" decimals="-3" id="f-639" unitRef="usd">3029000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-640" unitRef="usd">468000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-12" decimals="-3" id="f-641" unitRef="usd">4709000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-642">Income Taxes&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loss before income before income taxes are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(42,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(27,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(24,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(32,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(884)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(66,633)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(61,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The components of income tax benefit are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current income tax benefit/(expense):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred income tax benefit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A reconciliation of the U.K. statutory income tax rate to the Company's effective tax rate as reflected in the consolidated financial statements is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.238%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Increase (decreases) resulting from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign tax effects-United States:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6.54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-taxable or non-deductible items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,505)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5.73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign tax effects-Switzerland:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Effect of change in tax laws or rates enacted in the current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5.72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-taxable or non-deductible items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3.75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has adopted ASU 2023-09 and evaluated all required categories and determined that no additional jurisdictional disaggregation or reconciling items were individually material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income and for tax carryforwards. Significant components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Share based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Intangible amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Capitalized Research and Development expenditure&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Gross deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(46,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(30,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Right-of-use lease asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Undistributed earnings of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(10,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total deferred tax, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Specified research and experimentation costs under Section 174 of the Internal Revenue Code are required to be capitalized and amortized ratably over five years for domestic expenditures and over 15 years for foreign expenditures. This provision of Section 174 became effective for tax years beginning after December 31, 2021. As a result of the capitalization of these costs in the current year, the Company has recorded a $4.8 million deferred tax asset (2024: $6.2 million). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2025, the Company had a valuation allowance of $46.3 million (2024: $30.8 million) against its deferred tax assets, which consisted principally of net operating loss and research and development credit carryforwards. The Company considered the positive and negative evidence bearing upon its ability to realize the deferred tax assets. In addition to the Company&#x2019;s history of cumulative losses, the Company cannot be certain that future taxable income will be sufficient to realize its deferred tax assets. Accordingly, a valuation allowance has been provided against its deferred tax assets. When the Company changes its determination as to the amount of its deferred tax assets that can be realized, the valuation allowance is adjusted with a corresponding impact to the provision for income taxes in the period in which such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2025 and 2024 related primarily to the increase in net operating loss and credit carryforwards, and were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Valuations allowance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Changes in valuation allowance arising from in-year additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign exchange translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(350)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Valuation allowance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2025, the Company had net operating loss ("NOL") carryforwards totaling approximately $160.4 million which have an unlimited carryforward period, of which $114.0 million originate in the U.K. As of December&#160;31, 2025, the Company had $0.3 million of research and development tax credit carryforwards which also have an unlimited carryforward period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2024, the Company had NOL carryforwards totaling approximately $101.7 million which have an unlimited carryforward period, of which $75.6 million originate in the U.K. As of December&#160;31, 2024, the Company had $0.1 million of research and development tax credit carryforwards which also have an unlimited carryforward period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2025 and 2024, the Company does not have any material unrecognized tax benefit liabilities. The Company files corporation/income tax returns in the U.K., the United States, Switzerland, Australia and Italy. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate. In the U.K., tax years from 2022 remain subject to examination by HMRC. In all other jurisdictions, the tax years since inception remain subject to examination by the applicable taxing authorities as of December&#160;31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-643">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loss before income before income taxes are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(42,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(27,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(24,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(32,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(884)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(66,633)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(61,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-644" unitRef="usd">-42544000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-12" decimals="-3" id="f-645" unitRef="usd">-27510000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-114" decimals="-3" id="f-646" unitRef="usd">-24053000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-115" decimals="-3" id="f-647" unitRef="usd">-32833000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-116" decimals="-3" id="f-648" unitRef="usd">-36000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-117" decimals="-3" id="f-649" unitRef="usd">-884000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-650" unitRef="usd">-66633000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-651" unitRef="usd">-61227000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-652">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The components of income tax benefit are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current income tax benefit/(expense):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred income tax benefit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-114" decimals="-3" id="f-653" unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-115" decimals="-3" id="f-654" unitRef="usd">70000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-116" decimals="-3" id="f-655" unitRef="usd">9000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-117" decimals="-3" id="f-656" unitRef="usd">22000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-114" decimals="-3" id="f-657" unitRef="usd">-184000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-115" decimals="-3" id="f-658" unitRef="usd">-136000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-659" unitRef="usd">-175000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-660" unitRef="usd">-44000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-661">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A reconciliation of the U.K. statutory income tax rate to the Company's effective tax rate as reflected in the consolidated financial statements is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.238%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Increase (decreases) resulting from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign tax effects-United States:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6.54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-taxable or non-deductible items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,505)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5.73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign tax effects-Switzerland:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Effect of change in tax laws or rates enacted in the current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5.72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-taxable or non-deductible items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3.75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-662" unitRef="usd">-16658000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="INF" id="f-663" unitRef="number">0.2500</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-12" decimals="-3" id="f-664" unitRef="usd">-15307000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-12"
      decimals="INF"
      id="f-665"
      unitRef="number">0.2500</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-114" decimals="-3" id="f-666" unitRef="usd">6122000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-114" decimals="4" id="f-667" unitRef="number">-0.0917</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-115" decimals="-3" id="f-668" unitRef="usd">4002000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-115" decimals="4" id="f-669" unitRef="number">-0.0654</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount contextRef="c-114" decimals="-3" id="f-670" unitRef="usd">118000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-114" decimals="4" id="f-671" unitRef="number">-0.0018</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount contextRef="c-115" decimals="-3" id="f-672" unitRef="usd">0</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-115" decimals="4" id="f-673" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c-114" decimals="-3" id="f-674" unitRef="usd">506000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-114" decimals="4" id="f-675" unitRef="number">-0.0076</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c-115" decimals="-3" id="f-676" unitRef="usd">3505000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-115" decimals="4" id="f-677" unitRef="number">-0.0573</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount contextRef="c-118" decimals="-3" id="f-678" unitRef="usd">2000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-118" decimals="4" id="f-679" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount contextRef="c-119" decimals="-3" id="f-680" unitRef="usd">30000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-119" decimals="4" id="f-681" unitRef="number">-0.0005</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-1" decimals="-3" id="f-682" unitRef="usd">-598000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c-1" decimals="4" id="f-683" unitRef="number">0.0090</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-12" decimals="-3" id="f-684" unitRef="usd">-721000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c-12" decimals="4" id="f-685" unitRef="number">0.0118</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <brns:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount contextRef="c-1" decimals="-3" id="f-686" unitRef="usd">81000</brns:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount>
    <brns:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment contextRef="c-1" decimals="4" id="f-687" unitRef="number">-0.0012</brns:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment>
    <brns:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount contextRef="c-12" decimals="-3" id="f-688" unitRef="usd">3501000</brns:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopmentAmount>
    <brns:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment contextRef="c-12" decimals="4" id="f-689" unitRef="number">-0.0572</brns:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-120" decimals="-3" id="f-690" unitRef="usd">7513000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-120" decimals="4" id="f-691" unitRef="number">-0.1127</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-121" decimals="-3" id="f-692" unitRef="usd">2116000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-121" decimals="4" id="f-693" unitRef="number">-0.0346</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c-120" decimals="-3" id="f-694" unitRef="usd">2496000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-120" decimals="4" id="f-695" unitRef="number">-0.0375</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c-121" decimals="-3" id="f-696" unitRef="usd">46000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-121" decimals="4" id="f-697" unitRef="number">-0.0006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-1" decimals="-3" id="f-698" unitRef="usd">243000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="4" id="f-699" unitRef="number">-0.0037</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-12" decimals="-3" id="f-700" unitRef="usd">2784000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-12" decimals="4" id="f-701" unitRef="number">-0.0455</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-702" unitRef="usd">-175000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="4" id="f-703" unitRef="number">0.0028</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-704" unitRef="usd">-44000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-12" decimals="4" id="f-705" unitRef="number">0.0007</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-706">Significant components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Share based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Intangible amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Capitalized Research and Development expenditure&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Gross deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(46,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(30,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Right-of-use lease asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Undistributed earnings of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(10,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total deferred tax, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-8" decimals="-3" id="f-707" unitRef="usd">40691000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-9" decimals="-3" id="f-708" unitRef="usd">26040000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-8" decimals="-3" id="f-709" unitRef="usd">313000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-9" decimals="-3" id="f-710" unitRef="usd">47000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-8" decimals="-3" id="f-711" unitRef="usd">4190000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-9" decimals="-3" id="f-712" unitRef="usd">4753000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <brns:DeferredTaxAssetsLeasingArrangements contextRef="c-8" decimals="-3" id="f-713" unitRef="usd">2965000</brns:DeferredTaxAssetsLeasingArrangements>
    <brns:DeferredTaxAssetsLeasingArrangements contextRef="c-9" decimals="-3" id="f-714" unitRef="usd">3156000</brns:DeferredTaxAssetsLeasingArrangements>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-8" decimals="-3" id="f-715" unitRef="usd">28000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-9" decimals="-3" id="f-716" unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-8" decimals="-3" id="f-717" unitRef="usd">459000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-9" decimals="-3" id="f-718" unitRef="usd">452000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-8" decimals="-3" id="f-719" unitRef="usd">4765000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-9" decimals="-3" id="f-720" unitRef="usd">6185000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-8" decimals="-3" id="f-721" unitRef="usd">62000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-9" decimals="-3" id="f-722" unitRef="usd">10000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-8" decimals="-3" id="f-723" unitRef="usd">53473000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-9" decimals="-3" id="f-724" unitRef="usd">40643000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-8" decimals="-3" id="f-725" unitRef="usd">46266000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-9" decimals="-3" id="f-726" unitRef="usd">30830000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-8" decimals="-3" id="f-727" unitRef="usd">7207000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-9" decimals="-3" id="f-728" unitRef="usd">9813000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-8" decimals="-3" id="f-729" unitRef="usd">1130000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-9" decimals="-3" id="f-730" unitRef="usd">1815000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-8" decimals="-3" id="f-731" unitRef="usd">1060000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-9" decimals="-3" id="f-732" unitRef="usd">1149000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings contextRef="c-8" decimals="-3" id="f-733" unitRef="usd">1339000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings contextRef="c-9" decimals="-3" id="f-734" unitRef="usd">1248000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-8" decimals="-3" id="f-735" unitRef="usd">3932000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-9" decimals="-3" id="f-736" unitRef="usd">6039000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-8" decimals="-3" id="f-737" unitRef="usd">7461000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-9" decimals="-3" id="f-738" unitRef="usd">10251000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-8" decimals="-3" id="f-739" unitRef="usd">254000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-9" decimals="-3" id="f-740" unitRef="usd">438000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-8" decimals="-5" id="f-741" unitRef="usd">4800000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-9" decimals="-5" id="f-742" unitRef="usd">6200000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-8" decimals="-5" id="f-743" unitRef="usd">46300000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-9" decimals="-5" id="f-744" unitRef="usd">30800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c-1" id="f-745">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2025 and 2024 related primarily to the increase in net operating loss and credit carryforwards, and were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year ended&lt;br/&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Valuations allowance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Changes in valuation allowance arising from in-year additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign exchange translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(350)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Valuation allowance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-9" decimals="-3" id="f-746" unitRef="usd">30830000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-40" decimals="-3" id="f-747" unitRef="usd">25057000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions contextRef="c-1" decimals="-3" id="f-748" unitRef="usd">0</brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions>
    <brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions contextRef="c-12" decimals="-3" id="f-749" unitRef="usd">0</brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions>
    <brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision contextRef="c-1" decimals="-3" id="f-750" unitRef="usd">13634000</brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision>
    <brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision contextRef="c-12" decimals="-3" id="f-751" unitRef="usd">6123000</brns:ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision>
    <brns:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation contextRef="c-1" decimals="-3" id="f-752" unitRef="usd">1802000</brns:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation>
    <brns:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation contextRef="c-12" decimals="-3" id="f-753" unitRef="usd">-350000</brns:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-8" decimals="-3" id="f-754" unitRef="usd">46266000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-9" decimals="-3" id="f-755" unitRef="usd">30830000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c-8" decimals="-5" id="f-756" unitRef="usd">160400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-122" decimals="-5" id="f-757" unitRef="usd">114000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-8" decimals="-5" id="f-758" unitRef="usd">300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-9" decimals="-5" id="f-759" unitRef="usd">101700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-123" decimals="-5" id="f-760" unitRef="usd">75600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-9" decimals="-5" id="f-761" unitRef="usd">100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-762">Commitments and Contingencies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;In-License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is party to a number of licensing agreements, most of which are with related parties. These agreements serve to provide the Company with the right to develop and exploit the counterparties&#x2019; intellectual property for certain medical indications. As part of execution of these arrangements, the Company paid certain upfront fees, which have been expensed as incurred because the developing technology has not yet reached technical feasibility, the lack of alternative use, and the lack of proof of potential value. The agreements cover a variety of fields, including influenza, cancer, HPV, HBV and MERS. The Company&#x2019;s obligations for future payments under these arrangements are dependent on its ability to develop promising drug candidates, the potential market for these candidates and potential competing products, and the payment mechanisms in place in countries where the Company retains the right to sell. Each agreement provides for specific milestone payments, typically triggered by achievement of certain testing phases in human candidates, and future royalties ranging from 1 to 5% for direct sales of a covered product to 3% to 7% of net payments received for allowable sublicenses of technology developed by the Company. The obligation to make these payments is contingent upon the Company&#x2019;s ability to develop candidates for submission for phased testing and approvals, and for the development of markets for the products developed by the Company. The Company has not made or accrued any material payments under these license agreements during the years ended December&#160;31, 2025, and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company leases certain laboratory and office space under operating leases, which are described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;The Harwell Science and Innovation Campus, Oxfordshire&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On September&#160;3, 2021, the Company entered into a lease agreement for the lease of approximately 31,000 square feet in Harwell, Oxfordshire, which expires in September 2031. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date, being the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The Company has provided the lessor with a refundable security deposit of $0.7 million which is included in Other assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In 2024, an impairment charge to write down the U.K. operating lease right-of-use asset to the estimated recoverable amount was recorded and the estimated useful life of the asset reduced. In August 2025, the Company ceased the research and development activities undertaken in the laboratory and transitioned the remaining clinical and operational workforce to remote roles. The U.K. operating lease right-of-use asset has a value of nil as of December&#160;31, 2025. The Company is actively marketing the building in Harwell, Oxfordshire, for the remainder of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Germantown, Maryland&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On June&#160;14, 2022, the Company entered into a lease agreement for the lease of approximately 19,700 square feet in Germantown, Maryland. The site houses the Company&#x2019;s state-of-the-art wet laboratory in the United States of America. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The lease expires on February 28, 2034, with the Company having a single right to extend for an additional five years on the same terms and conditions other than for the base rent. The Company had a rent-free period up to February 29, 2024 and was entitled to up to $3.5 million for leasehold improvements to the premises desired by the Company. The Company has provided the lessor with a refundable security deposit of $0.2 million which is included in Other assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recorded a right-of-use asset and a lease liability on the effective date of the lease term. The Company&#x2019;s right-of-use asset and lease liabilities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liability, non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Lease Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company identified circumstances that could indicate that the carrying amount of the U.S. operating lease right-of-use asset and the leasehold improvements located in the U.S. may not be recoverable as of December 31, 2025, as it was more likely than not that the Company would cease some of the operating activities undertaken in the laboratory and office space in Germantown, Maryland in 2026, before the end of the previously estimated useful lives. The Company performed an impairment assessment of the U.S. operating lease right-of-use asset, which is part of the U.S. asset group, using the income approach and recorded an impairment charge within general and administrative expenses of $0.4 million (December 31, 2024: U.K. impairment $2.6 million) to write down the asset to the estimated recoverable amount. The impairment charge is subject to a number of assumptions and actual results may differ. The Company will continue to refine these assumptions as additional information becomes available. The significant assumptions used in determining the estimated fair value of the U.S. operating lease right-of-use asset are the timing of successful sub-leasing of the Company's U.S. lease obligations and the value of any charges associated with sub-leasing the Company's U.S. lease obligations. Significant changes in these inputs could have a material effect on the fair value measurement. See Note 6 Property and Equipment, Net for details of the impairment assessment performed over the property and equipment within the U.S. asset group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Maturities of the Company&#x2019;s minimum lease liabilities as of December&#160;31, 2025 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Maturity of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-lease and other costs paid to the lessors are primarily related to services provided by the lessors in operating the premises that includes fees, operating costs, taxes, and insurance related to the leased premises.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Contemplated Transactions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 29, 2025, the Company entered into a merger agreement to combine with Clywedog, a private company advancing novel breakthrough medicines in diabetes. The Contemplated Transactions are expected to close in the second quarter of 2026, subject to customary closing conditions. In connection with this strategic combination, the Company may incur additional or contingent costs, including transaction-related legal and advisory fees, and other expenses. The Company accrued transaction-related legal and advisory fees in the amount of $2.8 million for the year ended December&#160;31, 2025 (December&#160;31, 2024: nil). Regardless of the outcome, there are anticipated additional costs and a focus of management resources on the strategic transaction which may or may not complete.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Other contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of the date of issuance of the audited financial statements included herein, the Company does not believe it is party to any claim or litigation the outcome of which, if determined adversely to it, would individually or in the aggregate be reasonably expected to have a material adverse effect on the Company's business. However, from time to time, the Company could be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. Regardless of the outcome, legal proceedings can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <brns:PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement contextRef="c-124" decimals="2" id="f-763" unitRef="number">0.01</brns:PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement>
    <brns:PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement contextRef="c-125" decimals="2" id="f-764" unitRef="number">0.05</brns:PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement>
    <brns:PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement contextRef="c-124" decimals="2" id="f-765" unitRef="number">0.03</brns:PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement>
    <brns:PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement contextRef="c-125" decimals="2" id="f-766" unitRef="number">0.07</brns:PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement>
    <brns:NumberOfSquareFeetUnderLeaseAgreement contextRef="c-126" decimals="-3" id="f-767" unitRef="sqft">31000</brns:NumberOfSquareFeetUnderLeaseAgreement>
    <us-gaap:SecurityDeposit contextRef="c-127" decimals="-5" id="f-768" unitRef="usd">700000</us-gaap:SecurityDeposit>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-128" decimals="-5" id="f-769" unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <brns:NumberOfSquareFeetUnderLeaseAgreement contextRef="c-129" decimals="-2" id="f-770" unitRef="sqft">19700</brns:NumberOfSquareFeetUnderLeaseAgreement>
    <brns:LesseeOperatingLeaseExtendedTerm contextRef="c-129" id="f-771">P5Y</brns:LesseeOperatingLeaseExtendedTerm>
    <us-gaap:LeaseholdImprovementsGross contextRef="c-130" decimals="-5" id="f-772" unitRef="usd">3500000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:SecurityDeposit contextRef="c-130" decimals="-5" id="f-773" unitRef="usd">200000</us-gaap:SecurityDeposit>
    <brns:LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock contextRef="c-1" id="f-774">The Company&#x2019;s right-of-use asset and lease liabilities are as follows (in thousands):&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liability, non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Lease Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</brns:LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-8" decimals="-3" id="f-775" unitRef="usd">1638000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-9" decimals="-3" id="f-776" unitRef="usd">4384000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-8" decimals="-3" id="f-777" unitRef="usd">2023000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-9" decimals="-3" id="f-778" unitRef="usd">1920000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-8" decimals="-3" id="f-779" unitRef="usd">9258000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-9" decimals="-3" id="f-780" unitRef="usd">10087000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-781" unitRef="usd">1979000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-12" decimals="-3" id="f-782" unitRef="usd">1789000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-8" id="f-783">P6Y11M23D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-9" id="f-784">P7Y11M23D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-8" decimals="3" id="f-785" unitRef="number">0.075</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-9" decimals="3" id="f-786" unitRef="number">0.075</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-787" unitRef="usd">3332000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-12" decimals="-3" id="f-788" unitRef="usd">1443000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-789" unitRef="usd">3332000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-12" decimals="-3" id="f-790" unitRef="usd">1443000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-1" decimals="-5" id="f-791" unitRef="usd">400000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-12" decimals="-5" id="f-792" unitRef="usd">2600000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-793">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Maturities of the Company&#x2019;s minimum lease liabilities as of December&#160;31, 2025 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Maturity of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-8" decimals="-3" id="f-794" unitRef="usd">2025000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-8" decimals="-3" id="f-795" unitRef="usd">2050000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-8" decimals="-3" id="f-796" unitRef="usd">2076000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-8" decimals="-3" id="f-797" unitRef="usd">2102000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-8" decimals="-3" id="f-798" unitRef="usd">2129000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-8" decimals="-3" id="f-799" unitRef="usd">3940000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-8" decimals="-3" id="f-800" unitRef="usd">14322000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-8" decimals="-3" id="f-801" unitRef="usd">3041000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-8" decimals="-3" id="f-802" unitRef="usd">11281000</us-gaap:OperatingLeaseLiability>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-1" decimals="-5" id="f-803" unitRef="usd">2800000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-12" decimals="-5" id="f-804" unitRef="usd">0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="c-1" id="f-805">Employee Benefit Plans&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the U.K., the Company has adopted a defined contribution plan (the U.K. Plan) which qualifies under the rules established by HM Revenue &amp;amp; Customs. Contributions to the U.K. Plan are charged to the consolidated statements of operations and comprehensive loss in the year to which they relate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has 401(k) defined contribution retirement plans in which all its employees located in the United States are eligible to participate. Eligible employees may elect to contribute up to the maximum limits, as set by the Internal Revenue Service, of their eligible compensation. Contributions to the plans are charged to the consolidated statements of operations and comprehensive loss in the year to which they relate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December&#160;31, 2025, the Company provided a total of $0.5 million (December&#160;31, 2024: $0.8 million) in contributions under both the U.K. Plan and the 401(k) plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-1" decimals="-5" id="f-806" unitRef="usd">500000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-12" decimals="-5" id="f-807" unitRef="usd">800000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-808">Related Party Transactions&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December&#160;31, 2025, the Company incurred expenses of $0.4 million (December&#160;31, 2024: $0.8 million) from OUI which is a wholly owned subsidiary of the Company&#x2019;s shareholder, the University of Oxford, primarily related to patent costs. &lt;/span&gt;&lt;/div&gt;During the year ended December&#160;31, 2025, the Company recognized &lt;span style="-sec-ix-hidden:f-811"&gt;&lt;span style="-sec-ix-hidden:f-812"&gt;license revenue&lt;/span&gt;&lt;/span&gt; of nil (December&#160;31, 2024: $15.0 million) from OUI which is a wholly owned subsidiary of the Company&#x2019;s shareholder, the University of Oxford.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-131" decimals="-5" id="f-809" unitRef="usd">400000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-132" decimals="-5" id="f-810" unitRef="usd">800000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-133" decimals="-5" id="f-813" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-134" decimals="-5" id="f-814" unitRef="usd">15000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-815">Subsequent Events &lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On February 22, 2026, the Company, Topco, Merger Sub and Clywedog entered into an amendment to the Merger Agreement (the &#x201c;Merger Agreement Amendment&#x201d;). Pursuant to the Merger Agreement Amendment, (i) the definition of &#x201c;Scheme Exchange Ratio&#x201d; as set forth in Section 1.1 of the Merger Agreement was amended and replaced in its entirety to mean a number between 0.1 and 0.166667, as finally determined by the Company&#x2019;s board of directors (or a duly appointed committee thereof), (ii) the definition of &#x201c;Merger Exchange Ratio&#x201d; as set forth in Section 1.1 of the Merger Agreement was amended and replaced in its entirety to mean a number between 0.000305 and 0.000508, as finally determined by Clywedog and the Company in accordance with Section 2.6(d) of the Merger Agreement and correspondingly based on the change to the Scheme Exchange Ratio, in order to maintain the agreed ownership split of Topco following closing of the Combinations, and (iii) the Clywedog Minimum Cash and Beacon Minimum Cash (each as defined in the Merger Agreement) requirements as set forth in Section 8.9 and 9.6 of the Merger Agreement, respectively, are expanded to include required minimum cash amounts based on an assumed closing date of May 31, 2026 and June 30, 2026, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;respectively, in light of the unexpected delay in the overall transaction timeline due to the U.S. federal government shutdowns.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <brns:MergerAgreementSchemeExchangeRatio contextRef="c-135" decimals="2" id="f-816" unitRef="number">0.1</brns:MergerAgreementSchemeExchangeRatio>
    <brns:MergerAgreementSchemeExchangeRatio contextRef="c-136" decimals="6" id="f-817" unitRef="number">0.166667</brns:MergerAgreementSchemeExchangeRatio>
    <brns:MergerAgreementMergerExchangeRatio contextRef="c-135" decimals="6" id="f-818" unitRef="number">0.000305</brns:MergerAgreementMergerExchangeRatio>
    <brns:MergerAgreementMergerExchangeRatio contextRef="c-136" decimals="6" id="f-819" unitRef="number">0.000508</brns:MergerAgreementMergerExchangeRatio>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#f-143"
          xlink:label="f-143"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-144"
          xlink:label="f-144"
          xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">All license revenue is from related parties and is generated in the U.K. for the year ended December&#160;31, 2024.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-143"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-144"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-249"
          xlink:label="f-249"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-213"
          xlink:label="f-213"
          xlink:type="locator"/>
        <link:footnote id="fn-2" xlink:label="fn-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Indicates amount less than one thousand</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-249"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-213"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-314"
          xlink:label="f-314"
          xlink:type="locator"/>
        <link:footnote id="fn-3" xlink:label="fn-3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.75pt">Indicates amount less than one thousand</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-314"
          xlink:to="fn-3"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
